0001104659-15-019213.txt : 20150312 0001104659-15-019213.hdr.sgml : 20150312 20150312165127 ACCESSION NUMBER: 0001104659-15-019213 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150312 DATE AS OF CHANGE: 20150312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trovagene, Inc. CENTRAL INDEX KEY: 0001213037 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043721895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35558 FILM NUMBER: 15696518 BUSINESS ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-217-5420 MAIL ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TrovaGene Inc. DATE OF NAME CHANGE: 20110830 FORMER COMPANY: FORMER CONFORMED NAME: XENOMICS INC DATE OF NAME CHANGE: 20040719 FORMER COMPANY: FORMER CONFORMED NAME: USED KAR PARTS INC DATE OF NAME CHANGE: 20030106 10-K 1 a15-1864_110k.htm 10-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K

 

(Mark One)

 

x      ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014

 

o         TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM                 TO               

 

COMMISSION FILE NUMBER 000-54556

 

TROVAGENE INC.

(Name of small business issuer in its charter)

 

Delaware

 

27-2004382

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

11055 Flintkote Avenue, Suite B, San Diego, California 92121

(Address of principal executive offices) (Zip Code)

 

Issuer’s telephone Number: (858) 952-7570

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of each class

 

Name of each exchange on which registered

Units, each consisting of two shares of Common Stock and one Warrant to purchase one share of Common Stock

 

The NASDAQ Capital Market

 

 

 

Common Stock, $0.0001 par value

 

The NASDAQ Capital Market

 

 

 

Warrants to purchase Common Stock

 

The NASDAQ Capital Market

 

Securities registered under Section 12(g) of the Exchange Act: None.

 

Indicate by check mark is the issuer is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes o No x

 

Indicate by check if the issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes x No o

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  Yes x No o

 

Indicate by check mark if no disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated filer x

 

 

 

Non-accelerated filer o

 

Smaller reporting company o

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o No x

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates based on a closing sale price of $3.50 per share which was the last sale price of the common stock as of June 30, 2014 was $63,974,477.

 

As of  February 27, 2015, the issuer had 24,123,790 outstanding shares of Common Stock.

 

 

 


 

PART I

 

ITEM 1.  BUSINESS

 

We are a molecular diagnostic company that focuses on the development and commercialization of a proprietary molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines.  Our primary internal focus is to leverage our novel cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while our external focus includes entering into license agreements or collaborations to develop our technology in areas such as infectious disease, transplant medicine, and prenatal genetics.

 

We are leveraging our proprietary molecular diagnostic technology for the detection of cell-free DNA originating from diseased cell death that can be isolated and detected from urine, blood, and tissue samples to improve disease management.  These genetic materials are also collectively referred to as “cell-free nucleic acids”, which result when cells in the body die and release their DNA contents into the bloodstream.  The circulating fragments of genetic material are eventually filtered through the kidneys and therefore, can be detected and measured in urine.  Cell-free nucleic acids can be used as genetic markers of disease.  As such, the contents of urine or blood samples represent systemic liquid biopsies that can allow for simple, non-invasive or minimally-invasive sample collection methods.

 

Our fundamental cell-free molecular diagnostic platform, also known as our “Precision Cancer MonitoringSM” platform, (“PCM”) platform is protected by a strong intellectual property portfolio.  We have developed significant intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly our proprietary non-naturally occurring primers.  Through this proprietary technology, we believe that we are at the forefront of a shift in the way diagnostic medicine is practiced, using simple, non-invasive or minimally invasive sampling and analysis of nucleic acids, which we believe will ultimately lead to more effective treatment monitoring, better management of serious illnesses such as cancer, and the ability to detect the recurrence of cancer earlier.  As of February 27, 2015, our property intellectual property portfolio consists of over 50 issued patents and over 60 pending patent applications globally.  Our patent estate includes the detection of cell-free nucleic acids that pass through the kidney into the urine, as well as their application in specific disease areas, including oncology, infectious disease, transplantation, and prenatal genetics.

 

We believe that our proprietary PCM platform is uniquely positioned to address a high unmet clinical need in field of oncology.  Our PCM platform is designed to offer better cancer monitoring by tracking and analyzing levels of cell-free DNA from either urine or blood samples, and is intended to provide important clinical information beyond the current standard of care.  Using urine as a sample, our cancer monitoring technology enables more frequent, non-invasive monitoring of oncogene mutation status, disease progression and disease recurrence.  Our extensive research and development efforts were strengthened, due to investments to expand our intellectual property portfolio and were made commercially feasible following improved next-generation sequencing (“NGS”) technologies which are now available at a significantly lower cost.  This combined with our extensive patent portfolio around cell-free DNA in urine gives us a competitive advantage to leverage an emerging trend toward monitoring cancer using cell-free DNA as a marker of disease status.  Our proprietary sample preparation process forms the basis of our PCM platform. It includes novel technology for the extraction and isolation of cell-free DNA from either a urine or blood sample, proprietary non-naturally occuring primers to enrich the sample for mutant alleles, and the ability to sequence nucleic acids of interest using one of several leading gene sequencing technologies such as NGS or droplet digital PCR (“ddPCR”). We believe that our quantitative cell-free DNA detection and monitoring platform offers industry leading sensitivity, featuring single nucleic acid molecule detection.

 

Our PCM platform is poised to overcome a significant clinical dilemma in the area of cancer treatment.  Recent scientific evidence supports the molecular basis of cancer, and has resulted in a paradigm shift in the way cancer is treated.  Researchers and clinicians are now focused on specific oncogene mutations that are believed to be the drivers of cancer at the molecular level, and, as a result, there is a trend in the pharmaceutical research community toward developing targeted therapies.  As such, there is a need for oncologists to have an ability to track the mutational status of their patients, including a given patient’s response to treatments designed to target driver oncogene mutations.  Current monitoring tools such as imaging procedures, tissue biopsy, and circulating tumor cells are insufficient to meet the challenge of monitoring oncogene mutations.  Imaging only provides a rough indication of tumor size, and is an important tool for surgeons, but provides little practical advice to oncologists regarding mutational status and appropriate treatment options, especially for molecular targeted therapies.  Tissue biopsy usually involves a major surgical procedure and, in many cases, is not repeatable as there are limitations related to access for serial biopsies.  In some cases, biopsies may not be available, significantly increasing the need to determine mutational status using an alternative method.  In addition, tumor heterogeneity is important, as the surgeon may not obtain the proper tissue from the tumor sample.  In the case of circulating tumor cells, which are typically measured using blood tests, there is very low sensitivity, and such tests are technically difficult and can be expensive.

 

2


 

Targeted drug therapies themselves are not without issues.  Targeted therapies are typically very expensive and can have significant side effects.  In order to measure effectiveness, repeated monitoring is needed and serial biopsies can be difficult to obtain.  If resistance develops, fast and accurate detection of emerging or changing oncogene mutations is critical.  Our PCM platform provides a novel solution using urine, a non-invasive, plentiful sample source, and we are continuing to build a growing body of evidence supporting the clinical utility of our technology to monitor cancer using cell-free DNA.

 

Our goal is to improve treatment outcomes for cancer patients using our proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples.

 

Developing a Market for Molecular Diagnostic Tests based on Liquid Biopsies using Cell-free DNA

 

We intend to develop and expand our cell-free molecular diagnostic technology into a pipeline of potentially groundbreaking commercial molecular detection and monitoring products.  Our Clinical Laboratory Improvement Amendments (“CLIA”)-certified, College of American Pathologists (“CAP”)-accredited laboratory in San Diego will enable us to initially commercialize our testing services and launch our platform technology and associated innovative molecular monitoring tests.  Urine-based cell-free molecular diagnostics can provide relevant information across multiple therapeutic and clinical areas, and may lead to improvements in patient management.  We are focused on the oncology treatment market, and the opportunity to enable clinicians to track oncogene mutational status in cancer patients.  Repeat testing is expected with most cancer patients, and there also exists a need to chronically monitor for the re-emergence of oncogenes in people that are cancer survivors.

 

In order to facilitate early availability and use of our products and technologies, in February 2012, we acquired the CLIA laboratory assets of MultiGEN Diagnostics, Inc., (“MultiGEN”), which included CLIA approval and licensing documentation, laboratory procedures, customer lists, and marketing materials.  A CLIA lab is a clinical reference laboratory that can perform high complexity diagnostic assays (e.g. those requiring polymerase chain reaction, (“PCR”) amplification).  Through this CLIA laboratory, we are able to offer laboratory developed tests (“LDTs”), in compliance with CLIA guidelines.

 

Targeting cell-free nucleic acid markers will allow for the development of genetic tests that use non-invasive and easy-to-obtain urine samples, rather than other more traditional, more invasive methods.  These methods include imaging, blood testing, and bone marrow and tissue biopsies.  We are exploring a broad range of clinical utilities where cell-free nucleic acid technology holds the potential to replace more complex, less robust existing technologies, which are based on circulating cells and nucleic acids in blood.  We are developing more effective, non-invasive diagnostics, which align with the current industry shift toward highly personalized medicine.  Urine-based cell-free nucleic acid molecular tests can make it easier to address important health problems, and may lead to significant advancements in patient care.

 

Our patented technology uses safe, non-invasive, cost effective, and simple urine collection, which can be applied to a broad range of testing including tumor mutation detection and monitoring, infectious disease monitoring, transplantation monitoring, and prenatal genetic diagnostics.  We believe that our technology is ideally suited to be used in developing molecular diagnostic assays that will allow physicians to provide simple, non-invasive, and convenient screening and monitoring tests for their patients by identifying specific biomarkers involved in a disease process.  Our novel urine-based assays can facilitate improved testing compliance, resulting in more effective use of targeted therapies, earlier detection of disease, and improvements in both patient outcomes and cost of care.

 

The material terms of certain of our clinical collaboration, research and development, and technology license agreements that we have entered into are as follows:

 

In September 2014, under the strategic partnership we established in March 2014, we entered into a Sponsored Research Agreement with Catholic Health Initiatives Center for Translational Research to conduct clinical studies to evaluate use of our PCM technology in the management of cancer patients. Under the terms of the agreement, we may pay our collaborator in the study approximately $151,000 for services provided.  As of December 31, 2014 we have incurred approximately $30,000 related to this agreement.

 

In June 2014, we entered into a Sponsored Research Agreement with Dana Farber Cancer Institute to conduct a clinical study to evaluate use of our precision cancer monitoring technology in the management of lung cancer patients.  Under the agreement, we may pay our collaborator in the study approximately $42,000 for services provided.  As of December 31, 2014 we have incurred approximately $8,000 related to this agreement.

 

3


 

In June 2014, we entered into a Sponsored Research Agreement with Memorial Sloan Cancer Center to conduct a clinical study for the detection of oncogenic tumor mutations in the urine of lung cancer patients.  Under the agreement with Memorial Sloan Kettering, we may pay our collaborator approximately $146,000 for services provided.  As of December 31, 2014 we have incurred approximately $25,000 related to this agreement.

 

In May 2014, we entered into a Strategic Research Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University to conduct one or more research agreements to evaluate use of our precision cancer monitoring technology in the management of cancer patients.  Under the agreement, each party will be responsible for its own costs and obligations under each agreement.  No services or costs have been incurred by us as of December 31, 2014.

 

In May 2014, we entered into a Patent Assignment and License Agreement, effective as of April 23, 2014, with GenSignia IP Ltd., a United Kingdom company, pursuant to which we assigned all of our miRNA patents, including methods of using miRNA for detection of in vivo cell death and detecting cell-free miRNA in urine and blood.  Concurrent with the assignment, GenSignia granted to us an exclusive, world-wide, royalty-free, fully paid, perpetual license under the transferred patents in the urine field.  Pursuant to the agreement, GenSignia will pay us a low single digit royalty on net sales and will pay an aggregate $6.5 million in milestone payments upon the achievement of up to $150 million in net sales.  GenSignia shall be responsible for the preparation, filing and maintenance of all patents under the agreement.  As of December 31, 2014, we had recorded $10,000 in license fee revenue related to the agreement.  Costs have been incurred through December 31, 2014 and reimbursed by GenSignia.

 

In December 2013, we entered into a Clinical Trial Agreement with US Oncology Research LLC (“USOR”), pursuant to which USOR will provide the principal investigator and conduct a clinical study related to examining the utility of cell-free quantitative KRAS testing to monitor disease in patients with metastatic pancreatic cancer.  Under the agreement, we committed to pay USOR approximately $270,000 for services provided.  During the years ended December 31, 2014 and 2013, we incurred and recorded approximately $16,000 and $29,000 of research and development expense related to this agreement.

 

In August 2013, we entered into a Clinical Trial Agreement with the University of Southern California (“USC”), pursuant to which USC will provide the principal investigator and conduct a clinical study related to the genetic characterization of metastatic colorectal cancers.  Under the agreement, we are committed to pay USC approximately $232,000 for services provided.  During the years ended December 31, 2014 and 2013, we incurred approximately $38,000 and $0, respectively for expenses related to this agreement.

 

In June 2013, we entered into a Research Agreement with Illumina, Inc.  pursuant to which the parties will work together to evaluate the potential for integrating our cell-free technology for isolating, extracting, and analyzing nucleic acids from urine with Illumina’s genetic analysis sequencing technology.  The parties have agreed to share all results and reagents from the Research Plan.  The agreement will terminate upon the earlier of 30 days after completion of the Research Plan or the one year anniversary of the agreement unless extended by mutual written agreement.  In October 2014, the agreement was extended for an additional year to June 2015.

 

During 2012, we entered into research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by us to identify pancreatic cancer mutations, as well as to measure the degree of concordance between the results of cell-free DNA mutation analysis from urine samples and tumor tissue.  An amendment in 2013 increased the scope of the research agreements.  We have committed to pay approximately $266,000 for the services performed by MDACC.  As of December 31, 2014, 2013 and 2012, we have incurred and recorded approximately $124,000, $142,000 and $0, respectively of research and development expenses related to this agreement.

 

In December 2012, we entered into a sublicense agreement with Genoptix, Inc. for non-exclusive worldwide rights to develop and market laboratory testing services for nucleophosmin protein (“NPM1”)  for the diagnosis and monitoring of patients with acute myeloid leukemia (“AML”),.  Under this agreement, we have granted a license to certain NPM1 patents in exchange for a one time license fee of $100,000 due upon execution of the agreement and royalty payments on net revenues.  During the years ended December 31, 2014, 2013 and 2012, we have recorded royalty and license fee revenues of approximately $30,000, $10,000 and $100,000, respectively.

 

In November 2012, we entered into a sublicense agreement with Duke University and Duke University Health Systems for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Under this agreement, we have granted a license to certain NPM1 patents in exchange for a one time license fee of $5,000 due upon execution of the agreement and royalty payments on net revenues.  During the years ended December 31, 2014, 2013 and 2012, we have recorded $1,000, $0 and $5,000, respectively of royalty and license fee revenues related to this agreement.

 

4


 

In September 2012, we entered into a collaboration and license agreement with Strand Life Sciences related to the validation and commercial launch of a urine-based DNA test for Human Papillomavirus (“HPV”).  Under this agreement, we have granted a license for use of our tests to Strand in exchange for royalty payments on net sales earned in the territory specified in the agreement.  During the years ended December 31, 2014, 2013 and 2012, no royalties or license fees had been received under this agreement.

 

In September 2012, we entered into a sublicense agreement with Quest Diagnostics for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Under this agreement, we have granted a license to certain NPM1 patents in exchange for a one time license fee of $20,000 due upon execution of the agreement and royalty payments on net sales of Quest Diagnostics and its affiliates.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty and license revenues of approximately $26,000, $14,000 and $20,000, respectively.

 

In December 2011, we entered into an exclusive license agreement with Columbia University to license the patent rights to hairy cell leukemia biomarkers.  In consideration of the license we paid $1,000 as an upfront license fee and agreed to make royalty payments as a single digit percentage of net sales if sales are made by us or a single digit royalty rate as a percentage on sublicense income received by us if sales are made by sublicensees.  The license agreement shall continue until May 10, 2021, which is the date of the last to expire of the licensed patent rights covering the license product.  The license agreement may also be terminated upon a material breach by any party or by us if we determine that it is not commercially or scientifically appropriate to further develop the license product rights.  For the years ended December 31, 2014, 2013 and 2012, there has been no royalty expense recorded related to this agreement.

 

In October 2011, we entered into an exclusive license agreement with Gianluca Gaidano, Robert Foa and Davide Rossi for the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia.  In consideration of the license, we paid $1,000 as an upfront license fee and agreed to make royalty payments as a single digit percentage of net sales if sales are made by us or a single digit royalty rate as a percentage of sublicense income received by us if sales are made by sublicensees.  We have an option to purchase the licensed patent rights in the event the licensor decides to sell such licensed patent rights.  The license agreement shall continue until September 29, 2031, which is the date of the last to expire of the licensed patent rights covering the license product.  The license agreement may also be terminated upon a material breach by any party or by us if it is determined that it is not commercially or scientifically appropriate to further develop the license product rights.  For the years ended December 31, 2014, 2013, and 2012, there has been no royalty expense recorded related to this agreement.

 

In July 2011, we entered into a sublicense agreement with Fairview Health Services (“Fairview”) for the non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Fairview paid an initial license fee of $10,000 upon execution of the agreement and will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  Fairview is obligated to pay a royalty with annual minimums of $1,000 each year.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty and license fee revenues of approximately $2,000, $1,000 and $2,000, respectively.

 

In February 2011, we entered into a sublicense agreement with MLL Münchner Leukämielabor (“MLL”) for the non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  MLL paid an initial license fee of $20,000 upon execution of the agreement and will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  MLL is obligated to pay a royalty with annual minimums of $15,000 for the first year and $20,000 thereafter.  The term of the license ends on October 28, 2025, which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty and license fee revenues of approximately $81,000, $85,000 and $71,000, respectively.

 

In June 2010, we signed a sublicensing agreement with Skyline Diagnostics BV for the non-exclusive rights to develop, commercialize and market, research and diagnostic laboratory services for the stratification and monitoring of patients with AML.  Skyline Diagnostics BV paid an initial licensing fee of $10,000 upon execution of the agreement and may make future payments to us upon the attainment of certain regulatory and commercial milestones.  Skyline Diagnostics BV will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty and license revenues of approximately $0, $0 and $0, respectively.  During those same periods, we did not record any license fee expenses.

 

In December 2008, we signed a sublicensing agreement with InVivoScribe Technologies, Inc. for the non-exclusive rights to develop and market lab testing services for NPM1 for the diagnosis and monitoring of patients with AML.  InVivoScribe Technologies paid an initial licensing fee of $10,000 upon execution of the agreement.  InVivoScribe Technologies will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on

 

5


 

October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty revenues of approximately $25,000, $25,000 and $27,000, respectively.  During those same periods, we did not record any license fee expenses.

 

In August 2008, we signed a sublicensing agreement with LabCorp for the non-exclusive rights to develop and market lab testing services for NPM1, for the diagnosis and monitoring of patients with AML.  LabCorp paid an initial licensing fee of $20,000 upon execution of the agreement.  LabCorp will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends August 25, 2018.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty and license fee revenues of approximately $28,000, $20,000 and $5,000, respectively.  During those same periods, we did not record any license fee expenses.

 

In October 2007, we signed a license agreement with ASURAGEN, Inc. for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.ASURAGEN paid an initial licensing fee of $120,000 upon execution of the agreement and may make future payments to us upon the attainment of certain regulatory and commercial milestones.  In June 2010, we signed amendment No. 1 to the co-exclusive license agreement.  The amendment asserts that we may require a license from a third-party to perform laboratory testing services.  ASURAGEN will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  In March 2013, we signed amendment No. 2 to the co-exclusive sublicense agreement with ASURAGEN.  The amendment limited the field of use to research use only (RUO) kits.  ASURAGEN was also granted a non-exclusive sublicense for NPM1 laboratory testing services.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty and license fee revenues of approximately $50,000, $50,000 and $50,000, respectively.  During those same periods, we had no license fee expenses related to this agreement.

 

During August 2007, we signed a sublicensing agreement with IPSOGEN SAS, a leading molecular diagnostics company with operations in France and the United States for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.  Upon execution of this agreement, IPSOGEN paid an initial licensing fee of $120,000 and may make milestone payments upon the attainment of certain regulatory and commercial milestones.  IPSOGEN will also pay us a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025, which is the date of expiration of the issued patent rights.  In September 2010, we signed amendment No. 1 to the sublicensinging agreement.  The amendment asserts that we may require a license from a third-party to perform laboratory testing services.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty, milestone and license fee revenues of approximately $60,000, $60,000 and $180,000, respectively.  During those same periods, we had no license fee expenses.

 

In May 2006, we entered into a license agreement with Drs. Falini and Mecucci, wherein we obtained the exclusive rights for the genetic marker for AML with the intention to utilize these rights for the development of new diagnostic tools.  In connection with this agreement, we paid $70,000 to Drs. Falini and Mecucci.  In August 2010, we signed amendment No.1 to the license agreement with an obligation to pay royalties of 6% on royalty revenues and/or 10% of any sublicense income.  During the years ended December 31, 2014, 2013 and 2012, we recorded royalty expenses of approximately $23,000, $30,000 and $24,000, respectively.

 

History

 

On April 26, 2002, we were incorporated in the State of Florida as Used Kar Parts, Inc.  On July 2, 2004, we acquired Xenomics, a California corporation, which was in business to develop and commercialize urine-based molecular diagnostics technology.  As part of the acquisition, our corporate name was changed to Xenomics, Inc. (“Xenomics”).  In 2007, we changed our fiscal year end from January 31 to December 31.  In January 2010, we re-domesticated our state of incorporation from Florida to Delaware and our name was changed to Trovagene, Inc.  In June 2012, our common stock was listed on The NASDAQ Capital Market under the ticker symbol TROV.

 

The Basis for Our Urine-based Molecular Diagnostic Technology

 

Cell-free nucleic acids have been found in a variety of human bodily fluids, with the nucleic acids isolated from urine having been extensively characterized.  Cell-free nucleic acids in urine have been proven to contain mutated DNA and other markers of disease, including microRNA.  In contrast to other bodily fluids (e.g. blood plasma), urine allows for truly non-invasive collection of the sample, provides a larger sample size, and allows for frequent collection.  Importantly, urine enables the collection of nucleic acid material from the systemic circulation over a period of time, and those DNA and RNA fragments remain stable in urine.  These factors, combined with recently developed technologies to sequence, count, and track nucleic acids with low relative abundance, make the development of these non-invasive diagnostics commercially practical and scalable.

 

6


 

In the human body, about 1011 - 1012 cells die each day primarily as a consequence of natural physiological processes for tissue and organ maintenance, but also as a result of disease.  Together, these dead and dying cells contain more than 1 gram of DNA, which is mostly degraded into short fragments by specific enzymes.  A small proportion of these cell-free nucleic acids escapes complete degradation and appears in the bloodstream.  Our scientists were the first to discover that circulating cell-free nucleic acids cross the kidney barrier and can be found in the urine as cell-free DNA.  This simple yet remarkable discovery that genetic information from various cells throughout the body is present in urine enabled the development of new, non-invasive techniques for molecular diagnostics and genetic testing.

 

To unlock the full potential of cell-free nucleic acids, we have developed a proprietary method for the isolation of the short fragmented nucleic acids that pass through the kidneys, and proprietary “ultra-short” amplicon assays necessary for the efficient detection of cell-free nucleic acids, which can be analyzed at our San Diego-based CLIA laboratory.

 

Because of the small size of cell-free nucleic acids in urine, having an isolation method that efficiently captures short nucleic acids is critical.  We have multiple methods (patents and pending patents) for the isolation of nucleic acids from bodily fluids, including urine.  Many nucleic isolation methods are not properly suited for the isolation of cell-free nucleic acids in urine.  For example, many DNA isolation kits only capture DNA greater than 200 base-pairs (“bp”) in length, with a few claiming 100 bp or longer.  No manufacturer states that their product is suitable to capture DNA sequences shorter than 80 bp in length.

 

When compared to leading kits for the isolation of DNA from bodily fluids, we have observed by conducting internal studies, that our method is three to twenty times more efficient in isolating a 50 bp target.  Our method is also suitable for the isolation of RNA, including miRNAs.

 

Paired with our cell-free nucleic acid isolation method, is our technology for detecting ultra-short amplicons (patents pending).  By combining our proprietary nucleic acid isolation method with our ultra-short amplicon assays, we are able to detect at least six times more mutations in a urine-based cell-free DNA sample than any other PCR-based assay, according to our internal test data.  We believe that these methods are also applicable to other small or fragmented nucleic acids, including cell-free DNA from blood and formalin-fixed, paraffin-embedded samples.

 

Determining DNA and RNA signatures using urine as a “systemic biopsy” may provide a more powerful and effective tool for following and uncovering both pre-clinical and clinical changes, which may include:

 

·                  monitoring cancer patients to determine therapeutic response or non-response and disease recurrence;

·                  following organ transplant status to watch for rejection;

·                  non-invasively securing samples for the clinical diagnosis of infectious diseases; and

·                  screening and testing expectant mothers, who’s fetus may be at risk for certain genetic abnormalities.

 

Currently, these clinical needs are addressed by the use of invasive blood and bone marrow tests, tissue biopsies, amniocentesis, as well as costly CT, MRI, and PET scans.

 

Urine is a relatively simple aqueous solution and, unlike plasma, contains few components that can attack and break down cell-free nucleic acid fragments.  Since urine does not contain many cells, proteins and other contaminants, cell-free nucleic acid isolation is a procedure which can be easily automated for high throughput screening applications.  Cell-free nucleic acid fragments can be accurately analyzed using conventional methods that are either in use or in development within many molecular genomics laboratories.

 

Our urine-based cell-free nucleic acid tests are based upon a proprietary method of nucleic acid isolation, followed by detection of specific genetic markers.  These proven and well-established detection methods can be used to detect nucleic acids in blood, stool, and other specimen types.  Using enhancements of these techniques, cell-free nucleic acid markers can be isolated from easily obtained urine specimens.

 

Our urine-based cell-free nucleic acid technology may be applied to the detection and monitoring of an extremely broad spectrum of medical conditions.

 

7


 

Characteristics of Urine-based Cell-free Nucleic Acid Testing

 

·                                         The kidney acts as a filter, passing cell-free nucleic acids from complex, multicellular, multicomponent blood into urine, a much less complex aqueous environment.

 

·                                         The collection procedure is non-invasive and does not require the involvement of trained medical staff.

 

·                                         Urine as a sample type supports repeated testing when required and poses no discomfort for the patient.

 

·                                         Cell-free nucleic acids in urine are stable at room temperature for extended periods of time with the addition of a simple preservative.  Nucleic acids in blood and many other traditional samples are not.

 

·                                         Sample processing and tests can often be easily automated.

 

·                                         Isolation of cell-free markers from large sample volumes increases the sensitivity of the tests.  This cannot be done as easily using blood or tissue specimens, which have inherent volume limitations.

 

·                                         Blood or sputum samples for detection of infectious diseases may not be easily obtained from certain patients, including small children and the elderly.  Urine specimens typically present minimal acquisition concerns.

 

·                                         Blood and other bodily fluids can be highly infectious by nature, urine is not.

 

·                                         Blood and other bodily fluids are legally considered biohazardous, urine is not.

 

Clinical Applications

 

We believe that our urine-based cell-free molecular diagnostic test will make it easier to address important health problems worldwide, and will lead to significant advances in personalized medicine for improved patient care.  We intend to develop clinical evidence for our cancer monitoring tests in three distinct and potentially overlapping stages.  Stage 1 studies are qualitative in nature and are designed to determine the mutational status of actionable biomarkers in urine especially when biopsy is not an option.  These studies demonstrate concordance (agreement) of the oncogene mutation status between a urine sample and a tumor tissue sample.  These studies are considered to have diagnostic value, and would prove that urine-based molecular test results match the tissue biopsy closely.  The clinical utility of such a study would validate that mutational status of actionable biomarkers can be determined in urine when a biopsy is not an option.  Stage 2 studies are quantitative in nature, and are designed to assess patient mutational status in urine longitudinally (over time) as an indicator of responsiveness to therapy and disease status of the patient.  Demonstrated clinical utility includes quantitatively assessing mutation status in urine longitudinally as an indicator of responsiveness to therapy and disease status of the patient.  Stage 3 studies are conducted with the goal to demonstrate improved patient outcomes and eventually could lead to changing medical guidelines and the clinical standard of care for managing certain cancers.  Demonstrated clinical utility includes quantitatively assessing patient mutational status in urine longitudinally for mutational status as well as early detection of resistance to therapy as a decision tool for therapy selection.  Generating data with our technology that supports better patient outcomes and more efficient use of healthcare resources is a key component of Stage 3.

 

We believe that there are several specific applications of our PCM platform technology with regard to helping oncologists monitor a patient’s mutational status, and thereby, optimize the treatment approach and improve outcomes. Our technology can be used to determinie a patient’s mutational status for the first time when a tissue biopsy is not feasible, or it can be used to monitor changes in mutational load over time to provide information that can be useful to direct treatment regimens. Should a patient have their tumor removed surgically, our technology can be used to broadly search for minimual residual disease, which can confirm a successful procedure, or can enable early detection of recurrent disease for improved patient management. Treatment-emergent mutations can also be a major problem, and may be drivers of resistance to first-line therapy. Examples of this include the emergent mutation EGFR T790M in lung cancer, or KRAS mutations in colorectal cancer. Because our platform uses a non-invasive, easy to obtain sample from the patient, the ability to monitor more accurately and more often with fewer barriers to doing so can provide us with key competitive advantages in the marketplace, particularly with regard to monitoring for treatment-emergent mutations.

 

Oncology

 

Urine may offer an alternative to blood-based tests such as circulating tumor cells, biopsy and imaging.  By tracking mutations we can inform medical practice.  Our initial pilot study was focused on the BRAF mutation because of its link to discreet cancers and associated treatments, as well as the KRAS mutation because of its broad applicability in many cancers.  We are now developing

 

8


 

oncogene tracking tests using ddPCR and NGS for a variety of mutations seen in many cancer types.  We believe the potential exists to expand the use of this latter technique across many cancer types for multiple mutations in test panels.

 

During 2014, we had over 15 ongoing clinical studies with leading cancer centers and pharmaceutical companies to demonstrate the qualitative and quantitative clinical utility of our tests.  Clinical study sites include MD Anderson Cancer Center, USC Norris Cancer Center, US Oncology, pharmaceutical collaborators and other top cancer centers.  In 2014, we signed clinical study collaboration agreements with Memorial Sloan Kettering Cancer Center, Catholic Health Initiatives Center for Translational Research, Dana Farber Cancer Insititute, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, City of Hope Comprehensive Care Center, and Genomac International Ltd, (also known as the Center for Applied Genomics of Solid Tumors, Genomac Research Institute).

 

Initial clinical results for KRAS and BRAF mutation assays

 

The MD Anderson Cancer Center clinical study is focused on detecting and monitoring BRAF and KRAS tumor mutations in cell-free DNA from urine in metastatic cancer patients.  BRAF mutations are common in melanoma, thyroid, and other cancers.  Within the U.S., it is estimated that nearly 730,000 patients have tumors with BRAF mutations.  Several targeted therapies are either on the market or in development for BRAF-mutation positive cancers.  Pancreatic cancer represents an additional diagnostic and treatment challenge.  Each year, more than 43,000 new cases of pancreatic cancer are diagnosed, and 37,000 patients succumb to this disease.  It is estimated that KRAS mutations occur in >90% of pancreatic cancers and 11%-17% of these patients do not express the CA19-9 marker, which makes their disease more difficult to track.

 

Initial results from the MD Anderson Cancer Center clinical study were published at the AACR-NCI-EROTC International Conference in October 2013.  During the study, urine samples from metastatic cancer patients known to have BRAF V600E, KRAS G12D or KRAS G12V mutations were assessed.  Our researchers analyzed the urine samples using our urine-based cell-free molecular diagnostic assays.  Results demonstrated high concordance between urine and tissue mutational status.  In addition, preliminary results indicate that cell-free BRAF V600E mutation monitoring in urine correlates with clinical response to therapy.  The clinical study demonstrated that BRAF V600E mutations were detected in urine irrespective of the cancer type, and a multitude of different cancer types, including brain cancer (“glioblastoma”), were included in the initial study results.  The BRAF V600E assay demonstrated 95% concordance vs. tissue biopsy (both detected and borderline), and also demonstrated that urine DNA can be used to detect DNA fragments from circulation that harbor tumor mutations.  The following cancers were detected: non-small cell lung cancer, papillary thyroid carcinoma, melanoma, colorectal cancer, glioblastoma, adenocarcinoma of unknown primary, ovarian cancer, and appendiceal cancer.  In addition, preliminary results indicate that cell-free BRAF V600E mutation monitoring in urine longitudinally correlates with clinical response to therapy.

 

The study also evaluated the feasibility of using massively parallel deep sequencing (i.e. NGS) to identify DNA mutations in the urine of metastatic cancer patients harboring known KRAS mutations.  Leveraging proprietary enrichment methods, our researchers were able to detect mutant cell-free DNA in the urine of cancer patients with verified KRAS mutations.

 

CLIA validated BRAF mutation assay

 

In October 2013, our first urine test for cancer mutation monitoring was made available to clinicians through our CLIA laboratory.  The robustness of our ultra-sensitive assay procedure has been demonstrated for the detection of the BRAF V600E mutation from cell-free DNA in urine.  This mutation commonly occurs in melanoma.  Of the more than 70,000 cases of melanoma diagnosed each year in the United States, up to 70 percent harbor a BRAF-type mutation and of those, 80 percent may be positive specifically for BRAF V600E.  There are several approved targeted therapies for the treatment of BRAF-positive melanoma, making mutational status monitoring an area of clinical interest among treating physicians.

 

Our cell-free BRAF test is a LDT, designed to detect and monitor this mutation in metastatic cancer patients with biopsy-proven V600E BRAF mutation in their tumor.  It is the first commercial assay within our cancer monitoring portfolio performed using a ddPCR platform.  Using urine as a non-invasive, systemic sample, the cell-free BRAF test could help physicians monitor changes in mutation status for patients requiring therapy for cancers that have this mutation.  For patients with difficult-to-biopsy metastatic tumors, urine-based mutation testing may also provide a viable alternative to gauge mutation status as part of the initial treatment workup.

 

In April, 2014, we announced the presentation of clinical study results at the American Association for Cancer Research (“AACR”) Annual Meeting.  Of the 33 patients enrolled in the study, our BRAF V600E oncogene mutation assay was able to identify the mutation in 29 patients (88%) at least one time during the study, demonstrating a high level of concordance with tissue biopsy. 

 

9


 

Longitudinal analysis was performed in 17 patients who had more than one urine-based test during the monitoring period.  Of these patients, 13 (76%) showed a correlation between response to treatment and mutational status observed by the urine-based test.  The results were presented by Filip Janku, M.D., Ph.D., University of Texas MD Anderson Cancer Center.

 

In June 2014, we announced that expanded clinical study results demonstrating the utility of our PCM platform were released at the 50th Annual Meeting of the American Society of Clinical Oncology (“ASCO”).  Data from a study in multiple cancer types were published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology by Filip Janku, M.D., Ph.D., University of Texas MD Anderson Cancer.  In this study, longitudinal analysis of sequential urine samples demonstrated a statistically significant correlation between changes in the amount of BRAF V600E mutation load and treatment response with targeted drug therapy (p=0.002), per RECIST 1.1 criteria.  Results also demonstrated that patients with a decrease in BRAF V600E mutation load had a longer median time to treatment failure compared to those that did not (259 days vs.  61 days; p=0.002).  Patients in the study had melanoma (n=7), non-small cell lung cancer (n=3), colorectal cancer (n=2), and other forms of cancer (n=5).  Additionally, clinical results from a study in patients with histiocytic disease were presented by Eli Diamond, M.D., Memorial Sloan Kettering Cancer Center.  In this study, the Company’s PCM technology demonstrated 93% concordance for identifying the BRAF V600E mutation, and confirmed the absence of the mutation in the six patients whose biopsies tested negative.  Trovagene’s assay also detected the BRAF V600E mutation in two patients for whom tissue biopsy material was inadequate to determine mutational status, and these results were subsequently confirmed with follow-up biopsies.  Our PCM platform showed 100% concordance in monitoring response to therapy in six study subjects who tested positive for the mutation and were treated with a BRAF inhibitor.  Results from this study were published in clinical consensus guidelines for the diagnosis and treatment of patients with the histiocytic disease, Erdheim-Chester disease.

 

CLIA validated KRAS mutation assay

 

In March 2014, our urine based test for KRAS mutations became available to clinicians through our CLIA laboratory.  This assay detects and monitors the seven most commonly encountered mutations of the KRAS oncogene, and is our first multiplexed oncogene mutation assay utilizing next-generation sequencing as a mutation detection platform.  The robustness of our ultra-sensitive assays has been demonstrated for the detection of KRAS mutations from cell-free DNA in urine.  This mutation commonly occurs in patients diagnosed with either colorectal cancer, pancreatic cancer, or lung cancer.  Of the more than 1.1 million estimated cases of colorectal cancer in the United States, up to 40 percent are estimated to harbor KRAS mutations.  In pancreatic cancer and lung cancer, approximately 90% and 15% of patients harbor KRAS mutations, respectively.  Because of the prevalence of this mutation in several important cancer types, monitoring KRAS mutational status is an area of clinical interest among treating physicians.

 

The clinical study being conducted at the USC Norris Cancer Center is focused on mutation monitoring and the emergence of KRAS resistant mutations in colorectal cancer.  With multiple targeted therapies for colorectal cancer on the market, detection of KRAS mutations in tissue has a direct impact on the initial treatment selection for these patients.  The primary purpose of the collaborative study is to determine whether KRAS mutations can be evaluated in urine to monitor treatment response in patients that test either positive or negative for the mutation.

 

The US Oncology clinical study will test detection and monitoring of KRAS mutations in pancreatic cancer patients.  In addition to the US Oncology Research affiliated community cancer care sites participating in this study, additional academic research institutions that specialize in oncology have also elected to participate.  CT scans and CA19-9 blood levels are currently the only two methods available to clinicians to monitor metastatic pancreatic cancer tumor burden and response to therapy.  However, approximately 11%-17% of patients will not display elevated CA 19-9, even with high tumor load.  For patients that test negative for CA19-9, our method to follow disease status by detecting and monitoring KRAS mutations could be distinctly beneficial.

 

In November 2014, we presented clinical results at the EORTC-AACR-NCI International Symposium highlighting our ability to detect and quantitate KRAS mutations in blood and urine samples from patients with advanced colorectal cancer.  Results showed a highly correlated response.  Of the blinded retrospective plasma cell-free DNA samples evaluated, 95% displayed the KRAS mutation concordant with tumor tissue, and for evaluable urine samples in the study, 92% displayed the KRAS mutation concordant with tumor tissue.  The majority of patients in the study underwent surgery and received neo-adjuvant or adjuvant therapy, and serial monitoring of KRAS mutations using our assay showed a clear correlation between blood and urine samples.  An estimated analytical limit of detection of 7 copies per ~100,000 genome equivalents, or 0.0067% was observed in the study, demonstrating very high analytical sensitivity.

 

10


 

Research and Development of additional mutation assays

 

We have several programs to evaluate the detection and monitoring of EGFR mutational status in lung cancer patients.  A focus of these studies is the emergence of the resistant mutation EGFR T790M in lung cancer patients, which can be important for therapeutic selection when this mutation type is or becomes present.  Our collaborators for this program include Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center, UC San Diego Moores Cancer Center, and Genomac Research Institute.  In addition to our study collaborations with cancer centers for this indication, we also have an ongoing collaboration with a pharmaceutical company to determine and monitor EGFR T790 resistant mutations in lung cancer patients.

 

PIK3CA mutations are common in breast, colon and endometrial cancers.  Within the U.S., nearly one million cancer patients are positive for these mutations.  Among our platform applications in development, we are working on an assay for the detection and monitoring of PIK3CA oncogene mutations.  Other mutation marker assays in development include: EGFR, NRAS, HER-2, and ALK rearrangements.

 

Infectious Disease

 

HPV-HR Detection Assay

 

Following the completion of a pilot clinical study with a urine-based DNA test for high-risk HPV, our first HPV-HR Detection assay became commercially available in March 2013.  Initial data from the pilot study showed that our assay provided superior performance to the current leading HPV assay.  Our HPV-HR Detection assay showed a sensitivity of 93.0% and specificity of 96.0% for the detection of HPV virus in a comparative study of 320 high-risk individuals.

 

In August 2014, we presented results from two clinical studies at the 29th International Papillomavirus conference for our urine-based diagnostic test for the detection of high risk strains of HPV.  Results from both pilot studies consistently demonstrated that our urine-based HPV assay had sensitivity greater than 90% for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3).  Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples.  In one of the studies, urine collection was examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.

 

Urine-based HPV testing offers a significant advantage over the traditional cervical swab sample, which can present a logistic, invasive, or privacy concern.  A urine-based assay also makes both female and male carrier screening feasible.

 

Through licensing agreements, we are pursuing commercialization of our HPV-HR Detection test, particularly in those geographies where compliance with cervical cell sampling is problematic.

 

Prenatal Genetics

 

The combination of NGS or ddPCR with our proprietary cell-free nucleic acid technology would allow for truly non-invasive prenatal screening of aneuploidies and monogenic disorders.  We may pursue the development of our technology for use in prenatal genetics through licensing agreements.

 

Transplant

 

Patients who receive solid organ or bone marrow transplants are at risk of rejection, particularly during the first few months following surgery.  Non-invasive monitoring of transplant status could replace repeated biopsies and blood tests, while keeping both the patient and the physician informed about potential problems.

 

Changing the Molecular Diagnostic Paradigm

 

Diagnosis and detection of severe and life-threatening diseases are among the most important outcomes of the Human Genome Project (“HGP”).  There are four requirements to realize the full benefit of the HGP in relation to cancer diagnostics; large catalogues of cancer mutations; affordable sequencing of patient samples; detection technologies capable of identifying and quantifying rare instances of mutations at affordable costs; and large, systemic samples that can be collected easily and frequently in order to monitor an individual’s cancer.

 

The first requirement has been met through the Sanger Centre’s Catalogue of Somatic Mutations in Cancer database, which has catalogued more than 233,000 mutations in more than 20,948 genes; and by the National Institutes of Health’s (“NIH”) The Cancer Genome Atlas, which has data on more than 20 cancer types and provides a host of tools for their analysis.  The second requirement has been met through the dramatic and continuing decrease in the cost of both conventional sequencing and NGS.  ddPCR, capable of detecting rare mutations among thousands of wild type molecules at a reasonable cost, fulfills the third requirement.

 

11


 

Our proprietary methods provide the fourth and final requirement, the provision of a large, systemic sample that allows the purification of cell-free nucleic acids in amounts necessary to detect rare mutations.  Furthermore, the “liquid biopsy” provided by urine can be collected frequently, is truly non-invasive, and requires no specialized personnel to collect it.

 

Taken together, these developments will increase the effectiveness of cancer diagnostics, improve healthcare spending efficiency, and overall, enable better patient care.  These developments have made the era of personalized precision medicine in cancer possible.

 

The Market

 

The global molecular diagnostics market is forecast to reach nearly $8.0 billion by 2018, a compound annual growth rate of 9.7% from 2013—2018.  This molecular diagnostics market is segmented on the basis of application, technology, end user, product, and geography.  Based on application, the market is further segmented into infectious diseases, oncology, genetics, blood screening, microbiology, and others.  Infectious diseases secured the largest market share, whereas oncology was the fastest growing segment amongst the rest.  The driving forces of the molecular diagnostics market include the rising incidences of infectious diseases, genetic disorders, and cancer, as well as technological advancements such as assay improvements, new diagnostic tests with novel clinical utility, and portability of equipment.  The technology segment of the molecular diagnostics market comprises of polymerase chain reaction (“PCR”), Isothermal Nucleic Acid Amplification Technology, hybridization, DNA sequencing and NGS, microarray, and others.  Among these, the PCR segment had the largest share in 2013 of the total molecular diagnostics technology market, whereas the microarray segment will be the fastest growing segment by 2018.

 

Based on products, the molecular diagnostics market is segmented into instruments, reagents, and services & software.  Reagents occupy the largest market share and will also register the maximum growth rate in the forecasted period 2013-2018.  These reagents include assays that detect and diagnose diseases and are also used as biomarkers that predict the biological properties of the potential drug compounds.

 

Based on end users, hospitals was the largest segment in 2013, whereas reference laboratories will grow at the highest CAGR between 2013 and 2018.  Reference laboratories carry out complex, specialized, and obscure tests.  The government regulations to cut down healthcare costs will lead to the rise in the reference laboratories segment.  Therefore, reference laboratories are estimated to grow at highest CAGR.

 

North America accounted for the largest share in 2013 and is poised to grow at a high rate in the forecast period 2013 to 2018.  The growth can be attributed to the rising infectious diseases, cancer prevalence, and genetic disorders that are further adding to the overall prevalence of chronic diseases.  Europe was the second leading contributor to the molecular diagnostics market in 2013.  However, the growth of this region is expected to be sluggish in the forecast period and is estimated to grow at a lower CAGR than North America, due to factors such as the uneven reimbursement policies and the European economic crisis.  Asia is the most promising region for molecular diagnostics in the coming five years.  It is expected to grow at a higher CAGR than North America and Europe over the forecast period.  The high population base and improved purchasing power of patients are the major drivers of this market.  Moreover, economic instability in some western countries enables companies to focus on the Asian region in order to meet their revenue targets.

 

Cell-free molecular diagnostics from urine and plasma provide relevant information that can lead to improvements in personalized patient management.  Beyond cancer care and infectious diseases, new products that facilitate personalized care are also emerging in the areas of central nervous system diseases, diabetes, and autism.  Most major pharmaceutical companies have active pharmacogenomic programs included in their clinical studies, anticipating the need to utilize diagnostic testing to stratify patients for clinical response.  We believe that our broad intellectual property (“IP”) portfolio positions us to work within each of these markets, either alone or in partnership with other companies, to develop and market cell-free molecular diagnostic products, all of which we expect would address the large unmet market needs of simplicity, patient convenience and privacy, accuracy, and cost effectiveness.  Such products could play key roles in their applications to improve testing compliance and as such, reduce morbidity and mortality.  The use of urine as a sample should provide a paradigm shift in screening and monitoring practices as it provides an easier sample to acquire in a truly non-invasive fashion, with more nucleic acid targets present in the sample leading to greater sensitivity.  We believe these modified screening practices will most likely meet with wide physician and patient acceptance in oncology, infectious disease, transplantation, and potentially, prenatal diagnostics.

 

12


 

Commercial Markets — Internal Focus

 

Oncology

 

Cancer mutation testing and monitoring is the priority area for our scientists and commercial personnel.  Early data from ongoing clinical studies have shown that cell-free nucleic acid analysis may be useful for determining the presence or absence of actionable mutations, and for monitoring therapeutic response and recurrence in metastatic cancers.  Such testing could serve to help physicians monitor ongoing response to therapy, identify signs of early progression, or see markers of resistance emerge prior to clinical presentation.  Once therapy is completed, a simple urine test could be used to monitor for early signs of disease recurrence over time.  The market for these tests—diagnosed cancer patients possessing mutations known to have clinical or therapeutic importance—is already established.  Use of urine-based testing could be disruptive, and change the pattern of use of other cancer monitoring tools, including expensive imaging technologies, such as PET, CT and MRI scans.

 

According to the American Cancer Society’s (“ACS”) 2013 report, there are approximately 525,000 patients that die every year from cancer, not including cancers of the blood, bone marrow, or lymphatic system.  Using this number as a proxy for metastatic cancers, it can be assumed that all of these patients are being treated within 12 months of death for their disease.  Testing and monitoring these patients for response to therapy, progression while on therapy, or for markers of resistance to therapy (like T790M for lung cancer) would be a natural extension of our technology.  The average lung, breast, or colon cancer patient receives between 18-21 radiographic imaging procedures (PET, CT, MRI, etc.) during the two years following their diagnosis.  This averages to about 9-10 scans per patient per year.  Use of a urine-based monitoring test at the start of therapy, at several time points during therapy, and at the completion of therapy would represent approximately six separate testing events that could occur within a 12 month period.  At a reimbursed price of approximately $1,000 per test, the total available market (“TAM”) for treatment response monitoring in the U.S. could be worth more than $5.0 billion.

 

Once patients with cancer, primary or metastatic, have completed therapy, they will require monitoring for possible progression, and for the appearance of resistance markers, since many metastatic patients may remain on lower-dose “maintenance therapy” during the remainder of their lives, or until treatment is no longer considered an option.  According to the ACS, as of 2012, there were over 11 million patients alive in the U.S. who have been treated for cancers that have metastatic potential, not including cancers of the blood, bone marrow, or lymphatic system.  Use of a urine-based mutation monitoring test once a year at $1000 per test would equate to a TAM for recurrence monitoring in the U.S. at approximately $12 billion annually.

 

Both of these markets, treatment response and recurrence monitoring, are sizeable economic opportunities.  Capturing 10% of the response monitoring market would produce revenues of ~$500 million, and 5% of the recurrence monitoring market would yield annual revenues of ~$600 million.

 

Beyond cancer patients being actively treated or monitored over time, cell-free nucleic acid testing may eventually emerge as a viable option for pre-cancerous screening.  This was recently evaluated in a cancer clinical study at Thomas Jefferson University, funded jointly by the NIH and the National Cancer Institute (“NCI”).  The study demonstrated that DNA fragments carrying a specific mutation (KRAS), and released from pre-cancerous colon polyps, can be detected in the urine of patients.

 

Studies have shown that cancer patients who have KRAS mutations do not respond successfully to treatment with anti-EGFR (epidermal growth factor receptor) drugs such as Erbitux, Iressa, Tarceva, Tykerb, and Vectibix.

 

These anti-EGFR agents, particularly Erbitux and Vectibix, are a mainstay of treatment for colorectal cancer.  It has been estimated that 17-25% of all human cancers have been found to harbor KRAS mutations, with mutation rates as high as 59%-90% in pancreatic cancers and 35%-40% in colorectal cancers.  These tumors have a low probability of responding to anti-EGFR drugs.  By first testing for KRAS mutations, physicians will be able to better manage their patients and avoid costly treatments that are unlikely to have a positive clinical response.

 

Screening and monitoring for KRAS and other key biomarker mutations (i.e. BRAF, PIK3CA, EGFR, etc.) using urine-based tests would provide a simple, non-invasive, cost effective, and convenient testing alternative for physicians and patients.  Specimens may even be collected in the patients’ home as required, or as requested by the physician.

 

Simple urine-based assays would likely lead to much improved personalized medicine for patients, resulting in the right drug being prescribed for the right disease at the right time.  We believe this technology will lead to an improved quality of life for patients.

 

13


 

Drug Development and Monitoring of Therapeutic Outcomes

 

Cell-free DNA diagnostic technology has significant potential as a very simple, quick, non-invasive way of monitoring clinical responses to drugs in clinical development and evaluating patient-specific responses to already approved and marketed therapies.  Specific target applications include, but are not limited to; the detection of metastasis following tumor surgery, monitoring of response and tumor progression during chemotherapy and/or radiation therapy, development of optimal hormonal and chemotherapeutic treatment protocols, and monitoring of transplantation patients on immunosuppressive drugs.

 

With cancer treatment today, it is often difficult to determine if a particular patient is responding to their current therapeutic regimen.  Generally, patients are re-examined periodically to determine if a tumor has grown in size, reduced in size (i.e. partial response), disappeared (i.e. no sign of disease — complete response) or remained the same (stable disease).  If the tumor has grown in size or remained the same, treatment may be adjusted.  By measuring and monitoring tumor specific genetic markers in a patient’s urine pre-, peri- and post-chemotherapy, it may be possible to more quickly determine whether a patient is responding to therapy.  Use of cell-free DNA diagnostics may permit more rapid and real-time therapeutic decisions on a patient-specific basis.  About 1.6 million new cancer cases are diagnosed annually, and there are several hundred companies developing therapeutic agents in the United States alone.  We believe this indicates a large potential application to use cell-free DNA diagnostic technology for both drug development and the monitoring of therapeutic outcomes.

 

One of the largest costs associated with development of a new therapy is the size of human clinical studies required to identify the cohort of responders, and the resulting statistical power required.  By measuring specific genetic markers, it may be possible to pre-identify, and subsequently screen, for the most likely responders to the therapy, and to limit patient recruitment to this subset.  This strategy could significantly reduce the cost to develop a drug, and can improve development timelines as well.  We believe that there is significant commercial potential for our urine-based cell-free molecular diagnostic technology to be incorporated into these clinical trial protocols, and ultimately post-approval patient identification protocols.

 

Commercial Markets — External Focus

 

We will seek to license and/or partner with other companies who have vested interests or commercial strengths in the following areas in order to develop applicable diagnostic and/or monitoring tests using our cell-free molecular diagnostic technology.

 

Infectious Diseases — Human Papilloma Virus (“HPV”)

 

The rationale for screening HPV is that high-risk subtypes cause virtually all cases of cervical cancer.  We have developed a urine-based HPV test capable of screening for known high-risk HPV types that are associated with the development of cervical cancer.  Cervical cancer is the third most commonly diagnosed cancer, and the fourth leading cause of cancer deaths in females, worldwide.  Deaths due to cervical cancer are a significant global problem, especially in the developing world where screening practices are far from adequate.

 

According to the American Cancer Society, India alone accounts for 27% (77,100) of total worldwide cervical cancer deaths.  A recent clinical trial conducted in rural India found that a single round of HPV DNA testing was associated with about a 50% reduction in the risk of developing advanced cervical cancer and associated deaths.  This compares with the United States, where better patient compliance and screening guidelines have reduced cervical cancer death rates to only 4,290 cases in 2011.  The major drivers of poor screening in these developing regions are cultural acceptance, limited screening resources and funding, and poor cytology proficiency.  Further exacerbating the compliance hurdles, is that the primary screening mechanism involves an invasive cervical scraping procedure (e.g. Pap smear).  It is generally agreed that the early detection of cervical cancer leads to much higher cure rates, and lower rates of invasive disease.

 

Beyond women’s health and cervical cancer, HPV infection impacts the men who carry and help spread the virus.  While not at risk for cervical cancer,  men can experience clinical manifestations in the form of genital warts, as well as penile, anal, and oropharyngeal cancers.  Determining male carrier status is an unmet medical need within the sexually-transmitted disease community.  We intend to explore the viability of our urine-based HPV assay to be a potential screening test for both low-risk HPV types 6 and 11 (which cause up to 90% of all genital warts), as well as known high-risk HPV types that cause the development of cervical and other cancers.  Knowing HPV carrier status may contribute to more stringent use of safe sex practices, and can prevent further spread of the disease during active infection periods.  In addition to carrier screening, our test may also prove useful in monitoring patients with active HPV infection until resolution of the disease.

 

There is a tremendous unmet need for a new non-invasive, simple, private, and cost effective test to simplify the HPV screening process for patients, both male and female, and in turn improve compliance.  We believe our urine-based HPV test can address these market needs.

 

14


 

Other areas beyond HPV detection and monitoring include those infectious diseases caused by viruses, bacteria, fungi, and parasites.  Cell-free nucleic acid assays that detect molecular targets in such organisms can provide a quick, accurate, simple, and cost effective method for screening and monitoring disease.  Specific areas of interest include testing for molecular targets from organisms that cause Lyme disease, JC Virus, valley fever, and various fungal infections.  These organisms all tend to be difficult to identify with current technology, making differential diagnosis especially challenging, thus delaying the start of potentially curative anti-infective treatment.

 

Transplantation

 

According to government statistics, there are approximately 28,000 solid organ transplants performed in the U.S. annually.  Post-transplant monitoring for organ rejection episodes requires a highly invasive tissue biopsy.  Approximately 10 such biopsies are taken over a period of one year per patient.  Because organ rejection is marked by the early death of cells, we believe that an early indication of rejection can be identified by measuring a unique series of genetic markers characteristic of the organ donor that can be easily detected in random urine specimens from the transplant recipient.  Providing early evidence of tissue rejection is key to the administration and monitoring of immunosuppressive therapies used to fend off rejection.  Given the annual number of transplants performed in the U.S. and the annual number of corresponding biopsies performed per patient, this would equate to a market opportunity in the U.S. of roughly 300,000 urine-based tests per year.  Transplantation monitoring with our technology offers opportunities for partnering with companies developing drugs for controlling tissue rejection, developing cell transplantation, or developing novel transplantation technologies.  This illustrates the breadth of commercial potential of our cell-free molecular testing platform technology, and we intend to leverage such potential applications to maximize shareholder value.

 

Ultra-sensitive Analytical and Detection System

 

As it relates to detection platforms, which are required for final assay analyses, we have potential to develop a new instrument that provides features that would be synergistic and complementary to our cell-free molecular diagnostic technology.  In this regard, in August 2010 we acquired Etherogen, Inc. which owns the CMOS Sensor Detection Platform, and we may design a “next generation” version of this screening and detection device.  The major differentiating features of this platform are simplicity, unsurpassed ultra-sensitive detection of nucleic acids and proteins without the need for target amplification or the resulting investments in amplification-related infrastructure or capital equipment, significantly heightened speed, and the ability to perform multi-analyte assays.  We believe that such a platform would undoubtedly expand the user base for molecular diagnostics.  Currently, the cost of adding these new testing modalities in hospitals can be daunting.  These high costs include extensive capital equipment and infrastructure requirements (i.e. amplification technology, highly trained personnel, special facilities, etc.) that most hospitals cannot afford.  Our platform may address cost efficiencies, and potentially could help overcome these adoption hurdles.  Finalization of the system architecture, operating procedure, and software specifications for this platform are required, and system development will take place when resources are allocated to fund the project.

 

Technologies for the collection, shipment and storage of urine specimens, and cell-free nucleic acid extraction

 

Successful implementation of our cell-free nucleic acid technology in molecular testing is tightly linked to the availability of techniques and procedures for cell-free nucleic acid preservation, purification, and analysis.  Our strategic plan includes the allocation of sufficient resources for the creation of robust, feasible, and inexpensive approaches to improve the efficiency of working with urine samples.

 

Instrumentation/System Platform

 

As part of our product offerings, we intend to provide various types of automation alternatives that will further enhance the acceptance and use of our urine-based assays incorporating our cell-free platform.  In this regard, there are several alternatives that we will pursue.  For example, in sample extraction, we will either develop applications for existing extraction systems that already exist in laboratories or recommend that they acquire instruments that can be used with our assays.  An alternative will be to explore an OEM (original equipment manufacturer) arrangement with one of the instrument suppliers, which will allow us to private label the instrument thus supporting a complete system at the customer site.

 

Our Business Strategy

 

We plan to leverage our cell-free nucleic acid technology to develop and market, either independently or in conjunction with corporate partners, molecular diagnostic products in our core market, oncology, as well as other markets including infectious disease, transplantation, and prenatal diagnostics.  Our marketing strategy includes approaches across multiple fronts.  In the U.S. market, we have acquired a Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory.  At the late stages of development for

 

15


 

each product, while collecting clinical data for regulatory submissions, we intend to market the products as LDTs through our CLIA laboratory.  CLIA laboratories can develop and offer their own in-house tests that receive reimbursement under the provisions of LDT rules.

 

Congress passed the Clinical Laboratory Improvement Amendments in 1988 to regulate development, evaluation, and use of LDTs.  CLIA states that laboratories must demonstrate how well an LDT performs using certain performance standards.  Laboratories that perform testing on human specimens for the diagnosis, prevention, or treatment of disease, or for the assessment of health, must comply with all applicable CLIA ‘88 regulations.  These regulations, which were finalized in 2003, establish standards to help ensure the quality and accuracy of laboratory testing.  While most common laboratory tests are commercial tests, manufactured and marketed to multiple laboratories, some new tests are developed, evaluated, and validated within one particular laboratory.  These LDTs are used solely within that laboratory and are not distributed or sold to any other labs or health care facilities.

 

Because LDTs are not marketed to other labs or facilities, they do not require approval for marketing from the U.S. Food and Drug Administration (“FDA”) as do commercially developed and marketed tests.  However, these types of tests must go through rigorous validation procedures and must meet several criteria before results can be used for decisions regarding patient care.  These include demonstration of test accuracy, precision, sensitivity, and specificity.

 

We may pursue FDA review and approval for our products as clinical studies are completed.  Assuming we receive FDA clearance or approval for our products, we plan to market such urine-based test kits through a U.S. commercial organization directly to national and regional CLIA medical testing laboratories.  We also intend to complete business partnerships (out-license agreements) with diagnostic and pharmaceutical companies in the U.S., Europe, Asia Pacific and the rest of the world as appropriate given market conditions and opportunities.  This strategy would provide both short term (license fees) and long term (royalty) revenue streams.  Licensees of our technology will use our platform technology in the clinical development of their products, to monitor patients taking their marketed products (i.e. TNF inhibitors), and in certain situations to develop, market and sell our cell-free molecular diagnostic technology in predefined fields of use and geographic territories.  We plan to become a fully vertically integrated business in which we develop, manufacture, register, market, and sell our products.

 

The major advantages of our cell-free nucleic acids tests, when commercially available, will be the ease of sample collection, anticipated higher levels of sensitivity and specificity, larger quantities of genetic material for analysis (allowing for the detection of oncogene mutations that are low in abundance), patient convenience, non-invasiveness, and the ability to provide more efficient and effective monitoring protocols.  Our cell-free nucleic molecular diagnostic technology must be cost effective, and we believe the process to make, sell, and process our assays is relatively simple and suitable for automation.

 

During the last decade, medical laboratory operating margins have declined in the face of Medicare fee schedule reductions, managed care contracts, competitive bidding, and other cost containment measures.  If our technology were commercially available today, reimbursement would be available under the current procedural terminology, or CPT codes, for molecular-based testing.  We expect to market our tests through our CLIA laboratory directly to physicians, and we will work with public and private payers for appropriate reimbursement.  We believe this strategy, coupled with strong clinical results supporting the use of our cell-free molecular diagnostic technology, will lead to broad market adoption of our technology.

 

Research and Development

 

As of December 31, 2014, we have 17 dedicated scientists who are located in our office in San Diego, CA.  We plan to continue to grow our R&D organization to approximately 28 individuals that will represent a good mix of senior lead researchers and scientists (PhDs), laboratory associate scientists, and experts in clinical development and regulatory affairs of molecular diagnostics.  We plan to rapidly introduce new products to the market that could be used as LDTs within our CLIA lab, and simultaneously continue funding and collaborating on the necessary clinical studies that can support the utility of our tests, and potentially support regulatory submissions for marketing approval or clearance depending upon the nature of the product.  We currently have sufficient resources to complete these projects extending into 2016.  We plan to seek additional funding as required to supplement current commercial and licensing revenue.  Information and documentation systems infrastructure (e.g. design history files, firewalls, etc.) must be in place to support the confidentiality of multiple partnering programs, and the rigorous scientific and regulatory oversight needed for products in the in-vitro diagnostics markets.  Research and development expenses for the years ended December 31, 2014, 2013 and 2012 were approximately $6.6 million, $3.9 million and $1.9 million, respectively.

 

Intellectual Property

 

We consider the protection of our proprietary technologies and products to be a critical element in the success of our business.  As of February 27, 2015, our wholly owned and licensed intellectual property includes over 50 issued patents and over 60 pending patent applications in the U.S. and abroad.  The pending applications include multiple international applications filed under the Patent Cooperation Treaty (“PCT applications”) that will be used as the basis of multiple additional patent applications.

 

16


 

One group of patents and patent applications includes 7 U.S. patents, with 30 counterpart patents in Japan, Hong Kong and Europe, including the major markets of the European countries.  These patents are directed to the detection of nucleic acid sequences in urine and nucleic acid modifications and alterations in urine.  This patent family includes claims directed to prenatal analysis of fetal DNA and determining the sex of a fetus and detecting diseases such as Down Syndrome caused by genetic alterations.  Other patented claims are directed to detecting and monitoring cancer through urine-based testing; nucleic acid screening, and monitoring in cases of transplantation and infectious diseases, including infection by viruses and pathogens; and other potential diagnostic and genetic testing applications.  Additional pending claims are directed to the preparation of cell-free nucleic acids, as well as detection of cell-free microRNA and short cell-free nucleic acid molecules.  Members of this patent group expire between 2018 and 2026.

 

A second group is directed to detection of specific gene mutations and indicators of disease.  These include NPM1 mutations, BRAF mutations, SF3B1 mutations, HPV, AML, and hairy cell leukemia.  The detection includes analysis of cell-free nucleic acid molecules.  The group includes U.S. patents 8,222,370 B1, 8,501,924 B1, and 8,642,261 B1, as well as 6 pending U.S. patent applications.  There are also 25 pending non-U.S. patent applications, and one PCT application.  Members of this patent group expire between 2025 and 2033.

 

A third group is directed to our molecular detection platform utilizing proprietary probe chemistry on optical detectors such as CMOS (complementary metal-oxide semiconductor).  This platform technology utilizes a conjugated probe and optical detection of analytes in medical diagnostics.  The group includes one issued Japanese patent and patents in the major markets of Europe, with pending applications in the US, Europe, and Hong Kong.  Members of this patent group expire beginning in 2022.

 

Applications are also pending that are directed to detecting and monitoring mutations in histiocytosis, detecting mutations in disease over time, and synthesis and enrichment of short nucleic acid sequences.

 

Wherever possible, we seek to protect our inventions by filing U.S. patents as well as foreign counterpart applications in selected other countries.  Because patent applications in the U.S.  are maintained in secrecy for at least eighteen months after the applications are filed, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first to make the inventions covered by each of our issued or pending patent applications, or that we were the first to file for protection of inventions set forth in such patent applications.  Our planned or potential products may be covered by third-party patents or other intellectual property rights, in which case continued development and marketing of the products would require a license.  Required licenses may not be available to us on commercially acceptable terms, if at all.  If we do not obtain these licenses, we could encounter delays in product introductions while we attempt to design around the patents, or could find that the development, manufacture or sale of products requiring such licenses are not possible.

 

We may rely on trade secrets to protect our technology.  Trade secrets are difficult to protect.  We seek to protect our proprietary technology and processes by entering into confidentiality agreements with our employees, certain consultants and contractors.  These agreements may be breached, we may not have adequate remedies for any breach and our trade secrets may otherwise become known or be independently discovered by competitors.  To the extent that our employees or our consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or resulting know-how and inventions.

 

Manufacturing and Distribution

 

In 2015, we plan to continue introducing our LDTs into the marketplace through our CLIA licensed and CAP accredited laboratory.  We source all reagents and consumables needed for our LDTs from third party vendors, and we currently do not manufacture reagents kits for use in our own lab, or to distribute to 3rd party labs.

 

We have established a sales and marketing organization to directly market our LDTs for oncogene mutations to end users in the oncology market segment.  As of December 31, 2014 we had five employees dedicated to the sales and marketing of our LDTs in the U.S. market.  We intend to add additional employees as needed to support the introduction of new LDTs planned for 2015.

 

Reimbursement

 

Medicare and other third-party payers will independently evaluate our technologies by, among other things, a cost/benefit analysis, assessing other available options and reviewing the published literature with respect to the results obtained from our clinical studies.  Currently, CPT codes are available for molecular testing which we believe will allow our technologies to be billed following

 

17


 

completion of a test which has been prescribed (ordered) by a physician for a patient.  We believe that the existence of current CPT codes with applicability to our tests will help facilitate Medicare’s reimbursement process, as well as that for third party insurance providers.

 

Reimbursement of our novel tests is a top priority, as physician and patient access to our technology is essential for widespread adoption of our products.  To gain initial reimbursement, our qualitative tests will be billed and reimbursed under established Tier I codes for their respective mutation (ie BRAF, KRAS, EGFR, etc.).  These are CPT codes from the American Medical Association (MoPath system), which should enable us to bill and obtain reimbursement for our tests without much issue.  As we develop our tests and demonstrate novel clinical utility in cancer monitoring, supported by our high analytical sensitivity, quantitative performance over a large dynamic range, and clinical experience, we will pursue a Not Otherwise Classified (“NOC”) code for billing and reimbursement.  Under these conditions, premium pricing is expected.  Over time, we intend to pursue permanent CPT codes unique to our cancer monitoring diagnostics once sufficient value is being assigned under the NOC code system.  We will engage with 3rd party payors including integrated healthcare networks and Medicare for reimbursement of our tests, with the goals of obtaining strong adoption of our tests, positive coverage decisions, and appropriate valuation of our tests on a widespread basis over time.  In 2015, we plan to continue developing clinical evidence around the utility and performance of our testing platform, and interacting with payors for the reimbursement of our commercially available urine-based cell-free nucleic acid diagnostics.

 

Government Regulation

 

Regulation by governmental authorities in the United States and other countries will be a significant factor in the development, production and marketing of any products that we may develop.  The nature and extent to which such regulation may apply will vary depending on the nature of any such products and the policy of each country.  Virtually all of our potential products will require regulatory allowance or approval by governmental agencies prior to commercialization, except for the LDTs as mentioned above.  We may submit and obtain FDA approval or clearance for some or all of our diagnostic products.  Pursuing and receiving FDA approval or clearance may be vital to maximizing our customer base and revenue potential for our numerous products.

 

FDA clearance for our products may be obtained through submission of a 510(k) statement of equivalency.  Another regulatory option, albeit more complicated and expensive, is to pursue FDA approval by submitting a Pre-Market Approval (“PMA”) application.  A 510(k) submission requires that we show equivalency of results in a clinical study with parallel comparison against an existing and FDA-recognized reference method (predicate device).

 

The FDA also regulates the sale of certain reagents, including our potential reagents, used by laboratories under the LDT rules to perform tests.  The FDA refers to such a reagent as an Analyte-Specific Reagent (“ASR”).  ASR’s generally do not require FDA pre-market approval or clearance if they are (i) sold to clinical laboratories certified under the Clinical Laboratory Improvement Act to perform high complexity testing and (ii) are labeled in accordance with FDA requirements, including a statement that their analytical and performance characteristics have not been established.  Prior to, or in lieu of FDA approval, we can sell our reagents to laboratories that meet the established criteria.  The FDA also regulates all promotional materials and specifically prohibits medical and efficacy claims.

 

Assuming that FDA approval or clearance is received for our products, a number of other FDA requirements would apply to our manufacturing and distribution efforts.  Medical device manufacturers must be registered and their products listed with the FDA, and certain adverse events, such as reagent failures, significant changes in quality control and other events requiring correction and/or replacement/removal of reagents must be documented and reported to the FDA.  The FDA also regulates product labeling, promotion, and in some cases, advertising, of medical devices.  As discussed above, we must comply with the FDA’s Quality System Regulation that establishes extensive requirements for design control, quality control, validation, and manufacturing.  Thus, even with FDA approval or clearance, we must continue to be diligent in maintaining compliance with these various regulations, as failure to do so can lead to enforcement action.  The FDA periodically inspects facilities to determine compliance with these and other requirements.

 

Competition

 

The medical diagnostic industry is characterized by rapidly evolving technology and intense competition.  Our competitors include medical diagnostic companies, most of which have financial, technical, and marketing resources significantly greater than our resources.  In addition, there are a significant number of biotechnology companies working on evolving technologies that may supplant our technology, or make it obsolete.  Academic institutions, government agencies, and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize products on their own or through joint venture.  We are aware of certain development projects for products to prevent or treat certain diseases targeted by us.  The existence of these potential products or other products or treatments of which we are not aware, or products or treatments that may be developed in the future, may adversely affect the marketability of our products or product candidates.

 

18


 

We believe that direct competition in the area of cell-free DNA detection and analysis is precluded by our growing patent estate.  However, there are other companies working in the area of cell-free nucleic acids and circulating tumor cell (“CTC”) collection and analysis in blood plasma that could compete in similar clinical areas - including disease detection, therapeutic response monitoring, and minimal disease detection.  These companies include Johnson & Johnson (Veridex), Qiagen, Quest, Labcorp, Biocept, Exact Sciences, Boreal Genomics, Sysmex-Inostics, and numerous other smaller companies both in the R&D and early commercial development phases.  However, we believe that the advantages of urine as a specimen (large amounts of cell-free nucleic acid material, ease of collection, continuous collection over time, and virtually no limit on sample size and frequency) position us favorably even among such competing companies.

 

Employees

 

As of February 27, 2015 we had 31 full-time employees.

 

ITEM 1A.  RISK FACTORS

 

An investment in our securities involves a high degree of risk.  An investor should carefully consider the risks described below as well as other information contained in this registration statement.  The risks and uncertainties described below are not the only ones facing us.  Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business operations.  If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our securities could decline, and an investor may lose all or part of his or her investment.

 

Risks Related to Our Business

 

We are a development stage company and we may never earn a profit.

 

We are a development stage company and have incurred losses since we were formed.  As of December 31, 2014, we have an accumulated total deficit of approximately $81.4 million.  For the fiscal year ended December 31, 2014, we had a net loss and comprehensive loss attributable to common stockholders of approximately $14.3 million.  To date, we have experienced negative cash flow from development of our cell-free molecular diagnostic technology.  We have not generated any revenue from operations except for licensing, milestone and royalty income and expect to incur substantial net losses for the foreseeable future to further develop and commercialize the cell-free molecular diagnostic technology.  We cannot predict the extent of these future net losses, or when we may attain profitability, if at all.  If we are unable to generate significant revenue from the cell-free molecular diagnostic technology or attain profitability, we will not be able to sustain operations.

 

Because of the numerous risks and uncertainties associated with developing and commercializing our cell-free molecular diagnostic technology and any future tests, we are unable to predict the extent of any future losses or when we will become profitable, if ever.  We may never become profitable and you may never receive a return on an investment in our common stock.  An investor in our common stock must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of tests in the medical diagnostic industry.  We may never successfully commercialize cell-free molecular diagnostic technology or any future tests, and our business may fail.

 

We will need to raise substantial additional capital to commercialize our cell-free molecular diagnostic technology, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.

 

As of February 27, 2015, our cash balance was approximately $46.0 million and our working capital was approximately $42.0 million.  Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development and commercialization of our current product candidates.  This amount will be sufficient to launch our products in the marketplace currently under development as LDTs.  We have historically relied upon private and public sales of our equity to fund our operations.  We currently have a $15.0 million loan payable.  When we seek additional capital, we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which we may not be able to do on favorable terms, or at all.  Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment.  If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of our product candidates, restrict our operations or obtain funds by entering into agreements on unattractive terms.

 

19


 

Our Loan and Security Agreement with Oxford Finance LLC, or Oxford, and Silicon Valley Bank, or SVB, contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay the outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation.  The occurrence of any of these events could cause a significant adverse impact on our business, prospects and stock price.

 

We have entered into a Loan and Security Agreement with Oxford and SVB for a term loan of $15 million.  The term loan is secured by all of our assets, other than intellectual property.  The Loan and Security Agreement contains affirmative and negative covenants that, among other things, restrict our ability to:

 

·                  incur additional indebtedness or guarantees;

 

·                  incur liens;

 

·                  make investments, loans and acquisitions;

 

·                  consolidate or merge;

 

·                  sell or assign any part of our business or property;

 

·                  engage in transactions with affiliates; and

 

·                  pay dividends.

 

The Loan and Security Agreement also includes events of default, including, among other things, payment defaults; breaches of representations, warranties or covenants; certain insolvency events; and the occurrence of certain material adverse changes.  Upon the occurrence of an event of default and following any cure periods (if applicable), a default interest rate of an additional 5.0% per annum may be applied to the outstanding loan balances, and the lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan and Security Agreement.

 

These terms of the Loan and Security Agreement could prevent us from taking certain actions without the consent of our lenders and, if an event of default should occur, we could be required to immediately repay the outstanding indebtedness.  If we are unable to repay this debt, the lenders would be able to foreclose on the secured collateral, including our cash accounts, and take other remedies permitted under the Loan and Security Agreement.  Even if we are able to repay the indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned.  The occurrence of any of these events could cause a significant adverse impact on our business, prospects and stock price.

 

Our ability to successfully commercialize our technology will depend largely upon the extent to which third-party payors reimburse our tests.

 

Physicians and patients may decide not to order our products unless third-party payors, such as managed care organizations as well as government payors such as Medicare and Medicaid pay a substantial portion of the test price.

 

Reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that our product candidates are:

 

·                                          not experimental or investigational;

 

·                                          effective;

 

·                                          medically necessary;

 

·                                          appropriate for the specific patient;

 

·                                          cost-effective;

 

·                                          supported by peer-reviewed publications; and

 

·                                          included in clinical practice guidelines.

 

20


 

Market acceptance, sales of products based upon the cell-free molecular diagnostic technology, and our profitability may depend on reimbursement policies and health care reform measures.  Several entities conduct technology assessments of medical tests and devices and provide the results of their assessments for informational purposes to other parties.  These assessments may be used by third-party payors and health care providers as grounds to deny coverage for a test or procedure.  The levels at which government authorities and third-party payors, such as private health insurers and health maintenance organizations, may reimburse the price patients pay for such products could affect whether we are able to commercialize our products.  Our product candidates may receive negative assessments that may impact our ability to receive reimbursement of the test.  Since each payor makes its own decision as to whether to establish a policy to reimburse our test, seeking these approvals may be a time-consuming and costly process.  We cannot be sure that reimbursement in the U.S. or elsewhere will be available for any of our products in the future.  If reimbursement is not available or is limited, we may not be able to commercialize our products.

 

If we are unable to obtain reimbursement approval from private payors and Medicare and Medicaid programs for our product candidates, or if the amount reimbursed is inadequate, our ability to generate revenues could be limited.  Even if we are being reimbursed, insurers may withdraw their coverage policies or cancel their contracts with us at any time, stop paying for our test or reduce the payment rate for our test, which would reduce our revenue.  Moreover, we may depend upon a limited number of third-party payors for a significant portion of our test revenues and if these or other third-party payors stop providing reimbursement or decrease the amount of reimbursement for our test, our revenues could decline.

 

Our business could be adversely impacted by adoption of new coding for molecular genetic tests.

 

If our technology were commercially available today, reimbursement would be available under the current procedural terminology, or CPT codes, for molecular-based testing.  The American Medical Association CPT® Editorial Panel is continuing its process of establishing analyte specific billing codes to replace codes that describe procedures used in performing molecular testing.  The adoption of analyte specific codes will allow payers to better determine tests being performed.  This could lead to limited coverage decisions or payment denials.

 

The commercial success of our product candidates will depend upon the degree of market acceptance of these products among physicians, patients, health care payors and the medical community and on our ability to successfully market our product candidates.

 

The use of the cell-free molecular diagnostic technology has never been commercialized for any indication.  Even if approved for sale by the appropriate regulatory authorities, physicians may not order diagnostic tests based upon the cell-free molecular diagnostic technology, in which event we may be unable to generate significant revenue or become profitable.  Acceptance of the cell-free molecular diagnostic technology will depend on a number of factors including:

 

·                                          acceptance of products based upon the cell-free molecular diagnostic technology by physicians and patients;

 

·                                          successful integration into clinical practice;

 

·                                          adequate reimbursement by third parties;

 

·                                          cost effectiveness;

 

·                                          potential advantages over alternative treatments; and

 

·                                          relative convenience and ease of administration.

 

We will need to make leading physicians aware of the benefits of tests using our technology through published papers, presentations at scientific conferences and favorable results from our clinical studies.  In addition, we will need to gain support from thought leaders who believe that testing a urine specimen for these molecular markers will provide superior performance.  Ideally, we will need these individuals to publish support papers and articles which will be necessary to gain acceptance of our products.  There is

 

21


 

no guarantee that we will be able to obtain this support.  Our failure to be successful in these efforts would make it difficult for us to convince medical practitioners to order cell-free molecular diagnostic testsfor their patients and consequently our revenue and profitability will be limited.

 

We currently have limited experience in marketing products.  If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.

 

We have limited experience in marketing products.  We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time.  We will have to compete with other molecular diagnostic companies to recruit, hire, train and retain marketing and sales personnel.

 

If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our product candidates or future products, however, we may not be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces.  Any revenue we receive will depend upon the efforts of such third parties, which may not be successful.  We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves.  We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.

 

If our potential medical diagnostic tests are unable to compete effectively with current and future medical diagnostic tests targeting similar markets as our product candidates, our commercial opportunities will be reduced or eliminated.

 

The medical diagnostic industry is intensely competitive and characterized by rapid technological progress.  In each of our potential product areas, we face significant competition from large biotechnology, medical diagnostic and other companies.  The technologies associated with the molecular diagnostics industry are evolving rapidly and there is intense competition within such industry.  Certain molecular diagnostics companies have established technologies that may be competitive to our product candidates and any future tests that we develop.  Some of these tests may use different approaches or means to obtain diagnostic results, which could be more effective or less expensive than our tests for similar indications.  Moreover, these and other future competitors have or may have considerably greater resources than we do in terms of technology, sales, marketing, commercialization and capital resources.  These competitors may have substantial advantages over us in terms of research and development expertise, experience in clinical studies, experience in regulatory issues, brand name exposure and expertise in sales and marketing as well as in operating central laboratory services.  Many of these organizations have financial, marketing and human resources greater than ours; therefore, there can be no assurance that we can successfully compete with present or potential competitors or that such competition will not have a materially adverse effect on our business, financial position or results of operations.

 

Since the cell-free molecular diagnostic technology is under development, we cannot predict the relative competitive position of any product based upon the cell-free molecular diagnostic technology.  However, we expect that the following factors will determine our ability to compete effectively: safety and efficacy; product price; turnaround time; ease of administration; performance; reimbursement; and marketing and sales capability.

 

We believe that many of our competitors spend significantly more on research and development-related activities than we do.  Our competitors may discover new diagnostic tools or develop existing technologies to compete with the cell-free molecular diagnostic technology.  Our commercial opportunities will be reduced or eliminated if these competing products are more effective, are more convenient or are less expensive than our product candidates.

 

Our failure to obtain human urine samples from medical institutions for our clinical studies will adversely impact the development of our cell-free molecular diagnostic technology.

 

We will need to establish relationships with medical institutions in order to obtain urine specimens from patients who are testing positive for a relevant infectious disease or from patients that have been diagnosed with solid tumors.  We must obtain a sufficient number in order to statistically prove the equivalency of the performance of our assays versus existing assays that are already on the market.

 

Cell-free nucleic acids in urine are stable at room temperature for extended periods of time with the addition of a simple preservative.  Successful implementation of our cell-free nucleic acid technology in molecular testing is closely linked to the availability of techniques and procedures for cell-free nucleic acid preservation, purification, and analysis.  In the event urine specimens are not adequately preserved, improperly stored, or contaminated, we may be delayed in pursuing our clinical studies, and we may incur additional costs associated with procuring new human urine samples.

 

22


 

If our clinical studies do not prove the superiority of our technologies and demonstrate clinical utility of our technology, we may never sell our product candidates and services.

 

The results of our clinical studies may not show that tests using our cell-free molecular diagnostic technology are superior to existing testing methods and demonstrate clinical utility.  In that event, we will have to devote significant financial and other resources to further research and development, and commercialization of tests using our technologies will be delayed or may never occur.  Our earlier clinical studies were small and included samples from high-risk patients.  The results from these earlier studies may not be representative of the results we obtain from any future studies, including our next two clinical studies, which will include substantially more samples and a larger percentage of normal-risk patients.

 

We have limited experience in establishing strong business relationships with leading clinical reference laboratories to perform cell-free molecular diagnostic tests using our technologies which could limit our revenue growth.

 

A key step in our strategy is to sell diagnostic products that use our proprietary technologies to leading clinical reference laboratories that will perform cell-free molecular diagnostic tests.  We have limited experience in establishing these business relationships.  If we are unable to establish and maintain these business relationships, we will have limited ability to obtain revenues beyond the revenue we can generate from our limited in-house capacity to process tests.

 

We depend upon our officers, and if we are not able to retain them or recruit additional qualified personnel, the commercialization of our product candidates and any future tests that we develop could be delayed or negatively impacted.

 

Our success is largely dependent upon the continued contributions of our officers such as Dr.  Antonius Schuh, Chief Executive Officer.  Our success also depends in part on our ability to attract and retain highly qualified scientific, commercial and administrative personnel.  In order to pursue our test development and commercialization strategies, we will need to attract and hire, or engage as consultants, additional personnel with specialized experience in a number of disciplines, including assay development, bioinformatics and statistics, laboratory and clinical operations, clinical affairs and studies, government regulation, sales and marketing, billing and reimbursement and information systems.  There is intense competition for personnel in the fields in which we operate.  If we are unable to attract new employees and retain existing employees, the development and commercialization of our product candidates and any future tests could be delayed or negatively impacted.

 

We will need to increase the size of our organization, and we may experience difficulties in managing growth.

 

We are a small company with 31 full-time employees as of February 27, 2015.  Future growth will impose significant added responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel.  We may increase the number of employees in the future depending on the progress of our development of cell-free molecular diagnostic technology.  Our future financial performance and our ability to commercialize cell-free molecular diagnostic testsand to compete effectively will depend, in part, on our ability to manage any future growth effectively.  To that end, we must be able to:

 

·                                          manage our clinical studies effectively;

 

·                                          integrate additional management, administrative, manufacturing and regulatory personnel;

 

·                                          maintain sufficient administrative, accounting and management information systems and controls; and

 

·                                          hire and train additional qualified personnel.

 

We may not be able to accomplish these tasks, and our failure to accomplish any of them could harm our financial results.

 

If we do not receive regulatory approvals, we may not be able to develop and commercialize our cell-free molecular diagnostic technology.

 

We may need FDA approval to market products based on the cell-free molecular diagnostic technology for diagnostic uses in the United States and approvals from foreign regulatory authorities to market products on the cell-free molecular diagnostic technology outside the United States.  We have not yet filed an application with the FDA to obtain approval to market any of our proposed products.  If we fail to obtain regulatory approval for the marketing of products based on the cell-free molecular diagnostic technology, we will be unable to sell such product candidates and will not be able to sustain operations.

 

23


 

We believe the estimated molecular diagnostics market for many diseases in Europe is approximately as large as that of the United States.  If we seek to market products or services such as a urine-based HPV HR Detection test in Europe, we need to receive a CE Mark.  If we do not obtain a CE Mark for our urine-based HPV HR Detection test, we will be unable to sell this product in Europe and countries that recognize the CE Mark.

 

The regulatory review and approval process, which may include evaluation of preclinical studies and clinical studies of product candidates based on the cell-free molecular diagnostic technology, as well as the evaluation of manufacturing processes and contract manufacturers’ facilities, is lengthy, expensive and uncertain.  Securing regulatory approval for products based upon the cell-free molecular diagnostic technology may require the submission of extensive preclinical and clinical data and supporting information to regulatory authorities to establish such product candidates’ safety and effectiveness for each indication.  We have limited experience in filing and pursuing applications necessary to gain regulatory approvals.

 

Regulatory authorities generally have substantial discretion in the approval process and may either refuse to accept an application, or may decide after review of an application that the data submitted is insufficient to allow approval of any product based upon the cell-free molecular diagnostic technology.  If regulatory authorities do not accept or approve our applications, they may require that we conduct additional clinical, preclinical or manufacturing studies and submit that data before regulatory authorities will reconsider such application.  We may need to expend substantial resources to conduct further studies to obtain data that regulatory authorities believe is sufficient.  Depending on the extent of these studies, approval of applications may be delayed by several years, or may require us to expend more resources than we may have available.  It is also possible that additional studies may not suffice to make applications approvable.  If any of these outcomes occur, we may be forced to abandon our applications for approval, which might cause us to cease operations.

 

If we do not comply with governmental regulations applicable to our CLIA-certified laboratory, we may not be able to continue our operations.

 

The establishment and operation of our laboratory is subject to regulation by numerous federal, state and local governmental authorities in the United States.  The laboratory holds a CLIA certificate of compliance and is licensed by every state (other than the State of New York) and the District of Columbia, as required, which enables us to provide testing services to residents of almost every state.  Failure to comply with state regulations or changes in state regulatory requirements could result in a substantial curtailment or even prohibition of the operations of our laboratory and could have a material adverse effect on our business.  CLIA is a federal law that regulates clinical laboratories that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention or treatment of disease.  To renew CLIA certification, laboratories are subject to survey and inspection every two years.  Moreover, CLIA inspectors may make unannounced inspections of these laboratories.  If we were to lose our CLIA certification or our state licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able to continue our testing operations which would have a material adverse effect on our business.  Potential sanctions for violations of these statutes and regulations also include significant fines, the suspension or loss of various licenses, certificates and authorizations, or product suspension or recalls.

 

Changes in healthcare policy could subject us to additional regulatory requirements that may delay the commercialization of our tests and increase our costs.

 

The U.S. government and other governments have shown significant interest in pursuing healthcare reform.  Any government-adopted reform measures could adversely impact the pricing of our diagnostic products and tests in the United States or internationally and the amount of reimbursement available from governmental agencies or other third party payors.  The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability to set prices for our products and services which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.

 

New laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to healthcare availability, methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise our research and development programs.  The pricing and reimbursement environment may change in the future and become more challenging due to several reasons, including policies advanced by the current executive

 

24


 

administration in the United States, new healthcare legislation or fiscal challenges faced by government health administration authorities.  Specifically, in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably.

 

For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, (‘ PPACA”) has substantially changed the way health care is financed by both government health plans and private insurers.  The PPACA contains a number of provisions that are expected to impact our business and operations in ways that may negatively affect our potential revenues in the future.  While it is too early to predict all the specific effects the PPACA or any future healthcare reform legislation will have on our business, they could have a material adverse effect on our business and financial condition.

 

In September 2007, the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority, including the authority to require post-marketing studies and clinical studies, labeling changes based on new safety information, and compliance with risk evaluations and mitigation strategies approved by the FDA.  The FDA’s exercise of this authority could result in delays or increased costs during product development, clinical studies and regulatory review, increased costs to assure compliance with post-approval regulatory requirements, and potential restrictions on the sale and/or distribution of approved products.

 

If the FDA were to begin regulating LDTs, or if we decide to market our products as a medical device rather than a LDT, we could be forced to delay commercialization of our current product candidates, experience significant delays in commercializing any future tests, incur substantial costs and time delays associated with meeting requirements for pre-market clearance or approval and/or experience decreased demand for or reimbursement of our test.

 

We intend to develop products that are considered to be medical devices and are subject to federal regulations including those covering Quality System Regulations (“QSR”) and Medical Device Reporting (“MDR”).

 

The QSR includes requirements related to the methods used in and the facilities and controls used for designing, purchasing, manufacturing, packaging, labeling, storing, installing and servicing of medical devices.  Manufacturing facilities undergo FDA inspections to assure compliance with the QS requirements.  The quality systems for FDA-regulated products are known as current good manufacturing practices (“cGMPs”) as described in the Code of Federal Regulations, part 820 (21 CFR part 820).  Among the cGMP requirements are those requiring manufacturers to have sufficient appropriate personnel to implement required design controls and other portions of the QSR guidelines.

 

Design controls include procedures that describe the product design requirements (design goals) and compare actual output to these requirements, including documented Design Reviews.  Required Design History Files (“DHFs”) for each device will document the records necessary to demonstrate that the design was developed in accordance with the approved design plan and the requirements of the QSRs.

 

QSRs also include stipulation for control of all documents used in design and production, including history of any changes made.  Production and process controls include stipulations to ensure products are in fact produced as specified by controlled documents resulting from the controlled design phase, using products and services purchased under controlled purchasing procedures.

 

Incidents in which a device may have caused or contributed to a death or serious injury must to be reported to FDA under the MDR program.  In addition, certain malfunctions must also be reported.  The MDR regulation is a mechanism for FDA and manufacturers to identify and monitor significant adverse events involving medical devices.  The goals of the regulation are to detect and correct problems in a timely manner.

 

We may be required to participate in MDR through two routes.  As a manufacturer of products for sale within the United States, we would be required to report to the FDA any deaths, serious injuries and malfunctions, and events requiring remedial action to prevent an unreasonable risk of substantial harm to the public health.  Our CLIA lab offering services for sale is already currently required to report suspected medical device related deaths to both the FDA and the relevant manufacturers of products we purchase and use.

 

Clinical laboratory tests like our current product offerings are regulated in the United States under CLIA as well as by applicable state laws.  Diagnostic kits that are sold and distributed through interstate commerce are regulated as medical devices by the FDA.  Clinical laboratory tests that are developed and validated by a laboratory for its own use are called LDTs.  Most LDTs currently are not subject to FDA regulation, although reagents or software provided by third parties and used to perform LDTs may be subject to regulation.  We expect that, upon the commencement of commercialization, our product candidates will be an LDT and not

 

25


 

a diagnostic kit.  As a result, we believe that our product candidates should not be subject to regulation under current FDA policies, however there is no assurance that it will not be subject to such regulation in the future.  Further, if we decide to market our products as a diagnostic kit rather than a LDT, our products would be subject to FDA regulation as a medical device.  The container we expect to provide for collection and transport of tumor samples from a pathology laboratory to our clinical reference laboratory may be a medical device subject to FDA regulation and while we expect that it will be exempt from pre-market review by FDA, there is no certainty in that respect.

 

We cannot provide any assurance that FDA regulation, including pre-market review, will not be required in the future for our LDT product candidates, either through new policies adopted by the FDA or new legislation enacted by Congress.  It is possible that legislation will be enacted into law and may result in increased regulatory burdens for us to offer or continue to offer our product as a clinical laboratory service.

 

If pre-market review is required, our business could be negatively impacted until such review is completed and clearance to market or approval is obtained, and the FDA could require that we stop selling.  If pre-market review of our LDTs is required by the FDA, there can be no assurance that our product offerings will be cleared or approved on a timely basis, if at all.  Ongoing compliance with FDA regulations, such as the Quality System Regulation and Medical Device Reporting, would increase the cost of conducting our business, and subject us to inspection by the FDA and to the requirements of the FDA and penalties for failure to comply with these requirements.  We may also decide voluntarily to pursue FDA pre-market review of our product offerings if we determine that doing so would be appropriate.  Some competitors may develop competing tests cleared for marketing by the FDA.  There may be a marketing differentiation or perception that an FDA-cleared test is more desirable than our product offerings, and that could discourage adoption and reimbursement of our test.

 

We may be required to conduct clinical studies and we may find it difficult to enroll patients in such clinical studies, which could delay or prevent clinical studies of our product candidates.

 

If the FDA decides to regulate our LDTs, it may require that we conduct extensive pre-market clinical studies prior to submitting a regulatory application for commercial sales.  If we are required to conduct pre-market clinical studies, whether using retrospectively collected and banked samples or prospectively collected samples, delays in the commencement or completion of clinical studies could significantly increase our test development costs and delay commercialization.  Many of the factors that may cause or lead to a delay in the commencement or completion of clinical studies may also ultimately lead to delay or denial of regulatory clearance or approval.  The commencement and completion of clinical trials may be delayed by factors such as unforeseen safety issues, lack of effectiveness during clinical trials, inability to monitor patients adequately during or after testing, and slower than expected rates of patient recruitment.

 

Insufficient patient enrollment is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.  We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical studies, which might increase the cost of the studies.  We will also depend on clinical investigators, medical institutions and contract research organizations to perform the studies properly.  If these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, FDA requirements or for other reasons, our clinical studies may have to be extended, delayed or terminated.  Many of these factors would be beyond our control.  We may not be able to enter into replacement arrangements without undue delays or considerable expenditures.  If there are delays in testing as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our test.  In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all.  Each of these outcomes would harm our ability to market our test, or to become profitable.

 

In addition, in the event we are required to conduct clinical trials, it may be very expensive and difficult to design and implement due to the rigorous regulatory requirements to which clinical trials are subjected.  Clinical trials are also time consuming, and we would be unable to provide certainty regarding when we might complete the clinical trial process.

 

If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.

 

We rely on patent protection as well as a combination of trademark, copyright and trade secret protection, and other contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage.  If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies and they will be able to compete more effectively against us.

 

26


 

Our currently pending or future patent applications may not result in issued patents and any patents issued to us may be challenged, invalidated or held unenforceable.  We may not be successful in defending challenges made in connection with our patents and patent applications.

 

In addition to our patents, we rely on contractual restrictions to protect our proprietary technology.  We require our employees and third parties to sign confidentiality agreements and employees to also sign agreements assigning to us all intellectual property arising from their work for us.  Nevertheless, we cannot guarantee that these measures will be effective in protecting our intellectual property rights.

 

The patents issued to us may not be broad enough to provide any meaningful protection one or more of our competitors may develop more effective technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around our proprietary technologies.

 

If we are not able to protect our proprietary technology, trade secrets and know-how, our competitors may use our inventions to develop competing products.  We own certain patents relating to the cell-free molecular diagnostic technology.  However, these patents may not protect us against our competitors, and patent litigation is very expensive.  We may not have sufficient cash available to pursue any patent litigation to its conclusion because currently we do not generate revenues other than licensing, milestone and royalty income.

 

We cannot rely solely on our current patents to be successful.  The standards that the U.S.  Patent and Trademark Office and foreign patent office’s use to grant patents, and the standards that U.S. and foreign courts use to interpret patents, are not the same and are not always applied predictably or uniformly and can change, particularly as new technologies develop.  As such, the degree of patent protection obtained in the U.S. may differ substantially from that obtained in various foreign countries.  In some instances, patents have been issued in the U.S. while substantially less or no protection has been obtained in Europe or other countries.

 

We cannot be certain of the level of protection, if any, which will be provided by our patents if we attempt to enforce them and they are challenged in court where our competitors may raise defenses such as invalidity, unenforceability or possession of a valid license.  In addition, the type and extent of any patent claims that may be issued to us in the future are uncertain.  Any patents which are issued may not contain claims that will permit us to stop competitors from using similar technology.

 

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our cell-free molecular diagnostic technology.

 

Third parties may challenge the validity of our patents and other intellectual property rights, resulting in costly litigation or other time-consuming and expensive proceedings, which could deprive us of valuable rights.  If we become involved in any intellectual property litigation, interference or other judicial or administrative proceedings, we will incur substantial expenses and the diversion of financial resources and technical and management personnel.  An adverse determination may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all.  Further, if such claims are proven valid, through litigation or otherwise, we may be required to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the affected products and intellectual property rights.  In our European patent that covers using microRNAs to detect in vivo cell death, an anonymous third party has recently filed an opposition against the claims in the patent.  Oppositions against the patentability of claims in a European patent are considered by a panel of examiners at the European Patent Office, and we are considering the full range of options available for defending against the opposition.

 

Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours.  Any such patent application may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies.  There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our products or processes.  If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the United States Patent and Trademark Office to determine priority of invention in the United States.  The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions.  In addition, we cannot assure you that we would prevail in any of these suits or that the damages or other remedies if any, awarded against us would not be substantial.  Claims of intellectual property infringement may require us to enter into

 

27


 

royalty or license agreements with third parties that may not be available on acceptable terms, if at all.  We may also become subject to injunctions against the further development and use of our technology, which would have a material adverse effect on our business, financial condition and results of operations.

 

Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.  In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

 

The testing, manufacturing and marketing of medical diagnostic devices entails an inherent risk of product liability and personal injury claims.

 

To date, we have experienced no product liability or personal injury claims, but any such claims arising in the future could have a material adverse effect on our business, financial condition and results of operations.  Potential product liability or personal injury claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of our policy or limited by other claims under our umbrella insurance policy.  Additionally, our existing insurance may not be renewed by us at a cost and level of coverage comparable to that presently in effect, if at all.  In the event that we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, such claim could have a material adverse effect on our cash flow and thus potentially a materially adverse effect on our business, financial condition and results of operations.

 

All of our diagnostic technology and services are performed at a single laboratory, and in the event this facility was to be affected by a termination of the lease or a man-made or natural disaster, our operations could be severely impaired.

 

We are performing all of our diagnostic services in our laboratory located in San Diego, California.  Despite precautions taken by us, any future natural or man-made disaster at this laboratory, such as a fire, earthquake or terrorist activity, could cause substantial delays in our operations, damage or destroy our equipment and urine samples or cause us to incur additional expenses.

 

In addition, we are leasing the facilities where our lab operates.  We are currently in compliance with all and any lease obligations, but should the lease terminate for any reason, or if at any time the lab is moved due to conditions outside our control, it could cause substantial delay in our diagnostics operations, damage or destroy our equipment and biological samples or cause us to incur additional expenses.  In the event of an extended shutdown of our laboratory, we may be unable to perform our services in a timely manner or at all and therefore would be unable to operate in a commercially competitive manner.  This could harm our operating results and financial condition.

 

Further, if we have to use a substitute laboratory while our facility was shut down, we could only use another facility with established state licensure and accreditation under CLIA.  We may not be able to find another CLIA-certified facility and comply with applicable procedures, or find any such laboratory that would be willing to perform the tests for us on commercially reasonable terms.  Additionally, any new laboratory opened by us would be subject to certification under CLIA and licensure by various states, which would take a significant amount of time and result in delays in our ability to continue our personalized medicine services operations.

 

Risks Related to Ownership of our Common Stock

 

If we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.

 

If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to disclosure controls and procedures, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.  Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud.  If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly.  In addition, we cannot be certain that additional material weaknesses or significant deficiencies in our internal controls will not be discovered in the future.

 

The rights of the holders of common stock may be impaired by the potential issuance of preferred stock.

 

Our certificate of incorporation gives our board of directors the right to create new series of preferred stock.  As a result, the board of directors may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights which could adversely affect the voting power and equity interest of the holders of common stock.  Preferred stock, which could be issued with the right to more than one vote per share, could be utilized as a method of discouraging, delaying or preventing a

 

28


 

change of control.  The possible impact on takeover attempts could adversely affect the price of our common stock.  Although we have no present intention to issue any additional shares of preferred stock or to create any new series of preferred stock and the certificate of designation relating to the Series A Convertible Preferred Stock restricts our ability to issue additional series of preferred stock, we may issue such shares in the future.  Without the consent of the holders of the outstanding shares of Series A Convertible Preferred Stock we may not alter or change adversely the rights of the holders of the Series A Convertible Preferred Stock or increase the number of authorized shares of Series A Convertible Preferred Stock, create a class of stock which is senior to or on a parity with the Series A Convertible Preferred Stock, amend our certificate of incorporation in breach of these provisions or agree to any of the foregoing.

 

Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.

 

The market price of our ordinary shares historically has been, and we expect will continue to be, subject to significant fluctuations over short periods of time.  For example, the closing price of our common stock during the past 52-weeks has ranged from a low of $3.00 to a high of $6.74.  These fluctuations may be due to various factors, many of which are beyond our control, including:

 

·                                          technological innovations or new products and services by us or our competitors;

 

·                                          clinical trial results relating to our tests or those of our competitors;

 

·              announcements or press releases relating to the industry or to our own business or prospects;

 

·                                          coverage and reimbursement decisions by third party payors, such as Medicare and other managed care organizations;

 

·                                          regulation and oversight of our product candidates and services, including by the FDA, CMS and comparable ex-U.S. agency;

 

·                                          FDA, CMS and comparable ex-U.S. agency regulation and oversight of our products and services;

 

·                                          the establishment of partnerships with clinical reference laboratories;

 

·                                          health care legislation;

 

·                                          intellectual property disputes;

 

·                                          additions or departures of key personnel;

 

·                                          sales of our common stock;

 

·                                          our ability to integrate operations, technology, products and services;

 

·                                          our ability to execute our business plan;

 

·                                          operating results below expectations;

 

·                                          loss of any strategic relationship;

 

·                                          industry developments;

 

·                                          economic and other external factors; and

 

·                                          period-to-period fluctuations in our financial results.

 

In addition, market fluctuations, as well as general political and economic conditions could adversely affect the market price of our securities.  Because we are a development stage company with no revenue from operations to date, other than licensing, milestone and royalty income, you should consider any one of these factors to be material.  Our stock price may fluctuate widely as a result of any of the foregoing.

 

29


 

Because certain of our stockholders control a significant number of shares of our common stock, they may have effective control over actions requiring stockholder approval.

 

As of February 27, 2015, our directors, executive officers and principal stockholders, and their respective affiliates, beneficially own approximately 29.3% of our outstanding shares of common stock.  As a result, these stockholders, acting together, would have the ability to control the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets.  In addition, these stockholders, acting together, would have the ability to control the management and affairs of our company.  Accordingly, this concentration of ownership might harm the market price of our common stock by:

 

·                                          delaying, deferring or preventing a change in corporate control;

 

·                                          impeding a merger, consolidation, takeover or other business combination involving us; or

 

·                                          discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

 

We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future.  Any return on investment may be limited to the value of our common stock.

 

No cash dividends have been paid on our common stock.  We expect that any income received from operations will be devoted to our future operations and growth.  We do not expect to pay cash dividends on our common stock in the near future.  Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors as our board of directors may consider relevant.  If we do not pay dividends, our common stock may be less valuable because a return on an investor’s investment will only occur if our stock price appreciates.  In addition, under the terms of our Loan and Security Agreement, we are precluded from paying cash dividends without the prior written consent of the lenders, and the terms of the Series A Convertible Preferred Stock prohibit us from paying dividends to the holders of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid.  Investors in our common stock should not rely on an investment in our company if they require dividend income.

 

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

 

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.  We do not currently have and may never obtain research coverage by industry or financial analysts.  If no or few analysts commence coverage of us, the trading price of our stock would likely decrease.  Even if we do obtain analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline.  If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

Delaware law and our corporate charter and bylaws will contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.

 

Provisions in our certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control or changes in our management.  For example, our board of directors have the authority to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the powers, preferences and rights of each series without stockholder approval.  The ability to issue preferred stock could discourage unsolicited acquisition proposals or make it more difficult for a third party to gain control of our company, or otherwise could adversely affect the market price of our common stock.  Our bylaws require that any stockholder proposals or nominations for election to our board of directors must meet specific advance notice requirements and procedures, which make it more difficult for our stockholders to make proposals or director nominations.

 

Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law.  These provisions may prohibit or restrict large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us.  These provisions in our certificate of incorporation and bylaws and under Delaware law could discourage potential takeover attempts and could reduce the price that investors might be willing to pay for shares of our common stock in the future and result in our market price being lower than it would without these provisions.

 

30


 

A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.

 

Our common stock is traded on The NASDAQ Capital Market and, despite certain increases of trading volume from time to time, there have been periods when it could be considered “thinly-traded,” meaning that the number of persons interested in purchasing our common stock at or near bid prices at any given time may be relatively small or non-existent.  Finance transactions resulting in a large amount of newly issued shares that become readily tradable, or other events that cause current stockholders to sell shares, could place downward pressure on the trading price of our stock.  In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock.

 

If our stockholders sell, or the market perceives that our stockholders intend to sell for various reasons, including the ending of restriction on resale, substantial amounts of our common stock in the public market, including shares issued upon the exercise of outstanding options or warrants, the market price of our common stock could fall.  Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.  We may become involved in securities class action litigation that could divert management’s attention and harm our business.

 

We may be subject to stockholder litigation, thereby diverting our resources that may have a material effect on our profitability and results of operations.

 

As discussed in the preceding risk factors, the market for our common shares is characterized by significant price volatility, and we expect that our share price will continue to be at least as volatile for the indefinite future.  In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities.  In addition, many companies have actions brought against them by stockholders relating to past transactions or other matters Any such actions could give rise to substantial damages, and thereby have a material adverse effect on our consolidated financial position, liquidity, or results of operations.  Even if an action is not resolved against us, the uncertainty and expense associated with stockholder actions could harm our business, financial condition and reputation.  Litigation can be costly, time-consuming and disruptive to business operations.  The defense of lawsuits could also result in diversion of our management’s time and attention away from business operations, which could harm our business.

 

ITEM 1B.  UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2.  PROPERTIES

 

We lease approximately 13,000 square feet of laboratory and office space in our headquarters in San Diego, California under a lease that expires in December 2017.  We believe that our current facilities are adequate for our needs for the immediate future and that, should it be needed, suitable additional space will be available to accommodate expansion of our operations on commercially reasonable terms.

 

ITEM 3.  LEGAL PROCEEDINGS

 

From time to time, we may become involved in litigation relating to claims arising out of its operations in the normal course of business.  We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on us.

 

ITEM 4.  MINE SAFETY DISCLOSURES

 

Not applicable.

 

31


 

PART II

 

ITEM 5.  MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock has been traded on The NASDAQ Capital Market (“NASDAQ”) under the symbol “TROV” since May 29, 2012.

 

Our common stock was traded over the counter on the pink sheets under the symbol TROV.PK from June 15, 2007 until May 30, 2012.  From July 27, 2004 until June 14, 2007, our common stock was quoted on the OTC Bulletin Board under the symbol “XNOM.OB”.  Prior to July 27, 2004, our common stock was quoted on the OTC Bulletin Board under the symbol “UKAR.OB” but never traded.  The following table sets forth the range of high and low sales prices for our common stock on NASDAQ for the periods indicated since January 1, 2013.

 

The closing price of our common stock on NASDAQ on February 27, 2015 was $5.65 per share.

 

Fiscal 2014

 

High

 

Low

 

Fourth Quarter

 

$

5.17

 

$

4.01

 

Third Quarter

 

$

6.30

 

$

3.00

 

Second Quarter

 

$

6.01

 

$

3.50

 

First Quarter

 

$

6.74

 

$

5.13

 

 

Fiscal 2013

 

High

 

Low

 

Fourth Quarter

 

$

8.50

 

$

4.81

 

Third Quarter

 

$

10.27

 

$

6.61

 

Second Quarter

 

$

7.23

 

$

5.27

 

First Quarter

 

$

8.96

 

$

5.09

 

 

Number of Stockholders

 

As of February 27, 2015, we had approximately 65 stockholders of record of our common stock.

 

Dividend Policy

 

Historically, we have not paid any dividends to the holders of our common stock and we do not expect to pay any such dividends in the foreseeable future as we expect to retain our future earnings for use in the operation and expansion of our business.  Pursuant to the terms of the Series A Convertible Preferred Stock, dividends cannot be paid to the holders of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid.

 

32


 

Corporate Performance Graph

 

COMPARISON OF CUMULATIVE TOTAL RETURN

Among the NASDAQ Stock Market (U.S.),

The NASDAQ Pharmaceutical Index, the Russell 3000 Index

and Trovagene, Inc.

 

 

Equity Compensation Plan Information

 

The following table summarizes information about our equity compensation plans as of December 31, 2014:

 

Plan Category

 

Number of
Shares of
Common
Stock to be
Issued upon
Exercise of
Outstanding
Options

 

Weighted-
Average Exercise
Price of
Outstanding
Options

 

Number of
Options
Remaining
Available for
Future Issuance
Under
Equity
Compensation
Plans
(excluding
securities
reflected in
column (a))

 

 

 

(a)

 

(b)

 

(c)

 

Equity Compensation Plans Approved by Stockholders

 

4,784,306

 

$

4.74

 

1,371,832

 

Equity Compensation Plans Not Approved by Stockholders

 

129,166

 

$

3.15

 

—

 

Total

 

4,913,472

 

$

4.66

 

1,371,832

 

 

33


 

ITEM 6. SELECTED FINANCIAL DATA

 

The following table sets forth our selected consolidated financial data and has been derived from our audited consolidated financial statements. Consolidated balance sheets as of December 31, 2014 and 2013, as well as consolidated statements of operations for the years ended December 31, 2014, 2013 and 2012, and the reports thereon are included elsewhere in this Annual Report on Form 10-K. The information should be read in conjunction with our audited consolidated financial statements and the notes to such statements, included below in Item 8, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7. Historical results are not necessarily indicative of the results to be expected in the future.

 

 

 

Year ended December 31,

 

 

 

2014

 

2013

 

2012

 

2011

 

2010

 

 

 

(in thousands, except for share and per share data)

 

Consolidated Statement of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

280

 

$

259

 

$

450

 

$

258

 

$

266

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs and Expenses:

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

15

 

—

 

—

 

—

 

—

 

Research and development

 

6,665

 

3,948

 

1,920

 

911

 

1,024

 

Purchased in-process research and development

 

—

 

—

 

—

 

—

 

2,667

 

Selling and marketing

 

2,735

 

1,530

 

506

 

—

 

—

 

General and administrative

 

5,810

 

5,472

 

2,873

 

2,324

 

1,954

 

Total operating expenses

 

15,225

 

10,950

 

5,299

 

3,235

 

5,645

 

Loss from operations

 

(14,945

)

(10,691

)

(4,849

)

(2,977

)

(5,379

)

Gain (loss) on disposal of equipment

 

25

 

(23

)

4

 

—

 

—

 

Net interest (expense) income

 

(831

)

(13

)

—

 

(56

)

(337

)

Gain (loss) on change in fair value of derivative instruments-warrants

 

1,426

 

(1,084

)

(6,271

)

171

 

267

 

Gain on extinguishment of debt

 

—

 

—

 

—

 

623

 

—

 

Net loss and comprehensive loss

 

(14,325

)

(11,811

)

(11,566

)

(2,239

)

(5,449

)

Preferred stock dividend

 

(23

)

(30

)

(38

)

(38

)

(38

)

Net loss and comprehensive loss attributable to common stockholders

 

(14,348

)

(11,841

)

(11,604

)

(2,277

)

(5,487

)

 

Net loss per common share - basic

 

$

(0.76

)

$

(0.70

)

$

(0.89

)

$

(0.23

)

$

(0.77

)

Net loss per common share - diluted

 

$

(0.88

)

$

(0.70

)

$

(0.89

)

$

(0.23

)

$

(0.77

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - basic*

 

18,904,280

 

16,978,212

 

13,066,600

*

9,711,519

*

7,158,791

*

Weighted average shares outstanding - diluted

 

19,071,112

 

16,978,212

 

13,066,600

*

9,711,519

*

7,158,791

*

 

(*)    Weighted average shares outstanding reflects retroactive change of a one for 6 (1:6) reverse stock split effective on May 29, 2012

 

 

 

December 31,

 

 

 

2014

 

2013

 

2012

 

2011

 

2010

 

 

 

($ in thousands)

 

Consolidated Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

27,294

 

$

25,837

 

$

10,820

 

$

700

 

$

59

 

Working capital

 

23,232

 

24,060

 

10,318

 

(588

)

(3,137

)

Total assets

 

28,897

 

27,156

 

11,665

 

1,039

 

512

 

Total stockholders’ equity (deficit)

 

$

8,350

 

$

20,392

 

$

2,169

 

$

(4,231

)

$

(4,995

)

 

34


 

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

The information in this report contains forward-looking statements.  All statements other than statements of historical fact made in this report are forward looking.  In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements.  These forward-looking statements can be identified by the use of words such as “believes,” “estimates,” “could,” “possibly,” “probably,” anticipates,” “projects,” “expects,” “may,” “will,” or “should” or other variations or similar words.  No assurances can be given that the future results anticipated by the forward-looking statements will be achieved.  Forward-looking statements reflect management’s current expectations and are inherently uncertain.  Our actual results may differ significantly from management’s expectations.

 

The following discussion and analysis should be read in conjunction with our financial statements, included herewith.  This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future.  Such discussion represents only the best present assessment of our management.

 

Overview

 

We are focused on developing and commercializing our precision cancer monitoring technology, which can inform oncologists and guide treatment decisions by determining a tumor’s mutational status and enabling physicians to track therapeutic response and resistance over time.

 

We are expanding the body of clinical evidence supporting our urine-based cell-free molecular diagnostic platform through collaborations with major cancer treatment centers and integrated healthcare networks.  We expect that the benefits of our precision cancer monitoring technology will become more apparent in terms of its clinical utility and impact on patient outcomes.  Our intellectual property estate protecting our technology includes methods of extracting, purifying, preparing, and detecting cell-free DNA and RNA mutations in urine.

 

Through December 31, 2014, we have sustained a cumulative total deficit of $81,391,909.  To date, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities and commercial expansion.  During 2014, we have advanced our business with the following activities:

 

·                  Presented clinical data at the 56th American Society of Hematology Annual Meeting and Exposition highlighting use of our PCM platform for the determination of mutational status and longitudinal monitoring of disease dynamics from both urine and plasma cell-free DNA.

 

·                  Presented study results at the EORTC-NCI-AACR International Symposium demonstrating high sensitivity and strong quantitative performance with our PCM platform for the detection and monitoring of KRAS mutations in circulating tumor DNA of colorectal cancer patients.

 

·                  Published results from a blinded prospective clinical study in Cancer Discovery demonstrating the ability to accurately determine mutational status and monitor treatment response to BRAF inhibitor therapy from urinary cell-free DNA.

 

·                  We secured $15.0 million in debt financing with Silicon Valley Bank and Oxford Finance to aid in funding our clinical programs, commercialization efforts, and continued expansion of our oncogene mutation portfolio for cancer monitoring research.

 

·                  Presented clinical data from an ongoing study demonstrating the utility of our PCM platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy at the ECD Global Alliance’s Second International Medical Symposium, in collaboration with the National Institutes of Health.

 

·                  Expanded clinical collaboration with the Memorial Sloan Kettering Cancer Center by initiating a new study evaluating our PCM platform for the detection and quantitative monitoring of EGFR Mutations in lung cancer patients.

 

35


 

·                  Entered into a strategic partnership with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute to conduct a translational research program designed to assess the utility of our PCM platform in clinical practice.

 

·                  Entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

 

·                  Published study results in the 2014 ASCO Annual Meeting Proceedings demonstrating that oncogene mutation load in urinary cell-free DNA, as determined using our PCM platform, is significantly correlated with treatment response.

 

·                  Prepared multi-disciplinary clinical consensus guidelines for Erdheim-Chester disease which referenced the ability of our PCM platform to detect actionable oncogene mutation status and to monitor patients during treatment.

 

·                  Published data from ongoing clinical validation studies in Oncotarget demonstrating that our PCM platform is suitable to non-invasively determine oncogene mutation status in patients with malignant disease.

 

·                  Presented clinical data at American Association for Cancer Research annual meeting demonstrating the ability of our PCM platform to non-invasively track cancer patients’ response to therapy.

 

·                  Released first urine-based multiplexed oncogene mutation assay utilizing Next Generation Sequencing technology, for the detection and monitoring of seven mutations in the KRAS oncogene.

 

·                  Signed clinical study agreement with US Oncology Research to examine the utility of quantitative KRAS mutation detection and monitoring in metastatic pancreatic cancer patients.

 

Our product development and commercialization efforts are in their early stages, and we cannot make estimates of the costs or the time our development efforts will take to complete, or the timing and amount of revenues related to the sale of our tests and revenues related to our license agreements.  The risk of completion of any program is high because of the many uncertainties involved in bringing new diagnostic products to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols and/or CLIA requirements, the extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses, and competing technologies being developed by organizations with significantly greater resources.

 

CRITICAL ACCOUNTING POLICIES

 

Financial Reporting Release No. 60 requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements.  Our accounting policies are described in Item 8.  Financial Statements—Note 2 Basis of Presentation and Summary of Significant Accounting Policies.  The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.  Actual results could differ from those estimates.  We believe that the following discussion represents our critical accounting policies.

 

Revenue Recognition

 

Historically our revenues have been generated from royalty, license and milestones related to agreements we have with other healthcare companies, medical laboratories and biotechnology partners.  In the future we will also have revenues from our diagnostics services.

 

We recognize revenues when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

 

Milestone, Royalty and License Revenues

 

We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.  These agreements may involve multiple elements such as license fees, royalties and milestone payments.  Revenue is recognized when the criteria described above have been met as well as the following:

 

36


 

·                  Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.

 

·                  Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.

 

·                  Milestone payments are recognized when both the milestone is achieved and the related payment is received.

 

Diagnostic Service Revenues

 

Diagnostic service revenue, which consists of fees for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, bill third-party payors for testing.

 

Diagnostic services revenue will be recognized when the criteria described above has been met as well as upon cash collection until we can reliably estimate the amount that will be ultimately collected for our LDTs, at which time we will recognize revenues on an accrual basis.

 

We have not recognized any diagnostic service revenue to date.

 

Derivative Financial Instruments-Warrants

 

Our derivative liabilities are related to warrants issued in connection with financing transactions and are therefore not designated as hedging instruments.  All derivatives are recorded on our balance sheet at fair value in accordance with current accounting guidelines for such complex financial instruments.

 

We have issued common stock warrants in connection with the execution of certain equity and debt financings.  Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period.  Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity.  Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”

 

The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end.  We thus use model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classify such warrants in Level 3 per ASC 820.  At December 31, 2014 and 2013, the fair value of such warrants was $3,006,021 and $4,431,871, respectively, which are included in the derivative financial instruments’ liability on our balance sheet.

 

Cost of Revenue

 

Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

 

Research and Development

 

Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, regulatory and scientific consulting fees, clinical samples as well as clinical collaborators and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, Research and Development.  Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense.  We are providing the following summary of our research and development expenses to supplement the more detailed discussions under results of operations.  Costs are not allocated to projects as the majority of the costs relate to employees and facilities costs and we do not track employees’ hours by project or allocate facilities costs on a project basis.

 

 

 

For the years ended December 31,

 

 

 

2014

 

2013

 

2012

 

Salaries and staff costs

 

$

3,465,211

 

$

2,063,474

 

$

950,861

 

Outside services, consultants and lab supplies

 

2,435,917

 

1,301,190

 

594,342

 

Facilities

 

628,535

 

466,138

 

352,920

 

Other

 

135,243

 

116,787

 

22,175

 

Total Research and Development

 

$

6,664,906

 

$

3,947,589

 

$

1,920,298

 

 

37


 

While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited.

 

ASC Topic 730, Research and Development requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized.  As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense.  There are no non-refundable advance payments that are deferred and capitalized as of December 31, 2014 and 2013.

 

Stock-based Compensation

 

We rely heavily on incentive compensation in the form of stock options to recruit, retain and motivate directors, executive officers, employees and consultants.  Incentive compensation in the form of stock options and warrants are designed to provide long-term incentives, develop and maintain an ownership stake and conserve cash.  Stock-based compensation expense for employees and directors is recognized in the statement of operations based on estimated amounts, including the grant date fair value and the expected service period.  For stock options, we estimate the grant date fair value using a Black-Scholes model.  Share-based compensation recorded in our statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures.  We recognize the value of the awards on a straight-line basis over the awards’ requisite service periods.  The requisite service period is generally the time over which our share-based awards vest.

 

We account for equity instruments granted to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payment to Non-Employees” where the value of the share-based compensation is based upon the measurement date as determined at either: a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.  Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

 

Fair value of financial instruments

 

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities.  We have adopted FASB ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis.  These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature as they reflect current market interest rates.  Debt is stated at its respective historical carrying amounts which approximates fair value as they reflect current market interest rates.

 

ASC 820 provides that the measurement of fair value requires the use of techniques based on observable and unobservable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions.  The inputs create the following fair value hierarchy:

 

· Level 1  — Quoted prices for identical instruments in active markets.

 

· Level 2  —  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.

 

· Level 3  — Instruments where significant value drivers are unobservable to third parties.

 

Off-Balance Sheet Arrangements

 

We do not believe that we have any off-balance sheet arrangements.

 

Inflation

 

It is our opinion that inflation has not had a material effect on our operations.

 

38


 

Recent Accounting Pronouncements

 

See Note 2 to the Notes to Financial Statements in Item 8 below for further discussion of recent accounting pronouncements.

 

Results of Operations

 

YEARS ENDED DECEMBER 31, 2014 AND 2013

 

Revenues

 

Our total revenues were $280,178 and $259,246 for the years ended December 31, 2014 and 2013, respectively.  Total revenues consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2014

 

2013

 

(Decrease)/Increase

 

 

 

 

 

 

 

 

 

Royalty income

 

$

270,178

 

$

259,246

 

$

10,932

 

License fees

 

10,000

 

—

 

10,000

 

Total revenues

 

$

280,178

 

$

259,246

 

$

20,932

 

 

Royalty income increased by $10,932 in the year ended December 31, 2014 primarily as a result of certain licensees exceeding their minimum royalties in comparison to the same period of the prior year.  In accordance with our revenue recognition policy, we do not record royalty revenues in excess of minimum royalty amounts until we have received the payment.

 

The $10,000 license fee earned in the year ended December 31, 2014 related to a licensing agreement signed in the second quarter of 2014.  There were no license fees earned during the year ended December 31, 2013.

 

We expect our royalty income to fluctuate as the royalties are based on the portion of our partners’ revenues earned utilizing the patents they have licensed from us.  Milestone and license fee revenues are difficult to predict and can vary significantly from period to period.  In addition, we expect to have revenues from our diagnostics tests in future periods, but as the revenue recognition will initially be based on cash receipts, the timing of these revenues are also uncertain.

 

Cost of Revenues

 

Cost of revenues relates to the costs of our diagnostic services revenues and are recognized at the completion of testing.  Gross margin on diagnostic tests are affected by test volumes, the timing of collections and overall reimbursement for the amount paid per test.

 

Research and Development Expenses

 

Research and development expenses increased by $2,717,317 to $6,664,906 for the year ended December 31, 2014 from $3,947,589 for the same period in 2013.  Substantially all of the increase resulted from the expansion of our research and development efforts as we increased the average number of our internal research and development personnel from nine to 17, and purchased additional laboratory equipment to support the increase in clinical collaborations to support the commercialization of our tests.  The clinical collaborations with external parties involve validation of our tests to detect certain types of cancer in urine samples.

 

Research and development expenses consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2014

 

2013

 

Increase

 

Salaries and staff costs

 

$

2,669,203

 

1,514,009

 

$

1,155,194

 

Stock-based compensation

 

796,008

 

549,465

 

246,543

 

Outside services, consultants and lab supplies

 

2,435,917

 

1,301,190

 

1,134,727

 

Facilities

 

628,535

 

466,138

 

162,397

 

Travel and scientific conferences

 

119,562

 

95,399

 

24,163

 

Other

 

15,681

 

21,388

 

(5,707

)

Total research and development

 

$

6,664,906

 

$

3,947,589

 

$

2,717,317

 

 

39


 

To date our costs have related to validating our tests and supporting clinical collaborations.  These costs are expected to increase as we expand current collaborations or enter into new collaborations and as we engage in research and development in areas other than detection of cancer in urine samples.

 

Selling and Marketing Expenses

 

Selling and marketing expenses increased by $1,204,743 to $2,734,903 for the year ended December 31, 2014, from $1,530,160 for the same period in 2013.  The most significant increase was in outside services and related to reestablishing our corporate and product identity (“branding”), a commercial update to our website, and market research related to pricing and reimbursement of our tests.  We have three commercially available tests as of December 31, 2014.  We have increased our average internal headcount in this functional area from three to five, resulting in the increase in salaries and staff costs.

 

Selling and marketing expenses consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2014

 

2013

 

Increase

 

Salaries and staff costs 

 

$

1,139,855

 

734,060

 

405,795

 

Stock-based compensation

 

145,240

 

100,189

 

45,051

 

Outside services

 

902,181

 

274,625

 

627,556

 

Facilities and insurance

 

115,713

 

98,081

 

17,632

 

Marketing

 

258,658

 

193,701

 

64,957

 

Travel

 

139,710

 

92,030

 

47,680

 

Other

 

33,546

 

37,474

 

(3,928

)

Total selling and marketing

 

$

2,734,903

 

$

1,530,160

 

$

1,204,743

 

 

We expect our selling and marketing expenses to increase as we increase the number of tests we have commercially available and increase market acceptance of our tests.

 

General and Administrative Expenses

 

General and administrative expenses increased by $338,049 to $5,810,087 for the year ended December 31, 2014 from $5,472,038 for the same period in 2013.  This increase was primarily due to an increase in legal fees related to filings and maintenance of patents.  We have increased our average internal headcount in these functional areas from two to four, to support the growth in both research and development and sales and marketing, resulting in the increase in salaries and staff costs during the year ended December 31, 2014 as compared to the same period of the prior year.  In addition, the costs associated with being a publicly traded company, such as additional costs for insurance, NASDAQ fees, and Sarbanes-Oxley compliance have added to our general and administrative expenses in comparison to the same period of the prior year.  The overall increase was partially offset by decreases in stock-based compensation due to timing and quantity of stock-based awards.

 

General and administrative expenses consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2014

 

2013

 

Increase/(Decrease)

 

Salaries and staff costs 

 

$

773,353

 

663,190

 

110,163

 

Board of Directors’ (BOD) fees

 

328,184

 

241,229

 

86,955

 

Stock-based compensation - employees

 

691,128

 

927,404

 

(236,276

)

Stock-based compensation - BOD

 

437,820

 

601,097

 

(163,277

)

Outside services

 

1,472,448

 

1,394,796

 

77,652

 

Legal and accounting fees

 

1,314,960

 

995,185

 

319,775

 

Facilities and insurance

 

336,154

 

248,491

 

87,663

 

Travel

 

208,651

 

220,691

 

(12,040

)

Fees, licenses, taxes and other

 

247,389

 

179,955

 

67,434

 

Total general and administrative

 

$

5,810,087

 

$

5,472,038

 

$

338,049

 

 

40


 

We expect our general and administrative expenses to increase as we support the expansion of our sales and marketing of our diagnostic tests.  In addition, at times, due to the use of options and warrants for compensation of services, stock based compensation expenses can vary significantly as the expense is based on assumptions in place at the measurement date of the award.

 

Interest Expense

 

Interest expense was $843,259 and 17,005 for the years ended December 31, 2014 and 2013, respectively.  The increase results from the $15.0 million term loan we entered into in June 2014.  We expect interest expense to continue to increase in comparison to the prior year as average debt outstanding will be higher and the term loan has interest only payments through July 2015.

 

Change in Fair Value of Derivative Instruments - Warrants

 

The change in fair value of derivative instruments resulted in a $1,425,850 gain in the year ended December 31, 2014 compared to a loss of $1,084,114 in the same period of the prior year.  The gain was a result of the revaluation of the warrants based upon the change in our stock price from $5.74 at December 31, 2013 to $4.30 at December 31, 2014, and the changes in the expected term, volatility and risk free interest rates for the expected term. The increase in value was recorded as non-operating gain for the year ended December 31, 2014.

 

Net Loss

 

Net loss and per share amounts were as follows:

 

 

 

For the years ended December 31,

 

 

 

2014

 

2013

 

Net loss and comprehensive loss attributable to common shareholders

 

$

(14,348,499

)

$

(11,840,778

)

Net loss per common share - basic

 

$

(0.76

)

$

(0.70

)

Net loss per common share - diluted

 

$

(0.88

)

$

(0.70

)

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

18,904,280

 

16,978,212

 

Weighted average shares outstanding - diluted

 

19,071,112

 

16,978,212

 

 

The increase from a net loss and comprehensive loss attributable to common shareholders of $11,840,778 for the year ended December 31, 2013 to $14,348,999 for the year ended December 31, 2014 resulted from a slight increase in revenues, offset by increases in all operating expenses.  The net loss per share - basic for the year ended December 31, 2014 increased by $0.06 to a net loss of $0.76 as a result of an overall increase in the net loss, slightly offset by an increase in weighted average shares outstanding during the year ended December 31, 2014 compared to the same period of the prior year.  Weighted average shares outstanding - basic increased for the year ended December 31, 2014 due to 3.4 million shares issued as a result of shares sold through controlled equity offerings, and exercise of warrants and stock options during the year ended December 31, 2013, and approximately 13,000 shares issued as a result of the net exercise of warrants during the year ended December 31, 2014.

 

41


 

YEARS ENDED DECEMBER 31, 2013 AND 2012

 

Revenues

 

Our total revenues were $259,246 and $450,404 for the years ended December 31, 2013 and 2012, respectively.  Total revenues consisted of the following:

 

 

 

Years ended December 31,

 

 

 

2013

 

2012

 

(Decrease)/Increase

 

 

 

 

 

 

 

 

 

Royalty income

 

$

259,246

 

$

175,404

 

$

83,842

 

Milestone

 

—

 

150,000

 

(150,000

)

License fees

 

—

 

125,000

 

(125,000

)

Total revenues

 

$

259,246

 

$

450,404

 

$

(191,158

)

 

Royalty income increased by $83,842 in the year ended December 31, 2013, primarily as a result of more royalty bearing agreements in 2013 compared to the same period in 2012 and more royalty payments earned in excess of minimum royalty payments in the current year compared to the year ended December 31, 2012.  In accordance with our revenue recognition policy, we do not record royalty revenues in excess of minimum royalty amounts until we have received the payment.

 

A milestone payment of $150,000 in 2012 was received upon achievement of a milestone with Ipsogen SAS during 2012.

 

License fees decreased by $125,000 in the year ended December 31, 2013 as there were more license agreements entered into during the year ended December 31, 2012 as compared to the same period in 2013.

 

Research and Development Expenses

 

Research and development expenses consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2013

 

2012

 

Increase

 

Salaries and staff costs

 

$

2,063,474

 

950,861

 

$

1,112,613

 

Outside services, consultants and lab supplies

 

1,301,190

 

594,342

 

706,848

 

Facilities

 

466,138

 

352,920

 

113,218

 

Travel and scientific conferences

 

95,400

 

—

 

95,400

 

Other

 

21,387

 

22,175

 

(788

)

Total research and development

 

$

3,947,589

 

$

1,920,298

 

$

2,027,291

 

 

Research and development expenses increased by $2,027,291 to $3,947,589 for the year ended December 31, 2013 from $1,920,298 for the same period in 2012.  Substantially all of the increase resulted from the expansion of our research and development efforts as we began commercialization, increased the average number of our internal research and development personnel from four to nine, and purchase additional laboratory equipment to support the clinical collaborations we have entered into related to validating our tests to detect certain types of cancer in urine samples.  We also established a clinical advisory board during the year ended December 31, 2013.

 

42


 

Selling and Marketing Expenses

 

Selling and marketing expenses consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2013

 

2012

 

Increase/(Decrease)

 

Salaries and staff costs

 

$

834,249

 

227,914

 

606,335

 

Outside services and consultants

 

274,625

 

109,875

 

164,750

 

Facilities and insurance

 

98,081

 

75,485

 

22,596

 

Marketing

 

193,701

 

46,667

 

147,034

 

Travel

 

92,030

 

4,360

 

87,670

 

Fees, licenses, taxes and other

 

37,474

 

42,234

 

(4,760

)

Total sales and marketing

 

$

1,530,160

 

$

506,535

 

$

1,023,625

 

 

Selling and marketing expenses increased by $1,023,625 to $1,530,160 for the year ended December 31, 2013 from $ 506,535 for the same period in 2012.  We have increased our average sales and marketing headcount from 2 to 3 and our marketing costs as we expand our efforts to inform the major cancer centers in the United States of our current and future product offerings.  We expect these costs to increase as we continue to market and sell our tests.

 

General and Administrative Expenses

 

General and administrative expenses consisted of the following:

 

 

 

For the years ended December 31,

 

 

 

2013

 

2012

 

Increase/(Decrease)

 

Salaries and staff costs 

 

$

1,590,594

 

479,241

 

1,111,353

 

Outside services and Board of Directors’ fees

 

2,237,122

 

1,442,352

 

794,770

 

Legal and accounting fees

 

995,185

 

663,281

 

331,904

 

Facilities and insurance

 

248,491

 

163,312

 

85,179

 

Travel

 

220,691

 

80,166

 

140,525

 

Fees, licenses, taxes and other

 

179,956

 

44,375

 

135,581

 

Total general and administrative

 

$

5,472,039

 

$

2,872,727

 

$

2,599,312

 

 

General and administrative expenses increased by $2,599,312 to $5,472,039 for the year ended December 31, 2014 from $2,872,727 for the same period in 2013.  This increase was primarily due to an increase in non-cash stock-based compensation expenses, 2013 bonus amounts and addition of personnel in comparison to the same period of the prior year.  The increase in outside services and Board of Directors’ fees resulted from additional services received related to Sarbanes-Oxley compliance, investor relations efforts and equity financing services.  Legal and accounting fees increased primarily as a result of legals costs related to filings and maintenance payments for our intellectual property portfolio.

 

We expect our general and administrative expenses to increase as we expand commercialization of our current diagnostic tests and future tests.  In addition, at times, due to the use of options and warrants for compensation of services, stock based compensation expenses can vary significantly as the expense is based on assumptions in place at the measurement date of the award.

 

Interest Expense

 

There was $17,005 interest expense in the year ended December 31, 2013 compared to no interest expense in the same period of 2012.  The increase results from the $1.0 million equipment line of credit agreement we entered into in June 2013.

 

Change in Fair Value of Derivative Instruments - Warrants

 

The change in fair value of derivative instruments resulted in a $1,084,114 loss in the year ended December 31, 2013 compared to a loss of $6,720,805 in the same period of the prior year.  We issued securities that were accounted for as derivative liabilities at issuance during the years ended December 31, 2013 and 2012.  On May 30, 2012 we closed an underwritten public offering that removed the condition that required the securities issued during the nine months ended September 30, 2012, as well as certain securities issued in prior periods, to be treated as derivative liabilities.  Accordingly, the fair value of these securities of $3,317,463 was reclassified from a liability to additional paid in capital.  During the quarter ended December 31, 2012, we issued additional securities that were accounted for as derivative liabilities at issuance.  As of December 31, 2013, the remaining derivative liabilities were revalued to $4,431,871, resulting in a net decrease in value of $1,820,888 from December 31, 2012, based primarily upon changes in the fair value as a result of the underwritten public offering and the increase in the fair value of our common stock at December 31, 2013.

 

43


 

Net Loss

 

Net loss and per share amounts were as follows:

 

 

 

For the years ended December 31,

 

 

 

2013

 

2012

 

Net loss and comprehensive loss attributable to common shareholders

 

$

(11,840,778

)

$

(11,604,201

)

Net loss per common share: basic and diluted

 

$

(0.70

)

$

(0.89

)

Weighted average shares: basic and diluted

 

16,978,212

 

13,066,600

 

 

The $236,577 increase in net loss and the $0.19 decrease in net loss per share in 2013 compared to 2012 reflected a slight decrease in revenues, more than offset by an increase in operating expenses and a loss from the change in fair value in derivative liabilities.  Weighted average shares outstanding increased due to the issuance of 3.4 million shares of common stock during the year as a result of the public offering in July 2013, controlled equity offerings and exercise of warrants and stock options during the year ended December 31, 2013.

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of December 31, 2014, we had $27,293,798 in cash and cash equivalents.  Net cash used in operating activities for the year ended December 31, 2014 was $12,727,385, compared to $7,317,248 for the year ended December 31, 2013.  Our use of cash was primarily a result of the net loss of $14,325,484 for the year ended December 31, 2014, adjusted for non-cash items related to stock-based compensation of $2,070,194, depreciation and amortization of $234,813 and the gain from the change in fair value of derivatives of $1,425,850.  The changes in our operating assets and liabilities consisted of higher accounts payable and accrued expenses and a decrease in accounts receivable.  At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.  As of December 31, 2014 and 2013, we had working capital of $23,231,596 and $24,059,854, respectively.  The decrease in working capital is primarily due to the increase in the current portion of long-term debt.

 

Investing activities consisted of purchases for capital equipment that used $299,790 in cash during the year ended December 31, 2014, compared to $649,284 for the same period in 2013.  We expect to invest approximately $985,000 in capital equipment over the next year.  The investment will be predominantly for laboratory equipment.

 

Net cash provided by financing activities was $14,484,036 during the year ended December 31, 2014, compared to $22,983,688 during the year ended December 31, 2013.  Financing activities during the year ended December 31, 2014 included $515,964 of repayments on equipment lines, offset by $15.0 million of new borrowings, while in 2013 financing activities included $18,829,644 from the sales of common stock, $3,638,080 from proceeds related to the exercise of warrants and options, and $515,964 from borrowings on equipment lines.

 

On February 11, 2015, we closed an underwritten public offering of 5,111,110 shares of our common stock.  The offering price was $4.50 per share and net proceeds to us were approximately $21.3 million.  As of February 27, 2015, our cash balance was approximately $46.0 million and our working capital was approximately $42.0 million.                                  .

 

Our working capital requirements will depend upon numerous factors including but not limited to the nature, cost and timing of our research and development programs.  We believe that we have sufficient cash and cash equivalents to fund our operations for at least the next twelve months.  We do not anticipate that our existing working capital alone will be sufficient to fund our operations through the successful development and commercialization of products we develop.  As a result, we will need to raise additional capital to fund our operations and continue to conduct activities to support our product development and commercialization.  To date, our sources of cash have been primarily limited to the sale of equity securities and debentures and debt borrowings.  We cannot be certain that additional funding will be available on acceptable terms, or at all.  To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution.  Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business.  If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more of product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves on unfavorable terms.

 

44


 

Public Offering and Controlled Equity Offering

 

On January 25, 2013 we filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000.  The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other securities.  This form was declared effective on February 4, 2013.  In addition, in connection with the Form S-3, we entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.  As payment for their services, the Agent is entitled to a 3% commission on gross proceeds.

 

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

 

The following table is a summary of contractual obligations for the periods indicated that existed as of December 31, 2014, and is based on information appearing in the notes to Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.

 

 

 

Total

 

Less than 1
Year

 

1-2 Years

 

3-5 Years

 

More than 5
Years

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating leases

 

$

1,119,505

 

360,775

 

371,324

 

387,406

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Research agreements (1)

 

1,120,968

 

1,120,968

 

—

 

—

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term debt (3)

 

18,359,545

 

2,936,808

 

5,563,640

 

9,859,097

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase obligations - major vendors (2)

 

191,933

 

191,933

 

—

 

—

 

—

 

 

 

 

 

 

 

 

 

 

 

 

 

Total obligations

 

$

20,791,951

 

$

4,610,484

 

$

5,934,964

 

$

10,246,503

 

$

—

 

 

(1)         Payments under research agreements are based on the completion of activities as specified in the research agreement. The amounts in the table above assume the successful completion of the collaborative research activities contemplated in the agreements.

 

(2)         Represents amounts that will become due upon future delivery of supplies and services from various suppliers under open purchase orders as of December 31, 2014

 

(3)   Represents long-term debt and interest.

 

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Interest Rate Risk

 

Our cash and cash equivalent primary consists of securities issued by the U.S. government, deposits, and money market deposits managed by commercial banks.  The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments.  We also seek to maximize income from our investments without assuming significant risk.

 

Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates, particularly because our investments are in short-term money marketable funds.  Due to the short-term duration of our investment portfolio and the relatively low risk profile of our investments, a sudden change in interest rates would not have a material effect on the fair market value of our portfolio, nor our operating results or cash flows.

 

45


 

Recently, there has been concern in the credit markets regarding the value of a variety of mortgage-backed and auction rate securities and the resulting effect on various securities markets.  We do not hold any auction rate securities.  We do not believe our cash, and cash equivalents investments have significant risk of default or illiquidity, however, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.  Given the current instability of financial institutions, we cannot provide assurance that we will not experience losses on these deposits.

 

Foreign Currency Risk

 

We have no operations outside the U.S. and do not hold any foreign currency denominated financial instruments.

 

Effects of Inflation

 

We do not believe that inflation and changing prices during the years ended December 31, 2014, 2013 and 2012 had a significant impact on our results of operations.

 

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

All financial information required by this Item is attached hereto at the end of this report beginning on page F-1 and is hereby incorporated by reference.

 

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A.  CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2014.  The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.  Based on that evaluation, as of December 31, 2014, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a-15(f).  Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

 

As of December 31, 2014, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework - 2013.  Based on this assessment, our management concluded that, as of December 31, 2014, our internal control over financial reporting was effective based on those criteria.

 

The effectiveness of our internal control over financial reporting as of December 31, 2014 has been audited by BDO USA, LLP, an independent registered public accounting firm, as stated in their report which is included herein.

 

46


 

Report of Independent Registered Public Accounting Firm

 

Board of Directors and Stockholders

Trovagene, Inc.

San Diego, California

 

We have audited Trovagene, Inc.’s internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Trovagene, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

In our opinion, Trovagene, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2014, based on the COSO criteria.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Trovagene, Inc. as of December 31, 2014 and 2013, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2014 and our report dated March 12, 2015 expressed an unqualified opinion thereon.

 

/s/ BDO USA, LLP

 

San Diego, California

March 12, 2015

 

47


 

Changes in Internal Control

 

As required by Rule 13a-15(d) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation of the internal control over financial reporting to determine whether any changes occurred during the three months ended December 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. There was no change in our internal control over financial reporting during the three months ended December 31, 2014 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B.  OTHER INFORMATION

 

None.

 

PART III

 

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

EXECUTIVE OFFICERS, DIRECTORS AND KEY EMPLOYEES

 

The following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held by each as of February 27, 2015.

 

Name

 

Age

 

Position

 

Thomas H. Adams, Ph.D.

 

72

 

Chairman of the Board

 

Antonius Schuh, Ph.D.

 

51

 

Chief Executive Officer and Director

 

Steve Zaniboni

 

57

 

Chief Financial Officer

 

John Brancaccio

 

67

 

Director

 

Gary S. Jacob, Ph.D.

 

67

 

Director

 

Dr.  Paul Billings

 

62

 

Director

 

Dr.  Stanley Tennant

 

63

 

Director

 

Dr.  Rodney S. Markin

 

58

 

Director

 

Carl Feldbaum

 

71

 

Director

 

 

All directors hold office until the next annual meeting of stockholders and the election and qualification of their successors.  Officers are elected annually by the board of directors and serve at the discretion of the board.

 

Executive Biographies

 

The principal occupations for the past five years (and, in some instances, for prior years) of each of our directors and executive officers are as follows:

 

Thomas H.  Adams.  Thomas H.  Adams, Ph.D, has been our Chairman of the Board since April 2009.  From June 2005 through 2011, Dr. Adams served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS from April 2006.  Until November 2012, Dr. Adams was the Head of Iris Molecular Diagnostics since 2006 and the President of Iris Personalized Medicine since 2011.  In November 2012, IRIS was acquired by Danaher Corporation.  Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS.  In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997.  Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc.  in 1989.  Dr.  Adams is currently a director of Synergy Pharmaceuticals Inc., a biotechnology company.  Dr. Adams holds a Ph.D.  in Biochemistry from the University of California, at Riverside.  Dr. Adam’s executive leadership, particularly in the diagnostic field, and the extensive healthcare expertise he has developed qualifies Dr. Adams to serve as a director of our company.

 

Antonius Schuh.  Antonius Schuh, Ph.D. joined us in October 2011 as our Chief Executive Officer and was elected as a Director in December 2011.  Dr.  Schuh co-founded Sorrento Therapeutics, Inc., a biopharmaceutical company developing monoclonal antibodies, in January 2006.  He served as Chairman of the Board and Chief Executive Officer of Sorrento Therapeutics from November 2008 to April 2011.  From April 2006 to September 2008, Dr. Schuh served as Chief Executive Officer of AviaraDx (now bioTheranostics, Inc., a bioMerieux company), a molecular diagnostic testing company that is focused on clinical applications in oncology.  From March 2009 to January 2015 Dr. Schuh was a director of Diogenix, Inc., a privately held molecular diagnostic company, and since May 2009, he has served as a director of RScueRx, Inc., a privately held biotherapeutics company.  Dr. Schuh is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.

 

48


 

Stephen Zaniboni.  Stephen Zaniboni joined us as Chief Financial Officer in January 2012.  Prior to joining us, since June 2010, Mr. Zaniboni has served as Chief Financial Officer of Awarepoint Corporation, a leading provider of healthcare software.  Prior to joining Awarepoint Corporation, Mr. Zaniboni served as Chief Financial Officer of XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, from January 2009 through June 2010.  Prior to joining XIFIN Inc., Mr. Zaniboni served as the Chief Financial Officer of Sorrento Therapeutics, Inc. from January 2006, and as a member of its board of directors from November 2008, through September 2009.  From May 2006 to September 2008, Mr. Zaniboni served as Chief Financial Officer of AviaraDx (now bioTheranostics, a bioMerieux company), a molecular diagnostic testing cancer profiling company that is focused on developing and commercializing molecular diagnostic technologies with proven clinical utility.  Mr. Zaniboni has also held various financial management positions at Aspect Medical Systems, Behring Diagnostics, and Boston Scientific.  He was a practicing CPA with Arthur Andersen and holds a B.S. in accounting from Boston University and an M.B.A. from Boston College.

 

John Brancaccio.  John Brancaccio, a retired CPA, has served as a director of our company since December 2005.  Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies..  Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc.  (formerly Alfacell Corporation) as well as a director of Synergy Pharmaceuticals Inc. and ContraVir Pharmaceuticals, Inc.  Mr. Brancaccio’s chief financial officer experience provides him with valuable financial and accounting expertise which the Board believes qualifies him to serve as a director of our company.

 

Gary S.  Jacob.  Gary S.  Jacob, Ph.D. has served as a director of our company since February 2009.  Since July 2008, Dr. Jacob has been President, Chief Executive Officer and a Director of Synergy Pharmaceuticals Inc. and Chairman since September 2013.  Dr.  Jacob has been Chairman of ContraVir Pharmaceuticals, Inc. since May 2013.  Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company.  Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.  Dr. Jacob’s broad management expertise in the pharmaceutical and biotechnology industries provides relevant experience in a number of strategic and operational areas and led to the Board’s conclusion that he should serve as a director of our company.

 

Dr. Paul Billings.  Paul Billings, MD, PhD was appointed to our Board in October 2013 and has been a member of our Scientific Advisory Board since November 2012.  Dr.  Billings is a board certified internist and clinical geneticist, and currently is an Executive-in-Residence at the California Innovation Center of Johnson and Johnson, Inc.  He is also the Medical Director of the IMPACT program at Thermo Fisher Scientifiic, Inc.(TFS)  He recently finished serving as the first and only Chief Medical Officer at Life Technologies Corporation and the Genetic Sciences Division of TFS. Dr.  Billings served as Chief Medical Officer at Life Technologies Corporation.  Dr.  Billings has extensive healthcare experience in many aspects of genomics and molecular medicine.  In addition to serving as Chief Medical Officer at Life Technologies, he also serves on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics.  In addition to Trovagene, he serves as an advisor or director for many companies including Omicia, BioScale, Applied Immunology, Aueon and PAX Neurosciences.  Dr.  Billings holds an M.D. from Harvard Medical School and a Ph.D.  in immunology, also from Harvard University.  Dr.  Billings’ medical and managerial experience in the diagnostic field qualifies him to serve as a director of our company.

 

Dr. Stanley Tennant.  Dr. Tennant has served as a director of our company since December 2010.  Since 1983, Dr. Tennant has been a cardiologist in Greensboro, NC.  He graduated from Wake Forest University School of Medicine in 1978 and completed postgraduatetraining in Internal Medicine and Cardiology at Vanderbilt University in 1983.  Dr.  Tennant’s practical experience in the healthcare field led to the Board’s conclusion that he should serve as a director of our company.

 

Dr. Rodney S.  Markin.  Dr. Markin has been a director of our company since February 2014.  Dr.  Markin is Chief Technology Officer and Associate Vice Chancellor for Business Development at the University of Nebraska Medical Center and a Professor of Pathology and Microbiology; David T.  Purtilo Distinguished Professor Pathology and Microbiology and Courtesy Professor of Surgery.  Dr.  Markin is also a director on the Board of Children’s Hospital and Medical Center Foundation and on the Board of Trustees for Keck Graduate Institute and on the Board of the Make-A-Wish Foundation.  The Board selected Dr. Markin to serve as a director because he has valuable executive experience in the healthcare business.

 

Carl Feldbaum.  Carl Feldbaum has been a director of our company since December 2014.  Mr. Feldbaum has been a director of Exelixis, Inc. since February 2007 and serves as a member of the Nominating and Governance Committee.  In addition, Mr. Feldbaum is a member of the board of directors of Actelion, Ltd. and serves as Chairman of its Nominating and Governance Committee.  Mr. Feldbaum previously served as a member of the board of directors of Connetics Corporation from 2005 until its acquisition by Stiefel Laboratories, Inc. in 2006.  Mr. Feldbaum is a member of the board of directors of BIO Ventures for Global Health, a non-profit organization, where he has served as a member of the board of directors since its inception in 2004.  Mr.  Feldbaum is interim Chair and a member of the Board of the Life Sciences Foundation, a non-profit based in Oakland, California.  Mr. Feldbaum is president emeritus of the Biotechnology Industry Organization (BIO), which represents more than 1,000

 

49


 

biotechnology companies, academic institutions and state biotechnology centers internationally.  Mr. Feldbaum served as president of BIO from 1993 until his retirement in 2005.  Prior to joining BIO, Mr. Feldbaum was chief of staff to Senator Arlen Specter of Pennsylvania.  He also was president and founder of Palomar Corporation, a national security “think tank” in Washington, D.C.  Before founding Palomar Corporation, Mr. Feldbaum was Assistant to the Secretary of Energy and served as the Inspector General for defense intelligence in the U.S. Department of Defense.  Mr. Feldbaum received an A.B. in Biology from Princeton University and his J.D. from the University of Pennsylvania Law School.  Mr. Feldbaum’s knowledge and experience with respect to the biotechnology, pharmaceutical and healthcare industries, his broad leadership experience resulting from service on various boards and as an executive officer and his knowledge and experience with policymaking, regulatory issues and other governmental matters qualifies him to serve as a director of our company.

 

Family Relationships

 

None.

 

Involvement in Certain Legal Proceedings

 

To our knowledge, during the last eleven years, none of our directors, executive officers (including those of our subsidiaries), promoters or control persons have:

 

·                                     had a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

 

·                                     been convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor offenses;

 

·                                     been subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;

 

·                                     been found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, or SEC, or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated; and

 

·                                     been the subject to, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization, any registered entity, or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Board Leadership Structure and Role in Risk Oversight

 

Since April 2009, we have separated the roles of Chairman of the Board and Chief Executive Officer (“CEO”).  Although the separation of roles has been appropriate for us during that time period, in the view of the board of directors, the advisability of the separation of these roles depends upon the specific circumstances and dynamics of our leadership.

 

As Chairman of the Board, Dr. Adams serves as the primary liaison between the CEO and the independent directors and provides strategic input and counseling to the CEO.  With input from other members of the board of directors, committee chairs and management, he presides over meetings of the board of directors.  Dr. Adams has developed an extensive knowledge of our company, its challenges and opportunities and has a productive working relationship with our senior management team.

 

The board of directors, as a unified body and through committee participation, organizes the execution of its monitoring and oversight roles and does not expect its Chairman to organize those functions.  Our primary rationale for separating the positions of Board Chairman and the CEO is the recognition of the time commitments and activities required to function effectively as Chairman and as the CEO of a company with a relatively flat management structure.  The separation of roles has also permitted the board of directors to recruit senior executives into the CEO position with skills and experience that meet the board of director’s planning for the position who may not have extensive public company board experience.

 

The board of directors has three standing committees—Audit, Compensation and Corporate Governance/Nominating.  The membership of each of the board committees is comprised of independent directors, with each of the committees having a separate chairman, each of whom is an independent director.  Our non-management members of the board of directors meet in executive session at each board meeting.

 

50


 

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success.  Management is responsible for the day-to-day management of risks the company faces, while the board of directors, as a whole and through its committees, has responsibility for the oversight of risk management.  In its risk oversight role, the board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed.

 

The board of directors believes that establishing the right “tone at the top” and that full and open communication between executive management and the board of directors are essential for effective risk management and oversight.  Our CEO communicates frequently with members of the board to discuss strategy and challenges facing the company.  Senior management usually attends our regular quarterly board meetings and is available to address any questions or concerns raised by the board of directors on risk management-related and any other matters.  Each quarter, the board of directors receives presentations from senior management on matters involving our areas of operations.

 

Director Independence

 

Our board of directors has determined that a majority of the board consists of members who are currently “independent” as that term is defined under current listing standards of NASDAQ.  The board of directors considers Messrs. Jacob, Billings, Tennant, Feldbaum, Markin and Brancaccio to be “independent.”

 

Audit Committee

 

The Audit Committee’s responsibilities include: (i) reviewing the independence, qualifications, services, fees, and performance of the independent registered public accountants, (ii) appointing, replacing and discharging the independent auditors, (iii) pre-approving the professional services provided by the independent auditors, (iv) reviewing the scope of the annual audit and reports and recommendations submitted by the independent auditors, and (v) reviewing our financial reporting and accounting policies, including any significant changes, with management and the independent auditors.  The Audit Committee also prepares the Audit Committee report that is required pursuant to the rules of the SEC.

 

As of December 31, 2014, the Audit Committee consisted of John P. Brancaccio, chairman of the Audit Committee, Dr.  Gary S. Jacob, and Dr. Thomas Adams.  Our board of directors has determined that each of Mr.  Brancaccio, Dr. Jacob and Dr.  Adams is “independent” as that term is defined under applicable SEC and NASDAQ rules.  Mr. Brancaccio is our audit committee financial expert.  The board of directors has adopted a written charter setting forth the authority and responsibilities of the Audit Committee.  As of January 1, 2015, the Audit Committee was reconstituted with Mr. Brancaccio remaining as chairman and Dr. Rodney Markin and Dr. Stanley Tennant joining the Committee.

 

Compensation Committee

 

The Compensation Committee has responsibility for assisting the board of directors in, among other things, evaluating and making recommendations regarding the compensation of the executive officers and directors of our company; assuring that the executive officers are compensated effectively in a manner consistent with our stated compensation strategy; producing an annual report on executive compensation in accordance with the rules and regulations promulgated by the SEC; periodically evaluating the terms and administration of our incentive plans and benefit programs and monitoring of compliance with the legal prohibition on loans to our directors and executive officers.

 

As of December 31, 2014, the Compensation Committee consisted of Dr. Stanley Tennant, chairman of the Compensation Committee, Dr. Gary S. Jacob and John P. Brancaccio.  Our board of directors has determined that all of the members are “independent” under the current listing standards of NASDAQ.  The board of directors has adopted a written charter setting forth the authority and responsibilities of the Compensation Committee.  As of January 1, 2015, the Compensation Committee was reconstituted with Dr. Tennant remaining as chairman and Dr. Rodney Markin and Dr. Paul Billings joining Dr. Gary Jacob on the Committee.

 

Corporate Governance/Nominating Committee

 

The Corporate Governance/Nominating Committee has responsibility for assisting the board of directors in, among other things, effecting board organization, membership and function including identifying qualified board nominees; effecting the organization, membership and function of board committees including composition and recommendation of qualified candidates; establishment of and subsequent periodic evaluation of successor planning for the chief executive officer and other executive officers; development and evaluation of criteria for Board membership such as overall qualifications, term limits, age limits and independence; and oversight of compliance with the Corporate Governance Guidelines.  The Corporate Governance/Nominating Committee shall

 

51


 

identify and evaluate the qualifications of all candidates for nomination for election as directors.  Potential nominees are identified by the Board of Directors based on the criteria, skills and qualifications that have been recognized by the CorporateGovernance/Nominating Committee.  While our nomination and corporate governance policy does not prescribe specific diversity standards, the Corporate Governance/Nominating Committee and its independent members seek to identify nominees that have a variety of perspectives, professional experience, education, difference in viewpoints and skills, and personal qualities that will result in a well-rounded Board of Directors.

 

As of December 31, 2014, the Corporate Governance/Nominating Committee consisted of John Brancaccio, chairman of the Corporate Governance/Nominating Committee, Thomas Adams and Stanley Tennant.  The Board of Directors has determined that all of the members are “independent” under the current listing standards of NASDAQ.  The Board of Directors has adopted a written charter setting forth the authority and responsibilities of the Corporate Governance/Nominating Committee.  As of January 1, 2015, the Corporate Governance/Nominating Committee was reconstituted with Carl Feldbaum joining as chairman and Dr. Paul Billings and John Brancaccio joining as members.

 

Code of Ethics

 

We have adopted a formal Code of Business Conduct and Ethics applicable to all Board members, executive officers and employees.  Our Code of Business Conduct and Ethics can be found on our website (www.trovagene.com).

 

Compliance With Section 16(A) of the Exchange Act

 

Section 16(a) of the Securities Exchange Act of 1934 requires our officers and directors, and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission.  Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

 

Based on a review of the copies of such forms received, we believe that during 2014, all filing requirements applicable to our officers, directors and greater than ten percent beneficial owners were complied with except that Antonius Schuh and Steve Zaniboni each filed one Form 4 late.

 

ITEM 11.  EXECUTIVE COMPENSATION

 

Compensation Committee Report

 

Under the rules of the SEC, this Compensation Committee Report is not deemed to be incorporated by reference by any general statement incorporating this Annual Report by reference into any filings with the SEC.

 

The Compensation Committee has reviewed and discussed the following Compensation Discussion and Analysis with management.  Based on this review and these discussions, the Compensation Committee recommended to the Board of Directors that the following Compensation Discussion and Analysis be included in this Annual Report on Form 10-K.

 

Submitted by the Compensation Committee
Dr. Stanley Tennant

John Brancaccio

Dr.  Gary S. Jacob

 

Compensation Discussion and Analysis

 

Overview

 

We compete with many other medical diagnostic companies in seeking to attract and retain a skilled work force.  To meet this challenge, we have developed our compensation structure to enable our management to make decisions regarding our compensation programs, to manage these programs, and to effectively communicate the goals of these programs to our employees and stockholders.

 

Our compensation philosophy is to offer our employees compensation and benefits that are competitive and that meet our goals of attracting, retaining and motivating highly skilled employees so that we can achieve our financial and strategic objectives.

 

52


 

Utilizing this philosophy, our compensation programs are designed to:

 

·                  be “market-based” and reflect the competitive environment for personnel;

 

·                  stress our “pay for performance” approach to managing pay levels;

 

·                  share risks and rewards with employees at all levels;

 

·                  be affordable, within the context of our operating expense model;

 

·                  align the interests of our employees with those of our stockholders;

 

·                  reflect our values; and

 

·                  be fairly and equitably administered.

 

In addition, as we administer our compensation programs, we plan to:

 

·                  evolve and modify our programs to reflect the competitive environment and our changing business needs;

 

·                  focus on simplicity, flexibility and choice wherever possible;

 

·                  openly communicate the details of our programs with our employees and managers to ensure that our programs and their goals are understood; and

 

·                  provide our managers and employees with the tools they need to administer our compensation programs.

 

Elements of Our Compensation Program

 

As a total rewards package, we design our compensation program to enable us to attract and retain talented personnel.  The individual elements of our compensation program serve to satisfy this larger goal in specific ways as described below.

 

We design base pay to provide the essential reward for an employee’s work, and is required to be competitive in attracting talent.  Once base pay levels are initially determined, increases in base pay are provided to recognize an employee’s specific performance achievements.  Consistent with our compensation philosophy, we implement a “pay for performance” approach that provides higher levels of compensation to individual employees whose results merit greater rewards.  Our managers typically make performance assessments throughout the year, and provide ongoing feedback to employees, provide resources and maximize individual and team performance levels.

 

We design equity-based compensation, including stock options, to ensure that we have the ability to retain talent over a longer period of time, and to provide optionees with a form of reward that aligns their interests with those of our stockholders.

 

We also utilize various forms of variable compensation, including cash bonuses that allow us to remain competitive with other companies while providing upside potential to those employees who achieve outstanding results.

 

Core benefits, such as our basic health benefits, are designed to provide a stable array of support to employees and their families.

 

The four key elements of our compensation structure are:

 

·                  base pay;

 

·                  variable pay;

 

·                  equity-based pay; and

 

·                  benefits.

 

53


 

Consistent with our compensation philosophy, we have structured each element of our rewards package as follows:

 

Base Pay

 

We create a set of base pay structures that are both affordable and competitive in relation to the market.  We continuously monitor base pay levels within the market and make adjustments to our structures as needed.  In general, an employee’s base pay level should reflect the employee’s overall sustained performance level and contribution to our company over time.  We seek to structure the base pay for our top performers to be aggressive in relation to the market.

 

Variable Pay

 

We design our variable pay programs to be both affordable and competitive in relation to the market.  We monitor the market and adjust our variable pay programs as needed.  Our variable pay programs, such as our bonus program, are designed to motivate employees to achieve overall goals.  Our programs are designed to avoid entitlements, to align actual payouts with the actual results achieved and to be easy to understand and administer.

 

Equity-Based Rewards

 

We design our equity programs to be both affordable and competitive in relation to the market.  We monitor the market and applicable accounting, corporate, securities and tax laws and regulations and adjust our equity programs as needed.  Stock options and other forms of equity compensation are designed to reflect and reward a high level of sustained individual performance over time.  We design our equity programs to align employees’ interests with those of our stockholders.

 

Benefits Programs

 

We design our benefits programs to be both affordable and competitive in relation to the market while conforming with local laws and practices.  We monitor the market, local laws and practices and adjust our benefits programs as needed.  We design our benefits programs to provide an element of core benefits, and to the extent possible, offer options for additional benefits, be tax-effective for employees in each country and balance costs and cost sharing between us and our employees.

 

Our stock options typically have annual vesting over a three-year period and a term of ten years, in order to encourage a long-term perspective and to encourage key employees to remain with us.  We also use performance based vesting in our option grants.  Generally, vesting and exercise rights cease upon termination of employment.  Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including voting rights and the right to receive dividends or dividend equivalents.

 

Timing of Equity Awards

 

Only the Compensation Committee may approve stock option grants to our executive officers.  Stock options are generally granted at predetermined meetings of the Compensation Committee.  On limited occasions, grants may occur upon unanimous written consent of the Compensation Committee, which occurs primarily for the purpose of approving a compensation package for newly hired or promoted executive.  The exercise price of a newly granted option is the closing price of our common stock on the date of grant.

 

Executive Equity Ownership

 

We encourage our executives to hold a significant equity interest in our company.  However, we do not have specific share retention and ownership guidelines for our executives.

 

Performance-Based Compensation and Financial Restatement

 

We have not considered or implemented a policy regarding retroactive adjustments to any cash or equity-based incentive compensation paid to our executives and other employees where such payments were predicated upon the achievement of certain financial results that were subsequently the subject of a financial restatement.

 

Severance and Change in Control Arrangements

 

Several of our executives have employment and other agreements which provide for severance payment arrangements and/or acceleration of stock option vesting that would be triggered by an acquisition or other change in control of our company.  See “Employment Agreements” below for a description of the severance and change in control arrangements for our named executive officers.

 

54


 

Effect of Accounting and Tax Treatment on Compensation Decisions

 

In the review and establishment of our compensation programs, we consider the anticipated accounting and tax implications to us and our executives.

 

Section 162(m) of the Internal Revenue Code imposes a limit on the amount of compensation that we may deduct in any one year with respect to our chief executive officer and each of our next four most highly compensated executive officers, unless certain specific and detailed criteria are satisfied.  Performance-based compensation, as defined in the Internal Revenue Code, is fully deductible if the programs are approved by stockholders and meet other requirements.  We believe that grants of equity awards under our existing stock plans qualify as performance-based for purposes of satisfying the conditions of Section 162(m), thereby permitting us to receive a federal income tax deduction in connection with such awards.  In general, we have determined that we will not seek to limit executive compensation so that it is deductible under Section 162(m).  However, from time to time, we monitor whether it might be in our interests to structure our compensation programs to satisfy the requirements of Section 162(m).  We seek to maintain flexibility in compensating our executives in a manner designed to promote our corporate goals and therefore our compensation committee has not adopted a policy requiring all compensation to be deductible.  Our compensation committee will continue to assess the impact of Section 162(m) on our compensation practices and determine what further action, if any, is appropriate.

 

Role of Executives in Executive Compensation Decisions

 

Our board of directors and our Compensation Committee generally seek input from our Chief Executive Officer, Dr.  Antonius Schuh, when discussing the performance of, and compensation levels for executives other than himself.  The Compensation Committee also works with Dr.  Schuh and our Chief Financial Officer evaluating the financial, accounting, tax and retention implications of our various compensation programs.  Neither Dr.  Schuh nor any of our other executives participates in deliberations relating to his or her compensation.

 

Role of Compensation Consultant

 

The Compensation Committee has the power to engage independent advisors to assist it in carrying out its responsibilities. For fiscal 2014, the Compensation Committee engaged Barney & Barney, LLC (“Barney& Barney”) as its independent executive and Board compensation consultant. Barney & Barney, who reports directly to the Compensation Committee and not to management, is independent from us, has not provided any services to us other than to the Compensation Committee, and receives compensation from us only for services provided to the Compensation Committee. The Compensation Committee assessed the independence of Barney & Barney pursuant to SEC rules and concluded that the work of Barney & Barney has not raised any conflict of interest.

 

Barney & Barney reviews and advises on all principal aspects of the executive and Board compensation program. Its main responsibilities are to:

 

·                  advise on alignment of pay and performance;

 

·                  review and advise on executive total compensation, including base salaries, short- and long-term incentives, associated performance goals, and retention and severance arrangements;

 

·                  advise on trends in executive compensation;

 

·                  advise on Board and Board committee compensation;

 

·                  provide recommendations regarding the composition of our peer group;

 

·                  analyze peer group proxy statements, compensation survey data, and other publicly available data (and apply its experience with other companies to this analysis); and

 

·      perform any special projects requested by the Compensation Committee.

 

Barney & Barney has attended the Compensation Committee’s meetings, including executive sessions at which management is not present. Barney & Barney communicates regularly with the Compensation Committee’s Chair outside of Compensation Committee meetings, and also meets with management to gather information and review proposals. Barney & Barney is expected to remain the Compensation Committee’s independent consultant until determined otherwise by the Compensaton Committee or Barney & Barney.

 

55


 

Chief Executive Officer Compensation for Fiscal Year 2014

 

In 2011, we entered into an executive agreement with Antonius Schuh, Ph.D. in which he agreed to serve as our Chief Executive Officer.  The term of the agreement is effective as of October 4, 2011 and continues until October 4, 2015 and is automatically renewed for successive one year periods at the end of each term.  Dr.  Schuh’s 2014 compensation was $385,000 per year.  In December 2014, Dr. Schuh’s salary was increased to $470,000.  Dr. Schuh is eligible to receive a cash bonus of up to 50% of his base salary per year based on meeting certain performance objectives and bonus criteria.  Upon entering the agreement, Dr. Schuh was granted 633,333 non-qualified stock options which have an exercise price of $3.00 per share and vest annually in equal amounts over a period of four years.  Dr. Schuh is also eligible to receive a realization bonus upon the occurrence of either of the following events, whichever occurs earlier;

 

(i) In the event that during the term of the agreement, for a period of 90 consecutive trading days, the market price of the common stock is $7.50 or more and the value of the common stock daily trading volume is $125,000 or more, we shall pay or issue Dr. Schuh a bonus in an amount of $3,466,466 in either cash or registered common stock or a combination thereof as mutually agreed by Dr.  Schuh and us; or

 

(ii) In the event that during the term of the agreement, a change of control occurs where the per share enterprise value of our company equals or exceeds $7.50 per share, we shall pay Dr. Schuh a bonus in an amount determined by multiplying the enterprise value by 4.0%.  In the event in a change of control the per share enterprise value exceeds a minimum of $14.40 per share, $22.80 per share or $30.00 per share, Dr.Schuh shall receive a bonus in an amount determined by multiplying the incremental enterprise value by 2.5%, 2.0% or 1.5%, respectively.

 

If the executive agreement is terminated by us for cause or as a result of Dr. Schuh’s death or permanent disability or if Dr.  Schuh terminates his agreement voluntarily, Dr. Schuh shall receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus or realization bonus earned but not yet paid through the date of termination and (iii) all expenses reasonably incurred by Dr. Schuh prior to date of termination.  If the executive agreement is terminated by us without cause Dr. Schuh shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.  If the executive agreement is terminated as a result of a change of control, Dr. Schuh shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.

 

2014 Bonus

 

On December 14, 2014, the Compensation Committee approved a bonus of $154,000 for Dr. Schuh, which was 40% of his base compensation.  The Compensation Committee reviewed the following factors in determining the amount of the bonus awarded.

 

·                  Clinical development progress

·                  Business development progress

·                  Commercialization progress

·                  Financing of the company

 

Dr.  Schuh’s employment agreement allows for an annual bonus equal to 50% of his base compensation.  The Compensation Committee believed that Dr. Schuh did an outstanding job during 2014 in a challenging environment with limited resources.

 

In making its determination as to whether Dr. Schuh achieved his performance objectives for awarding 2014 bonus, the Compensation Committee looked at the above-mentioned performance objectives in totality and what the achievement of those performance objectives meant to us and our business.  The Compensation Committee did not assign actual levels of achievement to each objective.

 

2015 Bonus Criteria

 

As of February 27, 2015, the Compensation Committee had not yet determined the performance criteria for Dr. Schuh’s 2015 bonus.

 

56


 

Compensation Risk Management

 

We have considered the risk associated with our compensation policies and practices for all employees, and we believe we have designed our compensation policies and practices in a manner that does not create incentives that could lead to excessive risk taking that would have a material adverse effect on us.

 

SUMMARY COMPENSATION TABLE

 

The following table provides certain summary information concerning compensation awarded to, earned by or paid to our Principal Executive Officer and the two other highest paid executive officers whose total annual salary and bonus exceeded $100,000 (collectively, the “named executive officers”) for fiscal year 2014.

 

Name & Principal Position

 

Year

 

Salary ($)

 

Bonus ($)

 

Option
Awards ($)
(1)

 

Total ($)

 

Dr.  Antonius Schuh, CEO (2)

 

2014

 

385,000

 

154,000

 

399,999

 

938,999

 

 

 

2013

 

323,125

 

210,000

 

1,212,964

 

1,746,089

 

 

 

2012

 

275,000

 

137,500

 

468,916

 

881,416

 

Stephen Zaniboni, CFO (3)

 

2014

 

242,000

 

96,800

 

263,400

 

602,200

 

 

 

2013

 

201,750

 

132,000

 

492,727

 

826,477

 

 

 

2012

 

199,333

 

80,000

 

107,331

 

386,664

 

Mark Erlander, CSO (4)

 

2014

 

298,769

 

131,200

 

921,400

 

1,351,369

 

 

 

2013

 

169,692

 

100,000

 

1,366,187

 

1,635,879

 

 

(1) Amounts shown in this column do not reflect dollar amounts actually received by our named executive officers.  Instead, these amounts represent the aggregate grant date fair value of stock option awards determined in accordance with FASB ASC Topic 718.  The valuation assumptions used in determining 2014, 2013, and 2012 amounts are described in Note 6 to our financial statements included in our Annual Reports on Form 10-K for the fiscal years ended December 31, 2014, 2013, and 2012.  Our named executive officers will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options.

(2) Dr.  Schuh was appointed CEO in October 2011.

(3) Mr.  Zaniboni was appointed CFO in February 2012.

(4) Mr.  Erlander was appointed CSO in January 2013.

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

 

The following table sets forth information for the named executive officers regarding the number of shares subject to both exercisable and unexercisable stock options, as well as the exercise prices and expiration dates thereof, as of December 31, 2014.

 

Name

 

Number of
Securities
Underlying
Unexercised
Options (#)
exercisable

 

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

 

Weighted Average
Option
Exercise
Price ($)

 

Option
Expiration
Date

 

Dr.  Antonius Schuh (1)

 

537,499

 

520,834

 

$

3.92

 

October 4, 2021-December 11, 2024

 

Stephen Zaniboni(2)

 

110,834

 

225,833

 

$

4.46

 

February 1, 2022- December 11, 2024

 

Mark Erlander (3)

 

85,000

 

490,000

 

$

5.12

 

September 13, 2022 — December 11, 2024

 

 

57


 

(1) The unexercisable options of 520,834 vest as follows: 158,334 on October 4, 2015; 50,000 each on June 24, 2015, 2016 and 2017 and 12,500 each on December 11, 2015, 2016 and 2017; 43,750 each on December 11, 2015, 2016, 2017 and 2018.

 

(2) The unexercisable options of 225,833 vest as follows:  41,666 on February 1, 2015 and 2016; 15,000 each on June 24, 2015, 2016 and 2017; 27,500 each on December 11, 2015, 2016, 2017 and 15,000 on December 11, 2018.

 

(3) The unexercisable options of 490,000 vest as follows:  1,666 on September 12, 2015; 3,334 on December 10, 2015; 50,000 each on January 28, 2015, 2016 and 2017; 40,000 each on December 11, 2015, 2016, 2017 and 15,000 on December 11, 2018; 50,000 each on July 16, 2015, 2016, 2017 and 2018.

 

DIRECTOR COMPENSATION

 

The following table sets forth summary information concerning the total compensation paid to our non-employee directors in 2014 for services to our company.

 

Name 

 

Fees Earned or Paid
in Cash

 

Option
Awards(1)

 

Total

 

Thomas H. Adams(2) 

 

$

50,000

 

$

121,713

 

$

171,713

 

John P. Brancaccio(3) 

 

$

66,000

 

$

234,911

 

$

300,911

 

Gary S. Jacob(4) 

 

$

50,000

 

$

199,616

 

$

249,616

 

Stanley Tennant (5) 

 

$

52,000

 

$

184,395

 

$

236,395

 

Paul Billings (6)

 

$

37,000

 

$

144,849

 

$

181,849

 

Rodney Markin (7)

 

$

34,250

 

$

199,180

 

$

233,430

 

Carl Feldbaum (8)

 

$

—

 

$

103,200

 

$

103,200

 

 

(1) Amounts shown in this column do not reflect dollar amounts actually received by our non-employee directors.  Instead, these amounts represent the aggregate grant date fair value of stock option awards determined in accordance with FASB ASC Topic 718.  The valuation assumptions used in determining 2014 amounts are described in Note 6 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.  Our named executive officers will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options.

(2) As of December 31, 2014, 342,849 stock options were outstanding, of which 324,565 were exercisable.

(3) As of December 31, 2014, 121,701 stock options were outstanding, of which 103,417 were exercisable.

(4) As of December 31, 2014, 123,672 stock options were outstanding, of which 105,388 were exercisable.

(5) As of December 31, 2014, 61,158 stock options were outstanding, of which 42,874 were exercisable.

(6) As of December 31, 2014, 51,230 stock options were outstanding, of which 23,000 were exercisable.

(7) As of December 31, 2014, 36,230 stock options were outstanding, of which none were exercisable.

(8) As of December 31, 2014, 24,000 stock options were outstanding, of which none were exercisable.

 

Employment Agreements

 

In January 2013, we entered into an employment agreement with Mark Erlander, Ph.D. in which he agreed to serve as Chief Scientific Officer.  Dr.  Erlander’s initial salary was $200,000 per year, increased to $260,000 and to $360,000 per year in 2014.  Dr.  Erlander is eligible to receive a cash bonus of up to 50% of his base salary per year at the discretion of the Compensation Committee based on goals mutually agreed upon by Dr. Erlander, the CEO and the Board of Directors.  In connection with his employment, Dr. Erlander was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $7.04.  The option vests ratably over a four year period.  If we terminate Dr. Erlander without cause, he is entitled to severance benefits equal to six months of his base salary.

 

During 2012, we entered into an executive agreement with Steve Zaniboni in which he agreed to serve as our Chief Financial Officer.  The term of the agreement is effective as of February 1, 2012 and continues until February 1, 2013 and is automatically renewed for successive one year periods at the end to each term.  Mr. Zaniboni’s initial compensation was $200,000 per year and was increased to $242,000 in 2013.  In December 2014, Mr. Zaniboni’s salary was increased to $290,000.  Mr. Zaniboni is eligible to receive a cash bonus of up to 50% of his base salary per year based on meeting certain performance objectives and bonus criteria.  Upon entering the agreement, Mr. Zaniboni was granted 166,667 non-qualified stock options which have an exercise price of $3.60 per share and vest annually in equal amounts over a period of four years.

 

58


 

If the executive agreement is terminated by us for cause or as a result of Mr. Zaniboni’s death or permanent disability or if Mr. Zaniboni terminates his agreement voluntarily, Mr. Zaniboni shall receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus or realization bonus earned but not yet paid through the date of termination and (iii) all expenses reasonably incurred by Mr. Zaniboni prior to date of termination.  If the executive agreement is terminated by us without cause Mr. Zaniboni shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.  If the executive agreement is terminated as a result of a change of control, Mr. Zaniboni shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.

 

ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information regarding beneficial ownership of shares of our common stock as of

 

February 27, 2015 by (i) each person known to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, (iii) our named executive officers and (iv) all directors and executive officers as a group.  Except as otherwise indicated, the persons named in the table have sole voting and investment power with respect to all shares beneficially owned, subject to community property laws, where applicable.

 

Name of Beneficial Owner 

 

Amount and nature of
beneficial ownership (1)

 

Percentage(2)

 

Executive officers and directors:

 

 

 

 

 

 

Thomas Adams

 

704,258

(3)

2.9

 

 

Antonius Schuh 

 

537,499

(4)

2.2

 

 

Paul Billings

 

27,077

(4)

*

 

 

John Brancaccio

 

138,604

(5)

*

 

 

Gary Jacob

 

246,409

(6)

1.0

 

 

Stanley Tennant

 

308,157

(7)

1.3

 

 

Rodney S. Markin

 

12,077

(4)

*

 

 

Stephen Zaniboni

 

152,501

(4)

*

 

 

Mark Erlander

 

135,000

(4)

*

 

 

 

 

 

 

 

 

 

All Officers and Directors as a Group (9 persons)

 

2,261,582

(8)

8.8

 

 

5% or greater holders:

 

 

 

 

 

 

Bridger Management, LLC

 

2,587,301

(9)

10.7

 

 

 

 

 

 

 

 

 

R. Merrill Hunter

 

1,510,834

(10)

6.1

 

 

Gabriele Cerrone

 

1,569,404

(9)

6.3

 

 

 

*less than 1%

 

(1)                   The address of each person is c/o Trovagene, Inc., 11055 Flintkote Avenue, Suite A, San Diego, CA 92121 unless otherwise indicated herein.

 

(2)                   The calculation in this column is based upon 24,123,790 shares of common stock outstanding on February 27, 2015.  Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to the subject securities.  Shares of common stock that are currently exercisable or exercisable within 60 days of February 27, 2015 are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage beneficial ownership of such person, but are not treated as outstanding for the purpose of computing the percentage beneficial ownership of any other person.

 

(3)                   Includes (i) 332,086  shares of common stock issuable upon exercise of stock options and (ii) 45,686  shares of common stock issuable upon exercise of warrants.

 

(4)                   Consists of shares of common stock issuable upon exercise of stock options.

 

59


 

(5)                   Includes (i) 110,938 shares of common stock issuable upon exercise of stock options and (ii) 13,833 shares of common stock issuable upon exercise of warrants.

 

(6)                   Includes (i) 112,909 shares of common stock issuable upon exercise of stock options and (ii) 10,500 shares of common stock issuable upon exercise of warrants.

 

(7)                   Includes (i) 75,000 shares of common stock issuable upon exercise of warrants and (ii) 50,395 shares of common stock exercisable upon exercise of stock options.

 

(8)                   Includes (i) 1,470,482  shares of common stock issuable upon exercise of stock options and (ii) 145,019  shares of common stock issuable upon exercise of warrants.

 

(9)                   As per the Schedule 13G/A filed February 17, 2015.

 

(10)            Includes 666,667 shares of common stock issuable upon exercise of warrants.

 

ITEM 13.   CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

On January 1, 2015, we entered into a consulting agreement with Tom Adams, our Chairman, pursuant to which Dr. Adams will provide consulting services to us in connection with applying our technology to infectious diseases.  The agreement is for a term of one year and Dr. Adams shall be paid $9,500 per month for his services.

 

Any future transactions with officers, directors or 5% stockholders will be on terms no less favorable to us than could be obtained from independent parties.  Any affiliated transactions must be approved by a majority of our independent and disinterested directors who have access to our counsel or independent legal counsel at our expense.

 

Board Determination of Independence

 

Our board of directors has determined that a majority of the board consists of members who are currently “independent” as that term is defined under current listing standards of NASDAQ.

 

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit and Non-Audit Fees

 

The aggregate fees billed to us by BDO USA, LLP, our independent registered public account firm, for the indicated services for each of the last two fiscal years were as follows:

 

 

 

2014

 

2013

 

Audit fees (1) 

 

$

192,318

 

$

284,720

 

Tax fees (2) 

 

16,264

 

35,646

 

 

 

$

208,582

 

$

320,366

 

 

(1) Audit fees consist of fees for professional services performed by BDO USA, LLP for the audit and review of our financial statements included in SEC filings, and services that are normally provided in connection with regulatory filings or engagements.

 

(2) Tax fees consist of fees for professional services performed by BDO USA, LLP with respective to tax compliance.

 

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

 

Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our principal accountants on a case-by-case basis.  Our Audit Committee has established a policy regarding approval of all audit and permissible non-audit services provided by our principal accountants.  No non-audit services were performed by our principal accountants during the fiscal years ended December 31, 2014 and 2013.  Our Audit Committee pre-approves these services by category and service.  Our Audit Committee has pre-approved all of the services provided by our principal accountants.

 

60


 

ITEM 15.  EXHIBITS

 

Exhibit
Number

 

Description of Exhibit

 

 

(a)(1)Financial Statements

 

 

 

 

 

The financial statements required by this item are submitted in a separate section beginning on page F-1 of this annual report.

 

b) Exhibits

 

 

 

Exhibit
Number

 

Description

1.2

 

Controlled Equity Offering SM Sales Agreement dated January 25, 2013 by and between Trovagene, Inc. and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 1.2 to Form S-3 filed on January 25, 2013).

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Form 10-12G filed on November 25, 2011).

 

 

 

3.2

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Appendix B to Trovagene, Inc.’s Proxy Statement on Schedule 14A filed March 20, 2012).

 

 

 

3.3

 

By-Laws of Trovagene, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Form 10-12G filed on November 25, 2011).

 

 

 

4.1

 

Form of Common Stock Certificate of Trovagene, Inc. (incorporated by reference to Exhibit 4.1 to the Company’s Form 10-12G filed on November 25, 2011).

 

 

 

4.2

 

2004 Stock Option Plan (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on July 19, 2004)+

 

 

 

4.3

 

Form of Registration Rights Agreement (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K, filed on April 16, 2012).

 

 

 

4.4

 

Form of Warrant Agency Agreement by and between Trovagene, Inc. and Broadridge Corporate Issuer Solutions, Inc. and Form of Warrant Certificate (incorporated by reference to Exhibit 4.5 to Amendment No.  3 to Form S-1 filed on May 22, 2012).

 

 

 

4.5

 

Form of Unit Agency Agreement by and between Trovagene, Inc. and Broadridge Corporate Issuer Solutions, Inc. (incorporated by reference to Exhibit 4.6 to Amendment No.  3 to Form S-1 filed on May 22, 2012).

 

 

 

10.2

 

Executive Agreement between Trovagene, Inc. and Antonius Schuh dated October 4, 2011 (incorporated by reference to Exhibit 10.2 to the Company’s Form 10-12G filed on November 25, 2011).+

 

 

 

10.3

 

Summary of Terms of Lease Agreement dated as of October 28, 2009 between Trovagene, Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit 10.3 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.4

 

Form of First Amendment to Standard Industrial Net Lease dated September 28, 2011 between Trovagene, Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit 10.4 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

61


 

10.5

 

Form of Second Amendment to Standard Industrial Net Lease dated October 2011 between Trovagene, Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit 10.5 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.6

 

Form of Third Amendment to Standard Industrial Net Lease dated October 22, 2012 between Trovagene, Inc. and BMR-Sorrento West , LP.

 

 

 

10.7

 

Form of Fourth Amendment to Standard Industrial Net Lease dated December 2, 2013 between Trovagene, Inc. and BMR-Coast 9 LP.

 

 

 

10.8

 

Form of Fifth Amendment to Standard Industrial Net Lease dated May 14, 2014 between Trovagene, Inc. and BMR-Coast 9 LP.

 

 

 

10.9

 

Co-Exclusive Sublicense Agreement dated October 22, 2007 between Trovagene, Inc. and Asuragen, Inc. (incorporated by reference to Exhibit 10.6 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.10

 

Amendment to Co-Exclusive Sublicense Agreement dated June 1, 2010 between Trovagene, Inc. and Asuragen, Inc. (incorporated by reference to Exhibit 10.7 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.11

 

Sublicense Agreement dated as of August 27, 2007 between Trovagene, Inc. and Ipsogen SAS (incorporated by reference to Exhibit 10.8 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.12

 

Amendment to Co-Exclusive Sublicense Agreement dated as of September 1, 2010 between Trovagene, Inc. and Ipsogen SAS (incorporated by reference to Exhibit 10.9 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.13

 

Sublicense Agreement dated as of July 20, 2011 between Trovagene, Inc. and Fairview Health Services (incorporated by reference to Exhibit 10.11 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.14

 

Sublicense Agreement dated as of December 1, 2008 by and between Trovagene, Inc. and InVivoScribe Technologies, Inc. (incorporated by reference to Exhibit 10.13 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.15

 

Sublicense Agreement dated as of August 25, 2008 by and between Trovagene, Inc. and Laboratory Corporation of America Holdings. (incorporated by reference to Exhibit 10.14 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.16

 

Form of Sublicense Agreement effective as of February 8, 2011 by and between Trovagene, Inc. and MLL Munchner Leukamielabor GmbH. (incorporated by reference to Exhibit 10.15 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.17

 

Sublicense Agreement effective as of June 15, 2010 by and between Trovagene, Inc. and Skyline Diagnostics BV (incorporated by reference to Exhibit 10.16 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.18

 

Exclusive License Agreement effective as of December 12, 2011 by and between Columbia University and Trovagene, Inc. (incorporated by reference to Exhibit 10.20 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

62


 

10.19

 

Form of Exclusive License Agreement effective as of October 2011 by and between Gianluca Gaidano, Robert Foa and Davide Rossi and Trovagene, Inc. (incorporated by reference to Exhibit 10.21 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.20

 

Executive Agreement between Trovagene, Inc. and Steve Zaniboni dated February 1, 2012 (incorporated by reference to Exhibit 10.22 to the Company’s Form 10-12G/A filed on February 15, 2012). +

 

 

 

10.21

 

Exclusive License Agreement effective as of May 2006 by and between Brunangelo Falini, Cristina Mecucci and Trovagene, Inc. (incorporated by reference to Exhibit 10.23 to the Company’s Form 10-

 

 

12G/A filed on February 15, 2012).

 

 

 

10.22

 

Form of First Amendment to Exclusive License Agreement effective as of August 2010 by and among Brunangelo Falini, Cristina Mecucci and Trovagene, Inc. (incorporated by reference to Exhibit 10.24 to the Company’s Form 10-12G/A filed on February 15, 2012).

 

 

 

10.23

 

Form of Securities Purchase Agreement dated as of July 30, 2013 (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on July 31, 2013).

 

 

 

10.24

 

Research Agreement between Trovagene, Inc. and Illumina, Inc. dated June 20, 2013 (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed on August 14, 2013)*

 

 

 

14

 

Code of Business Conduct and Ethics Amended and Restated 2011 (incorporated by reference to Exhibit 14 to the Company’s Form 10-12G filed on November 25, 2011).

 

 

 

21

 

List of Subsidiaries.

 

 

 

23.1

 

Consent of BDO USA, LLP

 

 

 

31.1

 

Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.

 

 

 

31.2

 

Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.

 

 

 

32.1

 

Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2

 

Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

101

 

Financial statements from the annual report on Form 10-K of Trovagene for the year ended December 31, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations and Comprehensive Loss, (iii) the Consolidated Statement of Stockholders’ Equity (Deficiency) (iv) the Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements.

 

 

 

+ Indicates a management contract or compensatory plan or arrangement

*Portions of this exhibit were omitted and filed separately with the U.S.  Securities and Exchange Commission pursuant to a request for confidential treatment.

 

63


 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

TROVAGENE, INC.

 

 

 

 

 

/s/ Dr. Antonius Schuh

March 12, 2015

Chief Executive Officer

 

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

SIGNATURE

 

TITLE

 

DATE

 

 

 

 

 

 

 

/s/ Dr. Antonius Schuh

 

Chief Executive Officer and Director

 

March 12, 2015

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Stephen Zaniboni

 

Chief Financial Officer

 

March 12, 2015

 

 

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Thomas H. Adams

 

Chairman of the Board

 

March 12, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ John P. Brancaccio

 

Director

 

March 12, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Gary S. Jacob

 

Director

 

March 12, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Paul Billings

 

Director

 

March 12, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Stanley Tennant

 

Director

 

March 12, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Rodney S. Markin

 

Director

 

March 12, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Carl Feldbaum

 

Director

 

March 12, 2015

 

 



 

Report of Independent Registered Public Accounting Firm

 

Board of Directors and Stockholders

Trovagene, Inc.

San Diego, California

 

We have audited the accompanying consolidated balance sheets of Trovagene, Inc. and Subsidiaries’ (“Trovagene”) as of December 31, 2014 and 2013 and the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2014.  These financial statements are the responsibility of the Company’s management.  Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Trovagene, Inc. and Subsidiaries at December 31, 2014 and 2013, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2014, in conformity with accounting principles generally accepted in the United States of America.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Trovagene’s internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated March 12, 2015 expressed an unqualified opinion thereon.

 

 

/s/ BDO USA, LLP

 

San Diego, California

 

March 12, 2015

 

 

F-2


 

Trovagene, Inc. and Subsidiaries

 

CONSOLIDATED BALANCE SHEETS

 

 

 

December 31,

 

December 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

27,293,798

 

25,836,937

 

Accounts receivable

 

56,694

 

78,994

 

Prepaid expenses and other assets

 

369,259

 

152,789

 

Total current assets

 

27,719,751

 

26,068,720

 

Property and equipment, net

 

840,387

 

750,565

 

Other assets

 

336,708

 

336,450

 

Total Assets

 

$

28,896,846

 

27,155,735

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

747,799

 

286,608

 

Accrued expenses

 

1,841,808

 

1,524,092

 

Current portion of long-term debt

 

1,898,548

 

198,166

 

Total current liabilities

 

4,488,155

 

2,008,866

 

Long-term debt, less current portion

 

13,053,117

 

322,998

 

Derivative financial instruments

 

3,006,021

 

4,431,871

 

Total liabilities

 

20,547,293

 

6,763,735

 

 

 

 

 

 

 

Commitments and contingencies (Note 11)

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 20,000,000 shares authorized, 60,600 shares outstanding at December 31, 2014 and 2013, designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at December 31, 2014 and 2013

 

60

 

60

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 150,000,000 shares authorized at December 31, 2014 and 2013; 18,915,793 and 18,902,782 issued and outstanding at December 31, 2014 and 2013, respectively

 

1,891

 

1,890

 

 

 

 

 

 

 

Additional paid-in capital

 

89,739,511

 

87,433,460

 

Deficit accumulated during

 

(81,391,909

)

(67,043,410

)

Total stockholders’ equity

 

8,349,553

 

20,392,000

 

Total Liabilities and Stockholders’ Equity

 

$

28,896,846

 

$

27,155,735

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3


 

Trovagene, Inc. and Subsidiaries

 

Consolidated Statements of Operations and Comprehensive Loss

 

 

 

Year Ended December 31,

 

 

 

2014

 

2013

 

2012

 

Royalty income

 

$

270,178

 

$

259,246

 

$

175,404

 

Milestone fees

 

—

 

—

 

150,000

 

License fees

 

10,000

 

—

 

125,000

 

Total revenues

 

280,178

 

259,246

 

450,404

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenue

 

15,441

 

—

 

—

 

Research and development

 

6,664,906

 

3,947,589

 

1,920,298

 

Selling and marketing

 

2,734,903

 

1,530,160

 

506,535

 

General and administrative

 

5,810,087

 

5,472,038

 

2,872,727

 

Total operating expenses

 

15,225,337

 

10,949,787

 

5,299,560

 

 

 

 

 

 

 

 

 

Loss from operations

 

(14,945,159

)

(10,690,541

)

(4,849,156

)

 

 

 

 

 

 

 

 

Interest income

 

12,239

 

3,663

 

—

 

Interest expense

 

(843,259

)

(17,005

)

—

 

Gain (loss) on disposal of equipment

 

24,845

 

(22,941

)

4,000

 

Gain (loss) from change in fair value of derivative instruments—warrants

 

1,425,850

 

(1,084,114

)

(6,720,805

)

Net loss and comprehensive loss

 

(14,325,484

)

(11,810,938

)

(11,565,961

)

 

 

 

 

 

 

 

 

Preferred stock dividend

 

(23,015

)

(29,840

)

(38,240

)

 

 

 

 

 

 

 

 

Net loss and comprehensive loss attributable to common stockholders

 

$

(14,348,499

)

$

(11,840,778

)

$

(11,604,201

)

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share - basic

 

$

(0.76

)

$

(0.70

)

$

(0.89

)

Net loss per common share - diluted

 

$

(0.88

)

$

(0.70

)

$

(0.89

)

 

 

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

18,904,280

 

16,978,212

 

13,066,600

 

Weighted average shares outstanding - diluted

 

19,071,112

 

16,978,212

 

13,066,600

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4


 

Trovagene, Inc. and Subsidiaries

 

Consolidated Statements of Stockholders’ Equity (Deficiency)

 

 

 

Preferred
Stock
Shares

 

Preferred
Stock
Amount

 

Common
Stock
Shares

 

Common
Stock
Amount

 

Additional
Paid-In
Capital

 

Deficit
Accumulated

 

Total
Stockholders’
Equity
(Deficiency)

 

Balance, December 31, 2011

 

95,600

 

$

96

 

10,737,026

 

$

1,073

 

$

39,365,994

 

$

(43,598,431

)

$

(4,231,268

)

Units issued via registered underwritten direct public offering and private placement of units

 

—

 

—

 

4,383,333

 

438

 

16,899,562

 

—

 

16,900,000

 

Fees and expenses related to financing transactions

 

—

 

—

 

—

 

—

 

(1,576,452

)

—

 

(1,576,452

)

Derivative liability-fair value of warrants and price protected units issued

 

—

 

—

 

—

 

—

 

(1,796,610

)

—

 

(1,796,610

)

Correction of error in derivative liability—fair value of warrants price protected units issued

 

—

 

—

 

—

 

—

 

274,967

 

—

 

274,967

 

Warrants reclassified to additional paid in capital

 

—

 

—

 

—

 

—

 

3,317,463

 

—

 

3,317,463

 

Issuance of common stock and warrant to shareholder as finder’s fees

 

—

 

—

 

214,100

 

21

 

(21

)

—

 

—

 

Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.

 

—

 

—

 

125,000

 

13

 

187,487

 

—

 

187,500

 

Issuance of common stock in connection with consulting services

 

—

 

—

 

9,916

 

1

 

22,380

 

—

 

22,381

 

Issuance of warrants in connection with advisory services

 

—

 

—

 

—

 

—

 

142,508

 

—

 

142,508

 

Stock based compensation

 

—

 

—

 

—

 

—

 

532,140

 

—

 

532,140

 

Issuance of common stock upon exercise of stock options

 

—

 

—

 

200

 

—

 

600

 

—

 

600

 

Issuance of common stock upon net exercise of warrant

 

—

 

—

 

8,602

 

1

 

(1

)

—

 

—

 

Preferred stock dividend

 

—

 

—

 

—

 

 

 

 

 

(38,240

)

(38,240

)

Net loss

 

—

 

—

 

—

 

—

 

—

 

(11,565,961

)

(11,565,961

)

Balance, December 31, 2012

 

95,600

 

$

96

 

15,478,177

 

$

1,547

 

$

57,370,017

 

$

(55,202,632

)

$

2,169,028

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5


 

Trovagene, Inc. and Subsidiaries

 

Consolidated Statements of Stockholders’ Equity (Deficiency)

 

 

 

Preferred
Stock
Shares

 

Preferred
Stock
Amount

 

Common
Stock
Shares

 

Common
Stock
Amount

 

Additional
Paid-In
Capital

 

Deficit
Accumulated
During
Development
Stage

 

Total
Stockholders’
Equity
(Deficiency)

 

Sale of common stock, net of expenses

 

—

 

—

 

2,631,332

 

263

 

18,829,381

 

—

 

18,829,644

 

Issuance of warrants in connection with services

 

—

 

—

 

—

 

—

 

198,791

 

—

 

198,791

 

Stock based compensation

 

—

 

—

 

—

 

—

 

1,979,364

 

—

 

1,979,364

 

Derivative liability - Warrants reclassified to additional paid in capital

 

—

 

—

 

—

 

—

 

5,417,871

 

—

 

5,417,871

 

Issuance of common stock upon conversion of preferred stock

 

(35,000

)

(36

)

36,458

 

4

 

32

 

—

 

—

 

Issuance of common stock upon net exercise of warrant

 

—

 

—

 

7,284

 

1

 

(1

)

—

 

—

 

Issuance of common stock upon exercise of warrants

 

—

 

—

 

715,743

 

72

 

3,599,759

 

—

 

3,599,831

 

Issuance of common stock upon net exercise of stock options

 

—

 

—

 

22,955

 

2

 

(2

)

—

 

—

 

Issuance of common stock upon exercise of stock options

 

—

 

—

 

10,833

 

1

 

38,248

 

—

 

38,249

 

Preferred stock dividend

 

—

 

—

 

—

 

—

 

—

 

(29,840

)

(29,840

)

Net loss

 

—

 

—

 

—

 

—

 

—

 

(11,810,938

)

(11,810,938

)

Balance, December 31, 2013

 

60,600

 

$

60

 

18,902,782

 

$

1,890

 

$

87,433,460

 

$

(67,043,410

)

$

20,392,000

 

Stock based compensation

 

—

 

—

 

—

 

—

 

2,070,195

 

—

 

2,070,195

 

Issuance of warrant in connection with debt agreement

 

—

 

—

 

—

 

—

 

235,857

 

—

 

235,857

 

Issuance of common stock upon net exercise of warrant

 

—

 

—

 

13,011

 

1

 

(1

)

—

 

—

 

Preferred stock dividend

 

—

 

—

 

—

 

—

 

—

 

(23,015

)

(23,015

)

Net loss

 

—

 

—

 

—

 

—

 

—

 

(14,325,484

)

(14,325,484

)

Balance, December 31, 2014

 

60,600

 

$

60

 

18,915,793

 

$

1,891

 

$

89,739,511

 

$

(81,391,909

)

$

8,349,553

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6


 

Trovagene, Inc. and Subsidiaries

 

Consolidated Statements of Cash Flows

 

 

 

Year
ended December 31,
2014

 

Year
ended December 31,
2013

 

Year
ended December 31,
2012

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

Net loss

 

$

(14,325,484

)

$

(11,810,938

)

$

(11,565,961

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Loss (gain) on disposal of fixed assets

 

(24,845

)

22,941

 

(4,000

)

Depreciation and amortization

 

234,813

 

130,520

 

41,842

 

Stock based compensation expense

 

2,070,194

 

1,979,364

 

532,140

 

Amortization of debt costs

 

248,799

 

—

 

—

 

Accretion of discount on debt

 

57,117

 

—

 

—

 

Change in fair value of financial instruments

 

(1,425,850

)

1,084,114

 

6,720,805

 

Stock and warrant issued in connection with consulting services

 

—

 

198,791

 

164,889

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Decrease (increase) in other assets

 

(258

)

25,631

 

—

 

Decrease (increase) in accounts receivable

 

22,300

 

89,387

 

(69,241

)

(Increase) decrease in prepaid expenses

 

(216,470

)

(92,748

)

(17,383

)

Increase (decrease) in accounts payable and accrued expenses

 

632,299

 

1,055,690

 

(737,752

)

Net cash used in operating activities

 

(12,727,385

)

(7,317,248

)

(4,934,661

)

 

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

 

 

Capital expenditures

 

(363,290

)

(649,784

)

(274,080

)

Proceeds from disposals of capital equipment

 

63,500

 

500

 

4,000

 

Net cash used in investing activities

 

(299,790

)

(649,284

)

(270,080

)

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

Proceeds from sale of common stock, net of expenses

 

—

 

18,829,644

 

15,323,548

 

Proceeds from exercise of warrants

 

—

 

3,599,831

 

—

 

Proceeds from exercise of options

 

—

 

38,249

 

600

 

Borrowings (repayments) under equipment line of credit

 

(515,964

)

515,964

 

—

 

Borrowings under debt agreement

 

15,000,000

 

—

 

—

 

Net cash provided by financing activities

 

14,484,036

 

22,983,688

 

15,324,148

 

Net change in cash and cash equivalents

 

1,456,861

 

15,017,156

 

10,119,407

 

Cash and cash equivalents—Beginning of period

 

25,836,937

 

10,819,781

 

700,374

 

Cash and cash equivalents—End of period

 

$

27,293,798

 

$

25,836,937

 

$

10,819,781

 

Supplementary disclosure of cash flow activity:

 

 

 

 

 

 

 

Cash paid for taxes

 

$

2,400

 

$

7,650

 

$

—

 

Cash paid for interest

 

$

425,256

 

$

9,459

 

$

—

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

 

Warrants issued in connection with Loan and Security Agreement

 

$

235,857

 

$

—

 

$

—

 

Issuance of 125,000 shares of common stock pursuant to Asset Purchase Agreement with Multigen Diagnostics, Inc.

 

$

—

 

$

—

 

$

187,500

 

Reclassification of derivative financial instruments to additional paid in capital

 

$

—

 

$

(5,417,871

)

$

(3,317,463

)

Correction of error in derivative financial instruments

 

$

—

 

$

—

 

$

(274,967

)

Preferred stock dividends accrued

 

$

23,015

 

$

29,840

 

$

38,240

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-7


 

Trovagene, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

1.  Business Overview and Liquidity

 

Trovagene, Inc.  (“Trovagene” or the “Company”) is a molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines.  Trovagene’s primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while the Company’s external focus includes entering into collaborations to develop the Company’s technology in areas such as infectious disease, transplant medicine, and prenatal genetics.   The Company’s goal is to improve treatment outcomes for cancer patients using its proprietary technology to detect and quantitatively monitor cell-free DNA in urine.

 

Underwritten Public Offering of Common Stock

 

On May 30, 2012, the Company completed an underwritten public offering in which an aggregate of 1,150,000 units, with each unit consisting of two shares of its common stock and one warrant to purchase one share of common stock were sold at a purchase price of $8.00 per unit.  On June 13, 2012, the underwriters exercised their overallotment option in full for an additional 172,500 units.   The Company raised a total of $9.1 million in net proceeds after deducting underwriting discounts and commissions of $0.7 million and offering expenses of $0.7 million.   The units began trading on The NASDAQ Capital Market on May 30, 2012 under the symbol “TROVU”.  The common stock and warrants became separately transferable upon the exercise in full of the underwriters’ overallotment.   Each warrant has an exercise price of $5.32 per share, and expires five years from the closing of the offering.   The warrants trade on The NASDAQ Capital Market under the symbol “TROVW”.  Warrants issued in connection with the underwritten public offering and sale of units in May 2012 are not considered derivatives based on our analysis of the criteria of ASC 815, as the Company is not required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of warrant shares.

 

To date, Trovagene’s efforts have been principally devoted to research and development, securing and protecting patents and raising capital.  Through December 31, 2014, the Company has sustained cumulative net losses attributed to common stockholders of $81,391,909.  The Company’s losses have resulted primarily from expenditures incurred in connection with research and development activities, stock based compensation expense, patent filing and maintenance expenses, outside accounting and legal services and regulatory, scientific and financial consulting fees, amortization and liquidated damages.   To date, the Company has generated only limited revenue from operations and expects to incur additional losses to perform further research and development activities as well as selling and marketing expenses related to the diagnostic tests it has commercially available as of December 31, 2014.

 

Liquidity

 

  The Company will need to continue to raise funds until it is able to generate revenues from operations sufficient to fund its development and commercial operations.

 

Cash used in operating activities was $12,727,385, $7,317,248 and $4,934,661 for the years ended December 31, 2014, 2013, and 2012, respectively.  During the years ended December 31, 2014, 2013 and 2012, the Company incurred net loss and comprehensive loss attributable to common stockholders of $14,348,499, $11,840,778 and $11,604,201, respectively. The Company believes that it currently has adequate capital to continue operations for the subsequent one year business cycle. However, to carry the Company forward beyond the current business cycle until it can generate adequate cash flow from operations, additional cash resources will be necessary.

 

To date, Trovagene’s sources of cash have been primarily limited to the sale of debt and equity securities, as well as proceeds from warrant and option exercises.  Net cash provided by financing activities for the years ended December 31, 2014, 2013 and 2012 was $14,484,036, $22,983,688 and $15,324,148, respectively.  The Company cannot be certain that additional funding will be available on acceptable terms, or at all.  To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution.  Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business.

 

F-8


 

If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates.  The Company may also be required to:

 

·                  Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and

 

·                  Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms.

 

2.  Basis of Presentation and Summary of Significant Accounting Policies

 

The accompanying consolidated financial statements of Trovagene, which include its wholly owned subsidiaries Xenomics, Inc., a California corporation, Xenomics Europa Ltd, (an inactive subsidiary formed in the United Kingdom and liquidated) and Etherogen, Inc., a Delaware corporation, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  All intercompany balances and transactions have been eliminated.

 

On March 15, 2012, the Board of Directors and on April 27, 2012 a majority of the stockholders approved a proposal to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of not less than one-for-two and not greater than one-for-six at any time prior to April 27, 2013 at the discretion of the Board of Directors.  On May 24, 2012, the Board of Directors approved a 1-for-6 reverse stock split of the Company’s issued and outstanding common stock effective on May 29, 2012.  All the relevant information relating to number of shares and per share information contained in these consolidated financial statements has been retrospectively adjusted to reflect the reverse stock split for all periods presented.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of operating accounts as of December 31, 2014 and 2013 on deposit with U.S. commercial banks.   Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.   Cash and cash equivalents include money market accounts at December 31, 2014.

 

Concentration of credit risk

 

The Company maintains its cash in financial institutions, which at times may exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”).  All of the Company’s noninterest bearing cash balances were insured up to $250,000 at December 31, 2014 and December 31, 2013.

 

Revenues

 

We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.  These agreements may involve multiple elements such as license fees, royalties and milestone payments.  Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

 

·                  Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.

 

·                  Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.

 

·                  Milestone payments are recognized when both the milestone is achieved and the related payment is received.

 

F-9


 

Allowance for Doubtful Accounts

 

The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators.  At December 31, 2014 and 2013, the Company has not recorded an allowance for doubtful accounts.  When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed.  When payments are received on reserved accounts, they are applied to the individual’s account and the reserve is reassessed.

 

Derivative Financial Instruments—Warrants

 

The Company has issued common stock warrants in connection with the execution of certain equity financings.  Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period.  Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity.  Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”

 

The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene’s common share price, remaining life of the warrant, and risk-free interest rates at each period end.  The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements.  At December 31, 2014 and 2013, the fair value of these warrants was $3,006,021 and $4,431,871, respectively, and were included in the derivative financial instruments liability on the balance sheet.

 

Stock-Based Compensation

 

ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant.  The expense is recognized over the period during which an employee is required to provide services in exchange for the award.  ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.  Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received.  The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “Equity -Based Payment to Non-Employees” and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.  Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

 

Fair value of financial instruments

 

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities.  We have adopted FASB ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis.  These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature as they reflect current market interest rates.   Debt is stated at its respective historical carrying amounts which approximates fair value as they reflect current market interest rates.

 

F-10


 

In accordance with ASC subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  The three tiers include:

 

·

 

Level 1 —

 

Quoted prices for identical instruments in active markets.

 

 

 

 

 

·

 

Level 2 —

 

Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.

 

 

 

 

 

·

 

Level 3 —

 

Instruments where significant value drivers are unobservable to third parties.

 

Property, equipment and depreciation and amortization

 

Expenditures for additions, renewals and improvements are capitalized at cost.  Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets.  Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.  The estimated useful lives of the major classes of depreciable assets are 3 to 5 years for lab equipment and furniture and fixtures.  Expenditures for repairs and maintenance are charged to operations as incurred.

 

Impairment of Indefinite and Long-Lived Assets

 

The Company reviews its long and indefinite lived assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired.  If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows.  If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value.  Factors that would indicate potential impairment include a significant decline in the Company’s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company’s strategic business objectives and utilization of a particular asset.  The Company noted no indications of impairment for the years ended December 31, 2014, 2013, and 2012.

 

Income Taxes

 

Income taxes have been determined using the asset and liability approach of accounting for income taxes.  Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.  Deferred taxes result from differences between the financial statement and tax bases of Trovagene’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted.  Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.  The assessment of whether or not a valuation allowance is required often requires significant judgment.

 

Contingencies

 

In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters.  In accordance with FASB ASC Topic 450, Accounting for Contingencies, Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.  Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized.

 

Cost of Revenue

 

Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

 

Research and Development

 

Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, Research and Development.  Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.

 

While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited.

 

F-11


 

ASC Topic 730, Research and Development requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized.  As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.   There were no non-refundable advance payments as of December 31, 2014 and 2013.

 

Net Loss Per Share

 

Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented.  In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share.  Shares used in calculating diluted net loss per common share exclude as antidilutive the following share equivalents:

 

 

 

December 31,

 

 

 

2014

 

2013

 

2012

 

Options to purchase Common Stock

 

4,913,472

 

4,287,545

 

3,711,303

 

Warrants to purchase Common stock

 

5,251,660

 

6,233,483

 

6,985,070

 

Series A Convertible Preferred Stock

 

63,125

 

63,125

 

99,583

 

 

 

10,228,257

 

10,584,153

 

10,795,956

 

 

The following table summarizes the Company’s diluted net loss per share:

 

 

 

December 31,

 

December 31,

 

December 31,

 

 

 

2014

 

2013

 

2012

 

Numerator:

 

 

 

 

 

 

 

Net loss

 

$

(14,348,499

)

$

(11,840,778

)

$

(11,604,201

)

Adjustment for change in fair value of derivative instruments - warrants

 

(2,422,337

)

—

 

—

 

Net loss used for diluted loss per share

 

$

(16,770,836

)

$

(11,840,778

)

$

(11,604,201

)

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

Weighted average shares used to compute basic loss per share

 

18,904,280

 

16,978,212

 

13,066,600

 

Adjustments to reflect assumed exercise of warrants

 

166,832

 

—

 

—

 

Weighted average shares used to compute diluted net loss per share

 

19,071,112

 

16,978,212

 

13,066,600

 

 

 

 

 

 

 

 

 

Net loss per share diluted

 

$

(0.88

)

$

(0.70

)

$

(0.89

)

 

F-12


 

Recent Accounting Pronouncements

 

In January 2015, the Financial Accounting Standards Board (the FASB) issued an amendment to the accounting guidance related to the presentation of extraordinary items. The amendment simplifies the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2015. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.

 

In August 2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.

 

In June 2014, the FASB issued an accounting standards update that removes the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to: (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption.  The Company elected early adoption, and does not believe the adoption of the standard had a material impact on its financial position, results of operations or related financial statement disclosures.

 

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.

 

3.  Asset Purchase

 

                                                On February 1, 2012 the Company entered into an asset purchase agreement with MultiGen Diagnostics, Inc.   The Company determined that the acquired asset did not meet the definition of a business, as defined in ASC 805, Business Combinations and was accounted for under ASC 350, Intangibles- Goodwill and Other.   In connection with the acquisition, the Company issued 125,000 shares of restricted common stock to MultiGEN.   In addition, up to an additional $3.7 million may be paid in a combination of common stock and cash to MultiGEN upon the achievement of specific sales and earnings targets.  The Company is no longer offering these tests and has no plans to offer these tests. The Company does not anticipate any additional payments will become due. In addition, in connection with the acquisition, the Company entered into a Reagent Supply Agreement dated as of February 1, 2012 pursuant to which MultiGEN will supply and deliver reagents to be used in connection with a CLIA laboratory.   The total purchase consideration was determined to be $187,500 which was paid in the Company’s common stock and allocated to an indefinite lived intangible asset related to the CLIA license.

 

F-13


 

Under ASC Topic 805, Business Combinations, the Company was required to assess the fair value of the assets acquired and the contingent consideration at the date of acquisition.  Therefore, the Company assessed the fair value of the assets purchased and concluded that the purchase price would be allocated entirely to one intangible asset, a CLIA license.   The contingent consideration of the $3.7 million milestone was determined to have no fair value by applying a weighted average probability on the achievement of the milestones developed during the valuation process.   The Company assesses the fair value of the contingent consideration at each quarter and makes adjustments as necessary until the milestone dates have expired.   As of December 31, 2014 and 2013, no adjustments to the fair value of the contingent consideration have been necessary, and therefore the fair value of the contingent consideration remains unchanged.

 

4.  Property and Equipment

 

Fixed assets consist of laboratory, testing and computer equipment and fixtures stated at cost.  Depreciation and amortization expense for the years ended December 31, 2014, 2013 and 2012 was $234,813, $130,520 and $41,842, respectively.  Property and equipment consisted of the following:

 

 

 

As of December 31,

 

 

 

2014

 

2013

 

Furniture and office equipment

 

$

365,955

 

$

236,645

 

Leasehold Improvements

 

39,401

 

36,371

 

Laboratory equipment

 

968,901

 

826,151

 

 

 

1,374,257

 

1,099,167

 

Less—accumulated depreciation and amortization

 

(533,870

)

(348,602

)

Property and equipment, net

 

$

840,387

 

$

750,565

 

 

5.  Stockholders’ Equity (Deficiency)

 

All share and per share amounts have been restated to reflect the one-for-six reverse stock split effected on May 29, 2012 as described in Note 2.

 

Common Stock

 

During the year ended December 31, 2012, the Company closed five private placement financings which raised gross proceeds of $6,320,000.  In total, the Company issued 1,738,333 shares of its common stock and warrants to purchase 1,738,333 shares of common stock (“units”).

 

The purchase price paid by the investors for 633,333 of the units sold in the period January 2012 through May 2012 was $3.00 each, determined by the price paid by investors in recent private placements.   The warrants expire after eight years and are exercisable at $3.00 per share.  The Company paid $96,500 in cash for a finder’s fee.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene determined that the warrants issued in connection with these private placements should be recorded as derivative liabilities at the time of issuance since they are all price protected however the completion of the underwritten public offering on May 30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.   Accordingly, the fair value of these warrants were marked to market through May 30, 2012 and then reclassified from a liability to additional paid in capital.

 

The purchase price paid by the investors for 1,105,000 of the units sold in the fourth quarter of 2012 was $4.00 each, determined by the market price on NASDAQ.   The warrants expire after five years and are exercisable at $5.32 per share.  The Company paid $24,989 in cash for a finder’s fee.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that the warrants issued in connection with these private placements should be recorded as derivative liabilities at the time of issuance since they are all price protected.   The fair value of the warrants on the date of issuance was $1,031,281.  However, the completion of the public offering in July 2013 removed the condition which required these warrants to be treated as derivative liabilities.  Accordingly, the fair value of these warrants were marked to market through July 18, 2013 and then reclassified from a liability to additional paid in capital.

 

On May 30, 2012, the Company completed an underwritten public offering in which an aggregate of 1,150,000 units, with each unit consisting of two shares of its common stock and one warrant to purchase one share of common stock were sold at a purchase price of $8.00 per unit.  On June 13, 2012 the underwriters exercised their overallotment option in full for an additional 172,500 units.   In addition, the Company issued 92,000 warrants to selling agents at an exercise price of $7.00.   The warrants were immediately exercisable and expire on May 29, 2017.   Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging - Contracts in an Entity’s Own Equity”, Trovagene determined that the warrants issued in connection with this transaction were not derivative liabilities.   The Company raised a total of $9.1 million in net proceeds after deducting underwriting discounts and commissions of $0.7 million and offering expenses of $0.7 million.

 

F-14


 

During the year ended December 31, 2012, the Company issued in total 174,100 units to a selling agent, who is also a shareholder of the Company, consisting of 174,100 shares of common stock and warrants to purchase 174,100 shares of common stock.  Of the total warrants issued, 30,450 issued in the period January 2012 through May 2012 have an exercise price of $3.00 per share, are immediately exercisable and expire December 31, 2018.   The remaining 143,650 warrants issued in the fourth quarter of 2012, have an exercise price of $5.32, are immediately exercisable, and expire five years from the date of issuance.   The units were issued as a finder’s fee in connection with certain private placements closed during the year ended December 31, 2012.  The issuance of these units was treated as a non-compensatory cost of capital.

 

During the year ended December 31, 2012, the Company issued 40,000 units to Panetta Partners, Ltd., consisting of 40,000 shares of common stock and warrants to purchase 40,000 shares of common stock.   Gabriele Cerrone, previously a member of the Board of Directors of Trovagene, is a director of Panetta Partners, Ltd.   The warrants have an exercise price of $5.32, are immediately exercisable, and expire five years from the date of issuance.  The units were issued for advisory services in connection with the private placements closed in the fourth quarter of 2012.   The issuance of these units was treated as a non-compensatory cost of capital.   In addition, the Company issued a warrant to purchase 50,000 shares of common stock to Panetta Partners, Ltd. at an exercise price of $4.14 for consulting services.   The warrant was immediately exercisable and expires on December 10, 2017.   The fair value of the warrant issued was determined using the Black-Scholes method.   A total of approximately $133,000 was charged to general and administrative expenses in the Company’s consolidated statement of operations in 2012.

 

During the year ended December 31, 2012, the Company issued 125,000 shares of common stock in connection with an asset purchase agreement with MultiGen Diagnostics, Inc.   See Note 3.

 

During the year ended December 31, 2012, the Company issued 9,916 shares of common stock in connection with consulting agreements.   The fair value of the stock issued was determined using the Black-Scholes method.   A total of $22,381 was charged to general and administrative expense in the Company’s consolidated statement of operations in 2012.

 

In December 2012, a Trovagene warrant holder exercised warrants to purchase 16,667 on a net exercise basis and received a total of 8,602 shares of common stock.  The exercise price of the warrants was $3.00.

 

In December 2012, a Trovagene option holder exercised his option and purchased a total of 200 shares of common stock.  Trovagene raised gross proceeds of $600 as a result of the option exercise.  The purchase price paid by the option holder was $3.00.

 

On January 25, 2013, the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000.  The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities.   This form was declared effective on February 4, 2013.   In addition, in connection with the Form S-3, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.   As payment for its services, the Agent is entitled to a 3% commission on gross proceeds.   The Company has received gross proceeds of approximately $4.2 million from the sale of 488,476 shares of its common stock during the year ended December 31, 2013 under the agreement with the Agent.   In addition, the Company has received gross proceeds of approximately $15.0 million from the sale of 2,142,857 shares of its common stock through a registered direct offering that occurred in July 2013.

 

During the year ended December 31, 2013, the Company issued a total of 3,424,605 shares of common stock.  The Company sold 2,631,332 shares of Common Stock for net proceeds of $18,829,644.   In addition, 36,458 shares were issued upon conversion of Series A Preferred Stock, 715,743 shares were issued upon exercise of 715,743 warrants for a weighted average price of $5.02 and 7,284 shares were issued upon net exercise of 12,745 warrants at an exercise price of $3.00.   The remaining 33,788 shares include 22,955 shares that were issued upon net exercise of an option for 41,667 shares at an exercise price of $4.50 and the exercise of an option for 10,833 shares at a weighted average exercise price of $3.53.

 

During the year ended December 31, 2014, the Company issued a total of 13,011 shares of common stock upon the net exercise of warrants at a weighted average exercise price of $3.00.

 

F-15


 

Warrants

 

During the years ended December 31, 2014, 2013, and 2012, warrant activity was as follows:

 

 

 

Number
of
Warrants

 

Weighted
Average
Exercise
price

 

Term

 

Warrants Outstanding 12/31/2011

 

3,601,474

 

$

3.18

 

1-8 years

 

Granted

 

3,416,934

 

$

4.88

 

 

 

Exercised

 

(16,667

)

 

 

 

 

Expired

 

(16,671

)

$

3.00

 

 

 

Warrants Outstanding 12/31/2012

 

6,985,070

 

$

3.96

 

1 - 6 years

 

Granted

 

50,000

 

$

8.00

 

 

 

Exercised

 

(728,488

)

4.99

 

 

 

Expired

 

(73,099

)

$

4.50

 

 

 

Warrants Outstanding 12/31/2013

 

6,233,483

 

$

3.87

 

1 -5 years

 

Granted

 

85,470

 

$

3.51

 

 

 

Exercised

 

(36,666

)

$

3.00

 

 

 

Expired

 

(16,667

)

$

10.80

 

 

 

Warrants Outstanding 12/31/2014

 

6,265,620

 

$

3.85

 

1 – 4 years

 

 

The Company granted a total of 3,416,934 warrants during the year ended December 31, 2012.   Of the total warrants granted, 713,784 were warrants that were price protected.   These warrants had an exercise price of $3.00 per share and expire on December 31, 2018.   The fair value of these warrants was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which warrant holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  The completion of the underwritten public offering on May 30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.   Accordingly, the fair value of these warrants were marked to market through May 30, 2012 and then reclassified from a liability to additional paid in capital.  See Note 7.   In connection with underwritten public offering and sale of units in May 2012, 1,414,500 warrants were issued with exercise prices ranging from $5.32 to $7.00 and an expiration date five years after date of issuance.   Warrants issued in connection with the underwritten public offering and sale of units are not considered derivatives based on Trovagene’s analysis of the criteria of ASC 815, as the Company is not required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of warrant shares.  An additional 1,288,650 warrants in the fourth quarter of 2012 were warrants that are price protected.   These warrants have an exercise price of $5.32 per share and have an expiration date of five years from issuance.  The fair value of these warrants was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which warrant holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  See Note 7.

 

The Company issued a warrant to purchase 50,000 shares of common stock at an exercise price of $8.00 per share, during the year ended December 31, 2013.   The warrants were issued in connection with an agreement to provide services related to investor and public relations materials and expire three years from date of grant.   The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:  a risk-free interest rate of 0.42%, dividend yield of 0%, expected volatility of 97% and expected term of three years.   The resulting fair value of $198,791 was recorded as stock based compensation expense.

 

The Company issued warrants to purchase 85,470 shares of common stock at an exercise price of $3.51 per share, during the year ended December 31, 2014.   The warrants were issued in connection with a $15.0 million debt agreement. The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:  a risk-free interest rate of 2.53%, dividend yield of 0%, expected volatility of 73.8% and expected term of ten years.   The resulting fair value of $235,857 was recorded as a debt discount and will be amortized to interest expense over the term of the loan using the effective interest method.

 

F-16


 

Series A Convertible Preferred Stock

 

The material terms of the Series A Convertible Preferred Stock consist of:

 

1)  Dividends.  Holders of the Series A Convertible Preferred Stock shall be entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005.  Dividends shall be payable, at the Company’s sole election, in cash or shares of common stock.  As of December 31, 2014 and 2013, the Company had $244,055 and $221,040, respectively in accrued cumulative unpaid preferred stock dividends, included in Accrued Expenses in the Company’s consolidated balance sheets, and $23,015, $29,840, and $38,240, was recorded during the years ended December 31, 2014, 2013, and 2012, respectively.

 

2)  Voting Rights.  Shares of the Series A Convertible Preferred Stock shall have no voting rights.  However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its articles of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.

 

3)  Liquidation.  Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock shall be entitled to receive an amount equal to the Stated Value per share, which is $10 per share plus any accrued and unpaid dividends.

 

4)  Conversion Rights.  Each share of Series A Convertible Preferred Stock shall be convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, originally $2.15 per share.

 

5)  Subsequent Equity Sales.  The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning upon registration of the common stock underlying the Series A Convertible Preferred Stock.  The relevant registration statement became effective March 17, 2006 and during the following twelve month period the conversion price was adjusted to $9.60 per share.

 

6)  Automatic Conversion.  Beginning July 13, 2006, if the price of the common stock equals $25.80 per share for 20 consecutive trading days, and an average of 8,333 shares of common stock per day shall have been traded during the 20 trading days, the Company shall have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, to convert any portion of the shares of Series A Convertible Preferred Stock into shares of Common Stock at the conversion price.  As of the date of these financial statements, such conditions have not been met.

 

During the year ended December 31, 2013, 35,000 shares of Series A Convertible Preferred Stock were converted into 36,458 shares of common stock, on a net converted basis.  As of December 31, 2014 and 2013, and 2012, there were 60,600, 60,600, and 95,600 shares of Series A Convertible Preferred Stock outstanding.

 

6.  Stock Option Plan

 

In June 2004 the Company adopted the Trovagene Stock Option Plan, as amended (the “2004 Plan”), under which up to 6,000,000 shares common stock were reserved for issuance to directors, eligible employees, including executive officers and consultants.  The 2004 Plan provided for the grant of stock options to eligible recipients. Generally, vesting for options granted under the Plan was from three to four years, and options expird after a 10-year period.  Options were granted at an exercise price not less than the fair market value at the date of grant.  As of December 31, 2014 the 2004 Plan was expired.  As of December 31, 2013, there were 1,788,921 shares available for issuance under the 2004 Plan.

 

During 2013, the Company issued 260,000 options over the authorized number of options in the 2004 Plan.  As per ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s statement of operations.  Stockholder approval was obtained on July 18, 2013 to increase the number of authorized shares in the Plan from 3,666,667 to 6,000,000.  Accordingly, the options were remeasured as of the date of stockholder approval with the change recorded in stock based compensation expense and the $23,024 liability was reclassified to additional paid in capital.

 

F-17


 

In July 2013, an option to purchase 90,000 shares of common stock was granted to a Board Director for services provided outside of routine Board of Directors’ services.  These options were immediately vested.  The fair value of this option was approximately $500,000 and is included in general and administrative expenses.

 

The Trovagene Inc. 2014 Equity Incentive Plan, (the “2014 EIP’)  authorizing up to 2,500,000 shares of common stock for issuance under the Plan, was approved by the Board of Directors in June 2014 and approved by the Shareholders at the September 17, 2014 Annual Shareholders’ Meeting.  As of December 31, 2014, there were 1,371,832 shares available for issuance under the 2014 EIP.

 

Stock-based compensation has been recognized in operating results as follows:

 

 

 

Years ended December 31,

 

 

 

2014

 

2013

 

2012

 

In research and development expenses

 

$

796,008

 

$

549,465

 

$

136,148

 

In general and administrative expenses

 

1,274,186

 

1,429,899

 

395,992

 

Total stock based compensation

 

$

2,070,194

 

$

1,979,364

 

$

532,140

 

 

The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:

 

 

 

Years ended December 31,

 

 

 

2014

 

2013

 

2012

 

Risk-free interest rate

 

1.42% - 2.1%

 

.74% - 1.5%

 

.62% - 1.04%

 

Dividend yield

 

0%

 

0%

 

0%

 

Expected volatility

 

81% - 86%

 

82% - 100%

 

90% - 97%

 

Expected term (in years)

 

5.0 yrs

 

5.0 yrs

 

5.0 yrs

 

Stock price

 

$3.00 - $6.74

 

$5.53 - $8.15

 

$0.50 - $4.87

 

 

Risk-free interest rate — Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company’s stock options.

 

Dividend yield — Trovagene has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.

 

Expected volatility — Based on the historical volatility of a group of peer companies with attributes similar to Trovagene.

 

Expected term — The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment, (“SAB No. 107”), which averages an award’s weighted-average vesting period and expected term for “plain vanilla” share options.  Under SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.

 

Forfeitures — ASC Topic 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company estimates forfeitures based on its historical experience.

 

The weighted-average fair value per share of all options granted during the years ended December 31, 2014, 2013, and 2012, estimated as of the grant date using the Black-Scholes option valuation model was $2.19, $4.54, and $2.12, per share, respectively.

 

The unrecognized compensation cost related to non-vested stock options outstanding at December 31, 2014 and December 31, 2013 was $4,862,030 and $3,733,753, respectively.  The weighted-average remaining contractual term at December 31, 2014 and 2013 for options outstanding and vested options was 3.0 and 6.7, respectively.

 

F-18


 

A summary of stock option activity and of changes in stock options outstanding is presented below:

 

 

 

Number of
Options

 

Weighted
Average
Exercise
Price Per
Share

 

Intrinsic
Value

 

Weighted Average
Remaining
Contractual Life

 

Balance outstanding, December 31, 2011

 

2,426,192

 

$

5.22

 

$

—

 

6.7 years

 

Granted

 

1,294,668

 

$

3.74

 

 

 

 

 

Exercised

 

(200

)

$

3.00

 

$

640

 

 

 

Forfeited

 

(9,357

)

$

3.00

 

 

 

 

 

Balance outstanding, December 31, 2012

 

3,711,303

 

$

4.69

 

$

8,301,484

 

6.3 years

 

Granted

 

1,144,760

 

$

6.33

 

 

 

 

 

Exercised

 

(52,500

)

$

4.30

 

$

275,492

 

 

 

Forfeited

 

(516,018

)

$

4.35

 

 

 

 

 

Balance outstanding, December 31, 2013

 

4,287,545

 

$

5.18

 

$

5,896,329

 

6.7 years

 

Granted

 

1,410,038

 

$

4.42

 

 

 

 

 

Forfeited

 

(784,111

)

$

7.08

 

 

 

 

 

Balance outstanding, December 31, 2014

 

4,913,472

 

$

4.66

 

$

2,808,083

 

7.6 years

 

Vested and exercisable, December 31, 2014

 

2,434,124

 

$

4.65

 

$

1,990,187

 

6.2 years

 

 

ASC Topic 718 requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities.  Due to Trovagene’s accumulated deficit position, no tax benefits have been recognized in the cash flow statement.

 

7.  Derivative Financial Instruments - Warrants

 

Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that certain warrants issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital as they were issued with other equity instruments.  In accordance with ASC Topic 815-40, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s statement of operations.  The Company estimates the fair value of (i) certain of these warrants using the Black-Scholes option pricing model and (ii) estimates the fair value of the price protected units using the Binomial option pricing model in order to determine the associated derivative instrument liability and change in fair value described above.

 

Warrants - Black-Scholes Option Pricing Model

 

The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:

 

 

 

Year ended
December 31, 2014

 

Year ended
December 31, 2013

 

Year ended
December 31, 2012

 

Estimated fair value of Trovagene common stock

 

$3.00 - $6.74

 

$5.74 - $7.18

 

$0.02 - $5.93

 

Expected warrant term

 

4.0 years

 

1 month 5.8 years

 

10 months to 6 years

 

Risk-free interest rate

 

1.38%

 

.03%-1.75%

 

.06% - 1.54%

 

Expected volatility

 

86.4%

 

82%-100%

 

90%-97%

 

Dividend yield

 

0%

 

0%

 

0%

 

 

Expected volatility is based on the volatility of a peer group of companies with attributes similar to Trovagene.  The warrants have a transferability provision and based on guidance provided in SAB 107 for instruments issued with such a provision, Trovagene used the full contractual term as the expected term of the warrants.  The risk free rate is based on the U.S.  Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.

 

F-19


 

The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.  For the period ending December 31, 2013, the derivative financial instruments liability in the table below only represents the Black-Scholes calculation whereas the loss recognized in the Statement of Operations represents both the Black-Scholes and the binomial methodology.

 

Date

 

Description

 

Number of
Warrants

 

Derivative
Instrument
Liability

 

December 31, 2011

 

Balance of derivative financial instruments liability

 

1,103,727

 

$

994,627

 

 

 

Expired warrants

 

(16,667

)

—

 

 

 

Change in fair value of warrants during the year recognized as a loss in the statement of operations

 

—

 

5,258,133

 

December 31, 2012

 

Balance of derivative financial instruments liability

 

1,087,060

 

6,252,760

 

 

 

Expired warrants

 

(73,099

)

—

 

 

 

Change in fair value of warrants during the year recognized as a gain in the statement of operations

 

—

 

(1,820,889

)

December 31, 2013

 

Balance of derivative financial instruments liability

 

1,013,961

 

$

4,431,871

 

 

 

Change in fair value of warrants during the year recognized as a gain in the statement of operations

 

—

 

(1,425,850

)

December 31, 2014

 

Balance of derivative financial instruments liability

 

1,013,961

 

$

3,006,021

 

 

Warrants - Binomial Option Pricing Model

 

During the year ended 2011 and through May 2012, the Company issued 713,784 and 1,048,175 units, respectively, at $3.00 per unit.  The units had a per unit price protection clause whereby from the date of issuance until the earlier of (i) thirty months from the final Closing or (ii) the closing date of a Subsequent Financing which generates within a one year period an amount equal to or in excess of $5,000,000, if the Company shall issue any Common Stock or Common Stock Equivalents, in a Subsequent Financing at an effective price per share less than the Per Unit Purchase Price, the Company shall issue to such the number of additional Units equal to (a) the Subscription Amount Investor at the Closing divided by the Discounted Purchase Price, less (b) the Units issued to such Investor at the Closing.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital.  The price protected unit’s warrants had an exercise price of $3.00 per share and had expiration dates ranging from June 30, 2014 to December 31, 2018.  The fair value of these price protected units was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  However, the completion of the underwritten public offering on May 30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.  Accordingly, the fair value of these warrants were marked to market through May 30, 2012 and then reclassified from a liability to additional paid in capital.

 

In addition, during the fourth quarter of 2012, the Company issued a total of 1,288,650 units at $4.00 per unit.  The units had a per unit price protection clause whereby from the date of issuance until the earlier of (i) forty-eight months from the final Closing or (ii) the closing date of a Subsequent Financing which generates within a one year period an amount equal to or in excess of $10,000,000, if the Company shall issue any Common Stock or Common Stock Equivalents, in a Subsequent Financing at an effective price per share less than the Per Unit Purchase Price, the Company shall issue to such the number of additional Units equal to (a) the Subscription Amount Investor at the Closing divided by the Discounted Purchase Price, less (b) the Units issued to such Investor at the Closing.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital.  The price protected unit’s warrants had an exercise price of $5.32 per share and had expiration dates five years from date of issuance.  The fair value of these price protected units was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  However, the completion of the public offering in July 2013 removed the condition which required these warrants to be treated as derivative liabilities.  Accordingly, the fair value of these warrants were marked to market through July 18, 2013 and then reclassified from a liability to additional paid in capital.

 

The fair value of the warrants granted during the year ended December 31, 2012 was estimated under the binomial method using the following weighted average assumptions:

 

 

 

2012

 

 

 

 

 

Range of risk-free interest rates

 

0.53% to 1.61%

 

Range of expected volatility

 

90% -97%

 

Expected fair value of the stock

 

$0.25- $3.21

 

Expected warrant term

 

2 years to 6.75 years

 

 

F-20


 

The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Binomial option pricing method, for the periods indicated:

 

Date

 

Number of
Price Protected
Units

 

Derivative
Liability For
Issued Units

 

Change In
Fair
value of
Derivative
Liability For
Previously
Outstanding
Price
Protected
Units

 

Ending
Balance
Derivative
Liability

 

December 31, 2012

 

1,288,650

 

1,171,463

 

1,341,405

 

2,512,868

 

Reclassification of derivative liability to equity

 

(1,288,650

)

—

 

(5,417,871

)

(5,417,871

)

Change in fair value of warrants during the year recognized as a loss in the statement of operations

 

—

 

—

 

2,905,003

 

2,905,003

 

December 31, 2013

 

—

 

$

1,171,463

 

$

(1,171,463

)

$

—

 

 

The weighted average remaining contractual term of all of the Company’s warrants outstanding at December 31, 2014 and 2013 was approximately 3.6 and 4.0 years, respectively.

 

At December 31, 2014 and 2013, the total fair value of the above warrants accounted for as derivative financial instruments, valued using the Black-Scholes option pricing model was $3,006,021 and $4,431,871, respectively, and is classified as derivative financial instruments liability on the balance sheet.

 

8.  Fair Value Measurements

 

The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2014 and 2013:

 

 

 

Fair Value Measurements at

 

 

 

December 31, 2014

 

 

 

Quoted Prices
in Active
Markets for
Identical Assets
and Liabilities
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

Money market fund (1)

 

$

27,123,587

 

$

—

 

$

—

 

27,123,587

 

Total Assets

 

$

27,123,587

 

$

—

 

$

—

 

$

27,123,587

 

Liabilities:

 

 

 

 

 

 

 

 

 

Derivative liabilities related to warrants

 

—

 

$

—

 

$

3,006,021

 

$

3,006,021

 

Total Liabilities

 

$

—

 

$

—

 

$

3,006,021

 

$

3,006,021

 

 

 

 

Fair Value Measurements at

 

 

 

December 31, 2013

 

 

 

Quoted Prices
in Active
Markets for
Identical Assets
and Liabilities
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

Money market fund (1)

 

$

25,703,330

 

$

—

 

$

—

 

25,703,330

 

Total Assets

 

$

25,703,330

 

$

—

 

$

—

 

$

25,703,330

 

Liabilities:

 

 

 

 

 

 

 

 

 

Derivative liabilities related to warrants

 

—

 

$

—

 

$

4,431,871

 

$

4,431,871

 

Total Liabilities

 

$

—

 

$

—

 

$

4,431,871

 

$

4,431,871

 

 

(1) Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet.

 

F-21


 

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the years ended December 31, 2014 and 2013:

 

Description

 

Balance at
December 31,
2013

 

Unrealized
(gains) or
losses

 

Balance as of
December 31,
2014

 

Derivative liabilities related to Warrants

 

$

4,431,871

 

$

(1,425,850

)

$

3,006,021

 

 

Description

 

Balance at
December 31,
2012

 

Fair Value of
Warrants
Reclassified to
Additional Paid in
Capital

 

Unrealized
(gains) or
losses

 

Balance as of
December 31,
2013

 

Derivative liabilities related to Warrants

 

$

8,765,628

 

(5,417,871

)

1,084,114

 

4,431,871

 

 

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company’s statement of operations.  A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40.  At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

 

9.  Debt

 

Loan and Security Agreement

 

In June 2014, the Company entered into a $15,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing.  A portion of the proceeds were used to repay the existing equipment loan.  The repayment with the same lender was accounted for as a debt extinguishment under ASC Topic 470-50, Debt.  The interest rate on the new loan is 7.07% per annum.  The Company will make interest only payments on the outstanding amount of the loan on a monthly basis through July 2015, after which equal monthly payments of principal and interest are due until the loan maturity date of July 1, 2018.  The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge.  In connection with the loan, the lenders received a warrant to purchase an aggregate 85,470 shares of the Company’s common stock at an exercise price of $3.51 per share exercisable for ten years from the date of issuance. The original value of the warrants, totaling $235,857, was recorded as debt discount and additional paid-in capital as the warrants were equity classified.

 

At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount.  In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $1,050,000.

 

The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt and pay dividends.  In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.

 

As of December 31, 2014, amounts due under the agreement include $1,898,548 in current liabilities and $13,053,117 in long-term liabilities, which includes $191,682 of accrued interest.

 

F-22


 

At December 31, 2014, Trovagene was in compliance with all covenants under the Loan and Security Agreement.  .

 

The Company recorded $843,260 in interest expense related to the Loan and Security Agreement during the year ended December 31, 2014.  Closing costs are being accreted over the life of the loan to interest expense.

 

Future maturities of long-term debt at December 31, 2014 are as follows:

 

2015

 

$

1,898,548

 

2016

 

4,790,628

 

2017

 

5,140,519

 

2018

 

3,170,305

 

Total long-term obligations

 

$

15,000,000

 

 

10.  Income Taxes

 

At December 31, 2014, Trovagene has federal net operating loss carryforwards (NOLs) of approximately $49.3 million, which, if not used, expire beginning in 2020.   Trovagene also has California NOLs of approximately $ 29.9 million which begin to expire in 2021 and New Jersey NOLs of $11.5 million which started to expire on January 31, 2013.   Trovagene also has R&D credits available for federal purposes of approximately $698,000. The federal R&D credits will begin to expire January 31, 2025.   The utilization of these NOLs and R&D tax credits is subject to limitations based on past and future changes in ownership of Trovagene pursuant to Internal Revenue Code Section 382.  The Company has determined that ownership changes have occurred for Internal Revenue Code Section 382 purposes and therefore, the ability of the Company to utilize its NOLs is limited.

 

Signifcant components of the Company’s taxes and the rates as of December 31, are shown below:

 

Tax Rate Reconciliation

 

Tax computed at the federal statutory rate

 

(4,871,000

)

35

%

State tax, net of federal tax benefit

 

(891,000

)

6

%

Permanent Items

 

(320,000

)

2

%

Valuation allowance increase (decrease)

 

6,081,000

 

(43

)%

Other

 

1,000

 

—

%

Provision for income taxes

 

—

 

 

 

 

Significant components of the Company’s deferred tax assets as of December 31, are shown below:

 

 

 

Years ended
December 31,

 

 

 

2014

 

2013

 

Deferred tax assets

 

 

 

 

 

Tax loss carryforwards

 

$

19,010,900

 

$

14,211,400

 

R&D credits and other tax credits

 

698,000

 

235,300

 

Stock based compensation

 

2,193,900

 

1,547,500

 

Other

 

420,800

 

230,400

 

Total deferred tax assets

 

22,323,600

 

16,224,600

 

Valuation allowance

 

(22,323,600

)

(16,224,600

)

Net deferred tax asset

 

$

—

 

$

—

 

 

The difference between the statutory rate of 35% on taxable income and the actual income tax rate of zero is a result of the full deferred tax asset valuation allowance.   The valuation allowance increased by $6,099,000 and $4,398,700 during the years ended December 31, 2014 and 2013, respectively.

 

Trovagene records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.

 

ASC 740-10-30-7, Accounting for Income Taxes had no effect on Trovagene’s financial position, cash flows or results of operations upon adoption, as Trovagene does not have any unrecognized tax benefits.  Trovagene’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense and none have been incurred to date.

 

11.  Commitments and Contingencies

 

Significant Research Agreements

 

During 2012, the Company entered into research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of cell-free DNA mutations analysis from urine samples and tumor tissue.   During 2013, the agreements were amended to increase the scope of the agreements.   Under these agreements, the Company has committed to pay approximately $266,000 for the services performed by MDACC.   As of December 31, 2014, the Company has incurred and recorded approximately $124,000 of research and development expenses related to these agreements.  There were approximately $142,000 of research and development expenses incurred during the year ended December 31, 2013.

 

F-23


 

In June 2013, the Company entered into a Research Agreement with Illumina, Inc. (“Illumina”) pursuant to which the parties will work together to evaluate the potential for integrating the Company’s cell-free technology for isolating, extracting and genetic analysis of nucleic acids from urine with Illumina’s genetic analysis sequencing technology (the “Research Plan”).   The parties have agreed that all results and reagents from the Research Plan will be shared between the parties.   The Agreement will terminate upon the earlier of 30 days after completion of the Research Plan or the one year anniversary of the Agreement unless extended by mutual written agreement.  In October 2014, the agreement was extended for an additional year to June 2015.

 

In August 2013, the Company entered into a Clinical Trial Agreement with the University of Southern California (“USC”), pursuant to which USC will provide the principal investigator and conduct the clinical trial related to the genetic characterization of metastatic colorectal cancers.   Under the agreement, the Company is committed to pay USC approximately $232,000 for services provided.   As of December 31, 2013 the Company had not incurred any expense related to this agreement.  As of December 31, 2014, the Company had incurred approximately $38,000 of research and development expenses.

 

In December 2013, the Company entered into a Clinical Trial Agreement with US Oncology Research LLC (“USOR”), pursuant to which USOR will provide the principal investigator and conduct the clinical trial related to the examining the utility of cell-free quantitative KRAS testing in disease monitoring in patients with metastatic pancreatic cancer.   Under the agreement, the Company is committed to pay USOR approximately $270,000 for services provided.   As of December 31, 2014 and 2013, the Company has incurred and recorded approximately $16,000 and $29,000 of research and development expense related to this agreement.

 

In October 2014, the Company entered into a Research Agreement with Genomac International, Ltd., pursuant to which Genomac will conduct a research study of minimally invasive molecular monitoring of efficiency of targeted biological therapy in advanced non-small lung cancer.   Under the agreement, the Company is committed to pay Genomac approximately $175,000 for services provided.  As of December 31, 2014, the Company has incurred and recorded approximately $90,000 of research and development expenses.

 

License Agreements

 

In May 2006, the Company entered into a license agreement with Drs. Falini and Mecucci, wherein it obtained the exclusive rights for the genetic marker for AML and intends to utilize these rights for the development of new diagnostic tools.  In connection with this agreement, the Company paid $70,000 to Drs. Falini and Mecucci.  In August 2010 the Company signed amendment No. 1 to the license agreement with an obligation to payroyalties of 6% of royalty revenues and/or 10% of any sublicense income.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty expenses of approximately $23,000, $30,000 and $24,000, respectively.

 

During August 2007, the Company signed a sublicensing agreement with IPSOGEN SAS, a leading molecular diagnostics company with operations in France and the United States for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.  Upon execution of this agreement, IPSOGEN paid an initial licensing fee of $120,000 and may make milestone payments upon the attainment of certain regulatory and commercial milestones.  IPSOGEN will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.    In September 2010, the Company signed amendment No. 1 to the sublicensing agreement.  The amendment asserts that the Compay may require a license from a third-party to perform laboratory testing services.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty, milestone and license fee revenues of approximately $60,000, $60,000 and $180,000, respectively.  During those same periods, the Company had no license fee expenses.

 

In October 2007, the Company signed a license agreement with ASURAGEN, Inc. for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.  ASURAGEN paid an initial licensing fee of $120,000 upon execution of the agreement and may make future payments to the Company upon the attainment of certain regulatory and commercial milestones.  In June 2010, the Compay signed amendment No. 1 to the co-exclusive license agreement.  The amendment asserts that the Company may require a license from a third-party to perform laboratory testing services.  ASURAGEN will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  In March 2013, we signed amendment No.  2 to the co-exclusive sublicense agreement with ASURAGEN.   The amendment limited the field of use to research use only (RUO) kits.   ASURAGEN was also granted a non-exclusive sublicense for NPMI laboratory testing services.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $50,000, $50,000 and $50,000, respectively.   During those same periods, the Company had no license fee expenses related to this agreement.

 

F-24


 

In August 2008, the Company signed a sublicensing agreement with LabCorp for the non-exclusive rights to develop and market lab testing services for NPM1, for the diagnosis and monitoring of patients with AML.  LabCorp paid an initial licensing fee of $20,000 upon execution of the agreement.  LabCorp will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends August 25, 2018.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $28,000, $20,000 and $5,000, respectively.  During those same years, the Company has not recorded any license fee expenses.

 

In December 2008, the Company signed a sublicensing agreement with InVivoScribe Technologies, Inc. for the non-exclusive rights to develop and market lab testing services for NPM1 for the diagnosis and monitoring of patients with AML.  InVivoScribe Technologies paid an initial licensing fee of $10,000 upon execution of the agreement.  InVivoScribe Technologies will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013, and 2012, the Company recorded royalty and license fee revenues of approximately $25,000, $25,000 and $27,000, respectively.  During those same periods, the Company has not recorded any license fee expenses.

 

In June 2010, the Company signed a sublicensing agreement with Skyline Diagnostics BV for the non-exclusive rights to develop, commercialize and market, research and diagnostic laboratory services for the stratification and monitoring of patients with AML.  Skyline Diagnostics BV paid an initial licensing fee of $10,000 upon execution of the agreement and may make future payments to the Company upon the attainment of certain regulatory and commercial milestones.  Skyline Diagnostics BV will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $0, $0 and $0, respectively.  During those same periods, the Company has not recorded any license fee expenses.

 

In January 2011, the Company entered into an asset purchase agreement with TTFactor S.r.l.for a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker for $10,000.  In addition the Company agreed to pay the seller of the hybridoma for a period of seven years commencing with the first sale of the antibody, annual royalties on a country by country basis.   In addition, the Company agreed to pay a percentage of all cash consideration received from licensees as an upfront license fee pursuant to any licenses of the product and a percentage of all cash consideration received from licensees as milestone payments.  The agreement was terminated in 2013.   During the years ended December 31, 2014, 2013, and 2012, there were no royalty expense, license fee or milestone payments recorded related to this agreement.

 

In February 2011, the Company entered into a sublicense agreement with MLL Münchner Leukämielabor, or MLL for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  MLL paid an initial license fee of $20,000 upon execution of the agreement and will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  MLL is obligated to pay a royalty with annual minimums of $15,000 for the first year and $20,000 thereafter.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $81,000, $85,000 and $71,000, respectively.

 

In July 2011, the Company entered into a sublicense agreement with Fairview Health Services (“Fairview”) for the non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Fairview paid an initial license fee of $10,000 upon execution of the agreement and will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  Fairview is obligated to pay a royalty with annual minimums of $1,000 each year.  During the years ended December 31, 2014, 2013, and 2012, the Company recorded royalty and license fee revenues of approximately $2,000, $1,000 and $2,000, respectively.

 

In October 2011, the Company entered into an exclusive license agreement with Gianluca Gaidano, Robert Foa and Davide Rossi for the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia.  In consideration of the license, the Company paid $1,000 as an upfront license fee and agreed to make royalty payments in the single digits on net sales if sales are made by the Company or a single digit royalty on sublicense income received by the Company if sales are made by sublicensees.  The Company has an option to purchase the licensed patent rights in the event the licensor decides to sell such licensed patent rights.  The license agreement shall continue until September 29, 2031 which is the date of the last to expire of the licensed patent rights covering the license product.  The license agreement may also be terminated upon a material breach by any party or by the Company if it is determined that it is not commercially or scientifically appropriate to further develop the license product rights.  During the years ended December 31, 2014, 2013 and 2012, no royalty expense has been recorded related to this agreement.

 

F-25


 

In December 2011, the Company entered into an exclusive license agreement with Columbia University to license the patent rights to hairy cell leukemia biomarkers.  In consideration of the license, the Company paid $1,000 as an upfront license fee and agreed to make royalty payments in the single digits on net sales if sales are made by the Company or a single digit royalty on sublicense income received by the Company if sales are made by sublicensees.  The license agreement shall continue until May 10, 2021 which is the date of the last to expire of the licensed patent rights covering the license product.  The license agreement may also be terminated upon a material breach by any party or by the Company if we determine that it is not commercially or scientifically appropriate to further develop the license product rights.  During the years ended December 31, 2014, 2013 and 2012, no royalty expense has been recorded related to this agreement.

 

In September 2012, the Company entered into a sublicense agreement with Quest Diagnostics for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $20,000 due upon execution of the agreement and royalty payments on net sales of Quest Diagnostics and its affiliates.   During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $26,000, $14,000 and $20,000, respectively.

 

In September 2012, the Company entered into a collaboration and license agreement with Strand Life Sciences (“Strand”) related to the validation and commercial launch of a urine based DNA test for Human Papillomavirus.   Under this agreement, the Company has granted a license for use of its tests to Strand in exchange for royalty payments on net sales earned in the territory specified in the agreement.   During the years ended December 31, 2014, 2013 and 2012, the Company has recorded no royalty and license fee revenues related to this agreement.

 

In November 2012, the Company entered into a sublicense agreement with Duke University and Duke University Health Systems for non-exclusive rights to develop and market laboratory testing services for NPM1 for diagnosis and monitoring of patients with AML.   Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $5,000 due upon execution of the agreement and royalty payments on net revenues.   During the years ended December 31, 2014, 2013 and 2012, the Company has recorded $1,000, $0 and $5,000, respectively of royalty and license fee revenues related to this agreement.

 

In December 2012, the Company entered into a sublicense agreement with Genoptix, Inc. for non-exclusive worldwide rights to develop and market laboratory testing services for NPM1 for diagnosis and monitoring of patients with AML.   Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $100,000 due upon execution of the agreement and royalty payments on net revenues.   During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $30,000, $10,000 and $100,000, respectively.

 

Litigation

 

Trovagene does not believe that the Company has legal liabilities that are probable or reasonably possible that require either accrual or disclosure.  From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.  However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

 

We are not currently a party to any material legal proceedings.

 

Employment and Consulting Agreements

 

During 2011, the Company entered into an executive agreement with Antonius Schuh, Ph.D. in which he agreed to serve as Chief Executive Officer.  The term of the agreement is effective as of October 4, 2011 and continues until October 4, 2015 and is automatically renewed for successive one year periods at the end to each term.  In the event that during the term of the agreement, for a period of 90 consecutive trading days, the market price of the common stock is $7.50 or more and the value of the common stock daily trading volume is $125,000 or more, the Company shall pay or issue Dr. Schuh a bonus in an amount of $3,466,466 in either cash or registered common stock or a combination thereof as mutually agreed by Dr. Schuh the Company; or in the event that during the term of the agreement, a change of control occurs where the per share enterprise value of our company equals or exceeds $7.50 per share, the Company shall pay Dr. Schuh a bonus in an amount determined by multiplying the enterprise value by 4.0%.  In the event in a change of control the per share enterprise value exceeds a minimum of $14.40 per share, $22.80 per share or $30.00 per share, Dr. Schuh shall receive a bonus in an amount determined by multiplying the incremental enterprise value by 2.5%, 2.0% or 1.5%, respectively.

 

If the executive agreement is terminated for cause or as a result of Dr. Schuh’s death or permanent disability or if Dr. Schuh terminates his agreement voluntarily, Dr. Schuh shall receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus or realization bonus earned but not yet paid through the date of termination and

 

F-26


 

(iii) all expenses reasonably incurred by Dr. Schuh prior to date of termination.  If the executive agreement is terminated without cause Dr. Schuh shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.  If the executive agreement is terminated as a result of a change of control, Dr. Schuh shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.

 

During 2012, the Company entered into an executive agreement with Steve Zaniboni in which he agreed to serve as Chief Financial Officer.  If the executive agreement is terminated by the Company for cause or as a result of Mr. Zaniboni’s death or permanent disability or if Mr. Zaniboni terminates his agreement voluntarily, Mr. Zaniboni shall receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus or realization bonus earned but not yet paid through the date of termination and (iii) all expenses reasonably incurred by Mr. Zaniboni prior to date of termination.  If the executive agreement is terminated by the Company without cause Mr. Zaniboni shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.  If the executive agreement is terminated as a result of a change of control, Mr. Zaniboni shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.

 

Lease Agreements

 

The Company leases its facilities under a noncancelable operating lease that expires in 2017.   Rent expense for the years ended December 31, 2014, 2013 and 2012 was $315,000, $294,000, and $270,000, and respectively.  The Company is also a party to various operating lease agreements for office equipment.

 

Total annual commitments under current lease agreements for each of the years ended December 31, are as follows:

 

2015

 

360,775

 

2016

 

371,324

 

2017

 

381,026

 

2018

 

6,380

 

Total

 

$

1,119,505

 

 

12.  Employee Benefit Plan

 

The Company has a retirement savings plan under Section 401(k) of the Internal Revenue Code covering its employees.  The plan allows employees to defer, up to the maximum allowed, a percentage of their income on a pre-tax basis through contributions to the plans, plus any employee of the age of 55 can participate in the caught-up dollars as allowed by IRS codes.  The Company also has a Roth investment plan that is taken after taxes.  The Company does not currently make matching contributions.

 

13.  Related Party Transactions

 

Gabriele M.  Cerrone, the Company’s former Co-Chairman, and former member of the Board of Directors, served as a consultant to the Company from June 27, 2005 until June 2008 and is affiliated with Panetta Partners Ltd.  Transactions between the Company and Mr.  Cerrone and Panetta Partners, Ltd.  is disclosed in, Note 5, Stockholders’ Equity (Deficiency).

 

F-27


 

14.  Selected Quarterly Financial Data (Unaudited)

 

The following is a summary of the quarterly results of operations of the Company for years ended December 31, 2014 and 2013:

 

 

 

Quarter Ended(1)

 

 

 

March 31

 

June 30

 

September 30

 

December 31

 

 

 

 

 

(Revised)(2)

 

 

 

 

 

 

 

(dollars in thousands, except per share data)

 

2014

 

 

 

 

 

 

 

 

 

Revenues

 

$

111

 

$

56

 

$

57

 

$

56

 

Operating expenses

 

3,371

 

3,297

 

3,997

 

4,560

 

 

 

 

 

 

 

 

 

 

 

Net loss and comprehensive loss attributable to common stockholders

 

(3,198

)

(1,079

)

(5,382

)

(4,689

)

Net loss per common share - basic

 

$

(0.17

)

$

(0.06

)

$

(0.28

)

$

(0.25

)

Net loss per common share - diluted

 

$

(0.17

)

$

(0.17

)

$

(0.28

)

$

(0.25

)

 

 

 

 

 

 

 

 

 

 

Shares used in the calculation of net loss attributable to common stockholders - basic

 

18,902,783

 

18,902,783

 

18,902,783

 

18,904,280

 

Shares used in the calculation of net loss attributable to common stockholders - diluted

 

18,902,783

 

19,232,760

 

18,902,783

 

19,071,112

 

 

 

 

 

 

 

 

 

 

 

2013

 

 

 

 

 

 

 

 

 

Revenues

 

$

119

 

$

49

 

$

44

 

$

47

 

Operating expenses

 

2,509

 

2,423

 

3,121

 

2,897

 

Net loss and comprehensive loss attributable to common stockholders

 

(1,117

)

(5,279

)

(4,407

)

(1,038

)

Net loss per common share - basic

 

$

(0.07

)

$

(0.34

)

$

(0.25

)

$

(0.05

)

Net loss per common share - diluted

 

$

(0.07

)

$

(0.34

)

$

(0.25

)

$

(0.05

)

 

 

 

 

 

 

 

 

 

 

Shares used in the calculation of net loss attributable to common stockholders - basic

 

15,510,340

 

15,583,957

 

17,870,703

 

18,900,781

 

Shares used in the calculation of net loss attributable to common stockholders - diluted

 

15,510,340

 

15,583,957

 

17,870,703

 

18,900,781

 

 

(1) Basic and diluted EPS are computed independently for each of the periods presented.   Accordingly, the sum of the quarterly EPS amount may not agree to the total for the year. (2) Second quarter fully diluted earnings per share have been adjusted for dilutive amounts related to the derivative liability. We believe that these changes are not material to the financial statements or related notes.

 

15.  Subsequent Events

 

Public Offering and Controlled Equity Offering

 

On February 11, 2015, the Company closed an underwritten public offering of 5,111,110 shares of its common stock.  The offering price was $4.50 per share and net proceeds to the Company were approximately $21.3 million. The effects of this offering would materially change the number of common shares outstanding at the end of the reporting period had the transaction occurred before December 31, 2014.

 

Related Party Consulting Agreement

 

On January 1, 2015, we entered into a consulting agreement with Tom Adams, our Chairman, pursuant to which Dr. Adams will provide consulting services to us in connection with applying our technology to infectious diseases.  The agreement is for a term of one year and Dr. Adams shall be paid $9,500 per month for his services.

 

F-28

 EX-10.6 2 a15-1864_1ex10d6.htm EX-10.6

Exhibit 10.6

 

THIRD AMENDMENT TO STANDARD INDUSTRIAL NET LEASE

 

THIS THIRD AMENDMENT TO STANDARD INDUSTRIAL NET LEASE (this “Amendment”) is entered into as of this 22nd day of October, 2012 (the “Execution Date”), by and between BMR-SORRENTO WEST LP, a Delaware limited partnership (“Landlord,” as successor-in-interest to JBC Sorrento West, LLC (“Original Landlord”)), and TROVAGENE, INC., a Delaware corporation (“Tenant,” as successor-by-merger to Xenomics, Inc. (“Original Tenant”)).

 

RECITALS

 

A.                                         WHEREAS, Original Landlord and Original Tenant entered into that certain Standard Industrial Net Lease dated as of October 28, 2009 and Addendum to Standard Industrial Net Lease attached thereto (collectively, the “Original Lease”), as amended by that certain First Amendment to Standard Industrial Net Lease dated as of September 28, 2011 (the “First Amendment”) and that certain Second Amendment to Standard Industrial Net Lease dated as of December 27, 2011 (the “Second Amendment,” collectively, as the same may have been further amended, amended and restated, supplemented or modified from time to time, the “Lease”), whereby Tenant leases certain premises consisting of a total of approximately eight thousand forty-one (8,041) Rentable Square Feet and comprised of the following spaces: (i) the “Current Premises” consisting of approximately five thousand two hundred eighty (5,280) Rentable Square Feet, commonly known as known as Suites B and C and (ii) the “Additional Premises” consisting of approximately two thousand seven hundred sixty-one (2,761) Rentable Square Feet, commonly known as Suite A (the “Additional Premises” and, together with the Current Premises, the “Premises”) from Landlord in the building at 11055 Flintkote Avenue in San Diego, California (the “Building”);

 

B.                                         WHEREAS, Landlord and Tenant desire to extend the Lease Term; and

 

C.                                         WHEREAS, Landlord and Tenant desire to modify and amend the Lease only in the respects and on the conditions hereinafter stated.

 

AGREEMENT

 

NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:

 

l.                                          Definitions. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Lease unless otherwise defined herein. The Lease, as amended by this Amendment, is referred to herein as the “Amended Lease.”

 

2.                                      Lease Term Extension.  The Lease Term is hereby extended for approximately thirty-six (36) months and the Expiration Date is hereby amended to mean December 31, 2017. The period from December 28, 2014 through the new Expiration Date is referred to herein as the “Extension Term.”

 


 

3.                                      Minimum Monthly Rent.  Commencing on the first day of the Extension Term, Tenant shall pay to Landlord Minimum Monthly Rent for the Premises in accordance with the chart below:

 

Dates

 

Rentable
Square Feet

 

Minimum
Monthly Rent
1!£r Rentable
Square Foot

 

Minimum
Monthly Rent

 

Annual
Minimum
Monthly Rent

 

December 28, 2014 - December 27, 2015

 

8,041

 

$

2.35

 

$

18,896.35

 

$

226,756.20

 

December 28, 2015 - December 27, 2016

 

8,041

 

$

2.42

 

$

19,459.22

 

$

233,510.64

 

December 28, 2016 - December 27, 2017

 

8,041

 

$

2.49

 

$

20,022.09

 

$

240,265.08

 

December 28, 2017 - December 31, 2017

 

8,041

 

$

2.57

 

$

20,665.37

*

$

247,984.44

*

 

* Note: Rental amounts are based on a full calendar month and calendar year, as applicable.

 

4.                                      Tenant Improvements.

 

4.1.                            Tenant shall cause the work (the “Tenant Improvements”) described in the Work Letter attached hereto as Exhibit A (the “Work Letter”) to be constructed in the Premises pursuant to the Work Letter at a cost to Landlord not to exceed One Hundred Forty-Four Thousand Seven Hundred Thirty-Eight Dollars ($144,738) (based upon Eighteen Dollars ($18) per Rentable Square Foot of Premises (the “TI Allowance”). The TI Allowance may be applied to the costs of (n) construction, (o) project review by Landlord (which fee shall equal three percent (3%) of the cost of the Tenant Improvements, including the TI Allowance), (p) space planning, architect, engineering and other related services performed by third parties unaffiliated with Tenant, (q) building permits and other taxes, fees, charges and levies by governmental authorities for permits or for inspections of the Tenant Improvements, and (r) costs and expenses for labor, material, equipment and fixtures. In no event shall the TI Allowance be used for (v) the cost of work that is not authorized by the Approved Plans (as defined in the Work Letter) or otherwise approved in writing by Landlord, (w) payments to Tenant or any affiliates of Tenant, (x) the purchase of any furniture, personal property or other non-building system equipment, (y)

 

2


 

costs resulting from any default by Tenant of its obligations under the Amended Lease or (z) costs that are recoverable by Tenant from a third party (e.g., insurers, warrantors, or tortfeasors).

 

4.2.                            Tenant shall have until the date (the “TI Deadline”) that is the earlier of (a) eight (8) months after the Execution Date and (b) one hundred thirty-five (135) days after Substantial Completion (as defined below) of the Tenant Improvements to expend the unused portion of the TI Allowance, after which date Landlord’s obligation to fund such costs shall expire. In the event Tenant does not use the entire TI Allowance by the TI Deadline, Tenant shall be entitled to a rent credit equal to the lesser of (a) the unused portion of the TI Allowance and (b) Eight Dollars ($8) per Rentable Square Foot of Premises. Tenant shall deliver to Landlord (y) a certificate of occupancy for the Premises suitable for the Permitted Use and (b) a Certificate of Substantial Completion in the form of the American Institute of Architects document G704, executed by the project architect and the general contractor. The term “Substantially Complete” or “Substantial Completion” means that the Tenant Improvements are substantially complete in accordance with the Approved Plans (as defined in the Work Letter), except for minor punch list items.

 

4.3.                            Upon the expiration or earlier termination of the Amended Lease, Tenant shall not be required to remove any Tenant Improvements approved by Landlord in accordance with the Work Letter. Such Tenant Improvements shall be and remain the property of Landlord, shall not be removed by Tenant at any time during the Lease Term and, upon the expiration or earlier termination of the Amended Lease, shall remain upon and be surrendered with the Premises as a part thereof.

 

5.                                      Landlord Work.  Landlord, at its sole cost and expense, shall replace the current sixty (60) kilowatt back-up generator serving the Premises with a new one hundred twenty-five (125) kilowatt back-up generator (the “Generator”) and connect the Generator to the Premises’ emergency electrical panel (the “Landlord Work”). Tenant shall be entitled to use up to its proportionate share (after deducting any power from the Generator required for the Common Areas) of power from the Generator on a non-exclusive basis with other tenants in the Building. The cost of maintaining, repairing and replacing the Generator shall constitute Operating Costs. Landlord expressly disclaims any warranties with regard to the Generator or the installation thereof, including any warranty of merchantability or fitness for a particular purpose. Landlord shall maintain the Generator in good working condition, but shall not be liable for any failure to make any repairs or to perform any maintenance that is an obligation of Landlord unless such failure shall persist for thirty (30) days after Tenant provides Landlord with written notice of the need for such repairs or maintenance (subject to extension on a day-for-day basis as a result of Force Majeure and any other event outside of Landlord’s control); provided, however, that if the nature of Landlord’s obligation is such that more than thirty (30) days are required for its performance, then Landlord shall not be liable unless Landlord does not commence performance within such thirty (30) day period and thereafter diligently prosecute the same to completion. The provisions of Article 10 of the Lease shall apply to the Generator.

 

3


 

6.                                      Rooftop Installation Area.

 

6.1.                            Tenant may use those portions of the roof of the Building approved in writing by Landlord (the “Rooftop Installation Area”) solely to operate, maintain, repair and replace rooftop antennae, mechanical equipment, communications antennas and other equipment installed by Tenant in the Rooftop Installation Area in accordance with this Article (“Tenant’s Rooftop Equipment”). Tenant’s Rooftop Equipment shall be only for Tenant’s use of the Premises for the Permitted Use.

 

6.2.                            Tenant shall install Tenant’s Rooftop Equipment at its sole cost and expense, at such times and in such manner as Landlord may reasonably designate, and in accordance with this Article and the applicable provisions of the Lease regarding Alterations. Tenant’s Rooftop Equipment and the installation thereof shall be subject to Landlord’s prior written approval, which approval shall not be unreasonably withheld. Among other reasons, Landlord may withhold approval if the installation or operation of Tenant’s Rooftop Equipment could reasonably be expected to damage the structural integrity of the Building or to transmit vibrations or noise or cause other adverse effects beyond the Premises to an extent not customary in first class laboratory buildings, unless Tenant implements measures that are acceptable to Landlord in its reasonable discretion to avoid any such damage or transmission.

 

6.3.                            Tenant shall comply with any roof or roof-related warranties.  Tenant shall obtain a letter from Landlord’s roofing contractor within thirty (30) days after completion of any Tenant work on the rooftop stating that such work did not affect any such warranties. Tenant, at its sole cost and expense, shall inspect the Rooftop Installation Area at least annually, and correct any loose bolts, fittings or other appurtenances and repair any damage to the roof caused by the installation or operation of Tenant’s Rooftop Equipment. Tenant shall not permit the installation, maintenance or operation of Tenant’s Rooftop Equipment to violate any applicable laws or constitute a nuisance. Tenant shall pay Landlord within thirty (30) days after demand (a) all applicable taxes, charges, fees or impositions imposed on Landlord by governmental authorities as the result of Tenant’s use of the Rooftop Installation Areas in excess of those for which Landlord would otherwise be responsible for the use or installation of Tenant’s Rooftop Equipment and (b) the amount of any increase in Landlord’s insurance premiums as a result of the installation of Tenant’s Rooftop Equipment. Upon Tenant’s written request to Landlord, Landlord shall use commercially reasonable efforts to cause other tenants to remedy any interference in the operation of Tenant’s Rooftop Equipment caused by any such tenants’ equipment installed after the applicable piece of Tenant’s Rooftop Equipment; provided, however, that Landlord shall not be required to request that such tenants waive their rights under their respective leases.

 

6.4.                                 If Tenant’s Rooftop Equipment (a) causes physical damage to the structural integrity of the Building, (b) interferes with any telecommunications, mechanical or other systems located at or near or servicing the Building or the Center that were installed prior to the installation of Tenant’s Rooftop Equipment, (c) interferes with any other service provided to other tenants in the Building or the Center by rooftop or penthouse installations that were installed prior to the installation of Tenant’s Rooftop Equipment or (d) interferes with any other tenants’ business, in each case in excess of that permissible under Federal Communications Commission regulations, then Tenant shall cooperate with Landlord to determine the source of the damage or interference and promptly repair such damage and eliminate such interference, in

 

4


 

each case at Tenant’s sole cost and expense, within ten (10) days after receipt of notice of such damage or interference (which notice may be oral; provided that Landlord also delivers to Tenant written notice of such damage or interference within twenty-four (24) hours after providing oral notice).

 

6.5.                            Landlord reserves the right to cause Tenant to relocate Tenant’s Rooftop Equipment to comparably functional space on the roof or in the penthouse of the Building by giving Tenant prior written notice thereof. Landlord agrees to pay the reasonable costs thereof. Tenant shall arrange for the relocation of Tenant’s Rooftop Equipment within sixty (60) days after receipt of Landlord’s notification of such relocation. In the event Tenant fails to arrange for relocation within such sixty (60)-day period, Landlord shall have the right to arrange for the relocation of Tenant’s Rooftop Equipment in a manner that does not unnecessarily interrupt or interfere with Tenant’s use of the Premises for the Permitted Use.

 

7.                                      Utilities. Within thirty (30) days after the Execution Date, Tenant shall cause the electric and gas service supplied to the Premises to be transferred into Tenant’s name and shall pay the applicable utility provider directly for all amounts due in accordance with Article 10 of the Lease.

 

8.                                      Condition of Premises. Tenant acknowledges that (a) it is in possession of and is fully familiar with the condition of the Premises and, notwithstanding anything contained in the Amended Lease to the contrary, agrees to take the same in its condition “as is” as of the first day of the Extension Term, and (b) Landlord shall have no obligation to alter, repair or otherwise prepare the Premises for Tenant’s continued occupancy for the Extension Term or to pay for any improvements to the Premises, except as may be expressly provided in this Amendment.

 

9.                                      Relocation Space. Upon Tenant’s written request, Landlord shall endeavor to provide expansion space within the Center or to relocate Tenant to a larger space within the Center or at another property owned by Landlord or an affiliate of Landlord; provided, that, in each case, Landlord (or Landlord’s affiliate) and Tenant can mutually agree upon acceptable terms for such relocation or expansion space, as applicable. Landlord shall endeavor to provide Tenant with any such relocation options (or the lack thereof) within ten (10) business days after Landlord’s receipt of Tenant’s written request therefor. For purposes of clarity, Landlord’s and Tenant’s inability to mutually agree upon the terms for any relocation or expansion space shall not affect the validity of the Amended Lease in any way and the Amended Lease shall continue in full force and effect.

 

10.                               Option to Extend Term. Tenant shall have the option (the “Option”) to extend the Lease Term by three (3) years as to the entire Premises (and no less than the entire Premises) upon the following terms and conditions. Any extension of the Lease Term pursuant to the Option shall be on all the same terms and conditions as the Amended Lease, except as follows:

 

10.1.                         Minimum Monthly Rent at the commencement of the Option term shall equal the then-current fair market value for comparable office and laboratory space in the Sorrento Valley submarket of comparable age, quality, level of finish and proximity to amenities and public transit (“FMV”), and in each case shall be further increased on each annual anniversary of the

 

5


 

Option term commencement date by three percent (3%). Tenant may, no more than twelve (12) months prior to the date the Lease Term is then scheduled to expire, request Landlord’s estimate of the FMV for the Option term. Landlord shall, within fifteen (15) days after receipt of such request, give Tenant a written proposal of such FMV. If Tenant gives written notice to exercise the Option, such notice shall specify whether Tenant accepts Landlord’s proposed estimate of FMV. If Tenant does not accept the FMV, then the parties shall endeavor to agree upon the FMV, taking into account all relevant factors, including (m) the size of the Premises, (n) the length of the Option term, (o) rent in comparable buildings in the relevant submarket, including concessions offered to new tenants, such as free rent, tenant improvement allowances, moving allowances and brokerage commissions, (p) Tenant’s creditworthiness and (q) the quality and location of the Building and the Center. In the event that the parties are unable to agree upon the FMV within thirty (30) days after Tenant notifies Landlord that Tenant is exercising the Option, then either party may request that the same be determined as follows: a MAI appraiser with local knowledge of the Sorrento Valley laboratory/research and development leasing submarket (the “Baseball Arbitrator”) shall be selected and paid for jointly by Landlord and Tenant. If Landlord and Tenant are unable to agree upon the Baseball Arbitrator, then the same shall be designated by the local chapter of the American Arbitration Association or any successor organization thereto (the “AAA”). The Baseball Arbitrator selected by the parties or designated by the AAA shall (y) have at least ten (10) years’ experience in the leasing of laboratory/research and development space in the Sorrento Valley submarket and (z) not have been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least ten (10) years prior to appointment pursuant hereto. Each of Landlord and Tenant shall submit to the Baseball Arbitrator and to the other party its determination of the FMV. If the lower determination of the FMV is within ten percent (10%) of the higher determination of the FMV, then the average of the two determinations of the FMV shall be deemed the FMV. Otherwise, the Baseball Arbitrator shall grant to Landlord and Tenant a hearing and the right to submit evidence and the Baseball Arbitrator shall determine which of the two (2) FMV determinations more closely represents the actual FMV. If the average of the two (2) FMV determinations is not used as set forth above, the arbitrator may not select any other FMV for the Premises other than one submitted by Landlord or Tenant. The FMV selected by the Baseball Arbitrator (or determined by averaging the two (2) FMV determinations, if applicable) shall be binding upon Landlord and Tenant and shall serve as the basis for determination of Minimum Monthly Rent payable for the Option term. If, as of the commencement date of the Option term, the amount of Minimum Monthly Rent payable during the Option term shall not have been determined, then, pending such determination, Tenant shall pay Minimum Monthly Rent equal to the Minimum Monthly Rent payable with respect to the last year of the then-current Lease Term. After the final determination of Minimum Monthly Rent payable for the Option term, the parties shall promptly execute a written amendment to the Amended Lease specifying the amount of Minimum Monthly Rent to be paid during the Option term. Any failure of the parties to execute such amendment shall not affect the validity of the FMV determined pursuant to this Section.

 

10.2.                     The Option is not assignable separate and apart from the Amended Lease.

 

10.3.                     The Option is conditional upon Tenant giving Landlord written notice of its election to exercise the Option at least nine (9) months (but no more than twelve (12) months) prior to the end of the expiration of the then-current Lease Term. Time shall be of the essence as

 

6


 

to Tenant’s exercise of the Option. Tenant assumes full responsibility for maintaining a record of the deadlines to exercise the Option. Tenant acknowledges that it would be inequitable to require Landlord to accept any exercise of the Option after the date provided for in this Section.

 

10.4.                     Notwithstanding anything contained in this Article to the contrary, Tenant shall not have the right to exercise the Option:

 

(a)                                 During the time commencing from the date Landlord delivers to Tenant a written notice that Tenant is in default under any provisions of the Amended Lease and continuing until Tenant has cured the specified default to Landlord’s reasonable satisfaction; or

 

(b)                                 At any time after any Event of Default as described in Article 21 of the Lease (provided, however, that, for purposes of this Section 10.4(b), Landlord shall not be required to provide Tenant with notice of such Event Default) and continuing until Tenant cures any such Event of Default, if such Event of Default is susceptible to being cured; or

 

(c)                                  In the event that Tenant has defaulted in the performance of its monetary or other material obligations under the Amended Lease two (2) or more times and a service or late charge has become payable under Section 22.4 of the Lease for each of such defaults during the twelve (12)-month period immediately prior to the date that Tenant intends to exercise the Option, whether or not Tenant has cured such defaults.

 

10.5.                     The period of time within which Tenant may exercise the Option shall not be extended or enlarged by reason of Tenant’s inability to exercise such Option because of the provisions of Section 10.4.

 

10.6.                          All of Tenant’s rights under the provisions of the Option shall terminate and be of no further force or effect even after Tenant’s due and timely exercise of the Option if, after such exercise, but prior to the commencement date of the new term, (a) Tenant fails to pay to Landlord a monetary obligation of Tenant for a period of twenty (20) days after written notice from Landlord to Tenant, (b) Tenant fails to commence to cure a default (other than a monetary default) within thirty (30) days after the date Landlord gives notice to Tenant of such default or (c) Tenant has defaulted under this Lease two (2) or more times and a service or late charge under Section 22.4 of the Lease has become payable for any such default, whether or not Tenant has cured such defaults.

 

11.                               Broker. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment, other than Jones Lang LaSalle Brokerage, Inc. (“Broker”), and agrees to indemnify, defend and hold Landlord harmless from any and all cost or liability for compensation claimed by any such broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it. Broker is entitled to a leasing commission in connection with the making of this Amendment, and Landlord shall pay such commission to Broker pursuant to a separate agreement between Landlord and Broker.

 

12.                                     No Default. Tenant represents, warrants and covenants that, to the best of Tenant’s knowledge, Landlord and Tenant are not in default of any of their respective obligations under

 

7


 

the Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.

 

13.                               Notices. Notwithstanding anything in the Amended Lease to the contrary, any notice, consent, demand, invoice, statement or other communication required or permitted to be given hereunder shall be in writing and shall be given by personal delivery or by overnight delivery with a reputable nationwide overnight delivery service. If given by personal delivery, any such notice, consent, demand, invoice, statement or other communication shall be deemed delivered upon receipt; if given by overnight delivery, shall be deemed delivered one business (1) day after deposit with a reputable nationwide overnight delivery service. Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Amended Lease should be sent to:

 

Trovagene, Inc.

11055 Flintkote Avenue, Suite B

San Diego, California 92121

Attn: Keith McCormick.

 

14.                                     Effect of Amendment.   Except as modified by this Amendment, the Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. The covenants, agreements, terms, provisions and conditions contained in this Amendment shall bind and inure to the benefit of the parties hereto and their respective successors and, except as otherwise provided in the Lease, their respective assigns.  In the event of any conflict between the terms contained in this Amendment and the Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties. From and after the date hereof, the term “Lease” as used in the Lease shall mean the Lease, as modified by this Amendment.

 

15.                                     Miscellaneous. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.

 

16.                                     Counterparts. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

8


 

IN WITNESS WHEREOF, Landlord and Tenant have hereunto set their hands as of the date and year first above written, and acknowledge that they possess the requisite authority to enter into this transaction and to execute this Amendment.

 

LANDLORD:

 

 

 

BMR-SORRENTO WEST LP,

 

a Delaware limited partnership

 

 

 

 

 

By:

/s/ Kevin M. Simonsen

 

Name:

Kevin M. Simonsen

 

Title:

VP, Real Estate Counsel

 

 

 

TENANT:

 

 

 

TROVAGENE, INC.,

 

a Delaware corporation

 

 

 

 

 

By:

/s/ Stephen Zaniboni

 

Name:

Stephen Zaniboni

 

Title:

CFO

 

 


 

EXHIBIT A

 

WORK LETTER

 

This Work Letter (this “Work Letter”) is made and entered into as of the 22nd day of October, 2012, by and between BMR-SORRENTO WEST LP, a Delaware limited partnership (“Landlord”), and TROVAGENE, INC., a Delaware corporation (“Tenant”), and is attached to and made a part of that certain Third Amendment to Standard Industrial Net Lease dated as of October 16, 2012 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the “Amendment”), by and between Landlord and Tenant for the Premises located at 11055 Flintkote Avenue in San Diego, California. All capitalized terms used but not otherwise defined herein shall have the meanings given them in the Amended Lease.

 

1.                                      General Requirements.

 

1.1.                            Authorized Representatives.

 

(a)                                 Landlord designates, as Landlord’s authorized representative (“Landlord’s Authorized Representative”), (i) Federico Mina as the person authorized to initial plans, drawings, approvals and to sign change orders pursuant to this Work Letter and (ii) an officer of Landlord as the person authorized to sign any amendments to this Work Letter or the Amended Lease. Tenant shall not be obligated to respond to or act upon any such item until such item has been initialed or signed (as applicable) by the appropriate Landlord’s Authorized Representative. Landlord may change either Landlord’s Authorized Representative upon one (1) business day’s prior written notice to Tenant.

 

(b)                                 Tenant designates Keith McCormick (“Tenant’s Authorized Representative”) as the person authorized to initial and sign all plans, drawings, change orders and approvals pursuant to this Work Letter. Landlord shall not be obligated to respond to or act upon any such item until such item has been initialed or signed (as applicable) by Tenant’s Authorized Representative. Tenant may change Tenant’s Authorized Representative upon one (1) business day’s prior written notice to Landlord.

 

1.2.                            Schedule. The schedule for design and development of the Tenant Improvements, including the time periods for preparation and review of construction documents, approvals and performance, shall be in accordance with a schedule to be prepared by Tenant (the “Schedule”). Tenant shall prepare the Schedule so that it is a reasonable schedule for the completion of the Tenant Improvements. As soon as the Schedule is completed, Tenant shall deliver the same to Landlord for Landlord’s approval, which approval shall not be unreasonably withheld, conditioned or delayed. Such Schedule shall be approved or disapproved by Landlord within ten (10) business days after delivery to Landlord. Landlord’s failure to respond within such ten (10) business day period shall be deemed approval by Landlord. If Landlord disapproves the Schedule, then Landlord shall notify Tenant in writing of its objections to such Schedule, and the parties shall confer and negotiate in good faith to reach agreement on the Schedule.  The

 


 

Schedule shall be subject to adjustment as mutually agreed upon in writing by the parties, or as provided in this Work Letter.

 

1.3.                            Landlord’s Architects. Contractors and Consultants. Landlord hereby approves Tenant’s use of Biosources, Inc. as the general contractor for the construction of the Tenant Improvements. The architect, engineering consultants, design team, general contractor (if other than Biosources, Inc.) and subcontractors responsible for the construction of the Tenant Improvements shall be selected by Tenant and approved by Landlord, which approval Landlord shall not unreasonably withhold, condition or delay. Landlord may refuse to use any architects, consultants, contractors, subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony. All Tenant contracts related to the Tenant Improvements shall provide that Tenant may assign such contracts and any warranties with respect to the Tenant Improvements to Landlord at any time.

 

2.                                      Tenant Improvements. All Tenant Improvements shall be performed by Tenant’s contractor, at Tenant’s sole cost and expense (subject to Landlord’s obligations with respect to any portion of the TI Allowance and in accordance with the Approved Plans (as defined below), the Schedule, the Approved Budget, the Amended Lease and this Work Letter. To the extent that the total projected cost of the Tenant Improvements (as projected by Landlord) exceeds the TI Allowance (such excess, the “Excess TI Costs”), Tenant shall advance to Landlord any Excess TI Costs within ten (10) days after receipt of an invoice therefor, but in any case before Tenant commences the Tenant Improvements. Any actual Excess TI Costs shall be distributed by Landlord in accordance with Section 6.3. If the actual Excess TI Costs are less than the Excess TI Costs paid by Tenant to Landlord, Landlord shall credit Tenant with the overage paid by Tenant against Tenant’s rent obligations, beginning after Landlord has completed the final accounting for the Tenant Improvements. If the cost of the Tenant Improvements (as projected by Landlord) increases over Landlord’s initial projection, then Landlord may notify Tenant and Tenant shall deposit any additional Excess TI Costs with Landlord in the same way that Tenant deposited the initial Excess TI Costs. If Tenant fails to pay, or is late in paying, any sum due to Landlord under this Work Letter, then Landlord shall have all of the rights and remedies set forth in the Amended Lease for nonpayment of rent (including the right to interest and the right to assess a late charge), and for purposes of any litigation instituted with regard to such amounts the same shall be considered rent. All material and equipment furnished by Tenant or its contractors as the Tenant Improvements shall be new or “like new;” the Tenant Improvements shall be performed in a first-class, workmanlike manner; and the quality of the Tenant Improvements shall be of a nature and character not less than the Building standard. Tenant shall take, and shall require its contractors to take, commercially reasonable steps to protect the Premises during the performance of any Tenant Improvements, including covering or temporarily removing any window coverings so as to guard against dust, debris or damage.

 

2.1.                            Work Plans. Tenant shall prepare and submit to Landlord for approval schematics covering the Tenant Improvements prepared in conformity with the applicable provisions of this Work Letter (the “Draft Schematic Plans”). The Draft Schematic Plans shall contain sufficient information and detail to accurately describe the proposed design to Landlord and such other information as Landlord may reasonably request. Landlord shall notify Tenant in writing within ten (10) business days after receipt of the Draft Schematic Plans whether Landlord

 


 

approves or objects to the Draft Schematic Plans and of the manner, if any, in which the Draft Schematic Plans are unacceptable. Landlord’s failure to respond within such ten (10) business day period shall be deemed approval by Landlord. If Landlord reasonably objects to the Draft Schematic Plans, then Tenant shall revise the Draft Schematic Plans and cause Landlord’s objections to be remedied in the revised Draft Schematic Plans. Tenant shall then resubmit the revised Draft Schematic Plans to Landlord for approval, such approval not to be unreasonably withheld, conditioned or delayed. Landlord’s approval of or objection to revised Draft Schematic Plans and Tenant’s correction of the same shall be in accordance with this Section until Landlord has approved the Draft Schematic Plans in writing or been deemed to have approved them. The iteration of the Draft Schematic Plans that is approved or deemed approved by Landlord without objection shall be referred to herein as the “Approved Schematic Plans.”

 

2.2.                            Construction Plans.  Tenant shall prepare final plans and specifications for the Tenant Improvements that (a) are consistent with and are logical evolutions of the Approved Schematic Plans and (b) incorporate any other Tenant-requested (and Landlord-approved) Changes (as defined below). As soon as such final plans and specifications (“Construction Plans”) are completed, Tenant shall deliver the same to Landlord for Landlord’s approval, which approval shall not be unreasonably withheld, conditioned or delayed. Such Construction Plans shall be approved or disapproved by Landlord within ten (10) business days after delivery to Landlord. Landlord’s failure to respond within such ten (10) business day period shall be deemed approval by Landlord. If the Construction Plans are disapproved by Landlord, then Landlord shall notify Tenant in writing of its objections to such Construction Plans, and the parties shall confer and negotiate in good faith to reach agreement on the Construction Plans. Promptly after the Construction Plans are approved by Landlord and Tenant, two (2) copies of such Construction Plans shall be initialed and dated by Landlord and Tenant, and Tenant shall promptly submit such Construction Plans to all appropriate governmental authorities for approval. The Construction Plans so approved, and all change orders specifically permitted by this Work Letter, are referred to herein as the “Approved Plans.”

 

2.3.                            Changes to the Tenant Improvements.  Any changes to the Approved Plans (each, a “Change”) shall be requested and instituted in accordance with the provisions of this Article 2 and shall be subject to the written approval of the non-requesting party in accordance with this Work Letter.

 

(a)                                 Change Request. Either Landlord or Tenant may request Changes after Landlord approves the Approved Plans by notifying the other party thereof in writing in substantially the same form as the AIA standard change order form (a “Change Request”), which Change Request shall detail the nature and extent of any requested Changes, including (a) the Change, (b) the party required to perform the Change and (c) any modification of the Approved Plans and the Schedule, as applicable, necessitated by the Change. If the nature of a Change requires revisions to the Approved Plans, then the requesting party shall be solely responsible for the cost and expense of such revisions and any increases in the cost of the Tenant Improvements as a result of such Change. Change Requests shall be signed by the requesting party’s Authorized Representative.

 


 

(b)                                   Approval of Changes. All Change Requests shall be subject to the other party’s prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. The non-requesting party shall have five (5) business days after receipt of a Change Request to notify the requesting party in writing of the non-requesting party’s decision either to approve or object to the Change Request. The non-requesting party’s failure to respond within such five (5) business day period shall be deemed approval by the non-requesting party.

 

2.4.                            Preparation of Estimates. Tenant shall, before proceeding with any Change, using its best efforts, prepare as soon as is reasonably practicable (but in no event more than five (5) business days after delivering a Change Request to Landlord or receipt of a Change Request) an estimate of the increased costs or savings that would result from such Change, as well as an estimate on such Change’s effects on the Schedule. Landlord shall have five (5) business days after receipt of such information from Tenant to (a) in the case of a Tenant-initiated Change Request, approve or reject such Change Request in writing, or (b) in the case of a Landlord-initiated Change Request, notify Tenant in writing of Landlord’s decision either to proceed with or abandon the Landlord-initiated Change Request.

 

3.                                      Completion of Tenant Improvements. Tenant, at its sole cost and expense (except for the TI Allowance), shall perform and complete the Tenant Improvements in all respects (a) in substantial conformance with the Approved Plans, (b) otherwise in compliance with provisions of the Amended Lease and this Work Letter and (c) in accordance with applicable laws, the requirements of Tenant’s insurance carriers, the requirements of Landlord’s insurance carriers (to the extent Landlord provides its insurance carriers’ requirements to Tenant) and the board of fire underwriters having jurisdiction over the Premises. The Tenant Improvements shall be deemed completed at such time as Tenant shall furnish to Landlord (v) evidence satisfactory to Landlord that (i) all Tenant Improvements have been completed and paid for in full (which shall be evidenced by the architect’s certificate of completion and the general contractor’s unconditional waivers and releases of liens, each in a form acceptable to Landlord and complying with applicable laws), (ii) all Tenant Improvements have been accepted by Landlord, (iii) any and all liens related to the Tenant Improvements have either been discharged of record (by payment, bond, order of a court of competent jurisdiction or otherwise) or waived by the party filing such lien and (iv) no security interests relating to the Tenant Improvements are outstanding, (w) all certifications and approvals with respect to the Tenant Improvements that may be required from any governmental authority and any board of fire underwriters or similar body for the use and occupancy of the Premises, (x) certificates of insurance required by the Amended Lease to be purchased and maintained by Tenant, (y) an affidavit from Tenant’s architect certifying that all work performed in, on or about the Premises is in accordance with the Approved Plans and (z) complete drawing print sets and electronic CADD files on disc of all contract documents for work performed by their architect and engineers in relation to the Tenant Improvements.

 

4.                                      Insurance.

 

4.1.                            Property Insurance. At all times during the period beginning with commencement of construction of the Tenant Improvements and ending with final completion of the Tenant Improvements, Tenant shall maintain, or cause to be maintained (in addition to the insurance required of Tenant pursuant to the Amended Lease), property insurance insuring Landlord,

 


 

BioMed Realty, L.P. and BioMed Realty Trust, Inc., and their respective officers, directors, employees, agents, general partners, members, subsidiaries, affiliates and Lenders (“Landlord Parties”) as their interests may appear. Such policy shall, on a completed values basis for the full insurable value at all times, insure against loss or damage by fire, vandalism and malicious mischief and other such risks as are customarily covered by the so-called “broad form extended coverage endorsement” upon all Tenant Improvements and the general contractor’s and any subcontractors’ machinery, tools and equipment, all while each forms a part of, or is contained in, the Tenant Improvements or any temporary structures on the Premises, or is adjacent thereto; provided that, for the avoidance of doubt, insurance coverage with respect to the general contractor’s and any subcontractors’ machinery, tools and equipment shall be carried on a primary basis by such general contractor or the applicable subcontractor(s). Tenant agrees to pay any deductible, and Landlord is not responsible for any deductible, for a claim under such insurance. Such property insurance shall contain an express waiver of any right of subrogation by the insurer against Landlord and Landlord Parties, and shall name Landlord and its affiliates as loss payees as their interests may appear.

 

4.2.                            Workers’ Compensation Insurance.  At all times during the period of construction of the Tenant Improvements, Tenant shall, or shall cause its contractors or subcontractors to, maintain statutory workers’ compensation insurance as required by applicable laws.

 

5.                                      Liability. Tenant assumes sole responsibility and liability for any and all injuries or the death of any persons, including Tenant’s contractors and subcontractors and their respective employees, agents and invitees, and for any and all damages to property caused by, resulting from or arising out of any act or omission on the part of Tenant, Tenant’s contractors or subcontractors, or their respective employees, agents and invitees in the prosecution of the Tenant Improvements. Tenant agrees to indemnify, save, defend (at Landlord’s option and with counsel reasonably acceptable to Landlord) and hold Landlord and its affiliates, employees, agents and contractors; and any lender, mortgagee or beneficiary (each, a “Lender” and, collectively with Landlord and its affiliates, employees, agents and contractors, the “Landlord Indemnitees”) harmless from and against all demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages, suits or judgments, and all reasonable expenses (including reasonable attorneys’ fees, charges and disbursements, regardless of whether the applicable demand, claim, action, cause of action or suit is voluntarily withdrawn or dismissed) incurred in investigating or resisting the same (collectively, “Claims”) due to, because of or arising out of any and all such injuries, death or damage, whether real or alleged, and Tenant and Tenant’s contractors and subcontractors shall assume and defend at their sole cost and expense all such Claims; provided, however, that nothing contained in this Work Letter shall be deemed to indemnify or otherwise hold Landlord harmless from or against liability caused by Landlord’s negligence or willful misconduct. Any deficiency in design or construction of the Tenant Improvements shall be solely the responsibility of Tenant, notwithstanding the fact that Landlord may have approved of the same in writing.

 

6.                                      TI Allowance.

 

6.1.                            Application of TI Allowance. Landlord shall contribute, in the following order, the TI Allowance and any Excess TI Costs advanced by Tenant to Landlord toward the costs and

 


 

expenses incurred in connection with the performance of the Tenant Improvements, in accordance with Article 4 of the Amendment. If the entire TI Allowance is not applied toward or reserved for the costs of the Tenant Improvements by the TI Deadline, then Tenant shall be entitled to a credit of such unused portion of the TI Allowance, but only to the extent set forth in Section 4.2 of the Amendment. If the entire Excess TI Costs advanced by Tenant to Landlord are not applied toward the costs of the Tenant Improvements, then Landlord shall promptly return such excess to Tenant following completion of the Tenant Improvements. Tenant may apply the TI Allowance for the payment of construction and other costs in accordance with the terms and provisions of the Amended Lease.

 

6.2.                                Approval of Budget for the Tenant Improvements.  Notwithstanding anything to the contrary set forth elsewhere in this Work Letter or the Amended Lease, Landlord shall not have any obligation to expend any portion of the TI Allowance until Landlord and Tenant shall have approved in writing the budget for the Tenant Improvements (the “Approved Budget”). Prior to Landlord’s approval of the Approved Budget, Tenant shall pay all of the costs and expenses incurred in connection with the Tenant Improvements as they become due.  Landlord shall not be obligated to reimburse  Tenant for costs or expenses relating to the Tenant Improvements that exceed the amount of the TI Allowance. Landlord shall not unreasonably withhold, condition or delay its approval of any budget for Tenant Improvements that is proposed by Tenant.

 

6.3.                            Fund Requests. Upon submission by Tenant to Landlord of (a) a statement (a “Fund Request”) setting forth the total amount of the TI Allowance requested, (b) a summary of the Tenant Improvements performed using AIA standard form Application for Payment (G 702) executed by the general contractor and by the architect, (c) invoices from the general contractor, the architect, and any subcontractors, material suppliers and other parties requesting payment with respect to the amount of the TI Allowance then being requested, (d) unconditional lien releases from the general contractor and each subcontractor and material supplier with respect to previous payments made by either Landlord or Tenant for the Tenant Improvements in a form acceptable to Landlord and complying with applicable laws and (e) conditional lien releases from the general contractor and each subcontractor and material supplier with respect to the Tenant Improvements performed that correspond to the Fund Request each in a form acceptable to Landlord and complying with applicable laws, then Landlord shall, within thirty (30) days following receipt by Landlord of a Fund Request and the accompanying materials required by this Section, pay to (y) the applicable contractors, subcontractors and material suppliers or (z) Tenant (for reimbursement for payments made by Tenant to such contractors, subcontractors or material suppliers either prior to Landlord’s approval of the Approved Budget or as a result of Tenant’s decision to pay for the Tenant Improvements itself and later seek reimbursement from Landlord in the form of one lump sum payment in accordance with the Amended Lease and this Work Letter), the amount of Tenant Improvement costs set forth in such Fund Request or Landlord’s pari passu share thereof if Excess TI Costs exist based on the Approved Budget; provided, however, that Landlord shall not be obligated to make any payments under this Section until the budget for the Tenant Improvements is approved in accordance with Section 6.2 above, and any Fund Request under this Section shall be subject to the payment limits set forth in Section 6.2 above and Article 4 of the Amendment.   For purposes of clarity, the election of whether Landlord pays the applicable contractors, subcontractors and material suppliers directly

 


 

(pursuant to (y) above) or pays Tenant (pursuant to (z) above), shall be in Landlord’s sole discretion, provided that Landlord shall choose either (y) or (z).

 

7.                                      Miscellaneous.

 

7.1.                            Number; Headings. Where applicable in this Work Letter, the singular includes the plural and the masculine or neuter includes the masculine, feminine and neuter. The section headings of this Work Letter are not a part of this Work Letter and shall have no effect upon the construction or interpretation of any part hereof.

 

7.2.                            Attorneys’ Fees. If either party commences a demand, claim, action, cause of action or suit against the other party arising out of or in connection with this Work Letter, then the substantially prevailing party shall be reimbursed by the other party for all reasonable costs and expenses, including reasonable attorneys’ fees and expenses, incurred by the substantially prevailing party in such action or proceeding and in any appeal in connection therewith (regardless of whether the applicable demand, claim, action, cause of action or suit is voluntarily withdrawn or dismissed).

 

7.3.                            Time of Essence. Time is of the essence with respect to the performance of every provision of this Work Letter in which time of performance is a factor.

 

7.4.                            Covenant and Condition.  Each provision of this Work Letter performable by Tenant shall be deemed both a covenant and a condition.

 

7.5.                            Withholding of Consent.  Whenever consent or approval of either party is required, that party shall not unreasonably withhold, condition or delay such consent or approval, except as may be expressly set forth to the contrary.

 

7.6.                            Invalidity. Any provision of this Work Letter that shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other provision hereof, and all other provisions of this Work Letter shall remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist.

 

7.7.                            Intemretation. The language in all parts of this Work Letter shall be in all cases construed as a whole according to its fair meaning and not strictly for or against either Landlord or Tenant.

 

7.8.                            Successors. Each of the covenants, conditions and agreements herein contained shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs; legatees; devisees; executors; administrators; and permitted successors, assigns, sublessees. Nothing in this Section shall in any way alter the provisions of the Amended Lease restricting assignment or subletting.

 

7.9.                            Governing Law. This Work Letter shall be governed by, construed and enforced in accordance with the laws of the state in which the Premises are located, without regard to such state’s conflict of law principles.

 


 

7.10.                     Power and Authority.  Tenant guarantees, warrants and represents that the individual or individuals signing this Work Letter have the power, authority and legal capacity to sign this Work Letter on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.

 

7.11.                     Countemarts. This Work Letter may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document.

 

7.12.                     Amendments; Waiver. No provision of this Work Letter may be modified, amended or supplemented except by an agreement in writing signed by Landlord and Tenant. The waiver by Landlord of any breach by Tenant of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of the same or any other term, covenant or condition herein contained.

 

7.13.                     Waiver of Jury Trial.  To the extent permitted by applicable laws, the parties waive trial by jury in any action, proceeding or counterclaim brought by the other party hereto related to matters arising out of or in any way connected with this Work Letter; the relationship between Landlord and Tenant; Tenant’s use or occupancy of the Premises; or any claim of injury or damage related to this Work Letter or the Premises.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 


 

IN WITNESS WHEREOF, Landlord and Tenant have executed this Work Letter to be effective on the date first above written.

 

LANDLORD:

BMR-SORRENTO WEST LP,

a Delaware limited partnership

 

 

 

 

By:

/s/ Kevin M. Simonsen

 

Name:

Kevin M. Simonsen

 

Title:

VP, Real Estate Counsel

 

 

 

 

 

 

 

TENANT:

TROVAGENE, INC.,

a Delaware corporation

 

 

 

 

 

 

 

By:

/s/ Stephen Zaniboni

 

Name:

Stephen Zaniboni

 

Title:

CFO

 

 

 EX-10.7 3 a15-1864_1ex10d7.htm EX-10.7

Exhibit 10.7

 

FOURTH AMENDMENT TO STANDARD INDUSTRIAL NET LEASE

 

THIS FOURTH AMENDMENT TO STANDARD INDUSTRIAL NET LEASE (this “Amendment”) is entered into as of this 2nd day of December, 2013 (the “Execution Date”), by and between BMR-COAST 9 LP, a Delaware limited partnership (“Landlord,” formerly known as BMR-Sorrento West LP, formerly known as BMR-Sorrento West LLC, as successor-in-interest to JBC Sorrento West, LLC (“Original Landlord”)), and TROVAGENE, INC., a Delaware corporation (“Tenant,” as successor-by-merger to Xenomics, Inc. (“Original Tenant”)).

 

RECITALS

 

A.                                    WHEREAS, Original Landlord and Original Tenant entered into that certain Standard Industrial Net Lease dated as of October 28, 2009 and Addendum to Standard Industrial Net Lease attached thereto (collectively, the “Original Lease”), as amended by that certain First Amendment to Standard Industrial Net Lease dated as of September 28, 2011 (the “First Amendment”), that certain Second Amendment to Standard Industrial Net Lease dated as of December 27, 2011 (the “Second Amendment,”) and that certain Third Amendment to Standard Industrial Net Lease dated as of October 22, 2012 (the “Third Amendment,” collectively, and as the same may have been further amended, amended and restated, supplemented or modified from time to time, the “Lease”), whereby Tenant leases certain premises (the “Premises”) from Landlord in the building at 11055 Flintkote Avenue in San Diego, California (the “Building”);

 

B.                                   WHEREAS, Landlord has remeasured the Premises, Building and Project and desires to restate the Rentable Area of the Premises, Building and Project and amend Tenant’s Pro Rata Share accordingly; and

 

C.                                   WHEREAS, Landlord and Tenant desire to modify and amend the Lease only in the respects and on the conditions hereinafter stated.

 

AGREEMENT

 

NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:

 

1.                                    Definitions. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Lease unless otherwise defined herein. The Lease, as amended by this Amendment, is referred to herein as the “Amended Lease.”

 

2.                                     Minimum Monthly Rent. Notwithstanding anything in the Lease to the contrary, commencing as of April 1, 2013, Minimum Monthly Rent shall be as set forth in the chart below:

 

BMR form dated 9/5/12

 


 

Dates

 

Rentable
Square
Feet

 

Minimum
Monthly Rent

 

Annual
Minimum
Monthly Rent

 

March 1, 2013 - March 31, 2013

 

8,041

 

$

18,098.52

 

$

217,182.24

 

April 1, 2013 - December 27, 2013

 

8,303

 

$

18,098.52

 

$

217,182.24

 

December 28, 2013 - February 28, 2014

 

8,303

 

$

18,291.79

 

$

219,501.48

 

March 1, 2014 - December 27, 2014

 

8,303

 

$

18,642.79

 

$

223,713.48

 

December 28, 2014 - December 27, 2015

 

8,303

 

$

18,896.35

 

$

226,756.20

 

December 28, 2015 - December 27, 2016

 

8,303

 

$

19,459.22

 

$

233,510.64

 

December 28, 2016 - December 27, 2017

 

8,303

 

$

20,022.09

 

$

240,265.08

 

December 28, 2017 - December 31, 2017

 

8,303

 

$

20,665.37

*

$

247,984.44

*

 

* Note: Rental amounts are based on a full calendar month and calendar year, as applicable.

 

3.                                                    Tenant’s Pro Rata Share. Commencing as of March 18, 2013 (and pursuant to Section 6.2 of the Lease, effective as of April 1, 2013), the chart set forth in Section 7 of the First Amendment is hereby deleted in its entirety and replaced with the following chart:

 

Definition or Provision

 

Means the Following (As of the Term
Commencement Date)

 

Approximate Rentable Area of Premises

 

8,303 square feet

 

Approximate Rentable Area of Building

 

20,563 square feet

 

Approximate Rentable Area of Project

 

162,074 square feet

 

Tenant’s Pro Rata Share of Building

 

40.38%

 

Tenant’s Pro Rata Share of Project

 

5.12%

 

 

*For purposes of clarity, the term “Project” as used in the Amended Lease shall have the same meaning as Center.

 

4.                                     Broker. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment (“Broker”), and agrees to

 

2


 

indemnify, defend and hold Landlord harmless from any and all cost or liability for compensation claimed by any such broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it.

 

5.                                            No Default. Tenant represents, warrants and covenants that, to the best of Tenant’s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.

 

6.                                            Notices. Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Amended Lease should be sent to:

 

Trovagene, Inc.

11055 Flintkote Avenue, Suite B

San Diego, California 92121

Attn: Keith McCormick.

 

7.                                            Effect of Amendment. Except as modified by this Amendment, the Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. The covenants, agreements, terms, provisions and conditions contained in this Amendment shall bind and inure to the benefit of the parties hereto and their respective successors and, except as otherwise provided in the Lease, their respective assigns. In the event of any conflict between the terms contained in this Amendment and the Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties. From and after the date hereof, the term “Lease” as used in the Lease shall mean the Lease, as modified by this Amendment.

 

8.                                            Miscellaneous. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.

 

9.                                            Counterparts. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document.

 

REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK

 

3


 

IN WITNESS WHEREOF, Landlord and Tenant have hereunto set their hands as of the date and year first above written, and acknowledge that they possess the requisite authority to enter into this transaction and to execute this Amendment.

 

LANDLORD:

 

BMR -COAST 9 LP,

a Delaware limited partnership

 

 

By:

/s/ Kevin M. Simonsen

 

Name:

Kevin M. Simonsen

 

Title:

VP, Real Estate Legal

 

 

 

TENANT:

 

TROVAGENE, INC.,

a Delaware corporation

 

 

By:

/s/ Stephen Zaniboni

 

Name:

Stephen Zaniboni

 

Title:

CFO

 

 

 

 EX-10.8 4 a15-1864_1ex10d8.htm EX-10.8

Exhibit 10.8

 

FIFTH AMENDMENT TO STANDARD INDUSTRIAL NET LEASE

 

THIS FIFTH AMENDMENT TO STANDARD INDUSTRIAL NET LEASE (this “Amendment”) is entered into as of this 14th day of May, 2014 (the “Execution Date”), by and between BMR-COAST 9 LP, a Delaware limited partnership (“Landlord,” as successor-in interest to JBC Sorrento West, LLC (“Original Landlord”)), and TROVAGENE, INC., a Delaware corporation (“Tenant,” as successor-by-merger to Xenomics, Inc. (“Original Tenant”)).

 

RECITALS

 

A.            WHEREAS, Original Landlord and Original Tenant entered into that certain Standard Industrial Net Lease dated as of October 28, 2009, as amended by that certain First Amendment to Standard Industrial Net Lease dated as of September 28, 2011, that certain Second Amendment to Standard Industrial Net Lease dated as of December 27, 2011, that certain Third Amendment to Standard Industrial Net Lease dated as of October 22, 2012 (the “Third Amendment”) and that certain Fourth Amendment to Standard Industrial Net Lease dated as of December 2, 2013 (the “Fourth Amendment”) (collectively, and as the same may have been heretofore further amended, amended and restated, supplemented or modified from time to time, the “Existing Lease”), whereby Tenant leases certain premises (the “Existing Premises”) from Landlord at 11055 Flintkote Avenue in San Diego, California (the “11055 Building”);

 

B.            WHEREAS, Landlord and Tenant desire to expand the Existing Premises to include additional space in the building located at 11120 Roselle Street in San Diego, California (the “11120 Building”); and

 

C.            WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.

 

AGREEMENT

 

NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:

 

l.              Definitions. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Amendment, is referred to collectively herein as the “Lease.”

 

2.             11120 Premises. Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, that certain space located on the first (1st) floor of the 11120 Building with a Rentable Square Footage of approximately four thousand seven hundred fifty-one (4,751) square feet (as more particularly described on Exhibit A attached hereto, the “11120 Premises”). From and after the 11120 Premises Commencement Date (as defined below), all references in the Lease to the “Building,” shall mean and refer, individually and/or collectively (as the context may require), tn the t 1055 Building and/or the 11120 Building.

 


 

2.1             11120 Premises Lease Term. The Lease Term with respect to the 11120 Premises (the “11120 Premises Lease Term”) shall commence on the 11120 Premises Commencement Date (as defined below), and shall thereafter be coterminous with the Existing Premises such that the Lease Term for the 11120 Premises and the Lease Term for the Existing Premises shall expire on the Expiration Date (as defined in Section 2 of the Third Amendment (i.e., December 31, 2017)). From and after the 11120 Premises Commencement Date, the term “Premises” as used in the Lease shall mean the Existing Premises plus the 11120 Premises.

 

2.2             Condition of 11120 Premises. Tenant acknowledges that (a) it is fully familiar with the condition of the 11120 Premises and, notwithstanding anything to the contrary in the Lease, agrees to take the same in its condition “as is” as of the 11120 Premises Commencement Date, (b) Landlord has not made and does not hereby make any representations or warranties of any kind whatsoever, express or implied, regarding the 11120 Premises, including (without limitation) any representation or warranty that the 11120 Premises are suitable for Tenant’s intended use and (c) Landlord shall have no obligation to alter, repair or otherwise prepare the 11120 Premises for Tenant’s occupancy of the 11120 Premises or to pay for any improvements to the 11120 Premises, except with respect to the 11120 Tenant Improvements (as defined below). The 11120 Premises have not undergone inspection by a Certified Access Specialist. Tenant’s taking possession of the 11120 Premises on the 11120 Premises Commencement Date shall, except as otherwise agreed to in writing by Landlord and Tenant, conclusively establish that the 11120 Premises and the 11120 Building were at such time in good, sanitary and satisfactory condition and repair. Notwithstanding anything to the contrary (but subject to the last grammatical sentence of this Section 2.2), Landlord hereby represents and warrants that, as of the 11120 Premises Commencement Date, (x) the roof of the 11120 Building shall be in good condition and repair, and (y) the life-safety, plumbing, electrical and heating, ventilating and air conditioning systems serving the 11120 Premises, shall be in good working order, condition and repair; provided, however, that Tenant’s sole and exclusive remedy fur a breach of such representation and warranty shall be to deliver notice to Landlord (“Repair Notice”) on or before the date that is twelve (12) months after the 11120 Premises Commencement Date (such date, the “Warranty Date”) detailing the nature of such breach. In the event that Landlord receives a Repair Notice on or before the Warranty Date, Landlord shall promptly make any repairs reasonably necessary to correct the breach described in the Repair Notice (but only to the extent that Landlord reasonably determines that the breach described in the Repair Notice constitutes an actual breach of the representation and warranty provided by Landlord in subsections (x) and (y)). The representation and warranty provided by Landlord in subsections (x) and (y) above shall expire, and be of no further force or effect, on the Warranty Date and Landlord shall not have any further obligations or liabilities in connection with such representation and warranty (except with respect to any actual breaches identified in a Repair Notice delivered by Tenant to Landlord on or before the Warranty Date).

 

2.3             Permitted Use of 11120 Premises. Notwithstanding anything to the contrary in the Lease, Tenant shall be permitted to use the 11120 Premises only for office use (and for no other purposes) in conformity with all federal, state, municipal and local laws, codes, ordinances, rules and regulation of governmental authorities, committees, associations, or other regulatory committees, agencies or governing bodies having jurisdiction over the 11120

 

2


 

Premises, the 11120 Building, the Center, Landlord or Tenant, including both statutory and common law and hazardous waste rules and regulations (“Applicable Laws”).

 

2.4             Tenant’s Pro Rata Share. Notwithstanding anything to the contrary in the Lease, commencing on the 11120 Premises Commencement Date, the chart in Section 3 of the Fourth Amendment is hereby deleted in its entirety and replaced with the following chart:

 

 

 

Means the Following (As of the 11120

Definition or Provision

 

Premises Commencement Date)

Approximate Rentable Area of Existing Premises

 

8,303 square feet

Approximate Rentable Area of 11120 Premises

 

4,751 square feet

Approximate Rentable Area of 11055 Building

 

20,563 square feet

Approximate Rentable Area of 11120 Building

 

l0,140 square feet

Approximate Rentable Area of Project

 

162,074 square feet

Tenant’s Pro Rata Share of 11055 Building

 

40.38%

Tenant’s Pro Rata Share of 11120 Building

 

46.85%

Tenant’s Pro Rata Share of Project

 

8.05%

 

*For purposes of clarity, the term “Project” as used in the Lease shall have the same meaning as Center.

 

2.5          11120 Premises Minimum Monthly Rent. Notwithstanding anything to the contrary in the Lease, commencing on the 11120 Premises Commencement Date, initial monthly installments of Minimum Monthly Rent for the 11120 Premises shall equal:

 

Dates

 

Rentable Square
Footage

 

Minimum Monthly Rent
Rate per Square Foot of
Rentable Area

 

Minimum
Monthly
Rent

 

Month l -Month 12

 

4,751

 

$

2.20

 

$

10,452.20

 

 

2.5.1       11120 Premises Minimum Monthly Rent Adjustments. Notwithstanding anything to the contrary in the Lease, Minimum Monthly Rent for the 11120 Premises shall be subject to an annual upward adjustment of three percent (3%) of the then current Minimum Monthly Rent for the 11120 Premises. The first such adjustment shall become effective commencing on the first (1st) annual anniversary of the 11120 Premises Commencement Date, and subsequent adjustments shall become effective on every successive annual anniversary throughout the 11120 Premises Lease Term.

 

2.5.2       11120 Premises Minimum Monthly Rent Abatement. Provided that Tenant is not then in default of the Lease (beyond any applicable cure period), then during

 

3


 

the first (1st), second (2nd) and third (3rd) months of the 11120 Premises Lease Term (the “11120 Premises Minimum Monthly Rent Abatement Period”), Tenant shall not be obligated to pay any Minimum Monthly Rent otherwise attributable to the 11120 Premises (the “11120 Premises Minimum Monthly Rent Abatement”). Tenant acknowledges and agrees that the 11120 Premises Minimum Monthly Rent Abatement has been granted to Tenant as additional consideration for entering into this Amendment, and for agreeing to pay the rent and performing the terms and conditions otherwise required under the Lease. If Tenant shall be in default under the Lease, and shall fail to cure such default within the notice and cure period, if any, permitted for cure pursuant to terms and conditions of the Lease, or if the Lease is terminated for any reason other than Landlord’s breach of the Lease, then the dollar amount of the unapplied portion of the 11120 Premises Minimum Monthly Rent Abatement as of the date of such default or termination, as the case may be, shall be converted to a credit to be applied to the Minimum Monthly Rent for the 11120 Premises applicable at the end of the 11120 Premises Lease Term and Tenant shall immediately be obligated to begin paying Minimum Monthly Rent for the 11120 Premises in full. Nothing in this Section shall work to abate or reduce Tenant’s obligations under the Lease with respect to Additional Rent including (without limitation) Tenant’s obligations with respect to Tenant’s Share of Operating Costs.

 

2.6          Additional Rent. In addition to Minimum Monthly Rent, from and after the 11120 Premises Commencement Date, Tenant shall pay to Landlord, Additional Rent (as defined in the Lease) with respect to the 11120 Premises and all other amounts that Tenant assumes or agrees to pay under the provisions of the Lease with respect to the 11120 Premises that are owed to Landlord, including any and all other sums that may become due by reason of any default of Tenant or failure on Tenant’s part to comply with the agreements, terms, covenants and conditions of the Lease to be performed by Tenant, after notice and the lapse of any applicable cure periods.

 

2.7          11120 Premises Commencement Date. The “11120 Premises Commencement Date” shall be the day Landlord tenders possession of the 11120 Premises to Tenant with the 11120 Tenant Improvements (as defined below) Substantially Complete (as defined below). If possession is delayed by action of Tenant, then the 11120 Premises Commencement Date shall be the date that the 11120 Premises Commencement Date would have occurred but for such delay. Landlord shall endeavor to provide written notice to Tenant of any act or omission of Tenant that Landlord believes constitutes such a delay. Tenant shall execute and deliver to Landlord written acknowledgment of the actual 11120 Premises Commencement Date within ten (10) days after Tenant takes occupancy of the 11120 Premises, in the form attached as Exhibit C hereto (the “Acknowledgement” ). Failure to execute and deliver the Acknowledgment, however, shall not affect the 11120 Premises Commencement Date or Landlord’s or Tenant’s liability hereunder. Failure by Tenant to obtain validation by any medical review board or other similar governmental licensing of the 11120 Premises required for the Permitted Use (with respect to the 11120 Premises) by Tenant shall not serve to extend the 11120 Premises Commencement Date.

 

2.8          11120 Tenant Improvements. Land lord shall use commercially reasonable efforts to tender possession of the 11120 Premises to Tenant on October 1, 2014 (the “Estimated

 

4


 

11120 Premises Commencement Date”), with the work (the “11120 Tenant Improvements”) required of Landlord on Exhibit B attached hereto (the “11120 Tenant Improvement Plans”). Tenant agrees that in the event such work is not Substantially Complete on or before the Estimated 11120 Premises Commencement Date for any reason, then (a) neither this Amendment nor Tenant’s lease of the 11120 Premises shall be void or voidable, (b) Landlord shall not be liable to Tenant for any loss or damage resulting therefrom and (c) Tenant shall not be responsible for the payment of any Minimum Monthly Rent with respect to the 11120 Premises until the actual 11120 Premises Commencement Date as described in Section 2.7 occurs. The term “Substantially Complete” or “Substantial Completion” means that the 11120 Tenant Improvements are substantially complete in accordance with the 11120 Tenant Improvement Plans, except for minor punch list items. Notwithstanding anything in the Lease to the contrary, Landlord’s obligation to timely achieve Substantial Completion shall be subject to extension on a day-for-day basis as a result of Force Majeure (as described in Section 24.13 of the Lease). Landlord hereby represents and warrants that, as of the 11120 Premises Commencement Date, the 11120 Premises shall be in compliance with all Applicable Laws.

 

2.8.1       In the event that Landlord permits (in Landlord’s reasonable discretion during the twenty-one (21) day period immediately prior to the 11120 Premises Commencement Date) Tenant to enter upon the 11120 Premises prior to the 11120 Premises Commencement Date for the purpose of installing improvements or the placement of personal property, Tenant shall furnish to Landlord evidence satisfactory to Landlord that insurance coverages required of Tenant under the Lease are in effect with respect to the 11120 Premises, and such entry shall be subject to all the terms and conditions of the Lease; and provided, further, that if the 11120 Premises Commencement Date is delayed due to such early access, then the 11120 Premises Commencement Date shall be the date that the 11120 Premises Commencement Date would have occurred but for such delay.

 

2.8.2       Subject to all of the terms, conditions, provisions and agreements set forth in the Lease, Landlord shall cause the 11120 Tenant Improvements to be constructed in the 11120 Premises in accordance with the 11120 Tenant Improvement Plans at Landlord’s sole cost and expense. All costs incurred by Landlord in connection with the 11120 Tenant Improvements including, without limitation, costs of (a) construction, (b) [intentionally omitted], (c) space planning, architect, engineering and other related services, (d) building permits and other taxes, fees, charges and levies by governmental authorities for permits or for inspections of the 11120 Tenant Improvements, and (e) costs and expenses for labor, material, attached equipment and attached fixtures shall be referred to in this Amendment as the “11120 Tenant Improvement Costs.” In the event that Tenant fails to comply with any of its obligations under the Lease and such failure causes Landlord to incur additional 11120 Tenant Improvement Costs, Tenant shall pay to Landlord as Additional Rent the amount of any such additional costs within thirty (30) days of receiving an invoice from Landlord.

 

2.8.3       Notwithstanding anything to the contrary, if Substantial Completion has not occurred by the date that is sixty (60) days after the Estimated 11120 Premises Commencement Date (such date, the “Outside Date”), then the 11120 Premises Minimum Monthly Rent Abatement Period shall be increased by one (1) day for each day

 

5


 

thereafter that Substantial Completion has not occurred; provided, however, that the Outside Date shall be subject to extension on a day-for-day basis as a result of (a) Force Majeure (as described in Section 24.13 of the Lease) and (b) any actual delay caused by any action or inaction of Tenant (including, without limitation, any actual delay caused by a Tenant Change or a Tenant Change Request). By way of example (and without limiting the generality of the foregoing), if Substantial Completion occurs on the date that is five (5) days after the Outside Date, then the 11120 Premises Minimum Monthly Rent Abatement Period shall be increased by five (5) days such that it would consist of (x) the first (1st), second (2nd) and third (3rd) months of the 11120 Premises Lease Term, plus (y) the first five (5) days of the fourth (4th) month of the 11120 Premises Lease Term.

 

2.9          Tenant Changes. Any changes to the 11120 Tenant Improvement Plans requested by Tenant (each, a “Tenant Change”) shall be requested and instituted in accordance with the provisions of this Section 2.9 and shall be subject to the written approval of Landlord.

 

2.9.l        Tenant may request Tenant Changes by notifying Landlord in writing in substantially the same form as the AIA standard change order form (a “Tenant Change Request”), which Tenant Change Request shall detail the nature and extent of any requested Tenant Changes.

 

2.9.2       All Tenant Change Requests shall be subject to Landlord’s prior written approval, which approval Landlord shall not unreasonably withhold (provided, however, that, in the event any Tenant Change would, in Landlord’s sole but reasonable judgment, (a) delay the Substantial Completion of the Tenant Improvements, (b) increase the 11120 Tenant Improvement Costs, (c) affect the structure of the 11120 Premises or the 11120 Building, (d) affect the mechanical, electrical, plumbing or other systems within or serving 11120 Building, (t) affect the prior of the 11120 Building or (t) trigger any requirement under Applicable Laws that would require Landlord to make any alteration or improvement to the 11120 Premises, the 11120 Building or the Project, Landlord may withhold its approval with respect thereto in its sole and absolute discretion). Landlord shall have five (5) days after receipt of a Tenant Change Request to notify Tenant in writing of Landlord’s approval or rejection of the Tenant Change. Landlord’s failure to respond within such five (5) day period shall be deemed approval by Landlord. In the event that Landlord approves a Change Request in accordance with this Section, Landlord shall, concurrently with such approval, notify Tenant if Landlord reasonably believes the corresponding Change will result in a delay in Substantial Completion.

 

2.9.3       Notwithstanding anything to the contrary in the Lease, Tenant shall be solely responsible for all costs and expenses actually incurred by Landlord related to any Tenant Changes. Tenant shall, within thirty (30) days of receiving an invoice therefore, pay to Landlord the amount of any such costs.

 

2.9.4       The Tenant Improvement Plans shall be automatically updated to include any Tenant Changes approved by Landlord in accordance with this Section 2.9.

 

6


 

2.10        Landlord Changes. Landlord shall be permitted to make changes to the 11120 Tenant Improvement Plans (each, a “Landlord Change”) subject to the terms, conditions and provisions of this Section 2.10. Landlord shall be solely responsible for all costs and expenses related to any Landlord Changes (and Landlord shall not be permitted to include such costs in Tenant’s Share of Operating Costs).

 

2.10.1     Landlord may request Landlord Changes by notifying Tenant in writing in substantially the same form as the AIA standard change order form (a “Landlord Change Request”), which Landlord Change Request shall detail the nature and extent of any requested Landlord Changes.

 

2.10.2     Subject to Section 2.10.3 below, all Landlord Change Requests shall be subject to Tenant’s prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. Tenant shall have five (5) days after receipt of a Landlord Change Request to notify Landlord in writing of Tenant’s approval or rejection of the Landlord Change. Tenant’s failure to respond within such five (5) day period shall be deemed approval by Tenant.

 

2.10.3     Notwithstanding anything to the contrary in the Lease, Landlord shall be permitted to make Landlord Permitted Changes (as defined below) without obtaining Tenant’s consent. “Landlord Permitted Changes” shall mean (a) minor field changes and (b) changes required by Applicable Laws or by a governmental authority.

 

2.10.4     The 11120 Tenant Improvement Plans shall be automatically updated to include any Landlord Permitted Changes or other Landlord Changes approved by Tenant in accordance with this Section 2.10.

 

3.             Right of First Refusal. Tenant shall have a right of first refusal (“ROFR”) as to any rentable premises in the 11120 Building that is immediately adjacent to the 11120 Premises and for which Landlord is seeking a tenant (“Available ROFR Premises”). To the extent that Landlord renews or extends a then-existing lease with any then-existing tenant or subtenant of any space, or enters into a new lease with such then-existing tenant or subtenant (for the same space), the affected space shall not be deemed to be Available ROFR Premises. In the event Landlord intends to lease Available ROFR Premises to a bona fide third party, Landlord shall provide written notice thereof to Tenant (the “Notice of Offer”), specifying the agreed upon economic terms and conditions of the proposed lease (with respect to the Available ROFR Premises) with such bona fide third party.

 

3.1          Within seven (7) days following its receipt of a Notice of Offer, Tenant shall advise Landlord in writing whether Tenant elects to lease all (not just a portion) of the Available ROFR Premises on the terms and conditions set forth in the Notice of Offer. If Tenant fails to notify Landlord of Tenant’s election within such seven (7) day period, then Tenant shall be deemed to have elected not to lease the Available ROFF Premises.

 

7


 

3.2          If Tenant timely notifies Landlord that Tenant elects to lease the Available ROFR Premises on the terms and conditions set forth in the Notice of Offer, then Landlord shall lease the Available ROFR Premises to Tenant upon the terms and conditions set forth in the Notice of Offer.

 

3.3          If Tenant notifies Landlord that Tenant elects not to lease the Available ROFR Premises on the terms and conditions set forth in the Notice of Offer, or if Tenant fails to notify Landlord of Tenant’s election within the seven (7)-day period described above, then Landlord shall have the right to consummate the lease of the Available ROFR Premises on the same terms as set forth in the Notice of Offer following Tenant’s election (or deemed election) not to lease the Available ROFR Premises.

 

3.4          Notwithstanding anything in this Article to the contrary, Tenant shall not exercise the ROFR during such period of time that Tenant is in default under any provision of the Lease. Any attempted exercise of the ROFR during a period of time in which Tenant is so in default shall be void and of no effect. In addition, Tenant shall not be entitled to exercise the ROFR if Landlord has given Tenant two (2) or more notices of default under the Lease, whether or not the defaults are cured, during the twelve (12) month period prior to the date on which Tenant seeks to exercise the ROFR.

 

3.5          Notwithstanding anything in the Lease to the contrary, Tenant shall not assign or transfer the ROFR, either separately or in conjunction with an assignment or transfer of Tenant’s interest in the Lease, without Landlord’s prior written consent, which consent Landlord may withhold in its sole and absolute discretion.

 

3.6          If Tenant exercises the ROFR, Landlord does not guarantee that the Available ROFR Premises will be available on the anticipated commencement date for the Lease as to such Available ROFR Premises due to a holdover by the then-existing occupants of the Available ROFR Premises or for any other reason beyond Landlord’s reasonable control.

 

3.7          Notwithstanding anything to the contrary, Tenant’s rights under this Article 3 are subject and subordinate to any rights of renewal, extension, offer, refusal or any other rights of any other tenant at the Center as of the Execution Date.

 

3.8          Article 26 of the Existing Lease is hereby deleted in its entirety and is no longer of any further force or effect.

 

4.             Option to Extend Lease Term. Tenant shall have the option (“Option”) to extend the Lease Term by five (5) years (as to either the 11120 Premises or the Existing Premises or both) upon the following terms and conditions. Any extension of the Term pursuant to the Option shall be on all the same terms and conditions as the Lease, except as follows:

 

4.1          Minimum Monthly Rent at the commencement of the Option term shall equal the then-current fair market value for comparable office and laboratory space in the Scrrento Valley submarket of comparable age, quality, level of finish and proximity to amenities and public transit (“FMV”), and shall be further increased on each annual anniversary of the Option term commencement date by three percent (3%). Tenant may, no more than twelve (12)

 

8

 


 

months prior to the date the Lease Term is then scheduled to expire, request Landlord’s estimate of the FMV for the Option term. Landlord shall, within fifteen (15) days after receipt of such request, give Tenant a written proposal of such FMV. If Tenant gives written notice to exercise the Option, such notice shall specify whether Tenant accepts Landlord’s proposed estimate of FMV. If Tenant does not accept the FMV, then the parties shall endeavor to agree upon the FMV, taking into account all relevant factors, including (a) the size of the Premises (or portion thereof that is being extended, as applicable), (b) the length of the Option term, (c) rent in comparable buildings in the relevant submarket, including concessions offered to new tenants, such as free rent, tenant improvement allowances and moving allowances, (d) Tenant’s creditworthiness and (e) the quality and location of the Project. In the event that the parties are unable to agree upon the FMV within thirty (30) days after Tenant notifies Landlord that Tenant is exercising the Option, then either party may request that the same be determined as follows: a senior officer of a nationally recognized leasing brokerage firm with local knowledge of the Sorrento Valley laboratory/research and development leasing submarket (the “Baseball Arbitrator”) shall be selected and paid for jointly by Landlord and Tenant. If Landlord and Tenant are unable to agree upon the Baseball Arbitrator, then the same shall be designated by the local chapter of the American Arbitration Association or any successor organization thereto (the “AAA”). The Baseball Arbitrator selected by the parties or designated by the AAA shall (y) have at least ten (10) years’ experience in the leasing of laboratory/research and development space in the Sorrento Valley submarket and (z) not have been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least ten (10) years prior to appointment pursuant hereto. Each of Landlord and Tenant shall submit to the Baseball Arbitrator and to the other party its determination of the FMV. The Baseball Arbitrator shall grant to Landlord and Tenant a hearing and the right to submit evidence. The Baseball Arbitrator shall determine which of the two (2) FMV determinations more closely represents the actual FMV. The arbitrator may not select any other FMV other than one submitted by Landlord or Tenant. The FMV selected by the Baseball Arbitration shall be binding upon Landlord and Tenant and shall serve as the basis for determination of Minimum Monthly Rent payable for the Option term. If, as of the commencement date of the Option term, the amount of Minimum Monthly Rent payable during the Option term shall not have been determined, then, pending such determination. Tenant shall pay Minimum Monthly Rent equal to the Minimum Monthly Rent payable with respect to the last year of the then-current Lease Term. After the final determination of Minimum Monthly Rent payable for the Option term, the parties shall promptly execute a written amendment to the Lease specifying the amount of Minimum Monthly Rent to be paid during the Option term. Any failure of the parties to execute such amendment shall not affect the validity of the FMV determined pursuant to this Section.

 

4.2                               The Option is not assignable separate and apart from the Lease.

 

4.3                               The Option is conditional upon Tenant giving Landlord written notice of its election to exercise the Option at least nine (9) months prior to the end of the expiration of the then-current Lease Term. Time shall be of the essence as to Tenant’s exercise of the Option. Tenant assumes full responsibility for maintaining a record of the deadlines to exercise the Option. Tenant acknowledges that it would be inequitable to require Landlord to accept any exercise of the Option after the date provided for in this Section.

 

9


 

4.4                               Notwithstanding anything contained in this Article to the contrary, Tenant shall not have the right to exercise the Option:

 

4.4.l                         During the time commencing from the date Landlord delivers to Tenant a written notice that Tenant is in default under any provisions of the Lease and continuing until Tenant has cured the specified default to Landlord’s reasonable satisfaction; or

 

4.4.2                     At any time after any Event of Default as described in Article 21 of the Existing Lease (provided, however, that, for purposes of this Section 4.4.2, Landlord shall not be required to provide Tenant with notice of such Event of Default) and continuing until Tenant cures any such Event of Default, if such Event of Default is susceptible to being cured; or

 

4.4.3                     In the event that Tenant has defaulted in the performance of its obligations under the Lease two (2) or more times and a service or late charge has become payable under Section 22.4 of the Existing lease for each of such defaults during the twelve (12)-month period immediately prior to the date that Tenant intends to exercise the Option, whether or not Tenant has cured such defaults.

 

4.5                               The period of time within which Tenant may exercise the Option shall not be extended or enlarged by reason of Tenant’s inability to exercise such Option because of the provisions of Section 4.4 above.

 

4.6                               All of Tenant’s rights under the provisions of the Option shall terminate and be of no further force or effect even after Tenant’s due and timely exercise of the Option if, after such exercise, but prior to the commencement date of the new term, (a) Tenant fails to pay to Landlord a monetary obligation of Tenant for a period of twenty (20) days after written notice from Landlord to Tenant, (b) Tenant fails to commence to cure a default (other than a monetary default) within thirty (30) days after the date Landlord gives notice to Tenant of such default or (c) Tenant has defaulted under the Lease two (2) or more times and a service or late charge under Section 22.4 of the Existing Lease has become payable for any such default, whether or not Tenant has cured such defaults.

 

4.7                               Article 27 of the Existing Lease is hereby deleted in its entirety and is no longer of any further force or effect.

 

5.                                      11120 Building Roof Replacement.  In the event that Landlord replaces the roof on the 11120 Building during the initial 11120 Premises Lease Term, the costs of such replacement shall be excluded from Tenant’s Share of Operating Costs during the initial 11120 Premises Lease Term.

 

6.                                      Operating Costs.  Notwithstanding anything to the contrary in the Lease, in the event that (a) any portion of the Common Area of the Center is not in compliance with Applicable Laws as of the Execution Date, and (b) Landlord makes a capital expenditure (after the Execution Date) to remedy such non-compliance, the costs of such capital expenditure shall not be includable in Tenant’s Share of Operating Costs.

 

10


 

7.                                      Security Deposit.  On or before the Execution Date, Tenant shall deposit with Landlord an amount equal to Ten Thousand Four Hundred Fifty-Two and 20/100 Dollars ($10,452.20) as an increase to the required Security Deposit under the Lease (“Increased Security Deposit Amount”).  From and after the Execution Date, the required Security Deposit under the Lease shall be increased by the Increased Security Deposit Amount.

 

8.                                      Broker.  Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment, other than Hughes Marino (“Broker”), and agrees to reimburse, indemnify, save, defend (at Landlord’s option and with counsel reasonably acceptable to Landlord, at Tenant’s sole cost and expense) and hold harmless the Landlord Related Entities for, from and against any and all cost or liability for compensation claimed by any such broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it. Broker is entitled to a leasing commission in connection with the making of this Amendment, and Landlord shall pay such commission to Broker pursuant to a separate agreement between Landlord and Broker.

 

9.                                      No Default.  Landlord and Tenant represent, warrant and covenant that, to the best of their knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.

 

l0.                                   Notices.  Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Lease should be sent to:

 

Trovagene, Inc.

11055 Flintkote Avenue, Suite B
San Diego, California 92121
Attn: Keith McCormick

 

11.                               Effect of Amendment.  Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby raiified and affinneJ. in the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties. From and after the date hereof, the term “Lease” as used in the Lease shall mean the Existing Lease, as modified by this Amendment.

 

12.                               Successors and Assigns.  Each of the covenants, conditions and agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees.  Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.

 

13.                               Miscellaneous.  This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or

 

11


 

given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.

 

14.                               Authority.  Tenant guarantees, warrants and represents that the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.

 

15.                               Counterparts: Facsimile and PDF Signatures.  This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

12


 

IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the date and year first above written.

 

LANDLORD:

 

 

 

BMR-COAST 9 LP,

 

a Delaware limited partnership

 

 

 

By:

/s/ Kevin M. Simonsen

 

Name:

Kevin M. Simonsen

 

Title:

VP Real Estate Legal

 

 

 

 

 

TENANT:

 

 

 

TROVAGENE, INC.,

 

a Delaware corporation

 

 

 

 

 

By:

/s/ Stephen Zaniboni

 

Name:

Stephen Zaniboni

 

Title:

CFO

 

 


 

EXHIBIT A

 

11120 PREMISES

 


 

 


 

EXHIBIT B

 

11120 TENANT IMPROVEMENT PLANS

 


 

 


 

EXHIBIT C

 

ACKNOWLEDGEMENT OF 11120 PREMISES COMMENCEMENT DATE

 

THIS ACKNOWLEDGEMENT OF 11120 PREMISES COMMENCEMENT DATE is entered into as of [           ], 20[   ], with reference to that certain Fifth Amendment to Standard Industrial Net Lease (the “Amendment”) dated as of [           ], 20[   ], by TROVAGENE, INC., a Delaware corporation (“Tenant”), in favor of BMR-COAST 9 LP, a Delaware limited partnership (“Landlord”). All capitalized terms used herein without definition shall have the meanings ascribed to them in the Amendment.

 

Tenant hereby confirms the following:

 

1.     Tenant accepted possession of the 11120 Premises for use in accordance with the Permitted Use (with respect to the 11120 Premises) on [           ], 20[   ]. Tenant first occupied the 11120 Premises for the Permitted Use (with respect to the 11120 Premises) on [           ], 20[   ].

 

2.     The 11120 Premises are in good order, condition and repair.

 

3.     The 11120 Tenant Improvements are Substantially Complete.

 

4.     All conditions of the Lease to be performed by Landlord as a condition to the full effectiveness of Tenant’s lease of the 11120 Premises have been satisfied, and Landlord has fulfilled all of its duties in the nature of inducements offered to Tenant to lease the 11120 Premises.

 

5.     In accordance with the provisions of the Amendment, the 1 l 120 Premises Commencement Date is [           ], 20[   ].

 

6.     The Lease is in full force and effect, and the same represents the entire agreement between Landlord and Tenant concerning the 11120 Premises.

 

7.     Tenant has no existing defenses against the enforcement of the Lease by Landlord, and there exist no offsets or credits against rent owed or to be owed by Tenant.

 

8.     The obligation to pay rent for the 11120 Premises is presently in effect and all rent obligations on the part of Tenant under the Lease with respect to the 11120 Premises commenced to accrue on [           ], 20[   ], with Minimum Monthly Rent for the 11120 Premises payable on the dates and amounts set forth in the chart below:

 

Dates

 

Rentable Square
Footage

 

Minimum Monthly Rent
Rate Per Square Foot of
Rentable Area

 

Minimum Monthly
Rent

 

Month 1 -Month 12

 

4,751

 

$

2.20

 

$

10,452.20

 

 


 

9.     The undersigned Tenant has not made any prior assignment, transfer, hypothecation or pledge of the Lease or of the rents thereunder or sublease of the 11120 Premises or any portion thereof.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 


 

IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of 11120 Premises Commencement Date as of the date first written above.

 

TENANT:

 

 

 

TROVAGENE, INC..,

 

a Delaware corporation

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 EX-21 5 a15-1864_1ex21.htm EX-21

Exhibit 21

 

List of Subsidiaries

 

Xenomics, Inc., a California corporation

 

Etherogen, Inc., a Delaware corporation

 

 EX-23.1 6 a15-1864_1ex23d1.htm EX-23.1

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

Trovagene, Inc.

San Diego, California

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-186196) and Form S-8 (No. 333-190415) of Trovagene, Inc. of our reports dated March 12, 2015, relating to the consolidated financial statements, and the effectiveness of Trovagene, Inc.’s internal control over financial reporting, which appear in this Form 10-K.

 

/s/ BDO USA, LLP

 

San Diego, California

March 12, 2015

 

 EX-31.1 7 a15-1864_1ex31d1.htm EX-31.1

Exhibit 31.1

 

CERTIFICATION

 

I, Antonius Schuh, certify that:

 

1.                                      I have reviewed this annual report on Form 10-K of Trovagene, Inc. (the “Registrant”);

 

2.                                      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.                                      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.                                      The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.                                              Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b.                                              Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.                                               Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.                                              Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.                                      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.                      All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial; and

 

b.                      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

March 12, 2015

/s/ANTONIUS SCHUH

 

 

 

Antonius Schuh

 

Chief Executive Officer

 

 EX-31.2 8 a15-1864_1ex31d2.htm EX-31.2

Exhibit 31.2

 

CERTIFICATION

 

I, Stephen Zaniboni, certify that:

 

1.                                      I have reviewed this annual report on Form 10-K of Trovagene, Inc. (the “Registrant”);

 

2.                                      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.                                      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.                   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.                                              Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b.                                              Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.                                               Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.                                              Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.                                      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.                      All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial; and

 

b.                      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

March 12, 2015

/s/ Stephen Zaniboni

 

 

 

Stephen Zaniboni

 

Chief Financial Officer

 

 EX-32.1 9 a15-1864_1ex32d1.htm EX-32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Trovagene, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Antonius Schuh, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

 

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

March 12, 2015

/s/ Antonius Schuh

 

 

 

Antonius Schuh

 

Chief Executive Officer

 

 EX-32.2 10 a15-1864_1ex32d2.htm EX-32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Trovagene, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen Zaniboni, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

 

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

March 12, 2015

/s/ Stephen Zaniboni

 

 

 

Stephen Zaniboni

 

Chief Financial Officer

 

 EX-101.INS 11 trov-20141231.xml XBRL INSTANCE DOCUMENT 0001213037 us-gaap:WarrantMember trov:BinomialOptionPricingMethodMember 2012-01-01 2012-12-31 0001213037 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2014-12-31 0001213037 trov:MultiGenDiagnosticsIncMember us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 trov:MultiGenDiagnosticsIncMember 2012-01-01 2012-12-31 0001213037 trov:SellingAgentsMember us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 trov:ConsultingAgreementMember 2012-01-01 2012-12-31 0001213037 trov:PrivatePlacements2012Member us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 trov:MultiGenDiagnosticsIncMember us-gaap:RestrictedStockMember 2012-02-01 2012-02-29 0001213037 trov:MultiGenDiagnosticsIncMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001213037 trov:MultiGenDiagnosticsIncMember 2012-01-01 2012-12-31 0001213037 2012-05-29 2012-05-29 0001213037 us-gaap:MinimumMember 2012-04-27 2012-04-27 0001213037 us-gaap:MaximumMember 2012-04-27 2012-04-27 0001213037 us-gaap:RetainedEarningsMember 2014-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001213037 us-gaap:RetainedEarningsMember 2013-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001213037 us-gaap:RetainedEarningsMember 2012-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001213037 us-gaap:RetainedEarningsMember 2011-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001213037 trov:TTFactorSRLMember 2011-01-31 0001213037 trov:PublicOffering2015Member us-gaap:CommonStockMember us-gaap:SubsequentEventMember trov:PublicOfferingAndControlledEquityOfferingMember 2015-02-11 0001213037 us-gaap:PreferredStockMember 2014-12-31 0001213037 us-gaap:PreferredStockMember 2013-12-31 0001213037 us-gaap:CommonStockMember 2013-12-31 0001213037 us-gaap:PreferredStockMember 2012-12-31 0001213037 us-gaap:CommonStockMember 2012-12-31 0001213037 us-gaap:PreferredStockMember 2011-12-31 0001213037 us-gaap:CommonStockMember 2011-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2012-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2012-12-31 0001213037 trov:OptionExercisePriceTwoMember us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001213037 trov:OptionExercisePriceOneMember us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2011-01-01 2011-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2011-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2012-12-31 0001213037 trov:EquityIncentive2014PlanMember 2014-12-31 0001213037 trov:EquityIncentive2014PlanMember 2014-09-17 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember 2013-07-18 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember 2013-07-17 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2014-01-01 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2014-01-01 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2012-01-01 2012-12-31 0001213037 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2012-01-01 2012-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-12-31 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithQuestDiagnosticsMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithMLLMunchnerLeukamielaborMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithGenoptixIncMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithFairviewHealthServicesMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember 2014-01-01 2014-12-31 0001213037 trov:CollaborationAndLicenseAgreementWithStrandLifeSciencesMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithQuestDiagnosticsMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithMLLMunchnerLeukamielaborMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithGenoptixIncMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithFairviewHealthServicesMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember 2013-01-01 2013-12-31 0001213037 trov:CollaborationAndLicenseAgreementWithStrandLifeSciencesMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithQuestDiagnosticsMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithMLLMunchnerLeukamielaborMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithGenoptixIncMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithFairviewHealthServicesMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember 2012-01-01 2012-12-31 0001213037 trov:CollaborationAndLicenseAgreementWithStrandLifeSciencesMember 2012-01-01 2012-12-31 0001213037 trov:GenomacInternationalLTDMember us-gaap:ResearchAndDevelopmentArrangementMember 2014-10-01 2014-12-31 0001213037 trov:USOncologyResearchLLCMember us-gaap:ResearchAndDevelopmentArrangementMember 2014-01-01 2014-12-31 0001213037 trov:UniversityOfTexasMDAndersonCancerCenterMember us-gaap:ResearchAndDevelopmentArrangementMember 2014-01-01 2014-12-31 0001213037 trov:UniversityOfSouthernCaliforniaMember us-gaap:ResearchAndDevelopmentArrangementMember 2014-01-01 2014-12-31 0001213037 trov:USOncologyResearchLLCMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-01-01 2013-12-31 0001213037 trov:UniversityOfTexasMDAndersonCancerCenterMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-01-01 2013-12-31 0001213037 trov:GenomacInternationalLTDMember us-gaap:ResearchAndDevelopmentArrangementMember 2014-10-31 0001213037 trov:USOncologyResearchLLCMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-12-31 0001213037 trov:UniversityOfTexasMDAndersonCancerCenterMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-12-31 0001213037 trov:UniversityOfSouthernCaliforniaMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-08-31 0001213037 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2014-01-01 2014-12-31 0001213037 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2014-01-01 2014-12-31 0001213037 us-gaap:EquipmentMember us-gaap:MinimumMember 2014-01-01 2014-12-31 0001213037 us-gaap:EquipmentMember us-gaap:MaximumMember 2014-01-01 2014-12-31 0001213037 us-gaap:LeaseholdImprovementsMember 2014-12-31 0001213037 us-gaap:EquipmentMember 2014-12-31 0001213037 trov:FurnitureAndOfficeEquipmentMember 2014-12-31 0001213037 us-gaap:LeaseholdImprovementsMember 2013-12-31 0001213037 us-gaap:EquipmentMember 2013-12-31 0001213037 trov:FurnitureAndOfficeEquipmentMember 2013-12-31 0001213037 trov:PublicOfferingAndControlledEquityOfferingMember 2013-07-01 2013-07-31 0001213037 trov:CantorFitzgeraldAndCoMember trov:PublicOfferingAndControlledEquityOfferingMember 2013-01-01 2013-12-31 0001213037 trov:PublicOffering2015Member us-gaap:CommonStockMember us-gaap:SubsequentEventMember trov:PublicOfferingAndControlledEquityOfferingMember 2015-02-11 2015-02-11 0001213037 us-gaap:ConvertiblePreferredStockMember 2013-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2012-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2014-12-31 0001213037 us-gaap:InternalRevenueServiceIRSMember 2014-12-31 0001213037 trov:NewJerseyMember 2014-12-31 0001213037 trov:CaliforniaMember 2014-12-31 0001213037 2011-01-01 2011-12-31 0001213037 trov:TTFactorSRLMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithSkylineDiagnosticsBVMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithLabCorpMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithIPSOGENSASMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithInVivoScribeTechnologiesIncMember 2014-01-01 2014-12-31 0001213037 trov:SubLicenseAgreementWithASURAGENIncMember 2014-01-01 2014-12-31 0001213037 trov:LicenseAgreementWithDrsFaliniAndMecucciMember 2014-01-01 2014-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember 2014-01-01 2014-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember 2014-01-01 2014-12-31 0001213037 trov:TTFactorSRLMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithSkylineDiagnosticsBVMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithLabCorpMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithIPSOGENSASMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithInVivoScribeTechnologiesIncMember 2013-01-01 2013-12-31 0001213037 trov:SubLicenseAgreementWithASURAGENIncMember 2013-01-01 2013-12-31 0001213037 trov:LicenseAgreementWithDrsFaliniAndMecucciMember 2013-01-01 2013-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember 2013-01-01 2013-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember 2013-01-01 2013-12-31 0001213037 trov:TTFactorSRLMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithSkylineDiagnosticsBVMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithLabCorpMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithIPSOGENSASMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithInVivoScribeTechnologiesIncMember 2012-01-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithASURAGENIncMember 2012-01-01 2012-12-31 0001213037 trov:LicenseAgreementWithDrsFaliniAndMecucciMember 2012-01-01 2012-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember 2012-01-01 2012-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember 2012-01-01 2012-12-31 0001213037 us-gaap:WarrantMember 2013-12-31 0001213037 us-gaap:WarrantMember 2012-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember trov:BlackScholesOptionPricingMethodMember 2014-06-01 2014-06-30 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2014-01-01 2014-12-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2012-01-01 2012-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0001213037 2014-10-01 2014-12-31 0001213037 2014-07-01 2014-09-30 0001213037 2014-04-01 2014-06-30 0001213037 2014-01-01 2014-03-31 0001213037 2013-10-01 2013-12-31 0001213037 2013-07-01 2013-09-30 0001213037 2013-04-01 2013-06-30 0001213037 2013-01-01 2013-03-31 0001213037 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2014-01-01 2014-12-31 0001213037 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001213037 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001213037 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0001213037 us-gaap:ChangeDuringPeriodFairValueDisclosureMember trov:BinomialOptionPricingMethodMember 2013-12-31 0001213037 trov:WarrantsIssuedDuringPeriodMember 2013-12-31 0001213037 us-gaap:ChangeDuringPeriodFairValueDisclosureMember trov:BinomialOptionPricingMethodMember 2012-12-31 0001213037 trov:WarrantsIssuedDuringPeriodMember 2012-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2014-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-12-31 0001213037 trov:CantorFitzgeraldAndCoMember trov:PublicOfferingAndControlledEquityOfferingMember 2013-12-31 0001213037 trov:PublicOfferingAndControlledEquityOfferingMember 2013-07-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2014-12-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2013-12-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2012-12-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2011-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember us-gaap:WarrantMember 2014-06-30 0001213037 trov:SellingAgentsMember 2012-12-31 0001213037 us-gaap:CommonStockMember 2014-12-31 0001213037 trov:WarrantExercisePriceOneMember us-gaap:CommonStockMember 2013-12-31 0001213037 trov:WarrantExercisePriceTwoMember 2013-12-31 0001213037 trov:ServiceAgreementMember 2013-12-31 0001213037 trov:SellingAgentsMember us-gaap:WarrantMember 2012-12-31 0001213037 trov:PanettaPartnersLtdMember trov:ConsultingAgreementMember 2012-12-31 0001213037 trov:PrivatePlacements2012Member 2012-12-31 0001213037 trov:PanettaPartnersLtdMember 2012-12-31 0001213037 trov:SellingAgentsMember us-gaap:WarrantMember 2012-05-31 0001213037 trov:PublicOffering2012Member us-gaap:MinimumMember 2012-05-31 0001213037 trov:PublicOffering2012Member us-gaap:MaximumMember 2012-05-31 0001213037 trov:PrivatePlacements2012Member 2012-05-31 0001213037 trov:PublicOffering2012Member trov:SellingAgentsMember 2012-05-30 0001213037 trov:MultiGenDiagnosticsIncMember 2012-02-01 0001213037 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001213037 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001213037 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0001213037 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0001213037 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2014-01-01 2014-12-31 0001213037 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember 2012-01-01 2012-12-31 0001213037 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-12-31 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-12-31 0001213037 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-12-31 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-12-31 0001213037 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-12-31 0001213037 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-12-31 0001213037 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2014-06-01 2014-06-30 0001213037 trov:SellingAgentsMember 2012-01-01 2012-12-31 0001213037 trov:PublicOffering2012Member 2012-06-01 2012-06-30 0001213037 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0001213037 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001213037 us-gaap:InvestorMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001213037 us-gaap:InvestorMember us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 trov:PublicOfferingAndPrivatePlacementMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001213037 trov:PublicOfferingAndPrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 trov:PublicOfferingAndPrivatePlacementMember 2012-01-01 2012-12-31 0001213037 trov:MultiGenDiagnosticsIncMember 2012-02-01 2012-02-29 0001213037 trov:MultiGenDiagnosticsIncMember us-gaap:MaximumMember 2012-02-01 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember 2013-01-01 2013-12-31 0001213037 us-gaap:EmployeeStockOptionMember trov:StockOption2004PlanMember us-gaap:DirectorMember 2013-07-01 2013-07-31 0001213037 trov:ExecutiveAgreementWithSteveZaniboniMember 2014-01-01 2014-12-31 0001213037 trov:BlackScholesOptionPricingMethodMember 2014-01-01 2014-12-31 0001213037 trov:BinomialOptionPricingMethodMember 2014-01-01 2014-12-31 0001213037 trov:PublicOffering2012Member 2012-05-30 0001213037 us-gaap:MinimumMember trov:ExecutiveAgreementWithAntoniusSchuhMember 2014-01-01 2014-12-31 0001213037 trov:EnterpriseValueDollar7.50PerShareMember trov:ExecutiveAgreementWithAntoniusSchuhMember 2014-01-01 2014-12-31 0001213037 trov:EnterpriseValueDollar30.00PerShareMember trov:ExecutiveAgreementWithAntoniusSchuhMember 2014-01-01 2014-12-31 0001213037 trov:EnterpriseValueDollar22.80PerShareMember trov:ExecutiveAgreementWithAntoniusSchuhMember 2014-01-01 2014-12-31 0001213037 trov:EnterpriseValueDollar14.40PerShareMember trov:ExecutiveAgreementWithAntoniusSchuhMember 2014-01-01 2014-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember us-gaap:MinimumMember 2014-01-01 2014-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember us-gaap:MaximumMember 2014-01-01 2014-12-31 0001213037 us-gaap:ConvertiblePreferredStockMember 2007-03-17 2007-03-17 0001213037 us-gaap:ConvertiblePreferredStockMember 2006-03-17 2006-03-17 0001213037 us-gaap:ConvertiblePreferredStockMember 2006-07-13 2006-07-13 0001213037 trov:IlluminaIncMember us-gaap:ResearchAndDevelopmentArrangementMember 2013-06-01 2013-06-30 0001213037 trov:PrivatePlacements2012Member 2012-01-01 2012-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2014-06-30 0001213037 trov:LicenseAgreementWithDrsFaliniAndMecucciMember 2010-08-01 2010-08-31 0001213037 trov:SubLicenseAgreementWithMLLMunchnerLeukamielaborMember 2011-01-01 2011-12-31 0001213037 trov:SubLicenseAgreementWithFairviewHealthServicesMember 2011-01-01 2011-12-31 0001213037 trov:SubLicenseAgreementWithGenoptixIncMember 2012-12-01 2012-12-31 0001213037 trov:SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember 2012-11-01 2012-11-30 0001213037 trov:SubLicenseAgreementWithQuestDiagnosticsMember 2012-09-01 2012-09-30 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember 2011-12-01 2011-12-31 0001213037 trov:ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember 2011-10-01 2011-10-31 0001213037 trov:SubLicenseAgreementWithFairviewHealthServicesMember 2011-07-01 2011-07-31 0001213037 trov:SubLicenseAgreementWithMLLMunchnerLeukamielaborMember 2011-02-01 2011-02-28 0001213037 trov:SubLicenseAgreementWithSkylineDiagnosticsBVMember 2010-06-01 2010-06-30 0001213037 trov:SubLicenseAgreementWithInVivoScribeTechnologiesIncMember 2008-12-01 2008-12-31 0001213037 trov:SubLicenseAgreementWithLabCorpMember 2008-08-01 2008-08-31 0001213037 trov:SubLicenseAgreementWithASURAGENIncMember 2007-10-01 2007-10-31 0001213037 trov:SubLicenseAgreementWithIPSOGENSASMember 2007-08-01 2007-08-31 0001213037 trov:LicenseAgreementWithDrsFaliniAndMecucciMember 2006-05-01 2006-05-31 0001213037 us-gaap:WarrantMember us-gaap:MinimumMember trov:BinomialOptionPricingMethodMember 2012-01-01 2012-12-31 0001213037 us-gaap:WarrantMember us-gaap:MaximumMember trov:BinomialOptionPricingMethodMember 2012-01-01 2012-12-31 0001213037 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001213037 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember us-gaap:MinimumMember trov:BlackScholesOptionPricingMethodMember 2014-01-01 2014-12-31 0001213037 us-gaap:WarrantMember us-gaap:MaximumMember trov:BlackScholesOptionPricingMethodMember 2014-01-01 2014-12-31 0001213037 us-gaap:WarrantMember us-gaap:MinimumMember trov:BlackScholesOptionPricingMethodMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember us-gaap:MaximumMember trov:BlackScholesOptionPricingMethodMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember us-gaap:MinimumMember trov:BlackScholesOptionPricingMethodMember 2012-01-01 2012-12-31 0001213037 us-gaap:WarrantMember us-gaap:MaximumMember trov:BlackScholesOptionPricingMethodMember 2012-01-01 2012-12-31 0001213037 trov:PublicOffering2012Member 2012-05-30 2012-05-30 0001213037 us-gaap:WarrantMember trov:BinomialOptionPricingMethodMember 2012-12-31 0001213037 trov:WarrantsAtExercisePrice5.32Member trov:BinomialOptionPricingMethodMember 2012-10-01 2012-12-31 0001213037 trov:PriceProtectedWarrantsMember 2012-01-01 2012-12-31 0001213037 trov:WarrantsAtExercisePrice3.00Member trov:BinomialOptionPricingMethodMember 2012-01-01 2012-05-31 0001213037 trov:WarrantsAtExercisePrice3.00Member trov:BinomialOptionPricingMethodMember 2011-01-01 2011-12-31 0001213037 us-gaap:SubsequentEventMember trov:ConsultingAgreementWithDrAdamsMember 2015-01-01 2015-01-31 0001213037 trov:CantorFitzgeraldAndCoMember trov:PublicOfferingAndControlledEquityOfferingMember 2013-01-25 2013-01-25 0001213037 2014-12-31 0001213037 2013-12-31 0001213037 2012-12-31 0001213037 2011-12-31 0001213037 trov:SellingAgentsMember us-gaap:WarrantMember 2012-10-01 2012-12-31 0001213037 trov:PrivatePlacements2012Member 2012-10-01 2012-12-31 0001213037 trov:PriceProtectedWarrantsMember 2012-10-01 2012-12-31 0001213037 trov:PublicOffering2012Member 2012-05-01 2012-05-31 0001213037 trov:PanettaPartnersLtdMember 2012-01-01 2012-12-31 0001213037 trov:PrivatePlacements2012Member 2012-01-01 2012-05-31 0001213037 us-gaap:MinimumMember 2014-01-01 2014-12-31 0001213037 us-gaap:MaximumMember 2014-01-01 2014-12-31 0001213037 us-gaap:MinimumMember 2013-01-01 2013-12-31 0001213037 us-gaap:MaximumMember 2013-01-01 2013-12-31 0001213037 us-gaap:MinimumMember 2012-01-01 2012-12-31 0001213037 us-gaap:MaximumMember 2012-01-01 2012-12-31 0001213037 us-gaap:MinimumMember 2011-01-01 2011-12-31 0001213037 us-gaap:MaximumMember 2011-01-01 2011-12-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember trov:BlackScholesOptionPricingMethodMember 2011-01-01 2011-12-31 0001213037 trov:ExecutiveAgreementWithAntoniusSchuhMember 2014-01-01 2014-12-31 0001213037 us-gaap:LineOfCreditMember us-gaap:SecuredDebtMember 2014-01-01 2014-12-31 0001213037 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001213037 trov:CantorFitzgeraldAndCoMember us-gaap:MaximumMember trov:PublicOfferingAndControlledEquityOfferingMember 2013-01-25 0001213037 us-gaap:MaximumMember trov:PublicOfferingAndControlledEquityOfferingMember 2013-01-25 0001213037 trov:ServiceAgreementMember 2013-01-01 2013-12-31 0001213037 us-gaap:WarrantMember trov:BinomialOptionPricingMethodMember 2013-01-01 2013-12-31 0001213037 us-gaap:ChangeDuringPeriodFairValueDisclosureMember trov:BinomialOptionPricingMethodMember 2013-01-01 2013-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001213037 2013-01-01 2013-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001213037 2012-01-01 2012-12-31 0001213037 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001213037 2014-06-30 0001213037 2015-02-27 0001213037 2014-01-01 2014-12-31 iso4217:USD trov:item trov:item xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 FY 2014 2014-12-31 10-K 0001213037 24123790 Yes Accelerated Filer 63974477 Trovagene, Inc. Yes No -2422337 235857 235857 3317463 3317463 5417871 5417871 5417871 5417871 142508 142508 198791 198791 198791 150000000 30000000 3424605 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Allowance for Doubtful Accounts</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators.&nbsp;&nbsp;At December&nbsp;31, 2014 and 2013, the Company has not recorded an allowance for doubtful accounts.&nbsp;&nbsp;When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed.&nbsp;&nbsp;When payments are received on reserved accounts, they are applied to the individual&#x2019;s account and the reserve is reassessed.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 1050000 P1Y 16667 728488 36666 16667 16671 73099 73099 16667 3416934 50000 85470 P8Y P1Y P6Y P1Y P5Y P1Y P4Y P1Y P8Y P5Y P5Y P5Y P5Y P5Y P3Y 3.18 3.96 3.87 3.85 3.00 4.99 3.00 3.00 4.50 10.80 4.88 8.00 3.51 0.03 9500 235300 698000 P55Y 713784 1048175 713784 1288650 1288650 1288650 1288650 5000000 5000000 10000000 P30M P30M P48M P1Y P1Y P1Y 0.02 P1Y 700000 700000 5.93 0.02 7.18 5.74 6.74 3.00 P4Y P3Y7M6D -5417871 3.21 0.25 -320000 3.00 4.00 3.00 8.00 70000 120000 120000 20000 10000 10000 20000 10000 1000 1000 20000 5000 100000 1000 15000 20000 0.06 0.10 250000 250000 2 5 33788 1414500 715743 235857 235857 96500 24989 P30D P1Y P20D P20D 8333 2.15 9.60 38240 29840 23015 P12M 0.03 0.01 14.40 22.80 30.00 7.50 0.040 0.025 0.02 0.015 125000 7.50 P90D 3466466 274967 274967 2 1 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="bottom" style="width:31.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Date</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Price&nbsp;Protected</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Units</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability&nbsp;For</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Issued&nbsp;Units</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Change&nbsp;In</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fair</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">value&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability&nbsp;For</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Previously</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Outstanding</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Price</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Protected</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Units</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Ending</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Balance</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,288,650 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,171,463 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,341,405 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,512,868 </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Reclassification of derivative liability to equity</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,288,650 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,417,871 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,417,871 </td> <td valign="bottom" style="width:01.16%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:31.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a loss in the statement of operations</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,905,003 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,905,003 </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,171,463 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,171,463 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:15.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Date</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Description</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">Warrants</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Instrument</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2011</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,103,727 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,627 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired warrants</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,667 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.18%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a loss in the statement of operations</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,258,133 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:15.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,087,060 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,252,760 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired warrants</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73,099 </td> <td valign="bottom" style="width:01.10%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.18%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a gain in the statement of operations</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,820,889 </td> <td valign="bottom" style="width:01.10%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,013,961 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a gain in the statement of operations</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,425,850 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:15.38%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,013,961 </td> <td valign="bottom" style="width:01.10%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021 </td> <td valign="bottom" style="width:01.10%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> P12M P12M P3M P3M P6M P6M P10M P10M P10M P10M 500000 P6M P6M P10Y 260000 23024 25.80 3700000 1 6320000 16900000 16899562 438 -21 21 9100000 164889 198791 1576452 1576452 22955 8602 8602 7284 13011 -2 2 -1 1 -1 1 -1 1 172500 633333 4383333 1150000 1105000 40000 174100 214100 1031281 3599831 3599759 72 P10Y 3.00 3.00 3.00 5.32 5.32 P5Y 1796610 1796610 286608 747799 78994 56694 57117 1524092 1841808 348602 533870 87433460 89739511 532140 532140 1979364 1979364 2070195 2070195 532140 395992 136148 1979364 1429899 549465 2070194 1274186 796008 248799 10795956 99583 3711303 6985070 10584153 63125 4287545 6233483 10228257 63125 4913472 5251660 27155735 28896846 26068720 27719751 25703330 25703330 27123587 27123587 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">2.&nbsp;&nbsp;Basis of Presentation and Summary of Significant Accounting Policies</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The accompanying consolidated financial statements of Trovagene, which include its wholly owned subsidiaries Xenomics,&nbsp;Inc., a California corporation, Xenomics Europa Ltd, (an inactive subsidiary formed in the United Kingdom and liquidated) a</font><font style="display: inline;font-size:10pt;">nd Etherogen,&nbsp;Inc., a Delaware c</font><font style="display: inline;font-size:10pt;">orporation, have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;).&nbsp;&nbsp;All intercompany balances and transactions have been eliminated.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On March&nbsp;15, 2012, the Board of Directors and on April&nbsp;27, 2012 a majority of the stockholders approved a proposal to amend the Company&#x2019;s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company&#x2019;s issued and outstanding common stock at a ratio of not less than one-for-two and not greater than one-for-six at any time prior to April&nbsp;27, 2013 at the discretion of the Board of Directors.&nbsp;&nbsp;On May&nbsp;24, 2012, the Board of Directors approved a 1-for-6 reverse stock split of the Company&#x2019;s issued and outstanding common stock effective on May&nbsp;29, 2012.&nbsp;&nbsp;All the relevant information relating to number of shares and per share information contained in these consolidated financial statements has been retrospectively adjusted to reflect the reverse stock split for all periods presented.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Use of Estimates</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Cash and Cash Equivalents</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Cash and cash equivalents consist of operating accounts as of December&nbsp;31, 2014 and 2013 on deposit with U.S. commercial banks.&nbsp;&nbsp;&nbsp;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.&nbsp;&nbsp;&nbsp;Cash and cash equivalents include money market accounts at December&nbsp;31, 2014.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Concentration of credit risk</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company maintains its cash in financial institutions, which at times may exceed the amount insured by the Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;).&nbsp;&nbsp;All of the Company&#x2019;s noninterest bearing cash balances were insured up to $250,000 at December&nbsp;31, 2014 and December&nbsp;31, 2013.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Revenues</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.&nbsp;&nbsp;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&nbsp;&nbsp;Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Milestone payments are recognized when both the milestone is achieved and the related payment is received.</font></p></td></tr></table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Allowance for Doubtful Accounts</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators.&nbsp;&nbsp;At December&nbsp;31, 2014 and 2013, the Company has not recorded an allowance for doubtful accounts.&nbsp;&nbsp;When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed.&nbsp;&nbsp;When payments are received on reserved accounts, they are applied to the individual&#x2019;s account and the reserve is reassessed.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Derivative Financial Instruments&#x2014;Warrants</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The Company has issued common stock warrants in connection with the execution of certain equity financings.&nbsp;&nbsp;Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Derivatives and Hedging (&#x201C;ASC 815&#x201D;)</font><font style="display: inline;font-size:10pt;color:#000000;"> and are recorded at their fair market value as of each reporting period.&nbsp;&nbsp;Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1)&nbsp;indexed to its own stock and (2)&nbsp;classified in stockholders&#x2019; equity.&nbsp;&nbsp;Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption &#x201C;Change in fair value of derivative instruments.&#x201D;</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene&#x2019;s common share price, remaining life of the warrant, and risk-free interest rates at each period end.&nbsp;&nbsp;The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level&nbsp;3 per ASC 820, </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Fair Value Measurements</font><font style="display: inline;font-size:10pt;color:#000000;">.&nbsp;&nbsp;At December&nbsp;31, 2014 and 2013, the fair value of these warrants was $3,006,021 and $4,431,871, respectively, and were included in the derivative financial instruments liability on the balance sheet.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Stock-Based Compensation</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">ASC Topic 718 &#x201C;</font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Compensation&#x2014;Stock Compensation</font><font style="display: inline;font-size:10pt;color:#000000;">&#x201D; requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant.&nbsp;&nbsp;The expense is recognized over the period during which an employee is required to provide services in exchange for the award.&nbsp;&nbsp;ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.&nbsp;&nbsp;Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received.&nbsp;&nbsp;The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 &#x201C;Equity -</font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Based Payment to Non-Employees&#x201D; </font><font style="display: inline;font-size:10pt;color:#000000;">and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.&nbsp;&nbsp;Accordingly the fair value of these options is being &#x201C;marked to market&#x201D; quarterly until the measurement date is determined.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Fair value of financial instruments</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities.&nbsp;&nbsp;We have adopted FASB ASC 820 </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Fair Value Measurements and Disclosures (&#x201C;ASC 820&#x201D;)</font><font style="display: inline;font-size:10pt;color:#000000;"> for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis.&nbsp;&nbsp;These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature as they reflect current market interest rates.&nbsp;&nbsp;&nbsp;Debt is stated at its respective historical carrying amounts which approximates fair value as they reflect current market interest rates.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">In accordance with ASC subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.&nbsp;&nbsp;The three tiers include:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:36pt;"> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;font-family:Symbol;">&#xF0B7;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Level&nbsp;1 &#x2014;</font></p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Quoted prices for identical instruments in active markets.</font></p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;font-family:Symbol;">&#xF0B7;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Level&nbsp;2 &#x2014;</font></p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</font></p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;font-family:Symbol;">&#xF0B7;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Level&nbsp;3 &#x2014;</font></p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Instruments where significant value drivers are unobservable to third parties.</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Property, equipment and depreciation and amortization</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Expenditures for additions, renewals and improvements are capitalized at cost.&nbsp;&nbsp;Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets.&nbsp;&nbsp;Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.&nbsp;&nbsp;The estimated useful lives of the major classes of depreciable assets are 3 to 5&nbsp;years for lab equipment and furniture and fixtures.&nbsp;&nbsp;Expenditures for repairs and maintenance are charged to operations as incurred.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Impairment of Indefinite and Long-Lived Assets</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The Company reviews its long and indefinite lived assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired.&nbsp;&nbsp;If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows.&nbsp;&nbsp;If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value.&nbsp;&nbsp;Factors that would indicate potential impairment include a significant decline in the Company&#x2019;s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company&#x2019;s strategic business objectives and utilization of a particular asset.&nbsp;&nbsp;The Company noted no indications of impairment for the years ended December&nbsp;31, 2014, 2013, and 2012.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Income Taxes</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Income taxes have been determined using the asset and liability approach of accounting for income taxes.&nbsp;&nbsp;Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.&nbsp;&nbsp;Deferred taxes result from differences between the financial statement and tax bases of Trovagene&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted.&nbsp;&nbsp;Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.&nbsp;&nbsp;The assessment of whether or not a valuation allowance is required often requires significant judgment.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Contingencies</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters.&nbsp;&nbsp;In accordance with FASB ASC Topic 450, </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Accounting for Contingencies</font><font style="display: inline;font-size:10pt;color:#000000;">, Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.&nbsp;&nbsp;Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Cost of Revenue</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Research and Development</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Research and Development.&nbsp; </font><font style="display: inline;font-size:10pt;color:#000000;">Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">ASC Topic 730, </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Research and Development</font><font style="display: inline;font-size:10pt;color:#000000;"> requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized.&nbsp;&nbsp;As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.&nbsp;&nbsp;&nbsp;There were no non-refundable advance payments as of December&nbsp;31, 2014 and 2013.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Net Loss Per Share</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Basic and diluted net loss per share is presented in conformity with ASC Topic 260, </font><font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Earnings per Share</font><font style="display: inline;font-size:10pt;color:#000000;">, for all periods presented.&nbsp;&nbsp;In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. </font><font style="display: inline;font-size:10pt;color:#000000;">Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share.</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">Shares used in calculating diluted</font><font style="display: inline;font-size:10pt;color:#000000;"> net loss per common share exclude as antidilutive the following share equivalents:</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 76.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:53.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2014</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2013</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2012</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Options to purchase Common Stock </font></p> </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,913,472&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,287,545&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,711,303&nbsp; </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Warrants to purchase Common stock </font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,251,660&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,233,483&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,985,070&nbsp; </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Series&nbsp;A Convertible Preferred Stock </font></p> </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,125&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,125&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99,583&nbsp; </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,228,257&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,584,153&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,795,956&nbsp; </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 0.75pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The following table summarizes the Company&#x2019;s diluted net loss per share:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2012</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Net loss </font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,348,499 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,840,778 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,604,201 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Adjustment for change in fair value of derivative instruments - warrants</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,422,337 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Net loss used for diluted loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,770,836 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,840,778 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,604,201 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Weighted average shares used to compute basic loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,904,280 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,978,212 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,066,600 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Adjustments to reflect assumed exercise of warrants</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>166,832 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Weighted average shares used to compute diluted net loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,071,112 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,978,212 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,066,600 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Net loss per share diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.88 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.70 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.89 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;color:#000000;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">In January&nbsp;2015, the Financial Accounting Standards Board (the FASB) issued an amendment to the accounting guidance related to the presentation of extraordinary items. The amendment simplifies the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The amended guidance is effective prospectively for fiscal years beginning after December&nbsp;15, 2015. The new guidance will not have an impact on the Company&#x2019;s financial position, results of operations or cash flows.</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">In August&nbsp;2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity&#x2019;s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December&nbsp;15, 2016. The new guidance will not have an impact on the Company&#x2019;s financial position, results of operations or cash flows.</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">In June&nbsp;2014, the FASB issued an accounting standards update that removes the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to: (1)&nbsp;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&nbsp;label the financial statements as those of a development stage entity, (3)&nbsp;disclose a description of the development stage activities in which the entity is engaged, and disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2014, with an option for early adoption.&nbsp;&nbsp;The Company elected early adoption, and does not believe the adoption of the standard had a material impact on its financial position, results of operations or related financial statement disclosures.</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">In May&nbsp;2014, the FASB issued Accounting Standards Update (&#x201C;ASU&#x201D;) No.&nbsp;2014-09, Revenue from Contracts with Customers (&#x201C;ASU 2014-09&#x201D;). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December&nbsp;15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">3.&nbsp;&nbsp;Asset Purchase</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:3pt;"></font><font style="display: inline;font-size:10pt;">On February&nbsp;1, 2012 the Company entered into an asset purchase agreement with MultiGen Diagnostics,&nbsp;Inc.&nbsp;&nbsp;&nbsp;The Company determined that the acquired asset did not meet the definition of a business, as defined in ASC 805</font><font style="display: inline;font-style:italic;font-size:10pt;">, Business Combinations</font><font style="display: inline;font-size:10pt;"> and was accounted for under ASC 350,&nbsp;</font><font style="display: inline;font-style:italic;font-size:10pt;">Intangibles- Goodwill and Other</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;&nbsp;In connection with the acquisition, the Company issued 125,000 shares of restricted common stock to MultiGEN.&nbsp;&nbsp;&nbsp;In addition, up to an additional $3.7 million may be paid in a combination of common stock and cash to MultiGEN upon the achievement of specific sales and earnings targets.&nbsp;&nbsp;The Company is no longer offering these tests and has no plans to offer these tests. The Company does not anticipate any additional payments will become due. In addition, in connection with the acquisition, the Company entered into a Reagent Supply Agreement dated as of February&nbsp;1, 2012 pursuant to which MultiGEN will supply and deliver reagents to be used in connection with a CLIA laboratory.&nbsp;&nbsp;&nbsp;The total purchase consideration was determined to be $187,500 which was paid in the Company&#x2019;s common stock and allocated to an indefinite lived intangible asset related to the CLIA license.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Under ASC Topic 805, Business Combinations, the Company was required to assess the fair value of the assets acquired and the contingent consideration at the date of acquisition.&nbsp;&nbsp;Therefore, the Company assessed the fair value of the assets purchased and concluded that the purchase price would be allocated entirely to one intangible asset, a CLIA license.&nbsp;&nbsp;&nbsp;The contingent consideration of the $3.7 million milestone was determined to have no fair value by applying a weighted average probability on the achievement of the milestones developed during the valuation process.&nbsp;&nbsp;&nbsp;The Company assesses the fair value of the contingent consideration at each quarter and makes adjustments as necessary until the milestone dates have expired.&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014 and 2013, no adjustments to the fair value of the contingent consideration have been necessary, and therefore the fair value of the contingent consideration remains unchanged.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 700374 10819781 25836937 27293798 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Cash and Cash Equivalents</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Cash and cash equivalents consist of operating accounts as of December&nbsp;31, 2014 and 2013 on deposit with U.S. commercial banks.&nbsp;&nbsp;&nbsp;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.&nbsp;&nbsp;&nbsp;Cash and cash equivalents include money market accounts at December&nbsp;31, 2014.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 5.32 7.00 3.00 7.00 5.32 3.00 5.32 5.32 4.14 5.32 8.00 3.00 5.02 3.51 3.00 1 12745 92000 30450 40000 1738333 174100 50000 143650 50000 85470 85470 3601474 1103727 6985070 1087060 6233483 1013961 6265620 1013961 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">11.&nbsp;&nbsp;Commitments and Contingencies</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Significant Research Agreements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During 2012, the Company entered into research agreements with University of Texas MD Anderson Cancer Center (&#x201C;MDACC&#x201D;) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of cell-free DNA mutations analysis from urine samples and tumor tissue.&nbsp;&nbsp;&nbsp;During 2013, the agreements were amended to increase the scope of the agreements.&nbsp;&nbsp;&nbsp;Under these agreements, the Company has committed to pay approximately $266,000 for the services performed by MDACC.&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014, the Company has incurred and recorded approximately $124,000 of research and development expenses related to these agreements.&nbsp;&nbsp;There were approximately $142,000 of research and development expenses incurred during the year ended December&nbsp;31, 2013.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2013, the Company entered into a Research Agreement with Illumina,&nbsp;Inc. (&#x201C;Illumina&#x201D;) pursuant to which the parties will work together to evaluate the potential for integrating the Company&#x2019;s cell-free technology for isolating, extracting and genetic analysis of nucleic acids from urine with Illumina&#x2019;s genetic analysis sequencing technology (the &#x201C;Research Plan&#x201D;).&nbsp;&nbsp;&nbsp;The parties have agreed that all results and reagents from the Research Plan will be shared between the parties.&nbsp;&nbsp;&nbsp;The Agreement will terminate upon the earlier of 30 days after completion of the Research Plan or the one year anniversary of the Agreement unless extended by mutual written agreement.&nbsp;&nbsp;In October&nbsp;2014, the agreement was extended for an additional year to June&nbsp;2015.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In August&nbsp;2013, the Company entered into a Clinical Trial Agreement with the University of Southern California (&#x201C;USC&#x201D;), pursuant to which USC will provide the principal investigator and conduct the clinical trial related to the genetic characterization of metastatic colorectal cancers.&nbsp;&nbsp;&nbsp;Under the agreement, the Company is committed to pay USC approximately $232,000 for services provided.&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2013 the Company had not incurred any expense related to this agreement.&nbsp;&nbsp;As of December&nbsp;31, 2014, the Company had incurred approximately $38,000 of research and development expenses.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In December&nbsp;2013, the Company entered into a Clinical Trial Agreement with US Oncology Research LLC (&#x201C;USOR&#x201D;), pursuant to which USOR will provide the principal investigator and conduct the clinical trial related to the examining the utility of cell-free quantitative KRAS testing in disease monitoring in patients with metastatic pancreatic cancer.&nbsp;&nbsp;&nbsp;Under the agreement, the Company is committed to pay USOR approximately $270,000 for services provided.&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014 and 2013, the Company has incurred and recorded approximately $16,000 and $29,000 of research and development expense related to this agreement.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In October&nbsp;2014, the Company entered into a Research Agreement with Genomac International,&nbsp;Ltd., pursuant to which Genomac will conduct a research study of minimally invasive molecular monitoring of efficiency of targeted biological therapy in advanced non-small lung cancer.&nbsp;&nbsp;&nbsp;Under the agreement, the Company is committed to pay Genomac approximately $175,000 for services provided.&nbsp;&nbsp;As of December&nbsp;31, 2014, the Company has incurred and recorded approximately $90,000 of research and development expenses.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">License Agreements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In May&nbsp;2006, the Company entered into a license agreement with Drs.&nbsp;Falini and Mecucci, wherein it obtained the exclusive rights for the genetic marker for AML and intends to utilize these rights for the development of new diagnostic tools.&nbsp;&nbsp;In connection with this agreement, the Company paid $70,000 to Drs.&nbsp;Falini and Mecucci.&nbsp;&nbsp;In August&nbsp;2010 the Company signed amendment No.&nbsp;1 to the license agreement with an obligation to payroyalties of 6% of royalty revenues and/or 10% of any sublicense income.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty expenses of approximately $23,000, $30,000 and $24,000, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During August&nbsp;2007, the Company signed a sublicensing agreement with IPSOGEN SAS, a leading molecular diagnostics company with operations in France and the United States for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.&nbsp;&nbsp;Upon execution of this agreement,&nbsp;IPSOGEN paid an initial licensing fee of $120,000 and may make milestone payments upon the attainment of certain regulatory and commercial milestones.&nbsp;&nbsp;IPSOGEN will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;The term of the license ends on October&nbsp;28, 2025 which is the date of expiration of the issued patent rights.&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2010, the Company signed amendment No.&nbsp;1 to the sublicensing agreement.&nbsp;&nbsp;The amendment asserts that the Compay may require a license from a third-party to perform laboratory testing services.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty, milestone and license fee revenues of approximately $60,000, $60,000 and $180,000, respectively.&nbsp;&nbsp;During those same periods, the Company had no license fee expenses.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In October&nbsp;2007, the Company signed a license agreement with ASURAGEN,&nbsp;Inc. for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.&nbsp;&nbsp;ASURAGEN paid an initial licensing fee of $120,000 upon execution of the agreement and may make future payments to the Company upon the attainment of certain regulatory and commercial milestones.&nbsp;&nbsp;In June&nbsp;2010, the Compay signed amendment No.&nbsp;1 to the co-exclusive license agreement.&nbsp;&nbsp;The amendment asserts that the Company may require a license from a third-party to perform laboratory testing services.&nbsp;&nbsp;ASURAGEN will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;The term of the license ends on October&nbsp;28, 2025 which is the date of expiration of the issued patent rights.&nbsp;&nbsp;In March&nbsp;2013, we signed amendment No.&nbsp; 2 to the co-exclusive sublicense agreement with ASURAGEN.&nbsp;&nbsp;&nbsp;The amendment limited the field of use to research use only (RUO) kits.&nbsp;&nbsp;&nbsp;ASURAGEN was also granted a non-exclusive sublicense for NPMI laboratory testing services.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $50,000, $50,000 and $50,000, respectively.&nbsp;&nbsp;&nbsp;During those same periods, the Company had no license fee expenses related to this agreement.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In August&nbsp;2008, the Company signed a sublicensing agreement with LabCorp for the non-exclusive rights to develop and market lab testing services for NPM1, for the diagnosis and monitoring of patients with AML.&nbsp;&nbsp;LabCorp paid an initial licensing fee of $20,000 upon execution of the agreement.&nbsp;&nbsp;LabCorp will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;The term of the license ends August&nbsp;25, 2018.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $28,000, $20,000 and $5,000, respectively.&nbsp;&nbsp;During those same years, the Company has not recorded any license fee expenses.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In December&nbsp;2008, the Company signed a sublicensing agreement with InVivoScribe Technologies,&nbsp;Inc. for the non-exclusive rights to develop and market lab testing services for NPM1 for the diagnosis and monitoring of patients with AML.&nbsp;&nbsp;InVivoScribe Technologies paid an initial licensing fee of $10,000 upon execution of the agreement.&nbsp;&nbsp;InVivoScribe Technologies will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;The term of the license ends on October&nbsp;28, 2025 which is the date of expiration of the issued patent rights.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013, and 2012, the Company recorded royalty and license fee revenues of approximately $25,000, $25,000 and $27,000, respectively.&nbsp;&nbsp;During those same periods, the Company has not recorded any license fee expenses.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2010, the Company signed a sublicensing agreement with Skyline Diagnostics&nbsp;BV for the non-exclusive rights to develop, commercialize and market, research and diagnostic laboratory services for the stratification and monitoring of patients with AML.&nbsp;&nbsp;Skyline Diagnostics&nbsp;BV paid an initial licensing fee of $10,000 upon execution of the agreement and may make future payments to the Company upon the attainment of certain regulatory and commercial milestones.&nbsp;&nbsp;Skyline Diagnostics&nbsp;BV will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;The term of the license ends on October&nbsp;28, 2025 which is the date of expiration of the issued patent rights.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $0, $0 and $0, respectively.&nbsp;&nbsp;During those same periods, the Company has not recorded any license fee expenses.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In January&nbsp;2011, the Company entered into an asset purchase agreement with TTFactor S.r.l.for a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker for $10,000.&nbsp;&nbsp;In addition the Company agreed to pay the seller of the hybridoma for a period of seven years commencing with the first sale of the antibody, annual royalties on a country by country basis.&nbsp;&nbsp;&nbsp;In addition, the Company agreed to pay a percentage of all cash consideration received from licensees as an upfront license fee pursuant to any licenses of the product and a percentage of all cash consideration received from licensees as milestone payments.&nbsp;&nbsp;The agreement was terminated in 2013.&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013, and 2012, there were no royalty expense, license fee or milestone payments recorded related to this agreement.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In February&nbsp;2011, the Company entered into a sublicense agreement with MLL M&#xFC;nchner Leuk&#xE4;mielabor, or MLL for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.&nbsp;&nbsp;MLL paid an initial license fee of $20,000 upon execution of the agreement and will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;MLL is obligated to pay a royalty with annual minimums of $15,000 for the first year and $20,000 thereafter.&nbsp;&nbsp;The term of the license ends on October&nbsp;28, 2025 which is the date of expiration of the issued patent rights.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $81,000, $85,000 and $71,000, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In July&nbsp;2011, the Company entered into a sublicense agreement with Fairview Health Services (&#x201C;Fairview&#x201D;) for the non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.&nbsp;&nbsp;Fairview paid an initial license fee of $10,000 upon execution of the agreement and will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.&nbsp;&nbsp;Fairview is obligated to pay a royalty with annual minimums of $1,000 each year.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013, and 2012, the Company recorded royalty and license fee revenues of approximately $2,000, $1,000 and $2,000, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In October&nbsp;2011, the Company entered into an exclusive license agreement with Gianluca Gaidano, Robert Foa and Davide Rossi for the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia.&nbsp;&nbsp;In consideration of the license, the Company paid $1,000 as an upfront license fee and agreed to make royalty payments in the single digits on net sales if sales are made by the Company or a single digit royalty on sublicense income received by the Company if sales are made by sublicensees.&nbsp;&nbsp;The Company has an option to purchase the licensed patent rights in the event the licensor decides to sell such licensed patent rights.&nbsp;&nbsp;The license agreement shall continue until September&nbsp;29, 2031 which is the date of the last to expire of the licensed patent rights covering the license product.&nbsp;&nbsp;The license agreement may also be terminated upon a material breach by any party or by the Company if it is determined that it is not commercially or scientifically appropriate to further develop the license product rights.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, no royalty expense has been recorded related to this agreement.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In December&nbsp;2011, the Company entered into an exclusive license agreement with Columbia University to license the patent rights to hairy cell leukemia biomarkers.&nbsp;&nbsp;In consideration of the license, the Company paid $1,000 as an upfront license fee and agreed to make royalty payments in the single digits on net sales if sales are made by the Company or a single digit royalty on sublicense income received by the Company if sales are made by sublicensees.&nbsp;&nbsp;The license agreement shall continue until May&nbsp;10, 2021 which is the date of the last to expire of the licensed patent rights covering the license product.&nbsp;&nbsp;The license agreement may also be terminated upon a material breach by any party or by the Company if we determine that it is not commercially or scientifically appropriate to further develop the license product rights.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, no royalty expense has been recorded related to this agreement.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In September&nbsp;2012, the Company entered into a sublicense agreement with Quest Diagnostics for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.&nbsp;&nbsp;Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $20,000 due upon execution of the agreement and royalty payments on net sales of Quest Diagnostics and its affiliates.&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $26,000, $14,000 and $20,000, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In September&nbsp;2012, the Company entered into a collaboration and license agreement with Strand Life Sciences (&#x201C;Strand&#x201D;) related to the validation and commercial launch of a urine based DNA test for Human Papillomavirus.&nbsp;&nbsp;&nbsp;Under this agreement, the Company has granted a license for use of its tests to Strand in exchange for royalty payments on net sales earned in the territory specified in the agreement.&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company has recorded no royalty and license fee revenues related to this agreement.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In November&nbsp;2012, the Company entered into a sublicense agreement with Duke University and Duke University Health Systems for non-exclusive rights to develop and market laboratory testing services for NPM1 for diagnosis and monitoring of patients with AML.&nbsp;&nbsp;&nbsp;Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $5,000 due upon execution of the agreement and royalty payments on net revenues.&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company has recorded $1,000, $0 and $5,000, respectively of royalty and license fee revenues related to this agreement.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In December&nbsp;2012, the Company entered into a sublicense agreement with Genoptix,&nbsp;Inc. for non-exclusive worldwide rights to develop and market laboratory testing services for NPM1 for diagnosis and monitoring of patients with AML.&nbsp;&nbsp;&nbsp;Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $100,000 due upon execution of the agreement and royalty payments on net revenues.&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $30,000, $10,000 and $100,000, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Litigation</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Trovagene does not believe that the Company has legal liabilities that are probable or reasonably possible that require either accrual or disclosure.&nbsp;&nbsp;From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.&nbsp;&nbsp;However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">We are not currently a party to any material legal proceedings.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Employment and Consulting Agreements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During 2011, the Company entered into an executive agreement with Antonius Schuh,&nbsp;Ph.D. in which he agreed to serve as Chief Executive Officer.&nbsp;&nbsp;The term of the agreement is effective as of October&nbsp;4, 2011 and continues until October&nbsp;4, 2015 and is automatically renewed for successive one year periods at the end to each term.&nbsp;&nbsp;In the event that during the term of the agreement, for a period of 90 consecutive trading days, the market price of the common stock is $7.50 or more and the value of the common stock daily trading volume is $125,000 or more, the Company shall pay or issue Dr.&nbsp;Schuh a bonus in an amount of $3,466,466 in either cash or registered common stock or a combination thereof as mutually agreed by Dr.&nbsp;Schuh the Company; or in the event that during the term of the agreement, a change of control occurs where the per share enterprise value of our company equals or exceeds $7.50 per share, the Company shall pay Dr.&nbsp;Schuh a bonus in an amount determined by multiplying the enterprise value by 4.0%.&nbsp;&nbsp;In the event in a change of control the per share enterprise value exceeds a minimum of $14.40 per share, $22.80 per share or $30.00 per share, Dr.&nbsp;Schuh shall receive a bonus in an amount determined by multiplying the incremental enterprise value by 2.5%, 2.0% or 1.5%, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">If the executive agreement is terminated for cause or as a result of Dr.&nbsp;Schuh&#x2019;s death or permanent disability or if Dr.&nbsp;Schuh terminates his agreement voluntarily, Dr.&nbsp;Schuh shall receive a lump sum equal to (i)&nbsp;any portion of unpaid base compensation then due for periods prior to termination, (ii)&nbsp;any bonus or realization bonus earned but not yet paid through the date of termination and (iii)&nbsp;all expenses reasonably incurred by Dr.&nbsp;Schuh prior to date of termination.&nbsp;&nbsp;If the executive agreement is terminated without cause Dr.&nbsp;Schuh shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.&nbsp;&nbsp;If the executive agreement is terminated as a result of a change of control, Dr.&nbsp;Schuh shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:46pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During 2012, the Company entered into an executive agreement with Steve Zaniboni in which he agreed to serve as Chief Financial Officer.&nbsp;&nbsp;If the executive agreement is terminated by the Company for cause or as a result of Mr.&nbsp;Zaniboni&#x2019;s death or permanent disability or if Mr.&nbsp;Zaniboni terminates his agreement voluntarily, Mr.&nbsp;Zaniboni shall receive a lump sum equal to (i)&nbsp;any portion of unpaid base compensation then due for periods prior to termination, (ii)&nbsp;any bonus or realization bonus earned but not yet paid through the date of termination and (iii)&nbsp;all expenses reasonably incurred by Mr.&nbsp;Zaniboni prior to date of termination.&nbsp;&nbsp;If the executive agreement is terminated by the Company without cause Mr.&nbsp;Zaniboni shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.&nbsp;&nbsp;If the executive agreement is terminated as a result of a change of control, Mr.&nbsp;Zaniboni shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Lease Agreements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company leases its facilities under a noncancelable operating lease that expires in 2017.&nbsp;&nbsp;&nbsp;Rent expense for the years ended December&nbsp;31, 2014, 2013 and 2012 was $315,000, $294,000, and $270,000, and respectively.&nbsp;&nbsp;The Company is also a party to various operating lease agreements for office equipment.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total annual commitments under current lease agreements for each of the years ended December&nbsp;31, are as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2015 </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>360,775&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2016 </font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>371,324&nbsp; </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2017 </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>381,026&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2018 </font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,380&nbsp; </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,119,505&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Contingencies</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters.&nbsp;&nbsp;In accordance with FASB ASC Topic 450, </font><font style="display: inline;font-style:italic;font-size:10pt;">Accounting for Contingencies</font><font style="display: inline;font-size:10pt;">, Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.&nbsp;&nbsp;Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.0001 0.0001 150000000 150000000 2142857 18902782 488476 18915793 18902782 18915794 1890 1891 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Concentration of credit risk</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company maintains its cash in financial institutions, which at times may exceed the amount insured by the Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;).&nbsp;&nbsp;All of the Company&#x2019;s noninterest bearing cash balances were insured up to $250,000 at December&nbsp;31, 2014 and December&nbsp;31, 2013.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 32 4 35000 35000 36458 36458 36 15441 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Cost of Revenue</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 15000000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">9.&nbsp;&nbsp;Debt</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Loan and Security Agreement</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2014, the Company entered into a $15,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing.&nbsp;&nbsp;A portion of the proceeds were used to repay the existing equipment loan.&nbsp;&nbsp;The repayment with the same lender was accounted for as a debt extinguishment under ASC Topic 470-50, </font><font style="display: inline;font-style:italic;font-size:10pt;">Debt</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;The interest rate on the new loan is 7.07% per annum.&nbsp;&nbsp;The Company will make interest only payments on the outstanding amount of the loan on a monthly basis through July&nbsp;2015, after which equal monthly payments of principal and interest are due until the loan maturity date of July&nbsp;1, 2018.&nbsp;&nbsp;The loan is secured by a security interest in all of the Company&#x2019;s assets except intellectual property, which is subject to a negative pledge.&nbsp;&nbsp;In connection with the loan, the lenders received a warrant to purchase an aggregate 85,470 shares of the Company&#x2019;s common stock at an exercise price of $3.51 per share exercisable for ten years from the date of issuance. The original value of the warrants, totaling $235,857, was recorded as debt discount and additional paid-in capital as the warrants were equity classified. </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">At the Company&#x2019;s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount.&nbsp;&nbsp;In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $1,050,000.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt and pay dividends.&nbsp;&nbsp;In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">As of December&nbsp;31, 2014, amounts due under the agreement include $1,898,548 in current liabilities and $13,053,117 in long-term liabilities, which includes $191,682 of accrued interest.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:27.35pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">At December&nbsp;31, 2014, Trovagene was in compliance with all covenants under the</font><font style="display: inline;font-size:10pt;"> Loan and Security Agreement.&nbsp; </font> </p> <p style="margin:0pt;text-indent:27.35pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:27.35pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company recorded $843,260 in interest expense related to the Loan and Security Agreement during the year ended December&nbsp;31, 2014.&nbsp;&nbsp;Closing costs are being accreted over the life of the loan to interest expense.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:27.35pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Future maturities of long-term debt at December&nbsp;31, 2014 are as follows:</font> </p> <p style="margin:0pt;text-indent:27.35pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2015 </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,898,548&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2016 </font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,790,628&nbsp; </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2017</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,140,519&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2018</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,170,305&nbsp; </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total long-term obligations</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,000,000&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 15000000 0.0707 16224600 22323600 14211400 19010900 230400 420800 1547500 2193900 16224600 22323600 41842 130520 234813 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">7.&nbsp;&nbsp;Derivative Financial Instruments - Warrants</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity&#x2019;s Own Equity, Trovagene has determined that certain warrants issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital as they were issued with other equity instruments.&nbsp;&nbsp;In accordance with ASC Topic 815-40, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company&#x2019;s statement of operations.&nbsp;&nbsp;The Company estimates the fair value of (i)&nbsp;certain of these warrants using the Black-Scholes option pricing model and (ii)&nbsp;estimates the fair value of the price protected units using the Binomial option pricing model in order to determine the associated derivative instrument liability and change in fair value described above.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Warrants - Black-Scholes Option Pricing Model</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:22.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2013</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2012</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Estimated fair value of Trovagene common stock </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$3.00 - $6.74</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$5.74 - $7.18</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$0.02 - $5.93</font></p> </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected warrant term </font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">4.0 years</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 month 5.8 years</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">10 months to 6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk-free interest rate </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1.38%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.03%-1.75%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.06% - 1.54%</font></p> </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility </font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">86.4%</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">82%-100%</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">90%-97%</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Dividend yield </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility is based on the volatility of a peer group of companies with attributes similar to Trovagene.&nbsp;&nbsp;The warrants have a transferability provision and based on guidance provided in SAB&nbsp;107 for instruments issued with such a provision, Trovagene used the full contractual term as the expected term of the warrants.&nbsp;&nbsp;The risk free rate is based on the U.S.&nbsp;&nbsp;Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.&nbsp;&nbsp;For the period ending December 31, 2013, the derivative financial instruments liability in the table below only represents the Black-Scholes calculation whereas the loss recognized in the Statement of Operations represents both the Black-Scholes and the binomial methodology.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:15.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Date</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Description</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">Warrants</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Instrument</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2011</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,103,727 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,627 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired warrants</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,667 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.18%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a loss in the statement of operations</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,258,133 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:15.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,087,060 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,252,760 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired warrants</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73,099 </td> <td valign="bottom" style="width:01.10%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.18%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a gain in the statement of operations</font></p> </td> <td valign="bottom" style="width:01.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,820,889 </td> <td valign="bottom" style="width:01.10%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,013,961 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:15.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a gain in the statement of operations</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,425,850 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:15.38%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:54.98%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance of derivative financial instruments liability</font></p> </td> <td valign="bottom" style="width:01.64%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,013,961 </td> <td valign="bottom" style="width:01.10%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:11.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021 </td> <td valign="bottom" style="width:01.10%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Warrants - Binomial Option Pricing Model</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended 2011 and through May&nbsp;2012, the Company issued 713,784 and 1,048,175 units, respectively, at $3.00 per unit.&nbsp;&nbsp;The units had a per unit price protection clause whereby from the date of issuance until the earlier of (i)&nbsp;thirty months from the final Closing or (ii)&nbsp;the closing date of a Subsequent Financing which generates within a one year period an amount equal to or in excess of $5,000,000, if the Company shall issue any Common Stock or Common Stock Equivalents, in a Subsequent Financing at an effective price per share less than the Per Unit Purchase Price, the Company shall issue to such the number of additional Units equal to (a)&nbsp;the Subscription Amount Investor at the Closing divided by the Discounted Purchase Price, less (b)&nbsp;the Units issued to such Investor at the Closing.&nbsp;&nbsp;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic&nbsp;815-40, Contracts in Entity&#x2019;s Own Equity, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital.&nbsp;&nbsp;The price protected unit&#x2019;s warrants had an exercise price of $3.00 per share and had expiration dates ranging from June&nbsp;30, 2014 to December&nbsp;31, 2018.&nbsp;&nbsp;The fair value of these price protected units was estimated using the binomial option pricing model.&nbsp;&nbsp;The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate.&nbsp;&nbsp;The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.&nbsp;&nbsp;The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.&nbsp;&nbsp;However, the completion of the underwritten public offering on May&nbsp;30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.&nbsp;&nbsp;Accordingly, the fair value of these warrants were marked to market through May&nbsp;30, 2012 and then reclassified from a liability to additional paid in capital.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In addition, during the fourth quarter of 2012, the Company issued a total of 1,288,650 units at $4.00 per unit.&nbsp;&nbsp;The units had a per unit price protection clause whereby from the date of issuance until the earlier of (i)&nbsp;forty-eight months from the final Closing or (ii)&nbsp;the closing date of a Subsequent Financing which generates within a one year period an amount equal to or in excess of $10,000,000, if the Company shall issue any Common Stock or Common Stock Equivalents, in a Subsequent Financing at an effective price per share less than the Per Unit Purchase Price, the Company shall issue to such the number of additional Units equal to (a)&nbsp;the Subscription Amount Investor at the Closing divided by the Discounted Purchase Price, less (b)&nbsp;the Units issued to such Investor at the Closing.&nbsp;&nbsp;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic&nbsp;815-40, Contracts in Entity&#x2019;s Own Equity, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital.&nbsp;&nbsp;The price protected unit&#x2019;s warrants had an exercise price of $5.32 per share and had expiration dates five years from date of issuance.&nbsp;&nbsp;The fair value of these price protected units was estimated using the binomial option pricing model.&nbsp;&nbsp;The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate.&nbsp;&nbsp;The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.&nbsp;&nbsp;The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.&nbsp;&nbsp;However, the completion of the public offering in July&nbsp;2013 removed the condition which required these warrants to be treated as derivative liabilities.&nbsp;&nbsp;Accordingly, the fair value of these warrants were marked to market through July&nbsp;18, 2013 and then reclassified from a liability to additional paid in capital.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The fair value of the warrants granted during the year ended December&nbsp;31, 2012 was estimated under the binomial method using the following weighted average assumptions:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 56.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:64.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Range of risk-free interest rates</font></p> </td> <td valign="bottom" style="width:03.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0.53% to 1.61%</font></p> </td> <td valign="bottom" style="width:01.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Range of expected volatility </font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">90% -97%</font></p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected fair value of the stock </font></p> </td> <td valign="bottom" style="width:03.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$0.25- $3.21</font></p> </td> <td valign="bottom" style="width:01.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected warrant term </font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2 years to 6.75 years</font></p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments liability balance, valued using the Binomial option pricing method, for the periods indicated:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="bottom" style="width:31.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Date</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Price&nbsp;Protected</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Units</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability&nbsp;For</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Issued&nbsp;Units</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Change&nbsp;In</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fair</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">value&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability&nbsp;For</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Previously</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Outstanding</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Price</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Protected</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Units</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Ending</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Balance</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Derivative</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Liability</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,288,650 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,171,463 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,341,405 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,512,868 </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Reclassification of derivative liability to equity</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,288,650 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,417,871 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,417,871 </td> <td valign="bottom" style="width:01.16%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:31.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Change in fair value of warrants during the year recognized as a loss in the statement of operations</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,905,003 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,905,003 </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">December&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,171,463 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,171,463 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The weighted average remaining contractual term of all of the Company&#x2019;s warrants outstanding at December&nbsp;31, 2014 and 2013 was approximately 3.6 and 4.0 years, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:72pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">At December&nbsp;31, 2014 and 2013, the total fair value of the above warrants accounted for as derivative financial instruments, valued using the Black-Scholes option pricing model was $3,006,021 and $4,431,871, respectively, and is classified as derivative financial instruments liability on the balance sheet.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 994627 1171463 1341405 2512868 6252760 4431871 1171463 -1171463 4431871 4431871 4431871 3006021 3006021 3006021 3006021 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Derivative Financial Instruments&#x2014;Warrants</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company has issued common stock warrants in connection with the execution of certain equity financings.&nbsp;&nbsp;Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 </font><font style="display: inline;font-style:italic;font-size:10pt;">Derivatives and Hedging (&#x201C;ASC 815&#x201D;)</font><font style="display: inline;font-size:10pt;"> and are recorded at their fair market value as of each reporting period.&nbsp;&nbsp;Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1)&nbsp;indexed to its own stock and (2)&nbsp;classified in stockholders&#x2019; equity.&nbsp;&nbsp;Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption &#x201C;Change in fair value of derivative instruments.&#x201D;</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene&#x2019;s common share price, remaining life of the warrant, and risk-free interest rates at each period end.&nbsp;&nbsp;The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level&nbsp;3 per ASC 820, </font><font style="display: inline;font-style:italic;font-size:10pt;">Fair Value Measurements</font><font style="display: inline;font-size:10pt;">.&nbsp;&nbsp;At December&nbsp;31, 2014 and 2013, the fair value of these warrants was $3,006,021 and $4,431,871, respectively, and were included in the derivative financial instruments liability on the balance sheet.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">6.&nbsp;&nbsp;Stock Option Plan</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2004 the Company adopted the Trovagene Stock Option Plan, as amended (the &#x201C;2004 Plan&#x201D;), under which up to 6,000,000 shares common stock were reserved for issuance to directors, eligible employees, including executive officers and consultants.&nbsp;&nbsp;The 2004 Plan provided for the grant of stock options to eligible recipients. Generally, vesting for options granted under the Plan was from three to four years, and options expird after a 10-year period.&nbsp;&nbsp;Options were granted at an exercise price not less than the fair market value at the date of grant.&nbsp;&nbsp;As of December&nbsp;31, 2014 the 2004 Plan was expired.&nbsp;&nbsp;As of December&nbsp;31, 2013, there were 1,788,921 shares available for issuance under the 2004 Plan.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During 2013, the Company issued 260,000 options over the authorized number of options in the 2004 Plan.&nbsp;&nbsp;As per ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company&#x2019;s statement of operations.&nbsp;&nbsp;Stockholder approval was obtained on July&nbsp;18, 2013 to increase the number of authorized shares in the Plan from 3,666,667 to 6,000,000.&nbsp;&nbsp;Accordingly, the options were remeasured as of the date of stockholder approval with the change recorded in stock based compensation expense and the $23,024 liability was reclassified to additional paid in capital.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:39pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In July&nbsp;2013, an option to purchase 90,000 shares of common stock was granted to a Board Director for services provided outside of routine Board of Directors&#x2019; services.&nbsp;&nbsp;These options were immediately vested.&nbsp;&nbsp;The fair value of this option was approximately $500,000 and is included in general and administrative expenses.</font> </p> <p style="margin:0pt;text-indent:39pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:39pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Trovagene Inc. 2014 Equity Incentive Plan, (the &#x201C;2014 EIP&#x2019;)&nbsp;&nbsp;authorizing up to 2,500,000 shares of common stock for issuance under the Plan, was approved by the Board of Directors in June&nbsp;2014 and approved by the Shareholders at the September&nbsp;17, 2014 Annual Shareholders&#x2019; Meeting.&nbsp;&nbsp;As of December&nbsp;31, 2014, there were 1,371,832 shares available for issuance under the 2014 EIP.</font> </p> <p style="margin:0pt;text-indent:39pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock-based compensation has been recognized in operating results as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:44.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:51.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years&nbsp;ended&nbsp;December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In research and development expenses </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>796,008&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>549,465&nbsp; </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136,148&nbsp; </td> <td valign="bottom" style="width:01.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In general and administrative expenses </font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,274,186&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,429,899&nbsp; </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>395,992&nbsp; </td> <td valign="bottom" style="width:01.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total stock based compensation </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,070,194&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,979,364&nbsp; </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>532,140&nbsp; </td> <td valign="bottom" style="width:01.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:39.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:55.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years&nbsp;ended&nbsp;December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:03.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1.42% - 2.1%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.74% - 1.5%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.62% - 1.04%</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Dividend yield </font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility </font></p> </td> <td valign="bottom" style="width:03.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">81% - 86%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">82% - 100%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">90% - 97%</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected term (in years) </font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5.0 yrs</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5.0 yrs</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5.0 yrs</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock price </font></p> </td> <td valign="bottom" style="width:03.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$3.00 - $6.74</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$5.53 - $8.15</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$0.50 - $4.87</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Risk-free interest rate </font><font style="display: inline;font-size:10pt;">&#x2014; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#x2019;s stock options.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Dividend yield </font><font style="display: inline;font-size:10pt;">&#x2014; Trovagene has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Expected volatility </font><font style="display: inline;font-size:10pt;">&#x2014; Based on the historical volatility of a group of peer companies with attributes similar to Trovagene.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Expected term </font><font style="display: inline;font-size:10pt;">&#x2014; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#x201C;SAB&#x201D;) No.&nbsp;107, </font><font style="display: inline;font-style:italic;font-size:10pt;">Share-Based Payment</font><font style="display: inline;font-size:10pt;">, (&#x201C;SAB No.&nbsp;107&#x201D;), which averages an award&#x2019;s weighted-average vesting period and expected term for &#x201C;plain vanilla&#x201D; share options.&nbsp;&nbsp;Under SAB No.&nbsp;107, options are considered to be &#x201C;plain vanilla&#x201D; if they have the following basic characteristics: (i)&nbsp;granted &#x201C;at-the-money&#x201D;; (ii)&nbsp;exercisability is conditioned upon service through the vesting date; (iii)&nbsp;termination of service prior to vesting results in forfeiture; (iv)&nbsp;limited exercise period following termination of service; and (v)&nbsp;options are non-transferable and non-hedgeable.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Forfeitures </font><font style="display: inline;font-size:10pt;">&#x2014; ASC Topic 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&nbsp;&nbsp;The Company estimates forfeitures based on its historical experience.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The weighted-average fair value per share of all options granted during the years ended December&nbsp;31, 2014, 2013, and 2012, estimated as of the grant date using the Black-Scholes option valuation model was $2.19, $4.54, and $2.12, per share, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The unrecognized compensation cost related to non-vested stock options outstanding at December&nbsp;31, 2014 and December&nbsp;31, 2013 was $4,862,030 and $3,733,753, respectively.&nbsp;&nbsp;The weighted-average remaining contractual term at December&nbsp;31, 2014 and 2013 for options outstanding and vested options was 3.0 and 6.7, respectively.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">A summary of stock option activity and of changes in stock options outstanding is presented below:</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Options</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Price&nbsp;Per</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Share</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intrinsic</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Remaining</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Contractual Life</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2011 </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,426,192 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.22 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,294,668 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.74 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(200 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>640 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Forfeited </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,357 </td> <td valign="bottom" style="width:02.56%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2012 </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,711,303 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.69 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,301,484 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.3&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,144,760 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.33 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(52,500 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.30 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>275,492 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Forfeited </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(516,018 </td> <td valign="bottom" style="width:02.56%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.35 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2013 </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,287,545 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.18 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,896,329 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,410,038 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.42 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Forfeited </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(784,111 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.08 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,913,472 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.66 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,808,083 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">7.6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Vested and exercisable, December 31, 2014</font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,434,124 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.65 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,990,187 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.2&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">ASC Topic 718 requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities.&nbsp;&nbsp;Due to Trovagene&#x2019;s accumulated deficit position, no tax benefits have been recognized in the cash flow statement.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 38240 38240 38240 29840 29840 29840 23015 23015 23015 -0.89 -0.07 -0.70 -0.34 -0.25 -0.05 -0.17 -0.76 -0.06 -0.28 -0.25 -0.89 -0.07 -0.70 -0.34 -0.25 -0.05 -0.17 -0.88 -0.17 -0.28 -0.25 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Net Loss Per Share</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Basic and diluted net loss per share is presented in conformity with ASC Topic 260, </font><font style="display: inline;font-style:italic;font-size:10pt;">Earnings per Share</font><font style="display: inline;font-size:10pt;">, for all periods presented.&nbsp;&nbsp;In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period.</font><font style="display: inline;font-size:10pt;"> Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share.</font><font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-size:10pt;">Shares used in calculating diluted</font><font style="display: inline;font-size:10pt;"> net loss per common share exclude as antidilutive the following share equivalents:</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 76.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:53.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Options to purchase Common Stock </font></p> </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,913,472&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,287,545&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,711,303&nbsp; </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants to purchase Common stock </font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,251,660&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,233,483&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,985,070&nbsp; </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Series&nbsp;A Convertible Preferred Stock </font></p> </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,125&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,125&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99,583&nbsp; </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,228,257&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,584,153&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,795,956&nbsp; </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 0.75pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The following table summarizes the Company&#x2019;s diluted net loss per share:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss </font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,348,499 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,840,778 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,604,201 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Adjustment for change in fair value of derivative instruments - warrants</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,422,337 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss used for diluted loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,770,836 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,840,778 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,604,201 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Weighted average shares used to compute basic loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,904,280 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,978,212 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,066,600 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Adjustments to reflect assumed exercise of warrants</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>166,832 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Weighted average shares used to compute diluted net loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,071,112 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,978,212 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,066,600 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per share diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.88 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.70 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.89 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.00 0.35 -0.43 0.06 P6Y8M12D P3Y 3733753 4862030 0 4.00 0.00 0.00 0.00 0.00 P6Y9M P6Y P2Y P10M P5Y9M18D P1M P4Y P10Y 0.97 0.97 0.90 0.90 1.00 0.82 0.864 0.738 0.0161 0.0154 0.0053 0.0006 0.0175 0.0003 0.0138 0.0253 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">8.&nbsp;&nbsp;Fair Value Measurements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&nbsp;31, 2014 and 2013:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurements&nbsp;at</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">and&nbsp;Liabilities</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Total</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Assets:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Money market fund (1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Assets</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Liabilities:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Derivative liabilities related to warrants </font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Liabilities</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurements&nbsp;at</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2013</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">and&nbsp;Liabilities</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Total</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Assets:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Money market fund (1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Assets</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Liabilities:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Derivative liabilities related to warrants </font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Liabilities</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Times New Roman;font-size:10pt;;"> (1)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet.</font></p></td></tr></table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The following table sets forth a summary of changes in the fair value of the Company&#x2019;s Level&nbsp;3 liabilities for the years ended December&nbsp;31, 2014 and 2013:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:48.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Description</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Balance&nbsp;at</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2013</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Unrealized</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(gains)&nbsp;or</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">losses</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Balance&nbsp;as&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2014</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:48.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Derivative liabilities related to Warrants </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,425,850 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:26.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Description</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Balance&nbsp;at</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2012</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Fair&nbsp;Value&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Warrants</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Reclassified&nbsp;to</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Additional&nbsp;Paid&nbsp;in</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Capital</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Unrealized</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">(gains)&nbsp;or</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">losses</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Balance&nbsp;as&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">2013</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:26.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Derivative liabilities related to Warrants </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,765,628 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,417,871 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">)</font></p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,084,114 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871 </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company&#x2019;s statement of operations.&nbsp;&nbsp;A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&nbsp;&nbsp;At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40.&nbsp;&nbsp;At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level&nbsp;3.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 56.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:64.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Range of risk-free interest rates</font></p> </td> <td valign="bottom" style="width:03.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0.53% to 1.61%</font></p> </td> <td valign="bottom" style="width:01.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Range of expected volatility </font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">90% -97%</font></p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected fair value of the stock </font></p> </td> <td valign="bottom" style="width:03.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$0.25- $3.21</font></p> </td> <td valign="bottom" style="width:01.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.72%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected warrant term </font></p> </td> <td valign="bottom" style="width:03.92%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:29.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2 years to 6.75 years</font></p> </td> <td valign="bottom" style="width:01.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:22.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2013</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2012</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Estimated fair value of Trovagene common stock </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$3.00 - $6.74</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$5.74 - $7.18</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$0.02 - $5.93</font></p> </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected warrant term </font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">4.0 years</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 month 5.8 years</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">10 months to 6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk-free interest rate </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1.38%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.03%-1.75%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.06% - 1.54%</font></p> </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility </font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">86.4%</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">82%-100%</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">90%-97%</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:22.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Dividend yield </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurements&nbsp;at</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2014</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">and&nbsp;Liabilities</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Total</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Assets:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Money market fund (1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Assets</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,123,587&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Liabilities:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Derivative liabilities related to warrants </font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Liabilities</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;Measurements&nbsp;at</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;2013</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Quoted&nbsp;Prices</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">in&nbsp;Active</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Markets&nbsp;for</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Identical&nbsp;Assets</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">and&nbsp;Liabilities</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Other</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Observable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;2)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Significant</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Unobservable</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Inputs</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(Level&nbsp;3)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Total</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Assets:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Money market fund (1)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Assets</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,703,330&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Liabilities:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Derivative liabilities related to warrants </font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total Liabilities</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Times New Roman;font-size:10pt;;"> (1)</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet.</font></p></td></tr></table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;"> &nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:48.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Description</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Balance&nbsp;at</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Unrealized</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(gains)&nbsp;or</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">losses</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Balance&nbsp;as&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:48.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Derivative liabilities related to Warrants </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,425,850 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,006,021 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:26.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Description</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Balance&nbsp;at</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Fair&nbsp;Value&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Warrants</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Reclassified&nbsp;to</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Additional&nbsp;Paid&nbsp;in</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Capital</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Unrealized</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(gains)&nbsp;or</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">losses</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Balance&nbsp;as&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:26.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Derivative liabilities related to Warrants </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,765,628 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,417,871 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,084,114 </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,431,871 </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> -1084114 1425850 8765628 4431871 4431871 3006021 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Fair value of financial instruments</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities.&nbsp;&nbsp;We have adopted FASB ASC 820 </font><font style="display: inline;font-style:italic;font-size:10pt;">Fair Value Measurements and Disclosures (&#x201C;ASC 820&#x201D;)</font><font style="display: inline;font-size:10pt;"> for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis.&nbsp;&nbsp;These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature as they reflect current market interest rates.&nbsp;&nbsp;&nbsp;Debt is stated at its respective historical carrying amounts which approximates fair value as they reflect current market interest rates.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In accordance with ASC subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.&nbsp;&nbsp;The three tiers include:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:36pt;"> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;font-family:Symbol;">&#xF0B7;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Level&nbsp;1 &#x2014;</font></p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Quoted prices for identical instruments in active markets.</font></p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;font-family:Symbol;">&#xF0B7;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Level&nbsp;2 &#x2014;</font></p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</font></p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:04.28%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;font-family:Symbol;">&#xF0B7;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:11.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Level&nbsp;3 &#x2014;</font></p> </td> <td valign="bottom" style="width:01.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="top" style="width:80.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Instruments where significant value drivers are unobservable to third parties.</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 4000 -22941 24845 2872727 5472038 5810087 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Impairment of Indefinite and Long-Lived Assets</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company reviews its long and indefinite lived assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired.&nbsp;&nbsp;If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows.&nbsp;&nbsp;If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value.&nbsp;&nbsp;Factors that would indicate potential impairment include a significant decline in the Company&#x2019;s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company&#x2019;s strategic business objectives and utilization of a particular asset.&nbsp;&nbsp;The Company noted no indications of impairment for the years ended December&nbsp;31, 2014, 2013, and 2012.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">10.&nbsp;&nbsp;Income Taxes</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">At December&nbsp;31, 2014, Trovagene has federal net operating loss carryforwards (NOLs) of approximately $49.3 million, which, if not used, expire beginning in 2020.&nbsp;&nbsp;&nbsp;Trovagene also has California NOLs of approximately $&nbsp;29.9 million which begin to expire in 2021 and New Jersey NOLs of $11.5 million which started to expire on January&nbsp;31, 2013.&nbsp;&nbsp;&nbsp;Trovagene also has R&amp;D credits available for federal purposes of approximately $698,000. The federal R&amp;D credits will begin to expire January&nbsp;31, 2025.&nbsp;&nbsp;&nbsp;The utilization of these NOLs and R&amp;D tax credits is subject to limitations based on past and future changes in ownership of Trovagene pursuant to Internal Revenue Code Section&nbsp;382.&nbsp;&nbsp;The Company has determined that ownership changes have occurred for Internal Revenue Code Section&nbsp;382 purposes and therefore, the ability of the Company to utilize its NOLs is limited.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Signifcant components of the Company&#x2019;s taxes and the rates as of December&nbsp;31, are shown below:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Tax Rate Reconciliation</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="top" style="width:63.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Tax computed at the federal statutory rate</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,871,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">State tax, net of federal tax benefit</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(891,000 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Permanent Items</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Valuation allowance increase (decrease)</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,081,000 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43 </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Other</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Provision for income taxes</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Significant components of the Company&#x2019;s deferred tax assets as of December&nbsp;31, are shown below:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="bottom" style="width:65.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:30.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:65.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Deferred tax assets</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Tax loss carryforwards </font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,900 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.60%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,211,400 </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">R&amp;D credits and other tax credits</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>698,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235,300 </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock based compensation</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,193,900 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,547,500 </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Other</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>420,800 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,400 </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 30pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total deferred tax assets</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,323,600 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,224,600 </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Valuation allowance</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,323,600 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,224,600 </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net deferred tax asset</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The difference between the statutory rate of 35% on taxable income and the actual income tax rate of zero is a result of the full deferred tax asset valuation allowance.&nbsp;&nbsp;&nbsp;The valuation allowance increased by $6,099,000 and $4,398,700 during the years ended December&nbsp;31, 2014 and 2013, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Trovagene records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">ASC 740-10-30-7, </font><font style="display: inline;font-style:italic;font-size:10pt;">Accounting for Income Taxes</font><font style="display: inline;font-size:10pt;"> had no effect on Trovagene&#x2019;s financial position, cash flows or results of operations upon adoption, as Trovagene does not have any unrecognized tax benefits.&nbsp;&nbsp;Trovagene&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense and none have been incurred to date.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 7650 2400 0 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Income Taxes</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Income taxes have been determined using the asset and liability approach of accounting for income taxes.&nbsp;&nbsp;Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.&nbsp;&nbsp;Deferred taxes result from differences between the financial statement and tax bases of Trovagene&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted.&nbsp;&nbsp;Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.&nbsp;&nbsp;The assessment of whether or not a valuation allowance is required often requires significant judgment.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 6081000 -4871000 1000 -891000 -737752 1055690 632299 69241 -89387 -22300 -25631 258 17383 92748 216470 166832 17005 843259 843260 9459 425256 191682 3663 12239 133000 6763735 20547293 27155735 28896846 2008866 4488155 4431871 4431871 3006021 3006021 125000 10000 0 0 24000 0 0 0 0 0 0 0 0 30000 0 0 0 0 0 0 0 0 23000 0 0 0 0 0 0 322998 13053117 13053117 198166 1898548 1898548 3170305 5140519 4790628 1898548 25703330 25703330 27123587 27123587 10119407 15017156 1456861 15324148 15324148 22983688 14484036 -270080 -649284 -299790 -4934661 -7317248 -12727385 -11565961 -11565961 -11810938 -11810938 -14325484 -14325484 -11604201 -1117000 -11840778 -5279000 -4407000 -1038000 -3198000 -14348499 -1079000 -5382000 -4689000 -11604201 -11840778 -16770836 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In January&nbsp;2015, the Financial Accounting Standards Board (the FASB) issued an amendment to the accounting guidance related to the presentation of extraordinary items. The amendment simplifies the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The amended guidance is effective prospectively for fiscal years beginning after December&nbsp;15, 2015. The new guidance will not have an impact on the Company&#x2019;s financial position, results of operations or cash flows.</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In August&nbsp;2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity&#x2019;s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December&nbsp;15, 2016. The new guidance will not have an impact on the Company&#x2019;s financial position, results of operations or cash flows.</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2014, the FASB issued an accounting standards update that removes the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to: (1)&nbsp;present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2)&nbsp;label the financial statements as those of a development stage entity, (3)&nbsp;disclose a description of the development stage activities in which the entity is engaged, and disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2014, with an option for early adoption.&nbsp;&nbsp;The Company elected early adoption, and does not believe the adoption of the standard had a material impact on its financial position, results of operations or related financial statement disclosures.</font> </p> <p style="margin:0pt;text-indent:24.5pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In May&nbsp;2014, the FASB issued Accounting Standards Update (&#x201C;ASU&#x201D;) No.&nbsp;2014-09, Revenue from Contracts with Customers (&#x201C;ASU 2014-09&#x201D;). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December&nbsp;15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 5299560 2509000 10949787 2423000 3121000 2897000 3371000 15225337 3297000 3997000 4560000 -4849156 -10690541 -14945159 1119505 360775 6380 381026 371324 270000 294000 315000 29900000 11500000 49300000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">1.&nbsp;&nbsp;Business Overview and Liquidity</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Trovagene,&nbsp;Inc.&nbsp;&nbsp;(&#x201C;Trovagene&#x201D; or the &#x201C;Company&#x201D;) is a molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines.&nbsp;&nbsp;Trovagene&#x2019;s primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while the Company&#x2019;s external focus includes entering into collaborations to develop the Company&#x2019;s technology in areas such as infectious disease, transplant medicine, and prenatal genetics.&nbsp;&nbsp;&nbsp;The Company&#x2019;s goal is to improve treatment outcomes for cancer patients using its proprietary technology to detect and quantitatively monitor cell-free DNA in urine.</font> </p> <p style="margin:0pt;text-indent:27pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Underwritten Public Offering of Common Stock</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On May&nbsp;30, 2012, the Company completed an underwritten public offering in which an aggregate of 1,150,000 units, with each unit consisting of two shares of its common stock and one warrant to purchase one share of common stock were sold at a purchase price of $8.00 per unit.&nbsp;&nbsp;On June&nbsp;13, 2012, the underwriters exercised their overallotment option in full for an additional 172,500 units.&nbsp;&nbsp;&nbsp;The Company raised a total of $9.1 million in net proceeds after deducting underwriting discounts and commissions of $0.7 million and offering expenses of $0.7 million.&nbsp;&nbsp;&nbsp;The units began trading on The NASDAQ Capital Market on May&nbsp;30, 2012 under the symbol &#x201C;TROVU&#x201D;.&nbsp;&nbsp;The common stock and warrants became separately transferable upon&nbsp;the exercise in full of the underwriters&#x2019; overallotment.&nbsp;&nbsp;&nbsp;Each warrant has an exercise price of $5.32&nbsp;per share, and expires five years from the closing of the offering.&nbsp;&nbsp;&nbsp;The warrants trade on The NASDAQ Capital Market under the symbol &#x201C;TROVW&#x201D;.&nbsp;&nbsp;Warrants issued in connection with the underwritten public offering and sale of units in May&nbsp;2012 are not considered derivatives based on our analysis of the criteria of ASC 815, as the Company is not required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of warrant shares.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">To date, Trovagene&#x2019;s efforts have been principally devoted to research and development, securing and protecting patents and raising capital.&nbsp;&nbsp;Through December&nbsp;31, 2014, the Company has sustained cumulative net losses attributed to common stockholders of $81,391,909.&nbsp;&nbsp;The Company&#x2019;s losses have resulted primarily from expenditures incurred in connection with research and development activities, stock based compensation expense, patent filing and maintenance expenses, outside accounting and legal services and regulatory, scientific and financial consulting fees, amortization and liquidated damages.&nbsp;&nbsp;&nbsp;To date, the Company has generated only limited revenue from operations and expects to incur additional losses to perform further research and development activities as well as selling and marketing expenses related to the diagnostic tests it has commercially available as of December&nbsp;31, 2014.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Liquidity</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;The Company will need to continue to raise funds until it is able to generate revenues from operations sufficient to fund its development and commercial operations.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Cash used in operating activities was $12,727,385, $7,317,248 and $4,934,661 for the years ended December&nbsp;31, 2014, 2013, and 2012, respectively.&nbsp;&nbsp;During the years ended December&nbsp;31, 2014, 2013 and 2012, the Company incurred net loss and comprehensive loss attributable to common stockholders of $14,348,499, $11,840,778 and $11,604,201, respectively. The Company believes that it currently has adequate capital to continue operations for the subsequent one year business cycle. However, to carry the Company forward beyond the current business cycle until it can generate adequate cash flow from operations, additional cash resources will be necessary.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">To date, Trovagene&#x2019;s sources of cash have been primarily limited to the sale of debt and equity securities, as well as proceeds from warrant and option exercises.&nbsp;&nbsp;Net cash provided by financing activities for the years ended December&nbsp;31, 2014, 2013 and 2012 was $14,484,036, $22,983,688 and $15,324,148, respectively.&nbsp;&nbsp;The Company cannot be certain that additional funding will be available on acceptable terms, or at all.&nbsp;&nbsp;To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience significant dilution.&nbsp;&nbsp;Any debt financing, if available, may involve restrictive covenants that impact the Company&#x2019;s ability to conduct its business.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates.&nbsp;&nbsp;The Company may also be required to:</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;font-family:Symbol;">&#xF0B7;</font><font style="display: inline;font-size:10pt;font-family:Symbol;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font><font style="display: inline;font-size:3pt;"></font><font style="display: inline;font-size:10pt;">Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;font-family:Symbol;">&#xF0B7;</font><font style="display: inline;font-size:10pt;font-family:Symbol;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font><font style="display: inline;font-size:3pt;"></font><font style="display: inline;font-size:10pt;">Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 336450 336708 274080 649784 363290 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">12.&nbsp;&nbsp;Employee Benefit Plan</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company has a retirement savings plan under Section&nbsp;401(k)&nbsp;of the Internal Revenue Code covering its employees.&nbsp;&nbsp;The plan allows employees to defer, up to the maximum allowed, a percentage of their income on a pre-tax basis through contributions to the plans, plus any employee of the age of 55 can participate in the caught-up dollars as allowed by IRS codes.&nbsp;&nbsp;The Company also has a Roth investment plan that is taken after taxes.&nbsp;&nbsp;The Company does not currently make matching contributions.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 221040 244055 0.04 38240 29840 23015 606000 606000 0.001 0.001 10 20000000 20000000 95600 60600 60600 60600 60600 60 60 152789 369259 15323548 18829644 21300000 15000000 4200000 15000000 515964 -515964 4000 500 63500 600 38249 3599831 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp; </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">4.&nbsp;&nbsp;Property and Equipment</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Fixed assets consist of laboratory, testing and computer equipment and fixtures stated at cost.&nbsp;&nbsp;Depreciation and amortization expense for the years ended December&nbsp;31, 2014, 2013 and 2012 was $234,813, $130,520 and $41,842, respectively.&nbsp;&nbsp;Property and equipment consisted of the following:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:36.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;</font><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Furniture and office equipment </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>365,955 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,645 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Leasehold Improvements </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,401 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,371 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Laboratory equipment </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>968,901 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>826,151 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,374,257 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,099,167 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Less&#x2014;accumulated depreciation and amortization </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(533,870 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(348,602 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:59.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Property and equipment, net </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>840,387 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>750,565 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <p><font size="1"> </font></p> </div> </div> 1099167 236645 826151 36371 1374257 365955 968901 39401 750565 840387 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Property, equipment and depreciation and amortization</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expenditures for additions, renewals and improvements are capitalized at cost.&nbsp;&nbsp;Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets.&nbsp;&nbsp;Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.&nbsp;&nbsp;The estimated useful lives of the major classes of depreciable assets are 3 to 5&nbsp;years for lab equipment and furniture and fixtures.&nbsp;&nbsp;Expenditures for repairs and maintenance are charged to operations as incurred.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:36.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;</font><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Furniture and office equipment </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>365,955 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,645 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Leasehold Improvements </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,401 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,371 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Laboratory equipment </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>968,901 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>826,151 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,374,257 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,099,167 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Less&#x2014;accumulated depreciation and amortization </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(533,870 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(348,602 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:59.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Property and equipment, net </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>840,387 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>750,565 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> P5Y P3Y P5Y P3Y 232000 266000 270000 175000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp;&nbsp; </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">14.&nbsp;&nbsp;Selected Quarterly Financial Data (Unaudited)</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The following is a summary of the quarterly results of operations of the Company for years ended December&nbsp;31, 2014 and 2013:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Quarter&nbsp;Ended(1)</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">June&nbsp;30</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">September&nbsp;30</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(Revised)(2)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(dollars&nbsp;in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">2014</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Operating expenses</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,371 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,297 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,997 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,560 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss and comprehensive loss attributable to common stockholders</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,198 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,079 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,382 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,689 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.17 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.06 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.28 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.17 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.17 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.28 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - basic</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,904,280 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,232,760 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,071,112 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>119 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Operating expenses</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,509 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,423 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,121 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,897 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss and comprehensive loss attributable to common stockholders</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,117 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,279 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,407 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,038 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.07 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.05 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.07 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.05 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - basic</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,510,340 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,583,957 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,870,703 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,900,781 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,510,340 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,583,957 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,870,703 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,900,781 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">(1)&nbsp;Basic and diluted EPS are computed independently for each of the periods presented.&nbsp;&nbsp;&nbsp;Accordingly, the sum of the quarterly EPS amount may not agree to the total for the year. (2)&nbsp;Second quarter fully diluted earnings per share have been adjusted for dilutive amounts related to the derivative liability. We believe that these changes are not material to the financial statements or related notes.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp; </font><font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">13.&nbsp;&nbsp;Related Party Transactions</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Gabriele M.&nbsp;&nbsp;Cerrone, the Company&#x2019;s former Co-Chairman, and former member of the Board of Directors, served as a consultant to the Company from June&nbsp;27, 2005 until June&nbsp;2008 and is affiliated with Panetta Partners&nbsp;Ltd.&nbsp;&nbsp;Transactions between the Company and Mr.&nbsp; Cerrone and Panetta Partners,&nbsp;Ltd.&nbsp;&nbsp;is disclosed in, </font><font style="display: inline;font-style:italic;font-size:10pt;">Note&nbsp;5, Stockholders&#x2019; Equity (Deficiency).</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 1920298 3947589 124000 29000 6664906 38000 142000 16000 90000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Research and Development</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, </font><font style="display: inline;font-style:italic;font-size:10pt;">Research and Development.&nbsp; </font><font style="display: inline;font-size:10pt;">Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">ASC Topic 730, </font><font style="display: inline;font-style:italic;font-size:10pt;">Research and Development</font><font style="display: inline;font-size:10pt;"> requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized.&nbsp;&nbsp;As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.&nbsp;&nbsp;&nbsp;There were no non-refundable advance payments as of December&nbsp;31, 2014 and 2013.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> -67043410 -81391909 150000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Revenues</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.&nbsp;&nbsp;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&nbsp;&nbsp;Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Milestone payments are recognized when both the milestone is achieved and the related payment is received.</font></p></td></tr></table></div> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 175404 259246 270178 450404 0 50000 5000 2000 100000 27000 180000 5000 71000 20000 0 0 119000 259246 0 50000 0 1000 10000 25000 60000 20000 85000 14000 0 0 49000 44000 47000 111000 280178 0 50000 1000 2000 30000 25000 60000 28000 81000 26000 0 0 56000 57000 56000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:53.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Options to purchase Common Stock </font></p> </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,913,472&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,287,545&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,711,303&nbsp; </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants to purchase Common stock </font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,251,660&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,233,483&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,985,070&nbsp; </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Series&nbsp;A Convertible Preferred Stock </font></p> </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,125&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63,125&nbsp; </td> <td valign="bottom" style="width:03.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99,583&nbsp; </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,228,257&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,584,153&nbsp; </td> <td valign="bottom" style="width:03.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,795,956&nbsp; </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="bottom" style="width:65.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:30.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years&nbsp;ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:65.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Deferred tax assets</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Tax loss carryforwards </font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,900 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.60%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,211,400 </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">R&amp;D credits and other tax credits</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>698,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235,300 </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock based compensation</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,193,900 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,547,500 </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Other</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>420,800 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,400 </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 30pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total deferred tax assets</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22,323,600 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,224,600 </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:65.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Valuation allowance</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,323,600 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:13.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,224,600 </td> <td valign="bottom" style="width:01.14%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:65.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net deferred tax asset</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:12.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss </font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,348,499 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,840,778 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,604,201 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Adjustment for change in fair value of derivative instruments - warrants</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,422,337 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss used for diluted loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,770,836 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,840,778 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,604,201 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Weighted average shares used to compute basic loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,904,280 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,978,212 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,066,600 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Adjustments to reflect assumed exercise of warrants</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>166,832 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Weighted average shares used to compute diluted net loss per share</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,071,112 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,978,212 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,066,600 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:55.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per share diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.88 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.70 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.89 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp; &nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Tax Rate Reconciliation</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"> <tr> <td valign="top" style="width:63.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Tax computed at the federal statutory rate</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,871,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">State tax, net of federal tax benefit</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(891,000 </td> <td valign="bottom" style="width:02.88%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Permanent Items</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Valuation allowance increase (decrease)</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,081,000 </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43 </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Other</font></p> </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,000 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:63.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Provision for income taxes</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:44.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:51.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years&nbsp;ended&nbsp;December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In research and development expenses </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>796,008&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>549,465&nbsp; </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136,148&nbsp; </td> <td valign="bottom" style="width:01.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In general and administrative expenses </font></p> </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,274,186&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,429,899&nbsp; </td> <td valign="bottom" style="width:03.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>395,992&nbsp; </td> <td valign="bottom" style="width:01.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total stock based compensation </font></p> </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,070,194&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,979,364&nbsp; </td> <td valign="bottom" style="width:03.14%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>532,140&nbsp; </td> <td valign="bottom" style="width:01.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 61.00%;margin-left:54pt;"> <tr> <td valign="top" style="width:77.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2015 </font></p> </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.38%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>360,775&nbsp; </td> <td valign="bottom" style="width:05.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:77.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2016 </font></p> </td> <td valign="bottom" style="width:02.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.38%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>371,324&nbsp; </td> <td valign="bottom" style="width:05.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:77.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2017 </font></p> </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.38%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>381,026&nbsp; </td> <td valign="bottom" style="width:05.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:77.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2018 </font></p> </td> <td valign="bottom" style="width:02.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,380&nbsp; </td> <td valign="bottom" style="width:05.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:77.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total </font></p> </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,119,505&nbsp; </td> <td valign="bottom" style="width:05.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2015 </font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,898,548&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2016 </font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,790,628&nbsp; </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2017</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,140,519&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2018</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,170,305&nbsp; </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:80.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Total long-term obligations</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,000,000&nbsp; </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Quarter&nbsp;Ended(1)</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">June&nbsp;30</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">September&nbsp;30</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(Revised)(2)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:55.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(dollars&nbsp;in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">2014</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Operating expenses</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,371 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,297 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,997 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,560 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss and comprehensive loss attributable to common stockholders</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,198 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,079 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,382 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,689 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.17 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.06 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.28 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.17 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.17 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.28 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - basic</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,904,280 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,232,760 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,902,783 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,071,112 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>119 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Operating expenses</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,509 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,423 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,121 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,897 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss and comprehensive loss attributable to common stockholders</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,117 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,279 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,407 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,038 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.07 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.05 </td> <td valign="bottom" style="width:01.00%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Net loss per common share - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.07 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.25 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.05 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - basic</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,510,340 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,583,957 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,870,703 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,900,781 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Shares used in the calculation of net loss attributable to common stockholders - diluted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,510,340 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,583,957 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,870,703 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,900,781 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">(1)&nbsp;Basic and diluted EPS are computed independently for each of the periods presented.&nbsp;&nbsp;&nbsp;Accordingly, the sum of the quarterly EPS amount may not agree to the total for the year. (2)&nbsp;Second quarter fully diluted earnings per share have been adjusted for dilutive amounts related to the derivative liability. We believe that these changes are not material to the financial statements or related notes.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Options</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Price&nbsp;Per</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Share</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intrinsic</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Value</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Remaining</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Contractual Life</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2011 </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,426,192 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.22 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,294,668 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.74 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(200 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>640 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Forfeited </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,357 </td> <td valign="bottom" style="width:02.56%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2012 </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,711,303 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.69 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,301,484 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.3&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,144,760 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.33 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(52,500 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.30 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>275,492 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Forfeited </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(516,018 </td> <td valign="bottom" style="width:02.56%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.35 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2013 </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,287,545 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.18 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,896,329 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.7&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,410,038 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.42 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Forfeited </font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(784,111 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.08 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Balance outstanding, December&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,913,472 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.66 </td> <td valign="bottom" style="width:02.56%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,808,083 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">7.6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.62%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Vested and exercisable, December 31, 2014</font></p> </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,434,124 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.65 </td> <td valign="bottom" style="width:02.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:10.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,990,187 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6.2&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:39.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:55.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Years&nbsp;ended&nbsp;December&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:03.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1.42% - 2.1%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.74% - 1.5%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">.62% - 1.04%</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Dividend yield </font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">0%</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility </font></p> </td> <td valign="bottom" style="width:03.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">81% - 86%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">82% - 100%</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">90% - 97%</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected term (in years) </font></p> </td> <td valign="bottom" style="width:03.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5.0 yrs</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5.0 yrs</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5.0 yrs</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock price </font></p> </td> <td valign="bottom" style="width:03.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$3.00 - $6.74</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$5.53 - $8.15</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$0.50 - $4.87</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:39.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Warrants</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Term</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2011</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,601,474 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.18 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1-8&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,416,934 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.88 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,667 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,671 </td> <td valign="bottom" style="width:03.40%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2012</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,985,070 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.96 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 - 6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50,000 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.00 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(728,488 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.99 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73,099 </td> <td valign="bottom" style="width:03.40%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.50 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2013 </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,233,483 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.87 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 -5&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,470 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.51 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,666 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,667 </td> <td valign="bottom" style="width:03.40%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.80 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2014</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,265,620 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.85 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 &#x2013; 4 years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 506535 1530160 2734903 532140 1979364 2070194 P4Y P3Y 0.00 0.00 0.00 P5Y P5Y P5Y 0.97 0.90 1.00 0.82 0.86 0.81 0.0104 0.0062 0.015 0.0074 0.021 0.0142 3666667 6000000 2500000 1788921 1371832 1990187 2434124 4.65 P6Y2M12D 670 275492 9357 516018 784111 1294668 1144760 90000 1410038 2.12 4.54 2.19 8301484 5896329 2808083 2426192 3711303 4287545 4913472 5.22 4.69 5.18 4.66 P6Y8M12D P6Y3M18D P6Y8M12D P7Y7M6D 3.00 3.00 4.30 4.50 3.53 3.00 4.35 7.08 3.74 6.33 4.42 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Stock-Based Compensation</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">ASC Topic 718 &#x201C;</font><font style="display: inline;font-style:italic;font-size:10pt;">Compensation&#x2014;Stock Compensation</font><font style="display: inline;font-size:10pt;">&#x201D; requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant.&nbsp;&nbsp;The expense is recognized over the period during which an employee is required to provide services in exchange for the award.&nbsp;&nbsp;ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.&nbsp;&nbsp;Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received.&nbsp;&nbsp;The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 &#x201C;Equity -</font><font style="display: inline;font-style:italic;font-size:10pt;">Based Payment to Non-Employees&#x201D; </font><font style="display: inline;font-size:10pt;">and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.&nbsp;&nbsp;Accordingly the fair value of these options is being &#x201C;marked to market&#x201D; quarterly until the measurement date is determined.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.00 0.97 0.0042 4.87 0.50 8.15 5.53 6.74 3.00 10737026 95600 15478177 95600 18902782 60600 18915793 60600 4.50 10000 -4231268 39365994 1073 96 -43598431 2169028 57370017 1547 96 -55202632 20392000 87433460 1890 60 -67043410 8349553 89739511 1891 60 -81391909 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">5.&nbsp;&nbsp;Stockholders&#x2019; Equity (Deficiency)</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">All share and per share amounts have been restated to reflect the one-for-six reverse stock split effected on May&nbsp;29, 2012 as described in Note&nbsp;2.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Common Stock</font> </p> <p style="margin:0pt 0pt 0pt 36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2012, the Company closed five private placement financings which raised gross proceeds of $6,320,000.&nbsp;&nbsp;In total, the Company issued 1,738,333 shares of its common stock and warrants to purchase 1,738,333 shares of common stock (&#x201C;units&#x201D;).</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The purchase price paid by the investors for 633,333 of the units sold in the period January&nbsp;2012 through May&nbsp;2012 was $3.00 each, determined by the price paid by investors in recent private placements.&nbsp;&nbsp;&nbsp;The warrants expire after eight years and are exercisable at $3.00 per share.&nbsp;&nbsp;The Company paid $96,500 in cash for a finder&#x2019;s fee.&nbsp;&nbsp;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic 815-40, Trovagene determined that the warrants issued in connection with these private placements should be recorded as derivative liabilities at the time of issuance since they are all price protected however the completion of the underwritten public offering on May&nbsp;30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.&nbsp;&nbsp;&nbsp;Accordingly, the fair value of these warrants were marked to market through May&nbsp;30, 2012 and then reclassified from a liability to additional paid in capital.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The purchase price paid by the investors for 1,105,000 of the units sold in the fourth quarter of 2012 was $4.00 each, determined by the market price on NASDAQ.&nbsp;&nbsp;&nbsp;The warrants expire after five years and are exercisable at $5.32 per share.&nbsp;&nbsp;The Company paid $24,989 in cash for a finder&#x2019;s fee.&nbsp;&nbsp;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that the warrants issued in connection with these private placements should be recorded as derivative liabilities at the time of issuance since they are all price protected.&nbsp;&nbsp;&nbsp;The fair value of the warrants on the date of issuance was $1,031,281.&nbsp;&nbsp;However, the completion of the public offering in July&nbsp;2013 removed the condition which required these warrants to be treated as derivative liabilities.&nbsp;&nbsp;Accordingly, the fair value of these warrants were marked to market through July&nbsp;18, 2013 and then reclassified from a liability to additional paid in capital.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On May&nbsp;30, 2012, the Company completed an underwritten public offering in which an aggregate of 1,150,000 units, with each unit consisting of two shares of its common stock and one warrant to purchase one share of common stock were sold at a purchase price of $8.00 per unit.&nbsp;&nbsp;On June&nbsp;13, 2012 the underwriters exercised their overallotment option in full for an additional 172,500 units.&nbsp;&nbsp;&nbsp;In addition, the Company issued 92,000 warrants to selling agents at an exercise price of $7.00.&nbsp;&nbsp;&nbsp;The warrants were immediately exercisable and expire on May&nbsp;29, 2017.&nbsp;&nbsp;&nbsp;Based upon the Company&#x2019;s analysis of the criteria contained in ASC Topic 815-40, &#x201C;Derivatives and Hedging - Contracts in an Entity&#x2019;s Own Equity&#x201D;, Trovagene determined that the warrants issued in connection with this transaction were not derivative liabilities.&nbsp;&nbsp;&nbsp;The Company raised a total of $9.1 million in net proceeds after deducting underwriting discounts and commissions of $0.7 million and offering expenses of $0.7 million.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2012, the Company issued in total 174,100 units to a selling agent, who is also a shareholder of the Company, consisting of 174,100 shares of common stock and warrants to purchase 174,100 shares of common stock.&nbsp;&nbsp;Of the total warrants issued, 30,450 issued in the period January&nbsp;2012 through May&nbsp;2012 have an exercise price of $3.00 per share, are immediately exercisable and expire December&nbsp;31, 2018.&nbsp;&nbsp;&nbsp;The remaining 143,650 warrants issued in the fourth quarter of 2012, have an exercise price of $5.32, are immediately exercisable, and expire five years from the date of issuance.&nbsp;&nbsp;&nbsp;The units were issued as a finder&#x2019;s fee in connection with certain private placements closed during the year ended December&nbsp;31, 2012.&nbsp;&nbsp;The issuance of these units was treated as a non-compensatory cost of capital.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2012, the Company issued 40,000 units to Panetta Partners,&nbsp;Ltd., consisting of 40,000 shares of common stock and warrants to purchase 40,000 shares of common stock.&nbsp;&nbsp;&nbsp;Gabriele Cerrone, previously a member of the Board of Directors of Trovagene, is a director of Panetta Partners,&nbsp;Ltd.&nbsp;&nbsp;&nbsp;The warrants have an exercise price of $5.32, are immediately exercisable, and expire five years from the date of issuance.&nbsp;&nbsp;The units were issued for advisory services in connection with the private placements closed in the fourth quarter of 2012.&nbsp;&nbsp;&nbsp;The issuance of these units was treated as a non-compensatory cost of capital.&nbsp;&nbsp;&nbsp;In addition, the Company issued a warrant to purchase 50,000 shares of common stock to Panetta Partners,&nbsp;Ltd. at an exercise price of $4.14 for consulting services.&nbsp;&nbsp;&nbsp;The warrant was immediately exercisable and expires on December&nbsp;10, 2017.&nbsp;&nbsp;&nbsp;The fair value of the warrant issued was determined using the Black-Scholes method.&nbsp;&nbsp;&nbsp;A total of approximately $133,000 was charged to general and administrative expenses in the Company&#x2019;s consolidated statement of operations in 2012.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2012, the Company issued 125,000 shares of common stock in connection with an asset purchase agreement with MultiGen Diagnostics,&nbsp;Inc.&nbsp;&nbsp;&nbsp;See Note 3.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2012, the Company issued 9,916 shares of common stock in connection with consulting agreements.&nbsp;&nbsp;&nbsp;The fair value of the stock issued was determined using the Black-Scholes method.&nbsp;&nbsp;&nbsp;A total of $22,381 was charged to general and administrative expense in the Company&#x2019;s consolidated statement of operations in 2012.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In December&nbsp;2012, a Trovagene warrant holder exercised warrants to purchase 16,667 on a net exercise basis and received a total of 8,602 shares of common stock.&nbsp;&nbsp;The exercise price of the warrants was $3.00.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In December&nbsp;2012, a Trovagene option holder exercised his option and purchased a total of 200 shares of common stock.&nbsp;&nbsp;Trovagene raised gross proceeds of $600 as a result of the option exercise.&nbsp;&nbsp;The purchase price paid by the option holder was $3.00.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On January&nbsp;25, 2013, the Company filed a Form&nbsp;S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000.&nbsp;&nbsp;The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities.&nbsp;&nbsp;&nbsp;This form was declared effective on February&nbsp;4, 2013.&nbsp;&nbsp;&nbsp;In addition, in connection with the Form&nbsp;S-3, the Company entered into an agreement with Cantor Fitzgerald&nbsp;&amp; Co. (&#x201C;Agent&#x201D;) on January&nbsp;25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.&nbsp;&nbsp;&nbsp;As payment for its services, the Agent is entitled to a 3% commission on gross proceeds.&nbsp;&nbsp;&nbsp;The Company has received gross proceeds of approximately $4.2 million from the sale of 488,476 shares of its common stock during the year ended December&nbsp;31, 2013 under the agreement with the Agent.&nbsp;&nbsp;&nbsp;In addition, the Company has received gross proceeds of approximately $15.0 million from the sale of 2,142,857 shares of its common stock through a registered direct offering that occurred in July&nbsp;2013.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2013, the Company issued a total of 3,424,605 shares of common stock.&nbsp;&nbsp;The Company sold 2,631,332 shares of Common Stock for net proceeds of $18,829,644.&nbsp;&nbsp;&nbsp;In addition, 36,458 shares were issued upon conversion of Series&nbsp;A Preferred Stock, 715,743 shares were issued upon exercise of 715,743 warrants for a weighted average price of $5.02 and 7,284 shares were issued upon net exercise of 12,745 warrants at an exercise price of $3.00.&nbsp;&nbsp;&nbsp;The remaining 33,788 shares include 22,955 shares that were issued upon net exercise of an option for 41,667 shares at an exercise price of $4.50 and the exercise of an option for 10,833 shares at a weighted average exercise price of $3.53.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2014, the Company issued a total of 13,011 shares of common stock upon the net exercise of warrants at a weighted average exercise price of $3.00.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Warrants</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the years ended December&nbsp;31, 2014, 2013, and 2012, warrant activity was as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:39.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Number</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Warrants</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">price</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Term</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2011</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,601,474 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.18 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1-8&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,416,934 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.88 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,667 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,671 </td> <td valign="bottom" style="width:03.40%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2012</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,985,070 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.96 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 - 6&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50,000 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.00 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(728,488 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.99 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(73,099 </td> <td valign="bottom" style="width:03.40%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.50 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2013 </font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,233,483 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.87 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 -5&nbsp;years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Granted </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,470 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.51 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Exercised</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,666 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.00 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expired </font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,667 </td> <td valign="bottom" style="width:03.40%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.80 </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Warrants Outstanding 12/31/2014</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,265,620 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:15.06%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.85 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1 &#x2013; 4 years</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company granted a total of 3,416,934 warrants during the year ended December&nbsp;31, 2012.&nbsp;&nbsp;&nbsp;Of the total warrants granted, 713,784 were warrants that were price protected.&nbsp;&nbsp;&nbsp;These warrants had an exercise price of $3.00 per share and expire on December&nbsp;31, 2018.&nbsp;&nbsp;&nbsp;The fair value of these warrants was estimated using the binomial option pricing model.&nbsp;&nbsp;The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which warrant holders are likely to exercise their warrants and the expected forfeiture rate.&nbsp;&nbsp;The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.&nbsp;&nbsp;The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.&nbsp;&nbsp;The completion of the underwritten public offering on May&nbsp;30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.&nbsp;&nbsp;&nbsp;Accordingly, the fair value of these warrants were marked to market through May&nbsp;30, 2012 and then reclassified from a liability to additional paid in capital.&nbsp;&nbsp;See Note&nbsp;7.&nbsp;&nbsp;&nbsp;In connection with underwritten public offering and sale of units in May&nbsp;2012, 1,414,500 warrants were issued with exercise prices ranging from $5.32 to $7.00 and an expiration date five years after date of issuance.&nbsp;&nbsp;&nbsp;Warrants issued in connection with the underwritten public offering and sale of units are not considered derivatives based on Trovagene&#x2019;s analysis of the criteria of ASC 815, as the Company is not required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of warrant shares.&nbsp;&nbsp;An additional 1,288,650 warrants in the fourth quarter of 2012 were warrants that are price protected.&nbsp;&nbsp;&nbsp;These warrants have an exercise price of $5.32 per share and have an expiration date of five years from issuance.&nbsp;&nbsp;The fair value of these warrants was estimated using the binomial option pricing model.&nbsp;&nbsp;The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which warrant holders are likely to exercise their warrants and the expected forfeiture rate.&nbsp;&nbsp;The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.&nbsp;&nbsp;The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.&nbsp;&nbsp;See Note&nbsp;7.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company issued a warrant to purchase 50,000 shares of common stock at an exercise price of $8.00 per share, during the year ended December&nbsp;31, 2013.&nbsp;&nbsp;&nbsp;The warrants were issued in connection with an agreement to provide services related to investor and public relations materials and expire three years from date of grant.&nbsp;&nbsp;&nbsp;The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:&nbsp;&nbsp;a risk-free interest rate of 0.42%, dividend yield of 0%, expected volatility of 97% and expected term of three years.&nbsp;&nbsp;&nbsp;The resulting fair value of $198,791 was recorded as stock based compensation expense.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company issued warrants to purchase 85,470 shares of common stock at an exercise price of $3.51 per share, during the year ended December&nbsp;31, 2014.&nbsp;&nbsp;&nbsp;The warrants were issued in connection with a $15.0 million debt agreement. The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:&nbsp;&nbsp;a risk-free interest rate of 2.53%, dividend yield of 0%, expected volatility of 73.8% and expected term of ten years.&nbsp;&nbsp;&nbsp;The resulting fair value of $235,857 was recorded as a debt discount and will be amortized to interest expense over the term of the loan using the effective interest method.</font> </p> <p style="margin:0pt;text-align:center;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Series&nbsp;A Convertible Preferred Stock</font> </p> <p style="margin:0pt 0pt 0pt 36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The material terms of the Series&nbsp;A Convertible Preferred Stock consist of:</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">1)</font><font style="display: inline;font-style:italic;font-size:10pt;"> &nbsp;Dividends. </font><font style="display: inline;font-size:10pt;"> Holders of the Series&nbsp;A Convertible Preferred Stock shall be entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31, beginning with September&nbsp;30, 2005.&nbsp;&nbsp;Dividends shall be payable, at the Company&#x2019;s sole election, in cash or shares of common stock.&nbsp;&nbsp;As of December&nbsp;31, 2014 and 2013, the Company had $244,055 and $221,040, respectively in accrued cumulative unpaid preferred stock dividends, included in Accrued Expenses in the Company&#x2019;s consolidated balance sheets, and $23,015, $29,840, and $38,240, was recorded during the years ended December&nbsp;31, 2014, 2013, and 2012, respectively.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">2)</font><font style="display: inline;font-style:italic;font-size:10pt;"> &nbsp;Voting Rights. </font><font style="display: inline;font-size:10pt;"> Shares of the Series&nbsp;A Convertible Preferred Stock shall have no voting rights.&nbsp;&nbsp;However, so long as any shares of Series&nbsp;A Convertible Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of the shares of Series&nbsp;A Convertible Preferred Stock then outstanding, (a)&nbsp;adversely change the powers, preferences or rights given to the Series&nbsp;A Convertible Preferred Stock, (b)&nbsp;authorize or create any class of stock senior or equal to the Series&nbsp;A Convertible Preferred Stock, (c)&nbsp;amend its articles of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series&nbsp;A Convertible Preferred Stock or (d)&nbsp;increase the authorized number of shares of Series&nbsp;A Convertible Preferred Stock.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">3)</font><font style="display: inline;font-style:italic;font-size:10pt;"> &nbsp;Liquidation. </font><font style="display: inline;font-size:10pt;"> Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series&nbsp;A Convertible Preferred Stock shall be entitled to receive an amount equal to the Stated Value per share, which is $10 per share plus any accrued and unpaid dividends.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">4)</font><font style="display: inline;font-style:italic;font-size:10pt;"> &nbsp;Conversion Rights. </font><font style="display: inline;font-size:10pt;"> Each share of Series&nbsp;A Convertible Preferred Stock shall be convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, originally $2.15 per share.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">5)</font><font style="display: inline;font-style:italic;font-size:10pt;"> &nbsp;Subsequent Equity Sales. </font><font style="display: inline;font-size:10pt;"> The conversion price is subject to adjustment for dilutive issuances for a period of 12&nbsp;months beginning upon registration of the common stock underlying the Series&nbsp;A Convertible Preferred Stock.&nbsp;&nbsp;The relevant registration statement became effective March&nbsp;17, 2006 and during the following twelve month period the conversion price was adjusted to $9.60 per share.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">6)</font><font style="display: inline;font-style:italic;font-size:10pt;"> &nbsp;Automatic Conversion. </font><font style="display: inline;font-size:10pt;"> Beginning July&nbsp;13, 2006, if the price of the common stock equals $25.80 per share for 20 consecutive trading days, and an average of 8,333 shares of common stock per day shall have been traded during the 20 trading days, the Company shall have the right to deliver a notice to the holders of the Series&nbsp;A Convertible Preferred Stock, to convert any portion of the shares of Series&nbsp;A Convertible Preferred Stock into shares of Common Stock at the conversion price.&nbsp;&nbsp;As of the date of these financial statements, such conditions have not been met.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">During the year ended December&nbsp;31, 2013, 35,000 shares of Series&nbsp;A Convertible Preferred Stock were converted into 36,458 shares of common stock, on a net converted basis.&nbsp;&nbsp;As of December&nbsp;31, 2014 and 2013, and 2012, there were 60,600, 60,600, and 95,600 shares of Series&nbsp;A Convertible Preferred Stock outstanding.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.50 0.1667 0.1667 125000 125000 125000 1738333 9916 40000 9916 174100 2631332 5111110 200 200 10833 52500 41667 10833 187500 187500 187487 13 187500 22381 22381 22380 1 18829644 18829381 263 600 600 38249 38248 1 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">15.&nbsp;&nbsp;Subsequent Events</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Public Offering and Controlled Equity Offering</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On February&nbsp;11, 2015, the Company closed an underwritten public offering of 5,111,110 shares of its common stock.&nbsp;&nbsp;The offering price was $4.50 per share and net proceeds to the Company were approximately $21.3 million. The effects of this offering would materially change the number of common shares outstanding at the end of the reporting period had the transaction occurred before December 31, 2014.</font> </p> <p style="margin:0pt;text-indent:36pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Related Party Consulting Agreement</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:25pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On January&nbsp;1, 2015, we entered into a consulting agreement with Tom Adams, our Chairman, pursuant to which Dr.&nbsp;Adams will provide consulting services to us in connection with applying our technology to infectious diseases.&nbsp;&nbsp;The agreement is for a term of one year and Dr.&nbsp;Adams shall be paid $9,500 per month for his services.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 698000 -5258133 -6720805 -2905003 -1084114 -2905003 1820889 1425850 1425850 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-style:italic;font-size:10pt;">Use of Estimates</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</font> </p> <p><font size="1"> </font></p> </div> </div> 4398700 6099000 13066600 15510340 16978212 15583957 17870703 18900781 18902783 19071112 19232760 18902783 19071112 13066600 15510340 16978212 15583957 17870703 18900781 18902783 18904280 18902783 18902783 18904280 EX-101.SCH 12 trov-20141231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Income Taxes (Details 2) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Income Taxes (Details 3) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency) link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Business Overview and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Asset Purchase link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Stockholders' Equity (Deficiency) link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stock Option Plan link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Derivative Financial Instruments - Warrants link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Selected Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Stock Option Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Derivative Financial Instruments - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Business Overview and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Asset Purchase (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stockholders' Equity (Deficiency) (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stockholders' Equity (Deficiency) (Details 2) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Stockholders' Equity (Deficiency) (Details 3) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stock Option Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stock Option Plan (Details 2) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Stock Option Plan (Details 3) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Derivative Financial Instruments - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Commitments and Contingencies (Details 2) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Commitments and Contingencies (Details 3) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Commitments and Contingencies (Details 4) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 trov-20141231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 14 trov-20141231_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT EX-101.PRE 15 trov-20141231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 16 trov-20141231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT GRAPHIC 17 g18641ke09i001.jpg GRAPHIC begin 644 g18641ke09i001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S`H7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H`"`$!```_`/9J**************************************** M*****************************************R/%DTMMX.UJ>"5XI8M/ MG>.1&*LC"-B"".A![UHO=V\=REL\\:SR`E(RX#,!Z#O4U%%%-9T3!=E7)P,G M&33J*******S_$%_+I7AS4]1@5&EM+26>-7!*EE0L`<8XR*T**********SY MK^6/Q'9:<%3RKBTN)V8@[@T;PJ`/;$C9^@_'0HHK/AOY9/$=[IQ5/*M[2WG5 M@#N+2/,I!]L1KCZG\-"BBBDZ4`A@"""#T(IC31I*D3.`\F=J]SCK_.I***** M********************************1F5%+,0JCDDG`%8&G>(Y[RX2/[(L MT$F#'<0N%+`GKY;'=@9R3SQ704445B^,_P#D1]>_[!MQ_P"BVJS+:6EUJ3!W MF\R-5BL#C[PYZ'\*D@-[_:EP)D86NT>4WF*03QG@*"/Q)J[1169J_E MM):HTS1L)-Y`C#JRY`((/`Y9>>HSZ9K2``&!P*6BBBBBBN:\?WIM?!NJQ)$\ MK36-PI"@':OED%CDC@$CU^E=)2U'/,MO;R3LK,L:%B%&20!GBLN>XL=3ALYF MA=E>8K#(3@(XS@G!Y!(]ZV**@O+VWL(#/7&"!NP3S^%3`A@".AY%+16+= M?\CQI?\`V#;S_P!&6M;5%%8MK_R/&J?]@VS_`/1EU6P74,JE@&;H">33J*RM M2NWBU.R@2X$?F."4RG' M6I=$N[^[FO&O1;A5<>0(9-Y\LDD;B#C/X#\:UZ*R-4#8TBH23@*#U.<5=K&\.QRQ#4$F,Q(NW` M,LQD)''/(&`>N!QS1KTKPW6G2+")1YX7+("(R2OS9(P#C(ZC.XX/&*UI6=8V M:-`[@<*3C/XU4;4'CNK:&2VV>>N?FF0,K9'&W/(Z\C/TJ]111117,?$`QMX3 MU.)XHY&-A03T(!/-=/15?4/*_LVY\__5>2^_D_=P<]/:L*&XN$ MTRS-Q9W;RR7#"4(P)3DY9\8&?H,=:Z6BJU_+)%;@Q0>>Y<`)N*\Y]<&IHE*0 MHK8R%`.*?16+=?\`(\:7_P!@V\_]&6M;5%%8MK_R/&J?]@VS_P#1EU1KT,DE MS9,BR?(6)*1N^/N\?+C'U)Q[&MJBL76(0=5T^7[/9$07#J@P)(]X8@CDJ!SZD`9 M].:Q$LLS:1-+:IN0?>6$D1L7!(7/^K'^]SCY1S6AX?CLXCH//3)K9HK/U71;76!;BZ+C[/*)4V$#YAT[5H44444444444444444 M444444444444450U&_NK)E\C3)KM2"6>.2-0OUW,*H1^([N9MD6ASR-Z+>!:T'2[BUU?4+Z>%XOM3LP4LK`?-ZAB3QCKTZ#BN@HHK% M\9_\B/KW_8-N/_1;5;DD674VBN;4&&!%ECFDA&T/G'#$]>G8?6J6C:FUUK6I MVC_:U:WD.%E`"8W$`KQGMZD>E3^(/.^Q)Y2SME\,(2PP"I&3CL.N/:M6L;P[ M',HOY)8EC6:[>2/:6.Y6P8)5)R,CIR,=_TI MFKSS6VE3S6[!954;"PR,Y'6LJ[OIYH]'D+6Y>>=#*"[!-FX.>(DI(H921C@U)117,?$&^6T\(Z ME'*R+'<6%RG.=Q;RSM`Q[]:Z>BH[CR?LTOV@J(=A\PL<#;CG/MBN8L(!=:;8 MM-?1%XI96$BL\JRKN&6W`J>I'+9]\UU=4],FFGM`T[HTG<*02/8[21GZ5#K; MA+:%O(::19U:,+U4C)W`9&<`'C-:$;B2-7'1@#US3J*Q;K_D>-+_`.P;>?\` MHRUK:HHK%M?^1XU3_L&V?_HRZI^N:C_9\]F![\UKT5 MCZPUP^JZ9!#"77S?,=_/\L``CC&/GX).!CIZ9J?6XQ-IYB,<$A=P`D\[1*QZ M]5!.>.E+J#/_`&([IP'47_#\Z3?:MGD';(-WDPA"IY^5R"M^BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN6\ M1SVA\1V%MJLF-.$#R-&V=CR9`&X#KWX-1:C/X/GL)DA^QQRA"8GABV.K8X(( M'!S6MIK3:IX3M6N(H[B::W4NLI*J[8[D`X_*L_P_<0OJ*I'IMK;NT;-)Y,S. M\)R.'!48)S^E6-#M9;?7M4+WJ.CR%UMP6#(&;.=I`P,YY&0Q)/%=!116+XS_ M`.1'U[_L&W'_`*+:GZY?16K0PR)O^T(ZX+`#JO7+#/7H,G^JV%W/-KU];M/$ M\$*($C1BQ0]]QVCD^F35C5;:>ZM0D,WE8.6/F-'Q@]UYX/..,XZU>K(\/O(T M=TLDDSE)MO[[(/W1V+,1^GTIFO6D\UYIES!/,C0S[2L2!LAL9)]!@8S_`+7/ M%7=8C,NE3($9R0#M0$DX(/&/\#]#TK)EM/-N]&B23RC"N_8&:$;59>-F!NZ@ M8(`YS[5T=9OB%&DT*Z17D1BHPT]<_]GEN-.TUXXK:8"X;YHF<1@E\ADVG[O!Z^OXUU55K.W6U$ MD2!]H(P7.<\"JGB$JNDLSM"%5@2)FVJWMGU[_A6A`2;>,DY)09///'OS4E%8 MMU_R/&E_]@V\_P#1EK6U116+:_\`(\:I_P!@VS_]&752:YO!LV2>6("8;]D4 MC@KQG[G0^[?+R!TSQGGMGZ51U3<-6LV$E/\2")M$FBDECB\S"JTAP,]>.#S@'%2WK[-!ED@9E M"V^Y2$5FP!G&#QG'KQ67=ZI=6]QHYA)2*]E4-%*5##<_[!MQ_Z+:J?B/<^JV2-+#B-PZ*KG>,X!W+@_+_`+0P15^R MLYH=?O+F5W<3)B/,^\*H/3;L&WKZM2^(HKJ2RA-J8]R3H2))%0$9]2#^7?WZ M'6K,T*U>ULR'N#,7(8YB,9!V@'*DDY.,GZT_484EN+4@0--&Q94E&=R\9P.> M<<4:X\L>BW#0R>5+M`5P3\I)'IS64L,MW::).\;7JJRR&X$@&TEAAOF&3 MQ].,CO72UF^(81<:+-"5W;V0`;V7G>N.5Y_*K&F1F'3+:(JR;(E&UF+$<=R< M$_C5JBBN>\=W26_@O5T8J/-L+A1EE&?W;=,D9_#-=#15?4!*VG7(@W>:87"; M#AMV#C!]HJ9$N2UO)=JZ-(1TRN5P>O!_*NEJCIER;N.29[>:W M&-(Q`[K+E2Z@G M8>,9P.._)P..M7JRM0!DU2U2.%)9%`D(+,"JAUR1R!QG//I5BYDBM]0MY&@+ M/*/)60,>`2#C'X=:I>++N\LM$::PN5MI@Z@.55B1SD`$8)_^O3M8.I['\*T** M*******************************ANHI9[62*&9=1&8@R!BF6R0PVC:V M3DXST/I74445B^,_^1'U[_L&W'_HMJ?K@DB\E[>T@D:20>;(\98JH^BG]<5# MI)_XGU^JSO(H+?*8=@C.\\9_BSUY_05-XBC#VD#,SX6=?ECBC=F)!`QO^48) M!S[?B->L3PO`MO97"K:K;;KAG:-7WJI.,@'<<_DOT%)X@UA=)O-,7=&'NI_) M&Z#S&P2,X.Y=O;U[<<5J7ZQ-92^>Q6-1N9@H;&.E0V\OF6-H"\D_FD M8E$6`<JKJ*A].G4F-24.TR$A0W\.<<]<=*EM0HM8@A#+L&""2 M#^?-2T45S'Q#?44\%ZH+&.(H;.87#29.(_+(.T#OS]!CFNGHJO?SFUT^YN`P M4Q1,X)&0,`GI7.--`UI9&_>VN6FNW8&!6*E\X!!P<$=,_6NKK,T*S>RLWC>U M%M\WW`Y(Z`'`W'"YS@<<8X%:1.`3Z4B.)(U<9PP!&:=16+=?\CQI?_8-O/\` MT9:UM445BVO_`"/&J?\`8-L__1EU5W4=0>P,`2RN+KSGVGR5!V>Y]JNU!<7" M0A%+@.[J`NX`G+`?UK/UB>1=2TFWC909K@D@D`X522>A/3(XQ][K5O4UNWM- MMF`7+8(/=>XZC'X'--U!9I='D'D[YO+!*+UR,'Y<$HR)!JEA/)PBB1<^I.T`#GD^V">#BM2BBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBJ>K3-;Z9-*D>]E`(')YR.>.>.M8>@S;M6QY:G<'4E(Y5QC& M&^9B,-Z=O4UU%%%%8OC/_D1]>_[!MQ_Z+:K>IVWVP0P+=R6[EPX"YQ(%()4X MQQCW[T6B7D>H3"YFWQMN:)06XTZ&"M].M;K[/+*AE\E MF9$7*Y#G&2,$_P`0'!SD<5U-17#K';R.Y8*%.2HY'O1%AK=2Q)#+R3D=JH:# M&RVDC"/RXGD)C#.S'``7.6)XXXQP1SWK4HKD_B0;<>$;_P`^5HF-I/Y9W!49 MO+/RG/4GL.YKK**KW\33Z?#GJ?\:OUD:=>:E+;7[S6TCR17$BP(Z"+>@/RXS[=S4SP76HZ?$)Y& MLIA(2YA8Y7!(&#^74$>U:`&`!DG'<]Z6BL6Z_P"1XTO_`+!MY_Z,M:VJ**Q; M7_D>-4_[!MG_`.C+JG:]%$YM7?R]Z/\`(9)Q&`>.Q!W'VK8JO*KZL7C\/R,0=ZQJ?F8D@Y'4J5)_`C-9UMJ+Q'2+.UD62"[C$AE`V'&>,UH:*;=C>O;^3\URV?**G@<<[?<$X/J:U**Q]?NK^U:Q-D4Q). M$=6E1"]25B^,_^1'U[_L&W'_HMJOSC_B8VAR.DG'X"JFGW1D''3GH.#6G,T:02/+S&JDMQGCOQWK#FCAN9]+E$-U%%N)A,<>57#J5##; ME0R@\\8'!KH*:Z)(C(ZAT8$,K#((]#2,H\HJN%&W`[`5C^%9+N33)/MA!=)B MJLLK2*RA5P5+M;=%=+@V\CJV!(NT]=ARF[C..%/;K46IZL++PO!>36<=PLTZ[H6+J.7+#DH", M$#[RC^6>BC?S(E?CYE!X.:?16+=?\CQI?_8-O/\`T9:UM445BVO_`"/&J?\` M8-L__1EU5K5;62Y$.R%I-C$G$_EXZ>QS]*T*P]88?VUIP:=$*N#'&TRKO)8` M_*>6P.F.]:4UK))>1W$5/ESMZ M$C=QD9SSZ5:OY%AT1I%@2=51"(Y%R&Y'8?\`ZOI5"XU":;4M(EMY%2&8$F,R M`AP<`%=N=Q`YXX`))JUHT,D4EP7DBD5B-ACE#[1EOEZ#I[Y/)Y.*U:*R]:LT MN39NT4DC).!\DQCPIZYQU'`X]JU*CN"RV\K(<,$)4XS@XJAH-Y1(EW.P5<@9/J3 M@?K48O+8[L3QX7&3N&.20.?<@BGPS17$0EAE26-NCHP(/XBGT5B^,_\`D1]> M_P"P;G2H/$`#6D2>;=(7E"XMC\S#!S_"G%6[ZX>%X1'(BLSDU::2#2+J: M.80RI$S(^Y0`V..7^4<\7$]OHHN=1M%EF`:4&[17D)('R84AN_W=OH# M@FNFJ"]+"TD*N488((ZD@]!]>GXT6S2/91M.,NR98,,?F.U8W@ZYFNM+N))H M[>,_:6"B"Y$_RX7&7#-R.G;@#@"N@HKE?B->S6?@_453RUCGLYXW9R!R8SA1 MEAR1GIGITKJJ*K:BXBTRZD/187/Y*:YZ.V*VFCK-;QKB1\12,5*DL"-O(SQV M)R?>NJKE=$NIFT/4[B7SKYT?_ELJC>0BYP4!!QZX/3O4NLM:GP>&@B#1#&P3 M18!P3DL",#/)^8`9/X5T,&/L\>,8V#IC'3VJ2BL6Z_Y'C2_^P;>?^C+6MJBB ML6U_Y'C5/^P;9_\`HRZJ;7FD%G&D:.PDE5&V0"4@-P<`L,=>O.`#P:T^E9>I M27"ZOIB1_P"K>1@P[-\I.#SQ@9(X/('3K5?6@PUK3&W;5\P;OFD&[YA@'`V] M2#S_`(U8\1R,FE,BVINS*VWR!+Y?F#!)&[!QP/;ZBI-1"S:$Q,;D;%8)'&93 MP00-HY8?0BLWSKFZDT8QSQQ='D2ZD>*4C/("`D$^S$X]SS5GP]'/')?>G-J*V:F"6:*&<2L(G565A]T\]1U!'O^(V MJCGQ]FDRQ`V'D'!'%9'A7[2-+D%VSF03$`.,$#:N.,G&>OX\<8K;HHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHJCK00Z1<%YC`%4-Y@0N5(((.T*V"?E&RV:!4=?*:1E8?>S(#A?X0 M.#DYY%6?#<-Q#I\@N(I8RTN8UF148)M4*-JL0,`8['CD9K7HKD?B.S+X:O2K M!2;"Z&2VWCR^>QSGICC.>HQSUH.1D4M%9$T$\\EF6\ME5W24D.[9R"/ND`*= MIR#QG;6O7/Z#/W6I6\:Q7$[-$8^LT38VGKGO@9P<8JV]E!<:9!;/91W M"1GD!M@1UX)'<'.>:T8"S0J67:<=-V[]>])%QY/_`>:UJQM4GG36M/ACOOL\;-EX_E_>\].?P'' M//L:N7D$LUU;,I39$^XYB5B#TR"3\O&1P#UJ/7;*&_TMX;B6.*($,QE&4./7 MD?7KU`Z]"^X@A.CFWGCDNHC&$8?ZQG!P,\]?6JFG:9`;33I(2Y2!0HW`*=HS MC^'@YQG&`>^1@5'X=L+>TNM0FBF:62X=6=F1E)`W`'))R.H'3H:W:*I:G;6L M]MON;>.9HOFCWHK%6]5ST-6+IG2TF>/[ZQL5X)YQQT!_E6;H"RMH0CEVL1N4 M;&R,>Q''Y&I]&M4L[1H4C$?SY,8W':2HXRQ/\ZT********************* M**********ANA<-:R"T9$G(^1I!E0?>N,C(Y&1Z=B<55TU!%XDU*,RW#OM5SOD)0!N@53 MTZ'_`#G%C79(XK19);Y+54+$[_X\*>!R.>_?IT-:=96A0PPK?>3;R0[[R5F+ MJ%WG/48`X[=^G6JOB.6Y@O=+>$VZQO/Y;H&[T^Z2U6*2X5HMLS[73+*6&"P]#T!.<=!6W5 M:_D:*T9T0NP*@*'V9)8#KZ5E-.+B_P!/D;SBYA#2>5NVL#D#)QC`.'RY(/+NYG97 M`+!QE1P0<`G=W(Z5OUS6C'4;S2-1\^!S*\Y6-9+H.<87^)>%QST'&.A-6+U6 MM=$MC=[86CF&\M<,HR21DR*N>ADN(I+0Q#*`LSJ^%_B/ M&,8XP.N:I>'I+>74-6>&!8W,P\PK(&#GGD8`XZ]<]_2K6HZK-9W`MX;8322* M/*!)`)).23C`4`9)JDMP;GQ;I$K!03IMZ#M.0<2VPR/;BNAHHKD[^RGO/&MX M(9A"([&T+'S&3.6NU`RN#U(Z$5O:C8M=/!*LYA,#;B0"21QG&".>.^1UR#VO M5@Z[;R2:QI4JW4T")*-RHX"R?,N`1N!/Y'K^--UF(S^(=+"QLS1L),I'NXW` M'<<\`=>G6M;475+1A)!'.C_*T^[BDNGMVTPR7>4@VJS[&/R]#U7G`] M14EDMNMG&+1@T&/D(8MD?4]:R?#D;"YU280)%%/#BMJ4[8G;YN%)^49/X#UJ MCI'E1Z8QMO.*AW($P&[.3G(7WS4VGM<26_G7,:Q22X?8K$@?*/55(^A%6Z** M****************************I:PCR:7,D8D+-@?NQE@,C)'N!DU@16_V M30IY)DNC*)8SAP8C\K?+@X))[GW/:MW19FGTU78L3O;[[[S]X]\#^57Z9+(( M87E8$A%+$#VKE?%.MQW7A+7H8[>3:NG3I)(&4JCF)B$X/)QR<9QFM?5X(;O4 M+&VD8*S;V4G:1\I0\`G.[T(SCG/6I[6\CN-2GC1>6Y^8@89/X0,'KWZ5A!R#5'7G\O M1+I]L#,J;D6X3>C,"-H([Y.,>^*HPWL*-I?G7GEW=S``MO'D1N!R?E8;A^A_ M6JP'V^UMA9W'EQPS-&46(N,`+^[_`'?"KQW]!Q71/<11RK$[X=R`HP>203_[ M*?RJ6N0^)D7F^$+W-NDNRVF8.QCS&1&>0'!S^'/3%=?15?4)6@TVZE1E5HX7 M8,PR`0"3S4KV$M[X6AMQ'$6W9VS[0`-QQG1'Y8,H++MD&3SSEN.N M?NC''7T9?SZD-2>.R$9`2-B9)R@`R?@2?V??Y"R MF0`>?;X&X]>,5TE%%*;IK32=ZBV.Y]I^T(SJ,@]EYS[CIUJ;4 M,R>'9'`VD0B0",`X(P?E!X/3@'@]#Q4NCEAI%LTK$[D!!;`)!Z9P2,X(Z<9Z M53\/PW$<^HF61&C$Y2(*V=@!)P?E7UZ\GU)Q6U15'4H))/*DCN1"4)RI_C'4 M@TF64$QLC!@#@D8YJII)WZ6&D62)V+&0/P5.?H![\"GZ5 M+YMBN96D9"58NZL01V)``)QBKM%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%07L< MLME,D$K12%#M=`"0:YBU=X_#UPT\3/*L\;K(Z,Q=MP9=P8\@''\1]B*W="G: MYTM)FSN=W8@KMP2Q[Q)`]0*TZYG3-1NX=$N[A8_.E6XPJ^:)L[B/[@]^G]*T=;FMHS9I<);EI M)U6)IEW%6[%1Z]NHZCKTK1FE6"%I6!*H,MCL.YJC-N1T!/..E5?#+!K>81NYB1PJHTV\)QR/NC&,]LCT-7]7B$VESQL8MK`;A,V MU&&1E2<'&1QG'&:H+#)#+I(1(\QQ%0-VW'R\G:!V'\ZH:+;"YL56XEEO7-R6 M#7$@+`[4)Q@X"]2,9(!'OC7NBC:_:)*I^X3&1*P#-R>5V[3C''.>3QWK3W#= MMR,XSCO7,_$."ZE\&:F]L("([.L349KQKYH8;LPQ% ME#,&4,.,[$!'+M]2`#ZUI6$K36$4DA)9EYW#!_'W]:H1:O#-81O=''=3S]BNS')(`(]TB.V,G.%YRQ/`!XP!4BQC4_" M-J+JW*"1P9(K.#@SUW#COR.)[&XN_^$E>U=I1:K9AHT?"C.5[8R2, MG)!P.F*/#1MVDOV@78QF_>+LA'.3R#&`2/\`>&>#UIVIV*7.H-)'I5K?RB-0 M_P!K*A5&3C:=C'/7VJO"(%\5Z0MO;K;QKIU\OE*``A$UL&`QQUS71T45R.HE M8_&UW.;H6SQ6%H5/3&:*X2WG#`Q.XRH8<\_*<<9YQ3K^*.YT)H[N5%1X MU\QV7Z=. M]4M"CA32DCB2%4!(*PD%/P^9N/;/Y4[2+)+**9%AAA9I2SK'*TAR0.69N<]_ MQ%:%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%5-4D:'3+B1'@1A&<-<$B,?[Q'. M*PO#`N;K3+M5NW2.WO7#^([*VMO"FKR>7H\V_3K@1_9;=4 ME0^4WS;@?F]\`?TKJ=7:,W5G%(VT,6*'S`N7&,+@@@YR?IVZU)IT5M]JNYHX MS',965P9&.1GK@],U%XB19K&.#['#=O+)B-))`A#!2+YH1(;AE_=@A5VX"C&/0#/'<]L&K.L02M+;7*NBPPD^=N8@LI93C@'N MH/;H.<9JUJ:QOIMP)2-NP]6"@GL,GCKZ\>M9#VAF_LJ188IXHF'[U96(50RE M2-N%/(';''%7M'N[2Y$R69F9(B`S32.QWH!(Z5F-/<6]_IMNUE*H=`LA`,B(0>[[N?;(/7M5F^6"*2U5?G7S69@ M3NP"?F;)SP"1^?:H[[S_`/A)=.,,9*['\UM@(*XZ$XR.>>N#TJGI5G':^*[P M^08_-625"RX+,7&\@\Y'*=QC/3FJ/Q.EGM_"EU-;1*[FVGB=FWD+&Z$-P.,] M,$_AUKLJY^^%D^IW'VB/4\JRD&T,Y7.T<_N^`M+]+F[N(!- M!(T+8VQDDKR?O?E^=92W_P#:GAJ\NWMV@W\8?&&`QAAG`P1[_C3&N+=/"MF\ MDC)$KA"UR^XG!8?,4ZYQVJY90RKK;$QHL*0`#8S??PHSACZ<`@'CJ>U;%>G;K2VNP>)M%5&#*FF7JY$7ECB6V'W3T MZ5TM%%:]L;N4.TMO(1"H.!EL9)X[`$^G6KDLHB4$[(HC(+ M(^2\JK<#A688)X!PK#/?KD>O&:U9W,<$CJC.54D*O5N.@]ZS="6>ST%#>M.T MR!GD\YBS#O@$]0!P/I5C3+JWU!9KRW.5=]F2""-O!!'USTJ]111111111111 M11111111111111111139(TE0QR(KHW56&0:9#;06X(@@CB#==BA<_E4M%1S_ M`/'O)G?]P_ZO[W3M[UQ&OV3Q>&O$%\]C-:F73KA?+4*Q;,;?-(V>?7`Z>IKI M-85WO;-1Y7ED/YI>4H2N4XX!X)QZ=N:FE$6D07-\Z23NS$DJ"SX)X7J<`9]A M5?51)J.EP.+.X*,^Z2,>5N0`'DB0%3SCTZY[8K9K!LK:^N=(D$C17#33B53< ML'3&00>>G6DN+>*Z@:&8$HV,@,1T.>HYK#:2V2 M335BFA50WEJJR`9Q(O'S'/;MR3C/%6M!ENYTEFNY`Q<*47`&U3D@<=1[]ZTY MHO.B,>]TR1RC8/!SC/Z5B7%O;IKFFPL)9WB3B5H0Y3&<'?D;23P<`YP.G6K= MW+;0VTWG6B6L<+JR33!%3>Y^\#G@@GD\'/3-1-!%)XGM=12ZR);0I&@C;#C) M;(<''<<$'IFFZ7=QOK%S`D%M&1)*3Y;_`#YROS,/]K'X%>^>,WXD(Y\)7[(D MG%GU>2RCU!C=F\#$KL-F[+VXW[2#GK][C M!'O6F^Z70Y/M&)-T#;QPV1@^A`)QZ$"J@D5Q93W-U;Q"*5H]V?++'H%`)(.< M<\]N*EL-/DM-7O9Y+QYA<`,L1!VQ#)Z9)_STP.*K64-W;:%6S`8&,>6#Q],A3WR#VSWXJQHT<;7FHW& MV(RF=5WJO(7RHSM!],\U)I-Y>W4]VEW#Y:1.%A;RF3S%YYY_S^=:61N(XSWK M">83^,M+D"LG_$NOE*MC((FM@>GN*WJ**XK7XMWBB_E!D#QV-ECRW"G!>[SG MVQU]!D\XQ70ZV(8[6V$D:E/M"(,#!3.0",`XQ]*U*SM0$/VVS:34&MR)`!$' M(\XGHN,^O\JFN]/BO+BUGH7KZ]NAZ5U%M_QZQ.N#G M/3V/X5#HDMW,;MKF>64+*47S%1=I!.0`H!Q@C[W/]=6BLK79VA2W!\ORVD^= MG(&WWR2,`#.2.1Q[UHSR>7;R2!D7:A;<_P!T<=3[53LKE[K3))'GMKMAN4O; MH?+8@=`-S9].M2:7<)<:?$RK&A50&6(?(&P"0OJ,FKE%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%4=4O!9112L9@@DR_E1[SM`)/8\<55\/7=S=6\ANFF9VQ+B6 M(ILW9^5>!D#'!K8HI"0H))``ZDUA>.)Q#X)UKKZ;+? M26LD07,#Y.92F0<9'0@CCH1SCMUJQJ*F6S94MC='>N8EEV9^89Y]NN.]5+Z. M<:7;+&DRLH"M'&`[#Y2.[C./7)Y&>:UJKVUI;:?"R0+Y474@N2%X[9/`JQ45 MS<):V[S."50S?$L_P!ET=IBTB*LL>XH<8&X=>#Q MZC%8>D+-HI=0(#%%.CQ1 M2A2=KQC=DYP<T`.-N`.1D>O;I]:S-&E$OB.\/ MVG>R-,GEO`,=L5!\2(O-\'Z@?)MI"EI.V9U5MOR'EN:N7%OOT6>VN6C0-`Z,T2?*J MX(X7V':J$WD3VUG]GNC:QQLP"K%(`X!`.5&W`]21CGWYN:=;SPW-V[R02122 M$QM'G<.3D-VX/''I67I-G_9VC7ZFVFG#2;_*6$Q,V5'RJ`2<#M5K5T-AHL<4 M5F+M0X#Q_9S,#U.=N<_>P?:I+6.(ZXTPGN&F^S[6C:0^6GW3@*1UZ9/49YZB MK&FR7,PEEGSM+$1CE9^OK81R^=<:*E[+Y?^NE4"-0,\%CG'X"J] MG"+?Q-H\06W0#3K_``ML?W8S-;GC_/6NFHHKBM>TV34?%EZ(X[1_*L;-V-TK ML%&^[Y&TCGZUV@Y`-+6)K><5ISB"W=P"YE\L=S@GT(!!'?-2:?/8W;37%E>QW08A6,U<#XITT1^&]8D?3+'30EA.5\J`NSGRVX$@P!^5 M=9K&:\,BI\C(#(=^,9+,# MCIRJ@=#R#B]J5PR:1IMU%;+/,A25!NVA?D.X]AC:6'.`,YQQ6_7,72B\TN*W MEBEG>:=1C<22VWKSP,=<$$<5KZGJT6F26D>.W?BL*Y>9;O2!I[JP+$NX\LYBWJ#@L,@G(X'J<=J MW(H8K=Y5MX(HR0&.U0NX\]<5E77G:QX?9Y4C#>8'3R'\Q2%;@A@>>G7CITJO MH$J1_9K:5I0[S7)150;,K(VW=E+PLD,Q==A3&[RP21_>R M.2/E)Y'>M:]U>#3T-K#&\L\4+,/W?RJ%7()/'&<=.F>W6H]+N;IM=N[::/>@ M,CK*`PVC<`JG/!Z$\=/QK,^)B%_"%]A)3MM9F)C9!CY#U#$$CIG;S['I77UC MZGJ"VMPT<^HM8Y9?*/D[@XQR!QR<]NO'O5O=>2Z*S)E;MH&V;@%.[!VD@\`] M/I67JUSIT"V"7EM,[L2T7+KM?*YS^)JUI`M$U+4EB,;3><6=T8?,#ZJ.A!RO MJ<9I-/E@;0,3RBZ"(%FD@8R&4X&2-OS$_K6=J\]E%X626>.+[*+DD"X#*`-[ M8RNR0YZ<%?KCI5_2U#ZQ<3"2%0L2HL*MN9@50[^N%';&T$X!/858TIY/M%W# M)/),8W'S/WY/3G@8`';D$]Z6[O'L[[S'BNIHC&`JVZ;P#DY)`Y].>G6LJT5U M\3Z.)(Q$?[.OSLP,J#/;D9QQNQC/OFNFHKG=1@^U:G+#)?21VLDB1S0JG+L5 M!`#9X&.O%8\]M8V]D+F&2ZC9F$.Z.=XRR1[RJ<$]Y'Y]^>@KI]9U"?3TA:&( M.LK[&.#\I.,'(!`'7KCM6G6#K=LEQK6FOM>22%U81^4S*!O7+9!P",=3FFZQ M/(OB32X$;"N2S?-)G@@<;01WYW<8].M8T)DAT6Z)M+J'.H';]HD\EY04/S!M MJ[<^@'/(Z&NR$$<]DL,J!D9`"N-OZ=JRI"+'6[7$#N!"8\J1M0/(N,DG],58 MT::RN6NI[1HQ(\A\^-7#,K@D9;!XR`./:M2BLK69;-);6.ZLXKEG8F(OLRC# M'(W?7MS[&E?43($/QD%2"00<].OKBDTB0R:$)$@CMR5;` MC*D'&0&XP,G&>U)X`%"JY50LPEZ`9^8$CKGTQTK6HHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHJIJ=U#8V,EY,I80#TA$5AO6NFUVVDF>TE5E"Q288L<#G'^R<=.O&/Y9EVD,3:UY ML>(#M8RDHRN-V7!4*QX)QRIJYJ3VAT6PENYE@.U3&9E#$,4/7&`".>>@/.*A MT.)5\4:Q(+:.,N1^]7(:3!(Y!<]/4*M06FHP"QAO+BW:V"W!,6^,Q$L83@+E MCN;DKWR<\=ZZ:XE,*!E0.2P4`MCDU!JZJ^DW2M,T/[LXD52Q4]C@=><<=^E9 M-M8"XBT<+?>6T"[_`"FA\LS*I7^#/`!QPR#]3T7CM5:X\O^P9_M5I$\M1>'[Z/[-"CK-# MYUQ.5`!9"3(WRDXZC&>U9(B66SN+2"R2RE\J3Y(')W2,\14'..2"H(/J>.E1 MW(E9[>3*+$EHV0JC[S0'C=U`XX'1N?2MZ7Q"9=1%K:C'EW"PS!TY'SA<@YZ' MYL<=C5+XD6=O<^#-1DFD,;0VLS1D!?F.PG'//..W\JZ&VOXKJXN($5PUNVUR M0,$^Q%96J"_EOWBLA>JF1YDT;J53@?*JDCG'<\#/>M:W"W%@J2)(59"C+*?F M/8YQW^E4[I9-/6WM-.L`\,K$2*GRA`2,G/0=2<=\5+I\DQN;N.5)/EE)WNZG M()X`4$XP,=<9SZU5T31#8Z;+9W21;)'#%8VX/`SR%7N/\]*T;&'[/;>4`,+( M^W`(P-Q(Z^U9\%OGQ3//]H#*(=OD+/D*WR_,8\<$CC.3Q3M$96GO2K%F\P>: M2P),G()'^S@*!]#6=XBMX)=2&+=+BX>-1^\M/,2)(MQ7(Y7`8@8/4=CD8K?GO/L>CFZV>84B!"GY M,G'&>N/UQ6-=2'4M0T.\;9!)_K"N]VZD`@$+C\3C/2KV@B.-[N)))6*N"RM) MN52<]/E!'N"*V**R-=5FDL]L6\"0DL3)\HX_N?UXJO:HHOM6\P;U"ME0%;() M)P`#N;WST/`XJ[IH4Z0P0K)PPW`E]YQZECN_,T[15(L=S!@SMN8/$Z,#@<'< M23CIG)'8=*T*******************************IZEIZ:BD$;LZK',)24 M;!R`/Y5E/(%5BL;':W0X'0UP_ MB635)?"6KKP^IKI]>:+=:)+;";]YN4E02K` M@#!W+@\]LDX/%0W<$#?VHL#2M,=@V)G]V3R"!N`P3R0",X.:2]@2/0;&-YA9 M*D:I\TC0JO[LC!()QCT)[`9]9[!;EO$&H/)`L<"A5B82.V[/)(!^4>^/QK,N M[W?I,8EMY3&L@1?)=G=HRA)8EE8X93TZCGG-=25#?>`.#GD5GZ]"UQHMQ"F- M[@!<]-VX8_7Z_0]*S8MB)I4;.`Q'`61R%; MHJS@B.Y:3>,G`^8_*2.P.*J:BD:>'-L&G&)/M"%K:"/.0&!.$*C(P,D$#//U MI+34Q9Z5+]GC9R\UQ(CJN55?,;!/IVXK,M?,87;&S\WS!*'$$63+EX@PVX4_ M=(]_?-3D01K/;2W:"XCL"1;O"5=OW9&[.>V#QCCVS2%HI=9\[8OFB]$1F?%"*)_"]P\LD:[+:?8K&++-LXP'_'[OS9(Q6WIDC'7+ M^)EM\QG.^,$,03D!NQQ^)K.UR.VEU.0/:0,_RJTCZ;)<,/E!W;EXXZ;?QKF>BGD?0].E9>N,]\VF36JS[$NE:.FK=0W-U!-"D<7F-)&?-WLVYBM36D:_VQ)/\`98@TL6?/$@+$83Y< M`<#\3TINBWBWDUZ5%MM27:/(7!')X8YY;CMQ[GG":S/?(VRRNK>+Y"6!*^;G MG&-QV@?6J%HT;^)](:*6:5?[/O\`YYR"Y/GV^8) M;%HD1V,NU@UPL1VG&<;@<]!TP??DUM50N!&NK6LO!DVE#M;#!3ZC/(R!T'OG M`-276G07ES;SREMULV^,#&`?7I^%4KVQAL;`):M)&3)D%V:4<*1SN8'H.QZX MZUH&%;K3Q$99`LD8'F(Y5^G4,,$&L8%%GTF+[1=M(N?E8-*Q4'&YFV<">M;=K<"ZMDF"E0XZ,,$5-16'XAA$UWIP-O%.1(2GF,JE&RI#+N^\0`?E[Y MSVIFGLTFJZLA$D*+E?-\ME53D\HQ.WW.`.>>>M6]+NTFTJ6Y24R@,Y+'*]/Q M)`X]31X?FN)]-#7#SNP;"M-'L8C`[?UR<^O8:E%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%4]3MX[FT\N2[EM?F!$DG%:E%5[Y2]A<*`26B8``9/0UQGBFWL8/!5\WVG[1`"/O<8P`<8Q3=("+XHU M<"*#>2I::.X#,W`X,8/RXQC)`S68%M+G1"]M;V[0M=2LO+.J#:Q+\Y#D#DXR M#TR378ET#A"P#,"0N>3CK_,5%>>2;9EN$22-B`5?;@G/'7CK5$6J7=Y9R!2D M<,99/+/R@AA\O'RX_7CC%,TN5KBVO"YD.XDKYK9`4C@#.1M]\8/O69:I$?!Y MBM%V[YMJK<*9B&W#J"G)XZ;?QJ@;=C.ZF%1Y:W#^;MY/[V0;00,#[V2#[8`I MT,FS3YXX+O'E&>..4++N7,D1&0.<_-U7CG/K5B3RP;B-[F\,OV-CMF!"2#RR M?;YQWX/`Z=P-;Q1ZR969GEDO5(/SD*/,&1SP.HX_+O1\4(4F\&W>[3OMC)#* MROYNSR<1M\_7)QUQWQ6YIYN#J^H&2)%CW+M96!+<<9`8XX^F:R]?.=2*VC:G M]HVC>(Y)4MQQQN*\YZ?=_&M>$*=`VY9QY+`ELN2><_>P3^/-5(8UCTJ-3:O* M1(Z;9R8W9222<`<].!^M7K2XBN+V95C9'A&PYA901N/1BHST[9'O6;HJW,.@ M33"-$:0!X\D*&&T#)Y'S<&QD$X!SU M'![4RSB@_P"$NFF"?OGM/]9LVAAE.GS8;H,D+Z#-7=)18FN8Q;/&XD.Z1HV7 MS/0\DYP..O;L,56U.QGOM3,<(LN(T26.6U\JY$)+$E M:=9FHJOV^UW"X.YU`";=A(;(W9(/'7CT[U%K-X;:_P!,BWLBSW`4G>N&Z<%2 M"6YQR,8ZD@4_Q%`MQIJHUW':`2@^;(BOCKT#`C-:,!S;QD/OR@^;&-W'7%<\ MLTJW^EMAK>1U97BA&49=_0DJ=O8]5ST&34GA6WNK>34/M-U),))MZ(Q)$()) MV<]".X''3UKH:*R]6BADNK'S5:8B0A8/,`0GCYV7^+;CCT)^F([:"Z%_J4JW MR7(E!"1`@"(C@`D#(/XYX_*Y8P,EFZ3(Z;R20\A9L=.3DX_,U'HNP6)1(A&% MD;N#G/.3AFR>>N M5%<'-PA>./@_,P'4=OQJ#P[]G,$K6\-FH)&9;*(QQR=>Q[C\>H^@V:*BNFD6 MUF:$9D",4`&><<5Q/BN:6+PUKC?V4]HT]C,OFF*%6D'E-NWE6))[\`5VDT#R MSPN)<1(27C*`ASVY[8/-5+C26FT^ZM%F0?:96!6QJ>F2:A/:2+<>4L#[F7;G>,@XZ M\?=_6I=0TV#4D2.X+;$.=HQ@GMD$=J6'3XX([>-99"EO]U21@^F>.V:FBMXX M6-<-* M%"N1*I=<`,K.[8(SSG[%U),0ZVABP%'SL4*G//N<5';:%?IJLLSQ[83=B9,2$C!<$G!8CHH["K M?CG[0?!6M>3Y>W^S[CS-^F"TO[F[\]W-P MM5[VV!V_P`]*LK:_;-%-K+,K^="4+J1(.1ZL/FQZD<] MZA?1$FLK6VGE\S[-,)0WS1F"0#D<=!U/:F6.GQV+3%)&?S6W'O M?-9FM7EE#>[)[^2RD"H"8KE$9P21RK\$#UZ\FJUBT#^)-&-OM,?]G7X#+)Y@ M8B:W!;=WRT@N7B>5-QA?>G)& M#_7\?0>E35'+!'/L\Q=WEN'7G&".]25333XV$+W.9)H3D,';!YR,C/..V'/E[N0N<9..F>.M9^HB#26DO+7R M8KR[8)NGF(CXRQ."<#@$\=2:T+2YBU&PBN$P4F3.%;.,]1D>G3BI(88[>)8H MEVHH`'.3QZD\FI*******************************S]9MS>"00<9P>.>!VS3=+C07%U+'=F='V`*^=\9`/#9YSTZ\\<^M:5%07K MF.QN'5BI6)B".HXKA?%=^EQX5U>$:]]K*V5JQAG:,?Z(L4;,XR<'?.MLC*?+Q MTXKJ**Y37_*@U0O-?7-IO97CV1!UD<#``]_:H=)T^2"XE25[B1A&KM!&RHS$ M]R01_.K9>=[JXM3)<7$5OM(C23#C=U!(ZD8_6FI):Y%L5"PH^QU!& M=X MT,3;=NTX!([DXSZ8:HM72[>>5H22TB>7.]E!.5VD^^.WT[5-11161 MK!M%NX7DM);J>.&618HP#E!M)R#U^;9C'.?;-5UNI(M//V-7BD\R5I@Y!;>' M`;D`C')/`/`Z5:T;4GO@2SI(K;L,CJX&T@=5`!SG]#]!JT44444444444444 M44444444444444456O8[R6%5LKB.WDW\8P>V1[=Z980WT+2?;;V.YR!M MV1>7MZYXR:N44C*&4JP!!&"#WJ*:SM;F%X)[:*6*12KQN@96!Z@@]14U%%%% M%%%%%%%%%1S0Q7,$D$\22Q2J4DC=0RNI&""#U!':I*88HR23&I)ZG'6E551= MJJ%'H!BG444444PQ1LQ8HI8\9(YIHMH!*DP@C$B*RJX494,06`/8$J"?7`]* MEHJC=Z-IM]+YMU9132?WF7)H&C:<"I6T1&5=JLF5('H".:>=,LBBH(%4+G!0 ME3SUY'-#:99%$46ZJ$&%*94@=^1S0^EV+JJ_9D4*NT;,K\OH<=1[4-I=DQ!$ M`C(4)F)BG`Z#Y2.!4\L$4P`EB20#D;E!Q3C&C%2R*2O0D=*=11115>[L;>^5 M5G0DJ.`$1@\]2S% MB?Q/-2T4444444444444444444444444444451U6T%[;+&86F57#%%G:(G@] M".O7ID?6F:39VMJ)3;0W,);`=)V=B",]"Q.>O8D5HT45R7Q2O;K3_AUJEU97 M,UK<1^3LEAD*.N9D!P1R."1^-=;15:TO4NS(%C=#&<$/C/Z$X^AYJS111116 M1HTTLNJ:^DDKNL.H(D:LQ(1?LT#8'H,L3CU)]:U7;8C-@G:,X`R34=K&0H MM:=S'!(XVY521N.!T[FJND)Y=@L86%50D*(B2!WZGJM0:9YRV?E7$GF31.R.^`-YR?FP.!D8./>KE%%%% M%%%%%%%%4(-8MKBTN+E5=4MI&C?>57E3@\DXQ]2*L6ER+N`3*A56Y7+*V1Z@ MJ2*GHHHHHHHHHHJE9P6L=U/);W!=G=C)&'!`;/)QV/&*NT5F:E)(FH6*B254 M9\$1]#R/O>WY5IT4445'.YCMY'7.50D8&>WIWJOIETUY9B=V1B6(RF.QQT!. M#[9/]!PK-LKZ_NK&"Y$,>'D(D!+!T&\KC&.H'7 MTYZXR=6L75KZZMM:TZ"&:)8YVPZ-,BL>1GY6Y;C/W><^M+XCOA8P0,VIG3U= M]I<1&0D]AC!P/RZULT444444444444444445QGQ=_P"28:O_`-L?_1T==G12 M`@C((/TK%U^R%U>:9*;4SB&?EL(?+R5P?F81-JMN0C:PR#QT(K$^U76AFPLFBBNC=38DE,I MC,8)`S\Q8L>R3C'M:\0RR1Z7O@6V9M_'G[=HX/3<0,_YP:DL]4$^HS:>8 M@CPJ"&$J'<,+_#G<.6QTQQUYQ5FT9")0JD%96#9YRIK&6$GVR8IM(!W!B1U]ZV-,CFBL(UN%99>2P:0.0?J!5NBBBBBBB MBBBLC3&C&LZC$+-HY$8,T[+GS=W0!L#@`=.?K6O5.UU.*[O;FT6*:-[8@,9% MVALYY7G)''6H;JQ@N]:M99[1)/LT;/%,06>(DE'ESN(S[_\`UJO4455O;N6U\ORK5[@N2/E8*%/;)/'/ M2K).`3Z>E8<-Q9WQL[B9KI1([-$OF/C/FN=XQ6?XB\TVT"1*"6E')M&G`X/H#M_WL'%:]%%%%%%%%%%%%%%%%%%<9\7 M?^28:O\`]L?_`$='79T5C:#86&GSZC'8O*^^X+RB0YV.>JC@<=/7K3M;B8W% MC*06C$NQ@%8[22I#84'^[CG`^;K6O5/5?^09.-H;*XVDD!N>F1Z]*;HZ+%I< M,:HD83:=V9 M4=[D;1\HRZELS@BU">ZA52TW$KAB3D8P#S]>U7:Q-'U6_O=:U.UN4MA!:OMA,>0Y&3 M]X$_3L/;BI[ZWD;6+.YCCG.Q2C-'(JC!93ALGD<9P!^-:E%%%%1W&?L\FW.= MAQ@D'I[`_P`JI:&MVNGXO9VFE\QOG=2IQV&"J_RK1HHJEJ,BQB%I'9$#Y9Q& MS@?7'`^I!`Q5N1=\;+DC(QD'&*YM--EMO[(@FU#S9()&)5+IHQ*"X.<'<7(] M"?7Z5TH(/0YK/U&R-Q2W!X_+Z\5IU4U6)Y]+N(HSAF0C/'3O][CIZ\>M,T=/+TN*,'A"R@94[ M0&.%.WC('&!QQ44<>WQ!*^Q/FC^]YP+=%_AQG'XX[XYK3K%T+_D+^(_^PDG_ M`*26]:EW$)[.>$NZ"2-EW1C++D8R/>N8L4L?*L))KZ=;E+AEADF#0M)EERC` M,,\A3ALDA>E;$$UQ:6TDLR22EWX$8=V0X,HF;*J0?E&2>>3GK@8`X`' M;-5-3MXY=5LY7B<^6RG>(=P4[N,-D;>>O7(XK7HHHHJ&\8)93NW18V)P`>WH M>M9_AM)H]*V3Q)$ZRL"B+MQSQD9.#]36M16/IYN6\0:B98IA`H40O(F`2?O; M?4<"J>J3#6@D5NEPLEM=F-X<+^]"D;AN!^4$?GSP:W;W/V&?:RJ?+;!;H.._ M!_E6)%:2BTTJ:U2""V23,B1;TVJS9`"YQG)&[(XYQ4VB6ES'JNIW4DJ-%+,R MJJ$\88]O7!Y.><=!4FJ6J2ZM8W!4>9$PVL708RPSPPR3C/2F^(R!';EW\N,, MQ=]A;`QW`(R/4'@^AK:HHHHHHHHHHHHHHHHHHKC/B[_R3#5_^V/_`*.CKH-1 MMX[G5-/7>PD1S(565ERB^PZ_-LX]_3-:=5XA(+R8LZLNU<`#!'+?TQW[=JK: MHEP\EH8[9IXDEW/LG:-T/8\?>')R.]:-5[XH+&;S)W@38094QE/<9!'Z5%H\ M;0Z9%&S3/M+8:?/F,-QP6R!SCKQ3`I77F(BD*O#DOM^7.<8SCT[9[FM"L70O M^0OXC_["2?\`I);UL2(LL;1N,JX*D9QP:YVYLK/2-0TNVM8[F*)I6(\I@%@)F.P#:V=WRC"XQC&><<\FJ\UQJCZ MW?;)Y5CBMF6W1(@5#C86.,Y;[P['OWZ[6EF5M-A:=0)6!+XC*9))R=IY&>N# MZ]!TJY1111111111117-Z(DDFE:FL6=YO9MN#CG?]1_,5K6TRV&G0"_N41\! M2TCXRWIDD_S-7000"#D'O2T444444445C:6<"[I.V))""LF`=X`'8Y!`_3FYI3LUS?+(LX=)V&9+@2+@G*X M`/R\$<8'XT:E:>?>VG^W%6E5#3KE[FXO-YC_=3&-0JD'`[G/X_EGO5R3&SG M'4=?K3ZCG@CN8'@F7='(,,/:H;"'[/;M$N?+61@F6+'&>Y//7-58;>\7Q!// M)'']E9?W;@#<.%Z_CGU_"M2L70O^0OXC_P"PDG_I);ULL-RD9(R,<&L.SN)( MVMCIR76H6SR.DTLDR_NOF')W8+8YQCMFK'E37]O-!!?/&$D*-)L#9P""N"?H M<_E4;QNVKSVQL(FCDM<&1XMIFP0,>8">!D\$#VSS5W31Y.GQ))##;-D@Q1ON M53N/`/>KE%%%%%%%%%%%%01WI:R=/63^V;UVV[3P`H3'7L1\V>.0V.1P.]:U9&D M3R/J.I1O;I$JR@@KNR>QSD<],\9'/KFM>BBBBBH[C=]FEV2>6VPX?&=IQUQW MJGHLDLNGAIO,W;C@2+@@>GWFS^9K0HIKNL4;2.P5%!+,>@`KGKV_'YUGZ3<9T:R,; MB)0Q4HB@J%#[=H8#'!P,XYP>FI'>K MEP0&A^;!\P8`4$GMQGIUY/IFJ&N7D]FUHT-U;VX>7:YN)%56'&1SR3C.,5K4 M444444444444444445QGQ=_Y)AJ__;'_`-'1UTUZ(X[FWG"I]H)\I"TNWY6( M+``]?NCMGBKM4K%2L]UFWMH2SAF\@Y+,1R6.!STJS*S#&%)7N5/S`Y&,#^=2 M4UY$B1I)'5$49+,<`"H;/)C=_,5U>1BNTY`&?7]?QIL.I6<]V]K%.KS)G<@Z MKC&<_F*M5BZ%_P`A?Q'_`-A)/_22WK4NRPLYB@!81M@$#&<>Y`_6L&+6IM.7 M3+,6EJXNIC$66[1`@W`94$#?]X\+Z8R:OSZ='<36\KRR;[=RRD8&< MGOQR/_U]<&K=4=0U2+3I(4D7)E)`^8+G&.!G[S<\`<\&KU%%%%%%%%%%<[H, M*W&EZI"Y(5[R<$@9Q\Q[=Z9=W%K;^'[$^1'SYN_%:],26.0NJ.K M%&VL`<[3C.#^!%/HHHJGJLEM#IDTMXR+!&`SEQD<$$=QWQ2Z3%Y&CV4/_/.W MC7[P/10.HX-6ZP=)BN4\1:B9$?R>?+=H=@.6)(!QSC_Z];U8^D/&VJZBJ/(V M'_C$V/O,#C>=O7/W./TK8HHJ*XG6VMI9WQMC0L/,L7EN#@@ M-N!]P:DIK@F-@.I!QR1^HZ5GZ%:3V6G^5AVY_#-4O$_:1<6S16]O+&L@W/*V&CR0,KQUP3_*KM5[2UMK6-A:QB-'.[:"< M9]AV_"L_6_,DN;""-I1NEWXC&0VTKP<#(&"><@=CU%:,5W#/*T:,2RDY!!'0 MX/ZU#JZ^9I<\98()`$W,`0N2!DY[#/-+I*[-,A3>'V`KO``#8)&1CL<9IEOI MEK9W4;01;2J%5.6.!QQR?:K]8.E2"*_\42,XC"7ZL7(SMQ:6_.*U1*ALY'E< M2*H8/A".!G(Q6%I[6[V05KNT=8\C<(MLH7()498]U'()'`]*1+>1-*N&M5(\ MV;=$Z-L,HVGYNAYZ\<#CC%:272V]]N>F:6? M6"M[816T(F@NV8--D@+CI@XP<\\9K4K,U>2<`0HLC)-&Z`1H3N?C`)'*C&[G MCZCOI`;0`,\>IS2T444444445SFBB,:/JAG^3^(J^OSZW#B68&.%<)Y9"8/4[LXST]ZK^$FWV]VV) M!^^(._/4=AGICTKH*HV$H>ZNT)B#HXW1HH#+DG!;'7(P:O44452U90^GO&99 MXMY4!X$W.IR#D<'GCKVJU"`L**'+@*`&)R3[T^LZQOH;Z^GVR0>=`6B:..X6 M1@`W!('W<^AZ=*T:KPP0P74ODQ)'Y@#OL4#K<@?S(JS15;4(S+I]Q&`AW1D8=B%Z=R.@K*CUB9=!LK^V"7@FD)90W)3Y MSA2<=MQ.^1RQ/XG MFKE%0WD?G64\14MOC9<#OD5Q]EI6KR:1Y=Q;.TOVG?L=$.%50%P2PX..V/3` M'%=?>R/#9321QF1U0D(,_-[<`G]*IV*%=%A00S<./DFD:1A^\[D\^_/057TV MX67Q#J$7F2R>2`%9G4KR,XXJ+1[H3 M:YJD(1%>-AO8*`TG)`)X!X`QU/3MTK8G&ZWD4@G*D<#)_*DMB/LZ`*R[1MPR M[3QQTJ*17?4(LA0L88@Y.3GCZ?S_``JU6%I)VZAXG;9OQJ"G;C.[_1+?BM&- M(UTQU\L01[6^0H,(.?X1V]JK:0L26>V4QL#(?+/V<0AA@3Z5I7&+R%[5)`CLO)921D8.".,CD`C/?&:IF&ZB73%BF7R5< MM,&0ID'H%4@XP2,`G@>XR->LW6;-[I;:2)E$MO-YB$D\':1D``YP"3COZBM* MBBHGFVS)&%!W'D[@,<'MWZ?YQ3W)5&(QD#(R<#\ZAL6E:T1IFWN<_-@C//H0 M*ABNI7U62W>!UC124D((#?=S['K^AJ]1117-::TT'A_4Y;90TOVFV71+&35+9]^5PB-MVGMG!4?YZ55G7'C>(K''\T`^8CGC/3\^M:VE6 M\T,U8 M&J364/A5[A[QA#%*3'/*'D.=Y&#A@Q!!*]1P?PKH$.8U/'0=.E),J-"ZR'"% M2&.<8&/7M5+1"K:7&ZRR2[B27D;GL*YV=; MG4X8Y;J+/S+)";568YM392N@B."K%=_`X!X`SGL> MQSBL:RDNK*'2+:*VG@CDEE$D95F,8WD_,VT#VR>NJIYFKZ?FW MLY=KY1IT!=3N!.PGH<#/'/'2MBJUN)A-PV?NPN!Z9[UF>(8A-=::(Y M'$ZS;D18?,#`$9+`G``.WGJ.W>ETFY@.OZI912ONA97:,@@9;YB>0.YQU-:] MQY7D/YY418^'4',B0?9A_JV5SOZ+U M&,=<]^F*M5A:0P34?$[,&*KJ"DA`23_HEOT`YS]*OV%N8-)6WE/"JPXCQA<'KQ)&4(4^8-,(@PR/EWGA<],GCGO4NAHL>A6*)MVK M;H`%<.`,#^($@_45+YBR:H(_*.Z&+=O(X^8XP/\`ODY_"K5%%%<[8@'PY?YN MGM1]IGS,B;B@\PYXP/;GVJ\L$C:GYL\\ M;HL8\J,`AE;^)NO.?I4MFL21-'"CHJ.1AR3S[9[58K,TV%DU/4)6GGD$C+@2 M0E`N,CY2>"/IZ=\UIT4450UKR?[,D$[JB,R#HI&^Z>,\=/6N3:D<7^C^6 M`Q..&!'3'KR,CK71)]Q?I3+H9M)@65?W;=F*R0LI(>-B&`!```&#GOS^E6\F-U+N?,LD2HQPYQE02%(P..O'/--L55M=NY_-F;U3Q[_+7S,;\#=CIGO3J*****************XSXN_\DPU?_MC_`.CH MZV]6M(KC5M.D=UW)("BL&(4@[B<#C)`P">A.1S6Q56R4D22-,DS%MI=4*_=X MP>3S],5#J-Q)#/;B*>5"S89([5I@V2.I'W.,\G'7VJ#2'C;4+]?.N99A*VXR M2[D4;B`JJ&(7&/0$^]:%Y.UO;,Z;=Y(5`X)!8D``XYZFI5977HQ4^GP`6,#2N9W_UF]P,@D>WH#C/7'O!# M>WI6FDTUS:VLL\*Q2OU4J21\PZ9((R.<$<=^F*T:HWDF;^TMTN&BD?I&SM..N*;$"(4#$D[1DGO55XTAU))Y61VF(BAW#F/Y69L'W MVC@8Z=ZN,<*2%+$#.!U-16OF?9D$L9C<#!7CC\N*CA9'O)S$0=AV2[@3#J/A^SDOWBB=2& M0R)G:W88)Z^V3^-:9"1ZA$WDN[R1[?,`.%`YY[#K2:5.T]L[.VYA(RGYB>_N M!C\JG>\MX[N.T>4+/("40]6`ZXJGI4CR7=[NL#:J'X;RP@D.6R?]KL<^_M6G M156_U&VTV`374@1"2`20,D`GO[`U95@RA@<@C(-5M1-P+&7[++%#+CB24_*G MOT-/LHTAL;>*)PZ)$JJP.0P`X-3U'!*9HA(8GB))^5Q@C!Q4E5[>Q@MII9H@ M^^4Y;=(S#J3P"<#DGI5?49@EQ:0>0TC32A5.%(7!W$G/H%SQ2:7>"ZDND%Q) M/Y,FW5SC< M,>AQ71(,1J,8P!Q3+J5H;2:5`"R(S`'H2!5;2+J:]LOM,P*F1B54HR[1Q@89 M0?TJ]3)8HYXFBE7%H59)(0IB=6 MEG(<$H!MY`P`0JCGIGUX.A(B2:]>6Z&&*>2T8^:(I`R@[0"7##N.@(/`Y%.M M)+O3Q8V3@N'+^8XW$@E\\[V8]_4]>#C%7+&SMX[Z]O(0-T[[7P<\KP<\G^F* MDN=R7"R2RJ+7"J4)`/F%UVG/],\YJ#6K*TOH(8[R/S%297"^:4`P>6X89P.> M_P!*TJ******************XSXN_P#),-7_`.V/_HZ.N@U".X.K:;)!,L:[ MW612A.Y=I.,@CT[\9P><5IUE^'PTNEQ7DDS2RW"*SDG(R/3-9VHV=Q/X@<6E MNZ2NL;&Z5IH@%!Y!8?*W!X!Z>AK;7F^C/+E8F4R`\9RN1CIG_"HM9?R]/+!U MC?S(_+9@2-VX8Z`GKQ4UA#)!9HDO,F69R!@%B221Z#)X'I54RPR^(?((A,D< M(;._Y^O'&.W/?N/6M.L#32PO/%10D,+X;2.H/V.WJWI@6^T$I]J>=9E=?.WA MB M8L&,LOE,3RN`.F<=0`0>M;M]*8["659UMT$>1)LWE3V^7O\`3O6*CVLT^BS7 MJ-+<,\BPNI55B()XQW]./3-=+5*_B5I(9I&"10G<[;N3@@@8QSRH[]O>KM%% M94U^AU^"Q-H=P^<3LH(^ZW`..#S_`#_'5HK$L;@'Q->VV)PX!<@N-A&$`.WK MGT/UK;HHHKG+0,WAG4%10SFXN`N1GGS&P>.>OIS4]DC#P_IX$,MSM*;OEVL? M]KDC'KZ^U7#]M&M#:SFT,>"A08!]0JZR#,DD33!HU7R\KRX(.PY MZCO_`#S71T5E^(HVETB2-)O*9F'S`MG`Y;`')^4'CTS6DFW8NW!7`QCTJAX@ MC:;0KN-0A+)C#N4'XG!_ES[5;M-ILX=K%E\M<$]3Q4U9.D7\ES=7L+212K%. MX!CE+%,,1M88^4\=*UJKQ-7")O^1X]LL@+'+;2%QUST&!T'2M:-@\2LOW M2`14&HN\>FW3QG#K"Y4\\'!].?RK-TZZ33=(B:::2Y62;8C_`&CSR=QXR[8Z M>GX`$]=NBF"*,2&0(H=A@L!R:X]M/DTFP5)8&CS.6Q$G$AV_,3^\^Z0">2,] MQTSJWBQWMYJ+"&-!#;M!)A%&EB2..S:W99HQYD;,B94?O M.>2`01@C'3KQTJ:U=[:_U":=+Q4WDA%BW1XXY4*"6)ZG\>*>DD6(_*YWN%3)'.%!R<9ZX'/6M M2JFGSRW,'G2'*M@I^[V<8STR3WQSZ5#J5R(+RSC-R(!*Q'.<.*("Q7S+]5R.V;2W%7[5KB#1R\C)/.B,2(PVTL,_*O4XSQW-91I@JC[HY1NG' M;\:GOY@8+F&[,;1C:VUI2#QM/\*Y`SGWS1%-:!=/2WU(Q1L[B.*7.^;!Y`S@ M\'Z\?F-BL?Q`MKY<#7*SDACL\J/<"?0\';GL1@^A&:V*K7\\EO:M)'$LAZ$, M^T8/O@_RJ:%2L$:D8(4`C.<<5DW-W"WB6WT\QPK*4\X2?/YC`9X'R;O./K6@T7FZF29B46+:8L' M@GN#GT]JPC+8OX5D-_/*;19RBM$S,3\V`,OD_G6@9Y[76-,M8YV6SFC8!6C4 M[R%)'S9R,`9Z8JYINFG3VN6-S)*;B0OM/"I[*.WOZU>J'[3"+A;?S!YC`D#U MQUYZ9]NM9?BIK=-'\RZ>=8DD&X0,H+9!&,-U'.<#GBKYN<7\5JD\)8IO>-CA MRF"-P'?YL"N=M97@\.74NH+EOMJAEDC,@4_(,[>&'/S<@')SSG)Z>UC\FTAB MSG9&JYV[G:G31K-"\3$A74J2#@X/O65]BM&-A;I,)+?>\@`.`[`<8V```9/ M'`K8IDJR/$5BD\MST;;G'X56O)0JW0:97"VQ8P`X;OSDI[TV[>9[;68_LA@C57V279'E MN=Q)X90N">F6/X"GV4L`&C1W%TD#/$"J0A!'.=PVJ`N1P>?E.*O>)KJ.VL(Q M(TZB250#!(J/U]^H]:V:******************XSXN_\DPU?_MC_`.CHZZJZ MU"ULYH(9Y<2W#[(D`)+'([#L,\GM5FJ]HUJT?^B[`@``5!@`=N/2H=0>X6:U M$(&TR?,2K'^1]">O%4],M6@UW4&;S3DY#-YA0ACN^7(VC'3"D^O'2K^JS-;Z M7<[;LR8P&^8]/;\OH.E/8VPU-4VD3LA.= MIY`QWZ?Y]JMUAZ.2-2\3%652-17!;H/]$M^M6=-6Z70!'=W,;S+&RF:*4N,# M.#N.,G&,GCG-&F6L;6RAI;AFAD/6ZD?G@X))^;\>*:C2VB3>3;VB2M*"WD*6 MWDDY9@,$'CWY[U9BO#+JDUJ`2D2`EO*(&X\D;LXR`0<>_L:K7D%Q=ZE9SP#$ M-M*PE^=E)X[`':PSZ@GTK5K&\0VL]TMNL;W"JK%L0KN#OQM5A@X7KSVP*V:S M/$5RUIH=Q.@!9=H`,/F]6`^[D9ZU?@#"WC#,SML&688)..I':JDLMV-;@B3_ M`(]FB9GX'4<=>O=:DU)[F.PD>T&9AMVC;GN,\?3-/L'F>P@>X!$Q0%\C!S]. MU5XH737II66(*\(VLL8#M@]"VA7DUG)=(6N-A((X.>Q'&/>IUCEDUK1I3*B*D#%HVFPS$J?X2/ MF_2NAHK$ALBGB4W,@C=3&PCD8@,K9.5'`R,<]^G;O+KMXB644*>5+]JG%MM: M3:"2#E9!` M7NPV+;,P50%R`4).XX//OG'-=+$@CB1%SA5`&23_`#YI]9&G*HU[4F7)W%W@D>-U*-+'NVG<.G<&J6DRB;5]4;[4'/FA?( M+9:+`QG&<`$@D?Y`EOXP=6LV#H)#G:K1;R0""<$D!>"><9JMI&H7,\=V]['# M8Y8-$5V@.K$[7Z]3COZ5L6[,UM$SD%B@+$8Y./:LQ-3=8]4D2T"FUR1'(1$T MK8SDD\`'@!CZ'TI]K?%="%W?QK8M)O9D,ZN%)8D8<<'/6M)#E%/M4&HKNTVZ M7CF%QR<=C[C^=8:7$FG0:?01VRJKVTP);ECN*@_*V"!D=<<>@ MJZ:NGS:%/!]HDF@>ZV+]I@8,KMC:"/E/!(.<^_':W)O34M2:*&XBD6WRDVV1 ME)P,X'()X'`&>#US4UL;R9;24&1TW-O8QFW_`(^K(QR./8Y]LU#-'?6G]JW$ MMQ:-&T;&-9I7*KZ;Q@@#!_A'Y]:CM)&\C2E>%-TB+Y8MX"(EPP+8!'RC;TSB MK7B.3R;>&4IN4.5;DC@C'4*P'U.,>HK8HHHHHHHHHHHHHHHHHIDLL<,32RNJ M(@RS,<`"N'^+-_:3?#G6+:.XC>8+`Q0-R`9HR*Z+6XIY+[3C''+)&LZE]A&U M?G4@L,$G&.H''JHK9K,T?3Y[`W7G/N$LNY!YF\(O91\HP!V'.*75Y5B-F6A: M0_:%PV!L7MEB0<=>, M0,X_#O3-.C>/3K=9'=Y/+!=G7:2QY/';D].W2LM+F(^-7MUM(@XM26N%?YF. M5^4@>Q'7^M7KO5&M[@PPV%U=LN#(80N$S[L1D^PS6=H+K>W7B1X7*B:_7:Q! M!&;2W[<$'\C6E;3I<::[RR1W*`,&9$(5UQZ$G/'O6-8WA7[-':XCD\W,\4)0 M)RP!.PY;[N<8P,@DUI1P++;W)6W5664N%CDY\SG)R.^"*AO)3YMQB"ZA)MBP MGE=O+YV\`#(!]>`>N`>:22.,:G8P3W(@>++K"+@LKL2>"IP3QR#6Y44]M#<& M(RIN,,@D3DC#`$9_4U+67XAD2#3#,XDPCCF)D##.1QNX/7&.O/'.*OVW_'M% MQM^0<>G%57%G_:Z%IYOM6W"Q^:^S&#_#G;G&><9XJ35(1<:=-$9/++`;6S@! MLC&3@\9QGBGV,<<-E#%$^](UVALYSCCK6?8R6R^([Z,-(+AUW%0JA"HV\\$G M/S#DXXZ#BMBBBBL#3)GMM`OIXMH>.XN&&\X'$C47ET9]+T^^G0L/.5R%)`&> M.<`COZX]ZMB/_BH/-CF@QY6&C\T[_8[>F/>JEJ+F:RO8K>:.*;S0&=VX'_?) MR#5YH8!JMJSB9KE8R-ZN0F,?R-+I]U'Y6E>&"Y^TX0SY M525`52"3D<`97! M^6,DC(/K\IJO:!UUB[+PF-,?(YGW;^A/RY.WMZ<59FM?M+(XNIE0,&V)MVMT MQG(/''ZFK`C179PBAF^\P')^M5;ZU\Z2WG$DJ/!("/+`.X$@$'VQZ5S,-RMO&"T6-C?*.5 MQQCTQQ5"-Y+G3]222>1OE8,7X\I^O>C38([[PI%%;A[9&!,?EG M<?8V\M[ M=E&$K%#)"_).""!)\RD!3SSWYKH9I8[>%YI6VQQJ69CV`&2:S=56>ZT[>C6T M`X)%T@=&!/&>>/UHMD-MJXB=[`N\`SL7RY3@G^'G*_CZUGZYK'VFS2*QN!&' MN1"SM'D2#'S(`5P&`.?:J]JGV;4KZ[GE38V0Q-NR$8(`&X\-Q@<8_ M'K39;AK633XK6>);:=\#E5#Y8'`SWP3P*GUNTGO+:.*`/]\$[)-OY\@$>N<_ M[IIW]H>7KW]G.LC&6'SD8!=J@'!'7.V.>.G2O2 M[^RL;E[>>\3+6\JM$VXC#Y&.AYYQP>*N50TRXFN5D><,CY_U31LNSD]R><^H MJOK5Q=PW=@EM/Y0>0F3U)I4UT^LZI'/:31QI(#'+(^X$ M%1PO'"\9QZDUL5CVZR'4K?-AEA6]DAP,`;FPP4=.O4]LU-X01( MY]=2.02*-03YU>]:]A'"L$L*'HP!CO7*6<-U_P MD+V/DZ?>VT@65II80I$@'0;20#M`.1QQ6U/J@2"XN$9XHH9_+E:)68\;MWWH M\=3]/<4V0M%J]]<2JB6PM00[.078X[@9P,>^,\=2*PKT6LVL/+=_\(R)V=0Z M/(6D!R!RQ(!X]@?;-=CI@B6Q00_9M@_Y]ON?A5NBH;FV@NHBEQ%'*@YQ(H8` M^O-+:JJ6D*HX=1&H5EZ$8Z]3_.LQ[R8^)TM8Y"(ECS(I8QE26*65&`#)#G2":'$00 MM#(K#:1\O!&<[LYYP!BKU%%%8.ELJZ#>LSA`+BXY;I_K&Z\'^5-&Q]"LVN(Y MLEMFU#AL'@X!`.,=L`_2I1.1XG%LK7`41*0BD;>G4Y7/Y,?I52UA2+2+T7$4 MDR)<$^5$GS#G@C'7UK8DEF6]LEBE@2*0'S(Y6(D8;21M'KG&?;-0:9?_`&S5 MM4CWAEMG2-<1%>,$_>SAN=PX`QCG/%:M9`M0?$9N4MA\MN4>7.T\L2!UY'![ M=Q[XR(],G/AT)-.LH$VY3:2[\)Y>TJ/D.>XP!GIDGFMGRY#X@3=`P@2W!AD# ML,MDA@5Z=".O].((-)CU'PPEA<>:$<*P:9?G(!!!/.M;])MJG$;QYD^;AB.CA?S4U2U&6;5O-ABM;R)K2 MM227,44HB8D,0.W`R<#\S7,VL.H MW=CJS7\,DSI<[8XH#%N95(P"22#QC[W-=#I:LFDV:N&#"!`0^<@[1UR!S^`I MFG1R12SI+>S7#*0-LJ!=HYZ8'(YQGGH>34.H:@FC:/->EHC%'*O&`.GX]S7-Q MOYD!EO[N&[>34,&2P#;0"H!5@`=P'HW;Z5T/VR9=?DMPCO'Y`9OO;5QGD?+C M)R!C<3TXJ*TF-[%:WDNGSD.S8$IPT7[PX)0^F!SU`J6_CA32KK[;//#"9-QD M0EG4;AC;C)'.,8&:AL9+66VM+%7G+;/.C\TE&95D')[YZ=1WYQFK.K-`JP>= M9M::Z6[2@W**[+YC%!N4YPN!CCDL<#WZ5L[EW;6=O(\T3,B[DGN"V,F4[,$98C;][N`/3G8@6\74I_,RUNQW(21\O"C` MP?8GD=SR>E9NH:C)97TRBV+JTBEG_=`;=HZ;G4[L^N1Q]:B\(.TDVO.ZE2VH MJ<$*#_QZV^,[>/RXK8L[Z*?3S>KYJQ'<^)%*L`,YX(%4-'CTW4)/[5T_Y(]Y MPJQ[`3@@G&!UW$Y&?K573;)H$N1JAGAA,JK`!*ZG:%(ZJQ/0GC..!@5=O)LS MW4*W%QM%L5,0NXX/3?Z^E<[9S?9ITAFU":%D`4Q)I"L`1_M*&Z M]3@GJ>:[&P??:(PD:08X9HC'G_@)`Q5FBJ]_*D-E(\DRPIC#2$@;1W.21V_R M:?;,6MHF)!R@.0,#IZJ<6F^5K,VH*ZA9H]K(%;);CDG=C MH.FW\:OT45B-KL_GF-;5`L3'S6=V4#G"H,CESUQT'K533IE_X1:\EDNDM%-Q M,3,P)"?O3Z$?H:GU?8FC136J6=2BT>8R(T;B48()7"9]`1^F*N7"3G7=.D6W:6'8VZ7(`C.T]B M">>GWN]/TJ]BNKF\2%E*Q28VKC"'+`J<'KD%CT/S#-:=9-O`8-I(/U'O6=]DU*/3IH+/S3+)?*7F<@N(RHRP;`W<<<SLY9OW?E2DD!F/S?*5HU42$-SL'((4#G''ZU'/?QVVDRW,H)0 M3-&?+3<>9"O3CG^OK6BN"HQTQ4-PEQ+;7$<4BPR,I$4@&=O'!(^M8T)OK;3[ M*UO)4EN12T\ M@A6,Q+*R%7C[<9YR.Q]JFTV"VTN.'3?M#37"QY+R??<9/)/Y_E6/:QVTUG/) M96T-WYEPSS*Z1,8I&4''`'()P@J.$VUC]ET6UB144;AYK!.`^"0`.3GTP.13)TEGL=1;,ER3(T0MYOF M0_,.R@'O[TL:VZVNFQM:D&,KL'E+((FW`'YLG!'(R":VB`>HS44MU!#-%#+* MJ23$B-3_`!8ZU-11111111111111114%Z%:TD#)(P('$8RV<\$?3K7F_Q)NI M;KP%K45Q=37#6_DD+]F$:QDS(/F()RV#TXZ]*[G6;GS?8[6=(9P6DF!+ MIR,;,*<'.#U'W0.],ATN5/%$^HO$!&R81Q*"2=J@Y&W(''3)'?&35O6))H=+ MFF@_UD0#@%MH.#GDY''KS3%O5LK33X[M2)I552,@[3@`G(Z\D#CUJ#3)99M: MOS(K81MBN5X(!Z`XP,9`QD^IP>*NW\ZPHB-<)$925"X^>0X)PG(^;\ZH2ADU MFP8Q7!$D:JKM/C:0&+`IW)!&?7`]*TOM)%Z+8PN,J6$A*X.,=!G/?TK.U`S+ M=2"W:QD#NH9+M6&U]O&T@?,.W/ M;M6M86G ML>U3WT#3O;*(C(@ES)A]NT;3S[\XX%49K.]:XO6"M(DL6%4R?+P1MV\@AOO< M\LXZC-J+SPRKO3&R2)9&C\O#')SCG MI[5K+=B/4+*!9)/(GC(CVA2K,`3SQGH*32;!;*YO66.9?-DW?O%BP1N8\%!D MCD\,216I6#:[SXFF$KL"(W,<;'!(WZRJW15BP+#;R"!C."-I/MD\5MV,7D:?;P[E;RXE7*Q[`<`#A?X?IVK,O3;M MXGL0UC>O,JG;<(FZ%.#P<\`^X&><9[5$]]=264MH4G@NQ<&.-]V5/S''SD,. M5[$$C(XJW9P2Z<\LDK.;7RXEC7>\K*0`IR,?F<>YK06/;.S#(4KT[9R?UJ*X MT^&YNH;ES(LD/W=CE0>0<$="..]9$,L4NEW\\%Q<7+,[/Y$I,,D3%B0O9E'/ M&:W+5M]K"^TIN13M9MQ''3/?ZU4>V+P7L%K<$22H1YC_`+P(Y!'W3P<<#XX-;E\Q4<(?+A6/>0^Y5"`8QA1T[`UT2$%%*@`$<`4ZL75A-%-', M[CRC+M0%U4*3MP3D\CAL@AZ5CVFOVUGX<@U&^=E6 M9B1^[*Y))X`).![$]N]6K+5X=3U*06-R9H(8@7"Q_*6)/\77/'3'_P!;$D?3 MM4T-YXH[S2([2YY%M#M^=5X+!>JCU.W&.HZUL_:+1-:FF>=X_)@;>SRXCP-I M8X/`QE>>.O?FH+Z.U75=*:[`^U%V$9$)89!Y.X$;2T?DR(8BQ8(-P!R3QV[>]1Z997EIXF?S9Y9[8!U22:96);"\``YSZY' M8WRBD1G)#?ODS\I//7K75:V9#>Z:V:R M]3F^U6-U#!,\,D(#[XR&((;."%R<';R,=#TZBH;X1B+3A(Z.0%PTZNC-RG.U M0`#[$#!_&GZ=YYUF\Y?[/EMJA<(&SRHJ"ZV?\)%;9L)9&"#_2!OVI][C@;>W.3W'M34M+H>*Y+O[,BVQ@V> M=@!F;Y>.&R1UZCCGM4.I+IAOI?/DU)9@0?W`N-@.T8/[OC./QJMX+QOUW;N( M_M%>7W9/^BP,JPRPUDQ#H/X.WTKK=+DCE MT^-XGWJ1PWG^=G_@7>KE%%%%8=UXPT:QU*6QNKM8FA4;B0?O<_+C'I@_C4]Q MJ5\_AQ-1T^P\VYE@$JP,W*DKG\<'MQFI+"YU6XNC]LTY+.!4_P">PD9FR/3H M,9J^S*N-S`9.!D]:56#*&4@@C(([TM/*=6(=0H(`[ MJ?\`(ZT]F9O$\*,P5A"3LV8R./XL<\]LD?2J=A8I+?W=NN(D=-V%0KU8G.`1 M^O'UK:5[1KB(;!)-&3&LAC&5P.><?=N+Q+E!P#*W0@9Y)''2JMYJ-K:6)BT]([2!) M4"O&55?]8JDC@KCD\GCO70PKLA1?,:3:H&]CDM[FJ=PFF/J]L\[Q?;HE/D@R M8;#9S@9Y^Z?RJHVBRRW-_FZ,<5RRLK0RLC*PZ@[2.WN2<]@,5B341'KEKI@CW?:+::X\S=]WRVB7&,!SG.:1Y$2)I&/R*"Q(YXJBT<&O6,;$R1JL@?`QG(] M<@\$'/XBKTV?(DPGF':<)Q\W'3FN=U*._C\*$S7*6DBOF3;`H7:7XX#''4'. M?6M#3XI%NY7N=62_D>(*L2*J`*">=N3R9.;1HRJD)D?)QG?U/'.T=.O'.EIMJ M/[*AA=64Q2$X:;S2,.2,MW_I^%2A(XM3=]FUI4)9O,8C`P!Q]T=?K^M5;]KM MMJC/?H37I=W,U MO;/*B>8RC(3."WL/?TJ:N=MYHI="U#[6MW(3&4N8G^]G!4A6VKNZ8SBM2[MT MNIK;-Q(B)EP$Z,G'6LKPM7GB"X7;A]20 MC:VX'_1;?H>XKH:***Y:^-]_;TIC?640$8,5G"T73LQY_.NAL2YM4,C3,WHD/"RX1I9@/ MV6UE9`#$)MV]BY/4D M8S_D5J:=9>;>17!R/LTLGS`JP.1C&<9[^U;84AB2Y(/0'&!3JR=1U.2&XAAA MVC=-&A8,"<&10PQ]/Y^U9=OIL;^'6^T:?Y\/VI[@+#*58K@_,>?F)[@]CCM3 M)8)'U&WN0'$6\JN>.`.M6]/A;2KN['#,S,4W?(K%F4`#/09 MX^N>M7]+U*>]O;VWFC1/LQ0#;UYSG//M5F2=UU*"W&`KQNQSCYB,=.<\9].X MJ&U@V:M=2H\;1N`?EA4%6Z$%P6DLLI62`[D4/C=\R M^QXSCI@_AFI(+2U;5WNU5VGA1HBS3,PCW%690"<#.$/3M6C6;;M%=7%Y;3N+ MD.#E6A*KMW,NTY&#C!'7WP.]^&02PI(,890>.E8UGNTW^V)YX_L<0;S1U=,; M>7'UQR`!C`]:;KMTX\)O)<.D4TH0',989W#(VG!(P#Z''-;D?^K7Z"LG2+%; M2._1;WSPTAW^6FTQMC)``R,X*]!V[DU:TBU2SL1!&V45VQF)8SC/=5``_+GK M5FZG6UM)KAAE8HV<_0#-48(DU/27B>)%20E2DD"XP&[K_0]*2UTNVT_5"UGI MEM!"T0S)%$BD-D^G/2LR_M7:TCDCMF18;OS%26'S#QD$@-(``1SQTYXS6TRS MK=33)<23;8V"6A4(I.%/!QSZ9Z?-3]/WFT#21B)G9FV!PP`).,$=L8-4M::> M6WN(K:(R/Y6S&Q6Y)7'KCOU';/:JEM:71ET@NT!DCB'FQ2!2R$?>8!?E'<9& M.2/7%:FIQ>:L`SQ!'S`@@K^%4DTV=]>:2=;8V\;&:,+*QD#'`#%< M#'W3W(K;HHHHHHHHHHHHHHHHJO?7$=K8S3RJ&1%.58@`_4G@#ZUY?\1]2L[O MP)J<5F(8&40^=''=JZ.?-7`11U`SG.`/QZ=]JMH-0UW3+>2:6..#==@1D#+L, M;#Q%.P=W39N.)&*H2%&TKG`/&?H?QJOJZ0+=%[N/4"IP8VLRP'09W;2.<]VX MQCWIGA99$O-?650K_P!HID#'_/I;]<<9]<<9KH**********I)H^G)#+$EI& M!,,2,/O-]6Z_K5VBBLG78I))-,,<;/LNR6VC.!Y,@R?Q(_.IM`1XO#NFQR(R M.EI$&5A@@A!D$5H5E-JMZ'V_V4Q^0N#YZ8P._P"M9NCRW$'A*YDM87EF6>;8 MB+N)/F'MD9J34=]OIFE^:DTJ+(IF&,D<=6#9.`?<8IEOJYM](@:"$O)Y:%I3 M'\N&8#J/J:I6U])A.<'/48QW-*)Y MOLQFEN?MTLR+N:U3(;)4`(K<'C!QTSFK7AF03:AJ6NY@<@G')K*A,*)J8TN.2*:./;N(+9<;L$#G/7\ M:4W$EIH<-Q`"?PQW(%;*DE02,$BN>T:8?9]3,4Z MNT>0"6&%Y?`&SG:#W/S]<]!6CHC[]/R+E+D;V`D6L&TTF]U;1([.^F99+6<[9I(RYD7JN"2#C!P3WQ^-6I9DL] M;OK\6TLDD5LVX*N-P&T@`MUSS]W`XY!.*G@UV.X%E%#9W`^U%MC1*'C14?:= MS#('_P!?'%33L+5[N59I5`Q8#)/!'![\XKH:****************J:F&.GRA-N[C&]]@ZC^+M M]:\Z^)YO)?`.IM.MKM5XV'E781"#N`'"\-U/!XZ5H51UB016(=FE"B://E+N)&\<8]#T/L>]96O/#(VDD*ZQ MRL`JK\K`$IC`R"#^!`PF3^%6[F)I8F M\LA9<85NA'XU1N8"-;@F\B/RR,F3[2RMD!O^6?W6XQSG/MQ45M:NOBB[N6G# M!QA8RN2J[4Z'''()P#W!K,UPVQUIHYWM3(=I1)M.EN&90O0%3C;G)QZU+X+& M&UP`@@:@H&$*#'V6WP`IY`]CTKIZ***R+O1KNYU!YEUJ]MX&48BA91M;OU4\ M'_/M$FAR2%@GB75&*G#`2Q'!]_DH?P[<,%SKVI2`,K;)&0JV"#@X4'''K6Y1 M111111117)-IJM.TG]CVJI&Q9I3:Y,C$\*I!S@#DO4NDJS^$;E4=T9KB4!HW M"-_K3T)[^E699!%HEBBVR2+(RA@4>4`=9+RT6Y_TGR93'Q+)*_RKO/.64X_E[U/I)235UE-\V\E_P!TR<2< M=03T/?K72T5RNJO;MJRH@"L)H1AJ%Z@9V)(5;F55'/8```=@!3M'017%U$5 M9&&TA#(K;5RW`VX[YZ\^Y[7+=0UU<3?,&R(R",#"Y((]?O=:LUDWUY8:?92_ M:Y85$LC$*\GE[R#SR<"3QMS^OT]*FT>+3(K M=QI4BR1%@6*S&0`[0`,DG'`'%6KE(V@D,JLR[""%7=D?[O.3^!J.+3X0D'VC M_2Y8"3'/.BEP3W!``'X`=*;]G@FGN8VE9P^TR1#``.!@Y`![=R:JW&.2>#T&?>DUZ!+IK.!X1<*TI;R=^S>0I(^;(Q_6G6LL MW]JOYEI=1++N`:4Q[..FT!R1QGMSGMTK5HHHHHHHHHHHHHHHHJKJ3LFGRE$1 MWP`H==RY)`&1WKS7XD6K67@#5F8QS2R/%'-/Y!1LB5#M&3@#OA1CCKGKZDZ* MXPPR`0?Q!R*=5(Z5:K`\5N&MR[!M\9RP8'(/S9'YBI/L$/V>WM^?*MRNU2`V M=HP,Y'X^N14D=ND=Q+,"=TVW<#C'`Q4M4[C3DN=0M[QYINX1PNK% M1&Q,EP^GG,A[["!_X\3],UL:9IVH6WAZ:V58XKHS2/'YA#*,N2#QGM5R33V: MP@3`DN(,,CR/]UNYX`S],"LE/#]]'9B)1;^8ZQB5_-?!VD'&WIVZU)?Z#?3& M?[-+&AD"[6W$$8)-6[72;J/4(;I[@*(R^]$SB0$8Y'3KSTK8HK'U'2IKB[B> MW"!#+&\Q>5N0KAL!>F>O/X56FTB],LKPQ1%8HBENLDC9;A@=W7@ECQTQQ@=F MQZ-J8OUGWQI$P_>Q"0D?ZPOP,=N,=.IITFB7R6T@BDW2DAD)G?Y"'!'S')P` MO_UC5G1=-N;"\O9)R&$WE[6W9+8!R3^=:S(&*D_PG(ICP))+'(Q),1W*,\`X M(S^1-2U0UC36U6Q^S+<-!^\5RPWBA$5%&%48`JM]E=-.>WW+.Y#8,W(.22,YSQ MS65#I&J6>DFPM6LEWKS+@HR-V;Y0`Q''8=*OZ%I\VF:<]O<.CNUW8^O`QQCTX^N:DM('@,V]PV^0LO`X&` M.??BK%4KW2X+^%8[@*VR82HVP<$'..?4<'U!JQ#:V]N28((HBW78@7/Y5)2T M5$EO''/+.H/F2XWDL3G'3CH/PK/U71VU&]L;E;B6(VLF_P"5^#Z?+@@\X_#H M:L:B;S9&+2,R9;#`-M(XXYR./7&3Z#-1Z1'J#:3ICZHY%\ELGVM?E^:4H-WW M>/O9Z<>E:-%%%%%%%%%%%%%%%%5=3$9TZ?SHUDCV_,KC*D>_MZUYM\3;6QMO M`VI_9X=,)<1%&M$Q(%\U.3@].WXBO4Z******@$5P+LR&YS#C`A\L<=.=W7U M_.L756M6U%DNH[B]8NJV]J'4+O(Y(&0>!R2W`[,QQ_VBFU#_ M``_Z+;UT5%%%%%%%%%%%%%%%%BBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBJ4FC:7-;36TNFVDD$Y!EB:!2LA!R-PQ@\@'FKM M%%%,\Z+SO(\Q?-"[MF><>N/2GT45&\$3L6>)&8J5)*@G:>H^E)#;06V_R((X MO,8,^Q`NX@!E2T444444444444444444444444444444444450 M.O:,#@ZM8@C_`*>$_P`:GM=0LKXL+2\@N"F-WE2A]OUP:L44444444444444 M44444444444444444444452OKF8,+2S"MG>N!\?>(_B%;:]&GABVOC8&#.^VLTN ME=M[C.X(<'`7Y<\8'K7,?\)7\9?^?;5__!,O_P`:H_X2OXR_\^VK_P#@F7_X MU1_PE?QE_P"?;5__``3+_P#&J/\`A*_C+_S[:O\`^"9?_C5'_"5_&7_GVU?_ M`,$R_P#QJC_A*_C+_P`^VK_^"9?_`(U1_P`)7\9?^?;5_P#P3+_\:H_X2OXR M_P#/MJ__`()E_P#C5'_"5_&7_GVU?_P3+_\`&J/^$K^,O_/MJ_\`X)E_^-4? M\)7\9?\`GVU?_P`$R_\`QJC_`(2OXR_\^VK_`/@F7_XU1_PE?QE_Y]M7_P#! M,O\`\:H_X2OXR_\`/MJ__@F7_P"-4?\`"5_&7_GVU?\`\$R__&J/^$K^,O\` MS[:O_P""9?\`XU1_PE?QE_Y]M7_\$R__`!JC_A*_C+_S[:O_`."9?_C5'_"5 M_&7_`)]M7_\`!,O_`,:H_P"$K^,O_/MJ_P#X)E_^-4?\)7\9?^?;5_\`P3+_ M`/&J/^$K^,O_`#[:O_X)E_\`C5'_``E?QE_Y]M7_`/!,O_QJC_A*_C+_`,^V MK_\`@F7_`.-4?\)7\9?^?;5__!,O_P`:H_X2OXR_\^VK_P#@F7_XU1_PE?QE M_P"?;5__``3+_P#&J/\`A*_C+_S[:O\`^"9?_C5'_"5_&7_GVU?_`,$R_P#Q MJC_A*_C+_P`^VK_^"9?_`(U1_P`)7\9?^?;5_P#P3+_\:J'_`(3?XM?;OL.= M1^U^5YWV?^R4\S9G&[;Y>=N>,],U-_PE?QE_Y]M7_P#!,O\`\:ID/C'XOW,$ M<\$>J2Q2J'CD32$974C(((CY!'>G_P#"5_&7_GVU?_P3+_\`&J/^$K^,O_/M MJ_\`X)E_^-4?\)7\9?\`GVU?_P`$R_\`QJC_`(2OXR_\^VK_`/@F7_XU1_PE M?QE_Y]M7_P#!,O\`\:H_X2OXR_\`/MJ__@F7_P"-5#_;WQ:_Z!NH_P#@B3_X MU3X_$GQ?ASY5CJB9Z[=$09_\A4__`(2OXR_\^VK_`/@F7_XU1_PE?QE_Y]M7 M_P#!,O\`\:H_X2OXR_\`/MJ__@F7_P"-4?\`"5_&7_GVU?\`\$R__&J]!\+7 M=[?^%9Y_%$FIQZM)%']H62!(651-((MB;1U[Y%;7_$U_Y_-;_P#`:U_^)H'] MK^UK[1\WD?Z+;^V>@QZ=:FA_M$RW!BOM:W[QYO^BVWW MMH]1Z8Z5+NU92,WNM=#_`,N=N?Y"D$^J,0OVK6UQP6-C!S^G\JT-&:0W%T)[ MF\FG`CW+=1HFU?:MBBBBBBBBBBBBBBBBBBBBJ$]W-/<&TL-I=&`F MF896(>GNWMVZGL#8M;2*T1ECW%G8L[LI/^<54UE7*V;K+Y8CNT9SSRHS MD8`Y_P`GM3M"(;1X2"3RW+#!/S&M"BBBBBBBBBBBJVHRK!IEU*V=J0NQP<=` M>_:C3K7[%IT%L7=S&@!9V+$GOD_6K-%8'A^6:34]0661V"C@,%6K?_CVB_W!_*I******XS_`)K?_P!RW_[< MUV=8O@S_`)$?0?\`L&V__HM:VJ***********X[Q-;6[>*K"YEC#,C6ZY(SQ MOD/]*[&BBBBN:\0^&[S5]9L+NWOY+>.#AMI&8^0E:&EV>I6U[< MR7,\?-FK>@`C18,]?F_]"-:-%%%%%%%%%%%4=8^: MQ$(ZS2QQX'H7&?TS5ZBBN9TMKN'6+T6EM',"@+^9*8\?O[CIA3GO6PD^J'_6 M6%NO^[=$_P#L@ID5]J$TTJ+81`1/L8FYY)P#P-O3FI'N-052181L?07')_-: MK)J6JO*R'09$"]':YCPWTPWMM;2W#V,9 M6)"[!9^<`9_NT[[5J.W/]FKG/3[0,_RJ*6_U2.,LNC-(1_"EPF3^>*OP.\L$ M9X@LXP M,DO;C'U:2NMHHHHHHHHK*^;^VKS;G/EVW3TWOFM,#EO_;!P8 MU`/_`&VN*W*J67_'Q??]?`_]%I5NBBJFE_\`(-@_W?ZTS6O^05-_P'_T(59M M_P#CVB_W!_*H=6_Y`][_`->\G_H)JW116+XK_P"01!_V$K#_`-*XJVJXS_FM M_P#W+?\`[BV\,EM;I()&(>60,5CQT!"C.3T%1Z#?W&I7U MY<7-D]FYBMQY;DYZN<\@>M;X()(';K2T444444444444444450M68ZS?K_"% MB(^N&_P%7Z*Q_$-[]C731M5C/J,,(+(&QDGD9Z'CK5C0CG1K<\]&')_VC6A1 M11111111115%0)=>_NOL5A/V,>N=G7\*SH[RZM;NZ:6*`0M.&V;).[%P<#GL=G/Z5)ON_- M8>1#Y8SM;SCD^F1MX_,U2TI[[^QX#]GM_,_N^>V,>N=G7VQ^-1Z]/=1:5([6 M\;1@(9-DC,P.X+-`O0/)U6W!/19&\L_DV*UD=)%W(P93W!R*@O+J2U5#'9S7 M6YL%8=N5&.OS$#]:A@U7S;E+>:QNK5Y,[/."$-@9/W6/ZU?HHHHKC/$FW_A+ M;1G.%7[*3]/,EZ_E^IKLZ**3(SC/6LQ=8F812'2[A8)751*7CQAF"@XW9[CM M6I1116+C?^A&M"BBBBBBBBBBBJ&G_`+RZOY^H:XV* M?954'_Q[=5^J]_O^PS>6JL^PX##(/X58K&T9"-2O7W<%0,>F)I_\:V:YN**/ M4?%.HV-R[-#;&.X2,,5RS(%R<1`OH"Q8?HPK3JII?_`"#8/]W^M,UK_D%3 M?\!_]"%6;?\`X]HO]P?RJ#5\_P!C7N,9^SR8ST^Z:SM(L;35M/BU2[0SR7JB M5U9R4&1PNWIP..G.*SM2\/:5:W-W*EA$GEHEY$R`K@H?G48[8`_[Z-==6+XK M_P"01!_V$K#_`-*XJVJXS_FM_P#W+?\`[^37$ZM:_#D$XN#&[?\^;.W]"HKB]331E;_B5S7K@ M'G[1&HS[@@_TJM;75W:R9M+B:%VXS$Y4G\J^@823"A.2=HSGZ5%;V<=M-V%%6*****XWQ$,^+K4;=^?LOR^OSS<5V5%%2`!D9SZ] MCZC'844452U=0VES*P!4@`@C@\BL'P7IMA'I$&H;`LR(I+[B`O[I<\9QT.<^ M]:EGXJT*_NC:VVIPO-G`4Y7_P#; M/^57**R=>A>4:D0(ZE6&[(88/WC5^BBBBBB MBBBBBJ>E`BP#$Y\R220?1G9A^AJY574HUFTZ>-G1%9""SG"@>YJU63H__'Y= M_P"?^6LU:U<]=0O8^+6U**)I1)9;9(U(W%5;EAG@D?(,9'!J'5]H-<[X=FETC1K?3Y;::?RY'BB>)1\Y!.02YZI:H5_#Y!4UO MX&\3:E)YDMJ8RW)DN90"?YG]*W+/X4R'!OM45?58(\_JM-ID@ MENF'>:0_R7`K>L]+T_3UQ9V4%O\`])K9EP-_V M9%)]=\O^(KL***JWMK-FRM[(Z7+9A74D\/G&!Z9K;HHHJGJW_`"#9?P_F*QO#]D+_`,%FRD9HUN(!&2!R MF8U%0Z!X#L=,L+FWOQ%?/<$98QXV@=-IZ@]\BK23WGAIQ%?227>E$XCNFYDM M_:3U7_:[=ZZ!65U#*P96&00<@BEHHHHHHHHHHHHHHJG;?\A*]_[9_P`JN451 MU.X>V6U9)DBWW,<;;A]\,<;>AY.>/Z=:31)'ETB!Y&+,=V2?]XU?HHHHHHHH MHHHJO8`#3K8`8`A3`'T%6*JZD5&G3EU++L.0#C/XU:K)TC'VR[P,?_O9JUJH MWVY+VPF4?\M6C<_[+(3_`.A*M68K>"`L888XRQRVQ0,_E4M%5-+_`.0;!_N_ MUIFM?\@J;_@/_H0JS;_\>T7^X/Y5+69;V]O<3WUI<01S1QW`D5)%#`;E!S@C M^]N_.M%(TC0)&BHHZ!1@"G5B^*_^01!_V$K#_P!*XJVJXS_FM_\`W+?_`+I=:(B^ M6\&/^>LJK_,UFW'B[PY'&PEU6V=2""%._(^@SFN?T_QEHFE:BEG:7K2Z9,3M M#QL/LK>Q(Y0^G;Z5W2L&4,I!!&01WI:*************IVW_`"$KW_MG_*KE M%8_B#R1_9CS1++MU&+:IDVX8Y`(XYQG...E6=$0IH]N",'!/YDFK]%%%%%%% M%%%%5['_`)!]M_UR7^0JQ5>_9UL9FC(#A3@G&!^?%6*YVWU$:9J-U%=6TB%N M5)>-0P,LI!&6'&"/>KO_``D-I_=/_?Z+_P"+JI?ZU#.MOY(P8YT=LSQ#Y0>? MX_2M>RO8K^%I8@P56*G.#S[$$@]:LT5A6.N6T%FD+HP9,JJMQ8+%I-U;60:!Y8WVM&3N#D?>SUSFO M,M#^'^H:[8IJ,UY';QSY9=REW;GJ>G7ZUNP?"FS4?Z1JD\A_Z9QA/YDU?@^& M6@1#]XUW.?\`;E`_D!6A;*?#$T=F\C/I4S!()';)MG/1"3_">Q['CTK?HHHH MHHHHHHHHHJG;?\A*]_[9_P`JN45F:R(BVGF7(`O4VL`3AL,!T(ZYQGD<\C%/ MT)=FBVR^9YA"G+8QDY-:%%%%%%%%%%%%060*V-NIZB)1^E3U6OT1["9'W;67 M!VC)_*K-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%(&!R`0<<'!Z4M4`#;:R0N M?*O(RQ]!(N!^94_^.5?HHHHHHHJ"SM4LK1+:,DI'D#/IFIZ*@O;>*[L9K>>' MSHY$*M&,98>@SWJAX;&I)H\<.JPO'/"Q0%W5F=!]TDJ2,XX/TK6HHHHHHHHH MHHHJG;?\A*]_[9_RJY16'XGQ_Y!]M_P!>N,9]ZT?[2L/^?ZW M_P"_J_XT?VE8?\_UO_W]7_&@ZA8R`HM[;DMP,2J3_.K5%%%%%%%%%%%%%%%% M*X,DEPFX;S(,=`">23CCZ5TE%8'BIV5M%57V;M5 MA!/."/F../7_`#CK5[0"K:%:,F=ICRN<],\=:T:**********HZMY/V0">;R MD9\?,Q57.#A68=`3CZ].^*SK"66.*\33HU*1P$I"K[DCEYPH/(Y&W(!P/QJI M%+MNXVM`78LGEW!G+/<-D>8KIU``)X(^7%=#J()T^<"3ROD/SY(V^^15FBBB MBBBBBBBL6Z<2ZAM7-(E>;3U9Y3,H=A' M*1S(@)VM[Y&.>_7O5ZBBBJ]_)-#I]Q);C,R1,R#&?F`XX[UGM?3"PMI%NX7> M29%B,;!_M"Y&E;%%%%%%%%%%4]2D*0(OVC[.LDBHTHZJ#Z$\`D MX&?>LRP:[MM4CA,SR13.X$;M(S;`,ASOY!SA3@X.[-1:W>2:;?WMP;9VCEM( M$$S1;XD(DDW;N1V<&JIU+35(#:SI0)Q@&PZYZ?Q4'4M-&4:;%+L!9!IX.P]QG?Z MT\>'Y`,`Z8!_V#1_\52G0)2,%M,QG./[.'7_`+ZJ*X\,O<0/$9;&,.06:&P" M-P0>#N]JWQP,9S[TM%%%%%%%%%%%%%%%4940ZY:N44L+:;!QS]Z.KU4;5$75 M+YE4`MY>2!UXJ]16;K%L+AM/^4,8[Q)`"VT\`\C@]!DXXS@BI-%54T:T"8V^ M6-N#D8[5>HHHHHHHHHHI"`P*L`0>H-(D:1($C1411@*HP!5.**-=))'BC+,J`$DEL\_@*T:*********;)&DL;1R(KHPPRL,@CW%9^BVEO;6 M\K0PQH6GE!*J`<"1@!]`.E:)`8$,`0>H-9MGH<%I*93+)*Q))WG(;/J/;H.G M`%7OL\'_`#QC_P"^15698AJEI#'$JLH>8E1C``VX_'?^E7Z***********Q; M7_D>-4_[!MG_`.C+JMJBBBBBBBBBBJ;_T*.KE4[;_D)7O_`&S_ M`)5L.35=3NKR: M'3[0JD/&^6-7W'6BJ03SU$V1]WJ"#CBKFBZ&L4,DEREW#([_`'#>2'@="<.?4]S6B=*M6SN\ M\Y&#FYD.1_WU2_V58Y)^SKS[FL(*MS/*UIH"M$CX5W@C8MP#GF0>OI2/:22- MN?PO`QQC)LH#_P"U:O'>IK2Q9I$N[Q$6=T,7\WK+BU?6+P/-::>H@ MWLJ>8!N(!QG[WM4PO==W_N*V8'DDM MXWEC\N1D!=,YVG'(J2HYIDMX))Y#A(U+,<9P`,FJ<>KQ3('CM;ME/0^0?7!_ M*E@U`S:G]F,4T:F'>OF1EQMY0TEY=*!-4_P"P;9_^C+JMJBBBBBBBBBBJ_]L_Y5''K]Z2G:D(VTZ<2DA"AW$#)Q]*M5CZ(XD MN+EP,!AG_P`BRUL52U!P)K%/XI+D`?@C,?T!J[1169H7_'F_^^/_`$%:TZS- M8N1;R6`P[,USQ'&NYGPC'`'UQSP!WJ>VM7,YO+L*UP1A%'(A7^Z/ZGO]`*N4 M5@^$&!TAAM`PZ@GU_=)6]5*]8_;M/08)\YF/T$;C^9%7:*I+_P`A*[_ZX1_S M>HM!_P"02G^_)_Z&:TJI3L3K-H@&1Y,K$^G*#^M7:*IZM_R!KW_KWD_]!-&E M?\@Z/ZM_Z$:K.J_\);`V_P";[!(-N.@\Q.:U:**H:.[/:S;OX;N<#Z>8U1ZG MKUGI5Q'!.LK/(!M"*#G)(`Z]>#^52&]OI#MM],=3_?N)51?_`!TL?T%/MK%U MF%S=RBXN`,*0N$C]0H[?4Y/\JN4444445EV]Y._BJ_LFDS;PV-M*B8'#.\X8 MYZ\A%_+ZUJ44445BVO\`R/&J?]@VS_\`1EU6U11111111115.7_D-6W_`%[S M?^A1U>6*%G2%`,L[<*>3@`!7R3ZB MJ&XC$D,JR(1D%3D5)69H M7_'F_P#OC_T%:MW=V+9`J@23R<119P7/^`[GL*P)&>SUPR/NO=3%HVQ$S@LQ MX51G"JNSDG^\,\D5)-XCGTD0RZM"RP2.$=UMF3R21G).Y@1GC@_G70I(DJ*\ M;!U89#*<@BG5@>#R3I4F3G]XO_HJ.M^L._OQ'K;+#&9[FWM&\F%!DLSG///` M&Q>3C[P]:KS>)GTJ2'^UXW6&5MAF%J\8C/;/+`CKT;\*Z,$,,@@CU%4U_P"0 ME=_]<(_YO46@_P#()3_?D_\`0S6E6%<:@4U>\^SQ&>ZCB6*.-5SC^)B3V'S+ MW&<4P>*$L[^*TU-6B6?B.X-O)$F[/W3N''U!(^E;]5-6_P"0->_]>\G_`*": M-*_Y!T?U;_T(U6D8?\)9`OEC/V&4[_7]XG'^?6M6BBJ.DG-K+\N,7,X^O[UJ MP/%40EUJQ!!P)(SD>RSG^E=;111111116+:_\CQJG_8-L_\`T9=5M44445BV MO_(\:I_V#;/_`-&75;5%%%%%%%%%%4I<_P!M6WI]FF_]"CJ[5.V_Y"5[_P!L M_P"57**SM6@BGEL!)-%&R72O&')RS`'@8/)QFCP]_P`B[I__`%[)_(5HT444 MG2J=]JD-BT:M%<3-)N(6WA:0C&,YQTZBGV-_'J$;O'%/%L;:RS1&-LX!Z'ZU M:HJD=3B&MKI6Q_-:W-P'XVX#!2:,+DXSA@QQP>0`3^% M5]%TNTT]KR:UCB07,Y8^4?E`'&/;D'\2:U*Q;6U6/SK>*$8W27$6`2!G:X<]>O"FJV@Z5:Z<+R2UACB%Q<,V(SE< M`X`QT'0\>]:U8?A2-HM-D1L9$BY`(./W4?<5N5SVAJ9/%&NW,F=^^*.//]P` MCCVR#^5:.KA98[:V**YFN8P`PR,*=Y_134'ANPM+&QF:SA6))[B1\+G&-Q5< M>VT"K2?\A.[_`.N,?\WJ/0L#2U`(($DG([_.:T:P?#,9:;5;J2=9I);QE#*" M`(QRHY`Z;CS^M7-5CBN;JPM)8DE5Y79T<9&P1N"?S91^-1^&;."ST*W%O&8T MG'G;22<;N0.?;%6]5!;2+Q0"28'``')^4TFE?\@Z/ZM_Z$:@DW?\)3!^]&W[ M#+^[SR#OCYQ_GI6G115/385@MY0L@??<2N2.Q,C''X=*P_$V!JEHV.1+&.GK M'<5U%%%9NIZG-87-I#%9F<7#$,P<+LY4=#UZG@<\&M*BBBBL6U_Y'C5/^P;9 M_P#HRZK:HHHHK%M?^1XU3_L&V?\`Z,NJVJ**********SY6'_"0VRX&?LDQS MC_;CK0JG;?\`(2O?^V?\JN45D:\\$;Z>TUXMN5NU9=Y(#XZCCV]:F\/D#0;- M`P8QQ*C$=,@8/ZUHT4456U%/,TVZ3#'="XPHR3P>GO7*6LEI86T(UBW>V5I6 M:/;=_=PJ#DIM!)R/E(R`":ZC2IX[G389HEVQN"5&\OQD\Y/7/6KE%4SIL)UE M=4W/YRVYMPN1MVE@V>F5..@; M@CW)_#>K#\.Q1Q-.(]A#(&+*,;CYDO/05N5S_P#9S:G]I*RA9(+]V4MNY&P+ MMRI!`Y'0]AUIG_"-75U?)/>:GZV;@AS@>A8@<#^>#BL_P`,V4=G9S;6 M62267?+(JX#,54\=\<]__KG9K".E&\C+1R[)(+N9@2S*6#$Y&Y2".OKV'!J( M>&[RYODN+O5KF**)2L4$$Q)4D8)\PC/]?>MC3;!-,L([..6658\X>9MS'))Y M/XU:K"\(A5TAE0`*'7'RXZQH3^I-;M80TQ[N-9X7V217-QGYF0N"[#&Y3D=/ MIQTJ)?#M_=7WVJ^UBYC14,<4%O)R@.,G?@$DXSTSVR:T(?*T6P@T^)I[N6-, M1(S!I'`[D\`#D#)P*EM;::,3W%RX:><#*K]V,`<*/7J>>^>W2H/#L:1:-&D: M*B!Y,*HP!\[5J5S\6DR3V]CF['/;L.G>MZTMUL[."U5F=88UC#-U(`QDU#JXSHUZ/ M^G>3_P!!-5=*TO3_`.SH_P#0H#RW6,?WC4<5C9VGBJ)K6"*%FLI-ZH`NX;TP M<#OG/-;5%%5--*FVDVG.+B;\_,:N?\42I'J]FK2(I:2,A6."?DG''XL/S'K7 M5T45CZTX74-.#17+#>Q+03E`.5'SC/S+DCKTQ[X.Q11116+:_P#(\:I_V#;/ M_P!&75;5%%%%8MK_`,CQJG_8-L__`$9=5M44444444445G2_\C+;?]>W7BK-[7(SS;/Q^E4] M.NO(DO/-MKI1+<-(A^SN<@@#T]JN/J<:+E;>[<_W5MGS^HK+F\2RO-+9VVDZ M@MP`"&>$%54DC=@'/8X'&:DM=26T?R4TC5&W?-)<-""7;'5NG<59_M&'_GE<_^`TG^%0Q:P))61]/OXE'1WMS@_3&3^E+_`&NOVCROL-]L M_P">OV<[?\?TK&\,ZG!;:&=F!X7T(IL_B%)6-OI\%S),'"2.UI+M@[Y8 M8R3CL/Q(ZTW3[ZWMY)5DLM3\\\R7$UH[&7KT*@X`[#C&>G6II->B$DD1T_4@ MJ@_O?L;E3],#/Z57T?5(+>P$+Q7;,LCY,=I*Z_>)X95([U>&M6S$#R;[GUL9 MA_[+4.G:C%%8PPR07BNJ<@V0X622SD"-P>^.![G%:>E?\@Z/ZM_Z$ M:K2B3_A*[4D8B%E+@[1RV^///Y5JTA(4%F(`'4FJ']JI.=NGPM>'.#(A`B'U M<\'_`(#DTFA-(^E)-+MW3222@*20`SLPP2!D8/I6+XHB5]6M'(^821+U/3;. MV/S53^`KJZ**8\,4K(TD:.4.4+*"5/J/2GT4445BVO\`R/&J?]@VS_\`1EU6 MU11116+:_P#(\:I_V#;/_P!&75;5%%%%%%%%%%9TO_(RVW_7G-_Z'%6C5"S? M=JFH#^ZT8Z?[.?ZU?HJ//[_'HO\`6H-0=EM)BK%2(9""#C!`KF;"?Q@QT\*; M62!XHSO*DJ4*Y)8D[MW3IW(]Z[&BBBBBBJ]Q?VEJP2>X1';E4SEF^B]37.:[ M=:A=WUM_9D=Z(E!+GRI8P20RX^[_`+0/.!P.:ZNBBBJNHB,VA\T,5\R/A0"2 M=XQU]\5:KG_#*[)KL9!^5#Q[ES_6N@HJE=7$TDIM+$IYPP99&Y$(/MW8]A^) M]YK2SBLT98\LSG<\CG+.?4G_`#CH.*GK'\,'.DANQ*D#T'EI6Q11116#X0!& MD-G'+KC'_7).M;U9,%[=:N76WC>TMT=XWF8`NQ5BI"#\.2?H,]1HV]M#:0+# M`@1%[#N>Y/J3ZU+37_U;?0UGZ#_R"4_WY/\`T,UI44454U7_`)!%[@9/V>3C M_@)J+0SG2D.`/WDHX_ZZ-5&^O+:T\6VS22.7-E(OEHA8GYTQ@#DGKV[5?$NI M7?\`JX5LXS_%-\\A'LH.!^)/TI3I-O+()+MI+QAT$[94>^P87/OC-+JDC0Z; M(D/RR28ACQQAF.T'\,Y_"K44200I#&-J1J%4>@'`KFO$O_(3M/\`KK%_Z+N* MZBBBBBBBBBL6U_Y'C5/^P;9_^C+JMJBBBBL6U_Y'C5/^P;9_^C+JMJBBBBBB MBBBBJ$ZA=)+D2A1:S1Q?-W5SN"D^QQCZ@ M>M;5%,Q^]SC^'&:KZCQ93G`XAD_E3='`&BV(4Y`MH\'U^45=HHHHHK/EGEOY MFMK1VCA0D37*D9R."B^_J>W3KTLVME;6:D01!2W+-U9SZLQY)]S4]%%%%5[X M.;*3RD#R`912,C<#D=/$.<)(Q!(Y/E`C]*55\0$_,[#Z>6>U9^@#65TO;# MRHV[3\A_@7%:O_$[#%N3G'RD)@?K3MVL_P!W_P`=3_&F1MKV&\U5SN.-JKT[ M=^M/W:S_`'?_`!U/\:-VL_W?_'4_QK&\+G5!IKB$<;USPIY\M/?TQ6SNUG^[ M_P".I_C3(H]5@39%$$77@':>J(?\`V:J&BG7#I2^7M'[Q\%D0_P`1_P!H=ZMN_B09 MVJK8`Z0IS_Y$J,3>)LC,/'_7&/\`^.U7EU;7K(0)>PLLLQ`41VR,"W`P#YOJ M>!UP#Z&K9F\2=1#^'DQ__'J@U"?7QI-Z)(,@PN,F%!QM/I-Q^1K.TV'Q+=VD M+/+);PHSYBM43#MO.[+&4'KGIBM+2K:2W\2J);3R&^QOAQ$`9?G7.YO,?)'' M7GDUTM%4+H>?JMG!_#%NG;\!M4'_`+Z)_P"`U?KF/$O_`"$[7_KK'_Z+N*Z> MBBBBF--$DB1O(BN_W5+`%OH.]"312,525&(ZA6!Q3Z*P[1T/CG50&!(TZS!& M>A\RY_Q%;E%%%-=UC1G=@J*,LS'``]35&UM(VUBYU>&Y65+JVA@"I@@>6TIS MNSSGS<8[;??C0HHHHHHHHHHJAJ0VW&GR]DNL$\]&1U_F15^LR6WCGUBYAE0, MEQ9HK<\X5G_^+ZU8TZX:6!HIC_I%NWERY[D=&_$8/X^U6ZI@2?VTYS^[^S+Q MNZ'<>W]?:EU+_CQG_P"N+_\`H-&EY_LFSSC/D)T_W15NBBBBJ>J3R061$!Q/ M*RQ1'&<,QQG\.3^%3VUO':6T=O",1QJ%4?2I:*****K7\4LMH5A`,@96`9L` MX8'&?PI6ENALVVR-D?-^]QM/Y&Y+D7%\/(SA$VEI.O+8[<"MSS;SRMWV M5-^[&WSN,>N<4[S+GSE7[.OEG&7\SD?ABFB6[V.3:H&&-H\W[WZ<4&6[V(1: MH6.=P\W[OZ&IYET16%H[';S'7[)(54$AMRX;V'.?SIAN;CRMXL9=V[&S>F<>O7%8?A*><6! M1;5W5G3=)O4!?W29[Y..*W?M,^'_`-!F^7I\Z?-SV^;^=#7,XC5A8S,6SE0Z M97Z_-3A/-YI3[)(%&8R_9)-J@X?:;]IG\K?]AFW;L;-Z9QZ_>Q3O/E\Q%^R2;6`);< MN%]CSG\JIZG/.^CWX-E*I\AP,NG/!'][\>:9I5Q(FDP%+"=MS.652@*G>_O)\@D%81CT4;OY MN:N5R7BNVGEOS*HHI/&%L[7\T00#>Z MHY\CC/RD>O'YUHZ-J.BZ=>7CBX8*6"PDP/\`)]')P+L_C$X_ MI3E\2:0YP+SKZQL/YBLK1V%WXPUG4(,M;2V]K&DF"`S*92PY]-R_G74#/.?7 MBEHHK"UZY>X#V$!&%*B0XSF1C\B?^S-[#WK7M+:.SM(K:(82)`JY]!4U%%%% M%%%%%%4-9!&G^8,_NI8I./174G]`:OU0E&-?M6`7#6LP)SR2&CP/U:DU!39S M+J<8X0!;A1_%'Z_5A%4@?^)\ZYZ6JG'_`C3]2_P"/&?\` MZXR?^@T[3O\`D&6O.?W*<_\``15FBN:T:XU63Q?JL-U)FWCC7Y,\)ECY97GN MN<^X%=+167K<6I.MK+ID,$LT$V\K.Y48V,O;_>JC]J\8X_Y!NF_]_P!JBN7\ M97$)C%E8PD_QQW+`C]*J0Z[K.@;H=7L/M'R"5Y()6?RU^Z2SVUXL%Y9:E-!,"8[BW>=#D!G/?TX-:.E65OJ-FE\EUJRQRYQ%<7+JR8)'0'V]:M?V'%YV_[?J.W_`)Y_ M:WV_SS^M4/#=C%+I@9WF!&P?NYW0'$:=E(Y]ZU_[-@_YZ77_`(%R_P#Q58;7 M"6Z!2]U-++=3(H^U3$JB$\[4)8XP!T[]:KMJ#V]\+>]L=6:)U)CN+:2G/(\MRA#(N(KAT!Q%'S@'K6S_`&1!_P`_%[_X&2__`!58 MOZU5T;3HKFP\QIKM29'&$N71?O'H`<5?_LB#_GXO?_`R7_XJL9[Q M;>*S037$T\\;.Q-S*=N./NH"223TP!P>_%:1T4$@M=R,5Z$P0Y'_CE(VB(S%CHKA?%>M3V/B6"V2ZU"*%PID6!T!.1@;`0?Q_&M32HGO;JZB.L MZFRHP,19E&Y>Y^[SSD?A6H='<]-5U`?21?\`XFC^R'QC^U=0^OFK_P#$U6TX MSPZG?664,Q!(SG/(`K;HHJM?78L[?>%WRNP2*//WW/0?U/H`35&T MMB^I!&<.+/,DK@8WSN.?R4\>S#TK7HHHHHHJ,S1+.D!E02NK.L98;F4$`D#N M`67)]QZU)111535HFGTB\B099X'"_7:<5/!*L]O',IRLB!@?4$9JK>#;J6GR M8'+O'G/(RA;_`-EJZ1D8-4-/#6&<(]U(MLR&,,&&2W]X$=^>>O2LJ#7];N[B6V%K93&)<.R1RE2=S*1@CIE2 M*A:RE1"[>&]("J,D_8GX'Y4V&W:X@CGA\.Z0\4JAT86+_,I&0>E/^P3_`/0M MZ1_X!/\`X59@T.YF3?\`V#H,?.,26Y!/OC%2?\(]<_\`0&\._P#?@_X4A\.W M!&/[&\/?]^6_PI?^$=G(P=%\/]^D3#_V6A?#DFW#Z)H!`Z;8V'_LM"^&BL93 M^Q=%P3DX+\_^.T[^PKU+:>WM[+2K47`"NT)<'`.?3Z_G72T44445@>&UE6XO M#*Z/E8]NU<87YL`\G)]ZWZY[2V:/QIK4-DW?W"">/;)/YUIZKMC6VNB0K0W"88G M'#'8?T8_E4/AZ\MKNQE2VG25;>XDCRA!`&XE>G^R16F_^K;Z&LSPVS'1U5V5 MI%DD#;00,[B>_L16K7/^%MJ2ZM`8VCDCO&`#=?+QA?PX;'XU?U+;#?:?=EP@ M21XW8]-C(Q/ZHI_"F>'+F&YT.W$$RS+`#"75LYV?+G/N`#^-7+_/]G7..ODO M_(UDZ(-5_LQ=AL]N^7[P;.?,;/X5.?M7_"0V7VD0C_1Y]OED^L?7-:]4-7/F M0168P3=RK&1ZI]Y__'58?C5^BN4\3PH^LV359B!;PJPMR3QM_BD_'&![#WJ?2U/V)9G0I)<$S.IZ@ MMR`?<#`_"KE%%%%,F$9@D$IQ&5.XDXP,<\]J\^DBT/4YFM]*NA:PJV'O;F_D M'_?M"_S?4\?6MVQM[6T\1Z+!9W)N84TR]VRF3S"Q\VVR=WUS73T444A`((/0 MU1T3C1;-#UCB$9XQROR]/PIVH?++8R8'R7(Z^ZLO_LU7:IZC;R2PK+;_`/'Q M;MYD?.`WJI]B,C]>U9>L3&^;19[5#(!="?9A=^T*0>&(Y&[D=1^%4_!LZW-S M=7"#"RH7`/H;B*2-S#--;LLPSQVKH8XTB0)&BHHZ!1@" MGUC>%B3HZYQ_!C'_`%S2MFL34+%GUOS()&AN)K5O*F4_<=#T(PH_Z91UOUB7UBSZVTEO,T%U+:DPRJ1PRG!!R""#N3M_#Q56Y\ M-W&LM`FJR.+>)_,=!=%_-/H1M50/I711Q1PKLBC6-P2ZK+(UO;DN(#<%Q(W8L-J@`#L/7\^ABBCA0)%&L:#HJ*`*BOO^0?<_]Z?+:V__CTA_H$_\>J_ M17+>)6QJUFOK)&?_`"'OR`&K>:.>58H[FX@6.+]1>&H4CFN2@( MX/WFW'_7SYYK<=>N*WD5UC"M(7;^\0.?RJA>QSB]L93*K(LX&S;C!*,"0<^_2 MK:1W(SNN%;Y@1^[QQW'6D\J[V(/M2;AG*=Y=QYQ;SUV>/*3C&:W`DP*9F!Q][Y/OO/:KWEW6V,?:4R&RY\K[P].O%2R+(3\D@48/5<\]CUI-DOD!?-' MFX^_LXS],US_`(5%W)8*8[B-(8V16C,.2W[M"?FW>_I6WY5X`^+F,D_=W0Y` MY[X89XJI?0W9FL&6YC6?S73>(3M(*,?N[O\`9]:NB.X\TMYZE.<+Y?3\N06.:)$N\@B>'RPOS`PG)]<'=Q^1K-\/K>'1L?:8#)Y MC`?N3A?F.2-VSU2,J,?0DTC+?V5$(I88SOE+;X2V?WC8QAABHY)IAXPMH M)3&T?V25XRJ$%?F0$$Y(/Y"MJJ&D_O89KP];J9I!_NCY4_-54_B:OT5R'BLM M_;EEL^_QCZ[)ZZ^BBBBBBBDZ=:RX,'7+[!).R+KT[UJU!=W26D!E8%CD!5'5 MF/0"H["V:!'EF(-Q,=\ISG'HH/H.GYGO46G@W-SU8MYX4TZX<2VPDL9E<.'MFVC<#D$I]T\^U9VE7<][XBTF6 MYD$LJV.HQL^P+NVW%NN<#Z5UE%%%%4K,".^OH]P):19<<\`H%_FAHUG=_8UV MR_>2)G'N5&14FN@I7JV=I[^?/FM:\_X\I_^N;? MRJ'20!HUD%&`+>/`]/E%7************K7^?LIQ+Y7SIEMVWC<,C/N.*LU@ M-H=[;7DTMC=,(Y%&$:8K@C/'W3QSQ0NEZYC+:BV<=!-D9_[]TCZ3K$K(9+LX M3YAMNNC8.#_JZU=-ANX+)8[V;SI@22V<\9X&<#/Y5;HK"BT:_L&D33[ME@)R MBO*O'`&.8SZ=<_XU)%::V7(FO,*V`2DRY`[X_<_X4DECJTNS?.3Y;!E_TA>H M_P"V-:-A'=QVH6]E66;L2VTO5+%'AM[MFB\QF0M*BG!.>1Y1_G M4CVVMLI"W14^HG3^L%56TW7Y'262[/F19V$749Z]?^7:MZW$JV\2SL'E"`.R M]"V.3^=24R:(3P21,2!(I4D=1D51MM)DM;?R(M4O-N202(B1DY/\'J::EG(N MN13R7ON14EO`EM; M16\0PD2!%'H`,"I**Y+Q3"7UFTD^T01*JC/F.RM]V4<84C."3_P'WKK:**JK MJ5H^I/IJRYNDC$C1[3PI[YQBK5%%%8WB+0GUN")4N#&T;9V,6V-]0".?2JNA M:6=+O[VV>ZDN,)%\[DD]#QR3Q71UGQ-]OOS,&!M[8E4X^\_0GZ#I]<^E2ZE- MY5FP5L22D1QX_O,<#^=3PPQV\$<,2[8XU"J!V`X%2444444R;;Y+[W*+M.6! MP5&.M<<5=MM.BTKQ5I-I"\CHN MGW[;I6RQ+36S$D_4FNEHHHHJE&NS6YV[26\>..ZL^?\`T(5->Q>?8W$."?,B M9<#KR,4ZVD\VUBD_OH&_,5+5:ZF,;4[G2[?1K2&"&0W$>V1I9M@C"H"3T/'O]/6JVI: MO?KI[7-IJ%M(T+*[+!;LP=0H/N*M M44444444456U`H+7,BLP\R/A3@YWC'ZXJS111111115.ZU.WM3*C;WECB,IB MC0L[*"`2!WZBJT6JW=ZIEL+%)(0<9FF,39[C;M.*O65PUU:),T8C9LY4-NP0 M<'GOTJ>BBBBBBBBBBBBBJV$75`?F\QX3CC@!6_G\WZ5%>LSWEE:KCYI#+(#_ M`'$'_P`44J]117'>,',6KVDBD;E7('TCFKL:**RX[K=XEFM?[2W;;=6^Q>1C M9S][?W^E:E%%%%8>J&]TR6\U2&.":'RE+*\C*PV^F%(JIIWB=M;462QBVNY6 M8$*2VR,8RV2.O/%='!!';0)#$NU$&`*IG_2]9"_\L[-=Q]Y&!`_(9_,5H444 M4445%=1&>TFA4@&2-E!/;(Q7-)I/B:,Z?A]*_P")>I6/)D^;Y-O/X593[9_P MEND?;_)^T?V;>[_(SL_UMMC&>>F*Z&BBBBJL@_XFL!QU@D&?^!)5JJVFJ%TR MU4#`$*#'_`15FJEX`9[4D9_>?EP:YWP3$(;B_15`"?+ZD8FF[^E=/>?\>4__ M`%S;^5!'>%4AAA;&Q4:)F#`'J=Z$=^WI765A^&HF@CN@D*Q6 M@91D^G)JOI&IOJ7G,3$R` M@QM'W4DX[^V?QK3HHHHHHHJ"\$C6^(E#-O3@@'C<,GGVS4]%%%%%%%%<=JLK MC7]77)C/V-2C`<,!@G++D@KG/0GG/3J>1<3Z=8G3YY%#SJ[O&\K;BRJ2Q9!S MR23N&.:Z7255-/0*,#>Y_$N35RBBBBBBBBBBBBBJ[*_]H1L$&P1."V.ARN!G M\Z@M3]HU2[GZB';;I^`W,?S8#_@-7Z**X[QH%^W6A'WBK`_3RY383@<``=_QKI)IDMX7EE8*B#))-5=(B=;+SI05DN',S`]1GH#]!BKU%%%% M%%1W$OV>VEF(W>6A;'K@9JO9ZE;W5E!<&6.,S1J^PN,KD9Q5"X=7\:Z4R,&4 MZ;>X(.1_K;:MNBBBBJ-\WEWVGOQAIFC)X[QL?YJ*O55TT_Z!&N,;,IC.?NDC M^E6JAG'[R$\$U*W>H9QRQ/`Q_RVGK?O/^/*?_`*YM_*LI=,O[NTA^ MT7%@Y$:A6%FX=>`>&\S(.1G(J%_#%U=/_IWB"_ECQ@Q1D1J?KUS6C'H6FHJA M[59]H`7SR9-N/0-D+^&*NQ0Q0KMBC2-?15`%8WAY]UQ?8QM#`+CTRQ_K6Y11 M11111534E1K/#G"^9'VSGYUXJW111111115*[TFTO/.,B$/,A1G4^H`S@\9P M`,XZ#'2JUMIU_IRF*QFMVB9B[>0G*GA7"XFB:\1G9B`.6Z_ZZ:NCO/\`CRG_ M`.N;?RIFG$'3;4JS,/)3!;J>!UJS116+H`VSW:[-H!`!S][YGY_I^%;5%%%< MV;W6M2NYOL.((H]N!YJ`D'N.IRIJ;R];_YZ?\`CZ?_`!%1S/K,)C#.3YCA!ATZ MG_@'M6G8"[%MB]*F7.@':K-%S#);+(%0;4)(VJYZ8!K MP[BM^HKF01PG]XJ,WRH6.!N/`_6G0HT<$<;.795`+'JQ`ZT^BBBBBH;R-Y;* M>-!EWC95^I%2:XG\6Z1)=6WV:8Z M;>[HO,#[?WMMW'!KH:****H:V"=$O&5=S1PM(H]64;A^H%7ZHZ?QGXU9K)T'[DW_``#^5:U4K]LW6GQY/S7!)`QT$;G^>*NT M45B>%4*:6RMUS&?SACK;JE?'=>:?'@G,Y8@'L(WY/XX_2KM%%8'@_']E28SC MS$Z_]H["YDE$EO<[1C`]''L?T(([5,C')X:G> M''636M)D7)5[75&4XQD&Z@(-=I11113)HQ-"\3?==2I_$57TJ7SM)M)2>6@0 MGZX&?UJ.URFK7Z8`W".7@=I'!'0]15Q=8T[5+.1K:4S"*6-9 M$`*LC%A@$$<<_P`C6M63H/W)O^`?RK6K#OKV1_$/V2T3S;J"S9XU)P@+G&YC MVQM'`Y.[IW$$]_K&C103W4-Q>1EU2<#RB1NX!4J%)^8@8*_C6OI^K6.JK(UE M<+-Y1VN`""I]"#5RL/PHQ;2V).3N3_T5'6Y6+>7`^WJI/8CM5RL'PAM_LAMIR=Z[O8^6G],5O5AW=Y*^ORVUG'YEW!9GR MP3A$+GJQ]/D7ID\FH[G5-3T<137=M<75LSA)2J(70GH1M/S#.!C:/Z'5L-3L M=4B:6QN8YT0[6*'H?0U9?_5M]#63X8??I.>,^:^2!UYK8K"ENYY=:OX[*(R7 M$4*1(3@+'G+%CGUR!@9^Z:CGUF^T>:'^T;:>6TE)4SK&NZ-NO(5CD$`GH,>_ M;:L[ZUU"#S[.XCGBW%=\;9&1VI+[_D'W/_7)OY&HM)01V)0=%GF'/_71JRK? MRI?%<-X`P>:.Y53V*(T:?S!(]C714444A.!FJ-IK-I>S>5#YN\':0T9&T_-P M<]/NG]/45?JE<)Y>J6DXZN'@8#OD;@3]-A_[Z-7:*CGGBMH6FG<1QH,LQZ"E MBECGB66)@R.,JP[BGT50UL%M%N@,9\L]:S-"BO)K20PWBPIYA!'E!C]0<\'Z M@_2KR?Z,N[4XMPA;9R>,G"C;^6!ZUI]:6BBBBBBH;R9[>RGGC3S'CC9 MU3^\0,@50TZ"6\\/IYNHS22748D-Q$P4J6&?DQT`[5C:/=SWGB'29+B3SG2Q MU&+S<8\T+/;J&_$"NNHHHHHJCHY/V`H5V^5-+&![+(P'Z`4(=NO2@L?WEJF% MQ_=9LG/_``(5>J"X&6B.#P^:6UQ]EBV]-HQ4U%%%%%%%%%8OAP2!;GS&5OF7 M;M7&!C@'DY/O6U7.Z685\7ZQ*^5><1K$7;[VP88+]/E./<5J:JY\J"!.9)KB M,*/8,&;_`,=4U7M!))9W5Q;<27%X3D`?=5PF>?\`92M:L;PZ)`EQYCJV67;M M7&!C@'DY/O6S7.:0(QXPUN:0G?,8DA+="%0!P/H2,CZ5IZOB2*WMA]^:YBV\ M9^ZP@\M,"MZN=T)=OB? M7))3B2=T,88YRB@KQ^.>.W'K6GJIWBTMAG=-N^"23Y?1>O;.X?G6AJ`$M[I\&"3YQE..RJIY_-E'XTF@Q1II$,D<: M(+C,Y"KC[Y+>@[$?E5G4,_V=.XU6ST:XN=UHQCDG.W8W)\QN M!SW/%)96E]9ZQIEO<>0T4-G*BO$ISD&/J3ZXS^==#1117->)XM3O'EM=/N7C M*6C.8T!S*2<8&".>/UJB=!TL#)MM?_!W/]:/[`TO./LVO_\`?Q_\:MZ;H^GV M^HPS1VVKATSM,[-L'!'//H37445@^)U:^L)+*&&Y:9'61=L!9'(YP3T(_'M3 M="G72]&M[.2VOV=%^;-J_!].G2M#^V(A_P`NE]_X"/\`X4?VQ%_SZ7W_`("/ M_A5#7-9B&BW7^BWBDH0"]JX7\212>#I3-I?XCT.3["]BITN]"V[@`H!+;`<#I MQ73T444451T\;;G48^RW.0,YX,:'\.2:)3MURU^]A[>4>V0T?_UZO5'*0-H) MQEN*2V(-M&0C1F97 MNM&U*Y`7:L9D@2*,=_D60#/_`-;TJ823VE@MB/#<]M9(Z^6$GBJZ=O/+[-YT&?R\S^M4_#L[PZ=MBLIY01$249,`F&/(Y85 MK?;)_P#H&77_`'U%_P#%UC/ITMW:M%=Z;:;J-XVTHL2S1I&JGL%\W%7=/GN-/MEM+?PU>0V\>=BK/"W4Y[R>_K5C^U- M0\S'_"/WNS^]YT&?R\S^M9'A>_>WTYT%A=399#NB52!^ZCXY/6MS^TY<`_V7 M>\_[*?\`Q58S6C7<7E76F7JR+=2S1,(XF`W$D9W$CH?J/6HX=+C:9I[K3]7O M9"I01F18XT4XX53(!C@=SS6EI]S/8VHM(?#M[###\L2":%N.O4R?UJ5M4O\` M+@Z!>B/:?F\V`GIZ>95+0]2DAL#%]BN[C9*PWQ(I4\YZY'KZ5H_VL_\`T"K_ M`/[]K_\`%5CO9+-:6?F:=>BXMU;#>2C@;CDY!/ZC!]Z:FEVQDFFO;35[R28; M6#.555SD!1OX`]R:T;#4I(+5+9=!U"WBA4)&IV-\H&!SN_G3;G6;B2"ZC;1; M^./RF"R,$P>/3=Q3A^^2VLP,B6^F=Q_LI(S?^A!!^-37(7_A)]/.\[OLT^%Q MP1F/G/Y?G6I1116#XCL-6G66;2FC#-;-$P+%9.N1L(X!Z]:R%UB5YVMT\.WC M3+PT8U++#ZC=GL:F^V7_`/T*FI?^!Y_^*JUIMW1E0R>:ZJG;<<'IQ46A:-INJ:-;7<]M<)(Z?- M_I,HSCN,-T-:'_"+Z1C'DS_^!5$7:IN'(&,5T51S*7A=`%)92`&Z'ZTE MO(\MO'))&8G9060_PGTJ6BBBBBFR;_+;R]N_!V[NF>V:\]6\N;'5WGOM7T6[ MOE;`DG,K+!_LK@;4_G711-=/XKT=[QK=IFTR])-N28R/-ML8SSTQ71444445 M1@^36KM,\/#%)VZY<']%%%X-NHZ>_P`W+O'QTY0GG_OFKU5KI2SP<$@/DX^E M/M%9+2)&!!5`"#4U%%9-[K2)[_LW[N-9& MWIPRY'WASCVZ_A5BLG0?N3?\`_E6M11116)X5!&EMD@\Q\@Y_P"6,=;=%%%% M8'@[_D%2?]=%_P#14=;]%%%-?_5M]#61X6*G26VKM'G-BMFBBBJ]_P`:?<_] M-S2NS8/T"?E5VYQ_PDUA^[R?LT_S\\G_ZJU*****KPV-K`=T<*@AMP)Y(.,9!/3@G\SZU8JC-+YVK6]L@SY"F>0_W M<@JH_'+'_@-7J*9)&DT9CD171NJL,@TJ(D:!$4*JC``&`*=145S`MU;20.2% MD7!*]161:^$["U8/Y]U*RMN#22#\N`.*MG0[0RW$A:;=<*5?]X>A]/2H&\,: M>UD+,M<^6)#)D7#;LXQUSG'M6G;P):V\<$98I&H52S%C@>I/6I:*****@O4F MEL;B.W;;,T3"-O1B.#^=8.F:]H%AI$5E/)':211A);61,.&`Y&W'S$GZYJKH M<$MOKNCI+&T*M8:@\43#!CC,]N54_0$<=JZ^BBBBBJ,AV:Y;\_ZRVD!Y[JR8 M_P#0C2:FO[RQDQ_J[I3GTRK+_P"S5?HHHHHKDKRUV^,9;G)RZPKC;Z2P]\=/ MQ/0U9T32YM,NU6;=F661E#!<@;0!T)X]N,>E=)11117(V%AJ5S>W'!QVJ\-)UK/S:AD=\3N/Z58CL=61`IN\X[^=_BE)'9:RH;S+T.2Q((D M`P,\#[G;UJ*_LM4:U(:^$0WH=QFZ?,/]C\*L?9-6_P"?K_R,/_C=9.@V>JA9 MO]*_N_\`+;V_W*UOLFK?\_7_`)&'_P`;H^R:M_S]?^1A_P#&Z9'9:RN[S+W? MEB5_>`8'8?>HR?+3UA/;'?_$ZZV'B+<-U]QWQ^!Y%.^S:W_S\_P#DPG_QBJ]_;:V= M.N1]I_Y8OUG0]C_TPJMH>G:S;V#_`+]/-DGE:9DE10\F\AC@PGT]:LVL=^GB M2W.H2[LV\HB3SE;^),G`C7V]:Z"BBBBBJE[?"V*PQ1F>YD'[N)?YD]E'K_,\ M4ZQM6M8F,LGFSRMOEDQCN/7O65IM_-J'B72I;@( M)H['4(9"GW69)[921['&:ZJBBBBBL_4`1?::RYRT[(Q'93$Y_FJT[5\K8JZX MRD\+ M7$Y0$*)2N!GZ`5%<'1A@Y/F-GBMFBBBJ]]_R#[G_`*Y-_(U'I9)M&)&# M]HFX_P"VK56NV0>)K#*DO]EN"#GC&8\C'Y5=L+HWNGV]T8FB,T2N8VZKD9P: ML445@^(]8U#2Y(Q9);LK(Q8RJ20>HZ$<8!_2M#[%=R$&?4I<34U%%%%%%8MK_R/&J?]@VS_P#1EU6U11111111 M12$!@58`@\$'O6)_PC)C_=6NL:A;6O:WCD7"CT4D$@?CQ48M(+'Q;H]M;($B MCTR]"C_MK;9)]3[UT%%%%%%9'B*6:ULH[N&+S3%#P[ M?31Q"5HXBP4G`XYS^'7\*TD.Y%;ID9IU%%%%%%%%%%%<_I%A979F>YM()V79 M@R1AB.#ZUIKH^EIG;IMHN3DX@7D_E6.8+:(M;VVG6UQ<<<9 MP`,CK[&H766UNHH;WP];W$$_"26T*1.'`)V[2YSP,_>'?BI(="TBZTX7T5@T M#RR+N2:9CLQ(,C!;`Z'I]*T?^$7T;[3]H^Q_/Z>:^WIC[N=OZ56T73K&5)!) M9PR>6L:*9(PV%"]!GM6I_9.F_P#0/M?^_*_X5BR1VL#&WMM,MY[B2XDX,`?R MT'V>!G(.>O'%:&FZ#HD\ M(O8K)AYP.4ED=@ISR,,>.?:I_P#A%]'^U?:?LGS8QM\QMG_?.<53T+2M/N[` M23VZ2N%B7++T`ACP*T_[!TK_`)\8ORK$,=M&ODI9K=SR7,ZG(9_*C5FQD#MD M`8X_2E93:W4=M=:"[QR@^7-;2",D@9*[=_U[\X/'%6]+T;2[RW%ZD5\@FS^Z MGN7RF"1C`8@=/6K/_"-:;]H\[_2?]S[5)M_+=5/PWI5O_9NZ41RLQ3!1CP!& M@Q^GZUK_`-EV7_/`?]]'_&L(&.%3!%:>?I%>JMP-PCN+F3GINJMX;L;6?2O,EC#2&1MQY'-:W]EV7_`#P'_?1_QK!A M9$M;:".S\^Y??YN2[&,!B!D#/7';_T:U0W/F?\)'8XQY?V>?/3.-4_[!MG_Z,NJVJ**********IZA:2 MW:VXBE\ORKA)6//*J>43-*DI5T+`#"D< M`8'3Z\UO5S^D@V_B[6HG4J)EBDB.<[@`=WTY8<>]7];98K&.9B!Y=S`0Q[9D M4']":S].U"ROK*\2&9IH8]0`5T7@EY%88SU&YB/P^E=#6)XM;=/YDUIZTZPV426S'U`Z>5 M'CI[8K:KG]&=T\3ZQ;20K'C8T;#&7!+,3^;BM#66\NTBFR%,=S"'9 MMV0+F`#GTQBNPHHHHHHHHJK=*[S0!49MK;B1CCC%8MIJ.J:9IL-O-I"_Z-:D MEOM2_.$`!(`'N*Z""43P1S*"!(H8`]>1FI*******2LF2S@\0[)+M!)81ON@ MB/28CH[>HZX'0CDYXPWP\-LW7\*LUD:`0T4I!!!V$$=_EK7K'U&R2;6(6WF.2>W>-)58AD=>5(P1V9 MLCH<"H9/#0OS"NJS"XAB8.(@TA#L!_%N8@CG.`!VY[5N*BHNU%"CT`Q3JQO# M&T:80F<#R^O_`%QCK9K&OK%9-:5E9HI+FV=4F0D&-U(QT/.0QR.AV"H)O#1U M,Q+JTHEAC;>8%DE(=@.Y9L8Y/`4?6MY(TB4+&BHHX`48`IU8'@__`)!4A_Z: M+_Z*CK?K&O[)9=8!5FBFN+5UCF7(,;KC'3KD-G!X.P>E0R^&SJ9A&K2"2&)M MYMTEE97..,EFZ=3C`^OKNQQI$NV-%1?11@4/_JV^AK&\)C&C<_\`/5OZ5MUB M7.G[]7NA#(T$]Q`)(I$8K\P^5LXZC'E]:9)X;74+B&75G$\<&2MN))&0L<K_`/7Q-_Z-:J]U MD^)M/^3@6TYWX/!S'Q_GTK4HHHKE/&)^:-<'F,G/IPU=71165K%P\-Y8*LSQ MB20@A0V&Z=]4='N//\`$&D` MPPPM%8ZA$ZP+M0LL]N"5'8'&?QKKJ*********QM>(`ERY3_`(EUU\P[?+$7&1@`ICW&VMFJ.H#%SI\@7.VYP><<%'']15ZJNH*K6N&?8#)'SS_ M`'QQQZ]*M5C^'FW02-C&0AQZ?+6Q5#4F"76FMCG[5@<^L;BK]%%8_AE_,TS/ M.,1@9]H8ZV*I7XQ=:?)@_+<$''H8W'\R*NT45@>#O^05)_UT7_T5'6_5'4,+ M>:=)DC%P5X[YC2^3_P`!-,TS_CT?_KXF_P#1K57NB1XFT\;^#;S_ M`"<\\Q\^G_ZZU****Y#QM"))[=_,*E(V^4=^O^'ZFNOHHK*U>RN[J[L)+-6PH]%)0D#\>*T;%K!O$>BG3"#:#3+T(<$ M9_?6V2<\YSGDUT]%%%%%%%%%8GB+/DW&.G]FW6?R2M6U.ZTA.0V8UY'?BIJ* M****S;AAJLSV2!OLJ'%Q(K8#'_GF/_9O;COQHJJHH50%4#``'`%+6#<>&%:Z MDFM+IK=9,%D)D(S[8D7%1GPS=?\`03_2;_X]3T\-SC'F7PD"MN7/G_*?7_75 MK6%L]G9K!).TS*6.]L]"Q('))X!QR3TI]U;K=0-"SLF2"&3&00001GW%--M* M60B]G`4`$!4P_N?E_EBL*3PC,EQ_> MM+3M+N[*Q-O-K%UPR#^N?PJV;>;8BB\E!7JVU,M]?E_E1]FEW2 M-]MGPX(5=J83/9A^._[S//7C%5SX7U9U?S-?9V^4QEEE_=L.I'[WWQ6Q8:==VE ME%!+JDTTB9W2%1ELDG^+)XSCK5IH93(S"ZD"D$!`JX7CKTS2?9Y_*V_;9=V< M[]J9QZ=,5SQ\(WL%RQL=;E@MF%];8$#Q+*,C`P)>/ M?_6_SJ.7PCJ\T<2MXBDWQ,6$F)2&_P`_C76444444445BVO_`"/&J?\`8-L__1EU6U1111111115>_+#3[DJ M2&$38(ZYP:Y2T\6V4<^DJ]^_DQV;+=9C<_O,)C/')^]6DE[;ZAXMTBZM9/,A M?3;W:VTC.);8'@\]170T444444445B>(O]3/_P!@V[[^R5<%_:V4EC82,RO< M1XB)7@[0!@GL>15&'Q(JRW0NHPJQWGV:+8?KG=D]0%9C_LD=^L^E>)-.UF[F MMK-W9X5#9(&&4]Q@^XZXZUK445GW,MQ=W1LK;,<28^T3@X(_V%_VB.I[`^I& M+D$$5M"L,*!(T&`HJ2BBBBBBBBBBBBHYIE@B9RKN0,[47OO^%35R/C0'[3;G;QY3Y/IP:ZZBBBBBBBBL6U_ MY'C5/^P;9_\`HRZK:HHHHHHHHHJ"]=HK"XD0X9(F*GT(!K!M/$L)GTF*74;4 MI-9L]RS2+D2`)C)SP>6XJQ)/#<^,M*E@E26-M-O<.C!@?WMMW%;M%%%%%%%% M%8OB$CR+@9Y.FW7\DK`UGQ'!!KNFVTIAN55%_P!4A+02D=0V0#_"=I].>U<] M?7.H7E]/8:AJ#O=Q76Z."%F.Y\G!7C``R._`KJ?`-S9+%^!M]._M M3+V62Z5[:PF1;J-U)=DW"/D$^Q.,C&<\U!9WVIP++_;-G'&J'B>V8LC#U*GY ME_6M.*6.>)989%DC895D.0?QI]%%%%%%%%%%%%%%%0W%U;VD?F7,\<*YP"[` M9/I56349YK9WT^REF?!V&4>4A/ONPV/<"J]H^HP2I=:U+`AD`B6.V5MD9)_B M8GJ>!G`'YU6&0"4#!**1S].U7*X_QJZK=VX(/^I<\*3@>IXX M'(KL*********Q;7_D>-4_[!MG_Z,NJVJ*********CGDBBMY))B!$B%G)Z; M0.:Y>.SO;V%;RT\.:+';N-T<5PO[UU[9(7"DCMS4EA[*`SV MT.Y29&4%00S+@=20N/RKFW\+:AH_A:WOH1MO8V,UQ\QWQY*X(QU*J&!![,W6 MNE\&1Z@+&66_AA0R$?=C"2;APPSQ6<9_A@&]_P#OIA@?]\_C4MMIMK:OYB1[YNAFE)>0_P#`CSCVZ5;H MI``O0`%+QGW3'@ M(N[`Z;C[<_7VIUIKEO>WWV6&&8GDB0[=I``.[ALX(88../.-P(4X_)36'!I7B&53 M-!="&"4*T<7]H2/L&T<9:,U)_9'BC_G^7_P-;_XU1_9'B?\`Y_Q_X'-_\:JM M.UCO=]Q*"5`O&8(/[S?NAQGWR>U30:!XBA$C"]4RRVD:RW(NL?]OTO_Q-!TG6SM_TL9'7_3)> M?TIK:-KA'RW@!][R8_TJM>Z7X@MK*:X%^O[I"YQ=RYP!GN*ZT$$9!R#2U@>* M=3N;:P%K9I(ES=7$=M%*3L`9^<@_AC\:KPS2A%MWM;E[L7/V=E.I2;<^4)-V M[TP>F*GD2]B:-6TZ7,K[%QJTO7!/]#4=S#J8DMHHK>6W>6=0)#J4D@`!W,"I M'.55A^-=)1116)J;`ZG*9I[I(+>R,Q2"4H20QST/)P*IYE.3_9GB$<9_X^U_ M^.4F^7_H%^(__`I?_CE&^7_H%^(__`I?_CE.)D$8QIWB$GT%RN1_Y$IRO(`O M_$O\0<]WTW7X)9,[I8YDY/\`>(+X)^HIMNU_!(XO++6I M(T&5FBFY;V,>\\_0GZ"K=O]<^<,?EO MI0""3]EUWG_IL/\`XNEW-MQ]DUS_`+^C_P"+H#,!C[)K?_?U?_BJ7>__`#Z: MW_W\7_XJHH[M)C*J0:T3$VQQY@&TX!Q][T(ISSNJY6RUMSZ"5/ZO6>OB*V>\ M-G'9Z_).OWD1U;;]273RL]RD\RROG$HD*J6) M0$COMQ6K117/>(##]JDBN96@BN=/F@\WRV8*6*CM3%UZ;.TZMI98=0()/_BJ M=_;LW_03TW_OQ)_\52-K\B*6?5=,4#J3#(!_Z%1_;D^?^0IIF/\`KA)_\52_ MV[-_T$]-_P"_$G_Q596MK;ZSY#7>HZ5NA<%28)/FY'RDYZ'TJW'?M;7$D]O? M:2K-$D006\B@!2V.0?\`:_2ICKU[QMO])/'.4E'-*->O/XM0TH<]HY3Q^=6] M(N6O=1EGDO+69UB"!+=&&!DG)W&MJBBBBBBBBBF2R)#$\LC!412S,>P'4U2M M]2GN]):^@L)"S`M##(P5I%['_9SZ&LNWOXM3\5:1=1*R!M.OE9'&&1A+;`J? M<$&NDHHHHHHHHHK/UW_D!ZA_UYS?^@U/I_\`R#;7_KBG\A5FJUW>+:A4"F6> M7(BB4\N?Z`=SVI+&T>W5Y)W$ES,=TC@<>RCV'0?GU)JU11113)HDGA>&0921 M2K#U!XJMI4K/8I%*9;;'"CS?FR1R-K<<^^*BO03>:<0Q&+AB M1Z_NGJ[1117/ZZ<2:F1_T")/_9JZ"BBBBBBJ=QIL,TIGC9[:X/\`RVA."?\` M>'1OQ!IBSW]J#]JB6Y0#_6VZD-^*'^A/TJQ:WEO>QE[>59`#A@.JGT(Z@^QJ M>BJMSJ-I:.(YIU$A&1$N6=OHHY/Y5F7FDVNISF?^P;5I9/O37BJ"1C@X&2?H M<5#%X'T8R^;=6L,SXP$CC$48^@')_$FIF\'>&U4LVE0``9)Y_P`:N:!;BUT* MTB5=H\O<%_N[OFQ^&<5HUQDDSP:;!)'#),W]J7@"1C+N,,!SW`Q^%=556+_D*7/\`URC_`)O5JBBBN:M+'64\937D MG_'FV\,Q8;63"[`H[$$ZE+K,EI:FV6(!@#(C$@J(SV(SGS"/;;5+Q M6-5B\.7+&>VF&Y':K'`)\ MQ>IH\O6%!/VJRD/9?L[I^N\_RJ/1+^YO[7S+GRRS)'(K1J5!5T#8P2>AR.OI M6G5'_F.G_KU'_H57J*********BN8HI[66&;_52(5?G'RD8-8BCW-16-FT3-=7.U[R8`.P)(0=D7/8?J>:N44444451ND>VN!?0H\ MF0$FB3DLO9@/49_$9Z\59M[B&ZA6:"19(VZ,IK"\7??T+_L+P?\`LU4;J-I+ MZ9)+S[$3J[XF!VX'V48[CVJ#0-/2TU6-7OS./,!5(`[12.`P+EF."?7&<8KJ M[S/VS3\$8\]L_P#?MZN4445SVNC][JA_ZA$G?_>KH:********JW.G6]S()B MK1S@8$T3;7'XCJ/8Y'M5:6YU&SDB@:&*[\YMDBL_49C.PTR M`@RSC][_`-,XOXB?<\@>_P!#5^EKD$ECALK:21U11JE[RYP.D];'VVSET:R8 M7T"J[0;6\S[Q#*<#'TQ_.M965U#*0RD9!!X(JM%_R%+G_KE'_-ZM44445AM] MKM-?EF2PN+B(JYW1E,#<(L8W$=T;]/6JGBV^GE\.W,*V$\1;86>7:%4;QW!/ M.<#`]:Z5,;%QC&!C%.K/UOS!INZ&,22+/"44G&3YJXIPU*1D+)IMX2!]TJBG M/IRP_P`*K^'XIDM!YT4L96**+]Z,,2J`$X^OYX]*UJHC_D.G_KV'_H1J]111 M1111115>^1I-/N$0%F:)@`.YP:Y*UU&XBN](D;1=5*V-FT$N+8Y+$)C'/3Y3 M4F@QRQZ[I/G0R0.]GJ;[)5VL`US`1D?0BNQHHHHHHHHHK/UW_D!ZA_UYS?\` MH-+#=PV6C6TTS87RD``&2Q(&`!W)]*6TM)7E%[?!3<<^6@Y6!3V'J?4]_I5Z MBBLW6[^YL;0-:1QO*V['F$@#"D_TK%'AO79(FEFU?%T#\NR639[9[_ECVJ[H MESJD%ZVF:DT$K(NX/&[$\@$?>'(ZCDYK?HHJK+IT#R-+'O@E;K)"VTD^I'1O MQ!JC>:+<7TMD;C4!)'9W*W"@P@,Q4'`)!`[^E48[=#K4DIKS_C[L/^N[?^BWJW1116%KMGJ$ MTMS]DM!.MS8O;Y,H78QSSSUZU>.IO%S<:?>1)_?"+(/R0D_I5J"XANHA+!*L MB'CLTX!?'^RF3S[MC'H:M6MG#:(PB!+.BN3@@6XM[6%T#!]5O!@C/:?UJQ=P6)TRTCNM">3RS%&%,2X7+KD<'IG MMT.*UH[H0Q)%'87*HBA54(,`#H.M.M&>6\N)F@DB5D15\P`$XW9[^XJY5*P@ MC?386$T\HEB1O,>1PS<9SR* MKVV7P]=KY5Z@D*`/,D@4G>I_BZ=/05T<5K']F1-TV,`_ZUL]/7/Z5(+=`ZMN MDRN,?O6Q^6>:H:PEO;::\LLDBQB:%G8RN<`2+TYR/PIHOK)(T5X]114R0S13 MGCKDG'\Z6TN[2\NX[BVGN%+D@Q2>8`V5!!VG@#&#G%:M4./[?QW^R>O^W5^B MBBBBBBBBH+UWCL;AT)#K$Q4CUQ7#:9JF@Z9>HKH:*********S?$,B1:!J#R M.$7[+*,L<#)7`'YTS2;>::"VNKR,(8XE$$)Y,?RX+'_:/3V''$>9:9G?FH[:><7<:G5(;Q#*8G2.,`HP5CR03@_+TK4JA/<07%S8&":.4"Y.2C! ML?NI/2M"BLC1/^/[6O\`K_\`_:4=:]%%%!'Z5J7.GWL<2LFO7@/F(#Y@@`P6`(_U?7'3WJ9M/NA&?\`B5^Y3]WDG9P..>>*LT45B6P*^*9MS MDDB7`]/EM_\`/YTSQK(D?A6[+DO2NDJA=V=V]ZMW9W4,+"(QL M)8#)D9SQAEQ5JV$ZP*+F2.27G`*Y[5$;4]) MO;Z=66!+24VL+#&?D/[QAZ^@[`^IXVK#_D'VW.?W2\^O`JQ3))$AC:65U1$& M69C@`5AQ>)9[A6DM],DDBWLJNHE(8*Q&>(R.WK4RWD6K6\,=Q;>7()P);:53 MD#+;3A@,@XR./Y5:?0M(8%_PI#H&C'KI5GUS_J%_P`*3_A']&_Z M!5G_`-^%_P`*A\O3]&O]\<,5K$T)W"*/&X[E`&`.3S@5!_;.K&%)!I14LH9E M99,K[<*,]_K[5U3_ZMOH:K:4I72+-2%!$"#"]!\HZ5 M;JMIVXZ9:[I1*WDIF0-NWG`YSWSZU9HI*P="TJ&XM9-0U&VMKBXO)FF61HPV M$.-H&1P-H'%2:SX168F@Z1:03Q0VZ6RW?RN8W*EO8'.1]!50VT-GXOTBWMXUCBC MTR\"HO0#S;:M^BBBBBBBD)`&3P*S$+ZQ,)<@:=&+%U.W5GA-EM7.TKY>S'0<;MW;T_G75UB^*S,-'7R/ MO&XB!_[Z&/UQ3O"GV?\`X1JT^RG,.&VGGGYCZTW4EW>(M+*E1L60OZG[H7\. M6JOXR8I8VSJKLQF\M528QMEE(!&",XZD>GI6B^M0Q^83;792)F5I%A)4;203 MGTX-:-8VHX_X2/2LXQE^H[[&Q6NQ4(2V-N.<^E)(]1B&EJ#;X^4+$&W-Z.2?E7H M5/EY^S#MNS^M7M%E\3R7D8U)@+<2_.98UC<_*WRJ%)!`.*WKS_C[L/\`KNW_ M`*+>K=%%%86O:AJ%O]ICL7MT\BR:X8RQER<9X&",=.^:RK.V@ML26_B33\YW M*P,1QP1QD''4U<-U<]O%EE^<7^%"SN\D?VCQ1921+(CL@:,;@K`XXQZ5L_VS MI7_03L_^_P"O^-6+>ZM[M"]M/',@."T;A@#Z<5+145Q`EU;O!)G9(,':2#^! M'2J]OID5O*LHFN9"N2!+.S@'&,X)]#5M_P#5M]#7*:1_R&8_I;?^DTM=;161 MHG_']K7_`%__`/M*.M>BBL_7SCP_J!R1BVDY'4?*:YSPQD:1H>[K]ON,Y_W) MJZN\$A@7REW-YL>1C/&]<_IFIG_U;?0U6TDYT>R(+'-O'RW4_*.OO5NJVG&- MM,M6B5DC,*%58Y(&T8!JS15'5W8:<\4;;9+@B%#W!8X)'T!)_"KB(L:*B`*J MC``["G444456G*?;;7<&+$OM(/`XYS5FBBBBBBBBBBBBJM]8K?+`K.4\F=)A M@=2ISBL^Z_Y'C2_^P;>?^C+6MJBBBBBBBJFJ_P#('O?^O>3_`-!-0C2?L_-A M=S6H'2//F1_3:W0>RD54UN6_BT*]$UM'-FTE!>&3&/E/.UNWXDU=T[4;:>** M'S2LX09BE4HYXZ[3@GZBK]1S0Q7$+PS(LD;C#*PR"*Y>!8[`R0P:W(J++(0J MQNRKEB2.AZ9/XUH6-M&D%M<_:C>2S3X:X8G)`+X7!Z;(FDRO+J2-W'7BMC1-/M=.TJWAM M2CKY29E7_EKA0-WX@5H45R<4:R:M+OD>-1K$I+(^W'^C#O3KR\@D=)H)KF:W MMIUW2K=$820/B+SIB0Y)9,@?56%;M%%%8&IW M$]MK-Q)#LWBRC">8A*@F4CGD9Z]*F^P:U_S\Z5_X`/\`_'*0Z?K+#!N-)/UL M&_\`CE/_`+-OSG=_91)//^A-S_X_]*KW=M=Z?;/=F'2W\O!(6T*D\CONJQ;W MNGZ??7\$L]O;$S*RH6"Y!C09Q]65;2W21(7V M-)))L!8=0,`YQT/3G/I5/5+Q;SPOJC!&C>."5)(VZHP4\>_8Y]"*Q?"QSH^A M$_\`/_^=H]/N'0E66)B".QP:PM. MU_4CIEJ6T"_G/DIF7?'\_P`H^;EN_6I$N)+KQ;I$TMK):NVFWN8I""R_O;8= MB1[UT-%%%%%%%5-6_P"0/>_]>\G_`*":MU1UB&2XTJ\AB0O)):RJJCN2N`*F M>SM[BV2&Y@255`^610V#^-5SILL'-C>RPX_Y9RGS4/X'D?@161KNO:IIL+17 M&FM&DA51>6TF]1D\_+C(.,XZ\D5/X8TNW;08)+J&&XFE+R/(5+9)8GJW/YTD M]M%IVMZ=:VN8X)V>7RNJJR\$KGH3YG..N/K3/&<7F6MBZEU>*Y$@>-]C*H!+ M$'Z`_P#U^E672]%M=VBZ7(S2F95G$D>"'9B#][./FK;K(U1)9=5LX8Y?+28, MDI63:^T?-A>_.T#CL34J^']+1`B6@4`8&&8$?CFLCP5=71M197$AE6*!2K-G M*D,RE>1T^4?KVQ74T5R5Q:S)->R/$ZC[=<."5."IM<9^F1BG6MMVMX[4[',9\TQRL[$XR>XZ8Y)ZU MU%,$D;.4#J6'4`\T^JNHZC:Z5927EY*(XHQR3U)]!ZFL"TL[K5]5-_J(EB21 M4$5O#)PL8)96?UR1_C74T45F>)#CP]>D?\\^V?4>E4]&G@TZ/RKFXD:2YGC1 M9)-Y,CF!"?O6PIPS6I MI::A;M-;7DOVF)-I@NC@,X.K%Y=BVTZ>[C`D\J-G`!X.!ZU@ MM9S_`&NTCN=>U#[;=J[QO;[1;K@`XVXP1SQG)-;5A)=R6+"^0+/&S(S*,+(` M>&`]",&N:T&`P:R!ERI:V*[R3C_19,C)]_YUU%S?PVL@C999)"-VR*-G('J0 M.@J6WN(KJ$2PMN0Y'((((Z@@\@^QK-T3_C^UK_K_`/\`VE'6O16?HG&F+&2# M)&[I)C^\&.?UY_&J>K)_Q*=>8*55H6Y/1B(ADC]!^%9?AM0NEZ-Y>61=1N`# MCMMFQ73W[;;=3Y8D_?1#!_ZZ+S^'7\*G?_5M]#5/0P1H&G`D$BUBY!SGY15Z MJNF+&NE6BQ-NC$"!&V[W%=11111111535O^0/>_\`7O)_Z":MUG:X2NCW[*<$6M>LK4+>6;5 M;:2`J)H$,B!R0K$]*FT[2 MX9+F1FFDA0;3D;!R<'/?+'/X#M6]17G7B*1HFD9;?[01KA_<_P#/3]W'\OX] M/QI^@7XU:^MX+W1+&TC2XXDCM@JD[&/ED'OWS_LUM>(;"S%Q$(--@E=K:XX1 M$&T@+AN<=#6GJFJ364%F8HU:2[E6,?[)/<#OCTK,M+Q3`T:V,"-+#*_G"5?, M&=Y)VXR1D8S6]J.HVNE64EY>2B.*,?VQK$)CB5LV5FW M(0#I(P[L<\>GY5T2HB;MBA=QW'`ZGUI:0,I.`P/XTZL_7>-%N?\`='\Q6#K! M6QG^SVHGM76\6='BLFF0+Y6W/"D'GC`(-_F$H(>Y6TF+$XQP0O&.PJ/PS=6NF:9<6U] M'>,;B0YC^P2[=NT+T"]\9/UK/N="TJ>0@7^K)`""B'3YMT0&.%.T`=NU=+:: MSI&GZ>EG;17PCB3:H-E,2?J=O6LNWN%T75(([F&Y6,^2ZA('<`^1(&Z`\Y(X MIU]XDN;?5+BYTVTGG1X5&V:TF4,5SPI"YSSWX]Q3O#7B)TL[F;6+>ZANKBX, MA2.RE*@;548PI_NU9TO6[:WN]2:6"^47-WYD7^A2G%]5-6;WQ9:P6K MR6UG?7,R_=B%I*F[GU*X%9?_``G=[_T+%]^3?_$5GR>,=8BOIKBS\.7`6=1O M22-S\PXSPH[N3N8YR> M1M[Y'K73O]QOH:IZ&Q;0-.8DL3:Q$D]3\HJ]5;3MW]FVN^,1MY*90`@*<#C! MZ59JO?7/V.PGN<;C%&6"_P!XXX'XGBGVL/V:TA@SGRT"Y]<#%2T54U+48]+M M?M$L4LB;MI\M<[?<^@]_>LZ[O=0@@N;G^T+)%B$KK`]N2Y5"W?S/1>N*W**K M3L?MEJH7()8DY/'R_P#U^]6:***********:Z+(C(ZAE8$$'H163;>&[:RCF M%K=7:2R1B*.5I=[0(#D*F>@JK%8P:;XKT>UMP1&FFWO+')8F6V))/3_`-!-6ZSM=_Y`FH'_`*MZN7U?PLNI>)[>]-U)&A"RN@48+1D;>??<:ZB MLR]NC;:M;A(_,EFC,<:EMH)R"@%S<&`MM$FO!"=H/6. M,=""#^--\+Z'9"_GENX;6Y3[?+`!(@R-H8[B.F.@QC'/TIU@;33]8U22.WPO MG74:_9X"Q`VH0,*.!U]JZJ_TJ?5=-T^/SEC,,D4LG)P^W!(P/?UJO;FVBTYT M:X<3K')%Y(R%)RV.,>]6]4T?[;J-I?G$XM@?]&D;",3_`!#_`&A[\?3K5F#5 M+::00R%K:X_YXS_*Q^G9A[@D5=KE=?20:W*Q=_+;3I!L$IVG"OR4`///4D#T MYJZEKIT6IVK65G8PR1731NT`7.S9>%7/SCS.WOTJQH.JZKKMI+/'?6D1CD*%&LFR!U!_UG<57F\5QP7#1 M/K]B=A"NXL'*J3T_Y:;X]Q_Q[Z/^;_XU5EU7QVD M[P1Z=I\TD:AG\L-A0>G)89/'05:L+[Q;<0K=7;:5:V>PN\AC=F4`?W=PY^M* M-<6YT_2M0NYXO+&H2*951D4JJR@':22.!T-5Y?'-I?L+>WTZZF;SE*A2JL=L MBX.#T!;`J[?>+)K")VO-%N8E4#=B:)F4-P"5#$\GCZUJZ#_R+VF_]>D7_H`K M0JO8?\@^W_>^:?+7,F2=QQR.;DVNC02;8R/M*#YSY]IB81CSCE2V/,^1^!Z^N/;VJQ111111111114%Y(T-E/*APR M1LRGW`K,L]4N9;G1H7*L+RR::4[>2P"=/3[QK-TJ[GO?$FF37#[Y/LFIIG`' M"W,``X]@*ZRBBBBBBBJFK?\`('O?^O>3_P!!-6ZS]=_Y`6H?]>DO_H)J[%_J MD_W13ZQ_$]I)>:.5CW'RY4=@H).T'G`')P#G\*B\,ZE;OH<"2RP0S*75XO-! M*D,W'Z5'?7$5[XCTM[:02QV[,KNC97+J2!QWPA^F?>NAJM)G^TH/WH"^5)\F M[&XY3!QWQS^=6:PM498/$5AZ@2,R&9,`$_> M%5& M%W8Z9QUKG/$=E*=;-ZJ*4%E(C-L?Y1LD/7&WKWR",^_.FM]87%]9I:ZG%>.U MRS[5F1RH\M^@':M68R""0PJ&E"G8&Z$XXS7G_P!M\4W.FZO'?0#RIZGZU@?V?IP#'R2,%(9ESR1R![ MG/I6S-H$=CX)8SO-9P6=JK"YAE?9 M,SX&`XZDC!X/X5N>&+;[-HCJD]9VAQPQ7L2P\ M#SX2RA6X.8B%G M4$_=+EMP^F5S_P`"-5M$_P"/[6O^O_\`]I1UKT5GZ0!+#)?$[I+IRQ;_`&02 M$'X`?F2>]4K^,PZ)K=KN_=K'(T>3]T,F2/\`OK=^%8]E;"[\/V$#10RA]4G& MR==R'_6]17-:;=IHEP&MK.-KJ%Y$D,8\W>/.3J#_`*O`1L$_7OFMW5C#_P`( MS?-_:DNH3O*C%C"=WEJX;!PN0%&[GIU^@ZW0?^1>TW_KTB_]`%6[FYAM+>2X MN)%BBC7<[L<`"HM,>.72K22$$1O`C("6-IJ$(AO+>.=`=P611UEB_M2[6"7=F$+%M`8 MG(!V9[GO6G156[*"YLMP8DSG;@]#Y;]?PS^E6J***********;(BRQM&XRK@ MJP]0:Q?^$,\/9!_L\<<#]\__`,567H9B_MW25@@2"-+/4D5$)(XN8!GDD\XS M78444444454U;_D#WO\`U[R?^@FK=9NN$G0[_(P?L$RN/,22;#-N.2`JE>2">#5VVN;2>WTU M;6+R`EZP>%L[D.V3D@\\_>YZYKH*I7-U:V^J6B3NJ23)(D19L`G*$K[D_P!* MNUG7#Q0:L9YY$CB%J=S.0`/F'7\ZYY3I:VT;QZ//Y90,`;B5=J]LYX_6NFTB M:VGTFTDLP%@\E-B;MQ0;1A2?4=*N45QX\MM9='MVG1M5G5D`!W`VZ]C5N2!K M.>,PKJ2">[,BH$C8*Q0COSC`J]8*MMJ$KRBZ,M\P^:5%"Y53P-OL#6O15'4] M*M]4A"RC;+&=T4J_>C;U!JII6JSB\?2=4`CO$&8G[3KZCWXZ?X'&S128'I2U MG:^`=$N@1D%1D'ZBJUOI4;7E]Y$\UH@F7$=L0B_ZM.<8ZU++H$4^/.O;R3'3 M>ZG'YBH)M)VZA:(-0O<;7P?-&1@#IQ5L:2P((U._X]91_A4;:!"THE:\NVD' M1BZDC\<4]]);:Q_M*_Z'_EJ/\*S-,AC@GL%BBCC4^2Q"+C),$F2:U72YLKN6 M6WMVN8;@AGC1E#(^`,C<0""`._;OFI+&WG62:ZNMHFG(^1#D1H/NKGOU))]3 M531/^/[6O^O_`/\`:4=:]%9J_;-/=XX;0W5N[EX]DBJR$G)!#$<9)((/MCCF M*YMY8]!U*2ZV&>XAD>0+RJ_)@*/4``?4Y/&:R=$)&EZ9C_H*S_\`M:LZRTFW MEFMIYG=EFN)RR2`R("MY&``O09Y!/N:T?$MLL'A"XDFTZVMIC*J[8`,8,@`Y MQW7K]:W=!_Y%[3?^O2+_`-`%5Y[2'7KU3.N^RLI6N[&.N.>G%/N9TM;66XDSLB0NV/0#-1:;;O;:?#'+_K2-\I]7;E MOU)JU1111115>X$IFM3']T2DR<#[NQO7WQT_QJQ2'H<4B_='.>*=11111111 M3719$9'&58$$>HK%_P"$-\/_`//A_P"1I/\`XJLO0S%_;NDK!`D$:6>I(J(2 M1Q3_T$U;K.UW_D":A_UYS?^@U>B_U2 M?[HI]8OBIY4T<"(9+31@C&0W/`/L3@?C3O"@A'ANT,#M)&0Q#L"PNB9(R-D%R3DO@<*_P#M8[]#@].E4]1&_P`5Z=&W*%-\G'_```UHT45G:QH\.K0)EC%<0G=!.HYC;^HX'']<51L?$!MKPZ5K;)! M>H`4DSA)U)P"/?/;_P#4-^BBL_7O^0+<_P"Z/YBI;/\`X^[_`/Z[K_Z+2K=4 M+H`ZO89!X$F,#V'6K]%-?_5M]#7.:>?^)A8C(^Y;\8Y_U$U;>H:A;Z9:-Y<+&BG+P$\*'/0Y/''0D#GK2:)_Q M_:U_U_\`_M*.M>BBJ>K_`/(%OO\`KWD_]!-<[H?_`""M+_["LW_M:KFI>%[% MT1U:[&V<%4CG90F^0%B.XY.[\!Z43>"].EC(GN=0F7J4ENF8'\#5O3PS>$]/ M1)&C,EK`F]>J[@HR/?FM.&&.WA2&%`D<:A54=`!4.F!!I=J(\[/)7!88)&.N M*9J>V2&*U89^TS*F/4#YF!_X"K5=HHHHHHHJI>!#]36=S#=VD<\#^9&P^5L$9P<=_I4]%% M%%%%%%0W;*EG.[KO58V++G&1CI7,V^B>&YY=/B_LIE>^MC.O[]R%`"D@_-_M M#\J;HS6Q\0:2MI;"VA2RU)%C#EL8N+<$Y//)&?QKKJ*******J:M_P`@>]_Z M]Y/_`$$U;K-UW_D#:A_UYR_^@FK\7^J3_=%/J*XMXKJ!H9DW(W4?U]C6!9:7 MK>F0-:VKQF!9':/-RHX+$]/)/KZFI%L;BWDT^>_G,][)=;7?=D!0LA51@*.` M>3@9-=!5601G5;6[P3H'C<&].HJ7[)XD>W\N6\@+%<,5*X/'/6.KF@Z1 M'HVF0VX`\[RT$K!BM.BN6MO^1@3[W_(4GZ_]>XZ5OWBQM+:> M8V,3Y4;<[CM;CV]<^U0WI/\`:NFCG&^3_P!`-:%%%%G^ MZ*Q-1OY5\2W5JL\\?^BC8JN0/4N!DCN!T!^O4:-J;=+^);:^NYV$A21)9&(Q MM?G!ZC*$9'H:UW_U;?0UR:7EOIT]K=W4HCB2*WR3U_U,V`/4GTK5T^UN=0NU MU74HO*VC_1+5NL(/\3?[9_0<>M:EU;I=6LD#_=D4KGT]ZQ_"\K3C4IGQNDNE M9L>IABK=HHJGK'_(%OO^O>3_`-!-IX=T\Z?'%)1SUSCG-=41E2!Z5EV2L/#>FKNP1';9/7 M/*9K5JO8%FT^W+(L9,2G8HP%XZ8]JKD_:-=5>JVD!)_WG.!^("G_`+ZK0HID MS%()'7[RJ2/RK/L8KNZT^VN'U&<-+$KL`D>`2`?[M6/L=Q_T$KC_`+XC_P#B M:/L=Q_T$KC_OB/\`^)J-EN+:ZM0;R69)92C*ZITV,W8#NHJ_7.W?B"7[=$D& ME2SQI.RK*0XR0C9(PA'J.M2'Q%VEA+;1(A4GTR,5QAA^R6]IJ`\6J M8[96M;=DL0^1QD`#);[HYYZ5T58;L7B/I]_)YX7:'+3V['CMR:ZR MBBBBBBBJ6L@G1+\``DVTG7I]TU=K-UW_`)`NH?\`7G+_`.@FK\7^J3_=%/HH MIDD<]5()WTZ=+*Z8F%SMMIV.<_[#$_Q>A[_`%ZZ5%%3S3N6TV[&;Y=G!.T9SNSC/;'O6U#8BSO%<)&HFN M2V59B3\C]&!S()B@,DSR8`B?&`Q.,8&*W:*Q M?#L$=M<:S%$NU!?D@9)ZQQGO]:VJ**0@,"K`$'@@]ZYRUC6)+..-51%UB<*J MK@`?O>*VK\H+=/,5F'GQ8"G!SYBX_#.*LUFV0QX?T\#_`)YV_P#-:TZK:?@: M=;CS1+B)K!OV`R;"[_``53_6F'5<`G^S[[@X_U/_UZB-V]Y>V:I974 M8CE+L\D>T`>6X]?4BM2LJT&VUTX"78!.XVES\_RR<>_KSZ9[59G!.JVF#C$< MF??[M8/AX$W=F!SG2$_FM=51111111114-Y`;JRGMPY0RQL@8=5R,9KE[>2Y MM+RWDU"&UBETZU,-M:17*;IW.`64'&T8`P#SR:=I=E/8>)-*CN0JS266H3.B MG(0O/;MM'TS76444444453U<@:-?$G`%O)DG_=-7*PO%FI0:=I$PN`P2Y@EA M60=`Y0E0?K@UM1?ZI/\`=%/HHHK'\1V5U>6L36B!Y(7+A2VW^$^U9#>-(?MD M,C6IR:J;40V\B!5)D#;B!CC'!')Y M!QQ704R6*.>)HI4#HXPRL,@BJ232Z=*D%T_F6SMLBG8\J>ROZYZ!N_`//)T* M*Y6!T37E9B$`U2?)/`_X]Q6NVJ6EU?16UM>`O'("^W.UQAAM#`8//49[4W6+ M.UOKJPM[J%94:5_E8?\`3-J+70(+"'RK&[O+9_F0DJ/J MRY7]:L6]]:7>?LUU#/CKY<@;^53T45'/!%JBZ'ID8(A MM%@SU,),9Z8ZJ0:%L[JU;=;7;RI_SQN6W#\'QN'XYJHUXMWK&GKY;Q31&3S8 MG'S)\GY$>A'%79=(L)[M[J6W#S21F)F)/W?3]*=;Z796LHEAAVN.A+LIJZ"&4,I!!Y!'>EHKG8?^73_`+#$_P#[5K:O M%D:!1$%+>;&3N`Z;USU]L_TYJQ699_\`(OZ?_P!<[?\`FM:=8D]XB:`MO''< MQ.T:6X#PON4MA3CY?F(&3QZ5HK=6\,$>V.<1@;546\F0![8R*AFU>(79L[6* M2YN%;:X5&V1?+N^=L8'&/4\]*CME@0F_NY)))Q\N^6)D$>>R*1P/?J>YJX+V M%C&%\QA)]UEB8CKCD@8'XT"\B+.-D^4Z_N']<<<<_A2?;K<1&1C(B@XS)$R\ M_B*7[=;;T3S1NDQM&#SGI1]NMOWG[T?N_O<'CG%(=0M5C60S#:Q(!P><5GV- MS;RK90C<\J3.<*#A>'&3QTYQ^(JWQ`_B64'\@?Z5A^'=O\`:5CC/_() M7'TRM=51111111114%Z9UL;@VPS.(F,8]6QQ^M<_I=EX8FT..6:*REWQ[KB6 MXVF3?_%N)Y!SGZ56T)I'UO1BY=H_L&H"!GSN,7GV^PG/^SBNPHHHHHHHJAKK M;/#^HO@-MM)3@]#\AJ_63XEMX+G0;Y+B-9%2VDOKTR M;U<7<3/#J3R):"\9-4G(A`Y;_1Q['FFZ!?)<:M#))I:P-+(%62"1_+4E';;M M88!X.<8Y(KJ+U"=1TY^,"5Q[\QM_A5ZBBBH+BQM+O_CYM89B.A=`Q'YU7_LJ M-#FWN;JW/HDQ9?\`OEL@?E4=R=3L+:6X6[AN(X49RLL.UR`,_>4X_P#':TZ* M**Q-;2:/4;"[M54SPB0D8^:5``2@^O4>X%;$,J3PI-$P:.10RL.X/(-/HJE? MG%WIO!.;DCZ?NI*NT44E9OE_V/*IB!^PRN%://$#$X!7_9)(!';.>F:TZ*YR M'.;3(_YC$^/_`"+6SJ"QM;()6VKY\)!V[N1(N!^>.>W6C4K^'2].GOK@XCA0 ML??T'U)XJII[;_#>FOC&Z*W/_H-:M9]RRR:M`'=5CM8FGM7;>VAM81%!&L:#G`[GN3ZGWJ6BL+187O M[>2>\N;F65F0Y6=XP,Q(V`JD`#)-:7]FP?\`/2Z_\"Y?_BJJWMA$@@V37:[I MU4XNY>1Z?>J8Z-:LU__`.#"?_XNJVFZ-:M81DRW MH^]]V_G`ZGL'J*[TBV75M/02WF&\S.;V8G[HZ'=D55T"!;77(8HMY0Z<&)>5 MG(.Y>!NS@5U"J%4*H``["EHHHHHHHHJ.:58())FSMC4L<>@&:XTW44UY;W%] MX6M9[J^B\^S\G#LV,<2$@`<,#GD5J1_:_P#A+-(^W+$LYTV]++#G:O[VVP!G MK@8KHJ*******S]>7?X>U)3_`!6DH_\`'#6A6;K^/["U$YQ_H<5...-PZL5.22F MWH3VS6G1115.7_D-6W_7O-_Z%'5RN8MQC7HR5QG4YR#Z_N!707(E,EOY?02Y M?I]W:WK[XZ5!>L1J6G+G@R.^0MTDL87)EB!D7/MX<;@O,3CD_452N?%NC/J%C.EVWEH)"V(WSC'IC/;I6SHD\-QI:26YS# MYD@CX(^4.P'!]JT**H:B`;W2\L!B[)Y[_N9*OT444R:)9X'A<9612I^AJ#39 MWN-.@DEQYNS$F.FX<-^H-6JY*>U>]LTMX[F2V>369@)8CAE_UG3%.TOP[J&D ML9IKTW`+Q)Y`9W0_.N9"">&QSZ#'>MK4U6ZFM=/90RS/YDBD<%$P?_0M@_$T MVR&/#^G@?\\[?^:UIUEQ6,%SJMYG-7ZY_0+F6.T=4LIYA^Y^9"@'^HB]6!K5^V M3_\`0,NO^^HO_BZJ:A>3XMO^)9=?\?"?Q1?_`!=6_MD__0,NO^^HO_BZ0WLX M'_(+NS]&B_\`BZJZ7>3_`-GQ_P#$LNNK?Q1?WC_MTV[N774;&XGM)K>&-G5I M)"A"EA@9VL<<]^E4-(_Y&:'J,Z4/H?G'^?QKIZ*********CN(OM%M+"3M\Q M"N?3(Q7.Q^&-5BEM9$\0D-:1&&$_8T^53C(Z\_='6K\.E7J:Q87MS>)<_9K2 MY@DD*;&=I)(67"CC`$9!Y]/PUZ*******S_$`)\.:F!U-I+_`.@&M"JFHVS7 MEC1)#9@%E8@RL<[6#?W?:LJ7PS<3:A<7RQVB&K5II^ MH65YYX-HQVLK`N1G<5.>$]5/US6D)-3*@_9[3/\`UW;_`.(H:35`I*VUF<>M MPP_]DIC3ZH#G[/8[3T)NF'_LE.635B,FUL\^URQ_]DJE-<:F-9@_<661;RX! MN6'&Z/D_)]*N?:=0SS;V7_@6W_QNL\:1=._VC[;#:W'VMYTVCS5`9-F.=OUJ M2XTO5Y9(99-;A'D/O3_0QUVE>?G]&-/ELM3EN()6U2S#P$E<6A[C!S^\]ZRF M7Q2LS1G49W&\A9(K6V*D9X/S2`]/:@KXK,R1)?W&2Z@N]K;!0"1DG$A/`ST% M.N5\50W4J_;9I(PWR/#:V^P@C_;E##G(_"G.WBM5*PR32M_"[6UN%/U(FSC\ M*UA%JR@`ZK9$@=39GG_R)3A!K!Z:C9_^`;?_`!RJFJQ:JNDWF_4K/'D/D"T8 M$C:?^FE63%K"G_D)6)X[VC#_`-J5%X,9'RJO0(?3UIWVC5<9^QV/_`(&M_P#&JJW(UE]0LYOL M%IB+?G%XV.5QR?+JY]HU+`Q:V1/I]K;_`.-TOG:H#S9V8'K]K;_XW2-<:@N" MUM9@'H3=M_\`&ZI7L^H/=:8?L]J/]*.-ETQ!/E2<'Y/\XJ_YVHYQ]EM,^GVI MO_C='G:EG'V6TSZ?:F_^-UBW.D:U=WLT\]_)`KM^ZCMM0:-47`&,>5R MF#0=17G^U;W\=4/_`,:IQ\/ZFWS?VG??AJ9`_P#15:=C'?65JEND,$H4D[Y+ MQF9B2223Y?7)-6#+J0ZVMH/^WIO_`(W6=%IE['%$P^S-,NH2713S2%VL'&-V MW)/S#M5FZ.L3H(XK>WB82QL7%TW*A@Q'W.X!'XU!#+J+ZE<71M+8[0(%4W1P M,9)(^3OD#_@--WZG9Z1;PFSM7,'E(2MT>=I49Y3H<5<-WJN2!ID+8[B[_P#L M:JVMYJ@N+S&F1$F89_TH#!\M/]GGM5D7>K'_`)A47_@6/_B:#>:J#SI<7_@6 M/_B:QET:\'B?^V/L*[0I81?:A_K",%ON],9X]:W?M6H8R-.4_P#;P/\`"N:C MT?7K=G'V6&93M`;[?+!PJ*H^53CHO6GC3_$!S_H$/_@VN/\`&FS:5KLNS.GQ MJ%=6_P"0O.V_F1Q>2W==A7/'OG-=!H-S(O^1:U3_KSF_P#0#6C161IFKIJ]S/"88T:'/27> M1AV7YA@;3E2>_%2:E:F+RKZ$?-;$[U!(WQ'[X_``$>ZU?(+KRB,.V3G^E4!? MO-XD;3E53%!:^9*2,G1P1T--,9<_,>@[<4&%#V(^A(H: M)2,9/3N2:79A=J\#WR:55PFTG@?6FM'G&TD'.>IJEK$1_L6]*L=WV=^YY^4U M?"`'//T)I0`#FHVC;)VMQV%)]G']]_Q8UDZW>MIESIL@5Y%,K(P#!02V%!)/ M&,L*T+*=-0MHKQ`55B>`?0D=1UZ5:*!CDD_G3?*RK'\!^I%7O)Z88@]^3 M2F($8W-[?,:5$V+C))^I-*%"]R<^M((P/XF_[Z-,\@ECEWQG/4TR9EM()+F1 MR(XD+N"<\`9[U#I5I)#8Q?:,^:X\R09XWL2S:6*(1YI'B+'.3U_O4HB`R;_P!"CJY111111111 M535O^0/>_P#7O)_Z":MT445FWZ*^KZ:&4,-TG!Y_AK15510J@`#H`.E+15*^ MS]KT[&/^/DYS_P!JI9_P#'U?\`_7P/ M_125;HHHHHHHHHHHHHHHHHHHHHI#G!QC/;-8-I>^(KF2X06FG1/#)L<.\@W< M###CD$8_R*V+-9UM5%RD*39)809V=>V16)97^B7.M+=BXLHKT[X!%'*CM+DK MACCG/'X9-=%1111116=XB_Y%K5/^O.;_`-`-:-%%%9^M1O\`8'NH'"7%HK2Q ML1D<`Y!]B,C\CVJU9VR6=G#;(A(#L?Q!3_`+YK0JEJX)TN8#T!_45=JK:+BXO3_>G!_P#(:5:HHHHH MHHHHHHHHHHHHHHHHI"0!D\"J_P#:-C_S^V__`']7_&IHY(YD#Q.KH>C*<@U` M3$E[%:BV7:T;2!PHPI4J`/\`Q[/X5:HHHHHHK.\0G'AK5"/^?.;_`-`-:-%% M%5-6_P"0/>_]>\G_`*":MT44444453E_Y#5M_P!>\W_H4=7**********J:M M_P`@>]_Z]Y/_`$$U;HHHK/O<=LUI0P0VT0B@B2*->B(H4#\!6;+<7L.L'$.+8E$ M9VR01VQS@');)QV4=P1K44444450UR-)=%NXY9)4B:)A(84W.5(Y`'KBC3+J M:9I89V#M&$=7"[2R,,C<.S<$'^F<5?HHK-OQ+?7#Z8DIAC:#=-(J@L0Q*@+G MCLV3]/6I[&65C-!/())(7QOV[=RD`C(]>W=U<)>1 MR,LX@,D,#0'RFC;#;2_]["KSG`ST-=#%(LL22+]UU##/H:?111111116;J33 M732Z?$Z0QF',TS+NPK;@`HSUX/)Z>^:DT^\>=YK>9HVEAVG?&"%=6Z-CMT(Q MD]/>KU%%<_+=7]]J,$MM$%CC\QX6:$LK8.SYGR-NU345@WES)=7$5Q]I@MH[:Z80*\;,9'&Z,[B"-HRS#\C[5=_M": M:UM_L\*K/.S(PA&Y2,G^\ M,'_#G4HHHHJ&[N!:6DDY7=L&0N<9/8?G65!<3V.H2B:YMKCSID\](T*/"6"H MIP2=RD@#MU]L5MUD:Q<2R"6TB*1HB(\TK(7P&;`"J.IX)_`>N1.FHRQV5Q)< M0[IK=_+*Q\"1B%*X],[@.>ASUZU!:W=Q#=NEP]O*7E59EA!!MW*#:#D\@@#G MCKT]->BBBBBBBBBBBBBBBBBBBBBD.<'&,]LU@VM]XCNGGC^RZ?$\$FQE=Y!G MN"..00:V;4W)MU^V"(3\[A"25Z\8SSTJC]GU*5QY\%@8VD5I`H8L>@SSQG`K M4HHHHHHJ*XB>:(I'.\#'H\84D?\`?0(_2F6EHEHCA6>1Y&W222'+.<8R?P`& M!QQ5BBBJMU9"Y=94FEMYD!"RQ8S@]00001]13[6U6TC90[R,[%WDD.6<^IQQ MT`''I4]%%%%%%9W]CH%:%+NX2U8G-L"NS!Z@'&X`^@/TQ6@`%````'0"EHHH MHHHHHJK/9^9[D@28EBH4-M8]2N>A/7N,\XI6TV(6L,,+O";<[HI`Y`R3Z"K5%%%%1S1+/"\+YVNI4X. M#S5,:8\D\4MU=&;RB"`(PFXCH6(ZX//89[5H55N++S;A;B*9H90NQB`"'7J` M0?0DD?4TU--A6SFMY'>4SDM+(QPS,<<\8Q@``8Z8%-73F:>*2XN#*(FWJ`@7 M>V,!FQU('3H/;I5ZBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB &BBBBO__9 ` end GRAPHIC 18 g18641ke05i001.jpg GRAPHIC begin 644 g18641ke05i001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H`"`$!```_`/9J**************************************** M********************2EHHHHHHHJBVM:4C%6U*U4J<$&9>#^=)_;FD?]!. MT_[_`"_XT?V[I`_YBEG_`-_U_P`:3^WM'_Z"EG_W_7_&E_MW2/\`H*6G_?Y? M\::?$&C#KJUF/K.O^-6H+RUN85F@N8I8VZ.C@@_B*D\V/_GHOYT>;'_ST7\Z M/-C_`.>B_G1YL?\`ST7\Z<"&&001ZBEHHHHHHHHI#DJ<=:YV>"_L]/T837T_ MG)<(DPW`^;D_Q'J:UK2WN8M0OI9I6:*5U,*%LA0%`.!VYS5VJL^IV%M!@5:HHHHHKE=>G*>(H1'>/"(T228BY8")=_+>7T8'H2>FF_:]9_Z!D/\`X$?_`%J:;[5E95.GVX9ON@W/)_2G"ZUC_H&P_P#@1_\` M6IPN=6*G_B7P[O3[1_\`6IJ:E=-*8C;V_F!@A47'(;&<=/2I;2_EGO9K6:W$ M31`'(?<#G\*N@@]#FC(`R3QZT`@@$'(/>EHHHHHHHHHHHHHHHHHHHHHHHHHH MK,\07=O9Z1*UPR@28C78Q_/T+8S6G8BTF^&M[*EBEN`&RH![ M8Y!.37%6DZ/6<%S%)9$LDL096^X>0?>C3/"7AM[%& M;0-.)RW)M4]3[5:_X1#PU_T+^F_^`J?X4?\`"(>&O^A?TW_P%3_"C_A$/#7_ M`$+^F_\`@*G^%'_"(>&O^A?TW_P%3_"M*TL[:PMEMK.WCMX$SMCB0*JY.3@# MWJ>BBHS-$)Q`9%$K*6"9^8@<$X].14E74XU"ZO!/*IM+^"W2,2$(4;9NR MO0GYSS["NHHHHK+UNUO[I;46,=NWE3K*_G2%>%[#`-:=+6)JEN?[8M;A]2L[ M=>!'#-$"S-W(.X6 M\,XA)-1T?[/L^PJC>;O MSOW`'ICCK6O14-S2!MZUB7&LW%AHYU"'S)"+6#E\%B"7`;ZG MBM"QU5;6W^TWNXR7,L*'8N?G9%_(5+K6I/'IL%W:7`A60,PD8<`>6Q!(].*H MZU+F_P!'NS(1M@E;S1P!E5&4A<;3]G.*WH-O_"27&?O> M4,?^.U5L[\V>FIN&XS:A+%DGIF1_\*OVF3H$>3DFWZGZ59LO^/&#_KFO\JSM M9UU=(N;:.0*L":6+RR2,H%V@^YR:D MTCQ=?:AJZZ;-;6ZRF`ON1B5+XS@'TYP?H:C@\8ZG=P/,EE:VR0@B3[1*02ZC M+*H[]JT=1U^ZM+>UN(HXE6\C\Q//8J(\+N()]3P!6*/B!>RV_G#3XH`\GEJ' M,KNWECB@L%D: M>"%XR6./,D/"G\`>?:J$GQ%NBR2)IB1V[';ODD/+@`L.![BNDO-9>RU&"UE: M`"Y#LA+8*@*",_4YKFIOB%=1)._DVK")E4'+?-G'/L!FK=K\0([J(M]G6-EC MB)#O@%F?:<>V.:L:5XNN-3741Y$,3VB%U!8G&"1S^55[+Q1K=\;?R;:SVW%T M]NI);JJEB?IP:JW?CO5+'S!)9VLCQRO&8T9@?E)!.?PS3[?Q]=W$VMS(>3M9M^T>^.]5K/Q]?7'VMWM;58 M[2+<^'.6;=CCU'>M*Y\8F&^U>W6)&%E;+/"3G]YE0QS^==-;S)<6\3@$9X[56\*,7M[ED\PV[2`PM(&! M8;1SAB3UK?HHHHHJO?1SS6%Q':W'V:=XF$`,D@9]Z[33].\5W/@:[O%\8F.UA#@VZV$9W`8 M/WLY'6N4BL=6DFM0NO-O8AE_T9?E^9O?D]_QKH/!FD^)+Q=1-CXK:T"HQ?-D MDAD'XGBMZ'P]XP9[`+XW(+Z>[)_Q+8_D3Y,KUYSD<^U3Z?X<\9O%IIC\=&,/ M:[HQ_9D9\M<+\O7GMS[5B^+;OQMX+\,V^IIXP-TLMSY'D_V?$FW.XYSS_=_6 MN(7XM^.68#^V^I_Y]HO_`(FO>K?0=6^S1^?XLU)Y=@WLD-NJDXY('EG`]LFI M/[!U'_H:=4_[]V__`,:H_L'4?^AIU3_OW;__`!JIK/2;VVNDFEU^_ND7.894 MA"MQWVQ@^_6M6BBJ,D$1UV&X)?S5MW0`1G;@LI^]T!XZ52T[4M0N-:N+:=2+ M="X3_0Y(^AX^/3K3Y]#>;46F%RJVTLT<\L/EY9G3&"&SP/E7MVK8HHHK M%_X2[0_,>,7P+QHTC@(QVJIP<\>U/LO%>AZCJ'V"TU".2X(R%`(#<9X)&#^% M:]9&LZ+-JTD96\\E$`)783E@P(.01QQT.:UAG`SUJOJ,C1:?/(C2JRH2##'O M?_@([FJ/AV:XFLW:YGNY7W9_TF#RBG^R/E7./7%:]%8<<-X/&F-P8MTSG'..E)KNG7=Y=QR6\6]5$>3N`Z3(Q_0&M'28);;2X(9EVR(N&& MY MM$$@D4_Z^$D\^YP*ZI'61%=3E6&163XA?9!D<$03$?\`?!KE-1@27P?$DF1L MM+0_,<F*UUY@2&>WV`'DOL&,^U,NI_M7A73HYE$;W%I(H)/R( M?+/7\*I7MS*T\EN#N;>Z[6/'"1\#V-/U.V5KHR9!OIES?WJ`EDC7 MH,D`E0:SYU%QH6FRX#*VJ&0N>-N78Y_7'XUT%@Q/AN%F'S?9N0/7%6]/.=.M MS_TR7^5/EMH9V5I8EVC(WF3!'\1ZFGW-G;7<0BN(5D0$$*1TJ"71=.F:1GM$) ME7:Y'&1_2H?^$C:??W"3W-L))$&%;)&!^%0KX;TA>EDG7/4]?SI&\,Z M,SEC8IDG/4_XU:CTNRB698[=%$_^LQ_%2P:;9VR1I#`J+&Y=/9B,$_K43Z+I MTDQF>U0NQ)).>2>M*NBZ:@B"V<8\HDIQT)_G3DTFPC:9DMD!G!63_:!ZBFC1 MM-48%G&,IL/'\/I4C:;9.\KM;H6F79('I5E5"J%4``#``[4M%%%%95]KG MV.\-K%IUY>.JAG:!`0N>@))'/%0IXBFDD1/["U)-S8W-&N![GYJ9XMOEMM-% MNT887&1N:0(%VC=W!R>!@=ZK>!P/[,D<2&7+*J[F7(;X,'VO92AMDA0X!#=1].E>V:@-*U'PM=W5O-=JD8(PT\ MBG((S\N?YBLZSTG0M1N+Z:SO;J2&*U1D;[2X^;Y\]_:M&ST;3[69_*FG&^PW MG-T_4]NM.MK*U_XEG[R7G39"6^U/D']WQ]ZI-,L+5X]'9KB;FS);%VX[)[UQ M?Q<2.+X;6$4LS0M9.M6 ML\QMFMFAG:$HS!CE>O2M-B0I(!8@=!WKEO#LUP;+5;^V2^N;C[0T8M+NZ#!6 M4\A3C"CGWZ"NGC15S)Y:H[X+XZDX[GO3Z@O7\NRG?.-L;'/X5R&IZ;,=92[_ M`-(,%I98B<\(7X`/OR26+B'$,(PVT#HV1VR/TKG-(FT34Y] MVKW%Q3\H&,$#O6A8QS:-K-DC:=%:V]W>,F'8M(P((&?S%:$]I*T MVF&*&21+&[EBE:,'/E@G:/H`1^5=-I9SI\8!)"Y49]CBJFO';&IP3^ZFZ?[A MKF)CSM@=Q&"`7SG-.U5('\-DS+(J_:+8KDY8'8HYIZ7);0(8 M&B?%O92#W4:=;V2P1@-(65P>2`!,>/0TVTF@M]5LM160NI`=EYS_`,>_ M0>^!6[J2"2ZO3Y_V?]R/WF,[1E>U49;A=+T?2HV021MJ;0G(YP6?!^N<5OV` M`\/1``C%OT/TJQI__(.MO^N2_P`JLT5'//';0//,VV-!ECC-,ANDGM1<*DJJ M03M>,JX_X">:@36+.2&WEC>1TN"5C*Q,>1G(/'!X/7TI&UJP2.WD:5@MS_J\ MQMGT)(Q\HR1R<=:&%)'$ MDV[8KQ,N2O4XU[3[8S"224^1]\I"[#CKC`YQWQTH?7M/CQODD4 M&)903"^"&^Z.G4^G7VJS9WMO?1&2W^,;F1X]^X<9QR.@S47A^^N;^.>2;#1!P(I/),6\8Y^4\]> M];%%%%%%-?\`U;?0U\P>`[.&]UG4$FAMYBME*Z+.FX9!'(XZXSBO8=8T&P@L MY+=M"T*.4QA@T=H>!GUV\'@TZ7PK;+>7P&AZ$`MHC8%KPOW^1QUX_E0OA:`[ M,Z'H.#9;@?LWZ].M16OAFS+:;G0M&;?I[N08!\_W.3Q][GK[FI]/\,63II)_ MX1_16#VI9M\(RW"\GY>O/\ZY'XHZ+I]A\/;*YATRRM;IM0V/);Q!21B3C.,X MX'Y5X\G+K]:^L4\(^&BBG_A']-Z#_EU3_"G?\(AX:_Z%_3?_``%3_"C_`(1# MPU_T+^F_^`J?X5-:>'-#L+E+FST>QMYTSMDBMU5ER,'!`]*GM=1AN[N[MD#! M[20(^[&"2H;C\#5NBBBBBBBD/0UP>GZI'<:4NF/I5U#I-_,\!O#,I82.QX`Q MTSQFNNNM(M[N*RCD:0"RE26/:1R5&!GCIS5^LF\E@;47LVTV.XRBL[%0>&W` MY&/1N!4=[JDMAI,=U/;*L\A1/*,GR MJ[$#!;'0$]<5:LIKB:W#W5NL$N2"JR;U/N#Z'Z58HK@K.XOK#P[K6H6ER8VM M=2F<1A`1(-PR&SVQZ8KHI;ZXU'5UTVUN&M5CMUGFD106^8_*HR".Q)XKG;:[ MU+3_``CK=W:W$<5S#J,S.YCW`_,`<#/'ZUW4+%H48G)*@G\J?45RADM947JR M$#\JXO7-3NH[FV^TSM%:W40C(`RBL01R<=0<'\*Q/$+^6OVJ^:2X$ZM'&#(` MT4C$<8')5><5FZ3--#XFM_L=U;^5IT9>)IU6,S`]5/OSBMV?Q)/J6O64C6GD M6D-Z7&02[X7C]3@>M="IU.UEM9(Y46%!-+=_,&^=CG81[9Q6]IT;16$2N,,1 MN(]">?ZU2U\(8%$APGERY.W#1Y(P,R>]-U3SQ MX=E,[K,PO+4ROUR/+3D4RVQ'9I$SO+YEO)YB.VW_`)9#@MTQUYYITB2PR2WH M1%3"D6.?P-,NF9A%"WF_:1.,*1M3'VK@_7I1;1M92V\$Z8E(VLH^;& M1/42VT@2.-&?:D0.]B<+FV(KJ=2T^359+VRCD"/+`N'/3(VFF16K3Z3;O(T( M2UOY'E,O3`=QQQUR16O90/;Z%%!(5;9X4=VDF@=U)1]K#(P2/FR._P#6JLNG:C<6,G/2IY;>^^S:XJV$K-<3`P#>G[P;$3/7C[I/..*HZA:Z^]_<-8 MP7D8D8[&:Y78JF,`C;OX.X5-]@U,:5;;X+J2\B,ACF655DBR1@'+,&7UR3T% M3W-CJ%W+<2K`T;^0$82."LS@@J5P3M'!].HXIUW_`&C=>7 MX*A)+$[L=\=:2SLKNV,=U%92('E>2>V+INW8;##!QDY`//I[U7.FZ@L,0M[. M5'B9YX#+*I,;%@=C-DDDX89Y^]UJO'H]Z-=B=]/N3$E_YYF6=55AY00L0&R? MF&>G3/KBM+3M-O+;7[B"!QG`Z=ZDAM;R/77DBMY( M;:4L9PTJM%)V!4=58]^U4;;3;]=+A<6,DW=JY4*WV>4H&QTS57_`(1&!B/-U/495SRKW!(8 M>A]JL^)6G7194@LI+K=PRQ,`RCU&>M4/!`SIDA,_G,&"9W9*A1@#&!C%=-11 M11137_U;?0U\Q_#N-W\2W3(3A+*=FP.V,>GO7LWC%[2/4H;B3SAHRK`D,T4JV! M&V9"I8'&"/44MH")-)`SO&F28_\`(=2Z<2%T+=G)M2#_`-\K7!?&%MWPZL^, M8U0CKGM+7AZ?ZQ?J*^R8_P#5K]!3J**X74M.2P^(NBRK-+*]U)+)(TA'78`` M,`<``5W5(2!U.*6BBN8\8RWJW&CPV-[):23WFPNAX/'<=Q[5J:=J;W#265X@ M@OX1\Z#HX_OKZ@_I5#P+2:3SI!OD8L8T2,_`W%1GC./YG\ZS]6MKTVL:Z:=GEJ0$0[=IQ M\I]P/3O5R:,SV9CE@CFWKAXWY4^O:H=)LC86TD7E1Q*TK,L<1^55[`<"KU(Q M*J2%+$#@#O7#KIVM#PQK%A_8\HGO;F22(>='C:YSR=W;'ZBM2*SU*SUB#58K M%I$N+58+FWWH'C9>C`YP1U[UF2:1KR^'-:L3IRR27UV\D(CG7@,V^E<= M=Z/J*)Y-[$)KB'8+9U`(D`(VJQQC!/'4$5<\/^$/]/DU46<"NLG[N)YG7[.Z M]1C'/YXK334'U"X$EC)]NNE+QK.T92"W8<$`>O(.3VSBK>B:3%'*ZB-6P^^X MG5B5E?J`,^YR?PKI:R=<572-6`*E)<@XQ]P^M59F+@?,AVL^>W/>M>W_Y`\?RA?W`^4=!\ MM/T__D'6W_7)?Y59HHHHK$CUMKO7_L-HZM`;61]S0L/G5E&03@,OS=O3K5[2 M+J:]TR&>?9YK9W;!@9!(X&35'4M6NK35TMM\%M`R#RY)T8K*Q."N\'"D<<'. M:CQEE M>-ONNOS#`/XX.15V^U>2STA;CRU>Y:5;<+T7S"VW\L\U3.OR6.HG2]3NK:.X M+1&*5(FVRAR1MVY)!X/.<=ZGO=3NYK;4CHUS;7%S9MCR6B8X('*$[ADG_P"M M5*'Q!>-JFD*UQ:O9:C%NWK`P8.!G;G=@9YQ]"*EO]2UBUT;4-3CGM"D#,T`- MNWS(.#GY^YZ'V]ZBL?$5Z^MV=A,T&>TCDM)HW\R(@/QG;R.O&?PKTWQTLT(7;_Q-G&,Y_YZ MUXDG^L7ZBOLF/_5K]!3J**YS6-*O;KQCHFH0P[K:U$GG/N`VY'''4UT=&-+:[D0PR1EA$S8)D!&PKCG.<^U=5&,1J"2<`]2[:WFT_+>=L*2P-CH5.#@^AZT[P9IMU MI?AN""\"B9F:0@=MQS@^_-;U45;2C;1(IM/($VV-1MVB0'H/]K.??-7J2J]M M+=O9F2XMEBG^;$2R;A[<^]5KG5C;,4>VD#`HNX_=+,P7@]P">33[O4_LLCQ^ M1(2H&&(PK$D#@]^O-7ATYI:*R/#5[9(+B5`<`*Z*VY!" M):'&<..N3_?_`$IG]@R%W9&NU1UQL%N.GE[/7\:V&M)-2ENXGMY(8I8/+W2C MKG'H?:K/]D;M!CTIY1A(U0N%Z@8[?A5_RA]G\D'C;MS^%%O%Y%O'#G=Y:A<^ MN!4E%%%(1D8K)M/#T-E=1SPW=SB&-XHXR5*HC$'`XSP0,AX%9UUX6BN(V=KZZ>Y+I(9F9`S%.4!^7``/H/SJSI&GW-M=7] M[=^4LM[(K&.)BRJ%4+U(&'HVN[>YN[Z[O&M3NA68H%1L8SA5 M&3]:UZ**********QO$EM>7=G''9VJ7!RQ8,P`'RG`ZCKG%1^%],N=*MY[>> M'8I965N.3CD8!/0UNT44444AZ5XO>W#+X@E16ROD7`*E,]G.<^M5[60_8DMA M'D!9V)8X;[G3Z'.1Z9I+."**ZM3+;NQRH#+,,+\S'F/4P$_P#D,5P7Q:3;I/(L,EO*7C#$*Q` MX)'>NDKE_B&`?"Y)`R+B+!]/FKIU^Z/I2T5AZQIUV=,_6J.N6MYJ&D7\RZ.ML_P"[D.64RSA&!*MMR,8'')KI+6XBN[6*X@NWHJG/J=M9J'OG6T0\*\TB@$\\=>O&?QK+ MNEO+K6[:]M4DN=/\KYA'*NR0$-T!8#.=O./3D6B[4G* M`\MOR`?0BM/3DGCTVV2Y),ZQ*)"3D[L<\U9K!\7>+K'P;I<>HZA#<2Q23"$+ M`H+9()[D'=,L;F!K>].9Y)(04&2&).&P>.3VS6?;?%;0(M-TV MV-O?>;;7OVJ5C&NPY+%@,-G^+CCM4FH?%G0;R[U=Q#=!+ZT6VA.P<8W?,W/` MY[9K8M_CKX9@MHH38ZFQC0*2(TP<#_?J3_A?7AG_`*!^J?\`?N/_`.+H_P"% M]>&?^@?JG_?N/_XNC_A?7AG_`*!^J?\`?N/_`.+I/^%]>&O^@=J?_?N/_P"+ MH_X7UX:_Z!VI_P#?$?\`\71_POKPW_T#M3_[XC_^+H_X7UX;_P"@=J?_`'Q' M_P#%TG_"^_#?_0-U/_OB/_XJC_A??AS_`*!NI?\`?,?_`,52?\+[\.?]`W4O M^^8__BJ/^%]^'?\`H&:E_P!\I_\`%4?\+[\._P#0,U+_`+Y3_P"*H_X7WX=_ MZ!FI?]\I_P#%4?\`"^_#W_0,U'\D_P#BJ/\`A??A[_H&:C^2?_%4G_"^_#W_ M`$"]1_)/_BJ/^%^>'_\`H%ZC^2?_`!5'_"^_#_\`T"]1_)/_`(JGCX]>&<'-?M?$^A6^L6<XM]4O(K2SMVA=W*/*'W?,#R0&VY`8C MI63'XQU"-`JP6HPK*/D/\0P>].A\9ZA!-%(EO:8C`&PH=K?49YJ_HOQ,UO0I M&DM;>R9WC,;/)&Q)!.>N[MVK0@^,_B:!;95@T]OL\)B7="WS`XY/S=>*(OC+ MXDB%EBUTXFR0I&3$W(QCGYJR/$7Q!U?Q-HD>DWT-JL$=P;@-$C!MQW<9+'CY MS^EE#X[^*0`/L>E\?],7_P#BZ7_A?'BG_GSTO_OT_P#\71_POCQ3 M_P`^>E_]^G_^+H_X7QXI_P"?/2_^_3__`!==M\,?%5SX\U&]O]6L[1+G3%1; M>2W#K@/NW9!8@_=%>EUG:MH6G:XB1ZC"TR(M/JBNC6"0QQ+;@)'.;A1N/$F2<]? M4FKU%(0#U&:*6BBLS7?#NE>);)+/6+07,"2"14+LN&`(SE2#T)K`_P"%2^!_ M^@&/_`B7_P"*H_X5+X'_`.@&/_`B7_XJC_A4O@?_`*`8_P#`B7_XJC_A4O@? M_H!C_P`")?\`XJC_`(5+X'_Z`8_\")?_`(JC_A4O@?\`Z`8_\")?_BJ/^%2^ M!_\`H!C_`,")?_BJ/^%2^!_^@&/_``(E_P#BJ/\`A4O@?_H!C_P(E_\`BJ/^ M%2^!_P#H!C_P(E_^*H_X5+X'_P"@&/\`P(E_^*H_X5+X'_Z`8_\``B7_`.*H M_P"%2^!_^@&/_`B7_P"*H_X5+X'_`.@&/_`B7_XJC_A4O@?_`*`8_P#`B7_X MJC_A4O@?_H!C_P`")?\`XJC_`(5+X'_Z`8_\")?_`(JC_A4O@?\`Z`8_\")? M_BJ/^%2^!_\`H!C_`,")?_BJ/^%2^!_^@&/_``(E_P#BJ/\`A4O@?_H!C_P( ME_\`BJ/^%2^!_P#H!C_P(E_^*H_X5+X'_P"@&/\`P(E_^*H_X5+X'_Z`8_\` M`B7_`.*H_P"%2^!_^@&/_`B7_P"*H_X5+X'_`.@&/_`B7_XJC_A4O@?_`*`8 M_P#`B7_XJC_A4O@?_H!C_P`")?\`XJC_`(5+X'_Z`8_\")?_`(JC_A4O@?\` MZ`8_\")?_BJ/^%2^!_\`H!C_`,")?_BJ/^%2^!_^@&/_``(E_P#BJ/\`A4O@ M?_H!C_P(E_\`BJ/^%2^!_P#H!C_P(E_^*H_X5+X'_P"@&/\`P(E_^*H_X5+X M'_Z`8_\``B7_`.*H_P"%2^!_^@&/_`B7_P"*H_X5+X'_`.@&/_`B7_XJC_A4 MO@?_`*`8_P#`B7_XJC_A4O@?_H!C_P`")?\`XJC_`(5+X'_Z`8_\")?_`(JC M_A4O@?\`Z`8_\")?_BJ/^%2^!_\`H!C_`,")?_BJ/^%2^!_^@&/_``(E_P#B MJ/\`A4O@?_H!C_P(E_\`BJ/^%2^!_P#H!C_P(E_^*H_X5+X'_P"@&/\`P(E_ M^*H_X5+X'_Z`8_\``B7_`.*H_P"%2^!_^@&/_`B7_P"*H_X5+X'_`.@&/_`B M7_XJC_A4O@?_`*`8_P#`B7_XJC_A4O@?_H!C_P`")?\`XJC_`(5+X'_Z`8_\ M")?_`(JC_A4O@?\`Z`8_\")?_BJZ72-(L="TV+3=-@\BUASLCW%L9))Y))ZD MU=HHHJ*XMH+R!H+F&.:)OO)(H93WY!K'D\$^%Y9#))H%@S-U)A%-_P"$%\*? M]"]I_P#WX%'_``@OA3_H7M/_`._`H_X07PI_T+VG_P#?@4H\"^%!_P`R]I__ M`'X6C_A!O"G_`$+VG_\`?A:D3P;X810J^'M,P/6T0_S%._X1#PS_`-"]I?\` MX!Q_X4?\(AX9_P"A>TO_`,`X_P#"C_A$/#/_`$+VE_\`@''_`(4?\(AX9_Z% M[2__``#C_P`*/^$0\,_]"]I?_@''_A5RPT?3-*W_`-G:=:V?F8W_`&>%8]V. MF<#GJ:N44444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444444444 M444444444444444444444444444444444444444444444444444444445";E M!=BVV2[RN[=Y3;,?[V,9]LYJ:H%GD:\>`VTBHJY$Q9=K>P&<_F*GHHHHHHHH MHHK/AUS3;C5Y=)BN0UY"NYXL'@?7IWK0HHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJ.&>&X0O#*DBAF0E M#D!@2"/J""/PJ2BN7DN;D?$N.V$\OV8Z<6,6X[-VX\XZ9KH;9+E`_P!IFCE) M8E-D93:OH>3D^_%<9XHJQ117-Z'I]M<^(=0\10+M$Y:VVL/F#QN M4<_0E!BN@>:*.1(WD57?[JDX+?2I******************************** M****************************************Q/"?_((G_P"PA>?^E$E: M5]J%IIL`GO)A%&6"@GN3T%);ZE9W5Y<6D$P>:VV^:H!^7.<<_@:2TU.ROK>2 MXMIUDBB8J[CH".M.L;^VU.T6[LY/-AR17-PQP0S2'[O/09%>B4M%%%%%,CC2)`B#"CM3Z**PO"Z"31;A"2`U_>#* MG!_X^).]69=`M9;M+AI9R596(,A(.T[AUZ$_^01/_P!A"\_]*)*VZ*S->EGAL(WM[AX'-S"A9`#D-(JD<@]C48U"1/$; M6,LLA5P&A5$&T?*<[C6O1111111137=8T9W8*JC))/`%,BN()\^3*DF.NULX M_P`XJ6BBBBBBBBBBBBBH8;JWN&D6">.0Q-M<(P.T^A]*D1UD0.C!E/0@Y!IU M%%,DFBBQYDBIGIN.,U']LMO^?B/_`+Z%3`@C(.0:6BBBBBBBFB1#(8PP+J`2 MN>0#T_D:=111111111111111111111111116)X3_`.01/_V$+S_THDJMJ^MZ M+=0W=C?Q7#>1*$:$;D9^GS``@E>1STIMS>Z/H&N@?9+YKJXA4-*I=T*[@H!) M..">OO[UM6>E6=@)_LR2+]H;=)F5VR?7DG'X4NG:;9Z9;&"R1DB9B^#(S\GK MR2:Y._L-5M+&TT"-K,I?W4I:0LQ(^9I`.G'`%=L!@`4M%%%%%%%%%8GA/_D$ M3_\`80O/_2B2MNBJ>I:>NIVHMVGF@`D60-$0&RI!'4'N`?PJI;^'D@U)+]M1 MO9Y$S\LK(5;@CG"CU/2M>BBBBBBBBLGQ/:7E]X=O+>PN_LL[QG$N,X'G-:5G8R7-K#<-?:A&9$ M#&.1E!7(Z'Y:N?8>/^/JX_[[_P#K4GV#_IZN/^^__K5%<0Q6L+2SWLZ(OM460(!%S.?\`@=(UCE2!=7`)'!W] M*R?"6@KHMCHHHHHHHJC%_R'+G_KWB_]">KU%%%%%%(&!)`()'49Z5FZ-KEOK8NC M;QRI]EG:!_,`&6'<8/2M.BBBBBBBBBBBBBBBBBL3PG_R")_^PA>?^E$E<9KU M[:_\)EJ#>>F%B*$Y[XC&/S!_*M?Q9?VJ:K`3<)_QY@@;NN9HR/T!/X5T.EZF MVN:7<2&!H&5Y(2@<,>G85U-%%%%%%%%%%8GA/_D$3_P#80O/_`$HDK;HH MHHHHHHHHHHJO?'%A<'KB-OY5%;&$7,L@?$C1IO4_PC!_^O5Q6#J&4@@C(([T MM%%%%5[RZ%I$&V,[,<*J]S4%OJ8E>-9(M@F'[N17#HQ],CO5ZEK/U$@7-J7( M5-Q&XC@-CY2:Y?3SK5EXCEAU-!<6K9-Q=@L$'R#"D=,].U=;I:NFFP*X((7@ M'J!V_3%6ZJV/_'L__763_P!#-+I_E?8(?)+&/;\I;K5FBBL?4KQ].U:WG-O) M+#,AAW(5`5\Y&22,9Y'UJA!J%G8V%U>V>G7!CO9"QVRHQ>0\8`W9S[5MZ3!) M:Z19V\PQ)%`BL/0@#-7********JQB+^TYR')E,2;EQT&6P<_G^56J*****R M_$&O6GAW2GO[LDJ&"(B]78]`*MV<"*GVDVT4-Q.JM,4`RQQW/?%5]'T2UT47 M0M6E;[5.T[^8P.&/7''2M&BBBBBBBBBBBBBBBBBL3PE_R")_^PA>?^E$E0W@ M_P"*[TTXX^QSQ8D'Z&I--U:2Z\6:MIK>9LM%C M*[F4KR,\#:"/Q)K>HHHHHHHHHHK$\)_\@B?_`+"%Y_Z425MT444444444445 MD^*+F]M?#MW+I]K]IN-A"Q[MO7J<^W6N5\/Z9KNHZS?0Z^\1C2)5>6$LC2YY M7;CHHP01WKO8HEAA2)/NHH49]!3Z*BN+B*UA,TS;4&!TR22<`8IMK>07BLT+ M'*-M=64JRGKR#R.M3U1U-)1&D\432F,D,B]2I&"1[CK6'X8L98--M+&+>T$$ MK2O/-'Y;2$D\!3SQGK[5U-+48 MZ(`SXQN..M2T444444444444444445CZ7K5C=:YJNB6ML\,NF-&TQVJJ.907 MR,'KUSD=36G,\J!/*B$A+@-\V-J]S_\`6H@>9P_G0B(AR%^;.Y>Q]L^E5[S4 MHK&ZM;>2*5FNI/+1E3*J<9Y/:EU+4HM+MTFEBE=7D6/]VF<$G`)]!6?8V%O; M>+=2N4CF$MS#&[NS@JW48`QD=.];E%%%%%%%%%%8GA/_`)!$_P#V$+S_`-*) M*VZ******0D#J<4M%%,,B`,=PPO7VJ."\M[BWCGBE5HY0"C9ZYI+[_CPN/\` MKFW\JKV9']HW`QSY47;ZUH4452U73UU*S\DA&(8,`_W3Z@^Q!-,TW3WM))IY MF3S)0JA4)VJBC@<]>IYK0I*KV&#:*1ZM_,U9HHJE>VS[A=VVU9XQWX#CN#61 M#XWT^YC\RWL=3N$SC?#9.ZY[C(&#BK-SXH@MT1_[.U*3?@XCM6)'`//YU%X; M\166K">UC6:"YCDD8PSQE&V[SS@UIZ1_R"X,_P!W^M7:*************HQ? M\ARY_P"O>+_T)ZO4444445%-<)`\2L#F9]BX]<$_TJ6BBBBBBHHIUFDF10

:6N*\,?\E.\:?]N7_HHUOZVTB3::R7$D0-XB MLJG`<$'@TWPU+*]AX>9H[R>,/()>=$?' M_/6+_P!&+534IM62^N9M'M(IY#`D<;R2J$+!SN&,YS@_I6^FXHN\`-CD#UIU M%%%%1RK*R8B=4;U9=P_+(K-O;V\L=2TV%I(I(KVY,+#RRI4".1\YS_L@?G6M M2,<*2.PKS_X6^.M6\:/J@U.*U3[&8_+\A&7.[=G.2?[HK5\-7\T5Y#IZA?)N M)M2FH=H$WR*F>2JX.3^!J#1[FZ$E6(^;YB>1TX[5C>+_#>L:7I%I?:==7 MGDVURLGV?:C26Y+K^ M/)X)[A]0OO*MH$ED,2P?<*Y')]NE=5IMCXSOK&.Y;5]642C>G_'M]T\BIVT; MQD"3_;.KD8XP;:JATSXAI-.G2L.*'Q-X=T329I'NKBQF589;9[J.-1O'R@$#('UK5>_U%(_+?PQ M:C@C/]KQ''XXK*T3Q'?6>K:0DUC'//;6MS$WEW++HD@:2AQ_P!/T/\` MC0?%EX`?^)0A/H+^$_UH'C";@-H[@X_Y^X>O_?5./B^0==*1_7;=P\?^/4+XNO&W?\2"?'KAO]VYA_^*IJ M^,[P]?#=T.?^?F#_`.*J4>,)RV/[`O,>OGP?_%TO_"73_P#0!N_^_P#!_P#% MU`GB^Y^VL#X/OX_7O4_P#PETW_`$`[G_P(@_\`BZ7_`(2V M?MH=R?\`MY@_^+H_X2NZW;?[`N?C+%_P#%4O\`PE%S_P!`"]_[^1?_`!50W?C06%LUS>:1VED2D,_EILD0^;P.<@XXSZUJ?;;O_`*!5Q_W\C_\` MBJD-U.+7SOL,V_=CRMR[OKUQ^M.GN)H@ACLY)BPY"LHV_7)%0F^NP,_V3,`_FU.@NKB6 M4))830J1]]G0@?DQ-9^L:W=Z7:&Z73)'CCG6-QO&YE)QE`"Y`;.!UIEK:"._2(V%S-M8.;]YAAVQG.-V<=L8Q6W7%> M&/\`DIWC3_MR_P#11K8\16_VF_T6)H4E0WF3NE9-N$8Y&WN,9_\`UU1BTVUM MO#VI1Q(ZK]L=L&1CR'&.IJY?Z59W_BFRDN8W9H[9W0B5EVL&7!X/N:;I6E6> MH:')9W2/)#'>SE5\UP?EE;&2#D_C3;?[->ZG83FQ2)X9+B-=V&8;3C.??K^- M='1111116)KW_(7\/?\`80;_`-)YJVZKZA>0:?IUS>W3[(+>)I)&P3A0,DX' MM7EOP*TO4+&/5[F[LI[>&[6![>26,JLJ_.09^;;CY1ZX[_A2074-RNZ)P?4'@CZCM4U%%9\VDJT[S6UW< M6C2',@A*X<^I#`\^XJQ9V45E$4BW,6;<[NV6=O4FK%%5;4@SW6.TO_LHJU5/ M5_\`D#7O_7N__H)KSGPWX=O-YI-B@XSTP>E>H(BQHJ( MH55&``,`"G4444444445!>1-<64\"G#21LH)]2,5Q=OK=GI_AVST37=!OY7@ M2.W>,V9EC?'&X$`@CC/K5F0>$HHP[>%I&R<872&)Z9Z;?>LCPUH&F:QKJ7\/ MA]8-/MX[B-C3"N>OTJY_8>D?\` M0,M/^_*_X4UO#VBO][2;)L'(S`O^%1GPMX?)R=$T\_\`;LG^%'_"+>'O^@'I MW_@*G^%`\+^'QTT/3_\`P%3_``I1X9T`?\P33_\`P%3_``I?^$:T'_H":=_X M"I_A2?\`",>'_P#H!Z=_X")_A63J?@?3Y+Z.^L+&RCVC;+:M;J(YE'T'RGGK M5FST7PW=;D&CVT,R??A>(!E_Q'N*M?\`"*>'\Y_LBUS_`-NDVA_[9"@^&-")R=)M2?7RQ0WA?0F!W:3:G(Q M_JA3!X3\/B7S?[(M=Y[E,TU_!_AV1MS:/:D_[E)_PAGAO_H#VW_?-4[[P5X< M,EIC2K=`)QD!?O#:>*N#P;X;48&BVG_?%+_PAWAS_H#6G_?ND_X0WPU_T!;/ M_OV*7_A#?#8_Y@EG_P!^A0?!OAH]=$LO^_0H'@[PV/\`F"6?_?H5R?Q2\-Z+ M8_#W4KJUTNVAGC\K;(D8##,B@\_0U'\"B3X(GR.EZ^/?Y5KTJBBBBBBLS7@# M8PY./]+@_P#1JUI,JNI5@"I&"#WJA;Z3]E=1#?72P)]V`L"H]LD9Q[9K0KGM M`TJV3Q!K?B"VO3.NIR)$T1BV^4T&Z-AGOR#VK0U.UN)KO39H$#BWN2\@+8PI M1ES_`./"J#6]_P#V+?Q"PM76BN6\0V\_V9O(6U9& MDWK@,64XQG/\/ZT:#!,?N)??TR/UKH*Q?&0)\$ZX`"2=/GP!_N&L/X<^,-#U?1=-T2RNVDOK/3X M_.C,3+MVJJMR1@\GM5CPW9SR:C;WJH#!#)J<3MD<,UT"HQ]%;\JZZBLKQ"9$ MTQI(,O-&RNL2GF4`@LN.^1D51\,VUT+NYGO[>))D58ED6%4+CDD@@9(P5'U6 MNCHHHHHHJC8'-U?=>)^_^ZM7JIZM_P`@>]_Z]W_]!-_Y"_A[_L(-_P"D\U;=-?\`U;?0UX'\"O\`D>;W_KQ?_P!& M)7L?A/\`Y!$__80O/_2B2MNBL[6M)_M>U$'FK'CNT>\?ED5'HVB_V0NT2QRC M;C=Y.UNW?/MD^I)-:M%%%%%%4-/_`./O4/\`KN/_`$!:OU3U8;M'O1ZV[_\` MH)KD/A7<&YT:9S;36^Q8DVRKC=A/O#V-=W1111111111156_TZTU2V^S7L(F MAR&*$D`D>N.M5_\`A'M(S#_H,?[@8C'.%YSTJ]#!'!%Y<2!%R3@>I.326T)@ MMUB+ERO\1[U+111111117.Z=JLLVGW:MNFO_`*MO MH:\#^!7_`"/-[_UXO_Z,2O8_"?\`R")_^PA>?^E$E;=%%%%%%%%%%4=/!^UZ MA_UW'_H"TZ]U`6K"*.-IIB"VQ2!@>I)X`JK=7WVC2K^-XWAF2WA4\@CJ M*P_AQ_R"3_UQ@_\`0!794444444444444456L;LWD#2E-FV62/&<_=-IML+.68,]U&C1QE`'R< MC.X=00,57\.7&IP>$S/>6/GSS3EG#2*/,5F^8C'X\=ZS]V>C64HM M[>XE:;?*JK%^ZP<9."``:M*VO8[FXN845@UM($8GH25#GR+5'7K.1H;QMC26]U;F*78`7CZ_,`> MO7I[55\J2#0;J:2$Q00:RA2WJ!T_F:?11111137C5]NX9VG(]C3J*** M**XSXN?\DTU7_ME_Z-2HO@];Q0_#C3Y(T"M,TK2'^\?,89_("NXHHHHHHK!\ M11I+JOAU9%#`:B6P?402D?K6]116)X3_`.01/_V$+S_THDJGXSU!;)M(1Y(4 MCDOXRY<\A1SD>P[GZ5!H>M75Q;:+&8K9H+FXFC9@#D;`Q4J#].I_*HY-0N4\ M/>)KE+-&DCNI%,4IW#&Q>3CKZXK&\&>([+1_#VH'20.>/2MFBBBBBJU]>+8V_FF-Y6+!4C3 M&YV/0#/%,C2TU6*SO6B+&)O-AW9!C8J5/'KAF%1Z?;-#?ZC(QXFG5E^4C^!1 MWZ].U5?&?'@G7/\`L'S_`/H!KAOA_P##"SCTVQU74+XW]O=6:2I:-%L$3N%; M.X-DXY'XUT/AV61=9LX5D81,VJLR!CM)%VH!(]1D_F:[*BBBBBBBBBBJ=EG[ M1>_]=O\`V5:FND:2UE55W,4(4>^*Q]1U6UET"^@D;RIUM7#0S#:W"GMW_"L7 MX7S>;H\B[&4QQPH?B7_KZ?_T4E8MU M;E+?5])>,'[HC=,J/S8_]\U9O[>*0WMPX'FP0V31N>J'=U'H>U=J. ME+11115#5H)I8(I;>/S9()5D$>X#?C@C)XZ&JEK!=RPPPY?=G M<5SSN[\``U9L[V75-.,EL7MIJ7DDZM;Z=J>H6L:$< MJ'DB<8XZ9#=?6N^HHHHHHHHHJ"[O;:Q1'NIDA1W"!G.!D]!45DM.BBBBBBBBBBBBBBBBBBBBBBBBBBBB MN,^+G_)--5_[9?\`HU*/A%_R332O^VO_`*->NSHHHHHHK$U[_D+^'O\`L(-_ MZ3S5MT45B>$_^01/_P!A"\_]*)*T+W3+/49('NHB[6[[XB'9=K>O!%5(?#6C MVTD#16S*T$K2Q9G<[7/4\MWIS:!I2PW2-$ZI=MOG_P!(D&\^OWN/PJ:;1M/N M+:2WE@+1RQK$_P"\8,ZKG`+9R>I[]ZJ?\(EHA613:N1*%#YN)#N"\KGYNW:M MA5"*%'0#`R4)HEDV`YV[AG&?QJS+%'/" M\,T:R1R*5='4%6!Z@@]11%%'!"D,,:QQQJ%1$4!5`Z``=!6;H5GIUJE[)IL" M1)*D'Z4ZY$G_``A-^)?. M_P"/>;9YWW]GS;_Y"_A[_L(-_Z3S5MT M45E^'K*XL-.EAN4".UYP-17=C M)<7UK<)*B)`Q+`IDM]#GBH/$6BCQ!HTNFM.8!(RGS`N[&"#T_"M)%V(JYS@8 MJ!XKPQS!+F-79LQ,8.$8@@'))/3J2:M44444444452U72H-7M!;7 M#.JA@X*8SD=.H-.LAMENER3B4#)_W5JW6;XB&?#FI#_IUD_]!-([EQ\RQ@&NXHHHHHHHHHHHHHHK*\/\`_'O=_P#7[-_Z&:U:**** M************************XSXN?\DTU7_ME_Z-2CX1?\DTTK_MK_Z->NSH MHHHHHK$U[_D+^'O^P@W_`*3S5MT44444444444444444444444444444455M M/]?=_P#7;_V5:M5G>(03XNSHHHHHHK$U[_D M+^'O^P@W_I/-6W111111111111111111111111111111156T_P!?=_\`7;_V M5:M5GZ__`,B]J/\`U[2?^@FL3P$Q.EJO.!:VQZ?],A75T444444444444454 MT_[.T#RVS,R22NQ+?WLX/ZBK=%%%%%%%%%%%%%%%%%%%%%%%%%%%%<9\7/\` MDFFJ_P#;+_T:E'PB_P"2::5_VU_]&O79T444445B:]_R%_#W_80;_P!)YJVZ M*******************************JVG^ON_\`KM_[*M6JS?$+HGAW42[! M1]FDZG_9-8/PYNH;O1V:%L^5'!$XVXPRQ+D5V%%%%%%%%%%%%%%%9GA__D$K M_P!=9?\`T-JTZ****************************XSXN?\`)--5_P"V7_HU M*/A%_P`DTTK_`+:_^C7KLZ******Q->_Y"_A[_L(-_Z3S5MT444444444444 M44444444444444444454L_\`CXO/^NP_]`6HKV_D1S;VBJ\H&9'8_)$/4_X5 M1L8-*U0NLS/>S!_P`N<\[CD_B>:MT44444444444444444 M44444444445QGQ<_Y)IJO_;+_P!&I1\(O^2::5_VU_\`1KUV=%%%%%%8FO?\ MA?P]_P!A!O\`TGFK;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK->I*J!3Y+$1:/<01@O))&^X]W8CDUS/@W3IK?6+J;[0D\10_,@("%B,*M*$P1JUR2W][YS75T444444444444451TJ\EO(IVE"@QW,D8V MC'"L0*O44444444444444444444444444445QGQ<_P"2::K_`-LO_1J4?"+_ M`))II7_;7_T:]=G1111116)KW_(7\/?]A!O_`$GFK;HHHHHHHHHHHHHHHHHH MHHHHHHHHHHHIKN$1G8X"C)K)NM2N[>&*X9(((I7"CSG.0""03CITJE9W=U?/ M=E+<22V]\"\8<8*[!@@FM87E_P!]+:?83WLVE2&*WC:1]LR M$[0,G'-<]\,KN>]MM7NI;5[>.>^:>)''S;7^<$_]]5W%%%%%%%%%%%%%%%9N MB0RPP7(EC9"UW*P##&06.#6E11111111111111111111111111117&?%S_DF MFJ_]LO\`T:E'PB_Y)II7_;7_`-&O79T444445B:]_P`A?P]_V$&_])YJVZ** M***************************BN8S+:RQKU="!^5W3K6'XH-]DU"ZUJPO7,420?:)(PY$8!Z=B0<9KT+P\D^E^(-0T/[7 M-=6D4,<\!N'WNFXL"I8\D<<5TU%%%%%%%%%%%%-=@B,[0W]G%=V[%HIEW(2",CZ&I MZK//.NI0P+"3`\3L\F/NL"N!^.3^56:*************XSXN?\DTU7_ME_Z- M2CX1?\DTTK_MK_Z->NSHHHHHHK$U[_D+^'O^P@W_`*3S5MT4444444444444 M44444444444444444QHHW(+1JQ'0D9K`U"&2+Q7:O;S)#%+!()X@5!FP#@XZ MG%6FGM+33(K(6OF&:'F&,`#:1@DGH![UQFMZ9J$/AY[>WU^Z2W@FAVVT]NK, MJEQMP^>5'K[5%KVC:Q)XI9T\021;[NU3Y8%^4E6P?PQ^M=SHN@C2I9[J>]FO MKVY"B6XFP"0O0`#@#FM>BBBBBBBBBBBBHKG_`(]9O]QOY5G>%O\`D5M-_P"O M9/Y5K44444444444U_N-]*R?"?\`R*NG?]<%K8HHHHHHHHHHHHHHHKC/BY_R M335?^V7_`*-2CX1?\DTTK_MK_P"C7KLZ******Q->_Y"_A[_`+"#?^D\U;=% M%%%%%%%%%%%%%%%%%%%%%%%%%(S!5+,<`-%%+'@@AN'4]&'ZC\*M)(K'?H4/G-+:0VXM[=%+!'D`=VL;+QB&CU:6X M9K^U.V6?=U5OS[5Z#>3WPG6&P6SD8+N=9Y65A]`%/%2W#7PME-M';M/QN621 ME0>N"`3^E0(^M>1(7M[$2C'EA9W*GUR=G'Y&I;)M29F^W16J+CY?(E9B?KE1 M45R^LB=A:P6+0_PF69U;\0%(_6DG?6A)_H]O8,F!S).X.<<]$/&:M.;S['F- M(3=;1\K.0F>_.,X_"JL3ZV1)YUO8`[/DV3N+'6:9U;/T"FFS/K0\OR+>Q;Y!OWSN,-WQA#D4^5M4%I M&8H;0W!/[Q7E8(/H=N3^5$3:H;60S0V@N!_JU25BA^I*Y'Y&DLWU5IL7L-FD M6.L,K,V?H5%764.I5AD,,$5';6T-G;1VUN@CBB4*BCL!45ZVH*$^P16SGG=Y M\C+CZ84TRX?51'%]FALV MF#LYJ8MJ7V$$16OVO/*&5O+Z_P![;GI[5`'UWRF)M]/\S<-H$[XQSG)V=>E3 MP-J1MI3.,DJ".?8U#$^N'=YMO8#Y3MV3N>^[;]-F,_C2QOK1N0);>Q$&[E MEF.XVXZ^]$-Q=PP3S:L+2WBC7.^*5F` M'AS3Y+F"&2*.25$>8E8U)P7(&<#UXJ`-J?V[!AM/LF? MO"5O,Q]-N/UHW:G]NQY-I]DS][S6\S'TVX_6HYWUH3L+>WL6AS\IDG<-CW`0 MC]:1GUK[00MO8>1OX8SONV_39C/XU+>-J:NOV&&T=,?,9Y64Y]L*:BE?6P(_ M*M[`G;\^Z=QAO;Y.1TJ[`9C"AG5%EQ\PC)*@^Q(%2444445QGQ<_Y)IJO_;+ M_P!&I1\(O^2::5_VU_\`1KUV=%%%%%%8FO?\A?P]_P!A!O\`TGFK;HHHHHHH MHHHHHHHHHHHHHHHHHHHI"`P*D9!X(K"GTN2-GB?3H=1MV+>7N8*T88Y*G/!& M>G>KUG8,3)/?1PO-(1A0-RQJ.B@G\3]35Q;>%%95AC56&&`4`'ZTAMH&C6,P MQE%Z*5&!^%8.KO'#JT.GC2;:6VN8)&>0QC]V0"1V[XJSX>T/3=/T"UM;>TC$ M&!,$<;@K$9R,U6\;V<%QH#,]O%))Y\(4LH)'[Q>]8FKZ98CQ0CK9PJXOK3!5 M`,?*W^`KN_+02&38N\C!;'./3-/HHHHHHHHHHHHHID4LXJ*VLH;66>6)2&G<,Y/L``!Z#`J1 M88D+E(D7S#E\*!N/J?6HVCLTCCLGCA".,)"5&"!SP/:I6AB=T=XT9HSE"5!* MGIQZ4^BBBBBBBBBBBBN,^+G_`"335?\`ME_Z-2CX1?\`)--*_P"VO_HUZ[.B MBBBBBL37O^0OX>_["#?^D\U;=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<[K4 M<9U^VG:YFC,=M*/+`/EOE3C<>F>#UK5TV5$T:VD9@$6W5B?0!:XSQ/XIN=2T M-C9>'[^6T::(QW1*HLF)%P0"RO+7;YUM.,,H;.#D<$'!Y%:U%%%%%%%%%%%%%9NA?\@YO M^OB;_P!&-6E111111111111169??\AO3/^VO_H-:=%%%%%%%%%%%%%<9\7/^ M2::K_P!LO_1J4?"+_DFFE?\`;7_T:]=G1111116)KW_(7\/?]A!O_2>:MNBB MBBBBBBBBBBBBBBBBBBBBBBBBBBBBJEU=2I,EO;Q"25P6RQPJ#U-<_J;MKNEZ MGI=Z08T8QS&W)5T`_BYZBDMO"]W:^$I=/N->NIY!;LBS9"*%QQQ@\`5SEY?' M_A"I;.ZL?$22)9X#-!F-649#!@.F0#]*S/!DD+R?VGJEKKVJWB^3*LBPLR@[ MBBBBBBBBBBB MBDJO8-&]H'BW;&9F^8`'DG/2K-%%%%%%%%%%%%%4YEMY-5ME??YT2.Z8Z8X! MS^=7**************XSXN?\DTU7_ME_Z-2CX1?\DTTK_MK_`.C7KLZ***** M*Q->_P"0OX>_["#?^D\U;=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%96IHJS.9 MV=+:XB\IY(V*M&<\'(Z=:YC2;%[75=5%K?O=17*F"&!I"Q4\9L+H7&"JF M,87Z"NYI:*************IZ7="[M&=8EB"32QA5Z?*[+G\<9JY111111111 M11115.XN5AU*TA\I6:<./,[J`,XJY11111111111117&?%S_`))IJO\`VR_] M&I1\(O\`DFFE?]M?_1KUV=%%%%%%8FO?\A?P]_V$&_\`2>:MNBBBBBBBBBBB MBBBBBBBBBBBBBBBBBBBDQGK2*B)]U0OT%.K+\3#/A;51_P!.FG!P/,_]!K2HHHHHHHHHHHHHKC/BY_R335?^V7_HU*/A%_R3 M32O^VO\`Z->NSHHHHHHK$U[_`)"_A[_L(-_Z3S5MT4451T^1GN+]3GY+C`YS M_`I_K5Q65AE6!^AIU9'B:^O]/TDSZ_+')^^:P_&NKZCI\]I;V28Q* M?-;&7/S8R1Z^U:NGZI::G`DMM*&WH'VY^8`]"1VI+741/J-U9M&$:`C:0X.Y M2!SCJ.?6KM%%%%%%%%%9GB3'_",ZIGI]DE_]!-8_@.2.2P<(P9EAMPQ!X_U2 MUU=%%%%%%%%%%%%%)45K)++;J\R;'.:MNBBBJ-ES+?\`_7<_^@K7#>"M=ETVWMK` MVID2]O9%\W=]S&T=.IY.*]'KF_';2CPX?)D\MC/'\V[;@`Y//X5T2?<7Z55U M7_D&7'^Y5L?='TI:*****Y;PJ'7Q%XD5V8_Z6I&>G2NH[5F^'O\`D$)C_GI) M_P"AM7,^/07UK24"%SY5PP42;"<*,\]N.]/E(_X53*T5J\2O`QCB9@Y`+\K,KM*RHRA3P0/7&/RKI M:*********S/$G_(LZI_UZ2_^@FL#X<:;'I^ES&(G;.L+G)SR8P3_.NRHHHH MHHHHHHHHHHJEI+,]B"[%CYDG).?XS5VBBBBBBBBBBBBBL^\=EU:P4,0K>9D` M\'BM"BBBBBBBBBBBBBN,^+G_`"335?\`ME_Z-2CX1?\`)--*_P"VO_HUZ[.B MBBBBBL37O^0OX>_["#?^D\U;=%%%4;(?OK__`*[_`/LBUYUID*6=[X?&Z%Y' MOYO]5()%#?*#R#Z<_7VKU.N>\;1";P^8S++'F:,YBB$C$@Y''X5OK]P?2JFL M`MI%T`0"8SR3BKB_='TI:***S8=7CEU^XTH21&2&,2%`&W`''7C'?UK2KG_# M]JEMK>M$7<4[RS*[(F28NN%)/MV_QK?K.T$8TL<@_O9>1T^^U<=Q7-W6H7]V+BT\MX;=M/(^PH2R!@<;AGMU/7KBM/ M1M13PS<75]+"\ENUI:H$7A_N]<$]*VO"T]S)XFU?S4:*&54GC1N/O#)KKJ** M******J:C??8+;S!$978X50<=BHO!!SI"G_IC!_Z*6NEHHHHHHHHHHHHHHJGI:HEEM25)0))/F0Y&=YR M/J#Q^%7**************I7,0?4[*3S44IOPA/+9':KM%%%%%%%%%%%%%<9\ M7/\`DFFJ_P#;+_T:E'PB_P"2::5_VU_]&O79T444445B:]_R%_#W_80;_P!) MYJVZ**R=9OM3LI(?L-BUTC`^9M&2O*_TW?E3?#\\ES:SS3+MED*,^.FXQH3C MTKB],NX+:ZT6WMF@F+W[^9)R<'"C"Y`(///XUZ97,^/YFM_#+2JA;;,G"MM/ M6NDC.8E/J!535\_V3<[3@[#@XSBJVJZZFDW5C;M:RS&[D";TQB/)`R?Q-:U% M(6"C+$`9QS2US-C=H_C[4;%P5D&.W'\S78T444444457O;..^@\J0LI!W*ZGE3Z MUEZI8+9>&=69II)I9+23?))U.$.``.`!Z55\#9_L=U*6KEXS+(^=V?F9B6_4FK5%%%%%%%%%%%%%5IDMS>V[ MR2;9EW>4N?O9'/'>K-%%%%%%%%%%%%%<9\7/^2::K_VR_P#1J4?"+_DFFE?] MM?\`T:]=G1111116)KW_`"%_#W_80;_TGFK;HHK!\4SP0P0B>ZD@W;MNS/S< M>Q%3Z`GE6O.;%XI-3TV\D?`7499GW2;MJ!5)_+%=]/K M5W%$EU,UM:0.&;;+DE`,8W8Z$YZ=JRO%FHC4_!LD\92*2*:/>I?CURI'4$'( MKL8O]4G^Z*J:T=NC79W!<1-R1G%@%5[G5K&SL$O[BX6.VDV[9#T.>E8_B6>3^V=!@3/ES7.7 M()SP`1[5T32QHRJSJK,<*">37,64<)^(]_*MQ&9?LJJT0B8,!\O.[H>O\JOV MXF_X3"Z9[B)H_LRA(0PWKR.<=>>?;I5/PVY.OZ]$+@2HDHPH4J$)+$CGK]:? MX(LEL=*N8U$0WW+.1'('`)`R.#V/%:.@?\@HR?I7(02K.7:YN?*%QIK"2=DRI7)`^5>_?%27MLDEA>6MI"U MRWD6K-+MPKKM&T@=0?K79^%S%'XGU>WBMVC*Q0LQ+`\[1QCMCTKK:******* M*0G:,GH.MFPO[*6.[C MMY&BDC!ECW*0S(#W'U^@-2>"-W]CRLV\@E-I<8)'E)7#QZ8VH6$8M(HP?MTA M_>R",LQV'`!Y;I@8]JZF:Q:.PN9=)N5>XOGEGC5L*48@?*PWEQX2>6 M.%I)&,,.%4C<57:Y'MR1^%=]&,1J.G`JKJO_`""KG_KF:YSQI`S:CH,ZVBRA M+M`TQSF+++^'/O6SXH+CPQJ)0D,+=B"![5SOB7SD^'%AL8[PD`.%^]D8P:U- M9N);;4]`A0J=\F&+#)88'3^?X4S7)A_PF>@P"!69O,8R;22@`[AJ/PY.)=?UZ,01) MYA[#'%=CX3./%&K([[I_)@,AVGYFVC//3CVKL:* M*******R-;OFCMYK:$QJWE$R2RMM2('@$FJU_=O-X;U2WGB2*6.R=AY;95U* M'#*?2J?@#_D%R?[L/_HI:ZRBBBBBBBBBBBBBBJ&CRP2V!-NKJBS2KAR"HHHHHHHHHHHHHKC/BY_ MR335?^V7_HU*/A%_R332O^VO_HUZ[.BBBBBBL37O^0OX>_["#?\`I/-6W117 M.>*[6._>TM=L/FC=,K2C@!<$C.1UX%7M"G%Q:2.@"H=FQ5&`H,:G`KS>WN)E MU+27N)'G,>IR`>:69L@H"`?S(KT31KG3_$>GKJ8T^-0[L%\U%+<'&3^55O&] MM+-X9DCMAAUD0@!MO`//Z9KH(_\`5K]!5'7_`/D`WWS%?W#SW MNBW,"!K>"Y3SR6QC+ICC//(K.IKG-<19_AK;(UQ" MF8(<2/G:2`.G&"#R3VY`QZU6LHY8_B5?NQ^26T7&1C@;>GKSFI;<1CXCW1#?.;!GY5-H6KIJ.LZU;"U6!K.8(6'_`"TZ\GCV]ZI_#OC1;I/.:4+>/@DYZ@'O M]:WM(S]B;(`/GR]/]]JP/&4J17]@?LWF2-#.$D+#$?R@PW4,;;H[N(1R+P"N.X-5=0 MLYHM!U&:*I_#\YTN3C^"#_`-%+76T4444444444444 M54TV99[3S%B6(&1QM7ID,03^/6K=%%%%%%%%%%%%%4KBZ$>K6EJ858S)(PD/ M5=N.GUS5VBBBBBBBBBBBBBN,^+G_`"335?\`ME_Z-2CX1?\`)--*_P"VO_HU MZ[.BBBBBBL37O^0OX>_["#?^D\U;=%%8?B73+G5$@A@E@1`2763&X],;3@_3 M\:GT2.2*.XBFD65U9`S(,*3Y:]*\ZDM+O3[BQCEC5F?4IA$4DW%?E4+TX)`K MN_!(N%\,6ZW-N;>56?,;#!'S&HO':LWAT@"(CSDW>:/E`S_.NAC_`-4G^Z*I MZXP30[UR)6P'^=,9'?%;/B5%E\-:A&\R0JU MNP,CYPHQU.*PO$<-N_@"SC>]6*`+!^^);YAQZ#/-3^(#''KOAI0A8^G2J7AEHSXG\1^6K<2KNR1C/S=*F\!Q M>7HDI+,S27#,VX8P2!Q]!TK9TK_CT?\`Z[R_^C&K!\8/'%J6ERF9%D7S?+C( M.9#@'`.,#IU-<3>+*(/+DM#;S)ITFX-/N(4,V>,&)YY/*<);VWE MQQE-Y[988)QSWKH_!,/V;Q1J44K1/(UM"0Z-DX"@$444444444E9_B# M_D7=1_Z]9/\`T$USWPV@\C1Y@'9@_E.-QSMS&O`]J[*BBBBBBBBBBBBBBJ&B M@C3@""/WLG7_`'VJ_111111111111165>`GQ)IIP<"*;)Q_NUJT444444444 M4445QGQ<_P"2::K_`-LO_1J4?"+_`))II7_;7_T:]=G1111116)KW_(7\/?] MA!O_`$GFK;HHKE?%Z2-?Z88S(@#$NT8R2H9"0!CKD`_\!-:FB0I`+J.)F9%= M`K-U/[M:\YLKR0R6]J+.-Q+JDH+2`Y0_*-P.>"2!)P)$^1\X)W#'3WK?A),*$@`E1D"J'B+_D7-1_Z] MG_E63XMOEMI='M]O[RXND`;:.`&4D9/(_"MC7@YT&^V`%O(;`(!SQ[UA:ZC' MX>0*B%@(8/;F$S.839*PC+?*#NZ@>M1>'K MBZD\0Z_#<;?+BE7RP%`X.>X'/;K3O!5\=1TRXG\J:-1<,BB67>3@#O@<5K:5 M_P`>C_\`7>7_`-&-7.>/--FO'L)HF4",2HRLP^;SGK[4DUW#;KJ2V*1A/LT`57)`.,9`/!/_`-85U_AF#R]< MN9B)1YMNC`&-50'"Y"\YXXX(KK**********SO$&?^$=U+'7[+)_Z":POAX< MZ2WM'!_Z*6NNHHHHHHHHHHHHHI*BM))9;=7F38YSE<=.:FHHHHHHHHHHHHHI MA5_-#;QLVX*[>2?7-/HHHHHHHHHHHHHKC/BY_P`DTU7_`+9?^C4H^$7_`"33 M2O\`MK_Z->NSHHHHHHK$U[_D+^'O^P@W_I/-6W116#K\4ESJ>GP"WFEC`>5C M`0K`KMP-W8')X[U@YKT#P)-]H\*V\OFRREF?]3*EDDQC,43.HYP1R0>23WJ5-4>]\-WJG_43VHJ"6U MLFT]+>3`M5"A0)"HP.@R#1M,TK MFT?_`*^)O_1C5SGCLK,]E:#[29765E6(CRS@`?/D]!G-<9IQBCTF63[(CNVG M2[YMS`!2[<`>^/UI8Y?(6X6>W\Z);.V.V"8J0.,88#KUR>]=3X0B@/C'6)X& MWH8HPN[[Z\#@^O;GVKN:******JW=R\+QQ0H&EESC)P%`ZDUEQ:I=KJ%S!YJ M7+6X#%%BVY7`/#9P3STK:AF2>))8SE'4,IK.\3R&+PMJCCM:R?\`H)K$^',L M6S5Y&W,6;G\35FBBBBBBB MBBBBBBJDTLBZI;1!B$>.0LOJ1MQ_.K=%%%%%%%%%%%%%<9\7/^2::K_VR_\` M1J4?"+_DFFE?]M?_`$:]=G1111116)KW_(7\/?\`80;_`-)YJVZ**SM8U`Z? M"CBXMX2Q(S/NQ^&*J^&KF2\L9;B0[GD*DMC[QV+S7(/IXC.G/=06%LS7KN8T M&&8X!`[\YZUT7PZ*'PA`8U94\R3&X\_>-7_%44LVB-'%%%(QD3B;[HYZUFW% MA.MD=.LK>WO63RB2KJLD:A@VUL]1\I`H.B?V5X8ORP*!+25(HMV[RU.6.3W) M/7Z"NIC.8U/L*J:G06QCW&;&#N`QEE7_V;]*T****RH+Z MVT[2IKJ[E6*))IB6/^^U9'C#$LNFS!"\7SG<#C@@<>_&>/Q[5P\<\T-G!%;7 M,AM#IDW[O=A7(=AG'>K8D%KIUQ'>)O,)!P,YZXQ7.ZSK7B M34_!][<#0(8+::T8YEN@'"E>NW'XXK)^',NL6.D2Q:5H]B\3&-C_`*7C+&,9 M/3J:[K1=;EU&>YLKVS-G?6NTR1%@P*MT92.HX/Y5L4444444444444E5[&%X M+18Y!A@6/7/4DU9HHHHHHHHHHHHHJK+!(^I6TX`V1HX8Y[G&/Y5:HHHHHHHH MHHHHHKC/BY_R335?^V7_`*-2CX1?\DTTK_MK_P"C7KLZ******Q->_Y"_A[_ M`+"#?^D\U;=%%*\ZMX;<3:6J%F?^U'#!,!/X>E/\` M'20OX:D$YQ'YJ$GCU]ZI>!6MI+C6)H9"TDMSEPPP1C(&?"1T%8TDDJZ'?00PHL7V*4W"Q-NB MA;:&V\MG()Z@8QBJLNNW!UL#_2$??" M5!SY>UBH*].3\V65&!QBN7\=,?^$7A0J"C7\I)()P0SD5VL-K;W-E:F>%)-D:E=XSC@ M4#2=.$8C%A;[`"H7RA@`]1^M1R:%I4L31/I\!1U564(`"!R.GI5BWL+2UE>6 MWMTB>0`.5&-V.F:L44444445SOB*>"]N6\/WMB9K>\M7D$F?E!7/!'Y55L?! MMF/!W]F+)-*TML56225\@L.._09KGM7DDA\*)IA_K6?)!9>'/$J)I?A^_B5;V#:(RW?B#4-:NK)[..:& M."&.7&\A2Q)('3EJZ*BBBBBBBBBBBBDJ&SBEAMECF?>XSEO7FIZ********* M****88U,HEP=P7:.3C'TI]%%%%%%%%%%%%%<9\7/^2::K_VR_P#1J4?"+_DF MFE?]M?\`T:]=G1111116)KW_`"%_#W_80;_TGFK;HHJM?:?:ZC$(KN+S8P<[ M"Q`/U`Z_C4.G1)!/>11($C210JJ,`#8O2H%\,:*A4K8(-LIF'S-PY()/7V%7 M=/TZTTNT6TL8%@@4DA%)P,G)ZT7^GVFIVQMKV$30E@Q0DCD2/;B/&84!;'UJM+HUO+?&Z= MY#EUD:+(V%AT/3/8=^PJZL4:.[K&JN_WF`P6^OK38+>&V0I#&$4G)`]:Y+Q# MH5[KV@I#8D"6*\F;YB!P6<=_K74(MS!#;1)&C!5"R$MC``[>M6JKH]V;YT>& M,6P7Y)`_S$^X_P`]*2.2]-]*DD$:VH'[N0/EF/'48X[_`)59HHHJC,CL?2I:*QM4F`U..%9(`[6[Y5D!<\ M'H>O8_E6AIW_`"#;;_KDO\JS_%1QHF_Y"_A[_`+"#?^D\U;=%%%)@#MUI:***0@,""`0>H-+374.C*>C#!JI- MI-M/I*Z8^_R%55&&^;"XQS^%7!P,4M%%%%(%"C"@`9SP*6BBBBBBFN&*,$.& MQP3ZUS:17<_AFN?\`$49N MDDTP:M';:A)`9(BMN/,(&<[23[$'ZU26RI;W:0S#&Z1H=X/KQD?SJ.VM]1C207.H1 MSL<;"MOLV^O\1S5B))E)\V82#MA-N/UJI=6NJ2SLUMJ<4$1Z(UKO(_'<*G$5 MWL0?:EW!0&/E?>/<]>/I3IH[A[4I%<+',1Q*8]P'_`<_UJM;6NJ1LYN-3CF! M7"A;;9M/K]XY^E6(8KM),S72R+C[HBV_KFH[J"_EE#6M\D"8P5:#?SZYR*>L M5V(D5KI"X'S-Y6-Q^F>*E591"5,H,F#A]O`_"J5M:ZK'.KW&J131#[R"UVD_ MCN.*2.TU=9U9]6B>,-ED%H`2/3.[]:T:2.198PZ,&5AD$=#5>]AO9@GV.\2V M(SN+0^9N_48IPBNA9>6;E3<;<>=Y7&?7;G^M5K>UU5&8SZI%*"I"@6NW#=C] M[GZ4MK:ZK'<*]SJD4\0SNC6UV$_CN.*EO8+Z8I]CO4ML9W;H/,W?J,5$;75# M:+&-3B$X;)E^R\$>FW=^N:GLH;R&-A>7:7+$\,L/EX'TR:K"TU<7`/'W&MMYS]=PILUIJS^7Y.J11X0!\VN[X^E6[?S(XUBGG M668+EF"[<^^,G%<\GB33;275YENHWD,FZ).?WA$:C`X]1BMBZM]2FE#VNHQV MT94?(UMO.?KN%/FM[][2..*^2.=?ORF#<&_X#GC\ZC6UU46SHVJ1-,2"LGV7 M`4=QC=S4ME!?0E_ME\ER#C:%@\O;^IS45S:ZK)<,]OJD4,1^[&UKO(_'<,T7 M-KJDCJ;?4XH5"@,#:[LGN?O#\JG\R2UMH_/<32956<+M!).,X[59I**6DSFE MKC/BY_R335?^V7_HU*H_!K4A<>"K;3Q$5:U5F+D\-ND?_"O0**/PI:2EHKG_ M`!1/]FN]$N-N[RKV1\>N+>:MR)I&A5I%"N1R`#GM_6M.T=7LX67HT:D?E6)XNO;>'25C,T88 MW4`(+@%?WBG-8>KZC:KXP,+S1@B]M&!+C'W6S7=I(DBAD=74]"IR#3J***** M*******0]*AL_*^R1^2NR/'RCT%3T44444444444457S"-0Q@^<8NO;;FK%% M%%%%%5;_`/X]U_ZZI_Z$*M444445QGQ<_P"2::K_`-LO_1J5A_!,8T1CZPK_ M`.C):]/HHHHHHKF?&G32O^OF7_TFFKI%^X/I3J********************** M*******@N;N"S16G?:&.%&,DGT`KG]6NS>Q27>D>9)J$2,L4$S&..0 M_3N!3(]8U1_!TEU!I,UM-%:MM65UW*57KCZBL'4O#5D?!YOHM'AN)(T2YDN) MIA(\X4AF!;W`KD9=2T;4?$/VW4_#@M@9X)C&(FE8Q^7GHHP=V0:Z/PSX[\.Z M;K6I6]E%>Q::P1XXE@=O*DY#C;SM'`KJ1\1O#Q_BO?\`P#D_PH/Q&\/#^*]_ M\`Y/\*!\1O#Y.!]N/_;E)_A0?B-H`.#]NS_UY2?X4H^(F@GH+_\`\`I/\*/^ M%B:#_=O_`/P!D_PH_P"%B:#_`'=0_P#`&7_"HIOB;X&I?^`,G^%' M_"PM%/\`RPU+_P``9/\`"D'Q#T8C(MM4_P#`"3_"@_$/1L'-MJ?_`(`2?X57 MT[XA:.+"$&VU(G;U6RD(_,"K'_"P]&SC[+JG_@!)_A3)/B1HD*,\EOJB(HRS M&PDP!^5"?$C1)8UDCM=4>-QE66PD((]N*=_PL71_^?/5O_!?)_A2?\+&T?\` MY\M7_P#!?)_A2CXB:2>ECJ__`(+Y/\*7_A86E?\`/AK'_@OD_P`*3_A8FE?] M`[6?_!=)_A2'XC:0/^7#6./^H?)_A2?\+(T4KDVNJKGINL)!GVZ4J_$C03]Z M/4$YQ\UE(/Z4#XE>'6D,8:\+@9*_9'R!ZXQ3O^%BZ#_=OO\`P#?_``I#\1]` M'5;[_P``Y/\`"JW_``L30SJ8817Y'DD9^R/GKZ8JR?B/H0ZQZA_X!/\`X4?\ M+'T/_GEJ/_@$_P#A1_PL;0_^>.H_^`3_`.%+_P`+%T3_`)X:C_X!/_A2-\1M M$1"[PZBJ*,EC9N`!Z]*$^(^ARQK+%%J$D;C*LEFY!%*/B'HQ./LVIC_MR?\` MPJ#4/B#H@B53'?Y\Y%YM''<>U6/^%B:!@$M>`G^'[')G^52?\)[HVY0([\[N MA^Q2?X4Q_B#HJR;/)U%C[64G^%*?B#H:_>%\/^W.3_"FGXB:""01?`CJ/L4G M^%)_PL;0/2__`/`&7_"N7^)7C/2-5\!ZC8VPNQ-+Y>WS+5T7B13R2,#@5)\$ M_P#D!'_KBO\`Z,EKTZBBBBBBN9\:=-*_Z^9?_2::ND7[@^E.HHHHHHHHHHHH MHHHHHHHHHHHHHHHHHK(NFNEO;J:WMEGN(HU$$;OM!!ZG-8&G7UY^/>N=USP/H-KX=OW@MYH M_+MG*JMS(%!`/\.&H6B>(8N;0,6%TGX_P`8[&NATO4[35[%+NT;*,.5(PR'N".QJY@> M@HQBEHHHJMJ&GVNIV;VEY")8I!R#V]QZ'WK)TVZNM'O$TC4Y3-&^?LEXW_+3 M'\#?[0'YUO`YI:**0_=/>J^GLCZ?`Z1>2K1AA&/X<\XJS3719$9'4,K#!!'! M%6 M[DCU#3Y1;ZE;C$0<3V[_>0^H]0>QK2JON M3^T=GE_/Y6=_MGI5BBBBD95=2K`,K#!!Z$5S`:;P?=;:%,WRD#)LF/8_[ M'\JZ9'25%>-@R,,A@<@BJVHJK6Z;E!Q*A&1WW"K6!Z"EI*,"C%+7&?%S_DFF MJ_\`;+_T:E8GP4`&A9&6X=69E,IX!)R>![FM"LWQ&Q3PWJ3*`2+63&>GW36=X('_$D5R`&9("?^ M_$=='7/ZOHUS;WG]M:&`EZH_?0'A+I?0^C>AK2TG58-8L5N8`R')62)QAHG' M56'J*O4444456OK"VU&T>UNHQ)$_4=P>Q'H1ZUBZ?J%UHMZFCZS+YD;G%G>M M_P`M1_I(JU13)(TEC:.1%=&&" MK#((]ZY9([GP9=,P9[C09GR5/+6)/IZQ_P`JZI65E#*00PR"#P:=1111116; MJVF-=*MU9E8K^'F*7'WO]EO532:/K`U*%HYXOLU["=L]NQY0^H]0>QJUYDG] MHB+CR_*+'ZYJS11113719$*.H96&"K#((KF61_!UT9E=FT.=_G0\FS<]Q_L$ M_E6]=R)):QNI#HSH5(.01D!F+:*..`D`!]?W$==+16# MJ6E7EGJ#ZSHS`SN/])M&.$N0!QCT;W[U?TC6+76K(7-L2"#MDB?AXF'56'8U M?HHHHHJKJ&GVVJ64EG=Q^9%(,$="/<'L?>L:SU2?0KN'1]8=GCD^6TOVZ2^B M/Z/_`#KHZ*1N5/TJMID;Q:7:QR*5=8E#`]0<5:HHIDD:31M'(H='!#*1P0>U MR!['^\F>_:NIBECGB66)U>-P&5E.01ZT^BBBBBBLK M5M&-Y-%?6`V]W!$1/$>0#D8(/<'M M6[111113)8HYHFBE0.C@JRL,@BN+U9;OP9;*\3-<:(;F,L&)WV0W#./5/;M7 M9P3Q7,"3P2+)%(H9'4Y#`]ZDHHHHK!\;:!/XH\)WFCVTT<,MQLVO(#M&UU8] M/I7%_"OP]?:)J&N:9/>L?L4D<6^,?(QP6XSZ;J](%M./^7R3_OD5':-,+^XB M>-.VC3"=5!5X M@A7^)/)CVD^^*ZRBBL#5M*ELKUM=TB,_:@/])MUX%T@[?[P['\*T]+U2UU>R M2[M)-R,.5/#(>X8=C5RBBBBBJNHZ=:ZM8R65[$)89!@@]1Z$'L1ZUFZ2USHV MW3=4O5F5FVV<[\-(O]UO]H>O>MRD/2F6ZNEO&LDOFN%`+XQN/K4E%%%-=%D1 MD=0RL,%2,@BN8C_XHR[,;%_[#N&RK$Y%F_I_N']*Z1IXU@,^\-&%W9!R"*I6 M>OZ9>V4=Y'=(D,APIE.S/YU*E_)+?O!%:L\,>-\^\``D9&!U/6I;*[2^LX[F M-2JR#(#=15BBBBL'6M$N+S4(M2T^X^SWMK&PB/\`#)S]UQW7^57-(U=-2C:* M6,V][#Q/;MU0^H]5]#6E111115:_@6XMO+=592ZY#=",BN?+3>#KIV.1)8UDC=71AE64Y!%.HHHHKD?"0F_P"$I\5[I`8/MR;$ M]&\L9/\`+\JZF>=+>(NY^@'5CZ"LN>]CTJ#]Y)$MU,AN.D MKZW4H_\`)::NBC`$2!>FT8I]%%%%%%%%%%%%%%%%%%%%%%%%%%%4M0OVLWMX MXK9KB6X:E:6!47$H5G^ZH!)/J<"J>ORQS^%=0EB<.CVDA5E.0?E-9?@ M'_D$R?2#_P!)XJZJBBBN=UC1[JTO6US0E`O,?Z1:DX2[7W]&]#6II&JV^L6" MW=ON`R5>-QAHV'52.Q%7J*****KWMC;ZC:O;740DB<<@]O<'L?>LBSO[G1KQ M-+U60R0R';:7K?Q_[#^C>_>MYONGZ53TC_D#VG_7%?Y5=HHHHILD:2QM'(JN MC#!5AD$?2N2NDG\&F5X@T^@S`[X\Y:R)[C_IG[=JX+2S'+X/N9!&UX(]2=44 MY=1E<`A_09ST[5W%UK=WIFN6MC"T.V=HDEROWN$''/H?>NB\/G.B6_T/\S6E M1115(G_B=*/^G<_^A"H-8T<7QCN[5A#J%M\T$W3/^RWJI]*71M974UDAFA-M M>VYVSV[=5/J/53V-:=%%%%5=1.+8?]=$_P#0A5AT61"CJ&5A@J1D$5RTD;^# M+OSX0SZ%.W[V/.?L;'^)?]@]QVKJ(Y$FC62-PZ.,JRG((I]%%(QP,UYC\/)- M2O\`Q)XCO5N$_P!)E4L[H>""RX`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`XL=0>_2M72]4M=7LTNK2303># MKJ2:*)YM$G?=(B#+6;'JP']S^5=+!/%6_#34[7 M3KW5H;M9HY);@[6\HE<;G/)'3K7IT=Q#*H9)48'T-4KK5#')(L`C98AF661] MJ)[$^M3V=XT[-%-'Y*9C"1\AQ#- M\WL1G]:[>R_X\8/^N:_RJ>N,^)5G+>:1;@Q2/:I(3*\0+-$<<-CN.N:YS1[- M;>?5I4*WEO\`V:5N)\LL>`@PH/(-/5)X(JY16-XO\`^1/U?G'^AR\_ M\!-Q(TC4G9GN4BDMKG;B-LPIB//\`>`Q]:]%HI*6BBBL#5M(N;:\_ MMK1`%O%'[^WSA+I/0^C>AK2TO4X-5L4NHM[:[B$D;PJ"I[<=1Z'WJI;7DVA746FZC,TMM*=MK=OU]HW/KZ' MO]:WJ******:Z+(C(ZAE88(89!%HHK,UC23?I'/:R"W MOK<[H9@/_'6]5/<4:1K"ZAYEM/&;>^M^)X&ZC_:'JI[&M.BJU]_Q[C_?7^8J MS112,`RE2`01@@]ZY:Y0>#K]K^$2'1[EO])B7E;5O^>@'93W`KIX9H[B%)H9 M%DCHIQZ&O/?A=&JW&K,!R\A)_P"_DE=ZUK;L23"F3U.T5D:CH,<\ M%S:B`R6=W@R11OL96'<'WJ]86URLKSW&$RBI'$#G8H]3W)J_1117,^,4B\W2 M7D4?\?,H9@/FV_9IN];]E_QXP?\`7-?Y5/14%Q9V]U9RVDL8,,RE'0<9!Z]* M;:6%K911QP0JHB38AQE@OIGK5FBBBBBBBBBBBBBBBBBBBBBBBLKQ!I][J-AY M=C=>1*ISM/W9!_=-85UJ%DH8MJ#VE[(^)8+B;_CW.QN0,<#^=6-&LK_4;B'4 M/M;VUF($C"Q#:9RH^]C'`YXKH/L7&/M5Q]=__P!:@6..?M5P?J__`-:N3\?7 M4-KX;O[2.2^NIVMY"R0OD(NT\N<<"J'A+PU9ZSX=D@NKB[92MNRD2XV-Y,9! M4XX(S6E8R7F@:G%IFNWUU/'=/BUU`OA6/:-QCY6]/6NH%@`#_I-P<^LE13Z8 MS6\B17MS'(Z%5??G:<<'I7'?\(AX]"X'CDX]3!S7;:9!650+JRS_SK2T;6;76[+[3;%E* MDI+$XP\3#JK#L:T****0]#4%@8VL(#$AC0H-JGJ!Z4Z[M(+ZUDMKF)98I!AE M;O63!?3:+<0Z=J2>V#W6ALVY[<#+V?J4]4]1VKIK6Z@O;:.YMI5EAE7,&LUK+4?#(>YT';>Z4"9)+'=EX_41']<'TKH["_M]3L(KRU??%*N0?3V/N* MX?X7,"^J`J=WFMSVQYLE>A4444445SWBD`W>B`C(-Y)_Z335M6?_`!Y0?]G)/YULT4444444444444444444444 M445G7^B6.H7"3SVZ/(HVLQ`RR]=I]16@````,`=!2U6U&40V$SE]F$.&SC!Q M6-XCL[:'P-K"6X&'LY2S@Y+':>2>]9WPRGEGT&5I8##M,2*#_$HAC`;\1S74 M:GIMKJ^GRV-Y'OAE&".X]"#V(]:P]+U&\T&[CT779?-1^+._(P)1V1_1OYUT M]%%%%%%<[J^G3:;?'Q!I`35?3YGN-/@FDQO=`3@8%6:AN[2"^MGMKF)98I!AE85DV4 M\^C72Z;?S&2V?BTN7/)_V'/KZ'O6Y1111112$!@00"#U!KEI4E\'7C7%O$9- M#G;=-$@R;1SU8#^X>X[5TT,T5Q"DT,BR1N,JRG((J2JS3.-22'C88BQXYSD5 M9HHHHK(US0SJ7EW5I.;34;?F"X4?^.L.ZGTIVBZPU^'M;R+[-J%OQ-">A_VE M]5/K5R_.+<'_`&U_F*LT445A^(?N2.561X+626"-QN5I!CJ.^/3WK.TJ6YBD MT:1\6]S>(S7=O''M4D#@E?X>OXT_5+&^\.W-QJ^CJT]K+E[NP'KW>/T/:MF MSYLH/^N:_P`JGHK$T'_D+^(?^P@O_I/#6O/-%;023S.(XHU+.['A0.2361_P MF?AH_P#,;L_^_@K:ZC-+11111111111111111111111117.:\UR1?F!5>ZAA M1[2-EWAN?FPIZGM5;6EC_P"$>UI$?8ATQC*JI@(^T]NQQVJ?P1:_9=(VB02* M8X=K`C.!"@Y';I72U!>65MJ%J]K=PK-#(,,C#BLK2RV@JFF:A>M+&TFVTFF( MRXZA#[CU/6MRBBBBBBN?U32+JSOCK6B\7``$]H.$N5SS]'ZX-:NG:C!JEFES M;GY6R&4\,C#JI'8BK=%(WW3]*JZ4I32[96!!$8R#UJW145S;0WEN\%Q&LD3C M#*PK&M+JXT.Y33]1D:6TD;;:7;=O2-SZ^A[UO4444444A`92K`$'@@]ZY>YM MYO"=XU_9Y;1I6S=VPY^SD_\`+1/;U'XUTL,T5S"DT$BR1R`,KJ<@CUJNRG^V M(VYP(&'M]X5)/^18U3_KTE_]`-?/R=5^HKZ23[B_2G44444444444444 M44444444451OM1^S!EAC\Z55+%1_"/?TING:DUVL8N(O(DD0.BYX8>QJS,/CH>A'T(YK(\46T-KX)UE((PB_8IB0.YV&J?@%63271NH2W'7/_+!. M]=515:_L+;4K.2TNHQ)%(.0>WH1Z$5DIJ,N@WEEI>HS//#.NR*]=,9?LC$<` MX[GK6_1111116#>Z5<:?>W&L:/DS2KF:S)Q'.W][V;'<=:T-(U:VUBR6YMVY M'RR(00T;#JI!Y!J]2'I4=L)1;QB<@R;?F([FI:**BN;:&\MI+>=`\4B[64]Z MR(;NYT6X@LM1E,MHXV17K\$OV5L<#COWK&X61K>\MI4:&=.H^8<'U'L:GT;6S>SSZ?>HMOJ-LW[R'/WD M[.OJ#[5L44455O-.M;X`S1C>OW)5X=/H>U9VJ:H^A6BO?"2:T"[9+E4+,ON5 M'\ZQ/`Q8WNY0OE2:="RLO?YW_I7;4444445#=?\`'I-_N'^5)8_\>,'_`%S7 M^53T5B:#_P`A?Q#_`-A!?_2>&K'B3_D6-4_Z])?_`$`U\_)U7ZBOI)/N+]*= M111111111111111111111117/WD=X]M?1V=Q%!<>8S2^9'NWQXX`_"L;PZ=3 M;3X8IK=;:X^U*8"03F/;RW/;'%=6\UU:8DN&62'HS(N"GO\`2L?Q9KFDGPMJ MT(U*V:1K.50HE4DG:>*Y_P"&.MV]MHDT>IZI9^=F(H`X7">4FT8]0.#[UZ!; MW5O=Q":VF2:,]&1@14U%5=1T^VU2PELKN/?#*N&&<'Z@]C6#I>HW>A7Z:'K4 MIDC?BQOF&!(.R.?[X_6NHHHHHHHK"U6PN;&].M:3&'GQBZMP<"X0=Q_M#MZ] M*TM,U*UU:R2[M'W(XY!X93Z$=C5IONGZ54TDDZ3;$DDF,9)-7****BN+>&[M MWM[B-9(I!AD89!%9-I.^B7*:;>S,]M)Q:7#]O^F;'U]#WK;HHHHHHI,`]:Y6 MYSX7UY;B&)WTR:-FEC3G[*=PRX']TG&1VYKJ(I8YXEEA=9(W&593D$4^BBBB MBJU__P`>I_WE_P#0A5'7-"755BN;>4VNH6WS6]RG4'^Z?53W%)H>MO?F2ROH M?LNI6W$T/9AV=3W4UL4445'.,P2`XY4]?I7+>$+46]S%M88_LV+@=.7K6EM#\.U6UT.SDDN[=+> M`Q!2=\@"@[L>ISFLKPG'J/A^]73-7TG3G5[F&W+G:9$!C^4],$?+74Z"!#X\ MU^WM8T2T$-NVV,8428;/3@''6NLHHJM?V%KJ=H]I>0K+%(,%3_,>A]ZP]-OY M-`OH]"U69WC?BQO)3Q*/[C'^^/U%=+1111116#JVE7%M=?VSHP`NU'[ZWSA+ MI?0^C>AK2TW4K?5[!;JV8[6X96X9&[J1V(I^GPFWL(86()1`"5Z&K-%%%%17 M%O#=P/!<1K)$XPRL,@UCP7$^A74=C>NTMA*=MM=,IR1_A6-<02>&;E[ZT!;2I&S=6PY\@_\]$'IZC\:WXI8YXDE MB=7C<;E93D$4^BBBBJU__P`>I_WE_P#0A5FLW6-(74XDDBD-O>0'=;SKU4^A M]5/<5!H>N-?/)87\0M=3MQ^]ASPP_OH>ZFMFBBF2_P"I?_=-VTZ(PQI';K)OAD@?+M\C'/3K4>D: ME-'>1Z=9V\ER)+6.:9I"%\LL#DGW/I6?X06]M7\J&T1(VNIB0[D$'`SCVKLB MUZRD-;P\]B]<3XF\)6T5G%-!8+$6NX04CNY%3F09PN<"L?6_"RS^)S)+9QDR MW\"-_I4G.4)_SZ5Z%I6E_P!CVI@LK&WA4G<<.Q+'U)/)J\6O,<11?]]&D9[X M9(BA(`Z;CFN)D^)&JQR.A\&:F2K$9'0XKKM`U.;6-)BOKBQEL9),Y@E^\N#W MJ;5-+M-8L)+*\CWQ/Z<%3V(/8CUK(T^_O=%O8='UF3SHY?EM+\\>9CHC^CX[ M]ZZ.BBBBBBL._P!+N;.\DU71]OFN,W%J>%N/?V?W[]ZF\.:G8ZEI$;6,I=8A MY;HW#QL.JL.QK6HHHHHJ*XMXKNWDMYT#QR+M93W%8\-W9Y+X7'&,KG^E62`P((!!X(/>N>>WG\+O M)M:)%J\2.DC6UY`=T%S']Y#Z>X/<4S2-8>YE?3]0C$&HP#Y MT[2+V=/4']*UZ*9+_JG_`-TUR?A)7&H1%@?^0;'SC_IH]=?11111145S_P`> MLO\`N'^5,L.=/M_^N2_RJOJ.NZ5I$B1ZA?PVS2#*B1L9%5X/%WAZYGC@AU>U MDEE8(B*_+$]`*9H/_(7\0_\`807_`-)X:L>)/^18U3_KTE_]`-?/R=5^HKZ2 M3[B_2G44444444444444444444UW$:,YSA1DXKF;V^B!BN;][]EN9C%;QVBD MJF&VC..YZ\UIPWC61ER[L1]YJP!K0T36[*PU`RR_:2S)= M"W*J7(`V8'?O74RW\$$<;REE$C;5RIZ^_I6-XMU""#3(MP=Q]K@(*+N!_>+7 M,:AXCMI/'46GM#/%++?6[1^9&5#`(<_S%>ABY1KEK022QRC^!22I'0@]B.U<_IGB2? M1KQ='UR.Z96<)9WS1$"H2S:7!XC\/Z56<;#$0S?0=Z=)=K'`DIAF(?^$1DL/J.U5KB\MKJWD@N+*X MDBD7#HT!((K,M+YO#\T5E?2326%R0+.XD!S&3_RS<]O8FMF;4$AE,9@N'QW2 M(D'\:2+48Y95C\BY4L<`M$0/SJ9;@--+%Y4H\L`[BGRM]#WJ#^TU_P"?6[_[ M\FI(;Q9A(1#,GEC)#QD9^GK6//X@@3Q)9VWV6[9I;5V&(3Q\PZ_]\G]*TCJR M*0#:7G)P/W!J:2\6.W28PSD.<;1&2P^HK`NKB3POJ9D@@GFTN8&2>*.,D6Q) MY=?8]U_&M2U\06EZL;V\5R\_BN)?+190V,_,A`JK?WZG3)9O)N%$K(U&( M@?NI_P`8C3WO8X[6U MY;G=!H-$L]=5_ M::_\^MW_`-^33XKY)5D/DSIY8R0\9!/T]:7[:OV99Q#.0QP%$9W#ZBHSJ:C_ M`)=+O_OP:D:]18X7,4Q\XX`$9R/KZ47%Z+>38;>XDXSF.,L/SJ,:DI95^RW8 MW$#)A.!GUIFIWSPVURD-I-/*D)<*!@,/0,>,^U4M)\0V=QIMNT45TZB,#<(& MQD#FN)\;Z9K7B$Z?>VMC+ZCBC MNHV=V484!ADGFO4M!_Y"_B'_`+""_P#I/#5CQ)_R+&J?]>DO_H!KY^3JOU%? M22?<7Z4ZBBBBBBBBBBBBBBBBBBBBLU]+N(IWDL+XVR2MO>-HQ(N[N1D\9JS9 M62V<;#S'EDD;=)(_5C_0>U6:0]#7&^%!Q%7] M>DFC74)XB#=6]N#:QNNX')Y.WN<\>U<_XBDO8H[>*TBCD+RV M$?+=*/7T<=QWKIJ*****K7]A:ZG9R6=Y$LL,@PRG^8]#[UA:=J';E+.X9YM+E8+!<,X7K&W]0>XJGI7B(277]DZLJVFJ)@;"?EG_`-J,]QQT[5N2?ZMOH:X_ MP=_Q_1O\`Z->NRHHHHHHJ.?\`X]Y/]T_RJ+3@!IUL``/W2]/I4D%M M%;!Q$NT.Y)?Z9;0& M[MYVCB1G\L>8N&9L\X[U7O=1N]3\31G3==TV56U.'""(EB?+X;W`Z5UR"7Q# M)J?A[68XQ/9B.2.YM\C[V2K#/1@5-36&M7>EWT.C:^1YL@Q;7PX2XQV/]U_; MO71T444453U32[36+&2SO8A)$_YJ1T8'L1ZUCZ??WNAWD.D:Q)YT,ORVE^>- MY[(_HV._>NCI:**0]#5>PE,UC%(552RYPHP!5BN?U/1+FVU%M:T,K'>$?Z1; MGB.[`['T;T:K^B:Y;:Y:-+"KQ2Q-LGMY!AX7[@C^O>M*BBBBBHYX(KJ!X)XQ M)%(I5E;H16*D\WALQV]V[SZB/= MH_ZK^5;EI=0WUK'=6[AXI5W*P[BIJJZA_P`>;?[R_P`Q5FEHHHK.U;1+'680 MEU$/,0?NIEX>(]QR!5&RUB6TN3HVLL$NMI^SW!X6Z4#J/1O45F^#T1+V' M:V?^):A.?4R/FNQHHHHHHJ.?_CWD_P!P_P`JBTXYTVV/_3)?Y59HK$T'_D+^ M(?\`L(+_`.D\-6/$G_(L:I_UZ2_^@&OGY.J_45]))]Q?I3J************* M**********Q=0O+B:&=X+Q+2*,,$;`+2,.N,]L\?A6=%;V.K3V,VJQK=^4^Z MVGEC",D@&<$=_45KZO#I\NDW4$JQ;)8F3"@9.1C@>MAP3[_`%)K MN?#^F:A#J%_JNJ&!;J]$:>5;DE8T0'`R>I^8FM+4]+M-8L9+.]B\R)Q]"I[$ M'L161H^HSZ7=C0=9N3).,FTNG&/M*>A/3>.A'?K71T444454U33;;5K"6RNT MW1R#J.JGL0>Q!YK#TC5+S1[Q=$UZ0,3Q9WQX6X7^ZWHX_6NGHHI#T-5-*!&F M0`YSM[UYT MR5M]Q;*,M">[H/3N16[;7,%Y;I<6TJRQ2#*LIR"*BU#_`(\V_P!Y?YBK-+11 M116?K>CV>MZ;):7B97&Y'7AHV'1E/8BN/^'3ZE]H6'48T'DV"QP2!LF5!(X# M-Z&O0*******CF_U$G^Z?Y5#IO\`R#+7_KDO\JM45B:#_P`A?Q#_`-A!?_2> M&M+4;,:AIMS9,Y07$31E@,E=PQG]:X0?"&S!'_$XN./^F2UZ&!@`>E+11111 M1111111111111111117/ZI90BUFANK)KE0'>"18]VPG/'MSWJKX0<@[1P:SO%/'A/5^EVFK63VEY$)(VY'8J>Q![$>M9.FZC=Z5 M?)HNLR&0N?\`0[TC"SC^XWHX_6NBHHHHHJM?Z?::G:/:WD*S0OU5AT]QZ'WK M#TO4)M%OTT+5'=HVXL+R0Y\Y?[C'^\.GO724M(>E16HF%L@N"#+CYL>M3445 MS^MZ),+H:WHQ\K481\\8X2Z7^X_OZ&M#1M9M-;LOM-JQR#MDB88>)NZL.QK0 MHHHHHIDL4<\312HLD;C#*PR"*PD>?PW=K%*=^CRL%C?X><:C86HDLB2U[!$OS?]=%'M MW'>M"6[M[_25NK65989=K(ZG((R*OTM%%%%-?[AXSQ7,>&2C7\3*JHQL%)5> M@_>-74T444444R;_`%$G^Z?Y5#IO_(,M?^N2_P`JLT5B:#_R%_$/_807_P!) MX:VZ****************************CGF2WMY)Y,[(U+-CT%<[XN@OM0\( M7[_:'T\+;2/)&@5S(H4_*3VS[4WP-&J:=*P^\RP[N?\`IBE=111534]-@U6Q M>TN,A6Y5U.&1AT8'L0:S;#4IM,NH=(UB=7FD&+:YQ@3@=F[!O;O6[1111153 M4M,M=6L7L[R/?$_X%3V(/8CUK(LM1N-$O(=(UB;S4D&VUOGP/-/]QO1OYUT- M#?=/TJII+%M(LV9BQ,*$DG)/%7****P-4T*XBU+^VM$=8KW&)X&.([L#H&]& M]&JYH>MPZU:NZQ/!/"_ESV\HPT3>A]1Z'O6G111114%C9@28`>S'NOOVK0\P/J%NR.&1H7(P<@\KS5NBBBBB MD(R,&N1UJRG\+V]QJ.E1M+8R2*]S9#^#YAEX_?U%=/87UMJ5E%>6D@DAE7/^6CUUE%%%%%%,F_U$G^Z?Y5!IO. MF6O_`%R7^56J*Q-!_P"0OXA_[""_^D\-;=%%%%%%%%%%%%%%%%%%%%%%%%%% M%%96LWH%O-8PQ^;/)"<@L%6,'@%F/`R?SJIK-\+OPOK,#Q-#/%92;XVYX*'! M!'!'%4OAW?0:AHKRVSAT3RH]P'4B)0?UKK:***IZIIEKJ]B]G=IN1N00<,A[ M,#V(K(T?5;BPO_[`UJ;=Q![$5A:9JMWH>H1:#KKF17&++4#P)\?P-Z./UKJ",J1[57TZ%K?3 M;:%\;HXE4X.1D"K-%%%%8.MZ1=B]36]&*C4(4*O"QPERG]UO?T/:KFB:W;:W M:&6$-'-&=D]O(,/"XZ@C^O>M*BBBBBFR1I+&T:V M=$=62)NIMG8J=I_V..#VS74JP90RD$'D$=Z6BBBBBJVH`&S8$9&5_F*P+VVN MO#%W)JFFQM-ITK;[VS49*'O)&/YBNAL[RVU"UCNK29989!E74Y!J>BBBD(R, M5YU\-YI[GQ#K22RLZV3&"-6/W`9'.*]&HHHHHHIDW^I?_=/\J@TS_D%VO_7% M?Y5:HK$T'_D+^(?^P@O_`*3PUMT4444444444444444444444444445@ZYIT MUPEY%Y;RVM]"(Y?*`,D9'0@'J#G\,55U.VG/AW5[J:'R5737@AC8_-M"MRV/ M7TIG@`(ND.J*%P(<@#'/DIFNKHHHHJEJFE6FL636EY'O0\JPX9#V93V(K)T? M4;[3M070=;8R2$$V=[CBY4=F]''IWZUT=%%%%%5K^PM=3LY+2\A66&08*G^8 M]#[USVG:I=:#?KH6N2;HG^6POV/$P[(Y[./UKHK`1K80+$_F1B-0K'N,<&K% M%%%%%86NZ)-+*NK:2P@U2W'RGHMPO>-_4'L>U7-%UF#6;0RQJT4T9V3V[\/" M_=2*T:*****J3PP2WT:RMN8PR+Y1&5925SG]/SK%4S^%;L(Q,FB3/A6)R;-C MZ_[!/Y5T@((!!R#T(I:****K7_\`QZ-]5_F*L=17,ZC8W/AV];6-'A,EJYS? M6*<`CO(@_O#N.]=!97MOJ-I'=VDJRPRKN5E[U/1125YMX#E33?$NO)>12VTC MS%@7C.)%WMR#C_.:[S^V+'_GL?\`OAO\*?;ZG:74_DPR[I,;MI4CC\:MT444 M4R;_`%+_`.Z:IZ$2=`L">IMH\_\`?(J_16)H/_(7\0_]A!?_`$GAK;HHHHHH MHHHHHHHHHHHHHHHHHHHHHHKEO$NHZA;:O:PPS-#;':7((48.]DG_UKV$A;*[>=A[=JR_AQ?6U]HLLMM*)%4QHQ`QAA$H/ZBNPHHHH MHJCK&D6VM6#6ESN49#)(AP\;#HRGL1698:Q&]1O/#\-AH^N2(8)HPME M=]`<=(G_`-K'0]Z[&EHHHHHK#U7097U!-8TF9;;4$&UP?]7<+_=%X M945XW!5E89!![5SJM<>$B%E=[C1BV%<\O9CT/JGOU%=''(DL:R1L'1AE6!R" M*=1115:__P"/1OJO\Q5BEKF;K2;W0;V;5=#'FV\GS7.F]%<]W3T;VZ&MS3]0 MMM3LX[NUD\R*09!'4>H/H1Z5:HHJN/\`D(-_UR'\S5BJ"/\`:-:?;]RVCVD_ M[38./R`_.K]%%%%,F_U+_P"Z:IZ$0V@:>57:#;1X'I\HJ_16)H/_`"%_$/\` MV$%_])X:VZ**************************IWNIP60(99)7`R4B3<0*?:WT M5WD('1QR4D7:P_"II(HY0!(BN`<@,,X/K6=XF('A?5,G'^ARC_QTUY]X6BO( M;0^(O#LWVM8EBBN[%"-LZB-<[?1P<_6O1M(UBTUNQ2[LWW(>'1AAHV[JP[$5 M?HHHHHJGJ>EVFKV+VEY'OC;D$<%2.A![$5E:3JLUC>C0=7<_:5'^C7+<+=)V MY_OCN*Z&BBBBD.,'/2LV;3=/UK0ELYXO-M)8QMW<,.."/0BLK3=0N_#UY'HV MLRM+;R';97[_`,8[)(>S>_>NGI:*****QM:TFXFE74M*E6#4H1A=WW)U_N/[ M>A[5+HFMQ:Q;$E&M[J([9[:3AXF'7ZCT-:E%%%5I!#_:<)8MYWE/L';;E<_T MJS3719$*.H96&"",@BN8#S^$+SRY,OH4S?NWZFS8_P`)_P!@]O2NG1UD0.C! ME89!!R#3J**K7_\`QZ-]5_F*L4M%Q47 M%P?3[B>[&K%G;"U@"9W.QW.YZLQZFK%%%%%9=_JC6VIV^GFV=TNHWQ*O1"!G MG\*?X?\`^1>T_P#Z]D_]!%:-%8F@_P#(7\0_]A!?_2>&MNBBBBBBBBBBBBBB MBBBBBBBBBBBH[@RK;R-`JM*%)16.`3VKG],GN[K297Q'$X,GVN*0'>KY.!], M5E)=75G?-'9V)_M%[I@BOOVNFWESGHN<<].*ZE5UCRUW26@?'S85L5F>)QJJ M^&-2)FM,?99-V5;IM-8_@"WU2/3)/*>RCB(B.U8R.?*7TJYJ^AZW:WCZ]H[V MRWJ)^]MT4A+L>C?[0[&M+1]2O-9LDN[:ZM60\.OEL&1NZD=B*T!'J7\5Q!^" M&N3UO6/']GJDL&F:':WMJN-DQ;;N_#-;/A._\1W]K._B+3(["56`C6-L[ACK M704453U/2[35[-K2\C#HW((X9#V*GL165I6H7FF7Z:)K#&1F'^B7A'$ZC^%O M1Q^M=#1112'@$U!82F>P@E**F^,-M7H..U+>6=O?VLEK=1++#(,,C#@U@V6H MS>'KV+1]6E+6TAVV-XW\7I&Y[,.Q[UTE+111116-K>BF[D34K`B'5+;F*3H) M!W1_53^E2Z)K<6KPNIC:WNX#MN+9_O1M_4>AK4HHJL\VW488=BG?$[;CU&"O M`_/]*LT4UT61"CJ&5A@@C((KF&5O!ET9M[-H4[_,IR39N>X_V#^E=.CK)&LB M,&1AE6!R"*=15;4#BS<^X_F*L#I2T45SFIV,^B7CZWI%N9%?_C]M(_\`EJO] M]1TWC]:V=/U"UU.RCO+.42PR#@CL>X/H:M5CZAH]CJFJ*+J%BT<8=761E.<^ MQQBI-MQI*E@1/:#J`@#H/7C[U:42UGZ,\3;?,7^ZWJ*=H^C#3 M(V>6XDNKF0_/-*V2!V4>PK4K*\41K+X5U5'&5-I+_P"@FLCX?9_LAR3_``P_ M^B4KK*Y_4]%NK2_;6M#*K=$?Z1:L<1W0'\F]#^=:&C:Q!K5B+J%7B8,4EAD& M'B<=5(J_2T44452U;2K?6+%K6XW+R&21#AHW'1@?45E:?K-WI]_%HNO%?/#A+G'8^C^W>NBHHI&^Z?I532)XI45XW!5E89!'I7+A+KP6WR"2[T)G^Z.7L@?YI M_*NHAFCN(4FA=9(W4,K*<@@]Z?5;4/\`CR?ZC^8JP.E+1117-WN@7UEJ+ZIH M%T(&<[Y[)Q^ZN&_]E)'<=\5JZ1JL6KV0G13'*IVS0L?FB<=5-2@'^U2>WDC^ M=62`>M9UD&L]1FLBP,3CSH1W49^9?IGG\:TJ****:X!1@>F*J:,H31K-5&`( M5`_*KM%8F@_\A?Q#_P!A!?\`TGAK;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHK' M\6NR>$=69.HM)/\`T$UE?#R2*716:)PZA85R/41+D5UM%<_K&EWEI>G6]%&; MD`"YM2?END'\G'8UI:5JUKJUKYULQ!7B2)QAXF_NL.QJ]111115+5=*L]9L6 ML[V+?&W((.&1AT8'L1ZUEZ5JLNG7BZ'K+MYXXMKMQA;I>W/]\#J*Z&BD/0XJ M*T:5K2)ID"2%!O4#H:FHJKJ&G6NJV,EE>Q"6"4893_,>A]ZPM/O;KPY=)I.L M2O-:,=MGJ#_I'(>S>A[UT]%%%%%%8^M:*]W+'J.GR"WU.W'[J3M(O=']5/Z4 M_1]N1_PCA;I!U4^_H:T=(U:UUFR6ZM6.,X>-N&C;NK#L:O4444452U72 MK36;%[.[3Q%9.BZC>Z??#0=;E\R;!-I=G@7*#L?]L=QWZUT= M(WW3]*JZ42=*MB223&,DG)-6Z**@O+2"_M);6YC$D,JE74]Q7.V&H7/AJ\BT M?69FEM)6V6-^_?TCD/\`>]#WKJ:******R=JGL:MRD_VQ;KN.#!(2,\'E*N44444A M`8$$`@\$&N9D5O"%T;A&)T2=_P!Y'C/V1C_$/]@GJ.U;=Y(DNG&2-PZ-M*LI MR",CFK8Z4M%%%%(>*\X\!6T"^.O$5PIQ(TS@X/W@6[_0@UZ11111112-]T_2 MJFD_\@BT_P"N2_RJY16)H/\`R%_$/_807_TGAK;HHHHHHHHHHHHHHHHHHHHH MHHHHHHJ"\N?LMLTF-S<*B^K'@#\ZJ3V9BTB[!)>>6)B[=V.#_D5A>$FU*34Y MC?S1SE(L!XW##:2"H)'QK,T_6;K3=231==8&208M+T#"W/L?1_;O71' MD$5!I\+6]A!"^-R(`<'(S5BBBBJ]_86NIV0K-#*,,K5SUK>S^%+N'3-4 MF>;39?EM+Z3DQM_SSD/\C744M%%%%%9&LZ$NH2Q7MK*;34;<'R;A1_XZP_B4 M^E5M&U*;4M25+V%+:_LHWCN8=W=BI5U]5(!Y_"N@HHHHHIKHDL;1R*&1AAE( MR"*Y/54G\)64DMLIFT;<#)$3\UKEARI[K[=JZJ":*X@2:&19(Y%#*RG((/>I M******X[PK!%%KLC1PHA>&4LRK@L?/;J>]=C1111112-]T_2JFD?\@BT_P"N M2_RJY16)H/\`R%_$/_807_TGAK;HHHHHHHHHHHHHHHHHHHHHHHHHJK=W;1.D M$,?F3R#Y5[`>I]JS[35KH/(MU]G<1.RR"'<&0`]<'K5O4^E?;L*A58[EQ]00:Z^BBBBN>UK2[ZVO3KFA@&[4`7%J3A+M!V]F'8_ MA6CI&L6FL6IFMV*NIQ+"_#Q-W5AV-:%%%%%%5-2TRUU:R>TNX]\;<@]"I'0@ M]B*R-,U>XT^Y&C:\ZK/TM;KHERO;GL_J*VK%42RA2.3S45``_P#>]ZL44445 M7OK&VU*SDM+N%9891AE8=:YRSN;OPC.FGZG*]SI4C;;:^?DP>DT/^T-1MKZSO/LFIVT;F!@.)!D9#^J_XU/HNO+J):TO(OL>I M0\36KGG_`'E_O*?45L4444454U18GTZ59E#1D`,K#((S6&ZW?A6\$D*&;0Y3 MEXU&6LR>X]4]NU='#-%<0I-#(LD;C*NIR"*DHHHHKDO#;$ZUCG'D3?3_`%YK MK:******1ONGZ54TG_D$VO\`UR7^57**Q-!_Y"_B'_L(+_Z3PUMT44444444 M44444444444444445E:M$N]FG$@MIHO)DDB.&CR>#D=!7,:-ISV.IWQM]1>\ MAG1H8+?S"Y0Y^\Q/MWK5EDT32]4M=(NIYTN)82ZN\K!6Q@8SGK[4FKW]AH^F M7-]9:@TVLQ,:"W4J"Q$8R.1T'(_"N^\/W-];ZQ?Z'?7IOC:QQS13LH M#E'R,-CJ05/-=%11117/ZYI=S;W:Z]HL(>_B`6:#.T74?=3_`+0[&M+2=5MM M8L5NK9N.CQM]Z-NZL.Q%7J*****IZKI=GK&GR65]")87'3H5/J#V(]:YWPK> MWND+;:%K#H5:/_0+D'B51_`W^V!CZUUU%%%%%17-M#>6TEM<1K)%*I5T89!! MKF;2YNO"5VFGZE*T^DRMMM;Q^3">T?L MK?WU']WU'XUTL4T<\230NLD;C*LIR"*?1117*>&_EU8*9,GRISM_[;GFNKHH MHHHHI&^Z?I532/\`D$6G_7)?Y5NU0,UGZEI=EJ.I6+W=M',UN6 MDC+#E6&,$5OHWO5_ M1]4BU?3TND0QODK+$WWHG'!4^X-7J****0]#67<:3I^N:)':S(S0$!HW'RNA M'1@>QJA9:M=Z/J2:/K;[XY>+._(P)?\`8?T?^=='2T4445#=6L%]:R6MS$LL M,J[71AD$5S:7DG@VXALKZ2271Y3M@NWY-LW9'/\`=]#^%=2"&4,I!!Y!'>EH MHHJK((?[4@+%O.\E]H[;6S'+P9ZM'[=ROY5T=O<17=O'<0.)(I%#(P/!!J6B MBN4\.J?[9\S'6*89_P"VQKJZ******1ONGZ54TG_`)!-K_UR7^57**Q-!_Y" M_B'_`+""_P#I/#6W111111111111111111111125FR:I"26%Q MG(8C'(]JW:Q_%#`:0N2/^/J#K_UT6N:\16-MJ7B![2[598);ZW5XR>N8VK2T M^XOO"E['I6I.]SI4G%I?L/\`4GM'(?Y-75AE(R",?6@$'H:6BBDR!U-&0>]< MYK&F7NGZ@==T)-\Y'^EV><+AJO82K-802*@C#("%'04:AI]KJEE)9W<0DBD'(/8]B/ M0BL/3-5NM(NET;77Y)VV=\W"W`[*3VEHHJL\BC4 M88O+!9HG8/W`!7C\<_I5FBLC7-"CU58KB&7[-J%L=UMUM+RVOK:.YM9TFAD&4=#D&IZ M*Y/PU,&U8Q8((2X/_D8BNLHHHHHHIDCK'$[NP554DD]`*JZ.P;1[1@008@01 MWJ2"_MKA&D20!`Y0,W`8@XX]>>*G#*Q(#`E3@@'I6+H1']L^(1D9-^O'_;O# M6Y111111111111111111111139$$D;(W1@0:YB]TNW=T@U*VO'6%G$#VQ.UU M8Y&0/XA_3-:=M8+?227E[;-&7PL<;,0RH.F[!ZDDU=CL+:**2)$*K*,-\QY_ M6EEL;>6V6WDC+1H/E&X_SKD_#WAVS$@:XMKH-Y\I"W/RD#C&,'D>]=8]C;2+ M"KQY$!#1\G@UA>,=)L;O3EFN+<22?:8!N+$?\M%'8^E85YHFGVOBZ.2WM]C) MJ%OMPQ.,HQ/>NVN=)L;OS_M%NLGVB/RY0Q.&7TQ7(VNG6GA*^33M2B:;3+A\ M6MZ[L3$QZ1R'/`]#786UA:6I9K>$)O')!)R*$TZTCM#:K#B$G)7<:8-'T\=+ M<5VELGI7,:WX2M;>\_MW2;!7O$)-Q`&(%TIZYY^\.QK7T& M;2;^T^VZ8@4/\LBG(9".JL#T(J[_`&?:_91;"("$'.T$]:B_L;3_`/GW_P#' MV_QJ1M.M'M5M6BS"AR%W'@_7.:+G3K2Z;?-#O8+@'<1Q^!JAI&C6"Z;:L+8` MA`?O-U_.M,VD#7:W13]\J[0V3T^G3O5#4O#>DZM;R07MH)5?G)8Y!]1SP:Q= M!B_X1C4UT?43N64;;&]9C^^'_/-LG[X_6NFCL+6**6-(L),2SC)Y)J+^QM/_ M`.?X)]T9(Q4!T;3R"#; MC!_VF_QJ9[&VD>%VBRT'^K.3\O\`G%5]0T'3-55EOK19U==K*S'!'N,URL&G M6O@C4E%Q$\NCS/\`NKEG9C:.>BMS]ST/:NS2WMVE:Y106E7!<'.X57_L33O^ M??\`\?;_`!J:#3[6V618HMHD&&^8G/ZU0FTVS.I6=L8#N3OGWJR M-%TX?\N__C[?XU,^GVLEND#Q9CC.57<>#^=/EM()VW21[C]36/KGA2SU6%)8 M/]%OX#OMKI;_&IQIMFMJUJ(0(6.2NX\G\Z66PM9TC22(,L7W!D\57;0=+=6 M5K12&ZC<>?UK!N-'MO"6I+J]A9NU@WRW$$9)^S_]-$7_`-"'XUOK9:;J*"[5 M5F68!A(KG##UX-.71M/1U=;?#*00=[=?SKE/"UO`GB>2:*/89$N@YR?F(GZU MU?\`8VG_`//O_P"/M_C4D&G6EMO\F+;Y@PWS$Y'YTHT^U6T%H(OW(YV[C_/. M:B_L;3_^??\`\?;_`!J1M-M&MEMC%^Z1MP7<>#]PYZ5!-I4,)BM[S3;BYCMMRVSV_(*'H&&>",XS^-;6F03HLUQ8 MP<[```!GN<"L;1?^1OUK_KY/_HFWKIZ***************************JS M<:A;?1_Z5:K'\47292%M;QSDPL>DR:SH)5+MQ^_MFXCN@/7T;T-:6DZK!K%BMU"&0Y*R1/PT;CJK#U%7 MJ*0]*BM6D:UC:9`DA7YE'8U-15+5=*M-9L'L[R,M&W((.&1NS*>Q'K619ZI= MZ'?Q:3KR/Z/_.NDHHHHHJ.>"*YA>">-9(Y%*NC#(8>E`WJGOVKJ5=7171@RL,@@Y!%.J!S)]NB`B!C,;;I M,T%U"_EG^$]>.F0*W-.U"WU2RCN[9B4?LPPRGN".Q'I6#X=VG4@5'\ M-SV_Z;5U%%%%%%%(WW3]*J:3_P`@JV_ZYBKE%Z\*7::=?R M//I$AVVMXYR8#VCD/IZ-74`Y&1R*6BBBBBN=U;2;JQOVUW1$W7)`^U6F<+=* M/Y..QK4TK5[76+7S[9B"IVR1.,/$W=6'8U>I#T-5=+=I-,@=V+,4R2>IJW11 M574=/MM4LI+.[C$D4@P1W![$>A'K6'IFK7>CW:Z-K[YR=MI?D82X'96/9_YU MTU%%%%%,FACN(7AF19(W&UE89!%Y3[T;?U'J*AT35[B=CIVK1"#4HLY`^[,H_C3V]NU7-88)I4['H%_K5Q?N MCZ4M%%%)7.:GIM]I-^^M:(AEWG-Y8YP)Q_>7T?\`G69X-U--1U"*6+"JR719 M&/SH?.!`8=CSTKMZ******1ONGZ54TG_`)!5M_US%7**YC1O^1OUK_KY/_HF MWKIZ****************************RM5U8V0E*&-([=`\\TN2J`]!@

)':,2QN#A9$/0C-)UV7<+DZC;`(K@D81LUW-%%0W5M M#>6LEM<1++%*I5T89#"N:MKFX\(W4>GZA*TVD2L%M+M^3`>TWT^&&089%P15FBBBJVH:?:ZI8R65Y"LL,HPRG^8]#[US^ MEWUQX'&#WKJ`'Y6^K6)/\`./\`E70;//U&VNHB'A$#@.#D')0C]`:N MT44445GZQI2ZI:A4E:WN8CO@G3[T;>OT]1WK%&M3W&GW>DZJB6^J0QY(_@G7 M/WT/H>X[5U*_='TI:*****XSPKI-G9Z[/>V\`66X:Z,KYY8^=WKLZ******1 MONGZ54TG_D%V_L@JY17,:-_R.&L_]?#?^B;>NGHHHHHHHHHHHHHHHHHHHHHH MHHHHHHK*U72WNX[A(L-'=IY@P?N'-=Y2T45#=6L%[;26US$LL,BE71AD,*YR& M[E\(W4.GWIDDTB0[+:[Q'K6':7][X:O(=+UB5KFQF( MCM-0(Y4]DE]#V#=ZZBBBBBBFR1I+&T M1L_J/;O1HVM2R7DFD:JJPZC",C`PEPG]]/ZCL:VZ6BBBBN8\/'%^!SR;K_T= M73T444444A^Z?I532>=+MS_L5E2Z=S#UK"U9D_MU3@;AJEL#@_[!Q70PZB\M\;*OT44 M5#=6T-Y;26UQ&LL4BE71AD$5SMK//X3NDT^_F,FCR$+:74AY@/:-SZ>A_"NG M!!`(.12T44445SFL:1=V=T^N:"H^V8S<6IX2[`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`[]-_A4D.IVL\PA1VWMT! M0C/YBK=%%%%(>AK/T`J=&@VYQSU^IK1HKF-'_P"1QUC_`*^&_P#1-M73T444 M4444444444444444444444444R:/S87CSCAJMISK)81.L8C4CA5Z"LG5=$N(+V36M"8 M17Y'[Z!C^[N@.S#LWHU:.CZQ:ZU9"XMVPRG9+$W#1..JL/45?HHHHHJO?6-M MJ5G):7D*S0RKM9&'6N?MKB[\*W<-A?2/WD66*10R.IR&'J*EHHJIJF/[,GR<#95I?NC MZ4M9^KZ/:ZQ:B&Y#*R-NBE0X>)NQ4]C5/2]:E346T75L1WJ#=#)C"W2?WE_V MO45N445$Q`ND7')1CG\14M46V_]%TW4M`GAUJ#7]$C5=0CFF$T9.%NH\DE3[^AKI-( MUJTUB!W@9DEB;9-!(,/"WHPK1HHHHJ"\#FRG$:AG\MMJD=3CBL+2WM+C38/# M]_%#*\L#>;$N"H&3Q45G-<^$IUL-1G:;2'8+:WDART)/2.0^GHWYUU`(/0YI M:**0]#5/2?\`D%P?3^M7*Y[5]&NK:_.N:$JB]QBXMR<)=KZ'T;T-:6D:U:ZS M;L\&Z.6)MDT$@P\3>A%:%%%%%%0W=I!?6DMK$I%L= M5D:;2BP6VOFY,6>B2?T:NH5@RAE(((R".]+15&4?\3NV/_3"7^:5>HI"`P(( M!!X(-"198I%W(ZG M(8>M2453U;_D%7'^X:M)]Q?I3J*SM:T6VUNS$$^Y'1M\,\?#PN.C*?6JNDZC M>6]P-*UG:+H9\BX7[MRH[^S>HK;HJO(Z)>1EF"XC;J<=UJ!]3CD+16(^TS#I MM^X#[MTJ:QM/LL)#MOE<[I'_`+S?X59HHHHJ&:[MX98X99D22;/EJQP6QUQ^ M=4O#W_(&A_WG_P#0C6G17+Z.3_PF>KC(Q]H?([_ZFVKJ**************** M***************XO6%7711'_2(O^N\O]:I:WHDYNUUK M1F6'4XAAE/"72?W'_H>U7M%UB+6;+SEC:&:-MD\#_?A<=5/^>:T:***BNF9+ M29D`++&Q`/KBN`\&(T_BB"\=`)7TXM-V^8R'M]*[ZZM(+VVDMKF)9895VNC# M((KFK6ZN?"-W'IVH2/-I$K;;2\U1I8 MQ$Y'*`=*GHKG]&Z@>"XB66*12KHPR&'I7,Q7*5#AHG'1@:S- M/UZ?3[B+2/$#JEXQVPW(&([D>H_NGU'J:Z.L+Q!;:)+<6YUE456!5)';)_P"B;6NMHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHKC-87.MCY"2-6MB".WR5O1'_B80+GK),<>O-:M86KZ/&XA;9<6TG#POZ$?U[UIT457U!F33KET)#+$ MQ!'7.#7'^"GOFO(1)<"9?LF9PQY1RQ([`\Y_2NXJ&ZM8+VUDMKJ)9891M=&& M017.Q7<_A6]2QOW,FD2D+:W3=;<]HW/IZ&NG!!&0-QD,*YN-[KPA=QP2R-/H4 MI")*YR]FQZ!CW0^O:NI!#`$$$'H15661QJEO&&(1HI"5]2"N/YFK=%%%(0"" M",@]0:Y:Z2Z\'SFZM(WN-#8YGMD&7M23RZ>J^H[5TEI=07UK'VNX5EB<8*D?YQ6+8ZC=:)?C2 M-79GMW;;97S'A_2-SV8>O>M>[AANY5M+B%)H98VW1NN5.".OYTP::;:,)I\[ M6RKP$(W(/P/2L*9)=)UAOMEVDOVJ%C:;UVQQ2CKTZ9R#GV-7]$::06GGRI/= MI`1=2QG*DDC'(X-;M%%%)5'1AMTX#!&)9."/7E*-@'5;8-[CRS6\F/[ M3MS_`--)OZ5K45@ZWHT_VM-;T_H>U7='UNUUF!VAW1RP MMLF@D&'B;T(_KWK1HJ"\)%E.0S*1&V"O4<=JX[P?,USJ<+2ZF\[1VY"QD$D@ ML?F)`QGI7<45#=6L%[;26US$LL,JE71AD$5SMK/+X1F6QU"9I-)D8+:73\F$ MGI&Y]/0UTX((!!R#T(H;E2/:JVFPO;Z;;0R##I&JL/0XJU1116!K&B7"WG]M M:(5CU%`!)&3A+I1_"WOZ&KNCZS#J\3[4>"X@;9<6\HP\3>A]1Z'O6E111114 M5Q;PW5O);W$:R12J5=&&0P/:N8AFN?!^\/RW5K,DT,D6Y'0Y!%:*?ZM?H*=11115>]LK?4+22 MUNHA)%(,,I_F/0UQGAC4]:N/$U_HLLJ-;:8&2&=UR\BY7`/N/6NO\G4-V?M4 M8'IY=1?8+B6ZAENIXY%BS\HCZY&*OI&D:[8T55]%&!3J****IZ5_QYG_`*ZR M?^AFKE%M*HKIMEK,QQPA/(SVKA M?"#^7XD$=NX-K):E@=N,D'&,=17?T45#=6L%[;26US$LL,J[71AD$5S5M//X M/N4L+Z1YM'D;;;7;G)MR>D;GT]#759!7(/!'6H;)!'90H)/-"H!O_O8[U/11 M116'KFD7;SIJVCR"+48%P4;[ERG]QOZ'M5G1-4_V#.'6%V.3;.2/E/^ MQZ'MFNS!#*&4@@C(([TM%%%%(1D8KB/$=E=>%+.^OM)A:;3KE3]ILT_Y8L?^ M6B>@]1^-=E9W$5U9PSP2++%(@974Y!%3444445P7A1E/Q"U_D`[B`,_>Y'-= M[69JE[)!O2-S&D,+3S2*NY@H[`'N<&H=$U1M0@M[A)7FMKM&:)I(]CC!Q@BM MFBBBBJ6DG-D?^NTO_H;5=HKE-)'_`!6^J-D<7#C&.?\`46U=711111111111 M11111111111111111117#:S)"_BZWM7D4N=3MW$8;YN(FYQZ5KQ70_X2J.U, M@^[(ZIGD)MD]N_WXG[@C^O>K5\2+"X(&2(FQ^5<)X,@4Z[9W,".8/[/*(Y4CC?_ M`(YKT*BBBHKFVAO+:2WN(EEBD4JZ.,AA7-+>W/A*Z6TU&0S:-+\MO=-R;8]D MD/\`=]&K(=(N6O[?4M%E2VU($AB1\MPH! M.Q_\>U7]"U^VUR&3RU:&Y@.RXMI!AX6]"/3T/>M6BBBBBLZ^MX;K48(+B)98 MY()59&&01\M8P:[\'7*([-/H#G`9CE[(]LGNG;VKJ$=9$#HP96&00<@BG444 M452UA0^CW:D9S"PQ^%85S;W?A9UO]-1Y]*/-S9*,F'/5X_ZK71V=Y;W]K'=6 MLJRPR#"*GHHHHKD]'@C3Q2T@15D8W.Y@.3\Z=:ZRJ5_9&X'FQR>7($*G M*[E=3U!'<53\/V3)96\\FQ<1XCAC3:D0/)`K9HHHHJEI/_'D?^NTO_H;5=HK MEM)S_P`)GJO/'VE^/^V%O74T44444444444444444444444444444AZ5YAJG MAR"?Q]<7KZ?/R[O[25*MMX0`?PUJ^&/#]E%XD&I3M<#4Q&Q9'N"ZQ@D MY4`]1G/XBN[HHHHK"U?1YH[Y=:T=474$`65"<+W5-J%MQ(8#MUQ724444 M5#=VL%[:RVUS&LL,JE71AD$5S.BLWA.U6WO+X3:*VT65PXPT63]QO;T-=6"" M`0<@]#2T4445!-$7G@<$`(Q)'KQBLK6M"DGNDU;2I%MM4@&%?^&9?[CCN/0] MJL:-K2:HLD4D+VU[;D"XMI/O(3W'J#V-:E)6(=;N);R.&WCB`E#&))`VZ0#O MD<#\:U;.Y%W;+*$9")H MI45T<;65AD$>E&:.XA2:%UDC/PQ M764U_N-]#5726W:5;'UC%7*****J::@2T*APW[V0Y'^^:MT5D0:;'9:_+MY?\`BJ%A"*`H=MP')R6R/IQ7144444E86MZ/<";^U]%V1ZE$ M/F4\+=+_`'&_H>U6/#.I+J6AP2%?*GC'EW$)/,4@ZJ:UJ****0]#5.&&VU#1 MTBDMD^SSQ8:%N1M(Z5@07%QX.NDLKV1YM%E;;;W3G+6Q[(Y_N^AKJP01D'(- M+1115:X$9NK8O+M8,=B_WCM/]*LUB:]HDUY+%J>ES"VU2V!$;G[LJ]XW'<'] M*FT/7(]8AD1XS;7MN=ES:O\`>C;^H/8UJ5SEQIDUOJUE*D/G/$76V?SBBJ", MD,O?':MNPM6M+58I)#+(26=^F6)R:LU6EDC74((S%EV1RK_W0,9'X\?E5FFN MBR(4=0RL,$$9!%2:MI"&:R?YKNP4?F\?H?4=ZZ M"SO+>_LXKNUD$D,JAD8=Q63J^K3P17$D$T=NEN"-S@$RL!RH!]*=I^LR2",N M#-;R,%$_EE"I]&!^HK:KS#0?$EG!\1-5%_J,,4;?]=I?_0VJ[15*?_D,6G_7*3_V6KM%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%<=JP_XJ2W/_`%%8/_135;T_`\62Y!^ZX!Q_MMFNFHHH MHHHKF?$7A^^+2ZMX;N19:K@%@1F.Y`_A<>OO3O#/BL:O`(KZ#[+=H?+E7L)! MU4^A^M=&*6BBD;[I^E5-)_Y!-KG_`)Y"I[BVAN[=[>XB66*12KHPR&%R.?[OHU=2I#*&!!!&012T452O#B^L?>1A_XZ:N MT5C:QH?VN9=2L)!;:I`N(YATQJ>[(_M6Q7'7><_P#`:OT52G_Y#%I_URD_]EJ[13)8HYHFBE171QAE89!% MU,TD264%MHYGFN8I)=[WLT956YR%&?IC\17:5Y9 M'H4&L:WJ<%_;J]J3=/&5`5MXDR26'/I7?>']/M;;0;**.%-HA4\J,\C-87B^ MS@T.YLO$6GQBWNEN8X9O*&!/&QP0P[UV(.0#ZTM%%%%4M*_X\V_Z[2_^AM5V MBL*TNY[CQ$8YIK600B0*("24R1PW;.`/SK=HHHHHHHHHHHHHHHHHHHHHHHJK M>:G9:>I:[N4BPN[!/./7%5X]>T^6R6[BF,D;-M`49).2.GX'\J6TU[3+T!K> MZ5U)QG!`SD#'YG%.U36;+2(#/=NRHHR2JDX'K50^+M%%O'<"[W0O(L?F!20K M$9`-.3Q1I;QB3S652-RDK]X88Y'X*?RI=,\3:7J]XUI9RNTJIOPR%01QR"?J M/SK%U8C_`(22`=QJEN?_`"$U:.F/+_:[+(H\GS)O+8]2V\Y'Y8KH******** MY[7M$D:X_M?2X8VOD7;+"QPMU'_=/^T.QI-&U1KB!GLB\\<3;)K64XFMV[K[ MUN6]W!=*3$X)4X9>ZGT([5-12'H:BM"S6D1>(1,5&4'\/M4U17%O#=V\EO<1 MK)%(I5T89#`US5M++X.N/LM[,TFBR-BVN'Y-L3_`Y_N^AKJ00P#*00>01WI: M*K7(B^U6OF,0^\^6!W.T]?PS5FBDZUA^(M`EU!HM0TR<6FK6O,,W9QW1_53^ ME1:?J!U^+R9U.GZS8D&6#.3&3W']Y#ZUI1:EY,B6^H[+>=SM0Y^24_[)]?:M M"H)&87D*B'<"K9D_N]./Q_I4]%%-DC26-HY%#HPPRD9!%59895#(ZG(8'O4M5=2(&FW)8X'E-G\JL)_ MJU^@IU%%V5QX>OWU?2[=IK28YOK2/K_UT0>H[CO6Q;7EAK>FB>WE6XMIE MZK_G@TR&]2U<6EY($<#,ZNYXX]I\AE8#'0$Y]*S-3&L:SRJJ;<')7>>*LQ+XH MDME%K=^'_MBD[G1&(V_0'CH/RKC/$!\;W&NL]O\`97MX)H99KFSQA'5<<%CU MP>E,/$*ZW/D)MI+VY%RV-BFTPE3#Q=XREU) MDMM1O9(``0GV=6<\;C;"/DY]:L1^-_$\>M,3JM\=-#'&Z%3)C'IT MZTR'QQX[:UGE:]F(3`5UM,@'_:_"J]QXP\>7.GA+B[+PW.5*R6@VL/0'O3;; MQ/XTT:V@L[347%I&`%WQ!F4=QSSQ5M?&OCY.9KV51(/W)-K]\]J)?&OCN"!X MYM0ECNUD'RM;``+C^>:K77Q"\5BXLX(M3E^T%?G#P*27)(^4#M@U>M_&'CV2 M]DB^V3R!-V8UM?G7C@D?C42^-_&VQ@VJN9"0%Q;CCUS2KXP\>2H4AU"9Y$!9 MR+<$;?7BB+QIXV=A%?U&*L7GB'QEJFBR"]O)I(2XPYM?E!!XP1T(-6+CQ7X[MA`C:I+ M_'/V-$CU"[^VK(PF1H`%`_A_'KFG'Q9XWDU"*.#4+UH6"Y!M_G)Q\V`.V,XYF:;4+P6LBL8G^R`DMC@9/&,U7NO&OC& M72+I;K49&=@%55MU"D?Q9/7\JED\;>.A;6Y2^E7S%R"UIP_IM]:E;QGXWCNL M2W\\:#&8WM`&QCKS[U$GC?QN"X?4Y&+#$6VV4_-GC@=:?_PE_CYP(5O+G[0I M/F!;+.T8].M*WC3Q@TEL8M5N3&0OGAK=`V<_-M_#I63:ZWXPLM6N[C3)[AC< MR^8T,4(RX]<#@''7%5]5\2>+]:$5MJ=SXVMSXMN+2VO4U+0OL_EJ925=M2O]':"1#]G5$8<]LDGD4LLVLG3RL=[HPN5<%"`=@7'/!/6GRR>)(VA5 M)M'!<#.[>-Q]N>:9)-K?VQEFN-$\M>@;=N!_.FQ3>(9`ZK<:(\N?D"[CGU[T MI77_`"U6$Z+Y\>3*-K?+_A5Z*\D"P"2ZL%)CQ,R/SN_V?;/K5+1I-5BCDM'G MT^1DE/916DVJ"90RRL5`AV\;<^^?QS5_3@1J MUP%"+^YC-PL?W!+SG'OC'Z55M&L/^$HF6TC"2C=]HPN-S8'.>YQ704444444 M4444444444444444UVV(6QG`S7*7BRM*VH&>UB:=I%*R7#1X13@8`^\W7GMF MK<9GM(Y-&L4D);88Y0O^K1_O%C_>&&^O%:\>EV,<:HMLF%&!D9-"Z7IZN'6R M@#`Y!V#(-6/*C\WS?+7S",;LE>1^'O"%M>7]E.LLMJMY=W",UN^U\*7./8<+^5=Y M_P`(-`(A%_PD&L>4#]PW7RY^F*>W@FSE1?,U;5)0@VJS7>=H]N.*AC^']BK; MQJ^JDCG_`(^AQ^E:"^%H@0[ZMJ;2*,"0W.6`^N*KOX$TZ8EY-0U-RW))NB<_ MI1%X&LH)6:#4]5B9OXDNB,?IWJ8>"[-4>-=3U54?[RB[(#?48JNGP_L(V8IJ M6IC/K<9Q^E3P^#+:%&C&J:FT;')C-Q\I/KC%/G\(6UQMWZEJ9VC`S%8W9R!['%,?P19R,6DU/5&8]2;GD_ MI2Q>"[2`LT6I:HK%2,BZ((_2H+'P/;6]FL8U/58RP^=5NB`?KQS2R?#_`$N5 MMTE[J3'U-T?\*?'X$T^&-HH]0U18WY9!=G!/KTI\G@JRE\L/J.J,(ON*;HX7 MZ#%0S>"K4NNV^O\`&?F+7'4>G2A_!<4I#2ZMJDCJ0$9KL_*/0`#BH7\`6,\K MS7&J:G/D<;KH\>G..:RKSX9:.=9T^8W5^S"0G=YYW+A;K>K28X&ZXSC]*S[GP%$=6LG34-2:-=^]_.&5XXYQ4NK:' M-I9M+NWUC4I9OM"QCSY]ZX.>V*CT7PJ-2T>UOKG6=4:>XC#R,)\JH6DPQ%QR1@\9Q0/"8&J20?VYJ_ER1;V`N>ISCGCFJ]IX,BGAN'E MUC5&DCE=4;S\;0.G:F2^$1!HD/E:UJB^<\0E`N/E<$@'C%3W'@I)+JWM?[:U M7[*(W/EFXR`P(P1QQU-9=WX!AE34T&KZD5A4>6AE&/NY.>.:Q?%D5]X7OH[: MUUB^GC_LR66-;AP_E,N`"O'%)I_AS7-:<276N7\7F<0R3SAO-P<'G'Z5J+\- M];C<.GB&Z5E.01(`1^E8.MV?B#28KF]M]>U&81QMF[CFX+@$[>GS#CK6GX;T M6;Q7JFIO<:W>VWV1HE2*W*A0"@.>GK5[4O!7BBQU))=%URXEM]OSK)*L;@^Q M"USOB#P[XML;9-1N+RX@6V?<9S.'";N&)4#-UO"[(S1(6C^X2/N_2FM:V[N7:"-F/4E`2:5;6W1PZ01JPZ$*`12K! M"KNZQ(&D^^0.6^M-^QVO_/M#_P!\"J>I62+%%<6MJIF@F5P(U`8C.&Q_P$FL M74W6_P#,O+B2"V\F<011W9*8&W)SM.23G@>E:6B*MG-]BB;=`T"7"_[)8G(S MU(.,C-M;Z]J%YH\/SK+MN#(X8EE8!L+V&W]:[BRG>YLH9Y8&@>1`S1,> M4)[&IZ**********************Y_4O"=M?7`EVQ.`[.LI^E%+3'C#,KK.=[$_=&T_UQ4^P8QSTQ3737Y87RVQUSZTMO9ZM!%,GGVC&5V?)C88S^-1RZ?JT MME#;?:+,>64.[RVYVD'U]JG:#5FN$E\VS^0,,;&YSCW]J1K6>&TU":XD1GG0 MG$8(`PN.]>>_%(9UJ#_L$3_S%=CH!L_^$1@^V%?+W/@GKG<>GO\`2FA=8=W2 M\\TZ2#E63_7L/1_]GZ1:=:NRJB&69E;&T]8__'EIGB>9;WP3/,5XEB5BI[X]:M: M?IL=@K80_#TWEQ\0)%>4?9K6XG"IMYR=^.?Q->TT444444444444C?=/TJII./[*ML M?W!5LC((HI:***IWC,MW8A6(#3$,`>OR-UJY1111115&XQ_:UG_NR?TJ#Q"# M]B@P!Q=1?^A"CPQQX9T[_K@M:M%)1FBH+[_CPN/^N;?RKR[XKSQ0:Q;&:145 M]*G12QQDY'`]ZVO"VF>(X(8KFYBCN(&3?;)(PS"&Y[=^>M=-]HUX];*$?]M! M7)>+['7H]/O;T01I91V[N]NKC!8@C=[8!Z#K3_AE=6]UK&OO:R))$PM6W)R- MWE?,,^QKLM*_?/=WI'^OF*I_N+\H_#()_&LC72!X5U2V)P892OX,P8?HPKS+ MP)$J^.=-_<,L@N[HL^_(*X<#CM@_SKW6BBBBBBBBBBO/]1LX]0U6\%I#/D,Z M';+^\$@=3N4>@//-=S8H\=C`DK.[K&H9I/O$XYS[U/111111111111111111 M111111111114$2(+F=E?+-C/:F6^K:O<1F01ZD%).P_8$&1[Y:E M@U/6FA0S0ZBLA4;@MBF`?;YJD&H:N3RNIC_MPC_^*I3?ZL5R%U,9/`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`XYJQ2T4444EQ]JTJ*****RD:WE\1.R_/)'"$W#^$Y)(_E6K1111111114%Y; M)>V6[<8+<@\XZ5IZ#IMQ8VH> M]931&5+'YAZ?-UK3CD26-9(W5T89#*<@BG4 M44444444444C?=/TJEHQ)T>U)QDQCI5ZBBBBBJ5\/]+T\_\`3<_^BWJ[1111 M115.X_Y"=G]'_D*N4444457O[4WMA/:K,\)FC*"2,X9,C&1[URGAZR.@:"VB M:A=A;JTCFV_/A;A&)(?!ZGGFKND_;)+]X9I8YPMT9D=,$)%MX!QW)-=-1111 M6?<7$UU*]I9-L92!+,1P@]![U)%;16DEO#"NU0&^I/J3ZUD7EW9`I,KI!'.(I8I0H:-GY#*5X*DMC%=/1111111111165JE[(DK0I M.+6**+S9[@KN*@G``'J<'\JKZ+=Q*L"6M\;RRE_=QEEPR,%W8[9!&36[1111 M37=8XV=CA5!)KD[RZUJXN[2?RIHXV9)(VC53'$&.SYL\EL,"1TZXKI[2266W M4SJBS#AU1L@'VJ>BBBBD)"@DG`')K#=I[LI?MJ4=KM(\F-5#KASM3<>IW#^-6Z*****S-=\/:;XBL&L]1@\Q#T=3M=# MZ@CD5>M[:&TB6*"-451C`%2T4457NGF";+XO(';4C;22#,$`BRN&X7><=\5MVTDDD(,RHL MH.'"-D`U-11111111111111111111111111111111111111115:_M3>6IC5_ M+D!#QO\`W6!R#],BL&*._OKZY@.BC3VE79/?@@B9>^T`Y!/8FM75;)Y+59+7 M>)8%8*J-M+J1@J#V/3!]0*P_#>EW9@\B>TN;*VCG\]ENG5Y9FSD`L.P(!YYZ M5UU%%%%%%%%%%%9FJ6DVXW=M&LS[-DL#C(F7.0/8@YQ]:@TBWGG9+F>P73XX MB3';#!;<1C<2..G`^M;5%%%%(RAU*L,@C!%<3JN@Z@-5M#'%(':.S9Z@UAZ/I.H,'MKI)8H&*%S+@EPHX7C]2>M6);* M>UN$5=(2]>/:L5R<#:`*'=]^J[55L`>7U7'U_SBK4.F:ZJ3&35RS%"L8\O@'(. M?YC\:A@T;Q!N`DULA02<^7STZ=>F>:=;Z)K<-S$QUHLBNID7R_O@,21UXX(% M31Z)J(A5)M4:1A)(=P7'RLN`.O8X--CT+5DN(7;6W=(W!8%.7`;.#^'%27.E M:S/>O+'K'DQ98+&L?8@XSSVS^E0#0]:D@CCN=:WE2V6$9&05`'?L03^-`T'6 MFW^9K?!(^41G&!U[]3Q4T>C:I%YR)K#"-EQ$"G*'=G/OQQ4KZ7J6+@1:EM,L MP=O/Z4ATK4WO)9VU0HK-N2-$XXQ@'GIQ^M0PZ'JJ13+)K3LTDBL MK*F-HYROT.:EMM)U2WRKZNTZ,"#O3D'!''XD'\*AL_#]_!+$\VK/)L?)`7&5 MV@8Z^HS4\6D7\<$D3:D7\R5F)*]$((P/S'Y553PYJ2>6/[:D*+L++MX8C&3U M[X/YU?\`[-O#%?HU^S?:7S%E?]4/3WJL?#]V`VS595)D+`X[';E?IP?SI%T/ M4A`(SJS!C,KN57JH'*#GI1;:#?PSPM)JTDL:#!0K[8XJ%/#>I"-E;6GP5VX" M\'T)YZU+%HNK1LC-K#.1D'Y."-RX'Y!A^-%EH^LV]YF;6#-:[C^Z*<[><#/X MC\J2'1M9AB(76BV,[0T?^R1C\^:?=:+J<]RTT.L/;ACG8JY`&%X_,,?QIIT/ M5"DR_P!L-F1U*L4Y4!2#W[D@_A4+^'=7;(_MU\'')3G@CWHN/#6IRO(T>O31 M[XP!\O1@1S^56%T+4#:6T3ZL^^$L78+_`*S)R,TVXTG7)G8KK"1#:0FV(\'/ MU]*LQZ=J4>DS6IU$27#']W.Z?=''4?G52'1-:BAE#:ZTDC.&5FC^Z`I&.OJ0 M?PI1I&M`M.=6'F;2`@C.W^?6H3H7B#RG5?$&'*@!S%R#QGOTX-3W.BZO+#;I M#K;QF-V,K%,F12>![8%1IH.M>5*LFNLSG!CD$>"I_.E;0M96Q2*+7&$Z2LWF MM'G*$8P1GM3_`.Q=7\F6/^W'^93L?9RISD'\L"FMH6KLQSK38*L.$[GH>OKS M20Z#JZ/"TFMLPCQD!.IS]?3BI9M)UAXT,6L;)<)O+1Y&0N"1SW/--?1=8.GI M;)K3"0.2TQ3DC@X_3]:CC\.ZFL@9];E95FWJFW@+G./RS3/^$?UP22*NO,(B MV8\1_,@Y[Y^E6Y-)U5KFS==6/EP;?,4IS*0.2?KFJ[:)KOYU'%HNL M*T[RZX[&16"`)@(3C!_#G\Z%T?5_*6.36"P\QBQ"8.TC`_'K^=%CH>J01R+< M:R\Q9"JD)C;\N,_GS3+?1-:ATD6K:T))S.7:9HSRFW&W&?7FK<>D7@MI(Y=3 MED"X@D;7'E2/=YBLGWL@X_*I++1]5AE1[C6&D57 M#%`F`0,\?CQ^5(-&U?\`M(7']L$0>:6,`3@KV&=K;LT@VQG9]SGK^7%06VA: M^AA-SKWG*K@R+Y>-P![<]Q0?#^L+*#_;LCIY3K@IT)'RG\#3X](\0*\.2!@_@0?SIM[H^OSS;X-;6%5(*J(B?K4(T7Q-&!M M\0*Q)YS#_P#7JR=-UM96F35#_J@#&4R"VS&?SYIMSINN2ZF7@U1H+9G#%-F< M#`R`?SJ*ZTKQ))=W$D&MB.)I"8HS%G:OIG-/33O$/V6-'U;]XA8LPC^_GH.O M:HTT_P`2+.BR:H7C\L*S+'C+ GRAPHIC 19 g18641bmi001.jpg GRAPHIC begin 644 g18641bmi001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U26]O#?RV MMI:12^2JLS23%/O9Z#!]*7[1K'_0/MO_``)/_P`11:_\A[4/^NM%,L/\`D*ZG_P!=(_\`T6**`"U_Y#VH?]?[/<1SRQ(,ET4\C'Z_A3+OQUI&N^'KJS M\-W_`)NJRV4C6]ND;;XV"$\\<$=/K0!V*7MK).T$=S"\R?>C60%E^HZTC7UG M&%D\,JW_"3"ZB-V4#"08_UOF$]LU:U#0] M-U"#XBZA=6PEN;.Y9K=RQ_='&<@=,Y'6@#V5;F!YV@6:-I4&6C#@LH]QUIGV M^SR@^UP9D8J@\P?,1P0.>37E=AI5EHWBCP%=6$9BN-1MI#=R;R6G)C#?,3UY M-VELZI<7,,+/\` M=620*3],T2W=M`2LUQ%&0NXAW`POKSV]Z\0\>7*S:G>VFI6VGVU[;Z;#F>\C MDDFN7V<^5@X7!SSZ\FM:STVS\0^*?!MOJT?VN)]`#NLC']X1DC=Z\\T`>C:; MJU[=:KJD%W916UI9LOD7`G5O.4C))`^[^-:D-W;W$1EAGCEC'5T<,!^(KR.] MMK&6;QY:7>H?V9;M>6L8FV%E7`^56`YVG`W?G^`-8AL-.A@M8-0@6]N-* MWB&ZA_B90>1T&<>M`'M4%[:W*LUO@P.E`'NY8*"2<`TZQM_";WD%M''/-O>)-.\27/V*XN+]KF*:93MGC;I@XYQ_6@#T:PU2SU*VAGM9E8 M31"55/#[3T)4\BI5O;5U5EN86#ML4B0$,WH/4UYO)XETK3/B:=:NY7AL-0T5 M/LLK1,/-.[.T#&<^WTKEH88KWP-X:@E5ECG\2.CKDJV"6R/4&@#V_P#M&Q\D MS_;+?R@VTR>:NT'TSGK4C7,"R)&TR!Y/N*6&6^@[UY&/".@MXM\86!L$%I96 M"36\`=MD0`G/IGK7B M^KWUOJ/ACQ[>VVXPS:C;.A=2I*Y&#@\X/6F_$*ZM)]9U2WFM].M9H+*+RYKF M*22:Z)08\K!PN.F?SH`]>O?$^D6&N6VBW-TL=W=(SH#]T`>I[>V>M1:=K5U- MJFI6^H6L%G;VTRQ6TQN%)GR/3^$^U>:7UOHJ^(/!6I:]#"UK=Z9BYGG4L))` M@";CW(XJ6]TAM7C^(20C_2;6^BNH".H9%)X_#(H`]>-Q")A`94$K#<(]PW$> MN*;%>6T[ND-Q%*Z??5'#%?KCI7D5G>ZAXNLO%'B^QCE$\>G)8V04'>#M#2E? M?.>GK53P%:6K^)M#GLM;TM+A$82VUG;2K-*-GS"4GC(QU/>@#T?Q1XV@\*N3 M=:/JEQ;K&'>ZMX0T29.,%B1@_P"-6=%\56^KVDEU/8WFDQ*5"'446+SW]R%AF=40I\Q8GIC'4>]77U&RCA29[R!(Y/N.TJA6^ASS7A] M[IL?\`MH*`-+0?'5AKFJG2FL;_`$Z]\KSDAO8?+,B>J\FNA6\MGN&M MUN(FF7K&'!8?AUKR_38=2TSQ[+#K-Z^HZE/I#'1KK:(UZ$LFT<;L]_\`&N3\ M,6B7%UI#OK>G6>K)>J9$^S3?;6??RKMW!'X8H`]JT[Q3H^J:E>Z=:W:M<6+! M902`#P3\I[CCG'2M'[;:^4DWVF+RY#A'WC:Q]`>]>6>']/T2Q\?>*[`VD,.H MMG^S8]A#%6B;=L[8.:Q8M>TZX\`^%=#CD8ZA::I#]HA\L_N<2-]X]!G/%`'M MIO+4/L-Q$'W;-N\9W=<8]<=J1;^S=HU2[@9I?]6!("7^GK7GGAS1M.O_`(A> M+KZ[MUFN+*Z1K=F)Q&2GW@.F>!S7'66CZ?#\*['Q!'!MU--44+:1@> M@QVH`][!S2T@I:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@#.L/^0KJ?_72/_T6**+#_D*ZG_UTC_\`18HH`+7_`)#VH?\`7.'_ M`-FK1K.M?^0]J'_7.'_V:M&@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`2HH[2WAO&:`.X^SP[D;RDS']P[1\OT]*Q_#?A6U\.64ELDGV MK?5[CS1`SI"S1+(>B%\8!HA\*`-U[:&5P\D,;NHP&902*%MX59&6*,,B[5(494> M@]!6*/&>CG0K[6O-E^QZ?,T,[>46IR$V#`/KBL+5O'>@Z/]G\ZY MDG-S%Y\:VL+2GRO[YV]![U%XT\43:#X0&MZ:L4Y=X@GF@[2KD<\8/0T`=.5# M*5(!!&"#4<5O#;J5AACB!.2$4*#^5<]JOC[0M$OY+"^GF%W'$LIBC@9RP;TQ MUQW]*IZKXFM[]?#=[I6NFVM;^[VA5M_,^TCNA_N]Q0!UT<4<*;8HT1YP9H(Y=O3>@;'YUP^F?$B'7I])&,9RA90= MI]O2D^RP8`\B/"MO`V#AO7Z^]<9K7BXW<_A.ZT*_S9:G?^7*0H^=<./;*#C#-@]*`-_R(MSOY:;G&&.T98>_K2&T@:$0 MM!$8AT0H-H_"N?U;Q]H6B7\NGWT\PNXHTD,4<#.6##.1CK@#)]*GM_&FB77"W3VXL4 M\RX2ZB:)XT[-M(R1]*`-Q[:!T5'AC94^ZI0$+]*,MNSM/(^Z<'GM4EE\2M%D\/66KZ@TUDEU(( M3OA;:LFS<<''*^A[T`=9%!%`FR&-(USG"*`/TIL=K;PR-)'!$CM]YE0`G\:Y M(_%7PH+>20W5SOB8J\'V5_-4`9+%<<+[FM74/&>AZ=IMG?R79ECOAFU2",R/ M,/\`94<\=Z`-N2-)D*2(KJ>JL,@_A39+:&9`DL,A7MMJ$EI)/))80^<\36[*[IV91C)'3GWH` MZH^,+R\^*-MH-KJ%U96=N%WK'9[_/DWB8_B'%:/C_`,3W^FW%CH&F/;VMUJR2*M[51$9O.\ MI/-`P'VC=CZTW[);Y8^1%\[;F^0,_$-IK6E6WB6PLH;368FDMY M+5V+0D+NVOGKQCI5(?$7Q"+"W\32:99#P[<7?D*H=OM`4L5#GMU'3_\`70!Z M0L,:,[)&BL_+$+@M]?6F_9;<1"+R(O+!R$V#;GUQ4H.1D'(-+0`@&*6BB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`SK#_`)"N MI_\`72/_`-%BBBP_Y"NI_P#72/\`]%BB@`M?^0]J'_7.'_V:M&LZU_Y#VH?] MIJD_A*[L]'MY)KN\Q`-G\"L<,Q]@,_G7'WG@KQ-X?N]`U6U MU)M:_LF585M8K58BD!&&P0?FX]?6O4Z.*`/,9=+U^+QQY^@Z/?Z8);[?>R-< MJ]E<19Y?8>0Q'IWI=/TO7K;QM%)H^CZAI%H]XTFH+- MFX%&!0!X_>Z-XKM?#GB3PQ;^'I+D7EY)5^M=W@48%`'DR>%]:3X6VFFC2Y1>IJXG>'`W!/,)W M?EBF:]X2U*'Q;K-U+I6L:C9ZFP>)M,O1"/NX*2*>O^%>N8%'%`'E>O>'M0L[ M;3$T7P]JL&HVM@D5M>V5ZI\ILDF*7.`R@]^^:V_&^DZWJOPW@L3;_:M4W6YG M2`#!8$;B/:NYXHXH`XRSTB^3XGZCJ=6NFZU8ZQXQLFTB>2#5Q)-;W:, MNS/ED!<9SDDXK(GT/Q3#HGAJT^PZI)906)CN+6PN1!*L^3CN8%&!0 M!Y)HOA;7;71_"4$^F3))8ZQ+-<*2"8T).&)SR/>NM^)NEWVL>$&M-.MGN9S< MPMY:=%M=MOAII MZ\#:W<_#B%?(3>%-9F>6R\@Q:EJ(=[@%@2B]Q@#(.>M>I8% M'%`'EVDZ%XGN_#WB+33;WT&G3V9BT^VU.97F5\<@,.B]AFB;3-32M0A2XCD*M\B(`9.OW:]1P*,"@#@TT34/\`A+?&5X;%_)OK!(K:3`Q* MVP@@?CBN9N/!VN+HGA2\;3K^4Z=:R075K9W`AN(RS$AE/\Q7L5&!0!Y-<^$K MQ_!9BL="U"&:XU>&XDAN[D32NJ]78]OI737&C7\GQ/GU!+5ELY-%-N+C`V^9 MO^[^5=GQ1@4`<3\-K/5=/\*MH.J:9/8R6>]%G9E*S;F8Y7!SQD5RZ:'XH3P7 M)X"_X1PL7G(_M,R+Y.POOW^N[M7KV!1@4`<98:+?VGQ.-Z8)&L4T5+87!^ZS MAQQ]<%6UK3IB%\Q'4&.5CM5<'D9SU!KM<"HKBUM[M!'

)NBEB<<5C: M!H.N:A\.-4\)W>B7-A.XDFAGG90CL7W*G!R/K7K&`*.*`/-+33-?\4ZOH(U3 M1)=)M=%@=9GED5O.D*;!L`[<9K+A\/>*+CPM:>!)=$>**WO0TFI&5?*,0#2[N:)MKQP.RG MT(4D5YU\.O&6JR+<1>)[W[0)+`:C;3%0O[H9#C@#H17H^HP/=:==6\>-\L+H MN>F2"!7FNH_#'5KWPMX?L(;F&"]L$>WNW60@/`YRP!QS]/>@!W@;Q5XBU#Q! MJ$FK2RW%M)IWV^VLXHUW*K/\BKW)*^I[UJQ?$R3[3/:7/AVXM[I;62Y@B^TQ MOYP099%/AYJ^D M^)-,U&[M-(MX+2WD@E6T+EYLKC>V[J3G\*`.E3QU:7'_``CJVEJ\[Z]ED0.` M85`RS-ZXZ?A6QKEGJ5_8"WTO4_[-E9QOG$(D8)SD`'C/3FO._ACH6SQ=K%P+ MC[18Z/))9V!_A3+1I/+M+UHPHE1DGK3M)\*>)+S6]'O/$D]B(-#C*VZ6FXF9RNWG`'`H`6RU/Q'% M\4H])U+4(7M9K"2=;:WCPD>&POS'ECCJ??I53XAW7B7PY;2:Y:>)@@-PD=KI MHM5*R`G[N>2QZDT^30_'+^.8O$?V?1@(H3:A/.DYB+9W'C[V/PINJ^&_&5SX MVDUQ8-)OX+?Y=/ANY7"P#^]M`QN]Z`-_Q=KNJZ+X&FU6TL]UZL*LZ\8@)&68 M@]0#VKC=>\3:M`:[W6=*O=?\'76 MEW30P7MY:F-S'EHTH[^3(V&A50`>1] M[B@"[#\1%^P:W)>Z+#-4O\`4?%=Q"\`36+&*"WW.00RC!W<<"I]:\(ZE>^& M]"BLKB&+5=$,4L1DR8G=5P5/?!]:`)++Q_YC:G:ZEHMSINHZ?:-=_999%;S8 MP,Y5AQ4Y\;PC3?#M[]@D(UZ9(D7S!F'<,Y/'-9UIX0UK5-3U+5_$G MM800V>YDB1LY8D\DYK-L?!?B[R_#MKJ%QIGV/0;M'182^^5%S\Q)'!`XQ[T` M7]3^)[VD\QLO#EW?645Y]B%V)E17FSC:`>>O&:RO^$EU#1_B+XF:'2K[5-MO M`_V>*0!8%"`L23P.O8(KK47MXK^0:L\J:;+-(DS-OX;R5&S([$F MO5[+PUJ$?BGQ'JSF)8-6M8XX5W'<@_0BO-M$OO&U]X(E\6P>)FFEMS*[6,]LAC=$)!&X`'.!7>^#]%NM!\ M&V.D79C-Q;Q,C&,Y7))/!_&N,TOP;XYM?"[>%1/I5K83,XEND9WEVN26`&`. M^*`-J;XE0+8:2;33)+R_U&U%U]F69(A&G0DLQQUR`*E;XE6#^'[34;2PN;FZ MO;DVD-BF/,,H^\">F!Z^XK*UWX:2?;--N](M=/OTL[);-K34PVQE'(<%>C5+ M-X&U9=(TFXT^+2K'5M,O'NDMX$86S;L`J3US@#F@#3O?'S:;IEK)>Z%=0:G= MS-##I[R("Q7DMO)V[<'K5=OB=9Q^'+[59=-G2?3KB."ZM/,5BI#=?\2VFG:AJ*:3-J=C,[?8W5S;21M@;2>N1C.:@N?`6K77@O4-,CT_1= M.N[NXAD6.R#+&%1@?F8Y)/7MWH`OCXE7!U)M,_X1/5!?21":T@+)F:/^\3G" M<>N?2L7Q9XQ36?"_A_6K..[MP-92.>V0GS-RYW)Q][-=;_PCM]_PL"TU[=%] MEATTVK#<=^\MGICI7,'X=Z]_PC5GI\5Q:0W5OK37XD)+*J\XXQR<]J`.@T[X M@V\MUJ5IK&F7.CW&G6_VIXYF5RT7]X8[]./>H-%^)4&J:M9V5SI,]C'J.?L4 MSS(XDP,X95.4)'K52/P/K.N7VLZCXEN+6&YOK$V$"66XK&G7<2W?(Z5#X5\" M:GI&J637FC^'4CLNMY;HYGEP"`<'A3T)-`&YX7\;2>*+MTM]#NH;6)Y(Y;MW M78KJ>%'+O#7BK6/%5O>V\6FWFEV0#6]G=RNJF3'+L`/F M(/3/%`$%QXB\1:NWAC1(;D:1?ZM:-W>C>(K?^S8MU2Z%Q*LA98$']T$<\#-`">`O$-S<>" M[O5->O\`SC:W,XDG=0N$3V'%9?AGQ!XDO_B!;KJ,[0Z?J5C)>6]B4`\J,,%3 M)QG)`S^-2^&?!&M)H%]X;\21V?\`9ET[3%[.9O-WE@V.1C'%267PU.G>.K'5 MK>_O)+&VMR#Y]XSR&3/`Z?YJ"Z\0Z79E/.O%P\8EW(I8+&>`[$#"J?4T`:E%9JZ] MIK7XLA=`S%S&/E.PN!G:&QC=CMG-:(Z4`+129I:`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"D-+10!''#'$"(T5`3DA5QD^M2444`%% M%%`!1110`4444`%%%%`!24M%`$7V6#S_`#_)C\W^_L&[\ZDI:*`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`**2B@!:***`"BBB@#.L/\`D*ZG_P!=(_\`T6** M+#_D*ZG_`-=(_P#T6**`"U_Y#VH?].\CGN'G,%T\2O M)C<5`&,X`'>M2LK0_O:G_P!?\G\EH`U:***`"BBB@#.L/^0KJ?\`UTC_`/18 MHHL/^0KJ?_72/_T6**`"U_Y#VH?]U#_KG#_P"S5HUG6O\`R'M0_P"NL/\`Z%)6E6;!_P`C)>?]>L/_`*%)6E0`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110!R'BG:N;\2#.J2GT@7^=.\+ M._\`:,B,3@0X`STYKS85''$-=R$]3K**2EKTBPHHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"LK0_O:G_P!?\G\EK5K*T/[VI_\`7_)_):`-6BBB@`HHHH`SK#_D M*ZG_`-=(_P#T6**+#_D*ZG_UTC_]%BB@`M?^0]J'_7.'_P!FK1K.M?\`D/:A M_P!V&27-K#]S'' MS2>IJ[]KD_Y\KC_QW_&@"U157[7)_P`^5Q_X[_C1]KD_Y\KC_P`=_P`:`+5% M5?MN*D5O(\2QLEK*I:WP5XW-CC/7VKS>1^TY_,BVMS5N-0 M%O?VUH8RQN,_-G[N*N5SU]<,WB*P)@E4JI^0XR>OO6Q]KD_Y\KC_`,=_QKMA M)MR3Z,I%JBJOVN3_`)\KC_QW_&C[7)_SY7'_`([_`(UJ,M455^UR?\^5Q_X[ M_C1]KD_Y\KC_`,=_QH`M455^UR?\^5Q_X[_C1]KD_P"?*X_\=_QH`M455^UR M?\^5Q_X[_C1]KD_Y\KC_`,=_QH`M455^UR?\^5Q_X[_C1]KD_P"?*X_\=_QH M`M455^UR?\^5Q_X[_C1]KD_Y\KC_`,=_QH`M455^UR?\^5Q_X[_C1]KD_P"? M*X_\=_QH`M455^UR?\^5Q_X[_C1]KD_Y\KC_`,=_QH`M455^UR?\^5Q_X[_C M1]KD_P"?*X_\=_QH`M455^UR?\^5Q_X[_C1]KD_Y\KC_`,=_QH`M455^UR?\ M^5Q_X[_C1]KD_P"?*X_\=_QH`M455^UR?\^5Q_X[_C1]KD_Y\KC_`,=_QH`M M455^UR?\^5Q_X[_C1]KD_P"?*X_\=_QH`M455^UR?\^5Q_X[_C1]KD_Y\KC_ M`,=_QH`M455^UR?\^5Q_X[_C1]KD_P"?*X_\=_QH`M455^UR?\^5Q_X[_C1] MKD_Y\KC_`,=_QH`M5GSZQ!!JT.FE6>:49RHX7ZU*;UEZV7*`A)[N1TSP<<#D M=NE)IKH5&2=M=S8HHHJ30****`,ZP_Y"NI_]=(__`$6**+#_`)"NI_\`72/_ M`-%BB@`M?^0]J'_7.'_V:M&LZU_Y#VH?]G6MFMX2YHW&A,48I:*L8F*,4M%`"8HQ2T4`)BC%+10`F*,4M%`"56N MKZ&TD@27=F=]BX&>:M5A>(VVSZ_P#^1ML?]S_&M^N?O3GQ M?:>R?T-=!5T=Y^HT&*,445T##%&*KV][#`X<$59I)IJZ`3%&*6BF M`F*,4M%`"8HQ2T4`)BC%+10`F*,4M%`"8HQ2T4`)BC%+10`F*,4M%`"8HQ2T M4`)BC%+10`F*,4M%`"8HQ2T4`)BC%+330!4OM5LM.95N[A8B_P!T')S5E)$> M(2*P*,-P;/!%<[JMO9Z_:W5Q;Q2R75H#$HY&3UZ=ZKL]WIWA.9-1N`K31[(( MCPRCTK9032MNZ?;ZG'%YQ8K&XD4HV.12ZG;P7&G3)<1AT" MEL'U'-5_#D1AT&U4L3N3=R>F><5I,H=2K`%2,$'O6;T=NQM%*4;VW1P>AWUQ M92Z;&DC"&>1MZ`?>R<5U&A`!M2`&!]ODZ?1:E.B6'G6TBP!#:DF,*<`9]JCT M/[VI_P#7_)_):NI-3=T9X>E*FFFS5HHHK(Z0HHHH`SK#_D*ZG_UTC_\`18HH ML/\`D*ZG_P!=(_\`T6**`"U_Y#VH?]2T1%+,=V`!DGI7-BK^R8GL3Z/7<>0AC4?OY/Y&N MBKDM.U`#J*AM[J"[A$UO(LD;=&4\&I0O%6JSV9NK2CJAJHJ*%48 M`&`!VI<4M%(H3%9>A_>U/_K_`)/Y+6K65H?WM3_Z_P"3^2T`:M%%%`!1110! MG6'_`"%=3_ZZ1_\`HL446'_(5U/_`*Z1_P#HL44`%K_R'M0_ZYP_^S5HUG6O M_(>U#_KG#_[-6C0`4444`%%%%`&;!_R,EY_UZP_^A25I5FP?\C)>?]>L/_H4 ME:5`!1110`4444`%%%%`!1110`4444`%%%%`!115#4=1^PS6J;-PGDV$Y^Z/ M6IE)15V!>[UCZ'S>:F?^GBM66:.!0TKJ@)`RQQS65X?Y^W/_`'KEJSG\<1=0 MTWC7M3'NI_2MFL73O^1BU,>R?RK:HH_"_5_F"V"BBBMAA1110`4444`%%%%` M!112&@`K&U+GQ!I@]-YK7#JP.U@V#@X/>LF]Y\2:>/1'-8UOA7JOS$S8'2@T MM%;#$(XQ6'=016_B6Q>*-4,BL&P,9XK2OTJ++F_DWQ1VS[5RN-W&,?3O M5QBG=LRJ3<6DE>[%O[N33=;L=.TP!81S)!&.N3SG\.:Z@=*J-IMHVH"_,(^T MA=H?]*YK6!JNE26=U/=M<1QS$EA\O4\*1WXS564[)&-Y4;REJK_X:KNHV37]H8%N)+E5?#,=Z- M.DM]1B(6)]D:NO8?SYK>HI\[Y>47LH\_.O\`AS&U;1[1K&_F2W7SY4+%L9.0 M."*BT2U@U'PS:Q7<.]%[-D<@G%;M4O,O1JHA%NGV+R\^9NY#>F*:DW&Q+IQ4 M^;Y%Q0`N`,`<"G4@Z4M9FX4444`%96A_>U/_`*_Y/Y+6K65H?WM3_P"O^3^2 MT`:M%%%`!1110!G6'_(5U/\`ZZ1_^BQ118?\A74_^ND?_HL44`%K_P`A[4/^ MNU#_`*YP_P#LU:-`%#5-1ETZW:=+&6Y1$9Y#&RC8H&3U M(R?:J$_BNV2,RVUK<7445LEU.\8`\J)AD$@G).`3@=A3O$MGJ>H00V=FD;6D MA/VP&;RWD3^X#@X![GTX[U3N]$U,S:@;2*V6+5;2."17D(^S%05R,#YAM;IQ MR*`+#&QY.PQG."01G&,UN=JY.Q\,7MI;V>DDPG3[ M*]^U1S[SO902RH5QP(_[Z/\`C1_9MI_SQ'_?1_QH`M455_LVT_YXC_OH_P"-']FV MG_/$?]]'_&@"U157^S;3_GB/^^C_`(T?V;:?\\1_WT?\:`+5%5?[-M/^>(_[ MZ/\`C1_9MI_SQ'_?1_QH`M455_LVT_YXC_OH_P"-']FVG_/$?]]'_&@"U7-^ M+6*FT*]59F'X8K:_LVT_YXC_`+Z/^-8^JV,!U6RMTC"K('SR?2N?$J]-I">P M[Q%/YVAV\RG[[HP_*I_#*M_99D;K)*S5S8AN!##;SQ,JR3;5D;.1CC`'I76V MNCVMO;I$4\PJ.6)()_*L*+)(' M*"*,MNG\HY/;^]53Q+I\,5M#)!%AS)LX)."BI/J*YUU(>E5(["SDB5Q",,`1\Q_QJKJUI;VVEW$T M<05U0D')XK64K1;&<]:WMWI;M=H`\4[NNUCQD'^=6=,N6O?$XF+,5.XJ"?NC M'2I9-#:31[,6ZEY&8,[$XP#_`(4>'M)CEEFGG!)BFY&I MU-%5/[-M/^>(_P"^C_C2_P!FVG_/$?\`?1_QKU"RS6=KFGO?V6(A^^C.Z/!Q MSZ58_LVT_P">(_[Z/^-']FVG_/$?]]'_`!J9Q4ERL#G;:\BM?#4]M,VV5F>- M5[YIZRKIEYI\\V55[3:Y`_*FZ]HT<$T<]OD">0(8P.`?6KFJ:&)IK06\>$#; M9<'HOK7G\E175OAM8C4ST4QZ!:W//RWF_/U-=<.1FLG4](MO[*F6WA".J[EQ MGMS3M,M[.\TZ"?R1EE&?F/7OWKII1Y)SDFA@:=U&5C7JU/MI'FMXY7B,3NH+(W53 MZ5@V$NE)?C1UAF>2-3F21CR1SCK6S_9UI_SQ'_?1_P`:F2:T-(24]4RUBJ]W M8V]]%Y-S$)$#!L'U%-_LVT_YXC_OH_XU%(_[Z/^-`RU534]1BTNR>YF!8#@*.K'TJ.[MK M&SM9+B2`E(UW$+DG^=-AL=-O[2.;[(&CD`8+(#_(TUW9$GTB]2KI_B6WU2_2 MSB@?#QEF9N@/<8_K6O\`9H/(,'E((B,%`.,?2JJ:+IL;;H[.)#TRHQ4O]FVG M_/$?]]'_`!IR:;]TFG&27ON[,7Q$D&E1075I;JMR1]GC()`12#T%1PZ1K5GI M\;6]ZS7`CVF%FRHR>N3W`K3OO#]G>^5D-'Y3[OE/WO8YJU_9MI_SQ'_?1_QJ M_:6BDC/V-YMO;H9/AF[U*:2ZMKXLXMR%#L.<^F>]=#53^S;3_GB/^^C_`(TO M]FVG_/$?]]'_`!J)/F=S6G!PCRMW+5%5?[-M/^>(_P"^C_C1_9MI_P`\1_WT M?\:DT+5)BJW]FVG_`#Q'_?1_QH_LVT_YXC_OH_XT`6:6JO\`9MI_SQ'_`'T? M\:/[-M/^>(_[Z/\`C0!:HJK_`&;:?\\1_P!]'_&C^S;3_GB/^^C_`(T`6JRM M#^]J?_7_`"?R6K?]FVG_`#Q'_?1JEX?C6,:BB#"B^DP/P6@#7HHHH`****`, MZP_Y"NI_]=(__18HHL/^0KJ?_72/_P!%BB@`M?\`D/:A_P!?\`7K#_`.A25I5FP?\`(R7G M_7K#_P"A25I4`%%%%`!1110`4444`%%%%`!1110`4444`%8U_P`^(].'HKFM MFL:[Y\460](F-8UOA7JOS$Q^LVDUS+8M$A<1S@MCL/6M6@4M6HV;?<8TJ#U& M:S[C2$GU:'4/-*M'U3'!QG'\ZTJ*+ M8C_?MB/UK8K.EU7FQ(6BBDS6PQ:S]=D\K1KEAU*8_.K]9/B5O^)24_YZ2*OZ MUG5=J;?D)F$]Q)IEC0-H9R`3N?'M7F^RYJCIO9(BVMB?2M0B72;(S2!6D_=KGN1Q3_$ M!QHES[J!^HKE([]ECM(77Y+:7>".IYY%:MYJIU/1+[Y`FR10H[E2>,UM&NI4 MW%]OT'?0Z&S7%E`/2-?Y5,`!T&*CMQBWB'^P/Y5+774E+>;(FPC/';G]*M?:H1<_9O,'G;=VSOBG.2=K&=*#C=OJS/GT&UFU:/4 ME9XY4.6"GAS[U#K^JW&G2VZP%0&RSY&=1LKG4IY9& M+"38AZ8[&N;$3FTHQW*Y5&_*MSI7'B(:;ILPB\M?GWJ"">O\`*KFAZG=7]Y?QSE2D$FU, M#'K_`(5<32K:/59-14-Y\B[3D\?YXK&TPG0[34Y[UD60R%E4,"3UQ^9KM]V4 M;)'&U.$U*3TN_NL;U_?1:?9R74V2D8Z#J?:J^DZQ#J\,LL4;HL;;*WDWM"=K<=?IZBK@`%8^D>'(-)N6G29Y&9-OS#&*V0*B?+? MW=C:FYN-YJS%HHHJ30****`"BBB@`HI*6@`HHHH`****`"BBB@`K*T/[VI_] M?\G\EK5K*T/[VI_]?\G\EH`U:***`"BBB@#.L/\`D*ZG_P!=(_\`T6**+#_D M*ZG_`-=(_P#T6**`"U_Y#VH?]\-V(,LVH%^2SH%Q[ M]POB)AM!QFK>G:_;ZA<^0D M;HQ4D;L[LD6-GSNXXSQV^E<$ISA4DULFB+N MYT%]<&WL9YD8;HT)'L<<5S*^([V.>`W`.$0[U&!YF1P?:H3J2&+559CNN>4% M="NF6<^GQO+;HTGD`;B.?NT.(/G-C# M_P`]+E:C\-7T+V4=D&/G1@L1CC&:KWVHQW^M6=O$C;89^7/1CWQ6DJBE26NK ML.^A/XE4%K#C_EOBMB"VAM81%!&$0$G:/>J6L64UX;3R0#Y4X9LG&!6E6L(_ MO),9F+H%BL;1E&8&7S!D\@^@/I6)X@3[/J4BJN%N44G'J#778KG?%$&^>R<= M6?9^HK'$4TJ?NH4EH=!&,1J/0"GT@Z"EKK6Q044F:`L*T)7BTKNX.K&U M^A)XEU:6);RQX"&$;2.N2>?TK3T?3[?_`(1Z"V>(&.6(%U_O$]:YR[EM-;\0 M!?G\AW6,D<$XXR*[6*-8HUC0850`!Z"G3J-Q<7NG_P`,3&/-4<^EK&)K]V-$ MT18;)6B+?NXBHX3O6II[2/IUN\S;I&B4L?4XI;RQM]0MS!N/2M7))6$("ATSQ@]:K-._\`;;:F M&_="Y$.?48JQJ-N]WJNHQ1IO<6R[0.YR#2SZ<]IX4DCE`$JMYI`['->7)3[P[#'W:-A^9-274X.@R3,W!M\Y]R*=HRE-'M5 M(P?+%=?Q5%Z%=3,\,K):3W=C.NR1=KX_3_"I]:U.2ROK)%^NG@)9;>V.T^K`US.?)!TXO5/\`X)-[:'5C M!&:R-1\.6>H-*_S123,K.ZG.<=JCN=9:TT6SN8U#O*%&&]AS6U&V^-7_`+P! MKMIU4W[KU"48S5FAL,*00I#&NU$4*H'85)@5%<74-J$,SA`[!5SW)J6JO=E+ ML&**6BF,****`"BDHH`6BDK/UK4'TVP-P@4D.%.[I@TF[*X%36;Z2+5K"WCD M*@N&<`]1G&#^M;E<9JMU&_B))?-3:IC.=PZ=<_2NO6>)Y#&DB,P&2H8$@'H: MPHRE*4KB1)1245T#%I*H:KJ\>DI`TD$THFE$8\I=V">YJ.:ZU&:_N;&&T,,8 M@W0WC'*ESVQ3LQV-`SQ";R?-3S,;MFX9QZXH:>)95B:5`[_=4L,M]*Q4\/13 M0";5)!)J$EN8);F,E,@^@]:@N+>RM;.UN]-M1JMSIV(HL3990>"2:=E>UPL; MES?6MF\2W,Z1&9]D88XW-Z"J>A_>U+_K_D_DM9TC6VD:3]NUVZ_M$+/YD#%` MQ0GHHQ4_@^:.XTF::!&2&2ZE:)7.6`)[_CFI=D[7U*Y)ESD4`9T'_`",EY_UZP_\` MH4E:59L'_(R7G_7K#_Z%)6E0`4444`%%%%`!1110`4444`%%%%`!1110`U^$ M/T-9/ACG2<^LCG]:U9>(F/\`LFLOPR,:,GN[?SK&7\2/HQ=37HHHK884444` M87B5=QL3_P!-P*7Q/:RW%K`8HV=EDQA1GJ*UKBUAN=GG1A_+8,N>Q]:EKGE1 MYN:_45CF4T&2;0%3R5CN]^[YA@XST)^E=$B;+<)Z)C]*DHJX4HPV"QR.A6\M MMK$!E4H94?"D8.!4FF6Q7$:YCCNY"YSTK0U)UA\0V$CL%78X+$X%/\,\ MZ?*W9IW-@6%,DBCDV[T5MIRN1G!]:?24`%&136=4 M4EF"CU)Q7-^*;#4IWCN;.61XT(`ACSD'^]Q50CS.S9E5J.$;I7-K4;_^SXDD M^SRS[W"8C&2,]ZN`U7L4FCL8%N7+S!!O8]2:I:AXAL]-O/LUP)`1'OW`9!]J M+7T0W-17-)V1=U"[%EI\]S@$Q(6`]3VK$\*6T[K5(^67!('7!KL:R/$L3RZ8!&A=A*IPHR>M35J2 M5YHQ="/LO9G+V&8M1@9APDRAOSKH+GQ%/OF2SM"YMR?,9^@`JEJ&FS6OVZXV M8CWQO&V??FM#0[O,I1J1;@M.II%-:&O;3BYMHIP,"10 MV/2L#Q(D\VHVT=L"95C9AM.#[UBS:>7+-]K$(^G^176QH(XU0#A0`*Y*8;/$ MXAQ\INE?'U%=1)>6T,ZV\DR+,ZEECS\S`=<"L<-K?RT%$I:KI;:A=6C84Q1L M?-!/4>U+8Z);V#3F)G83+MVMV%5(?%`O9(C8Z;=7$#B3=+MV[67M@^M-/B^V MCLU>:UG6\(#/9AIB7,I;3(+4')@DDR/09KLK">.: MRB,1=`""!Z1FNA%)7=C8R*H:EK5 MCI<,CW$P+1J&,2$%R"<<"N-_X2'Q)X@F`TB%K9(XBS87(=AUPQ'Y"K5IX-O] M4NUU#7[P^:57"18#C'3)`Q^5)-&_L>7XW8ZI=8L#I_V\W48@"Y+$_=]B/7VI MD6NZ?-?P644X>6XB\Z/:#AE](O!XN;>"'2+>.(F6#4I/+G.UWC7!4CGCVIRE%!3HQJ+26O1'H.J:K;:1;+<71?8SA!L7< M(\EKJWN=26=+DHT5IC!B4=35SPU=0:M/=:A'J$LWFA0UI+C]P1W'UJ M/7M&LHKK^T5C/VFXE1'8L2,=\#\*RKR:I/D,I1Y+J6Z.7O4TLA5F0I*ZK'$, MG&T#!_7%:J7EF9I+;0@T&M/;(-S#*L%'*#/&<#K6K:>%K6YMYHM2M0Q$I\IP M<,!Z@BI/#5K:Q37A6-#-'+L\PC+;>@YK"C*K!QYGN"E!)7O?]15\6V5G:%=4 ME$-Y`J_:(D!;:Q["M4:C;/IG]HJQ-OY7FY"G.W&>E<#K4NO:3J>HR&,R6LD@ M/G2P*ZX/W>3Z=*U+K7?MO@Q'-TUK?"(2".`CX M7_B2VTZZCUFVDN;O^T(<1VK':L87^+'7K_6K_AV]\2:E.EY?16\5A*A*J!AO M8CO^=4/"V@W5Y>1^(-5=9&=`8$`QCL"1T''3ZUV@J-9._0JJZ=-H^A!/Y5Z M3574+&'4K&6SG&4E7!XZ>X]Q1*">O4FCB)0M%_"5M(LM,CT>*"Q"36?++N.\ M')SWJ'PY#';07UO$NV.&]E51[<'^M6-#TE-$TN.QCD,H0DEV&"Q)S4>A_>U/ M_K_D_DM4KO5[F,G9M1>AJT444R`HHHH`SK#_`)"NI_\`72/_`-%BBBP_Y"NI M_P#72/\`]%BB@`M?^0]J'_7.'_V:M&LZU_Y#VH?]&.<#@\ M@5U$]I;W0`N((I@O02(&Q^=-^PVN^.3[-#NB&(V\L90>WI0!Q%LR3-9W`.-9 M;6V68$_O1%N;*L/[HC`XZ=#7?#I40M8!<&X$,8F(P9-@W$>F>M2@8&*`,D&X M'B6[\A8S_HL.=[$?Q2>@J]NO_P#GG;_]]M_A5:#_`)&2\_Z]8?\`T*2M*@"M MNO\`_GG;_P#?;?X4;K__`)YV_P#WVW^%6:*`*VZ__P">=O\`]]M_A1NO_P#G MG;_]]M_A5FB@"MNO_P#GG;_]]M_A1NO_`/GG;_\`?;?X59HH`K;K_P#YYV__ M`'VW^%&Z_P#^>=O_`-]M_A5FB@"MNO\`_GG;_P#?;?X4;K__`)YV_P#WVW^% M6:*`*VZ__P">=O\`]]M_A2;K_P#YYV__`'VW^%6J1B%4L2`!R2:`*= MO_WVW^%6J*`*VZ__`.>=O_WVW^%&Z_\`^>=O_P!]M_A5FDH`R]0T^?48MD\% MN2N=C"1LJ?RI-+LK[3K)8-L#')8DN>I_"M1FP,GI5"'7=,N;@017:-(3@#GD M^WK4JFG+G2U)K&WFI2:>JM=-:Q!SA0NH+?A0V6GS6^G2-;RR@9F)W'(K6T+:/4R4 MJO,[I6_$N;K_`/YYV_\`WVW^%&Z^_P">=O\`]]M_A7(Z?_;4VL/+!/-,L5P$ ME);`('?'IQ6]?>(K*WL[F2*3?)"YBV@?QU4J;326I,,1&47*2L3WUE/J-JUM M-;V.-8UBM]JC`_>-T_*L[PS#??8S=WMU)*;C#+&_\`]? MQK=O_P!]M_A63K6@3ZQM=A!%,HP'5V.1Z$8K M?S1UI1DXNZ'.$9KED4X4O884B5+ MX:PL0UL#Y<4Q0DAO4_X5;T73M=GUYM1U:S@5)X3%(=V&VXX``/>ILKZ[FWL) M)7EH7(+\6VI:C=&6V\H(K._F$H.W!`YK./B5;;7Y[MFM3`\.`YD/S8Z!>,G/ MTJOKFB+I,\=O9,T=C*GSPG)#\]"3[UKZ7X*TM;)'OH#<3R("Q<_&Z@B9I,Y3S&W>7]*H>-=*O;DVFHV$(FELR=R8R M2/IW^E='/)+5&RC2G-1B[+S*=Y>1W.KV5W#<1#[<0('0DC<..X[&I[VZ7PU' M9W&LB._OU#+%<`'>>^.F!UK`T;5YY=^I,J7L9VFM#S\Z[XA\0W\%K8(^FJP9E*J<,!W)(_"K MWAG5]6NM1>VNM,22YC!26\==A`'120.:[3%&*%%IWN7.O&47%02/.-?T7Q&= M3DNR#/Y.9DGB&"H_NCN2*MZ%XH\Z]GN[E8H7=%3YB0K-V`XZG%=YBN.U_2;2 MUUZUO7W^2\@DDB7`4L,?_6-%1I).70REV4E_JLM[Y@$$=P7&.K- M5[1D2'5=4BVA7,H?..2#6,)1E/G<;7T)IU.1W2.=TG3O$VI:S%=ZH\T2VA#* M)#M#'T`'ZFNIM=.:SN;BYM[.V2:Z8-*WF-\Q_*M,"C%=7D$YN;NRJ!>J,"*V M`'8.W^%+F^_YYV__`'VW^%6J*""KF^_YYV__`'VW^%1S0W-Q'Y?RK>K&\1 M?=L?^OE:QK+]VPG)RU9H;K[_`)YV_P#W\;_"L73([NTUN]@`B9W'F$%B!@G/ M''O71UCM^Z\6H?\`GK;D?D:55:Q?F)EJY@N[JVDMY8KY6582+4.PRJ>89'"3R,X&>:Z&WD\Z".7^^@;\Q64*G-*4> MQG7H%0CJ!WQ5G3O"MK9-;32.SSP9)*\*Q[<>U:FFVILM. M@MF(+1H`2.A/>K+D*I8]`,FKE4:NHZ(RA132<]6%%<3>^+M0UC4$T_PTG.,O M*Z*J76EV-X%$UNC!7\P8&,MZGUJC=^*+.ST6WU26*81W!`2/;A^?:JNA^ M,+;4[:ZGNA'9K`X`+/P5/3\:OG2>YB\/.46W'1'1@!0`,`"J5SK>EVS70)VO+F2&WD`4RP\L,GC&*YJV\(6(N;B`V%S=6[0"6&Z: M4+N;'W0.WXT-2Z%4XT[>^W\C7OO'.E6.H"U/F3)@%IHL,HS_`#KR:M"YTY/%8VJ>*])TB5H+B=FF49,<:DG_``KD[63Q M5I6IW>FVWF7TA09=\E5R/O*3]:W?#WA9K:1]0U@K=7TI#9<;O+_^O1MN/V<( MZR=RQ?>*XK73[:\2SNFBNHVFW6JV^H!3"T!!,<:@*Y!R,T7\B:;I6]Y&=X,L;F M6:\UN^\T7-RY0*X(PH]C[\?A6WK6AVFN6H@N@PVG*2)]Y?H?>M'O3J5B95). M?,M"K9:?;:?;+;VL"11CLHQD^I]ZL8IU%,S;OJRG?Z=#J,*Q3;@%8,"O45;` MP,4M%+E2=P"D(I:*8&;%H6GPZO)JBP?Z3(,%B<@>X'8UHTM%*UAN3>X4444Q M!7/>*H_,^QCIND*Y^N*Z"L3Q&N6L/^O@"L,0KTVA/8U+.TBLK9((5PJC\SZU MB:C=3:5KK7*0[XYT523T'/-=$*RO$BYT64^A4_K2JQ_=Z=`>QJ@Y&>U+4X!!!XXZU MC6^`3V-NL?4OW>O:;*/XBR&MBL?Q'&RV4=VAP]M('%%;X+]@9;N-16WU*VLR MA/G@_-GIBKM<9?:K]HUN&XX$<#@*?;/)KH+[6$L[VUA(4QSC+/G[H[&LZ>(C M+F;>EQ)HHZPGFZPZ?].3_P!:@TG6YWNK:T`40B/:33XM-NH\`E&SD=1NYJ?2"!K4%P.D\DHI0KR7 M+'^M03.OK+T/[VI_]?\`)_):U#_KG#_[-6C0`4444`%%%)0!G0?\ MC)>?]>L/_H4E:592RI#X@OI)&"HMI"2Q[?-)6A!<17,0EA<.C=&%*ZO8"6BD MHI@+129HH`6BDI":`%I"0.IQ5+^U83JKZ?M;>D7F,_\`"![UC^()KW4Y5TVQ MMY#$VUVN%/RL#[^E7&#;,IU5&-]S8UB01Z1LG1M5MY(S'WLH[>ZU+6!IQ\X!8 MX9,ACGIGIS35G&ZW"4)QJ\KM;NG<[K.1Q7GVMZE8VVO79O0VHRK\L4,1(5/9 MC[>U;/B&TU+4KB:#2=4!2SADDGD/EQF-=VPGN:/M-U_:30II"I,;7S/M1QMWX^X3Z9I(]4N M8TL]/U%#%J-Y&V&@7=&A&>GM7(WNGO%K+I?31/&9U^UQV@.(\G M`&/IZ=*]9Q426L"2O*L,8DDQO<*,MCIFDU&6Z-J=>=/8HVVGW,=]('FC?3?* M5(;4Q_<(]S6G@>E%+08;B8HP*6B@!,48I:*`$HI:*`$I:**`"BBB@`HHHH`* M***`"BBB@`HHHH`*8\4BMM.1D9P?6GT4`%9OB`9T.Z]E!_6M*J>JQ>?I M=S'UW1FHJ*\&)DMD=UE`?6-?Y5-5'1I?.T>U?OY8!_#BH['47NM5O+8A=D&- MF.OO4QFE&/F!IT4E+6HPI*6DH`CN&VV\C>B$_I7(>'B\^IVT3'*0!W4>F:ZK M46V:;U6[L1WTHY#>3I^[@]&% M=-J,?F:=<)US&W\JP/"MI()I+B2)A&T>%9APW/->=*@HS4([,BUM";PWILT> M+Z5OE:/$2@]CS3O%>Y8+9U."'(!_"M]5"J```!T`%4-6TY]02!595\N4.V[N M.]=,J/+2<(E6TL5I-&630H[_45T= M!&1@\BK="+^ZP6.+BTR^OUCNUR3I_6MOPM"+?3)8^`XN'\Q?[K<^HDK&K111724%%%%`&=8?\A7 M4_\`KI'_`.BQ118?\A74_P#KI'_Z+%%`!:_\A[4/^N)M9N]$TT7=K9+<`.HD9Y-JHI8#/J3SP!5?5-?O;>ZU".Q MMX)$TNW6>X\UB#)D$[5QT.U3R>Y%`'0TE+^S+R\%K'R?-& M25#GMC<,8].(I?)NY5&!]HM0K>^&./YG\ZJZ5K$FFP36DD)RH9UR M<$'&<$5/XC>V76(&NIA'%'#O?U8`]!ZDUC:MK-OK3+-IBE)BFUED7!+>GOQ7 M!.G5YW->GR(\S3;5M8B,,+.&?'FY_O*1G!K5;Q-9QQ1,ZL6>/>0G.#Z5Q[O= M:UJ"P>>L+*@@>13A4`&#_6JU_9WVDW4=K`(YX\?NY$?N?2NAT*M/[>K%3 M=+2W54#8BG?.".^1Z^U4K/7M2US6H M((;MED=6"F/A8^#R1WKLQ%HRV_V=4LQ#NW>7\NW/KBI(3I<#M)$UK&[(K.V$J1N))D'R@?=)^M93J*'O-V-E M6E%6.4L/[7TW6I;*V1]1GL]Q#2,0NPCID]#[58UO5));FV:YMX_-2#]["'SL MD/\`"Q'X<5NZ%.%-W/=R11//(&P7'IVYJ8:?H0-V1]GS>'=-^\'S'UZ\5-%4 MY1]Z.YA5VFHZH]OJ`2V,B;O,4[$!&.F?6M6ZBN=8UN:TBNS;6 M]F@$94\;B..GK2:_X?L+JT4:4]I%\[/\_P#(74-7U'1XSH^G[+I[:(R75Q+\ MRH#VP>GXUC(^IZM=P_;;U;7R[8RP':5B=!U/R\#ZUZ"(M'6>>5YEKY>S9MW+C;Z?2AI.5WW^HPI'.3 M=K;L;-Y5+)D>_IUYKL9++5YCITAO8XVA.;I53(EX[>E6X9=.MXTBAEMHT0;5 M"LH"CT%2_;;3_GZA_P"_@K2=3F9RTZ<::M$RY?#4,L%]$+N[3[;*)'82';6[N!A!%1?;;3_GZA_P"_@H^VVG_/U#_W\%#`R/#5 MSBUFM&4@VS'GU&36-##J#F?4K=FC3YW\Q3UP>AJU/=V^F:AJ`B;>EQ%\A0[L M,>O-:NG-:QZ%';M<0AC$<@N.IKSE!U+1?V;_`/`(L+8:P;N]CMM@^:W$A<'O MW%:W:N)T:9;&^@N9G"Q,6C.3RO'4^U=(OB#37V8N`-[;1D=/KZ5M0K7C[[LQ MIFG25`+VT_Y^H?\`OX*7[;:?\_4/_?P5UE%?6VV:-='_`*9FI--79IMLOI$O M\JHZ_=P/H\Z1SQNS``!7!)YJ[;W=HEO$OVF$80#&\>E8K^+\A=2W2U!]MM/^ M?J'_`+^"C[;:?\_4/_?P5L,FQ0!CH,5#]MM/^?J'_OX*/MMI_P`_4/\`W\%` M$])4/VVT_P"?J'_OX*/MMI_S]0_]_!0!-2U!]MM/^?J'_OX*/MMI_P`_4/\` MW\%`$]96A_>U/_K_`)/Y+5[[;:?\_4/_`'\%4-`=7_M)D8,#?R8(.1T6@#6H MHHH`****`,ZP_P"0KJ?_`%TC_P#18HHL/^0KJ?\`UTC_`/18HH`+7_D/:A_U MSA_]FK1K.M?^0]J'_7.'_P!FK1H`R?$&D7&MZ:UC%=I:H[*78Q;R<,&&.1CD M56N_#<]U/_#28S\Q'>MJ#_D9+S_KUA_\`0I*N/:027,=RZ`RQ@A6] M`:55RG!11DJ45)M=201H,X11GD\=:CN(U>WE0*/F0CI[5-28H>J-3*\.%7T: M$%1E"RGCWK4V)_='Y5C:%&+6^U&T4G"2!ESZ&MJLJ/P)=A+838G]T?E1L3^Z M/RIU)6PQ"B?W1^58FD0PW=WJ,LD:2+]H^7(!Z>E:6IW0L]/FG;LN!]3P*@T& MT^R:7$&7;)(-[_4UA)F<4;%_NC\J=10!%-;PSILEB1U]&7-9M]H M-I.'EBA59?+954<*3V)K7I*SE3C+=`RCO M6W6U%-MS[C7<38G]T?E1L3^Z/RIU%;C&[$_NC\J-B?W1^5.HH`;L3^Z/RHV) M_='Y4ZB@!NQ/[H_*C8G]T?E3J*`&[$_NC\JS-"P&U+'_`#_R?R6M6LK0_O:G M_P!?\G\EH`U:***`"BBB@#.L/^0KJ?\`UTC_`/18HHL/^0KJ?_72/_T6**`" MU_Y#VH?]>;3Q:T9P%N44'ZXX_E M6Y%-',"8W5PIVG:1V-H]Q)R%'`'<]A5FL?Q)\UE"G]ZX05O5DXP; M0V9MUJ;:I;6UK,@CF-RHDC]NHKJ0,=*QSH[/XA-\^/)4!E&>2V,5L"LZ,9)M MR!+N+11170,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@!*JW>F6E\0UQ"&8#`;H0*MT4G%-68$<,,<$2Q1($11@`=JD MHHH2ML`4444P"BBB@`HHHH`****`"LK0_O:G_P!?\G\EK5K*T/[VI_\`7_)_ M):`-6BBB@`HHHH`SK#_D*ZG_`-=(_P#T6**+#_D*ZG_UTC_]%BB@`M?^0]J' M_7.'_P!FK1K.M?\`D/:A_P!.TU;3[M\(H+*S>V*VZK7UA! M?P>7,F['*\]#656+E'3<3,VXU]8M5BACVO;$#S)!S@GI3]?^9]/C'\5RM5;' MP_+_`&5/!.1'-(X*DU/_`*_Y/Y+0!JT444`%%%%`&=8?\A74_P#KI'_Z+%%%A_R%=3_Z MZ1_^BQ10`6O_`"'M0_ZYP_\`LU:-9UK_`,A[4/\`KG#_`.S5HT`%4KK6-.LK MI+6YNXXYW`98R?F()P#CZU=KF/$:M;WDMYILMZNKF!8X8XX2\4V&)"MD8`R3 MDY&!0!MR:OI\5^MA)>1+=/C$1;YLGH/J?2K?45P]W:7,D6I:6]K-]MNM5CN( MI!&2FP&-M^_H`H5AUSQ[UW`Z4`9T'_(R7G_7K#_Z%)6E60(Y9/$EWY4_E8M8 M<_(#GYI/6KOV>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH`M455^SW M?_/Z?^_2T?9[O_G]/_?I:`+-%5OL]W_S^G_OTM'V>[_Y_3_WZ6@"U157[/=_ M\_I_[]+1]GN_^?T_]^EH`M455^SW?_/Z?^_2T?9[O_G]/_?I:`+5%5?L]W_S M^G_OTM'V>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH`M455^SW?_/Z M?^_2T?9[O_G]/_?I:`+5%5?L]W_S^G_OTM'V>[_Y_3_WZ6@"U157[/=_\_I_ M[]+1]GN_^?T_]^EH`M455^SW?_/Z?^_2T?9[O_G]/_?I:`+5%5?L]W_S^G_O MTM'V>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH`M455^SW?_/Z?^_2 MT?9[O_G]/_?I:`+5%5?L]W_S^G_OTM'V>[_Y_3_WZ6@"U157[/=_\_I_[]+1 M]GN_^?T_]^EH`M455^SW?_/Z?^_2T?9[O_G]/_?I:`+5%5?L]W_S^G_OTM'V M>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH`M455^SW?_/Z?^_2T?9[ MO_G]/_?I:`+5%5?L]W_S^G_OTM'V>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_ M^?T_]^EH`M455^SW?_/Z?^_2T?9[O_G]/_?I:`+5%5?L]W_S^G_OTM'V>[_Y M_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH`M455^SW?_/Z?^_2T?9[O_G] M/_?I:`+5%5?L]W_S^G_OTM'V>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_ M]^EH`M455^SW?_/Z?^_2T?9[O_G]/_?I:`+5%5?L]W_S^G_OTM'V>[_Y_3_W MZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH`M455^SW?_/Z?^_2T?9[O_G]/_?I M:`+5%5?L]W_S^G_OTM'V>[_Y_3_WZ6@"U157[/=_\_I_[]+1]GN_^?T_]^EH M`M5E:'][4_\`K_D_DM6_(N_^?T_]^EJEH`91J(=]["^DRV,9X6@#7HHHH`** M**`,ZP_Y"NI_]=(__18HHL/^0KJ?_72/_P!%BB@`M?\`D/:A_P!N?:NS[5GI MH>F1Z@;Y;8"8N9/O':'(P6"YP&([XS6AQB@#,R]OKMQ.T,K1R6\2JR(6&0SY M''U%6OMZ?\\+C_ORU6>**`*WV]/^>%Q_WY:C[>G_`#PN/^_+59S10!6^WI_S MPN/^_+4?;T_YX7'_`'Y:K5%`%7[>G_/"X_[\M1]O3_GA%Q_P!^6JU10!5^WI_SPN/^_+4?;T_YX7'_`'Y:K-&:`*WV M]/\`GA%Q_WY:K.1ZT M9H`K?;T_YX7'_?EJ/MZ?\\+C_ORU6:,T`5OMZ?\`/"X_[\M1]O3_`)X7'_?E MJLTM`%7[>G_/"X_[\M1]O3_GA%Q_WY:K.:,T`5OMZ?\\+C_ORU'V]/^>%Q_P!^ M6JS10!6^WI_SPN/^_+4?;T_YX7'_`'Y:K.:,T`5OMZ?\\+C_`+\M1]O3_GA< M?]^6JS10!6^WI_SPN/\`ORU'V]/^>%Q_WY:K5%`%7[>G_/"X_P"_+4?;T_YX M7'_?EJM44`5?MZ?\\+C_`+\M1]O3_GAG_/"X_[\M1] MO3_GAG_/"X_[\ MM1]O3_GA%Q_P!^6JU10!5^WI_SPN/^ M_+4?;T_YX7'_`'Y:K5)0!6^WI_SPN/\`ORU'V]/^>%Q_WY:K.11F@"M]O3_G MA%Q_WY:C[>G_/"X_[\M5G-%`%;[>G_ M`#PN/^_+4?;T_P">%Q_WY:K-+0!5^WI_SPN/^_+4?;T_YX7'_?EJM44`5?MZ M?\\+C_ORU'V]/^>%Q_WY:K5%`%7[>G_/"X_[\M1]O3_GA%Q_WY:C[>G_/"X_[\M5FC(H`K?;T_P">%Q_WY:C[>G_/"X_[\M5G-&:` M*WV]/^>%Q_WY:JVBQ2QB^>2)XQ->/(@<8)4@8./PK2S1Q0`M%)2T`%%%%`&= M8?\`(5U/_KI'_P"BQ118?\A74_\`KI'_`.BQ10`6O_(>U#_KG#_[-6C6=:_\ MA[4/^N".X$(DDM?(>)XO7.X_, M.V16^X+(0"5)'!':N.M/=VR+<-+-;PW$9+,F?W:+M(QE1G)SRU23>)]06WN]06VA2TL)HH M9X7R9&+!-^&!P-N\8X.<'I6Q>Z5/<6ZVMK>FTMA%Y+1B%7!7&.,]#CBL]/!] MO`C6L%U,FGR-&\MJ0&\QD"@?,>0#L7/KCMF@"P]U?W?B"[MK&9$BLH%5O,7* MF9SGGN=J`'&1]ZJ%GXBU._N8].A2U%P9[A/M15C$Z1;065M7+;0 M[QM`NK66[:SO;^1Y9YX/F*%CT4GT4!<^U(GAF2%+)K>^$$]BK1P/';J%$;`` MJ5SSR`<^HH`J'Q3J+Z=I5W%8PA;J\6VNF:0X0^88SL'4\@G)[5H7NHW]AK5A M;G[/+!>SF)8E5A*BA2Q?.<$#'/'<%R^FV-A:W[V\5G,LX+1!VDD5MVX MD^IR2/>IX=#N8]>DU9M1,K2!4V/`#LC'54.?E!/)]?P%`&U1110`4444`%)2 MTE`&+K>KWVG:AID4%K$]M=720332/RN[/"J._'4\47&K7\'BJRTS[+$ME`.`.<<]:DUK1I]6DLVCOS;+:3K.JB$/N=G)XJ/4='O;C5+ M;5(;[$EDCB*`Q#:Y8`$%O?`^E`%=M4O);S5+B*\@M[.S=+=6G3*;QS(W&"3D MA>N.#4%CXBU'5(M/@MH[>&XNTFD,SJS)Y<;!0RKD'YL@X)X%:&GZ1=V6A6UI M%>>15VG**P?S2"XV=`,@$8Z8 M[T`06VO7>KC1H[8"WGN#)+=*OS!4B)4C/HSX'KBDN?$>H:;)J4%S%;W4EK%" MZ/"&10\K;51LD^QSZ'I5K0]`?2[B[?.!Y:P6S$[F5!EBQ[99V8D?2H[;PF4T MFYTVZU![E+D^8\WE!93+N#>86[G(';'`'2@"O?>(=9TZ'5K?[-:W5Y86ZW"R M`F.,H0Q.1R<@H1@'G(ZU/4[ZW\/#5K=[2-8[;SY%F5CO.T$*,$8STSSU' M%,G\-37-IJ"2:DQN=0C$,UQY*\1@$!57H/O$Y]31=>&[FZM].A?5&VV'(4P* M4E8<*S+G^'MVSSVH`VK65Y[2&:2(Q/(BLT9ZH2,X_"IJ9$KK$JR/O<#EL8R? M7%/H`****`"BBB@#G]10VX#:2I`7CG)J:_OKF M36;"PLIE4F-[F=NJE`,*"?0L1TYPIJQJNF7.IQR6ZZ@\%M-&8YHUB4E@>#AC MT.#CO5;3-'FM;C4)F80M*$@MBAW&*%%PG7ODL<>]`%*RU_4;K^TXK=+34)+1 M$,XO'U$O>SP+`)O(4*J`DXV#J1@=14=CKVIO/ M8+=6]O(-3M'N+>.'*LC*%;8Q/!R&'/'(JTWAZ636;G4);XRKSWQJ/)4XY./O'"J,GT]Z`*UAKNH7>AW M%W=/8V$UO>202,VYXU"MCU!)_*M+P]J4VK:+!?3Q+&\N[A>C`,0&&>0"!G!] M:IV&@7^G6\\<.L,6FN6N"QMDQN8DL,>F3QZ8K1TC2X])LVMT=I"\CRR.V!N= MCEC@<`9/04`7J***`"BBB@`JO>R7$5K(]I`L\X'R1L^T$^Y["K%0W,!%UR"SMY+PP-*Z%RL2;=V3ZD<=.M6KW4KF6WT> M"V?RKG471F*C.R,+OD(S[?+_`,"%-@\,SV_A9M!74V,;(T7FF!=P1LY&,XSR M>:?IFC7=MJAGNYA,EM:):VK@`$CJ[$=`>%'_``&@"C+XIGL;N_CF-M>1V=F] MP_V8%3$RG`0Y)SGU'3!XJ9O$-YIDMU%JRV[&*P^VHT`('!VE,$G)SC![YZ5/ M<>&!J$C-JMZ]Y_H\EN@6-8\*^-Q..IX'L/2JMQX8NI[NU>XNS>`/&D\DBA/W M,9+A0!U+/M)/M0`Z:_UO2--TZ:ZDM[F25X8I860B61W8!MI'`VYZ8Z*::_B. M]60W@B@-@-1^P;,'S3\VS?G./O=L=.]7[O0[BZUV+5%U`KY*;(H7A#K'G[S+ MSPQZ9]*B'AA%NB1=R?8S=_;/LNT8\W.<[NNW=SCUH`;I>L:E?2:Q#>U2>'M8FU5KU)&AG2UF$:7,`*I+E03P2<8)QZ&BST*\M+ MK4;D:LQDOR&8BW4;&`"@CUX'0U9TW2#97=U>37+7%U=[!(^P(N%!"@*/J>:` M-.BBB@`HHHH`*SM=N[NPT:YNK*'SKB)043:6SR,\#DX&3@>E:-0W,4TL#I!. M8)#]V0*&Q^!ZT`8PUY8_#][J#7<5W):Y7;%"T9#\;4*L<@DD?F*K3ZMJ6D2Z M9:7%S;74\[0Q20%2)7+???(X`')QCH/6I'\-S&^AD>;[0)KM;F^E8!2_EKB) M0HXP#@_A5S4M$EU20QW%^YLS(DA@$:@Y4A@`_4#('O[T`,TW5KZZ\1ZCIMU: MQ016T4ZMX;59W6$W"$HL<8P6X(ZL M&Y)Z"GW&BZG%>ZCJ=G?B2ZNK;R8XFB"*N-VP[NO!8GWQ3KOPR+C1+'28;MK> MWM=F]!&'6?:.C@]1GDCOWH`SE\5:I=Z;/?6]I!"+&QBNKB*;<2Y92^U3V^4= M3GKTK177+UO$MC8_98DL;RV>9)6?,C%0IZ=`/FQSSQ27'AA[AYW.HR)]MA6& M]"1J!,JY`Q_<."1QVJ6ZT"2YUBUOA>^7%:Q-"EN(0048`,"V<_PCZ4`1:5K\ M^I^(;FT6&,6"P>9;2\[Y<.58^FW(./IFM^L6P\+:=IFK+J%FCQ;+86Z1!V** M,YX!/X8K:H`6BBB@`HHHH`*PM+UC4+O5M6L[JSBB^Q"-H423BZM;F_%Y=AHPAXYV@#J"RKP?0UI:KHDNK[X)[]ULI"I>W6-,GK5R?0)Y M9HKJ/46@O$@:V>6.%0*`$77[B;Q9%IL$,9L2LB/.<[C*@!(7M@9`)]>.U=!6&GA33(=5M;^WC>%K M9I&"+(VUF?J2,^N3^-;E`!1110!G6'_(5U/_`*Z1_P#HL446'_(5U/\`ZZ1_ M^BQ10`6O_(>U#_KG#_[-6C6=:_\`(>U#_KG#_P"S5HT`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`&=8?\A74_\`KI'_`.BQ118?\A74_P#KI'_Z+%%`!:_\ MA[4/^N8K>;]S!`ZY!&,5=UJQDU/1;RPC=4>Y@:,, MPR`2,$YX!<)I\EO#`[V]Q'"00JSQL-W3HK`#Z'FJ,C8FUW38"RO=#/\MI(;CR6;-PS* M%$C(?E5ASR.M`%NX\3VGV4361%P?/AB92&0A9&"AN1R.20>AQ5FPU66^T^YN M4M09(9Y85C#_`']CE1R>F<5D0^%)ULDC*6D-PLEN6E221S(L3AL'=T[X';/6 MM.RTNZL-+N[=&@EEFN)I5$@.PAW+;3WZ'%`%4>*L)-$]BWVV.[2T6%)0RO(R M[AA^F,1E MKB![6VD2\CN8+2+/D*54JV3C.6#')`[#K2P>&]3LM6N-:MYK1KV]5TGC?<(U M!QLVG&3C;SD#.3TH`E;QG%):/>65C+E?\^Q_P"^S_C64G4O[J0M30^T0_\`/:/_`+Z%'VB'_GM'_P!]"L__`(1O M2O\`GV/_`'V?\:/^$;TK_GV/_?9_QI7J]E]__`#4T!<0GI*A_P"!"LO4=9O[ M+5+:RBTQ)Q=,RQ2&Y"Y*KN.1M..E2#PWI8((MSD?[9_QI][ITESJFF7:.JI9 M/(S*>K;D*C'YU<'/[2`H1>*BVHK;RV)CA>[>S682ACYBJ225QD+P>:$\5%K: M+46T]TTN:142Z,@W89MJN4[*21SG.#G%0)X2>'4#J,3P+=-?RS2/M/[R"08: M,^^,$'U%+'X:\:,&5-IX!X`)R>G3TL9;_X2>+^S M4N?LK^>U[]B^S;AN$N_:>>F,#=]*OR:DL>M0:88R6F@>8/G@!2HQC_@59:>& MY5\6MJOGI]B/[X6VWD7!787STQL_6K>H:==OJMKJ=BT)F@B>%HYB0KJQ!SD` MD$%1V[T`4U\6">>WMK:RWW$[S!4DF$8(B?8<$]6)Y"^E7=5UB33C8QQV?G37 MLWE*C2!`IVECD\^E9D_AFY?0QIC1V%V)#)))).&4QRNQ;2"$7VGVL4PN%;?$T8Y``]0<<]".]`&O)XL@M MM9339X]S2SR1J\`9]@15;YOEX//09Q6E!K%A@$XO;9K=K@7$1A7K)O&T?C2M=01B,O-&HE("$L!N/MZU13P]ID>E M2:6MJ!:2$EH]QY)YSFI)]#T^YBM(Y;<,MF081D_)CI]:-`+?VB+SQ`94\TKN MV;OFQZXHCN(IF=8Y4=HSAPK`E3Z&J_\`95F=474S"/M:IY8DR>GTHL]*L["> MXGMH0DET^^4Y)W&C0#&A\:VTMKJ4K6]\%W-QIT4<-W%%=QW4CF3!VR0O+O:,_H1[B MI%\(7R"&[&JM]N34#?,"!Y1+$AE'&[&P[>O:D!;7Q7YEKJ-[%8E[6P\T,WG* M'+1YR"G5,$9'&.AK+U?PO>:M M=S7`%E:2M#-$9H=VZX#*559..@X/?D<8J2]T#5M23S);BVMYX;1[:W$19@I< M`,Y)`.=HX&/QH`FL_&5C;.6Z1G@/FB0-MY93CHP!SZ=>>*R+CP/(6,<&IRF"2R6U83!25,;!H6&T`' M!!SGJ#5N:SUR;7=+OKJUM)8;;>C+;S$,C.`#)\P&0!D;1SSU-`%Z?69CJ4UA M86)NY+95:X)E$:INY"C/5L#./IS4O]NZ<+Y;$W*BX+^7MP&-47^TM$WP+ M!):6T$MPZ-R`&W%.QX.,'�!UYUW3?M_P!A^U+YY?R\;3MWXSMW8QNQVSFH M6\06LL4,EG-%(KW*0EGW*"&)'RG'S=..Q]:H#PU>!C:^?#]A_M#[<'Y\W.[= MLQT^]_%GIVJ.W\+7L3`":""W2\AN([6-G:./827VY^[NR/E'`Q0!=L/%FGWM M@]XPE@5;AH`CQ,69@Q'R@#)SC.!T[UKVMU#>VT=S;RK+%(,JZ]"*YA_"=XT4 M*M+!+]DOI;F$&1T$BR;LJQ7E2-W!&>E=#I=DFG:=%:I#%"$R=D1)4$DDX)Y/ M)H`LRRQPQF25U1%Y+,<`55_MC3O^?ZW_`._@J6\LX+^W:WN(]\;=1G%9O_") MZ/\`\^I_[^-_C5QY/M&4W5O[B1K131SH)(G5T/1E.0:'GCC=4>159SA03@L? M:H[*R@L+=;>V39&O09S3;G3[:[GAFGB#O`VZ,YZ&ITN7[UO,L@YK*\1:Z/#] MA'=M:2W0>98MD1^8`Y);WP`3BM4"L_5]-DU$V/ENJBVNTG;=_$%!R![\TBBM M+XFM(OMKA2\-K:QW"RJ>)0^=H'UP/SJ)O%<*Z#;:F;9E>XF%OY+N%\J7<5*N MW0`$$9_QK*7P/=I?7$4>HB/3)9X9(XT'[R..,LXC!((QO8$9[#%:-KX?O;"/ M4H$EM]0MKVX$WE7H_O#]X#A<^,;*UT:TU1(994N6(\O&'C"Y\PD?[&#GZ54TSPWJNC7*3VDMI)^X MDB$4CN%AW2;PJ\$E5Z8./PHA\%.'BCFU&3R(;62$>4`&D>5BTK$$$`'@`#H. M]`&M<'DX.![4)X@@E\.3:RD,FV".1I(6P M'5DR&0]L@@BLW2?#^KZ,8IH;FVNIOLJ6LWFEE#",GRW!`/.TX(_6G:;HVH?\ M(KJ&D7<4<-S/YX\Y7W1RM)D[P.H&6Z'GCO0!+%XGDD2=);2*VG@,!8//NC*R MG`^8#[W7C'IZUH?V_IGVPVGVH&8%EP%8@LHR5!Q@L!G@$+I4E*_8[02 M"V!@M]QC8Q2!BYX'S$#`XJU#X;O$DM[:2>$V5M?M>HXSYK$LS!".G!8\YY`Z M4`6-/\7:=>Z/!J3^;`LQ(6-HV+9&);::CO;S/IQFC53+)&LL;G.25Y5A@<D:@T MEB+1;:>*&.2([AY/E@CY/4$'N10`NC>++'4K$2S2);S!))'C.2`J,0Q!Q@XQ MD@=,U:@\2:1<02SQWT?E0HLCLP*C8>C#(Y!]1WK(7PG=KI=C:?:8=UK%=(S8 M."90P!'TSS2W?A.YN8HE6ZB1H;""!25)!DCD#@D?W3C'K0!H2^)+9EMC:?OO M-O$M9%8%&C+`G)4C/0?K5B+Q!I4\[PQWB%D5FR00I"_>(8\''?!XK,?P[>W. MH?VC<30).]U!*\<>2H2-6&`2`2QW$YQ6=?>&=0@T%+9VCN(],MIQ;+"I,DY9 M&4;@>!@,<@$Y/I0!OV7BC1]0O5LK:[W7#?=1HW7/&[C(';GZ5?LKVWU"V6YM M95EA8D*Z]#@D']0:\^EM-0?1[MK4S7%]$UL]K?>2ZYEY39M(Z*I.2/[W->@: M?91:;I]O90C]W;QK&OO@8H`LT444`%%%%`&=8?\`(5U/_KI'_P"BQ118?\A7 M4_\`KI'_`.BQ10`6O_(>U#_KG#_[-6C67)!J$&ISW-K%;R),B*1)(5(*Y]`? M6G^;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-` M&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\` M$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-` M&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\` M$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-` M&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\` M$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-` M&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\` M$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-` M&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\` M$T>;K7_/I9_^!#?_`!-`&C2`8K/\W6O^?2S_`/`AO_B:/-UK_GTL_P#P(;_X MF@#0H`Q6?YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$ M-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_ M`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$ M-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_ M`!-`&C16=YNM?\^EG_X$-_\`$T>;K7_/I9_^!#?_`!-`&C16=YNM?\^EG_X$ M-_\`$T>;K7_/I9_^!#?_`!-`&C28YS6?YNM?\^EG_P"!#?\`Q-'FZU_SZ6?_ M`($-_P#$T`:-%9WFZU_SZ6?_`($-_P#$T>;K7_/I9_\`@0W_`,30!HT5G>;K M7_/I9_\`@0W_`,31YNM?\^EG_P"!#?\`Q-`&C16=YNM?\^EG_P"!#?\`Q-'F MZU_SZ6?_`($-_P#$T`:-%9WFZU_SZ6?_`($-_P#$T>;K7_/I9_\`@0W_`,30 M!HT5G>;K7_/I9_\`@0W_`,31YNM?\^EG_P"!#?\`Q-`&C16=YNM?\^EG_P"! M#?\`Q-'FZU_SZ6?_`($-_P#$T`:-%9WFZU_SZ6?_`($-_P#$T>;K7_/I9_\` M@0W_`,30!HT5G>;K7_/I9_\`@0W_`,31YNM?\^EG_P"!#?\`Q-`&C16=YNM? M\^EG_P"!#?\`Q-'FZU_SZ6?_`($-_P#$T`:-%9WFZU_SZ6?_`($-_P#$T>;K M7_/I9_\`@0W_`,30!HT5G>;K7_/I9_\`@0W_`,31YNM?\^EG_P"!#?\`Q-`& MC28S6?YNM?\`/I9_^!#?_$T>;K7_`#Z6?_@0W_Q-`&AMYSFEK.\W6O\`GTL_ M_`AO_B:/-UK_`)]+/_P(;_XF@#1HK.\W6O\`GTL__`AO_B:/-UK_`)]+/_P( M;_XF@#1HK.\W6O\`GTL__`AO_B:/-UK_`)]+/_P(;_XF@`L/^0KJ?_72/_T6 M**-.MKV.[N[B[$*>>RE4C8MC"XZD#^5%`&C1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% 0%`!1110`4444`%%%%`'_V3\_ ` end XML 20 R39.htm IDEA: XBRL DOCUMENT v2.4.1.9
Asset Purchase (Details) (MultiGen Diagnostics, Inc, USD $)
 1 Months Ended 12 Months Ended
Feb. 29, 2012
item
Dec. 31, 2012
Feb. 01, 2012
Merger and asset purchase activities      
Common stock issued in connection with an asset purchase agreement (in shares)   125,000us-gaap_StockIssuedDuringPeriodSharesAcquisitions  
Issuance of common stock pursuant to acquisitions $ 187,500us-gaap_StockIssuedDuringPeriodValueAcquisitions $ 187,500us-gaap_StockIssuedDuringPeriodValueAcquisitions  
Number of intangible assets to which purchase price would be allocated 1trov_SignificantAcquisitionsAndDisposalsPurchasePriceAllocationNumberOfAssets    
Fair value of the contingent consideration     0us-gaap_BusinessCombinationContingentConsiderationLiability
Maximum
      
Merger and asset purchase activities      
Consideration to be paid in common stock and cash upon the achievement of specific sales and earnings targets     $ 3,700,000trov_SignificantAcquisitionsAndDisposalsContingentConsiderationPotentialPayment
/ dei_LegalEntityAxis
= trov_MultiGenDiagnosticsIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
Restricted common stock
      
Merger and asset purchase activities      
Common stock issued in connection with an asset purchase agreement (in shares) 125,000us-gaap_StockIssuedDuringPeriodSharesAcquisitions
/ dei_LegalEntityAxis
= trov_MultiGenDiagnosticsIncMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RestrictedStockMember		    

XML 21 R54.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Details) (USD $)
 12 Months Ended 1 Months Ended 3 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Jun. 30, 2013
Dec. 31, 2014
Aug. 31, 2013
Oct. 31, 2014
Commitments and contingencies              
Research and development expense $ 6,664,906us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost $ 3,947,589us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost $ 1,920,298us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost        
License and Services Revenue 10,000us-gaap_LicenseAndServicesRevenue   125,000us-gaap_LicenseAndServicesRevenue        
Research and Development Agreements | MDACC              
Commitments and contingencies              
Amount committed to be paid   266,000us-gaap_PurchaseObligation
/ dei_LegalEntityAxis
= trov_UniversityOfTexasMDAndersonCancerCenterMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		          
Research and development expense 142,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ dei_LegalEntityAxis
= trov_UniversityOfTexasMDAndersonCancerCenterMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		 124,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ dei_LegalEntityAxis
= trov_UniversityOfTexasMDAndersonCancerCenterMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		          
Research and Development Agreements | Illumina              
Commitments and contingencies              
Period of termination of agreement, after completion of the research plan       30 days      
Period of termination of agreement, on its anniversary unless extended by mutual written agreement       1 year      
Research and Development Agreements | USC              
Commitments and contingencies              
Amount committed to be paid           232,000us-gaap_PurchaseObligation
/ dei_LegalEntityAxis
= trov_UniversityOfSouthernCaliforniaMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		  
Research and development expense 38,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ dei_LegalEntityAxis
= trov_UniversityOfSouthernCaliforniaMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		            
Research and Development Agreements | USOR              
Commitments and contingencies              
Amount committed to be paid   270,000us-gaap_PurchaseObligation
/ dei_LegalEntityAxis
= trov_USOncologyResearchLLCMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		          
Research and development expense 16,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ dei_LegalEntityAxis
= trov_USOncologyResearchLLCMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		 29,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ dei_LegalEntityAxis
= trov_USOncologyResearchLLCMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		          
Research and Development Agreements | Genomac International, Ltd              
Commitments and contingencies              
Amount committed to be paid             175,000us-gaap_PurchaseObligation
/ dei_LegalEntityAxis
= trov_GenomacInternationalLTDMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember
Research and development expense         $ 90,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ dei_LegalEntityAxis
= trov_GenomacInternationalLTDMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_ResearchAndDevelopmentArrangementMember		    
XML 22 R48.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements (Details) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Liabilities:    
Derivative liabilities related to warrants $ 3,006,021us-gaap_DerivativeLiabilitiesNoncurrent $ 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)    
Assets:    
Money market fund 27,123,587us-gaap_MoneyMarketFundsAtCarryingValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 25,703,330us-gaap_MoneyMarketFundsAtCarryingValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Total Assets 27,123,587us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 25,703,330us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel1Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Recurring basis | Significant Unobservable Inputs (Level 3)    
Liabilities:    
Derivative liabilities related to warrants 3,006,021us-gaap_DerivativeLiabilitiesNoncurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Total Liabilities 3,006,021us-gaap_LiabilitiesFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 4,431,871us-gaap_LiabilitiesFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Recurring basis | Total    
Assets:    
Money market fund 27,123,587us-gaap_MoneyMarketFundsAtCarryingValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 25,703,330us-gaap_MoneyMarketFundsAtCarryingValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Total Assets 27,123,587us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 25,703,330us-gaap_AssetsFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Liabilities:    
Derivative liabilities related to warrants 3,006,021us-gaap_DerivativeLiabilitiesNoncurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
Total Liabilities $ 3,006,021us-gaap_LiabilitiesFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember		 $ 4,431,871us-gaap_LiabilitiesFairValueDisclosure
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_EstimateOfFairValueFairValueDisclosureMember
/ us-gaap_FairValueByMeasurementFrequencyAxis
= us-gaap_FairValueMeasurementsRecurringMember
EXCEL 23 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"8/!UL/@(``)LD```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VLV.VC`4!>!]I;Y#Y&U% MC']"IQ4PBVF[;$?J]`'K+IS\-^7&K(G+Z73&2V)_'4!I;=[1<.O1;,]'W;E":FI/S)5J^Z3)X[Y&GG MN";431_>I1B,'^TPO/E[@^=]W]+1^*:B[-[X^-5T*0;?MOR7\YN?SFWRTT6. MI'2K55-2YS:?+SGG6GL2^X3_4@P_\;"U^8 M0X+D4"`Y-$B.`B3'#"3'>Y`<-R`Y/H#D$%.4("BB"A12!8JI`@55@:*J0&%5 MH+@J4&`5*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K`I%5H4BJT*1 M5:'(JE!D52BR*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM& MD56CR%J@R%J@R%J@R%J@R%J@R%J@R%J@R%J@R%J@R%J@R#K[7[+&-'I!?+S^ MNZECF3/?_D/_J-*UQY4,X MU#W5/XV0W'O7AS1,X^GR`"_3,L/N29\*D8\-'>9ECLV='#JF09S+&[X:?*%A MU*>BZDAO/HX6+7\#``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+ M``@"7W)E;',O+G)E;',@H@0"**```@`````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````C)+/3L,P M#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO> M[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MB MU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\U<%J M"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5\YS3 M$$X4UD M^&'!Q0]47P```/__`P!02P,$%``&``@````A`.G>_OB/`@``*"0``!H`"`%X M;"]?A+D8$`538^WN?"/;]P\_CX?B>QAC-_2U MTJNU*D+?#-NNW]?JZ].G=[>JB,GW6W\8^E"K9<^UJI-Z?2^+&/3AJ./J^$4^GQF-XQ'G_+AN"]/OGGV^U#*>EV5XY][J,W5 MGL7CME;CXU8;53R=3_G2KV\^['9=$SX.S;=CZ--?KE'^&,;GV(:0\J9^W(=4 MJVDIEIW$&CJQL)U8H!,+VXD%.K%A.[&!3FS8TVW@>%NV$UOH MQ);MQ!8[,3L?.YB/JT5]I_&'YD/KNW[VXVD)/4ZQ2X0KM"B>IM@PWY)IZ7>2 M@*!B3Q,<)LWF@H9[!:EYL0#@`B8UJM%73FF\R'_YC9_*7HY1OAF%P?6ACW6 M<*HUFP@:$D'81!!(!&$302`1#+MU#.P=RR:"A41P[*SE8-;2;$!I""C#]D`# M3="R`64AH-RB@/H?7L+'AHK=.Q7L'7JM$,O9IC-Y3GGU_Y[-+P```/__`P!0 M2P,$%``&``@````A``T3O]0$@`+?&6"-:URJOLPGH?I\9DD"GSAYM)5+[]=L(* M9](Q)4_8A#GIZ?[UF9B+[^]QU'E5F=%I,G'ZWWI.1R5!&NKD>>+\N[KY:^QT M3"Z34$9IHB;.3AGG^^6??UR\I=G+4YJ^=$@@,1-GD^?;\V[7!!L52_,MW:J$ MKJS3+)8YA=ESUVPS)4.S42J/HZ[;ZPV[L=2)LU1[ MD4Q%,J?TS49OC7-YL=:1>MSOJ".WVWL94][OD=.)I,GGHC;H#9SNY6&3BZP3JK4LHGQ%V_M0IWJYGNL.RU^6I7C4ZLT<%Y5A MY_V73L+TK?PIE79WB`:4P%MUZ9<.\PU=[_5ZA^]^*/V\R3^^)/DNZ%<5I/M4 MGYVDVMY'101U2LR37.<[<9OLJZ]3:F%9]5O:6=_I9.>:_LANPWZ9.*IK^4Q,K^ZN[J_G8OEC/E\M0<(%"?<$";&0H#(`E:K65B+4S332H:1> MB65.'V6[C4C7XF&K0,4#%8_E\KG*,L>B#+$J_@DRU])`,D-(IH+BBULB%4K@ MT*(1R(SJR4P+HQ-EC'B@H7TEPJJ.W^G?A2:R066(;1HS&6ET5DS6BL=0JJT#[&())G1H0U# M[$.?(3I3F7ZELKTJ<:,3F01:1C1R)L]*:T(=8KL]B*)+B.Q:2J9 MQACYW)^=:)-L(GD68V359:RV#R:6=XRTNHS63R:S(2'$UF78E@/:L`@Y'3!. M<4X;%B.<`P9GZ[@*X&*,I`X8J>W#8I4221UP4EM/+10:6&5AI+8C3WTX(%\^ M8!U\D(*:#[0+41)'(:M&S%#;A2B)HY!5(\9MNQ`E<13":1XP;NU#F<[%7.H( M_6ELK6>\?N(&7,?#4::@5N(F.S@>TMATCX)#KR@X20A]SL.)IN`D(:3'PY&F MH$D(GQL:JNPAR11\54)8&T**/48Q=\O_NR2LS2#!'B.XW3"M;)!@CQ'\F6'N MXRF?<6M;+5Y\A]3Z#M6FUU5(?&:6@ MMOG&]=A-']&DH+:^W?NQ>#X"2L%)0HB%CY!2<)*0M34$U6>@MF\-/=M'4"FH M9=3X'-HPPCYR2D%-IOUXM"ID$<I$H#D51 M?E3_XWO^8@#TD%>V5>AMS&,Z9&<\A M7G_[*$_6NZB;HCIO;+HDMB7.>;4KSH>-_<_?SXO(MIHV.^^R4W46&_NG:.QO MVU]_65^K^K4Y"M%:$.'<;.QCVUY6CM/D1U%FS;*ZB#-O;99%7Y05"O!2GHOW9!;6M,E]]/YRK.GLY@>X/ZF7Y+7;W81*^+/*Z M:JI]NX1PCB(ZU1P[L0.1MNM=`0IDVJU:[#?V$UUQYMO.=MTEZ-]"7!OM;ZLY M5M??ZF+W1W$6D&VHDZS`2U6]2NCWG5R"FYW)W<]=!?ZLK9W89V^G]J_J^KLH M#L<6RNV#(BELM?O)19-#1B',4M'(JQ,0@-]66V&RS] MD+@4X-:+:-KG0H:TK?RM::OR/P6BDM00A/5!/&#?7V=S@SB*4*>/9VVV7=?5 MU8*F@47[Z)'AC M@]PA6T&`F"A(T)6=A82&D0E(#8`?,P]%X#J`AKY''N02]LI\YA*,F*,J)@JB MY1`O<+40=MJH3^!GT&;D-/@*,PE&S%#*$@7IGVL\MJM^JJZ/S+EQ`Y-,[Q,- MOT)4@A'1>`BKVE!!%%$6W2F^`;A7?!W@^>1A\:67:I/J\PTDP>8&"L>$*.8* M,J8PQ0M<6S"*'7^%B02;.0S1X$L4Y-9DGH>NI^KZR)1K"P8Q"H-E?HXZ-**& M1F'28Q2W(`B\F*#-FQH0-_9"/T)-P@T(C1EA\=CPI@(Y\V=7F2J'T*=3./$= MA>D[-'1!`8*D?9A;`5Q"`]0LW(#X)/#=<1Z;`J0SS!>@?,00,,X^U:=4810[ M/Z*$1&B.I2;$"QEQQ_QV4;@!85'(X-^PE4T%TC?F*U`N8R@84],K4)A;?AGS M77=\>(=)J8$AL1>'6"8W,#Z+8U^KDZE!.LI\#!^@&T8F5^E`\[DJOS*XHI9-J.YIB\ASV33A!H2&A*#>XWV0.WRE[\SG MJUS*X(M2EU#=R1@4%G%)#<""L7C:&WH([Z&)4^E,&O=Y+Y7=7>:\C]"<2WI, MWQ\>\R,?05(#LJ`D\BA%,XN;F``&4J15QNP;:6::EL]]G2KKT^L0(;M,>LRP M5:%OH!C#L.OGC0IT`U&8J_%T:"*0'_AQ,#[.T,&^Y+T=&M4">V^/Z2DRL"7< M4`@11QXJ%C<1;L0TA$D?&>^\EF)3`XZ0NR8]1GT_@,GIRI&']DZ*0!24A/A[ M!,>@@'B,/"H'M,C\MF(2C'BE M)B:`-PA&T:;B)L8E\$[[Z*N2/)K16VBFF*D+XQ>9I(L\N'!,0DHQT=3$/!"C MFS6]+T:=::DSGU+4!Y&*TZFQ\NI-GEV+R6`&M)W#&UAU(.<,% M..*Z9`?Q(ZL/Q;FQ3F(/(6%G`*U:'9*I#VUUZ4Z:7JH6#K>Z/X]PF"G@D(CV_\!``#__P,`4$L#!!0`!@`(````(0!-A&B;40,``.<) M```9````>&PO=V]R:W-H965TF M=IX(%Y2U8^*Y#VI)5M-W.W=^_[F]RUQ$2MQ6N64OF[@L1[NWB\Z?9@?%' ML2-$.L#0BKF[D[*;>IXH=Z3!8L(ZTL*=#>,-EG#)MY[H.,%5OZBIO=#W4Z_! MM'4UPY1?P\$V&UJ2@I7[AK12DW!28PGZQ8YVXL36E-?0-9@_[KN;DC4=4*QI M3>5+3^HZ33E]V+:,XW4-?3\',2Y/W/W%!7U#2\X$V\@)T'E:Z&7/R$,>,"UF M%84.E.T.)YNY>Q=,B\!WO<6L-^@/)0=A_';$CAV^<%I]HRT!MR$GE<":L4<% M?:A4"19[%ZOO^P1^<*"B!(2-7\U*#A2 M:9+P2!*#^N/]A1D=PIEKD+VQVZ$)#/TR)'^*!W M$`U6F*)?C^&D38&5MA/K4A>`>Q`;CH2\@LAL2'$)2>,!8HF-/B)6@6%W&-IR MA`;>WI6EQL1#0ZMQH3`*EA0(V/1-A1W!87C;/[5H[D*_@UUY'HTD:4S:)Q_Z MF1^@LQF]Z)6)"%"&(L,N';:)2*(PB/WA(583<&+,)MX6K\"V>.2?>;6?&F/X M.2X41L&2DGY$B@*_%ZW&&%+&A<(H6%(R6\IUT:I%MCN7T6I,UD>;H=3W1^=Z M90*2&,5I,N2F@S4!090&\9G!:D%-2^-5]':P"FQ+1_[H?;+4&,/-<:$P"I84 M]!$I"OQ>L!IC2!D7"J-@28&Y9MER7;+]*MN?RVB/('UL@S"+@SRULUO9D#A$ M%Z\C-7A5_YHE0@E"Y]>I[D3/53UV&L*W9$7J6C@EVZN9&<+6&JK#/+\+U?MM M5%^J.:_JWG`#QFR'M^0[YEO:"J,R=.%>L#P%VWQ#P``__\#`%!+`P04``8`"````"$`P657ID,( M```3)0``&0```'AL+W=OV11HG4)XA25R.XNL`LL%GMY5FPE$6I;AJ0T[=_O4*0LSE#UI2G0QL/# M\5QY1BH?/GS=[Q9?JK:KF\/:8W[@+:K#IMG6AY>U]\_?G^Y2;]'UY6%;[II# MM?:^59WWX?'GGQ[>F_9S]UI5_0(T'+JU]]KWQ_OELMN\5ONR\YMC=8"5YZ;= MESU\;%^6W;&MRNVP:;];AD$0+_=E??"TAOOV&AW-\W.]J42S>=M7AUXK::M= MV8/]W6M][$9M^\TUZO9E^_GM>+=I]D=0\53OZO[;H-1;[#?WO[T>U]9/>2 MN^LWQ?=:_/^2UMO?Z\/%40;\J0R\-0TGQ7TMZT2P>:EL_O3 MD($_V\6V>B[?=OU?S?NO5?WRVD.Z5^"1]WO:O:R^*_5421`S@BZ>JZS_52J6WV+QU?;/_3X.84:65 MA$8)[#!*PNC2YJ4V9/!+E'WY^-`V[PLH%OBJ[EBJTF/WH'!T2'_]R<7O>0BN M*24?E9:U!U4.QG>0EB^/61`^++]`*#<&D[L8AA'%B%!Q4VH%%4A+L`0'3EY` M2&POYM,Q&JO`RMCQ:W(M`-TGZXGMQ0PBP<8+%Q)S#)$N)&$3!CD$";4=4FF) MH%K/.Z8V`<[R(^7$DUQCAA898EQ0@:`":0F0C1S;>-XV!5Y[$(%3C%.^PO') M-<:RC0J$%L1#A45XM[3`R$RH:AI*#K+SYJI-.)190+XPUQC+7"H05"`M`;(Q MQC:>MTV!<2BS8"JC(:NYQNA`!3A0A5Z;[!94("T!,C.YQ4P%QF8F/,.FY!HS MF5)0@:`":0F0;8IBK8/L?`@5F*:75J/&6+91@:`":0F0;=DMMBDPCEL:D13F M&L-6?.@$LEJ<715G5Z5>';Q&+C`X?:Z/[X#&3F1!3))O0-"WIS,AH9X6UX#$ M-2!Y`BF"M\F#*5:Q2N>ZPW;815TDI)`;4#:D*?09J?\"K7-_1=I8H'783TYS M:=9GTJ6XQO+I?#LPS4QPT)\RD04I39<&60UAMDT2X4BD+<%15[1RO86:A&S^ MF+%0@Y(AVCR-P\`M)QL2)5&4K,BQ+IB&3%Y)6X)]4)QC^7!EY6BFPKZ0RLC9 M2&=32A).3"UF0!DCIX$X@<9Y1]H2[(_B)\N?"U6CV0S"-54-(S-=KJ9C.,ZF M:!:.1#@2:4NPA8J:+`NOC+@F-!1QVDLYTR!3/6&:K.B`4B!(E#`6T:%`($C( MPYAE3M-^CUZ9XC;+N0OAUTQH.Y5&3M-JD':*<18$%%(,W[KV#(1QGL1."2$M M8<;CF'R1-%J&/..,*5*\WBE-H=@IIS/ MS?ATDT;#C/V*$:^W7_.G;7_&2-OF3(.,M4G*&6V;`D-6+`X8B;C`D"Q:$?*1 M!N"Z%!(NOZZ)AEV$\*S'%SUW&I!VC8/K/"'E7V#(7)\)!)GM,XD@M,]0`88_ M1._#+NHM'1$-2'L;\HBSD#!X82#3^2<C5%GT@H->8&9->3WC9ZYQBOE^>?Y6UMN,X(_U_(PASODV,R#S5( MVYGX=.XMT#KW(Y[9/Z1:A4%_QZWO,7](F/_*]G$G@(RV1SZH'ML'VH,87*!U MM[T$6K_47A*A47OA-"HVOOVXT!R.CPLZ'(0:-)9=#*.`]4-:I##HJ6R%(Y&V M!'M!1@.5M5JF3^@1H?`+YBLT-9\^EPPJQZDW3`/X M0TZH`D%6:19'(2DV@2#PFH;QE%28-)`A3C@GBH%O[H%(\S;J`4IBN0'I0XAE M&0R/Y-0K#&1*GW`DTI9@TW^([:,9M@])T',#`OJ<'BJ=H6H.Y#SWSH%",L') M.9"E"7M-)H#K#NG(G02RD!S"N0%AKYV4:4UVRJA$GA0Y+703Y40#) M#6BRIW`DPI%(6X+#>Q.U1YI*\2E*LIL;D&VAQ<##$XMP,-*68`L)2U\XAEQV M3B/G&-*@\4TN@R'08JL@8/*.3*A%A+D:829$L,+R+13^ILD6;+ M$#H^/S MEWQ7'FG0[!!8F$4]H*Q\Y_TC6@]\4M/2++M^\)LX?D`3DJ1O2W,#LOK'D0A' M(FT)*AU^$XT/:/P8FP4D&KD!V19J]I\DPL%(6X(M))Q\OA:XR\5NAQO06-SP M$A^WZTR'DRUP**!NS3+G4!#.EH`[(&E`,Z5#^/R"VRZ/NSW--6AT&WJ:<%Y! M$*3E!5D._(SPH32(&7<4+5J3U05W-(F>[VBX5#*]A(B=1^T"K:<^(W4JT#KW MZ3BF+JTH_98O^@Z*OJNQK]J7JJAVNVZQ:=[4_9(0_H_C)#W=??D8JDL-1)[# MG9CA`LGRM`!74H[E2_5'V;[4AVZQJYY!9>`GP/JMOM2B/_3-<;@A\M3T3Q?P```/__`P!02P,$%``&``@` M```A`+E\8W@S#P``&54``!D```!X;"]W;W)K&UL MG)S=;]LX%L7?%]C_(?![''83IS$FB0/;G<[\]TN* MM'3O/:JE>!ZF[<^'C`Y)71[1CC_]\L?+\\WOV\-QMW^]6R3+U>)F^WJ_?]B] M?KM;_.??YD.UN#F>-J\/F^?]Z_9N\>?VN/CE\U__\NG'_O#;\6F[/=VX'EZ/ M=XNGT^GMX^WM\?YI^[(Y+O=OVU?WRN/^\+(YN7\>OMT>WP[;S4/7Z.7Y=KU: M%;[N=T M][(Y_/;][[Q9?DHZV3Q>WG M3]T`_7>W_7$D?[\Y/NU_V,/NX>^[UZT;;3=/?@:^[O>_>>FO#QZYQK?0VG0S M\,_#S;E*$R>_^;H]GLS.=[FXN?]^/.U? M_A=$G:.^DW7LQ/T9.UF[O\YLG,;&[L]S8_?7F8VSV-C]&1LG^;+*\ZRHROG7 M[Y3=(+@_S[VLE^LJ3_+B':-0Q%[*H9=\F:WSLIHQEK=A7KII5IO3YO.GP_[' MC;MWW,@?WS;^3DP^NI[/\QMFHY_QGTVXFVG?R1??R]W"W?1N+H]NE?[^N4Z3 M3[>_NY5U'S4-:H2B/2O\,O+=*@FT!"8`]__^!Y>EZ-:.:%9%?W&W;B#ZT7#+ MBH[&^"H_F_9B;_I\N4T`]&+6_8_I#+4CBI)+%$J*C$LT2LI$:$S4Y&DW&UFR M*E:\%XN]D!_$1L7=+W14_!I)726Y/#J^D=.1F:E3,1Q-T&3]"+82*`FT!$8" M2P!SX>[A][OPC>X6;JCZ]56E8L::H"F[@2[6:9I5*1_JEBGJ*E^58C(45:3% M*LE*,:$Z*(:Q,I--+&G"1L+5(3H2E^?1B\4(9.+JFZ`)(_`A*8I"#%'+!&6Z MJFL^0HH)7`_R)M9!0.Q+8`E@;EW=I&[GK5[?2+H6=:4)FO.\%ZZ8BW%IN6)D M92BF&%L9.BB(<0GLI3[82+CZ+D?Y](SX2=2K6=Q,T12@U69I45:N<]ZAA0(X$E@#E/G$TYR=-KMVLEO8N+:J(HF$_=X\5J+>[T MEDFRL06NHF3PIH$8()82[M>'%K*H+]^C28@X=)NJTR'B=-FCB:+A"EL@"H@& M8H!82K@+GS&(BWFU-PG)Q.WC_::+T2&*J)O0;"`*-!J(`6(IX6Y\LA!N9JS! MD$?XW,`:)*$E),4DD+`JD\0%/%E'U+1$1\DP)@:(O=@-'P`?*,0`3->?),00 M/@`B(#11-%QH"T0!T4`,$$L)=^,#@W`SO6_XAU]73MWL7%J<)(O$Z91$Q8X& MQQJ(`6(IX6Y\"A!N9BS.D!WXW(C]JDEDXF@CB8LSS9),EGH%C300`\12PNWY MS5_8FS%9(3)0>[C+)R17Q,D*)&Z'X_L\M-)`#!!+"??GMWSA;\:M%8("]8=[ M>T+21/072/"WKE?Y:B7F7$$C#<0`L91P>WY?%_9FK,Z0!K@]*)TD,D1[@<3I M^TGME*UT(HD!8BEA_M8BGES>KCLUCR5I(K?K*!KJ0PM$`=%`#!!+"7\ M[7H=PL?EBAA%U$UH-A`%&@W$`+&4<#=NW<@U-UTR_,DBQ&7Y8!!%;F,CFX!X MI&U'1%4N3D!4+SH?(FD@!HBEA'OVJ4'<9S,\AZQ![[,R!<]!-,Q7NY9$`=%` M#!!+"7"YI_.FQ6ZSNRGNKL,3:7G1>8@J(!F*`6$JX,1$])HQAY*C@K'@=1$F>=6<* MR3*M]`=Q[[11-,RA`J*!&""6$FY,A(X)8Q@V*CCQ7`?1V=AJ615IS?[CC\QM M;$!-ABX&HD%C@%A*N$F1/"9,8N*H4G%4T*R#J#/+@WT#Q%+" MS?I-_OWU,40#5E%P9F5^:->2*"`:B`%B*6%N?"U\OYNN%4\?>*8=13'AKY*T M+D3Q:86D*N$M!L4ER2HMU^+!3T<)F<[I1I8VXB,B$LSEQ9R&"$)K;`4[110- M%]A&$O/EV&DVM-&\S<@1N8$VEA+NTF>4=Z_BU+<2\PX[2A1=G/?0SP6)$KV, M+`W-)6-+PT3),/*6-UKQ?OD0^6PBAFCZ@2,-B88N"#SLCJ+@?_0PL&42]Q[O MNI3OOBDFJ>NLP#LC7,Q@WTRVL5'1M>'CX=.-&(_IY\LT9"(^'O+L.(KB[9", M'AX+3>4.ARN1EU74#'XU:Y6[0^E$OO-@H)&EA`^!R%_^Z6;&DAC)8:E\!DV# M*`S!^!$RDXRN&L4DHZM&,\G8JC%1,8RB96UDMWR$1)";]_R78J"K,Y'5FB@: M+JL%HH!H(`:(I82[$>EMIIN0KMA>CWN"C&!M*HD"HH$8()82[D;$M)EN,*[5 MF3CK:=(@"F_?B1?;^&+=Y?!\*=^65NSUU7(E)E['UX>)-T`L)=RTB&L3VWG( M6ZQ:X08G0UF;GLGP$%5GHLBI49$H`[H7G9^T#!!+"?.:B3!WV6NG%ILY/$5% MT3#V;23G9+Y>LD>/NB[U!^E<-,EEDQR::/BY!HBEA(_#NR)<-A+A()I'$1V' MT.P\#NXQ3*Q;%=L,"K%=:>C4`+&4<),^0XGMV(?:B4GWK?BDN^#`GZZ:+(BH M64D4:#00`\12PMV,A*T9;D*^N5QILR"B;B11H-%`#!!+"7S;2,XE M)%F6[HT6\M\:CK04-,DS$&GX20:(I80[%ZEHPGF(-:Z`#`>,6%YE]FFS0'KG MO$0I\?)J68L5H*-B&$P#Q%+"+5X5E3*,2F4JBGX31<-UM4`4$`W$`+&4<#QM)/*E85U4A/]6DH)$&8H!82K@]$5YFV@MIA$T6W&5Y$%%[DBC0:"`&B*6$ MN_'!0:047U(OUXP\Q`U:,_`0)8JHF]`L3-8Z3]95(;<_:*2!&""6$F[/)PEA M;WJC=Y^HEB$,/U,01=1>:!9/2<8_4P"M-!`#Q%+"_8T$F>DS'_>6B_2'GRF( M(NHO-!N(BIHXH6.?,M#0C0%B*>'V?``0TS=C=8;8P%>G>)!K[(;[%9EE9FW![%)GXL9JQA0REJ\4]'D$%`BB7?C3_S)5AKZ,4`L)=S?5:DDQU129S*51-%P[[5`5"07 M)E1#(P/$7NR&^[TJM^0ADK#;4V[:3111OS+)*-!H(`:(I82Y\753%IOIO:)K M)3XL"(>)443<`%%`-!`#Q%+"W8B8BQ"ID5 M6B"J)V0XY$.L[D5#]9-=6ZKAQD3$F#"&T0)/M8H@&B:C!:(B.5>)9%DD>&@% MS0P02PDW)K+$A#',$"/E3R:&MI!$17(V-G).!6T,$$L)E2FZ5GS3JJ'^ M11&9-B`JDE#_TJ7\I2<-+0P02PGW)A*&3_/3#V?E2-+(15UNHHAZ@Z0!&@W$ M`+&4<#)+!L[LH(I4(B`*B(XGG>Z-;"I>,[RFT8V[XJGA3C<0;^<'0)HJH M88@WH-%`#!!+"7?C$\>[`T$5<@I;C/!X%T7436@V$`4:#<0`L91P-SYQO-]- MR"ETB\!X4P71<.TM$`5$`S%`;"3CQ[/D(I,?E."&[PJNU1SLDL448,RS2C0 M:"`&B.W)8)#F&V[PJJ!2S0DJ440-RNBB0*.!&"`VDK`TD_CQG)^LT*N"234G MF$01]0?!!#0:B`%B>^+#BSN9'C[HR.?NJD!2A:Q!JV9=##^A^WWL)HJH-QE1 M%&@T$`/$]F18G.[7<<8GK[XJHW2MQ#LX9`B#P2@B!H$H(!J(`6(I8=/EOO/Q MBDVN:S65N**(NH$``AH-Q`#Q7U3I'SUC*I/ON@9_X9LHPU<4OFP/W[;M]OGY M>'.__^Z_97+M/H;>T_X;,+^L_3?("=XD'W7W-9*W_0ONBRG?-M^V_]@ MCS?/VT?7Y%JZ<2/ M^_WI_`\?['^&PO=V]R:W-H965TF=D)#>0%BCL^[A;^G]\/-Q/?DXJ6&]G,J+I*[=YZ-`7/*V%%%LU`+H`A79SG@;3 M`)B6\XQ#!KKL7LVV"_^.S-9DX@?+N2G07\Z.TOKLR;TX?JEY]IV7#*H-?=(= MV`CQJ*'?,KT$FX/.[@?3@9^UE[$M/>3JESA^97RW5]#N&#+2B1@3@WH9)]<`UI>^E!ZE$ M\0]!Y$2%).&))`+UI^_#03B)29Q<9@E0D4GPGBJZG-?BZ,&I@9BRHOH,DADP MZ\PBJ,_YS"`EO>=.;S);`2VA'4_+:1+-@R3N4 M1MS:@>@ICJ)A4SE'W?@:=1KLJHM)NR.(Z57G0'K5Z5^GJT=?;W)53I.DR1Z[ MAQBK>]:"4Y^IJZ#_W&AP^]RTNX<8*[*UX$0FX''7)V]VN=EW)_L$PB:='VT' MTCO;I.7/_24R:%=?3":M[IQ`O?K0FA'2KT\;IW6(+NA#F[6=<9JTQFM%$&0U MT5YQN]BRYPO1T5'AM?'EF+2=AR#(CFZMN-%;QGLA^CG';9]?@J#>`7M%;>#+8/^V,\[ MZ3KU&1>P??@=%[`A_5/6LNH+)ZWKT6=<`$%]%Q"X46O'1SK8P8\/!&$Y"C?=E?%"B,A?'C5!PSS4?]_"_AL$=;#@`\%8(]?J@ M;^3-/Z7E?P```/__`P!02P,$%``&``@````A`*[)`%*?`P``C0L``!D```!X M;"]W;W)K&ULE)91;Z,X$,??3[KO@'AOP$`@B9*L MFJ#>K70KK4ZWN\\..`DJ8(2=IOWV-X,)V*;;S;ZT8?CSYS=C>YCUI]>J=%Y8 M*PI>;UPR\UV'U1G/B_JT<;_]]_2PY:R67F>R,ZLHF+&&U;#G2-O*RKALCUYHFD9S;N'JM(+?#_V*EK4 MKG)8M?=X\..QR%C*LTO%:JE,6E92"?SB7#3BYE9E]]A5M'V^-`\9KQJP.!1E M(=\Z4]>ILM7G4\U;>B@A[U<2T>SFW5U,[*LB:[G@1SD#.T^!3G->>DL/G+;K MO(`,L.Q.RXX;]Y&L4A*ZWG;=%>A[P:Y"^^V(,[_^U1;Y/T7-H-JP3K@"!\Z? M4?HYQQ`\[$V>?NI6X&OKY.Q(+Z7\EU__9L7I+&&YYY`1)K;*WU(F,J@HV,R" M.3IEO`0`^.M4!6X-J`A][?Y?BUR>-VX8S^:)'Q*0.PK+T7J&G6:W93#3$5^YL""XBVJ1;P M@'>`AE+HT.\OPXT-Q:\"20?[$"31,AY73NT[[1&# M+?X=-A3;;-9&VRE-CT*B8+Z86Z7=*\F(GVH!`R[Y'3@4VW"AM:A*H^!"^.#X M@57:O5)H;%K`8,,/H=9E/M[[*#;90A);;$HSOGEO!U(M8*`L393[CB,^]*OC MJ#0:DAU(M8"!1*`=W%^>3FW69WH@>Y%&,XFD?40M\"*)X3LR]FP3$!NQMG[W M%8VH]FUV#JN/[GJ1#JH>&R-IK^F/R3PBB=Y?3%+LRQKIQSN-J"YN$MIGM!>- M//M)).TCBI#XBXB0,5$3$'OR_8"J@YN`]CF%R0=WIPYH1W`Z0LW['5H!JNE' M#0<5:T]LS\I2.!F_X&030+L*[W`:P[@WW(!AJ*$G]H6VIZ(6 M3LF.8.G/$FBTK1JGU(7D33>2'+B$,:C[>8:QE\$PX,]`?.1```9````>&PO=V]R:W-H M965TE MQ\:^-RJ.ZVI3'E^7WM]_B4^1-VK:_+C)]]6Q6'H_BL;[_/3K+X_O5?VUV15% M.X(*QV;I[=KV]#"9-.M=<0LOZ]=)\O M)H>\/'JZPD-]2XUJNRW7!:_6;X?BV.HB=;'/6SC_9E>>FG.UP_J6\_OIV M^K2N#B0*6GQTT)#E3;1W6Q77K/[$$&L3=Y>NP:]$]9O#?6_Z-F5[UG M=;GYK3P6T&V8)S4#+U7U54F_;!2"P1,R6G0S\$<]VA3;_&W?_EF]RZ)\W;4P MW7-PI(P];'[PHEE#1Z',.)BK2NMJ#R<`OT>'4BT-Z$C^O?O[7F[:W=*;+L;S MT)\RD(]>BJ85I2KIC=9O35L=_M4B9DKI(H$I,H.S-^\'XR":L_GBCBIPO.Y4 MX.^YRGP\"^9A=,^Y+$P5^'NN\A/G$IHJ<)F]Q-&<_;_.FQKMY' M\%K!F[%Y?7 MZ]FR$BO+Y\,D&MCG%B!_%Q2A*^%4LIBYDI1*PA`=25!-%,9NG>R")O)=C;RD M&6;-:=[TGN8I,5S6UCQ&$?*0:,VL;_`*`XY!BH'`(,-`6L"Q`_N&O1;4=3&% MG?#C-:$&+3UH6K\\HVCJMC31FD5WD01^Z+,83?#*5K`XC*=X"7!;,9\&;(;F M+=6"H7<"@PP#:0&G$;#UV8WXN`%*C!N`["5:,YS;"@..08J!P"##0%K`L0-[ M\.UVE/C:,M4:RPX&'(,4`X%!AH&T@&,';@JVG=N6J1J$9VF.EJG66+8PX!BD M&`@-0KW4Y[[Z<8^2X2'2`HY/E0W1;>KZY:@&89\+]PP2K='GR*8ABZ9H'UII MQ=`)CD&*@<`@PT!:P/$9NSX_OMJ4V/47SM`NGVC-V)Z'];/JB=6. M*8I'O!>=/UBDA`A",D*D35RK*DM85F_+#$PG$,=RA$.#$=F6K>!B/M-ADI)1 M@I#,$+T/++HH@?HM'(:5G$#&9[!\KRR*^F0XAB.T;DGS$HRQK`FVG#0S96; MN3@9DQ(B",D(D39Q_:H\8OF]XE.G%]JCV\R M1F3[TL,&PHDF)400DA$B;>+Z@B5V^[(,E!K/%UICB1$-+E8]&6XRX0Q-,^]% M_4V&$$%(1HBTB6M519.;K\!`!QGW"L0W%R.RK>IA`^%$DQ(B",D(D39Q?=V5 M?X);\H\1#2Y6A'!"4D($(1DATB:NK[ORC_H&_?K2)/G'#(.F#'%PCC9:WHN& MI8D+":+)")$V<:W^5/X)+N2?&-_]C2IQV.-&DA`A",D*D35Q_*-UY)4$V#""4D)$81DA$B;N+XNA)CKWP$%%T),A#[\)49DSQN.-9QH4D-T M`(CIMUN"#,D(D39Q[:JL/OEC$&^KJCV_4`?H'T4__0<``/__`P!02P,$%``&``@````A M`(L'3'M^!P``OB(``!D```!X;"]W;W)K&ULG)I= MCZ)(%(;O-]G_8+P?!10!T_9D^"BH9#?9;/;CFE9LR:@8H*=G_OV>H@JH.L>Q M=6_:]N&M`^?4H7@!GSY_/QTGWXJZ*:OS9FK/K.FD.&^K77E^W4S__HM]\J>3 MILW/N_Q8G8O-]$?13#\___K+TWM5?VT.1=%.(,*YV4P/;7M9S^?-]E"<\F96 M78HS;-E7]2EOX6O].F\N=9'OND&GX]RQK-7\E)?GJ8RPKN^)4>WWY;:(J^W; MJ3BW,DA='/,6CK\YE)>FCW;:WA/NE-=?WRZ?MM7I`B%>RF/9_NB"3B>G[9J_ MGJLZ?SE"WM_M9;[M8W=?2/A3N:VKIMJW,P@WEP=*&^W_27.HWM.ZW/U6G@NH-LR3F(&7JOHJI'PG M$`R>D]&LFX$_ZLFNV.=OQ_;/ZCTKRM=#"]/M0D8BL?7N1UPT6Z@HA)DYKHBT MK8YP`/!WE? M*;)5*!G$44&6?Q0`A4$/OL@,)5WUG8N9[MKGCAO\^>GNGJ? MP!D)\]E<-G..ACW[61M`_(L@7$64SA?2@0QKH_6_/ONL_S;]! MOVZ5)J0:VU1$O4(TIP@;8Y!(`'^'_7C6RHS"^D&ZQC,U::_I]Y1AP"7HNGL. MI1KJ!1VNU^OZV=6718A%6?K=A!)`[.'X'?/(HBL*=/`QE:R69I3D8PFC$M\- MS##I%+O*8M!F"OL8BNJO M4%E#J5D.,Q%)L.H.:.$&@;]`!QWC(0D&#(,4@PP#K@$C<5@P];:Z+W$QR$S< M\U"SA%*C)2Z!UR5N![X7X+P-`:RZ%CJ1$QR289!BD&'`-6#4`99\O0ZW)UZ( MS?S]U<)LSU!J9+K.PK)=4$PP8!BD&&09<`T8-X,*K MU^!V0P@QSAU->"@ULB%6L!"A"8\^V![+[5KV&#`,4@PR#+@&C.R%.=>NSK>S M%V(S>\]'*WHH->/11QC$&"08,`Q2##(,N`:,_,!QW)^?$)OY^2MT\0^E1LL/ M@[@'PJ2XLP6Z4"2W-[-^**5 M2*L$(3$AR4#&:ZFW0&<(&T1#$0C)".$Z,9,75NON)K>E,=.O]@%N`J71C M1A(334(((R0E)".$Z\1,5-@@+='[UG-;FB<]86IOE&C,+U)$KG/"X'C8W<5D M4$(((R0E)".$Z\0L@?`_CY=`NB:]!-3HV)JUZNX>(D5N6!U3<)F:AP M.?L+^BG2\ M9I]4QIC$-B8)(8R05!'IE!UWAFZ%,C*"Z\3,7WB@Q_.7SLG,'QU%:$N1[2X[ M1V_-+&3X(Z48VS@F)"&$$9(2DA'"=6)60#BAQRL@_9-9`>)VI$BM!,NEY2+; M']F&PK$M?"<7*\58HX001DA*2$8(UXE1$>I3=]'UT0ED@\VKMWPFH(K M:Z(AN+8F*L%8*$9(2DA&"->)61;D".];*ASJ#'W\8"Q4(ED>&RV=D=HZ9A83 MDA#""$D)R0CA.C&SAU9__#1QQ"C4'![*+U2B,;^(D)B0A!"FB%P6@QGRWRD9 MD!D#G!E^"L/U$68QKAC&)5SV;]LDAQI&WT//N4(ETHN!+61,-`DAC)"4D&P@ MXWV5[Z%;3SZ(X+[*+`+RB.)\"#Y\+.I0K^A[XPUH=Z$,E4@O`K:&,=$DA#!" MTH'H*:/K4C:(^EM)KA.S",@_BB*L/B["%1_IH6M#*%Y-P;FC%P&3F&@20A@A MJ2+RNN0O%JC\&1G!=6+FCXSBG?E3P^A[Z'P-'>P/(T)B0A)"&"'I0&XV`=X] M'X:1,T&X.,U"?+`,2,]G6`?R@-S!QC!21$[:PK7P(\*8#$D(882DA&2$<)V8 ML_^_W*-#W:,78.^D1'KWRV&J`*LE?I47DR$)(8R0E)",$*X3LP#(/'XP\]=, M(SGM=4MX[5$PO*X?[R^O"&)#$+CD87+RD8`IP5C\E)",$/$[@F'!DE62/PN0 M;W9/1?U:1,7QV$RVU9MXY2_>NPUT^#G"%T>\#D,\M-?PVI5R9J_A):DX'XS*FGFP=M;R]P?R2UM=NO?,+U4+OQOH_CW`[T0* M>,-KS4"\KZJV_R)V,/SRY/D_````__\#`%!+`P04``8`"````"$`+"0G@E0* M``!6-```&0```'AL+W=OJJE6_;7S_VZ_=V^1G?3ANF_W#-)HMII-ZOVF>MON7A^E__JV^%-/)\;3> M/ZW?FGW],/VS/DY_>_S[W^X_FL/WXVM=GR:VA_WQ8?IZ.KW?S>?'S6N]6Q]G MS7N]MT>>F\-N?;)_'E[FQ_=#O7YJ&^W>YO%BL9SOUMO]U/=P=QC31_/\O-W4 MHMG\V-7[D^_D4+^M3_;\CZ_;]V/7VVXSIKO=^O#]Q_N73;-[MUU\V[YM3W^V MG4XGN\W=[R_[YK#^]F;C_A6EZTW7=_L'ZWZWW1R:8_-\FMGNYOY$>WJ\?]K:"%S:)X?Z^6'Z-;HSV6(Z?[QO$_3?;?UQ!/^?'%^;#WW8/OVQW=:J?US_>3O]J/DR]?7D]V>'.;$0N ML+NG/T5]W-B,VFYF<>9ZVC1O]@3LOY/=UDT-FY'UK_;WQ_;I]/HP39:S+%\D MD95/OM7'D]JZ+J>3S8_CJ=G]SXNBT)7O)`Z=I/;LP_%X%A=9E"UOZ,5^7GLJ M]G?72S9+XRPO;CF79>C%_NYZ6=[>2QYZL;^[7CYQ+G:1M1'9WUTO=AA&YF7N M1ZH=>+$^K1_O#\W'Q*XF.Q;'][5;F]&=[;D;<3\^_1SXJRE@Q]YU\M7U\C"U M[>WH'NV\_?E8)-G]_*>=:YN@*;DFPHJJ4[B)Y;H5%$@/[+_]Y^2+`O>BN(9\ MCN:*?+'$O9A.XY:+356?+SL[8;[.KXPN+4[LTM(%5'H`SS_&GUN=4>18(KAD MF6*)#)(L:<D5XTU]`/,NR#LE7_02AOR2UY!6S:)+;>7IX-K]#"U*>MG;Y&0P2V] M)F_';1DG25HD?4+;15$AQ:K(%CD96P$5R7(1I3D96>D50_(4!9H"`P#*A"VP M,!.7,^#$-`-D_99>XS-09"F-KH+'LX7]P?D1\'B21LM50J/W"A`]!9H"`P"* MWFX,XZ-W8AK]L%S:T2V]QD?_)5G:'QQ>A01Y7*0%2:!`BLCV0.:8]`(0/P6: M`@,`BM]N:>/C=V(2?TI&K_2:$/^9DZ^0($\6*Y)!@02VAYR4?^D%('P*-`4& M`!2^W?%@^./*@&M$TT#.L?2:K@PLK?4AB:JPXDRA$$AQKE!(KP"9H$!?[<.` M)B@UJ\^DQC4BA3\E.V3I-<-)5Q0("B0%B@)-@0$`A179*D^'/+75X7+=:UO1 M,2>%O0RB55O[DUE!EFU%CJ](91#D>$3J@@S'A\PI1C0C!A*<"6>1@'6\D@%O MJ-#FEY+"7$9>U&4@(ZNB"L>7WF'BPBA0XW1&RZ(,QV'X_N,&HIG&0(+#=]9G M?/C>*.'PF4/V(A\>F1U5Y`_ZW*0S5O;"\;.-93@X1*H8T8P82'#LSA:-C]V; M*!P[F;QEY$4^O&@Q(Y.W0L?3&4F="(?_(GK@XMI=5@7YD`_-B($$1^^L$(C> M5?T1)<`;*)P%LL3+R(NZ!5"0,"MZG+07Y#@M$3(<'^)6C.@K?1C8`N?%F220 MERL%P5LJ.S2#&T[)J)?NYH/=$(;SK1@1C$A&%".:$0,)CLN9'Q#7N%T^\I8) MCG>>D_$J@PC&YYOYB1RMBGQ%BJ`(;8+"WM*@5\"2]:H8T8P82'#\SOW<'K_W M3##^@GB8,O(:;W,B&XJ]FL%5O4*2+]&B2"-ZG2JP9IG'BV)!5HX,FB'3BA'- MB($$Y\39'I"3*W/=FR28BYQNSV4$G)2_TF-$,"(948QH1@PD."[G>\;'Y5W2 ME34,K%2(BQ(142(948QH1@PD**Z8V+;+X]6JL5W+5]2L!-$PHRI&!",RD&[* M1ZF]A,537K%&FA$#"0Z4N+)QQ2KF[LQ>6N+S*H,(!DP-E&`:R8AB1#-B>N+N M)6:S9+@(P-':)35^NL9.388U)I>/91#!*'VS@0BFD3T9=C-[;8H3J'I1=S]0 M,V(@P:$Z$S-Z9<;>\J"*PVZA!=$06,6(8$0RHAC1C!A(<%S$35U9F=X@P8J3 MQ&QE>A&,BQ(14R(948QH1@PD."[BAD8N1&]XX+@5*9NBG2L:)AO?.-VSDM8Z M71"),2+9B[IIJWIRH6_=B[IF!A*TZLF%$]"]J&MF(,&Y^I0;B\^X,;YNO`BN&TI$Z&C02$84(YH1`PF. M[R9G%7O3!.N!O2-*YP!S5J'9$(5@1#*B&-&,&$AP7,[B@/H]LAYX8P3KP9F- MF;JG*J9$,")[PK98?XW<'^_FI&;$0(*B=0]#8+27JWJK)ALS>S(21,.858P( M1B0CBA'-B($$QT7LU96XO#^"LY/O5@DU414C@A')B&)$,V(@P7$YCW/S[$Q< M*SQN?+<*(ER!!S_G+PG.B)A_$F=$14;ND\E>U$U;U1-0@1=D3]6]J&MF(,&Y MOUE8",TUBFQ M6R,3X!T5-,U%1FX(EVW7Z-$"(Z(GKNA0H]$?[(J.8D3WY+S'-OUQ-O+$CUV> MY.D9'Y;1)VQ!!$?<-QN(8!K)B&)$,V(@P0/JK`/P`U?B\D;C\GZ9>M$01<6( M8$0RHAC1C!A(<%R?\CGI&9^3DLJIZX142N[45_L)-+1A0CFA$#"0Z5.*$K,_:< M`Z+;34K]3M43L$VDI."(7C2$2CM23*,9,9#@4(D3&CFJ9QP1>]"9,D<4R(4' MG:R-9$0QHADQD.!X;W)(J7=(QU;!A%6.J4CH;=4@@G'Z9EV2!7NJK?WHZ33?/#O:(1V^G6T_[UD:^Q^\(TX65T)]IW,.;]`?M6Q_OZ MI?['^O"RW1\G;_6S[7(QRVUQ/OCW0OP?I^:]?8?@6W.R[W.T_WVU[^_4]MO[ MBYD5/S?-J?O#?O"\?R/H\?\```#__P,`4$L#!!0`!@`(````(0`*$G]!J`,` M`-,+```9````>&PO=V]R:W-H965TKN2#O2:C4?SPXXB57`"#M-^^_W7IP0F\RTZ4L;+L>'<\\Q MYB[O7YO:>6&]Y*+-73+S78>UI:AXN\O=[]^>[N:N(Q5M*UJ+EN7N&Y/N_>K/ M/Y9'T3_+/6/*`896YNY>J6[A>;+A8"W>VHF^H@LM^Y\FN9[0:%C6U M%_A^XC64MZYF6/2W<(CMEI>L$.6A8:W2)#VKJ0+]69KREOH&MH_'[J[ M4C0=4&QXS=7;0.HZ3;GXLFM%3SN8>+*_J&E[V08JMF0.=IH=<] M9U[F`=-J67'H`&UW>K;-W0>R*$CH>JOE8-`/SH[2^.W(O3C^U?/J']XR;S&$!NQ/B/0 M0*0MC(('>D?18(4I^M+8%M]2"Y[1K\O&F,8.BT4 M1L&2DGU&"H(_RE9C#"G30F$4+"D$#F73EMO"'5;9_ER_O">0CC<.8I(DOAW> MVH(D01A&\TMZI[,:!>:N9DFR>>RG%Q:[%3S6;TZ8Z(^`>?YD%V*=\`EC^'I5 M*/\MOEZ(/__1.::)"I9UHI3(RM!T]O0\^-2>LS'Q[SSC$-,Y*1$4X? MTYP_`."4=6'(LMC8!KH)/4/I$:-A_8ZM65U+IQ0'G(\"^$*,U7%V>PCP6S:I M/^),AW5OO`$C54=W["OM=[R53LVV0.G/4CB:>SV4Z0LENF&PV0@%P]3P"N$.E_@`\9Q?/4_````__\#`%!+`P04``8`"````"$`R#%9'$%'XN= M49X*$6_J0=G!L$S3,[(X/>HJPK#X2HQ\NTT3$>;)2R:.E0I2B$-P.7FS8#7'L2916E,J2N)2]EE6?_*:A>41/$.@>Q8?;GOUL#RW>9ZWTC MBG..`J]-E"]/`29;KP->F\'?7H=W#L+;0;Z]#FBM>BKPVDSER^L(SH,9>-J, M_NI"#)79)1' M&6:DP[I@>`FU_OK`7?/>>(7Z3,[,N(5%N$Z?X8FM+L1E8NN68("7C:'@(3*TO]TNODE:^G8).U8"!&^,M/!,)EV" MFP%FPB[C8&+:)3@C"8NZC,5QF%D7X8Q8-^]CR*(6?8R-OVO994B450]!)KSN M(M[5&I1(V+*^D4A)0^>T\L9=8L18,4Z3[`D50BI,J1!184:%.1465%A2846% M=4M`GL`&_`U/)#W2P?&FEIE%/5&,5V\9=X[G!Z9)RG""$-?VX1Q!D!`AS.3= M*%.$V"SP.U$BA##3[B(SA#B.R3M1Y@AQK9ZY+!#"&.M&66+$L1W?"4B7KS## M?)@.]W'3K`GCF8YE7G.`D@L/2)38::_]`ASJ_3@6/4-,R5-]UKR ML!@KIF4F%4(J3*D046%&A3D5%E184F%%A75+0`4F?X?UG_5!38^0^=I!B:<8&E6)YB!XNCI",P$EFUQC]38%#.]<:(.T],4 MF.GO"LSTMP5E^OH",[W^K##3WQF8N=D:<"^"TWU[TZMQG&:+DTUB?(8"]?27 MEQ[XJ#3I`/+\U_I'`H:49V3/F7X&1!0PR91F%*!SGE/`)L6]P``?M-8CW_+I M'>G))1YA#GQRI%Q1@"Q;7FK)+:HQVK^>6U5/JRLK=0V1B6(G)N)P*+4D?Y'7 M438DJ%&;J[)'2_YL(OJ8#>&W?%=?RJLUJ1O-`+C9.L4[\4=<[-)CJ1W$%K[* M''`XWA7J;DQ]J/)3?2GRE%=PIU6_W<,=IH"["',`\#;/J\L'^07-K>C#3P`` M`/__`P!02P,$%``&``@````A`#]W2E#$`P``LPP``!D```!X;"]W;W)K&ULG)?;CILP$(;O*_4=$/?E&"`;):DV6-M6:J6JZN&: M@).@!8RPL]E]^\Y@2&S3;M+>A##Y_?-Y[!F:,=+UJQLW_%LBS8Y M*\IFO[)_?']X-[RY:-;G=]B5V?=X[%]E[.Z!8MM697BI3>UK3I??-HW MK,NV%C=WTSLZS+O&&<[X8"=*T&G<[YS[UQP6B^+$F:`:;2K2TK?S(!:M_29$_6$F38#"!ZV#B M1\XLB)+YO[B$@PM<1Y?XWUUF@PM<1Y?`">:1'\779^3*[/3))IG(ULN.G2S8 MP3!_WF98#_X"G/^<74@K:N]1O+*APB!Q'+;$TSJ)HJ7[!,N8#YJ-U,#G1>/- M=4TZU?BZ@HP*W"%`>L:%A;@=%\6(BYL#^3`)(^A_2:@$A!/TD-.?D?9!RD(R>Q0;21 MFIE$-FC'W\8:(TI`H\/WLM)H<,VO)Q0'F71&J]A(C;+F9H",`6Q8E[EI='O+C&*#*C3*IVE5U^KU$&DT$PB1(WH/-B+C96[ M7JV^[.!JN29QH&^>S2!2N>2P2X0,&EDP80(5K%2,#HI]60&]DCC9Q77`T`24 MH@M.ZIL1HD9T'NS$M_/(OOUZR_6E2.4Q(T35Z#S8CA6>V]HNG/',W3[MNX/H M[WTV'107E M+1-P6.R_'N#/`85CA>>`>,>8&&_P`>>_&^O?````__\#`%!+`P04``8`"``` M`"$`(,E$-@($``"S#0``&0```'AL+W=OF-MYHQRO6;DVRLDV#M@4KJ_:X-7_\\_(4F0;O\[;, M:];2K?E!N?EM]^LOFROK7OF)TMX`AI9OS5/?G]>6Q8L3;7*^8F?:PC<'UC5Y M#X_=T>+GCN;EL*BI+<>V`ZO)J]84#.MN"0<['*J"9JRX-+3M!4E'Z[P'_?Q4 MG?F-K2F6T#5Y]WHY/Q6L.0/%OJJK_F,@-8VF6'\_MJS+]S7D_4Z\O+AQ#P\S M^J8J.L;9H5\!G26$SG..K=@"IMVFK"`#++O1TL@O=?\WN_Y. MJ^.I![M]R`@36Y4%5!1H5HZ/3`6K00#\-9H*MP94)'\?_E^KLC]M33=8 M^:'M$H`;>\K[EPHI3:.X\)XU_PH0&:D$B3.2>*!^_-Y9.9%/_.!K%DLH&A+, M\C[?;3IV-6#7P#OY.<<]2-;`?,M,Z)AR_;]4(44:6K0G;';+@X,_;+@R\ MC?4&-2U&3#+'$!61WA!80*3-I(`%>B?14`I9].+B`9(90!Q;=^Q589,!G@D\NZ6*,KAN"Q7CF!5 M>1CH1128<%!.W-!S?,WI5$'8<4P"#9$)Q&"$(C90Q2YS'A?IH@.U6(G`"-%/ MONM&H5;.5$&`(8%]+Z@X6P(Q%QVJHA]O4P2K8EW-^41`A-;(LT&KFDPJ`T+? M]G6+,@&8*\7;56I=CY4B6%4:ZCXF`B,=*#V020'%Z5B5LLQI7/35&1<829(> MR*2`(HE`CUE>G@&MUT<_*R-(>.D&?NQKB%1!.&X0>!HB&Q%S-PDV^\5V#FA= M;Z3NK&0$2=6;13(YHM8/.[RD9YFG1-P+CQOW"))UB67W2"9C5%W8U"5=C[<] M$5>`W+WG/7`$C;[&GCV[F`7+S7@WU`#9R/")J]C7EZL5MX"J-M9=%:![K5*B M1S(YHE8/>[6D9Z&KHL-_X:IT#0PM-L41$4[X76DF1U1=V(XE75^X*IJW6B?M MI"4P$./;Q:4/I[@QQ&%D=%>`?C`6'][P!=,/[=V_P$``/__`P!02P,$%``&``@` M```A`+7NKP[((```3M0``!D```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`Q@__2>YRY<2SI1LY9G MRB9J].?-AYK@][[=A,]5C#7C3UPJ5!<\4SU5(\_43-5(A]NI&EE/-];T!S_; M3HX;BVW+P<8R?:`;MXF^NM\FQM][-\!LM3AL(,O9[4J>>.\JO.CF83.CB0KY M#6.6W"W#M23G2U)72YJ^U^4/-\KC/[P>X.Z0Q7ZPV*]E;(UTB5D@4 M4H5,(5:KQ^*T0*\0#K M(9'Y8B.GO4072!4RA5RA4"@5*H5:H5%H%3H/@G;;9Z7"MN]7LO!>C?4 M>.T>8&CFW?S.KI;E+!&%%8O%*TP^6*>0*A4*I M4"G4"HU"J]`-,#1H<7<[6WJ'C""T]56A]4MI:').VPTUI][L%:(!W`^YVFXW M"]DI8ETD44@5,H5'Q<((-G*PW[D:+P,G;E.W+=F.[^$E M:!24_#"[W2QGWM6R&W+[G_GCS;":'^[6\]O-K9R<$CQY"LD@.:2`E)`*4D,: M2`OI?`E#ZF=0__#T^N[1WZZ1_6.]ENERYXK\=(;%3A*Y&I?79C/?WBWEHBL. M:U8+NZY=RG,E>*X4DD%R2`$I(16DAC20%M+Y$H;1#W1O"&.8_X(Q;2VS\:Z_ M,6:)G5J_=^*.5S:WR8D\"@K6\\UR(UV/@XI^])-34X)G32$9)(<4D!)206I( M`VDAG2]A+/U\Y\=RX8%L&`O]>&8SN2C=S;S9\7`(VD,B2.QDB'!C)YSP4)=@ MB12207)(`2DA%:2&-)`68B\AG#;4L/W]N'=%^X08@49)(<4D!)206I(`VDAG2]A[_MYS^_]F1U@&`_#GF,'\&9(=S0:9+Q, MVLY6ZRT.2E)S.U]O9,WQ3-><0%)(!LDA!:2$5)`:TD!:2.=+&$8__/EA7+@C M##-C&(JT=S?S!DL7BDKD:L:8IJ]F=:D$:TXA&22'%)`24D%J2`-I(9TO803] M&.A'<&9_&*;&L/4R`.QFWFCI6J\2H2:&))`4DD%R2`$I(16DAC20%M+Y$C1Z M/C56+^VL]WK##XN%8_5Z+H>)G2LZ7:+L(9$3MZW/UTN9CV,LDD!22`;)(06D MA%20&M)`6DCG2]A_G9@O.];,)R;GNP]W:\>,-!9MZ7A]O\%BT?:OR6JT1N/:>:&))` M4D@&R2$%I(14D!K20%I(YTO8Y^LFWCDGWO5&#@\[5W1JYAX206(G[JBSMCSH=_G"\^JPTCI]YLO MWL]U[MQ#(DCL9-C0YQ,OX&.1%))!& M_<<17X?/_5PE@L1.AOYOMS.Y2YU@B12207)(`2DA%:2&-)`6TOD2MK\?#OWV MG[F8'V9)O^WKC31H-]>!C8]'8Z12207)( M`2DA%:2&-)`6TOD2]OZZ27G*B^`[5^1G,"QVD@@UL9/A0#1;+'A"P#(I M)(/DD`)20BI(#6D@+:3S)0Q`)]O+3LB+B0E7WZ:P!KG[?D24#O;;HB?_O743A"37R4_DR\?#];^!_K MV,I!+GE3=7JL'L\=&22'%)`24D%J2`-I(9TO85`Z(;\^HBTX&:\W.$OK'+QW MBYTBBR`Q)(&DD`R20PI(":D@-:2!M)#.E[#1.@M?>(":FHEU1%M@)H9$D-B) M.R4O%W?ZWM+D;$4:5"QNE[J*#$^;0XIS*RFQ2`6I(0VDA72^A'%=-U$O)B9J MO![FBDY[PQX20>*C_-TH,4[ETX^GP?+R"EMV?'`\@N60XBC]$\@*RN.#XPHJ M2`UI("VD\R6(:/FV*?M0?F[`<$5>-)`($D.2H[PR]UTG[]M+&TS8J(DA"22%9)`<4D!*2`6I(0VD MA72^A(W6*?JRT\9R8IK6C\GL7)'?<$S3J(F=#*>-]6RQWL@;7)*@8C;?;'!F M2;':#))#"D@)J2`UI(&TD,Z7,!&=K<]L^A,S->YK+'6"WD,B2`Q)CO+J84>? M+#LN-AZ(CDQ5F_U74*NR-\;AL5.$J$FAB20 M%))!CDQ1^L[;'>NR.\_YFC4Q)`$ MDD(R2`XI("6D@M20!M)".E_"ANL\?.'YEG/QQ`:/N7BI$D%B)VY,FWJ/$)9) M(1DDAQ20$E)!:D@#:2&=+V$`.B>?.;UR/N:1'>/Q4B6"Q)`$DD(R2`XI("6D M@M20!M)".E_"/E\WX"XYX/*M*:[(/[*,P^EXA1&A)CY*/U_*!S>2XX/C"E)( M!LDA!:2$5)`:TD!:2.=+T/N53JZ7'60.BX43+`\RKLCK/22"Q$Z&@\S$VU*P M1`K)(#FD@)20"E)#&D@+Z7P)VZ_#ZX7MGQAB<6]GI2/K_B@3MTVBXX/C9AU# M$D@*R2`YI("4D`I20QI("^E\"7M_W3R[FIAGU_K6(%?D;_J89X\U?1KZ15CQ M\=$QC@220C)(#BD@):2"U)`&TD(Z7\+FOVUTM6\OTZOX]5:&_9TK\INN\V7D M:L9;!JOU4FX?QEA+`DDA&22'%)`24D%J2`-I(9TO8>.OFUM7G%OY66M7Y`

W,SF91FX1EX=]%#Z_7-%I^]Y#(B=NB[]; MV'NRY(YHC(422`K)(#FD@)20"E)#&D@+Z7P).W_=!+SB!+S6;^7;N2(_`4S` MQYK#\?T.AW]=(#DN,%Z=II`,DD,*2`FI(#6D@;20SI>@^W?7S<"'Q<(9>(W/ M(KDBK_N0R(D[\MPM]=N$8RR20%)(!LDA!:2$5)`:TD!:2.=+V/_KAN`[#L$; MO339N2*__SH61Z[&]=]>192W><5820))(1DDAQ20$E)!:D@#:2&=+V'_KQN$ M[S@(;V[E^G[GBOS^8Q!&30Q)("DD@^20`E)"*D@-:2`MI/,E;/C;AM^[J>%7 MK@IWKLAO-(9?5S-LZ$O[6C%YKV&,E220%))!V'[./HFD!22`;)(06D MA%20&M)`6DCG2Q#&^KIA]K!8.,QN\$<:7)$7!B2"Q)`$DD(R2`XI("6D@M20 M!M)".E_"AE\WO:XYO:[G>K9U17[#,;VB)C[*X6Z.3&3)\=%Q^T\A&22'%)`2 M4D%J2`-I(9TO8?-U='W]$F?-D94?;W=%?M,QLJ(F=C)<],QG$]^?A&522`;) M(06DA%20&M)`6DCG2]AX'6'[DVS_WL$S`7"4Q?>_[]8ZN.XA$22&))`4DD%R M2`$I(16DAC20%M+Y$C;\NMEU/36[XC"CD^K>+7;:!R)([,1=YJ\7=ITOETO) M^9(4Z\T@.:2`E)`*4D,:2`OI?`DCN6Z@77.@G3CR#T6G`/9NL9-$D-C)$,G= MPEZIU1NB"19*(1DDAQ20$E)!:D@#:2&=+V$";YMPUYQP-[=R?;AS1:<^[R$1 M)(8D3H9O:I:W-:0HSR`YI("4D`I20QI("^E\"7NNT^V9(SZGVHW^]ZXC[9F>7NN*_#@P%Z,FAB1.W+&K_WOE M>L,UQ4(9)(<4D!)206I(`VDAG2]A`F\;CC<3PS$^'NJ*_,YC.$9-#$F.\MK' M0R>*-K?R%1_9L6@\PN20`E)"*D@-:2`MI/,EC&-J9.Z_0.[,\6EB9)[)46&W MP<@,B2#Q40ZG#GE3Y_'!L:\I)(/DD`)20BI(#6D@+:3S)>S]U/3L_I M>:-O8=YM,#U#(D@,22`I)(/DD`)20BI(#6D@+:3S)6RXSL9G&LV9>#.3-P'N M-IB)(1$D=N*.\9.W*;!0"LD@.:2`E)`*4D,:2`OI?`D[_[:9>,.9>#W#Y<]0 MY!_U52*WHE--#$D@*22#Y)`"4D(J2`UI("VD\R5LM`["E[W.N.%`S-L_KNC4 MS#TD@L20!))",B?##K*U[_W'`)=CH0)20BI(#6D@+:3S)4Q`Q^(+$Y@8C^=R MAV:WT6%X#XD@,22!I)`,DCL9#UKV=X/EC%]@F1)206I(`VDAG2]A`#H-GSG* MS\U$1[ M_C6O[<1$BS\,Y8K\!##1HB:&))`4DAVEO^R7EX?SXX/C97\!*2$5I(8TD!;2 M^1+V7F?9RP[UVZF95G;TG2OR>X^9%C4Q)(&DD.PHTW?K\N/CI_;KSU*BIH+4 MD`;20CI?PO;K[/KZ@7[+F94?UW5%?MMUBHU0$T,22`K)(#FD<.(.3,N9?8.D MG'1++%1!:D@#:2&=+V'GIR;7\W<-ME.3J]R>7F9WDL&M.H(#6D@;20SI>P]]=-M-NIB59?5G=%?@;#8B>)4!-# M$D@*R9P,1_+UU$"+90I(":D@-:2!M)#.ES``'6C/G&:G!EGY3,]NBT$6$D%B M2`))(9F3UQJO/TV!M920"E)#&D@+Z7P)&Z^#[(67EQ,#[4S?7;7%0`N)(#$D M@:20#))#"D@)J2`UI(&TD,Z7H.%VF\F^T<7_@UR7=7Q83N99_`G,L>IT;-F3 M(E),2D@I*1MIV/2W_3NOPM=3\K'B]#,5I))4D6I20VI)74`2R-1T>_Y"WG'?O5O**Z6ZL"L+0*=/V#B4+0\G"4+(PE"P, M)4M`R1)0L@24+`$E2T#)$E"R!)0L`8\D@;=-O+-;CKP;_9.*UGF=<&TW4++. M*UGGE:SS2M9Y)>N\DG5>R3JO9)T?R(W#A]MT>DRS+'0YRT+)LE"R+)0L"X\D M"YV!7[\LLF^!Y+>%;63FM"QTQ+0LE"P+)>MJ=F8_D=+!*=22T2)8M$ MR2)1LDB4+!(EBT3)(E&R2)0L$B5+0,D24+($E"P!)4O`(TE`!^1+$^"DO,$+ MO;-;'8PM`25+0,D24+($E"P!)4M`R1)0L@24+`$E2V"@F7W#6G_6OWVO'^"T M1'0I2T3)$E&R1#R21'1L/G=XXKP\=:K0\=B24+(D!AJ.#,O#&_[EPM.BT<4L M&B6+1LFB4;)HE"P:)8M&R:)1LBB4+`HEBT+)HO!(HGC;`&T?3K_H3*%#JT6A M9%$,Y*+8;);ZMD5+0I>R))0L"25+0LF24+(DE"P))4M"R9)0LB24+`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`]\ MUR0P#(I^`FM\B\ILYHV38P)*EH"2):!D"2A9`B--W&NU,,9'QRW1PE"R,$:: M6(?E,CXZKL-R4;);&674]Y0.>:B M9+DH62Y*EHN2Y:)D82A9&$H6AI(EH&0)*%D"2I:`DB6@9`EX)`GTTYZ?P+F3 M\S`=AIW'W;^9-T..G5>RSBM9YY6L\TK6>27KO))U7LDZKV2=5[+.#^2NB=S- M6;F@MC!T00M#R<)0LC`\DC#Z@<\/X](3Q3`HAJ'H^Y%F,V^<'$-1LE"4+!0E M"T7)0E&R4)0L%"4+1>Y M.WCSY-AY)>N\DG5>R3JO9)U7LLXK6>>5K/-*UGDEZ_Q`P^ZP.+SA0\=+RT*7 MLRR4+`LER\*C,(NYSMIGLCC4AS/V>J'OE+&IVQ*V;].Y&<]U>U)$BDD)*25E MI)Q4D$I21:I)#:DE=0%)Y_M9[@U[P7R8_?R]8&)N<%5!Y[VA\;!C6.>5K/-* MUGDEZ[R2=5[).J]DG5>RSBM9YY6L\TK6^9&&N<&^!?@N^+Z\\&T+%LM8/VZ- M%HM'$HLU.(CEPM/#O%\NW#$V^$C.S%4%\0P+GLCB4;)XE"P>)8M'R>)1LGB4 M+!XEBT?)XE&R>)0L'B5+0,D2\$@2Z&<\?\>X-(%A-K3UG@9KSA%S;X)TIPF0 M):!5EH"2):!D"8S4;YNK]_I=%I;'6#!NC):'DN4QTO1J+)VQ8%R-I:-DZ2A9 M.DJ6CI*EXY&DT\]_UZ0SS(U^.AM\6^!L[DV78SI*EHZ2I:-DZ2A9.DJ6AY+E MH61Y*%D"2I:`DB6@9`DH60)*EH!'DD`_Z5V3P#`A^@FL^;ZSN3='C@DH60)* MEH"2):!D"2A9`DJ6@)(EH&0)*%D"2I:`DB6@9`D,-%Q_;5;+M8PB%HBWD`32 M#W[7!#(,C$$@:]P)G'MCY1B(D@6B9($H62!*%HB2!:)D@2A9($H6B)(%HF2! M*%D@2A;(0$,@\\4*[Q>Q1+RE))%^^KLFD6%J#!*9.(5XL^68B)(EHF2)*%DB M2I:(DB6B9(DH62)*EHB2):)DB2A9(DJ6R$C].8X&=DR2/?A;T M\S@W90RSHY_#9LXIPYLPQQP&&CX..WPR4\*5H[DV88Q9*UGDEZ[R2 M=5[).J]DG5>RSBM9YY6L\TK6>27KO))U7LDZ/]#X=IWU^]MP%-G&/\B-"HO& M6TT83?]>Y2":"Z]\#\OI[($W,+NJTZ"QGX$B4DQ*2"DI(^6D@E22*E)-:D@M MJ0M($NCG0G_GN#2!89[T=Y*):ZN%-W6ZG01D"6B5):!D"2A9`DJ6@)(EH&0) M*%D"2I:`DB6@9`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``_':J$DL#(I)][U]? MREUWW+C!:A%&?B``[CP5;?>Y1)>NDS^W75W]1R"A79$3J9W`JW8BPL52AE'\ M'B^!]@*O5R^K]WM9:B_P>O4B%S(.1;AZ>T<>1:0]Y!!L]DP2)8-?(D<81LXV*&8PJ`AHD/F!ZM$8*11HZ8N)0J.WC$H1OKYR"2=6)2V$+=EE/@K.=:!R0W%>CXW MDO:!F]5X6T'/.3?;HC2&N(5BZ8=B+`.3&VKU?&ZD[`.W<<,Z;O2<<[,M2I"% MN`4"CD+^6!HF-Q1OQFV>2`N2?(C)J-*Q;S6!!G&B;%+TFU$<8_)"P6:\7A\: M>%JTFG(ZR#2(\Z%EHT5QC,D'M9CQF1DG4G`C3I-I)@@TLDBUY79+ZL"Q1291 M5.#W$R7=-HE.NH*)>\\B%6311&\/,8WIMV479K[+&:QQ8S:M!2YHLYL-T>'@];BMN,2F^:V;(Z\P8=266=AEJD`B)7+3P M5XGQ\\N=%?=4+QE;3'&+21@RR+,^,Z:XRHQI%(^2V^=Q*PFD:S%<1E8IIAK` M:=*2:?-(5'A6G#-ITEP`IX-N1VRB:IK7<8*'BF`16DV6]A_-#Q6*6\Q@6M/E M]1:7MZ:*?235((`.6XCM[RSI`!H+E(T>DZ(U:&8&DB:'$`)9R/)Y/FA`21O#*!I7;)90JJDEVE5\GM9,C5`:#1UOT-[Y$K&*KY15?8P;2&CLS$WYK_$R4:3)^I&U1W&+R0I5G'?U& MW&@F0*L.;3`]\4@V.'1B;8OB&(,/?E6?SZ='FP*8Q/;158/&G M$XOB%I,/ROE\/B3^7-ANY)%`G`]96!ZM`P5>(`]?18D?W0?3%655-(#D,5B'>^C'_AK:LJ=R#?=C(/6674FXMT:[-SR`:^-+=BC^R)I# M>6Z=4[&'C_(7$:AN0Q?/]*:K+_V%Z5/=P85Q_^<1_D%0P-6BOP#POJZ[ZQO\ M@.%?#@__`P``__\#`%!+`P04``8`"````"$`8@+NMK\"```@"```&0```'AL M+W=O\JW4FGTWT\.\:`%8R1[33MO[^UG=(&*I6\A`"S,SN[RWIU^R1K],BU$:K) M,(DF&/&&J5PT98;__+Z_6F!D+&UR6JN&9_B9&WR[_OQI=51Z;RK.+0*&QF2X MLK9=QK%A%9?41*KE#;PIE);4PJTN8]-J3G,?).LXF4SFL:2BP8%AJ<=PJ*(0 MC&\5.TC>V$"B>4TMY&\JT9H7-LG&T$FJ]X?VBBG9`L5.U,(^>U*,)%L^E(W2 M=%>#[RR%V]\,Z*5@6AE5V`CHXI#HT',:IS$PK5>Y``>N[$CS(L-W9+DA M!,?KE2_07\&/YLU_9"IU_*I%_ETT'*H-?7(=V"FU=]"'W#V"X'@0?>\[\%.C MG!?T4-M?ZOB-B[*RT.X9.'+&EOGSEAL&%06:*)DY)J9J2`!^D11N-*`B],E? MCR*W58:OYQCMN+'WPE%AQ`[&*ODOO/1.NN#D%`S74S!)HF0Q([,YB'W`$H=, MO+$MM72]TNJ(8%I`T[34S1Y9`O/[3L""P]XYL`^!9`V4_W&=II-5_`@E8R?, M)F!@XCM,TB%B$.V406V\L@/WE4G'Z[/;!,S"=_"MT/4E0@Z<8:#JTD_35P-! M*&"F`Z'I)4(.#/T_$[KN.0J8H1"T>WSI'+CO:-H3"IC4MW2:1J]YG'4,9G6\ MK`/W96<]V8`9^KNY1,B!/RIDP`R%W&(>/?T.W'?4+V3`3'TADS1*.\-GA4PO MD77@ONR\XPT3&3!#?P16W'B#'OU1*4^@=[0N6R5A3YQ_:/UJPBYWWL-<$A*] MSD\H9UC489])KDO^A=>U04P=W!(FT(7N:3@@-G!`)/Z[[5[`?FYIR7]078K& MH)H7$#J);N"3T&'#AQNK6K^`=LK"AO9_*SB).>S%203@0BG[&PO=V]R:W-H M965T[OGG.,^N)2<5%$=G$\6R+%;%( M>+&+[-^_'B9+VU*:%@G-1,$B^X4I^V;S\49UR\5J6WE\>KKKA"2;C/( M^YG,:7SBKBX&]#F/I5`BU0[0N1CH,.?0#5U@VJP3#AF8LEN2I9%]2U9W9&&[ MFW55H#^<'57KMZ7VXOA9\N0;+QA4&_ID.K`5XM%`OR;F%AQV!ZZKI9BW%T8*I`4U54C.#9`7,ES."5`SVUH`C&Z8:@E70AJ=-&"[6 M[A.4+JXQ=XB!SP9#&H0+HHTRJ(U7-F"C;&IK0KG#&VV9Z66965?&M&X&`_!Z MHN80X%I)A.&RX<<($#.O!J>=U_P]@N909$-23=5\?]X31$Q0U7TR7RZ(YWD- MI%-:&*KQI37@OG2_J8A9H/0RO*XGW:BXQ2K4]V,.SEAL6L4\>?5K'G.[%R4SH@3XS.M:H\,`MVI_9Q! M$/V.5]Q@B$T07M!TIAN$<:%6$*^;"D'/ZHF?;:NN`*):XF=$5_Q=SD;0MMI! M^(.1KT&G&":>,Y]=J<"[W(X,[0[:<):H*X&H4Q17O,Z\A]_0@Z';@7+?:2O. MR+XP^F_R-X+FU7Z-@-AYH.LT$75!K&=I_YFNH9>!V'EP:S%$X4LD")=#.\4E M"'>$G,D=^\2R3%FQ.)@%A\!CV=QMEJ_;:?46;/Z`W:>D._:=RATOE)6Q%(YZ MS@**+W%[P@LMRFH#V0H-6T_U:9F66%.B0-)) M?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\ M_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ( M[]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\! MW8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6 M-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1 M+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P M]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS) MBZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F> M"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8 M>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20 M$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3 M>H<] M,9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_ MD%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G? MP9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW M"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8T MO;>$#6C\S210*:D M`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5- MX*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY M"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R M<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]3 M1>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_ M((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%B MC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL M,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q; MK:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$# M47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;, M9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TP MP:&POS!)],/+,]=#<>7H^'`=+?>SG*?5L,_/^H7U\-!$!KNSK`]UUP- M7\U@^/7=+W]Q&X2OMOG#LVF&`Q#A!JOA;C0MV#Z;CA%<>@?3A;_L/=\Q M0GCI/VG!P3>-7VII%E$MM MJ8&DNUOWZ.A.&`RVWM$-5\-)=FD0_^6;W6IX-1S$0UY[.P#QFW\=O?"K7\7_ M?/&[+[X8_>/+K_[VO;G[^X^_+?[MQR^'6JH&R00;5,N\'%6*A3_'DK5D!'>W M>\]%`UD`38RMFX^N]]G5V=_`&6!X[&UWM\%/@T^?&#-[6LSU_$(*587S1 M%==PS/@=:\.V-K[%WK8W',M^C2]/V(7(,9+W.1:8B5W48@WGU;-A:-(Q73,8 MW)BF[`H>DP-#,MC%ZC$9_RP9$Z=K+M?5AC].5S2*ZG$ITU7TBP*';71EMD)Z M_*?-:JCKD$/&HQ&C%1NL(V7+]0CTG4W9U?QL(YOJ4WVA=&2<+Q;MQA1.=954 M2A3J[Q;OST:G>F6BT25I^%P1P`).+8L6A&Y%?"]T]G,./SES0>O&8I%4+NE' MH9?GQD?+,8/!!_/SX'O/,5Q&+"YJT;NYFLPYGGKQG/G5BT\]:W%9++TGS"AJ M7=`8LA)5C)G:9A#QI%)'2M8X:M#%(?G]\/4!K[,*$B<67%K]/\NXGWW@=3R(OI=T0 M>+:U8RB>UE%#GG"YOGK0UP^17H2,BD(@5-?7BPZ$/MPOU^J1KI=+U4(G.OPH M%OINSGX4"]7A?VMEG":Q,U,%,I,W""TV@1Y=+I;+Y?7XZOKZ>CF;CF>SB.1- MXM&6NS-?3#:G5D93$<$<$"RGU\NK"0`9S:XC56=%,`4`B_G\>CY>3F;P_Z@N M=8]`-:?S8=]610AZLBI"T)-5HSFK+I0G(%A MO:]GJR($/5D5(>C)JE&7JC!689FX9ZLB!#U9%2'HR:K*FL\D`R][MRI"T)-5 M$8)S6S6=5JT?'O1H':K8F2GKCQ-=K(FOKRN:-<(\=>/Y.]C/2S>IQ@N8(\;7 M[FYM( M[J"-$=U`'".Z@SI&")VRX$J9W'E'V)H^-;"N7X]&\DR28Y">VNAWO"9'37?EPI>)+1BV]I]G0R2-& MD&!0+2OHB0G?`K\=0Y**1_RF-I'>T\[D4O$(DL#D2?<$S=C6M.T?6'OTUWW6 MD<$BY]WMRQZ=[X%#5^P`##L^Q'Z%G83DU[C[BE^`+M%-$^%-`^-PL%\_')V- MZ>O12:Q(1725[5CDK^ZCMC%__%$!H)5*48KM*\4@LT.DY13` MBPH*=*BZ:DK>6)3S>R,$)5W`D#,"::"*$75>B7(NZ,P!5#-RK[`/04[!4E'? M$`!.+Q"0(>!H3_\8>JK`V!MZ*L$8`E>#SQ@3V!NX"MD3!L#32U3D?<*8JQAG MI`%!Z"M#(F^8])4B,8:^LF0V!)]I4B,H:\*1!#ZRI#($M..4Z2&ETWC152T?CJ>L\/7HK5' ML%`Z_S\UULM>NI(Z%LV:0%9Z>SQ]BJ>.8(QH,H7FTNQCDT:Z>#IX]GSK)YAE MLH]/;F$UU?2'[..VH;7%5S[[QN'1?(&Y:+P-^+)O-4`)IEP_+&4/!W64*^>G M!1:"I25$2$<>S>JE*_,GGL&O;DL]1`J"N63?&-@*4]\8F+T3#,K=4%&80I5, M(9*]4[6[8)H8GF31&2YS342C;";U5:P` MV+D+OH@,V`NCMT1;6L/?*2UNTR2SJAJ MQ:\($-LBJK+/?;(S)>WH.Z,,OG_GC2!$Y6%ZNEA9Q:$>;2_68K"BOY!/EG$X M=`&TCN/ABL]C8;MR=-8:^6%TUC4Z)UO9CB&[0C2TGS#@4&AE2$R>[/)UT`A3@S(T16>260MCZL):&%&K M[(7;".5YE1IX:`VV!G'ERXLZ+*2RS89D+Z-^5U91,@4XJWFCP*R1QDH]CP*L MF/HIR,@1BSVR/H5\C!0#EP+U;+V(L+I*2A?)RHTF?L)B6F2R*CY:&%M1=2TZ M:4=X2\,([)=N62D>09:4T%4_]=0`7>J&`IP<;\5`H>!L$>"E2+&%11/L(E(^I%M@DD>( M@$K>Y,4D2>%269S+F&4DD[8ZA7ZGI)L&&(TBM9;R_]F=55QON$!O2CONQRIF M"(2-3%%@JT#6J-MA04T*"#[1*`D/Y7:J$QZ][BE/5!\@JS5RU#1R0A&@ M3LJ=6H1O9J]%U!06"S(?R8U:AB8YL=OA$OCDD MQBVCE@=.)KI.+&-P'96Z%BS2.L9"[>N_8Q0`YQ@N6I^"F^P%V)TKUH``TCX] M[MCQ.KL2OQQ#GJIJ?:+@E9*TU\YX)U[7*/MU MZW6(3&$NE'`IC%AIR<#*1?UT4^78<$W:9^5LM`6$6T_>KR04\0XDM!;&5Y%? MD\,(2*=9_X._*K#AQ@K@#P1NF2_=M%UL3/,56\6\E:1]ZO.L_O9P&' M/9`8!&@6P+E:L03RTVPR8>TPG=#6_9G&)DYXSAU`,CZ6W61]1B'U4N8SI!1, MAHD3,O)%WNX%G+PO\J'\L\`71Z]\EXU$7W'MH8J_%I'=&"\,0VV5H_(GF+;P M[L<^L5ZJ<#:PLM_%6*R2-^D93FTI$L*N= MGX):+4Y!Y7CC[))\X@R9\$R;"07O?M,IO9B*>+CDQ%3L)AO7G"G,V@T4QR]FS M^%'4-QNS/+/PBI\?\"%+9E8:%C]O&B6K.V0:%38)O)V[`UBK7O!!`]6CROD: MU@N%'/(3!UD-:8A7&CI@R;UL/:S8-#0,9(7L\1XH,7:+$)%YH+@IZ"(JFJP? MGK?RJ44(9QJK@KB%7>6U61`99PG;EH&"SP2?X)5X9<,T@_%6[*3)SPE6()?$ M>$/D=1*D\H_9*5$NJQSD(*F#1CS[**X*\\7B#'8Z.SCL_O'<1%8V,$2NE,&+ MJHQ78WK4&$*/7Q/1*2WTE:>I]-M;,%`^PTH,R+L_R9Q=X5;N=Q69/WXV;>7I M#G3NY#R,XGQ7YR@[`GI."N7%$SLEATS9&@>FK'E^D80(N6`5TZZJKNXM=DGX M"Y+I7\I+62HB9:&TL<\_R9!>D3H%ZU#222;[M>QL:<$GRH$+H9:!B+[;'+[- M'#T;DG\R9/;=YP/7<."QVI/1KP<7@W=;-K+L,TGL0-SF:-FAY;+/A[/OI=\> M`WC4]'U\,?DB\2I9F3M-V!H%D@4];5U9("%N$";L605(%AP3J2LK:ZFG,%HD M"QZ;65M6=AA@"K]A63"'JXLKF_9->>[G1.YG97:,GKF"^((A4W!A6;D=@3DT M1C;DNK)R.X+AL"P85V!"M@6>!N=65E=IR!X9"L.9'[ MJU([\K[*'I!`P85EY7;D?75*]%4L*[ MF!'S!!YC;D>>^SF1^].,RGO\A.CQL93<=O`;XHCUC!2.8BFYU7@OGQ*]/):2 MVXOW[QG1OV,IN:5`'AK1#/Y`'U%FHRG/[HS([KVQ2RL+[S"LSE!@K`U[>[0- M]LSB5!#;N4(#8HL[)$G/YO;C8`W/<\X$\?'`RBA%T,/+P39<(_3\UP%[YDDB',$L;:NCI@L%GAZQD2+I6C@ M[A@-[W]L.E$'#=P=B^&3*NN?*&*^<0_'S$)\+F6EFR+B6\O]:.YXS^&S!%L, MITCZ8!Y#W\C\CP^I"9&8#^PIX)D,/D5$#_4^[1D_P$._4Q)9NX]BA_70%.!_ M.H:(1G87$L*^KH$BY-$*[1P()X+!(HGPX#D\V5A.,@I1QE\,WV71PH7NB8\* M1I0_U@BZ_]U+_D3XB/?0V-AF]*SX;#X`1.W,O7&TP\?LCZMA_OL?S9UU=,"9 MDG=]9WWRPDC$:IC__JWU]!Q"%,/<&-+-MT$8_3LX^M9J^.^'^\7R_8,^N;@> MW5]?S*;F_&(YOW]_,9^M[]^_UY>CR6C]'Z#,L=W@YF4\6PV?P_!PHVG!]MET MC.#2L;:^%WC[\'+K.9JWWUM;4PL./B25X-DT0\?6)J/14EMJCF&Y[,%-X]E- M8,.[_&2P"?@?\FNK(7H1PX\6OP`^?/]G.@@M"%^!,:;D[K\```#__P,`4$L# M!!0`!@`(````(0#.U'V!MJ```'T^`@`4````>&PO#Z7`TN?SFWMNSDXV#>\5BV9\,^^/I MI/SFWDVYN/=O3__[?_MZL5@6C)TLOKEWM5S.?OO55XO!57G=7SR:SLH)3RZF M\^O^DC_GEU\M9O.R/UQ7R>OS5]N;FXZ^N^Z/)O6(P74V6W]S;?O)DZUZQ MFHS^NBJ/_*>MK3WP%`"\> MO#T]+NX__/JKY=.OO](0'[:U77P_G2RO%HP9EL/FX^-R\*C8V>H5VYM;N\V' M)^7YHV)[WQ[N-1_^835AY&;WR$\`VYPK;.=->3E:+.=]-OFR?UTVWSJ;3]_U M+\M)V6/C@T?-QV&2(W`T[X]Y95C^5/RQO&F^EV`[NYFUUMC:W/CCV@&OR_EH M*N0/B^/^LC7V$/(,C40GX_YE397]^P[IC6+SYVI_+UD]A M9(3W33F;SI?(0G&Z["]7ZUZWZ8LCT'(YG;=P?C@8E"S/TZ$#TH0C+/IZ=3X> M#8J3\;2_7//*T?3Z&G8_74X'/_:*TZO^O%P4KU9+DU#`;`Y+Y,X1?X(PM7;2 M?#.0N_/=DS\WUSEZ]?+TU8OGQX=GSXZ+;P]?'+X\>E:<_O[9L[/3=;*9"]]. M:[[`+_W%HEPN?MMZW%]C=_UQ.5FV=@7JI4T6Q;PN/AD7Y$VIK`3JE8J;+JW)>^.K-Q<^F2UAX4(.P^<[K.4IPCI+29()O M)M'H%9.R1=E7GURJ&XS(HN-1_WPT'BU'91M/:?NS_DW7WGD^7\&5<>_-;<0U M3`C@N^E%@16XW%B6\^MB6)ZW-E/'309:<^87M6EZQ;A<+!).PW+-,<=HH'?] MY>A=65R,)OW)8`0=1A.4IMF&%O$=F%N`D#2-EJ*,4WV`K4"(L'\@LWCP+S9>[RY&9],*[$O^LL">2JO MS^'::-",][!L.SU(M1A=3DP!]1>HT[GV=U@<32=8_N4(J2@JX&PKQ?O1\JH8 M8X]'0U`.[6<&/;@IQ0;W'V\^%JBWK]S$4E!?^?;K^]_:NQ4!6P>])UM[O?TG MN[8Y_;FYW=L_V"E&L@Q#E]V[XP7M.2L'RW?EN$6LP^$0F9I.8#&IAXW1I!CT M9R-$O[DIA&AUO1H;=H?EQ6@P6B,6MNU/\(CS[(M*IFU+1I(T\AE$:7/7K2KX M-88"/ZAIY%NF:&ZZ8I=`S,3$Q0-0-9R.Q_WYHD`).KNVA*@U08O? M/[ED&)')07/(73@=W=/-Y=D^6M#7&?ES]UX?_KMR`(#;"8 MCB7B"(]/>>%YJ`WTYO^&&,Z(C!I>\;?X]O!A!.L0MEVZ%Z, M!C+KG<]V'\(JTX0+OHV5^WI0+W-R!.RI#%AE/ MS0MH[NX41U<>IER%Z_[\1X2T[E\4W(_H![3 M1N";[QD)+^;3ZR*\"RLTWWD^P=*#W#683X_#&LWAWQ'B%0_&\,K#`@LR'"UF M4U`EC"6?Z+8Q!MW@JH])!H+BHC\*AE(S8&FC-Y#Y`!OO^W/%4*VMO"R7^"YP MK3`(&V7,K)^;8#34$["_&PV)<)KO5=,NE_/1^6HI-ZM83K6$//5(40-X?\4(XNKR3G8@`W M]7H'FXV;=CWK3UH>RO>K\7*$7BB.1_W+"9IH-%A8G"79,*O@V M;BL>28_IQG<-ZIT&W[70M(4R0K\TLA)2$ MG$L4^#O+>3>!.AS^9;4(.5TH@:J?DLY%W4@.+`#D5_W;7+>5C#\(JL+E:N96 MM/_@A46REXIJ&^'LQ>@G)NI.U!^7<#JY:G-J+'Z_5DWI;YW.QCJG)&K%UG:S MN22G1MF!,A>M-\GUDUH`<+U&'4Z%$=M'1Q[_:$W0?:>\N^]!.PT\&,6G@Q.A M3@P8UKEZ#@L15XU,5A@R-13-=56?-D/ZG*TD/8ISQ$#*$ MB`.@H7ZMP-0D3!Q5/(BC+#I)"X;:30^FKU=K;/>^E:HJDV&CN=#+NW!]<]!S ME-W"`[HD:"%N+&D%A?GQ1J03[J M@*JYX(G7B&K:H@5Y@DJZ_N=X)6D"VU:'#_`)1.0CUOCHWTYQ4M\34Z,8Q4LW MEJ-]Z(A,B31B4E*@PB:)B'8)(IO$DA2N*9*'V$1>PCA.M3)?P^+\)G/>*RW9 M.3!I#U.R%@O@WJZIT9K>USOVLO837MSXEL3*9*)D`MLB24;_07.Y]8.?,>/: M8:>KV6QLV0EU!T@;8AK@6N=&[-`%=BA:F9L6U]BJ)M2*_9?]G]KL7G\%K\`2 MJ4WP,SC`FT\F&823C=;94!5`5#5KP_1"C8[EH;N%0M+7`^L54\0(3GI:4 MLM5/<#-X"0)`NU.NW)YX7Q1TC'[?%< MYR)-0%\W'-R8\"64=;7;''!'3Z99>5N;M6O5F+Y=+9!H,M:O<#??C4KX$7*] ML&)51_UOZY'JTI\YJ.HJ^O@!.V13//CGW_]W^OV??_^/0BQ.&I*?B41G9"+Y M$1,%9HKKZ1CVH=0'\\8DI"53>(M!>)`7:C8A(8#?H4FR.HAM1P&QDB?]<7"( M)(%]A?*$V*7U[L"=DW(CY&G4%'1!8K%[Y64YN)I,Q]-+=!50L["%]J1F%`X/ M2YXG+XSL_&A)9=WLP]PJ`U3AM>B-8+A&B0[@:^F&T4RZ=6'8R3#SOZAOSD>4 M;%290KXE!K9=X08O#:GGO%^RMYNEG.^)]_!\CRISIPD\%X14<`?7[\ MKOV'F(62[?DTUOQ8/]"J-5^&94`A74T"+40YH3VGF=ZV!CN MIF$57.+,P,MX1C0E@#5RR2I-.X8_?CBKDMZV@U; M@>N.7QZ*HXR,K1Z\MWGR/S1SO;JX2AK9HC0.+ M>1]&!F9$4KPJ.)\\VBJN1Y1MP0@3P[SB+W=O^Q=(%;(S7*%K8+X$JOZ0-O&& M-*%0.,5"*R]KTVX^VD_3&HHC56-*K/E6!JVG/,^A-]IAWA\:(2>%1.GEX>GQ MX;_3GFCM*_"9:LQ2R#6.`YQ,T(4-$7LZV0,.WTF?HU< M1XY3I$SS57RT]VAG^^,'E56-$UW;@$0*[&*ZDCSTQS=(O]C+L($_R+M]_7UX>E0;".6 MU_(,8Z2Z47314KYGV"O8KE?4#71Y@<"COJZH?Q?GI?"(R<.BHR!P_,MWE`P, M>#BCLUNC!T?+049XA7'$W)P(_L3(F(W1S](1>B5$LD%%=:4L8)G^Z&[P&'-A3!TA9EF.-CJ[3S9HB?N20`@ MD8PCBL:F,'8_[%_3.9&$1O*7^$]B)';]5J8P!I?P.X$UDP7.=F*5"+1^@QTOL=KT7\7_#?B*_47)=0R&]@"SB"/F1^_)/[=$>-S^NZ/. MWOKO^B.<17Q-GJ`DCD/O:<7B+?E<&[?4C>U[K"J,[_!`)2B]LGX:L\*8\,D0 MKXZ?<0AI2T(R0K]-Q'[$=U#N&<(7JPLU9\(0VJMF,L=F?402L\+P2FL[%MX3 M7ZS-'F.E%L5]_)5]SI#L'*!`[_/?K?W>]NZ!T?[^;N_)SF[O\>,M\TG$36Z4 MD#^F;:/4_)\=MV7N"<$(XA]S5DWBCUU1W74N@Z-RJI)JCV(?%9"]A]*950V` MXLZDE2(-UNFEK=W>SNY!;_?)$["PM=4[V-WL[>\'-/#WX\W='F#TQ-G5ALQW MB3"=E]@$,I'8#)Q'^:O>?P\SFALPQ`[!QE$!B\*)>S(>D/'<0*$UJ:LV46T@PQ!U%SLVW`5TJ)>-&*O,OD$R6X7=>X`2"MUDQQAVTZT MVE*IGMY,_IHKU)?1-6#[O MWI_2(.^F8SP7&)5N2--,B"'MM$][5@046LL8GQ(*-6?HV:)FI9J%84% MB0^@U/R]FIO>3U>$[BRJTR0>U)E4(P9B9^=8A1UVEN>B_XYW8,D<;`3-T>&>(3/:2>2 M_DSD)[L%?'5XMF*5'&_>+$<]HH',!K% M"-<[:6;+!9-XY)&IG;?DEOCKC^QF2"52F*^$![_H6\NJ?1)5LU M@].?R="S54_RVWD`Y(O4D>"MU)R9*CM4K'=Y]@:;8H'*D8ZLR4;A[@'0<[+? MB3$DJH3\.,7,K\AKCGKP*'0Q(Y>N`8P7\PF25OEQN'7SR4 M6%6;(.`LW\G!H%9@5P0HBVI1J.0#=$R:W5?":DKFU8;)Q_>\B0LWU/ZT@E+` M8*D@D$OA)T4<>'+J'8+?`()R(*4M)T07(P&Z/#?!15E:]073YATB]=8MU+,% M1(\+8+B].&C2L$$`Z!'UEJL>;FFQHUEMB?XM! M"01CW3R>GF7*SNZ6^P M7/7'8$E9'R4SY,H,1\JO>V*&0[:0*6&JI1IS+Z/+Q0T+LH'&4'P#<9T`+E]3BO&I1X:LZ M\7Q+UNF(VB@^EA+'IA-UEB%$EY-(L2C]!;L(-,2O8E:=.*/- M2<5D_+Y0<4-9H-8E@HJI5`VRC;LL,5Z"DE!_4D()4$AWH)'TN1Z;QW"4F3/9 M^Y/CYT\\V,N*9H:19Q+P`*`8E\:;DJ0GJY`Y8\2W"L)I)Q=W?]M/6DLLU MC-?Z>:D6>1!I>W M:>Y[K,*'RC2,!WXUW?E(>?A8[$=W+DF^IE@)44Z=34Z/&)ER4'M).1]1]S)$ M5;F.T'D^>&Y'3N-JU/K`K,*U6-4P[@U;5_1)"\J4T)EC^A9A65TU+`%[$'9" M,;;&FV@EVJ;M%&UI9PH'%FFA-%5+AP6"]BY_0EG`7$2?(G)J<<`^6"CLF4)%?\H1HCT,3-VD0EB&SXD=8*86/3_^9U,P MWLYHN4"YX]E,,(OD."RNRQ&F8FYUEB$V$BDHA\N#?+Q'PZ@*,TFI.?.'/;EM MG#^%1:A72ZA,865(9>])\[,5\7_E;D35HE\3W8U-#/6?C8+O.5Y[O;HN,B:` M=G5H$#+B%\=Q]1Y*0I)/;A0AU2E=31.-J7@[FT054?U=CF9F%`)K.;O485Y' MJ^KH<^3+)MX,`>?$LX:RBH_A!4JI2JEB[).Y]4I`!,3X1=>F='#)(?7U]T8T M.4+'T]7YDO*Z#@Z:X]!DH;-,MT)'FID4>TO4C3MC]@>D)05OF+$;6U!B2K2# M+8F(ZF$+\V]X^PH902D,LAQ6+^5AU?JM>%*6EY*6ZVIMUL+[N+9)!L^))XAJ MW%M8JP]EB-O5.WG\(NQ\:-B47Y@A9QB1$[=F:_P@I1!_,:I%V64.M\4"F/-`Y`A9T?D97_SW(O_`'197=-"":K&,$ M%[;#?#!(H&H&`V$[,`^;VG.=])?X98KQ;;A12U M>I?$*;4N2>V-_H*!67KS'T+F5[X57GCP"&C--7R>J@LJS6>VK#J]LV[_$7 M[((PSB_/O[EWV?FH+RDE_#-E$A!3R_Z:(6;,(U^^,IF MY\ZU!*R;W-^70[R^2\M!A*X`N24MN+X@3-U$-C:+RM5ET`2"5B`[OA=<1Q!` M*5%&E#-FZB/IC!3J)!P2C2+/#+Y8.OAQP\ZOZLC)$B^/$[=>A8R#^BK!]N\D1US MA5'M84CB(W(A[V],F)V7J)]>7,-]-OD+!X!`N.?8/N6(_<_;IP. M0);"%`-T0YZ3>/EZBGL5N@1E9&-@K+ZYN95R*&C@D9`ZLJ[0E-@T-1?5B-W9 M8,Z8*DB*'30WB4M+4`F(`&5P%P@^O(DU^>SJ&T#*.$HLQO3`E?Y,U])G3)`B MM:N5NAIYV4#?,)K"-V+NX#EA\C$2H\F,9);9BRFUSKE;4L@2TJ,N%)8Q3V@S MTF?HE:V4*C=,H",2"P:ON<+]I'B!*T$:<,<2-:8>N,OJUU=:)[HCY$\FZ=_3 M?8J':Q%LXK&H/+^@DGIJ4GAX!Q\B0S62!9\0MR2<6O_`#G=L<<_6]I;I.%H& M=NDA.MAOE,J=K4*$9T%S2G9G,E^/7L.=:7!IO,80O"/(!!JN M:^6!2\FH/(%SZY?KH*\R/5NYT'J16-82@L2JM2MUJDG01/HC!E:7A*7>CWNF MX=Z5Y?%D"GO5=6N#@O8**;G4C9PV8VZHH<#,G;D\E(;2'M=NS>6JQE'42,U` M!TP(YO=D7Y*:3JZK1>4Z4I/`,`L:CQ5D7&RK5!/(P*L'R31E]&N%\87?SP>Z MH6.J%,2>MW"4R\0VB73P/J%V#DG6C"GXZR0Q*.N3DGZ+6L)J\.:)N',#:JV8 M3#8=L49C.U=9N&ZEB/8"^D767MZ*&1!-GVCA05B(%LYX5>*D%L\8$AA>#,1CPZV=FQV2(;%0DA+*E:J8F]S;V-O4]I">588>>/7UAK=?J9KO-=^ MT$DR^Q)^>A9DE);E_VB;NR^I2YK6691T-G!C$AQ(:9FHH05TG?7@&(^N+1NA M*8(BL@C;Y-_BEJ6EE5`\\E'(`2/K_8>5CN#7(.BR_ZI1&&$E&7[!9D@^<4,T M.1,X[/RA9M)ZOD8T@B*ZUE5$7FR).*N&,#H84F)DF.5,RJU>WF24W9 M=IIC9_1X@;5,:#EN.2Z@_L,X7`=$N/!6F4]B34#)YIH5ESN/J&$_>X3 M3RR/=8?)+1@CW4\%WV<=7Q@T+]->7R*(I8NZ4F MCJG3H%Q4OO[)7!=ILFJSU/^L21BQ9DY"\3FZ!8U5T.1`"*"@GT!DXQ?YH(_]]QATWY29%F: MMWVPO;FQ1?PES1=-=N`3]&3(8:WA,VB3P:JL:Y/2(6#6Y,LK:GX;5`!#KL4- M$(GEN;I(Z)1SRA$@M$;=!)?6PINN M7K>ZZEP^#0'I%DK]'\UG_[ZR8Q\6LGM+'.X/JET'/G..-3=%_=6!4]K=7&&5 M[;NMLJ#O1H=E;UWC=]B;]>#).^N>)47T44](G#W:MPZ[GYX!II6:J?[O9:A%9_3@C\39O6C-`.)%D="7RNP2- MK)AE0U'J:">KSK88\3E!TV@>BU;Z.`<6DBY$F]ZNPG^A*EMQ:(1ILO$9I(M* M/!;/9(MTZ8MS7C6AZ!T)+`"32VK=V@1NJM;[B9Y82X8^<*>:%E3%L;8ZS:X& MB,FEW0T?\&QAFA+5`7CG+6'("VIV"4T-`&%KABY#M5(38P'#0P@GGY,`3W4W M\88_-2Q9\;MNOD)<(9+D;^J0DC8J&"F[.INKYYSFXY2VU:_>YE0AAQ:8B!P9 M'K0/;SFS-MP/P1;.MYMCYKT=OA:EFW"DEYF5&+'[!R]6QF;F>^LF$6VM%BJ&*?*= M5>N8J)Y@2=3U:")71*)<\+$]IU^WD$/R@>FO+"L@B:PM673/8M@-CF( MG9U33EK4LQ/2B&#,I$]LJC-*Y]/ICVZ3R)1DG=.>%1(K.^(KAJ#Y5#9CP$E! M%+JD3CR4SI!92PZ2Y-&34=#]Z5MFKV]%"?U+TI[Q``,&\B]JPY`VEL104&S< M>-&`)^G'*/FP"+NF>2*@/18),ZF1=1)6/^\<65M;V37KQ5G7M3;/_9E=>9-U M%$=)`L*J\N)XS<,8\D9RX57C0*9"(&IN'Y##,-SCX+?IV.[?HFJT(2QB'*:P M]**T,ZD.`GH:'2Z5IHT'N>.1Y;1($^A4BVX("((IE:T6&HF[,X47`8$[AAH" MS-2PT2D/P"2H04AY'XAU`Y!!RKW)=:#49NB-A=YDZ&" M$ZH$NRRL&>V4AO2J^AJP&"704O>JV"!G?68,]:4P/XWLYFY1[[8,,OAE/!9. MRLLVI"C:Y2WU,OA+KF#8/IA$"E?T'^44B:@S]'IYTQ*2X]&/=B.`VJ&EZSR6 M]L%7)-.QTRYDR&= M_"&DRW3$7U;#2YF(7E=`^<+$^+T-<)N).E``CC*7336FFBZ0&LN/I M%ENN3"L(F::C/=D0L3%50C5N!'';FCV\ZL+5DNM))T8 ME8X,J#F>6$.P])X@!TY0>987Z=TD1,:)=47-M*@X\MA*Q,?EY-V(IC&-!A-1C`@((Y.']8W=0)N401[. MIE22EX]V:57\]3-*AYXJBQJJ@R54-/H5ZD8YWT0;;]S19AM7;2Y[$.0\)O\E M)XD,UDQH/?!0WWQ6IPN\ZWI0'.)S([$ND8O0.!C=$=<4246)D5I4-.5]J6\( MH8=1WE/TFD16>[!VR<)NTZSQ?4BR)AWPM7W4#RQG^0]]FT,@A@Y,?R6F39=/ MX^/0,LAR,[<2[D(I$@LB0(\+\1NL"\>K]T=":VV7]A^ILZD"112>>;\F@]S8 M@I0H;T4WC5J$+2FAW^AJ)7::8OCA>7?5>\H>6_N`-CGG6A6_;<-.S2(GJ;T3 M54Q4(8<&B[70I5*F8LT&RN7%T?0.*XLGS>UE3]B91WA1.JC?@M43\8)+;S?T MM^>@LB=A:RC=)C;?8ATR.5>?O^I#)>J58&Y^?C0RH]A218S%4%V.\#4N! MMEI+EN%B@VX;-*N(FB#+9T[]PCJKR8FHU#>,L:5K+BP<6]&5@Z(E!/5*!+%N M3D7[\68)$Y;L<@E@%"5,3_AU$M5Y:",[EK4^,1D@;_=&(8ID7-J6-^'5\Z,UO\;K68X`.?NUN%:K-V M>QT@NR_!]]!+4+%<`4\ MM-3:>G55$[5?7\2>KI.FEJQ_04GJEG/8Q8I#`<?1)I!A6.QB M"T]G57"&(W8:F]PA(CDY]U%+F'/\49=0\)+U=['*I]#.#(A(Z^3.KFDC-;!W MZAS=P_%"E[J\9@>G?F6XM_`)K<;(\!ENC<&!'JHH&!G)H)RM9-5 M?%"LL$=UDK$2NFV^-"!G:K%*70=QS.$ M[\,7QC;B%\;BN^(A6#$[4CU<6;58,5_JW$4+HO M0F8A+J)6Q`@0MEE3\XB:2>AE(O1N(0:7L:*U800Y,Y:WUEKGS_Y8R4%SZ3K9 M.@*@72*N?E31A'?)?09\BTWI0X%SP1D.N[T[(%\JE-PKDA"_UPN#9:%-37#K M,KBF&>25]32;M8P>K1*KHO>I7<#6F.4I-T]QC&5WGSL2VX^V#_9[>[N44IJ/ M=GK[W-6TL[G3>M1M+7Z(EQQ"KB9\`\D%[ M<1X]X7JMS?WVJ&ZX3I&PL]V7O<'H<=R-C)KQ*B9YW";RJL0_<9WI+E"SOY MUOB]53_G@R=J_YO.FT^Z42AC8=F!)I;N-W]X4-W]U7S4NO#Z074U6/-=/0JW MA#4?51_\L-AI\%GG#_C"4^S.;,[[8+NWRU51.SO[S2<==>R$$'-HI,LC\@U- MR0XVIWJP]9B;T#9[!SN/FX^.[3(4@HTV49ZN^S2CK>[:467CH/MN!Z'"GVF0 MV")#-@&>4$W++]>53[$.57<%)^(D&9FU>$GX3&]$A#;1]&#ST<%!QX_[FQT_ M'CQI_OB&;`NQ8);H>TW6DC.,_IG&UF4-&.(_]"B%D`F2+8\2*>UB[HC$X M4LG"<6/8O&^'-.PJ(",P-2'NG&ZP$9-T0O.L#:+7'%2-EL=++$UF.GX/CCG) M6\NR4EV5#=8E4#"CQ?)J\5I-5APWIEX0^KL8[\_8&M?#6]W'XD^`X_50Z@;& M1\6S54A&M]]GP1VE>J!?SN M3;*SWM/I97:"_!#PYZ:%#@!B/5*GE/?]JW5*CRD'9L%'UA8!9%D9O"E^B-/A MZG*U6)HT<7V-F,E2__^:B'#!3"Q@P9(*J&A!H)/<="/_U*6B-17@K`-1N4$>US*B"._,KWRHR))$V]O;[%@9UQ=*9B1L MUO$XXH0[MT]0!P<%T2$_DPY*2LGNF;NTJG7B0_::RKW59OG16VRE713:N7KR MG:+`_,H?0">I9*5K@6'-**$4*<'YQ=&54?2+B=+C_S*BY#?E8Y;6"%)5S1(_ MNFU:S:P!WQ2NJ:U@(BI6JGC$E3'9%S1"K&7G67=FI;9HHB9+(PI[9U`U17IH MMX-^Q]5%CPJ40.RI=H:3MUP^IT.ZU!TH M(6FB"G_9E*@BI&0^P]@Y2:)&YW,*/8`('Y/:HU51&ZL MS(?!\+,A9EG)%V!C[8P#!+";RXK5.' M=#JW;UV!^*$*?2OB(>>B0)+4T,;FDUX1:K3NZ!RI",JNG$#%$::?W`Y]96&\ MKHO3,,WC+)&P$_*H^;E))Q;]')-+VD'],+?40N9$Z\]8!HZM$J9[9&0S2/A* M48#$!'P%'Y&;1HM9>9P0(4X24\@`RQ5JT,-P7'*TMMVODWITXZ9@O:3/A+]HB:0V?./17#-Z8H[ MJG">4!;>T257U/<0-0X[#!,A$U:T9J[H\H:H(RJ/:A'Y\5(D\$]UMT.'@FAK MA4-KD'S-U>/-E`%A:>O)L5)>3Y?63SM7\?8-MZ* M6V7O5A="O>MV31A8O9HIG5C=]F2JH//C:LJ>#PPG^S^HWJAQ.]CA?M9IA6390\9"&SM>MKGGX4Y60UA7QF#M:RZN MV?H7KFOI%=_&"^Q!WCD!FL`,"8P,A*ZJX;^^?'>>T)PE51N"0@8YDO:5-;4( M1SNT=47FR6#\@FAZGMK:%QO%=U0G+>J5SG\%%N8MBGT9=/D=$5;701QKT5QB MPQA7ZXDJOM8MS(FWI,%JBPF+%NQGJQ;I8'&X;\PB:T8F M\TA_3@@6T(I>F.&[?V12O&O^K+;]K,P:/](DP<7'"SU.@*"+GO!5]<4Y,X'V M8OY679LF'TTANKX,9.H1W'FL!&[@*#/HF9= MN>$HX9WC:=A'0;/O<=H1::DD(;RM+E&&Z>H]]_HCQ1WM(]_]7Q`!@K*4<'?KJ.9*&E:Y1`83FBM#V'`C4%9&I#/.QO MZ"8!D.Y*E&&W0!W<9!7L*L,8G+!,.")SB-[Z7]M1!F#8XUH<0`#+V(6+!XQ` MNLH9ULD^;R\UEYI%5Y#",P\)<-,;X=-G]*3(KPDP'IHJJ9+"\<-DMA`1V$Y/ M"C1?"P(+*9^Q!Z.+A?P)2(^)F2=N5R6U*E9=Q+N&K3O-^?1DI-O;@GR;#)-,@F18KB_JP\VT6NJE+.B":Q>6GAY3AIQTL)Q9>&JJ"X4YSO$AG79_GG]>]V]AD$S]_U05WQ?P#C]@# M/6F5<*;5X@KAG!Y\LO)_\Q1Z`YZG#_;HA#CHJ&_J&UN/-[<;[W>S>S?M$'NB MJSM-X)J\0VJLY22TY/RFD!!2=WEPC+G6M]<&-ZVR_YYQ=SX,'^`N`P_QQ2P3 M:WQ*O!__"IUUE0:2=QR]@5C@EO+)O\R@!$CS:Q&>I!`GQ[P8^2STX[:<,4_* MJL48U^DEI_/(>;42:L=5RY,%_51[&5#C=YNP;L!UJSZOV9=*,;Y:NE'WPB$JA?<5Z%C]$B_3=?\RGK385*AB.GV/L]`W;^F(QINCM M[QS0[K"3116>+JA:OPS1L0M`1C^Y"%L=HVM>G/)[]IE2R^PU6.SI&<1(<[F[ M8;YA*NKJ)JGX^:+'\+_@#.K%/WY*2L,((;)Z\JA6J%=6P3,L_F$*T5"^!&X& M'JF,K8X6DFO@TF8P']:M0^*'H`0%!"M11T/6MS'29ARZ\L19!8@UZ1/ M(7F=UH2=/&#HLK!V.XR_0Y4XVH@G%$6_PG!S_\EC%2;SHN.[+KW)-N,>2<4Q?-6?R)=@-/MZ77;"6(2TYCFG? M@;4$83O*)69K8P_FBY^94OK3;W.5K'5>G!L<55V[+V[0$8^G9^BO_NI]Y-3"J+H[*JBN6H8CW+#>_O!N5`4;2E8'7S9(K[V%C ME$T9)664@(8=)]1X3&2?,>>AJ9.N+1H!Z56STW$X#V.J0V+QEB.6SVV=PG8= M",OJ(R!VD+HF``EV<2`3&D-79Q@L0YZ?%V.:6CSLZ8#09]W2>F>?(\Y\F9Q8 M2^F,M0)]P1D&KC"/[C#OF1(V`=Z]38##UEV.H9M_"CL@55`F>M1$-/M$]#H) MU2>FI6A<6ZZ14#[(\^3@B43H_Z&$*AWR_ZF49H1J,7Q%.N@JD8A!,8NII#KX_I:Y@Q;<=KHNRE$$B:]Y+_K=/4GF`?!T MG:">&8BE35&+/A`(5YF)7 MI>E>-:@I-4&.R[ZW$VO/X(5S4V,W[+44[=;^MIE^0TL0DN?5&W5"!"/\9-MT M;%)X:/3T96AEGL@ML$,=/0D-G]46]]EB)HII"K]QF%-=?,!OJ310S8W!L`2E MBH"ZU^7>\WZ8ZPOX)3B9Q\E58$?`\/MP;?T&WE.L^()9=OJ,E,G26Z5?<=^Z MARJXI[^(>Z,2;M71&`_O+-=X,AEVCT)B,3CU?7?9C=6>/-I26FHL1X4M*%9+ MWK[[E@07*_ISR'LE=M,?ZO7P#WH)(V)PF$+5(9MV,\OWZWE*K(><0NNMEKW_ M>5%.8$QVXLGDK7UZXA$FXVK))U?'Q&^7BT-UF1S7GT!6??V4ASI[$;IP)/\( M64`>'3LUU1!GKM1#3 ML.V(0D(`GJ5[;XW>#9HSP!3=+0)Q?L0I#]#A@V6^?I_TZF0#'IS9S;Q45F!8 M3QBNP7K[ET2-_-H@;+!U0?-<4F#/MI&/'=-^(X$/" MK`%)`CU;L\&J_)!X^Q8I^T)<*SYI\ZQ%[T,^_B)F2*=0T1AHLE9]>#W'!A73 M+:.9T/QRC.HX??X)[X,RC!\'J_E=_Y>],]MM(\WR_*OP0MEP`;)*E*BM$Q"@ M])*M'COMMNPL]-Q1$F43*9&"1-KI>HVYFHL!?#&/,5?N%YO?_YQOBR^"$N4M M75T)5'=:C(AO/?L:I+L%``8E7G"/BT65P5I_8`*3&$`HR1!/L]A^7(Q4A-L) M)PQP4MCL5%@5L2Z*,;K/A=I))/V:J%#"*@$?M,T*`Z(ENUMI>S(/.#I_/HK%[)%5N M%PK(;3LI`#1%,97&PS9(80&EWWR0FCX3H%8V2&W;[=\=@J(4\,4`",J1Y1*! M&+)`INV);,1HZZ"=+!+8MDD?W1&ZPF*!DB2+*`O8]0$9;@FN`T,R>IG?9,'= M&3(*Q]-823$2;TJ,1!=B=ML6BMRRPQ!IW-J@ZMZ%9T+H*)0V%KX!$>BFGKYL M2@\HTD-EO\8R`G>Y"!B"I:O(LPAFY+EAYKCI=`IQ&4$#+JWTS8TL/H]G90X= M419<.HJR#C,`%;+;N5W08_)(2,V^OTELS.M`S+C;HQGJIL41P2(\ND9:$J;5TXV1<=IHB:,F@1`U*UNM81KJ1LA@MHA.9]F("Q*1 M&Y8*BPB$[,:YPM%,"$+U@IKZ8B68,D2W\V'BC%HPHS;D4X80+.@%1H*9%61E M=^%BS&-@?\('B""QOR5+E%O3:2!>E5/I)\_-2&(4YT>L,\&-H2;N1^I.`((, M=F%DXI32G2@::/76,%H!JMQ%CD%XW:9OSB@4A@$K1T2U"KNM.U]N\?52] M9LQG["?JP?D/B--B]8_'L[^_%KL[_?CA7X87ES\"/6L>1BYET0+165_.U@R0 M)@'$:*BQ28.9T`X798W+,<8*;'2C%6#J;B36?Q&V>J!`IO<&CSIY69ZBR.$; M.]"")*3RG_%,H,T:AKW-'^R66(QY'B85=H;17Q9X(5-NHE]M7*ZDA,':1C(7 M)$5*T78"_<'N+A4`2H;5LI@MJ?UL`J=8]PR!$R?SJ](EV^:[@$(/(\+?;6/] MK;7UQ3O;6.T3KK"[M5-<86MO\1I%]D19#.!<@\AX;`ZM5"89(,[&X!:17U)V MJ`A=8.8%*Z+(`5Z#[?6M8O4E+MM)EC!AQLF-U6VLW)NX)#+82 M5U;I_+6UNC-(;N760)'%""KCNY'R!J=F1PA7-+\""GCC(98[&/D'"U?;$`:8 M"#%C9["5*/QBA4*FE@(3LY4$$7QG-QT/#D=%S_40J_:VTMT9`+4V7*\%9A)8 MIVZ)%]ID!VM8:+1OH5%YA,W1T%5V-]/9FPV[=9CIZR38(,=L?;)X M#!\H4;L-XG#[]7X_[I#+*.$[^ZGK8THP<8==<'=UJ,'?.EO(TNX4W@>?UM+= M-S_J#M4(;,XM5BZOAI41GHFNI7`7R3[\SP.?8IF7K&=0;0/K1KVPZ5G]2ZRK M4/]^@""`6%?__"C(QO7O=JWUCR\)=:A_BT?3>U84[>EO_'6S_U79ZB>R$W;W2S-38[C9T1 MJC7NWX/(;V^W:H_97U$33)WNWEX#[\CLO?VQQD M6KRDW+$1R/*S3@M\F$KL1X2:X6'Q>8Y,F9WHI<"03.O+B`JEKT)8.RDE^E,R MQ1M%#F9LA,^LV(8(V]+@WE+PRPE%010NJF30LJ8ZV@LMS:5L>#:P5B^R97F# M239(;WDZ88A/]S!D:[TC7ON6=$A3%T(S'OD@>PJE*;,9G;N$ZNEN@/`#RWUQ MG=S+P&1IL/Z8'+:9Y35"K&.\_Y6H0B^$!IK/(I8%)P$O>AV9$'_HNU@[*G.X M,#PL\HQLO3F7J:+F:><F"^^>XJ3PY]D`H]FQ8\?HEWXL*WT)J>LRM'7P28"]:B=N>;/):=H MQ=5>'THY\`2:B!VE:&D)D`F-#`M1%I6.`7DP]6_%8I;`A14Y]`WPC:;!9#W2 MV&"H\+X%GW*`+`ER\FT9W'S\D'A$$/!8;&VL%03><,B5]!=7) M?L3TC`(?;4\:K]`?@PF/DR#9?RX:&\],_XY([I*]G>)!]II`$12FA"6RX7EU M.M#MSNEB:3H_I\"WRM&9HF\%)]I(U@85M%?!B4!:WG,C+GWP.SC9(Z%6*2TRAK,;@@=F9(\M,"A6(7&G21!I ML9KA/7/UV)"](74$QJ#U9M&UA?UQ+_RWX1(-(D]CQ**94--/&J3?G(/G@FYV MJZ:<([D+YQ[N4_G27'-)(BGUWF=0Y MGT2UU,Q9$T[HI+<$/"?X$4S$&$:JI@YV%OF/;K*(;?6SQK,T.$<;XYW`66Z3 MPM9[JIZL"<`]C?L?%=0V,+'=%=1V-M=V%P$;$J4AYC*@MK&Y909RH6`):JKK MQ`G'<$$#ZY#R'G/2W'F1$"?`H`6PFGB5@7]$B5CH4<;)[#=*GX=XAQJ"LS7Y M0>'U>MZT+-2*#5C%^7&LY%3@O"JO(4K5))/^2M?9,J%=UV MGQZ)DH$P7:\%*T^QG*]4J>+?2*Q2R/*=SA).AR_V&$90>+R"YZJL*H>,)8[&@*O%9%^1+&WF%3J MRD[3&G.[7O*:P!C<+7'#0*TT3PQK!I502#B[KC M4[H$*H2+_3I&B'@*,#=L/;#3;2X/@^O`\$\^U:9%7<:HE8W!8'4=3X.T1H(Y M2'-07E:9HRL;`5FF5W-0MB@J-)^8S_XR(9/SEW03T?K#5PQ`3H(-\,AY32H\ M5.Y9NAK]1<2YR9RCVXZ2KRB:204/MY*368S%'Q5L!6_3KM9IJR;=<$-_-*A0 M)1S)9]HI'768XJ32ZH;&&]\%&O\ZM1CM%\H$_(:H?!1*\M^%*CK4 MF_Y'28"WOO`K7[C$J9110TBV-Z25Q$@(8YIK.>HKQ;7H%="$>%_$9#KS%!`5 M3Q5=IY43774]P(V5F?U+OT<38R!9=UT*0^"1RRX0ZC$.J<=(?Q,E"$-R3KS& MN*:Z)(U0O?(:RECH,;>S> M*8MD.3*"AO*)\6QH-&*.-#N/NX';(O*P^5V0AR=C$+=SB6[.-1^K7:T14EW['2T4X@"!XV%J0EX+RWB`*4!PC7KS2A=2ER%3& M49.G;_0=8; M:_VMK.G<`VBSC(H(#T=TQQV#;QMA!DLS&* M_L_G;-DV%3>J];6.3C*QUU]RA7ME;VV[`.%%T+C]74#CP9Q2NK"O$YPMPGYA MV+<#Q9\2J(0DZ$V_%10;!Q3#]M2*HUYI.#RH8@J*J4)UU8I2X-RWP7H,&MS M)D'+@Y`B6GRNGTW8$J;%,G]*,^,66*Q+H)_"GF'LZK9E1-S$`Z1"EP;\,(TO MF,RX'&,P.I\_8BLY2#'PAQH9"AU9VY2>&6X/B;"K@"U2J3IG,X[GZ(<::!P& M=`2!'*M3!P*U0L`6J9[`$_8SY=_D?2RW>;/>A\,T_9JS;899`CDEI,"1@"J+ MW,R?62Y#<2@W&@X$F1ZEQMFA8]D2:+&W3:1S+_Y7+]%TBM_NO*5"3PIGFN/< MCBQAY9E'JCS'+E";[+9M%[>^=A@3ZK'*#(S/1PRP`LJBD,!%<@F'KF?%O"`H MY%2:#N]:'QX2Q6TPK4JAXJLAB-D%2`\(WT[AX.&>RYOQ@\3D,"(V74P*S,@S9ZJT4[,3F(VP\(->#P2O*5OPR(#1KL155*\Q5AP M"SD',1,+9V0J\JD$IW.#S.EQ*%@%Q:RJGP"I#0M"UC"*XPLX'I9C`&_`3B[\ MMF>5,4PB"7Z4=56FQO$1*FZ!6YP?9\=.="011`U/6]N@9X6]Y0?7."-'[,5> M0*,:FL&,K1N#=%D>C\"EO-F";9V0Z@L_JG!5)500_%BPT(1:%YT(L[U`C-*LKLE];:% M])H_,ZU#BM2+4P^B!L-;>N?P.3O'-)9MA<(J9UQ6'*82 M4!KWL8`^^3RF>AAFL;6@*7=DX+/IW&_(H,_1,7]T))M8*&UZP]$RNB:^#9,?''X_W_""RE\:M+(I]0^!2$E=\CI9>=>]M() M_MCK5A#X#M4"U]<)V*]EL*W!WNI@NZ.S:1_)M#]H?]'MG&112^!`:UG$O*GJ MRVY'MU/B'>4NVMMKKWE3'5+WVNUKNY?V4C4O@V34<:7U@5`GB8Z<_;U!>][^ MZM[.WNKF=L>C+2J<]`?K[6^$Y8MB%$IIK3FB/C+Q>;?UX1._BRAT^VW_1'4!3'V1?P31D66!( M^Z%^MK8ST*/^VE;[T;9]U5];']3/NN_W83-:IYJJ^QOY,RU/2BJG?]?6EBB&)CW5W4STNY! MC73!1*7W5ZO8][JB]ZD+R_FW'FX1D<+JJ6C6WVH]7%>^&0\':[M5GH[\JMU+ M60`G85E?/W2!,LN]GW`;I7CZT^$8RVX91Z]X`S<\-F/MI_1]I`P=ABL/X%=D M"3*ZDJ/!1Y@9_C'YFS$Q2`X2BHKT&DC9;9HTD4PU0:Q5_88@F0264SNHNP^R M$\*_S?EE`46L;X()Q<('Y"@ZC<$H,E(TY`NOORJG(C*2-]US3C7E^#0&>FUL MM4$TA227QF"M=%U00T>,W`+C"TGN$;'AS,:O1S3W1GC^IAJ<.C5`&"ZICO!53H0`UG' M^:]^%-T@+EPU5AFQ*(CAMC+Z@NGBL5T8&`0/@>&AL=`@J04.JE""C(S6>Z2P M4C4S;%*#WU-9!=_@=TCJ!S!'H8DS,@A<#Q:4_D0]1DFE5F?@Z.`GJS)@[>[Z MZQC_6R?X%1L9F;A\WT'JN9_:(JI+_YT=>T!O!GA4[CJ`XLAXW3,.9 MS)T5=%^`.Q672(8Y27XVE,82-H3.7E*+XW=P>PZ+O<5#!5M,"^'D.,:0[Z91 MWC*(6JK*JI,-;>YQR])A]S0_;HJ98>/8G)]A@9\3/B;WM*/=.SV M@B1WHDF/TWJC$O/5*=*^B$\VB.WT=U&PK&RWB0;A^,R<"O!D83[HM+'\N,OF MVKU*V2%VF,>IZ'[";:@7='#4.N##(B'YGA*8KPH58$P\#5V]KZ87@(6:F,9Y MLT'X0?`#I2?%91>9A.*F!;<1EE&L`<;<<2\S*\7?0M;"?,?'$059..ZK"`L1 M$PKOE:L3INAV*N]N[]2)N8LB;J2TF/FIFOZ30XF74WL06.3%I^HL8NL6Q@+- MI%^H,96VT0R:#$>2?1CB2?-)H>V+':<0?*O:6.14".S=PE19XDL&!-BT+1FV MMM;/FZ8.KM"791NU=-/C6%=(:%;UB2WLT9)!%6Q*@R)ORJ+UMJXO5ZV`]("K M#F["^`DPT;C8RFN5,NP;]$OJK4Y;\KG>@`J7&#$ M)X"WZ;7(511T6SR$[E+8R*S(I;Z,H2Z'Z,D<%T0$"%NWUOJ+!8NIX4R]EF?. M*^J?GTN'^OCA>;M4@_'>^O5#3G8,HSFI'UB44OUCK.W06U#,X<7H`KX']ZD_ M?%#[^E,'*/=RF1\"AD<9^V!KJ'[V.IE0;R MSRU6K^_?P_*R5>F>"Q3/Y;:[T9IB>VVS>[LTW3&C:FM-6Q0O6.\O5_MAN56U MZS?AK6L),I:24"2O2-9RAC?\'1N8E;*6`@[?5"$UCWR5:%:$LW>1 MXV29A:$F]A2E'228,-B,68ZQVY_!(/\BL;!PD4#++-^7%O&V0%M6B#5@E5!0 ME%^S!NBT[%5PJW@W6X3SNR:L/L1?62IL)AWC:BNZ0:E5$GKV-'8`)?"Z7&L1 M,%+P)0[)CB8>*@PH>-%:/.TA_-\SJJFB-B%<7P4E#B<4"_6H7NP\?UM0)<>3 MVS]C`%=83.K5Y)BT3P][/>!A;^.CTTWZE,EM5]>BV+`CV+=<=9P=CRO82,!LR2" MRB7\,L-1%I)MA&(6/C-]C0@+NVK^9@[$ZG0&MTB7LJB*0'FFJ;`^J'=H@Q@' M$5"TYN:,^L4ML5@59FX=]-(.Q60W573142D1U)2[!+4V$Q;\*8@K@ET`6@:% MP@%L),IS%II'GUN8T<[N;=0'LI`6J0`$H2EQN\34DX2D,WDZ)>2L)OVZ%M6? M,`=NZ6^8RR(+W#?WTSZY=#,6Y%%6P6DNQ@50.^A\0846(G5GBF`%*CMZR"\0LD!0Z5[9S=Z&#-1KZYL_W.^O[71XGM:W@U.JY7F2S^<^ MS2EJQ\X^'I_[;7_/?K*L%K9=$;I(,449BD=0(P4^@^?)]BO!Y@YF7T4"".,2 MTGC)#F]"8I89;WAKYDT+>1=52.MYK8033`)-\^?!3Q\_8-TS+3!3%C#)HY*, MLUBH)8M7U(;&+7FM8SJKLCXV;=W3:6;3[.>$.>W#&)J1$IR.2(<$GEF.:'V8 M5)I)N]5NU_-WJ*4=J2H9,9Q_*FB8D5F(U&,2@'&"`UQAT4'-C^S0S*='4<2 M_KG*VM\D]M3T.IE3PT()2>\4C.\8.@D^OF.,86P0AT75U=W?OUO76/'>?;P<; M*LY06TOV6WMMR2!_BV7!D-:B4+F,H/9PCMTJ5SX-8>\")#,%1*=$48JLH%21 M%\0RBT(;):/OKO9WMK"`R!1!P+9 MSI6/%D@P4QY=25P)[D`$>R[NQ849Z+[;!7D+@.^,T_GZ$E@A?$,=A("VF M<^E<"XO*13J"XI+,_1&`&VK$ M<^P:C3#LF,AL.==Z68N-A+1WX,F@A^2C8`R^BI'?\6:ZTY?.X@UL25+IC$H/7+F3$^?H@:^>?;,=@*B-&M<8;-#*&,6JU*1:X:.E>%EHN>A M+L+,Q>/`/MRK*?NTR$]21#K4#P.55&5#;Y^@0'S/[:H5+W,E'>$?HUGU(1PQ M=2HIS$;=13>;#"X0U:)_0R[B*31"KD78L1;5Z!XF#B74]^??0-@!RF;O[WO; M^>]Y7A)HL;OU7;=W,2:_SN)/)U%>3M$GKH<;]17 M=!8R\"7R\Z>$$PK;R??UIX3SG4LX=;%T!*OP7$;#*D'7AB]?4J*IE%6WP94/'L7!;2:)9>_'8Z:S]9!MX#$9+Q3$*5V#+ M"?V6UE&"_Q$<8XD=1>.F'I\2^AI M^W>Z1\9$ZC[>%FT-T8#UZ+C?-K;POFVN;;2,MAON']/>B,+:ZO:6V45/8YRR M6]+_6'=#-#S66N]MGH86*)@YB>B[Z#BOS\Y,-O6/R4C^\0->B_KIH;FM/G[H M_-0MQ1\_'$[JSQ[C=JU_,S]+5RSA\]3&NO[D60Y7K!_97ML_AI"!^L$C<\#4 MOP8C?_WSBT16R.B3]13;90>EHR`6Q>DMG*0>`9-TZ$O0>D(!Z?[.ZFZ[%Q/? M],G%'6RW#-R"V!9)R/XWJ''V=2$6*58CA$%`\():/BVONUF-V<*T6K,AD[NBN*LKM=#LB`3!C M#&6P4.L,A5"]7ZURQU,OD6#%)&OP@J;U6F=)Y294Z>`7SIS9.;)SYI((?!4\8?2HMQ*0&>B]'> MX)]02O?[4"WB!C!NT4J=T<Z)C M(=H@%##+X1I'8]+LB8@D?JS^Z!F@UEK*,Q(LKM[*IUR_?CBYA`37O\:98V7@ M//.KR73A6/&K6#`T?^7[;UW14V4%D46J,R0<`KBZU][KQLYJGUK)6[M$7=?K M]"SV[M,M#K:>N%M2>=@=FEAD,B2W;;V.1$D6+;%83/TMGLV=]4WZE';DR2>2 MU!Z72AAJKDEDLOS$,G]:_(20R")OA;]27O!^;? MA>ZO2%X9GJM017T;]^3;OE8V5PN)Y(MO(VF>!2K02J/X5$A+;NMZ?0VJUIIN M/TLVHF:S:?WY07(M0NN&8]X9MT2[!\/+,<4AZD]U^4KZ\7/KV3G)'>S'$D&K M8-PI733J9L(I+SFN"#KD`S\YLZ ME(J`=QQ:F5')P>Q=`RU8FM>O,TV6W%B-'+BG>+HO,(1/$7.CVH&P2H\D:IK2 M)3>/2`708+?Q9[+H8E71.K#YEADE2RX873CH[OO%^VFX?LI3F!>\P@^+Z"[Y M\U-D=AQ;)1[YG4@VJ]=*O)/(%U-2D)_T=@_N/Q^KS9A&(/8?P8'`/$NQO`2X M)B=\PHM-&2V2E18A>TA'CQJ^]^R4NIX\4C(F\&_IW\W,7>ZR^8@)&4N M2+[!GY(+`S7OF%'8IBKF`#5#-7>)YGY0*TR`3T7Y*-UBP"'F8N(+FR06B98J(#XL)"4RW<,[`D(9G+JN MI%&(;3P9C4Z)YE`8?@Q?!IPIX:GGH]^5$@Q\ES>]-^MHA) M?7*M`K*^9!/06[I`:,4R^ET#S\?7;^Q[%RDSS-._Y_X6'FV_FR)1]BLFGF>P M*>;[.IGFW2PEG6O#-!2I\F3TSH$).D6?PYT?+)+(VH>D#R-86&\;Z_J7AK(( M1"Y6QPT*.REN:)@>@1(XNX$M;PT]E@AL=C4@!DTE(R7=+[P[TS83D+.)4^%AFE=POA34H?FR-GG!G4V=2A+0C&.X%@.YD4+P&H@G;`H))J)XF@3.LT#9#C13P4F7,UL5A1`\C13L@)[/J"7I6],TF3ZK M>*D*J5#&[/)<">%V"="(KB@4+=,I1L1F&.F(;\'1J#<+ZU/9.=&,UQ`H9ACU M6OVLA&@E%STI&J\(Z17N%#(6`Y'E5M7[O.AO%=^P(%43TV*CI<6!9]Z8*M82 M]YCV?40;7T$)V`F;O[9L?%FAM0RV-PA1Z+EKQ`^"4W'#][BY2\S0$L2L8RM MCG,N^Z*(B"0,/,%+0KX?A&WQR4!]4+9T*U8G(L1+0^(LFL%#D-G4O_H0KRD. M'3*J7`O2#LR(-SWW2[K^47^_'4$?:)YRO@K7(W:&_R#44$Z;DPNU(R3M6%K; M.VHG4/^`XDK\5U?,46?.ZI8QIV$WWS(3(\+/F((]S:\@P-A_U=[Z]9Q*'H@B M)F`=R_MGV&W,.234Z]K(%P+_1J<3,D]54CK)G'''3@TQJK)'#^@AR!2P$S_H M7O.B8_?2&L:).`7(*14Z;(P$UI2.P+F`(82=LQ0+L&%O2OY23SQN65#F\8^3 M4W=;064CO8CUC07MQ@P*7+AQ9RW(SOZT*5@!ZU"`=))K@D@C6($F>'X_VP&* M)J\IRF)(=XH>0&JK+3KP(%G?@@ATW8+Z`TZTN_BCTP6"`HPQ1EQ/6].]RW`@ ME-JEN^+68%<8']I"-!1P'>`*C;;6*:K0[^_H-74SNN]B8W##L@O6U;7YE%(ZZ@92OL:YQ3.D6*NQ#Z292DCR)_ M/X@B/!2TE:I5TI3$>U9V!YNK%!W6O'$W%J4&QO8**Y'`Z8;Y6C'_(Y.WV]LU MTAZ#>%54`W!`X/&\4`#C:B10AWH%:D[=`QUX@F;#5NY*>JO<>EUM,1];P;!( MR05QC)`OV?&HZRYL*=R!^S3;F8,)N-J6JP$=/:FUOM&NHKF_M4JYR-6M_E[[ M*T"0"I2;ZQU%.=T*F%==U*EKZF>S_:Q]O8921!+KJ[>(S`ACYQ>]^[]\NP)2?:BYI<(C+];RBR2[\I@ M;VVS1QFS<\AH0"X+_9I0)4Z:EK5=)?$$6*`SBPIB""8WUC=\!Q\_Y#1(8X=: MU0/D*F:>C(<]3=LQ*TF<>VM[<=X@N-H,(OQ`D&;T>=QC\@M:Q;^C7F+#C4.N M]*E>60V!G88&6<;TPR#P@G\?3F`X[U-^SJ:=?>?*7_S+\.+RQX=B7`0Q@`1O MJ5B81,]XVHB_XHU=&]N&S$ERL%IJ\?UZU-#2D_,L=ENMDA88'TDI9)6@.,67 ML2`F_R%H!QFP%,)*"6)E')X.019]?V9(V9A19V^HYKR]9NQ M%<'+%UPJ_HC_`YQ=LEK(R+TECSL/BU3,H0 MA=X+J54OL&6BD<)Z=+0UE=%KXDP4)#R53J7E1+B3U9)6,-3X4>Q&_>4]JAKA M@`1:ZR>M)-LC!L("-OQ]U2D-7><#X>$WUF\U/.I1[NW"F3M&?XYT-53^9>^0 MU,"V/VB3W*V.S^1=3@ MR;,&;XPJJLS6VE2Y\(;=`@>G([)^!<(ZHFCR_`0X4%X\YG[CW/5.'K;GJ%[I M%GE>LJ0.)E%]NQ\)2R0J`FH7(;6G\&O]D7/(CMW7+W9<:/W*O8V-U4T<8?<:X MH%$E4#=2I6(9W]+\"Q]7?`I/U2UZ5064^T9-0)&C6$G*Q8X8LVXKNE3%/?EP`"U@ M3@!KK0.R:@4F_Y6%H;@,*8/%7(6.5:`U5BBD'M,&BU^#PF,H1P'"X$*R+@6\ MY7(,TY["0P/D<7.%\>\!9M'QS`W>(BD/B,'BUB%+K*0F6S>^7`$V.DC?CN/& MC^H92A;W`D'3^APD%;:UH)"]C%N:7TMG$E?M`R3C@N;G*_$2K MQ!QAA0A?CG[GWI\^I"<%BLTUL/5`C)Z$6N0%_J.ZMT\?'CQX8(5_.51TF;?J M48(_!_.VRUWT#A2=5!B1*@IC;%/!&TSNY>JD6%O0C$);8F`>ZY88`:R@/MF\ M%W-$'T`8PP,+HWL@;@$#HN!DM3%/1U+P1=LEJ6$:,N$D[.%SX>%;S?<>R>Z#=$::LQU M(^'A^?E<)8Q7%6E[LF88%7\SI"J5O.R.Q_%M=-'8Z;OIU6\0TM>@EPQ"L(*( M<0*P2\+;(&"HAKI\6:^PS8J@E?AG=#FCPVQT\F9BI3W\(Z*$[!-9'RP>59_K MNI6')/1,&,/]3N:TS=9O)V.0O4`ALXKFS?UOFB#5GWLQ8"NB5:PAMOI)AZC. M/#J=`*O``^9>/Q'G2$(^:9YH8))((LX[A"I["A735J83:@SK$LHQ**)V/="I M0A`-Y=GG$TO@YW;TF""&WD64P"1+PA`2X$-6UVH<3!_/;^>V00W(\<#_'Z*ED3" M$)SF;24[>I,M'>%K`]3%C9)E2ZSHU9$Q(JH9S^N0"![Y%44.I?/+;KJQ%5!0 MBPO;*_%SI,W,3UQ_/XG+HZ`MRVM2IP3#&$Q"/?1L&8+C8=5Q!@8Z01S5>L=Y MF?LD%'T/:[6K3L??I+'PH19YUW8JTK=!QYU(XC-Y=WY\&D!V`5'?M.DCY7)Y M4E[M("R9].!6Y.;F65E:L\VP8/P6TY`C/P[>M']NFKUN*3;1!7+9IJ.XP.8Y MFL@"1D,"%6US,]"].NH]0W90=:-,'YX\>6`$^M71LQ+@R,"?3P6!P$+'Z)99PBS&`/G&HA?+WG9 MZ*$A6P&QE[7T%8#H$P&68ZDA%JO^)T+L`()D5=*K.Y8LE$'K)GG$Y2&-LD); MK25EAAO`OQ;;NRELQ+$*%A,'JDC?SZ,)G:-/HLE5S&)XCJCP9':ZU@5\\7T3 M"R(),V.'2_O7L_FI"?:"HPLXHR(9WQ*H#[1<3(E@H938E<)P(GS`SBG80%5+ M"[/C+PSZR!GBBV,AAU%MT>+AI8:"1]"9XH3'JOQ^K1EZYW/@S$G>YP!0W%H% M0U15N@6&EJ5)2P).Z.RXC!S;(E!/W,>?&5Q+>P-J0ETITE,:5+F"F!`ND.DO M-(>Z;0^OQ%8>*Y!F;"CRE#L].1G+E83,S`WA:$ZM0<4#<=J?DZ<(`%B_;,2B M('@@))EH9S'Z=%[@YX.G3VQ0"9$XU25J&A7Z.]99D].K(4KA7H(A3J/3\?#U M!(`:&%*LQ4'55(KN-DV:$%MFY$25NI^4L3B.H)9Q-2Z"HDP MZ4(`:0M!-2!10J>*IK#=8G8,:\TGK+8_74><]VJJ0U2.'6H/GQ\]^_G1+[VC M@R/T>D7$6,!-ID@9:DP6NM3A&;P7]BI@^S%A+)B5M'RM07F-7*]Y2S)2PRPNHI#?#(_DPD9%5,C>8Z*G4,PF?!C7I!,'I(4\P2$.,-2DQW#QFA0 MU";'!:GLVE])8R#^3NVO^1<01*FT0L"2AAC.R1``,`3)3;%S(-+!II@I=]J$ M#2C1YCQ`@:'E1GC,<>SC!`E(,"%`D*P.=V??.0)-PH-7#J4[[XP>73&&QD3FU_X M"EYRX>6G$;&,4#%E5G=VA3<;6SD\4\N4-5"SFIN:ZXLW(".EM9SFTB#!@4C: MA(`VA;M.Y&[?J]4**X7$C&&,RY#8XR&5(2K M0-TF#0K!#8D`!58;.?(7HT>%8:Y$27CNS3R_<2^M.UT:,Z%O7P,UT^W\,]%9 M$/"IG![1D/0.S.Z\Q-Y&E-P:MYB(;`F4)CW$XPSDO$ER8ULX45O"3,_QM9_) M=:$YL">Z+*"_IRK2?._%JV=_Z?U&Z$H8+(YMIC3CB+',""D`*$=9!BG6)^KP MR_.GAW\0C394C4!_"V'VD&P(L__#/@W_[J#+7X(R<^K((@AT1C-*T:B+9APD"`V!B)GV!*7_[(:TAW$ MD@TS4P+]A9P=ZA.+.#1[T*7E)J'$]+HF5,IR)8]ZTMLD(Y>X>).`4IH]US\% MW`\GOX[?3H^H*XSGXV7T_BC`._BE(M1^*3SX##18N-9E9!97<)=!C,73?*>H M\E64G`2[RZ$:ZCO$##WH-FO$77#-LV+!-3?UZ=,52D.8R6()9%N@`7P&NB6W M5RE:+LM9CGY[CW5NU'N8+&&$$_[T:T*(6S!LM=#"R9TJ&,]B$P4<*6I\4=-+ MTWVBM6+1+F[G35[3U"T/WYG6L&A3?R)\%2SM+F.YV+X"OLL0&6R0_/./0?"8 MHL`6$=E*Z;%IA\>4I?H^109NT[+Y\N5C3(E(]4=K5VOG:^*BP]Z;]\=7XU,< M.SV+7D6*=!NB3#C(@5.2[Q7)+T_>\11_C?M<9"+20B1%ROM2V.57'*=,GD-; MBH[ZQKK-+F&R<[3,*?T0SS-:C8;-B_)%.M74TVL9L(,IVBR`!,*Q%M.@].79 M^(K,A6LZ*L2QXLK%#?;- M/:A#U!5)DS/B.32SG$T6V(@OP?J;NQD/@P87C)184MBM2FX1"YL\=C-<%Z?QZ.Q M'%H=!T)(HX4VB)HI*=7-RC@&DP4O+C6+JW=2SAZ/CJ_FE@-T&X)E):UQ'/)U M/7WRI/?TO_[?A%`EP/C):/[;?_W?"Q1U,3N+1=8+`N9;.*K=HUOY;]*[;2A# MOB@+WUV#TXJZ.:2R1`R*HT9QBXAJB_[C^)(V@N;:2NO.5GXC#P']HZ%>6!J* MG"3YPZE'B'"28.<2.GA&C.09,)^PX=M:]^^(5'8?`/,7E'MW+5T'9D@AA^25 M\PRABBUVQ!ZD0ALWLJ\;L$O5IE2!J/=O1.F#;4_Q%/$,3?/AT`+: M7Y##.TY$J^$,E#V2ZC%>CN#$X@%3++E+26%#>O'D#>(&P0_G[R\NWT`^"0_4 M7S"OT<5X:'>#^-.48(*$%G;0%(F,F\0S7"C1:"-9>#)G<.3UB9,C4TBX45*4#3.0A&26?O)FP2B).[7ABP!B2:26/4)"+B(OE8I*;_&> M3)J;_6Y'M"U(*<$LPIS22;I>L!W5/K"8OKR5)*K>L$JYJ&OD#!-_$`= MX<0LZ/48;LPA<%.2B-VGS$FU;X[X(NA4ZF6L2`R"L/U7V3=-@[`8`KPFC'"M MV#(/EU`XFKE_B!T!Q/!#I=>1.X>?@&#HZ")0".]"7KC:YK M_4EJNDA:)ZF)1YWY1R=^6_2>HD`(,?EOAMGX71-:_]-B=4F_6](^A`RM)468 M9S@J-7E)'?\Q5V66P@+\G>FI,<1;SLEHT&K*'>*XV:$=D0.J3?.5N[PAVFG#HM)1^+KDZ(*0T<6!HY<)!70'Y@"V&"+]'$G M^IAPNCAP9OA85^98:\Q6U_.L2J]^HNQ+A:(9%OS;G`C,WG.J^%%7X@+I^VH> M#8.?"I8".8O4.+.+UU0FW(7-(0@VH/-FF$*%4M!PD!Y!>!*L%$N7ZY&%1^DD M333Y4N`EQ$L@5D@MY1TV0C<:MU,B=%?4Q"\(D1&33GI^^4Q+[;5$^T:B*/2,.W MFBS%_V`@V"<10*SGNP3"1/ANA2R@KXHD]MP&\5;?H("2?R_#7)\09D]J*!RM M9KL=)3&.1^3[DD[3#-5&:1;E/JPJ@<=YW4VIF5-2;LU$<:RN9Y0(M66D1KU4<`]'*/,`DG$L6#^>R-*/!P[1 MP$5');:[P1$Y@(0R"D\H1-SJ]?BTFB@41Y6%`AY,C1K9,6QIYN#!>+)^)*-(ZXA:+/41.=Y3 MK\2K,WV`9Y*R0R(6!U&N;N6`!=OL;9ZQE"P"K"51(P2=D^$Z&7.A1R=OYF\@ M=<_?K#UKW9AX!3M8*JU*T-8]=*6O2262X4T#EB)A9P\%S!Z!Y!*@L,* M=P)<:9Z4%!]B>WJATAK)'F8ODZD*J+@P&#QLVOEX]53"IWO3]9;6+`D^;84$.0["8`%0/IY.@`Q@0=B5BK?3$6M`C1#^3X\">3%O.J.0!D1%?U-M&WOB MD?6?.::`A=+@#BE1PHZL$.N!^(1SIRD0)V="FLMA+TP.^5E`%K;^#WE498 M=,S%MCI/-QE-[!`NA/^7Y]9_1Z?06A8F59JO_=`&75U9QY8U2%IC>[BX&6RY MROF=&[2C7ZX-UO-G<,6-C;7=XA>=`^F`:T@":?#5$I`@]BJ),-I4PA($*S_)DUSW&KE[/2$O M.[T"H6\\15#\$D)WX=`H6G9O3$D+'W@/1]Z7FS'L(X2R]ZR`A"H$T)( MD&ZZF**&7,4W>>)H\(7EPV^?L`Z6W1.K`6F?O3&G6+GS0(!4<26\X&TN#-7/ MSE2/%9&_>CI(07YQ&/B@.0SVQNU5C`5&>=[M9#:C2'VI@<5'2JV0C>\E9&(QU; M$&K/YA(:H``XF,!2I&;=5\G(B_/U^M51$$A7DI&D16&R9':C^GF#9'8TDVKP M/X<3(OO(T(>DWRZ1/89L$7('F2PELJ6I'?@EX'L0V)P.9!'Q>RHY(2YN:?K7 M^"J!+&;"&TA@\YL:(_\YJ6#S3!+5[@),2SU>EA!6`-"DB\U)ZXNX.S[_H+#95U`S5#@/B3`]!A5SQ[C M(KWAUI5M>I<:Z%9`&+Q=Z$,AFX9 MLDZ"N4C_Z@BCL31\9+/29,]N%!CDL1*(7]'*4N\G"0!N!K\TM3MW>&EN(:_H M'$(KI8_%8J4./JNKI8AF.XYJ<`OB0(*<#A=90)`$_()L&SRLD8O_]&E/-X8U MHA/75M?;_@IKBF5<_;9]\.W"VK/EYN>!*MEJ$-7TZZ"S]LIW"QM]S2'<^(*H M]@(KPCM"4/8I&U@;?%96#7?F>K?$8%GSI#C<4GK!RF;R*29!@3E`\ M4_G]]>65)S^KLZA#OK^"?@K@$56':#4GQ=8C41E%.>`/*'S.@!(`#?H&'0\U8J54 M.V%7BAY6N?>>D5(!XT`M2(U>(F5\>_Q!K*:S]88$#T(F\K[5UCA">[A126.@ MU*#7FAW@O!\,U[[^?DS2R"GL<,\&W,+OB!6L8Y,PB0WYCAHMB'N+6PH`PI?J MMM3P^[FY]^)9O;BD&XG^L0T6*T^%@S5[('*XT!LHR%Y)/D?$K7@4IFV$/#A* M_JPN+V\$PUY,CEM^9I*Y&&%TM)^X>7(?19IR,_AXKV_5V,+KF1D'+2#9J;P9 MIQ7?M4N6"L0&`)NC'G`AC\CTP3(.6^V;@&/=4M2''/BQ3!9_(UL";`9-LS:P/0:& M3WZX&-.>C'?J5@O]3%10[NEZA#U(OW_)?,_%I+).I7.7)0/#J%6<$^53G3#L MPLWY9BTN2C@%]A@/6ZK*],O;3I_[O^T`'0#V^V\[<.*3GM[B>UY28FVEIEC' MW[6FPT$17M$^S+[)=L`G![3RI>3U-T_:GNI/`@M4,^;??Y/!X@845]:U['97 M%$]%^/G]-^3R:S`)56!<'_/S-TD\BF:6>D>O,=M8>PE1SS%ZX/7I!TQ&,D3X MS[<4-H7+F[3%'<(KR6X=D+8>\@D]F;Y[UOS*+?_TN^;7#2[YU>97>D4\:]]= M7EIYVKR*&?+;GA]7VP4L+ZUNU&\>"GBAZGBZ@LY4ZC#:TQ3B/"\D1HO6TO3X MT6R!/$_GE]EU.::T/=#VO+B^MK3 M"#J6%2EN0390%^RX5HT0<2-".A8:/#[Y]SL\(^Z@LB_,&FZ+Z'0MT*+A_I-? M0#K17?``?UH:X7&L7<8RZYIK`QZ***Z-))]CD/%R5P?5%S8)U'P7UT$RX1O$ MGOKHC/?#_AN)^_EA-BOND.YYVPHRW@!KYGO[5M-0IBIVBR`EGK/EWAGZW<:; M+SZN%_B&(GXI-U!1TS!W[D]!+]X*\G(S4!2R8WWK*Y\7[>F@S^:5W^.G`R'+NV(E81?.))(HXKLS3**NI@ M=27WQ'6?HX+Z@L3J+C.O=`XY8BG'I6.3K3GXUQLLZ@JS'&[CT^XY MUM1/+1TJ\0BB\2)@-HB;AC;1C.`BXQ'1#)LGXW/D4_GLMI)H6^;JNBG5+/WV M+I]B3.:T+(.G&%PB+GY:.T"T&"X%'G;*CW**[J+3;+>Q'@J65'5O,"N^XB5" M0>6LHR5M6QXG,;?0:)WS2"YK85&Q1C@*BWR+7B7'RI^DRCK.F4W(UJ+!"-5+I17C&AMOG)Z)-J8?2N&GN_2P=IX; MAR]&:D/T;&7C#U4E\CEP)W"X?Z5WN.A$H;AA/8K%=<(KM)L_M!.1%B80HTMR M78M)HS>:K>$=JBBLS>ICN?<=V`-/N_QK-M5S<">7?@N>PGX#!IP3QH?MPG1^ MTU1A:L>DJB%#PT8ON#,A*A$]H7SB,>/RK"<)@^7!]>PD$V$DG_S*VR)TK@KU M`W0GE/9FPD*!/S`.>UAH=HZ%M@.8%%V#C+W8]E/4P0#.=2`7!576#Y$B^+.F M=-,+@7"S!/(DW$F]D*93<7?<1&-PH\+QKS@K MC[1Y<38^_GF1*!3JC`-86^BB+EN]<(Z]![^?O6QMJ>VQ)*CW6"CT!AYT6!N& M8M,F4]R=V3PB\]"=",'"VA4JH&[,^I(6$6:1$MZ$5;I)A%B0G[W]CPI:PSZI MO@6@(3",R`HA9P[Z#DLBW.PVL>Q*KBN;CAW MV0Q,W;/MIHEFZBA)\6U(/X9J.OD?.HFJ!">A9`U8K\ELZ," M"N\3D\^#!+EE"0/2@>NW2V'76KGC\4P]T)J(1Y_+_; MV^J1.$A]K^K\.@3LAU%BM#"WBW#@B>.?3`J[??!/':H\D8U=F# M5H`N2Z2T+._E6"Q=QBR;LX>ML1'ME)YDGD(@13$8W?IQG?LRDJ:`0'>1]T(T MDVB,';ELHQ/-1KH[B_[N!1.#)!'H9.#NZT>IK)J6?-I(T;F_13+KN.T/;9YS MEO[*Y1VYFM.GZ+OXD9!`_^7D].VMB0'%G1ZM>%P[1M28\KS]G+JFCN^TF6DF*+;LZL`#.("**[II2O M/12]0'-&79DINV@F>IU_8%V!0:PP)!X<7!*`(@#D0A;JPP5"";LCDR7SE"52 M:NVFR-E2H0.$ABQ-*F8.-ZRU53K&"F)AXAZEG_)OKKCEU@T?*J7@GK^(H!HH$M;RK`QD^D[,JK(0+@S@(>ZP M9?)C.)F$$5'G>20AH<06B>C7)T'K;I%%>2?680NLXA@\G2\8J"(3\SQ`J5K*'I(@7[<'; M;:L5/'AI\'5L#R$`ZJ.T!_MM[4VDVHUV,BD#0PL-6EDZ`AN]Y# MW`*,J=\`K\XCB_*'6^Y?_\BYKC'$@.),@(Q;1V%7[Z1+V,2Q%I2T<@Q.Y#/> M&`OK'5.J?:?G4:Y/)%!%3P<9]FP)KA!;4`N,9G]D/WE@&/\=EFS!7WP_B!I( M!L+FGC/+'*GO`-(2*,@/RFTG3,4+"3D/'&6S#SMLY MD'A5BCTJAXQSJCT&ZHMW#3?5V.,3)57A#$';PY87AH<<28&[^'0O\ND<_1]Z MY,^'3K=!N\K,07)>K'3`R2Z#,6`7;E9>II4-2"CWJ)!".8L00_!C9;`W.3O1$/5Q7F<(2-"WB?^#ON*6$6N#Q'!G1&08J:86N]%`U@&JOB1%)D#>((7WNY6F*S"0\1#(6,.$B4YM`3,A+1* MG'++GAZ/=S[?*4-%#B6=_4$D]#QD+,O=CV"FN8&SN".+BQ]TX)X6U"-CL$0S=1 MCUP(?`)@):.GTWHVD;!-47\\\7H[Y;A=#"V`HP$*:LD0Z#=/934U>"+K25], M:$ENR:@!NZ9N_>6`(7((NN66NBN?90_,!D#(I91Q4`8*B/:8[+([_:2(^[$X M/F()9&8[D\8CRC=>G$>C8,JU5-Y/-9#*;51G42[&!\RG8[[[T5II\*Q'-H/< M/-`+C3:Q%D2>S/HE-"Z:35#F['KL7;\GCY0Q,Q_#*,+*N@C8/3O+P3$^IM\M MQJ*>NX28&O3%:+5IPR;Q5I8LQX]Z6&";TN/$1[*Q-C^+#RM2+(9R\,8@%Y/7:;Y4"B:N7]>EFQZGN^GVP%^59_$?KE6/R2[)`W;/"R';1ZB M9*4Y^Y)6TK!-JL7WEY+,0?UC+,GU@K;NJ$CCYHLHN\N(%E)"D*NYH"!"$_X+ MB:8>Y@?IU#$6NXX!!X3-HM2C@LG'"^N0;L#!.MA.FV_8*!PTK=[N]&W#A\D(A#B0J3H6WUX8ZOP6IQ\@B< MJBHEP39M+J9.)FFW`=S.KU8%PZ:0#T$9EIXKZ4Y;Z5]W\=1P-1C,-'XK\6^^ M)QJ;`GAF7_#:2+*=N-PEBHT22HSFE6&A66NSPLU4?2JM0XBJ?#U9_1F#H75( M1$'TY5;F[U,,?33PU7!,P'!0@D-IR4*5V=`\DB.M^*R>8,,SU>J?OXXB-HL+ M;E[!CNB(*%[5$-IK"HW$\,:WJ*X"L7G!@X`G\SM6:MF,0N)PO8E#B\*Y09^W M`,G)9?U"(5='^5&6^&@"@X-$:-=?[GE-JN9GSV"N?_XI"N>?1P\0P\NO[R7$ M?M5#'+5)@*]R>\:D38X^CP9@LQ-]0#)HDJJ$M$AH4`VJM7Y\')JJ']XO[S!T MF'U4E/AN\JO^OAE>VO#[_>-_7<"NM0RFM$Z0Y!4EX1TWM01>O-6U]R0CWC[\ M]E"7TL+(.4T-8Z<+YZ;-`7S=O:T/2D#SVT?+'MF4L-` M]TZO96D7"9B2D9O+9.=`/6"66N"]./NM@FM08<4.K9)JE`G"_>[Y7QCQ=5,? M<]LV\JQITYT`-8S?\H[+Y<6?N>MAO1Z$O_Q0(AW36,(1^-`1@^S*'=]\\/ZL M4AJ(.%,]6T,D+L#4YPB'JP1%H)+LH=ZHLB&%`ZQ!2#"RUY=SU6LX?Q=Q`_K4J_,QJ=76`M0\Y5,8F=,U.?MY#_LA_KK+H-# MZI!*2)%\_#'6+XT7O%F?/'L'WD)B!^*`IV#]P3-#ECC04T( MZ!ZT>MIT7SN2WSD[$7UX5`C_-KF121(+*\6/*3I`EY#2RO$S*N#67,7&,T4( MA7S87#`#XX2H79.18ZKAM&'`X"!5RUKN83XM0T_PB,H#"4F0K[/;9FE3)-[N M][-EWW8HE_S#S8=YV#4-7\_L\3)S#%<%*4X-KWM=)MJ:%R&\7.M_?1\'4*65 M!0[+IW]:HZ1IC6EY09$_F2Z*N4^!6[4"%SMSJL:@:5`P"XZ8!($"L(W52J*=LX=)0*7S0X-"!%]GPE*TVD.$%VX$NO$I9I)D#! M959?18U&8;)Y"&R(8LKMP;:1"*6YUQ.U7YN&64"SW&"'V=1#=;;U.;J\TN=) MW;=<_H=\K+KY[J!.`JZSD8WF*JS6$K`D'Y8M9F"\C:7E1O"LQK/C">&>+*$P ML=?[@E"I,X&$1\JE"QU"%+/MZ(_CDJ(D\D1"EF"8A-+.6\'SWF=?"%PAQ6<4 M%YV9K`P%F^LI?W4/D]9+9>=>X_15^)V)#_7.G_6KO1GA.(,N:&+(.0GC]6"/ M"D;CSE_(V4IBMFBF64PHPR$SALXYPX;-'*E#J<&1/T[X,NWUF1;AF6SV>PGP M\K87PI&T#N&PK[]>XJ9I0I]'M0%:2,Y=J!+Q ME(JTIGK^KCPH"@UP#JP->,$5.Y4FT-[1+NN!]D()O\_T40+E[V-8SY]^&12R MT1<;W:T\OLG*"A$=A]"F+,CD>;_.*03S%UAR;Q"8J0=A:EO:Q^?1JTM$.*%` M,`%]RLTW:KCG3;-'$@"N%.AI9NKZS=UH4Y4[<_3$+-X!51IF-_]Z6&T4+NH) MY[!X&D5AY7K0UK<5PG4*E#Y19A!1?NJ.#OI3YV=\M1.#%8MD_NGSI"^4Q%]# MA,(^5AZN_MW8XES:,L;8(<]BYG:#!Q)2M>%&B2$6,3DQ.^\MS3,NK!`!+XHE M@"7J*C)%5OQ>U4\XQ"FO['1T+NHZ3AWGQ7R;$%[,O?QD$=P,%L&X M6*+U9#!)AM7ZX-*'T938RG$)TFAF`N8TZ,[61$M`SWX[;L,!.L_[&?RSWW[` MYOM/98ZI@A^%+/SUNU!N75H.]_8.H#;]!5`]K"ENZ+[RY873%!JTUY\7GS8:!N^F?7LTQN>XS_H]-_[0HT;6ZI,M M5](<>[`MFM'NK57S`$-3T1<,7OJ[$=<52#?:V=VOI\K@`1G)6EB4^,V]`%B+5-N_[SV,"^DVZ'6T".] MGMC!&^?ZK!MQO;<]@8GP;D77BH2O`P;?O)0X;!!>%/QE("S`>Y&BZM++GORB M9(%ZL6\<'RV(C/R,G0PD@V.WQ>VE M'QO2QDU/`7Q7Y/`/8L?[_HT','FZ12#;*0JFK>0>V19XT7&TJQ8!NEB1@TO' MSEYR^[[(4]WLYJF&+Y;NL8]AD>]0HD?8!Y:SS`8V5<3SO0<.$&M8OA>+_VPB M%!-WYI"[(I_7!1)"=TV*;2U8>F3GO(C"[6@PJD(S871I;/ MK1XHZ#^C9T%@&2&Z3+_1PZ'4`R4]K7EZ_HQC2="8[9\B%@FCUJ M0"?U%S;'.62_JR*L!)V1=VI1)#6JQ4_>9%331U._*18?9IIZQC/'ZUU#8@C1 MP+4EWP+18!+*7_58*I^Z]6'T-%+?M[W$%XET+;Y&=<<^(NW?Y`*EY(.GI;DWG M<[&JN'',JF^%7QA`KZ"+8/57K"9_S:PU7"\FL9].A,;G!7_H&R%^J/I"8J(@!F`71EO<+;]:QJX4(D&!;E@1=&8G2R&O:M) M)!E-VOD"!]Z):?2Y-T((]RRF<1!K217BC=>Z0,,_H9B?E1VTL^Y'F!J`218* M&&5%Q.J7?KI7*#Y0'V`9.RF:O;NX7'6THT[-QU56G'_6:\9?1"01V6+U@_MO MII]-A220T7%4IC.&0E)[K]!Y)O!LL('=U>!(!SH`[8VEM=4O@/9Z5(+J><'' M"19N@5UL4]OJK)A=Z0P*9TX]@MTH'A*]5]0^GQV>3QWO<1]F*M-PVF',@-B/>,LV$VQI3`#V:W4_$KQ MIN(A61,SE<]KR+QU$:VY`Z(DWFHD>2N>M?5 MO`UGKM\OH`1Z)DH!`F<(`*3-.^D5EI1]-99!VMOJ#[.W()DBVZ8_I2:$*;]E MO]:GTP-QF8N!A;G@83(,@GCUJJO/%XI*!-&<./NK>M"77KOK/B4.IH0"07)E MG$X]68KW.75SFUN>E.=0O_F2H,NBC+08R1D12/5K^:I^.[[X&>.7,3MW":5@ M;=5>!;2G1''4WY?JK;A5_1R0*X^%([K2'XZAXM)G"I_T_!XZKW@!M>;CX!\E M>XFY6[O4_'`<%@H0JQ?#]![0.3T4Z'Y3]E_SY(RI$E2H<#%+4=R]0&HE(!Z] MB/:Z%Z0[43`!QG+]48'_R954P^XEU]_U^*S^^0VW(.P)8W%3WPL4W_G7!RD9)>@G#\%LT+<^(96.Y5&C7@G=)*.0$3;,. MFVBN6S)\Z`$J(N3LE,4@-&0R7='3`^W^87Q^]4_;HV,X@`HF?*8_7B]Z&7#L M)3)6"M2J#R2_UZ!6/FPM*WHPABW_&JK%Y7K"0PM-:-V$S7LS6U/:>E1O]L9N_16;<;&?I9'OKVYM55_&HX) M$@&&$H$]4D'9@O6K\\VR>X:KGXNO_AIB590(^*#[4]G-X99,UR\!18-%<[2EF?V7:>^>`0(G.J#B'K7UL+AW#SG/YZBW`(./"E MG2/Y@/XQ+#RMM][A?/#YX;`Y@WD_?'/PL"EQ3EZ>CX]ES:(C9XJ M/SE+MWE8K':E>5C6)&KRC%Y?_C)P!JS&(#*-UZ=99PO' M@C'>^:T;XFZ-U>H!#BX_P7NI8'\^01Z[55=-*7>4&K69)=EBK15':JZWN-BT M.I>XMRE]\Q*AZF)B(^VAB!\?3T9_W[,NJ(U`$[A3+S?RM:F"YU4G:>0Z/!A: M6=B4/AQ7GV*-B7OSRZX!B.^V@<(`#Z=_+QXJ!U8%B-W]PS??[[P>'6X>#NY^ MRN>;AS\<;.I[Q(B'?$]I$GPQUU49:21.?)];-BJ._J!RSG\ M^1-8!7IM3\;O+W#-3XYO1B]^'%R=&6!(/")"`QDBA^TZDAT=H14BGHX.EZZ7 MSD9_'PUAEYMQ4A)>XNP+YIZ92/33-51CP91SV7OU:K1W=W'\@;+E=`>\^WE\ M3H*'B@X,[^7B0M<+5^+DG$;;$7TENKZ;7!-^J+2+>@F;_1_Y!3K\V925R]1A M1>'^B@'E]@/J>9`Y!FFS=PGU0JWZRXU,:2TA:(O[*`>(]0?RI1*V3:NFT??( M'F.*;K^\'!NA'9"8-LPB'C#!EJ(1WT[&\R?B M-%"I'C"+Y`JBU7Z=2O5SBA3#B@^FEQ!87;'0S0MNI,G=C>K#WGT8W$`0!!'D M>LP]F-)./R+F=2-SNRY3R]&4T%KC]@&4$FJ7C-Y>7K`2BLY3?<8:IZ+MIK`_ M%(/>Z/!ZP._Z1=FL2KEQT]'(9\2F8S$7HJ3G(O%H64Y1V!\'SZ+]8:2"V>*]< M&58@.Z#RK1.#;`;%+$[9TMO)U9G\'2*=&.D@`VO#DVKZN"\#GP*UE?6E]7G` MUK>4B8;K$!Z`P$.9'YXO\L65M&./V-$+#_ZVA(EDJ&YL[BJ/IGZKLABA%I() MA\#1E]]P]`%KGM5I$]-Q:V.ZEOGG^1C1E5)&QQ\6[ZXX^3R<-3*6.5!60(M( MV#TXY(V3QAZZ,5`@]IYUOF>YK+905'7S!:ML8P-!0+\A=TQGM8.5!/UFIC': M+%(K7AMQHT:[TCK4/*PG2U<*[/1^M2GX0`C*^1U:7-#LFA#W6@P8$LMD98'^ M)RE^V]?D)(S/&S@>(=H)SDD_KP%#?,7M!ZA8!BE=3Y*WN;#(ZR=Z)/:GRA_] MY>;F]OG_"@```/__`P!02P,$%``&``@````A`#3WN>KQ`@``,@D``!@```!X M;"]W;W)KE@I&*\Q1)N^2H0/2>XU$%M$\1AF`8MIATR#A-^C0>K M*EJ0>U:L6]))8\))@R7PBYKV8N?6%M?8M9@_K?N;@K4]6"QI0^6K-D5>6TP> M5QWC>-E`WB_1$!<[;WUS8M_2@C/!*NF#76!`3W/.@BP`I]FTI)"!*KO'296C MNVBRB$(4S*:Z0+\IV8BC:T_4;/.9T_(K[0A4&_JD.K!D[$E)'TOU%P0')]$/ MN@/?N5>2"J\;^8-MOA"ZJB6T.X&,5&*3\O6>B`(J"C9^G"BG@C4``-]>2]74 M@(K@%_V[H:6LTLBY`-5EL@KUD*R]H\115LK8Q)O309`OQV/ M_7B<1$GZ;Y?`$.D$[['$LREG&P]F#3Q3]%C-P6@"SBJS`=3G?&:0DHJY4T$Z M%-0"VO$\2P;3X!DJ6&PE\U-);"L69Q2CO20`O#TC9'[,>)E-B2$'Y!W8AGM; MC3\WDJ&NKLIG'/8@AO: M<)>KHL0.5.I`&:P!:>.LZ.]XG)3E=B&2IVBS(W$-#5*SD^YRQH++WL/GA([>)%3,R/9XHVS M*!EE[DIU)&$\&A^V.0L.CJ=W%$^K';R#L5D26XW%Y_;5U9P#-*>>.11ZO"+? M,%_13G@-J6`'"_T1K"UNSCQS(UFO-_\EDW!6ZZYU^<:-E]>Z[/W4K9=)9JM MCU:A[Y5-(?95<]SZ__S]<,=]K^OS9I^?15-N_1]EYW_9_?K+YBK:I^Y4EKT' M$9INZY_Z_K(.@JXXE77>K<2E;.#*0;1UWL/7]AATE[;,]\--]3G`81@%=5XU MOHJP;F^)(0Z'JBCO1?%^!?W>J+MU;M+JX)5R=MT_/E[M"U!<( M\5B=J_['$-3WZF+][=B(-G\\0]ZOB.;%6^SARRQ\716MZ,2A7T&X0!&=YYP$ M20"1=IM]!1E(V;VV/&S]KVB=8>8'N\T@T+]5>>V,SUYW$M??VFK_1]64H#;4 M25;@48@G"?VVES_!S<'L[H>A`G^VWKX\Y,_G_B]Q_;VLCJ<>RLT@(YG8>O_C MONP*4!3"K!2-0IR!`/SUZDJV!BB2OP[_K]6^/VU]$JU8'!($<.^Q[/J'2H;T MO>*YZT7]GP(A26H,@G40`NSU=;S"G"$6_3Q*H!@-"=[G?;[;M.+J0=?`FMTE MESV(UA!99D9`G_-CV(%^JB!T4%?FDQD_6`M#E-L7EN"M#Z&FA1-G M806)E&(Q3DB<.-PR"\(XB0`T1K'(T27D)-@F1\(QK%)%0>*!'(NBA-K7,_-Z MS!/CND4+&OIVS238H87L95,%4;1`#(PGU2UR\1)R$NR0(PXY!5'D.`T)GYIH8)^9@)B% M+&)C!(N8'&&&/WR^]R38(>9T4:H@NIPDBD-W`S@`RCY0+%E"3((=8E.^JIP* MHLO)>1)QZGA:9D%BQ%A,IBB6:@@L]';9!K3M6<19.]48P[3,7^S%'4__O&9( M^;#I6X;C*&TT1HD3TSA.ICVFVLE"8!Y%1EUM MC^:F3Z?-I"MKNCJEG$-7CT:@Q3,A&G&%O(1:,!*5>'G3PM/O6WKK/"F.9K_&(MCAWG'QX50FCUSUUXN,V> M4-1I]%1CZ'!"BYR=G'UTU6;GC`;)+OXYN?F(<#TLQ0HSVMS4Y*K/W.L3?9O@ MHO&`Y^.!NOZK,8H83V*2,#0C9\X''E-"J*&O37#1@,#S`6&<9U1S:8PB>,<1 M25`2.EED-@B.3910])&&TK!O'K%8V3LH,/:_>XY--49K2&C"F.LC%@2')(%) M\1$_9TS<9B3R&=<9%\SU8XW1#UCO'^)LS/NG./4B0#TG7_)C^3UOCU73>>?R M`"*%*[EE6O4:0'WIQ65X'GX4/3R^#Q]/\+JFA(?+<`7@@Q#]VQ?YHF%\`;3[ M'P``__\#`%!+`P04``8`"````"$`-1R"K>$#``#I#```&0```'AL+W=O1?%5D+>/L*!R0<]'H.//27;J@M%WG!2209;=: M>MS8#V25D,!VM^NN0#\+>N7*>XN?V?6OMLB_%C6%:L,\R1DX,/8DJ5]R"<%@ M=S3ZL9N!?UHKI\?T4HI_V?5O6IS.`J8[A$0RV"I_C2G/H*(@X_BA5,I8"0;@ MU:H*V1I0D?2E^W\MV$'DA',O($"W#I2+QT)*VE9VX8)5_R&)W*10Q+^) M!.#^]KGO^(N0A-%OJ,QN*O"]=Y70F?GA?#'!BXNYNC+%J4BWZY9=+>@]<,Z; M5'8R68'RO3Z8IJ_8KPH&E9(B#U)E8\.B@5IPF.7G+2&>OW:?86JR&VGW!DEG M[.\,.0]2-T8`7GO=N3?7!R5O<18]QX6-F/*=&LMX*1QA0H5:"3DC=)@Y(6"KIJ>BA)AAY6"AJ%1H@=;).N%FR^-J=LA1_%F`C$"\ZY%0B+_C"9* ME"&:67GX*WOB^X649-WLPHN,24:.8M8$8@26G=F98S1)HM`UHTO=Z+3E)0?I MAL?+"SF*81.($<#J^B3PY)^>.E'&:*X)K!RUOM-L=Z,,WV14Z1M+<3Y"XA&2 MJ(AN51XNDUN!X%$$FV&_<1(5T1W*HV*Z0SQ8M+V5F"?J MCB!K,+0?(?$(27ID2+\(AY[07*5J:+MB>YI67(K8Q=Y:_1AP?9H?Z-]\.79:>`[LH+[#>!N M_P%<-)OT1+^E[:FHN572(TAZSAPV^!:OJO@@6--=U`Y,P!6S>WN&GQ04;DB> M`^0C8^+^(+^@_Y&R_1\``/__`P!02P,$%``&``@````A`*-]B_F\!0``.A<` M`!D```!X;"]W;W)K&ULG%C9;NLX#'T?8/[!\'MC MR;N#IA?-O@TP&,SR[#I*8C2.`]O=_OY25N*:E-.;3A^:A#PZIG@H2M;]C_?L M8+R*HDSSX\#D/68:XICDF_2X&YC__#V]"TVCK.+C)C[D1S$P/T1I_GCX_;?[ MM[QX+O="5`8P',N!N:^J4]^RRF0OLKCLY2=Q!,\V+[*X@I_%SBI/A8@W]:#L M8-F,^586IT=3,?2+6SCR[39-Q#A/7C)QK!1)(0YQ!?&7^_147MBRY!:Z+"Z> M7TYW29Z=@.(I/:351TUJ&EG27^R.>1$_'6#>[]R-DPMW_4.CS]*DR,M\6_6` MSE*!ZG..K,@"IH?[30HSD&DW"K$=F(^\O^;U`G\6QD9LXY=#]5?^-A?I;E^!W![, M2$ZLO_D8BS*!C`)-S_8D4Y(?(`#X;V2I+`W(2/Q>?[ZEFVH_,!V_YP7,X0`W MGD1935-):1K)2UGEV7\*5,^H(;'/)`Y$?_;;/3OTN.=_@\4]L\!GPW)S"!!L M/0_X;`9_>Q[^F21HDWQ['K"TZE#@LPGEYGE$Y\$<9-)&TI8PC+J@-!`E[K$/\S-4A(Z%E(2+DT M'&C#7PLJ1P&NI1]T.CR1H<*XC>@C:AA3PX0:IM0PHX8Y-2RH84D-*VI8MPPH M-]")46Z^SHE$#TS(_&=-,R+=4&'\NG=X/J/-8X3\@>8?([\^?M+V<]F<:+&W M`:[^@!GRN]KX.?)'FG_1]G.N`Y9M@!TR'H2X;%8(X$6V2YKGN@UP/>:R*Y4- M6^$WU)-HK!ZDCZSQH0*U2IH:QM0PH88I-(0B+W"@("63= MAGAV%$%BFV6#!(6C&Q+TMG8N1U%A20A#A5&MZ\[U0WVN(P3QG!#>A3[#5`<= M!.$LT%DF".+P*-18I@C"F:-#9@CBNDPOLSF">'9'+`L$@8:JLRPQQ'72!9X=WG&[)*-)&5Y&FH(-=EI?Y?R$K@ M5+;)+_Q3XM=D)7Y-5N+79$7^6V1%`U@OI$<1XB=ENB;N:[)R.$TC765/=F%' M_GK9UL.PP#X]"PW/H/-)`'JR"V.<9X7NA$'DG_@F)@'W#)W)<8TYF?%<;XL/O:G#2`-<8XS/?A\-WD M&:UBN.WZ7W*K-^WVZX/ODBD/:^Z!>98[8O`62D,=80Q,N4MN];`+C^W80>M` M4??\R0T\4PW3)3=ZUA6Y$>:*W`33*3?"=.9GA6.^(C?BZ99;74FJ:Z9,%#LQ M$H=#:23YB[QN=&`O;:S-5>BC+=^&B7W(^W!5H]N7\NI4VJUF`-Q05WEO77/=Q1"[AJ8CT`;_.\NOR0 M#VANO1]^`@``__\#`%!+`P04``8`"````"$`"\`$Q%0"```U!0``&0```'AL M+W=OU<]N][C!,VVVRE]`6P&<^<.6=@_GA2%3F`L5+7*4VB MF!*HA(.EZ9@MC'`L_:0JE@OCD=,<5G3P#`S]W#H/)<"UEKL M%=0ND!BHN,/Z;2D;>V%3XAXZQ6E!(E9D]%K0W?5NC[ ME`RXN'"WBQMZ)8715N2;1@6\[,9"G=)G,5@/*%O.V M/[\D'.W5,[&E/GXV,OLJ:\!FXYC\`+9:[SST*?-;>)C=G-ZT`_AF2`8YWU?N MNSY^`5F4#J<]1$/>URQ[68,5V%"DB7I#SR1TA07@E2CIDX$-X:?V?I29*U/: M'T7#<=Q/$$ZV8-U&>DI*Q-XZK7X'4'*F"B2],PG>SR3)*!KTAN/)'2PL5-0: M7'/'%W.CCP1#@YJVX3Z"R0R9WW>$5CQVZ<$IQ5!CL1:G<%@D\70T9P?LG3B# M5@&$UU=0AV"HVDFCW/W2'NRE?7-]+:NP<2W3>U^F_S\R'HS3N2X^GHX[XB`= M0&W>WA@:O%7R*1G\,R67GOI#*44WK^V*IY._%`,(K]>@:0<*583XANDJ,`5\ M@JJR1.B]CV:"\^IVNZ]FV6N#W[W`U#:\@&=N"EE;4D&.1^-HC#9,R'U8.-VT MV=EJAWEM'TO\/0%.)HX0G&OM+@O_974_O,4?````__\#`%!+`P04``8`"``` M`"$`7W_,?8\#```A"P``&0```'AL+W=O<^(G/CBMEP6'"'3:G99M5^XM7F0X!'ZQ1L2P^E^BF.7QC?[164 M.X*(=&"+XOF.R1PR"C8>B;13+DH`@+].Q?76@(S0I^[_D1=JOW*#V(MF*,`@ M=S9,JGNN+5TG/T@EJK]&A'LK8T)ZDP#H^^?$(_,(1_'_77Q#U`5X1Q5=+UMQ M=P)JRH7H/X@4XGR(S'$.LKX4*,6J36^VRD%D:W(3@I="^`;("'T,>3EM)]8M%BSZ#)HN-3<`.\!CDS6O:!X@;=(($77 MDV@QE'JT`D.,_;6(&C;,% MV5A``O1J0?79-6H,;W]S6CPAFTT63HVFSQH)2!"?L8TE."8D'$NLHB;OH=/B M*1VVTY(:C:&[(9?Q+,W;?!C.F.O3UZEM0@S?XP2Q5\%^ZCX*Y`63XF>]HNLF M5KJP[JQ75[-3G^%,,]:K!AR;-NL?7V#1W7;$HH^<`-+U]@[#ID?;+0U/&GG: MJTP98Y3`ESG)8F9)PB"9ST82.VFZ%8]`_P-H&O<$,+"SDL*4HO>B:;IG:&>] MWTPDYL"N6+MC&2M+Z>3BH*<-`OM@N#M,0K=$'R:3^ZF>D/1]?W@``TI#=^P[ M;7>\ED[)MF")O!GTU=:,..9"B:8;$S9"P6C2_=S#*,K@:$4>B+="J-.%7F`8 M;M?_````__\#`%!+`P04``8`"````"$`T.*(;B$&```O&P``&0```'AL+W=O M#_ADGO4]*C!&!]I M5UJM]O),"4E00XB`7LZWWS%VP)[)-NE+V_SR]^#_V(.G\/#]HSPZ;WG=%-5I M[08CWW7R4U9MB]-^[?[]%_^V<)VF34_;]%B=\K7[,V_<[X^__O+P7M4OS2'/ M6PVC;\\KSFNR0EVDSJL[Y";[95769MO"QWGO-N<[3;3>H/'JA[\^\ M,BU.KHJPJN^)4>UV19:S*GLM\U.K@M3Y,6UA_LVA.#>7:&5V3[@RK5]>S]^R MJCQ#B.?B6+0_NZ"N4V:K'_M35:?/1_#]$4S2[!*[^T#"ET565TVU:T<0SE,3 MI9Z7WM*#2(\/VP(6>@B-I M;+7]R?(F@XQ"F)&:1E8=80+PTRD+N34@(^E']_N]V+:'M3N>C:9S?QR`W'G. MFY87,J3K9*]-6Y7_*E$@)]4'"760"?Q^.PL4TF,Z^$`6NUTUE-D29CB;A M=+[XRESF.@K\'N;RY2A0'MU`S^8/'AOL#LR+=I<$=F* MZ**0ZR?C,@QB!>!G?Z&YO["C\&N:F:U)+IK+E80!/$A-GQ_8/F9^KF_=2QJD M6*;A$G6C@#G=T)Y(=$4QMR6,2F8HM3&5S`-T)4XU2)%0!:SBU)Z-N"H:TFLE M;_R5Y$DQ5+BQM'!UE(N-$DWZ#$<8,`QB##@&"0;"`)8?N(?.U"NOJM M"G[07MTHT:PKF=EL-EGZ0RJ[$HA,Q7@YF4\72WM%F*D(EJ$?+M%58J48LL8Q M2#`0!K!2`#?"^U,@Q20%:/H;)9KKNX;O^[:]2'T_3)Y9`\(I&1'C$1R#!`-A M`,LNW.]-N_+V.(9S\//;@!R$;8?(UD:)!EL1!@R#&`..08*!,(#E"TX@T]?G M?J3X9F4JD>$'`X9!C`''(,%`&,#R`T?/_7ZDF*Q/8&^[C1(9?A10^S2\KO&X4=AZB8VZC52>9C@PU&K3&-JW$`8T<2$<$(20H1);&.R03",W;ERJJVP3\MPC&HR M4*K!3D0((R3NB9F\$+50O%==FK>$$&$2V[3L&)#I"9PI-U95]1G(-&JX-H'1 MC:B6@!!&2-R3P?1BBDJ<]Z+!,[Z8,#6V9]DB(,^WS\9`-1;(,VIZ-EIE+K31 MD.C_#3")R2A.2$*(,(EM4#8%AL$;BZE:",C?IR5J-!IZ,3%A\E]DN'\/YF-" M."$)(<(DMC'9%=QO3/40:,7P<1D8G88VA@DCFI@03DBBB3YXQ_2D$N88VZAL M%^XWJIH+VR@Y-P.E4M,9+\BQ&&G!L'R,D)@03DA"B#")[5.V#8;/.^^YJMFP M_8;D4#%:$KVPF+``DY@03DA"B#");5#V"8;!&Z6HNHI;I6CT'MH8)BS`)":$ M$Y(0(DQB&0M1G_.YL4Y-^AM)R0A1)C$M@T6S(TK*_-V M8Q#*462=T7_U&ZT:IAH1P@B)">&$)(0(D]@&9<-P=V6&JKVX49E:91I3XP;" MB"8FA!.2$"),8AM#[YU%^/#9.5KW*=P\A/'CJ:?]>Y"F4CQ@1WP0K>"(-W.N_@-<5YW2?_Y[6 M^^+4.,=\!R']T1PF4:L7'NI#6YV[9^W/50LO*KH_#_!B*H>'W/X(Q+NJ:B\? MY`7Z5UV/_P$``/__`P!02P,$%``&``@````A`!&ISQ6J&@``T+H``!D```!X M;"]W;W)K&ULG-U;4QM)MH;A^QVQ_X.#^VTC0&`[ M;$\(ZGP^G^YH&[>)MHT#Z.F9?[^SJ)*4N5X9$#<&/[6J5%)^9*66)/CPK__\ M^/[JWU>W=]+%X?'KRZ^OGYYLOUSS\_'M25\W]O#U[=W5_^_'+Y_>;G MU<>#_U[='?SKT__^SX=_;F[_NOMV=77_2AWAY]W'@V_W][_>OWES]_G;U8_+ MN];NU^W5Y9>'G7Y\?W-T>'CZYL?E]<^#Z0CO M;Y]SC)NO7Z\_7UDWG__^;'[_4(?ZX_GY]_]^'@QZ\^O'YO?_GSYO;RS^^J_O]G\7)Y>?UL1_^ M@\/_N/Y\>W-W\_7^M3K9_?O7GW1AWITXC`_[J]NKKQ\/5HOW MJ_.SY<&;3Q\>'J'F^NJ?.^W[5W??;OYQ;Z^_1-<_K]3#K09J'((_;F[^&DO] M+R.IG=]@;^=A"++;5U^NOE[^_?V^N/G'N[K^\]N]&N^ENDOC/7O_Y;_6U=UG M]9"JP[P^>CB-SS??U0FH?U_]N!ZSH1Z2R_\\?/WG^LO]MX\'QZ>OEV>'QPM5 M_NJ/J[M[YWH\Y,&KSW_?W=_\:*>BQ7A2FX,[G&4 MD_DHZNOF*,\^!76R#_=#?=WLO/?].)T/]V.A8C2-JAJ9[6'VOB<+-:#3<8R1/3E:GKW=)Q^+]=".WZS/1P5R MWX2,P9[.QQCF_<]G/=`+]S>/UV MN3PY?:NN5$_\$+R9KA\/ER/K\O[RTX?;FW]>J8N\&O.[7Y?CDF'Q?CST^D(T M738VEZ;?79G4U60\RFH\S,<#M;^ZZ-RIZ^F_/RT.C]Y]>/-O=0W\/!>=L^CL M\-2LN5C7C->I\L.#L4 MF;58Q6;%V>+0K'%8*`BN[EBJ+B(V>%\*M+B(L&28$MP M)+@2/`F^A$!".,'IM/AZ]_;LW?9'Z&$E%1D%:GDO%R>Q/&0B(9602<@E%!)* M"96$6D(CH9702>@E#!)6*X@^MD:\;V=]CNZ]L7"Q8$>L'1V\/% MF;ADA4;!\MW1B;B"1GK!R?+PY%`\R/%4L/V9322D$C()N81"0BFADE!+:"2T M$CH)O81!PFH%F5/V\``8P59/;5\0['$O!%NL??QR.E8_N?J:BK282+`DV!(<":X$3X(O(9`02H@DQ!(2":F$3$(NH9!02J@D MU!(:":V$3D(O89"P6D'.-3%BHMI`>\1DK,9L(J;X\ZE(BXD$2X(MP9'@2O`D M^!("":&$2$(L(9E@NN2/%UQQR4_E#IF$7$(AH9102:@E-!):"9V$7L(@8;6" MZ$-II$8UP8W4/&_-/NZ%](AGQN=3D98>"98$6X(CP97@2?`E!!)""9&$>(+% M\N1AA7CX6C9,$[E'*B&3D$LH))02*@FUA$9"*Z&3T$L8)*Q6$'TLC?B,+YZ] M(#\/NR%`8@EZ/E=I"8)8$!OB0%R(!_$A`22$1)!XEFV8Q#/$!+NDD`R20PI( M":D@-:2!M)`.TD,&B&I#CW'Y>+`=4=6'ULB,UMC%UE\D>7S=LYB:WJ*/(/IG MYW/5]@0N(!;$AC@0%^)!?$@PRW19.CK&92DT"L;MXKH5&05'?*H8XT832`K) M(#FD@)20"E)#&D@+Z2`]9("HP$VIV(ZW"IQ&9N#&MJD>N.=="Q=3M]4,WE(, MT_E> M&2FS(#;$@;@0#^)#@HV,[X@1%^+PL8W18QOCS<;UFQT22`K)(#FD@)20"E)# M&D@+Z2`]9("HD,D152'3R`S9V-O40_;,A=34$A5A$Z\JG(_O0C2B=0&Q(#;$ M@;@0#^)#@EFF:69\*0B!FT[XMP61<83%6QXBQJTFD!2207)(`2DA%:2&-)`6 MTD%ZR`!1R9,#KI*GD9F\L3GZ@N1-/54S>4OQ//U\?">K2)X4"S4VQ(&X$`_B M0P)("(D@,22!I)`,DD,*2`FI(#6D@;20#M)#!HC*DAPPE26-S"R-350]2T\L MX:>>ZU-+>-F9O1C?SFRDRH+8$`?B0CR(#PD@(22"Q)`$DD(R2`XI("6D@M20 M!M)".D@/&2`J0W+`5(8T,C,T=E+WR-#4>#7G(2[A97OV8GPKN\B0%!LU#L2% M>!`?$D!"2`2)(0DDA62S_'Y1GV.?`E)"*D@-:2`MI(/TD`&B,B6'2V5*(R-3 MXPQL7$`MB0QR("_$@/B38R*XE_&,;H\,D#4NT*U3OOT^8%SG;[\Y;P1SN;\'() M/U?I8=-ZLM,'$%!C0QR("_$@/B2899I4EEQ_AT\51$\5Q+C1!))",D@.*2`E MI(+4D`;20CI(#QD@*GAR=-6[CS4R@Z/"D6 M:FR(`W$A'L2'!)`0$D%B2`))(1DDAQ20$E)!:D@#:2$=I(<,$)4E.6`J2QJ9 M61H[J\]??1U-C=@G5O!SE9ZA:;^M6*BQ(0[$A7@0'Q)`0D@$B2$))(5DD!Q2 M0$I(!:DA#:2%=)`>,D!4AN2`J0QI9&9H[*3ND:&I\:H2J;^0(]]7=:2U9Q\N M=Q<0"V)#'(@+\2`^)("$D`@20Q)("LD@^2S3Y7='G[[`+B6D@M20!M)".D@/ M&2`J4G)$5:0T,B,U]DWWB-349A61P@)>:\;.D9)BC9_--9XFVA`'XD(\B`\) M-K)S`;\^D1T;H\?VC#<;MPOX];'6DJ(F@^20`E)"*D@-:2`MI(/TD`&B0B;O MJ@J91F;(QA:I'K)GKJ.FSJH(&Q;P6O]U#IL4:_P`MPB;%`,D!4EN00JBQI9&9I;*OJ67J\`W\T=6&?6K]K MO=IY[I)BS4?:KNAMB`-Q(1[$AP20$!)!8D@"22$9)(<4D!)206I(`VDA':2' M#!"5(3E@*D,:F1D:VZA[9&CJNIKS$#KP1UIO=LZ0%`LU-L2!N!`/XD,"2`B) M(#$D@:20#))#BEGF+CTOMR5VJ2`UI(&TD`[20P:(BI0.-N/- MQNT"?GVLM:2HR2`YI("4D`I20QI("^D@/62`J)#)NZI"II$9LK%#JH?LF0OX MJ;$JPH9UE-9^G<,FQ3J68D,VQAO-JZCE4!22`;) M(06DA%20&M)`6D@'Z2$#1(5-CI\*FT9FV,86Z@O"-G5>S;`MY>\4.M;ZLW/8 MI%BHL2$.Q(5X$!\20$)(!(DA"22%9)`<4D!*2`6I(0VDA720'C)`5);D@*DL M:61F:6REZEEZ8M$^=5Z?6K1K_=DY0U*L8RDVQ(&X$`_B0P)("(D@,22!I)`, MDD,*2`FI(#6D@;20#M)#!HC*D!P>E2&-S`R-O=,],C2U6LUYB"U2K2$[9TB* M=2S%AC@0%^)!?$BPD9T7O?6)[-@8/;9GO-FXO>BMC[66%#49)(<4D!)206I( M`VDA':2'#!`5,GE75<@T,D)V(OOPSUMA/>PF.U4GQ(<$D!`206)(`DDA&22' M%)`24D%J2`-I(1VDAPP0E24Y8*OSF7:U3,QHJ>N><;%\YCPV[B;GL:7\)6PG M4Y4>+2D6:FR(`W$A'L2'!)`0$D%B2`))(1DDAQ20$E)!:D@#:2$=I(<,$!4M M.6`J6AJ961K;J,]?>)U,7=,D!4AN2`J0QI9&9H[)OND:&IS:H2^5C'_41K MQDZ+=X@%L2$.Q(5X$!\20$)(!(DA"22%9)`<4D!*2#7+_#(YWU938Y<&TD(Z M2`\9("I2L@` M4<&38ZF"IY$9O+%CJ@?O\6;6R=1@-0.WE+^7=*[:7OTN(!;$AC@0%^)!?$@` M"2$1)(8DD!2207)(`2DA%:2>95XN\Z>BP2XMI(/TD`&B(J4UUA^F$!4IC,D!4M.3XJ6AI9$9K[*>^(%I3&]:,UJGX",OY MB=:LG:,EQ4*-#7$@+L2#^)``$D(B2`Q)("DD@^20`E)"*D@-:2`MI(/TD`&B MLB0'3&5)(S-+8]M4S](35[ZIR_K4,T&M%SMG2(IU(L6&.!`7XD%\2``)(1$D MAB20%))![^NAXT6:NTJ,EV[(6:FR(`W$A'L2'!+-LUQWF MITI#8SN?YD7&]O&3\>;^,6XQ@:20#))#"D@)J2`UI(&TD`[20P:(2ITMFF_K5BHL2$.Q(5X$!\20$)(!(DA"22% M9)`<4D!*2`6I9]E.6V;F&^S10CI(#QD@*E%R^%2B-#(3-79/]>75^"QP;$,\ M<8FX5-?:JM/3O:44"V)#'(@+\2`^)("$D`@20Q)("LD@ M.:2`E)`*4D,:2#O+[ZZ"'?;H(0-$)4H.GTJ41F:B]FN=+W>USO$>OKEJNT*Z M@%@0&^)`7(@'\2'!1G:]K>JQC=%C&^/-QLW;JB`I)(/DD`)20BI(#6D@+:2# M])`!HD*F=N8R:NJ@FM/7J?QU,4NMSSI/7U(LU-@0 M!^)"/(@/"2`A)(+$D`220C)(#BD@):2"U)`&TD(Z2`\9("I+PZK''`%&)DH.E$J61 MD:C3_7KH#^6R]81EU%RE+:,@%L2&.!`7XD%\2+"17^OFJOTL,G6 MJX4:&^)`7(@'\2$!)(1$D!B20%)(!LDA!:2$5)`:TD!:2`?I(0-$94D.V.I< M)S-+ZFJVQR7P="S_>/#$,FJNTC,T[;<5"S4VQ(&X$`_B0P)("(D@,22!I)`, MDD,*2`FI(#6D@;20#M)#!HC*D!PPE2&-S`R-K<[G+Z-.QW)<].2G9.:J;6(N M(!;$AC@0%^)!?$@`"2$1)(8DD!2207)(`2DA%:2&-)`6TD'Z6;:O=8H7*P?L MHB(UC?MV1%6D-#(C-78^]4@][VUWIU/#5`55;Y;C$J>U5:<5^KS?]M0LB`UQ M("[$@_B08);YP1S_JJ#Y*EAH%"SX5[\CHV#'+U6/<:,))(5DD!Q20$I(!:DA M#:2%=)`>,D!4\.1XJ^!I9`9O;)"^('A37]4,WJG\W0JG6O=U#IX4"S4VQ(&X M$`_B0P)("(D@,22!I)`,DD,*2`FI(#6D@;20#M)#!HC*DAPPE26-S"SMUU,_ MG=JF:DK4)R_Y:O%L@`41G2^N,/TX#*D$9FAL;^YPOFHZEM:LY'>`?5J=9Q(<$&]G96%B?VHZ-T6-[QIN-V\;"^EAK25&307)(`2DA%:2&-)`6 MTD%ZR`!189-W585-(S-L8Z-4ANWIM[F<3OU5,VRG6-!K7=@Y;%*L^4C;R_0HW>^Q:41D[\V&/ M-SNOEU`))(5DD!Q20$I(!:DA#:2%=)`>,D!4Y.2XJLAI9$9.K8N,"^'S6EEG MXVYR,CN5O_!EKM(C-^VW%0LU-L2!N!`/XD,"2`B)(#$D@:20#))#"D@)J2`U MI(&TD`[20P:(RI(<,)4EC,D!4AJ:!W@ZARI!&9H;&UN<> M&9HZI2J1>E=*/KD[T_JIT\(<8D%LB`-Q(1[$AP20$!)!8D@"22$9)(<4D!)2 M06I(`VDA':2'#!"5H6D(MZL%^3*$RI0VRF:FQA:HGJEG7N.FSJG(EGRYYDSK MK\[9DF*AQH8X$!?B07Q(,,OIP;AL.N9'+4.C8/R@GW@])V*!J(AQJPDDA620 M'%)`2D@%J2$-I(5TD!XR0%02Y?"JY&DT)>_-W;>KJWOK\O[RTXW5U\_'JP6[U='!VJU*OQ\\=Y?[/!@\3[:Y?'B M?;7+&W7\U<.&-YM;N/OTX=?EGU?QY>V?US_O7GV_^JK.[?#U>&]NK_\/CVV]7EEZO;L4`5?[VYN5__1]V#-__?[]CC\/%-H%#5+5)^LW,-Q=_-MY\^U375_6KENE)YHGE<,NM(#_'%B9)S5\+(]N=2EILA=&^=GU/2]R\R0K M;/2P+J?X8(=#EM)GEK[GM*C124G/20W\JU-VJ6[>\G2*NSPIW]XO#RG++^#B M-3MG]7?AU+;R=/WU6+`R>3U#WI\D3-*;;_%!J\Y[JSJQZV]EMO^6%12J#7WB M'7AE[(U#O^[Y5V#L:M8OH@-_EM:>'I+W<_T7N_Y.L^.IAG8O(".>V'K__9E6 M*504W#C^@GM*V1D(P&\KS_AH0$623_'WFNWKT]8.(F<1>P$!N/5*J_HEXRYM M*WVO:I;_AR"14>/$ET[@KW1"(B?T%_%R@A<7&8D$GY,ZV6U*=K5@:B!F=4GX M#)(U>+YEACR:7(=2A1RYDT?N96O#N$,6%?3G8T>\:+EQ/Z"HJ00](0A^MZ`& MX0*=AA/PZ'(R5_D6FH-Y:%YUSN4)O^B&\Z':LLP@AB?O=YD8:BT!A@:!(C'T01A'\ M-(A>(?AVH*RU:'3@N)%&(6P"X,`A2"G$H@'U6*SFL.!&&HLV362!H"Z+53A` M@D#>/UX+8:71B)L\D89$=7G`6+1JU*L&X:KTPTT15AH1508DJDMDN""*Z/&E M.CZ?!,6N+T?+=AW*@B"JRV,YM$S(+%445FH]ENIRE:@NCSN-`9C:F`D%X58: MD5829$$0I>LEW]35H.-[@K`:DV@),L0TZ..$1$T"N52EB2!J);0I=H86XRQM M)"9Q7*K*)%%D$0H.GN.UB/Y"-*CCA#*8Y''9YBG[?=-'?LCK;LC$((83^HU" M=W]+%JYA#6N'`-\@?>.)"BMML-5^2Q3VFX3.0*U]@^A-H,"M-`KJ)B!\PVE2 M-MQW%E[O17Y]:)=CKQG^+`D45AHK=4^0*$,W9NF=SZW&5KP$&6+.DC;?*&W: M!"`*)\#WG8%MCS]WJ$(W80+PU*=L-]H$(.HV`;#DAQH^2_E\H_*U>>*2ERA# M\0UB-[[D?12[^TM>@@PQ9VF;;]0VK>&(DL?/=NOO+RV#SDUH-^K<6+L1=6LW M<<)5_S6XX'G9U2$<;X6PTA:\>O:2*+T7@4'[)@1%[;O??^':)/G!+&435FJB MJ[;#..@2-;+%![-D3EAI#-1CG43A!,)=!,A]?*&0W1[XNE7W"!V M$XB83G:Q*O,!HKI$!I]N`H,`3N!A$L!8W=J%;[[J>@5I]X-^00Q".(&(20AC M37(0U24R6)#0('WC@BRLU/6H/>Y)5)?'X.,>W)K.D&!AI?%0=4&BNCP,CWMX MZ8IWDCDMC_07>CY75LK>^84J@:>&YMOFLO?1%Z?JYA]PUWI)CO2/I#QF166= MZ0%,/2>&]5GB;2U^J-E%W'B^LAIN6<7;$]RJ4[@V]!P`'QBK;Q_XHT)S3[_[ M'P``__\#`%!+`P04``8`"````"$`/90>>4H#``"Q"0``&0```'AL+W=ONP M.A<%K_>I^^OG_7#L;G)1=6`Q9:77#^WIJY3Y8LO^UI( MNBTA[R^W,?G%;+@D,&6'9'LEWJWI%% M1@+77RW;`OWF[*2LWXXZB-,GR8NOO&90;>@3=F`KQ`-*OQ08@IO]J[OOVPY\ MET[!=O18ZA_B])GQ_4%#NR/("!-;%,\94SE4%&R\,$*G7)0``)].Q7%K0$7H M4_M]XH4^I.XD]J(DF!"0.UNF]#U'2]?)CTJ+ZH\1D<[*F(2=R13HN_70"V<1 MB>+_N_B&J$TPHYJNEE*<'-@U\$S54-R#9`'.Y\P,1Y_KOU*%'-'D#EU2%[8[ M9*&@/X\K$LPG2_\1BIIWHO4+HJ%BUAL,0EZW[8J:Z.9]@EMQH', M"@Q0H,-OKQN*4Q?R[,L$3;WD:%B,*&Y[/B%1$(Q@-[8@G$^O!-E`D,#ZQ6'` M#B?%9L>=.H&3_'KO\:9A.2&':%1/([+J.0YD5F#`%`^97F=!,=83CT<8D#&% M64Y,)>,@24:"C1%<,#,K,*!*WD.%8HLJ'M7&+'=4"9F$HPVP,0*+R@H,J'`8 M6F^:UVN%8HMJ=/C69KFCFI$@'&%OC,"BL@(#JOE[J%!L4S"[[ MN#TJ&[-L,5F!`1.,LG>4JE4CE7U.1\]>=R)S3@DA\R@8;Z].8O'9$0-H)J09 M(!63>[9A9:F<7!QQ^N'6[J/]9+X+\44UBJ]Q8F/<[Q=@8#9TS[Y1N>>U6\;YPWWM";=WD5+WW5P5Y"R M[DY[]Z\_7Q9/KD-9WI5Y0SJ\=S\P=;\/3-VV7H> M+F27'`'5RK2MSF#O_W)HY<>Y^5P4]MX@>^OO3:O.UNS?O7ZV51D/8"%L>ZJ=G'8.HZ;;']>NI( MGQ\;F/<[BO)">@]_[NS;NN@))15;@ITG0._GO/$V'C@==F4-,^!I=WI<[=UG MM,U0['J'W9"@OVM\H]IOAY[)[:>^+G^I.PS9ACJQ_/@';G#!<`F5D2,A MK_S6KQ#R81`Z"/@@]%\YS'/`1_'4,/IO.>3+4+;?>J?$57YMV._D]C.N3V<& M(ZT@#3P;V_(CP[2`,L!8RV#%70O2@`5\.FW-UQ.D,7\7='7)SGLW7"]7L1\B MD#M'3-E+S2U=I[A21MI_A`B-5L(D&$W@^S9>7R^C8!4_/>(2CB[P+5V"9?"T M0JOU`RS1Z`+?RN5[$_%$4H9\9SG+#[N>W!Q8[3!M>LGYWD%;,)3)%:E0Z?Z_ M;$.:NS!^61< M;)(]F>,F0A$-:Q`%*/1#FTPJ%)D6,,C6CY!QL4FVL1=$3$"8Z0.`7&VNP-ODZ MW,11%$_+P`3D'5O+(']I"6'C?-YM^#NC#6JWFU&C@XJ[X@$KB%`0QALKMYE^ MEPG*^[<&^AU`T>WU4@=VTT'RB<#[3.`C:[>GZOI49GG'79EY#Y\/)SJ^`6<- MGL#1@6=8WRC!7:N1F@E0BXCLB6.!>$UM<7_"*6X:ZA3DRE_S$91"1=6Y93Q0 MJ`MP`KCD)_QKWI_JCCH-KN!6?QE#.7MQAA!_&+D,+\%'PN#=?_AYA@,BAA=0 M?PGBBA`F__`,JB/GX3\```#__P,`4$L#!!0`!@`(````(0#_1".>#0,``,4) M```9````>&PO=V]R:W-H965T&YF9VZY977] M7.3.D]!&JC)BOCMACBACEPZ'25,;B3L6[0I262+3(N87Z328K/N^HB5D4%%!N9 M2_M2DS*GB)``8W>T2"-VXR]O_9!YZU4=T%\I]J;UVS&9VG_5,ODN2P%IPS[A#FR4>D3H M0X*W8+$W6'U?[\!/[20BY;O<_E+[;T)N,PO;/0-':&R9O-P)$T.B0.,&,V2* M50X%P*=32&P-2(0_U]][F=@L8M.Y.UM,IC[`G8TP]EXB)7/BG;&J^$<@_T!% M),&!!+X/)/[<#8/9XG($BT<5U0;ON.7KE59[![H&-$W%L0?])3"CLRGD0W4T M7E^S"AZ1Y`99(@;M#LL-[,_3>A%.5MX39!H?,+>$@<\&XS<(#ZII2H(RVB6= M#_FHC&!4QM"QE%NZT98)SLM,/R*#X(@!=U/\(CR53\J$J=NPXR?L"ATC?ML7 M+H*M:`D&P:PQ0H*$&0I"3XT/$,%]9Z?$2(@P(-=R/VV*Z9B=?T0;P7WML.$E M;<(,32ZZ0N-2Q47OI4J8H2`>YJTGY>WM0W#?63]5PG12G9X>FDZJ5Q_11G!? MN]\ZA!F:].'9;[L<%VN]ZKU<#Z`SFG@RC$[6IW.D^RCVHSV`.MF&KW2LCR?& M>'DZ7[KR\U[/UI01.V.U=^B,C)=.EKBN^B#PW3JQV."E]F!+-W6:*WP3U'&[^@"%:\:WXP?56EL;)10I+ M)^X"#B1-8Y@NK*KJ4;91%L9G_3.#UR4!`V'B`CA5RAXO<-`W+V#K_P```/__ M`P!02P,$%``&``@````A`-1R[(WF!P``V"4``!D```!X;"]W;W)K&ULI)K;)^P+(-AE22J0&?S[6UAVL"3D(- M8`H[DYFWWY9E&ZF;S<#L30@?OQJINW5HX?O/W_>[P;?B5&W+P\.0C;3AH#BL MR\WV\/(P_.M/]]-L.*CJU6&SVI6'XF'XHZB&GQ]__^W^O3Q]K5Z+HAZ`A4/U M,'RMZ^/=>%RM7XO]JAJ5Q^(`GSR7I_VJAK>GEW%U/!6K3=-HOQOKFC8=[U?; MPU!8N#M=8Z-\?MZN"[MU@W-^9N5IWMILWQ/Q^NSZ55?E-\XZ.]M\5Y)_P^JU_+= M.VTW\?90@+$Q:NTT$\M-@4SROWG;U'^6[7VQ?7FL( M]P1&Q`=VM_EA%]4:/`IF1OJ$6UJ7.^@`_!WLMSPUP".K[\WK^W93OSX,C>EH M8FD&`_G@J:AJ=\M-#@?KMZHN]_\($6M-"2-Z:P1>6R-,O]F(T1J!U[,1?39A MD^D-73%;*_#:6[EZ'##BQAE3J?'-X[!:(_#:]V!T\SA@?C9=@=?>RM7CF+>- M&82M;WWS0%@75O;_0L*ZF/!_NNY,1J8^L6:W9!E/:Y&K\$]G!_IX99(RB*IH M+H479L65&386$Z>9A_:J7CW>G\KW`2QNX./JN.)+);OCW]'-0#%?^CGY7U,2 MYB*W\H6;>1A"N&&V5;".?'NTM,G]^!O,_76K65S23%7-LM/PJ!CX&`08A!TX=Y^I'8LZ1=>Q&(,$@U0`^"OYQ%+-9ETC63-3-7FGX0LI1*T/ M'22/$KK+BV87(:[F$>H&L!!`[IZN?O&2*BQMKFILJC%5A4,5%M-4C4LU.O*4 M1R460T'R+VG0H()+&D/M3D@UR$IT08$Z'%/)%+DFH1*+(4W::B9&,ZM,IDU0 M"+)+5M#AA"\,Y+"$-YMA": M:9,>GV;,F+,YGJ5+H3G'P,;`P(KDHE^H2^!(F&,42NA*H&9/S/G:->)5`V;07"LU4=@4S8F%T)P[N<3`QL#! MP,7`P\#'(,`@%$`D+#,A+)J!MMM(ENCZ?&9,9S@LLH1-#-UD>(8G/Y>D0G+V M289!+@$E3OSV1JXY/EY?N5J-C\70B!9"<^[+$@,;`P<#%P,/`Q^#`(,0@PB# M&(,$@Q2##(-<`HI?H7"^P:]!CX&`08A!A$ M&,08)!BD&&08Y!)0W,K@F':#7QLY3EBT>BY:D>1:0FQ"'$)<0CQ"?$("0D)" M(D)B0A)"TI:T*Q2;P`Z%MLN,-,IEHGJ>E[[R2G'=UL\OCO"2H:-N+%J1'`'1 M[$QLHG$(<0GQ"/$)"0@)"8D(B0E)"$E[PB]AT(3.^@^[6X!<)JKO><-^C06?] MAV??2VY0?<^K2.Q[$\[''^^4_*:3Y#U*@44KDGTOU:SMI1LF#FGE$N(1XA,2 M$!(2$A$2$Y(0DO;DHN_Q@/)>CF_5^#4O\?W/*_6F&5KU=72OM&A%LN^E&K3U M/28.:>42XA'B$Q(0$A(2$1(3DA"2MD3<0:"S64;DN4S4O.&GU"P$0%9D:`%Q#\5\74``PL8G&(<0EQ"/$)R0@)"0D(B0F)"$D;8EP M]YSQ$P_R=T8:Y3)1(\"+IE^(@*BUU`B@TG#!I(*L66R6A-B$.(2XA'B$^(0$ MA(2$1(3$A"2$I"T1$>#7&30`>.2Y;$4-`*^NY`#\9,\5Q9CJ>'S/Q*2*K74\ M)C;1.(2XA'B$^(0$A(2$1(3$A"2$I"T1Z_YEQ^-QYK(5U?&\_I(=?^5A7Y1M M:@#0'K1@4FW7!@`3FV@<0EQ"/$)\0@)"0D(B0F)"$D+2GO!#SV1DH,->UG]^ M/G-*XU;<#X]YJ.[_..\;.3[OX"JW%4GG'4)L0AQ"7$(\0GQ"`D)"0B)"8D(2 M0E)",D+X8S-BNY-^NS'.&X/PO7@P1OP@OR].+\6RV.VJP;I\XP^]F'!/W]/^ M@9PO.O\I#?$%NX-?M2D/V1W\,$UY!@_V-'S<&X+G:HZKER)9G5ZVAVJP*YZA M"]K(@E/223R9(][4Y;%Y;."IK.&)FN;?5WB"JH!?Z[41B)_+LN[>P!>/^V>R M'O\%``#__P,`4$L#!!0`!@`(````(0"^"%S6AQ,``/AI```9````>&PO=V]R M:W-H965TA8]PMP M<+"[YSF=N+N-2>)&[)Z>^?;+4K&D(O\:Q\Z>66`S\RN2*K%(%2G+\H>___'\ M=/7[]O6PV[]\O`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`YYWBBA7I+RLF-TDT6RS?6HZ0 MPL]&@XE#7NGE6=X)AT"B?W&J7B2=<&SHPL?\"ZO&LS-G["(H/#N$;FT&]`F5 MWA_O/WUXW?^ZHJL43?SPX]Y<\\*U,>=2R4Y]2*Z_RBU**F/ELS'S\9H6C=+F M0!>$WS_%L]F'V]\IB1]8Y@YE0BFQ<1(F8XW95(-,@UR#0H-2@TJ#6H-&@U:# MS@.WY,G!G;28_Q_N-&:,.YTC[AP8_1LIWSD)IY)JD&F0:U!H4&I0:5!KT&C0 M:M!Y0/B.HD_X;OIJ[B+.2'^\IO\_$7%69K8:_+@!D@+)@.1`"B`ED`I(#:0! MT@+I?"(<1MO`!0XSTF:C.^DQ*S3OM]\^!3=`4B`9D!Q(`:0$4@&I@31`6B"= M3X3':/^[P&-&NO>8RZD[2^:4_5[4S54F#D).+062`DQ2_R``I("R8#D0`H@)9`*2`VD`=("Z7PBW$/UC7"/V3[C MI:DZN8X[>PLX2%6M+%6N#T!!K0#(@.9`"2`FD`E(#:8"T0#J?"&>:LE]X\W2P M]>+29XQ6ML,T]>H&48HH0Y0C*A"5B"I$-:(&48NH$T@ZR]2[YV>FZ8M4@#%2 M$;92$39*#2&&*$.4(RH0E8@J1#6B!E&+J!-(^L_4O!?XSY;(5*LY-]R9-I%< MZE_;$*6(,D0YH@)1B:A"5"-J$+6(.H&DLTS!ZSOKW=;^ MIKP`Y(@*1"6B"E&-J$'4(NH$DOXS5?,%_K-%MO"?7W=SL`%*24-Y)D.4(RH0 ME8@J1#6B!E&+J!-(.LL4Q;ZS^AMQ=$.9JO_ONX??[O94[-&V.I&P,=UOZYWS M.;25-1W%1=(=H_EX+VG#B'H4)Y4R6HK&=JYN,66CE%/,$16(2D05HAI1@ZAE M9&;*'-UFIO02L7CG:B4T8*VFT$QFJD2,G.*,I358N1.:C1?G&6^ M=(K2O+K573FIT7Q]EOG&*4KSZ@Y3ZZ1Z\V*E(MW5O.X7F:Z=XTGSCI*1YE>ZM,"\737=F?<+82UN_\?YC M_^.O-E[O.A=AQ\;(:Q@VB%)$&:(<48&H1%0AJA$UB%I$G4#2B:9=\O>'TYM" M9+LK?U-@)"OEA;JL;D8IEXXIH@Q1CJA`5"*J$-6(&D0MHDX@Z3_305W@/]MP M"?]!#[:)`*6(,D0YH@)1B:A"5"-J$+6(.H&DLTPCY#OK75N<,:*V.(O\2ID2 MW$AYA57*Z(U*>91R@9HC*A"5B"I&](=L24^8QN<_]H0QHCQAD?"$1782?;.1 M1A8MPK\J>%G`T\F=3N!TU#Y0H$X).FIKJH2.=)#IA\!!Y]2MD=%47K%(;<.J M--NPHMB&K>***EIO@U6U4^:.&(PU8\Y,::KBJ9C0+* MYSG;TXB+DT6R>%RJ6FL362G:JEW.I(S"P,:8TLBYR+;VP@7622#:PDUGI42P<6V`BI`QNA:JAS)(B?F1Y=C4A52THF- MJN5@3JJJLJMBL8GX(O1.Y_6:,C,9J?C2Q0-+^?'E;(E6=*E2.G.*7IB=I5B@ M8GF68N44,>CBR1[CG"M:KZG\9GL-%73JPK1A19K3D)?.5B`=IRY,V2`VJN8# MDZKJRE0,8J-J.3"ANE)7A8K%['Q%QL:F2/4LB^;B&K'2U[1XD!K#"U"&4CFB M`E&)J$)4(VH0M8@Z@:3_+JOI8ZSI&7F1M4&4(LH0Y8@*1"6B"E&-J$'4(NH$ MDL[2-?T;F8G5>\S5NPPVM0UN1JDQV`9%AS*4RA$5B$I$%:(:48.H1=0))/UG M:O$+KFRV=/<+D-@B$6R`4I3*$.6("D0EH@I1C:A!U"+J!)+.TEW!&\&&K4!L MD;JRJ<)I,TJYR$H198AR1`6B$E&%J$;4(&H1=0))_^G>X`W_84,06R2"#5"* M4AFB'%&!J$14(:H1-8A:1)U`TEFF>O8ST]RM>-\3@C$7XMZG>XQ4(*HR?#-* MC8%H;9&B0QE*Y8@*1"6B"E&-J$'4(NH$$KY-=!-Q.A![<5FB,/(#$5&**$.4 M(RH0E8@J1#6B!E&+J!-(.DMW#F\X"S^'2"Q2P:;;K%'*15:**$.4(RH0E8@J M1#6B!E&+J!-(^N^RYB&QG8*_Q3(2P6:E/)2B5(8H1U0@*A%5B&I$#:(642>0 M=):IX/VKWAO!9@M^X2SN`2C%Q]L:*]6:;Y)!:@PV0!E*Y8@*1"6B"E&-J$'4 M(NH$DOZ[K'E(L'E@Y$76!E&**$.4(RH0E8@J1#6B!E&+J!-(.NNRYB'!YH$1 M.[(9*N8.464X*D;JCFPQ M2KE8+AT:)U$YY-M*`M54UZ.4L]4X--IJ&8D32@)5JG8L%0;]DWW"\[/+6HM> M7+86C'S/,_(]STA-5#DP0\7<(=];<:1NKA:CE/-6Z=#HK-ZB9&R`V90GE#M$LEY\ MJ[N*Q2CE/%,Z-'JF8N1]&[E&U*!BRTBY5%4G'4M-NO2RUF6&K0LCX5(KY7DK M92G?I2"4L]#*=VD20."RXOAA<.D4?9=:*>%20`TJMC#3CLFD^TQ'X3 M8`U.HW73&"?;#9H35UG=YGB>/;W5S;#C862:JB%7DT#752SE?YKI%)?VH90D MFH1JMD M/E?+G:%:SLA\V7$X'CP56[`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`&;;<.>;N10[@;F5<7 MX9I=N!OU1M3R&;OTP;9?Q.%NQ(I>$J2,U&ZDFMO,'5'L,[A\=A)O)!3;XLJ. MEB]9^?^HR"EQSA4C/[T0-:C8,O+32TC)]#*=[+NN;>836G5/A)%*+U4M;UA* MI)>U1?(L*T9TG\9UGS6B!A5;A_R=AX\_L?.8-A\RX]+%L?<*1))8))(DT1]!;.96 M2B2)14O[7:1D%<:)_M9KAFHYH[>2A&?EDD3?EBG1C94#_4Q5( M@\;;P3A-;(Q%_8%!)S1EV885 M1:JQK<#>#8J2F,H/U8)DJ)BNMK'7>J*B/FOEME/ZHI,3C5&<=IV8IWK;" MU2H(EZH6:M!XRTAM6Y$*BTYHRL4U33(L[L7?@I[;7ELLJ$54D;J+RX:E/)0B MRA#EB`I$):(*48VH0=0BZ@223IRZG_"N]_/1-R^A@+/(5/9>^JH`W["B<.V@ MZ!8@0ZD<48&H1%0AJA$UB%I$G4#2M:8)]>/S='-O/BK3!;!%GFW;Q''FI&-=HG5BTJ%GVB=T8CI3V@8G1A(Z4WK\>&J$?@Z" M'JR=&HEHI'\&7<\@B6FDKTCU2$PZ]+6U"6LQZ5!;/S5"OJ8J?&J$?$VUX]0( M^9J^1#(U0GZCKT=,C(1T''JAW-0('8=>E38U0L>Q.Z8^TXC.E%ZZ,:$3T9G2 MZR2F1F@&].Z$B1%:TLD5I06=7,^0UI.JW`E+(:TGO>MR:H1F3"]VG!JA&=-[ M"7&$VH^UZ3=PA'Y%Y/.T+3(U(7]GW#7%35A,\,_)^C-=&/#`=R8SISBMX>02 MT@I.!@K%R528T(-'9&AJ2O01XMI\9HASHL]$:&3*&MWMI9&I):0;5>3:*5=1 M0TXCDS.@N9F'K*9F$-!QIOQ%C[;0R.1Q9A&-3"T*/61`(U,SH.>YUN;1`IP! MO7QC;=Z0@2-WI',WJ;.ADJQM;1Y:FQB9!6OS4-742$@C M4SZ@)UYH9,H']-`&C4S-@)Z/6Y>3(_2JOK5Y+1[.(`V7:_.2.1RAE\JMS7OC M<(3>$T?6ID;2*%B;UW*A#KV&BU9A:H1>JK4VK\PBG=OA6D:_N_/C_MNVNW_] MMGLY7#UMO]+V&O2OCGNUO]QC_^/([UGZLC_2+^Y0/4*_14*_L+2EURK3+\=< M7WW=[X_N/\P!AM]L^O1O`0```/__`P!02P,$%``&``@````A`#/@*5$`%0`` MI6T``!D```!X;"]W;W)K&ULK)U=<]LXLH;O3]7Y M#R[?CRV*U&9! M=Q-\`9#=($V_^]N?ST]7?VQ>]]O=R_OKZ&9R?;5Y>=@];E^^O+_^OW\6ORVO MK_:'^Y?'^Z?=R^;]]5^;_?7?/OSO_[S[L7O]??]ULSE<4827_?OKKX?#M_7M M[?[AZ^;Y?G^S^[9YH9;/N]?G^P/]Y^N7V_VWU\W]X^CT_'0[G4SFM\_WVY=K M'6']>DZ,W>?/VX=-MGOX_KQY.>@@KYNG^P/U?_]U^VUOHST_G!/N^?[U]^_? M?GO8/7^C$)^V3]O#7V/0ZZOGAW7]Y67W>O_IB<[[SRBY?["QQ_^`\,_;A]?= M?O?Y<$/A;G5'\9Q7MZM;BO3AW>.6SD#)?O6Z^?S^^F.T'A;Q]>V'=Z-`_[_= M_-A[_[[:?]W]*%^WC]WV94-JTSBI$?BTV_VN3.M'AP8FCSXTC M_;2.\7F>"^-)/XUGM#C/DY;=V%GZ:8_IR7VBLROC2#\O/&1$=,>/*^QG"XQ6EHKR M485Y?TVC3&MG3U>%/S[0E'QW^P>MY`=CR.`3)I@J%/V$Z+1@RIH+ILF<;F'> M57`I)MW1Z#CI@.1`"B`ED`I(#:0!T@+I@/1`!I\P#2EIOT!#92\`OTTSD[I8AV9MVIDI@D77I)M4$KE]]D!LUI;;@+9CSA M$S='Q^(LQQ(=J[,<:^;(E5%)M:^,KIEO%I2S'+YN'WZ_V]&9T'P*W#IBJHU- MQ:Q3EU3M9-#94VUH9V-FT,J?9_%2 MW)AS8Q5-G&<1\DQBL;M1!CRKL*X0V@T MSM+C)DTLTV&UETJ.4[WAJ3=A3"PN.2AG'/6FJW(L3"PU,;RE+>Y)I3VBPJUTVEP[^FFTZDV8S3B,^X1*RWE#Q@QIE8D]6X(1;=Q,O\-['< M@G3: MBDTY$XMN[VHO<7*SG,BJ601MJ*7>],++K#CQ)*P4PSN]"=="G-0?RI6ED6 M/DK-^L7GFN)[IU)DIH]'*#7D:`H1#0QQ_50I MX*_V7Y^MNJCP+P13C<1LE8F-LW*S]>AH48Y6!:(2486H1M0@:A%UB'I$`T-< M;97[^VJ?OK9.E;FX`&C$9BN@S#AZ5CFB`E&)J$)4(VH0M8@Z1#VB@2&NGZQ7 MWM`/JY2I1E3)>9EO(E+FU%AY-5IF$5U`7,JD6(0*Z,I9>)W_1(= M*XO8$6GHBBCKLS)6D4I-CKV8SL7JKSTS-TUU M_P/;,E-59D@QX]6%&X!C%'';U?4+$U8C)JQ&[,R3F3BEW(3W'`M[1%82@Q@E M>E8&+9-Q8L^FLV44BX54.QLGH=]Y-A^I6RCA62M]].2R&<2V&9*96'BIL:*9 M8/N7V5AL*W4F%SHZ%O:("[W0)\O%9"YNF26Z508MU0[G'Q_H+:_I0KK5SL9V MLV&1N(PTK6$FGK6L8^4I9-0H]@IJ8\4T,XY<,[FLT;$P**8\\K@28[G_6-I^ M^>%Q65LKE0,?@\%,KCTS)Z;NOSXE+J8J!_[C91WKHL(O4`QBPFHK)JQQ],\\ MF8F<,3>Q/,?"'E'M(_]K,^.S+5A^/#&[Q3V2.X9*TXNIJD-#Q_T;$Z.M)-_'A,3$N/ M9CI^3+\.,9G"%&;Q^1Q6]8?4VMS"1KG_N?M&D_.M`B`V!9`[\SN#_.?WB#)$ M.:("48FH0E0C:A"UB#I$/:*!(:ZK*G]\74\74+&IEGS]-.*O,LU%VI<:1[*R M:RU#E",J$)6(*D0UH@91BZA#U",:&.*2JHK@`DEU`>&MX[M8(S8E`65HE2,J M$)6(*D0UH@91BZA#U",:&.+ZJ7+`UV_<_9A0+G'A(XM8UQ5,68WX)O!H1#0QQ2579N"QA#9)H1$62[5IJD+>#DQD4T2-):Y8S,]Y!F=E[ M#Y'>Z"`F^8E&8C]%[IT:*Z^&SPR*5/IV+`^3N:S^F2<_#9E-GW\:F%C3[HRZ M,/$MX+G8R4J-%9/>Q*(+FSN+A=C+S9DC/XM@3GO.*YH))K$&\<&0^T&IL6*# M86+QP5C`I-=FVI.=QDQFBV#^&#(G=[46/F#86/QP1`59\X<^5G( MG.WT][LF'/YRTF68<[*7NXR1#FB`E&)J$)4(VH0M8@Z1#VB@2$NJN-='&/E MO0:1&<1?')&OU.3H6%A$EQ=W3Y&OU)3.RBZ"RB+WV**VB,5:B!M;XZQLK-8B M%ZNSB,5:BAR_=U8VUF#1&(L/C\JS+IC>F,_--/)?]3&(C86V8F.1+$3%G*-C M81$[YX7(;TIG9<^YLLCI5UO$8LEWL1MG96.U%KE8G44\ENA7[ZQLK,&BP%C( MQ/6-JS=FJS.-V%AHQ,9"(S$68AKE)I;G6%C$SGDA,L;26=ESKBQR^M46L5CR M5PL:9V5CM1:Y6)U%+)9D2# MC1505%8S;RB*)0R=K,JIF:(:>>><&2M?43`JC)$G7XFH,LB+7EO$%%V*J=8X M*Z6@1#396 M0%%5C?EIL;>=]Z&>5ID!GEO<.=H5=A@DX5W/3#']%B% MKK4]`!-[(7+`QEDYL75\K[-=H!M]@`V&:5=^29!%XBCWA7O-_XN@WUW[1(DKD*Q>E9V1UK3!6[9F- M?8@3^D0EK`=SUO12OHW58JQ.Q)K.Z(SD7F_O&=E8`XO%!TV6CFK0SODJP!R+ M2(/XCJ/\Y?[46/D[C@:I)VMN@)>BO,[M$?U7,_V7Q\9WX`MK-;XH9E_2@I=2 M2\_,JE09YO6L/II1EN>ZMA([TXUG9J.UEIWL;F>MU+OO/S]`[YG9`PR6_>P` M?)Q5N2BOA>837Z?3R[DN--GU3R.^0R[??4^-(UN0)M:$KC_'LX7!R=&SL+V@ MP3GA67IF5J<*H]4&414_/IA:36:3">11NJ]D8R.U&*D[(U+O;&RD@47B`Z4J M-#E0T:5745WFL3'3B"].>&5WKJV\)9`9%)U^L3E'S\)ZJE\<&WIK-7I$^JMV6G%!F.F MM>9S0-64_AQX8X7J$I2-MD;>+X6F]*Q6)8P>RA#EB`I$):(*48VH0=0BZA#U MB`:&N'ZJ@KQ`/UUP,OTT4O6/-VM$\9JJS3>2E*SLPLX0Y8@*1"6B"E&-J$'4 M(NH0]8@&AIBDZGM%%T@ZFO-ZSR!/K!11ABA'5"`J$56(:D0-HA91AZA'-##$ M]5,%X_E3D?HS"NX> M:=.]!5K(AY[6!EKFR[6Z,89:5M0R[CG*:(L)]6"\AT&+^CL2XU,`V9*0#[VV M&SA.0C[TCFFHA+Y6O\81\(D7U#+.D]^Y`/:4TOA0=:J"'((]*3OK,5\(CH M/.G#3J$6"D;?)@JT3"F:WIR2?9Y2-)UQBA;ZDR$?@YJIPP>/08%"G"0.C>3' M9/V1UE*@LVJ$0WQ&XQOB-%+!@:)Q"@X3C5)HD&BG8*VV`;!'5/6O54F/+52N MKU4MCBU4H%*T4+^HV*1HH18J'BE:N"6BEI#LM"E*+2'A:0>/6D(*TYL#)%FH MA7:ZJ-VU-+:!3H(3*U!!6=+:@E-#_H<1VUA&8(/7:BEM`"Z^83TB"T7&D[EQ0- MG2F]5[)6F[AX/O1ZR5J]/!)JH9D8/%-Z]$XMH3.EY\74$CI3>LA)+:$SI8=U MU!(Z4WKH1",7.E-Z>$(MH3E*C[K7ZMDVG@\]GZ664`_H.2.UA'I`S\M(T5`/ MZ+D/M01[0#.Q#,Y$^NW_M?KM?NQ;%4?4$HI&OZ%-+:%Y3;\)2RVAD;NC,;T+ MCG9*+6FPA=YB6JLG!-@W>IF)U`D=AUZMH9;06J`7/:@E-$/H:T-K]2TA/`Y] M;8=:0M'H0S/4$HI&GR!:JZ_)A*(MR2'U^I;NMA"7Q9>JX_E8LL=G<]=\'SH4U%K]3T?]*$O1JVS M8`M])6J=!UOH,U!K]44?BG9[O!?3'\GZ=O]ET]^_?MF^[*^>-I\IHYR,WS1Y MU7]F2__'P?PZ[J?=@?X\%B6=]#>#Z,^A;>B#KQ/UY@_T,=X/@'UC[\ M6P````#__P,`4$L#!!0`!@`(````(0#;8B%#.10``%!H```9````>&PO=V]R M:W-H965TSW[['[N77_;?M]O6,%)[W[\^_O;Y^7UU>[N^_;9_N]A>[[]MG M*OFR>WFZ>Z7_?/EZN?_^LKW[/#D]/5[&B\75Y=/=P_.Y5EB]'*.Q^_+EX7Z; M[>Y_>]H^OVJ1E^WCW2O5?__MX?N>U9[NCY%[NGOY];?OO]SOGKZ3Q*>'QX?7 M/R?1\[.G^U7]]7GWGU^>6'=U.`_OVP_;%W_OUL_VWWHWQY M^-P]/&\IVM1/J@<^[7:_*M/ZLT+D?`G>Q=0#__-R]GG[Y>ZWQ]?_W?VHM@]? MO[U2=Z?4(M6PU><_L^W^GB)*,A=QJI3N=X]4`?KGV=.#&AH4D;L_IK\_'CZ_ M?GM_'B<74;*X(NNS3]O]:_&@%,_/[G_;O^Z>_D_;1$9):\1&@_X:C>7517J] M6$9*Y(#CTCC27^.87L0W:91.5S_@F!A'^LM7O+A)T^3JYOKP%:ET:B[]94>G MJD>V]\J(T%\C$B\NDCB]OGFKP=?&D_[RY>.+ZVAQNWRCWG2[3O6FO\8QNCG* M\=8XTE];UV.N&-%0U"-#C4G=[4.K6.>ZRE_I&FN[+[.[U[L.[E]V/,YKLJ,W[[W=JZHQ62H[O2#V< MYWOT9[7]._4VWWY[FE=\_)+?)N\O?:2ZX-S9KM(FDQ88MU(VO M9#,?Y#XH?%#ZH/)![8/&!ZT/.A_T/AA\,#K@DF(]!YQ&RO]'P)6,"CB':LW` M]D#L19Z#P@>E#RH?U#YH?-#ZH/-![X/!!Z,#1'3I7A+1#3]8>-0J MZ_?G],\#HU;;I+=SI#=`,B`YD`)(":0"4@-I@+1`.B`]D`'(Z!(15)IN3@BJ MLJ;9A!XW!Z*JC:ZFU<)TJV^`9$!R(`60$D@%I`;2`&F!=$!Z(`.0T24BJC39 MGA!593U%E>_>M297-,\X<4Z]>WXV8K<,2`ZD`%("J8#40!H@+9`.2`]D`#*Z M1$25AMT)4576,JJ:N`,32`8D!U(`*8%40&H@#9`62`>D!S(`&5TB0DC+O1-" MJ*QE"#6A$+H#\\H;F+/1/#"!Y$`*("60"D@-I`'2`NF`]$`&(*-+1%15"NLN MM`X_F92UC*HF[L`$D@')@11`2B`5D!I(`Z0%T@'I@0Q`1I>($%)6($*HUZH7 M*ADY'$WE**.IR95=/VTT,5GGM/C4Y%9.L-=R'.>S$8_C`D@)I`)2`VF`M$`Z M(#V0`-12/0+27M.@WJ8`2D=&>=-^? MN^$VR(VW03\["X<8;UXZ9C;.YYC*9%\.E8V?E MTH67^U6.&9>H MY./XJ5SM#?@]9=(7MZ+QFY6NG"6RU6 MUHJU:D96JV$DM;QZM=:*M3I&5JMG9&L_(!H938ZR+U32YVLI1MYMM3<'(MKED)+6\!5)EK3A^-2.KU3"26MY#JK56K-4Q MLEH](UO[`='(*-`7*M4YH2]T9D2)(E=J'6DD^D(CT1<&R3;#C8,W(#/[>1KSBR52#P*JUR`^\L4D]80^GD3/2'1J(_-!+]8:QD M#)?^,V.VXA85:K]&=:2-86E0M)A>"$V+NRK`:G1M`F9M@'7HVAM$JT"NVX!H M%([RB:`RL)]TP!M+*IV[D31?>1UI=$WS^OP(3B-OJMD8JZ6-7690:E&.J$#' M$JTJ1#4Z-FC5(NK0L4>K`=$H'&7`5;X&`3\U:=!)GXB]1BJ[3$JXC_;8R5,_8RUEJ*>]._*W+'C">@`M7*V,N,"YT8)WX]$?I#\?IC\9,Z\MQH38M8%RDT[;ZE+$<.4GKO0\Q,C1R MWUG$@#)$.:("48FH0E0C:A"UB#I$/:(!T2B0#+5*X7\2ZL.Y2:P\O4>@1NZF MNK'2N\OZ"QJ#WGB+8:WX[BP0E8@J1#6B!E&+J$/4(QH0C0;I9LN`J]0=`GYB M;J*6X7[L-1*QUTC$7B/OA8:7P>1&WDEX"T0EH@I1C:A!U"+J$/6(!D2C0?2' M1HZ,O=I1<&/_Q@C7&Q!B_M#(W?*(-7*V*3*#WGJAX9C9,6ZNZ;[0<.R<^1I> M:#AF+%?/S+Z!:&9&$Y^=_GVYUC%CN6YF5JZ?F2N'+S0<,Y8;#=.ADSVE=CE. MZ"EE[LU%&HF>TDCTE$'NDSRY]?/R>+;BJA>,[**I9.1JX0L-:\5:-2.KU3"2 M6EZ]6FO%6ATCJ]4SLNN<`='(*+!*4_L9)_2%WOX0=XU&HB\T$GUAD&RSMUF= MQ[,5M[E@9-M<,I):7B)062O6JAE9K8:1U/)6T:VU8JV.D=7J&;E]`0T:V2K0 M%RHM/Z$O=!8O^D(CT1<:B;XP2+;9VV7,U1Z"VJ&UK2D8V3:7C*26%[_*6G'\ M:D96JV$DM."%AK5BK8Z1U>H9V=H/B$9&V!<\,@T1_:"O1'QJ)-52Z\'9I<]:RC2P,,N8`O7+X_0K-CO\OJ'&"S3L>;@! M+9L=OD"'%^@-\EYH>$T?K!4/ZU%HR5$0S-5/'068ME.NH0:&=P?Z+S2,E;@# MM>/A-PZY<;RE1?0\5-+(BT2!\B4[4DHT.\(8JXS56R\T4+\Y2K\]3K]#_?XH M_8&M#H9G%/)R5*B4_L#<<-Q>&;U\@,E!(V]R\%]H&$LS&. MXM8T6F^\T.!+TE^>@`I4*V>S@^\;*C9[XX4&7J!A3[7H^_F]WK(GS3NS51I[ M*6+'5G:MT!^G/[#G0?V1K0(K4[51\+>'@=YM<).VI4;>K>@MVS?&2MR*QI$2 MM3E@,(7FQC%2*SYKYK_]*E"_Y(H=U*^.TZ]1OSE*OYWUQ0L-'!7TH')\&!:-^O!_ZD0!A_GY]J7W<0&'1%3U2G!_TDR5KQ@S1#E",J$)6( M*D0UH@91BZA#U",:$(T"R2C[.P)O1%GG_"+*&E&4.7Z;!%"&*$=4("H158AJ M1`VB%E&'J$5G)KK5BK$UHRS"J'/6%^T"FO M&+D&49CY>IM$,Q%3C41,X\0^"*:7X[EQ)"O6*E"KM%9N'+S4K+)6K%6C5F.M MK!;4J[56K-4)+1E3E0"Z,?U+&[2)22/MC+!F1-,]5V-CF`BU]J3UF#KV(U[X MG]#FQH<,6*9`F=):V<9(8S_1,)YNOLEB:F$V>V*F829)E='/MW0(% MJI?'J5?&3.PT)5>>?FVLU)+!UM2W:HZ[9&O,3(.6=';7PEG<3?=T9VQTN&0_ MJHP$^O'DO"#1B8V8E#02CU-`F7%TK')$!:(2486H1M0@:A%UB'I$`Z)1(!EJ ME2BYH7[C<:KS*A%2@]YZG&HS,1]I)*;^P.-TMN(9H$A`JS1(?3HQC]XT]I[I M%3K684=O&FK0L0T[>@_=3CC*R*LDZH3(ZYQ+1-X@\8353(19(Q%F>)+EJIAV MV<03%K1*8R7"O(Q@[@?'.N28QMZCN3%63NW;D"/4OA..(LST'NR4,$_F,G=D MY(;9,*>BF4%4$_,H\U*AW!K,`QEE2H-$A-.EMY=7H6,==/0?RPTZMM8QO"SH MA(\,[FE99(I9)",17&TF@JN1\U(]-YX.*@QR'$N#O'!ZS[X*'6N#[(9!@T8M M&'7"2,;*SP7_TNHOQ121D;OZ,\R)1,9FSCOU/,`*="T-4M]"V]B4M-.FF'TMH@=U,/488H1U0@*A%5B&I$#:(648>H1S0@ M&@62H0XEF'&J3H4Y\93(%)-,@^1^W]+;_-A8*W[(98AR1`6B$E&%J$;4(&H1 M=8AZ1`.B42#9`7X">G@UG6*J:9"3>FP098AR1`6B$E&%J$;4(&H1=8AZ1`.B M42`94I6>N=/'&R'5V9R[3*9CDM7*]LKN:FP098AR1`6B$E&%J$;4(&H1=8AZ M1`,B=3JT;;8.J3[M69\J^[1]^;K=;!\?]V?WN]_42>5DY0DE+)]`L$*+FBDFERAQ*Z#C4F4`,J"/*; M%1U-%K"/EROUFY]`R9)<:(\F4)(LJ)73OII?KX2.X*:M?_2A;'&EUCE80NG@ M2JUML(3.\_X8XFNZ2.@::^J6H#TU,=3"C\GJ8SB(U%?AKJ*H!RJZIGX*=1/M M):_4UAPV;4V-7@<;O:&23;`DHY*<80E]+742GT=A27T,=1* M??R$)?2M$UTG5)(MK^@ZP1$?7ZW49\0!-2I1GPYC"?VVA^[/4`E]MTO7"8XJ M*E%?XJ(:?7E+[0F5T*>U5(-0"?WV::6^FPZH48GZ>5.HY)I*0E,M_0J$2D+W M*?TF@4I"]RE](4^U#MVG]/$VE83J5E#=U(?B6+>22JI@K>F71U02JC7]#H9* M0K6F7V502:C6]!L!ZH50K>EK=2H)U2V+DY7Z&236.HMIO-%'%EBRIO:L@VH; M*MD$2^B7=:L\&(.,8I`'8Y!1#-2OAK`&&<5`_88E4$(QR(,QR"@&ZMM^]*$C M3%;J@!(LR6)2H\,0L(0.<*!>")70^0PTJD(E=/P"13140J<8T'5"=:.3"%?J M9".L`9U'2+4.E=!Q@_1$#I7044(K=780JM%902MU.!"6T&%`*W7Z#Y;0:3]4 M@U`)'<>X4D/V"V4)B^FX@1?]?X31__%JSH;YM'NE_Y4+)1+T/Z>@_W//EDYL6:B]AR^[ MW2O_!U7W&PO=V]R:W-H965T7] M-B0DL"#@M!"[/:F5JNK:/F=#@&@)04GV]NZ_[XR='QY/RL*J+\OR>6;RS3>V MQP[+S]_ST^A;6E99<5XYWL/8&:7GI-AEY\/*^>NK_/3HC*HZ/N_B4W%.5\Z/ MM'(^KW_^:?E6E"_5,4WK$40X5ROG6->7A>M6R3'-X^JAN*1G&-D791[7\+4\ MN-6E3..=

  • 3]T\SLZ.CK`H;XE1[/=9DD9%\IJGYUH'*=-37`/_ZIA= MJC9:GMP2+H_+E]?+IZ3(+Q#B.3ME]0\5U!GER>++X5R4\?,)\O[N!7'2QE9? M6/@\2\JB*O;U`X1S-5&>\]R=NQ!IO=QED`'*/BK3_JD$^CM+ MWRKC_U%U+-Y^*;/=;]DY!;6A3EB!YZ)X0=,O.X3`V67>4E7@CW*T2_?QZZG^ MLWC[-DZK6F88TADEKU5=Y/]H(Z\)I8/X31#X;(),I@_A;#SQ M,,@5QTGC")^-H^_?Y!@TCO#9.`8W^0$=E>ZT\[O^0%?+I=2/XCI>+\OB;013 M&@2I+C$N$&\!P5K9=:Y=(?ZK#E``#/*$458.K$60N(+)\VT=3H*E^PT*GC0V M&V[C48MM:X'5Q;"1#0@;D`;@0D9=6E#!_R$MC()IM80V+=#GZ5LYM!:M2V0# MP@:D`9`<8#*9.0ROA+8":+QRX.^5"FB;4*UB)?"6(1%#!$.DB1#&,(MO9XS& M,.M@TEVAK(VF:N_0E!D2,40P1)H(H0P+Z7;*:*PHM]7=:&0*T]!((K3F1&?4 MND4,$0R1)D(H@V*W4T9C2EDCIJ0,B1@B&")-A/";W<,/C2D_C4QA51B23BU) M.Z-.4H8(AD@3(93Q%&'L@M>7&AI3RAHQ)65(Q!#!$&DBA-^<\E.[M!<\S&". MW+E38R1*7B-`WM1[9NG=&75Z,T0P1)H(R<>#I]TNN+*FI!O(E)Q#$8<$AR2! M*$UL+\:\0-TGCW@`N5=V3SY7)`,-6=K/;>T[ MJUY[!@F/09)`-"EL1$92[VBOVQ9A;G8RW1$]!D4<$AR2!*(TL?D8-%%[/_R( M]AC(6KH:HMH'8UO[SJK7GD$";P@0WIACDD`T*>Q81E+O:*_[&]%>0W-]_\`3 MZA:&D8`!11P2')($HC2Q2]U.4_20=?RC&X:V)<$ MK[-JA8XX)#@D"422\N_JJ,J:+LL&,F;RED,1AP2')($H3:NC7E^#/N^:#63M M'A-K]^BM.H$Y)#@D"429W]4U?=XU&\C8J[8JD^([ M6NLV9DYF7T.SB;K1^V//OM@T!I/^>A:U/K!&N^.['UJ=5;2.L`XZJS"PWAC( MUDJ_.2+7>ZN-XA*^+4O>47T-P5D:WUM`EO9=HS&`J=%/IB9,``H9"5CZB,;3 M`[/659)HM'38S#Y4.MT%2>DTU)?./M#C&18:%RF=AN8P=8V<+#5$XPA6?4IF M+)J2U7)5G=09KCYFRG774TFI_5JU5^,W5!4`E^+2XJP3NRY?W6(RM&2V\M69E0T,_@*J`#7EXXA(5WMF`=%LGLYAU^JW/H(A#@D.2 M0)0^=F.#_CLT=>\F-)MV/NNFS!9>E:N#:0]%'!(V>5H> MTFUZ.E6CI'C%]^'@L%YVL'Y9O_'G[=MZ>\1[7.#1".8V&P$?.%\,C/ACB*8V M8=O'QU\%U+[(1GP847L$&P$&4(R!YWC@`_?!H9$)C*A-U([F!3"BUBH;"6%$ M'=79R!1&U(&9C3X2 M^<$"6\S02`@C0[E'_A1&AC*!'WB>AK6'QP\\8X,%'L*A5$.5>@H@_F#J4,&A M)#90/Y6"V]4"?O"YQ(?T][@\9.=J=$KWL`#&ZG!3ZI^,])>ZV7:?BQI^ZE$[ M\!%^VDOAQC;&2^R^*.KV"ZCG=C\6KO\%``#__P,`4$L#!!0`!@`(````(0`" M^6TH=@H``'$Q```9````>&PO=V]R:W-H965T-3LU^WC9O]\,_[S#_'; M;#PZGE;[Q]6VW3'KX=7YKF-*((^^/-^.5T>EU,)L?U M2[-;':_:UV9/(T_M8;MJLF[Q=O^V:_4D'.33;U8FN__BR>3W::+OU)>%VJ\.WM]??UNWNE4(\;+:; MTT\5=#S:K1?U\[X]K!ZVE/>/,%FM;6SU#PB_VZP/[;%].EU1N(F^4,QY/IE/ M*-+M]>.&,I!E'QV:IYOQ7;BHDV`\N;U6!?IKT[P?G;^/CB_M>WG8//YCLV^H MVC1/<@8>VO:;-*T?)2+G"7@+-0/_.HP>FZ?5V_;T[_:]:C;/+R>:[I0RDHDM M'G_FS7%-%:4P5U$J(ZW;+5T`_3G:;61K4$56/]3G^^;Q]$)_BZ_"),C(>O30 M'$]B(R..1^NWXZG=_)$6=7Z32(0QGDC&-L'.G3.$9I]^5G M_!+C1Y_6K[_H,WYT-2I9^K1^%.*,0V8YDE)LQ73WURI$6P??;*)I?3[Y3XZZ-S3W:A-QB:2UD ME\JPN0\*'P@?E#ZH?%`[8$)%Z"I!W?M_J(2,(BMA<[BWP"F-E[:UL"ZY#PH? M"!^4/JA\4#N`I4UKSTU[>-^P\RR-;\;TYYEYUC;IO"O!$D@.I``B@)1`*B"U M2UB>M-`OSU,:TXJ@97\F46V4J?U9]>L22`ZD`"*`E$`J(+5+6**TN5V>J#16 MB=KFN]RG9%URX$40`20$D@%I'8)2Y1FY_)$I3%/5!-W^H#D M0`H@`D@)I`)2NX1E1;<.-RNY(6?QU92J\,D]60;B&6M"&;M3ZV_"G5$WM4`* M(`)(":0"4KN$%4&J4^>N='Y3DL8\44W:H&N3.(*$=4(!*( M2D05HIHAGI_4$!?W9Z@5!]U-[)S<&^3-9>S-96]E'7-$!2*!J$14(:H9XBE+ M_7!YREIML)0U8E,**`\!%8@$HA)1A:AFB.2*C2\51ZL45AR-Y`VMN_HTG79?K)54J*VBL%LSN4$QK^J,.Q;&2J[= M+OQ`<71XBB6+TV>MOKPWW(HQL>UD2KG2[71\HC51B/>-W[7+\E#UH;UC49) MINO`NU9F*5T8AW3>`M^*5Q9%UC''5EALJB#1P?8;\_<)=AE,$2 M,J'=/>KC-I&*Z7^MBU9=K"X:>1T#V["V8AUC8L7N0Q#D6(3@*0Q*DF[;*ID5 M;P>IG_RT4W7+4?WP1_OZ43_0N5K7$%J%L<0U8K=:0'D(J$`D$)6(*D0U0RSO MZ%/J4%ES=6@05T^9W_"]5:>>$!6(!*(2486H9HBG_"G!2+WH:W^#W"E%E",J M$`E$):(*45![8PIV4C+?+S,Y@;-(G5W MCX+0V]^+WL#Z"`Q3]E9*]`1A?PM7]]VJ-[!A:A:&5T1**+\B>F?_QRURJ,96]00OEU>C[- M/-6_C$"_Y08Q91:EGI8NC)41A^$\"(.YKPX%1B\OBEYYT9,HI%_6/.U9L^B\ MD%)$?:F06GVQ0AI$F;J%].JQC+29H_AR@U(I.>A9:3Y#^=R;V,4A,%#96ZDU M%J>Q7XNJ-[&!:A:(ET?JKR^5Q^@[YT`F,HCU61AZ&^K2F-&-T%Y?;M!,/TI& MX3R&!BIZ&^LF,%+96\GZA&DR3;%`^CKIVVRDFD7B!9(*SR_09S=FK1)9*QG$ M6PD>.")MQEI)HUFB6BF)`NHE_GQ9&"\RL0D*#%3V5KJ5`EA656]B`]4L$*L4 M7216ZI(-6SER=6I10DNIW[*F7J)+8^:VDD$SO=*B*([B#`K4&]F\!(8J>RO5 M2UD4)1"JZHULJ)J%XB7R)*S2.Y]L)OE`Y1UJ&\1O;U-_W1DKNCI[I;E!J:N` MTJGW?%[T5M91V&^DE=1-#YP0E;UC;Y5.?5706]GP]:_"\Z)ZNOE+144U'6O$ MGWRGGC):&BO6@<:1UFE?&[AI&L=0IMJ;^3I<8/S27MC9^-5E\6L6GY=5JF-_ MX_OTD[4\^O&[52/W,2("D0"48FH0E0SQ*LA-;'3!>>E=ZP5M'NC,\B9VB6B'%&! M2"`J$56(:H9X?E+T7IZ?4=*.Z(DU\J;4.\I;]E;]E':.%A5H)1"5B"I$-4,\ M92E/+T_9:%XW98W8E`+*8T`%(H&H1%0AJAGB^4EYY^0G[P=?6\!&S[JI:^3- MMO\@&7=6=FIS1`4B@:A$5"&J&>+5D'+1J<8O%K`6EVP!:\1F&U`N?VZC?=ZQ M*A`)1"6B"E'-$,N/W@O]1'[*FDM-@[)I)XN6B')$!2*!J$14(9)OMZKRJ8O0 M^>FW5?5[AKOF\-PLF^WV.%JW;_)-5#H=O[WNL'Y-]CZ>+60G4-/!R)Q&U+F@ M/Y($]MU:?R2BMVZUKO%'XIBBJ:EGC`_BY9W%&SX!??4^4'"T]U'RP[57VPZ%3SP9)3;PVU5A[- M%_*!$Z^('C`7\@D21_(X6!3Z.<2;6'KF6LA'JB&?D'R&2DB/&>0S-))'*5W; M4/9T/D?7-C1"1S7D,U0!.GLAGZ$1.K\@GZ'JT'D$^0R-W$?1XI[.@S'3)8TL M!T=R&I$'[.B31S&-#$6CTW?JL*$1.O:EJQ[J&3K)I6AJ9-)-$+WP_KIZ;OZY M.CQO]L?1MGFB;2A0O[0=]"OS^A\G\XO;0WNB=]W5CV\O]%\;&GH7.9`J^JEM M3_8?E,BD^\\2M_\%``#__P,`4$L#!!0`!@`(````(0!BTXDLJ1$``*QE```9 M````>&PO=V]R:W-H965TSCN]L_O+R=7-Y<7V^?[_OV^WI@D9X/KZ__'HZO=Q>7Q_OOVZ? M-L>K_OAR?7PY;#GQ^OJYF9^_;39/5_&$6X//S+& M_O/GW?VVV=]_>]H^G^(@A^WCYD3;?_RZ>SEVHSW=_\AP3YO#K]]>?KK?/[W0 M$)]VC[O3'^V@EQ=/][?NR_/^L/GT2'G_/IEN[KNQVU]@^*?=_6%_W'\^7=%P MUW%#,>?5]>J:1OKP[F%'&039+P[;S^\O/TYN_;*^O/[PKA7HW[OM]V/V[XOC MU_UW<]@]_&WWO"6U:3^%/?!IO_\UA+J'@*CS-?36[1[XQ^'B8?MY\^WQ],_] M=[O=??EZHMT]HXQ"8KAG M-\K\:K:XJ2?TH:]UK%-'^IDZ5K.K:CF;S.9G>DY33_K9]:RNIM5LL3SWF;1% M;?J;X2?4CGT-'9MPCH1:BV&U4)F$43Z&8=Y? MTG91'1RIQ'_[4-_*`^)RPU&GN&)%ZB*8CB8[_ M5XZ#O)^VVS-=`&B`*B`9B@%@@#HC/"N:.\BF=/AE:DA MC_D^J.O6`%%`-!`#Q`)Q0'Q.6.ZT"T?D'J)Y[I'D.QE(`T0!T4`,$`O$`?$Y M88G2N6=$HB&:)QH))9KO9#F?]4']3@:B@&@@!H@%XH#XG+#<@\/-3WZOSVLA MFN<>2;Z3@31`%!`-Q`"Q0!P0GQ.6Z&I4HB&:)QK)BF;)_DA>R7W?()K:;#R0I1@T@ATH@,(HO((?(,\9R#H\D+ M.[@Z(*Q2L M3J[0ZX?^)#HC)D-$^<&?HC+4(%*(-"*#R")RB#Q#/.=@00>89XSL$RY3G_'V41W1=]5K=W[R:](1OL1'TSEV711W4=FZ%CAQ0BC<@@ MLH@<(L\0ERB8K5RB,V41O1F3(:)57',+ZQWK":`&D4*D$1E$%I%#Y!GB.0>7 ME>?\UC-(=&M,C(C$5+&0-=%'=0703``I1!J10601.42>(:9/-LJ$V*Y'3XE1"I%&9!!9 M1`Z19XCG')Q:ONO#6>)-5Y_A^QVQ$I$0KXJ)^*IA/41U)=`@4H@T(H/((G*( M/$-.Q)Z_Y=7A5R( M*52/,XYM.#>."64EL$;4(%*(-"*#R")RB#Q#/.>2<5S0/0&C5QYJ](T)B=.$ M7*0?6 M,*%\UR-J$"E$&I%!9!$Y1)XAGK.TAJ_O^BGZOX26V0UF":V&^ZZ:A.:TNVF) M(MVW.!&KBPH[Z@[1!P\=*[$*88:HKHQLAX:-*MO?I?B=)Q+ M;,-%@41+R,2*B(F5C",72ZS'J31\UE%WB"3==U/"=H$HHB])= M%%='7,.9(6I0!S[1891GG\BG'^DW,W7.E!!:SVE$"]ICV50AK6>*HJOE+HLF MH>DRWDX]OYE,%V)64-A-=Y]'&O2?5\W$86JZCI,X^)6<]&P7,&R0*XU<5Z+, M/>O(997^]<=E12L[C2CVCJKF8]W6*FK4/P+3SBD%D<2,<(L\0UTT:Z%:W M=K%IQ'R'MIJ.SO`-!2_#6AB!=8K*ZJE):$E*]N+4M1!'I2A>=2AAVJXSM1FC M4FV*:=3B)CI$GB$N<+#,T((7ZG5$XN-/GK=*]:1R3J3[O^' MC_>V)Y/O,/;JC+<%RFJ,B%>E978Y'6*RJNR0U0_?7G5M;``JAN>%2$F3 M3IQ0J!'Q0JVA4&,4*]2(NNFSJNOI4LQ5*GU>UDTG=&;Z[#IVT^=2["_;!>1E MFC+)CXFZ%B7O64)NL\1J"E6M$HEQA^HQ1K%PC2M/GVV)R]5V&K/HKBJX3H!ZG+LC!HO-EB)1B1*%&;4 M&,5*-"(^HX*CGZ5/9',E"ER*0H%C5*K<"3U1+C6.`=E6NO3Y&?(,<8W#1"J.N_4L1K$BCFB9S&DUIP?8H82AFTXC\:I&.5/'?G:%,Q2, M[$HCUU-ALSW+A"L):A(L#T&+:OE)A[),4]%@T"!(199]9R*DX-Z]31Z91W[&S M@PJC-"*#R")RB#Q#3*.P]4RCUYU-&\[K(J$LP36B!I%"I!$91!:10^09XCF7 MKD#J97C3QMBR"%]ABN,DH?#QPY7%5%J2(:JK@0:10J01&406D4/D&>(2!6^= M'SIGRB(9]F'Q^&X>$H3K4&D4*D$1E$%I%#Y!GB$@5KFTMTIBRB$V8R1)3?[C`' MU"!2B#0B@\@B1PV['I#"*(W((+*( M'"+/$)7/;,\!-8@4(HW((+*('"+/$,\Y^+,1.4<[QW9] M1.*H%U?9ZWD?->QZ0`JC-"*#R")RB#Q#7`;I*<\<]>@=Y^@=$36(%"*-R""R MB!PBSQ#/N>0=WW@R0.L8OI8FVT"'0NX1Q-76>H@:RJ+OV"&%41J10601.42> M(2;18IQU;,.Y=4PHGQ$0-8@4(HW((+*('"+/$,^Y9!W#*NW(![,7Z!L3$C4A MUM760U17``TBA4@C,H@L(H?(,\3U&><;%^@;$V(U$:,RU&"40J01&406D4/D M&>(YEWSCFYZM"NL7XFHB(5X5,[%$L1ZBAJJ(8V6B*8S2B`PBB\@A\@QQA8+# M^_'SZ"(:POP\FE"6S1I1@T@ATH@,(HO((?(,\9R#=\MS#E<3;ZN*Z`*9',D8 MLO.'7&=>AR7'>)89J@*0PBB-R""RB!PBSQ!7:)RC7*"C3(A5!3I*C%*(-"*# MR")RB#Q#/.=@Z_Z\Y]G-A=H-A,292'7*8>HH2S0 M;&*41F00640.D6>(2;0<9S;;<&XV$\IV^!I1@T@ATH@,(HO((?(,\9Q+9O-- MIY`EVLV$^)7I3"Y3#E%]52!2B#0B@\@BE;:,^=!%;:B%UZ/*MU$+JT$5.J874(7-?:IE22_L. M1M@VZD/KR(4^<^I#JZVE%M*:%B!++:0U+=.56DCK6#"P!:0UK>\4^DQ)'7K0 MI=`RHS[T?6*IA;2F;]$*+7,:+4X?L`6D-7W%4NI#6M,7$866FM2AIRY++:0. M/8A8:B%UZ'&]4@NI0T^PE5HH4WK.J]1"F=)-'866BOK0&P5*+=2'GJ0OM-2D M3OS"7:I3DSKTG'6I#ZE#3R.76JBJZ.Z$0DM%?>C--Z46ZD,O@RFUD-;TRI12 M"VE-WP:66DAK>J%&J86TIG=,%%HFU"?Z=*G!A/K0Z\Q*?4AK>NE7J86TIM== M%5HJTII>"E5J(:WC'1JP!=2'[FM-?H86Z%'M0AV)\F"1*XY#(18U)XJ+")'!)7WI0[-;2$RJXI?2\ MV&UXG`5;Z!DQ2J+40C?9WX:[ZK&/GDUNPRVCV$)_E>)C67>2L!!_%PZ*$@^' M48%_G-Y^I),P?O`=I7%73&--+>MB"SVC=QL>(<+1Z%$]2KVTP?1<&K64-IF> MRZ*6TK;1,TG4TG[.=5_=]+I#O&O;<1? M3NENF$_[$_V1#+I@H+^V0'\594M/%M^$MUY\WN]/W2^4R'7_=U8^_%<````` M__\#`%!+`P04``8`"````"$`DJNE;;D&``#$&@``&0```'AL+W=O"'S]\NY\5KV;15?5UK9&EH MB_):U/OJ>EQK?WZ-/WG:HNWRZSX_U]=RK7TO6^WSYM=?'M[JYKD]E66W`(5K MN]9.77<+=+TM3N4E;Y?UK;S"G4/=7/(._FR.>GMKRGS/G"YGW30,1[_DU57C M"D%SCT9].%1%&=;%RZ6\=ERD*<]Y!^-O3]6M[=4NQ3URE[QY?KE]*NK+#22> MJG/5?6>BVN)2!-GQ6C?YTQGB_D96>=%KLS^0_*4JFKJM#]T2Y'0^4!RSK_LZ M*&T>]A5$0-.^:,K#6GLD049\3=\\L`3]595O[>3_B_94OR5-M?]274O(-LP3 MG8&GNGZFIMF>(G#6D7?,9N#W9K$O#_G+N?NC?DO+ZGCJ8+IMB(@&%NR_AV5; M0$9!9FG:5*FHSS``^'=QJ6AI0$;R;^SZ5NV[TUHS+6WQ5+9=7%$I;5&\M%U] M^9O?)$*".YO"&:["V7*6MFM8!)YUKP@\CHT`KKT(6:Y,V_68RCN/7PE/N`I/ M9VEZ-K$=^OAW'.$N>R1[AJKSPF!U%N9=OGEHZK<%+%XH@?:6TZV`!"#6%QC/TE!R/ZHX*#4J M\DA5UAI$`475PC)YW9B>^Z"_0FD7PF:+;8ALL>LM:!U3V5`%D0IB%20J2%60 M38`.21@R`67^/V2"JM!,]#%L>S!)C1)V;]&[A"J(5!"K(%%!JH)L`J2P86%. MPY[?6?IYIL9K#?Y]9YZYCPE)^.`N377D@#F12]@WE)D=C/JLA(A$B,2( M)(BDB&13(N6`=K23<^K];8H:RX%R,IU91$)$(D1B1!)$4D2R*9&B@A-W&A4[ M?:''@H5VJHKG;0TS#:MN)E@+#EE^]%().59.G/$,VG$B.D1VLG+B24O:5\[C M:##J)SY&)$$D123CA#]>"I_`WOE?XV<:<@($FF9`H&D*!/),WJ\89"77?30: M#/$+Y)K##I&,5JSM,8@ERZ2C02^3"327$=J=3.J<]V-+%TIBI@I`H"\#0AV5 M-'#DPI$X[MN^*0]O)QRM<=,+!7+A/!D=;67#CX35RF/YLQS;MVU9.\;:R5W: MJ:QM6HZS4K0S25NN*MKJ_*L<\AX)COU^IK:$(YK_,16^,L4[867R]R?>NHI^ MBR[4UXWEKPQU=0DGSQJ>%F.=9+1B.H[E*CKI:-&/.I-TY-S0_DC-S0=W',)[ M+"E-'"FEIBRHG7"42HT[>BN6)M_Q?)RGP:2/+\9"B4!"R#,=8J-$(:%,$I(3 M19LI-5'V/0N1=V%2=CBR^!LZ+8\=X4BJ&(X\NJ9?-\1RZ5NRO*`BX08V8RZ0 M4C):,27#]XFC**6C3:^426.2DP'EKR;#A+?Q#QU4]+N%ND-QI)2-LM)WPE$J M&^YHR^>7HV9KL.ICC(66"R?RN)X=I5(28:7(HQ0B^>QG\G)6:<.GEMA'UR)O M&J5JXTC9LM3W$O"@LR$5H'"$XWK,#=[VN95GL#+U5H:EONG'6#L1R'U7.Q56 M0MNU#=M1BB&3M.5TTMY132=?L:R;^EK??M1-3<]1WH'"8_J:V9)I4\K?:#$* M,8HPBC%*,$HQRB0DQTV[RTG"\JQ3>TIY-Y]Y7C?D<&JSXQ(4811C%& M"48I1IF$Y)!I1WE_R+S_E$+FR'&'6=[!9URZ("8HQ"C"*,8HP2C%B'XX'I_( MX^,?@OD'NDO9',M=>3ZWBZ)^H1]Y37I*#IA_@=X2O_\$K=ZQ`WA1ALE2N1/` MJ^8,=P-X_9KA7@`O,#.<@`.4Y=P=<('9PW="L@KH(8;OP*$5T$,)WPF)#3YS MD<`^#3YS=^"[_"/KT=78Z??ZF6=LS0`^D.%G;ZT`OBAA_K@*'F'Z\(WM*H#/ M,)B'?@`O1C.<&!`Z1?"9NQ,2"WSF0H'."7S8 M'7T8`OR&<,N/Y6]Y)<'J#\#-;]-/Q7"/Y')_;4I[J#7Q'8]GJ"7XM* M:'$,^AI[J.NN_P."UX??GS;_````__\#`%!+`P04``8`"````"$`,U=E"-P" M``!N"```&0```'AL+W=ORY0W\DDM54P.OJB"Z59QF=E%=D6@R MF9.:BL9W#(D:PR'S7#!^*]F^YHUQ)(I7U$#^NA2M/K+5;`Q=3=7COKUBLFZ! M8B_5++DO&JGHK@+?SV%,V9';OIS1UX(IJ65N`J`C+M%SSRNR(L"T M66<"' /<7SU-^&R4T8^62SM@7Z(_A!GSQ[NI2'KTIDWT7#H=JP3[@#.RD? M$7J?80@6D[/5=W8'?B@OXSG=5^:G/'SCHB@-;/<,'*&Q)'NYY9I!18$FB&;( MQ&0%"<#5JP6V!E2$/MO[062FA*X$VVLCZ[\=JN-R M+%''`O>.93H/9HO)=`0)<1E9@[?4T,U:R8,'70.2NJ78@V$"Q)<=@17$;A&< M^M#5D*N&;7C:1,MH39Z@=*S#W#@,7'M,V",(B/;*H#9>&<&HC+7%5&YI`T*XGZ4PO5Q/::'PU M$6S5^W)VD4$]E_%E*4AZO!2"AU)=Q'UQIP5<#'GQ(YLN)@&D]GY7XKJA1!<9 M%FYVV0W.Z-$?`(*'4EUD>M8.JR$ONHE6L*/O>\%50X$N,O0RO^PE!-1X,Q8] M%#N&SC>"FNQM^ M-5<%_\*K2GM,[G%R1S#.^FA_JFSMH?(V'B=;=]J0_A>8]BTM^`-5A6BT5_$< M."?!`II7N?/"O1C90E8P\J6!,6\?2SC7.8PTV^FYE.;X@B=2_T]A\P\``/__ M`P!02P,$%``&``@````A`'@>OL#V$0``TFL``!@```!X;"]W;W)KK\#@N1B21ZO;LE:KU5I6\*?__'U_=_;7]O'I=O?P^=SY M,#D_VS[<[+[>/GS_?/Z__Q-W^T>MI_/_]D^G?_GR[__]>G7 M[O&/IQ_;[?.9ZN'AZ?/YC^?GGQ\O+Y]N?FSOKY\^['YN']26;[O'^^MG]=?' M[Y=//Q^WUU_WC>[O+J>3R>+R_OKVX5SW\/'Q+7WLOGV[O=EZNYL_[[]WZGW_[W-X^[I]VWYP^JNTN]HWS/Z\OUI>KI MRZ>OM^H=M(?][''[[?/Y;\['9KXZO_SR:7^`_N]V^^MI\.>SIQ^[7^'C[=?L M]F&KCK;*4YN!WW>[/]K0^&M+JO$E6@?[#%2/9U^WWZ[_O'MN=K^B[>WW'\\J MW7/UCMHW]O'K/][VZ48=4=7-A^F\[>EF=Z=V0/W_[/ZV'1KJB%S_O?_YZ_;K M\X_/Y^[BPWPY<1T5?O;[]NDYN&V[/#^[^?/I>7?__SK(,5WI3J:F$_6SZV3V MYL:N::Q^FL;.[,-J/I\M5LNW[X)ZO?W[4#^[77C_^U`OM^]$_32=3!?OWY6% MZ47]['IY^]%8FL;JY^%H3%=S9[YX1T+4V;U_(^KGZ4=C;3I1/[OW<<+1<-20 MUB-,C:&NG[\?:4XWU-H_=&_K'<>V&VS.8;1-W]&\&V7.89@YSELG MCTL]$>WG->_Z^?K+I\?=KS-UL5##Y.GG=7OI<3ZV/7$AR/"0]'I*-A"SM?[&;-NJ';/M9;H= MQ!L-ZG7[$;H^O.`^Y&HDQ+'WVQL)$8?9'PF9V;T$(R'B`(4C(6)?HI$0L2_Q M2(C8EV0D1.Q+.A(B]B4['I(?#RETR"%IY?$VU?&0^GA(\VJ(-1S55<\:CJ\/ MPS;:&H8:K&$HCN55%](-7:^#P=`5;?SC(<'QD+`+Z5XYZN#E5XZ/AR3'0](N MI'OE3$(NH=`P&"PRHI)02V@&8"597;G?D>0V^O.Y&D+]U.),1((V.F;6ST=7 M&A;[R^E:7%D\&>U+""2$P_ZRWD%!*J"34$AH-^NA=S*;J%FMQN)99J517BG>DLHV6J11+D(V. M&:12PU*G3J1@CD6P32T@DI!(R";F$0D(I MH9)02V@&8*5&K;2MU+3+4U?=X[P^I;:M5)QUMHG1OM$Q@Q1)\"3X$@()H81( M0BPAD9!*R"3D$@H)I81*0BVA&8"5`76SUG)!K6$YN4> MK,RI9?P)F6M;RG M0+8()4028@F)A%1")B&74&C0.^HLN:.E;%%)J"4T`[`RU-;23DC1OIG,D;@7 MWYB@09(@7B_M7#9S#XN7?4I\:_-4S")!O[6;[$)(9,0RHO<;$S0,+VZV4$\$Z,/@DJOJ_ZSCX&/;@)("(D@,22!I)`,DD,*2`FI M(#6D&8J=I?:V^X0LZ;MU.TNB3K5IB]QJ-CWDY`KB07Q(``DA$22&))#4B#E1 M5.5[(D9:AC8YI("4D`I20QHCHWMC)ZV]:3XA:?I>VTJ:(^:%3?N9@DB:%`\Q M/B2`A)`($D,22&I$'R;759>IA3BQ,S3*(06DA%20&M(8&=\=.VWM+?,P;:_? M9;4?R\C%B".N0QL3-#S'Y)VZAQ@?$D!"2`2)(0DD-:*/S]R=J@^[[&DX0YL< M4D!*2`6I(8V1T;VQD]7>,@^3];9;X_;#,"1-7/0W)FB8M,$-NJY8(,:'!)"P ME['[LWYCMYB((0DD[66_0A'C+^NW=GWFD`)20BI(#6F&8N>JO;D^(5?ZGMR> M#\54LFD_C!3SH10/,3XD@(1&]%!<+29BE$1H$4,22`K)(#FD@)20"E)#&B,C M[\E.6'N+?4+"])VYG3!9]F@__A4)D^(AQH<$D!`206)(`DE[:<\HU"JS?O/A ME))OH$!,":D@-:3I1>Z*G:[V)ON$=.E[=J-_<'>88DD!22`;)(06DA%20&M(,QY-]0H;TO;F=(5GO<`8W M\/MKTQ7$@_B0`!)"(D@,22"I$3WK7#CSY6(V%[-IAE8YI("4D`I20QHC+^R/ ME;BI+(*\OB;!`?$D!"2`2)(0DD M-=(-\N5ZL9`WDQE:Y9`"4D(J2`UIC+RP/W;BU(2'V?(-B6N;V2>?XXB"P6:J M@X9GGQ0/,3XD@(20"!)#$DAJ1!^HZ7*V7HC!EZ%-#BD@):2"U)#&R.C>V$D[ MK>@Q'2MZR$J5"1HF#44/Q/B0H)=VR>&(6XFPW]JM.")(#$F,Z`/DK):SE4A7 MBC89)(<4D!)206HC_=[,Y;JJ&;:Q$RC+'^T=]1O.NI$RR%0LYC;M@Y[V*A+B M07Q(8,2\/54/E&\O1)L($D,22`K)(#FD@)20"E)#FJ'829)ECR/KD9%RA_P0 M8],^ZBV2(\5#C`\)("$D@L20!))",B-Z(%PXZH'U^7HABA\YFA60$E)!:DAC MY*67MU,FJQ]'4C92]9AB#2EK'%?33MJI#4]+]5N[J76)T"B&))`4DD%R2`$I(16DAC1#L;,T5@IIHU\_U]R14LA$WIR9H&&6 M9''$0XP/"2`A)(+$D`22&C'#>;U:KN7)A38YI("4D`I20QHCHWMC)ZTM3`S7 M%F\\M70]PUICR,K/QM5!PZ1)\1#C0P)("(D@,22!I$;T89K/G.5JB:S)7<[1 M30$I(16DAC1&QG?'3ILLA!PYQ\8*(.*=;EQ9[KB">!`?$D!"2`2)(0DD-=*- MZJ7ZUQ"'*\;^8XD,C7)(`2DA%:2&-$;&=\=.UUC9XPU3XTC9PQ%W*!L790^( M!_$A`23L95_)$A^=]1O[10@D@:2]M%U>B!&8]5N[/G-(`2DA%:2&-$.QJ(++ZMW%ES>,*XD%\2``)C>BQN)RNQ'D1H44,22`I)(/DD`)20BI( M#6F&8J=(5CO>F**QJH?\I-/M:AS=&+R">!`?$D#"7MJQOQ2G<=1O[5XWAB20 MU(A.N_J'7^OE7"R=,C3*(06DA%20&M(8.>S.:O#OT.P4RIK&&U,X5ML0Y82- M*\L)5Q`/XD,"2&C$G&7J0^:9N$./T":&))`4DD%R2`$I(16DAC1#L9-T6BG# MU54*:W$XJ&WM+]0;$S1<',KBAH<8'Q)`PE[V=\_RLB5?).[#NQ,O@:2]["]; MXM3-^JU=#SFD@)20"E)#FJ'8N9(5CC>>4&.5#C&%;%Q4.B`>Q(<$D-"(/J&F MT_5`72[:HW]B-_1B20%(CYCJAGO0X5+[U,AY- M8>+$COJ-AS-,OFR"F+27MDM9=\SZK5V?.:2`E)`*4D.:H=BYDC6,]HIU_%F` MV4@M8[#*U*L+$Z1'_87+S_"O3,0P=[+^X2,F@(20"!)#$D@*R2`YI("4D,K( MR\>B1IMF*';23JMDS$8J&7)4;DS0;/\;'"Y<<6=VU6_N!JT'\2$!)(1$D!B2 M0%)(!LDA!:2$5)`:T@S%SM!8_>(-I]5(_4)>*S9M-_93'!`/XD,"2&C$7(35 ML[MB11"A20Q)("DD@^20`E)"*B,O[G"-)LU0[)3)>L;KU=P9ZQAX`-C$'*:W M*X@'\2$!)(1$D!B20%)(9L1,5%/U6VS$)3A'FP)20JJC_=9HT[S6QLZ=+&0< MR=U8`4,LJCX8I6VF+G7=F=S?S(JY6"PG,U?]9@B97GD0"KQ8":D@-:0Q MHM_X=.*NU;_E.;RZG5U9"#F2W9$"B(O;,Q1`9EKT#BTF?%K*!!PF8!\20$*K MVS;!TZ6MK0H,2Q^OSWMS M7410_S\\;XC?+&""ALF2M0&1KED`)2 M0BI(#6F,C.^.G:ZQZL?Q1P+F(]4//!)@@H9ID[4-#S$^)("$O8S5@ON-W9HF MAB20M)>V2SP2T&_M^LPA!:2$5)`:T@S%SM5I18_Y2-$#CP28H&&N=+.#>(CQ M(0$D-*+'HN-.Y-D=H4D,22`I)(/DD`)20BI(#6F&8N=(ECV.3'\L=\B%UF:. M:@?$@_B0`!)"(D@,22`I)#.BDWXQ55D7TV&.-@6DA%1'^ZW1IGFMC9V[]]4_ MYJQ_./@'1R;H$V=@N-)CXD@(1&=+=M?N?J.5&[ M4!&A50Q)("DD@^20`E)"*D@-:;]SJ:^]ZVSIKU#27S5ROWW\OKW:WMT]G=WL M_FR_'FFJ/D;IM?_JIM_<]G>?"R^H;U3Z>?U]FU\_?K]]>#J[ MVWY374X^M-]?]*B_DTG_Y7GW<_\%)[_OGM5W*>W_^$-]=]96?=?#Y(,*_K;; M/7=_:5^@_S:N+_\5````__\#`%!+`P04``8`"````"$`-M>?XJP'```'(``` M&````'AL+W=O#BVF^5SUYUNU^MV^UP>BO:F/I5'N/)8-X>B@Y_- MT[H]-66QZV\Z[-SMLY[@[%,V7E]-J6Q].X.*AVE?=]][INO3;7[O3J6D&VHDZW`0UU_L=#?=M8$-Z]'=W_N*_!G ML]B5C\7+OONK?OU?63T]=U#N""*R@=WNOINRW4)&P+%5\$^E`"8`O'LJV^UQ9E\O%]J7MZL-_".HCNCB1SDD( M[-UU.=?)&@GU\9FB*^[OFOIU`4T#CVQ/A6U!<0N.SX$AC4NH;T4*(5HGGZR7 MS1*Z'8)HH3Q?[X5*[]9?(:5;A\DF,!21GQ$V?]:M\0QKX'LA#9GP24]7X#[0E8R(A,(32%F#(G#"X205=>0M6!H#H^;"(.+WSXK&6+"2T`Y M-QC/0*A`@>?GS8(W2XCSDB8A!:."F+BO^$J$2D9A,J2AIYM3C$A$D*J$^C$, M$\51&@_/(C'`>O%CL`VK8#V_WP/V)I[6P3^F%3%>6KG!>`9"*::4WJ=BP2RM M(>N_##$:TRHAI1'-5^X#I$Q#%HOQKZ_"(!A:B!#7UQ"W8$Y<45X98I"X5&$B M&"#W`4(%D1R8X9+W`:%(O-00YE98O;'U?LHMF#-G79HAQC$/="!2ALA]A$AU MJKP%C]Q]1*2DOW()^?0:\A;,R;-VR!#CR(>)3MGLS1$P]+;Q#(2:@*4T/[$] MFI.+64\X$+*+M!!LE.8.X+'S+92>502O[O-6OT`=(:,L9"PR!T*:,,MDE$2L M.7."$4$2"L&ZQ!!(K&60!$.U:"Q60JZ/!86'QL+&:280-&0T=Q:,3J30(GQD M4$0<)LG01)2W59?K>:,FP=]!3L+A"3B"A2=NC0'6B47`)%$3"I(A#/5J-!))* M';+Z&.I$:)4,>D0#L;+#`@DA31_T$(H5#61X@NMI7]%B!6K-NCX7/D($412G M+%1#("NMM(Z&A-%(K`AYD7P0`4H6C8"-M$SXNK824DM(Y##47%,1D%9"P[Z% M*H&ACL)4A?%;NSQA!6I^&"AG9+A$C&'6N]PL_:'HJ6`?A?$Q)*WR*EWLT4P7 M(ZZ+#N0$1T%K\++G%!*'J>:[:T,AL`9`<"YIIR'\D';*">V,V,#('`A#B54T M&CD.@(-T=-F0^]_>KDKHT_E-T:-Y$5A+9@[DB@!K4X^+8)]ZGJ+H)5N-E]+5$/:5^S\9$YD-?7(XOQ+;0IF&C.TR$Y(9[QT'8X^!S(YX6W M8;)%DL@T#MFP,>XNAX%=M()7RC<:VNK8_%RBZI%1YTT?QQE!/F>T(!\5I6DR M$GG["0<:I+^))I?)X_NS6$[(8CQ,>4<003Y!7P55(OFFRCB_N/9B;VE2KA,* M^/%[M9Q0P)@KH`.Y-18)>+=G5<\)9`IA'&(BR5<)GIP0/,XFS89PS!AF#G2.(HH3OC!S"HD"H0475$,Q@8!7^&!0 M*E(2]4-:V-_%@QF>@"O4@3`8>(E4<:H8)B<8>(^$SPD)V\8;@@%%47I8-#06 M*S[>&)S77@HEB[87:XO,@5PL6D(D*I?G31!\&Y%\]>4$D881R[YQUR?8,I6<67&4/;(UTEPM MU4@M1Q;C6VC%?T@1U80B:JZ(#N0JK^!+TVA"H)NA5XV[9R)_3`!GYF]""+T) MXV89@LX=.O%A42'"Y^E9:#XG9/#C=VPU(8.:RZ`##2QR9T'FJR@4.N$];2A& MP2MKZ.U="/>0B=Z\'/=W,;W07/PW_IPY'I MZ..R'CQC$S@0'O+`YR3!LI]30`I[$#K([,FL?0QZL%O4`8#D\=P5SR4/9?-4 MYN5^WRZV]8L]4Y7P^>UBO9SW?I+V`(S9,S@'[@]-UY<+<`Q[*I[*/XKFJ3JV MBWWY""Z#&PU3K\/S1U:?^-/2A[N``MO_O,QRXEW`.&=P`^+&NN_,/>/#Z M&PO M=V]R:W-H965T&ULE)1=;YLP%(;O)^T_6+XO!D(^&@6J9%&W M2ILT3?NX=LP!K&*,;*=I__V.<4*3M96Z&\#PGN><]_B8U%!\_K`[:W-L&P!$D=#:GC7/] MDC$K&E#<1KJ'#K]4VBCN<&EJ9GL#O!R"5,O2.)XQQ65'`V%IWL/0524%;+78 M*^A<@!AHNZ(I\1Z>K]DU0U*Q*B4Z\&TG!JJB6WTX;.1Y5?9`38;M\EOP$[K>R^]*_TK#&8OHF^'#?AN2`D5W[?N MASY\`5DW#G=[BH:\KV7YM`4KL*&(B=*I)PG=8@%X)4KZR<"&\,?A?I"E:W(Z MF473>3Q)4$YV8-VM]$A*Q-XZK?X$47)$!4AZA.#]"$EF499.YXMW4%BH:#"X MY8X7*Z,/!(<&<]J>^Q%,EDCVSB;8GU#'Z/4MJ^C10]:>DE.<=@RWN#T/13)? MK-@#]E0<-9N@P>NS9E0PK&8L"['/[)ON2]F$%^=I9MGK>2;_ MD\>+WXSE:I\-1&#_@'/>\AF_ M_?G?T]>UZR@=9G&8B(SMW7>FW+O#ES]V5R%?U)DQ[4"$3.W=L];YUO-4=&9I MJ&8B9QG\L4<175*6 M:1M$LB34L']UYKDJHZ71F'!I*%\N^==(I#F$>.8)U^\FJ.NDT?;;*1,R?$Z` M]QM9A%$9VSQTPJ<\DD*)HYY!.,]NM,MYXVT\B'38Q1P88-H=R8Y[]YYL'^C& M]0X[DZ!?G%U5[;>CSN+ZE^3Q/SQCD&VH$U;@68@7=/T6HPD6>YW53Z8"/Z03 MLV-X2?2_XOHWXZ>SAG('P`B);>/W1Z8BR"B$F=$`(T4B@0W`IY-R;`W(2/AF MOJ\\UN>].P?/=4"")?@[STSI)XXQ72>Z*"W2W]:+%+%L%%I$@>\RRG(6K/PY M^3R(9W=D"#Z&.CSLI+@ZT#4`J?(0>Y!L(7`_(Z""OO?HO'>AJV&O"LKP>B"K MSI\%E.`T!E2OOP0J7"RO5F'@IX9GSIT-E!5[@I+/7ED[?>G#W8X M'@J=FU"%I4MAU8R+$T6#8+:"O7W<@[BPB5%88*IO+;W.SHWH0I+ ME\ZF&=?06:(8?,(&US4A"@OT=XW-0&\3X#R>CO%N@I6F+B&"LS[Z\/F:0*QKN%5@A##Z.6$I@:K)%*9FOP4#1":I`:I;J[E+4T]U>@0A M("/T@'0%H30UB[,H-'5)T1YAH&0U^U3JS,(62J\TK`F(:3(K6S"%:C1)#1P:Z"2),-XMM,%S`]Q: MI@QJ5Q9,`$`SUP[;7O8:8T_Y*9,G]B=+$N5$XH)7%`KG]LI:79_N*0Y%V[[8 MWMMKE5?]`]>:/#RQ[Z$\\4PY"3M"3-\40=J+D7W0(H==P=U&:+C/F)]GN,`R M.+O[J!5'(73Y`,A>=24^_`\``/__`P!02P,$%``&``@````A`/1I,5!_&P`` M`Z4``!@```!X;"]W;W)KW?_^\.WZ^O%`+?QX>'_X M[?'QY]NCHX>K;]>WEP]O[GY>_U#)E[O[V\M'_?/^Z]'#S_OKR\_;2K??CY;' MQ^NCV\N;'X>^A;?W+VGC[LN7FZOKZN[JC]OK'X^^D?OK[Y>/.O^';S<_'V)K MMU[V\O[W/W[^Y>KN]J>:^.WF^\WC/[:-'A[<7KWMO_ZXN[_\[;NN^^^+ MU>55;'O[#S1_>W-U?_=P]^7QC9H[\B?*:SX_.C]22Q_>?;[1%3C9#^ZOO[P_ M_+AX.RV6J\.C#^^V"OWOS?6?#\G_'SQ\N_NSO;_Y/-W\N);[*WG[^1W7] M<"5)UKNNTY`_SVXO7&Y(4DN__[^<*D#WWQ^_/;^\&3]YG1S?+)0 M^,%OUP^/S8UK\O#@ZH^'Q[O;__-!B]"4;^0D-**_L9$W9Z>GJ_791HT\47$5 M*NIOJ+@\>;,\.UVF]"(_H;#K]ZLEJ>;L^W%/W%T M#9_MT?5W/N_-XOC\Y)D+/@\5]7<_I1;*C.TAW?_L=[*+V,?N?_8[W872PA\U MR8\GN_;(Y][H;QHB5R'F4R'&1ES$"#<>7+-5#NH<-#EH M<]#EH,_!D(,Q!U,"CB3<3CT)]J]0SS7CU(O7_2F"6EL=%:^1JMGUBW/F@]?:&M1U6%R`52`W2@+0@ M'4@/,H",(%-*C#ZZP>RACXO>ZA.'R2=/UAK0B6(GV3RT"XK5*I`:I`%I03J0 M'F0`&4&FE!A]E`I[Z..BK3Z>I,D"4H'4(`U("]*!]"`#R`@RI<2((0-AQ'`W MM^7I&XFWY^W--61U\D0ZI7FTRO)H%[3+(Y`:I`%I03J0'F0`&4&FE!CIW$HD M]05/ST,NVNKC29I'(!5(#=*`M"`=2`\R@(P@4TJ,&+*%1@R71Z>:0O;,(M>, M5VR"*0&:4!:D`ZD!QE`1I`I)48XYXJ-HIJH M(6J).J*>:"`:B2:#K%C.5.XAEO>@LD7QFC^YI8WT,VD$5#&J)FJ(6J*.J"<: MB$8B;54D9V^5<48R5>;5M[B%MZ1&-(^RZ6F39]@N*JI=A;82M6NBAJ@EZHAZ MHH%H))H,LCHZPYGJ^,Q$Y?VI$2NUK-YF+X`JHIJH(6J).J*>:"`:B2:#K#+. M:NZAC'>F1IE@5I7$R41UEJ?1+FI.(Z#:[:&Y<;S<#>V&J"7JB'JB@6@DF@RR M8CDKNH=8WKD:L5(S&]((J%*-;#JKB1JBEJ@CZHD&HI%H,L@JXYQFJLSK)RKO M676HF"B?%CL;FV;8>9YANZA8L9HK1E03-40M44?4$PU$(]%DD-71F=14QVD'%4R^-%EF%SU"[#B&JBAJ@EZHAZHH%H M))H,LCHZS_KRX;CT%C<=C@&9#/-1":H851,U1"U11]03#40CT62052;W[$]/ MX4L:\X#,TF]YC(\(@C&?O5(U5XR951,U1"U11]03#40CT620%6L_8Z[/=/-U MJ(>J*!:"2:#+(Z.B^=ZOC,-,9@Q2[6Q8NC[,M]`KU MZEA/!C6I-V^:VDMP-G:/SO6NUW1N,,(GN^7&Q1*H(JJ)&J*6J"/JB0:BD6@R MR"KC/&NJC)L^W*;V,^GOK:Y1R*.T:T/0,UV;UZN7H9[T3;IVWM(T%^`^/#87 M\/2);\.MA0UHG70M4454$S5$+5%'U!,-1"/19)!5IF1A3\[<-XV>Z=T36M:` MDMZ-04_W+NK5L9[MW7D[T5[#?O;QA/8QH'5ZYL$^SJAB5$W4$+5$'5%/-!"- M1)-!5IG][.,)[6-`:Z5#,LSR#;DY*GK%BJ@F:HA:HHZH)QJ(1J+)("O6?O;Q MA/8QH/6\W71!5!'51`U12]01]40#T4@T&625<=XMG__#)+'GYYHGKJEL:O5( MJJ4IEN_(A8J)MA513=00M40=44\T$(U$DT%62&?U4B&?N0]Y9YC>0$^"64Q3 M#*AB5$W4$+5$'5%/-!"-1)-!5AEG`_=0QH5G:>21G:D6^8[J8##GD?;IQ",[4RWR+;DY:DZQ7<6(:D8U1"U11]03#40C MT620$7*UGV/>AMOQ&%":8D0544W4$+5$'5%/-!"-1)-!5IDG'/.>-\,5+71` M68KEVW5S5,RGBJ@F:HA:HHZH)QJ(1J+)("OD?K9]1=L>D$FQ8-OG45LQJB9J MB%JBCJ@G&HA&HLD@J\Q^MGU%VQY0=C/,]^3FJ#F-?%NJ&%'-J(:H)>J(>J*! M:"2:#+)B[6?;5[3M`9DT\E$)JAA5$S5$+5%'U!,-1"/19)!5IF3;_9[4I-,%4454 M$S5$+5%'U!,-1"/19)!5QEGGU&X]O9Y9>:>=&M&`LHEJWJ'U^[]SU)Q&=.V, M:HA:HHZH)QJ(1J+)("O6?JY]1=<>D$DCNG9&U40-44O4$?5$`]%(-!EDE?G7 MN?8577M`4BW97UC,.\4AQ6#1J[EBS+J:J"%JB3JBGF@@&HDF@XR0I_NY]FVX M=>T!I3NA1!513=00M40=44\T$(U$DT%6F=RU/SU3N0\WLOV%@+(TFK>D?1K- M43%G*J*:J"%JB3JBGF@@&HDF@ZQ8^SGS4SKS@-*9BJ@BJHD:HI:H(^J)!J*1 M:#+(*I,[\_F#]&<2BA[]U"/W]:)Y:WV1;ZW'*/]S[>TO72.R%;,-TSI&S16; MB$S%Y;Q%9B\U]]7N4A>G;]S/HY^Y5EKL4X]TK7%87$0TGU\5T?PA6QW1'-5$ MM(VRI_QKP_O,&=/?GGKT7.^$J/GTJF+%9;9)5,>HN6(3D>V=>>EO+S7WI"_O M'=K34X],[P0TGU\5H]+>051CHNPIYV;QQ6.'MO'4H^=Z)T2E%U&JN,P6QG5L M?J[81&1[9U[OV$O=S^J=TNH%9"906CU&U40-44O4$?5$`]%(-!EDE?I%((V^>-I?YBF&.BA-.1503-40M44?4$PU$(]%DD!'+??=SC^75 M-MS:N8#2-"*JB&JBAJ@EZHAZHH%H))H,LLKD=L[-):_;YW>_[\ZL7D#6ZBWS M%<,:"`:B2:#K)#[63WW-=)<+(],B@%5H6(251,U1"U1 M1]03#40CT62052:W>D_/5/IF$)3QR.YM+/,50ZB8[+A61#510]02=40]T4`T M$DT&6;%RL_B,6'2(6G%NI_5YX_Z"J"*JB1JBEJ@CZHD&HI%H,L@JXQQBND7F M9JKUR=9&[[D+ZQ(I'WP>93-5OH8(%9/!5Q'51`U12]01]40#T4@T&62%=%XS M%?*9%//6--UK="I)OT2&"Z**J"9JB%JBCJ@G&HA&HLD@JXSSM'LHXRVP4<8C M)W[BJ;(5Y<5Z%S7?\(!J1C5$+5%'U!,-1"/19)`5:S]KOJ8U#TC]$66X(*J( M:J*&J"7JB'JB@6@DF@RRRN36_)_P5+3MZV#;-0;G%#N9]Q[\]MD<%;6MB&JB MAJ@EZHAZHH%H))H,,D)N]K/MVW!KVP-*4XRH(JJ)&J*6J"/JB0:BD6@RR"J3 MV_:GY_`-K7E`=J8ZR797+N:H71H1U40-44O4$?5$`]%(-!EDQ=K/FF]HS0,R M:41KSJB:J"%JB3JBGF@@&HDF@ZPRN35__4RUH6T/R-UODYEJWH?S,]4<-:=8 M\/OSC:%F5$/4$G5$/=%`-!)-!EDA][/M&]KV@$R*PT`FQ>C:&543-40M44?4$PU$(]%DD%6FY-I?=2\\HVD/*,NP?*]]CIHS MC*:=40U12]01]40#T4@T&61UW,^TG]&T!Z1-ZRC#!5%%5!,U1"U11]03#40C MT6205<8YYW^)VSKS'CQU6P%E&99OM<]14=J*J"9JB%JBCJ@G&HA&HLD@JZ.S MWJF.3WN*,^_4C5@>F3D,J`H5DZB:J"%JB3JBGF@@&HDF@ZPRSCGOH8PWVD:9 MX+VMV\JWVL]V47,:`=6,:HA:HHZH)QJ(1J+)("O6?J;]C*8]H"1!+H@JHIJH M(6J).J*>:"`:B2:#K#*Y:?\GW!8-_5GPY1IP\P;6*M]JGZ/F%-M5C*AF5$/4 M$G5$/=%`-!)-!ADAS_1Z_W5S]_NE.N:&8PM1^HI>R;/<./I[3R@>D9TW%'+F(:/[-6!60^PES MDH+9-GT]1\6V&J*6J"/J`])S2]2652)WY&ZP[:T$??JY1T:)@%(E`CK;ONE& M#_#+]F?JV,QP](.O1SCVSJG>;WO1!E4L]7=`]`F24\Q6P5 MHN8,:F);3U9L8]1B]"?1"T/51R45F]B\K8BABHI=N2*&:EK1IIPSS]#+#]7M[?"O=S]_=3O4 M+65W/_0>W"@6;'EZ/P2JSH%JHH:H)>J(>J*!:"2:#+**[6?>SVG>`Y*S2K,$ M,YJOF/BO:JX8D[`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`1UJ6?)":O_=G%/-*?^ MVX7%YM19:7-9S[AE3=XS+UK]+X[]BLA.9V&59*^9TYD/LR/1,_?$J%FN/#_5 M(2','B$;Z^HC'^;>:S&WEN1GO+._Y*#JH^)!.1)?>):9?H(>LU(]":9N0UW-EHA3AX!I MT*"NI$:<=`73"$GK9HJYQ=LK%?/K/JN89_9>M''-M&9F=]S?9[5@B M^JHV$SW3S^VW[QX_.S]>+<^RFLK-75246K*B-SVPB M;[*[H/K`A]E$]DP/"_"JK<].,LW4`[N8>)7J`;2E'@AQRKUDHN===A<6FU,7 MH#EUP2[NB>;4![NPV)SZ(&W.]L'V[9[H@Q>E?W@QJ)E#`LO2/Y/P8A'"3/H' MII_H;Z4_/]XL%GG"ZB6??IFIJ'AY>LNG9TEK>LWG+NZI])^C8FMZ]2=:T[L_ M;6N_2/\Y*K:F]X&FK672NZ5<+OW+#$YXS:B5WJ\,TRU2";@='2;%`S-S-9E4 M15VIZEE25V]/!9.&J"L-$:<7J())L;1NIIA;M[U2,5`C;9*D!2^R/8UF@)BV'Y0=4AX7SM0;/U@_KH)0=5 MMY7"\H.J)XL'S28[=6ZIM>1*L_YV2[FTOY_>OER$=Z/:8>&7@^EWRF)=6*/LH%U8T\R^I/BWB MFU1GIBG#QZ4?'A289$*<9`*33&"2"4PR@4DF,,D$)IE2ELGDUB"I3,XCN_V) M/1\4L%#*<1;VS'XX&9E^%UKE:YX,'G.X$R#TPR M@4DF,,D$)IG`)!.89`*33&"2"4PRI2R3R9GE?63RYMK*%`SW_%FZ9`*33&"2 M"4PR@4DF,,D$)IG`)!.89`*33"GS,AT]?+N^?JPN'R\_O+N]OO]Z?7']_?O# MP=7='S\TEA;:(TCXP?WUE_>'GS0?OE5CVP_#=W5V90M7MOW:),N6KFS[E3>6 MG;BR[8<6+%NYLNU>/,H6KDPK(HUIEIVZLNW2CF5K5[9-?)9M7-FVMUEVYLJV MNW4L.W=EVP]H\K(S%>G;]86S/)>8^G9YJ42GH>^-E4IT$OJ25*E$Q]&7A`HE M6G"[LRLJ?*8B_0ZN4.M,\NIW8*42B:M?-I5*)*U^V5,JT17I9RRE$EV1?L91 M*-FHCGZO7BI1'?U>NU0B%?3CY$+)F=36CW-+)4I<_=JT5**TU:\M"R4;U=%S M94HEJJ/GJI1*I+4>%%(JD=9Z4$:I1%KKJ1"E$FFMIR(42M:JH]V/4HGJ^#M> MGJ5K::TG>I7J2&L]T:I4(JWUB*9"R49:ZQ%%A9)3U='36`LE:]71TTA+)=): MC]H%"HL])9ZWMNA9)3G;7_(E#> MVJG.6AL+I3HZ:SW_O%2B,_"?!^2MK51';S,JU%GI2O7JGE*)KE2OKBF5*$/T M,I92B3)$+R,IE2A#].:-0LF)ZNBU@Z42U?'?0\NOYT17JG?,E>I(:[TTK5"R MDM;:6"Z52&M]IZ%0LM1Q]-;E0LF)6O,;X3@W:>T_>T")M-;7DTJM26M]N;U4 M(JWUNLI"R5)G7;Y?+G4&Y;OE4F=0OE.%\YM MH3J_N'^JSB_NGNKM7]P[U0N_N'.JM\OW36EIDK'<-U.WV@@IJ:Y]C^.WVN@HE6E?X_BM-C)* M96ISX=HL*:8V%Z[-4IG:7+@V2V7ZNS5*9VMRX-DME:G/IVBQEK]I MPP]K?KM[?+R[U=KM\.#;]>7GZWL7H(]"OMS=/<9_Z,2._KR[_WV[^/OP_P(` M``#__P,`4$L#!!0`!@`(````(0"'!GN0_@0```44```9````>&PO=V]R:W-H M965T$RY/RY?7R+17Y!4(\9^>L M_FB"VE:>+G\<"U$FSV?P_S:A+T3\:O%7IO52=QCNY_E-2]>;UF^_JTML?^:#ISQPSDUC.OZBB3(6TK?:UJ MD?^K1*P-I8)X;1!X;8,P^+GYE$W]!Z*,VRCPVD7Q1FSB/A)CTL:8X1A#1^*H MW#2I#I(ZV:Q*<;5@_H+[ZI+(U<"6$%GF>`R54AGIL_Y_28=LRR!/,LK:AH4' MEU>%,7_O00X5>"B(:,$=!/^1P4LQ+6:%F<7_^23'UYQ-_2H/\41!0$%(041`C MH(U^\;>F0H-$!HDQT2W*SCUX>C'5Y_7=F[3*;2O"%M5E-Q(8FM`@D4%B3'07 MLO<.=Z$Z-;2UO@<9NS13FMN0=P8)#!(:)#)(C(EN0O;9X2945]9+8RRR,W]K5@^-7VUF[4:;`)U\M8$):%Q5620&!/=A.RG MR,3`DJ@NK)>$3)XM0ZVZG6V4!*WF7N_4))\W3TT"SW/>S"$)4N]83LB"=EJ&>WB:$DL#0A`:)#!)CHKN1C1BY^6*.JK8-2_S. M3HA:>VN"DH!1$AHD,DB,B6Y"-F1D8N`<56U<+XDQ1U&O;]U0$L#YBERYMU49 M&B1J2?<$PKRY3W8H>4S3AU'VU*F+.@K(>7GD.WX^5U8J7N6)B@?WDSWM3WN> M//DP1_B6+>&Q';C3?P&',)?DR']/RF-65-:9'R"D.YK![E&J8QSUH1:7Y@#B M6=1P_-*\/<%Q&X?G?'<$XH,0=?=!_D!_@+?Y#P``__\#`%!+`P04``8`"``` M`"$`8^K=Q8L,``"E1```&0```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`?!0AY>%O;#U9QA<':Z7*U=A/X9_.' MB;.#W-E1;H;X#&-J#EATWV_GB\OKT7>80D:LV@B[*NRP*@4Z!28" M(U34E869_PEEV5%L66U"]RT(=4Z2&MJ(MHM*@4Z!B8"H`:LPKB'_"6IGP`;C MLR)F8"ESNWLHV M6*;L2"PI$45$$S$Q$?DM^N1G@V5^CI3X5$22IEM%%]1)2D03,3$1*=NKCV@7 M_/BC9H-ERH[$DA)11#01$Q.1WU+F9W?I[6A?4 MR4U$$S$Q$>44^&VGZ]U$RZ0]6KHK".L5*T:*D69D!))I6G>)EH65?0[6UQR= M26&G:]6[+QQ*5)\F^T:(:CLJ1IJ1$4B69,TF*NGCE5XX:Q*9.R24)Z1\QRA* M,S("R32MQ41IGJN\B0Y:49&()FF=:DGIO.,[G1`G> M^J3X92I^%Q7$)Z0+0D8@697UM*BJ3\1W#B@RCTW1BT](%80T(R.03--ZU>EI M.F<3:7JSPUX87;8L4H&[J"`P(5T0,@*)S">]O+2)EE[J4?196C%2C#0C(Y!, M\^=XZ82]U*-D1T].GZL0U2G/2#,R`LF2K.^=O&8FSB7C->.14-Y%14AQE&9D M!))I6I>*TK3[RN7RG'UEXOQ.E-!98+SLDX/GRG<4574=V_G0'&4$DE7ULM,) MVZE'44XK1HJ19F0$DFE:HTK$+\:8Y)[7D-8%D@MWCU!`)/TR/7N&J%9GQ4@S M,@+)FJS1135]O*5/G"V*1>-0='6X\E$14HPT(R.03-/:5)3FF5K MY2C-R`@DT\Q8[7D+?\I6ZU$B?GIR#5%!?+9:CC("R:IZ6>V4K=8C(;Z+BI#B M*,W(""33S%CMF>*SV4X=2L1/#Z\A*HC?=6R1YB@CD*RJE]E.V6P]BI1>,5*, M-",CD$SSYYCME,W6HT3Y].0:HEJ9%2/-R`@D2^IEME,V6X^$\BXJ0HJC-",C MD$PS8[;G7=Y/V6P]2L1/3[4A*HC/9LM11B!1U:R7V3;1TFP]BJ]T&"E&FI$1 M2*;YL\QVQF;K4:)]>JX-49WVC#0C(Y`LJI?9SMAL/1+:NZ@(*8[2C(Q`,LV, MV9YQ=W[&3NM1HGQZJ`U107EV6HXR`LF2>CGMC)W6HVA_63%2C#0C(Y!,,^.T MY]VIG+'3>B3$+\?IL39$!?'9:3G*""2KZN6T,W9:CX3X+BI"BJ,T(R.03//G M..V,G=:C1/GT6!NB@O)NK*A*S5%&(%E2+Z>=L=-Z%"6P8J08:49&()EFQFG/ MV7#89F>=6X8;"N4X/=.&J*!\U[%%FJ.,0**D>2^;;:*ES7H4*\](,=*,C$`R MS<1F/[[O8>2\OG;.7>B0$=E$14ARE M&1F!9)H9+SUO1Y^SG7J$?./5G1Y<0U00G^V4HXQ`LJI>=CIG._4H4GK%2#'2 MC(Q`,LW$3C]9W6R9\\[Y8H'3PVF("@)W'5ND..O8SH;F*".0J`ECB9O8 M'R^:)EI:HT=13BM&BI%F9`22:2;6:.^UGW6[US[#F+BF1_:71\L^/8&&J%9H MQ4@S,@+)HGJYIG7U-'.'HN/FRD=%2#'2C(Q`,LV,:YYWZZ5DU_0H$3\]A(:H M(#Z[)D<9@615O5RS9-?T")FW.:T8*4::D1%(IMG+-4MV38_L](;57:0'S1#5 M%J,8:49&()EY+]=^\>). M3Y0A*@C<=6R1YB@CD,A\T5!2>JWK`_!P5)N9\JBPMS>C#34YY^DHK.UJQ&BRJ(S%GE84 M.RHFR%XGA'E*KR)]@)@GUR>9IV2"M>^(J%"2Z^C&DB4E_FKWU:+Y@O[XO-U\ MO:_MO[,O7-D%UCP!>;=@U_4H3%EZG>8#Q)2Y89;8P*(92^9:^XZ("M6YCFXL M65UBRV=5QV9M7W5PL^IFE:U^0;Z^8J08:49&(#EIB=5_L@6RG^.- M4CL]\-UVB:P8*4::D7T[-8SETG1OF[KW%G?5_JE:52\OA\&F_F;?)%U<0L$. MN]=<[QB/E.T3+-] M9FB9Y5KFZ(.[<)G?,T)XB MUP*M\0A#K@5:XS&`3,L,6N.;]TS+!'WPG%ZF98H^;GM.U_446N/YLEP?:(U' MNG(MT!J/1>5:H#6>1,JT3-`'3RWG6M`'#PKG6J`U;"#7`JWQA&NN!5KC0=%< M"[3&LYF9E@)]\*9&K@5]\')$K@5:X^6#3,L$6N-Y_UP+M':7!NDL3*`UGE3/ M]"G0!Z^MY5K0!V^*Y5J@-5ZXRK5`:[SCE&N!UGA5*-<"K=TU<)HUNF1[H$-V M;B!S5F6(G-48$F<5+J`PWD[D7'%\N+*'@US+!"TYM=1BBI:<6FHQ0TM.+?RQ MB+O<6/=VLC*__=Y.;X[;#U*&W\VN[F#W7,:]W\>=`*KPC.K8W+Q[K^MC^ MP_Z"[@^,W/X?``#__P,`4$L#!!0`!@`(````(0`#]P!8H`(``!@'```9```` M>&PO=V]R:W-H965T#.2VH)`J M7=6MTB9-TR[/CC%@%6-D.TW[[W>.35BR5%WZ8O#A\_>=FP^KZR?51H_"6*F[ M@J1Q0B+1<5W*KB[(SQ]W5Q](9!WK2M;J3A3D65ARO7[_;K77YL$V0K@(&#I; MD,:Y/J?4\D8H9F/=BPZ^5-HHYF!K:FI[(UCI#ZF69DDRIXK)C@2&W%S"H:M* MV!2_A$XQ\[#KK[A6/5!L92O=LR+Y?=UI MP[8MQ/V43AD_\I$L*3.M5*2$"3'MD1%6039K? M+`E=KWQ^?DFQMT?OD6WT_I.1Y1?9"4@VE`D+L-7Z`:'W)9K@,#T[?><+\,U$ MI:C8KG7?]?ZSD'7CH-HS"`CCRLOG6V$Y)!1HXFR&3%RWX`"LD9+8&9`0]N2? M>UFZIB#9-%ZDR7*R`):ML.Y.(B6)^,XZK7X'4#I0!9)L(('G0#*9Q[-%,DE! M\S\D-#CDX[MECJU71N\CZ!F0M#W##DQS('XY((@$L1L$%P1Z&GRU4(3']3S+ M5O01,L<'S$W`P#IBTA%!0714!K7+E1&,RIA:=.4F&(YE_CIR(C-YBPR""P+K MZ/QY@`$S]?UR',_T+4((AI3/7U4:0*$UCZ6@W)>G#L%>:LS=8#E.WCR;O%PE M\/!R*02?2@V6\Q`6I[S^0J6S&%Q[O07QW*G$8($[?52TZU^,I,+3L;M:("RB3&263":`L;IWMP$R:+=C"2_&L#?R`! MUR_!0E5:N\,&A.GX3UO_`0``__\#`%!+`P04``8`"````"$`!99_BG$3``"+ M8P``&0```'AL+W=OCJYO)B\_*P_?SX\O7]Y3_^GOTVO[S8 MO=V_?+Y_VKYLWE_^M=E=_NW#?__7NY_;U]]WWS:;MPM2>-F]O_SV]O9]>7V] M>_BV>;[?76V_;UZHY,OV]?G^C?[Y^O5Z]_UU<_]Y[_3\=#V^N;F]?KY_?+FT M"LO74S2V7[X\/FR2[<./Y\W+FQ5YW3S=OU']=]\>O^]8[?GA%+GG^]???WS_ M[6'[_)TD/CT^/;[]M1>]O'A^6)9?7[:O]Y^>J-U_CJ;W#ZR]_P?(/S\^O&YW MVR]O5R1W;2N*;5Y<+ZY)Z<.[SX_4`A/VB]?-E_>7'T?+?C:]O/[P;A^@?SYN M?NZ"OU_LOFU_YJ^/GYO'EPU%F_K)],"G[?9W8UI^-HB?-Y\ MN?_Q]/:_VY_%YO'KMS?J[AFUR#1L^?FO9+-[H(B2S-5X9I0>MD]4`?KSXOG1 M#`V*R/V?^\^?CY_?OKV_G-Q>S>YN)B,RO_BTV;UECT;R\N+AQ^YM^_Q_UFCD MI*S(V(G0)XM,SA:9.!'Z="+CJ^EX=C<_IR93)T*?3F1T-9_-IK?SN].;0Y;[ MF-`G-^?\F-PY$?KDFDRO[D8WB\D9-:%9NJ\)?3J1^?DQ63@1^G0BBZOQ?#:: MW9[1Q2,:F7:@F"'J!L'YH1T-XXW^PC+TUQ,'VH@'B?D+NY]U&2S-Y>!+9(3],JU_-*II.1N6CD7E_27U%$V9' M2\$?'V[GBW?7?]#T?7`V*[0928LU6YBY:F03#5(-,@UR#0H-2@TJ#6H-&@U: M#3H-^@!<4ZR'@--"\9\(N)$Q`>=0K1CX'ABKZ+(%NR0:I!ID&N0:%!J4&E0: MU!HT&K0:=!KT`1#1I;DAHAN_%O"H-=:TZ@>C=KJ8RJBMK,UL,41Z#20!D@+) M@.1`"B`ED`I(#:0!T@+I@/0A$4&E*\H90376M)K\:2L&%VI'F`Y&7.<,A/+!QO?P[&8F>[@8C%BH!*%JL`F%5(WJ MP8B%&A!JP:8#TH=>(O:4B9P1>V,M8V])&'M+PM@[$L9^I@=,.AAQ2S,0R@>; M,&2W*O:#$0N5(%0--J&0NM+4@Q$+-2#4@DT'I`^]1.Q-(G=&\/?F,OH.A>%W M*(P_(]D!>K'W5MS>C)%?X7)&4DN%KO!6K%4R\EH5(Z$U4BM)[:U8JV'DM5I& M]C3$;"D:1P)O4*5S]@TWF MZ9N@D4W`:)?/C5PY)/K#6HG^<)F;C*':^:>LY1N9.11HY5R)F[NA%D6$E>A: M1I8@R=,S1JD!4HF.%5C6B!AU;M.H0]<)1!MSD6S#BS]SUCVS2)@:\ M128[\TO+2"TM:^XA=4['FX`36;'?Z"!K^@=6A!VZBA9K.1:GKGK7@F]D)+C@*3%/[; MH\"(J,N016H&JK1A;8Y6R5',0(L6E$`-;8P,`F=U9!"`?.Z^\;!\X:Q&8]HT M^5K@&`#]ZB3]^C3]QID%X6E/TN_8ZF!X>B$O1X5)7P^,BK]OOU-W'SM^,8== M>EA8I!8'E;>LG:-8')S6Q-ZR,CNKE/4#EJ%K'C$K(JQ$URIB5D=8@ZYMQ*R+ ML%ZXRDXPF>J!3CCI6&9D1-34M$A-3;6^K9UC,/82UII07_QZ5J2!&2]`&:KE M@YDX[=3+?<%FYD+VZR\M\0LJ]J0F!)[Z"VKV#)?[V4BE$@U;^8U!>YI^QYX' M]7NVBNQ,3=+\;P\#FWG38.,N68TL4E-1;=O7SDI,1>#/NW,AW$7&1V=F]>7R8!)Z M&!>S_;'X/F,Y<9$V,FJ!L(AN0_!@68\`)8A21!FB'%&!J$14(:H1-8A:1!VB M7B`1ZO%Y)R1[SC'H_&O1ZE#(J36*D`)6J6(,D0YH@)1B:A"5"-J$+6(.D2]0#*DY@SA%PO" MD>C:TX?PZC"V*+Q[XY"]IV%O-#ATY%Z9M^+U)$.4(RH0E8@J1#6B!E&+J$/4 M.V2;+0-N3AD@X&=FT&-[5"%B;Y&(O44B]A:I>VKAH8C06_2=%R=6#&)29+/Z"F;4XOY8)'H*8M$3SD4[C>G<&^-AI(9".&1-B._W\U;<1A*1EZK8B2UU*E6[:U8JV'DM5I&_M2L0]0SVCO*OC!9]!E]X9+N(&L8 M6R3ZPB+1%P[)-JM;*JG3$GT!6KFW"H>X2E<+;\7Q*QGY^%6,9+U4KE=[*]9J M&'FMEE'8%T.SV;%GJTA?Z/3^R`J&B?S8(M$7%HF^<$BV69V%ITY+]`5HY=XJ M[`L5O\);<1A*1CY^%2-1+[CMYJU8JV'DM5I&85\,S6;'GJTB?6&RN#/FA4WZ MQ!IED>@+BT1?."3:#+?=QH,55SUCY-N<,Y):*G\OO!5KE8R\5N50>-L-48.. M+:,P\%#[GJTB@3^6Q)YTR&6.:?75W2+1'Q:)_G!6,H;J0#UU\F(/!5HY5R*\ M[19AI6-!-:J(61UA#;JV#@5UZQ#UPE%<$H%XXRX#36,.!G)@WF M4$T->(?4<9Y*!];.BI)('WNG978-PQX2[[@X3W7;36UC,M3/'=K_9N/7^@6; MF5M5W@QNN>`75.QYN`$UFQW^@@:_H'5(W7933>^\%8>V%UIR%$1S]7-'`:;M M$XO4#-2WW9P5#5*N:N+0X?MB*5O1M77HH]E(12)#^9P=:8,T.,(8*YS5L=MN MJ%^=I%^?IM^@?GN2?L=6!\/3"WDY*DQ*'VY#]HNQ'Q6GG>B:5%4O#A:IQ4'? M=G..8G%P6L$MMI3U`Y:A:QXQ*R*L1-N,I.,&G[@4XX M:4=".3_T@45J:JH\9NTYI^QYX']7NVPITIC>[_P#"PIPUAHK#7 M?7^IIJ+:MJ^=E9B*5NN.=IY#P&`)39WCL=MNJ)]SQ0[J%Z?IEZA?G:1?#_IT M(1N:&1D7-AA!?-J3]+O3]'MG9O7E\F!R?%@>SK[M9B:S7J0M"NY>K)U5@!)$ M*:(,48ZH0%0BJA#5B!I$+:(.42^0#+5)X76H)W/SL^4C/_R9V.1?S#N+_&GG MFHWN]C_,_$VE*8DK]@XI.U""&PQ-[R M`$H0I8@R1#FB`E&)J$)4(VH0M8@Z1+U`(J13?2)P>.#NS??'`'Y2W"[\I-C? M*%PYJV`A6R-*$*6(,D0YH@)1B:A"5"-J$+6(.D2]0#+*^AC@2)0QX9]:)$(* M*$&K%%&&*$=4("H158AJ1`VB%E&'J!=(AE3GU$="BMGSU"(Z-/1C>3I5Z>W: M604'>`DCBG]P9=#GB-Z*E^J,D=_?YHRDEDKA"V_%6B4CKU4QDEKJO+[V5JS5 M,,)]\53GJ$>BC,GH7H%^I!_\A-$A$5+K*!XM&$_5NI*RHS_/RACY,.2,9!A4 M^EMX*PY#R_IO3Z8N3?3IWXH1/8;# MU5@[)D)M/>D,V;RA8GRCGRA/G4]PR)RA3.ZMPDF@$MS"6W&52M2JO)6KDAK_ MM3=@F4;(R)7!9`L08'^NYGQC+%HF+ MJT5!9)*I0V&4X2*6>BL?9=#*G96(\F0$RSXXEC''V5A=E2NNA+^$U3%'J'TC M'&6437YW1I1M.BBB;)&(LD4BR@X-UU5U-RZ=#@8^P""3.RL1X-E$G906K.7C M5$8=QZIG*G2LO6-\0]`('Q%;NH5[3FSWYO(FLD-A;!T*8^M0\,1"BBA#Q]PA M%4UU&2K0L73(GP=5:%2#42.,9*AH]HEA^/_:]LV,BHJ@0^&VSYF)$#JSX(&% ME-4"EJ%K[M!=>,0_FZCA7:!CZ=#<;U(KM*K1JA%6,HPZ[5,WS4[:W)D=G(ZB M0TCD;[*815JZ1;=EC;"3?:73B#UL#_M+N<,$TN'%OXG@FM$":(4488H M1U0@*A%5B&I$#:(648>H%TB&6B>6A[<3]%92F`06A:>CSBI`":(4488H1U0@ M*A%5B&I$#:(648?(O)_51,*VT8;4OF_5OB3R>?/Z=;/>/#WM+AZV/\R[5$?T M^[T/[P9NW_2Z&M.K7NTM)%TRN5V:&Q]TV8>2.97LWT\&)0LJV1^:J)*/TYOE M1ZIR1(U*S"%DK(3J1F=IL1*J&^4&D9+9A%Y=.XF63/FEMJINM$M>FB4>U6@; MO#3+.I;0&W(_CB-\156.V:_&%.:8/54W5MN/T^7':"!7U(IH&$<4>OIY&%9U M-:8`V^NL:C@=H2W-D43$AQJ^BC9\327K:$E")2GE#:A&>WDJB0V89+J@DEBM MD]G-TFR7(FJS$97$@DP)UM)L!="',JBEN=9C"9UE+LU)9:QD0B6QSJ%C)"J) MQ8T..)?FK`C5Z)QS:4XQ8R43*HE]#QTQ44E,;45JYN@,U>CH=VD.T+"$3H`I MUK$:)-,)E<1JD%`-S-$:JM&Q\-*^AIUJPA)[$69HG M;["$'K19F@=KL(2>HZ'OB94D$ZHU/3:!/O23DJ5Y1!5+Z(C"82F)URZAN6;2$?F*T M+**UIE^U4$FLUO0;"RJ)U9J>^*>26*WI^7,JB=6:GH2FDEBMD_&8QD%TEHQI MO-&OO3#6*VK/*JJVII)UM(1^M;5,HS%(*`9I-`8)Q<#\(@5KD%`,S.\C8B6T M]D9CD%`,S'/CZ$,O<5F:5[1@23*B&MA3!C6JZ!462_/*"O2A-U0LS1LIL(1> M0$'?$RNA]SC0]\3:T]`5F=[0%!&[(ZU807]'%\98`;U)B;XDUJ'TJB1J3*R$ MWH5$C8F5T,N.J`*QDO)N:5YDA56N:+K%VEC19(N-VHJF6JR_Z/5P5*G8RD$O M*Z.2V%I,[]&BDEBM,KJ(1@MRFF>QZN8TRV+5S6F.Q:I+;\:CZ,:J2^]IHY)8 M=>F-8502JVXR6])[9#&X"8VMV-!:T-I\H>W] MS?ZM"J_V/U.P_WASK\#YM'VC_P2!,@!Z23S]IQ<;>C'-C7ES[I?M]HW_8;Y@ M^&\T/OQ+`````/__`P!02P,$%``&``@````A`,>C&+TA!```6@T``!D```!X M;"]W;W)K&ULK%=;CYLX%'ZOM/\!\=YP)PE*4H7; M;J56JE;=[C,!)Z`!C#"9S/S['F,N-J;M;+4OP_#Y^.-\YV*?'#Z\5*7RC%I2 MX/JH&AM=55"=XJRH;T?UGZ_Q^YVJD"ZILZ3$-3JJKXBH'TY_O#L\>5%6JU/MXJW&;7$K0_6+823IR]R\2?56D+2;XVFV`3F..RIKWVEX#IM,A M*T`!#;O2HNM1/1M>;!BJ=CKT`?I6H`?A_E=(CA]_MD7VJ:@11!OR1#-PP?B) MFG[,*`2;-6EWW&?@2ZMDZ)K\@W0[H(@*\[+7$)$4(@HT&].A M3"DNP0'XJU0%+0V(2/+2/Q]%UN5'U7(WSE:W##!7+HAT<4$I526]DPY7_S*C M7M%$8@XD\!Q(3&MCF\YV]U]8[($%G@.+L=DYCNWNMK]T16.R^BB%29><#BU^ M*%!ZX#AI$EK(AN>JRA@>)F8*V(_B!8&B)&?**_H9L'63'7Q]]PX<-I3+E&''7H0EFJW&2,8\E:!F M^YMJZ#Y1#4/F9&T7:M@ZGRR&[*%9.3&+($23T:2%)Q*TT`%C>?#"S0+T>9$^ M^1B^`H?;2A'2`F.G+J4093%D3M)N(8NM\TD:.&QH$$[7(AS1;#4)XZD$85"I MDK`MO5R9LJ^XZ96]728E%&4R!++'^[S4RHSX%`Y$-L1UTBHWW&@E9GK1EC'/ M+L@W8$21],^)'>6O)!9"-&:V)Q$UCY`^7T?!"A:N8-$*%HN8*('>JEQM_L)7 M=@?#03[6A@\#'4V9NYV@0(9"&8IDB`Z',Q=SDPU[;(RI4'M#`2I+HJ3X3@+[$MQYT\PJ^\Z`;9!SFV+.Y@OOTPVNXZ<'% M+_/XE@?WJXR?;>\,RN0%W_;@=EO!#1V^S(;C21M,MDUR0Y^3]E;41"G1%0*F M]]==RV9C]M(-37K!'E7T>D[````__\# M`%!+`P04``8`"````"$`!1588)<(``!@)```&0```'AL+W=O"CY[K=OQ\/D:WEIJOIT/V4S9SHI M3]MZ5YU>[J=_?TX^+:>3IBU.N^)0G\K[Z?>RF?[V\.LO=V_UY4NS+\MV`@RG MYGZZ;]OS>CYOMOOR6#2S^ER>X,YS?3D6+?QY>9DWYTM9[#JGXV'.'2>8'XOJ M-)4,Z\LU'/7S<[4MHWK[>BQ/K22YE(>BA?$W^^K<:+;C]AJZ8W'Y\GK^M*V/ M9Z!XJ@Y5^[TCG4Z.VW7^JMWO MU:F$;,,\B1EXJNLOPC3?"0BR:9-*4$XGV]>FK8__2B.FJ"0)5R1PU23>;.G[7K!<7,_B*1:X*I;ES./^ M8GG+4.!Q73QP[4D6S%FY-PPD4!QPU>',^-)G?G!#3A:*!*X]"?.<6RA@C7:Q MP/7#L:P4!UP5![MV>N>R5+K*BXJV>+B[U&\36,Y0#,VY$,V!K8%7EYPLD+X( MWZM!*#Y!\BA8[J<0&Y17`POGZT.P\N[F7Z'8M\IF0VT8M@BUA:AL01O90&P# MB0VD-I#90&X`^[V"CLC?K9)4A,D(0@*4$R@N0F M@F*'!GI][,*XBUV/>",1"%0C(4$B@L0$20B2$B0C2&XB*"J8'3,JV;IF8F_X M\>0*/QR@1!90.\9,6OTKE$;ND(5((=`V#3>K2F+%;?9&'EB=+^F91.MT+8IT MA,+W@[[04%)@B_I04H0?3HI$1#J-Z!;]4[L.'4HC+B5$U[,EXN)<+K%;K)YF M+AV:E)ZIVT\P0SK"\&Y.(/DH[V?XD)QK'4=*BNS4K2C3,M(3JA/HB#FF&N.!T.#Z(:9:FJSP-XM#R94 MDJT+;\V+5%JPB^I]8]/10EY04PGL3JNLS&I1$'.!TU@>5HPQ]4P4Y'G]*%)D MAR@@442BF4$*AE$(9A7($ MX;B%;#+B'JEW,SYA;16\A(+N="RW!D:@B$(QA1(*I13**)0C",!)U_((Z/>NTS..'JAB3X4O1)39O0*\J`9&.%;$C]DT@QMXLK35&;RI@H3,Z8=%V#.+W>,,7N19PC-'["B1?$PO7E-&G2-NL!J" M2(<1^X&5CU"9F76D(%](#O&J;4FU\V"BRS:A1.E@U:TQUW?M7&2#B2;*$1%. MCY!\'ZDS*!-[_]$0JC/&K(8:*C.SSA2T%!(=3DELY9("B@<;'59"F=+!2C`Q MWUOX-$%RZ/`TS90C)IR@,8%Y8V/F5%YJ")<2.7`H,U1*DFSI=;GRN`.U9!U, ME1>8Z``32I0.5K*4'+*LLL%$$^6("&=*R,P-\&,&! MALH,9D^/+U+04JXTSEWN!C1!DAZ,M%]"J5),Q0+./4*5#4::*D=4.$66JOW( M+L][K:L?N%$0/KPNR+J3CJB6).2;"LA?6,?S6-&#E7YBHI\(VV,_/>3=1SHX M#E;^PE8%@Y6FSW]&CY,J-*Y==[>N4*F340E*")]\%Y8R"D%&B3:(*E`YPMXY MY(9LFLKQ)^?CA/*G"EK\D#^[CC]'_#BM0AV_G];K#M9<2FR45P4YAB;59@86 MC6#Q"):,8.D(EHU@.<9P^$(F&^'_6'/"1V:R&TK(/&`K*P.**!13**%02J&, M0N+CMQB7?**,3W[,EI\4C^7EI0S+PZ&9;.M7\:':%6>`'M9?T;WU(S#!\K3N MP)%Z+4ZT(W=X`)_>.Q%J^_"%_BAOW8&O]8]\C`N^XG>]Q[+?<"`:LW?7\%6) MCND1PH`W#O3&!J(8#<)?P\>,$7L&3X9W,V-WX-FCSX@X7\>P>5(?V(C78J>E M=V`S`Y^Q$!#YC=R+N@<]8--".P6?L3L26:W&NH2.`<\Q:'%SHG8@[\)SN M7&1-"VA4>,[8G8@S\!F;2M!MX#-V9\/\]4;V#^LY(=P)1^]$<$>\B!@9-0O@ MSEA9PEL*F+FQ.W`\ANR,E3^<>(&MNS/O!P>_[S@7+^4?Q>6E.C630_D,R\KI MWDA>Y"]$Y!^M>C/Y5+?PRX[N)>4>?LE3PF=T1[S.?J[K5O\!@&ULK%?;CJ-&$'V/E']`O"\W&S#(]FJX)2LE4A3M;IXQ M;MMH@$8T'L_\?:J[`??%NYEL\C(,IZL/=:JJJ\O;CZ]M8[R@@=2XVYFNY9@& MZBI\K+OSSOSRN?BP,0TREMVQ;'"'=N8;(N;'_<\_;6]X>"87A$8#&#JR,R_C MV,>V3:H+:DMBX1YUL'+"0UN.\#J<;=(/J#RR36UC>XX3V&U9=R9GB(?W<.#3 MJ:Y0AJMKB[J1DPRH*4?PGUSJGLQL;?4>NK8WQBI:;15 M_.GJ:]W[(`?:W1C0C_&^2";[\,]?&WND,0;<@3S<`!XV=J^NE((=AL M:[L+EH$_!N.(3N6U&?_$MU]1?;Z,D&X?%%%A\?$M0Z2"B`*-Y?F4J<(-.`!_ MC;:FI0$1*5_9\U8?Q\O.7`66'SHK%\R-`R)C45-*TZBN9,3M7]S(G:@XB3>1 MP',B":S0=:)5^'Z.]<0!SXG#M3:^OPXV_X($/L?4P',BV5C>QG?]X)_5V#PR M+-!9.9;[[8!O!E0O:"=]2<^"&P>F,4>8QV.)^;="#K&F)$^496?"L8-H$JB3 MEWT0A5O[!7);33:);N/*%NEL01-):3,5R%6@$``;%"VR(%G_@RS*0F7-#B4S M<-?I*1IFBWE+I@*Y"A0"(&E8R1H>%_V<`6H,Y2UDP`\CV;>$V_C1HB?5D$Q# M<@TI1$3R&,I;C/KW/:;&4'50=$+1;!27N5$`G4,P4G2EB]$2=`W)-:00$4D% MG"]1!3\2%CVHWQ=$]S%!LQL)1\(5.Q&>X_JRNI2OKU@3Y!7/D0A*XJ[77KB7==2B'+XL@]2`J<2M$;DFN M"YU)2Z//F@7+XV??4I<#DD-.G0<^8RG=ZMY8Z9#N0X5$B1[3F_-]WO.[UC)\;N9M\IN6C5HN&,TI1TQ"CPE8$?=PA&38=VWA/&X_Q"/[#\7-S_ M#0``__\#`%!+`P04``8`"````"$`E%F^$[P-``"80P``&0```'AL+W=O-H? MGJ]ZP>6@=[%[WAYN]\_W5[U__ROZ;=:[.)TWS[>;Q\/S[JKWY^[4^_WZ[W_[ M\NMP_'YZV.W.%\3P?+KJ/9S/+XM^_[1]V#UM3I>'E]TSM=P=CD^;,_WW>-\_ MO1QWF]M&Z>FQ'PX&D_[39O_.P]W=?KM;';8_GG;/9TERW#UNSM3_ MT\/^Y:39GK9=Z)XVQ^\_7G[;'IY>B.+;_G%__K,A[5T\;1?I_?/AN/GV2./^ M(QAMMIJ[^0_0/^VWQ\/I<'>^)+J^["B.>=Z?]XGI^LOMGD8@W'YQW-U=];X& MBWHX[/6OOS0.^L]^]^MD_7YQ>CC\BH_[VV+_O"-OTSR)&?AV.'P7HNFM@$BY M#]I1,P/_.%[<[NXV/Q[/_SS\2G;[^X81B0&MKC]<[4[;L/)Y7@Z&`8D?O%M=SI'>T'9N]C^ M.)T/3_^50H&BDB1#14(_#!CH4Q"\?ZFM`P2.-FBCJY-5`!X[XY8.]U9$3F-#I%@%B=FMAY MJ[=]N6*:!;C:G#?77XZ'7Q>TJY&;3B\;L4<&"T&JEYZ,VG8QOK86:1$*EJ^" MYJI'\4'+[$0;R,_KZ2#XTO])BWZK9&Y0ADDLM818X8)VQ8$U!R(.Q!Q(.)!R M(.-`SH&"`R4'*@[4%M`G7[<.I^CZ?SA>GP)R`J0-2`1(#$@"2`I(!D@.2`%("4@%2"UC3C.I4W*<>[;3A72 MM*O0&67M"2PF;Z30A&;($AJZKE^V0FWD`K(&)`(D!B0!)`4D`R0'I`"D!*0" MI+81Q]&T#SN.;C9ERFC(2P_[[?>;@TQF//X?TMXK=V3!T;A?.^U&(A.S9RPE MHE*J9L.5R(PVKW8^)N'&:4U'+6;_1JA"/1B+40[J#6E(W=*$R.E!YX"5::%3!=RA`K0 M*U&H0JBV]1Q'BQLUIH,='"T474=+Q':T1&Q'2V3N;#=#=O*N6R'MK@B0&)`$ MD!20#)`TQ[6(.!VPW7"JI4-82Y*5%](*X[*0F'/-#5-.+$_OG=1"P_3I"XEA!;Q,G M+O%XXNX^*?)FG7ASQCMU>0OD+3OQ5HR7];=V>-W9%E>L3VU6HCC`%I."1N[6 MS3JS5%+VDE+06)PY/Z^'PRF;R+41T,LP0IK82#4TX9SY-S$"FB9%FLQ(-31S M3I,;`4U3($UII`3-:#QA:4EE!#1-[="X$R5N:Y^;*'G/HTN$-G,CZC0T=[0L M-;14D+,&I=38')]K)65!$2K&*)4@E*)BAE(Y0@4JEBA5(50[BJYWQ7V->S>< MB$KI.\F1*%CQ92`AM@Q8+"Z5HK,,I.*<_-[NEI/AS-TDUDJ1I/3D10J:THG9 M*H83MHABHVBD)D.VIR9&2M.GG>@SHVC1CUC0YT9*TQ>=Z$NC:-.S,59&2M/7 M[]&[@2#NDSP0@BY9LB@_\D"0D'/ZS7B"H?2HWCG\%#L%33OIDQ$[6R/= M+8<+0Z.+Q41QT5,,VR*[DJ2=+&9>*7[`YWZ+S(6%EXN/L?1*<8N5WR)+IVLO MEV71C2EQ;_Y<3`E-EE%)R-E<9JQ[2U&$%ON[E;4JR-TB^.C76I&RP[=B2M*[ M7-;HFZPX[F0QZ60Q]7)QBYE7BH\Q]UN$F.HRQK*3Q6RQNC&E+CF M?RZF9('`20MD#[P(@595+&1$KFHGRHQ0IHJ1:K,2+U.E1LA354@56FD--4HG+&$H3)" MFJIVJ-R)$S4#/G%#VLW>KG`%LM1``:%MW"C(.;LG(TCB5(W"7B82FJD[Z2NS MU@II@Y$RZ"R<5JKQSSPU0N;,FBA%\UKHE7;*,X4R#<4I91/>;?1=-,/#8WFNF#&-J2EDK#B M>*4@ZYA8(Q2A8HQ2"4(I*F8HE2-4H&*)4A5"M:/H.OO3]11R&,_U%.2<'%@] M4U)V="O(3=!X(K36BG(J@X#=!"/=;K+(N!-QHA4E\8CQIKK9\&:=>'.MJ'AY MRJ:;#6_9B;?2BHJ7;?*U;FYXW=D6%9+/+2U96[$WKE!"[HDSY'F"DJ(^Z>UM MI2!UXH3C`7/XV@AHG0AI8B,E]O5P%+*5G1@!39,B36:D!`V]/<:NZ+D1T#0% MTI1&JNG-C!?A*B.@:6J'QITH45GA$]4IH0ME3<:9*`DYRW(R9%&S5(K.LI2* M;GUGQ.L[2M&N[RC(7<_6U4!>N(RB?7ECP9`8*>VWM!-]9A0M^C%+UW(CI>F+ M3O2E4;3I6?!41DK3U^_1NX$@"AT\$#JE&J$JD5@YHH*<%0OU'27D+-@NU9:U M9J>@,7?Q,4NT(MVMM^L[7BE^("1^BVP;2+U;3<^*6XQ\5N$F/)Q<8M9IS'F7HL84UTLEITL5EZ+&%/O M6'1C2E16/A=3LB;CQ)2$[/I.*"%G5Y*0DZ4#%*%BK"!+,4$H1<4,I7*$"E0L M4:I"J'847>^*H@GW;K=T0)9;'.]*R%FQ6-\)I923#DA(UW?&XV`PY,]+UDJ/ MA/2!%R%5;*2:._EX/!O.QRPC28R0IDJ1*C-2#=5T-AW01P#N,ZC<"&FJ`JE* M(]5042ED0!\"N%25$=)4M4/E3IRHB/")>[^^$\I"BC-K$G+.;JSO*$5GF;A% MF5=FK172@XJ0*E:0+A6],FM`E2)5QJA>F36@*I"J9%2OS!I0U0Z5.VNB_F+/ MVMO5N%"6:YS9DA"]XZK]N512%K1":(U0A%",4()0BE"&4(Y0@5")4(50[4". M2VD?<5TJ7F\-Q^+UU@]^==`PN44>!3EO%$_&+"M;&BD])RN$U@A%",4()0BE M"&4(Y0@5")4(50C5#N1.`"_TO!W30ZSN*,@*X"5"*X36"$4(Q0@E"*4(90CE M"!4(E0A5"-4.Y+J45U/><2F64(82<@)W.F#)_=)(F+];[AX?3Q?;PP_QH>5T2C7R M%I9?@=X,A_HS4-9"WX=^;5[I8?@-?3?:%/LX'B[H"QX*5XX+`Q[\ZVCQE8;@ M41@MZ"L*#Q[.R4+SK0Z8&)"-YBR&%O&5J[>[0^HO127:6873A4ASL872VH7( M6K&%LM2%2$*QA9+.A<@IL645SLA.\^4&ZS4E8F3'UT)Y%=GQM5":1'9\+:MP M2'9\GHZI1=3?L&]47",[OA:JBY$=7\LJG)"=IAP%XYF0'5\+7;G(CJ^%[E1D MQ]="CV_(CF^VZ?D,V?&UT`,8LN-KH22JVT//3A7@\BBWT.'0AGG9B"SUC)#N^]4,/ M$$I(=7PL]!B0[OI950'$@DV4>!]0B7K7`OM&K%63'UT+O3I`=7\LJ MH'5*C]Z1C5XO(#N^%GI;@.SX6NCA/]GQM:P"B@-Z5=-GA^+`VT)OCI(=GPZ] M&DIV?"VK@-8IO1SHLT/KU-M"+SF2'9\.O9](=GPM*PH0;WQ0>/CF,Z;@\.$9 MA88/+RDP?/@J"&A\OKV87I2F\?E:Z-UG&I^OA5YGIO'Y6E;C!7TKAEY<45CZ MXBBFH/3A&86D#R\I('WXBL+1%S\Q!:,/SR@4?7A)@=C@_7;YT-]%>-G<[\K- M\7[_?+IXW-W1<3YHON`YRK^L(/]S/KS0S8G^.L+A3'\1H?GU@?X"QHX^NQZ( MJ]C=X7#6_R$']=N_J7']%P```/__`P!02P,$%``&``@````A`.R->=*8`@`` M&0<``!D```!X;"]W;W)K&ULE%5;;YLP%'Z?M/]@ M^;T8R*4+"JG21=DJ;=(T[?+L&`-6,4:VD[3_?LK]^^61Z4? M3"J:54:6-@(X$1Z]C7I`%`:;5LA`0@4L[ MTKS,\3K)[A>8K)8^/[\$/YJS=V1J=?RD1?%%M!R2#65R!=@I]>B@#X4SP6%R M=7KK"_!-HX*7=-_8[^KXF8NJME#M&03DXLJ*YPTW#!(*-%$Z``K$@* MUQF0$/KDGT=1V#K':1+-;N-)`G"TX\9NA:/$B.V-5?)W`"4]52!)>Q)X]B23 M^5@2$ASR\6VHI:NE5D<$/0.2IJ.N`Y,,B%\."")QV+4#YQAZ&GPU4(3#:IXL MEN0`F6,]YCY@8!TPR8`@(#HH@]IX90=VRBZUSI7[8#B725^6F;Q%QH%S#.O@ M_'6``3/U_7(>S_0M0@X,*9^_JM2#0FN>2T'/C$^=`WNI(7>]Y3QY\S1^.7W@ MX7@I![Z4ZBW7(=Q>\H8+-8ENP;?7>]`=O-3H+7"I_U8M_4_3N7D\NMT=^%*J MMUR'LW@+KP-?\O86/SK")0FC*%Q5R77%/_*F,8BIO1LS*5R^P3I,P'7JFO)? M^S1;^\E(A@\PF3I:\:]45Z(UJ.$E4,8^]SK,MK"QJ@,W83XI"S/)O];P"^)P M_^(("E4J94\;$";#3VWU!P``__\#`%!+`P04``8`"````"$`M0.:)L6>)9A]K:FMV]5FPY4<6V7)(RF7G[;1`-`GV(+;EV+B;)A^XF M\`,@&B"I3__X\_GIZH_MX;C;O]SVHNM^[VK[W]^_?BMW'OZGC: MO#QLGO8OV]O>7]MC[Q^?__ZW3S_WA^_';]OMZ0HBO!QO>]].I]?IS7.\WK]N7Z#D<7]XWIS@GX>O-\?7PW;ST#H]/]T,^OWAS?-F]]*S$::'?MRLD$.VZ?-">I__+9[/;IHS_?GA'O>'+[_>/WM?O_\"B&^ M[)YVI[_:H+VKY_MI_?5E?]A\>8)V_QDEFWL7N_V'"/^\NS_LC_O'TS6$N[$5 ME6V>W$QN(-+G3P\[:(&1_>JP?;SMW473=3KJW7S^U`KTG]WVYS'X^]7QV_YG M>=@]+'!/#!)=7)$AQH`_78SS6S%"9_@3G4?7XS1-AN/1^4%@7K6M@#]=#8:71YE@ M%/CSXU6)8#"U=3%_P3#CZV20CL:7=&[DAHCYBVO3Q3T3P0"SE0E&VG64](=F MG+TQMJ+8.<)?\/+I68YN5$9^6)X]HF[L-&EG7;8Y;3Y_.NQ_7L&M##0XOF[, MC3&:FL!NOMD6=#/P5Q,09IZ)8/F.GW:#.3 M-A&UF#L+,ZU-V(R#G(."@Y*#BH.:@X:#!0=+#E8\X`,FIK-P+AD'.0<%!R4'%0`B`DSAHBI+PIN M3!KK=B$(QF1*19I9FW32"3L7)!,D%Z00I!2D$J06I!%D(A&](`4C>AA5^%KDZ>=ONWNO\_VT`988I0;7@RKK5V#31`JDR6A3):$,EDR M@I0JD(DMS+EP*U0W=F\HA5NENL6T4^K0C5 ML61$[FPQ2UCFUB@.QI0EDW!,Q>,QK7Z.5^M[OT+Q2V*V%I72KU+]V-VCMD:V MFD0NJ*:0*TK;4?6V7L:1ZF5).QY=@I?$(]KPN34:V+U4F[]A("HSUPO=[&[. MN!6JVX1>K11NE>:6L!E?HUM;2:*6V55\3*[6D^J%B`ZPA$VK.5J%(\S%ZD_: M+#JZCL?Y;VQ>Y9U1,,0Z!LF3G\E\N2X[,^]:=8RZ\FF)9LI`,SNI#TIG\V98 M'[M[>QOLMD?&6CP6TEG'<+"A8P3U-!N0_O5X&$_(?W0$Y>B`YPCMR',QR(A- MV(VAE(Z5[LBF>.T&MSE]==2E<=HM`M'Q3)>+(IBJCO=U5SLSDW9@'+%)8K MK%!8J;!*8;7"&H4M%+94V$IA:\JHKB;9#0??V\N#.2?@8EHT;$\&;0J+5@'* M),HE*B0J):HDJB5J)%I(M)1H)=&:(*J?270OT,_FQ6Q3P%;3F3GU!)7#78%$ MF42Y1(5$I4251+5$C40+B982K21:$T0E-;GR!9+:U)JL(Q9!]ANNARSYF)M. M`)7#C-@A6&&"A92E'[FS\NMH@8AL.6`%HC?14CI6#I$KINQ^77LKMU8V#K65 MH/J9)/H"_6S.#?%<[%ED4;A[0$3$PF3=)WVYM"H0464BELB6TK%RB"K#DH': M6[G:-PXIRIA\.53F0YNM"+/U4#!$`S\DYFA&%+-FXU`QBP*K`AW'/GXI8U7. MBLK#TL7:6WEYPBO2@6,29"[/8&B>MKRSRXHP__95GCEDEG0_EU*66<[1C&0B M-M@(UI7`D25BN70L$"5CFS]'_7@T8+?64KI5B,CU!BF;NS4-/IDD0QZ[(;&) MLC`NI+)GI7BM)\U>$"5Q-V'GB$(5$8V@MP,565::2\?"H?#F&0^8'*46?C!D ML[-"JPAR=5^+P9#-_CHPZX:IJX:.A;OBR$[T_GC4'[(ELY1N M%:*Q.1V"IU2#=##B;K6W<=5L2"0JH]DS]W5LJTQDH890(S-@=J%PS,O)AAS:B8?"=B M%N?+I[7HMF=]K: M6WD1E;J&O41UY3L4H^M9J[I9]]EF#Q$Y7DCX))JC57#SRYPC;:N8Z_:*@6.! MCFY1[T?QA"\SI;Q>Y:Y'.D4LZC1XDL31>,36L(8$I\KRCF?E;<]8Q4X?N$%RN5'C1X*I%YXI)J3Y^ MI6/5.89YF$Q+.S,;/X97UOH#,81)?#J&S6Y`+&'PWA2J_?O^%9*D]_+_@8G" MDBE$P7G:W)D%+%-8KK!"8:7"*H75"FL4ME#84F$KA:TIHQJ;#4VH\=MG;`.[ M_PE&T0Q1<*`VERB3*)>HD*B4J)*HEJB1:"'14J*51&N"B'YPT[M$O]:+\NO) M<,SRYQE:A_2""3,\E+!DB>#G"[!4'_8B-]YSXT(J;[%Q4_)R'[S'F M]3[UF"$*-R^(@CU(YAQAQ^5:D!,S6D&397^L@C8_#Y". MY.J7(8KZX282WE"F9^8Y\:3-,#GEQYIALU'2#$Q03=[397A#MA>;Q]:*2(^Q M8*!YQQ$[CD,C$4[@QV5Y<21MH)G:NT]YZQ6R*0M1A1DNW.% M90K+%58HK%18I;!:88W"%@I;*FREL#5E1-?DL@RN-:?;"41A!BQ1)E$N42%1 M*5$E42U1(]%"HJ5$*XG6!%']+LO7$IMXP?W-WY/@TP]Z9YVA59A>2)1)E$M4 M2%1*5$E42]1(M)!H*=%*HC5!5-++,K:DR]C<`C9#],Y39K0*'O!EB.@C4?ZP M.)>.A4/0O7ZMX0^+2V_EJEHYY)??VB$2:\06O,9;N5@+AWRLI4,D%D]G5][* MQ5H[)!_RP-D771;?3JA;L4RR]%:NS95#7K_:(1*+OX/8>"L7:^&0 MC[5TB,3B\W7EK5RLM4-*7_#<_9V^D`E[8A'I"XL"23.T2KI\/4<2&!6(@@U^ M*5$E'6N'WA2F\59.F(5#H1J+9:XKY^@?/ZX=4D0V.7V8D[\C,FX!@D0\ ML8B(;%&@7X96H(`D6E48$H5%2B2CK6#E%%68K8>*M.48=:8=HWHY>(@DJL)%H31[)K,4]> MR7TT.*`X_^EH&X4);0(#@M>N7/WG:$:4MF;!NXFYM"I<_+Y_)[Q46"5=:T3P MBF2PQ1FQ'+#Q5JZR"QEKB2@*JK%2V)JX4KGY)O$C9]"IW#HZQ%Z.9%GZ',W" M@SKG"6^%F(/I:#`>#WE&F4N_HO,;6K]H%"5#=I\M`R.G:R5CU8%96X!48NUIK$HIW&MXZFT\[Y5C"U>\'P6!@1 M/8GDG_W-T2H\B41D-KA^JSYFV^O<73%\Z2A\+:*]:13.RCSK[X+)%P<#,Z=2 MA2RH6=V9P0K:14LF[,2Z"\KIS:C2;I:(OHR7G*[CMS="03$F/U8?!TK16=DTO/PM4".N<- MSS(P MWB"UFVTEH]?G16_0;!S>#I()>^EGX8+]:BYA0H*ROMV@E0OVMF)K-+-:TS%@ M]I1B#)SS9"6UNU$R61&%3U:<6<`RA>4**Q16*JQ26*VP1F$+A2T5ME+8FC*J MJ]E9AKJ^O6F!W^\2L\BB\,D*6@4HDRB7J)"HE*B2J):HD6@AT5*BE43F9\M, MLVV#K'[V9\CL#R(];P]?M_/MT]/QZG[_P_S$V-B\3M=A_/VS>#"]@VNE*N`R7F`SVE9#">FE?=M!)HJ1XMAI;:)9/5`%X: M@A*M/?!;JGN"@V<^@`U3[&"Z@U38!(15^!Y+`/4YI'BBB"A+!%>!%6L4C M@FNHL2"AFY:0ZD@?2,ZF)O.2)9!534W*)$L@CX!H6ITA)X!H6@FL\1!-+4DF M4[/)E]>!O2OX:`,6-EI0HG4+/.`!V;02V)!`K;4N@^T%U%HK@9IE58"O0`/2K024!2.[;62%$JTL0.GJE"B M35HX'802[18`IUQ0HDU`V'6#HEI[X/'?U.RU9=W@*>#4/./32F`DJBV%)R10 MHK44CO6A1&LIG$5#B=92.%.%$JVE<#8()5I+X8P+2K0Q"D\DIN81A&P/'*-# MB58#.`Z&$JT&<*P))5H-X'@.2M0:P$@LU9$(GQ]-S>=%LF[5((82;53!)R)0 MHFD-K^)#B=8>>"X]G:F]/8<26P#-G:*E6:W@""B5:K>%Y M')2HM8Z@UC:38TL!?.X+)5HOP)>N4*+U`GP#/6W4$OCP$-31[@?P+1V4:"V= M#:PD#3>`U-U_@,6C%36P%?J$_-9\2R5S(HR=02^#A] MFJLE\/7YU'Q(#-%N.O'A]U-?-U^WJ\WAZ^[E>/6T?83DI]]^2GFPO\!J_W'" MSP"^[$_PRZEP3@@_%PF_E+N%G^SIFV\%'O?[D_N'N4#WV[N?_R<`````__\# M`%!+`P04``8`"````"$`V+I]8>L'``#"(0``&0```'AL+W=O[?=Y99"#-#SC.'S/?[GX[.SO+WLVOW\ZGR=>\JHOR;R=_O4Y^L6?3NHFNQRR4WG);Z??\WKZZ]W//]T\E]67^ICGS008 M+O7M]-@TUV`^K_?'_)S5L_*:7^#-0UF=LP9^5H_S^EKEV:%U.I_F]F+AS<]9 M<9DB0U"]A:-\>"CV^;;3\SY('B]EE=V?8-S?+"?;=]SM#T%_+O9569;5?#4'IKN;0P$CT+)/JOSA=OK)"E);3>=W-ZU`?Q?Y43L#?U230_Z0/9V:/\OG."\>CPU,MPLC MT@,+#M^W>;T'18%F9KN::5^>H`/P]^1!H6?V8Y M"^\='8'&VM'`TU!8[QZ,9SC@V0UF9ONNY;8=>46%I7&$IW%T9TMKL5):`^DW MQYEH)W:;-=G=354^3V"U@-;U-=-KSPHL"(AN2I&BG^3_FF.87,WR2=/<3F&= MP_35$)A?[[RE?S/_"L&T-S9K:6-1BTUGH2-'TVXY$'(@XL".`S$'$@ZD`V`. MLO3:0(3]']IH&JU--ZIU![R(93,A.HO.9ILAD4-G+!VZ$85@HM^AD+:F"B$R5`B1H4*(,(583(7"+3((58@EW%UOU"LD MB!)ADPYMB!RP&;U##FU-Y4!D*`*#PZYG2PEJ6J(H0#4S% M=K^-<22!B8XF6WHKWUTLV62$TBTR$(U4*2"2JY5)F"N6^6+)G(PQ*\7$3XDC ME547NQ^3%UWZ]-E\ MQ9(Y&6-6BH5\2ARIK+JP_YBL>"0@LB+$PE6D3[0BX8J029^^Z\@]23A%%D(T M>J6H:-5MZC.751"QH1ET)Y%02B"JH"[G/Z8@'@2(@@C1P)09%*T&$;:U#`2/ M?B]1CMB$##UHTEN-%)QC5E+8OD5=R;-%$'?]&9:CQN$%2HD54=6&;"-5?6=& M;4GH%F4@%J(\HQJK04QL#40SJJCHNQ9)KA09==1*"&RL3.1:BQG+3[$Q&/0R MD5!*(*KQZ%'IO1K+4Q-T2.]'-(@=MNXVQFH8Q`;R\2COV1YIS>87P_%'];\M350TD%$LHD9"^J-5=Q7[AF/'B%>_GSGGUF&_RTZF>[,LG?:D*2_/NIH?QQG?M M!/#]'BH5CMLV7`6W-:MXH[I+8O8F=H.X#1"&)VX`G_AD&ZD;P(<^B<,GB$!_ MPLWVF-,:SV\D1;6,+CVRP?G=X!_[,7:#=9C@]BX MP68,#]T`/J6.#`U&-C:PR`O@*_N(_3*`S\TCN!_`-U?`Y_T(X`;]FCWFOV?5 M8W&I)Z?\`8)AT7X)J/`.'G\T)CW9X@C_5R*'B]2%_C#S4)9-]T,W MT/_OB[M_`0``__\#`%!+`P04``8`"````"$`X!VXP8@.``"320``&0```'AL M+W=OMK;T\$XQCZMC&!20YY]]O:R0AJ3^%8'9?@O-U]]>C5NO6:/CTVQ^O+S?? M-_O#=O=VUPMN![V;S=MZ][A]^WK7^]<_D[_->C>'X^KM]O<]?[<''J_ MW?_U+Y]^[/:_'YXWF^,-,;P=[GK/Q^/[HM\_K)\WKZO#[>Y]\T:2I]W^=76D M_^Z_]@_O^\WJL3-Z?>F'@\&D_[K:OO4DPV)_"?M^T&ROZTOH7E?[W[^]_VV]>WTGBB_;E^WQSXZT=_.Z7N1?WW;[ MU9<7:O[PZ[I^,MT?7E@V*;Y_UYGYCN/SUNJ04B[#?[ MS=-=[W.P:(?37O_^4Q>@?V\W/P[6WS>'Y]V/=+]]K+9O&XHV]9/H@2^[W>]" M-7\4$!GWP3KI>N#O^YO'S=/JV\OQ'[L?V6;[]?E(W3VF%HF&+1[_C#:'-464 M:&[#L6!:[U[H`>C?F]>M2`V*R.J/NUY(CK>/Q^>[WG!R.YX.A@&IWWS9'([) M5E#V;M;?#L?=ZW^D4J"H),E0D="GA^2,X4@9TJ?=:XLZ?-C MSQI0'G4^Q1\?>]I`9X3XXX//&U`62;:`]9*YP%U`E=CJ37$@!>T$0=B#B0< M2#F0<2#G0,&!D@,5!VH.-!QH+:!/L3X%G'+L_Q%P02,"KD/UH`'3`R&+KM;0 M)A$'8@XD'$@YD'$@YT#!@9(#%0=J#C0<:"W`B2X-0XCND&83_\*BLU=8T1)R M-GNESGA^BO@2D`B0&)`$D!20#)`E'2<(T!B0!)`4D`R0')`"D!*0"I`:D`: M0%H;<:(J3K7V'NS\O"JTW:A*Q$Y,0")`8D`20%)`,D!R0`I`2D`J0&I`&D!: M&W%"2&<-)X3=-I:.A#0#/F_7OS_L:"*DZ=`3V2'M5N4>5G"X@97(Q.RREA)1 M9])NBRJ1F3O7SMV4CD]*.J430%)`,D!R0`I`2D`J0&I`&D!:BNPFC9 M7&P/7AHMS54A5VVT;*ZAV\;&:&FNUN%R.TV<1^Q)1A[T;D7%PC,J*.)Z6(@3 M-1L7"G)Z2FHY/:4,AZ/3BAEK,@M+%&:9IBO&/8A2!?6%$W@)6=&+E-:IE%/!0%G-EF4AQVIHPCF+;V84-$V.-(71ZFCFG*8T"IJF0IK::`F:T7C"=C2-4=`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`P1:T,H1P-"]0J$:K0L$:M!J'6,72C*THIUT57%6&LLTVHH-%<5\_8 MA+14&LZ0D$;.R@%0@H:I@BS##*$<#0O4*A&JT+!&K0:AUC%T@RTJ&=<%6]9` MG%26D+-R8/5,G%%9/45!Y[=>L3:471D$["28:+FI@Z87$6?:4!*/&&^NQ8:W MN(BWU(:*EV_9M-CPUA?Q-MI0\;))OM7BCM?M;5$AN:ZW96W%Z6T)N2L.5,]" MJ>4,+PFI%2<<#UC`8V7CK#9`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` MWHMRJ1JCI*E:A\KMN.OJ.T.L[RC(W6U#?4=I.-C-`@79 M%V(1BA"*$4H02A'*$,H1*A`J$:H0JA%J$&H=R`VIJ)_8(167_\*QN![[P?>\ MZ-X>1%M"[J7N,=N5+96AU2<10C%""4(I0AE".4(%0B5"%4(U0@U"K0.Y'2"J M+G8'_"*G99'&WNF)J8?2W(K?$J$(H1BA!*$4H0RA'*$"H1*A"J$:H0:AUH'< MD(J:Q`="*DL83D@EQ!*7?]4R/&GIR3E"*$8H02A%*$,H1ZA`J$2H0JA&J$&H M=2`WRKP4\HO$Q?H'O4;>)6[W-GEW%E@B%"$4(Y0@E"*4(90C5"!4(E0A5"/4 M("3>GC?-EB&5;\/+MV]?-_NOF^7FY>5PL]Y]$V^ZTQL$]Y].L'P-_V$XI/?P MN^\F0#(B27?7"B1CDG1WM4`R(4E7D0#)E"1=#S$)_1#`Y^[J$,,?Z`<"NJ^Q M.!XNZ-U,&BD<%PWQX)]'B\]>QP_4/F_SJ'7>QE';O$VCEOD:]C!;T-LD^*"T MSUZ(;31*:-N\$+MBE-`N>"$VN2BA3>U"[%E1$@U#\N,+%6WTR(]/0OLV\N.3 MT#:,_/@D43A=Q%3TPB=(22+J>RBAXMU"E.900G6WA:BJH20:#J@]W7F%=3V= M^*@]/@D=Z:@]/@F=V:@]/DD4CJ@]OLR@[W^H/3X)?<%#[?%)Z!L<:H]/$H43 M\N/+*"I]DQ^?A*K9Y,CK5O+C MDT3AD/SXAB!]24E^?!+Z%I+\^"3T-2/Y\4FBD/*`[DI@AM#-#O+CD]#5#?+C MD]#=#/+CDT0AC5-YTN+Y1A)Q.P&?@&XCD!^?A"X7D!^?)`HH#^2N@?LAB;BI MZO%#$G$5%25T]70A[IJB)`IHG-+E0Y3034SRXY/0)4KRXY/0_4?RXY/0RR$D M\69(0!E"-_U]3T`9XI70BP?T!#X;>K.`_/@D43`F/[XYG*YDDQ^?A&Y9DQ^? MA"Y.DQ^?))HOZ*TV;$T44(92!1PE]#X8^?=)Z.TN\N^3T+M:Y-\GB0+*4'HO MR.>',M0KH5>5R(_/AMY$(C^=I']*1/I)G/?5UTV]VG_=OAUN7C9/M)$8=-=/ M]_)'=>1_CKMWJO'1#^/LCO1C.-V?S_3C1QOZB8V!.`0^[79'_1]ZW/[IYY3N M_PL``/__`P!02P,$%``&``@````A`"AMM50(`P``C`D``!D```!X;"]W;W)K M&ULE%9=;YLP%'V?M/^`>"\&FI`$):G25=TJK=(T M[>/9`0-6`2/;:=I_OWMM0B%)5_)"X.9PSOWRO2QO7JK2>692<5&OW,#S78?5 MB4AYG:_:%@-_V1"5E3#H\R):B2CJ7FI*DGH^Q&I**]=RQ#+,1PBRWC"[D2R MJUBM+8ED)=7@ORIXHPYL53*&KJ+R:==<):)J@&++2ZY?#:GK5$G\D-="TFT) M<;\$$YHAKS@BP(,*V7*8<(,.V.9-G*W03Q;3!U MR7II$O2'L[WJW3NJ$/NODJ??>$/J1H@I?)R=OWI@(_I).R MC.Y*_5/LOS&>%QK*/86(,+`X?;UC*H&,`HT7&C<248(#<'4JCJT!&:$OYG?/ M4UW`W=P+)GX$:&?+E+[GR.@ZR4YI4?UM,>A3QQ&V'/#;"A M5&LY#6$VY,7S%$9X=CYH07QO*-%:H"%Z15NAN1_!0JK6<1K,8\IKI M$,Y'A(,O#C5:"TRHMW`B_WPX`:#&QV/00[&#Z32B`,_QZ%09]!$U$H!I4)?H MG5F`J`O4VL,?O8T#0P!J9P(Y&@"F-G[HS3YLM<">=#BDW6?R!!=- M!(,^2N&[`P!7SP7Y:@]\/Y#69':5'U&ULK)Q;;QO+ M#Z?SYN5^\W1XV7WN_[D[]?]Q^_>_??IY.'X[/>YVYQY$>#E][C^>SZ_S MFYO3]G'WO#D-#J^[%SCR<#@^;\[PU^/7F]/K<;>Y;YR>GV["X7!\\[S9O_0Q MPOQX28S#P\-^NUL=MM^?=R]G#'+X+K_".+-UL9N_J+"/^^WQ\/I\'`> M0+@;;*B^YMG-[`8BW7ZZW\,5&-E[Q]W#Y_Y=,%_'8?_F]E,CT'_VNY\GY\^] MT^/A9W;N#+X?#-F!;W!H'SC?).FQ[XY[%WOWO8?'\Z_^OP M,]_MOSZ>H;M'<$7FPN;W?ZYVIRTH"F$&XH`'P_[WGO1D:H,CFC^;W MY_[^_/BY'XT'H\DP"L"\]V5W.J=[$[+?VWX_G0_/_T6C@$)AD)""P*\-,AJ$ MTU$P&E\1):8H\$M1@N%@$@QGT>3RIH!E!'6CF#_9:XHM;<8-COTFEU>:\N?UT//SLP?P$;3F] M;LQL%\R#J-^S281#ODVKO\HJ2"<3Y]]MOBP.N]YZ1%\&DAE.=B='H:#-M@63L2"54=S4R&9`KS M1JM^-!8YG+1&-G2J2*9(KDBA2*E(I4B-!!O-5(,A\\NJF1A<-22N:DA7O(8=B&''G7'D"B*9P/S@C"EQ>4LTBKJ,7I$;)$GK%HYF7)6$ MW/AX%?*G*G9V2>S<&UO,W86*75X2N_+&'O.+J]W8K'/,UE!50U?.#R8&[RU1C90[09BHT*C4J-*HUFC-$-?/[!]<_3Y2])I;`W(( M(G(+.+)R*SA"[Q2^G95=-%*-,HURC0I"GCHV,/N"7U8"-Q1%?528L\X["K;U.\I2J;,XYG[/46-5)`5-I8K M9^K]CRF'.P4VGA#Q@E'>3EN:&0XD=RM&0L$0QYBHS!+K@3?#38V9ONV1:8_\ M;8_">C1U+)?(5-T?DPCK=0C=I1PB/KBFLL@+T(H-+HHUA`6@&UU3D2,)>09L M=/E=54I:LVY@YFTX?E91@!6LO5P\4T-_3#RLOIEXB,3X$ANP9>"6[70[EF*Q M'>=4I'1B'=UA=HECIAUS0F9.=WI+G+&PCIY!9VK:C^F&U3#3#9$8=&)B6@9H MQ08=Q1KRRQ`34T*>?-#Y7<7,E'E<\Y:QL\[$K%"P]K)!%WK+_DN6@\:35ZP6 MN:6^AZT\+/&PU,,R#\L]K/"PTL,J#ZL];,T9U_"Z4A]F<[F.$G+J^J5&*XT2 MC5*-,HURC0J-2HTJC6J-U@QQL4Q5[F;KV_NB$(MXL^2TD\-X*N;C!5FYI;Y& M*XT2C5*-,HURC0J-2HTJC6J-U@QQ_2#3K]'/F(LL131U'IF$B&;=K_LK&RLRJ(N5DV( M75`\%"OBFJP"G,*X\G)K\<[(U9N($!%3'A%3'I%HJ!`PH5B.8VJ1JU84BH(I MZZRL6KE%G5J%16ZL>"B*F;*SLK$JB[I8-2%Q06*!7Y.55WFY9WE'>;U1@0V7 M20.F/")'P!59Q6T-FA!QC%*+7&6B4!2766=EE2O6L[F=PF=9LXWX M"V7?27O:@'3G682(8EC>VK4H'HJ:?$E6;C5O':=X4R8.Q\%,")=HMY30!&;P M]GSJ`4-F'7$'#Z^2B M;V83\[%^H^V/VV^((IBB6QVC2*P^RQ"MH-:T<^R*4#QN^BT(9_%X++H[T6XI M(7,[OSV?I]^H5>8]@1^WT6`B&I3KR`6A43.:V;%Q(>A^T'Q M&T]>'Q+B21.(^F-)5O#3BF\1R-2J&`=B&D_(:@(#NK6"].+//%.OE7R"G75G M;'J$Q\CMT:Z)Q45A2^LX:SIZ'(MKK^SQ+G!M47=_>&U18\6["V9DG2M7/H.. M3!#1XY:A>STCU'3:5\9N3MUUO6W5Y^HW:C:?%@0$HDD)HTE6<%H ML8XKZXBK3S0)@DAN>A+MEA+BF:65QX9&.+CCP7@V=/\3S8J+SE.256S> M;OEQ.XW@S9ZI"%[IX#6A@-U'BP.Y3V.>O`O-7O9#"U&$NV"WR"7$,DHO1&3E MC+H5(;L0!7$\&8MI)-%N*:%W%B*R@A\C[7@0B1UQKB,7A%C^X/4ZJ-*.-2&6 M/^B(U\O%-WO7CXF/NUXF/B*1/T+%9816+'\(\85(5$$).?)TT=,9QN)6.JG: M,YH>B0>J0U0C"^_I9>"2K"B+PLDHEG5HI06H+7)7([<%O,_,1ECUV;6K$>ZF M6?8I#^-`B%O-SHMU20N]E$@:GY6DT"$2#`U M(;$@J9T1\^2=9G;3'^LTW(>S3D-D1DU;J7D6)+1R!N@J0F07I!B>0$5"VH1L M'+>4$,\RG3_4*IL_L:@Y[U4T'M)0JVR22)OR^0ZO MV^#N9!++!P9KYLGZ+_;>=IB83S'Q8PO[TNCEMT2;D'Q72XBGFKQGMB0K-]5L MK"'>#0KC",H/L05)M%]*Z)VTLH[M/FKD;J/DHY+$4[?3X`/K3P"TR9?K#OHE#NOP/"$'=K;/$428L&]\KFY.:[/`S?_0"S? M>>"V!ASQ72;LR.!(\WZ:/$\T@2/^%D`T>`/`TX(PAB,^=>`9+ASQGB<8:F6[`*HKEY%5H?68#/PNNSA"-+[Q%X<6-N'AGJ:/#^ MQMR\G>$[$L,1GP;P3!R.^#2`1[MPQ*-NF6K M\1P^$]0\&\_ATS_-R_$%]?CFO]S^_IET#7NKZ\[,LSOJ"U M_HXZ_>OFUU]6K[A]ZDX(]1HP7+JU?NK[:V08775"3=DM\!5=X,X!MTW9P\_V M:'37%I5[ZM2<#=LT?:,IZXO.&*+V'@Y\.-05BG'UW*!+STA:="Y[6']WJJ\= M9VNJ>^B:LGUZOGZI<',%BL?Z7/?OE%37FBHJCA?D/A;ZI MJQ9W^-`O@,Y@"U4UAT9H`--FM:]!`0F[UJ+#6G^PHL)R=6.SH@'ZJT:OW>1_ MK3OAUZRM]]_J"X)HPSZ1'7C$^(F8%GL"@;.A>*=T!WYOM3TZE,_G_@_\FJ/Z M>.IANSU01(1%^_<8=15$%&@6MD>8*GR&!U;L.#ZWU_6NN. MO_"6IF.!N?:(NCZM":6N5<]=CYN_F9$U4#$2=R"!ZT!B+0+/<_U@>3\)6-*5 MP'4@^?Q"_($#KN-"/BMF.7#`=>3XM!@H+RH&KO]:3#APP'5V8/S]*'\@;0O)`6-8Z:(/,Z"#G7S;^ MTE\9+Y"GU6"S56TLT6+'+4A2$MI8!A(92&4@DX%5$@=O05Z_,UL/_GSOB9\HGB%+J*S)OLI-C!DYMV*(!S?( MTYN;%XJ"$F;D!C1HCN^%GB=:I`IQ=@]Q+A#;CN^[$G$Q)18RB$S"RBOQCL@1 M/S%R#"$QOX4@E/9TQXQL-D#10F)(0.KQ9>.$KBD7T6C`TR!52++1AI+XSE(B MR4<#3E),282(P&"@1.23+850B,%AB)164M'LF-$TK1@2N#0XH1^$2G1&"RXL M55BRT89$)[!]RY/#,UIPEF+*(H3'@B%=B<\]M48=Q:@,D,-&IJ'>#U31A!L@3WTO2=)KZE9WJ^E`R%P"V&DXR)/P[G M=WR%JOS9F])BLZ80SP$R)X,2-YM@\0R6S&#I#);-8/D,5HB8*)\,CQ/Y'T\$ M<%HA]^X!\I=C.N]4*%:A1(52%6W*$-/.,K1W!9Y[Z["U(G%/XX$8/$,09!U`^ MA\=>!*.X:A_[$8RW*I[Y$8RL*AX'44(K1!*6!1&,)3/V8930[TG9/HQRBAOC M#3C*NI9']%O9'NM+IYW1`3;>I--;RP[#V(]^*/%'W,,A%JWV$QQ:(GCAFN1C MZ8!QSW_`@HSQ&'3S#P```/__`P!02P,$%``&``@````A`"WYY?U;'0``"K`` M`!D```!X;"]W;W)K&ULK)U=<]RX=D7?4Y7_X/)[ M;'6WNB6Y;*?4S6\R5:G43?*LL>6Q:FS+)6GNW/OOL]$`21PLC"0J\S(>+1R` MY,8!N,'FQ_M__\?W;Z_^?GUW?W/[X\/KU9N3UZ^N?WRZ_7SSX]/SU;?;'][MV_M/7Z^_7]V_N?UY_4,E7V[OOE\]Z,^[7]_>_[R[OOI\K/3]V]OU MRKFQ^O?0OO[I[3QNV7+S>?KHO;3[]_O_[QX!NYN_YV]:#]O_]Z\_-^ M;.W[I^6ST]:OOG]ZUO_ZXO;OZY9N. M^Q^KTZM/8]O'/]#\]YM/=[?WMU\>WJBYMWY'>JJ6/[S_?Z`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`I0$J0"J0&:4!:D`ZD!QEB8F32E&MD>EP>%ZV1J]EV&G>KBYU-E;T/ MVJEC_CSH,`5-"052@E0@-4@#TH)T(#W($!,CF[([GM"/ MT\X!I``I02J0&J0!:4$ZD!YDB(D10ZE@Q'#S^7K[1O$+9W37D-7)$^D4Y]&9 M3;;#%#3*6X"4(!5(#=*`M"`=2`\RQ,1()[MAI'M\Z+EHJX\GN[-Y'@(I0$J0 M"J0&:4!:D`ZD!QEB8L1P*Y'8%SPNAHO&/'1N4V/O@Y)Y*`DZ3$%3_H"4(!5( M#=*`M"`=2`\RQ,1()O.X0#(7;?/'DW@>`BE`2I`*I`9I0%J0#J0'&6)BQ'!^ MV*CQXHGHV))5*J!D*KJP^7:8HZ9<(BJ)*J*:J"%JB3JBGF@PR.KHK.?S!Z); M2R1I%5"<5T0%44E4$=5$#5%+U!'U1(-!5AGG-!YR@3+>C!H7J>M%=C3M5S[*3-^(.LQ1H\H% M44E4$=5$#5%+U!'U1+K^XWM_[1+"ZN>LY@+]O#,UF17,:N0I5T`%44E4$=5$ M#5%+U!'U1(-!5AGG.V-E7CZK>P=K1)M,[6PPUR>X1C!%S1D&5+IK;6YHSQU0 M$=5$#5%+U!'U1(-!5D=G0F,='[=7;FBFLWIL8_VJ)41%QUP0E40544W4$+5$ M'5%/-!ADE7&.=($RWL"JO3$;]JO8TP9E@`I&E40544W4$+5$'5%/-!ADE7'& MB@J@DJHAJHH:H M)>J(>J+!(*M,ZM6=;SC3+UI/7?]=T[4'=#K-^(O)5(\)O0]HMXGV/'C0&16,*HDJHIJH(6J).J*>:##(*I/: M9=>Y6R7WXZ9F3=L<4-RU(>B)KO51<[UR;-QV[7QEW!Z`,XO//S.XGT`3-Q:0 MZ=K@0..N!2I9L2*JB1JBEJ@CZHD&@ZPRJ4]U7;LY=[]9/]6[M*QKC^9>.@3B M/$\T`#%PTWKE6,_V[GPIVAZ#,W\+>M>%)Z,QH,1LIQ?& MYZ@IQ8A*HHJH)FJ(6J*.J"<:#+)"II;R<;>QH9$,R*28CXI0P:B2J"*JB1JB MEJ@CZHD&@ZPRRYSJADXUH'A:)RJ(2J**J"9JB%JBCJ@G&@RRRJ1.]8F^A!)0-,`.1`512501U40-44O4$?5$@T%6F4>,\M)IG[ M>:'JKT7-46,^%40E4454$S5$+5%'U!,-!EDAG8M>D&+>=)L4"SY\OO1_V``5 M1"511503-40M44?4$PT&6652M_[_<`YT\IM@V^.[>W:[><$<4FR*FE,,J)S; M&J,JHIJH(6J).J*>:##("KG,W&\FS3X@,XL%-^5<0E40544W4$+5$'5%/-!AD]5OFUD_IU@.* MQQQ10502540U44/4$G5$/=%@D%4F=>MN6O>7QA<:AU,:^8`2XS!?*/.S^APU M9YAO*U*[9%1%5!,U1"U11]03#099'9=Y^]/)VX_'O`\H.N8#44%4$E5$-5%# MU!)U1#W18)!59IEK/Z5K#\C,ZCXJ0@6C2J**J"9JB%JBCJ@G&@RRRJ2N_8E9 M?7+F\:R>V/#]:3#KFL+FRWRK).HP1XWY5Q"51!513=00M40=44\T&&3U6V;6 M3VG6`S)CCF:=42511503-40M44?4$PT&666<*XZ7,2\WZZ?>8,=+G("2:3V] MDCQ'S2E&L\ZHBJ@F:HA:HHZH)QH,LD(N,^NG-.L!7?C'+-UC90>B@J@DJHAJ MHH:H)>J(>J+!(*/,=IE9/X9;LQZ02:/U*G4'<]241D0E4454$S5$+5%'U!,- M!EFQEOEW]^MU\E-70/%,1500E40544W4$+5$'5%/-!ADE4F=N9NI_!-#CY\- MM_3H`;G[*J)37SHOC5'^8>7C:L]FK[ MQCT<_,2QTEIO/=*QCL/B,*)Y_XH1S7N=EX=/+'']+=; MCY[JG1`U[UZ1K;A.;LPMQZBY8C4BVSOS/8CV4%.;Z@[U>;U#Q[KUR/1.0//^ M%6-4W#N(JDR4W>74/SY[[$Q._=:CIWHG1,4'D:NX3JXBE&/S<\5J1+9W MYI\W[*$NLWI;6KV`S`1*J\>HDJ@BJHD:HI:H(^J)!H.L,JG5>V)@TLYM@RN+ MGAPD*HA*HHJH)FJ(6J*.J"<:#++*+/-N>H([G'2CL\:H M<8`51"511503-40M44?4$PT&&?V<,3.+B,]`EE)B<:CZ9D ME;G7S95'L90ZT9A+H@YSU)AL!5%)5!'51`U12]01]42#058_9S'C:T-/Z.<= M:7S]9^=1-,`.1`512501U40-44O4$?5$@T%6&6=E8V7J(>J+!("OD,K>NJ_B8UF'-#R$JRKJ" MJ"2JB&JBAJ@EZHAZHL$@J\PRM[ZC6P](FQ@3Y$!4$)5$%5%-U!"U1!U13S08 M9)59YM9W6;>>7++9ARAWFHVF]23J,$>-DA9$)5%%5!,U1"U11]03#089_;6S^C6`XJG=:*"J"2JB&JBAJ@EZHAZHL$@J\PR MMWZ6<^N;Y%KO/D39:3V-.LQ1\YB;;/Z(2D951#510]02=40]T6"0U6^96W>_ M)20KY("B`78@*HA*HHJH)FJ(6J*.J"<:#++*.%LDZS'I!$FV?U]6;^S=&;]3EJ MRC"BDJ@BJHD:HI:H(^J)!H.LCLO,^CG->D`FPVC6&542540U44/4$G5$/=%@ MD%5FF5D_IUD/*)K"#T0%44E4$=5$#5%+U!'U1(-!5IEE9OT\:];37TQ#5#*K M)U&'.6H>!Q3?\DQ4 M$)5$%5%-U!"U1!U13S089)2Y2$W[BS/LV)+U\P&9#-N=)5>^#G/4J'9!5!)5 M1#510]02=40]T6"0U3&U^(]?1[Z@CP\HGL.("J*2J"*JB1JBEJ@CZHD&@ZPR MRTS[!4U[0+$U)2J(2J**J"9JB%JBCJ@G&@RRRBPS[1>3:8\7>LGENWV(2JQI M$G68H^8QYYM7Q1&5C*J(:J*&J"7JB'JBP2"KWS)K?S%9^_$`]P&9,1<<^GSS M5<&HDJ@BJHD:HI:H(^J)!H.L,JEI?_EU9)WQTJOO`273^GP/NK_B,$>-O-Y]^V]^ZO[-/@6ST-;-CCEQ>T,H'I)LJQK0Y!*0W)(ZH M",A=*IIO@CA-G$4Y1XT5*Z*:J"%J`_([897(F?3%2M"?7WADE/#(*.&1?N%V MGXC3R]V3*W]E:":J4P6DVPM"G>1Z=,TZ#>HDX[TU=:Q`J?L^ILIS'A*ZH!$/ MR#VU'O5\LC.'$*67QHT]7XS(IDQRY.48-5>L1F0K)C+78]1-)N9.X]8%'59*VH#[^X M'=:S;G-5??G%LZ1J0UA`R+JDHYWUQ2 M-1W%8UA45`SS51/EG+=.?]?C(B;MP#1>P204F/()3*J`*7G`]+4F,'VN"4S?:XI9(I_SY+%\ MC[NPU8GW\%8FSXQI76\Y^4UAHYI2#DS*@4DY,"D')N7`I!R8E`.3SN!BH[`Q)R6BKQHU)Q&?TYQTG<+&YJ0K MFI.N4]PC>R>II["Q.4D=-Y=(_5>L&U8G7#B,S*KNXR*9I+IG6CO\B6..(L9# MDN!H28*G+25G(FD]18PM26NT)*VGN+!/R7E9,D\18TN2.6XID=DM"^(IGP8JYK1$ZJZEXU$/9IX3WU7 MTB^!%#8.,GU8TC-WPUM4%;T6D[)2QTY`HB>3"EA:IF-([- MN9?CS'73)%6O^$VX-Q7.8;MDP*NC?)@[]"B,'17"'M^J.BJ[58S'9VU5O?FL MK:HWLUO%@!R;^[-C3;KV.5^T6:[W#.-PS'A-.@\BS)8'V[U3.^0&>/4 MEV#J.-35MUL1IQX!T\A!76F-..D*ID$2UTT4A95%HH:6Y/0:$U"3W''UC8G>KEU^HU;23]%C:U)^KBU M1'JW2(/T"T_!?J%G^\`SF\BX%6$5OB\:):-F`U]5[_;QJNW.-XEFZH$I9CQ* M]8!G45OJ`<]6R?D\.3>J#^:XL4%U`AI4)\R!\-#:H?X@:3?G`K M./3#\X:`7_Q9^3U+AD`BHR9C'Q8EK>3W3._$.[1(3!%C:U)?;0F]:>X1X?`%#6V)NGCUA+IW:HNE?Z9/LGLZ]KY&DRJ>A;5E:J(4PJ#24/4E8:(4[:"2;&X;J*86\*] M4#&_^K.*>98D:V)EE*P^S":K9]9S9XQAJ*K5R>SXSI*+T9(ZUUJT>CG^B"KU M#1X$T6CON5)DCWHZ&]$>LL"3M$8>.4+3&GJB.3F&`2$TQB@DE,,(D))C'! M)":8Q(Q9(J9;FBP1TR]E;,YY9GYP<"]Q=&K.5Q$E$YAD`I-,8)()3#*!228P MR00FF<`D4\P2F=SB(Y;)79YUIG#A;=VK\`U9JY]?V=B?NLZ2RP[*O"ELS#)) M"B9)P20IF"0%DZ1@DA1,DH))4C!)&K-$4K>HB"5]XJ0P?L\V]DJ!15DFF?QB M)6*2"4PR@4DF,,D$)IG`)!.89`*33&"2*6:)3,[SQS*].//"BL+HYUF2>V8]2S* M,LD$ILP#DTQ@D@E,,H%))C#)!":9P"03F&2*62*3,_"Q3"[S7O8JLE7X`J^5 MT"\0;/*E%TNDZA06)1^85`63JF!2%4RJ@DE5,*D*)E7!I&K,$E6=;]M M]?,LR;SD`KXR;PJ+,@],DH))4C!)"B9)P20IF"0%DZ1@DC1F5E(M?*VD3V3> M,3ZYBRXPDWEDQ8JLS+`JP^H,:S*LS;`NP_H,&RQ+9')F.GO_]?KZH;AZN/KX M_OOUW:_7A^MOW^Y??;K]_8=.#RM]C2#BK^ZNOWQXO9?<[XZ::QQ-=::RE2L[ M_A":E%UJX?+N,E_FUFNJIY5-KLWUVI4=GXQ)VE2]C2L[_E3$LE-7=OP%A&5; M5W:\:X]E.U=V=%8L.W-EQQYFV;DK.]XZS[(+5W:1.;[+BXUDT:H^<^@JB(_/75=*=N-!QZ9&"3!W=_J?=TSV`V3(GH^YRRY8Y&75K5ZYL MY0Y9%TAR96N70MECOCP_?7>II[8RM53B'I7/E6@W]*AXKD3'K&>?CXQ5Z+,UCUFN1+E=?9(+\\NWEWJI0J9.BIQ M+X')E)QK#_02E%R)]D#W6^5*M`=ZK46N1`F1W8/+,_6/KK!FZJC$O7B_M&+E'(EZI_L'ESNI)O>')>IHQ+WJLM,R9ETT[,8N1+I MIB<[_NRY5(M^P>7.ZDF[\[+AV7*G%O5\ZTMI-N>KMPKD2ZZ76YN1+I MYA_6Q':D6W8/+K?23>_'SK2F$O="_TS)3KIYYX#M2#>]H3U71[KY1QQ11[IE M]^#R=/?N4C\_95I3B?N66ZY$&NA;9KD2::"/<^5*=*3Z.%6F9*LC]3?0I7N] MU9'ZNWY0HCW0)S9RK6D/LL=S>:KSH[[MEZFC$OKOM4CW M[53YIJ\KYNHHW[)[<+E1]NIKLIDZ*G%?6,^5J#7_PU>Z!QOUG+^3"27239^, MSK4FW?0-Y%R)>D[?`,Z4G*KGLGM]N5;&ZZ&83!V5#-D3]=[Y'EGA3)V-^B=K M>O8;]<\FVS\;]4]V#RY7Y^\N_\1&2`/]6)/9@^/)-JN!.]5FS[1[Y[GRELNY MJKRI6JM/\[9IK9[+&Z.U]CI[/'*#LC[9WE:)?&3V2)5ONH4AIX'V33^JYTJ4 M;][2I_FVTEYG]^!2G:`[?3*-Z6BR7:"\R7;`2AV@N\LR+:W4`;HE*U>BM,EN M_5)S1':O7%.YEM10-MYE7R;^TIW=,WSOYHP>NPO@G7Z;RY6Y7]5=F[GMN5_-79NY,O>KN&LS5Z8V3UV; M.2W4YJEK,U>F-D]=F[DRM;EU;>9T5)M;UV:N3&UN79NY,K6Y=FWF^EYMKEV; MN3*UN79MYLK4YL:UF;*U.;&M9DKT\W5YVI3MX'G^EUEQUO.6>;N M,%>;V7K:SQ.WG[DQI_T\=W[L%D[HE[D,0=02X#W5,A M[@AR93H"E[G9,O>8A&LSMSWWX(-K,U>F-EWF^K*WTUQW__']SZM?K__CZN[7 MFQ_WK[Y=?]'B_N3X%8J[FU_=M3C_QT-X#NZ7VX>'V^_'1^*^7E]]OM8G1D_> MZ`K\E]O;A_$/"?'VC]N[WXX7$#[^GP````#__P,`4$L#!!0`!@`(````(0#( ML>Y3R`D``)LM```9````>&PO=V]R:W-H965T?6LUVV-Q"=UB?O[V=?MLTAQ-0/-?[^O*S(QT. M#IME]GILSNOG/-])]!_ZNJ]-?X_:'?->W*NMV5]K$!M6">Q`L]- M\TV89EL!@?.(>5?S7M:U:^["RRW!S,2$UMN?X95NP%% M@>;.]033IMG#`.#?P:$6H0&*K'\\#%WHN-Y>=@_#B7_GS<83!\P'SU5[B6M! M.1QLWMI+<_BO-'(4E20!RXX$?BJ2Q9T[]QS/_P3)3)'`3T7BW,T];^K/9[>/ M!,*Z&PG\_/I(%HH$?EY'\EE)'%C);B3B/U>63\_'T>LC_O/U&3FPO'(T_3H[ MMR[S2(9,%X'A^K)^O#\W[P-(:QA2>UJ+3<)9BAYT[,E(N4;CGP4C1*%@>1(T M#T-8,8BS%C+H^Z,_F]R/OD/4;Y3-BMLXV"+0%B+$!6U(@8@",042"J04R"B0 M4Z"@0&D`(Q#NJAX(]O]03]`(]?2\5QKHY72)5-I"NX04B"@04R"A0$J!C`(Y M!0H*E`:`I)I8I)I`7MDW.1U7P@NV,R.NG`618B5MO,55OH`A(4,BAL0,21B2 M,B1C2,Z0@B&EB2"9ID2FC^41UI"YOJ&//YOB4%E)([\[@[JT"A@2,B1B2,R0 MA"$I0S*&Y`PI&%*:"-('CA&><7#:@0*[>O-MU?Z" M`\]?(N;\)6+.7R(SI]O=W;%#PBQB'K'R&&L/3OS,=$-JB8L#/_1O4$LX8K4D,@&=#;5\/)!`&KFRX.R22;EAD6?8+6)N ML=5MCMT2YI9:W1;8+3/=D%I00G*U/KGE"`XLG$1PF'EC/*9`&IEAIA#8'WN] M/;H+,;?X%K>$N:56-Y(+F>F&A!-E\U]6KB/!TBD(@DYG7Z`@,\2T%>P9AE0T M([EC;'>D.:VGV\[8NK#A5)0O[,B"H&AAV\X&AU9LH)N>E-:*<@LJQ1DUE4*6N#*@6[I MO96FCSE7TEL9>QXM4M/>2G-EG"OOK3[@*GHKS54B+JRN*&N9NOT&=U/U+E[& M:.I*"`DM(22TA*""%^\3E@I6,8.!GDNL((,FZ:T4#3E2TMY`TV2<)N^M%`TY M5HO>0-.4B`8K*RICINPM!;!(="JGA$AM0JJS0#F:Q8F"O+XLCC@4<\>$6Z4< MRKACSJT*#I7($>LF:N2OZ2:K:Z#6R[-R5,$-<694'*0\#905*E44%]1+AB,I M4"--CXIFGY2,L;(254;/Y9/M)+%:>:3'U-XC"=3,RD5[S*U6M,?"WB/)L-+* M9?2(EU@4]G2)75#\]@<#1]X-T%I+".>(3XK$0#FB')&.'MKN?7*^1LH1K'1T MQ0J:@?]'"ZN&.D%EKT]N9*F>$9CI#C(^V-PP,SLE;(5AIME*Q(871%P8Z((X M-^U5\JJ!UD'=/E#.^6RODE8HYQ07;%;&U&A`1HXTFT(E:*A.$6Z4LF+F94-]<7?Q[]Q7N?*Z]T MYA:B(+R5S\BY&B@K%&^2RQ.OB=\?G?EB/'7GQ"]2?F"D0S?F5$EOU5'YB]G< M=4C*I[V1ILHX5=Y;=523L>_[8S*JHC?25"6BPFK3&Z2X%'WN!'6OMTK=WTI! M.%QGI%`)E!6$@G8,%>3Y4G;?GT^(4E%OHKUB3I0HR"%G,3G=4L-,LV6<+3?, MS*."L!6&F68K$1N6WG8?O2W0^7W4E1`)=*)=H*Q0H$M';RX57XQGCD.C,U)^ M8*3G%7.JI+?Z*-"O_6FJC%/EA.I/`IU1E8@*JRUNB'1;N:DR$1L/N44IR'RE M5!`*9NF(]EX&Q=PQ49#AF'(HXXXYMRHX5")'+-*7KYHNOVHJB(0D*3P"985" M4G+A:IA5;]H1"I>^>J-_((V5%>:BI51BM:(]IO8>27F?6;EHC[G5BO98V'LD MVTYIY3)ZQ$LL[J-F'GS\F"J.`AK\$H+W04/X.5O7JY7.\U!Q&0^+$8=B#B4< M2CF4<2CG4,&A$D%8+''C^H18ZH+67[Q6\&V9T,]X4PXX%'(HXE#,H81#*8^,#M7YM0JJ_;X=;)HW\14;)/OC_176G]A-ED_` M!'%`6N"I>2D>;"TM[@R^R^N>ZZF/.]=?[)$6^)3OR;5QP2=^78E![%L#6E:=D\G#&`)NM!0X18+.UA*X+;#8%H,8%-EL+E*S`9FN!6@_8;$)# M\09LMA8HQ(#-UA*Z8V#K'B?93,?`9FN!*QZPV5I"UP$VV\K!O0C8;"UP\0$V M6TOH^$OQ6&I94V@1KZ&\!5X_E^*YD[>$SAS8;.F40(MX_>$^\-@#;+:6$,+` MNM8.Q"&\]G,N^$,$]&)K@3\K0"^VEM"!.(07;AL;#,#:`J_HP-;YC*Y+"I_& MGM:OU3_6Y]?ZV`[VU0ML.N/N3SAG^7&M_.6B_ISZW%S@H]CN+ZL[^`BZ@@\/ MQ^*#HI>FN>A?8%"CZV?5C_\#``#__P,`4$L#!!0`!@`(````(0"GG[SWE0`` M`*D````0````>&PO8V%L8T-H86EN+GAM;#R.00H",1`$[X)_&.;N9O4@*DD6 M%'R!/B!D1Q-()DLFB/[>>/'24#14MY[>.<&+JL3"!K?#B$#LRQSY:?!^NVX. M"-(J6]2_X27&3H!A:#H;7EI)3X0-G)4!;BWCQ*S:YUK$\E M2R4W2R!J.:G=..Y5[@*TVD,U>#XBQ/X!(?U26:W^(_8+``#__P,`4$L#!!0` M!@`(````(0!QCP:>D@,```D.```0``@!9&]C4')O<',O87!P+GAM;""B!`$H MH``!```````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````)Q7P6[;.!"]+[#_ M8.C>R$G38!'(*AQ;00*DM;MRLT>"EL8U$8I424J-^_4=2DTB;T?L;DZ6R7GD MFYDW0S)Y_UC)20O&"JUFT>G)-)J`*G0IU)=9]'ES_>:O:&(=5R676L$L.H"- MWJ=__I&LC:[!.`%V@DLH.XOVSM67<6R+/53WP6YRG%\@5C?'KV-(/]DQPXICC1C@)=K5;<^,(RA<4_H*8L,M<$RY3!>[%;UV19ZR/S9A\7J8[ZZNUW.-]F27T<6XY#PI1VZQ6Y8`=OP1QC+;%4)U\O,UP+JR6$C0'>Q-Y)[954M]0&` M78'"T&#PQYS^&V2G9%^B![8Q7%E>^#C1"^<@L>F@\C\U"``C#X-8+4DN>;.U M\+7!=+*L]:5"6ET%936BWB#FC-R'%AH&?XN=BD10>ON=^5!KH;7#DJ.]'M%< M>)NM"\T/%1BR6^B`$!D=O:!@:`_#76D$$]3"6Y);6'/GK\"\>P7F@L0<]TQL M<(X+20MT1-(A"*7IEQY*1SB,H:LMC*&STF&."NBWGE#6+,"(M*?9A"N4WF.L M0GL_R'2'(71"_($2%,9168>"2!F.Q(\TI4,7[A:T3V$,'>XPYC7W-+\3?,\-E'C!?II_&4AN M\`5AI%]DL>=XRRB?;'Z=\(^>^_YEEYZ>GTS?3O&-,!A+XI^]">\IZ0\```#_ M_P,`4$L#!!0`!@`(````(0``P@J:,@$``$`"```1``@!9&]C4')O<',O8V]R M92YX;6P@H@0!**```0`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````````"< MD5]+PS`4Q=\%OT/)>YO^82*ES4!E3PX$)XIO,;G;@DT:?<7\X]J9:];J)/<*A:4Y,L24D$1K12F5U-GC:K^)I$Z+F1O&D-U&0`)$MV M>5$)6XK6P8-K+3BO`*-`,E@*6Y.]][:D%,4>-,KVU'+Q3O? M`STXC7\.C,J9 M4RL_V+#3%/><+<51G-T]JMG8=5W2%6.,D#^C+^O[QW'56)E#5P((._33EHLBG->*GES3/)N!>@KP;^()P,;&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`$V$:)M1`P``YPD``!D`````````````````#A8` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`+@79=^@`P``;@T``!D`````````````````>C$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,@Q7.%5!0``6A4``!D````````` M````````.U8``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`+7NKP[((```3M0``!D`````````````````^V,``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`&!PS_EU`P``?`L``!D`````````````````.XX``'AL+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(```` M(0"0G*#7N0\``,BD```-`````````````````*R8``!X;"]S='EL97,N>&UL M4$L!`BT`%``&``@````A`,[4?8&VH```?3X"`!0`````````````````D*@` M`'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`#3WN>KQ`@`` M,@D``!@`````````````````>$D!`'AL+W=O$#``#I#```&0````````````````"T40$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A``O`!,14`@``-04``!D`````````````````OUL!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'%X!,Q`!```MPX``!@````````` M````````.HP!`'AL+W=O#0,``,4)```9`````````````````+"0`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A`-1R[(WF!P``V"4``!D` M````````````````]),!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-MB(4,Y%```4&@``!D````````````````` M!L4!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`&+3B2RI$0``K&4``!D`````````````````!^L!`'AL+W=OOL#V M$0``TFL``!@`````````````````Z@8"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``/W`%B@`@`` M&`<``!D`````````````````754"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``456&"7"```8"0``!D````````` M````````-'`"`'AL+W=O0(`>&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`.R->=*8`@``&0<``!D`````````````````B8L"`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`.`=N,&(#@``DTD``!D`````````````````@*@"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,+T7"6[!0``2Q4` M`!D`````````````````%,D"`'AL+W=O&PO=V]R:W-H965TY3 MR`D``)LM```9`````````````````)CL`@!X;"]W;W)K&UL4$L!`BT`%``&``@````A`*>?O/>5````J0```!`````````````` M````E_8"`'AL+V-A;&-#:&%I;BYX;6Q02P$"+0`4``8`"````"$`<8\&GI(# M```)#@``$`````````````````!:]P(`9&]C4')O<',O87!P+GAM;%!+`0(M M`!0`!@`(````(0``P@J:,@$``$`"```1`````````````````"+\`@!D;V-0 C XML 24 R55.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingencies (Details 2) (USD $)
    		 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
    Dec. 31, 2014
    Sep. 30, 2014
    Jun. 30, 2014
    Mar. 31, 2014
    Dec. 31, 2013
    Sep. 30, 2013
    Jun. 30, 2013
    Mar. 31, 2013
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Aug. 31, 2010
    May 31, 2006
    Aug. 31, 2007
    Oct. 31, 2007
    Aug. 31, 2008
    Dec. 31, 2008
    Jun. 30, 2010
    Feb. 28, 2011
    Dec. 31, 2011
    Jul. 31, 2011
    Oct. 31, 2011
    Dec. 31, 2011
    Sep. 30, 2012
    Nov. 30, 2012
    Dec. 31, 2012
    Jan. 31, 2011
    License and Sublicense Agreements                                                      
    Value of warrant issued using Black Scholes model                   $ 198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration $ 142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration                                
    Royalty, milestone and license fee revenues 56,000us-gaap_SalesRevenueNet 57,000us-gaap_SalesRevenueNet 56,000us-gaap_SalesRevenueNet 111,000us-gaap_SalesRevenueNet 47,000us-gaap_SalesRevenueNet 44,000us-gaap_SalesRevenueNet 49,000us-gaap_SalesRevenueNet 119,000us-gaap_SalesRevenueNet 280,178us-gaap_SalesRevenueNet 259,246us-gaap_SalesRevenueNet 450,404us-gaap_SalesRevenueNet                                
    License Agreement with Drs Falini and Mecucci [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                         70,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_LicenseAgreementWithDrsFaliniAndMecucciMember    		                            
    Royalty as percentage of royalty revenues                       6.00%trov_LicenseAgreementRoyaltyPaymentAsPercentageOfRoyaltyRevenues
    / us-gaap_TypeOfArrangementAxis
    = trov_LicenseAgreementWithDrsFaliniAndMecucciMember    		                              
    Royalty as a percentage of sublicense income                       10.00%trov_LicenseAgreementRoyaltyPaymentAsPercentageOfSublicenseIncome
    / us-gaap_TypeOfArrangementAxis
    = trov_LicenseAgreementWithDrsFaliniAndMecucciMember    		                              
    Revenue and license fee expense                 23,000us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_LicenseAgreementWithDrsFaliniAndMecucciMember    		 30,000us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_LicenseAgreementWithDrsFaliniAndMecucciMember    		 24,000us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_LicenseAgreementWithDrsFaliniAndMecucciMember    		                                
    Sub License Agreement with IPSOGEN SAS [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                           120,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		                          
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		                                
    Royalty, milestone and license fee revenues                 60,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		 60,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		 180,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithIPSOGENSASMember    		                                
    Sub License Agreement with ASURAGEN Inc [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                             120,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		                        
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		                                
    Royalty, milestone and license fee revenues                 50,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		 50,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		 50,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithASURAGENIncMember    		                                
    Sub License Agreement with Lab Corp [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                               20,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		                      
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		                                
    Royalty, milestone and license fee revenues                 28,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		 20,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		 5,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithLabCorpMember    		                                
    Sub License Agreement with in Vivo Scribe Technologies Inc [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                 10,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		                    
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		                                
    Royalty, milestone and license fee revenues                 25,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		 25,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		 27,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithInVivoScribeTechnologiesIncMember    		                                
    Sub License Agreement with Sky line Diagnostics BV [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                   10,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		                  
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		                                
    Royalty, milestone and license fee revenues                 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithSkylineDiagnosticsBVMember    		                                
    Asset Purchase Agreement with TTFactor S.r.l [ Member]                                                      
    License and Sublicense Agreements                                                      
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember    		                                
    Royalty, milestone and license fee revenues                 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember    		                                
    Assets purchase agreement, consideration                                                     10,000us-gaap_SignificantAcquisitionsAndDisposalsAcquisitionCostsOrSaleProceeds
    / us-gaap_TypeOfArrangementAxis
    = trov_TTFactorSRLMember
    Sub License Agreement with MLL Munchner Leukamielabor [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                     20,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithMLLMunchnerLeukamielaborMember    		                
    Royalty, milestone and license fee revenues                 81,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithMLLMunchnerLeukamielaborMember    		 85,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithMLLMunchnerLeukamielaborMember    		 71,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithMLLMunchnerLeukamielaborMember    		                                
    Annual minimum royalty for first year                                       15,000trov_LicenseAgreementMinimumAnnualRoyaltyForFirstYear
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithMLLMunchnerLeukamielaborMember    		              
    Annual minimum royalty after first year                                       20,000trov_LicenseAgreementMinimumAnnualRoyaltyReceivableAfterFirstYear
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithMLLMunchnerLeukamielaborMember    		              
    Sub License Agreement with Fairview Health Services [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                         10,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithFairviewHealthServicesMember    		            
    Royalty, milestone and license fee revenues                 2,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithFairviewHealthServicesMember    		 1,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithFairviewHealthServicesMember    		 2,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithFairviewHealthServicesMember    		                                
    Annual minimum royalty                                       1,000trov_LicenseAgreementMinimumAnnualRoyalty
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithFairviewHealthServicesMember    		              
    Exclusive License Agreement for Patent Rights with Gaidano Foa and Rossi [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                           1,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember    		          
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithGaidanoFoaAndRossiMember    		                                
    Exclusive License Agreement for Patent Rights with Columbia University [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                             1,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember    		        
    Revenue and license fee expense                 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember    		 0us-gaap_LicenseCosts
    / us-gaap_TypeOfArrangementAxis
    = trov_ExclusiveLicenseAgreementForPatentRightsWithColumbiaUniversityMember    		                                
    Sub License Agreement with Quest Diagnostics [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                               20,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithQuestDiagnosticsMember    		      
    Royalty, milestone and license fee revenues                 26,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithQuestDiagnosticsMember    		 14,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithQuestDiagnosticsMember    		 20,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithQuestDiagnosticsMember    		                                
    Collaboration and License Agreement with Strand Life Sciences [Member]                                                      
    License and Sublicense Agreements                                                      
    Royalty, milestone and license fee revenues                 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_CollaborationAndLicenseAgreementWithStrandLifeSciencesMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_CollaborationAndLicenseAgreementWithStrandLifeSciencesMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_CollaborationAndLicenseAgreementWithStrandLifeSciencesMember    		                                
    Sub License Agreement with Duke University and Duke University Health Systems [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                                 5,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember    		    
    Royalty, milestone and license fee revenues                 1,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember    		 0us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember    		 5,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithDukeUniversityAndDukeUniversityHealthSystemsMember    		                                
    Sub License Agreement with Genoptix Inc [Member]                                                      
    License and Sublicense Agreements                                                      
    Amount paid                                                   100,000trov_LicenseAgreementAmountPaid
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithGenoptixIncMember    		  
    Royalty, milestone and license fee revenues                 $ 30,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithGenoptixIncMember    		 $ 10,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithGenoptixIncMember    		 $ 100,000us-gaap_SalesRevenueNet
    / us-gaap_TypeOfArrangementAxis
    = trov_SubLicenseAgreementWithGenoptixIncMember    		                                
    XML 25 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Option Plan (Details 3) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2011
    Weighted Average Exercise Price Per Share        
    Exercised (in dollars per share)     $ 3.00us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice  
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures        
    Tax benefits recognized $ 0us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions      
    Stock options        
    Weighted-average assumptions        
    Dividend yield (as a percent) 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Expected term 5 years 5 years 5 years  
    Weighted average grant date fair value (in dollars per share) $ 2.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 4.54us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 2.12us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Unrecognized compensation cost        
    Unrecognized compensation cost 4,862,030us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 3,733,753us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		    
    Weighted-average remaining vesting period for recognition 3 years 6 years 8 months 12 days    
    Number of Options        
    Balance outstanding at the beginning of the period (in shares) 4,287,545us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 3,711,303us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 2,426,192us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Granted (in shares) 1,410,038us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 1,144,760us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 1,294,668us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Exercised (in shares)   (52,500)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 (200)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Forfeited (in shares) (784,111)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 (516,018)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 (9,357)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Balance outstanding at the end of the period (in shares) 4,913,472us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 4,287,545us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 3,711,303us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 2,426,192us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    Vested and exercisable at the end of the period (in shares) 2,434,124us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		      
    Weighted Average Exercise Price Per Share        
    Balance outstanding at the beginning of the period (in dollars per share) $ 5.18us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 4.69us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 5.22us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Granted (in dollars per share) $ 4.42us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 6.33us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 3.74us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Exercised (in dollars per share)   $ 4.30us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 3.00us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Forfeited (in dollars per share) $ 7.08us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 4.35us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 3.00us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Balance outstanding at the end of the period (in dollars per share) $ 4.66us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 5.18us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 4.69us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 5.22us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    Vested and exercisable at the end of the period (in dollars per share) $ 4.65us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		      
    Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures        
    Options Exercised, Instrinsic Value   275,492us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 670us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Options Outstanding, Intrinsic Value 2,808,083us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 5,896,329us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 8,301,484us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Vested and Exercisable at the end of the period, Intrinsic Value $ 1,990,187us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		      
    Options Outstanding, Weighted Average Contractual Life 7 years 7 months 6 days 6 years 8 months 12 days 6 years 3 months 18 days 6 years 8 months 12 days
    Vested and Exercisable, Weighted Average Contractual Life 6 years 2 months 12 days      
    Stock options | Minimum        
    Weighted-average assumptions        
    Risk-free interest rate (as a percent) 1.42%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 0.74%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 0.62%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		  
    Expected volatility (as a percent) 81.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 82.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 90.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		  
    Stock price (in dollars per share) $ 3.00us-gaap_SharePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 $ 5.53us-gaap_SharePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		 $ 0.50us-gaap_SharePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		  
    Stock options | Maximum        
    Weighted-average assumptions        
    Risk-free interest rate (as a percent) 2.10%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 1.50%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 1.04%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		  
    Expected volatility (as a percent) 86.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 100.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 97.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		  
    Stock price (in dollars per share) $ 6.74us-gaap_SharePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 $ 8.15us-gaap_SharePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		 $ 4.87us-gaap_SharePrice
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		  
    XML 26 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Selected Quarterly Financial Data (Unaudited) (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Selected Quarterly Financial Data (Unaudited)  
    Summary of the quarterly results of operations

         

     

     

    Quarter Ended(1)

     

     

     

    March 31

     

    June 30

     

    September 30

     

    December 31

     

     

     

     

     

    (Revised)(2)

     

     

     

     

     

     

     

    (dollars in thousands, except per share data)

     

    2014

     

     

     

     

     

     

     

     

     

    Revenues

     

    $
    111

     

    $
    56

     

    $
    57

     

    $
    56

     

    Operating expenses

     
    3,371

     
    3,297

     
    3,997

     
    4,560

     

     

     

     

     

     

     

     

     

     

     

    Net loss and comprehensive loss attributable to common stockholders

     
    (3,198

    )
    (1,079

    )
    (5,382

    )
    (4,689

    )

    Net loss per common share - basic

     

    $
    (0.17

    )

    $
    (0.06

    )

    $
    (0.28

    )

    $
    (0.25

    )

    Net loss per common share - diluted

     

    $
    (0.17

    )

    $
    (0.17

    )

    $
    (0.28

    )

    $
    (0.25

    )

     

     

     

     

     

     

     

     

     

     

    Shares used in the calculation of net loss attributable to common stockholders - basic

     
    18,902,783

     
    18,902,783

     
    18,902,783

     
    18,904,280

     

    Shares used in the calculation of net loss attributable to common stockholders - diluted

     
    18,902,783

     
    19,232,760

     
    18,902,783

     
    19,071,112

     

     

     

     

     

     

     

     

     

     

     

    2013

     

     

     

     

     

     

     

     

     

    Revenues

     

    $
    119

     

    $
    49

     

    $
    44

     

    $
    47

     

    Operating expenses

     
    2,509

     
    2,423

     
    3,121

     
    2,897

     

    Net loss and comprehensive loss attributable to common stockholders

     
    (1,117

    )
    (5,279

    )
    (4,407

    )
    (1,038

    )

    Net loss per common share - basic

     

    $
    (0.07

    )

    $
    (0.34

    )

    $
    (0.25

    )

    $
    (0.05

    )

    Net loss per common share - diluted

     

    $
    (0.07

    )

    $
    (0.34

    )

    $
    (0.25

    )

    $
    (0.05

    )

     

     

     

     

     

     

     

     

     

     

    Shares used in the calculation of net loss attributable to common stockholders - basic

     
    15,510,340

     
    15,583,957

     
    17,870,703

     
    18,900,781

     

    Shares used in the calculation of net loss attributable to common stockholders - diluted

     
    15,510,340

     
    15,583,957

     
    17,870,703

     
    18,900,781

     

     

    (1) Basic and diluted EPS are computed independently for each of the periods presented.   Accordingly, the sum of the quarterly EPS amount may not agree to the total for the year. (2) Second quarter fully diluted earnings per share have been adjusted for dilutive amounts related to the derivative liability. We believe that these changes are not material to the financial statements or related notes.

     

          

    XML 27 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 28 R57.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingencies (Details 4) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Lease Agreements      
    Rent expense $ 315,000us-gaap_OperatingLeasesRentExpenseNet $ 294,000us-gaap_OperatingLeasesRentExpenseNet $ 270,000us-gaap_OperatingLeasesRentExpenseNet
    Total annual commitments under current lease agreements      
    2015 360,775us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent    
    2016 371,324us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears    
    2017 381,026us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears    
    2018 6,380us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears    
    Total $ 1,119,505us-gaap_OperatingLeasesFutureMinimumPaymentsDue    
    XML 29 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Property and Equipment (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Property and Equipment  
    Schedule of components of property and equipment

     

     

     

    As of December 31,

     

     

     

    2014

     

    2013

     

    Furniture and office equipment

     

    $
    365,955

     

    $
    236,645

     

    Leasehold Improvements

     
    39,401

     
    36,371

     

    Laboratory equipment

     
    968,901

     
    826,151

     

     

     
    1,374,257

     
    1,099,167

     

    Less—accumulated depreciation and amortization

     
    (533,870

    )
    (348,602

    )

    Property and equipment, net

     

    $
    840,387

     

    $
    750,565

     

     

    XML 30 R50.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Debt (Details) (USD $)
    		 1 Months Ended 12 Months Ended
    Jun. 30, 2014
    item
    Dec. 31, 2014
    Dec. 31, 2013
    Debt      
    Amount borrowed included in current liabilities   $ 1,898,548us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent $ 198,166us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent
    Amount borrowed, long-term liabilities   13,053,117us-gaap_LongTermDebtAndCapitalLeaseObligations 322,998us-gaap_LongTermDebtAndCapitalLeaseObligations
    Value of warrants recorded as debt discount and additional paid in capital   235,857trov_OriginalValueOfWarrants  
    Amount borrowed     15,000,000us-gaap_DebtAndCapitalLeaseObligations
    Future maturities of long-term debt      
    2015     1,898,548us-gaap_LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths
    2016     4,790,628us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo
    2017     5,140,519us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree
    2018     3,170,305us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour
    Loan and Security Agreement | Secured Debt      
    Debt      
    Amount borrowed included in current liabilities   1,898,548us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Amount borrowed, long-term liabilities   13,053,117us-gaap_LongTermDebtAndCapitalLeaseObligations
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Interest expenses recorded   843,260us-gaap_InterestExpenseDebt
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Face value of term loan   15,000,000us-gaap_DebtInstrumentFaceAmount
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Number of banks, with which agreement is entered 2trov_NumberOfBanks
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		    
    Interest rate (as a percent) 7.07%us-gaap_DebtInstrumentInterestRateStatedPercentage
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		    
    Number of common shares that can be purchased upon exercise of warrant 85,470us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		    
    Exercise price of warrants (in dollars per share) 3.51us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		    
    Exercisable term 10 years    
    Value of warrants recorded as debt discount and additional paid in capital 235,857trov_OriginalValueOfWarrants
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		    
    Amortized portion of final fee upon repayment   1,050,000trov_AmortizedPortionOfFinalFeeUponRepayment
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Accrued interest   $ 191,682us-gaap_InterestPayableCurrentAndNoncurrent
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Loan and Security Agreement | Secured Debt | Minimum      
    Debt      
    Pre-payment fees (as a percent)   1.00%trov_PrepaymentFeesPercentage
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		  
    Loan and Security Agreement | Secured Debt | Maximum      
    Debt      
    Pre-payment fees (as a percent)   3.00%trov_PrepaymentFeesPercentage
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		  
    XML 31 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Deficiency) (Details 2) (USD $)
    		 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    May 31, 2012
    Dec. 31, 2011
    Dec. 31, 2012
    May 30, 2012
    Number of Warrants              
    Balance of warrants outstanding at the beginning of the period (in shares) 6,233,483us-gaap_ClassOfWarrantOrRightOutstanding 6,985,070us-gaap_ClassOfWarrantOrRightOutstanding 3,601,474us-gaap_ClassOfWarrantOrRightOutstanding        
    Granted (in shares) 85,470trov_ClassOfWarrantOrRightNumberGranted 50,000trov_ClassOfWarrantOrRightNumberGranted 3,416,934trov_ClassOfWarrantOrRightNumberGranted        
    Exercised (in shares) (36,666)trov_ClassOfWarrantOrRightNumberExercised (728,488)trov_ClassOfWarrantOrRightNumberExercised (16,667)trov_ClassOfWarrantOrRightNumberExercised        
    Expired (in shares) (16,667)trov_ClassOfWarrantOrRightNumberExpired (73,099)trov_ClassOfWarrantOrRightNumberExpired (16,671)trov_ClassOfWarrantOrRightNumberExpired        
    Balance of warrants outstanding at the end of the period (in shares) 6,265,620us-gaap_ClassOfWarrantOrRightOutstanding 6,233,483us-gaap_ClassOfWarrantOrRightOutstanding 6,985,070us-gaap_ClassOfWarrantOrRightOutstanding     6,985,070us-gaap_ClassOfWarrantOrRightOutstanding  
    Weighted Average Exercise Price Per Share              
    Weighted average exercise price of warrants at the beginning of the period (in dollars per share) $ 3.87trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights $ 3.96trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights $ 3.18trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights        
    Granted (in dollars per share) $ 3.51trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted $ 8.00trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted $ 4.88trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted        
    Exercised (in dollars per share) $ 3.00trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised $ 4.99trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised $ 3.00trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised        
    Expired (in dollars per share) $ 10.80trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired $ 4.50trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired $ 3.00trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired        
    Weighted average exercise price of warrants at the end of the period (in dollars per share) $ 3.85trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights $ 3.87trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights $ 3.96trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights     $ 3.96trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights  
    Warrants, additional disclosures              
    Fair value of warrants issued for services (in dollars)   $ 198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration $ 142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration        
    Gain (loss) from change in fair value of derivative instruments-warrants 1,425,850us-gaap_UnrealizedGainLossOnDerivatives (1,084,114)us-gaap_UnrealizedGainLossOnDerivatives (6,720,805)us-gaap_UnrealizedGainLossOnDerivatives        
    Underwritten Public Offering 2012              
    Warrants, additional disclosures              
    Warrants issued for cash (in shares)       1,414,500trov_NumberOfWarrantsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		      
    Exercise price of warrants (in dollars per share)             5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member
    Term of warrants       5 years      
    Minimum              
    Term              
    Balance of warrants outstanding at the beginning of the period 1 year 1 year 1 year   1 year    
    Balance of warrants outstanding at the end of the period 1 year 1 year 1 year   1 year    
    Minimum | Underwritten Public Offering 2012              
    Warrants, additional disclosures              
    Exercise price of warrants (in dollars per share)       5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		      
    Maximum              
    Term              
    Balance of warrants outstanding at the beginning of the period 4 years 5 years 6 years   8 years    
    Balance of warrants outstanding at the end of the period 4 years 5 years 6 years   8 years    
    Maximum | Underwritten Public Offering 2012              
    Warrants, additional disclosures              
    Exercise price of warrants (in dollars per share)       7.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		      
    Price protected warrants              
    Warrants, additional disclosures              
    Term of warrants           5 years  
    Number of price protected units issued (in shares)     713,784trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_StatementEquityComponentsAxis
    = trov_PriceProtectedWarrantsMember    		     1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_StatementEquityComponentsAxis
    = trov_PriceProtectedWarrantsMember    		  
    Exercise price of price protected unit's warrants (in dollars per share)     3.00trov_WarrantExercisePricePriceProtectedUnits
    / us-gaap_StatementEquityComponentsAxis
    = trov_PriceProtectedWarrantsMember    		     5.32trov_WarrantExercisePricePriceProtectedUnits
    / us-gaap_StatementEquityComponentsAxis
    = trov_PriceProtectedWarrantsMember    		  
    Service Agreement              
    Warrants, additional disclosures              
    Number of shares that can be purchased from exercise of warrants   50,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ServiceAgreementMember    		          
    Exercise price of warrants (in dollars per share)   8.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ServiceAgreementMember    		          
    Term of warrants   3 years          
    Fair value of warrants issued for services (in dollars)   $ 198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ServiceAgreementMember    		          
    Expected volatility (as a percent)   97.00%us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ServiceAgreementMember    		          
    Risk-free interest rate (as a percent)   0.42%us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ServiceAgreementMember    		          
    Dividend yield (as a percent)   0.00%us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ServiceAgreementMember    		          
    XML 32 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies (Details 3)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Net Loss Per Share      
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 10,228,257us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 10,584,153us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 10,795,956us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    Stock options      
    Net Loss Per Share      
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4,913,472us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_EmployeeStockOptionMember    		 4,287,545us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_EmployeeStockOptionMember    		 3,711,303us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_EmployeeStockOptionMember
    Warrants      
    Net Loss Per Share      
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,251,660us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_WarrantMember    		 6,233,483us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_WarrantMember    		 6,985,070us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_WarrantMember
    Series A Convertible Preferred Stock      
    Net Loss Per Share      
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 63,125us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_ConvertiblePreferredStockMember    		 63,125us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_ConvertiblePreferredStockMember    		 99,583us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
    / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
    = us-gaap_ConvertiblePreferredStockMember
    XML 33 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Details 2) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Effective Income Tax Rate Reconciliation, Amount [Abstract]  
    Tax computed at the federal statutory rate $ (4,871,000)us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
    State tax, net of federal tax benefit (891,000)us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes
    Permanent Items (320,000)trov_IncomeTaxReconciliationPermanentItems
    Valuation allowance increase (decrease) 6,081,000us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
    Other 1,000us-gaap_IncomeTaxReconciliationOtherAdjustments
    Effective Income Tax Rate Reconciliation, Percent [Abstract]  
    Tax computed at the federal statutory rate (as a percent) 35.00%us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
    State tax, net of federal tax benefit (as a percent) 6.00%us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
    Permanent Items (as a Percent) 2.00%trov_EffectiveIncomeTaxRateReconciliationPermanentItems
    Valuation allowance increase (decrease) (43.00%)us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
    Provision for income taxes (as a percent) 0.00%us-gaap_EffectiveIncomeTaxRateContinuingOperations
    R&D credits | Federal  
    Tax credit carryforwards  
    Tax credits $ 698,000us-gaap_TaxCreditCarryforwardAmount
    / us-gaap_IncomeTaxAuthorityAxis
    = us-gaap_InternalRevenueServiceIRSMember
    / us-gaap_TaxCreditCarryforwardAxis
    = us-gaap_ResearchMember
    XML 34 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Derivative Financial Instruments - Warrants (Details) (USD $)
    		 12 Months Ended 5 Months Ended 3 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2011
    May 31, 2012
    Dec. 31, 2012
    Changes in the Company's derivative financial instruments liability balance            
    Balance of warrants outstanding at the beginning of the period (in shares) 6,233,483us-gaap_ClassOfWarrantOrRightOutstanding 6,985,070us-gaap_ClassOfWarrantOrRightOutstanding 3,601,474us-gaap_ClassOfWarrantOrRightOutstanding   3,601,474us-gaap_ClassOfWarrantOrRightOutstanding  
    Expired (in shares) (16,667)trov_ClassOfWarrantOrRightNumberExpired (73,099)trov_ClassOfWarrantOrRightNumberExpired (16,671)trov_ClassOfWarrantOrRightNumberExpired      
    Balance of warrants outstanding at the end of the period (in shares) 6,265,620us-gaap_ClassOfWarrantOrRightOutstanding 6,233,483us-gaap_ClassOfWarrantOrRightOutstanding 6,985,070us-gaap_ClassOfWarrantOrRightOutstanding     6,985,070us-gaap_ClassOfWarrantOrRightOutstanding
    Balance of derivative financial instruments liability at the beginning of the period $ 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent          
    Reclassification of derivative liability to equity   (5,417,871)trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount (3,317,463)trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount      
    Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations (1,425,850)us-gaap_UnrealizedGainLossOnDerivatives 1,084,114us-gaap_UnrealizedGainLossOnDerivatives 6,720,805us-gaap_UnrealizedGainLossOnDerivatives      
    Balance of derivative financial instruments liability at the end of the period 3,006,021us-gaap_DerivativeLiabilitiesNoncurrent 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent        
    Derivative Liability For Issued Units            
    Changes in the Company's derivative financial instruments liability balance            
    Balance of derivative financial instruments liability at the end of the period   1,171,463us-gaap_DerivativeLiabilitiesNoncurrent
    / trov_ComponentsOfChangeAxis
    = trov_WarrantsIssuedDuringPeriodMember    		 1,171,463us-gaap_DerivativeLiabilitiesNoncurrent
    / trov_ComponentsOfChangeAxis
    = trov_WarrantsIssuedDuringPeriodMember    		     1,171,463us-gaap_DerivativeLiabilitiesNoncurrent
    / trov_ComponentsOfChangeAxis
    = trov_WarrantsIssuedDuringPeriodMember
    Binomial Option Pricing Method | Change in Fair value of Derivative Liability For Previously Outstanding Price Protected Units            
    Changes in the Company's derivative financial instruments liability balance            
    Balance of derivative financial instruments liability at the beginning of the period   1,341,405us-gaap_DerivativeLiabilitiesNoncurrent
    / trov_ComponentsOfChangeAxis
    = us-gaap_ChangeDuringPeriodFairValueDisclosureMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Reclassification of derivative liability to equity   (5,417,871)trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    / trov_ComponentsOfChangeAxis
    = us-gaap_ChangeDuringPeriodFairValueDisclosureMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations   2,905,003us-gaap_UnrealizedGainLossOnDerivatives
    / trov_ComponentsOfChangeAxis
    = us-gaap_ChangeDuringPeriodFairValueDisclosureMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Balance of derivative financial instruments liability at the end of the period   (1,171,463)us-gaap_DerivativeLiabilitiesNoncurrent
    / trov_ComponentsOfChangeAxis
    = us-gaap_ChangeDuringPeriodFairValueDisclosureMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Warrants            
    Changes in the Company's derivative financial instruments liability balance            
    Weighted average remaining contractual life 3 years 7 months 6 days 4 years        
    Warrants | Black Scholes Option Pricing Method            
    Range of assumptions used to determine the fair value of warrants            
    Expected warrant term 4 years          
    Risk-free interest rate (as a percent) 1.38%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		          
    Expected volatility (as a percent) 86.40%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		          
    Dividend yield (as a percent) 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Changes in the Company's derivative financial instruments liability balance            
    Balance of warrants outstanding at the beginning of the period (in shares) 1,013,961us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 1,087,060us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 1,103,727us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		   1,103,727us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		  
    Expired (in shares)   (73,099)trov_ClassOfWarrantOrRightNumberExpired
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		   (16,667)trov_ClassOfWarrantOrRightNumberExpired
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		    
    Balance of warrants outstanding at the end of the period (in shares) 1,013,961us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 1,013,961us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 1,087,060us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 1,103,727us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		   1,087,060us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember
    Balance of derivative financial instruments liability at the beginning of the period 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 6,252,760us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 994,627us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		   994,627us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		  
    Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations (1,425,850)us-gaap_UnrealizedGainLossOnDerivatives
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 (1,820,889)us-gaap_UnrealizedGainLossOnDerivatives
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		   5,258,133us-gaap_UnrealizedGainLossOnDerivatives
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		    
    Balance of derivative financial instruments liability at the end of the period 3,006,021us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 6,252,760us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 994,627us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		   6,252,760us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember
    Warrants | Black Scholes Option Pricing Method | Minimum            
    Range of assumptions used to determine the fair value of warrants            
    Estimated fair value of Trovagene common stock (in dollars per share) $ 3.00trov_EstimatedFairValueOfWarrant
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 $ 5.74trov_EstimatedFairValueOfWarrant
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 $ 0.02trov_EstimatedFairValueOfWarrant
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Expected warrant term   1 month 10 months      
    Risk-free interest rate (as a percent)   0.03%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 0.06%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Expected volatility (as a percent)   82.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 90.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Warrants | Black Scholes Option Pricing Method | Maximum            
    Range of assumptions used to determine the fair value of warrants            
    Estimated fair value of Trovagene common stock (in dollars per share) $ 6.74trov_EstimatedFairValueOfWarrant
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 $ 7.18trov_EstimatedFairValueOfWarrant
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 $ 5.93trov_EstimatedFairValueOfWarrant
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Expected warrant term   5 years 9 months 18 days 6 years      
    Risk-free interest rate (as a percent)   1.75%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 1.54%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Expected volatility (as a percent)   100.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 97.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		      
    Warrants | Binomial Option Pricing Method            
    Range of assumptions used to determine the fair value of warrants            
    Number of price protected units issued (in shares)   1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Changes in the Company's derivative financial instruments liability balance            
    Balance of derivative financial instruments liability at the beginning of the period   2,512,868us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Reclassification of derivative liability to equity   (5,417,871)trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations     2,905,003us-gaap_UnrealizedGainLossOnDerivatives
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Balance of derivative financial instruments liability at the end of the period     2,512,868us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		     2,512,868us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    Number of Price Protected Units at the beginning of the period (in shares)   1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Reclassification of derivative liability to equity (in shares)   (1,288,650)trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		        
    Number of Price Protected Units at the end of the period (in shares)     1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		     1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsOutstanding
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    Warrants | Binomial Option Pricing Method | Minimum            
    Range of assumptions used to determine the fair value of warrants            
    Expected warrant term     2 years      
    Risk-free interest rate (as a percent)     0.53%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Expected volatility (as a percent)     90.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Expected fair value of the stock (in dollars per share)     $ 0.25trov_FairValueOfCommonStockPerShare
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Warrants | Binomial Option Pricing Method | Maximum            
    Range of assumptions used to determine the fair value of warrants            
    Expected warrant term     6 years 9 months      
    Risk-free interest rate (as a percent)     1.61%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Expected volatility (as a percent)     97.00%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Expected fair value of the stock (in dollars per share)     $ 3.21trov_FairValueOfCommonStockPerShare
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		      
    Warrants with Exercise Price of 3.00 per share | Binomial Option Pricing Method            
    Range of assumptions used to determine the fair value of warrants            
    Number of price protected units issued (in shares)       713,784trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		 1,048,175trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		  
    Offer price per unit (in dollars per share)       $ 3.00trov_IssuanceOfCommonStockAndWarrantsForCashOrServicesPricePerUnit
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		    
    Period of price protection clause per unit       30 months 30 months  
    Period of price protection clause per unit pertaining to subsequent financings       1 year 1 year  
    Minimum amount of financing needed to trigger per unit price protection clause       5,000,000trov_DerivativeFinancialInstrumentsPerUnitPriceProtectionClauseAmountRequiredToBeGeneratedFromSubsequentFinancing
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		 5,000,000trov_DerivativeFinancialInstrumentsPerUnitPriceProtectionClauseAmountRequiredToBeGeneratedFromSubsequentFinancing
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		  
    Exercise price of price protected unit's warrants (in dollars per share)       3.00trov_WarrantExercisePricePriceProtectedUnits
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		 3.00trov_WarrantExercisePricePriceProtectedUnits
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		  
    Changes in the Company's derivative financial instruments liability balance            
    Reclassification of derivative liability to equity (in shares)       (713,784)trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		 (1,048,175)trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice3.00Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		  
    Warrants with Exercise Price of 5.32 per share | Binomial Option Pricing Method            
    Range of assumptions used to determine the fair value of warrants            
    Number of price protected units issued (in shares)           1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice5.32Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    Offer price per unit (in dollars per share)           $ 4.00trov_IssuanceOfCommonStockAndWarrantsForCashOrServicesPricePerUnit
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice5.32Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    Period of price protection clause per unit           48 months
    Period of price protection clause per unit pertaining to subsequent financings           1 year
    Minimum amount of financing needed to trigger per unit price protection clause           $ 10,000,000trov_DerivativeFinancialInstrumentsPerUnitPriceProtectionClauseAmountRequiredToBeGeneratedFromSubsequentFinancing
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice5.32Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    Exercise price of price protected unit's warrants (in dollars per share)           5.32trov_WarrantExercisePricePriceProtectedUnits
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice5.32Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    Expiration term of price protected unit's warrants           5 years
    Changes in the Company's derivative financial instruments liability balance            
    Reclassification of derivative liability to equity (in shares)           (1,288,650)trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_DerivativeByNatureAxis
    = trov_WarrantsAtExercisePrice5.32Member
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember
    XML 35 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2014
    Basis of Presentation and Summary of Significant Accounting Policies  
    Basis of Presentation and Summary of Significant Accounting Policies

     

    2.  Basis of Presentation and Summary of Significant Accounting Policies

     

    The accompanying consolidated financial statements of Trovagene, which include its wholly owned subsidiaries Xenomics, Inc., a California corporation, Xenomics Europa Ltd, (an inactive subsidiary formed in the United Kingdom and liquidated) and Etherogen, Inc., a Delaware corporation, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  All intercompany balances and transactions have been eliminated.

     

    On March 15, 2012, the Board of Directors and on April 27, 2012 a majority of the stockholders approved a proposal to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio of not less than one-for-two and not greater than one-for-six at any time prior to April 27, 2013 at the discretion of the Board of Directors.  On May 24, 2012, the Board of Directors approved a 1-for-6 reverse stock split of the Company’s issued and outstanding common stock effective on May 29, 2012.  All the relevant information relating to number of shares and per share information contained in these consolidated financial statements has been retrospectively adjusted to reflect the reverse stock split for all periods presented.

     

    Use of Estimates

     

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

     

    Cash and Cash Equivalents

     

    Cash and cash equivalents consist of operating accounts as of December 31, 2014 and 2013 on deposit with U.S. commercial banks.   Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.   Cash and cash equivalents include money market accounts at December 31, 2014.

     

    Concentration of credit risk

     

    The Company maintains its cash in financial institutions, which at times may exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”).  All of the Company’s noninterest bearing cash balances were insured up to $250,000 at December 31, 2014 and December 31, 2013.

     

    Revenues

     

    We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.  These agreements may involve multiple elements such as license fees, royalties and milestone payments.  Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

     

    ·

    Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.

     

    ·

    Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.

     

    ·

    Milestone payments are recognized when both the milestone is achieved and the related payment is received.

     

    Allowance for Doubtful Accounts

     

    The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators.  At December 31, 2014 and 2013, the Company has not recorded an allowance for doubtful accounts.  When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed.  When payments are received on reserved accounts, they are applied to the individual’s account and the reserve is reassessed.

     

    Derivative Financial Instruments—Warrants

     

    The Company has issued common stock warrants in connection with the execution of certain equity financings.  Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period.  Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity.  Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”

     

    The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene’s common share price, remaining life of the warrant, and risk-free interest rates at each period end.  The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements.  At December 31, 2014 and 2013, the fair value of these warrants was $3,006,021 and $4,431,871, respectively, and were included in the derivative financial instruments liability on the balance sheet.

     

    Stock-Based Compensation

     

    ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant.  The expense is recognized over the period during which an employee is required to provide services in exchange for the award.  ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.  Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received.  The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “Equity -Based Payment to Non-Employees” and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.  Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

     

    Fair value of financial instruments

     

    Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities.  We have adopted FASB ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis.  These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature as they reflect current market interest rates.   Debt is stated at its respective historical carrying amounts which approximates fair value as they reflect current market interest rates.

     

    In accordance with ASC subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  The three tiers include:

     

     

    Level 1 —

     

    Quoted prices for identical instruments in active markets.

     

     

     

     

     

     

    Level 2 —

     

    Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.

     

     

     

     

     

     

    Level 3 —

     

    Instruments where significant value drivers are unobservable to third parties.

     

    Property, equipment and depreciation and amortization

     

    Expenditures for additions, renewals and improvements are capitalized at cost.  Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets.  Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.  The estimated useful lives of the major classes of depreciable assets are 3 to 5 years for lab equipment and furniture and fixtures.  Expenditures for repairs and maintenance are charged to operations as incurred.

     

    Impairment of Indefinite and Long-Lived Assets

     

    The Company reviews its long and indefinite lived assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired.  If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows.  If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value.  Factors that would indicate potential impairment include a significant decline in the Company’s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company’s strategic business objectives and utilization of a particular asset.  The Company noted no indications of impairment for the years ended December 31, 2014, 2013, and 2012.

     

    Income Taxes

     

    Income taxes have been determined using the asset and liability approach of accounting for income taxes.  Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.  Deferred taxes result from differences between the financial statement and tax bases of Trovagene’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted.  Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.  The assessment of whether or not a valuation allowance is required often requires significant judgment.

     

    Contingencies

     

    In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters.  In accordance with FASB ASC Topic 450, Accounting for Contingencies, Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.  Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized.

     

    Cost of Revenue

     

    Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

     

    Research and Development

     

    Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, Research and Development.  Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.

     

    While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited.

     

    ASC Topic 730, Research and Development requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized.  As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.   There were no non-refundable advance payments as of December 31, 2014 and 2013.

     

    Net Loss Per Share

     

    Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented.  In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Shares used in calculating diluted net loss per common share exclude as antidilutive the following share equivalents:

     

     

     

    December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Options to purchase Common Stock

     
    4,913,472 

     
    4,287,545 

     
    3,711,303 

     

    Warrants to purchase Common stock

     
    5,251,660 

     
    6,233,483 

     
    6,985,070 

     

    Series A Convertible Preferred Stock

     
    63,125 

     
    63,125 

     
    99,583 

     

     

     
    10,228,257 

     
    10,584,153 

     
    10,795,956 

     

     

    The following table summarizes the Company’s diluted net loss per share:

     

     

     

    December 31,

     

    December 31,

     

    December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Numerator:

     

     

     

     

     

     

     

    Net loss

     

    $
    (14,348,499

    )

    $
    (11,840,778

    )

    $
    (11,604,201

    )

    Adjustment for change in fair value of derivative instruments - warrants

     
    (2,422,337

    )

    —

     

    —

     

    Net loss used for diluted loss per share

     

    $
    (16,770,836

    )

    $
    (11,840,778

    )

    $
    (11,604,201

    )

     

     

     

     

     

     

     

     

    Denominator:

     

     

     

     

     

     

     

    Weighted average shares used to compute basic loss per share

     
    18,904,280

     
    16,978,212

     
    13,066,600

     

    Adjustments to reflect assumed exercise of warrants

     
    166,832

     

    —

     

    —

     

    Weighted average shares used to compute diluted net loss per share

     
    19,071,112

     
    16,978,212

     
    13,066,600

     

     

     

     

     

     

     

     

     

    Net loss per share diluted

     

    $
    (0.88

    )

    $
    (0.70

    )

    $
    (0.89

    )

     

    Recent Accounting Pronouncements

     

    In January 2015, the Financial Accounting Standards Board (the FASB) issued an amendment to the accounting guidance related to the presentation of extraordinary items. The amendment simplifies the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2015. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.

     

    In August 2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.

     

    In June 2014, the FASB issued an accounting standards update that removes the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to: (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption.  The Company elected early adoption, and does not believe the adoption of the standard had a material impact on its financial position, results of operations or related financial statement disclosures.

     

    In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.

     

    EXCEL 36 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E M,F%B-C0X-C,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%S M#I% M>&-E;%=O#I%>&-E;%=O M#I.86UE/E-T;V-K:&]L9&5R3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K7T]P=&EO;E]0;&%N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I% M>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-E;&5C=&5D7U%U87)T97)L>5]& M:6YA;F-I86Q?1#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O5]A;F1?17%U:7!M96YT7U1A M8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K:&]L9&5R#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M&5S7U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D)A#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%S#I7;W)K5]A;F1?17%U:7!M96YT M7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O5]$969I8VEE;F-Y,CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R3,\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC M:65S7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/D5M<&QO>65E7T)E;F5F:71?4&QA;E]$971A:6QS/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;',\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H M965T&-E;"!84"!O M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T M.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^665S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!&:6QE3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^06-C96QE2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^,C`Q-#QS<&%N/CPO'0^ M1ED\'1087)T7S%C M83(U-&9D7V(W8C-?-#DY-5\X9F$W7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A M;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-EF5D.R`V,"PV M,#`@F5D.R`Q."PY,34L-SDT(&%N9"`Q."PY,#(L-S@S(&ES3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W M,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A M,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6%L='D@:6YC;VUE/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W,"PQ-S@\'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A M-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S&5R8VES92!O9B!S=&]C:R!O<'1I;VYS("AI;B!S:&%R97,I/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2UF86ER('9A;'5E(&]F('=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2`M(&9A:7(@=F%L=64@ M;V8@=V%R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES M92!O9B!W87)R86YT("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5R8VES92!O9B!S=&]C:R!O<'1I;VX@*&EN('-H M87)E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA&5D(&%SF%T:6]N(&]F(&1E8G0@8V]S=',\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S6UE M;G1S*2!F'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!D:7-C;&]S=7)E(&]F(&-A3H\+W-T M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3QB6QE/3-$)VUA M3I4:6UE6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/E1R;W9A9V5N92PF;F)S<#M);F,N)FYB#(P M,4,[5')O=F%G96YE)B-X,C`Q1#L@;W(@=&AE("8C>#(P,4,[0V]M<&%N>28C M>#(P,40[*2!I2!U2!F;W(@=7-E(&EN(&1I M2!I;G1E28C>#(P,3D[ M'1E2!I;B!A2!T;R!D971E M8W0@86YD('%U86YT:71A=&EV96QY(&UO;FET;W(@8V5L;"UF3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M&5R8VES960@=&AE:7(@;W9E6UB M;VP@)B-X,C`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`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`M,3AP=#MF;VYT M+69A;6EL>3I4:6UE6QE/3-$)V1I3H@ M:6YL:6YE.V9O;G0M3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X- M"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@-31P M=#MT97AT+6EN9&5N=#H@+3$X<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M$8P0C<[/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V1IF4Z,3!P M=#MF;VYT+69A;6EL>3I3>6UB;VP[.V9O;G0M3I4:6UE3H@:6YL:6YE.V9O;G0M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4] M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O M:F%V87-C3X-"B`@("`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`P)3X\ M=&%B;&4@6QE/3-$=VED=&@Z,3AP=#L^/'`@3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$=VED M=&@Z,S9P=#MF;VYT+7-I>F4Z,'!T.SX\+W`^/"]T9#X\=&0@=F%L:6=N/3-$ M=&]P(&%L:6=N/3-$;&5F="!S='EL93TS1"=W:61T:#H@,#`N,#!P=#L@9&ES M<&QA>3H@:6YL:6YE.R<^#0H)"0D\<"!S='EL93TS1"=F;VYT+69A;6EL>3I4 M:6UE$(W.SPO9F]N=#X-"@D)"3PO<#X-"@D)/"]T9#X\=&0@F4Z,'!T.SX\+W`^/"]T9#X\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1'1O<#X-"@D)"3QP('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0[;6%R9VEN.C!P=#LG/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6%L=&EE3H@ M:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,3`P)3L@8V5L;'!A9&1I;F<],T0P(&-E;&QS M<&%C:6YG/3-$,#X\='(^/'1D('-T>6QE/3-$=VED=&@Z,S9P=#L^/'`@6QE/3-$)W=I9'1H.B`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`^#0H)"3QP('-T>6QE/3-$)VUA'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M6QE/3-$)V1I6QE.FET M86QI8SMF;VYT+7-I>F4Z,3!P=#MC;VQO3H@ M:6YL:6YE.V9O;G0M2P@86YD('=E2!O;B!T:&4@8F%L86YC92!S:&5E="X\+V9O;G0^#0H)"3PO<#X- M"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#MC;VQO#(P,30[ M4W1O8VL@0V]M<&5N6QE/3-$)V1IF4Z,3!P=#MC;VQO&-H86YG92!F M;W(@=&AE(&%W87)D+B9N8G-P.R9N8G-P.T%30R!4;W!I8R`W,3@@9&ED(&YO M="!C:&%N9V4@=&AE('=A>2!465E2!M96%S=7)A8FQE('1H86X@=&AE(&9A:7(@ M=F%L=64@;V8@=&AE(&-O;G-I9&5R871I;VX@;W(@6UE;G0@=&\@3F]N+45M<&QO>65E#(P,40[(#PO M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE M.C$P<'0[8V]L;W(Z(S`P,#`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`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z.#`N.#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z,#$N.#`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#MC;VQO#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z.#`N.#`E M.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$=VED=&@Z,#0N,C@E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#$N M.38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#0N,C@E.W!A9&1I;FF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&-O;&]R.B`C,#`P,#`P.R<^)B-X1C!"-SL\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`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`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`T-3`L(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[8V]L;W(Z(S`P M,#`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`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`P,#`[)SXF M;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(V)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N.30E.W!A9&1I;FF4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXF M;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(V)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO6QE/3-$=VED=&@Z,#,N,C8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D) M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z M8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXR,#$R/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQOF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`S+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C8V)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$=VED M=&@Z,#,N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+#(S M,RPT.#,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.C$U+C8V)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C8V)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXV,RPQ,C4F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C,P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M-#$N.30E.W!A9&1I;F6QE/3-$=VED=&@Z,#,N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"PR,C@L,C4W M)FYB6QE/3-$=VED=&@Z,#,N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"PU.#0L,34S)FYB M6QE M/3-$=VED=&@Z,#,N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"PW.34L.34V)FYB6QE/3-$ M=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.VQI M;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)VUA6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E M;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC M;VQO6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.V-O;&]R.B,P,#`P,#`[)SY$96-E;6)E6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MC;VQO6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXR,#$R/"]F M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-34N-3`E.W!A M9&1I;F6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#MC;VQO6QE/3-$)W=I9'1H.C$P+C6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M'0M86QI9VXZF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)OF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX- M"@D)"0D)/'`@F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C$P+CF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,3$L M-C`T+#(P,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C`P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)V1IF4Z,3!P M=#MC;VQOF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)V1IF4Z,3!P=#MC;VQO6QE/3-$=VED M=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#MC;VQOF4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-BPY-S@L,C$R#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#MC M;VQO6QE M/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE M/3-$)V1IF4Z,3!P=#MC;VQOF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ-BPY-S@L,C$R#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,"XX.`T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[ M8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0MF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`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`Y+"!2 M979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@@0W5S=&]M97)S("@F(W@R,#%# M.T%352`R,#$T+3`Y)B-X,C`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`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1IF4Z,W!T.R<^/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1IF4Z,3!P=#LG/D]N($9E8G)U M87)Y)FYB2!E;G1E6QE/3-$ M)V1I6QE.FET86QI8SMF;VYT+7-I>F4Z M,3!P=#LG/DEN=&%N9VEB;&5S+2!';V]D=VEL;"!A;F0@3W1H97(\+V9O;G0^ M/&9O;G0@3H@:6YL:6YE.V9O;G0M2!A;F0@9&5L:79E M2XF;F)S<#LF;F)S<#LF;F)S<#M4:&4@=&]T86P@<'5R M8VAA28C>#(P,3D['0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M2!A<'!L>6EN9R!A('=E:6=H=&5D(&%V97)A9V4@ M<')O8F%B:6QI='D@;VX@=&AE(&%C:&EE=F5M96YT(&]F('1H92!M:6QE6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X M-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B M,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M3I4:6UE6QE/3-$)V1I2!A;F0@17%U:7!M96YT/"]F;VYT/@T*"0D\+W`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`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP M-B4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`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`Q#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P M.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ+#`Y.2PQ-C<-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/DQEF%T:6]N(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C0P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-BXS-B4[8F]R9&5R+71O M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M MF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ-2XP-B4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B`F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@/"]F;VYT/@T*"0D\+W`^ M#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\ M+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2`H1&5F:6-I96YC>2D\+W1D M/@T*("`@("`@("`\=&0@8VQA6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1I6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D%L;"!S:&%R92!A;F0@<&5R('-H M87)E(&%M;W5N=',@:&%V92!B965N(')E'0M:6YD96YT.C,V<'0[;&EN92UH96EG:'0Z;F]R;6%L.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY#;VUM;VX@ M4W1O8VL\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D1U65A2!C;&]S960@ M9FEV92!P2!I#(P,40[*2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M2!T:&4@:6YV97-T;W)S(&9O29N8G-P.S(P M,3(@=&AR;W5G:"!-87DF;F)S<#LR,#$R('=A'!I65A&5R M8VES86)L92!A="`D,RXP,"!P97(@2!A29N8G-P.S,P+"`R,#$R(')E;6]V960@=&AE(&-O;F1I=&EO;B!W M:&EC:"!R97%U:7)E9"!T:&5S92!W87)R86YT3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M2!T:&4@:6YV97-T;W)S(&9O#(P,3D[28C>#(P,3D[7-I2!T;R!A9&1I=&EO;F%L('!A:60@:6X@ M8V%P:71A;"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M2!E>&5R8VES86)L92!A;F0@97AP:7)E(&]N($UA M>29N8G-P.S(Y+"`R,#$W+B9N8G-P.R9N8G-P.R9N8G-P.T)A28C M>#(P,3D['0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M29N8G-P.S(P,3(@:&%V92!A M;B!E>&5R8VES92!P2!E>&5R8VES86)L92!A;F0@97AP:7)E($1E8V5M8F5R)FYB&5R8VES92!P65A2!C;W-T(&]F M(&-A<&ET86PN/"]F;VYT/@T*"0D\+W`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`R,#$S+"!T:&4@0V]M<&%N>2!F M:6QE9"!A($9O2!C;VUB:6YA=&EO;B!O9B!C;VUM;VX@2!B92!C;VYV97)T:6)L92!O&5R8VES86)L92!O M&-H86YG96%B;&4@9F]R(&-O;6UO;B!S=&]C:R!OF=E&EM871E;'D@)#$U+C`@;6EL;&EO;B!F M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D) M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M&5R8VES M92!O9B`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`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`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5&5R;3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#$N,S8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U+C`V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXS+C$X#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M65A6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$=VED M=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT M+C@X#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/D5X M97)C:7-E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D5X<&ER960\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,38L-C6QE/3-$=VED=&@Z,#,N-#`E M.SX-"@D)"0D)/'`@F4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$=VED=&@Z,#$N,S`E.W!A M9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$U+C`V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,#$N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$U+C`V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXS+CDV#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,SDN,S8E.W!A9&1I;F6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D5X97)C:7-E9#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S M+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M-BXS-B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I M9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D5X<&ER960@/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H M.C$V+C,V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,38N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C,Y+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$ M)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXV+#(S,RPT.#,-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB65A6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX M-2PT-S`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U+C`V)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#$N,S8E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,S8L-C8V#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I M9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,SDN,S8E.W!A9&1I;F6QE M/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"XX,`T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C0P M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z,#$N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYB#(P,3,[ M(#0@>65A6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/E1H92!#;VUP M86YY(&=R86YT960@82!T;W1A;"!O9B`S+#0Q-BPY,S0@=V%R&5R8VES92!P'!E8W1E9"!S=&]C:R!P'!E M8W1E9"!F;W)F96ET=7)E(')A=&4N)FYB'!E8W1E9"!S=&]C:R!P2!Y:65L9"!C=7)V92!I;B!E9F9E8W0@870@=&AE(&1A=&4@;V8@9W)A;G0@ M9F]R('1H92!E>'!E8W1E9"!T97)M(&]F('1H92!W87)R86YT+B9N8G-P.R9N M8G-P.U1H92!C;VUP;&5T:6]N(&]F('1H92!U;F1E29N8G-P.S,P+"`R,#$R(')E;6]V960@=&AE(&-O M;F1I=&EO;B!W:&EC:"!R97%U:7)E9"!T:&5S92!W87)R86YT29N8G-P M.S,P+"`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`P<'0@,S9P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!M871E3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,S9P=#MT97AT+6EN9&5N=#HS-G!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M3H@:6YL M:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/B!(;VQD97)S(&]F('1H92!397)I97,F M;F)S<#M!($-O;G9E6%B;&4@<75A M'!E;G-E28C>#(P,3D[65A2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C(I/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#LG M/B`F;F)S<#M6;W1I;F<@4FEG:'1S+B`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M2!C:&%N9V4@=&AE('!O=V5R6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,S9P=#MT97AT+6EN9&5N M=#HS-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M3H@:6YL:6YE.V9O;G0M3H@:6YL:6YE.V9O;G0M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C0I/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V1I6QE.FET86QI8SMF;VYT M+7-I>F4Z,3!P=#LG/B`F;F)S<#M#;VYV97)S:6]N(%)I9VAT6QE/3-$)V1IF4Z,3!P M=#LG/B!%86-H('-H87)E(&]F(%-E2!D:79I9&EN9R!T:&4@ M4W1A=&5D(%9A;'5E+"!C=7)R96YT;'D@)#$P('!E6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T(#!P="`P<'0@,S9P=#MT97AT+6EN9&5N=#HS-G!T.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M3H@:6YL:6YE M.V9O;G0M3H@:6YL:6YE.V9O;G0M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C8I/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V1I6QE.FET86QI8SMF;VYT+7-I>F4Z M,3!P=#LG/B`F;F)S<#M!=71O;6%T:6,@0V]N=F5R6QE/3-$)V1IF4Z,3!P=#LG M/B!"96=I;FYI;F<@2G5L>29N8G-P.S$S+"`R,#`V+"!I9B!T:&4@<')I8V4@ M;V8@=&AE(&-O;6UO;B!S=&]C:R!E<75A;',@)#(U+C@P('!EF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S M='EL93TS1&UA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X- M"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.C$P<'0[)SXV+B9N8G-P.R9N8G-P.U-T;V-K($]P=&EO;B!0;&%N M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/DEN($IU;F4F;F)S<#LR,#`T('1H92!#;VUP86YY(&%D;W!T960@ M=&AE(%1R;W9A9V5N92!3=&]C:R!/<'1I;VX@4&QA;BP@87,@86UE;F1E9"`H M=&AE("8C>#(P,4,[,C`P-"!0;&%N)B-X,C`Q1#LI+"!U;F1E65E65A'!I6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0MF5D('-H87)E2!W87,@'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.W1E>'0M:6YD96YT.C,Y<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T* M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,Y<'0[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N M=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD M96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D) M/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L M;&%P6QE/3-$ M)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,30E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^665A6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,30E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$T)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3(\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$ M)W=I9'1H.C0T+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C`S+C$T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW.38L,#`X)FYB6QE/3-$)W=I M9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXU-#DL-#8U)FYB6QE/3-$)W=I9'1H.C`S+C$T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S M+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,S8L,30X M)FYB6QE/3-$)W=I9'1H.C`Q+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#0N,S@E.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#(W-"PQ.#8F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,30E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/E1O=&%L('-T;V-K(&)A6QE/3-$)W=I9'1H.C`Q+C,P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+CF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$S+CF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S M+CF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M:6YD96YT.C,V<'0[;&EN92UH96EG:'0Z M;F]R;6%L.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H M92!E65A3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B M;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#,N-#(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^665A6QE M/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#(E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`S+C0P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,V)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE M6QE/3-$)W=I9'1H.C,Y+C,T)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/C$N-#(E("T@ M,BXQ)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BXV,B4@+2`Q+C`T)3PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,SDN,S0E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z,#,N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/C`E/"]F;VYT/CPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,38N,S8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C,T)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXT,B4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C@Q)2`M(#@V)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D('1E6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,38N,S8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/C4N,"!Y6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C,Y+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G M/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0S+C`P("T@)#8N-S0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,RXT,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD M+6-O;&]R.B`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`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`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/E=E:6=H=&5D($%V97)A9V4\+V9O;G0^/&)R("\^/&9O;G0@ M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/E)E;6%I;FEN9SPO9F]N=#X\8G(@+SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I M>F4Z.'!T.R<^0V]N=')A8W1U86P@3&EF93PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R M+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,"XY-"4[8F]R9&5R+71O<#HQ<'0@'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`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`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C8R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`R+C4V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HQ,"XY-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ M6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M,"XY-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,SDN-C(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$R+C(T)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$=VED M=&@Z,#(N-38E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z M,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$P+CDT)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,3(N M-#@E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I M9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XY M-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XY-"4[ M8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z,SDN-C(E.W!A9&1I;F6QE/3-$=VED=&@Z,#(N-38E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+C,S#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-38E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/D5X97)C M:7-E9"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU-B4[8F%C:V=R;W5N9"UC;VQO M6QE M/3-$)W=I9'1H.C$R+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF M;VYT+69A;6EL>3I4:6UE6QE/3-$)W=I9'1H.C`R+C4V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D9O6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH-3$V M+#`Q.`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`R+C4V)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,"XY-"4[.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$=VED=&@Z,3(N,C0E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C,Y+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$R+C(T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXT+#(X-RPU-#4-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C$R+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M65A6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#0Q,"PP,S@-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z M,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$P+CDT)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,3(N M-#@E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M,"XY-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$ M)W=I9'1H.C$R+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$=VED=&@Z,#(N-38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$=VED=&@Z M,#(N-38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HQ,"XY-"4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CDT)3L[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M65A6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C8R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M&5R8VES86)L92P@1&5C96UB97(@,S$L(#(P,30\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,BXU-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$R M+C(T)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE M(",P,#`P,#`@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#0S M-"PQ,C0-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R M+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M65A M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/D%30R!4;W!I8R`W,3@@ M"!D M961U8W1I;VYS(&EN(&5X8V5S"!B96YE9FETF5D M(&EN('1H92!C87-H(&9L;W<@3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE M/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y M.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`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`P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M M8F5R)FYB6QE/3-$=VED=&@Z,#$N,#`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`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/C$P M(&UO;G1H65A6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C(R+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C`Q M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P M=#LG/D5X<&5C=&5D('9O;&%T:6QI='D@/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z M,3$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE M6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/CDP)2TY-R4\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`Q+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C(R+C(T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6EE M;&0@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$S+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/C`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`@6QE/3-$ M)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/D1A=&4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C8T)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E6QE/3-$)W=I9'1H.C$P+CDX)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#$N,3`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`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/D)A;&%N8V4@;V8@9&5R:79A=&EV92!F:6YA;F-I86P@:6YS=')U;65N M=',@;&EA8FEL:71Y/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$Q+C@X M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY.30L-C(W#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C$U+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0MF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M M86QI9VXZ6QE/3-$)W=I M9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C$U+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0MF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[ M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,34N,S@E.W!A9&1I;F6QE/3-$ M=VED=&@Z-30N.3@E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`X M-RPP-C`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$S+C$X)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N-C0E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/D5X<&ER960@=V%R6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXH-S,L,#DY#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#$N,3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,3,N,3@E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N-C0E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/D-H86YG92!I;B!F M86ER('9A;'5E(&]F('=A65AF5D(&%S(&$@9V%I;B!I;B!T:&4@6QE/3-$)VUA3I4:6UE6QE M/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,2PX,C`L.#@Y#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#$N,3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/D1E8V5M8F5R)FYB6QE/3-$)W=I9'1H M.C4T+CDX)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D)A;&%N8V4@;V8@9&5R:79A=&EV92!F:6YA M;F-I86P@:6YS=')U;65N=',@;&EA8FEL:71Y/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q M+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$Q+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXT+#0S,2PX-S$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C4T M+CDX)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D-H86YG92!I;B!F86ER('9A;'5E(&]F('=A65AF5D(&%S(&$@9V%I;B!I;B!T M:&4@6QE/3-$)W=I9'1H.C$P+CDX)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C$X)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,2PT,C4L.#4P#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D) M/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@F4Z(#$R M<'0G/@T*"0D)"0D))FYB3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C8T)3MB86-K9W)O=6YD M+6-O;&]R.B`C1D9&1D9&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD M+6-O;&]R.B`C1D9&1D9&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9&1D9&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I6QE.FET M86QI8SMF;VYT+7-I>F4Z,3!P=#LG/E=AF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M2!F2!M;VYT:',@9G)O;2!T:&4@9FEN86P@0VQO M65A2!S:&%L;"!I2P@=&AE(&5X<&5C=&5D('!R:6-E(&UU;'1I<&QE(&%T('=H:6-H('5N M:70@:&]L9&5R2!W:71H:6X@=&AE(&)I;F]M:6%L(&UO9&5L+B9N8G-P.R9N M8G-P.U1H92!R:7-K+69R964@6EE;&0@8W5R=F4@:6X@969F96-T(&%T('1H M92!D871E(&]F(&=R86YT(&9O2!T;R!A9&1I=&EO;F%L('!A:60@:6X@ M8V%P:71A;"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`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`@F4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`Q+CDT)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE6QE/3-$=VED=&@Z M-C0N-S(E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N-S(E.W!A9&1I;F6QE/3-$=VED=&@Z,#,N.3(E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/CDP)2`M.3'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D(&9A:7(@=F%L=64@;V8@=&AE('-T;V-K M(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`S+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1IF4Z M,3!P=#LG/D5X<&5C=&5D('=A6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)V)O6QE/3-$)W=I9'1H.C,Q+CDT M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/E5N:71S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)V1I3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DES6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)V1IF4Z.'!T.R<^=F%L=64F;F)S<#MO9CPO9F]N=#X\8G(@ M+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^1&5R:79A=&EV93PO9F]N=#X\8G(@+SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L M9#MF;VYT+7-I>F4Z.'!T.R<^3&EA8FEL:71Y)FYB6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/E!R;W1E8W1E9#PO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^56YI=',\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`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`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$S M+C@T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M6QE M/3-$)W=I9'1H.C`Q+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S$N.30E.W!A9&1I;F6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXH-2PT,36QE/3-$=VED=&@Z,#(N.#@E.SX- M"@D)"0D)/'`@F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H M.C$S+C@T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T* M"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@F4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C@X)3MB86-K9W)O=6YD M+6-O;&]R.B`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`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`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`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1I3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-34N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^1F%I6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`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`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#(N-3`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`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`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/D%S6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R M+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P M+C3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P M,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPQ,C,L-3@W)FYB M6QE M/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.V)A8VMGF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$P+CF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@ M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P M+C'0M M86QI9VXZ6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R M9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZ M6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O M='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C M>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$P+C3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS+#`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`P-BPP,C$F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C,P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW M,"4[8F]R9&5R+71O<#HQ<'0@'0M86QI M9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N M=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@ M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D M97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE6QE/3-$)W=I9'1H.C4U+C4P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$=VED M=&@Z-#$N,#`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I M>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^475O=&5D)FYB M6QE/3-$)V1IF4Z.'!T.R<^ M261E;G1I8V%L)FYB6QE M/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/E-I9VYI9FEC86YT/"]F;VYT/CQB6QE/3-$)V1I MF4Z.'!T.R<^26YP=71S/"]F M;VYT/CQB6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`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`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5&]T M86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1IF4Z,3!P=#LG/E1O=&%L($%S6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C$P+C'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M,"XW,"4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-2PW M,#,L,S,P)FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/D1E6QE/3-$)W=I9'1H M.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P M,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A M9&1I;F6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#0S,2PX M-S$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M3I4:6UE6QE/3-$=VED=&@Z,'!T.W=I M9'1H.C!P=#MF;VYT+7-I>F4Z,'!T.SX\+W`^/"]T9#X\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1'1O<#X-"@D)"3QP('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0[;6%R9VEN.C!P=#LG M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M'0M:6YD96YT.C,V<'0[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M28C>#(P,3D[3I4:6UE6QE/3-$)V1I MF4Z,3!P=#MC;VQO6QE/3-$)V)O6QE/3-$)W=I9'1H.C0X+C$T)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C$S+C6QE/3-$)V1IF4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXR,#$S/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$S+C6QE/3-$)V1I M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#MC;VQO6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY"86QA;F-E M)FYBF4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXR,#$T/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z,3!P=#MC M;VQO6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXT+#0S,2PX-S$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE M/3-$)W=I9'1H.C$R+C4V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$ M.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXS+#`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`P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#MC;VQO6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L M9#MF;VYT+7-I>F4Z.'!T.V-O;&]R.B,P,#`P,#`[)SY"86QA;F-E)FYBF4Z.'!T.V-O;&]R.B,P,#`P,#`[)SXR,#$S/"]F;VYT/CPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXX+#F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXH-2PT,36QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#MC;VQO6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M28C>#(P,3D[3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y M.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`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`P)3X\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M M8V]L;&%P'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C(P,34@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT M+#'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/C(P,3<\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W=I9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+#$T,"PU,3DF;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I MF4Z,3!P=#LG/C(P,3@\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y M1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,RXW,"4[8F]R9&5R+71O<#HR<'0@9&]U8FQE(",P,#`P M,#`@.V)O'0M86QI9VXZ M6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)VUA3I4:6UE6QE/3-$)V1I&5S/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D%T($1E8V5M8F5R)FYB2`D-#DN,R!M:6QL:6]N M+"!W:&EC:"P@:68@;F]T('5S960L(&5X<&ER92!B96=I;FYI;F<@:6X@,C`R M,"XF;F)S<#LF;F)S<#LF;F)S<#M4&EM871E;'D@)"9N8G-P.S(Y+CD@;6EL;&EO M;B!W:&EC:"!B96=I;B!T;R!E>'!I2!.3TQS(&]F("0Q,2XU(&UI;&QI;VX@=VAI8V@@'!I M29N8G-P.S,Q+"`R,#$S+B9N8G-P.R9N8G-P.R9N8G-P M.U1R;W9A9V5N92!A;'-O(&AA&EM871E;'D@)#8Y."PP M,#`N(%1H92!F961EF%T:6]N(&]F('1H97-E($Y/3',@86YD(%(F86UP.T0@ M=&%X(&-R961I=',@:7,@'0M:6YD96YT.C,V M<'0[;&EN92UH96EG:'0Z;F]R;6%L.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E-I9VYI9F-A;G0@8V]M<&]N96YT28C>#(P,3D[F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH-"PX-S$L,#`P#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXX-"4[8F%C:V=R;W5N9"UC M;VQO'0M86QI9VXZF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#(N.#@E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N.#@E.SX- M"@D)"0D)/'`@F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$S+C@T)3L[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R M/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,S(P+#`P,`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`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`P,`T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX M."4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$ M=VED=&@Z-C,N-38E.W!A9&1I;F6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,3,N.#0E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`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`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C$S+CDP)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ.2PP,3`L.3`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXV,"4[ M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1IF4Z,3!P=#LG/E(F86UP.T0@8W)E9&ET6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV.3@L,#`P#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG M/E-T;V-K(&)A6QE/3-$=VED=&@Z,#(N M.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ+#4T-RPU,#`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/D]T:&5R/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H.C$S+CDP)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,S`L-#`P#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q M+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z-C4N,S0E.W!A9&1I;F6QE/3-$)W=I9'1H.C$S+C@T M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O'0M86QI9VXZ M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ-BPR,C0L-C`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,30E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)W=I M9'1H.C$S+CDP)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH M,38L,C(T+#8P,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,2XQ-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$=VED=&@Z-C4N,S0E.W!A9&1I;F6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[ M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXU-"4[8F]R M9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`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`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1I3I4:6UE6QE/3-$)V1I6QE.FET86QI8SMF M;VYT+7-I>F4Z,3!P=#LG/E-I9VYI9FEC86YT(%)EF4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2!O9B!497AA M&EM871E;'D@)#(V-BPP,#`@ M9F]R('1H92!S97)V:6-EF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M#(P,4,[26QL=6UI;F$F(W@R,#%$.RD@<'5R7-IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2!I2!H860@:6YC=7)R960@87!P2`D,S@L,#`P(&]F(')E3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M2`D,38L,#`P(&%N9"`D,CDL,#`P(&]F(')E M'!E;G-E(')E;&%T960@=&\@=&AI M6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2!'96YO;6%C(&%P<')O M>&EM871E;'D@)#$W-2PP,#`@9F]R('-E2`D M.3`L,#`P(&]F(')E'!E;G-E3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/DEN($UA>29N8G-P.S(P,#8L('1H92!#;VUP86YY(&5N=&5R960@:6YT M;R!A(&QI8V5N2!R96-O&EM M871E;'D@)#(S+#`P,"P@)#,P+#`P,"!A;F0@)#(T+#`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`W M+"!T:&4@0V]M<&%N>2!S:6=N960@82!L:6-E;G-E(&%G&-L=7-I=F4@&5C=71I;VX@;V8@=&AE(&%G2!T M;R!P97)F;W)M(&QA8F]R871O2!O;B!A;GD@;F5T(')E=F5N=65S(&1U&-L=7-I=F4@2`H4E5/*2!K:71S+B9N8G-P.R9N8G-P.R9N8G-P.T%355)!1T5.('=A M2!T97-T:6YG('-E65A2!A;F0@;&EC96YS92!F964@2`D M-3`L,#`P+"`D-3`L,#`P(&%N9"`D-3`L,#`P+"!R97-P96-T:79E;'DN)FYB M6QE M/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DEN M($%U9W5S="9N8G-P.S(P,#@L('1H92!#;VUP86YY('-I9VYE9"!A('-U8FQI M8V5N&5C=71I;VX@;V8@=&AE(&%G2!N970@65A2!A;F0@;&EC96YS92!F964@2`D,C@L,#`P+"`D,C`L,#`P(&%N9"`D-2PP M,#`L(')E2XF;F)S<#LF;F)S<#M$=7)I;F<@=&AO6QE M/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DEN M($1E8V5M8F5R)FYB&5C=71I;VX@;V8@=&AE(&%G2!N970@'!I2!R96-O2XF;F)S<#LF;F)S<#M$=7)I;F<@=&AO2!H87,@;F]T(')E8V]R9&5D(&%N>2!L:6-E M;G-E(&9E92!E>'!E;G-EF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M2!T:&4@0V]M<&%N>2!A(')O M>6%L='D@;VX@86YY(&YE="!R979E;G5E65A2!A;F0@;&EC96YS92!F964@2`D M,"P@)#`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`P,"!F;W(@=&AE(&9I M'!I6%L='D@86YD(&QI8V5N M&EM871E;'D@)#@Q+#`P,"P@)#@U M+#`P,"!A;F0@)#'0M:6YD96YT.C,V<'0[ M;&EN92UH96EG:'0Z;F]R;6%L.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DEN($IU;'DF;F)S<#LR,#$Q+"!T:&4@0V]M<&%N>2!E;G1E M#(P,40[*2!F M;W(@=&AE(&YO;BUE>&-L=7-I=F4@&5C=71I;VX@;V8@=&AE(&%G M2!T:&4@0V]M<&%N>2!A(')O>6%L M='D@;VX@86YY(&YE="!R979E;G5E2!A;F0@;&EC96YS92!F964@2`D,BPP,#`L("0Q+#`P,"!A;F0@)#(L,#`P+"!R97-P96-T:79E M;'DN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M&-L=7-I=F4@;&EC M96YS92!A9W)E96UE;G0@=VET:"!':6%N;'5C82!'86ED86YO+"!2;V)E6UP:&]B;&%S=&EC(&QE=6ME;6EA+B9N8G-P.R9N8G-P.TEN(&-O M;G-I9&5R871I;VX@;V8@=&AE(&QI8V5N6%L='D@<&%Y;65N=',@:6X@=&AE('-I;F=L92!D:6=I=',@ M;VX@;F5T('-A;&5S(&EF('-A;&5S(&%R92!M861E(&)Y('1H92!#;VUP86YY M(&]R(&$@6%L='D@;VX@2!P87)T>2!O2!T:&4@0V]M<&%N M>2!I9B!I="!I2!O2!A<'!R;W!R:6%T92!T;R!F=7)T:&5R M(&1E=F5L;W`@=&AE(&QI8V5NF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M2!E;G1E2!T;R!L:6-E;G-E('1H M92!P871E;G0@2!P86ED("0Q+#`P,"!A6UE;G1S M(&EN('1H92!S:6YG;&4@9&EG:71S(&]N(&YE="!S86QE2!T:&4@0V]M<&%N>2!O2!A;'-O(&)E('1E2!A;GD@<&%R='D@;W(@8GD@=&AE($-O M;7!A;GD@:68@=V4@9&5T97)M:6YE('1H870@:70@:7,@;F]T(&-O;6UE2!O2!A<'!R;W!R:6%T92!T;R!F=7)T:&5R M(&1E=F5L;W`@=&AE(&QI8V5NF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6%L='D@<&%Y;65N=',@ M;VX@;F5T('-A;&5S(&]F(%%U97-T($1I86=N;W-T:6-S(&%N9"!I=',@869F M:6QI871E6%L='D@86YD(&QI8V5N&EM871E;'D@)#(V+#`P,"P@)#$T+#`P,"!A;F0@ M)#(P+#`P,"P@'0M:6YD96YT.C,V<'0[;&EN92UH96EG M:'0Z;F]R;6%L.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/DEN(%-E<'1E;6)E#(P,4,[4W1R86YD)B-X,C`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`D,S`L,#`P+"`D,3`L,#`P(&%N9"`D,3`P+#`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`P)3X\=&%B;&4@ M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D M97(M8V]L;&%P6QE/3-$)V1IF4Z,3!P=#LG/C(P,34@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXS-S$L,S(T)FYB6QE/3-$=VED=&@Z,#$N,C0E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S M+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P M=#LG/C(P,3@@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$U M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI M9VXZ'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1O=&%L(#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C(T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA65E($)E;F5F:70@4&QA;CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SXQ M,BXF;F)S<#LF;F)S<#M%;7!L;WEE92!"96YE9FET(%!L86X\+V9O;G0^#0H) M"3PO<#X-"@D)/'`@F4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M65E"!B87-I2!E;7!L;WEE92!O9B!T:&4@86=E(&]F(#4U M(&-A;B!P87)T:6-I<&%T92!I;B!T:&4@8V%U9VAT+75P(&1O;&QA2!)4E,@8V]D97,N)FYB&5S+B9N8G-P.R9N8G-P.U1H92!#;VUP86YY(&1O97,@;F]T M(&-U2!M86ME(&UA=&-H:6YG(&-O;G1R:6)U=&EO;G,N/"]F;VYT M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!42!46QE/3-$)VUA3I4:6UE6QE/3-$)V1I2!4F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M28C>#(P,3D[3H@:6YL:6YE.V9O;G0M M#(P,3D[($5Q=6ET>2`H1&5F:6-I96YC>2DN/"]F;VYT M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!&:6YA;F-I86P@1&%T82`H56YA=61I=&5D*3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.C$P<'0[)SXQ-"XF;F)S<#LF;F)S<#M396QE8W1E9"!1=6%R=&5R;'D@1FEN M86YC:6%L($1A=&$@*%5N875D:71E9"D\+V9O;G0^#0H)"3PO<#X-"@D)/'`@ MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2!R97-U;'1S(&]F(&]P97)A M=&EO;G,@;V8@=&AE($-O;7!A;GD@9F]R('EE87)S(&5N9&5D($1E8V5M8F5R M)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V)O6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;FF4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^475A6QE/3-$)VUA M3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DIU;F4F;F)S<#LS,#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^4V5P=&5M8F5R)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D1E8V5M8F5R)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I M;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$ M)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/BA2979I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I M;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/BAD;VQL87)S)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M,3$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ M6QE/3-$)V1IF4Z,3!P=#LG M/D]P97)A=&EN9R!E>'!E;G-E6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I M;F'0M86QI9VXZ6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DYE="!L;W-S(&%N9"!C;VUP6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,RPQ.3@-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,2PP-SD-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$R+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXH-2PS.#(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXH-"PV.#D-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXH,"XP-@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HQ,"XW,"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[ M8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED M=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PY,#(L-S@S#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z M,3!P=#LG/E-H87)E6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PY,#(L-S@S#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.C$P<'0[)SXR,#$S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z M,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,3D-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT-`T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N9"UC;VQOF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D]P97)A=&EN9R!E>'!E;G-E6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M,BXP,"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z M,3!P=#LG/DYE="!L;W-S('!E6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXH,"XR-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$=VED=&@Z,#$N,#`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)V1IF4Z,3!P=#LG/DYE="!L;W-S M('!EF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQO MF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-2PU,3`L,S0P#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I M9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ."PY,#`L-S@Q#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I M;F6QE/3-$)W=I9'1H.C$R M+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-2PU.#,L M.34W#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C`P M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B@Q*29N8G-P.T)A2!F;W(@96%C:"!O9B!T:&4@<&5R:6]D2!%4%,@86UO=6YT(&UA>2!N;W0@86=R964@=&\@ M=&AE('1O=&%L(&9O65A3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M3H@:6YL:6YE.V9O;G0M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`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`@/&AE860^#0H@("`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`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I6QE.FET86QI M8SMF;VYT+7-I>F4Z,3!P=#LG/E)E=F5N=65S/"]F;VYT/@T*"0D\+W`^#0H) M"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA M3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/E=E(&QI8V5N6%L=&EE6UE;G1S+B9N8G-P M.R9N8G-P.U)E=F5N=64@:7,@6QE/3-$)VUA6QE/3-$=VED=&@Z M,3`P)3L@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D M('-T>6QE/3-$=VED=&@Z,S9P=#L^/'`@6QE/3-$)W=I9'1H.B`P,"XP,'!T.R!D:7-P;&%Y.B!I;FQI M;F4[)SX-"@D)"3QP('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$P<'0[;6%R9VEN.C!P=#LG/@T*"0D)"3QF;VYT M('-T>6QE/3-$)VUAF4Z(#$P<'0[)SX@)B-X M0C<[/"]F;VYT/@T*"0D)/"]P/@T*"0D\+W1D/CQT9"!S='EL93TS1'=I9'1H M.C$X<'0[/CQP('-T>6QE/3-$=VED=&@Z,3AP=#MW:61T:#HQ.'!T.V9O;G0M MF5D(&%S(')E=F5N=65S(&]N('1H92!E9F9E8W1I=F4@9&%T92!O9B!T M:&4@86=R965M96YT(&%N9"!W:&5N(&-O;&QE8W1I;VX@:7,@2!A6QE/3-$)VUA'0M M:6YD96YT.B`M,3AP=#ML:6YE+6AE:6=H=#IN;W)M86P[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M6QE M/3-$=VED=&@Z,3`P)3X\=&%B;&4@6QE/3-$=VED=&@Z,3AP=#L^/'`@ M6QE/3-$)V1I MF4Z,3!P=#MC;VQO6UE;G0@=VAE;B!C;VQL M96-T:6]N(&ES(&%S3I4:6UE6QE/3-$)V1IF4Z,3!P M=#MC;VQO6QE/3-$=VED=&@Z,S9P=#MF;VYT M+7-I>F4Z,'!T.SX\+W`^/"]T9#X\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$ M;&5F="!S='EL93TS1"=W:61T:#H@,#`N,#!P=#L@9&ES<&QA>3H@:6YL:6YE M.R<^#0H)"0D\<"!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE$(W M.SPO9F]N=#X-"@D)"3PO<#X-"@D)/"]T9#X\=&0@F4Z,'!T.SX\+W`^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O M<#X-"@D)"3QP('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$P<'0[;6%R9VEN.C!P=#LG/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6UE;G0@:7,@6QE/3-$;6%R9VEN+6QE9G0Z,'!T M.VUAF4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M6UE;G1S(&%R92!R96-E:79E9"!O;B!R97-E2!A#(P,3D['0M:6YD96YT.C,V<'0[;&EN92UH96EG:'0Z;F]R;6%L.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0MF4],T0Q/B`\+V9O M;G0^/"]P/@T*"3PO9&EV/B`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`@3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N M=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X- M"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M&-H86YG92!F;W(@=&AE M(&%W87)D(&]F(&5Q=6ET>2!I;G-T'!E;G-E(&ES(')E8V]G;FEZ960@ M;W9E65E('-T;V-K+6)A2!A8V-O=6YT65E2`M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#LG/D)A6UE;G0@ M=&\@3F]N+45M<&QO>65E#(P,40[(#PO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SYA;F0@86-C;W)D M:6YG;'D@=&AE('9A;'5E(&]F('1H92!S=&]C:R!C;VUP96YS871I;VX@=&\@ M;F]N+65M<&QO>65E2!I;G-T2!T:&4@9F%I#(P,4,[;6%R:V5D('1O(&UA'0M:6YD96YT.C,V<'0[;&EN92UH96EG:'0Z;F]R M;6%L.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\6QE/3-$;6%R9VEN+6QE M9G0Z,'!T.VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M#(P,4,[05-#(#@R,"8C>#(P,40[*3PO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SX@9F]R(&9I;F%N M8VEA;"!A6QE/3-$)VUA MF4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/DEN(&%C8V]R M9&%N8V4@=VET:"!!4T,@2!M M96%S=7)E2P@=VAI8V@@<')I;W)I=&EZ97,@ M=&AE(&EN<'5T3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE M/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C M:6YG/3-$,"!S='EL93TS1&)O6QE/3-$=VED=&@Z,#0N,C@E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(WA&,$(W.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DQE=F5L)FYB6QE/3-$=VED=&@Z,#$N.38E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E%U;W1E9"!P6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#$N.38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,#0N,C@E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(WA&,$(W.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DQE=F5L)FYB6QE M/3-$=VED=&@Z,#$N.38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/E%U;W1E9"!P6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#$N.38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,#0N,C@E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(WA&,$(W.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DQE=F5L)FYB6QE M/3-$=VED=&@Z,#$N.38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/DEN6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0MF4],T0Q M/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\F%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M&5S(&AA=F4@ M8F5E;B!D971E#(P,3D["!B96YE9FET('=I;&P@;F]T(&)E(')E86QI M>F5D+B9N8G-P.R9N8G-P.U1H92!A3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P M/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@ M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S M='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M2!C M:&%R9V5S(&YE8V5S2!T;R!R96YD97(@86X@:6YD:79I9'5A;&EZ960@ M=&5S="!R97-U;'0N($-O3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F M;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M3H@:6YL:6YE.V9O;G0M3H@:6YL:6YE.V9O;G0M2!T:&ES(&=U:61A;F-E+"!P M871E;G0@9FEL:6YG(&%N9"!M86EN=&5N86YC92!E>'!E;G-E2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0MF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V1I6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#LG/E)E6UE;G1S(&9O'!E8W1E9"!T;R!B92!P3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$ M,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`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`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$U+C8V)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$U+C8V M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)V1I'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/D]P=&EO;G,@=&\@<'5R M8VAA6QE/3-$)W=I9'1H.C`S+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C8V)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#(X-RPU-#4F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-#$N.30E.W!A9&1I;F6QE/3-$)W=I9'1H.C$U M+C8V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+#DX-2PP M-S`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)V1IF4Z,3!P=#LG/E-E M6QE/3-$)W=I9'1H.C`S+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C$U+C8V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV,RPQ M,C4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N.30E.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@28C>#(P,3D[6QE/3-$)V1I6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1I M6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D1E8V5M8F5R)FYB6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^1&5C96UB97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-34N-3`E.W!A M9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB M6QE M/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$)V1I6QE/3-$)V1IF4Z,3!P M=#LG/DYU;65R871O6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ M3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXH,3$L.#0P+#6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[ M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N,#`E.SX- M"@D)"0D)/'`@F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D%D:G5S=&UE;G0@9F]R(&-H86YG92!I;B!F86ER('9A M;'5E(&]F(&1E6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@F4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX- M"@D)"0D)/'`@F4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXH,3$L-C`T+#(P,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI M9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/E=E:6=H=&5D(&%V97)A9V4@6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,RPP M-C8L-C`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ-C8L.#,R#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.2PP-S$L,3$R#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,3(N,#`E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DYE="!L;W-S('!EF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS M,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R M/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.W1E>'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@ M/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I6QE.FET86QI M8SMF;VYT+7-I>F4Z,3!P=#LG/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC M96UE;G1S/"]F;VYT/@T*"0D\+W`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`Y+"!2979E;G5E(&9R M;VT@0V]N=')A8W1S('=I=&@@0W5S=&]M97)S("@F(W@R,#%#.T%352`R,#$T M+3`Y)B-X,C`Q1#LI+B!4:&4@2US<&5C:69I8R!R979E;G5E(&=U:61A M;F-E+B!4:&4@8V]R92!PFEN9R!R979E;G5E('=H96X@=&AE(')I2!T:&4@2!I M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&-L=61E M9"!F'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P M)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL M93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#,N,C8E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I M>F4Z.'!T.R<^1&5C96UB97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q M+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N.30E M.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M)FYB6QE/3-$)W=I9'1H M.C$U+C8V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C8E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q,SPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED M=&@Z,#,N,C8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q,CPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C$U+C8V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXT+#DQ,RPT-S(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`S+C(V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$=VED=&@Z,#,N,C8E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$U M+C8V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#$N,S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$U+C8V)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV,RPQ,C4F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C`S+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`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`\+V9O;G0^/"]P/@T*"3PO M9&EV/B`\+V1I=CX\'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED M=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$=VED M=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^1&5C96UB97(F;F)S<#LS,2P\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4U+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I M;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,30L,S0X+#0Y.0T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C4U+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ6QE/3-$)W=I9'1H M.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-34N-3`E.W!A9&1I;F6QE/3-$)W=I9'1H M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`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`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-34N-3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4U+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-BPY M-S@L,C$R#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D%D:G5S=&UE;G1S('1O(')E9FQE8W0@87-S M=6UE9"!E>&5R8VES92!O9B!W87)R86YT6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E=E:6=H=&5D(&%V97)A9V4@6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,RPP-C8L-C`P#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M-34N-3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C4U+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`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`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)VUA6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/D%S)FYB3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`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`Q+C,V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C4Y+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$U+C`V)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS-C4L.34U#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$U+C`V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR,S8L-C0U#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,3(E.W!A9&1I;F6QE/3-$=VED=&@Z,#,N-#`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M-BPS-S$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/DQA8F]R871O M6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE M/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4Y+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M#(P M,30[86-C=6UU;&%T960@9&5PF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXH,S0X+#8P,@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS-B4[8F%C:V=R;W5N M9"UC;VQO6QE/3-$=VED=&@Z-3DN,3(E.W!A9&1I;F6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ-2XP-B4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U M+C`V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXW-3`L-38U#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B M-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T M.#8S+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`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`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXS+#8P,2PT-S0-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z,SDN,S8E.W!A9&1I;F6QE/3-$)W=I9'1H.C$V+C,V)3L[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI M9VXZ6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP M-B4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,38N,S8E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXS+C`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/E=A6QE/3-$)W=I9'1H.C$V+C,V M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+#DX-2PP-S`- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/D=R86YT960@/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C$V+C,V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O M;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HQ-2XP-B4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$=VED=&@Z,38N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C,V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+CDY#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C0P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH-S,L,#DY M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#,N-#`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED M=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$U+C`V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z,#$N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I9'1H.C`S M+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/C$@ M+34F;F)S<#MY96%R6QE/3-$)W=I9'1H.C`Q+C,V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,SDN,S8E.W!A9&1I M;F6QE/3-$=VED=&@Z,#,N-#`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+C4Q#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D5X97)C:7-E9#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C$V+C,V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1IF4Z M,3!P=#LG/D5X<&ER960@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$V+C,V)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT M+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/E=A6QE/3-$)W=I9'1H.C$V M+C,V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XP-B4[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C$V+C,V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C$@)B-X,C`Q,SL@-"!Y96%R6QE/3-$)W=I M9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$ M=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#,N,30E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L M9#MF;VYT+7-I>F4Z.'!T.R<^665A6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#,N,30E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`S+C$T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C(R)3MP M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0T+C,X)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C`S+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXW.38L,#`X)FYB6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C

    3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU-#DL-#8U)FYB M6QE M/3-$)W=I9'1H.C`S+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$)W=I9'1H.C`Q+C(R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#0N,S@E M.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ+#(W-"PQ.#8F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$=VED=&@Z,#,N M,30E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1IF4Z,3!P=#LG/E1O=&%L('-T;V-K(&)A6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$S+CF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.V)A8VMGF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$S+CF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P M,#`P,"`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`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/E)IF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C$V+C,V)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUA M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BXW-"4@+2`Q+C4E/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6EE;&0@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$=VED=&@Z,38N,S8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/C`E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/D5X<&5C=&5D('9O;&%T:6QI='D@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C$V+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/C@R)2`M M(#$P,"4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXT,"4[8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W=I9'1H.C$V+C,V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/CDP)2`M(#DW)3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z,SDN,S0E.W!A9&1I;F6QE/3-$=VED=&@Z,38N,S8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/C4N,"!Y6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E-T;V-K('!R:6-E(#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`S+C0R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0U+C4S("T@)#@N,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXT,"4[8F%C M:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$V+C,V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE2!O9B!S=&]C:R!O<'1I;VX@86-T:79I='D@ M86YD(&]F(&-H86YG97,@:6X@'0^/&1I=CX@/&1I=B!S='EL M93TS1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D) M/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L M;&%P6QE/3-$ M)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`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`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`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C8R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C$R+C(T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N M;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR M+#0R-BPQ.3(-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M M86QI9VXZ6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,SDN-C(E.W!A9&1I;F6QE M/3-$=VED=&@Z,#(N-38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE M/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXS+C6QE/3-$=VED=&@Z,#(N-38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D5X97)C:7-E9"`\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,BXU-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$R+C(T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,C`P#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`R+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N M9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C0X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#(N-38E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XY-"4[.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,3(N,C0E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$R+C(T)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXS+#F4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C0X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M65A6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#$T-"PW M-C`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CDT)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$=VED=&@Z,3(N-#@E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CDT)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+C,P#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-S4L-#DR#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,SDN-C(E.W!A M9&1I;F6QE/3-$)W=I9'1H M.C$R+C(T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$=VED=&@Z,#(N-38E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D)A;&%N8V4@;W5TF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R M+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CDT)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+C$X#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`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`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C`R+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C`R+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`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`R+C4V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$P+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF M;VYT+69A;6EL>3I4:6UE6QE/3-$)W=I9'1H.C`R+C4V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$P+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ+#DY,"PQ.#<-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/C8N,B9N8G-P.WEE87)S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y M.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA6QE/3-$)V1I6QE M/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/EEE87(F;F)S<#ME;F1E9#PO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^1&5C96UB97(F;F)S<#LS,2PF;F)S<#LR,#$T/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M M8F5R)FYB6QE/3-$=VED=&@Z,#$N,#`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^665A6QE/3-$)V1I6QE/3-$)VUA3I4:6UE M6QE/3-$)W=I9'1H.C(R+C(T)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$Q+C`P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$ M)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0S+C`P("T@)#8N-S0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0U+C6QE/3-$)W=I9'1H.C$S+C`P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0P+C`R("T@)#4N.3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XR-"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$ M=VED=&@Z,#,N,30E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C0N,"!Y96%R6QE/3-$=VED=&@Z M,#$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/C$@;6]N=&@@-2XX('EE M87)S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$=VED=&@Z,3,N M,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED M=&@Z,#$N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/C$N,S@E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M2`\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`S+C$T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z,#$N,#`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/C@R)2TQ,#`E/"]F;VYT/CPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,3,N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C$Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/C`E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV M/B`\+V1I=CX\2=S(&1E2!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\9&EV/B`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`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N M,3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q M+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,2XX."4[8F]R9&5R+71O<#HQ<'0@'0M86QI9VXZ6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`Q+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H M.C`Q+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H M.C$S+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`Q+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C`Q+C8T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N-C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D)A;&%N8V4@;V8@9&5R:79A=&EV92!F:6YA;F-I86P@:6YS M=')U;65N=',@;&EA8FEL:71Y/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$P+CDX M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O'0M86QI9VXZ M6QE/3-$=VED=&@Z,#$N,3`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`@F4Z(#$R<'0G/@T*"0D)"0D))FYB M3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`Q+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q M+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,2XX."4[8F]R9&5R+71O<#HQ<'0@ M6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$U+C,X M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE M/3-$)W=I9'1H.C$U+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9&1D9&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE M/3-$)W=I9'1H.C`Q+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9&1D9&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$P+CDX)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$Q+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$ M.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P M/@T*"3PO9&EV/B`\+V1I=CX\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P M)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL M93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#,N.3(E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q M,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#$N.30E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#,N.3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ M6QE/3-$=VED=&@Z,#$N.30E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C(Y+C0R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/C`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`P)3X\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M M8V]L;&%PF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^1&%T93PO9F]N=#X\+W`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`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$S+C@T)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M6QE/3-$)W=I M9'1H.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+#,T,2PT,#4-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M2!T;R!E<75I='D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C@X)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXH,2PR.#@L-C4P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#(N.#@E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,RXX-"4[8F]R9&5R+71O<#HQ<'0@F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C,Q+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$S M+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR+#DP-2PP,#,-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG M/D1E8V5M8F5R)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXU-"4[8F]R9&5R+71O<#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HQ,BXU-"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXU M-"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB3I4:6UE6QE/3-$)V1I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35? M.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@ M8VAA3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B`F;F)S<#L@)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z-#$N M,#`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^)FYB6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D9A:7(F M;F)S<#M686QU929N8G-P.TUE87-U6QE/3-$)VUA M3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R M)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/FEN)FYB6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^4VEG;FEF:6-A;G0\ M+V9O;G0^/&)R("\^/&9O;G0@3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]T:&5R/"]F;VYT/CQB M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I M6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$)V1I6QE/3-$=VED M=&@Z,#$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/DUO;F5Y(&UA6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C6QE/3-$)VUA M3I4:6UE M6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M,"XW,"4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPQ M,C,L-3@W)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A M8VMGF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+CF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/DQI86)I;&ET:65S.CPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$R+C`P M)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$P+C6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#`P M-BPP,C$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/E1O M=&%L($QI86)I;&ET:65S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[ M8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[ M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@ M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P M.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\ M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS M1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C4U+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-#$N,#`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^475O M=&5D)FYB6QE/3-$)V1I MF4Z M.'!T.R<^261E;G1I8V%L)FYB6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/E-I9VYI9FEC86YT/"]F;VYT/CQB6QE M/3-$)V1IF4Z.'!T.R<^26YP M=71S/"]F;VYT/CQB6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`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`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R M9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1IF4Z,3!P=#LG/E1O=&%L($%S6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR-2PW,#,L,S,P)FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D M97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/D1E6QE/3-$ M)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q M+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q M+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F]R9&5R+71O<#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M6QE/3-$)W=I9'1H.C`Q+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N M,#`E.W!A9&1I;F6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT M+#0S,2PX-S$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M6QE/3-$=VED=&@Z,3AP=#MF M;VYT+7-I>F4Z,'!T.SX\+W`^/"]T9#X\=&0@=F%L:6=N/3-$=&]P(&%L:6=N M/3-$;&5F="!S='EL93TS1"=W:61T:#H@,3@N,#!P=#L@9&ES<&QA>3H@:6YL M:6YE.R<^#0H)"0D\<"!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UEF4Z,3!P=#L[)SX@*#$I/"]F;VYT/@T*"0D)/"]P/@T* M"0D\+W1D/CQT9"!S='EL93TS1'=I9'1H.C!P=#L^/'`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`S+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,2XR,"4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXU-B4[ M8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#`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`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^56YR96%L:7IE9#PO9F]N=#X\ M8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*&=A:6YS*29N8G-P.V]R/"]F;VYT M/CQB6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D)A;&%N M8V4F;F)S<#MA6QE/3-$ M)V1IF4Z.'!T.R<^,C`Q,SPO9F]N=#X\+W`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`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M-2XP,"4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`X M-"PQ,30-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#0S M,2PX-S$-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.VQI;F4M:&5I9VAT.FYO M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N M="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B M-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T M.#8S+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS M1&UA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P M/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P M'0M:6YD96YT.B`M,3!P=#MF;VYT M+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/C(P,34@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/C(P,3<\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+#$T,"PU,3DF;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/C(P,3@\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,#$N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C)P="!D M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[ M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ,RXW,"4[8F]R9&5R+71O<#HR<'0@9&]U8FQE(",P,#`P,#`@.V)O M'0M86QI9VXZ6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^ M/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S("A486)L97,I/&)R/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)W=I M9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXH-"PX-S$L,#`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C@X)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,RXX-"4[8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$=VED=&@Z,#(N.#@E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C@T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B4\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT M9"!V86QI9VX],T1T;W`@6QE M/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`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`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ+#`P,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX."4[8F%C:V=R;W5N9"UC;VQO M6QE M/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z-C,N-38E.W!A9&1I M;F6QE M/3-$=VED=&@Z,#(N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,3,N M.#0E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M:6YD M96YT.C,V<'0[;&EN92UH96EG:'0Z;F]R;6%L.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4],T0Q/B`\+V9O;G0^/"]P M/@T*"3PO9&EV/B`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`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$S M+CDP)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE M/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ.2PP,3`L.3`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXV,"4[.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E(F86UP.T0@8W)E9&ET6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV.3@L,#`P#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R M+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/E-T M;V-K(&)A6QE/3-$=VED=&@Z,#(N.#@E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA3I4 M:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ+#4T-RPU,#`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/D]T:&5R/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$S+CDP)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,S`L-#`P#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C$T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M-C4N,S0E.W!A9&1I;F6QE/3-$)W=I9'1H.C$S+C@T)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ-BPR,C0L-C`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,30E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H M.C$S+CDP)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,38L M,C(T+#8P,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,2XQ-"4[8F%C:V=R;W5N9"UC;VQO6QE M/3-$=VED=&@Z-C4N,S0E.W!A9&1I;F6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXU-"4[8F]R9&5R M+71O<#HQ<'0@3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,BXV,"4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B8C>#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV M/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUA6QE/3-$)W=I M9'1H.C`R+CDX)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)V1IF4Z,3!P=#LG/C(P,38@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C$T+C,X)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$T+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXS.#$L,#(V)FYB6QE/3-$)W=I9'1H.C`U+C,R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-S6QE/3-$=VED=&@Z,#(N.3@E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#4N,S(E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C(T)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$S+C$T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE M("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!R97-U;'1S(&]F(&]P97)A=&EO;G,\+W1D M/@T*("`@("`@("`\=&0@8VQA6QE/3-$)VUA6QE/3-$ M=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/E%U87)T97(F;F)S<#M%;F1E9"@Q*3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/E-E<'1E;6)E6QE/3-$)W=I9'1H.C$R+C`P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.C$P<'0[)SXR,#$T/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/E)E=F5N=65S/"]F;VYT/CPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS+#,W,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXS+#(Y-PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#DY-PT* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I M9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXT+#4V,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z M,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M,BXP,"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HQ,BXP,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z M,3!P=#LG/DYE="!L;W-S('!E6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXH,"XR.`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$=VED=&@Z,#$N,#`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)V1IF4Z,3!P=#LG/DYE="!L;W-S M('!EF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQO MF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,2XS,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE M/3-$)V1IF4Z,3!P=#LG/B9N8G-P.SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PY,#(L-S@S#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I M9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ."PY,#0L,C@P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I M;F6QE/3-$)W=I9'1H.C$R M+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.2PR,S(L M-S8P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C`P M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0MF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I M;F'0M86QI9VXZ6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT.0T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[8F%C:V=R;W5N9"UC M;VQO'0M86QI9VXZF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#$N M,#`E.W!A9&1I;F6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXR+#4P.0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#$R,0T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#@Y-PT*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Q+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I M;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXH,"XP-PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XW,"4[.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C'0M86QI9VXZ M3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXH,"XP-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,"XP-PT*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,"XS-`T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[ M8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$P+C3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$P+C3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXH,"XP-0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$=VED=&@Z-#$N,#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,3(N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E-H87)EF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$ M)W=I9'1H.C$R+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ-2PU.#,L.34W#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ-RPX-S`L-S`S#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA2X@5V4@8F5L:65V92!T:&%T('1H M97-E(&-H86YG97,@87)E(&YO="!M871E3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B`F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF M;F)S<#LF;F)S<#L@/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4] M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!P'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T M.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT M:6YG(%!O;&EC:65S("A$971A:6QS(#(I/&)R/CPO2P@97%U:7!M96YT(&%N9"!D97!R96-I871I;VX@86YD(&%M M;W)T:7IA=&EO;CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2P@97%U:7!M96YT(&%N9"!D97!R96-I871I;VX@ M86YD(&%M;W)T:7IA=&EO;CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'1U'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\65A'0^-2!Y96%R M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O M;&EC:65S("A$971A:6QS(#,I/&)R/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X M-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B M,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&5R8VES M92!O9B!W87)R86YT'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!A;F0@17%U:7!M96YT("A$ M971A:6QS*2`H55-$("0I/&)R/CPO2P@97%U:7!M96YT(&%N M9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ MF%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`S,"P@,C`Q,CQB2`S,2P@,C`Q,CQB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R M8VES92!P&5R8VES960@*&EN(&1O;&QA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES960@*&EN(&1O M;&QA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!E86-H('=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!O9B!W87)R86YT/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!P'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5R8VES92!O9B!O<'1I M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960@*&EN(&1O;&QA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!/9F9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!/9F9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&EM=6T@?"!!9V5N="!\(%!U8FQI8R!/9F9E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES M92!P'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!!9W)E96UE;G0@?"!787)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!W87)R M86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA M=&EL:71Y("AA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W M,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A M,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA2`S,"P@,C`Q,CQB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES960@*&EN('-H87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES M960@*&EN(&1O;&QA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y M96%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$65A65A65A65A65A M65A65A65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA'0^-2!Y96%R65A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^-"!Y96%R65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^."!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^,R!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y M("AA6EE;&0@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B M-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1? M8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2`S,2P@,C`Q,CQB M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!S96-U'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!D=7)I;F<@=&AE(#(P('1R861I M;F<@9&%Y'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7,@:6X@=VAI8V@@=&AE M('-P96-I9FEE9"!V;VQU;64@;V8@8V]M;6]N('-T;V-K(&UU'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D('-H87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M-"!Y96%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E M;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T M.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES960@ M*&EN(&1O;&QA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/ M<'1I;VYS+"!!9&1I=&EO;F%L($1I"!B96YE9FETF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\65A'0^-2!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^-B!Y96%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UE;G0@07=A M&5R M8VES960L($EN'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A65A65A&5R8VES86)L92P@5V5I9VAT960@079E7,\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL M:71Y("AA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`H87,@82!P97)C M96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF M83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA2=S(&1E2!B86QA;F-E/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\2!T;R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(&%S M(&$@9V%I;B!I;B!T:&4@8V]N9&5N'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A="!T:&4@8F5G:6YN:6YG M(&]F('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA2!T;R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,R!Y96%R7,\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6EE;&0@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!W87)R86YT M('1E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y("AA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^-2!Y96%R'0^-B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D M(&%S(&$@9V%I;B!I;B!T:&4@8V]N9&5N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!A="!T:&4@96YD(&]F('1H92!P M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA2!T;R!E<75I='D@ M*&EN('-H87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!V;VQA=&EL:71Y("AA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!T;R!E<75I='D@*&EN('-H M87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,2!Y96%R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R2!T;R!E<75I='D@*&EN('-H M87)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!M87)K970@9G5N9#PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!M87)K970@9G5N9#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X M-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B M,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!P'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES86)L92!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XQ,"!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!!9W)E96UE;G0@?"!396-U'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!C;VUP=71E M9"!A="!T:&4@9F5D97)A;"!S=&%T=71O"!2871E(%)E8V]N8VEL:6%T:6]N+"!097)C96YT(%M!8G-T2!R871E("AA M"P@;F5T(&]F(&9E9&5R86P@=&%X(&)E;F5F:70@ M*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA&5S("AA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B M-C0X-C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1? M8C=B,U\T.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M&5S("A$971A:6QS(#,I("A54T0@)"D\8G(^/"]S=')O;F<^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L"!L;W-S(&-A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V$R M-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T.3DU7SAF83=?-S,P M93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7,\2!U;FQE M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPP,#`\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`S,2P@,C`P-CQB2P@;6EL97-T;VYE(&%N9"!L:6-E;G-E(&9E92!R979E;G5E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!R979E;G5E M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%L M='D@87,@82!P97)C96YT86=E(&]F('-U8FQI8V5N2P@;6EL97-T;VYE(&%N9"!L:6-E;G-E(&9E92!R979E;G5E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\6%L='DL(&UI;&5S=&]N92!A;F0@;&EC M96YS92!F964@'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6%L='DL(&UI;&5S=&]N M92!A;F0@;&EC96YS92!F964@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\6%L='DL(&UI;&5S=&]N92!A;F0@;&EC M96YS92!F964@'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%L='D@9F]R(&9I2!A9G1E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%L='D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&-L=7-I=F4@3&EC96YS92!!9W)E96UE;G0@9F]R(%!A=&5N M="!2:6=H=',@=VET:"!'86ED86YO($9O82!A;F0@4F]S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\6%L='DL(&UI;&5S=&]N92!A;F0@;&EC96YS92!F964@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@1'5K92!5;FEV97)S:71Y($AE86QT:"!3>7-T96US(%M- M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\2P@;6EL97-T;VYE(&%N9"!L:6-E;G-E(&9E92!R979E;G5E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2P@;6EL97-T M;VYE(&%N9"!L:6-E;G-E(&9E92!R979E;G5E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6UE;G0@86YD($-O;G-U;'1I M;F<@06=R965M96YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!A="!T:&4@96YD(&]F(&5A8V@@=&5R;3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^,2!Y96%R/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@;G5M8F5R(&]F(&-O;G-E8W5T:79E('1R M861I;F<@9&%Y'0^.3`@ M9&%YF%T:6]N(&)O;G5S('!A>6%B;&4@96ET M:&5R(&EN(&-A'0^,R!M;VYT:',\'0^,3`@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0L(&EF('1E6UE M;G0@97%U86P@=&\@-B!M;VYT:',@;V8@8F%S92!C;VUP96YS871I;VX\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^-B!M;VYT:',\F%T:6]N(&)O;G5S(&-A;&-U;&%T:6]N+"!E;G1E M2!W:&EC:"!E;G1EF%T:6]N(&)O;G5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XT+C`P)3QS<&%N/CPOF%T:6]N(&)O;G5S(&-A;&-U M;&%T:6]N+"!E;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UE;G0@86YD($-O;G-U;'1I;F<@06=R965M M96YT'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5C=71I=F4@06=R M965M96YT('=I=&@@06YT;VYI=7,@4V-H=6@@6TUE;6)EF%T:6]N(&)O;G5S(&5L:6=I8FEL:71Y+"!A;6]U;G0@;V8@9&%I;'D@=')A M9&EN9R!V;VQU;64@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#$R-2PP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@86YD($-O;G-U M;'1I;F<@06=R965M96YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6UE;G0L(&EF M('1E65E('=I;&P@ M8F4@96QI9VEB;&4@9F]R('-E=F5R86YC92!P87EM96YT(&5Q=6%L('1O(#,@ M;6]N=&AS(&]F(&)A'0^-B!M;VYT:',\'0^,3`@;6]N=&AS/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE M;G0@:68@=&5R;6EN871I;VX@;V-C=7)S(&1U92!T;R!C:&%N9V4@:6X@8V]N M=')O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3(@;6]N=&AS M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!P97)I;V0@869T97(@=&5R;6EN871I;VX@9'5E('1O(&-H M86YG92!I;B!C;VYT7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!&:6YA;F-I86P@1&%T82`H56YA=61I=&5D*2`H1&5T86EL3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q8V$R-31F9%]B-V(S7S0Y.35?.&9A-U\W,S!E,F%B-C0X-C,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-A,C4T9F1?8C=B,U\T M.3DU7SAF83=?-S,P93)A8C8T.#8S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ XML 37 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Deficiency) (Details 3) (USD $)
    		 12 Months Ended 3 Months Ended 0 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2012
    Mar. 17, 2007
    Jul. 13, 2006
    Mar. 17, 2006
    May 31, 2012
    Fair value of equity securities at issuance for cash (in dollars)   $ 3,599,831trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration            
    Fair value of warrants issued for services (in dollars)   198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration 142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration          
    Accrued dividend during the period 23,015us-gaap_DividendsPreferredStock 29,840us-gaap_DividendsPreferredStock 38,240us-gaap_DividendsPreferredStock          
    Stated Value per share (in dollars per share) $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare            
    Number of shares outstanding 60,600us-gaap_PreferredStockSharesOutstanding 60,600us-gaap_PreferredStockSharesOutstanding            
    Warrants | Selling agents                
    Exercise price (in dollars per share)     5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		 5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		       3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember
    Term of warrants       5 years        
    Additional Paid-in Capital                
    Fair value of equity securities at issuance for cash (in dollars)   3,599,759trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		            
    Fair value of warrants issued for services (in dollars)   198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		          
    Deficit Accumulated                
    Accrued dividend during the period 23,015us-gaap_DividendsPreferredStock
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 29,840us-gaap_DividendsPreferredStock
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 38,240us-gaap_DividendsPreferredStock
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		          
    Series A Convertible Preferred Stock                
    Share price for 20 consecutive trading days for automatic conversion           $ 25.80trov_SharePriceForAutomaticConversion
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		    
    Cumulative dividend rate (as a percent) 4.00%us-gaap_PreferredStockDividendRatePercentage
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		              
    Accrued cumulative unpaid preferred stock dividends 244,055us-gaap_PreferredStockAmountOfPreferredDividendsInArrears
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		 221,040us-gaap_PreferredStockAmountOfPreferredDividendsInArrears
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		            
    Accrued dividend during the period $ 23,015us-gaap_DividendsPreferredStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		 $ 29,840us-gaap_DividendsPreferredStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		 $ 38,240us-gaap_DividendsPreferredStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		          
    Stated Value per share (in dollars per share) $ 10us-gaap_PreferredStockParOrStatedValuePerShare
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		              
    Conversion price per share (in dollars per share)         $ 9.60trov_PreferredStockConversionPricePerShare
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		   $ 2.15trov_PreferredStockConversionPricePerShare
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		  
    Period during which the conversion price is subject to adjustment for dilutive issuances             12 months  
    Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted           20 days    
    Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted           8,333trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		    
    Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted           20 days    
    Number of shares converted   35,000us-gaap_ConversionOfStockSharesConverted1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		            
    Number of common shares issued upon conversion   36,458us-gaap_ConversionOfStockSharesIssued1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		            
    Number of shares outstanding 60,600us-gaap_PreferredStockSharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		 60,600us-gaap_PreferredStockSharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		 95,600us-gaap_PreferredStockSharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		 95,600us-gaap_PreferredStockSharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		        

    XML 38 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Fair Value Measurements (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Fair Value Measurements  
    Schedule of the Company's assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy

       

     

     

    Fair Value Measurements at

     

     

     

    December 31, 2014

     

     

     

    Quoted Prices
    in Active
    Markets for
    Identical Assets
    and Liabilities
    (Level 1)

     

    Significant
    Other
    Observable
    Inputs
    (Level 2)

     

    Significant
    Unobservable
    Inputs
    (Level 3)

     

    Total

     

    Assets:

     

     

     

     

     

     

     

     

     

    Money market fund (1)

     

    $
    27,123,587 

     

    $

    —

     

    $

    —

     
    27,123,587 

     

    Total Assets

     

    $
    27,123,587 

     

    $

    —

     

    $

    —

     

    $
    27,123,587 

     

    Liabilities:

     

     

     

     

     

     

     

     

     

    Derivative liabilities related to warrants

     

    —

     

    $

    —

     

    $
    3,006,021 

     

    $
    3,006,021 

     

    Total Liabilities

     

    $

    —

     

    $

    —

     

    $
    3,006,021 

     

    $
    3,006,021 

     

     

     

     

     

     

    Fair Value Measurements at

     

     

     

    December 31, 2013

     

     

     

    Quoted Prices
    in Active
    Markets for
    Identical Assets
    and Liabilities
    (Level 1)

     

    Significant
    Other
    Observable
    Inputs
    (Level 2)

     

    Significant
    Unobservable
    Inputs
    (Level 3)

     

    Total

     

    Assets:

     

     

     

     

     

     

     

     

     

    Money market fund (1)

     

    $
    25,703,330 

     

    $

    —

     

    $

    —

     
    25,703,330 

     

    Total Assets

     

    $
    25,703,330 

     

    $

    —

     

    $

    —

     

    $
    25,703,330 

     

    Liabilities:

     

     

     

     

     

     

     

     

     

    Derivative liabilities related to warrants

     

    —

     

    $

    —

     

    $
    4,431,871 

     

    $
    4,431,871 

     

    Total Liabilities

     

    $

    —

     

    $

    —

     

    $
    4,431,871 

     

    $
    4,431,871 

     

     

    (1)

    Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet.

        

    Schedule of changes in the fair value of the Company's Level 3 liabilities

     

     

    Description

     

    Balance at
    December 31,
    2013

     

    Unrealized
    (gains) or
    losses

     

    Balance as of
    December 31,
    2014

     

    Derivative liabilities related to Warrants

     

    $
    4,431,871

     

    $
    (1,425,850

    )

    $
    3,006,021

     

     

    Description

     

    Balance at
    December 31,
    2012

     

    Fair Value of
    Warrants
    Reclassified to
    Additional Paid in
    Capital

     

    Unrealized
    (gains) or
    losses

     

    Balance as of
    December 31,
    2013

     

    Derivative liabilities related to Warrants

     

    $
    8,765,628

     
    (5,417,871

    )
    1,084,114

     
    4,431,871

     

     

    XML 39 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Derivative Financial Instruments - Warrants (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Black Scholes Option Pricing Method  
    Derivative financial instruments  
    Schedule of assumptions used to determine the fair value of the warrants

     

     

     

    Year ended
    December 31, 2014

     

    Year ended
    December 31, 2013

     

    Year ended
    December 31, 2012

     

    Estimated fair value of Trovagene common stock

     

    $3.00 - $6.74

     

    $5.74 - $7.18

     

    $0.02 - $5.93

     

    Expected warrant term

     

    4.0 years

     

    1 month 5.8 years

     

    10 months to 6 years

     

    Risk-free interest rate

     

    1.38%

     

    .03%-1.75%

     

    .06% - 1.54%

     

    Expected volatility

     

    86.4%

     

    82%-100%

     

    90%-97%

     

    Dividend yield

     

    0%

     

    0%

     

    0%

     

     

    Schedule of components of changes in the Company's derivative financial instruments liability balance

     

    Date

     

    Description

     

    Number of
    Warrants

     

    Derivative
    Instrument
    Liability

     

    December 31, 2011

     

    Balance of derivative financial instruments liability

     
    1,103,727

     

    $
    994,627

     

     

     

    Expired warrants

     
    (16,667

    )

    —

     

     

     

    Change in fair value of warrants during the year recognized as a loss in the statement of operations

     

    —

     
    5,258,133

     

    December 31, 2012

     

    Balance of derivative financial instruments liability

     
    1,087,060

     
    6,252,760

     

     

     

    Expired warrants

     
    (73,099

    )

    —

     

     

     

    Change in fair value of warrants during the year recognized as a gain in the statement of operations

     

    —

     
    (1,820,889

    )

    December 31, 2013

     

    Balance of derivative financial instruments liability

     
    1,013,961

     

    $
    4,431,871

     

     

     

    Change in fair value of warrants during the year recognized as a gain in the statement of operations

     

    —

     
    (1,425,850

    )

    December 31, 2014

     

    Balance of derivative financial instruments liability

     
    1,013,961

     

    $
    3,006,021

     

     

    Binomial Option Pricing Method  
    Derivative financial instruments  
    Schedule of assumptions used to determine the fair value of the warrants

     

     

     

    2012

     

     

     

     

     

    Range of risk-free interest rates

     

    0.53% to 1.61%

     

    Range of expected volatility

     

    90% -97%

     

    Expected fair value of the stock

     

    $0.25- $3.21

     

    Expected warrant term

     

    2 years to 6.75 years

     

     

    Schedule of components of changes in the Company's derivative financial instruments liability balance

     

    Date

     

    Number of
    Price Protected
    Units

     

    Derivative
    Liability For
    Issued Units

     

    Change In
    Fair
    value of
    Derivative
    Liability For
    Previously
    Outstanding
    Price
    Protected
    Units

     

    Ending
    Balance
    Derivative
    Liability

     

    December 31, 2012

     
    1,288,650

     
    1,171,463

     
    1,341,405

     
    2,512,868

     

    Reclassification of derivative liability to equity

     
    (1,288,650

    )

    —

     
    (5,417,871

    )
    (5,417,871

    )

    Change in fair value of warrants during the year recognized as a loss in the statement of operations

     

    —

     

    —

     
    2,905,003

     
    2,905,003

     

    December 31, 2013

     

    —

     

    $
    1,171,463

     

    $
    (1,171,463

    )

    $

    —

     

     

    ZIP 40 0001104659-15-019213-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-15-019213-xbrl.zip M4$L#!!0````(`'>&;$;G^3;(VUX!`.(\%P`1`!P`=')O=BTR,#$T,3(S,2YX M;6Q55`D``V'\`55A_`%5=7@+``$$)0X```0Y`0``[)UM4^,ZLH"_WZK['[A\ M!^($)D#-G*T08):]86`)<\[6_4(IMDA4X\@9OP1R?OV5[<0OB>W8B6Q+3M=N M39W8LG%W/VI)+:GU]1^?4_UHCDV+&/3;L7+:.C["5#4T0L??CAWK!%DJ(*H?7VA7+>NCIX?_8*?(U,_8I]&K6_' M$]N>79^=?7Q\G+J73PUSS!YJ=&76#U@F\8\5MJ]@,:8XE/5F+I?=*ZTP^]A)A\C-`N> M>$?6R'OW\D:2"!9)TB+[&.7L/X^#H3K!4W02",+,>W3TU=7NM>7=>L'O1YZV MK^W%#'\[MLATIKL">]WXZ,Q_D8N406W\:1\-L>I2 MZ!'$[JC+RT3[=GSK^(2^*>Q_[#WMMU?CC?W;6?Y:2O=VBTTR9R7G^&;Q`]F. MB7N?Q`IN_X5,$U'[$4]'V`RN_HETQWO[*U8GE/QV_(?<;WZ[(=28$J0_S=P" MSR916S%\A?[333WRCO!YI&G)QQ3\HJJ_L/_'O_1 M8JIN*YU6I_OU+'PL?)6%QU-V-;C`+OG07N//FA9Y^=>S)::;S/:LMZ?W M$-+S@+<'YJ"G^!5]]APFL,F^.@;I`WN%29'^@N>8.GB(S3E1\NIOAUC$?23T@H^.;I/OF-X2-*:&91/58M9: MXW%HLSKBRGC'WF`O^L9T9E#VTXHQV=,T[^5(?T9$>Z!]-",VTN5`-$5)2Z>6 MI26>=&8J.B0T4],-\*^EDWVX-#;(^L,),K$WG/EN&)K5H]H/5EE8#]58X%4; M8KVR+I"%O-[GS6+HS)A2L!E",L0ZZ\N.>V.WDNWD]=CEJ4&'MJ'^8D;0'7=\ M)K4GW$^M2T03]%J#GRQLFT.J/0=*-Y`C@M_M&]1R6S'719C8,X@D_/#PCJG2 M'P!%GOE?%S/\]/[T_LY>R9008/'L133PLXY43RN6^\AA-\L>,)OZ6I*4H3!H M;ZOEO1WAO?W6OO)_:)B\#?`8Z7?>A^\Z\.[KR+*>WCW5K@>";).H-M:\>V*S MS)1QO::,N@;8ZPJ-A7\V-5HVJ.UVBQJ94R1+2AW2:YVA2" M=_*UHE)7CJ^4R155RX?GDK:[[@H?K/G]K=P.5A#^"S@"B MX_BTZ".A9.I,Q48]:'E7GQ^ZL=CWEPWW^4F[F\.2?K'*+8D^Y;9D]/L;8,G4 M.>!\O9\7;"/6F]#ND$G9*,F2PZXY.Q_)PHD[D[JG+:6,*X@\Y5B:93M02VNL MI9U:;0FU5!;+%IVD@EK*TY;M6FT)M506RRI02VNLI4JMMH1:*KIE-PSK3R'V MW"7A8T_Z,#SZ^GJ/5-LPAR\#.2R8*,LR.KHA3*FF\K9;[&>J]IOBF>IBR]2X M,V)?O[KNEB\\5[@Q)Q`^ZXPL_-MQZ\2<_>-^0^S)M?OKR]73T8I_=8]J[HX0 MT]!UYBJ]VK>Z)39X6R;A4TQ3\<1EX2F?0G\_F9#PKRJ*1#V;F,EI2K$8H&!SG"1:8^-.8$R-,F*5-;'>^!'41+$B#+O:$6JB:!8,1QD]=S?TQNC_;K6]P97-W]>_ M%@&0?.%13.S0HJER\QS65KWHJ8)5$QPIDFG1DV@4E;G@JH*1,O@B(2BJR!>5 M-4X'7R0$117YHK)B!>"+A*"H(E]45J0"?)$0%%7DB_:D:'VS4R>VV2D2B`XV MI+L#4R:_]Y1WU5JFV_H;:S^IALV(II]U1*V;Q=TG-E5B83=-&PXQ\Z9N_8*Q M$J\?1MJD<\.&_/R5NIRIS-)JX[<)=O)M(.OPW28H0LUYHAAJ#O>:$V@5:DXI M-4>)U1QEUXZ,Z,SR[J#L96DEGZ65_2R=&L,'T\H1L]]Y5`$6JVD<&,;'W=;N M!YI&>@Q^4_-`5??;YM@M[1:2PV)1<99M=:8\HL>BK]Z4+ABL*H.UKDZ4[GX& MZ[XIEWRBOIN&CI1MMUH2&;G.J$L"8*EZ+#4:W.J>*)=[P]4%N`"N9+AV]ESK M0ZWSV%`+5F0(%C.N+`W->;[AWSG?@7X%],&,A9@S%@+0EQ:@!=\G!'V5^3ZQ MI@?`]PE!7V6^KQ[ZTK*P@N\3@KXJTP\*D$$5?)]0]%69,E%>^@Z-*@DMS;N/ M52"4!BVC6"$W:5KD9HQ&.-44:,7EJRD-'SFEQ2PSLA$-G=&`J$QW.#AWZ2]B M3_[M8,N.9-.7`_.L?#B%!&U@1)$?&X^#P:-#U0G%Y@`[O]"48!V-#+.QC&0+ M#*QDL/(=4X/Y^4_ASQ;9`X\-&8&(#"+N$3'G!'_\$R/=GJR.!VPL'%GB`B<9 MG-PZO_!/2N;8M)C(/?9UL0M+?2XL&T^;2T]Q)0!3_EFJNM=">^]A:DO2[=!F M#[([[WBH$DP;X83VD;N!Y*1%#F`\)-)X2*RH$HR'1!X/R`"!@/U3$> MDIT3&`^)-QZ2ABD8#PDV'A)K91V,AT0:#XFU\@C&0R*/AV1G!<9#0`2,A^H8 M#\G."8R'Q!L/2<,4C(<$&P]534XK>6I1P^1M@,=(O_,^/03&;<.G2'U@[S(I M\L_`'+S>KJT2328N6$.*+8Q,=>)64SS'NC'SBH2EQ>:+Z>9Z33=+JC*54\%Y M=\&*SWP*+GFB4VG5/T6>RO'/X1-5#=T8+U;*&@SZ0+%+<89J#HYA$99YI#,< M]&^>WE_Q)[(>;WMN\DS+H'W$VBNSCUU/!%1[5!=1%G`N*N=#P[$GK'7M(YV\ M&R8E"/!>QSM-1T!U!52O3TI!#P1Z(+)-C^5G&'H@T`.1A_-EUMT6A#D@S,$K MIW"+Y\EDT%F`SH(8YYM!HP^-O@2\7A;#%:('$#W(F\'YDN,!;6D[]YY-@[W0 M7KB)/VPFK9MJWY/U9K&1S^7>8;:P'1.SR=,8Y=!&R$BZ.AJ3 M94B,L&QUK,J42$@25AN>'9H'J\&]`W:F:SH`#RH3E8UUFQ53V3!?F7[$6`$, M!QA9>&+HVL-TQ@8*7N=;DN5_A5#+D%/T(\GX.II&6;6@`Y'4DEZ4(]K%?'I_ M)RINHF&]8,564:6Q-'0=:_[9J:M;I+@F)<`HR=0FZ`SEG'DHQT_&QBIA<3:Q%J1*V#A6I"IH3B=H?7K-H& MJPIAU79)`4:P:IU6+2ML_$!58XI?T6?/L2>&N1J7A+>]E=OZ"V;MI(.7R58> M7H9RF#19NM">6\1KCCV]_NT/_/$O;%IX(;?QO$[4FBP-L]3ZBDJI355T>6A] MMEJ/X"BQ"(Y2NA4*==V5?&$`I?:3)5Y?[Y%J&^;P92`'S5F#MPUA&K#^H[P3 M:8:_%CJA.)(,].9/^1DH+"PPDL'(`(WZACEK+!8Q^8"$#!(>GH=/W^]^#'N2 MC"YV@&%=1.`ABP?Z)YD;0]4D(_R*U0EU]VX2;#4Y\^U6F8&8#&)ZPY\O/5:_ MFDS(AHQ`A$M$DJIN3>N>#3XIZ5'M$:N.JA+YL2@D*+#ALG'WJ>J.1>9X77?W MAOG,OHC:+V0\L2TO]3@B&J+&O8&8+E\,RVH`,CSD!Y**DM0W=&51,&C8@*B9X5*R1)$%4K(:HF#1G)T-43)KSX'B?3@E1,6`$HF)5 M1<5D)P&B8L`#1,7JC(K)3@Q$Q0Z6"(B*51X5DX8-B(H)'A5K)$D0%:LA*E8- M2:G)3^X1,?]$NH-O%@."1D1GW^VE'HCMP/\+NW3BN^T+=O8HW8]TCUQ(VGSB64.3:_@"]6>,N@8QN; MTUL\2D@^QGI4["'WWMICKG:]C_*&:N2W$\G_>:,C]==0G1@ZMIYF;J%GDRG4 M30%E3PQ-#H0VM1G)T+NA3I[9MI(L$DGVM6X2GG\ZV:K+%C"76#OTEUW)H M5JS3*GMA_2U[VYR5G#,O\P-Y26!3'>;AU)MDK>SH*G,]U88.QE+//U(@=E,7$B">+3Y!$WPU#J8!`L)N@@,&_? M!@S8M)Y`VD(XL'1S%JJU$BNU6(G>&-:M"NGO1E1RM0J9B*:17.'J23M23B*>1/)ZDP]>3=**>1#R-Y.N3.,($NY?U9$WYC.#,I^QN>> M7K"-",7:'3(IH6-)#OW+E"WLFB8+U\`1R%8&(!5_5:GX!:`A;3P*'J$.CR#6 MEBI@H`X&Q%J*!JU"O:U"S7,^D14\P7_^D^D>F>ID,25CQA9CNDOWS.]H]/41?+[(B6M%W?IA?@GYB4L@LI084A;A@YYSG7F M,$/"-V780<+Y,:`;Z*Z?;MX'A?N'_00=FJ?W_L1=2!UOM+U+K!/`!'SV_DR@ MA%MBJ;KAZJ'(NA-"C2E!NG1K3OS#A!*5%>D`Y-=6=..V2XAS7N/6 M"/FND;&"<58(KNV+:,Z8;^4Q/K%2\D'$M]Z(;S4T;(S!-$S>!GB,]#OO4Z/' M!E/;,.^)_?<8FTC7>E3K&VL>+&/#^K,S8BIZ>F=*9%T,[V'*;N@ZUOQJN+HE M-CQ,/==KZ@E.(D[5#T_GE;4IOJ".11]3=HND"6T(7[*9N=4MHPL/^^%@/US= MDT+`(#!85P@5&`0&ZPVG*<`@,%B8084'@S6GTLD7A9,J_U)CHL$E1/FJ2CH5 M[([CW$483I");Y"%M>^&H5EL-/B#B;G:7XO-.5&Q]&P M&4EBBW7='4F.7?7(@?1^8J\2VV[*+4T#7733#KL\-:B,X=GL^KLAET1#S>C< M\MTG-E5B8;?!WIQYCMU]HNM+(QJ&0'1F>D,O\8GK9,74T(Y4R6$IZZZ*<_CZ M8323HT`PB6S(MS_@%0MRZHIM9&@]'YADX=)=?4I)1[5\%Z)%VXF MU)F^?3>C-]P9SNB'87I@1/^M(]?>CN(^(39U_/.&& M/"NTT@62R&:\_92HMJS<@]1MXPOH2.U/"W2D=H"W=<$1WNPV);9^*/2_H5?; MV*_S2"B9.E.Q\=O2\*1(S1.JE\V].S'-'3!`Z!,`V@V@J.::`A#T:D4R68M' MG3^PB],]QVKSE/6<7AZ#TIO3X0` MN&?C7D2IP+]PJ;3`NX-WWY/NLA97@'>O'W?P[J7SG_M8*O8]&M$==QN$MY:; MV`1;WM'<&M;N36/JAM4=VWO9T_LJ>>XS-OVQZR+Y!?).?)2HD(JF)`1(15XG M;?(>M%4%>8=T0%N=%$J>6*42%N&(!FB%#Z,5%BLM%+3"=9-W&(=GUD\AM,)B MM\)B'9(#K7"S6V&QCN.!5KAN\NIIA0^/0FB%Q6Z%ZR$R+3KS0%5CBH.UW0-# M]1Z+$?6"+>Q.+O38E[C3"\;,6P;^.6.VPW)0E2%F],RZK7(V,$JR#QG?,753 MMS*%];0IH<2R32_%4_/8R"5I`^E(&T^"WQ#';X@5:0"_(9;?$&O4#WY#'+\A MUM@(_(98?J-B.KY$>J/U)+04G9O&)*7)D]LN13O@]K#Y=L.ZD$ M<&CMJ$/;<[_$5+(G3RS' M^(7&*K4F3^28+"NRS^4#F=K&7%_JVN.@!/.C]`>:1@YPB91MMUKG;@&Q>0HZ M"5$5<%A_7>1O1]6XFN9)TZ,\Z1Q2-U4!;(<*6YU+K+H1*KMU0!D\\TILG?57 M'ZA&YD1S4#R;SRTQL1J$M8#D:D@N\G<3[1?*'C=@V56HFZL*L6+EKWWWAV$] M=ZOD-)V"9=`RC@DNA=5"N+L6J+7Y+SO%5VRR$MNS?^ M/6JS!M&QF'MT)F+;/BOR4^3&KB.S>WK16FV+/B#$/:Z*JG&%8SX]0NV0 MOW9T6J"(J%^R%\_VNW32Z@?'.I'@B*A?LA?/Y3STW.H'QSJ1X(B MH7[4%]BJ8J>M[.>F-FY';I6A`Z@KW.J*#*N5.ZK'JTNFYE M"7]LK";OZ\BRGMZ]^>TF)2Y,%5"(M(/N['KG1.ENH2$LQHF&+U$:O@`-@M#P M)1\-7SC1T'U3.@$-X0^@01@:NB=*)P<-?C$^F3$ZT&VU:3T6I'28K.3OCQ\0R$5C)?#[:VYE%KV6K$\.3XZY:8`REX3D'Z\ MO:B\;5D6D"Y0`_8<^>L](.U8HP=N>QW^NW0E>ZY0N?1=2 M$-5-^Q>+4]Z:UCW2"27,%S\R9:AJ`U:>%A*T5,_3.FE=YO`\7C%^H28EULHH M>=@8.J,DK3T.!H\.52<4FP/L_$)3@G4TDF4U?A8C.PE<*BM*OE9*X1N6Y,>* M>_KNG."/?V*DVY-5`K_&DI(E;J,X:2=W77<'Y3NFQLPFG\+OK-Z#C@T92^[@ M*OGV6W-"(C::48(5SKLC<>O\PC\IF6/3-IB6Z@Q[&3U*,G_+L$E43?G;0NHUUA]FMW2![HGV1N#%63C+"W5=O0C3'!XN>] MVX.5K3*7NE+B,E>7UR_&H0&ZC!!SR0&8`1KU#7/66#AB\I4,0I[9(;\8O[&/ MO[AR-?:)K*XLCD)O^/.E]_WN1Y-]Q8:,):^PS#.&\8OQ\PW=J&_8!XB'Y^$3 MT]6P-VPL#^LBEKW@-H^'Z'+R$!<^#MX*RXLE#E]@:8&(2PO<7N=%#C2\8N4? M[W&+O;5=9(YO%C^0[9CQ!4M_(5>;!7=N'4:>I&3-A4N48JH3:0]6D;\E<#(H M,9+2\ZY'T0U"4(\JKT=%]F=!/=JC'J5E57:CR][^\)O%@*"1M^S4VS>17IU$ M!SQ3I!TYEREC\99]M$4\I^BFYNK+9-K_N:56@XVA'ID'UC"8@ MR7`I]:GXB`+J4R-&%0=:GWCT0:!]$KH^'6C[5$]_K^SZ!.U3[?7I0-NG>NJ3 M>#,Q4)^@?9(WDBS>C`S4)VB?)*Q/X8DW_BH2./ZFJB0W_@$X6_?D7>RQ$'GM MS-P]W21,2)?A^L2:)(Z=T<3I1-W63DVVA]52ZU;/OOO$IDHL[.H`7YQVV@#G MDI&M.FHNK>L[X/-L**RH(QKD?[S[[;A3_\9T9E#LFBF:,4YEMC)LK-I86YE1 M#B(SQ0L3R*7*UZ0N5)2$"Q[NK7/::H%[RW9OH8X.QKWEA)KK"N*T)`Y`-5#- M@^IZTJA=>%0OH;X(VVQG9&&F'=:JS=D_FXD\X_?78,[8<-$WJ.7HMCONC&]% MZ&E(EA1)*.3:'\OWM%/]9$ZX@D6H>K:&V11-LS9K4FFB*2:$I%X3CO M4+X;9&'MNV%H%O-#/]C(?CK3C<7_LW>ES8WC2/9S3\3\!ZY[JZ(W0E;QT$'9 M4Q4A6W:MH\MEK>WJCOK409.0Q"F*U!"D7>I?OP!XB!1%\3[%GJ,M403P'C*! M1"*1`,!)_/.,!C`HB-;M?T_F!HU`0/><-P:*0J9BX"[X8SI&&ADQEN^M"Q+Z[TZ&<[:Y:=';GG*V#<[9441@>=,YVV]LE;&^7 M[JP,4_='H*#"I3EJRM8S#<.KK?>)1P`$%1B&@+]5@0Z_&`WQ.,;'Z64ZS`0=K:JX5=/=[['2RUCV9ZUGH[@Q9-07^.WOH%1!/WGS\IO&IHJFQ"Q*&Y:H8D'K_: M*R;(%OJ1PF0B>&6]^RAX8_WNT8'KYG>;Q/NWS===9H(<[$:N(`EY#E^'>/0$ M!N\3V4*Y#+,1XT4[H:_7FOID:.*/9HA:S&BB`*X66%AVC&`^(==Q,T]TH=F% MAV:7F8*BQF'@OCAA.[H[4S"MJRB=S'>B5Y+HQ9Z=WG%8C M.P]JS3(2T".2"S2+.X[]BQV3I#=U0C8\I]ES=IR7MV=/BRM'6I(8_]?Y^3=5 M-J@G0#PVY^?6UR;^#M.$'S(CEPU)?D5(=I7CWWTUUP!QJ?D6)FL@X(7,)QEJ M`Y897WQ[FOWK@_/E3K4/OT^*G0&\*%'#"B8+%QF-/F'%!M__UP=/\ZT?'4*[ MD_*(NL*+&`2*P&.V0!IH3C""PDA_E"3O84@ M-7@V-PK8UP/T_8U"9KC])WCK:8H>2/CAK2(L*5NO'L$BQNBR$!2(1"%0RJ[P M:U/7\9`Z69-6O!OOF`X4UCCRQ ME)62@"BOD2I\/+O[>HN8'3`L-Y[0OK8KVI:8G[(&I*`(%C\5`HD@QWMI]Y>Y7:NV\W2J:8!Q@?6>. M[K'.>FFGSSZ-N,EX,!C[!,!3]'ZMCV`I0P/[X[\*ZX0"_8PF4F$)5-"C[E2Q M[ZW17^Q^I7]HBJDBV\-EDC1=:V8$5_N^J`A\',>,!R,N.<`#[:H$8)G"T#RR]MWW M$0"'`V;,CYGF`BQ3&II/5CTWLEM/>X4Q+U5S&UH.,JF3H)XT'G<9\9PG3VT) M:ED\ATO4JTL$Y`[5CZ<<.YZ9),,\X'BI1?!Z%&M#VOK'(>X8QERX:-J)EZCU M44;^B#_37CE[#$[+PUF@K@4/C47Y9+D!.QC1PWV@1P%X$2N*]B:H(D"*-]/, M%V-A*E-1Q&83G&NH2[;/".F5@DI+YF)[KQB7DOSZ?FE<4O;?%#2V"OAXMA;T MI:R>*V!A7-`;X]+^K,O+E?7%&7[KG__XY1?\XL;_&OG!`K7D?"&L965[\2RO M49=\!6_4H[865.L9E/\&%Q2#?NN610K##YWR)!EN%&%[09?`&*6.%1SHT M<(B&\$).S5+:@A+L_D$_$P%:Z[PH@'K!1@6%YDX!_1="`"'Q_Z%?KV2(!CU9 MI,!/O#)I.2( MI`/Y8-U_KH"Z(P4-"FA,6?N MT.V^[7N3?/".\,X'9RJ*/[-XYZ,UWL?[&TAS_&]-?5CU]8TJ/2QN!''UC!J+ MK*Q,^QGYI..8,]\=H(F;[<%\C?TY#PM[7?"@/V*-^FKB.IR+]J0L[IB`3<6, M1B-GIR5.Y7FV-6+Y'VCKF.4'/%]18R.V^X+&*B)V5$!;-[(>T=*:Y4S*30() M\OQH2J$IKI.VS'8FUA*.GDRJ;V?=Q:XJFI*.(T6HQV?\3<[JP0V8T80;1+?4 MKCR_EB95$*]54F8[D_8\/QR,\VNG97-X(M8W.W*LCK-3YE.>CEL!J4F^ESD@_'[8$5I-Z*_6='O-!2V!5T5O)QXD\ M[DJ*-7F5!:C0B\%B#25%(LWUGKO*T11^@6-M$690MKI"RC;A:MGK;H4 M97.N`.Q_DDT,($U?@2XL@>.?(^H8P4G@^NV]%1[G7>*Q:,G<9XYZ,Y,UI3Q@ M`6=`$-CDJ.NSKL`"OH,@,/ZH+Z:NP`+.A@/`AG4%ELO&1Q#P<1]0RB96@3S" M_[6/?-`_[O=L$/((CUI#^SSSUD71N&-YFO-'G5C.AVU`G5#&&;K/UQUV#ML/ MP\32?=HY9AF+`Q]G*C05G/S(6=/= MHZ:LE.TM.'XP?V@QQ=D?W&6C^0+!?TR\&'ZUDTWX@Y'\S^-39C>4K,$],3TS M?2H):Q@OL&DRW*G=$=P>>F8`]0,:1Y^%GU,(@0'1'U8$UC42Q^U"T]\$78*/ M``)!%U>H)Q_L`,OX:Y4#AZ@YMYTI&U`LA.A\$!.>SA<"CODD2B*_F"1R0!'4 MYY4.X$I#VK<$UX(AKKYMO#])%@L^'[H.F735^=KK1$[@4#E5E'$>%&CH)/\* MM'9_'Q9^1R'FT3Y.DF>0$-$=9^B<&KXQ%9N719Z7#(9N,-R8'[@L9R*I)+KW M_-I-8INA!SPS'C:/[@+\[JV2S(+W*"+EBN7YT9!N!UDI%'G8Y]AR%;E1A-?] M%'_]Z3V>"BV^$+>`U$"BMAC%H64/?M=;&@*!5IPF!%:RA4>T`L'>D6?M"GP& MJI4Y#0?Z[U8G=L'J\9R,#3+&`LDK?(=/RV2TCAW9'#.OZ\>VS//!8U?U[TIK M:_Y8Y8T=+S_-.?H^%O?1))3%9XV'K6;1V8#1X]-\P->0T#:93)Z8V`)HJ9#T M6H\3K>.\$8-)2:S?+!;XQZ_@3A6U-7@6?CXB.^01YZ?`1]P)`E3Z6L`>JCL# MK#/E)#ZP,<;:,),WQ(N"Q#UB0A[T`QM1F*3F;99Y9"`&/B\;Q*^(_1TX=8)E M;>ZBAF]^;H`*PS(0#>V4XLZ(1&>)%S]F4)\/SSZ-O?9TO%9'PORF2D#'Z470 M2SBE)\D5079PG8W7AB"/`<1+!C10\7@%X>0S=7?D4SGT4[FL(H[J%'<(>3^2 M8=B?.!ON1XAI`'W>(T'ET><=E@NE+U%)S,I6LJ1$VP-,TZ3[B$$ M1Q$[VL2X.I!=R)C+;>/Y0)JK&\W_K26Z`:S'RP$=51,<6X[S24.0N M0(3#;T7]"W*MP=,K?\6]A:.):P@AYY.AE]B.%4W:_(\JC"6T%! MTQ1J[CT035&4XYE'8\\`'HX@`TS>@CG&,'D;YC@.S"?SY1#2N_G3P^>;KT_3 MIYC1#&S1".W!T(*(/F3'.'WZ]CA%(-&,6A>0=C?RWF[D,T#\(KQ<:_HFYG5^ MA79\-VI?\BOVI.HRR^`3%^:HBUE`.-W:=&81]8D0V/(S@6K=`;$ M3S^V.,/V3!:6J@8-6817?]0$*NLQ"]F_6-YO%2:'>O_ER[VIHDX%^A=@_A#6 M,E"$%TVOB32//7#'`2,X.5R\`,'W!?PO$!34S\XYM7KTK6.*,M[1-Q[;Z1180QE>@0]G8U@/^Q&,I3UQ#,;VH_Y\)H.$9PFJBT8S/S\'D`'1F_@"[ MSD0R[?_"5O4MQ&OV^`'`94AZV)HS.0>?@:JAY>//9'-R)I"V)VFJJJ:@/&I; MQ/+Q.]93Z'5!HW@([$.($A)PBT^PZ]#X#H3C=Y/G1T:V&9PY(NM1`!-R\^A> MP3-=&*!A/!T;%Y.`/<*9_>;U]U*R)5;P)I!/57V1S8_T^N?;?/O,W96@_CB4@Y.1'-<>23 MY9!/EWDN82;3%!=`0.S[AX+61MI?X.OK&V3Q3%D>>@QTP@UW6 MF70H"J*A(ED8,\/Q@,N+D`==7N+KR/SA,_4=T0XD^^&'3FK2$#"IX":85Y(U MP9[GR35PJ$/@+8BX;;:@[;1`_=_$XS M9#W7*]"/KVFZH`B.8>`R"VI:OMO8F# MM?ZT+A*-N*FP=A2Z)SN*X,!+L6XG]R(S`!JDB1\+U8&FRR6IS3-!7"L:1(KR M)"CV5KXS^C_K`L[P,!.V(6HX_@O1Z6S:[CX$IBH[K:"U@>R?IG#+R"VQ_B:[ MC+$[HB^;B_F+%+UNY#863MQX*P?688P94/1;ZHQU[4X_)03_HC M.A?4,WR/-!JQIZ*H)TRP%F6/<#P[.-S(O4IS:5Q$%MV`L33A2VQR8KY"YC)TP*KXC\$C*5_FU"@YB:%2DXLCC8^X-H4Z'P,@[;2Y+NH+)HF)CY-CT!0Y+\)"5>::L)K01%-A7S& M9PL@QK;"#<)3,$G)?(.]K!M=AH`LB6.%Q>_S2HS^(U5?;?=J\00+^!_,-$41 M=&;0']!.2^*?"H]_*WI4KGI0&HQ'Z;PA=(6A\^)U,%:+-T_%:KEN9$Y%] MJ>O:\6#BA)YZ=CR8C,8NEHPMJPIEPNBCD.P@,6,MBF(,;P8CW;+:@JO>J1L9 M@_#$#N_4&T%\6XE.37]TOCDK+_IJ"Q5<#' ML[6@+V7U7`$+XX+>&)?V9QV?-B-?G.&W_OF/7W[!+V[\KY$?+!">\X6P1D;) MQ;.\!I#Z"MZH1VTMJ-8S*/\-+B@&_=8MBQ2&'SKE23+<*,+V@I)5?'#5\R+C M-N*]L-Y MDBI#GUJED^=04V2)^M6Z4L#]@=77P?=M:OQ2\$NX(."..U\!JS1ZU!^-W\45 M#MXK&W'%X\VJZD53)$]9O-/:&9HL?(+B%Q);:`PI6;?0:#G-O\N%&SP*G).Z M+O"F%-!CJQ*[3Y=?,[)B9+@^WWS12TUO$<)HS3&[?M(6`=%\T:D/SM]9JR-6 M^:XV]_ZD0BO%,R;L-"X$(YHUT-RBXJ5JIWUE3P6N=5:H`K@6WTXZT+*YT"JM MLQ&[^CH=['2PGCIH+95V?7:G%JH8^(1]H16\8H]U:1-Z>T>PN0Y>915;0V?,=1/)Z4XD-\4KL7UDOETC>OZZS/2947-UV?JL^SX?<=(A MW8WEH3NLG;&5^^#S,-U^$<0?2UTS50E[)S7]@OKU^OKFYO8V::=0SO^8HSV$ MSYRJQ@5USJ1V_*;T_%([I4=C[7]@8 M)!$I\8P@I*++,U3-FRYL/IY9_W9]_YZ=@86B"<8%QN4^_6#ODS`]EN=[HR'= M"5).1D\G5$BHF#'3&XRX3J@ZHJO-8);3/)]Z.C*&U!2>ZBEE*UV2!/M*BLS MNVA!R$.'_B>52E0[O242IIR=0Y:0E=E#1+U__8FC\2Z[\:MIXE?I6#;L#9AQ MCQ\SW5C6"5,MA,DRR-LG3+FY\D_&GVY%8Z!?4`M!UBD2S(`-^#:A$LHI1 MQ@I06YSB7@>BME11(1(E0$J@%`U"_#K^`73.9>`2M(V=D+6XW>.FKR@3+00* MQ=I^TZHMLI)XGNSDII.;7.6F6G?DA![V:+K;..DZMO,SGY:?.33T@^O\,2=X MEJNE]D:+1`Z-QQS=>)$K4\+^.W^Q8MC^L%J];TF@3:>8G6)VBIGC!F]NFMD$ M`4JW*=)I<:?%G5F=54OR.IQ2^M+?^HA3U.P/G\[3J*:KFKX6E'0MC^K+7>?% MS<6S<6!8Q:(Z/YXQI!@JO..]L"GO!R>-4UX)F9J1Y$D1Q!^H>9H"8)?HR?NI MQ$1/J.1`IB?_P!+ALSL\E0S['-_XJ22F<#0HT1/3'R7WIM;F=&,LC,-!?])\ MT:O5Z>09@*(NDQ&ZD\E4EC7=R63.,EER\K%`X5D+=!)S%K-*H)NO4$GV@IE. MN7(>\$O)X[!+,UQH-06GBVBPKNVMT9-OSQ^V\[MT$:7&##"%&65-#S_)L&!H MI`Q7[I6VDPSM'9M<.)XE]*J;6'YWF+(3W_S7%O40WXJWRVFN-V;'V:?WDY"C MPUMP]9"CI@V#16S.,5:D;QV[ITHUGTP&O5&GY(EM^:-N^Y.QJ4-V93HC)*4- M70NL>0C&S<^-K`/)/3O8B4<>-FHM9Y#?F%%O-"IT!FF"Q*>+ZDKLI>V.\'56 M2F>E=%9*9Z6<;L:#$Q*YZG?^NQGWM&?I0I:VQ^X4F- M,51.13Y&R!QA>^/3D8\<74=MLSM*4MB75HJZV38A*MY?&7(^> M3+*/TDV0T7(VD3K'53>K=[-Z-]2W85;/O(6S%-"[%6WAM$A\JM^HZ6:U]LQJ M#=QTJ38$J\>S=(_G.S,YNXD4?DKO9`)F2DVO>T+1#*T+H*G7WDT]>&W]KDX] MPPN8'AJ>>I-1ULN06A!>$!=K=UZM.Z_6-#4?]`;(%LE^YUD+U#Q'U]_IF+9= M+'AGRK;/D5B/;FB]B[&+!3_M&;>!;LEZ6G&_,;T!.^SQV>YT/[UCHP6Z,F_) M/ZVS]T)=F8,R)^-TY-9Y,@ZW_RK`>A*NS/;)4.ZN3-1>2M),G-X]P_QH$]U> M9V;[)"EW9V:NDM2TH;`)[LS6J#K7H^E1CV8[5=^W;JV/W94WY5]Y`UZ!CHVA MN;#%!L_-?TQ!>=:N!`AP)4"%Q)UUIUZC;QX6ST!?H\+Q5S,3/&M6Y>@IPJ-K MRAPU09-2W7[SO-V@\J?8`;IFY2Y5?QEG7SMN-)[M[ M]R4%D9"%'8I4`-(>Y==?=P,D08FR)%N298]2E2G)(H'N!XT'C48#V()F+P*X MZPQ$_S^6B`'@]YR`0^'3/#MGN>*ZV-]AKBFAHDC@[Q]A!'A"TVL]'L`5-'Q9 M2#;;X@M"\LM=^I0VV=D^DJ#ART*RV2:?*9+7$QZ*H>"1KO!TF''Y=CCD(:J- M-V<]Z6#M;A;4I3_4;I1Q<);JF*W":1:)$^$]*2FB$ MMZOA;2&\78-NJT27RD:("=7BKV_'DSB=%D(!8*DV+.7DBM":_PP?/?^5$`#), MVA5>POEK0)&=HD6W".HZ;:<6U0.&*D.A<%IML>&2N=!^>(*[U?FEH[W,6WR& M:)L^1(-%LU-'?*1300_.^CT6[4>2F:^F;%CT/S]I52.8\^PF!D MB7N:PQ`C*7=L7R&<86:;F*\^7+[ZU>\LI>;UD%@*K'X!WV#4K.(L+7O+-+U,)R*5C>"^$;@ZO*'AUH6O0`C3/M.0F?N!W M],L"-#P+C9*$?*VZ=B(^PH0!RZP@^40+-!QX)-2C$;ZR&J-T6KYM/6NJL!_: MYX-8A.7?DV@6CM60\#I]]SN!8IZW868+G:Q:_JOQT6FDXXA(#2+"V>Y$9"Q> M%=9>OQ]T_`.LL[#"G\=IP=8-V.A^X-D\$?++:&LOJS1S5<<0]$%ZWN;'#G( MIX<)([CTZ.&BDX8N3W)SS>4MN")KVF[W>GU;\J75;U;>F?GI4GG[O6[? M>Y2\B#H&=<_!>52GT7]RE8TI.*O[PD;1#;J==E`;^Y;4OD5A=SKJ;T3Q>J^A M>9^RYL[*A+)X](%G#PJ";(@&YP,;?C\(9I5?1YM5T2@X9F4DEACPG":]CCO7 MBJL*LBLEMMZ<>PG"KFVZZ_?:>P?"HG#[MD#P6J[G;0\%<@R>@.$>Z3_?#\B] M2NTO)NL[O]N'8<=,^3BS6-)/%BJTGUBL;0[[IOY3,L3+PN+9F\+C1LV790I; M]B"V8`I8;O7;V922/>^DR+A4M'9/JW]QG-+\JE@Z;0:A8U%C9[-1DGG?J>L' M99#D84K,HC`/($8`F!K55K:6CPK!QM=9YK3OM/`_6_O5A-^6RGL>^Y[#K]WJ M/3V`VXPJSO<7+["BBD]E,NYVUR,;M':#[6G](4W"1_65!X3B-20LX5G&\*\) M4-R[+%K5[E>R@2:]=@M(E8[R6YI&N)`.1?,B.<:$8BVDSJ;7^602"RZMO!@> MQVA(F)N@5AY5VMZS`&CO%F_FHY;>)J`D%^;CX:`]2 M9$M`/&BMI!7T^[W6LU%GE],0A*8;]%\H-&O/2KK^AI`P+UHYQHMS?#O6!*R8 M>U3SKW/)H7TO64@)C#7UWHD$]ZK3`S/4^"Y-;F`*,;[@@VPN5?.:ASF\A+\U MY/@VB[Y0-YT69OY),QX"@Q-GWMNN7JU=O6I+0[G'_FSZ@64@9D5H16.B;).!PEXL_<*N5,).E8L%A/I+`$:-/W/!NE"SR1SDP*)M;7"-5" M)#:,W>P(\6#DY:_GXH_H+>@,KOL+9L! MS]YO\:+0^_53,#=D+5%V'A^E`SFS#U+Z/NU//%65KL4V`L'5/;L''Y@AT^UW M.MX,2SQ*NB=4=J<9-EL"S@CW^C0,TQQ*_,2FZ`N=YU(V;X-8?3[B]SH=M_=? MO]Q?Q6/%:"]U=MO=;K__,#$^\Y`#?/#8!YYM`I-NK]]OS\O25,]F)%H*3]#I M/%@BR6GWT?!"*'IKG967I7)U/:];DVNVMGEQ8/)B6?DFVLL+_+;;]^MR-%:S M`6F68N+UVEYOIDNM*$T^SBGJ=,$G$HK4.S_Y)"9,@49.QZG,Q%]Z:Y#$\^>S M*6Y4R^`W9+7)@EU1:X0GVCJO:M-"[5[5Y;;;:O6Z[M95;1Y/'M5(O6Z[U6IW M;-F;:WFT*$M![/6[K7Z`Z5=KBE*DFJHOZ8(W*'@]F-U+^9GKC6%%^%I'0#[K M.QOP@8U[0T'+]]HUK+WL^VZ_U6D?H-IMM/I[AGU-+]%W MNZ[7#PY0[3:MZZEAU[NS>=1\*(+9';35D7HE";8MM;5R'*9C7C;\.[-WO=;@ MO_$$4ZS0UXS&(A$JDQ07,/6NN)#6#_JUZ=#SP^$S5YS)<(1[__DMCU-RK==" MP6MUO';OR5%X]&B^%V+OWHB]MM_OU4)"SP^(#5AQT.ZW.\&3H_"@$?_IK7C1 MZ+L[*_:[;:_7>=9`;,"*N_V.ZSZ6BZW@R\L:<+M7 MCT> MZK84^5;7\UKN`?N'8V_6,E?=5]'O!6XMMOX<\5[BN3=0;-!K>\%S-[.%AU,^ M`XKMM#P_..#_!!3;]GO=H'W`?F<4Z[=:[6?O3BSQRALHUO=[?M!]66H?*/8[ MPO\1%-OW6NVN?\!^1Q0;^('7Z6S9BYT_@W?M#+ZN%P3=EMTGK5-P5Z]H>4RD MU^MW>NW.*A5M)#6QXW9Z7=^=K:\Y>VK5:I>KV>UZ_6[@K5'M)1.25L`P*!2G M*I?\7LU+@RQ?/)N6'_\NN,1PV_0=!MOJW*$RD#/C'X?ETPU5SV0V6W6\YPP? MP/#=I:3K3\+Z+I[R6>M)S#($U2GE>:5EQZ#KMEJMN69KD/0IL2R?N4J@RRIZ MP/NNH&N_;#/L>GXKZ'7W',N]-,.'0G?&E%`?A^!7*JA6KR0D4>U8=XJ9X\[% M-!8AC)[E/;5KS1-^-?'&P^:YOCZY=E+SHJN$'W*>2WNF;E@=I'#6*[I]8PI>?R`"<=.C8)N"P)'*N\S'(/<7?+'MP M*H-P"HMX(!2/N!_ZZ=N1+A\72020O6YU=FF"7T;<8=`(XPE+IM@,T`WI^G9< MG7.&Q>724*19(J3F_2+36W;#$W[DW(U$.((:R`EVT535,'2A@#'6*Q,E`+>0V^/8/T"I*QV2%L?@SUZK][+"Y MR[G7Q0X*?`L5R120:%#I@L?LCN&X\>B:;$1&#)0><)XX$\DG4#XIC&TH(SS+ MU[D3V8B^FXXU`>8/Q22&!KC1:]K0.O`[GV1S8-%*,#7QZ9A+Z*/.3Z38W[X! M[YZ_^>WT]%/U_>+-SXTL$U+$-A]`-X(N+X]F0"?`+6Q\!64[KHQ4'8=+)/3Q8Y0D<1K))41Q`%0 M1%;(UEB;H%,7M*+@IV7P0;,EGNI@2F%4,-:%125IYD"?4U`FT%4*I@CT=)S= MI50(_GHC.<@IZP\H\8T*@FX#7C;'WIM*%+T9W!8^C%)#RYK-5X4>\^W4V%NI MN:=6P>UEC5TUET&8CGC2D6)`)X.I M[D`\D]M0DEB8A@%B- M\R&=,>=(H;X>>&S7/E?1_<T*?Z;XUKDUI:]%IRXOKLY7BT[= M-S=-TH2"5T!E0'&,?"12L(QBW7&:'VIQ\PERX0]^X!ZYKGL_F1`[+?RY=>": M)^::S\9//O#*+GGE7QP2,85`(@2YB-D!N2&4QWQH(/'5KE*1Q>C.%TO19WXW,\(4B.^P& M?!+MQ"!1@5.3QK?@.^`%AI,8YC>Q^57E2&JJ%'[(41"93D&^HG9`#T^+3F"V MJF_P;J[9&)XC%$RO:%/U7QA6`H^(,ZC$5`D\RBG^).E)\!A5SA1&R/@M>&G( MC7IRFCB4Z&2FM/P;^)@@6<1C>%9.*3*5AK@DS",=Y9O@^618YE!\@XJAWHCC MD:W`YX.8'VFO*HTQ5(6L2V(RE>*O4YHZ/KXHUG@RA MF__]S2LGY'$\81&&/'&]G;ZK"0O-][(`67Z*ZN403.5SDX8?*]U<^U$M/WW* M(JMT<)3%3?+?K[)T\LHQGW$!_56]:,=U3UPLT)G%LHYZ*=$:[?;&,HFJM+E& M7#!07$_'@S2>;5)=D&/&][/N?*,VM&H=F7K[]>[!G7ZT/J[9!#74[?;8$K)K M]@[H_:E\_3>Z4]A4P24TT+#=Q*(J_(ZFE,"#<,!U]0]JW*)*I*KB5ZI7,:MW`CIF5E1.7 M$9&N1V@+V^Z7JI_^0GV^_&825.XA/Z?X/VC/,*%S3$;T1%S8T-H'9CPPXX$9 M5^LK[T4BQOG8]@7G:`MFE@FZ7TA'U7,PB<:9L:+HV-@44T3R9PK))[2B&7(Q MH1"B\3";R.W`:`=&.S#:@=$>P6BS\]A9-B+6&:39B-RM:MZ+[!..!+\U^1XF M-X/R)@K&TM->#C[;+BA*LQ*A_AI#RUP^5U+:G_!9@R9XQLL=^>\8Q[A(\T$V MS.,BX_>9Q=BVT5)/$G%K4,2.Z\-D2O`[1;W4N!`Z%8$R]\HE,UD>/.[068$. M97E3"H-2U*7AZ9'`>])$2!D'4F!\ZL@)S0XM(`Y*[,4YGSZ(4&E?*,7X5LU] M23"RMS!][71IP!U#ZT>UQ4L,@&$"'M*7U#F$F&5EF6M4F&NAK'!HDS] M=S-319QY7";: M\XX&OFAJKNZ;<"[+);LK,$&9D]54[=U^4]QB<>#K?>1K9#*33%M+GKTSK682 MX!+#I92+04&R;SS,RQ5U+G$MEU(F@.C-*FYRTTQZU[CL499/RS#E528XL8TJ MX[+SV'3(3R\VI+="430/*K\\O3YS3J_/G9X7.'/.W_8L7Z_/_)U'-QANK*TC M&VEJ2\D/D.P^.716H?&@]1!$_"^D,V3PC\E1N:7SA74B$*T$K92H5V^A**6Q M;LQY5C2]3F4TBT44=94L!&U&E-*'3P]JN3_,;E11\H0CAHX@[_TG[^>J>NPB MW_0P@LD!Z5V9'P\Z_^1;3UJ&(Y+:G@![Q#%VV:CJ^0B7N(G6"5L.-68*WQSK:/VW-`VA#!_&Y[QYM?WC! M'=*./A3>WG^]X<'CT?.@NE'K#2TEBG_3F#^VC-A35ZWIH M:=56%FU8)AU*GX)2D*K%?/6L,,.!)2M/BW6[8L:C1C!2':8/>SQ]H*.+CNG4 M7L<^MO24:SV%PVU'C&J:JV]I0I M8K2S1W.R\?ITXCTWYW$Y2E]M486BS6*<=NTP*$1Y!'=F/Z29+-F45H;"R,TV MVV"B>;8UA45"SQG,Z]KQF%;>2Q4APY(3<(@JS(E)-&ZA91K-,)0%FCP1 MW:A%.`H+-SLY:6-5-1L^,O./U/A;-&A5GAS-GG%#J"793&/6F["A4$R9*[TM M,=13*_V"0">)IATXY('_HJV0'"':^=LX(I?3+U84/V>?2[VT&NYU"*P-N+AG MH]@26T.@X52!JN$#-S@.W!JUZ)MLG..M4XP>>3Z9Q2.0^P/(79RKIVH\L&&. MF75%L:%JK:91MDVY`=?"N&@!GU;+*E]1TP&K32_001<4%F<_5Y3!LJ*?UY*E MT/!%5BVK@6>/:09@`8.?:Y13OH]_23@F'>`9&G99N&&>2<-G\WPG-+W&(.F" M#8-UI)K,Y%W`QD;9YV<"KW MV*F\K!E'XYSAX%_NBW]YV3BEL[8SAHOVXATU+2):?YSH"Y\Q6WV@EYB:(WG- M2U\FE91%*9UM4\66???))O]ZTT^YZULUQ)I]=ZNQ9AS^JPZU8)^Y#@:3GU+Y MB8.24FD4J@C\R!QBDARO7K!><5VA<%I-1O/0A];A:"GNV['1'&#`*LVI,&5L MO0I>E*O3>`$N.&YT]E61:&?&53SGY!LY\2BN)5^4<[-(*M#G3"64#V.,D^#F M5AJ]:4VU.-RC6/,V0?UZ^&W)IE:\:@9'L4H305WG87JH6EQM/3$?P5@O-==F M7^CXJME35_D@(V<=".;8<^LY$*;KJ7+U;_'Y$TMZIA7^IOWM%\:%<=? M%CM!Z4PC*/XOKDRF`46)8LL(FBK\N/A2':-*AFE5&:JFMSL:KLCAGTTQKXKGM$[_WXQLC MSFP2Z$JMX[F=DT[WQXNUO4_%G4ZE:YAD;S1N!Y)U[G&1L!E32SVN19D]?V=DR@OV/,MFD"/7?G M%KUY$_B?/*5,9DFA.?2T<2=N1OY8+58RN^2Y*-&Y&4W]77Z_I'O?L'C@U[W@ MU\VI?@\_W/#EIZSZ??_#Y]ISU=N'S*0%B,'F_QX=+5HN=Q<6E ME#ER=B!5%ZWSB!^4@X<+UO2SLJYC,.%-+$C.OG%P6`\.Z\L:'`X.ZYY3]\%A M/3BLWQDG;=UA;1TBNKF-C;&'8=_'3+\]VK)_RWF M@TN*;_6/0R)-@B\0+:IH5L&U0E3SF3NGEC-ICIJ,-<)N+_V7O3YK:M M9&'X^ZVZ_P'E2:J<*HC!QLV>I$J6[!G/8T>^EI+4O%]4$'@H8@P"#!;)G%__ M=I^#E03%#2`!LB>5B4@"9^F]^_3I%OE&^,G^SFFA=(%+Q(*=4^RX;Q7<%+QE(:;8/%^L)C/AW(\0Z7#,1B+C<+-67O,&\=A1=2P4.99 M!`]%/>N1:(]G\^AB:+J/=DX*\>2QA;F"7&$>7,]%80'\%K*'1;IMK@QL3H$K MKJ=\'.?J^2"%VAF]\CK5Q22U^#("+B#_9(AIB7CUAQ>;B96&A9>AU*,;TI+XH_E"\OR8^-MQ,6"4DAD_:C*KPOELO=$?8-%F#D>0,H>%_=: M-D1^IVOR[SZ8HB,@)ZYG7CPB):^4)/*+2!JQF`4'9,0L;BK$5X=+NS*(BS6B M3KG06CQ)-35FDD9]4]$1-:X]X<(C#Y[W+4E:SL]J9:4C^.YS9:Z$JV-%&(P7 M]@",)\P=OK/`YG']#-4B'?J%T5?L"<=[M"WI`5,H>=7/A_^(O%Z!R@B+`61F MSO+"UMX!<_F)@^LEB$G*KN20DMSW$\:&:*JY^BJY'-\CCV^4:V0---D:<($C MF'1G?F];4XM3UO4Q5D+$2JX#!><5/&AHX!F1MJ> M8JN6B'ZJNT7C"1!+Y:;#]>(BL0VA:!8FFA"*93VP\)G%ZRAIE"BJUL%>T!\, M7JBR\D(+1UXK+VGBBE#/"WL8VD_[1N(GQWP.XIK,\6/X/L/VY2N,I#^2$]RL M*.%"Y2+>.7846:R`NM2&P\E$829^\]BQOS%^!1,L`C0RXKI/'`JP[S%O&^$GGXGHP$K=4BSSF!A1_&XWCONTO/S"_7-O'/*NN/$-_;S6_$\T>L1Q2:DT M6*E<>7'/4LLFK=(DK2)N1`2^41=S41%'"70,KCU4Y M:V[$'F$T4!3H%&!-0'&KTS%M],I\FRLJ+^*2`"WN;#8N9;A@!YGPC-4F>$LB M7MC>#$'5P3/"'X`A9%05.!**$OCA$=]S8Y^!5RB(&X#(HL:#*!/'96MDXZU2 M6"'(0R'>F?MD^QY_&SM")7I33D5R/'^Y@[9\ERJ]1BI*'QC=0Y22NBPJ]M5, MMS_EY"DC<1XY_I<)(Z];`.0/214+E/N9@9*V/D]"AFFMV,RY%F.#1A(:)^F] MDL917RX!(I=5I^!6S6-D\Z_`JO%85N:7%TR1L-#NPH9$\8!,YY'B:;#B$9?+ MXVYIA*K&ZJ($4W%OILRC2"J+BY^1T7TPSU%^@SS&.K4._Q&^X/]!4]/#,ZBD MCS!71`%7.G@#&G;D!ID6P6:!$VSTQS,J11A5QD(A7"KQ.J>>`[+(=.8!BX,V M:5<\<>X1Y$JA<"N;^TNFFZN&S4_.>`A2^"`=Z:I\K2)XR3TY%H0+)KRX?9W[ M)=X:R:!&RZ"O0,9XESENY?K$'(\?R9$=W!394\#0*,-0(EC$%?0D$LWR1Z,E MQ;(YYU],O"@0A>Y+1TZ;CH*-&9B.F38?#4)S/$XFSEJBVU@3EG/[RC'Q%/\Q MXZ:V)/8P0H<63'GPL!VTCQ9%L$+*SF]$#&C M%^I\]74L'7#1[5YH!S!Z5W%7SABLNJ37I1-X'(*HH2S??DA:4!=LR;@+[1CL MV_@\+G]L'A?GB_,KLKK9PGD"^":%0805[+.QMU0V/,!WMU5 M#"_'QWND'YHK?/ZL MPX^E!!EP^G.N*"/VVS@WKT MT4,:SE?J%/2,H77L!!2(`P[A4L2Z-V:`EX.\-#+N8O"JREZ7SE MJ7))?H1(JA.+%*V*N.,C%L63XI)EFX(ET7F)2T>F)SO+>Q29"SPO!'@Z?RCT MP)(ZLW&7\6S=Y0TM39ZS$&N[-76Q[G@:,R\][GIKT2,Z:&Q0'YUT:X-]K]]8 M*'W"L.$7H+1;#`.3U]44-?#.#$`%)`76S"(9A7"&L$XD"CT M!:8RCY"$\T6W0^L=0I>\-WV7GVG,2@FJBL@Z3\T&!9"8..G^-SU\6'!$'EZ& M\\U*+GKDJV;'G7B$,X2B%MF%C2Y,S$][9(6I M`CP"`F?7Y8/'59#AKN/(`0[ZYJZVDU4;+O<0H@ M*OO0YO.CD\L=$P\3!GAP5SR;U8W=M:;?J2CF0Q3YBQL_]WL=[%V=+_G7UV9; ME/PKO1=HJ)VA<="+=(-=[M$),??F`81#;JS!$:[WZQVMHGN4RW[PIA2__\U* M@!J0(&RR^^KE_7;UCC'X\6U,G*$W>Z/.N-_%I+]=#_$?*?F1D^3*7\7H_'?> MUDV*498^X`O@++U_5%#73ZREWD\-=*MV](HNS!Z#;L7GC0L'D*@C4;?1'M5N MI]=;$F_E`HKDVRX4BG$50;PA-8D.9TZ6_KY*+JX&\X8P4A>.Z/E$;U_!-,^^.?OE ME?AO&N+*!<#&CF>&;W!;Z:])%2%#'JJZ;/2U#-Y$4411>U&4-NC+7:-+%$44 M50E%Z7)?565=T:NA*&%JM9VBCA=W:YEA]6?2N+C$L@KJM:S:04G;R*9CBH&N MK'55N==3JE0LA*(J4=23-1VLR4%%DII05`>*AH.NK/0KXJ+JXA:M4IGG&J6X M97A5)YLGY@?\I)H6981A2Q.(93;3'>@I\NJ1MXED1.1$Y%3X\AI.)2[ M5=F_%*DXJTA%2U*&3E0`P7*ED1>A';NI!#JFG%$56=,&LM;MDZ]-]%%*']V! M(:M=BL40?9331W_8E8?=WMD'@L3';7OLG/)E^=1P4CK][O'N2-X5KCB).SM! M-(5UPEO!ZCKAJV]4[GHKJJ6H/>`E*!AYZ19440KL8O=WNYWN8<5*RV\&:)7! MJQ&7H+0UEZ!4C1/=B>><'NHF$A$/$0\1#Q'/,>Y`'AV81XYPDJ5#\F8#>4,7 M>^HBUIJN0Q*9$IFVX&HDD2F1:2NN29*=R#GU7!,0?XNFC%<.?U.;$&Q[OD5% MPK`9]XXJ9G5Q=-:0$TBB-Z(WHC>BMY.E-V&MM9W>CA?=:YMMEARW-]H_;0YS M'#IAIGJ,_U`]IE6ETU>.>T7NM6K(NC&0C>%P?Y)M'U)_JL5O)V)O*K&K\L!0 MY'Y_0,1.Q'[ZQ-Y3#%E3U/WMVO8A=3MBIVCEW@"_'/TG"D+>F`C[6E@3WM#; M=J6Q:?L(N8CW^`+7T7X2K>ML-PC]2#3AN9">X]HE%.L\G8.?9EY;?*W)AJ;) MNMZODZA.762>%#D>-315/2:S*P)&?>E()$^)@%M*P!2L/<]@+6]RA=9I&.*8KF;%VHXW@$3!1O*@PU'1,EQXQP]N=]7Y('>HZ`>L7@#4$(L3G%[8G%B M<6)Q.JV@TXIFNH0'N*[7]O#"SO&Q9@:I*.&4D$Y()Z13])BBQUN9"M?,]::V M6^]%K';0S*Z"XJ3%`2&0$$@(/+Y";@<"R7??6R'_R=?&1I+YQ'SSD8G#V_AT M-_2`-Z:S*&32@QG8UJ&.>-MN#E;O`QPSG*@.Y"%&$P<*8?;$,-N3A_V!K*D: M8?;$,*O+2J\G]Y2]>):<\[-RSK-;![SIJ<_&#K-"R0R":`K6`/O.?,L.^,V# MVB\8M(.T=A8:QTM[/:Z^ZVT'Q=!! M.B&0$$@(;!@"*2)R5A&1WY8B'$GP@R(=>_*1WIB]5D\V-5X_;*2K\UKI#"JX M^DO%NHAISHII^K6FO[6/!(AIB&G6:YJ]*J&OBZ>UCP2V8YH%IT!\-!\GL!I':(FCI9F?K-E?CNO&W-W8(D+,VV,E7AL"5+BT+ M"#4$&25]\3T7_K883ZC;<7\GA*J\KZ@9G6Z]V'MI*Q]=Z5^F&YG^/-N4IJA= M60HG3/I@NZ9KV::31^9M:+HCTQ\%TCL/_B.]YD]>WK[[2;*#(,)C>%RXF5@*0?-/S05,&T(!A^>^%(7WV5V3[@@:Q@/1M]!!Z M,]N2-*U[H2G2PUQBCLVO9.(R<4#+@W6"U[]J->^7OY30V69/?!(`E`0/N(%I MX0IPD68H"6\\P$DB.Y@``&!FF,WVI780:SFT[H/3(8T@<(3KVGS6`C MC7UOBL\$]@B[#<)@.>3!GE,JL`.)C2B=ZMAV`K!=*$_,)82L!$``Q$FP3 M]W/EP4=WGJ4F#=_"+E(.F'F!C;N0`0I!Y`!V8>/>+-X;?/(ERPPF$A@!ST&G M.L%`8J\>L7<9/49!6)!Z1BSU0);M*)X%K\/\YF M0?0`(\+T0,XC#Z2?9#YX49BMKSBTF8WYPJ)1DL*?+N,B#I@LG*`(F9D^/I3Q M3RI@`L[6S+0F,+&+T@[%G(WFF#V%_;"8,NQ/Q-SE5HG"!+>K'ID0R1_L@MC']<7G[I2+`##(<(B@SS`B-( M;3K&?R@8@;QD\^K90^^-]%K]*8-+;!JAS026#TQV$7H7?/-Y"6,+#LH)/.`- M86;).:Z0^>[XXY:H*IQG>1`T7Y\$3&!SSQ,;9#=7#D,NL5:^[GN1X[B/`8/4>!('!`#/0"WXL`FV47V`D(QW%LRV]+X3?+A)6 M+J@FH9`"KN+X7+C%^+F-13'P%5>1P$R>@+K0ACY,;X[$5YV<;$G_NLN$,I`T M+!FOH15>BX'OL8#+=2`;&T`AV"%^)$%QPKP<>"88%[A#V'6F`^QP2W&?6$`E M5)H0!+@TI`N:KPL^F_-UJJ`T'/"[T`.O,YOAZNWE[>_9Q^NW/TF_>9WBX!?* M4):^HMT%9A(7Z5>P2!_(4'":=`5F.HA.8/;%D:7X_<(,@MM3`@<&?P(/-."7 M`$P719C@/_"!W4>'25-O!/(5F3"GW,:Q0YM?FY6NC'Z2`^L[Q'E_-0*HED5`I.A%%\^&L$0_GS"Y1&Z*>G;R9/BWU9GH]" M"UZT9PY+V%GLP8ZOJO*9_LO2$;@QRQ?N.RI%B!<<5*:K[5.Z'$]^+'I&HK6@: M.:(-FIE>819[2)2'G0X$O`&8Y[(\<5CCV$ZB!\8YS2%T`D9T,$5ZE:S?6<"W M59HGYP]B3ACWEU`=*Y)WC6=]^_=__D:2_IR-%(+X`S8#_!QX@]-PK M[I8^PL!7^0#=)SMQ75%:P&A?V?B75Y?!_<^M MLDO@W7L@\*?[SV`7V/]@[K5M/KH>,+05?'2MSYSQ7@&WVV*XW^$/57L%9IIE M`Y*#7UXIKWY5/<'"3DGE,D2EE2WN;+/6M^ED(@0=PBDJW MH9?:QY=!P$+I2^1;$S-@[1)"C3\`3%>Z.-"+D^:MVAQKI*R22V&0]%Z69/DV M.S[/B\_-EJGO^7Z&D!M7^L`>_.+AF,KM!BT?(Y/X43+CCJ+'HR2<%&]R3S"->XZ$>RSBT]QF&,7K&-DC;M),&0MC M!QGTMIT&IZ6'6&!R0X__R/<"MM>5-%"Z.\#QA?-B#EE92H2TE)/2RQ54MA9P M:'@^8ZQ5*,>X*Y>P-'$[>E>15_!9-3O["+K:?;0?'!9<2/\`(YN'67%9-V@C M[KW#-:3Q<3D6GU)$D`N/9;8@=^=4K2OC=;?XWC10!?PG]&T>9`!3=XI'AB%J M32!P0;_O?UN_E"PD%\VDF#7BK\!D_$'O]"60&PXN=6K.P6J79J;-2<_$61.Z MP/44%H'@Y'&TW&I@BCAR;5H3C'MPAH,W4X#N$"`EA@5FQ\<`ARYW"_B#^:>*=G@:J,&3!7#GT'?&[W,@ MFIES8?ES*GI@_*1V%+&%@&?)"NF.\#_O038#H2$Y M7X97IN^C7/F#4]YR;"V--*GKXF1]1='[1K;*C6:L>)':ND6JRD`=]@?J<9>I MKUNFUAWHO:'>/^XRC;7+[&NPR.&@AF7RP/'\S$*BZSQXA!%7'?R/'+3.4?X? MSP1/T<`=?9:A0>CI(,QE(*#%)@(^0>RM;F!UH!4W8CRQ07B;OW=N.]RQP]*^ MX$,^F.ZW=?;9U>+B,+<[,232Q.[4A!,.YP1H` M<(R-<8`IIH.+_!MNMX"#+H'_&4[X$:Z#/@8_G*T9G,,7@%Q%D@T'68ZK_S?A/49;ZQO^*T'L?%ZS^ M@MY:^F,0_QJ4:*CNO:Z($S]^NG?3-9GXVR2T#1Q9FY:&RS:#:[RA*,Z&J;@)5'P@\9%\<,[XIMCDYZ>W> M^#IR^HHN*'\^^>:S^=V>1M.S((L=H&.[FT.GN:(HAD[-0B4;/TGB><\3D=%J M@?'1M\C#-EYZJ_DRS?._Y*C2=%D8FOBMR_S@4SAJ M-;7E(%*7C&[^SJNFA4HY%W.?\&`-F3<^H=L,[D9'-=H!]Q8*N*83M5XQ;BU\I#)1MO>S7NV?O--3@SA"X<=E./';%#]!O\?Q\4SY3FLAG MO=A?-+*=^6QDAQ],BY\5%C;]R79A5/'``M0^>>XC'E!>LX<056_AO5MF1?`2 M_K8IN775!@(K"Q_732T'X;??(ES*S9BCAT?GKDS'8:-W\_>F-2D^6W^`)0^! MC[]]>/7K.@K89OGU0Z-&8;P,&:UO=)L"G=,+2BW!>Z@I:]EQ^/M!UO8TP.;:H4_N&VDYJ.HW8QQ)" MNFWE[C8K']70>VW4/L<(EK2<8IOA`"\!<=`U^@3$EX%8JP@X.`)NHI`7?8A+ M;&V<8KEL.?<`$?UU$?/<=!4N+@7V->/VF_W$WLU_X\4@5^,B_?:/)+O\CED3 MU_XKRGG,[\`0_'9K33R'!3?\1C\ZS;">SRR<>)O:RJJJZ'VM?PS8+*6=+BVN M-QQTE;5$5\_B&H\X9=!7>D>!S5(B[C+B-%TW!NO\C7H6UWS$J?JPMRZ65PML MEE*32Q#7Z_:THU"5<>J(\Z936Z2%8OY?-<;KL6=4#0=7[B;[R=H2DN(Q'7G0,0^,3_@EU''$@A-,Y`^ M7TN7>&\Y\%SI"HN5^=(5'ZU8-^_S]>755;$F'\P4E\F3`O@A+9.0%)*>R$7Y9;7F\>P#3^PP^6I(E5C*-PN3"-"SUF6%1#'[1<\I,E/MQ M81++TJN)65B6#'MR$0Q,4=A='4 M\Z605[U85Y3-H0#K0B>5FV$/-M]M(#816-XLNTV=OK1FNM^38GCY M>C$+M\NQOH3%!6I<-V!F\CO+OO?=Q@J>SESZ0>OU>"4/+'O"5Y.4]YLQ'RO4 M"@1R&MCS^N[RV@`,6/5P%)?_0P3BA^("58_0L3&MHFT^;;B1W4&25"*&Z-!XCO?P=V71I<,2U^6`],$* M8RBA4Z$)O.%&EL/P.\L>%:1H`2;%J9?&"42?$K[>;#&\34P>>"GDOSBF6RSA MNKXH0@)-4;P>41?7IL#2FHFF$'(H+C637I`KS)M4UA&ECT:ILLEA;(/5Y&D' MAA.5)A";:5$BK-1L\^)!DJY((W,>Q*5)L9"HP_)%+(KKB^4X5F#@(LATA>K' M,@WQ"]GLD(+!:)>8L4N"6<#Q(`Z9;_\W-5S!TC6QE"W^C(5AF875I(0- MN[$)ES'*8K&U9?,-M[EHPNE::L)EYIN`PIXU5_0%FTT4!LS9;?/$""H"#5;^ MLN#8UE@$MXZ;)DF6,[RE-?K^5;EQ+6`RI(OSTZ6I1@-Q\ MW4""W'RM282`OPT*/C'(HC`N"Y5W3/_"Q=BA*,7]_[Y>WO(2@*+4._9#X/[B MU'-MF#W^=@8/9RY^3A0MN=/U2"(`UZ(HZBMUB:)\^:?='$GAZ.(C/VC#387& M2W*-I,F1I6WML_F`LKM*2/^+BHWF0Z.5?N4SCJE,F,Y#TN-A)Y8&94 M%831B#,ZLC]@UL$`V),9()-//8=9D0.F;XZML;3^>(SEV9/&C;SD*-KF-DHY M(6/`6C)G/)9FCIZ0PU$QNQ7"Q1?EUP=CZ8:`QQKOL,$LZR;!D;OO@, M8_^AY#V$9ER`'"TCRXFX./1%LEL2B$Z\+EY'R.=?7W[^E/;74^ZBE1;%SJO^(HAX\=\?8LL'UK0.&*OF+/&S ME<)$@?V(8,MZ6Q9Z(ZF)L;D"1Q@;>G#0?,5="6'N>W/329VSF+1QSI=(^65\: M?,=%+3K$B`H9?$,E9_(9XDOL?YJTUB'YWXA#S67"5_IR*>5GI,>#T@L1^"^W M-UA$_/;R%DL%.\SD.4&9F94Q?]*/:1[73"8OAQ><9+DMO\3"$#^%@EG,W6*)AR)EP)EUPOY@`\@S#(BH+SB>>$FNJ7DY3J0.E3%6] MM"=L+!H`G)/V<,OA4VQ'D5L3>4#-T(#E08R5ZF^%:7=Y^_O72Q"(BV?/;5-6 MR3ZV4$%1B7[+PZ>@HL81WV*JGY)6&C&8:U-7)4D&>`MX'&)%G86P.YA M)'"*75+;I33R&5EM\6#DF:TA#DDKI8Z,=>=RSH,:);N!X7.;U\^ M?VR8";"-WN\F>K^;T_O=3=5^E09`3><;E'I14^J%,MC!,_YD/EQY_BQ5UT76 M6C((*;HOW5R7/3+7;%QBH^+Z7< MN''[Y[1_[H)LO[O[8%J8D7S;\3M.AU^ND2;S!]\>P08D$]OGBONZHPA/M5'$ M>I;#[]U@QO&#-YK'288)DW"3]\'V[3%%K$6X[V]>5P]9E#& M6]`!FJ,9?,U#K1GCYA-._.WDY0LG'Y\_?9(^ M\Y'^]OW#U5L7O&"01I]8]"W^\KWQ=FHS;K+*2#7X`LJF[>((J\XDZ@@GX`K+ M[5NV9;R4+Z$YUB-N#*\8BXS%O*A-UA$G-7)IGPPEK/DL$3U3%O%=V%$*#BX_ M^)5:LEXWM%X':AR+&.1B$7V5\BH;*#C_%3G5",T/I@WB"];Y3P;T,I&26K;% M"W;)4]EW6-A@MSCL(>5GNKMU0G2+$$%SA&BZNUTE*=\S,T&>H>AI?*PT%D]J M+E)*PJF!PJGLWMX:)_B%O*?X!I]MNDYDF=(_@)--UY-A[3!'*'WP3$X+UR:_ MT_O5"P([E2`%]2L)40B4@D%)?@,EK14E)HGIB#/@!+PU#'#.I[,),).7^J(\,)DP3NKHV,(MQXBG@S+ST0ZY M"8/"!WUH>&(<_X'=R*F!YQYYK/A,[RS-^P_W!YWKA82X):L7D0(#H,L:!6&!G(R;& M2LKNB&\Q:IG%OAT^0H!W7\6Q`'[#9?P,I@QY'&L<^6BYIZ9#R5[K-::7@PV< M*!]$Q;E:0PJ4CU!?#8I]U<^5YT33!]O,E[8)LY2[4ETS`?-LSDM`I'HC"[N^ M=#615,@.*F1#.5VX#XNGK>#4G[B$?F:9>";I3-+YJ-*Y_*+:2T5O7XI>_!]X MBF'^L+SA\=RD(L?JV^9(SEF2?*I?LH@`7Y&0.UQPPT8GIOO(XE,V/`,)`8>K MPL2CB&T4Y5C2$05U`*\L@Y[?W<.8D0LZ&PDP+J3Z@#W%>-EJE#^;/0_EYV9:4H+YX]WQD] MXY$%28["06PU?LI19,<^+HB>W!E6\[5"%/)!FEC6,(SKK-%]F4,*ZSO?>S+Y ML>W(8R)^^<`<&WA*6JIX@0+*88\\U<-\P(+,F"PL6D+X/%KYP'.GT:MA9N"Y M\`FD")X>\Y1J?#"IF,%L'O4T+6)&;RW!(HW5/CP7U[H`>.Z M#XR'OVWWR7.>A$?T9/JV%\%JS><@LN,V%6+IL$J+,2QS%L0A:GB6!]'Y7D'6 MV"XV?K"\R!=>W`,H%Y<%Y6+OG]XSP,K'[-F$@#$.G$L[L5U,F^.=(V)!CF`3 MR1R\IP.:PRQNJ!$O(^!`]#B(0)B!H@Q$")LO=;P("@%:?&!B8A9,Y.<638+M MF/SU)^.\P<\%L!"O&SH\^3VI#",JR<3'#TL42M@[LEIZS]O1IY;1E>/W,C]VG)G[B$!UP;M,.M-8DF.:_BRZ1SW4$)+/1"8A>/1*Z+ MCR,%TM7$9F/I?3KX#98>WS`C.EL(J`@V'@OK$T>%!Y8RO(1=K,;Q3G'B&L1' MKBL>[HH#`]!W40B@#^,C1Q`[[#EN(Q1$%O@YW%U*&Q[%5^2D6-\SEV^9'X7B M\E<=J^6A@H_FD]`&?JB_"BV;A*XC1VVF0\@3L;#T"^>?X?8 MP1:V^D._TU7XA17/STJ08J^O\E=&)M!H.M<3)B$P/HX:WQ>/AUJX-,P/OC$) ME#?\"F#PZSS2.2W!YAX\-^+.&:KV*=Z;XBZ8+AN]'O[+_39A^_";1MQ6>K0# M0;N%A7)@P3<6?JG"<2?OM%EL3_%FFV^S"I4(4M989"4<",YD2!P/[1RS147;TAMT&1\P, MN60"VH,=X."P-N'Q"?E7-D8V>R`5HEQ&J.YR?QJ\CE25MXZ,>E#'.#5%RZ/.8U]C(5!^3M\<9YR6KY/=77]N($ M@I&$)^LDW52 MGSGMVE$NU]--E$Q3+LDV)1LTD#S8F""=#7"%]XY%\>\X6I@A;1DC(ND#6S>! ME@LG/`4N#Z%8KV`3Q?@!T<"1KSTUE_*Y9,7`96!_?WED<,M%Y\Q0D$`Z3]JY MLCC-?L!<8+L2];$1.VP/XF?F/*4PYG$&&##BO;A@6;%U,1/5V\5L]G0*'J<( MF^)C_*TXL#*.T-"`[?H62@&'+5\^S^`^]AS'>TZT2RE]4L+8@@HQ&M@6_24' MZC;$\.#_9[HV"$1[,X?I`Z#?Y?D:+SE,&[/60D;F2]KN>7ODMI[2>V5PZP^S;=`445%N!D"21?NIPOK@O(IJL-6*[]CGC/RIJ`4O#W2 M:6-.PCJ(B8#G2(Y-*SE-C'B:!"]ESOLQ.N)$470;`C;B;XG8E;@_$L3U<_IK MLA*^;B_E,I*Q)6/&Y2H1RT9_MD0!%5[T;57L@K@_%J`*+Y9]S,B1-S?.Y7CCH> M9(\5^'IJQ-"@F6B5X,VIHWED/R5C/]NC<`+C*#^*8>#7D(L&O`LXPXIC[N,O MKY17_',P,ZWD<_S^`R81^1<\:7T6L#?)'V_%P-(`@ZT_OA50NG#8.'S3-9)% MI[L-_?2C^#SBB>F/[B^O0F_VJKA8&+)G_/CVP;2^/8*)[(XN>+_[-]+?KJ[> MO__PX6V\[#=*89Z5>).2?]5%)*I*K]/K_UA@`>E"W5G5[HA;?@!50&L1I3&* MP]%*(#YX8>A-%^"HZ!U5JQ".I:#;%$[:(IR*]+S!7F'Q0)^P6>W5R_M6NYPD M5^][PT6K"^$3GAOY]A6HV&??G/WR2OPW9:LD^1 M^_UNMOU]$*QVM"H9Y4@(%I_]O07&"8J%7GUBH1VTL2OS'Y7%^ZJL:T:5+-X. M9%7%R&>E^?ND^<]$\V--0ZU'FI\T_P9B84":?T?F%PXKT,H;=89'+BZ3_G8] MQ'^DY$?NIJ[\58S.?P\\QQY)?U/X_]('?`&*I?>/*5UZLCY0R.0@DV.SH!O9 M''NRB+XL:LJ%Q4:R!M8KC;P(XW*;"IMF`+H*BORA>F)4]4Z_N0@ZIIY0954= MREV%(E"KM8CXB%'R1>B=Q.G`+-F5F`5&^N65RH=Y02WDH2#E/_S]YRBX>#3- MV9NK[`3GTAU=>7CSXA'[J;#@.KVC>`?T_,[QK&^__N__2-+?-WCW"W"M-4_? MXVD/\.$K&__RZCH2973N5?@'CQSO[[Q[5;O7Q:=7O\:,D:XZQR3Y(PL$9/Q9 ML'.!7E=A_(C'\04(;8+S5A-LHTXMX]L-`F(EUUUE*;L;7+S1"AP0Q#>28LS) MH@QP>C\X?\F67U]R3'L:\.NKO'Q"%";ED;+9^)D^+_\3W1,L[FB3WQ75Q<&5Z>F'@.'L4F]X'E0AL@YC[9 MON?&MR"2N\US<80?FM^3^5>VS+)=^7S?&DU*^U"'7GLBQ(,05SJ>0GY>`_(C>M?IG?`Q:WP#)A9 M3W\WG[&;\:7/E1>2^N5W.[@/04C=?^$ECF[&8U[1 M..8`WW,<-GK_%ZBE>?+39Y[ZLW:+FFIH@V[_A0V*=>^ZN6U(8#!4M/Y`.\!: M[D?,OO^$9L9[D!_A/(/OE>F&GO_!#O_[R'S3&7$("U@>`SW&8&#T>_5#9`-> M&`S5;G^H[[N6FR@,0E#;:'+432ZYN:I9U<9@,O9<%1?!6\%'RR]%$>`I700? M>O>)ET!0,G&YABF=V,6+6,)Q_6H'WZ[`J(/!X2_R;6/?-@,0O^C``22!$_2- M7-UCI9U/L0`3_"LRSWD-!K#_Q^GU-/@%M$H4.X]QA:B0EUD2-9C$E?Z\YP*O M1'YVA>@#PU83CG3-9EX`^/Z(/W./Y,KS9TG!Y&(ON.N/5]GGZ[<_E7HZEXZ3 MI`K'NRE>8W,]U^9W^`(LXF7R:WY\@P^F8_*JR[SW:[+<:(;._`]:-RZ.%[Z0 M`B_JMZ[Z62<7J3H7::5471*_O(ZNY]Z,N8B^Y,0H]+CZH@36"Q(X,UVY!X$V MD3!WD,8\ESMK:",E3UW&W9U-YXMICSZZ5^8,A6"Y4;2H8/2"RG]I!PW9;4X' M;K9#HZ(-"GM#?!WNO<"'Y8WVC.Y@[4:W88I*=ED?1^R[WY*I4S*X\VXPXGW+K,@7 M%^9.A4&6-$5O$89;P641L$%X,_XJ*@5OY9VL^#FI7(H':B#D/-=E#O\1 MON#_D4"^>):=UA82)X,!/P7D/4Q`=@39L1Y6-Y]XCO>(A0MQ[\984XBPL&\=-ZY&80E\U+?HFW1@=&57I#JX1F4;A> MLX<0`[;"%>%W_&]$\VY>U&&O6%QW\1CAY(K\U52.>!8L]>,ZH M=.G#\M:+@-MSC.,=T4CXY)FBH%!LZ,VS2A[GB(FC)@_]*W)9M@-1)^.%_BX_ MQ/4R,-3H)&@,$C0N5!@+G[&8C_LMP&;E062*&D4B&,L;I'*MSM--L$/]J#"Q M*4K9XB1)`!*N(I4ICIU&@:AN!O:0.8]+ M']FBA4Q:?8//O++:!W\SMU/L$6Q.DRWQE9HBL2>NXLDK)XU`UL!4.%%D!Y.I MZ">`+^3RC/K*14VI1DNB;A>:60F2-&CM\_I(<5X:$"ZG$SN0^AVE_R.OA(M% M-LKK4=\5BG+ORG%]+D%PHB15\FXV[Q@KF+F6/>,%0T;9^M"`'*4=E=,E@($M M&"0I'56<6(3?!ZL;(<<`Y'PF3BC,C.G2R3%O:LW9`MC&##:`AQ^SD+_I.,S" M(M3((8`:S)=+6S[GD@5-P"2:1D_`2@X;/:ZH(\93L%RLE0-03SE#\'">X],F MUR:P"I[B\TE`2H#UC]558">/($L>$5R#K@P\(1(`@Q=W5ZB[C8EK;E+@BV7% MQW_0.UTU7^QYH008EE`3)5S2"FH)UK!@.)[`=*0[WF/$!@D.D"L4*8^W@YF0 M>+4%:?('3>_*@VY?YF(A[WEP>8`=4SC1\IIF:5B>E^6[P*0V8:$FGDHR@9!D MC`=L,#,3O#'L)-F12(4>4H5>AJOI452CDS&I$H\<9T+=Y'@T+[DRB1*?\\EY M_DN:A\$8%XGF&3.LNVBZCSQW%(E5_1&?U7_,M%ZJIH1@7%\@G5?U&]N"`,6K M.6&:%$-*)5NNQ'Q<#]]>&"U;0EXH\T8WL5#$3JN\@[L[SZVX:(:`-/*$=R8T M=Z*W85N@YS$2L*#PQ1;2WFFR(LY'J:;6T8[LD\)H)52-?;']J5`O*`5378.) MY*Z9%>$JH[LL[.384Y"4(EB`#9PPHA/G+8?>&S'$8S;K95'Q2TZZUHQ,WE&0%\9]8#P?VXE3H^/B=*)'%2H4-A*9^"5P%GH? MX?-6]"B$D9@`UHHUKUZJZ,3XC24%=^U0,'#"[&ZNNS$L173D0N[E2@_?1A[F MP3PP"E9GY<<*47Z!`E[8OPQ+=LGQ[V\ M1G%*2,[WP3.4$&CKD19[>UM2R_$ MRG(BCOPSF1$156#M9H^R!HPG9^1Y/O-O7NG*W MI0KU2L3,DE,]<"`?&`^;@$ABN!!^<8_K07O,"A8[MR^*RR?!=7R:^Q"!%\42 M9\H6$9),)PECZ^6MJ6AE5-B5X4J MIU`%/ZK=>YJU>PVY/U3DGE8ID[<#756Q\EE917TRBBKF_F8J_ZZL&HK<58>D M_$GY;U*^EW3_<:OW[E"P\9CR19?5OB+KU99E;`>ID-VQ==2;E_#-0HY>ED5/ MYD@5,9I,"+T@1JBP;R,*^S8*0T>-3Z5YXF2C4FE?K]+[9"NN8RW?V?KH!J$? MX?'I!]-BHF[#BY65LIO3O%['!]'1=%ZX!OT)8',S%@\LW*/^!$H0=2#.C27* M"N_=BNQM_&VSN]/E=];*]O32SC_&A[9?S9")XH)?F(_'KN9C696IWKVN'!\4 M1AX4!J^:V%?ZJP#QTA8702.NG=^9WR]Y*OP_?"\(KN),G[TN&/8TS>@5D?7" M7!4M:^W-=DW3-;VR9=TDF7"?\!73]^=CSW\VL:KL7K`S-%4U7ESDZIEK6?+Z MB@%#156&-2V9)QGN`U!-5]:`$Z?8=QEK@61HRF#O9<`?R7?O1=K)5:XU_*4[ M>L=<-K;#@%?D>&<&;)1_@%^!W^_FL-'OOKB+"E9X7!BLER+J4'^9V.N'`=8N M%(-AG@IFWAU(;*^A+\=%F/J4ERI$/7M7KKAKA5N MN&MKI8$Z,+3\LM=/7_&"%PKIK*4-7>EJRE%7O&4=&TTW!JJ^WXI]^XG?O5/6]23MLLOW,XX MM>%577`1!8%-(UY.=.'Z:4J5^4L.(J$]+L3#+_\6+Z5*2Y=2YW%)4K$H_KZX M*1-?3[4S2M^T^\8R.`N77WG2*MXF$_G+/KN8,E,41`5P,=-*RZ5*P82Q4-SA M?>#8!DBEO2BDL6G[X@:OJ$,DQGA!>CXJOB&%IV?0YO$.4S!K#TGZ!>H*D MMAJ23WR5R'/+X9!/($^6*&[]YJ:'85[;/V4O);0AJ#/(`2D*DHSQ=T`(WRYN MK8GGL.1>*K\2C0],O1$3]]A?V_F!7UI!3&46KZP0`OWQNV)V<5+;]:8HZ$KG MPQ7[_)J$EY&[N)B3%7#*46A&0[EV)+PK31F.1BP`-GU`D#5*!A[ZUDO9HXC=.Q<7)M$I*D3N7Y4`J;_BW MH^W$3NY:"\A&VQL%O,2;)>JWF3O?1V@-,;3I[D'IT8RF'?IX?[#+:6"YX3Y8 M@[/*#JTK@M#RU:F&'%:KZK'[71\5O'60Y+^9F;NOQ>_[+='F@R_]7#QEVWV^ MTCMBQ=I@-?"&H)O3Y@V->./D>4,GWM@QA89XX]1Y0ZN%-ZJR.H_!&WNGF<96 M]_FDF;XO"=FA!YH%3@OE_VJSXMN>@K:'-5\N5S<6RZ6_'R?O='>6KR03%76> M="']T.OTZS.IFPK!HQC;1+H5D6X72!9)M]^IY5;1>9-NJ2U,I%L1Z2H=14/2 M[7:&]3AK)YBAOK-A>G+FY_>9..5,ZU7C7:=&QXJ;(M6:$,6H@@2,CB(J@U.D M9P_#K/UTH(J.`%*W,R!ZV-O:.0%Z4`1!!'A8WLN@5!]MG-%UZK.+*I*9[3T-U7 M0SR]'Z4+2>UTC7K(AV(J9Q!3>?(<,Q09W111.:.(RJ#7J4EL'!\^%$W9D`8T ML#Y@*T0&9QU$&2H_7@S[]=D0[1#_%"[9EFZNXP9BTMQFSHBB)!0E>9E>:E0T M304;A4B(:!I'-*T_@Q'LP/9$C[QT?8^1+0I'\-_C>@RWE^^RP56ESWN[Y^I0%(I5!)&% M%2_2\?/E.,0M:+SX'/$>CZ*F1V0Z(@,H[LK.$AB*$LC%B]$K-^S;P3>)G_7Q M([Y%H/_>N2U_U>>U+N9)\]DY?YT7M`OL(,02"6DID'1A/L-FM_RN=2=(QE9$#/Y72-[,@K8@0OEB7)5=88IQ6)\OR1 M%=E(^]%O>;^?A1-O)'/&*[W>7TK;'PI/8Y=+'"NY8B3%70MU40YFBTW$L!#0 M>V``3.`R!VN]S'P6\(>7=V29CA4YHDS7\X0AV\4-,8.`5W]Y=.W_9O5?;O.E M7F[24B_Y.4"K3THF0GF&WSXD)5,$\$"W/\[/D/\.6!,!1EXJBE`TGM;$8%;U MC]`'K;_5N"%QU'&'\1HXJ1;S>8<.+^WRK+I&9]A^TFO4A=IK7DR*:S>BR9V\ M?85HLF*:_"TJ7KGVQDND6>4=[Z7!]QVPM-QE50RE'OU([)"]JO2.2LQ5LKCUG([OY4W-IM_TEM69@2#`6IM1EG;X^Q[.`RM MI.&C]QA[%T=/O?$6L2DBW^I]BV:0[X8PJJ7 M&/5H$[)2R$HA-4162D885V6MG[QQEM68ZRZ#U7CR.5MF()DBD2O.WEK1J(M( MKMTG_Z1QSUOCMO`\O9E^0E?6N@-9U76BJ:K.C4_-4%MY1%M/`XBJ\N8:HBMC M\ZQM1EBSSCQ/B!Z.?[)YW/-+9="7E9[2C/2DUA@JYT(?/3!'-+E_/O118>CH MU.R.`P2(VD$CIVQG'.Q(ZH10'9L01SU>ZNNR,ASN+Z7;0*.'.42BP!5I==+J M).I/0:OO?83S:,*[1SK".2'R.?Y!#6FUT]%J+3QT.6X*ECS0%'DP(#-Y?Q-I M]2V]LTF867D.4T_?P[/)9CBY!)IFG=TT`ZXG?ZK3S/0"5<:R7L.>2ND%F^Z5 M[JO1?;6VL;DA&V"+#/K$YE6&_L['M*5<<#)E3R^0V`PTG'R(D7+!SUOCMC`L MV4PK[K4J&UI7'G0KR+XZIVNC-88R/_#_G9R]MS*4:1Q2&>\&W"8KX]7VWQ'V M>A:AS-.CH:>1%6-Y]#_T8`_IT@YFG1TF5!S,KI:2VB<(VA#-/AM5U M65%ZLJ(1JR]:M^+CMFV]6M.DI&SQ-:X4?WMCAT!&5NG:DX+JTH7T+NDB_J)A[F/9QX/[40AP02LAPS"IAH@O0PE\:^-Q4=F+!O&9C< MN$)N?D=N:#NB\YCI.S8,"+^^MG_*)@TGMA_.I2E`:Q)D(Z&E[DA7CL>[2WD^ MO%1\B\$BQ(_)I*9T&ST$[*\(`[4?A*4//S]/;&LB8?,VT18->Z'9+CR-VH1C M(6XN9<*74Q"WH01C8$,W3^)-XB3VW6(!;Z7U0Q?$N\+_E>QQ`2G!Q'0<@1H) M/\/WL"?I-O2L;SA.X?/[OR)P21ST/F2)+Z9TZ8`V6!0;CP4F$SP`%&$VGTD. M+BN:L[_-WE#20X&$&W()(!`K]S M8DBA\=I9"(`Z3-_HS M@:MY&$`45YYH",C+R+P'X@\79KAY=CGVPWF^JR!L M']Q4[,3'YP"4\OT$K,AZN/X\&&`.6)@;,V7:Y&_&_5WXKV-:3+BXTR@(I0?& M3SG\D3CCR/G%B0><]6S$KG'^(Z>1'$',3%O,:LY0]ZR4(F6K+L(AU]R1,O)8*+$'L*.;P8887OT03MA%G:!CG$2F,RXY_12[+!8<4$1S";:P, M'0U6;J-X=/020IX!GD")]M0,"RWQT@YNB]WP4/>NG#?K^X:/`=*`8$"@\Q%M M=Q;QT9#`Z$*`0H5P03SP&J`3Y!X6-_`]V"D$UQ!P,!P+(FDG$;NW3LL>>/F1U& MONAPN7+_B;`"'0,$8B.'VQ:``_!M\@EC2"\.R&=P]?$D6EF[BT4(+!DIR8Q$V206+Q@^%N;/2O$9)$Z+D'H-UK0T&S6FC MF>8T-H&=7W!Z:8M-K2ID5)-134;U08SJ;D?7-C&JQ[@#Y.18?BR*(K*9R68F MFWG)3(9E_"MRBM$[O=4V=3[)?4G[U4E91HG4Y8S\&.! MW7@/&0>OHT*`#P`[NK7<2M.2*!3N6ZTD6PZU-6T+;5W%12D=+KZ MCQ@94#L]]&\3P]7EL*AX@"$;!BR85Z^4Z-TM.X%YBAJ*EDP9,'L)GZ28TY^&$FF MRQF9+EJ<6P%>4*_3[XI/9,?L?U^,$B@K/"Q.CVG%663`P@`S*>*,*,R&\%R> M"07&D\4++J7M7-UY\F#Y/)G3YW[GR7IL][3[)/&(YX;70.T=E)*'1\\O]8I/_(\_6P^XD'BP6;RH"A"F^'LHULK8WPP M[7HYC_MB!U/HIRO!OOCLR?:BP%FN.%?E-#=1&(2FBSQU`,NKWAG(F"-%7%T+LVY_(E4?HFM''Y-2."5=?N:I-1[7]Q'F/ M4-^>-'P*9=S3,A=$2!49/4140%1J7Y6-GDY$1415'5'I!A"5TB6B(J*JBJ@T MN:MJ\J`WV-\_:#M15>4GG)I)_C4M=F&921F0DKH=6.*XZJT]EWNKP%"6M%=+\[@VRJ\6D=]195E7-M3^ MOOU\2981,55&3,(@/SUBJBR4?S;Q]+U;`CM>D.:W'ZXE\&F%*3:2=]27EVAE M%SU)=$-T4RG='#<<.52PW1`=G!!B*DL#JZ$FN=[G'Y_D02;8@QB3&),2L\X*V,,]M`0+L=BA`7$Q>36;TO MEU1U.>7@KK_XN%.UI\(=FM84ZVE>N:>E7CP^FYJVBT=B^3Y=2>TJ/U;SL&BHVYUH9VQ"=['EW*6PI9,YFOO>==Q5RYI+>Z?&?C8XBBJ456]Q3 MO]7%W?2U0]+/Y49X%9E7@-(^0]__SD*+AY-<_8F MNTWZ,0/VI3OZ)QMA/_A+Q!KOD8=M41TOB'QV!PSRSO&L;[_^[_](TM^71_J4 M==;[S7.MR/?QB!_%'[SYE8U_>749W-^,[U7M7E?O@:;5^WB0^VR0=_/?3.RO M>/G=#M*?_Q1T_9GS2/KM'T"Q/'/@CED3U_XK$B^%OO=TSXDWIMT;3KI?!.5^ MYI7NQ$BO>)-)OC*\OJYJKX`>+9":3H#UW'X=#HV>UB\#6NE6*X.+)O9PE=8( MO!F+_(ML?S%$`E'/Y9HG7WSA1?LVVYH*7A4X54W;6X):\55^6UB?`Q'.,H+< MAASBNH<[DX*J&ZJA=(\!K_IX9%^@:%U5&_0&IP64*@1'3^MJ_9YR>,#HZU9F M@'(&W7R$E9VP3'MY;XV5:1='!%BRP10$[^;IG_^TP87RK7G)\FM\))B&+'+'@_E"Z1A%B3^+@XY"H'Y5 MN*?&V`[^]L8.3=CZBFRT-,#U(0UPY6(N^5.-Q``^^:!6X\+W<1!>FIB!9'/W M`SLT3#U7$CVMTL"J[2)9NQC5A!^?[;B=`_L.PBBYU&XQ/S3A07&)/8EKNH]! M)P>E]*_;R)KD`K<^6QTA=3)V!)Z&'T2O!I`$=H`7:'#R#Y>W[Z3+VRMIH':7 M0X15TG/`([IQP%!ZG1'RU=MX_NRKZY*#[6WQQ*=#^.#5(G^$T`D1`+8OXN%` M3-]8&(?%30X,9@)L?3;S_!#7*+I:;("%D2>Y7BA-&0L3]$Y%_#NJ8C M!1,OS)''';\$(A_F"O(GR#%M%>ZU:NLV4CQ'&$%I15`'M_@PHWBZ3.V M!EEUG2M'HI8IH)>GD54WRDK!%K-.3$MT7G5T@;GB%J"-\@H/.>'==6=)%\6S M)/$P$'FB<">(,'BV$S.G<(Z]C@] M+(N7*XZD5K5B1NG"Y8>0&A)SRR5'7GV$DPC(/H"7^9XN."TSGGD0Q4SQ/($Y M8"JTBSEK>0\!\Y]X?QG@!9,?E\6RC+>X2N')EYZ#.Q>'%O(E[,^99VHCD(*" M-(-AN06>.US$30DMH2ER'6H"+7:)F^Q2WF;?6PF4HF";`]2EH],@=VRZ]7GF MLT"FY40YX7BD,\T6B[?:#SD7?9,%'R;U]&_&R,K,#3BW?F4.*K@K+PB#6Q0K M[\R`C;Z8N0'(S2WA1$M?@!W)"3LD/7UTI7]% M;JX_@J8H1CX_2C)'8#:@B0S?I1:`M(0VF9<;``9%@?P:'\X;G7Q4CMV\:R+' MINKSQ`:]&YF7XONH+"AT-?!8'"QRLW([C/ M^((E$1;@CA#@>V/ENU@SG+!'?"9VJ@M$1DYOY9-H.MPH+U)5A(5W( M&=H+C1)=XD0W9V(F$BL.)&D](4<2?O">8@R:43CQ?%XBQ>7MWH3_+)Z*;4 M@38'[YC)XO5R=N;"3)=[O1[\VR^H@'+89ZY7";S1W^%NSR@.1>5%4%"ZO2*D M"T`5@OP!K4_>.38Q4%'^P-_"%\1W?]#`>]&,G(>!4/-9+FH$&\,<=WP=9IV9 M-I_!,F?HS>TE2TXTEWQX<#LH3]="K`!]Q@FX@+Y9Y`.-`-:'!0,%(\_%F'6F MO!'ITCO/!#U\'1LG7!"@`0-Z-,B,"$PXAS]P-!_^QKB#>`]U66+7%$*-R1BK M3)5@@37LZ92-;)&9C@;'"O6Y'&4*)W::A[R.@Q!P65:-'A26G1@Q+^7<&L_^A:'6%SO1>'*/`%K`D1)HS\$LL> M'_[X)4^:/Y715:(%4'$)4U^3N\J+G+3"`A,K22D1/8&'N0AW+G$,4N&B@Q/' MIA9?YI&&.*:?&*^W#'R?HAFI]F.K]-)U\6I)_K4"?WYF#(WZG4S>!1M5[ZOR M0->VL%$%4HBYCFNB ME*=*ZJ.ULBWW259.TSO]IJ)G0]C64AFQ/\3SZ4'&#/L;XLV@0V)W8O=FHN>8 M[-XUAK+1ZU;&[J3=CT]/Q.[$[JL*DNL]634JTN[":6P&'1[?>3Q!%W&#_*;Z MG,1V4$\+8V)'E3^RUC=D=="KTK\@2CE)2C&TH3P8#JLT38E23I!2]&%7'@ZU M*FV:=M`)A;VWS@;F9:Y77GN@@'>C7&)8KS3R(DR,W%0.-0/0Y^(45XJ@8ZH0 M35;ZBJP.#0I[$],3TY\'TZORL#^4]5YU3$^:O@DT14Q/3+_ZO$O79-50*`!> M1]/'BU<5,[779',9],?B=)BN=)X<>&O0E&2=;V7TBIR2?>E MI&*`N)FW6#YO).I2X`.\*@OL9F1;?+D/#)ZGBWS57>3KZTL7^7@/L?TN\NG# MCG[88&@+[[88+3;E(I]>4??1%N1UD[`[9V'W MLD/4XXQ`E_ MT0F[*`,5/91!CSQKHIVM:4=XMTJ-QDI3P4?$LR_Q#!4DGF&?`B,4&-G1SL'4 M:NFU[8IDYY\H1').#E*WHTAS?[F].+G)1`5$!40%%#&AB,E&3=+BOM(4*6F3 MPR(NG!Z25G[`^U[@L?S0Z_3KRZUNJL='Y+,O^70[71W)9]!1NT0^1#Y;DH_2 MZ7+I8W0&?8J8;&8!B8]T7?Y0U^7QMS?84]ZVMDF:7C:]=H(2;WYLO)7>\>)Q MZ6U[V&><06-%_A/C,P:\>_'OG=N.=.0]`'^8<=-RO&8_-=F>X\6]+P;2#ERP-4TW><"+-" MPER7:K47/68MSK'ULNN%TLRT1Q+0B#2*YPV07`O]QP,;VVK;(6]JS^*R$M@, MR&-B#-,-;(?O,S#E6?2@,AF\6!K3=N&X$]A9BHH-W!`3.B!J;1HT;G>-7 M)R(G-E`(N,"FDY\0I)DIH2TPPS]GC/F\'J?IHCSD\M$,0]]^B%":!C;`R?11 M+J;43G356+KBZJIB(9=7AW'Q&CZ-SV8H<=PPX,0V8[[MC81"#7(MZN.2.::? MUZJ>],`D+PJ#$$0?BKB'/-T"TVS#-U,63F#4&=`>B$#>S_XV-,=CZ=*R MP)KE;>W?18[#X"_I=;;PJ[>WE^^RC]=O?Y)^\SH9TE6E+^\"J'68N)W`1B\$ M%WXQY]C:;6]TR$L;6]I+8:>R]#RQL<7<$_.!80'V<>&BHN4BKE.RT47\G/2$ M)9``GC$F42D5[2`TK?(K@97;6,G(M1W'S"]!"A`,F564\5KZU^_`.;Y4MA8_3C`5_`.;]E&HV6X#-3;8Y*&8P#(MEE8#4;$NR8(4F;,T'&6E;P1OIM?U3 MM@Q>P@FFS$]FAA_/`%%<-B<)%[GA\ICRO7Q[4YC$"[)YR\737>;O94\61DPU%AKD.4L+1:9O,[#M MB=P/3>[+5?V6E%RNN!_@*5%40#..D^J=1/HO%=WC]:2DTC)2$I(]_W]=YD2+ MY0CD/'4'21Q!$#:O%KAMD4`8Y`>MHPYE#!=V#3$3?@-3I=N140V@WK:?F#,G M*CP^%4:NSRSOT85?%IH?6!Z&RIACQF8QZDM4YO"I$%DJ&,L@*%?3(">)E3_K M@H8,>=#39$57!`'IL?0HC+Q4_+9X,KV*-;,]V-$-!$_BOV MN'GO.&*%JEGAS]@FK94!+H6]6^L<[^.P7*V3?,',R(S`OX`0J7,Z'A8GL4%B MHW%BXR.XJ[8;V%:M]/\'!ISJH?^3O\J@=0RJDE^+JI0.HYRH6= M/MGC.GA-Y8YQ*],E]W':S^?.R#O3,3$W*Q=^DE?'+M4Z[I4(>Z;MR;I[1`.: M49]P0QC5U!75T'JR.M2(CC9.<*^TZU[#ZEP>4@+6T111Z0R)S4M:(G8TXG#B M<.+PQJ/GJ+?#\CE5M<4/FD'>1XDC$)E60J:]3C]#%\^5JLT!;SNQ5NB:GYH# M_H\DZ[K)!P7-$6?H/A_3A%5E;6C(O=Z`$+-LK9)AF!B&QR11O=,WSHTZMSU- M/*KQ43E3'82CKW?[^!-$&@Z`^!X%,HV8$H*LP]MLE MVB@`30'H=B.-`M`G'H#>+M5?HS!U#>9L,U*OCFH(R:DJ3/(4FZJ\E= MRI.N+PVB&23>;..SF:QA`/Y(Q!&MGP.M:_VN;.Q=\JLQ)'#6H6+*E:8([U[" MCW*E]T\N.9MLDHS88=?6E8#2#O9IM^#:3-_H=A0+5.QO+#8WA'<:,/A6DMSA82_G*%&,] M8'J(0:'8(^2`P'JED1<].*P5:B?7:2-XL#MB0/W>D2=1)W-I$Y- M'B@#61GL6]BE-4'3UD2ZJZ#9?J=WJ-R(=F"?0N8[4-$?+,!X.5CL$A.U1DRP M#S/37:K=8F^[4[BC+?^",5Z7,=_,P*$F&[HAJUH%/9K/@I0H4M[R2#DX#71] M@6C]+&A=E8=#158'^W;R:@P1G/4I034IW1JE=._DT(B/:)XOVFN`XW+SSI'>V]4UVF7IE[=7TITWLRVIKPXDG_T5V3[, M%D[,4++,8"*!T'L.X(<@U,I-+]+(S:*K-#VW`#&!Z?*8D$@>6-X ME4E6-(T<,[2?X$]O.F-N8.*3\"$(82S+>W1A&2-I[/F2-Q.#L+0$Y.MX,)SE M@;EL;(?!3_"79#EF$-AC&QVY0"S/=L4"^;+&MFNZ%J[2A)4]V:$-6T&7CS_J M16'N66_&?#,L/MO)(3+]ZSIB4NA)=[[W9#[":O@O?_L.ON+P+8QNQ7N%-8U@ MI98=2C,OL'%/,NB4PB:DB0D0>6#,S0,!H,=AED`;T`?#38$6.CN24WMX(>%P M,0N,],LKE0_S0F9;7B)(^0]__SD*+AY-<_;FV@XLQPLBG]V,KW($^)5Q3%T! M&0:W$]-G[TP@N"_F'*$=W`$7OG,\Z]NO__L_DO3W;+`G&SAS%'SQV9CY/AO= MAO`0$+.+?/N5C7]Y=1WY?()[%?[!+EKW=]X]_+\N/KV2(M<63_X.?^`7(V;9 M@)C@EU?*JU_U@68H^>67SECYLN[CL>YO$XJ[0@Z[&?.1+K_;0?K$E><^,3^T M02H7Y_O,PR>MV>![$'#A'&G"F*VCW\L@Y(4TW98!TTMDAF^,#_1 MEV`J[J'Y]/RBM%>_7BB=P3!;5.E\^RZ),["^2FZ6K$CI'V)%JT5YR9+Z2EU+ M,G)+ZMWKRJ8KTHVZ5M3/K6BXQ8JT;FUH4W;%FU+?FG*21%\EP$M6I-9-W&MT M2AEQ]VHF;B-/W)NL2*EM1?W;#J9-XQOV7 M5:E*J795E:F5_9=5AVK9?U5UJ)<*4%B+BJF,M"I5,]6N:BN1-7A!C%9&\%NK MFWJ!58?*J8[@JU4[&ZWKB^?8UCP-]VU%8K_&AX)I]#%W0"A"L"*O!0.B\6>1 MIU(X@UD5N:TQ3(N_O;%#$[9>&KC]C872)R\()("2Q,%T\M'G1IW$"`L-3RM& M,=NX@!$',3(#C`2($=H/45>#J+O M3R8)+_%%+9/)+CN7^3F0Z3@XINV-/^$TE$GFDVD[+^TH.9;RIK,H%,=WWK@$LBQ/$'R?%6PD M0[:T@J5W&?968"$*8N8Q'8L?4R(VQ&[V7_EJ0F/?.1+PZ-)T0YO/B">D".6Q MYSC>,RXD?O:OR'XR'8S\O:E*DK5&+N<7=UPK)$KMD5QLJ3U4Z8/;% M8)>,%2&LWCP`P^?&&JS!6369*WI'J^A&4"[+QT*=X1_C^GMWS?7WKB[RG8Y7 M:>2HH*Z#/$LOW=:28U753:]C4.I";A6),Q)GNZ9L=CN]7M6E^L]AL MJ9$4ZG[$J!,Q$C$VA1@U,N;J,^;.Y^;O39Q?'GK2+/*MB1DPZ4K$942>5FTR MK^WW,HYG%IY$!Z>XJD\&;Z(HHJ@J>H(111%%54)1NMQ755E7]&HHJDF7F!MA M9)V:*?6GZ6.+F5);*JC7EFH'[6PCC8[)^%U9ZZIRKZ=4J4H(156BJ"=K.MB/ M@XID,Z&H#A0-!UU9Z5?$185NJ^5R=R@L<0HA MV6::_#U=5C7R((FV)L&B0Z[A^Y-TKK\^^JZMS3B.M$&W32KZE?2J*S/0]WI(7(A MM:VK&G_V_%LTQ?8QL,7:!%W;,QB-Z(WH[57H[ MR2Z)!XS+-=\:2PZU&^UU-H<=#IUZ4@6.Z^DHW%>.>X7LM6K(NC&0C>%P?R)M M`QI_JL7_)H)N#D&K\L!0Y'Y_0`1-!'T:!-U3#%E3U/UMT#:@<3N"INCA#B"^ M'/TG"D)L\\@['U@3TWW$(OW2V+1]A%7$L-8^N'+VD^BB;;M!Z$>\2[%T(3W' M=3@H]G@ZARW-O)#W6I,-39-UO5\G49V>6#PI`CQJ<*@*W&6I\$9]J3PD,XED M6T.R%!(]EY`H;W:$5F9R`ZAX^XP0V%`I)0P!&1<-PH1$_N]Q5Y MH/82JF6$B2K,DI!/2">D4 MS:5H[AKCX)JYWM1VZ[UPU`XJV54TG+0`(`02`@F!QU?![4`@^><[J.`_^6K8 M2#*?F&\^,G%\&I^OAAYPPW06A4QZ,`/;.M0A:]M-ONKM_&.&!=6!/,2HX$`A MS)X89GORL#^0-54CS)X89G59Z?7DGK(7SY(#?N(.>):QSYM?^FSL,"N4S""( MIJ#_V7?F6W;`L_9K3\YO!S'M+":.ETYZ7`W3DP=Z!>J%J*,=U;!.+J68R(_( M[^@9[>T@/PK`U!B`6=WI@L(P]8K#9I0R.JH5-Y25OBJK%"<@HJ+@$Q%5@XF* MXEX4]VI$5FH[:(0.O0F!A$!"8,,02%&/$X]Z_+84Q4@"'!3-V)-S],;LM0I" MJ?&27R,=F-=*9U#!)=IS+$I%C''BC-&O-0&M#4@GQB#&*-,8>U797A?M:@/2 MMV.,!9-=?,2&Z8NP37XMV_)R4ZL\$!K=.GZ6[%/,`B/]\DKEP[S0:B`/%RG_ MX>\_1\'%HVG.WKPW?1=$1?"%^;=HTW_Q'-N:WP&@WCF>]>W7__T?2?I[^O!X MS"RL`OO1M;PINS._?S5#=@53VVX$H]S,L!65[;D!^,8N0OLK&__RZCH2W]ZK M\`^>NM_?>?>J=J^+3Z^DR+7%D[_#'_C%B%DVX")`U_I7;&2?6_#&:]AD[5\9 M+-2R'9N_>+C:3>G==9O::G';[_:*%_O]Z%ZS,?-] M-H*'+H.`A<$?IA.)*1W'>S9=J]*=7R@=0]]NZUNL='LP(#C9I3OZY%FFDS[' MJB;AWG9;7K6JA?U-9XXW9^R6^4^VQ3@'OS,#-KKRIC/F!GRHWSSWB07@IU\^ MF_XHN/-"T\G_?N4%X6]>^&\6XA(>79`M(Q`'MC?ZX/GQ5_B<^B)$]`)$]/MX MB?=\TKOYC%U^MX/TVW3A(0B9FQD.])EWQ'[UZY?>OP>?5>TZ!Z^#[K*Q$%Z@ MN3T@K/_[Q(&;VW21CR^#^YMQ%62ZP/!:GN&55[_J?5WO=_4#@#F_U89!=W<2 M70-=8]#3%%UI/G1!9+]C+AOC9L#NA`$_^-[T?9RC?S->"\]W2.-W(QO0$'Z8,MQ M:N'??^']!]@7Q[08O_N`KY03B[Z@>XVB^?C">HL[^V#:/MH7[!*O5HB]O_\^ M`\W-1M?VDSUB[FBM5;BXR83TK].&"N_FOX$YYQMK0W!4`-8%ME3!#8=K(0 M"&SE8.OEP-:[UY4BU*[`T[###R;:Y.&\`+%/X-/?C,4#"V#[Y+F/(?.GU^PA M7-)XM\P"X(_PMU.#]AWL^7"B\"LZA(7G/IO?[6DTW0:L-I:R,9W5($5?9/AY M,ZCA_D\:6AL1(4+L).%ENS50ET:PVHJV5.4XS%BI.7)(9NR"^%('UR<)M/JH M[#A$UC#C[=5X`>PF2%/NM\H# M^S6^=))F^.E?B&&)HUCZS$Q$,,]:VW%W[;FELNK237QM7>\=DJKN)DP:>W@S`+A< MXK>%I!FPFJB=##]B"J3ISK-ZD,.W`5929O"[Z8XDQS8?4&S9#)\W0PDOO4\% M/D?\"3_-%)7@YS%B_8ECW7,E$W^-?$QDY+T8`LER8'![;,/3$0#$YXLP9S/? MF_DVRE>'/3$'2S?C#[G1)C;S3=^:S&%U^/,UL[BXRI"CJ[*$$H&O"BV#-Z=. M:SE)EUSY4WY,K]H);%O,<>++D)@7RS\',]-*/L?OQW6S+*`5,F,P2[7]LH%X*!E=9F6K_X=H4Z,JJXI%+-;[:YJ M-UP'D:`ZS.#&]6+VL:`@TV_-L):+TS74X3D8/551MH:$#@F=%96,3J:B^/'E M7:E]EGU`0XVD&TDWDFY[2[>C5-T]<^GV?Y&'5=]2I&$F7+S4/`_"=> M*ZE6$>;.HIKEU:+HT$ATD.@X7]'QN^N=+&OKQ-K$VLUC;5XTAD(W^X5N@!++ MXS;G4TQ=.'=O:I-QS:@->W19UXSN2B?=]X'HC>B-Z(WHC>B-Z(WHK2I/H.WT M5I5'<&IV_V<@\;DTY<=+TAC0*[UN^/E'<_A";W\LXY"D5F-3C>,A84,(UM*U M0^O+JJ;+W4$_HVWB4>)1XM%:@[[;F6=58"6[#V(T.P.+^)[XGOB>^+ZQ\0(R M#8]]'-@>5_]\#O_X(;*T(K^3(I9[6QY[1"EAO=+(B_#NZ*9RIQF`;I55TA0$ MG9+*(*YO"%$1US>$2#U9=2>=.T?$0\1#Q$/$0\1#Q-,BXJ'3WE,^ M[A:UXP.)0C"GDXY"44,BV19D3C8#S*V*&9X.>DB* MD!1I`9F2%*D-/<<\=]!E1>G)BJ92`A0Q/#$\,3R=,R9;IW/&.$G^I:+$YQFU M;7P6"BF`1N2:D'](O-]*HB/>;P0:B/>)]XGWV\?[)^3@$9L2FQ*;-IY-6YR^ M(C[R_@D+,$I^I1;)XOV8G*E%,O7S:T2WTI/K+$$MDH\032>A0T*'6B0WM$6R M3M*-I!M)M[VE&[5(IA;)U")YQUFI1?))2SDRX?8@4VJ1W/P^JM0BF43'&8L. M:I%,K$VL32V2CTZ96X9NZ-X\M4AN19R'6CH2O1&]$;T1O1&]$;T1O5&+9+KX MN9_=3RV2=^<+:L/8S-SRL^F#UY7[BB[KND(W0(A'B4?I@B;Q/?$]\3WQ_>GR M?8O.&D_)-&SQK4,Z_*,6R4>V/)K2]XJLDD;<1F]FON+ZTT;0 MZ?LIS2!PDB0D24X;021)2)*T@E!)DI`GLD7PJAG$>/RPUJD%KZA%(AXB'B(>,Z4>.BT]Y1/>Z^I17(31%9SNI11U/"<2+;AF9/-`'.K M8H:G@QZ2(B1%6D"F)$5J0\\QSQT,V=!5>="G%LG$\,3PQ/!TSDCGC-0BN?59 M**0`&I%K0OXA\7XKB8YXOQ%H(-XGWB?>;Q_OGY"#1VQ*;$ILVG@V;7'ZBOAX MUBV2EWY_^VI=V^1T`#_]:[1`$^ER\R#,?LMV5GA2K#Z'L[+@5_PWI^SBR)(Z M`%*$`:5%2!9AGBYH"ZR]S>'_59&^\BC,/;4%@XL1ETI!9A0[*Q+L:%>X[XR! M`M#SZ*@)L%NRAHC\QK(WZ5EB.=&(P=(#R90L;SH#^0L#>F/),H.)9+HC\0?[ M*[)A1]A]6/)<*9PPR;3P>=.=`\'#JRY7#3Q;Z\%T3-<"KIDP%G96J*8%\/V< M\212LW%X>8]=ZN`>;]-W('.!][CN,](\)CN M'P*I2$$TA67/.?%,3/<1%F8+4AF;MH\,$3'\$;^Y$J23N;##MX&TV-VFD`H( ML_`WY\ST`XFY2+6E'60E=(@YY6('V3<[0KVE!+2),ENCN)+W8]L,5N28LX"] M2?Z(Y:,T4+A)(V`F3,"NL22?MFY..^BH1NLKM&U(*A4WWRDAGFL66+X]"VW/ MK2%$I'=4K;T->;;/E]4[_4'K:;,IK:)*J/6=,!PR%)JU]88KY96R?N2'F[^F MAN=GR*3M5R`-9M+?79_!RO[+1@?DC=>/INT&/V5T4U^KZ9+9'2\(:LFM(-XD MWJQ7@>;:LWOC\U*F1@T,JW8TH[T,NQ#8K=!!:V7/HR:G]Y6RU+H[DG_6>$=2 MJ*JV)Y)NS.7'/OIJ!J"K)^(Z3BJU3G?9+6\*NAIQADF,3XQ_FHS?:RRZCLGX MKU79T+KRH*O4R?GM(\*?JB="DADD,TY"9NBRHO1D1=O+6!#^<3/H\<@)4$OG M]G2D?)PC9:W7T999OFU1Q\;$&.E(N/?8)9C.+B)^9D?*&C'I3G8B,6:] MC/G!M'-L\02QLBV)MR^=%OVC<#T.TXNFK`C?QF'ET-Y'ZO*_>T`3'^'O8I M41+X7%W94/MUITRU3YS5D#A!1+B*"%59&1BRJAHDSHB2CI\`*GS!ME/2@D\H M/E*AB886FHC2@*O$HZ"2YTLB(IF4'QF5>XFFS\!3M)!9DZHFO!8%EJ(HEJ%8 M,4!#/FFWB"$G1RH$__NI3&MFNZEFTZ,&80^A&^6!S/ MP8(7TK,=3I8+94QL&-ZW)G/)#J0',X#MQ#MWO&<6A/'+L!!8)LPPBT+XU0SQ M\0`(U![;%OC(Z"XOC#QE9A#Y?!_E*P\E9EH3`./,\T,L]@$[M;V1G`<,_/ID ML^=`E(()>"$0K+F1!R5?#B(DB![^PRR^ELO;*^G.F]F6-%"[%X:RY0I,QUDU M&Q8(>9[8\-KJ_19@F8=2Y'H/`?.?>#83!R8GN0QQ03*V;X[PB;'/_HK@>V?. M%P)3^@Q6`'@S.4&%(0P$([B>-/-MB^&+;C`#:+C6G`,E.P%$.EVL?=+9D8G; M*H^*T5$8]Y=7*A_FA1A/7FI+^0]__SD*+AY-<_8&3YGYV?*U'5@@0(`.@CN0 M<^\G1CQS]N:+J_Q'_GW:O:O1Y_BN>\Q_G$6,R:N#90U.5W.[@/?>_I M_IWM>E.0'C<\U>H+$!$PPF<63KS19QYR?O5K;`BD^\\9!?D)"@`=./!4:@IS6IX+O'?1#8=J@WLEMJ["@I2.EW]1XR? MJ)V>^F-M9D[;R:4JT72R`HA]GS$+LVB>/,<,,;XQKR>)YC3-G_8+DJ'RHW0Q M[-R']H'R8X[:JDG;YO"O@&M-/(<%='B<_]3^4C9:9?6'3_?P6&WQ>=U&>U15NEY:,4G^&VR)#$N\ MN]02;59TB?.%:Z/IA]JJEU?5A+*YO*$1;YP\;]1SX_GT>4,GWCAYWJ@G!^J, MNEXLA]1BJ_N,8OU!:$_-Y6#_';B7YB,#CK:\Z113Z.N+_*LG$,S=PYIO9:&) M!@8-?T"=)UU(/_0Z_?I,ZJ9"\"C&-I%N1:3;!9)%TNUWU`&1[B%L82+=RHYZ M%0U)M]L9UE2>Z@3,@ZH,TY,S/P]WUEM5K+@I4JT)48PJ2,#H*#6>[QX?1HC="&IG:Y1#_E03.4,8BIU7_RCB$HSI<>@UZE);!P?/A1-V9`&-+`^8"M$ M!F<=1!DJ/]9V!9C"):<;+KFVGVR8>R3-;>:,*$I"49(U14O(RZ40"1'-T8GF M]$,C-1'-"09$Q$>Z(7R<&\*Y83Z+JN2C&_\V0LC+UWM+8J`-9Y$J;0QJG.@-\16ZV[V:IWNT=WO_54UD!,0 M'6Q255^]O.%N]_@;KH-(7NS\_CEKUI!KZ6J&%++:+WQ!0H>$SA9"A^Z(5D>? M=->?I!M)MT-(-VV-<*OEOMJ92[?_B[R0C3*D8:VIDH+F55Z"M]ULNDL+_?!: MI_ML^M]8WAH%G[_6"3_B`8]MF;E^8)>\YUFMLYIN#HNY0$6MD[Y>Z'NF_D12 MKAXI1R;<'F1Z:Z>M`FMEAQOL(UCO#&F;PWI%&(^:'E1T:"0Z2'22'8Z!2ZJ3BOSJ@X6Z/Q>77"N7M3FXQK>PI#,^(\S2SN MTJPVAD1O1&]$;T1O1&]$;T1O[)1XM%:@[[;F6=58(6SQ=^^8Y9>LS.P MB.^)[XGOB>\;&R\@T_#8QX'M/RPUJD%KW+7A.M+7V\'B500)']!B-2357?2N7-$/$0\1#Q$ M/$0\1#PM(AXZ[3WET]YKYMM/O'2PY&2VL^0SQ\3F3*&7]+P.ZFBO<%HAF!:E MHU#4D$BV!9F3S0!SJV*&IX,>DB(D15I`IB1%:D//,<\==%E1>K*BJ90`10Q/ M#$\,3^>,R=;IG#%.DG^I*/%Y1FT;GX5""J`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`#_] M:[0P3M;++@_#W(_9WI3\HV+].:R5A;_BOSEM%X>6U`$0(PPH+<*R"/5T15O@ M[6V.`EX5*2R/Q*W[9O.QQ8A+Q2`SFIT527:T"O+*"X#'W[*_ML1``>AY=-0$ MV"V90\1^8^F;="VQG&C$8.F!9$J6-YV!!(8!O;%DF<%$,MV1^(/]%=FP(^P_ M+'FN%$Z89%KXO.G.@>3A597]YI<;3K%3O>0!)^0]__SD*+AY-<_8&^TKS M;M*Y.''<3GITXWYE5N3[@,%W9F`'=Z!%WSF>]>W7__T?2?K[+D/D&^[PGCCP ML^=:\)89VIZ;SH`4@TK[*QO_\NHZ\OFO]RK\@Q[M_9UWKVKWNOCTZM=84J?; MS$GMQ8;S\6=A5!3X917UY*/X>N]`Y+2]ICIY-;M&I2;OQU8C\*-CS@+V)ODC MEMO20.'&5IXNNL:2W-RZ;>Z@HQJMKQVW(7'4T^\YL'Q[AFQ>0[A*[ZA:>YL# M;9^[JW?Z@]938Z/:5KT31DN&-+/>SG3E_<_KG+&FENIGR'KM5P2-8KW?79_! M6O[+1K72_^M'TW:#GS+:J+EAM>,%02TY&<1QQ'%5*[M<(W=O?'J*SZB!#=6. M9K27#1?"O!4Z1:WL@-3X9+_U=R3_K/&.I%`Y;4\DW9BOCWWTU0Q`-_5L4NMT MEYW?IB"H$:>6Q.K$ZJ?"ZKW&(NB8K/Y:E0VM*P^Z2IV\W@:R^ZEZLB.Y0'*A MI7)!EQ6E)RO:7B:`\&R;08%'3F1:.ARF(]=#';EJO8ZVS.1MB_O1D6LCPU_; M1Z&[QRZ7=`91Z!,\8&@KZRW$MRJ,L5`&!V5P-#.FNRE?'_T.>3,`W=3CFP;< M+F_F\Z'KBXTZ9#`47M36I#$VHC;!I88,5I1/B8:<`^3_M M<+(T6E`0%05*WXZ/[WO1=>"QXL9Z"7JBGH-_'J[M/5_=N MGDYQA40T>JDR0'X5.!2 M[0_5%[=W9`CJZZ!@@#H%;7KB4*B3CLX"@FMEE*XH/44[$A1NQA]LUX0Q3.>C M&X1^A),%7\!?I0A@)>,,T.7JZT)O,::Q$^[C.+V9R30C["J/2( MH5-6D^Q/)DU,>,X<>3,\?OAP>?M.NKR]D@::LFQ55T270OKDY$3`EWUM!Y;C MX7>!]#HK;'WU-EY/]M5U231G6X1(8\_/,0:H!!:O(W\L$TY,@*G/`/2`$5\< MT#PP:1K[!Q+\/$YY3>;O@UM]L?G`KA=N-CA6W#.1!(2TE!Y07)8B]6["`E;. M]'S*(.1'33!Z"(SLPYC!C%F<7B9`C9YO6_"6!4J15_4SIX+0GB>V!20ZF_G> M=U`$()@!+X#$7D&LV5_72.IVD-N)S=ECMWT$^5ULN$ M_HB7FGP&>X-+KR!Z"+V9;:'8`%]4YJ4JKT2ARH2]0/HR/P17:!6+KN<^*0KP M;QP\G/B,7GKM0/<9TE;_AQ:M[X`LMRSRG%Z&B#P]9\WO.P)#_- M[7SZX#F%3A,?E'?].CI-J)U!:VICKT>[JG;4BG**#GE&]HD]L5P"LRIE)EVBF(TI?4&TG-1DC-^G/02,(UX[CT'`0.V6[ME$(UV&X:V6X-EVSU MV&Z!#1.;_LN6VUOIKQ>,OM6CQ*\7@Y=BZ+<\?#+U1LRYX/%GQL$=B3,>Z7G" M_#3:@6]FAT(XG_@Y`.388U@#`"$.*>)`_N(;9'B2X=EVD4^&9\/%,QF>9'B> MO!2JP?#4R?!LN&2K`NFYM)N-C+9"7O8<^+CR7:FK#WI M^:5N/>F@Z\]\7W9LP/YU\

    BFCJ>W:0$L\ M!^G]]QES`U8E76B#O@;_Y-;[\MS5+71+8N@:?4W1!T=8Z);X[PY411GL"M&/ MTQF($R2)&_\:)*`7F,[-^)/G/G["0,`ESZ\0V>:@Y#ZZH>D^VB"QQ0]"UHC_ M;V)GR!H5P[ITN0RPF"+XT1VQ,>`B9#S8@O"]X`"6!"`W42>MUH6-2CVZRZ44 M^>S)9L\!ST)S/,PU%N82R4Q>")897\]%80%HD,V\$.-] MIN/`!)S*V*@TT^CC.%F`![8<4*&=T23[#G*AF%P%:F(,-(0+R#\98LH<;!Q7 M$(C4)Y]9'MB'<;HWCLS["8_'S`JSM3[,4V!A6A38FGQ3^.A"8A^.$$28V2?> M9-\MQD9BK@AV$/!\61B9?9^)*<813TSD";=CQWLNSSK\6+ZP+'HVU)#YCZAZ3L/?Q'Y)P*5$:AG>ZM=&$KT_D2 MNG%Y9-[U$L3P^'F1[S!>CVN<,Q-PR5SLW5U:CDE"]# MVF^7X8LR\\[WGDS4(-PJ&[,1ND-#,>7RU5Z!?846N;4JXG)+5Y!(%AIUALJXX29VO`!5HO"*Q#I4K M$$3&OY@?L'DZ]`^JVNDN#!&$H/:$5H\'@9_^9;J1Z<^7H*UOO\.O_%?\]UJR MP'Q`T\%\,FV'!QCYU9X88[/(![G,RH#0&PYD15$Z$JK?Y/FRD9]A;TM06;$; MK;MN-VB/%JV$D%_8X?!$&.>7$)K?TV7@A9>(FQNX#,>>@B$ES(,'$R\0P&`S M,Q!WP!+;-C-JO&>PAH*)/<,9,Y`"?((([1\8\B->17$1".B/1&B3@.EWB_:- MY^8V.M#66C&(I-3+B9V9;`7)LOC=L]3C0;1MOH0,L[A?]`H8#!`;X0M>1;(J MV*,`O7"F.,0!JAR4Z/^WE(+GGUO M,/5TT63K;`JT(I6B^(FR.[*I<8#W3:/0\^= M["^VX4+KJ9MH8,TQM`[KQ&8;3OI_JI[*&XUYO;L/QG51QZ\1_%L%]G_<)S5C M9V5S:BKE-N35$LSOL@@@C%.%@N[=`[AA8WNYZ555VN3T=,91-<-@6)%>:`/_ MUR?]CXG#WOXBG@0Y>0UY^'YAX(%BP$+Z&+)I'1V"R#5HAH'X6M<4<@S.SS'0 MR"\XMCHY-:7Q1W)!4C(=QWOF-:QLU_*9&3#I]8B)OVI@-/(,ZK`J9650D6M` MB*DVF*>?G\'_$UG\]0+X!H^)9>FG]J4UU@J37K=CEZ1 MP-P00X-=U&+YS:+!&IPU34DNM[PXG$X!<@*B@TUV7[V\7UWI]+2C!B2."NHZ MR//?>$]6GD\62C5\SE'O5YVLVL3=\TX MY6B[0B[]??L3UI,.5)XOO96H6:*W`]1[5VL_!6^/]MQ51VH-U9%X)[FDV$RC MW8+F<(;>PO2]'ZK'K:IUND?.Q%2'LJ(J\I!R9(E&5]%H3SDRC1JRIJJRL1^- M5N?%MD?K5N^S-E4?EY8?2RONYFIVD2=;M2?;R(3=N)(UC\1%&+SH923="I[12UI:3MG%!'(XVI87<511H\FZILL]P?2Z2M5UCO47R4W;EP*KU(WG1(''/D-JJA[]C84E'ATY M=!NG3;6^RDK[<[:Z5.QF3[Q0L1OB_7;R?N\4T'#*O-_B,(SXN&W-I-94T&E6 MB21LWSJRQV"),BQ$_L#"9\9<7A^IV/<.2R#IW1^QWRS8J[S.3UP@,.G$:5IA M9#JYLH'I>_]EOH28W_#-M+PM//?`R3XF>>'O,VWY^-,0..B*W'9'+RW-+[^@"LUL3Q7WOL=]X-$,>&GDS\8H9Y!J*CSQ`#!(T;^Z-7;\ M"\J[B):#4K%1CG.^3$<$.(2@L43;\Y]AQ3/FFDYHPR)\YIAQ$_J<)IJ: M(;S`6Z+GOF7?,7E7:#!N7O+5/Z`"A*=$?W(89P0#[LJ=[6'&(MW!2+^\4@5A MK39/\\:9E/_P]Y^CX.+1-&=O!(T#B5_;@>5X0>2S.^#Q=XYG??OU?_]'DOZ^ M]"0+OI@V1JU=E`9?V?B75]>1H,)[%?Y!O7M_Y]VKVKTN/KT"?P="-9Q9PU$_@C!K0,1`XB/PH29T"X(Z@>'-M\ ML!T[G$OF;.9[IC5![6@6]7F^8GJIFOL=-NS#R.@+QT$ ME256KT6E^L1P?M2C((E*5WZ]N$CNQXU];YIS'X."_YC9&>A)LBENB?N*:`R` M3\87MD+QKUHO?,8UFZ/_1`%N$:%N@2W^R+AN3YS.()W(,<&DX:!)'L/W088A M\$IW6I+BD`'*'PF0`R0B:X5MCY.M\QC,O$FTPAU8X>;B-$'`H0GP@]GX]5.` M`PY0[N[8B+"_(ILC>0Q^3?(Q`$6?E4C^3S1ZQ''/T!.IV_A9T($K-.57H##@ M&*!X1.`5)]B/;L)Z\,`E)[&40B]3#%>H_WO*0%5*#96=E[?1=G/&!KK+S"_6VTM\4% M;+1JWNL<#,)/GF4Z.<.V4NP,AAMM8-5:EC;"`X/7<;_%CV[LFX,Q/L?H)HP` MW_@1&WW**:"7]J,5]J.MW4]?[_>[6F$_.RRI]FUMZ6JI2K?;&RJ-W]:V4E'7 MM.'P4+L"BF;VDRBF7QW%]8::H6ZRA6SZBA>\)2T!R^N#_E%7O*V0TC1=V8CX M-U\QE\@W(@[G/@H=6RF4M6Y/?Y$NRE90^:JW#:9T!U4O^0MX3N#_;!)3V9+S MU+X^T%]:;G'J"A>Z)2T,M;[Q(EQK6^BVZ%=[1O]%1EN[4C1O3.?*FT[!:)B` MAQ=!MDB5?1Z`WW1`-AM58O;VSPZ MN*UZ[RM*-[_D%R.`M04I!X:N=8>[K>.:/83;K.4^'N?^BI=W^F!:/!!T^=T. MTI\^@1MZ,Q8/?.9GQME/GON(H26<]FX^8X7W;ID5P4OXFWAMDXWWE)4;QX'* M-U]U2'UHE,&_+)*]X?Q;4H"A=4%O;;<";IA=X;F.&P+S_.:)0QZW2`Z7P?W- MN*GX5X=J;Z"5;7OEYA:A\<2$:R=\(\Q$KI`L]%ZOH.B6)MMO-=MZO&".#;=9 M3A!$&+"X&?,B/SD!^\'S;YG_9%LLN/&O'-.>;N4,I@C_*HXGOYA^.+^#D0,\ MX`19_FZ>_X732.A[3_=?3)>%H8G?NLP//H6C#>E$UXO.\C8[*P)EE4>UP"=K M2:/7[^E]/:<\5CI&&\ZXWDA0ND9?&^K;30FPX3":>,X(0/[^KPC#_OOL7.NK MW>ZJK9=.5]WBU@-I,!CV!D:O@L5=K9>FZV&E*(-!KWPU5V4";;OYU^L58S`` M;.TT_P?3]C'ZR;*S[A=AD4J%],5W\_3/?]K@O/C69/Z)/3&GH#7>!R$L.`1F M3I\NF7I!#^7F^`P6Z'W6K.719X*$//^+B9FP7_$4-_C3#B=7GA--'VP3MO8$-@$8!)O1S/*.^5:: MNKR]O>OE_]X_QNX`H-O+VW;OXY/Y<.7YLW9OXO;;''-EKFWST85I;2MX]T=+=G1W]\&T0L^_ M_?KI&"M>B("=ICJM>9/-4*<[;+)2=:J7VGT'WE$SU6EU&VF8.JUP8T=5I]7M MXXCJM+I--$6=[K"C(ZO35:>K)Z5.:]YD,]3I#INLUCO5JU:G.^RHF>JTNHTT M3)U6N+&CJM/J]G%$=5K=)IJB3G?844WJU',?[^*L$9"+5^8,+Q-^PM2VFP?' M?HSO9.]STLHSFG/)?IM-6?4RUP?+=:6KJVK_Z`MM5A[0`:%2Q;&^.ARHA5/] M;6:N:='K26\P''2-K5FDYE4WBPX/#J+/9ACY_*#Q*YN93/^XMNN9<_P MQL^_F>E_\")_/^&H]A4]G^E:\>)JV_G=!-3J7EOOJH;258>U;)VOKKZ]/WM[ M[=SH#Y6>MC4Q;[JV7?:]8L3?8(MWS\QY8I]AOY/]#($=>7C#I15W#=^Q^6?3 M_\;"#Y$["B[#*^QN;[N//&7@?-.EM"X('%W/&8=K0'5\N)8EIJAG"\;33IK2 M^JJF=_.7\1H/UT:2YWY@_(W!K\'D"_B=]HB-WLU_#]CHHWOE80V2"-ZYRU,*>U/58T35#S5L>^ZWM8/O%IO9#?S#$:TQU(W>!IIRP[4=;)_;4FU?5_O:!DJE:?OR-UZ?6<&ME6Q:.@I!CRY8J'K5U/?5C@OZ!MQY(7.MX(E M092F[F0[X6(H_?XJACS*5HS<5GKWNK(A4KH:&'K-0DH_MY/AYCLQ`"4-VXFJ M;$]?@E44?="TO>2DM;Z1SN`[T=5ADW>RG?H#A9&O['?\K1BYK21,OP%25*6I M3&_DF7Z#G73U@=:PG21,OPU]"0'6&QP%*]>V$V&%[*:8+?%ZZMS.(17^`;:S MM2CK]?O*8"$JN=]VGK.&->!LN_"G)8Z]1#UKZNS@+1<>Q\*>,$:NU4\1=.?> M[4$S.MW#]GN0_F6ZD>G/LVT`!79%=ZX/:9."',+`275')K8/>^?!?Z37_,G+ MVW<_27801-A:P95,P.:(E^&/.X;EFD$\1G@_PV+Y;D3X2-S9@3,&5N\'L/BF MYX]@$?YXQ07PK,5FX.*3\#X+N3IF<7L# M'[L*\B!R9`<3T7X/9K-]$&)1@&T"79,WML#WQ6^PWG%R[AXW"(3'>6\+WEP" MEK*P].)Z+<<,`M[*@(,B![>780:SFT[H/8H^"@`\[VDSV(CN%_!,8(_BV&(. M>;#GE`KL(.[*93\A#7A9PT#>P&)L!Q9`1'0>?&#`-!CTD,QQ"`NZ7NI!B*2+ M!"PF%V?H66LED8[ZP:)26\*?+N!@#1@HG*"9F)F\,6M+*)N"L MR[`1D.FZ*-%0E/&^=/8T[L&#KP+[V-YH$29@M'G2(XB`(`,^=II+FA!EN_90 MD&(.&!>0R!U\@6++@"^`D\@7']F"2W$9L7!.6@+5"+=#2KP>23R2>-*_HKA9 MU!IYEXFW(#7GHAGV(@:6LUPAQ";R8,LQ`DF>"< MI#65%YL0R1#IC]Q2^,?EY9>.]!%[:(YBJ@OS0B%(;3,6]_'*&7/(-2_,'GIO MI-?J3QEI+CN8\`@]5[ MB+L&NR#Y;,";$'-VR#NTQMU%RY\,VXZF9 M[K]Z>WG[>_;Q^NU/TF]>ISCXA3*4I:3D(Q?;F$*";8@%-TE78&Z#>`2&7AQ9 MBM\OS"`X.B7BF4A9P;-SY`\44X+').PYZ3!IZHU`AB*C+?26].,U@4'*VU,F MSF=^;5:Z-BZO(Z#Z@/'9XFN%R2!Q(V7.9XFTD5'P.]$(!P=LPU#^_`(E#OK4 MZ9O)TV)?%C8XG(F[/PY+6%;L8;%E>.-I;P9LGG1B%!/@L@M3[1*GN\L MQ-LCL6MJ7;EM\+]X=)"FXL5]22K-K.MJPV$WWP1E:;9]%K-E`HS658KG>]4O M9HMK+LK0&/;SUXNJ6>=DP&T0;#?GUDLV4^ MAZ[W:X'-;I8 MR%.XXU$OZS[9K M3Z/IE[@$P/6:2[QKN5Y5A]U\O8T-)]UII574AM%[2K^__7I+"Y]L^.Y'%RN' M_)M'D_99>D\?E#'MQI/ON'A>^V/_U>L#5='*F'SS^7?=P+-7P?+[JJX9NRP_ MGOW%Q7_%S'HA?->U4MM2NN)5P%)97S9Q56O<]O[IT#C\&K<4P+K:W7^-(*)Y ME8"QYXNPQD;U$])FZ)=1./%\.]]G[LIT;!C-M8?; M!GBM_\*@UR9%7W$7*L=&@W:1_1PRWS6=.!09-X;Y^'638I6X,6.H[[HQ_]%T M[?]R&K]*PROPX=(=?/"$EPEHPJ/K)_BNR1Y@Y<.I!MG7'(OU#4M<=2#KSD;E, MSC8!XJ04<85#BO3%_!$%1G@QR)I_<"EM`L]*;$S^F'H.LR+']*516JLU#C_' MQYYCSXK0U?26SSB19N#9*?-1:L0R1AP'SWQOYMLLQ.RZR$>Z>#`QPF\QQ[D8 M8TF[TIG#I"*Q.!&-Q$DN`!&5*4^G$0?X.//4`TGI\7P>T_+1KS*E)Q,GY?F& M4S:R\3@53P#M&0(_*#_=7`8B)I7`ZJ<\-3`6W`(.\2F(`T#P\7P88]:N!Q`I M;+)T:T`&(9[4X_MC4>.1']]/\0RI&((?V\P9\7-.4"H(#!F/KAVV.@4&:+>P M2G[RP_!P'(]7^0D0S_MQ'//!2XY.>8(2Q^;J@7,(@<69V(M="B),DL)9^'&) M!Q/&&)+%>0QL%:B#(P"`(@Z'9^`FF2&L$$&-!8%+D5%ZZ%QQ@ M4F;RHPC)BT)4PR*_PL(S%5^:P78Y="-^T(8HRU-G;H=QQI8E*/NO").K0C,^ M6(G)+4?!U[]=(E`XYBLY7.ZW788>,4W_=SSO>_;Q5,V5OD0/\)QT,QX+Z@=6 M$G:G#=8[#0I'L%>61.1/(]!)DIHD\ MF!7V^.BS1Y2C@&)5!NM?!B.9&]-!G.["4SKQ"Y':+8Z"\9SZV1,I4"))2IRZ M(HD$2"(B_PL3-T5;;90-L\BW)JB'\'O^*KY9>.L9XF\-I<($N^R>7G\6#)(S0D["$1J#PRK=/KIL!PE"16P)`2^\-0&N^"[ MQ5-\``;H*YXA`BZ^WKS M1R$]965RU1+AQ42'B[1,O.J`B;,"/Q;D?7ID8 MXRD]ILBR$11I+R=':?SJ#::,)/=28#;X?_N)FR5`(-S@1*L[0N8VG3F(N`2` M%L>W;>+GR]LK:8!Y*690D+MQ1DJ<"<)3<*;F-TR]GHN,T:0H,/H5R-7\RX"% MHN+=R%YEH]BQM#'G M%^4>UV.@D#%#%?TV/$\J%2BK`)Q+D99C%1*[VK`D4)'"*8_5I1Q#'<2ODZ!D M:J*/ZW+^3+2JC)X4RIM\VB(^[(#6=+*T/I&*]XB0]7QP4\'5QI1IS##$G[(, M+A1?L'^>Z(_XW M@/]F0$==5#!D%BYK%:(BV.?&%CHW"[A@8F%R"9QG48Y?X`T2M$=V4"FX>A0% M)Y5[,.*>&4OD?GP?#O48NC;`X2Y>+X*O'>0[#)4BD\'OB7!)Q$FP)$^":`SR MSXYM(QR)>Y>K`Z>YET\_O;51Q(%5)S'(S!6NEQRHY<7W,\C5'\#U[FM]61^` M^?P#_%?MRYHQX%C\P9"'NB'W>BIWKY,$:HR\X@7*EVP5/`$7/I%P[O'.;)+& M7:KZKH49M>TD.45"$(>LN&9[0_)R9,"9L_A5$A!2#VBP M8B*]Z<])B3?;6TH0AV%!1&7!:XJM_L07*,FX"%4N M[B9AG\Q(]O@]8C:+91GSIX&X$8,W^%=XG5Y2FX0K=)PJ+*XF-AD6%A`@9#'N MP6W\99RN/'$KR-6I.><.@F]CR10IL!]=7A*%WVQTHI57-B_=N:"H%+>R9(\S M2,A\9-M]\ASAFX*(%S>?+.\)?<$PD<'BJL[*U1:K"F"`EQL[B7#<2V"!*?WH MOK'X&29)K!TO7(X7HWV1FRCR);I-U"J_;Y=&!($_2OD&=!T2$9=Q,%J.-GED M"%:&\0`4;P^F]0V'X:'^Q-1>SB7X&4]7R]()4'G#;U-/G+C$)[BG462@E_W:-A:U)%^K@0`2;G^.6A^9SF_O;]P_* MNWYQ>_N/O[CV%_>9!TLN82U-8)LA*[F/')X(M`2H\2YV6[F^Y_L9C=PR]BV7 M`N+Y0LDO)JLN$V?)#!QN[*$G3,F#Y8-6,'(V10!2HE<9MB"3N:*>QI@ M.U`TG3%5(\?S+QZXS2R,"VB\8RX; MVW1EHOE'=6NO3&BEON3[Z!U4/,Q+UV%J`0:ZT--*:R7'=8XQ^(+I\Q>A M^1U3.S#W/4Z%X667\&PFR>A$`<_B2M:29(7% M,"V:9YDP=G@!ZQVAM^CS)(9XK1C5_/CU%F8>;1!RX>$6@:BO8&)BP)&)HD$" M6B+$""LWOS$W3A.%76XPRMN[M=8>7PF[&8+'\)$ZQJ MX.C0!E^EN*0-FWUKJF+DS8AMMU4G5-8V:*L-*H:A=+LU025Y^BMLXDLF(AL! M"",/".W5KTI',5:!H7P?F^P\$!>+T]5_%`E]0Z14NHF\Z:?5+75\9 MI8:E?C']&Y]C8<2?!7:^Y7>!MH&IGE_HQ]\^<.F1;\2TV9Q5KW,)H$U=9WU2 M?7G'ZDH"VF6[_($@+A+QWX664>O(9FEMFJ(LE(5X>;:J5K9$*`=8V4T4\KJ[ MB76_8FDE'92KHHVE36+9RC4[S*VZLBVNIPLN^(ZPL`/"_DA;7$_YQUI8*V%? MA3FR:B%K57D5!L9VD\],>Q27@TI\:G%8L4$)N_758KM:?S`L+&C=?)4N<(,X M_%#K[K=`D?WXP?>F'^,[A3?C7/O#*OTBM:MK>M<8Y->[9OHJ5[MMJ>#!0!OV M#./0J]7N5;[`+BXW^\"K=]W-9S!$4H4AJ^HERC,DW^/S0NYL)<'2=2V^FR9] MO\>N2;B&PIL+OR^\+99\B6FUHJ_5JE4#M?).`I[C,'Y>%,Z3GS:MN*8NEO2J M!&.?//?QCOG3:TS_K+2.[[)!MV[^#=;KWYH.O"4@N%7<;\3L^T]X'?$];]*2 MKWWGAI[_P0[_^XAWVT<<5O?MCIP+1L0:#I(UH2QDFK6+**> MU6]+/HU:_):TT]-K6#XJL1M^425XGY:NJ9!>>BN77#9SE0O=DC0PZ#ZL9*EQ M+9+DR4KEG]X=#@>Z6K[.Q8F7EEA.'90?LW@O66I=AHQ1>CZ?H)QG@J?X/OFC M]T9ER'RPOV-A+NY")P7/,-LC3?J?R[R<1%*'`N_[1F'<`3*[G#ZVOXN*)+SS M$J]F9GE!>7VH:S;S06ADE3P*I3WB\A95W"?4=$,>X)WI'\!SDKN:$M_`QJO& MF]R?+M`GR^M,A!(;)0DR8P]S73!/_-1I-R(O,%A7[Z M47P>24_\&B!.$(;>]%5QO=UA1]5^S.?UYP;<#$&JTNOT^C]NBJ%!'D'[R=/! M&IP5\17C+QQM!R%%[QA*-1!:OI2Y*55KBT`K;GB#/0(Y`='!)KNO7MZOWN,4 M$9-CZ,W>J+-0ET$^8?(%8MUWHE)]4`-+J!V]UUZ6$)]]DILD-[>0F]H:N:GV.%,LR,UR MR4>"F*> M_T;ZV]75^_O8)IG MWYS]\DK\-PU%Y0)58\XK:SH0GPZ\K#;)28G)BW#/V M8G)A*S:#^HYO,YZ:9<@36;"`HO0QWUNMT2&BYOJ^1]7G0]E05,)0@S'4D_7^ M7ABJSF]OC\0]'R_]4YIV0+[YP>*3ASSL;*:-..P-Y&$5FH,HBBB*4]1`Z\EJ MMP)-UW:*.M[I<^.574N.HULC=0X9ZSBF;%'!AC9DK=LG^B#Z**4/93B4U=Y> M]$%^UDG[62S(M?4UWII6W.^2MXM]*3^;G#$RG>L57Z^[NBX/^DJ=)-6&,Z*? M=F(U(K]]R0^;TO44K4[7[?3(CPZ7RJ%8?H=(YDT4R>L[0M(!K%<:>1'>5#ID M2B4E%^R-AJ.&\PQ%U@=GYW`3:Q)K-ITU^UU%[O8JR.]I!VLN&%KB(UZ\781+ M\FNK+QPWI>3"RW]M5)`AP8]81745][>HF[%AQ8U_^-C&>Z_*@LIPJ/;Z&ZR2 MSU79NM)B52O'>#=/"[SQTE7IM0"L)L@O!:2/;EC.7N_UC&ZS=YH\N^76!EI/ M[:KMV%J:Q)?/X=MLFWI/[Q]\E^O+Y^E]0^L>G(6,(["0WNL.NP=GH>UVNB,+ M#7N#H7)XXCHX"PV-RG?)6\_OH8/`+@2S<(-%P435+&DM3X,7"4YDI4OZ`G:^ M-3^SRECXVQNL06A;+P;=Y(4J12^>;.UHC;;:E#Y>W2E>PWEDBZ)16.LI:2L? M8&$FEST#SW`4V?FFK)PXHVPCYKX'0L^83VL*3\KC0(VCAS)L9^P;ZXH!^4S<8XJBFJ5KNTR MOQ2LMI5>02ALUPZRI146$$S@?>8G,SKV..O6AK-*\IULY%%\2Y$KV,^+)8,*US(30J(E7=2 M7"067@?<%P0R-6T0>=C@E@GZF`!]PSY@)2@%XB*I9H#M\;!&^&C7YFY+S-(> MUC^T[[F@E3;496>FQ:@.&]43.I]Z0E2'C>JP57#@=#XU6TANDMRDDE-4AXWJ ML!%3-(0IJ`[;GCJ=;AY0';96I611B:9&IVJ=2(DFJL-&3$Y,?N),3G78Z*H, MU6$[F.][5'U.==B:CB&JPT9>.M5A:U9\DNY>4QTVHBBJP]8$'4AUV,C7H#I; M+\L6JL-&]$%UV,C/VBOF1778FBFDR'2F.FQ4A^V8Y$=UV'8@/SI+\"&`W*%1*"Y%O3-R(V?>?V*/IO'=#.YQG M9%P,[[T?=P;KJZPOZ\L8":L M"I9_S9Z8X_$-Y)[>M'2@!DH]!YJEG>X`B5P=O8U``7+7##Y?PU;@&P\@XEK, MO^+WIXX"DU[O2#"YO7$Q.O0X3W;RZ=/542#05VJ`@))*@940^`=SP!P?]%)M9#,]A0^>M9E9=;4L-VH MCW2[?,)6$JHX^8^V8*ZV($O2UNML9][IH M7E4,W8+*#B332*9MDNRA<8J@PC05TN=G=#CSMA^1:3UD2IIW#RK]5^2R')$J M1*1$I(TCTELV"Q==::)4HM3F46I9S(=\&/)AR(=IIP]S5G5,B9R6R>GD--3K MK^S)#MCHI]=:'=$UHI(V[I=P>FXX)0N2+,AS8_Q-3_9.3^>/\*S M",%V?B4%M&KI:1VSB0L\33%Y".F$=$(Z(9V0?I)(K]A6:L;]S0-ZMLTS#A=L MP:_LB;D1"QKMZ#:'&_0#[ZBI]]^53E\Y;E5S5=VKT"L1)Q%G?<39[1%M$FTV ME#;WJJA#M$FTV52Y>?"SIV:X)"<Y4&IS#RB8>16Y(QU5S& M/^E3)$(@(9`02`@D!.YI0;4#@13;VL&"^HV%DN,%`2]C9GG3F<\FS`WL)Q9_ M'8:^_1")ZEZAAX],/1=F\*QOV$B=^10,.P]O[+4NJ\-!G5AMPP'(3SM1^XE0 M@"HK_2%1P!E30%?6!WNURR(*:#D%&')OL)<,6&=AG1X%4`!OO?DY8WYJ6^*5 M-.E">C`#VZ*X'N62;`Z)!N22O%8Z:@4G46U`X&YZD$BY1:2L5)!1V@8$$BF? M/"EK%<0NVH!`(N73)^4]6R`J)TG*%/^OV`$;V4X4LA'%]RN0G7&!7I`L)2;5@:RIH.6-JO$!)AB7B)L`2\I/15 M657WNL%*4;$3CXH=X%RQ[19V];[320?2">F$=$(Z(9V0?I)(IZC9J47--FAE MJU/(BS(F"(&$0$(@(9`02$EG^YE,YQ->J[WU:]L-\4WYA.Y"M?DNE*K66DF5 M2)U(O2FD;A"E$Z6?!Z4;1.E$Z6=!Z7M5_J"(^:E%S!?8X8`M<]M!*VW,E]+D MKE*!Z48(J@]!AD89APU&D"ZK6@4-I`E!]7'08+^^P12N/O%P-35(:Y[$:*9+ M]!I3RZD@XD[4?B(4T)4U:I!VUA1@R(9",N"<*4"5%7VOZI]4Y)`":& ME!5JD%:OFW6&\7]JD%:K<]:,O39;JC8TXE6-0W=.`2]BC#-AC"K<0V(,8HR3 M8XPJG$UB#&*,DV.,*ES7CRL%OKL0=A]@B8[E97D^$J0SE_D`031-QOHK,OV0^3`+7\04#/M0 MFIIS8*90,A]]QLT[?#+T0M/A:\%/FUEMO7+;,\V%0\HC2.'!@UV2(\ M[L(*1"JQR"&>F$],>F#,EQQB8KEO:O>Z^/3JUU@MILO-J4A!`Q>H(SDAQ)^YCBTJM*.33H.)?%T3 M)54OE=DQPB6.<2F/\G.40?EPB-X[)&7]PWSP;>8PZ7,IFJZ8[WLN$\KT"I2V MZ<[YKW_[#OPU?!N@(IN"HKOR+JXFI@UP=V6N\>/OIVSZ`/^)=?`[S_1'^.': M]ID5>GX@2P'SGX`03-!=R-I!Y(0F["'66_&VY6+DK?>M36&YAY.D3M&_X MC+H\OSRU>*(<=_69Q07C\C+'LD9!\WDN1=]`3^]L8&6\:V2G'_&^C\ M;,:N+-WFRYGEL"R]_RL"VT-Z?5=]]_MYP(+=]+"W#EL]%']XOO62P(KKP@?%%G:@6="0YL MY-KBR=_A#_QBQ"P;$!7\\DIY]:LZU!1M.,AO:.=U'6:#>F&#^KH-ZD.CWQT, MV[O!^Q&S[S^Q1]-Y#Y(QG%]^MX/[T/>>[F&_3\#;\-W-&*C,##Y?PUK@&\^] M`E.-^5?H9?F?N="^CY=]?S>?L9OQI>^CBX$KY@,FOY9O*O>T&&TM66F&HB@G M"?3;&QK]V/"C[2(#,-%A962'$2:NV"X2LLNXYRB"&J8+WUY,O"A@DK]J9,=\\(#F M/7\N2X'IF+[-1,GS(#3'XV3B603OFB+P<#$3W+9R3!E^><3$&1A4#(4!@M`> MVU82SL$&,6/&8&0SD)Z9X^!_D1%]<'V+`]OP@H]J5N8G&:9EX7LEW7DSF*NO*Q>JR0@,S-#1"8&M0"RN)ZI:0.47`Z7I!5/?,[F!C98+S".@UH! M80C2/_)%8`H-20:@A0<=,P@`:2(2]\APP_ MSW<-`RVQ'0F1G9;^Y\1V`'O,#X$$,++J1?YJ_N<,S@\]^9'D..*4\`#8'MO( M^?CR3"A*&$J@FM,8\.S*08N2B=/NR+9XN-434=(Q\CD_K+P#4\1$ZH(%!)+K M24#97'+`=$%DH:091PY/LF,^'AW9_TU3\J:>PS!%#P].S4<7M@)L#^)I%%FP MJ=##:Q=(UG.)P4]X`)J$G=TH"4+'.T[.E?F:GKW(`39+X8"GS'N0@9)$LVQ2LQ8]^1C+^_#R) M#TJ6]R@R%23'`]_!YT+$BG,?8*7`UD^@MT9RG`B1K#M.E##YUBWOT<7E\[,C M-]%,:U)$[E#E@14B9E^''A@93ZN8Q1V;;!1=Q;,GU>"0Q/#?&>K!VLY'UGIQ MBVX?ZCXV>A\GWEQ:5C2-.-6*\ZJB"WT9W-^,MS@.N.CU%4,WU(+'NF[&*E>X M-O!Y,5#UH3I4AONL\(FY$?LJ>`HU[F>P*T`UN^PS"R?>J/@`,EV51TK=Q8C` MMJM9MQM!-V>60[)>!W(P4<;%82UVS.:S4)@)=SEZ2#YRZUOX=IR`N%$[8:83 M3JPD:=)T;72DI]S$=C*'/G'D'VPO9-;$Y<%4&$TD')0G-?#$09[Y*)0=^@6V M^^0YX!I,T6^?@4ID3OPKF.<3U(?):H5'[WMS6%\R^S1ATU2#KDC^X82'SD). MBZ?)G_&4J?'@\R?!L`@BD[=D8V@;H)[F=A*H?C,+08(98/,H1FRFS+FGX8'\ M0PM"V!,S'_:`8X[M[\*,&3&PUL'/12M`CIO`.4X<7^'+-`,/?YT#"/",?C\? MH94*/R?VDB);RH]I=KFX(+7T^]M7X)PZ3IPGCM*>?PYFIA5_3@?PT[]&Q7$X MF-+G9B4_9GM3\H_^G-HH<39X/'J2V1YZLU=2_#=/E2\.+2E*1\$!I458%J&> MKF@+O+W-D40NJWT1B2L4Q>U\^N`YBRC-YX/^[?N[_C)22[!:A$P1?X,7X,Y_ MS/VY)0H*4,_CHR;(;LD=XL+GWQ3^/S',[[.+L8\C@,^0%EP26W@K!LTO%$?9&QAE@DWDF@DT4BBD43;0Z(M^K&+THA+G0B*QA-O+P&8[A(AJSJG4OD*IOHCSFG#A0G21JZ]Y$L2H,@[:[QJ*D5M8 M8::=5[%E_KO6'6I&K_)5;)G-J_45M3_8;!6W)K!?_`MV\JD0)497*:!D8:K* MUK$F`X^G\%V!D2/B?3#.I3OZ)%S/R\37^],.)[BC;U>7M[U\O__'^MX^NM=EV%@X4&KBEZ^@;RW*-\;"K\,4_>=CW=AZ$ M;+HA"KM-W_('T_:?;/8<[RT^"-[P[D+3-X?YM;/0_KXQB:I*XVGTH_N'_>3= M\D2TN^14`?RVC?<(0KSI6_QR>P."Y?;R=D.L#1J/M4_FPY7GSTY$:'S^].ES MY`+M,?\3B[Z!AWVUZ?O[OP@\A^LTH6T+<=CL?=U^FZ,/D-O9NS]: M98K85_'M9B-W+I[][JRF<5L5&TP]W/+&&Z^C,JI M4]G><.<+J2EB8^0=F9>#_\*1J>1!OKRU2XQ8;X,M7M:#M?9M#T[>SIRS1>)NX8_>\U M?5_-\F5VV%,X>;+J-R%**]U52T\K`D;10Z2@QO: M267^6V9%/K]%+^I0L=$'WYM>\>8%?&TWX^2&[1?F\ZY29W;'M.;[9&ORB9/W M02.,F(]MVAQS%K`WR1]QTJHT4'BWDCPD^]I2SN@.S=&&QD%[H`QVZ7U67J%] ML`9G17SMVB5&[VB]RMM#QUFLFU)UA=U]NFNZ^W3UCC'X\6U,CJ$W>Z/.^(4Q M)OWM>HC_2,F/G`A7_BI&Y[\'GF./I#AK-GU`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` M5JI0:N>(UN&+Z-OMPETYQ,\Y5ES-`$)[.[W@,DNH%G:(H\ M((M_#XN?*&K1V5"J"3JUG:*VU'D5IB:FRDUOJ'*[\T+3D48'S)AH!\FT,"_B MJ*)&DW5-EWOD[#0XD>&H?E9/UC1C7P(A1^N4\_;^,)V(![LDTW&\9].U&+E= MY';5*YA>5ZFZ5F^Q#:?O/^W$;>2F[4N!5>K&#:?, M^RT.PXB/5$)I\Q)*6Y4X6E4G:;&PTCLSL"T8Z!IK,^'85">IF7628.2E0DE% MAM_E,*W;[70/>SVAA74^JH)0.ZHI:)S,3JZDP:%J!Q&Y$+D0N1"YU%69[.C@ M.W+Z#UDL)%-*90K5?ZJ./&LK3$:$282Y)V'649B,"),(J\_>.Y_D MN]^B*?/-$+98FZ`[OYR[4H%'MB-Z.TTZ4W89VVGM^/%Y9IO MC;%0E&=LM-?9'':@8G=Q'D"G?^2"&J]50]:-@6P,A_L3:1O0^%,M_C<1=',( M6I4'AB+W^P,B:"+HTR#HGF+(FJ+N;X.V`8W;$31%#W<`\>7H/U$03F%V:>SY MDC4QW4<&+TACT_815A&3O+$$KIS]9&(S3O@M"/T(WPBD"^G9]'W3K:GJ!/GF M=-LR=]]7-O#*K]ZODZA.3RR>%`'2!0^2F42R)T6R%!(]EY!HA+61T-FN[N[]SA*J982)*LR2D$]()Z13-I6CN&N/@ MFKG>U';KO7#4#BK9532^SL<.L$%N%1%/0_^P[\RT[ MX%G[M2?GMX.8=A83QTLG/:Z&Z4E;XJJQ0G(**BX!,158.)BN)>%/=J M1%9J.VB$#KT)@81`0F##$$A1CQ./>ORV%,5(`AP4S=B3<_3&[+4*0JGQDE\C M'9C72F=0P27:"FS$:45@:MT%X4.\;-D.V)&&/675VH\Y$IPY;?7OT:LU*ZH1Q;+3:TCS^+F'=! MX*VB@KP?I?<.218`)PD!)14AM0E=K&%@U_.GIG.XG6Q%U#GL)<)9^3$5BIR+ M)8LY3JRV?GFEO.*?@YEI)9_C]^,3#A!WCCD+V)ODC[=B8&G0XY(Q3R0F=@--9$,>1!7Y65_4[EUF'S].R4]F->[^Z#<;U!Y[!58/_' M?:S4G97-J:F4VQ"MGM#\+O-D.&^<*A3X3GI@+AO;86W:Y/1TQE$UPV!8D5YH M`__7)_V/B<.]2K?J!S_I:Z\@/Q^OX0L##]3%1C(?0S:MY\X9N09-,!!?ZYI" MCL'Y.09[)?V27T!^P3(4_S"=B(=`)=-QO&?3M;#!F.4S,V#2ZQ$3?]5QA$:> M00U6I:P,*G(-"#'5!O/T\S/X?R*+OUX`WX03YI.=7X6]U\3&9<<46+4?/)P@ M#36SX'`5@J;F^_KDFI!K4A+/\KTG.T#7!%O6V3S/!4\K6'VAK1,42I5==H7U M2B,OPE01JE-"1/<2T9WT-:O#^V*57;,2'[?-V5S*UFM-VML!G+%;YC_9%DLR0]GHRIO.F!OPH2X=&(+_=3/&21Y=V-/H"_-M#YX+PJ") MV9[-I(U#ID0J2RF176.;E,A20608'?VPVF.PBT9]%E,]>,XH-]9@#>NVM%ZIU28;CM0UT&>_V:F'V0H8Z`%1]G':V:Q MZ0/SLV]T5:Z!C@&O6GOI>$O_EH0=";M-*CIT:RCF=.;2#HW!>BBSQ>*K(LHD M-;P?8>HD,HDPFTB8&AE\51]HQ-;>^1SD?W0EGP7@:U@3R71'TH@],<>;88\) MB7W'\`],7YL`;,;!VX&*_#2Q^&?;SC?KJ!:ABVH1343/,?,P^L.>K"B#C!GV M-\2;08?$[L3NS43/,=F]:PQEH]>MC-U)NQ^?GHC=B=U75E[OR:I1D7873F,S MZ/#XSN,)NHB/S.4W]M%#-$=3V[6#$`_VG]@!G,1V4$\+8V+'S?+6^H:L#GI5 M^A=$*2=)*88VE`?#896F*5'*"5**/NS*PZ%6I4W3#CJAL/>V-LV=%_**=IBO M^("YCKSJ79+L2`'O9KG$.UP`:`:@S\4IKA1!QU0AFJST%5D=&A3V)J8GIC\/ MIE?E87\HZ[WJF)XT?1-HBIB>F'[U>9>NR:JA4`"\XCM[>US1*ZQ\'0,U\DY> MM3?I5EW8^Q"%D<\^VZX]C:9?P8,VG2_F'%.V@@^>?S-C&)IW'S]A_:R@L:T8 M=I*LNXC5?!>.DK^6D;_M!$V]_==3][S]MQPHZO>K;3_4^$`1,$*WCG"0UAF> M4)&:S0/4ZP*-1XT?]Q2YWZ\H!:;;T4_/)-A98)R@6.C5)Q;:01N[,O]16;RO MRKI6D:,O6+P=R*J*D<]*\_=)\Y^)YL?:M5I%N2BD^4]<\P](\^_(_.>9E]*3 M]4%%@48R.4[9Y!!9*61S[!N+/W;UR68`NKE'4FIS$73<P*)A7N'!6)1>H("LY8CQ7.X&GE,)C?D_E"1>UJE3-X.=%7%RF=E%?7)**J8 M^YNI_+N87BQWU8KN+9/R/W'E/R#=?]S+[CO$D8^:LR"K?476JXH6D]UQRG:' M.%ET//?Q(F3^5/(>`#0\Q%A'2[O3,D>VO`'W@ABA\\9&7(%K%(:.&I_J8J]= M_)=LU.:<.+;^&MQF!UZKCLO^+S)]T%'._(/MFJYEF\Y'=XP07.YH=XYG9GL? MTA[]=`U&7CI>*TJ$-?9<>9\F]=#=,5O7ITGK="N"4".:CJCJNJYT7;YAZCI2 M'7W&PCG#VGOL2_=:_:D&&O6>JYH^/V/SFPQGNDID M6@^9DN;=@TK_%;DL1Z0*$2D1:>.(]);-PL6^Q$2I1*G-H]2R!MKDPY`/0SY, M.WV8K5KRM!W41$[+Y'1R&NKU5_9D!VSTTVNMCN@:44D;]TLX/3>%;N!QGL;#?[.YQX46"ZHT#.OF/?+38+L\^SO$L;8`'B[./( M#$TZJ*M11)UP/FDYX182V(W:!%O;,\IV=I%KW?=2-F%33!Y".B&=D$Y()Z2? M)-(KMI6:D25^0,^V><;A@BWXE3TQ-V)UW"RJSM%M#C?L4"7W)._I*/R>SH;; MJ.<^C*H2<1)Q-I,XNSVB3:+-AM)FGVB3:+.AM+F7W#SXV5,S7)(3CF0O$'U: MTE5BW[%'8XUN2]M=WNKC',>4"[JL]RLP]PFIS4*J-JS`%B&D-@NI0T+JJ2'5 MD+L]A<+(%$;>MCK\^0:2CYP8V:Q3)$(@(9`02`@D!.YI0;4#@13;VL&"^HV% MDN,%@62Z2/K3F<\FS`WL)Q9_'8:^_1")ZEZAAX],/1=F\*QO$\\9,9^"8>?A MC;W6974XJ!.K;3@`^6DG:C\1"E!EI3\D"CAC"NC*^D`C"CAC"C#DWF`O&;#. MPCH]"J``WGKS<\;\U+;$*VG2A?1@!K9%<3W*)=D<$@W()7FM=-0*3J+:@,#= M]""16/)3:\'K+\'4'O*5C,7&!7I`L)2 M;5@:RIH.6-JO$!)AB7B)L`2\I/15657WNL%*4;$3CXH=X%RQ[19V];[320?2 M">F$=$(Z(9V0?I)(IZC9J47--FAEJU/(BS(F"(&$0$(@(9`02$EG^YE,YQ-> MJ[WU:]L-\4WYA.Y"M?DNE*K66DF52)U(O2FD;A"E$Z6?!Z4;1.E$Z6=!Z7M5 M_J"(^:E%S!?8X8`M<]M!*VW,E]+DKE*!Z48(J@]!AD89APU&D"ZK6@4-I`E! M]7'08+^^P12N/O%P-35(:Y[$:*9+]!I3RZD@XD[4?B(4T)4U:I!VUA1@R(9" M,N"<*4"5%7VOZI]4Y)`":&E!5JD%:OFW6&\7]JD%:K<]:,O39;JC8T MXE6-0W=.`2]BC#-AC"K<0V(,8HR38XPJG$UB#&*,DV.,*ES7CRL%OKL0=A]@B8[E97D^$J0S ME_D`031-QOHK,OV0^3`+7\04#/M0FIIS8*90,A]]]O^S=Z6_;>/:_OL%YG\0 M,C-`"RBN]J5+@#1I![VX;?*2W`[F4\!(=*PWLN31DL3OKW\D)=N2E]BR28NR M>8LW+[8E+N?\SLI#DKAW^,DLSD!(QH(_C2%(>M(;K3*O6^C%:%)EBU(_#U&K MDRFBQR,T@J*4N*@A'H`G*#U`&$G`_]\\Q4_AULD;^(B18C"IE$#D@*(?RW$@ MWS)X`N2),``/01ADXY[T)VXJ#"#Z-AN`##^9(H(.0/2(V(J[PQ,:HH:2`$VC M;*L?1"#R\!=IAGX:0MP?&L.D2_0.3'M;HDN(QB8CE5['[NM_29O,;J+.BI&A MWC^=J&77*P.3JOJ3JA\^OLO3TT<`1N]OO0'T\Q!>]?]G(D-?)W#Z%O4QPW'8 M=( M0;W>'E(9$;:$-[#_Z>0R3\AK]RKZIRFJ<7\7WZO:O5Y\.CDKK>%T4A7+6+#^ M%)M&PO_R,S&M=3O6.F(:8;LRQ4D-E/+[U/@7\:L'P[`TV9].E!/R&?DMWN1S M^?X#4J(PP5F/$(Q2^'[RQX>B830SA5C_>5+69]LTUZ"[/4O;JTOAT+LURME7 M.8Y%?;75PY8UX66Y%3G(FO'[AQ*"63QZKXXR9)XB*/UZZ>)_TN1'@KN5OQ:M MD]_3.`Q\Z5>%_&_Z0"'QB^^W2EX6D/R1#Q]@,N-3W%^`YD,BO:M;C^V[*]6X M@#^%6%&(`EU1^)/\O"112U,`SI]@`AXATSZ^O,#$"U*VG5PG@0=G`+]&2H1E M=\0U%&I#J`WNU,:W*$N":%E1#TW\_P1AS@C_]&OTN/,:#4=@GH6IE/9ASF[@ M$`0X;<:TEPOT50*\+`>A])^@ST+6.IP6WR5H/YYBT<\@!)$'I3C/T@Q$>&ZR M=`D]6(^Q=%66-$557\F\[>C/=+T\98=LP'+-O+%B7_K[*KW.9YT3OA/"DE57 M$SC:5"^3/;,\XDALU\7;=5TAYHMB;O8T(>%"PH6$<\^>K7>O4=L"_NL+7OID MMPF<#WBWDD<0,*4"4ZMGS]B%RVI8K!&)VOW=UM.Y#\#_2`"N!&,76'<#(4W" MYU:K367--63+VNFRC(-CC#A*>,XQ;!.B>L_>]0"_SJ&SZ6KB09_PT,4=!YNX ML0?--+'2\JK=,PF!Q1NB& M*4DNY4+OL96+`])O`NL=Q[HESDYJYM=SFB/>C\??=4:+U.Y*Q?S6OK08.KJSO?!J(=8@7@(D$=/<2T#2<_6ZI-I&`%@GH;C--)*`//`'= MK-1?$VEJ!NXL'Z57K3H'LJVJLK[SF6K'@B.1#NQX.M#H6:[`NL#Z,6#=08I= ME0V'Z06B!P1XOA/@=(JD=5$D+3+I.Z)(%$DW#CS:+9)6#4.VK:/+`HH<=5=R MU,@N48A`NX5.D:,6.>IN,TWDJ`\\1RV*I(^A2-K49%/42;,K@^`#XGP[GWR* MAH'X)U2

    XML 42 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Option Plan (Details) (USD $)
    		 12 Months Ended 1 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Jul. 31, 2013
    Sep. 17, 2014
    Jul. 18, 2013
    Jul. 17, 2013
    Stock Options              
    Total stock based compensation expense $ 2,070,194us-gaap_AllocatedShareBasedCompensationExpense $ 1,979,364us-gaap_AllocatedShareBasedCompensationExpense $ 532,140us-gaap_AllocatedShareBasedCompensationExpense        
    2014 EIP              
    Stock Options              
    Number of authorized shares under the plan         2,500,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
    / us-gaap_PlanNameAxis
    = trov_EquityIncentive2014PlanMember    		    
    Number of remaining shares available for issuance 1,371,832us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
    / us-gaap_PlanNameAxis
    = trov_EquityIncentive2014PlanMember    		            
    Stock options              
    Stock Options              
    Number of unvested options terminated (in shares) 784,111us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 516,018us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 9,357us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		        
    Number of shares of common stock granted 1,410,038us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 1,144,760us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		 1,294,668us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember    		        
    Stock options | 2004 Plan              
    Stock Options              
    Expiration term of options   10 years          
    Number of authorized shares under the plan           6,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember    		 3,666,667us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember
    Number of remaining shares available for issuance   1,788,921us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember    		          
    Number of options issued over the authorized number of options in the Plan   260,000trov_ShareBasedCompensationNumberOfOptionsIssuedOverStockOptionAuthorized
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember    		          
    Option overage liability   23,024trov_ShareBasedCompensationOptionOverageLiability
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember    		          
    Stock options | Minimum | 2004 Plan              
    Stock Options              
    Vesting period of options   3 years          
    Stock options | Maximum | 2004 Plan              
    Stock Options              
    Vesting period of options   4 years          
    Board of Directors | Stock options | 2004 Plan              
    Stock Options              
    Number of shares of common stock granted       90,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember
    / us-gaap_TitleOfIndividualAxis
    = us-gaap_DirectorMember    		      
    Fair value of option granted       $ 500,000trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
    / us-gaap_AwardTypeAxis
    = us-gaap_EmployeeStockOptionMember
    / us-gaap_PlanNameAxis
    = trov_StockOption2004PlanMember
    / us-gaap_TitleOfIndividualAxis
    = us-gaap_DirectorMember    		      
    XML 43 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Debt (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Debt  
    Schedule of future maturities of long-term debt

     

    2015

     

    $
    1,898,548 

     

    2016

     
    4,790,628 

     

    2017

     
    5,140,519 

     

    2018

     
    3,170,305 

     

    Total long-term obligations

     

    $
    15,000,000 

     

     

    XML 44 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Income Taxes  
    Schedule of significant components of the Company's taxes and the rates

    Tax Rate Reconciliation

     

    Tax computed at the federal statutory rate

     
    (4,871,000

    )
    35

    %

    State tax, net of federal tax benefit

     
    (891,000

    )
    6

    %

    Permanent Items

     
    (320,000

    )
    2

    %

    Valuation allowance increase (decrease)

     
    6,081,000

     
    (43

    )%

    Other

     
    1,000

     

    —

    %

    Provision for income taxes

     

    —

     

     

     

     

    Schedule of significant components of the Company's deferred tax assets

     

     

     

    Years ended
    December 31,

     

     

     

    2014

     

    2013

     

    Deferred tax assets

     

     

     

     

     

    Tax loss carryforwards

     

    $
    19,010,900

     

    $
    14,211,400

     

    R&D credits and other tax credits

     
    698,000

     
    235,300

     

    Stock based compensation

     
    2,193,900

     
    1,547,500

     

    Other

     
    420,800

     
    230,400

     

    Total deferred tax assets

     
    22,323,600

     
    16,224,600

     

    Valuation allowance

     
    (22,323,600

    )
    (16,224,600

    )

    Net deferred tax asset

     

    $

    —

     

    $

    —

     

     

    XML 45 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Business Overview and Liquidity
    		 12 Months Ended
    Dec. 31, 2014
    Business Overview and Liquidity  
    Business Overview and Liquidity

     

    1.  Business Overview and Liquidity

     

    Trovagene, Inc.  (“Trovagene” or the “Company”) is a molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines.  Trovagene’s primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while the Company’s external focus includes entering into collaborations to develop the Company’s technology in areas such as infectious disease, transplant medicine, and prenatal genetics.   The Company’s goal is to improve treatment outcomes for cancer patients using its proprietary technology to detect and quantitatively monitor cell-free DNA in urine.

     

    Underwritten Public Offering of Common Stock

     

    On May 30, 2012, the Company completed an underwritten public offering in which an aggregate of 1,150,000 units, with each unit consisting of two shares of its common stock and one warrant to purchase one share of common stock were sold at a purchase price of $8.00 per unit.  On June 13, 2012, the underwriters exercised their overallotment option in full for an additional 172,500 units.   The Company raised a total of $9.1 million in net proceeds after deducting underwriting discounts and commissions of $0.7 million and offering expenses of $0.7 million.   The units began trading on The NASDAQ Capital Market on May 30, 2012 under the symbol “TROVU”.  The common stock and warrants became separately transferable upon the exercise in full of the underwriters’ overallotment.   Each warrant has an exercise price of $5.32 per share, and expires five years from the closing of the offering.   The warrants trade on The NASDAQ Capital Market under the symbol “TROVW”.  Warrants issued in connection with the underwritten public offering and sale of units in May 2012 are not considered derivatives based on our analysis of the criteria of ASC 815, as the Company is not required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of warrant shares.

     

    To date, Trovagene’s efforts have been principally devoted to research and development, securing and protecting patents and raising capital.  Through December 31, 2014, the Company has sustained cumulative net losses attributed to common stockholders of $81,391,909.  The Company’s losses have resulted primarily from expenditures incurred in connection with research and development activities, stock based compensation expense, patent filing and maintenance expenses, outside accounting and legal services and regulatory, scientific and financial consulting fees, amortization and liquidated damages.   To date, the Company has generated only limited revenue from operations and expects to incur additional losses to perform further research and development activities as well as selling and marketing expenses related to the diagnostic tests it has commercially available as of December 31, 2014.

     

    Liquidity

     

     The Company will need to continue to raise funds until it is able to generate revenues from operations sufficient to fund its development and commercial operations.

     

    Cash used in operating activities was $12,727,385, $7,317,248 and $4,934,661 for the years ended December 31, 2014, 2013, and 2012, respectively.  During the years ended December 31, 2014, 2013 and 2012, the Company incurred net loss and comprehensive loss attributable to common stockholders of $14,348,499, $11,840,778 and $11,604,201, respectively. The Company believes that it currently has adequate capital to continue operations for the subsequent one year business cycle. However, to carry the Company forward beyond the current business cycle until it can generate adequate cash flow from operations, additional cash resources will be necessary.

     

    To date, Trovagene’s sources of cash have been primarily limited to the sale of debt and equity securities, as well as proceeds from warrant and option exercises.  Net cash provided by financing activities for the years ended December 31, 2014, 2013 and 2012 was $14,484,036, $22,983,688 and $15,324,148, respectively.  The Company cannot be certain that additional funding will be available on acceptable terms, or at all.  To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution.  Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business.

     

    If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates.  The Company may also be required to:

     

    Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and

     

    Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms.

     

    XML 46 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingencies (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Commitments and Contingencies.  
    Schedule of annual commitments under current lease agreements

         

    2015

     
    360,775 

     

    2016

     
    371,324 

     

    2017

     
    381,026 

     

    2018

     
    6,380 

     

    Total

     

    $
    1,119,505 

     

     

           

    XML 47 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Property and Equipment (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Property, equipment and depreciation and amortization      
    Depreciation and amortization $ 234,813us-gaap_DepreciationDepletionAndAmortization $ 130,520us-gaap_DepreciationDepletionAndAmortization $ 41,842us-gaap_DepreciationDepletionAndAmortization
    Property and equipment, gross 1,374,257us-gaap_PropertyPlantAndEquipmentGross 1,099,167us-gaap_PropertyPlantAndEquipmentGross  
    Less-accumulated depreciation and amortization (533,870)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment (348,602)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment  
    Property and equipment, net 840,387us-gaap_PropertyPlantAndEquipmentNet 750,565us-gaap_PropertyPlantAndEquipmentNet  
    Furniture and office equipment      
    Property, equipment and depreciation and amortization      
    Property and equipment, gross 365,955us-gaap_PropertyPlantAndEquipmentGross
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = trov_FurnitureAndOfficeEquipmentMember    		 236,645us-gaap_PropertyPlantAndEquipmentGross
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = trov_FurnitureAndOfficeEquipmentMember    		  
    Leasehold Improvements      
    Property, equipment and depreciation and amortization      
    Property and equipment, gross 39,401us-gaap_PropertyPlantAndEquipmentGross
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_LeaseholdImprovementsMember    		 36,371us-gaap_PropertyPlantAndEquipmentGross
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_LeaseholdImprovementsMember    		  
    Laboratory equipment      
    Property, equipment and depreciation and amortization      
    Property and equipment, gross $ 968,901us-gaap_PropertyPlantAndEquipmentGross
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_EquipmentMember    		 $ 826,151us-gaap_PropertyPlantAndEquipmentGross
    / us-gaap_PropertyPlantAndEquipmentByTypeAxis
    = us-gaap_EquipmentMember    		  
    XML 48 R53.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Details 3) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Deferred tax assets    
    Tax loss carryforwards $ 19,010,900us-gaap_DeferredTaxAssetsOperatingLossCarryforwards $ 14,211,400us-gaap_DeferredTaxAssetsOperatingLossCarryforwards
    R&D credits and other tax credits 698,000trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther 235,300trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
    Share based compensation 2,193,900us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost 1,547,500us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
    Other 420,800us-gaap_DeferredTaxAssetsOther 230,400us-gaap_DeferredTaxAssetsOther
    Total deferred tax assets 22,323,600us-gaap_DeferredTaxAssetsGrossCurrent 16,224,600us-gaap_DeferredTaxAssetsGrossCurrent
    Valuation allowance (22,323,600)us-gaap_DeferredTaxAssetsValuationAllowanceCurrent (16,224,600)us-gaap_DeferredTaxAssetsValuationAllowanceCurrent
    Statutory rate (as a percent) 35.00%us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate  
    Actual income tax rate (as a percent) 0.00%us-gaap_EffectiveIncomeTaxRateContinuingOperations  
    Amount of valuation allowances increased 6,099,000us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount 4,398,700us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount
    Interest and/or penalties incurred $ 0us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense  
    XML 49 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
    CONSOLIDATED BALANCE SHEETS (USD $)
    Dec. 31, 2014
    Dec. 31, 2013
    Current assets:    
    Cash and cash equivalents $ 27,293,798us-gaap_CashAndCashEquivalentsAtCarryingValue $ 25,836,937us-gaap_CashAndCashEquivalentsAtCarryingValue
    Accounts receivable 56,694us-gaap_AccountsReceivableNetCurrent 78,994us-gaap_AccountsReceivableNetCurrent
    Prepaid expenses and other assets 369,259us-gaap_PrepaidExpenseAndOtherAssetsCurrent 152,789us-gaap_PrepaidExpenseAndOtherAssetsCurrent
    Total current assets 27,719,751us-gaap_AssetsCurrent 26,068,720us-gaap_AssetsCurrent
    Property and equipment, net 840,387us-gaap_PropertyPlantAndEquipmentNet 750,565us-gaap_PropertyPlantAndEquipmentNet
    Other assets 336,708us-gaap_OtherAssetsNoncurrent 336,450us-gaap_OtherAssetsNoncurrent
    Total assets 28,896,846us-gaap_Assets 27,155,735us-gaap_Assets
    Current liabilities:    
    Accounts payable 747,799us-gaap_AccountsPayableCurrent 286,608us-gaap_AccountsPayableCurrent
    Accrued expenses 1,841,808us-gaap_AccruedLiabilitiesCurrent 1,524,092us-gaap_AccruedLiabilitiesCurrent
    Current portion of long-term debt 1,898,548us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent 198,166us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent
    Total current liabilities 4,488,155us-gaap_LiabilitiesCurrent 2,008,866us-gaap_LiabilitiesCurrent
    Long-term debt, less current portion 13,053,117us-gaap_LongTermDebtAndCapitalLeaseObligations 322,998us-gaap_LongTermDebtAndCapitalLeaseObligations
    Derivative financial instruments 3,006,021us-gaap_DerivativeLiabilitiesNoncurrent 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
    Total liabilities 20,547,293us-gaap_Liabilities 6,763,735us-gaap_Liabilities
    Commitments and contingencies (Note 11)      
    Stockholders' equity    
    Preferred stock, $0.001 par value, 20,000,000 shares authorized; 60,600 shares outstanding at December 31, 2014 and 2013, designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at December 31, 2014 and 2013 60us-gaap_PreferredStockValue 60us-gaap_PreferredStockValue
    Common stock, $0.0001 par value, 150,000,000 shares authorized; 18,915,794 and 18,902,783 issued and outstanding at December 31, 2014 and 2013, respectvely 1,891us-gaap_CommonStockValue 1,890us-gaap_CommonStockValue
    Additional paid-in capital 89,739,511us-gaap_AdditionalPaidInCapital 87,433,460us-gaap_AdditionalPaidInCapital
    Accumulated deficit (81,391,909)us-gaap_RetainedEarningsAccumulatedDeficit (67,043,410)us-gaap_RetainedEarningsAccumulatedDeficit
    Total stockholders' equity 8,349,553us-gaap_StockholdersEquity 20,392,000us-gaap_StockholdersEquity
    Total Liabilities and Stockholders' Equity $ 28,896,846us-gaap_LiabilitiesAndStockholdersEquity $ 27,155,735us-gaap_LiabilitiesAndStockholdersEquity
    XML 50 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Option Plan (Details 2) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Stock-based compensation expense      
    Total stock based compensation expense $ 2,070,194us-gaap_AllocatedShareBasedCompensationExpense $ 1,979,364us-gaap_AllocatedShareBasedCompensationExpense $ 532,140us-gaap_AllocatedShareBasedCompensationExpense
    Research and Development Expense      
    Stock-based compensation expense      
    Total stock based compensation expense 796,008us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_ResearchAndDevelopmentExpenseMember    		 549,465us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_ResearchAndDevelopmentExpenseMember    		 136,148us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_ResearchAndDevelopmentExpenseMember
    General and Administrative Expense.      
    Stock-based compensation expense      
    Total stock based compensation expense $ 1,274,186us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_GeneralAndAdministrativeExpenseMember    		 $ 1,429,899us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_GeneralAndAdministrativeExpenseMember    		 $ 395,992us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_GeneralAndAdministrativeExpenseMember
    XML 51 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Statements of Cash Flows (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Operating activities      
    Net loss $ (14,325,484)us-gaap_NetIncomeLoss $ (11,810,938)us-gaap_NetIncomeLoss $ (11,565,961)us-gaap_NetIncomeLoss
    Adjustments to reconcile net loss to net cash used in operating activities:      
    (Loss) gain on disposal of fixed assets (24,845)us-gaap_GainLossOnSaleOfPropertyPlantEquipment 22,941us-gaap_GainLossOnSaleOfPropertyPlantEquipment (4,000)us-gaap_GainLossOnSaleOfPropertyPlantEquipment
    Depreciation and amortization 234,813us-gaap_DepreciationDepletionAndAmortization 130,520us-gaap_DepreciationDepletionAndAmortization 41,842us-gaap_DepreciationDepletionAndAmortization
    Stock based compensation expense 2,070,194us-gaap_ShareBasedCompensation 1,979,364us-gaap_ShareBasedCompensation 532,140us-gaap_ShareBasedCompensation
    Amortization of debt costs 248,799us-gaap_AmortizationOfDebtDiscountPremium    
    Accretion of discount on debt 57,117us-gaap_AccretionOfDiscount    
    Change in fair value of financial instruments (1,425,850)us-gaap_UnrealizedGainLossOnDerivatives 1,084,114us-gaap_UnrealizedGainLossOnDerivatives 6,720,805us-gaap_UnrealizedGainLossOnDerivatives
    Stock and warrant issued in connection with consulting services   198,791trov_StockBasedExpenseForConsultingServices 164,889trov_StockBasedExpenseForConsultingServices
    Changes in operating assets and liabilities:      
    Decrease (increase) in other assets (258)us-gaap_IncreaseDecreaseInOtherOperatingAssets 25,631us-gaap_IncreaseDecreaseInOtherOperatingAssets  
    Decrease (increase) in accounts receivable 22,300us-gaap_IncreaseDecreaseInAccountsReceivable 89,387us-gaap_IncreaseDecreaseInAccountsReceivable (69,241)us-gaap_IncreaseDecreaseInAccountsReceivable
    (Increase) decrease in prepaid expenses (216,470)us-gaap_IncreaseDecreaseInPrepaidExpense (92,748)us-gaap_IncreaseDecreaseInPrepaidExpense (17,383)us-gaap_IncreaseDecreaseInPrepaidExpense
    Increase (decrease) in accounts payable, accrued expenses and other long-term liabilities 632,299us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 1,055,690us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (737,752)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
    Net cash used in operating activities (12,727,385)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (7,317,248)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (4,934,661)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
    Investing activities:      
    Capital expenditures (363,290)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (649,784)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (274,080)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
    Proceeds from disposals of capital equipment 63,500us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment 500us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment 4,000us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment
    Net cash used in investing activities (299,790)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (649,284)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (270,080)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
    Financing activities:      
    Proceeds of sale of common stock, net of expenses   18,829,644us-gaap_ProceedsFromIssuanceOfCommonStock 15,323,548us-gaap_ProceedsFromIssuanceOfCommonStock
    Proceeds from exercise of warrants   3,599,831us-gaap_ProceedsFromWarrantExercises  
    Proceeds from exercise of options   38,249us-gaap_ProceedsFromStockOptionsExercised 600us-gaap_ProceedsFromStockOptionsExercised
    Borrowings (repayments) from equipment line of credit (515,964)us-gaap_ProceedsFromLongTermCapitalLeaseObligations 515,964us-gaap_ProceedsFromLongTermCapitalLeaseObligations  
    Borrowings under debt agreement 15,000,000us-gaap_ProceedsFromIssuanceOfLongTermDebt    
    Net cash provided by financing activities 14,484,036us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 22,983,688us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 15,324,148us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
    Net change in cash and equivalents 1,456,861us-gaap_NetCashProvidedByUsedInContinuingOperations 15,017,156us-gaap_NetCashProvidedByUsedInContinuingOperations 10,119,407us-gaap_NetCashProvidedByUsedInContinuingOperations
    Cash and cash equivalents-Beginning of period 25,836,937us-gaap_CashAndCashEquivalentsAtCarryingValue 10,819,781us-gaap_CashAndCashEquivalentsAtCarryingValue 700,374us-gaap_CashAndCashEquivalentsAtCarryingValue
    Cash and cash equivalents-End of period 27,293,798us-gaap_CashAndCashEquivalentsAtCarryingValue 25,836,937us-gaap_CashAndCashEquivalentsAtCarryingValue 10,819,781us-gaap_CashAndCashEquivalentsAtCarryingValue
    Supplementary disclosure of cash flow activity:      
    Cash paid for taxes 2,400us-gaap_IncomeTaxesPaid 7,650us-gaap_IncomeTaxesPaid  
    Cash paid for interest 425,256us-gaap_InterestPaid 9,459us-gaap_InterestPaid  
    Supplemental disclosure of non-cash investing and financing activities:      
    Warrants issued in connection with Loan and Security Agreement 235,857trov_OriginalValueOfWarrants    
    Amortization of debt costs and final payment 248,799us-gaap_AmortizationOfDebtDiscountPremium    
    Reclassification of derivative financial instruments to additional paid in capital   (5,417,871)trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount (3,317,463)trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    Correction of error in derivative financial instruments     (274,967)trov_ReclassificationOfDerivativeFinancialInstrumentsCorrectionOfError
    Preferred stock dividends accrued $ 23,015trov_PreferredStockDividendAccrued $ 29,840trov_PreferredStockDividendAccrued $ 38,240trov_PreferredStockDividendAccrued
    XML 52 R59.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Selected Quarterly Financial Data (Unaudited) (Details) (USD $)
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2014
    Sep. 30, 2014
    Jun. 30, 2014
    Mar. 31, 2014
    Dec. 31, 2013
    Sep. 30, 2013
    Jun. 30, 2013
    Mar. 31, 2013
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Selected Quarterly Financial Data (Unaudited)                      
    Revenues $ 56,000us-gaap_SalesRevenueNet $ 57,000us-gaap_SalesRevenueNet $ 56,000us-gaap_SalesRevenueNet $ 111,000us-gaap_SalesRevenueNet $ 47,000us-gaap_SalesRevenueNet $ 44,000us-gaap_SalesRevenueNet $ 49,000us-gaap_SalesRevenueNet $ 119,000us-gaap_SalesRevenueNet $ 280,178us-gaap_SalesRevenueNet $ 259,246us-gaap_SalesRevenueNet $ 450,404us-gaap_SalesRevenueNet
    Cost of Revenues                 15,441us-gaap_CostOfRevenue    
    Operating expenses 4,560,000us-gaap_OperatingExpenses 3,997,000us-gaap_OperatingExpenses 3,297,000us-gaap_OperatingExpenses 3,371,000us-gaap_OperatingExpenses 2,897,000us-gaap_OperatingExpenses 3,121,000us-gaap_OperatingExpenses 2,423,000us-gaap_OperatingExpenses 2,509,000us-gaap_OperatingExpenses 15,225,337us-gaap_OperatingExpenses 10,949,787us-gaap_OperatingExpenses 5,299,560us-gaap_OperatingExpenses
    Net loss and comprehensive loss attributable to common stockholders $ (4,689,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (5,382,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,079,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (3,198,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,038,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (4,407,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (5,279,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,117,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (14,348,499)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (11,840,778)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (11,604,201)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
    Net loss per common share - basic $ (0.25)us-gaap_EarningsPerShareBasic $ (0.28)us-gaap_EarningsPerShareBasic $ (0.06)us-gaap_EarningsPerShareBasic $ (0.17)us-gaap_EarningsPerShareBasic $ (0.05)us-gaap_EarningsPerShareBasic $ (0.25)us-gaap_EarningsPerShareBasic $ (0.34)us-gaap_EarningsPerShareBasic $ (0.07)us-gaap_EarningsPerShareBasic $ (0.76)us-gaap_EarningsPerShareBasic $ (0.70)us-gaap_EarningsPerShareBasic $ (0.89)us-gaap_EarningsPerShareBasic
    Net loss per common share - diluted $ (0.25)us-gaap_EarningsPerShareDiluted $ (0.28)us-gaap_EarningsPerShareDiluted $ (0.17)us-gaap_EarningsPerShareDiluted $ (0.17)us-gaap_EarningsPerShareDiluted $ (0.05)us-gaap_EarningsPerShareDiluted $ (0.25)us-gaap_EarningsPerShareDiluted $ (0.34)us-gaap_EarningsPerShareDiluted $ (0.07)us-gaap_EarningsPerShareDiluted $ (0.88)us-gaap_EarningsPerShareDiluted $ (0.70)us-gaap_EarningsPerShareDiluted $ (0.89)us-gaap_EarningsPerShareDiluted
    Shares used in the calculation of net loss attributable to common stockholders - basic 18,904,280us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,902,783us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,902,783us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,902,783us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,900,781us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 17,870,703us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 15,583,957us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 15,510,340us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,904,280us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 16,978,212us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 13,066,600us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
    Shares used in the calculation of net loss attributable to common stockholders - diluted 19,071,112us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 18,902,783us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 19,232,760us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 18,902,783us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 18,900,781us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 17,870,703us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 15,583,957us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 15,510,340us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 19,071,112us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 16,978,212us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 13,066,600us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
    XML 53 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies (Details) (USD $)
    		 0 Months Ended
    May 29, 2012
    Apr. 27, 2012
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2011
    Basis of Presentation and Summary of Significant Accounting Policies            
    Noninterest bearing cash balances insured, maximum     $ 250,000trov_NoninterestBearingCashBalanceFDICInsuredAmountMaximum $ 250,000trov_NoninterestBearingCashBalanceFDICInsuredAmountMaximum    
    Derivative financial instruments            
    Stock split ratio 0.1667us-gaap_StockholdersEquityNoteStockSplitConversionRatio1          
    Derivative liabilities related to warrants     3,006,021us-gaap_DerivativeLiabilitiesNoncurrent 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent    
    Minimum            
    Derivative financial instruments            
    Stock split ratio   0.1667us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		        
    Maximum            
    Derivative financial instruments            
    Stock split ratio   0.50us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		        
    Warrants | Black Scholes Option Pricing Method            
    Derivative financial instruments            
    Derivative liabilities related to warrants     3,006,021us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 6,252,760us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		 994,627us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember
    Warrants | Binomial Option Pricing Method            
    Derivative financial instruments            
    Derivative liabilities related to warrants         $ 2,512,868us-gaap_DerivativeLiabilitiesNoncurrent
    / us-gaap_DerivativeByNatureAxis
    = us-gaap_WarrantMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BinomialOptionPricingMethodMember    		  
    XML 54 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Subsequent Events
    		 12 Months Ended
    Dec. 31, 2014
    Subsequent Events  
    Subsequent Events

     

    15.  Subsequent Events

     

    Public Offering and Controlled Equity Offering

     

    On February 11, 2015, the Company closed an underwritten public offering of 5,111,110 shares of its common stock.  The offering price was $4.50 per share and net proceeds to the Company were approximately $21.3 million. The effects of this offering would materially change the number of common shares outstanding at the end of the reporting period had the transaction occurred before December 31, 2014.

     

    Related Party Consulting Agreement

     

    On January 1, 2015, we entered into a consulting agreement with Tom Adams, our Chairman, pursuant to which Dr. Adams will provide consulting services to us in connection with applying our technology to infectious diseases.  The agreement is for a term of one year and Dr. Adams shall be paid $9,500 per month for his services.

     

    XML 55 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies (Details 2)
    		 12 Months Ended
    Dec. 31, 2014
    Laboratory equipment | Minimum  
    Property, equipment and depreciation and amortization  
    Estimated useful lives 3 years
    Laboratory equipment | Maximum  
    Property, equipment and depreciation and amortization  
    Estimated useful lives 5 years
    Furniture and fixtures | Minimum  
    Property, equipment and depreciation and amortization  
    Estimated useful lives 3 years
    Furniture and fixtures | Maximum  
    Property, equipment and depreciation and amortization  
    Estimated useful lives 5 years
    XML 56 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Basis of Presentation and Summary of Significant Accounting Policies  
    Schedule of antidilutive securities excluded from the calculation of basic and diluted loss per share

     

     

     

    December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Options to purchase Common Stock

     
    4,913,472 

     
    4,287,545 

     
    3,711,303 

     

    Warrants to purchase Common stock

     
    5,251,660 

     
    6,233,483 

     
    6,985,070 

     

    Series A Convertible Preferred Stock

     
    63,125 

     
    63,125 

     
    99,583 

     

     

     
    10,228,257 

     
    10,584,153 

     
    10,795,956 

     

     

    Summary of the Company's diluted net loss per share

     

     

     

    December 31,

     

    December 31,

     

    December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Numerator:

     

     

     

     

     

     

     

    Net loss

     

    $
    (14,348,499

    )

    $
    (11,840,778

    )

    $
    (11,604,201

    )

    Adjustment for change in fair value of derivative instruments - warrants

     
    (2,422,337

    )

    —

     

    —

     

    Net loss used for diluted loss per share

     

    $
    (16,770,836

    )

    $
    (11,840,778

    )

    $
    (11,604,201

    )

     

     

     

     

     

     

     

     

    Denominator:

     

     

     

     

     

     

     

    Weighted average shares used to compute basic loss per share

     
    18,904,280

     
    16,978,212

     
    13,066,600

     

    Adjustments to reflect assumed exercise of warrants

     
    166,832

     

    —

     

    —

     

    Weighted average shares used to compute diluted net loss per share

     
    19,071,112

     
    16,978,212

     
    13,066,600

     

     

     

     

     

     

     

     

     

    Net loss per share diluted

     

    $
    (0.88

    )

    $
    (0.70

    )

    $
    (0.89

    )

       

    XML 57 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 58 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Statements of Cash Flows (Parenthetical) (MultiGen Diagnostics, Inc)
    		 12 Months Ended
    Dec. 31, 2012
    MultiGen Diagnostics, Inc
    		  
    Common stock issued in connection with an asset purchase agreement (in shares) 125,000us-gaap_StockIssuedDuringPeriodSharesAcquisitions
    / dei_LegalEntityAxis
    = trov_MultiGenDiagnosticsIncMember
    XML 59 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
    CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
    Dec. 31, 2014
    Dec. 31, 2013
    CONSOLIDATED BALANCE SHEETS    
    Preferred stock, par value (in dollars per share) $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare $ 0.001us-gaap_PreferredStockParOrStatedValuePerShare
    Preferred stock, shares authorized 20,000,000us-gaap_PreferredStockSharesAuthorized 20,000,000us-gaap_PreferredStockSharesAuthorized
    Preferred stock, shares outstanding 60,600us-gaap_PreferredStockSharesOutstanding 60,600us-gaap_PreferredStockSharesOutstanding
    Series A Convertible Preferred Stock, liquidation preference (in dollars) $ 606,000us-gaap_PreferredStockLiquidationPreferenceValue $ 606,000us-gaap_PreferredStockLiquidationPreferenceValue
    Common stock, par value (in dollars per share) $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare $ 0.0001us-gaap_CommonStockParOrStatedValuePerShare
    Common stock, shares authorized 150,000,000us-gaap_CommonStockSharesAuthorized 150,000,000us-gaap_CommonStockSharesAuthorized
    Common stock, shares issued 18,915,793us-gaap_CommonStockSharesIssued 18,902,782us-gaap_CommonStockSharesIssued
    Common stock, shares outstanding 18,915,794us-gaap_CommonStockSharesOutstanding 18,902,782us-gaap_CommonStockSharesOutstanding
    XML 60 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2014
    Income Taxes  
    Income Taxes

     

    10.  Income Taxes

     

    At December 31, 2014, Trovagene has federal net operating loss carryforwards (NOLs) of approximately $49.3 million, which, if not used, expire beginning in 2020.   Trovagene also has California NOLs of approximately $ 29.9 million which begin to expire in 2021 and New Jersey NOLs of $11.5 million which started to expire on January 31, 2013.   Trovagene also has R&D credits available for federal purposes of approximately $698,000. The federal R&D credits will begin to expire January 31, 2025.   The utilization of these NOLs and R&D tax credits is subject to limitations based on past and future changes in ownership of Trovagene pursuant to Internal Revenue Code Section 382.  The Company has determined that ownership changes have occurred for Internal Revenue Code Section 382 purposes and therefore, the ability of the Company to utilize its NOLs is limited.

     

    Signifcant components of the Company’s taxes and the rates as of December 31, are shown below:

     

    Tax Rate Reconciliation

     

    Tax computed at the federal statutory rate

     
    (4,871,000

    )
    35

    %

    State tax, net of federal tax benefit

     
    (891,000

    )
    6

    %

    Permanent Items

     
    (320,000

    )
    2

    %

    Valuation allowance increase (decrease)

     
    6,081,000

     
    (43

    )%

    Other

     
    1,000

     

    —

    %

    Provision for income taxes

     

    —

     

     

     

     

    Significant components of the Company’s deferred tax assets as of December 31, are shown below:

     

     

     

    Years ended
    December 31,

     

     

     

    2014

     

    2013

     

    Deferred tax assets

     

     

     

     

     

    Tax loss carryforwards

     

    $
    19,010,900

     

    $
    14,211,400

     

    R&D credits and other tax credits

     
    698,000

     
    235,300

     

    Stock based compensation

     
    2,193,900

     
    1,547,500

     

    Other

     
    420,800

     
    230,400

     

    Total deferred tax assets

     
    22,323,600

     
    16,224,600

     

    Valuation allowance

     
    (22,323,600

    )
    (16,224,600

    )

    Net deferred tax asset

     

    $

    —

     

    $

    —

     

     

    The difference between the statutory rate of 35% on taxable income and the actual income tax rate of zero is a result of the full deferred tax asset valuation allowance.   The valuation allowance increased by $6,099,000 and $4,398,700 during the years ended December 31, 2014 and 2013, respectively.

     

    Trovagene records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.

     

    ASC 740-10-30-7, Accounting for Income Taxes had no effect on Trovagene’s financial position, cash flows or results of operations upon adoption, as Trovagene does not have any unrecognized tax benefits.  Trovagene’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense and none have been incurred to date.

     

    XML 61 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Document and Entity Information (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Feb. 27, 2015
    Jun. 30, 2014
    Document and Entity Information      
    Entity Registrant Name Trovagene, Inc.    
    Entity Central Index Key 0001213037    
    Document Type 10-K    
    Document Period End Date Dec. 31, 2014    
    Amendment Flag false    
    Current Fiscal Year End Date --12-31    
    Entity Well-known Seasoned Issuer No    
    Entity Voluntary Filers Yes    
    Entity Current Reporting Status Yes    
    Entity Filer Category Accelerated Filer    
    Entity Public Float     $ 63,974,477dei_EntityPublicFloat
    Entity Common Stock, Shares Outstanding   24,123,790dei_EntityCommonStockSharesOutstanding  
    Document Fiscal Year Focus 2014    
    Document Fiscal Period Focus FY    
    XML 62 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2014
    Commitments and Contingencies.  
    Commitments and Contingencies

     

    11.  Commitments and Contingencies

     

    Significant Research Agreements

     

    During 2012, the Company entered into research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of cell-free DNA mutations analysis from urine samples and tumor tissue.   During 2013, the agreements were amended to increase the scope of the agreements.   Under these agreements, the Company has committed to pay approximately $266,000 for the services performed by MDACC.   As of December 31, 2014, the Company has incurred and recorded approximately $124,000 of research and development expenses related to these agreements.  There were approximately $142,000 of research and development expenses incurred during the year ended December 31, 2013.

     

    In June 2013, the Company entered into a Research Agreement with Illumina, Inc. (“Illumina”) pursuant to which the parties will work together to evaluate the potential for integrating the Company’s cell-free technology for isolating, extracting and genetic analysis of nucleic acids from urine with Illumina’s genetic analysis sequencing technology (the “Research Plan”).   The parties have agreed that all results and reagents from the Research Plan will be shared between the parties.   The Agreement will terminate upon the earlier of 30 days after completion of the Research Plan or the one year anniversary of the Agreement unless extended by mutual written agreement.  In October 2014, the agreement was extended for an additional year to June 2015.

     

    In August 2013, the Company entered into a Clinical Trial Agreement with the University of Southern California (“USC”), pursuant to which USC will provide the principal investigator and conduct the clinical trial related to the genetic characterization of metastatic colorectal cancers.   Under the agreement, the Company is committed to pay USC approximately $232,000 for services provided.   As of December 31, 2013 the Company had not incurred any expense related to this agreement.  As of December 31, 2014, the Company had incurred approximately $38,000 of research and development expenses.

     

    In December 2013, the Company entered into a Clinical Trial Agreement with US Oncology Research LLC (“USOR”), pursuant to which USOR will provide the principal investigator and conduct the clinical trial related to the examining the utility of cell-free quantitative KRAS testing in disease monitoring in patients with metastatic pancreatic cancer.   Under the agreement, the Company is committed to pay USOR approximately $270,000 for services provided.   As of December 31, 2014 and 2013, the Company has incurred and recorded approximately $16,000 and $29,000 of research and development expense related to this agreement.

     

    In October 2014, the Company entered into a Research Agreement with Genomac International, Ltd., pursuant to which Genomac will conduct a research study of minimally invasive molecular monitoring of efficiency of targeted biological therapy in advanced non-small lung cancer.   Under the agreement, the Company is committed to pay Genomac approximately $175,000 for services provided.  As of December 31, 2014, the Company has incurred and recorded approximately $90,000 of research and development expenses.

     

    License Agreements

     

    In May 2006, the Company entered into a license agreement with Drs. Falini and Mecucci, wherein it obtained the exclusive rights for the genetic marker for AML and intends to utilize these rights for the development of new diagnostic tools.  In connection with this agreement, the Company paid $70,000 to Drs. Falini and Mecucci.  In August 2010 the Company signed amendment No. 1 to the license agreement with an obligation to payroyalties of 6% of royalty revenues and/or 10% of any sublicense income.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty expenses of approximately $23,000, $30,000 and $24,000, respectively.

     

    During August 2007, the Company signed a sublicensing agreement with IPSOGEN SAS, a leading molecular diagnostics company with operations in France and the United States for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.  Upon execution of this agreement, IPSOGEN paid an initial licensing fee of $120,000 and may make milestone payments upon the attainment of certain regulatory and commercial milestones.  IPSOGEN will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.    In September 2010, the Company signed amendment No. 1 to the sublicensing agreement.  The amendment asserts that the Compay may require a license from a third-party to perform laboratory testing services.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty, milestone and license fee revenues of approximately $60,000, $60,000 and $180,000, respectively.  During those same periods, the Company had no license fee expenses.

     

    In October 2007, the Company signed a license agreement with ASURAGEN, Inc. for the co-exclusive rights to develop, manufacture and market, research and diagnostic products for the stratification and monitoring of patients with AML.  ASURAGEN paid an initial licensing fee of $120,000 upon execution of the agreement and may make future payments to the Company upon the attainment of certain regulatory and commercial milestones.  In June 2010, the Compay signed amendment No. 1 to the co-exclusive license agreement.  The amendment asserts that the Company may require a license from a third-party to perform laboratory testing services.  ASURAGEN will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  In March 2013, we signed amendment No.  2 to the co-exclusive sublicense agreement with ASURAGEN.   The amendment limited the field of use to research use only (RUO) kits.   ASURAGEN was also granted a non-exclusive sublicense for NPMI laboratory testing services.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $50,000, $50,000 and $50,000, respectively.   During those same periods, the Company had no license fee expenses related to this agreement.

     

    In August 2008, the Company signed a sublicensing agreement with LabCorp for the non-exclusive rights to develop and market lab testing services for NPM1, for the diagnosis and monitoring of patients with AML.  LabCorp paid an initial licensing fee of $20,000 upon execution of the agreement.  LabCorp will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends August 25, 2018.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $28,000, $20,000 and $5,000, respectively.  During those same years, the Company has not recorded any license fee expenses.

     

    In December 2008, the Company signed a sublicensing agreement with InVivoScribe Technologies, Inc. for the non-exclusive rights to develop and market lab testing services for NPM1 for the diagnosis and monitoring of patients with AML.  InVivoScribe Technologies paid an initial licensing fee of $10,000 upon execution of the agreement.  InVivoScribe Technologies will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013, and 2012, the Company recorded royalty and license fee revenues of approximately $25,000, $25,000 and $27,000, respectively.  During those same periods, the Company has not recorded any license fee expenses.

     

    In June 2010, the Company signed a sublicensing agreement with Skyline Diagnostics BV for the non-exclusive rights to develop, commercialize and market, research and diagnostic laboratory services for the stratification and monitoring of patients with AML.  Skyline Diagnostics BV paid an initial licensing fee of $10,000 upon execution of the agreement and may make future payments to the Company upon the attainment of certain regulatory and commercial milestones.  Skyline Diagnostics BV will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $0, $0 and $0, respectively.  During those same periods, the Company has not recorded any license fee expenses.

     

    In January 2011, the Company entered into an asset purchase agreement with TTFactor S.r.l.for a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker for $10,000.  In addition the Company agreed to pay the seller of the hybridoma for a period of seven years commencing with the first sale of the antibody, annual royalties on a country by country basis.   In addition, the Company agreed to pay a percentage of all cash consideration received from licensees as an upfront license fee pursuant to any licenses of the product and a percentage of all cash consideration received from licensees as milestone payments.  The agreement was terminated in 2013.   During the years ended December 31, 2014, 2013, and 2012, there were no royalty expense, license fee or milestone payments recorded related to this agreement.

     

    In February 2011, the Company entered into a sublicense agreement with MLL Münchner Leukämielabor, or MLL for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  MLL paid an initial license fee of $20,000 upon execution of the agreement and will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  MLL is obligated to pay a royalty with annual minimums of $15,000 for the first year and $20,000 thereafter.  The term of the license ends on October 28, 2025 which is the date of expiration of the issued patent rights.  During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $81,000, $85,000 and $71,000, respectively.

     

    In July 2011, the Company entered into a sublicense agreement with Fairview Health Services (“Fairview”) for the non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Fairview paid an initial license fee of $10,000 upon execution of the agreement and will also pay the Company a royalty on any net revenues during the term of the agreement, subject to certain minimums.  Fairview is obligated to pay a royalty with annual minimums of $1,000 each year.  During the years ended December 31, 2014, 2013, and 2012, the Company recorded royalty and license fee revenues of approximately $2,000, $1,000 and $2,000, respectively.

     

    In October 2011, the Company entered into an exclusive license agreement with Gianluca Gaidano, Robert Foa and Davide Rossi for the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia.  In consideration of the license, the Company paid $1,000 as an upfront license fee and agreed to make royalty payments in the single digits on net sales if sales are made by the Company or a single digit royalty on sublicense income received by the Company if sales are made by sublicensees.  The Company has an option to purchase the licensed patent rights in the event the licensor decides to sell such licensed patent rights.  The license agreement shall continue until September 29, 2031 which is the date of the last to expire of the licensed patent rights covering the license product.  The license agreement may also be terminated upon a material breach by any party or by the Company if it is determined that it is not commercially or scientifically appropriate to further develop the license product rights.  During the years ended December 31, 2014, 2013 and 2012, no royalty expense has been recorded related to this agreement.

     

    In December 2011, the Company entered into an exclusive license agreement with Columbia University to license the patent rights to hairy cell leukemia biomarkers.  In consideration of the license, the Company paid $1,000 as an upfront license fee and agreed to make royalty payments in the single digits on net sales if sales are made by the Company or a single digit royalty on sublicense income received by the Company if sales are made by sublicensees.  The license agreement shall continue until May 10, 2021 which is the date of the last to expire of the licensed patent rights covering the license product.  The license agreement may also be terminated upon a material breach by any party or by the Company if we determine that it is not commercially or scientifically appropriate to further develop the license product rights.  During the years ended December 31, 2014, 2013 and 2012, no royalty expense has been recorded related to this agreement.

     

    In September 2012, the Company entered into a sublicense agreement with Quest Diagnostics for non-exclusive rights to develop and market laboratory testing services for NPM1 for the diagnosis and monitoring of patients with AML.  Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $20,000 due upon execution of the agreement and royalty payments on net sales of Quest Diagnostics and its affiliates.   During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $26,000, $14,000 and $20,000, respectively.

     

    In September 2012, the Company entered into a collaboration and license agreement with Strand Life Sciences (“Strand”) related to the validation and commercial launch of a urine based DNA test for Human Papillomavirus.   Under this agreement, the Company has granted a license for use of its tests to Strand in exchange for royalty payments on net sales earned in the territory specified in the agreement.   During the years ended December 31, 2014, 2013 and 2012, the Company has recorded no royalty and license fee revenues related to this agreement.

     

    In November 2012, the Company entered into a sublicense agreement with Duke University and Duke University Health Systems for non-exclusive rights to develop and market laboratory testing services for NPM1 for diagnosis and monitoring of patients with AML.   Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $5,000 due upon execution of the agreement and royalty payments on net revenues.   During the years ended December 31, 2014, 2013 and 2012, the Company has recorded $1,000, $0 and $5,000, respectively of royalty and license fee revenues related to this agreement.

     

    In December 2012, the Company entered into a sublicense agreement with Genoptix, Inc. for non-exclusive worldwide rights to develop and market laboratory testing services for NPM1 for diagnosis and monitoring of patients with AML.   Under this agreement, the Company has granted a license to certain NPM1 patents in exchange for a one time license fee of $100,000 due upon execution of the agreement and royalty payments on net revenues.   During the years ended December 31, 2014, 2013 and 2012, the Company recorded royalty and license fee revenues of approximately $30,000, $10,000 and $100,000, respectively.

     

    Litigation

     

    Trovagene does not believe that the Company has legal liabilities that are probable or reasonably possible that require either accrual or disclosure.  From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.  However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

     

    We are not currently a party to any material legal proceedings.

     

    Employment and Consulting Agreements

     

    During 2011, the Company entered into an executive agreement with Antonius Schuh, Ph.D. in which he agreed to serve as Chief Executive Officer.  The term of the agreement is effective as of October 4, 2011 and continues until October 4, 2015 and is automatically renewed for successive one year periods at the end to each term.  In the event that during the term of the agreement, for a period of 90 consecutive trading days, the market price of the common stock is $7.50 or more and the value of the common stock daily trading volume is $125,000 or more, the Company shall pay or issue Dr. Schuh a bonus in an amount of $3,466,466 in either cash or registered common stock or a combination thereof as mutually agreed by Dr. Schuh the Company; or in the event that during the term of the agreement, a change of control occurs where the per share enterprise value of our company equals or exceeds $7.50 per share, the Company shall pay Dr. Schuh a bonus in an amount determined by multiplying the enterprise value by 4.0%.  In the event in a change of control the per share enterprise value exceeds a minimum of $14.40 per share, $22.80 per share or $30.00 per share, Dr. Schuh shall receive a bonus in an amount determined by multiplying the incremental enterprise value by 2.5%, 2.0% or 1.5%, respectively.

     

    If the executive agreement is terminated for cause or as a result of Dr. Schuh’s death or permanent disability or if Dr. Schuh terminates his agreement voluntarily, Dr. Schuh shall receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus or realization bonus earned but not yet paid through the date of termination and (iii) all expenses reasonably incurred by Dr. Schuh prior to date of termination.  If the executive agreement is terminated without cause Dr. Schuh shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.  If the executive agreement is terminated as a result of a change of control, Dr. Schuh shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.

     

    During 2012, the Company entered into an executive agreement with Steve Zaniboni in which he agreed to serve as Chief Financial Officer.  If the executive agreement is terminated by the Company for cause or as a result of Mr. Zaniboni’s death or permanent disability or if Mr. Zaniboni terminates his agreement voluntarily, Mr. Zaniboni shall receive a lump sum equal to (i) any portion of unpaid base compensation then due for periods prior to termination, (ii) any bonus or realization bonus earned but not yet paid through the date of termination and (iii) all expenses reasonably incurred by Mr. Zaniboni prior to date of termination.  If the executive agreement is terminated by the Company without cause Mr. Zaniboni shall receive a severance payment equal to base compensation for three months if termination occurs ten months after the effective date of the agreement and six months if termination occurs subsequent to ten months from the effective date.  If the executive agreement is terminated as a result of a change of control, Mr. Zaniboni shall receive a severance payment equal to base compensation for twelve months and all unvested stock options shall immediately vest and become fully exercisable for a period of six months following the date of termination.

     

    Lease Agreements

     

    The Company leases its facilities under a noncancelable operating lease that expires in 2017.   Rent expense for the years ended December 31, 2014, 2013 and 2012 was $315,000, $294,000, and $270,000, and respectively.  The Company is also a party to various operating lease agreements for office equipment.

     

    Total annual commitments under current lease agreements for each of the years ended December 31, are as follows:

     

    2015

     
    360,775 

     

    2016

     
    371,324 

     

    2017

     
    381,026 

     

    2018

     
    6,380 

     

    Total

     

    $
    1,119,505 

     

     

    XML 63 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Statements of Operations and Comprehensive Loss (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    CONSOLIDATED STATEMENTS OF OPERATIONS      
    Royalty income $ 270,178us-gaap_RoyaltyRevenue $ 259,246us-gaap_RoyaltyRevenue $ 175,404us-gaap_RoyaltyRevenue
    Milestone fees     150,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
    License fees 10,000us-gaap_LicenseAndServicesRevenue   125,000us-gaap_LicenseAndServicesRevenue
    Total revenues 280,178us-gaap_SalesRevenueNet 259,246us-gaap_SalesRevenueNet 450,404us-gaap_SalesRevenueNet
    Costs and expenses:      
    Cost of sales 15,441us-gaap_CostOfRevenue    
    Research and development 6,664,906us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost 3,947,589us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost 1,920,298us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
    Selling and marketing 2,734,903us-gaap_SellingAndMarketingExpense 1,530,160us-gaap_SellingAndMarketingExpense 506,535us-gaap_SellingAndMarketingExpense
    General and administrative 5,810,087us-gaap_GeneralAndAdministrativeExpense 5,472,038us-gaap_GeneralAndAdministrativeExpense 2,872,727us-gaap_GeneralAndAdministrativeExpense
    Total operating expenses 15,225,337us-gaap_OperatingExpenses 10,949,787us-gaap_OperatingExpenses 5,299,560us-gaap_OperatingExpenses
    Loss from operations (14,945,159)us-gaap_OperatingIncomeLoss (10,690,541)us-gaap_OperatingIncomeLoss (4,849,156)us-gaap_OperatingIncomeLoss
    Interest income 12,239us-gaap_InvestmentIncomeNet 3,663us-gaap_InvestmentIncomeNet  
    Interest expense (843,259)us-gaap_InterestExpense (17,005)us-gaap_InterestExpense  
    Gain (loss) on disposal of equipment 24,845us-gaap_GainLossOnSaleOfPropertyPlantEquipment (22,941)us-gaap_GainLossOnSaleOfPropertyPlantEquipment 4,000us-gaap_GainLossOnSaleOfPropertyPlantEquipment
    Gain (loss) from change in fair value of derivative instruments-warrants 1,425,850us-gaap_UnrealizedGainLossOnDerivatives (1,084,114)us-gaap_UnrealizedGainLossOnDerivatives (6,720,805)us-gaap_UnrealizedGainLossOnDerivatives
    Net loss and comprehensive loss (14,325,484)us-gaap_NetIncomeLoss (11,810,938)us-gaap_NetIncomeLoss (11,565,961)us-gaap_NetIncomeLoss
    Preferred stock dividend (23,015)us-gaap_PreferredStockDividendsIncomeStatementImpact (29,840)us-gaap_PreferredStockDividendsIncomeStatementImpact (38,240)us-gaap_PreferredStockDividendsIncomeStatementImpact
    Net loss attributable to common stockholders $ (14,348,499)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (11,840,778)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (11,604,201)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
    Net loss per common share - basic $ (0.76)us-gaap_EarningsPerShareBasic $ (0.70)us-gaap_EarningsPerShareBasic $ (0.89)us-gaap_EarningsPerShareBasic
    Net loss per common share - diluted $ (0.88)us-gaap_EarningsPerShareDiluted $ (0.70)us-gaap_EarningsPerShareDiluted $ (0.89)us-gaap_EarningsPerShareDiluted
    Weighted average shares outstanding - basic 18,904,280us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 16,978,212us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 13,066,600us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
    Weighted average shares outstanding - diiluted 19,071,112us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 16,978,212us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 13,066,600us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
    XML 64 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Deficiency)
    		 12 Months Ended
    Dec. 31, 2014
    Stockholders' Equity (Deficiency)  
    Stockholders' Equity (Deficiency)

     

    5.  Stockholders’ Equity (Deficiency)

     

    All share and per share amounts have been restated to reflect the one-for-six reverse stock split effected on May 29, 2012 as described in Note 2.

     

    Common Stock

     

    During the year ended December 31, 2012, the Company closed five private placement financings which raised gross proceeds of $6,320,000.  In total, the Company issued 1,738,333 shares of its common stock and warrants to purchase 1,738,333 shares of common stock (“units”).

     

    The purchase price paid by the investors for 633,333 of the units sold in the period January 2012 through May 2012 was $3.00 each, determined by the price paid by investors in recent private placements.   The warrants expire after eight years and are exercisable at $3.00 per share.  The Company paid $96,500 in cash for a finder’s fee.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene determined that the warrants issued in connection with these private placements should be recorded as derivative liabilities at the time of issuance since they are all price protected however the completion of the underwritten public offering on May 30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.   Accordingly, the fair value of these warrants were marked to market through May 30, 2012 and then reclassified from a liability to additional paid in capital.

     

    The purchase price paid by the investors for 1,105,000 of the units sold in the fourth quarter of 2012 was $4.00 each, determined by the market price on NASDAQ.   The warrants expire after five years and are exercisable at $5.32 per share.  The Company paid $24,989 in cash for a finder’s fee.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that the warrants issued in connection with these private placements should be recorded as derivative liabilities at the time of issuance since they are all price protected.   The fair value of the warrants on the date of issuance was $1,031,281.  However, the completion of the public offering in July 2013 removed the condition which required these warrants to be treated as derivative liabilities.  Accordingly, the fair value of these warrants were marked to market through July 18, 2013 and then reclassified from a liability to additional paid in capital.

     

    On May 30, 2012, the Company completed an underwritten public offering in which an aggregate of 1,150,000 units, with each unit consisting of two shares of its common stock and one warrant to purchase one share of common stock were sold at a purchase price of $8.00 per unit.  On June 13, 2012 the underwriters exercised their overallotment option in full for an additional 172,500 units.   In addition, the Company issued 92,000 warrants to selling agents at an exercise price of $7.00.   The warrants were immediately exercisable and expire on May 29, 2017.   Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging - Contracts in an Entity’s Own Equity”, Trovagene determined that the warrants issued in connection with this transaction were not derivative liabilities.   The Company raised a total of $9.1 million in net proceeds after deducting underwriting discounts and commissions of $0.7 million and offering expenses of $0.7 million.

     

    During the year ended December 31, 2012, the Company issued in total 174,100 units to a selling agent, who is also a shareholder of the Company, consisting of 174,100 shares of common stock and warrants to purchase 174,100 shares of common stock.  Of the total warrants issued, 30,450 issued in the period January 2012 through May 2012 have an exercise price of $3.00 per share, are immediately exercisable and expire December 31, 2018.   The remaining 143,650 warrants issued in the fourth quarter of 2012, have an exercise price of $5.32, are immediately exercisable, and expire five years from the date of issuance.   The units were issued as a finder’s fee in connection with certain private placements closed during the year ended December 31, 2012.  The issuance of these units was treated as a non-compensatory cost of capital.

     

    During the year ended December 31, 2012, the Company issued 40,000 units to Panetta Partners, Ltd., consisting of 40,000 shares of common stock and warrants to purchase 40,000 shares of common stock.   Gabriele Cerrone, previously a member of the Board of Directors of Trovagene, is a director of Panetta Partners, Ltd.   The warrants have an exercise price of $5.32, are immediately exercisable, and expire five years from the date of issuance.  The units were issued for advisory services in connection with the private placements closed in the fourth quarter of 2012.   The issuance of these units was treated as a non-compensatory cost of capital.   In addition, the Company issued a warrant to purchase 50,000 shares of common stock to Panetta Partners, Ltd. at an exercise price of $4.14 for consulting services.   The warrant was immediately exercisable and expires on December 10, 2017.   The fair value of the warrant issued was determined using the Black-Scholes method.   A total of approximately $133,000 was charged to general and administrative expenses in the Company’s consolidated statement of operations in 2012.

     

    During the year ended December 31, 2012, the Company issued 125,000 shares of common stock in connection with an asset purchase agreement with MultiGen Diagnostics, Inc.   See Note 3.

     

    During the year ended December 31, 2012, the Company issued 9,916 shares of common stock in connection with consulting agreements.   The fair value of the stock issued was determined using the Black-Scholes method.   A total of $22,381 was charged to general and administrative expense in the Company’s consolidated statement of operations in 2012.

     

    In December 2012, a Trovagene warrant holder exercised warrants to purchase 16,667 on a net exercise basis and received a total of 8,602 shares of common stock.  The exercise price of the warrants was $3.00.

     

    In December 2012, a Trovagene option holder exercised his option and purchased a total of 200 shares of common stock.  Trovagene raised gross proceeds of $600 as a result of the option exercise.  The purchase price paid by the option holder was $3.00.

     

    On January 25, 2013, the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000.  The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities.   This form was declared effective on February 4, 2013.   In addition, in connection with the Form S-3, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them.   As payment for its services, the Agent is entitled to a 3% commission on gross proceeds.   The Company has received gross proceeds of approximately $4.2 million from the sale of 488,476 shares of its common stock during the year ended December 31, 2013 under the agreement with the Agent.   In addition, the Company has received gross proceeds of approximately $15.0 million from the sale of 2,142,857 shares of its common stock through a registered direct offering that occurred in July 2013.

     

    During the year ended December 31, 2013, the Company issued a total of 3,424,605 shares of common stock.  The Company sold 2,631,332 shares of Common Stock for net proceeds of $18,829,644.   In addition, 36,458 shares were issued upon conversion of Series A Preferred Stock, 715,743 shares were issued upon exercise of 715,743 warrants for a weighted average price of $5.02 and 7,284 shares were issued upon net exercise of 12,745 warrants at an exercise price of $3.00.   The remaining 33,788 shares include 22,955 shares that were issued upon net exercise of an option for 41,667 shares at an exercise price of $4.50 and the exercise of an option for 10,833 shares at a weighted average exercise price of $3.53.

     

    During the year ended December 31, 2014, the Company issued a total of 13,011 shares of common stock upon the net exercise of warrants at a weighted average exercise price of $3.00.

     

    Warrants

     

    During the years ended December 31, 2014, 2013, and 2012, warrant activity was as follows:

     

     

     

    Number
    of
    Warrants

     

    Weighted
    Average
    Exercise
    price

     

    Term

     

    Warrants Outstanding 12/31/2011

     
    3,601,474

     

    $
    3.18

     

    1-8 years

     

    Granted

     
    3,416,934

     

    $
    4.88

     

     

     

    Exercised

     
    (16,667

    )

     

     

     

     

    Expired

     
    (16,671

    )

    $
    3.00

     

     

     

    Warrants Outstanding 12/31/2012

     
    6,985,070

     

    $
    3.96

     

    1 - 6 years

     

    Granted

     
    50,000

     

    $
    8.00

     

     

     

    Exercised

     
    (728,488

    )
    4.99

     

     

     

    Expired

     
    (73,099

    )

    $
    4.50

     

     

     

    Warrants Outstanding 12/31/2013

     
    6,233,483

     

    $
    3.87

     

    1 -5 years

     

    Granted

     
    85,470

     

    $
    3.51

     

     

     

    Exercised

     
    (36,666

    )

    $
    3.00

     

     

     

    Expired

     
    (16,667

    )

    $
    10.80

     

     

     

    Warrants Outstanding 12/31/2014

     
    6,265,620

     

    $
    3.85

     

    1 – 4 years

     

     

    The Company granted a total of 3,416,934 warrants during the year ended December 31, 2012.   Of the total warrants granted, 713,784 were warrants that were price protected.   These warrants had an exercise price of $3.00 per share and expire on December 31, 2018.   The fair value of these warrants was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which warrant holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  The completion of the underwritten public offering on May 30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.   Accordingly, the fair value of these warrants were marked to market through May 30, 2012 and then reclassified from a liability to additional paid in capital.  See Note 7.   In connection with underwritten public offering and sale of units in May 2012, 1,414,500 warrants were issued with exercise prices ranging from $5.32 to $7.00 and an expiration date five years after date of issuance.   Warrants issued in connection with the underwritten public offering and sale of units are not considered derivatives based on Trovagene’s analysis of the criteria of ASC 815, as the Company is not required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of warrant shares.  An additional 1,288,650 warrants in the fourth quarter of 2012 were warrants that are price protected.   These warrants have an exercise price of $5.32 per share and have an expiration date of five years from issuance.  The fair value of these warrants was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which warrant holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  See Note 7.

     

    The Company issued a warrant to purchase 50,000 shares of common stock at an exercise price of $8.00 per share, during the year ended December 31, 2013.   The warrants were issued in connection with an agreement to provide services related to investor and public relations materials and expire three years from date of grant.   The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:  a risk-free interest rate of 0.42%, dividend yield of 0%, expected volatility of 97% and expected term of three years.   The resulting fair value of $198,791 was recorded as stock based compensation expense.

     

    The Company issued warrants to purchase 85,470 shares of common stock at an exercise price of $3.51 per share, during the year ended December 31, 2014.   The warrants were issued in connection with a $15.0 million debt agreement. The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions:  a risk-free interest rate of 2.53%, dividend yield of 0%, expected volatility of 73.8% and expected term of ten years.   The resulting fair value of $235,857 was recorded as a debt discount and will be amortized to interest expense over the term of the loan using the effective interest method.

     

    Series A Convertible Preferred Stock

     

    The material terms of the Series A Convertible Preferred Stock consist of:

     

    1)  Dividends. Holders of the Series A Convertible Preferred Stock shall be entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005.  Dividends shall be payable, at the Company’s sole election, in cash or shares of common stock.  As of December 31, 2014 and 2013, the Company had $244,055 and $221,040, respectively in accrued cumulative unpaid preferred stock dividends, included in Accrued Expenses in the Company’s consolidated balance sheets, and $23,015, $29,840, and $38,240, was recorded during the years ended December 31, 2014, 2013, and 2012, respectively.

     

    2)  Voting Rights. Shares of the Series A Convertible Preferred Stock shall have no voting rights.  However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its articles of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.

     

    3)  Liquidation. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock shall be entitled to receive an amount equal to the Stated Value per share, which is $10 per share plus any accrued and unpaid dividends.

     

    4)  Conversion Rights. Each share of Series A Convertible Preferred Stock shall be convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, originally $2.15 per share.

     

    5)  Subsequent Equity Sales. The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning upon registration of the common stock underlying the Series A Convertible Preferred Stock.  The relevant registration statement became effective March 17, 2006 and during the following twelve month period the conversion price was adjusted to $9.60 per share.

     

    6)  Automatic Conversion. Beginning July 13, 2006, if the price of the common stock equals $25.80 per share for 20 consecutive trading days, and an average of 8,333 shares of common stock per day shall have been traded during the 20 trading days, the Company shall have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, to convert any portion of the shares of Series A Convertible Preferred Stock into shares of Common Stock at the conversion price.  As of the date of these financial statements, such conditions have not been met.

     

    During the year ended December 31, 2013, 35,000 shares of Series A Convertible Preferred Stock were converted into 36,458 shares of common stock, on a net converted basis.  As of December 31, 2014 and 2013, and 2012, there were 60,600, 60,600, and 95,600 shares of Series A Convertible Preferred Stock outstanding.

     

    XML 65 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Property and Equipment
    		 12 Months Ended
    Dec. 31, 2014
    Property and Equipment  
    Property and Equipment

     

    4.  Property and Equipment

     

    Fixed assets consist of laboratory, testing and computer equipment and fixtures stated at cost.  Depreciation and amortization expense for the years ended December 31, 2014, 2013 and 2012 was $234,813, $130,520 and $41,842, respectively.  Property and equipment consisted of the following:

     

     

     

    As of December 31,

     

     

     

    2014

     

    2013

     

    Furniture and office equipment

     

    $
    365,955

     

    $
    236,645

     

    Leasehold Improvements

     
    39,401

     
    36,371

     

    Laboratory equipment

     
    968,901

     
    826,151

     

     

     
    1,374,257

     
    1,099,167

     

    Less—accumulated depreciation and amortization

     
    (533,870

    )
    (348,602

    )

    Property and equipment, net

     

    $
    840,387

     

    $
    750,565

     

     

        

    XML 66 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2014
    Basis of Presentation and Summary of Significant Accounting Policies  
    Use of Estimates

    Use of Estimates

     

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

    Cash and Cash Equivalents

    Cash and Cash Equivalents

     

    Cash and cash equivalents consist of operating accounts as of December 31, 2014 and 2013 on deposit with U.S. commercial banks.   Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.   Cash and cash equivalents include money market accounts at December 31, 2014.

     

    Concentration of credit risk

    Concentration of credit risk

     

    The Company maintains its cash in financial institutions, which at times may exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”).  All of the Company’s noninterest bearing cash balances were insured up to $250,000 at December 31, 2014 and December 31, 2013.

     

    Revenues

    Revenues

     

    We license and sublicense our patent rights to healthcare companies, medical laboratories and biotechnology partners.  These agreements may involve multiple elements such as license fees, royalties and milestone payments.  Revenue is recognized for each element when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

     

    ·

    Up-front nonrefundable license fees pursuant to agreements under which we have no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured.

     

    ·

    Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured.

     

    ·

    Milestone payments are recognized when both the milestone is achieved and the related payment is received.

     

    Allowance for Doubtful Accounts

    Allowance for Doubtful Accounts

     

    The Company reviews the collectability of accounts receivable based on an assessment of historic experience, current economic conditions, and other collection indicators.  At December 31, 2014 and 2013, the Company has not recorded an allowance for doubtful accounts.  When accounts are determined to be uncollectible, they are written off against the reserve balance and the reserve is reassessed.  When payments are received on reserved accounts, they are applied to the individual’s account and the reserve is reassessed.

     

    Derivative Financial Instruments-Warrants

    Derivative Financial Instruments—Warrants

     

    The Company has issued common stock warrants in connection with the execution of certain equity financings.  Such warrants are classified as derivative liabilities under the provisions of FASB ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period.  Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity.  Changes in fair value of derivative liabilities are recorded in the consolidated statement of operations under the caption “Change in fair value of derivative instruments.”

     

    The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of Trovagene’s common share price, remaining life of the warrant, and risk-free interest rates at each period end.  The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements.  At December 31, 2014 and 2013, the fair value of these warrants was $3,006,021 and $4,431,871, respectively, and were included in the derivative financial instruments liability on the balance sheet.

     

    Stock-Based Compensation

    Stock-Based Compensation

     

    ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant.  The expense is recognized over the period during which an employee is required to provide services in exchange for the award.  ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation.  Trovagene continues to account for shares of common stock, stock options and warrants issued to non-employees based on the fair value of stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received.  The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “Equity -Based Payment to Non-Employees” and accordingly the value of the stock compensation to non-employees is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.  Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

     

    Fair value of financial instruments

    Fair value of financial instruments

     

    Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, debt and derivative liabilities.  We have adopted FASB ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis.  These financial instruments are stated at their respective historical carrying amounts which approximate to fair value due to their short term nature as they reflect current market interest rates.   Debt is stated at its respective historical carrying amounts which approximates fair value as they reflect current market interest rates.

     

    In accordance with ASC subtopic 820-10, the Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  The three tiers include:

     

     

    Level 1 —

     

    Quoted prices for identical instruments in active markets.

     

     

     

     

     

     

    Level 2 —

     

    Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.

     

     

     

     

     

     

    Level 3 —

     

    Instruments where significant value drivers are unobservable to third parties.

     

    Property, equipment and depreciation and amortization

    Property, equipment and depreciation and amortization

     

    Expenditures for additions, renewals and improvements are capitalized at cost.  Depreciation and amortization is generally computed on a straight-line method based on the estimated useful lives of the related assets.  Amortization of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.  The estimated useful lives of the major classes of depreciable assets are 3 to 5 years for lab equipment and furniture and fixtures.  Expenditures for repairs and maintenance are charged to operations as incurred.

     

    Impairment of Indefinite and Long-Lived Assets

    Impairment of Indefinite and Long-Lived Assets

     

    The Company reviews its long and indefinite lived assets to determine if any event has occurred that may indicate its intangible assets with indefinite lives and other long-lived assets are potentially impaired.  If indicators of impairment exist, the Company performs an impairment test to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows.  If the affected assets are not recoverable, the Company estimates the fair value of the assets and records an impairment loss if the carrying value of the assets exceeds the fair value.  Factors that would indicate potential impairment include a significant decline in the Company’s stock price and market capitalization compared to its net book value, significant changes in the ability of a particular asset to generate positive cash flows, and significant changes in the Company’s strategic business objectives and utilization of a particular asset.  The Company noted no indications of impairment for the years ended December 31, 2014, 2013, and 2012.

     

    Income Taxes

    Income Taxes

     

    Income taxes have been determined using the asset and liability approach of accounting for income taxes.  Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.  Deferred taxes result from differences between the financial statement and tax bases of Trovagene’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted.  Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.  The assessment of whether or not a valuation allowance is required often requires significant judgment.

     

    Contingencies

    Contingencies

     

    In the normal course of business, Trovagene is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters.  In accordance with FASB ASC Topic 450, Accounting for Contingencies, Trovagene records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.  Trovagene, in accordance with this guidance, does not recognize gain contingencies until realized.

     

    Cost of Revenue

    Cost of Revenue

     

    Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result. Costs associated with performing tests are recorded as the tests are processed.

     

    Research and Development

    Research and Development

     

    Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, purchased in-process research and development, regulatory and scientific consulting fees, as well as contract research and insurance, are accounted for in accordance with ASC Topic 730-10-55-2, Research and Development.  Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.

     

    While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that Trovagene has no history of successful commercialization of molecular diagnostic products to base any estimate of the number of future periods that would be benefited.

     

    ASC Topic 730, Research and Development requires that non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized.  As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.   There were no non-refundable advance payments as of December 31, 2014 and 2013.

     

    Net Loss Per Share

    Net Loss Per Share

     

    Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented.  In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share.    Shares used in calculating diluted net loss per common share exclude as antidilutive the following share equivalents:

     

     

     

    December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Options to purchase Common Stock

     
    4,913,472 

     
    4,287,545 

     
    3,711,303 

     

    Warrants to purchase Common stock

     
    5,251,660 

     
    6,233,483 

     
    6,985,070 

     

    Series A Convertible Preferred Stock

     
    63,125 

     
    63,125 

     
    99,583 

     

     

     
    10,228,257 

     
    10,584,153 

     
    10,795,956 

     

     

    The following table summarizes the Company’s diluted net loss per share:

     

     

     

    December 31,

     

    December 31,

     

    December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Numerator:

     

     

     

     

     

     

     

    Net loss

     

    $
    (14,348,499

    )

    $
    (11,840,778

    )

    $
    (11,604,201

    )

    Adjustment for change in fair value of derivative instruments - warrants

     
    (2,422,337

    )

    —

     

    —

     

    Net loss used for diluted loss per share

     

    $
    (16,770,836

    )

    $
    (11,840,778

    )

    $
    (11,604,201

    )

     

     

     

     

     

     

     

     

    Denominator:

     

     

     

     

     

     

     

    Weighted average shares used to compute basic loss per share

     
    18,904,280

     
    16,978,212

     
    13,066,600

     

    Adjustments to reflect assumed exercise of warrants

     
    166,832

     

    —

     

    —

     

    Weighted average shares used to compute diluted net loss per share

     
    19,071,112

     
    16,978,212

     
    13,066,600

     

     

     

     

     

     

     

     

     

    Net loss per share diluted

     

    $
    (0.88

    )

    $
    (0.70

    )

    $
    (0.89

    )

     

    Recent Accounting Pronouncements

    Recent Accounting Pronouncements

     

    In January 2015, the Financial Accounting Standards Board (the FASB) issued an amendment to the accounting guidance related to the presentation of extraordinary items. The amendment simplifies the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2015. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.

     

    In August 2014, the FASB issued an amendment to the accounting guidance related to the evaluation of an entity to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance will not have an impact on the Company’s financial position, results of operations or cash flows.

     

    In June 2014, the FASB issued an accounting standards update that removes the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to: (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption.  The Company elected early adoption, and does not believe the adoption of the standard had a material impact on its financial position, results of operations or related financial statement disclosures.

     

    In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). The standard provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company is in the process of evaluating the impact of adoption on its consolidated financial statements.

     

    XML 67 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Employee Benefit Plan
    		 12 Months Ended
    Dec. 31, 2014
    Employee Benefit Plan  
    Employee Benefit Plan

     

    12.  Employee Benefit Plan

     

    The Company has a retirement savings plan under Section 401(k) of the Internal Revenue Code covering its employees.  The plan allows employees to defer, up to the maximum allowed, a percentage of their income on a pre-tax basis through contributions to the plans, plus any employee of the age of 55 can participate in the caught-up dollars as allowed by IRS codes.  The Company also has a Roth investment plan that is taken after taxes.  The Company does not currently make matching contributions.

     

    XML 68 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Fair Value Measurements
    		 12 Months Ended
    Dec. 31, 2014
    Fair Value Measurements  
    Fair Value Measurements

     

    8.  Fair Value Measurements

     

    The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2014 and 2013:

     

     

     

    Fair Value Measurements at

     

     

     

    December 31, 2014

     

     

     

    Quoted Prices
    in Active
    Markets for
    Identical Assets
    and Liabilities
    (Level 1)

     

    Significant
    Other
    Observable
    Inputs
    (Level 2)

     

    Significant
    Unobservable
    Inputs
    (Level 3)

     

    Total

     

    Assets:

     

     

     

     

     

     

     

     

     

    Money market fund (1)

     

    $
    27,123,587 

     

    $

    —

     

    $

    —

     
    27,123,587 

     

    Total Assets

     

    $
    27,123,587 

     

    $

    —

     

    $

    —

     

    $
    27,123,587 

     

    Liabilities:

     

     

     

     

     

     

     

     

     

    Derivative liabilities related to warrants

     

    —

     

    $

    —

     

    $
    3,006,021 

     

    $
    3,006,021 

     

    Total Liabilities

     

    $

    —

     

    $

    —

     

    $
    3,006,021 

     

    $
    3,006,021 

     

     

     

     

    Fair Value Measurements at

     

     

     

    December 31, 2013

     

     

     

    Quoted Prices
    in Active
    Markets for
    Identical Assets
    and Liabilities
    (Level 1)

     

    Significant
    Other
    Observable
    Inputs
    (Level 2)

     

    Significant
    Unobservable
    Inputs
    (Level 3)

     

    Total

     

    Assets:

     

     

     

     

     

     

     

     

     

    Money market fund (1)

     

    $
    25,703,330 

     

    $

    —

     

    $

    —

     
    25,703,330 

     

    Total Assets

     

    $
    25,703,330 

     

    $

    —

     

    $

    —

     

    $
    25,703,330 

     

    Liabilities:

     

     

     

     

     

     

     

     

     

    Derivative liabilities related to warrants

     

    —

     

    $

    —

     

    $
    4,431,871 

     

    $
    4,431,871 

     

    Total Liabilities

     

    $

    —

     

    $

    —

     

    $
    4,431,871 

     

    $
    4,431,871 

     

     

    (1)

    Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet.

     

    The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the years ended December 31, 2014 and 2013:

     

    Description

     

    Balance at
    December 31,
    2013

     

    Unrealized
    (gains) or
    losses

     

    Balance as of
    December 31,
    2014

     

    Derivative liabilities related to Warrants

     

    $
    4,431,871

     

    $
    (1,425,850

    )

    $
    3,006,021

     

     

    Description

     

    Balance at
    December 31,
    2012

     

    Fair Value of
    Warrants
    Reclassified to
    Additional Paid in
    Capital

     

    Unrealized
    (gains) or
    losses

     

    Balance as of
    December 31,
    2013

     

    Derivative liabilities related to Warrants

     

    $
    8,765,628

     
    (5,417,871

    )
    1,084,114

     
    4,431,871

     

     

    The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company’s statement of operations.  A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40.  At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

     

    XML 69 R60.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Subsequent Events (Details) (USD $)
    		 12 Months Ended 0 Months Ended 1 Months Ended
    Dec. 31, 2013
    Dec. 31, 2012
    Feb. 11, 2015
    Jan. 31, 2015
    Subsequent Events        
    Proceeds of sale of common stock, net of expenses $ 18,829,644us-gaap_ProceedsFromIssuanceOfCommonStock $ 15,323,548us-gaap_ProceedsFromIssuanceOfCommonStock    
    Subsequent Event [Member] | Public Offering and Controlled Equity Offering | Common Stock | Underwritten Public Offering 2015        
    Subsequent Events        
    Shares of common stock sold     5,111,110us-gaap_StockIssuedDuringPeriodSharesNewIssues
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_CommonStockMember
    / us-gaap_SubsequentEventTypeAxis
    = us-gaap_SubsequentEventMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2015Member    		  
    Price per share (in dollars per share)     $ 4.50us-gaap_SharesIssuedPricePerShare
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_CommonStockMember
    / us-gaap_SubsequentEventTypeAxis
    = us-gaap_SubsequentEventMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2015Member    		  
    Proceeds of sale of common stock, net of expenses     21,300,000us-gaap_ProceedsFromIssuanceOfCommonStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_CommonStockMember
    / us-gaap_SubsequentEventTypeAxis
    = us-gaap_SubsequentEventMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2015Member    		  
    Subsequent Event [Member] | Consulting Agreement With Dr Adams        
    Subsequent Events        
    Term of agreement       1 year
    Monthly fee for consultant's services       $ 9,500trov_ConsultantServicesMonthlyFee
    / us-gaap_SubsequentEventTypeAxis
    = us-gaap_SubsequentEventMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ConsultingAgreementWithDrAdamsMember
    XML 70 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Option Plan
    		 12 Months Ended
    Dec. 31, 2014
    Stock Option Plan  
    Stock Option Plan

     

    6.  Stock Option Plan

     

    In June 2004 the Company adopted the Trovagene Stock Option Plan, as amended (the “2004 Plan”), under which up to 6,000,000 shares common stock were reserved for issuance to directors, eligible employees, including executive officers and consultants.  The 2004 Plan provided for the grant of stock options to eligible recipients. Generally, vesting for options granted under the Plan was from three to four years, and options expird after a 10-year period.  Options were granted at an exercise price not less than the fair market value at the date of grant.  As of December 31, 2014 the 2004 Plan was expired.  As of December 31, 2013, there were 1,788,921 shares available for issuance under the 2004 Plan.

     

    During 2013, the Company issued 260,000 options over the authorized number of options in the 2004 Plan.  As per ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s statement of operations.  Stockholder approval was obtained on July 18, 2013 to increase the number of authorized shares in the Plan from 3,666,667 to 6,000,000.  Accordingly, the options were remeasured as of the date of stockholder approval with the change recorded in stock based compensation expense and the $23,024 liability was reclassified to additional paid in capital.

     

    In July 2013, an option to purchase 90,000 shares of common stock was granted to a Board Director for services provided outside of routine Board of Directors’ services.  These options were immediately vested.  The fair value of this option was approximately $500,000 and is included in general and administrative expenses.

     

    The Trovagene Inc. 2014 Equity Incentive Plan, (the “2014 EIP’)  authorizing up to 2,500,000 shares of common stock for issuance under the Plan, was approved by the Board of Directors in June 2014 and approved by the Shareholders at the September 17, 2014 Annual Shareholders’ Meeting.  As of December 31, 2014, there were 1,371,832 shares available for issuance under the 2014 EIP.

     

    Stock-based compensation has been recognized in operating results as follows:

     

     

     

    Years ended December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    In research and development expenses

     

    $
    796,008 

     

    $
    549,465 

     

    $
    136,148 

     

    In general and administrative expenses

     
    1,274,186 

     
    1,429,899 

     
    395,992 

     

    Total stock based compensation

     

    $
    2,070,194 

     

    $
    1,979,364 

     

    $
    532,140 

     

     

    The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:

     

     

     

    Years ended December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Risk-free interest rate

     

    1.42% - 2.1%

     

    .74% - 1.5%

     

    .62% - 1.04%

     

    Dividend yield

     

    0%

     

    0%

     

    0%

     

    Expected volatility

     

    81% - 86%

     

    82% - 100%

     

    90% - 97%

     

    Expected term (in years)

     

    5.0 yrs

     

    5.0 yrs

     

    5.0 yrs

     

    Stock price

     

    $3.00 - $6.74

     

    $5.53 - $8.15

     

    $0.50 - $4.87

     

     

    Risk-free interest rate — Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company’s stock options.

     

    Dividend yield — Trovagene has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.

     

    Expected volatility — Based on the historical volatility of a group of peer companies with attributes similar to Trovagene.

     

    Expected term — The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment, (“SAB No. 107”), which averages an award’s weighted-average vesting period and expected term for “plain vanilla” share options.  Under SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.

     

    Forfeitures — ASC Topic 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The Company estimates forfeitures based on its historical experience.

     

    The weighted-average fair value per share of all options granted during the years ended December 31, 2014, 2013, and 2012, estimated as of the grant date using the Black-Scholes option valuation model was $2.19, $4.54, and $2.12, per share, respectively.

     

    The unrecognized compensation cost related to non-vested stock options outstanding at December 31, 2014 and December 31, 2013 was $4,862,030 and $3,733,753, respectively.  The weighted-average remaining contractual term at December 31, 2014 and 2013 for options outstanding and vested options was 3.0 and 6.7, respectively.

     

    A summary of stock option activity and of changes in stock options outstanding is presented below:

     

     

     

    Number of
    Options

     

    Weighted
    Average
    Exercise
    Price Per
    Share

     

    Intrinsic
    Value

     

    Weighted Average
    Remaining
    Contractual Life

     

    Balance outstanding, December 31, 2011

     
    2,426,192

     

    $
    5.22

     

    $

    —

     

    6.7 years

     

    Granted

     
    1,294,668

     

    $
    3.74

     

     

     

     

     

    Exercised

     
    (200

    )

    $
    3.00

     

    $
    640

     

     

     

    Forfeited

     
    (9,357

    )

    $
    3.00

     

     

     

     

     

    Balance outstanding, December 31, 2012

     
    3,711,303

     

    $
    4.69

     

    $
    8,301,484

     

    6.3 years

     

    Granted

     
    1,144,760

     

    $
    6.33

     

     

     

     

     

    Exercised

     
    (52,500

    )

    $
    4.30

     

    $
    275,492

     

     

     

    Forfeited

     
    (516,018

    )

    $
    4.35

     

     

     

     

     

    Balance outstanding, December 31, 2013

     
    4,287,545

     

    $
    5.18

     

    $
    5,896,329

     

    6.7 years

     

    Granted

     
    1,410,038

     

    $
    4.42

     

     

     

     

     

    Forfeited

     
    (784,111

    )

    $
    7.08

     

     

     

     

     

    Balance outstanding, December 31, 2014

     
    4,913,472

     

    $
    4.66

     

    $
    2,808,083

     

    7.6 years

     

    Vested and exercisable, December 31, 2014

     
    2,434,124

     

    $
    4.65

     

    $
    1,990,187

     

    6.2 years

     

     

    ASC Topic 718 requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised (excess tax benefits) be classified as cash inflows from financing activities and cash outflows from operating activities.  Due to Trovagene’s accumulated deficit position, no tax benefits have been recognized in the cash flow statement.

     

    XML 71 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Derivative Financial Instruments - Warrants
    		 12 Months Ended
    Dec. 31, 2014
    Derivative Financial Instruments - Warrants  
    Derivative Financial Instruments - Warrants

    7.  Derivative Financial Instruments - Warrants

     

    Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that certain warrants issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital as they were issued with other equity instruments.  In accordance with ASC Topic 815-40, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s statement of operations.  The Company estimates the fair value of (i) certain of these warrants using the Black-Scholes option pricing model and (ii) estimates the fair value of the price protected units using the Binomial option pricing model in order to determine the associated derivative instrument liability and change in fair value described above.

     

    Warrants - Black-Scholes Option Pricing Model

     

    The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:

     

     

     

    Year ended
    December 31, 2014

     

    Year ended
    December 31, 2013

     

    Year ended
    December 31, 2012

     

    Estimated fair value of Trovagene common stock

     

    $3.00 - $6.74

     

    $5.74 - $7.18

     

    $0.02 - $5.93

     

    Expected warrant term

     

    4.0 years

     

    1 month 5.8 years

     

    10 months to 6 years

     

    Risk-free interest rate

     

    1.38%

     

    .03%-1.75%

     

    .06% - 1.54%

     

    Expected volatility

     

    86.4%

     

    82%-100%

     

    90%-97%

     

    Dividend yield

     

    0%

     

    0%

     

    0%

     

     

    Expected volatility is based on the volatility of a peer group of companies with attributes similar to Trovagene.  The warrants have a transferability provision and based on guidance provided in SAB 107 for instruments issued with such a provision, Trovagene used the full contractual term as the expected term of the warrants.  The risk free rate is based on the U.S.  Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.

     

    The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.  For the period ending December 31, 2013, the derivative financial instruments liability in the table below only represents the Black-Scholes calculation whereas the loss recognized in the Statement of Operations represents both the Black-Scholes and the binomial methodology.

     

    Date

     

    Description

     

    Number of
    Warrants

     

    Derivative
    Instrument
    Liability

     

    December 31, 2011

     

    Balance of derivative financial instruments liability

     
    1,103,727

     

    $
    994,627

     

     

     

    Expired warrants

     
    (16,667

    )

    —

     

     

     

    Change in fair value of warrants during the year recognized as a loss in the statement of operations

     

    —

     
    5,258,133

     

    December 31, 2012

     

    Balance of derivative financial instruments liability

     
    1,087,060

     
    6,252,760

     

     

     

    Expired warrants

     
    (73,099

    )

    —

     

     

     

    Change in fair value of warrants during the year recognized as a gain in the statement of operations

     

    —

     
    (1,820,889

    )

    December 31, 2013

     

    Balance of derivative financial instruments liability

     
    1,013,961

     

    $
    4,431,871

     

     

     

    Change in fair value of warrants during the year recognized as a gain in the statement of operations

     

    —

     
    (1,425,850

    )

    December 31, 2014

     

    Balance of derivative financial instruments liability

     
    1,013,961

     

    $
    3,006,021

     

     

    Warrants - Binomial Option Pricing Model

     

    During the year ended 2011 and through May 2012, the Company issued 713,784 and 1,048,175 units, respectively, at $3.00 per unit.  The units had a per unit price protection clause whereby from the date of issuance until the earlier of (i) thirty months from the final Closing or (ii) the closing date of a Subsequent Financing which generates within a one year period an amount equal to or in excess of $5,000,000, if the Company shall issue any Common Stock or Common Stock Equivalents, in a Subsequent Financing at an effective price per share less than the Per Unit Purchase Price, the Company shall issue to such the number of additional Units equal to (a) the Subscription Amount Investor at the Closing divided by the Discounted Purchase Price, less (b) the Units issued to such Investor at the Closing.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital.  The price protected unit’s warrants had an exercise price of $3.00 per share and had expiration dates ranging from June 30, 2014 to December 31, 2018.  The fair value of these price protected units was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  However, the completion of the underwritten public offering on May 30, 2012 removed the condition which required these warrants to be treated as derivative liabilities.  Accordingly, the fair value of these warrants were marked to market through May 30, 2012 and then reclassified from a liability to additional paid in capital.

     

    In addition, during the fourth quarter of 2012, the Company issued a total of 1,288,650 units at $4.00 per unit.  The units had a per unit price protection clause whereby from the date of issuance until the earlier of (i) forty-eight months from the final Closing or (ii) the closing date of a Subsequent Financing which generates within a one year period an amount equal to or in excess of $10,000,000, if the Company shall issue any Common Stock or Common Stock Equivalents, in a Subsequent Financing at an effective price per share less than the Per Unit Purchase Price, the Company shall issue to such the number of additional Units equal to (a) the Subscription Amount Investor at the Closing divided by the Discounted Purchase Price, less (b) the Units issued to such Investor at the Closing.  Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities with a charge to additional paid in capital.  The price protected unit’s warrants had an exercise price of $5.32 per share and had expiration dates five years from date of issuance.  The fair value of these price protected units was estimated using the binomial option pricing model.  The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate.  The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model.  The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant.  However, the completion of the public offering in July 2013 removed the condition which required these warrants to be treated as derivative liabilities.  Accordingly, the fair value of these warrants were marked to market through July 18, 2013 and then reclassified from a liability to additional paid in capital.

     

    The fair value of the warrants granted during the year ended December 31, 2012 was estimated under the binomial method using the following weighted average assumptions:

     

     

     

    2012

     

     

     

     

     

    Range of risk-free interest rates

     

    0.53% to 1.61%

     

    Range of expected volatility

     

    90% -97%

     

    Expected fair value of the stock

     

    $0.25- $3.21

     

    Expected warrant term

     

    2 years to 6.75 years

     

     

    The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Binomial option pricing method, for the periods indicated:

     

    Date

     

    Number of
    Price Protected
    Units

     

    Derivative
    Liability For
    Issued Units

     

    Change In
    Fair
    value of
    Derivative
    Liability For
    Previously
    Outstanding
    Price
    Protected
    Units

     

    Ending
    Balance
    Derivative
    Liability

     

    December 31, 2012

     
    1,288,650

     
    1,171,463

     
    1,341,405

     
    2,512,868

     

    Reclassification of derivative liability to equity

     
    (1,288,650

    )

    —

     
    (5,417,871

    )
    (5,417,871

    )

    Change in fair value of warrants during the year recognized as a loss in the statement of operations

     

    —

     

    —

     
    2,905,003

     
    2,905,003

     

    December 31, 2013

     

    —

     

    $
    1,171,463

     

    $
    (1,171,463

    )

    $

    —

     

     

    The weighted average remaining contractual term of all of the Company’s warrants outstanding at December 31, 2014 and 2013 was approximately 3.6 and 4.0 years, respectively.

     

    At December 31, 2014 and 2013, the total fair value of the above warrants accounted for as derivative financial instruments, valued using the Black-Scholes option pricing model was $3,006,021 and $4,431,871, respectively, and is classified as derivative financial instruments liability on the balance sheet.

     

    XML 72 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Debt
    		 12 Months Ended
    Dec. 31, 2014
    Debt  
    Debt

     

    9.  Debt

     

    Loan and Security Agreement

     

    In June 2014, the Company entered into a $15,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing.  A portion of the proceeds were used to repay the existing equipment loan.  The repayment with the same lender was accounted for as a debt extinguishment under ASC Topic 470-50, Debt.  The interest rate on the new loan is 7.07% per annum.  The Company will make interest only payments on the outstanding amount of the loan on a monthly basis through July 2015, after which equal monthly payments of principal and interest are due until the loan maturity date of July 1, 2018.  The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge.  In connection with the loan, the lenders received a warrant to purchase an aggregate 85,470 shares of the Company’s common stock at an exercise price of $3.51 per share exercisable for ten years from the date of issuance. The original value of the warrants, totaling $235,857, was recorded as debt discount and additional paid-in capital as the warrants were equity classified.

     

    At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount.  In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $1,050,000.

     

    The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt and pay dividends.  In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.

     

    As of December 31, 2014, amounts due under the agreement include $1,898,548 in current liabilities and $13,053,117 in long-term liabilities, which includes $191,682 of accrued interest.

     

    At December 31, 2014, Trovagene was in compliance with all covenants under the Loan and Security Agreement. 

     

    The Company recorded $843,260 in interest expense related to the Loan and Security Agreement during the year ended December 31, 2014.  Closing costs are being accreted over the life of the loan to interest expense.

     

    Future maturities of long-term debt at December 31, 2014 are as follows:

     

    2015

     

    $
    1,898,548 

     

    2016

     
    4,790,628 

     

    2017

     
    5,140,519 

     

    2018

     
    3,170,305 

     

    Total long-term obligations

     

    $
    15,000,000 

     

     

    XML 73 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Business Overview and Liquidity (Details) (USD $)
    		 3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
    Dec. 31, 2014
    Sep. 30, 2014
    Jun. 30, 2014
    Mar. 31, 2014
    Dec. 31, 2013
    Sep. 30, 2013
    Jun. 30, 2013
    Mar. 31, 2013
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2011
    May 30, 2012
    Jun. 30, 2012
    May 31, 2012
    Going Concern                              
    Cumulative net losses attributed to common stockholders $ (81,391,909)us-gaap_RetainedEarningsAccumulatedDeficit       $ (67,043,410)us-gaap_RetainedEarningsAccumulatedDeficit       $ (81,391,909)us-gaap_RetainedEarningsAccumulatedDeficit $ (67,043,410)us-gaap_RetainedEarningsAccumulatedDeficit          
    Net cash used in operating activities                 (12,727,385)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (7,317,248)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (4,934,661)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations        
    Net loss and comprehensive loss attributable to common stockholders (4,689,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (5,382,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (1,079,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (3,198,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (1,038,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (4,407,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (5,279,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (1,117,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (14,348,499)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (11,840,778)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic (11,604,201)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic        
    Net cash provided by financing activities                 14,484,036us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 22,983,688us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 15,324,148us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 15,324,148us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations      
    Underwritten Public Offering 2012                              
    Common Stock                              
    Units issued (in shares)                         1,150,000trov_UnitsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Number of shares of common stock in each capital unit (in shares)                         2trov_SaleOfCapitalUnitNumberOfCommonSharesInEachUnit
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Number of common stock purchase warrants in each capital unit (in shares)                         1trov_SaleOfCapitalUnitNumberOfWarrantsInEachUnit
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Number of shares that can be purchased from exercise of each warrant                         1us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Offer price per unit (in dollars per share)                         $ 8.00trov_IssuanceOfCommonStockAndWarrantsForCashPricePerUnit
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Exercise of overallotment option by underwriters (in units)                           172,500trov_UnitsExercisedByUnderwritersDueToOverallotmentOfOption
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		  
    Aggregate proceeds for stock and warrants issued as a unit (in dollars)                         9,100,000trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Amount of underwriting discounts and commissions                         700,000trov_EquityIssuanceAmountOfUnderwritingDiscountsAndCommissions
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Amount of offering expenses                         $ 700,000trov_EquityIssuanceAmountOfOfferingExpenses
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Exercise price of warrants (in dollars per share)                         5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		    
    Term of warrants                             5 years
    XML 74 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Income Taxes (Details) (USD $)
    In Millions, unless otherwise specified
    Dec. 31, 2014
    Federal  
    Operating loss carryforwards (NOLs)  
    NOLs $ 49.3us-gaap_OperatingLossCarryforwards
    / us-gaap_IncomeTaxAuthorityAxis
    = us-gaap_InternalRevenueServiceIRSMember
    California  
    Operating loss carryforwards (NOLs)  
    NOLs 29.9us-gaap_OperatingLossCarryforwards
    / us-gaap_IncomeTaxAuthorityAxis
    = trov_CaliforniaMember
    New Jersey  
    Operating loss carryforwards (NOLs)  
    NOLs $ 11.5us-gaap_OperatingLossCarryforwards
    / us-gaap_IncomeTaxAuthorityAxis
    = trov_NewJerseyMember
    XML 75 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Selected Quarterly Financial Data (Unaudited)
    		 12 Months Ended
    Dec. 31, 2014
    Selected Quarterly Financial Data (Unaudited)  
    Selected Quarterly Financial Data (Unaudited)

       

    14.  Selected Quarterly Financial Data (Unaudited)

     

    The following is a summary of the quarterly results of operations of the Company for years ended December 31, 2014 and 2013:

     

     

     

    Quarter Ended(1)

     

     

     

    March 31

     

    June 30

     

    September 30

     

    December 31

     

     

     

     

     

    (Revised)(2)

     

     

     

     

     

     

     

    (dollars in thousands, except per share data)

     

    2014

     

     

     

     

     

     

     

     

     

    Revenues

     

    $
    111

     

    $
    56

     

    $
    57

     

    $
    56

     

    Operating expenses

     
    3,371

     
    3,297

     
    3,997

     
    4,560

     

     

     

     

     

     

     

     

     

     

     

    Net loss and comprehensive loss attributable to common stockholders

     
    (3,198

    )
    (1,079

    )
    (5,382

    )
    (4,689

    )

    Net loss per common share - basic

     

    $
    (0.17

    )

    $
    (0.06

    )

    $
    (0.28

    )

    $
    (0.25

    )

    Net loss per common share - diluted

     

    $
    (0.17

    )

    $
    (0.17

    )

    $
    (0.28

    )

    $
    (0.25

    )

     

     

     

     

     

     

     

     

     

     

    Shares used in the calculation of net loss attributable to common stockholders - basic

     
    18,902,783

     
    18,902,783

     
    18,902,783

     
    18,904,280

     

    Shares used in the calculation of net loss attributable to common stockholders - diluted

     
    18,902,783

     
    19,232,760

     
    18,902,783

     
    19,071,112

     

     

     

     

     

     

     

     

     

     

     

    2013

     

     

     

     

     

     

     

     

     

    Revenues

     

    $
    119

     

    $
    49

     

    $
    44

     

    $
    47

     

    Operating expenses

     
    2,509

     
    2,423

     
    3,121

     
    2,897

     

    Net loss and comprehensive loss attributable to common stockholders

     
    (1,117

    )
    (5,279

    )
    (4,407

    )
    (1,038

    )

    Net loss per common share - basic

     

    $
    (0.07

    )

    $
    (0.34

    )

    $
    (0.25

    )

    $
    (0.05

    )

    Net loss per common share - diluted

     

    $
    (0.07

    )

    $
    (0.34

    )

    $
    (0.25

    )

    $
    (0.05

    )

     

     

     

     

     

     

     

     

     

     

    Shares used in the calculation of net loss attributable to common stockholders - basic

     
    15,510,340

     
    15,583,957

     
    17,870,703

     
    18,900,781

     

    Shares used in the calculation of net loss attributable to common stockholders - diluted

     
    15,510,340

     
    15,583,957

     
    17,870,703

     
    18,900,781

     

     

    (1) Basic and diluted EPS are computed independently for each of the periods presented.   Accordingly, the sum of the quarterly EPS amount may not agree to the total for the year. (2) Second quarter fully diluted earnings per share have been adjusted for dilutive amounts related to the derivative liability. We believe that these changes are not material to the financial statements or related notes.

     

          

    XML 76 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Stockholders' Equity (Deficiency)  
    Summary of warrant activity and changes in warrants outstanding

     

     

     

    Number
    of
    Warrants

     

    Weighted
    Average
    Exercise
    price

     

    Term

     

    Warrants Outstanding 12/31/2011

     
    3,601,474

     

    $
    3.18

     

    1-8 years

     

    Granted

     
    3,416,934

     

    $
    4.88

     

     

     

    Exercised

     
    (16,667

    )

     

     

     

     

    Expired

     
    (16,671

    )

    $
    3.00

     

     

     

    Warrants Outstanding 12/31/2012

     
    6,985,070

     

    $
    3.96

     

    1 - 6 years

     

    Granted

     
    50,000

     

    $
    8.00

     

     

     

    Exercised

     
    (728,488

    )
    4.99

     

     

     

    Expired

     
    (73,099

    )

    $
    4.50

     

     

     

    Warrants Outstanding 12/31/2013

     
    6,233,483

     

    $
    3.87

     

    1 -5 years

     

    Granted

     
    85,470

     

    $
    3.51

     

     

     

    Exercised

     
    (36,666

    )

    $
    3.00

     

     

     

    Expired

     
    (16,667

    )

    $
    10.80

     

     

     

    Warrants Outstanding 12/31/2014

     
    6,265,620

     

    $
    3.85

     

    1 – 4 years

     

     

    XML 77 R49.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Fair Value Measurements (Details 2) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Dec. 31, 2012
    Dec. 31, 2013
    Reconciliation of the beginning and ending balances      
    Balance at the beginning of the period $ 4,431,871us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue    
    Correction of error   (274,967)trov_ReclassificationOfDerivativeFinancialInstrumentsCorrectionOfError  
    Unrealized gain (1,425,850)us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings    
    Balance at the end of the period 3,006,021us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue    
    Warrants      
    Reconciliation of the beginning and ending balances      
    Balance at the beginning of the period     8,765,628us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
    / us-gaap_FairValueByLiabilityClassAxis
    = us-gaap_WarrantMember
    Fair Value of Warrants Reclassified to Additional Paid in Capital     (5,417,871)trov_FairValueMeasurementWithUnobservableInputsReclassifiedToAdditionalPaidInCapital
    / us-gaap_FairValueByLiabilityClassAxis
    = us-gaap_WarrantMember
    Unrealized gain     1,084,114us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
    / us-gaap_FairValueByLiabilityClassAxis
    = us-gaap_WarrantMember
    Balance at the end of the period     $ 4,431,871us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
    / us-gaap_FairValueByLiabilityClassAxis
    = us-gaap_WarrantMember
    XML 78 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stockholders' Equity (Deficiency) (Details) (USD $)
    		 0 Months Ended 12 Months Ended 3 Months Ended 5 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended
    May 29, 2012
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2012
    May 31, 2012
    May 30, 2012
    Jun. 30, 2012
    May 31, 2012
    Jul. 31, 2013
    Jan. 25, 2013
    Feb. 29, 2012
    Apr. 27, 2012
    Jun. 30, 2014
    Dec. 31, 2011
    Stock split ratio 0.1667us-gaap_StockholdersEquityNoteStockSplitConversionRatio1                            
    Value of warrants recorded as debt discount and additional paid in capital   $ 235,857trov_OriginalValueOfWarrants                          
    Common stock issued in lieu of cash for services       22,381us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations                      
    Warrants continued to be accounted under derivative liabilities (in shares)   6,265,620us-gaap_ClassOfWarrantOrRightOutstanding 6,233,483us-gaap_ClassOfWarrantOrRightOutstanding 6,985,070us-gaap_ClassOfWarrantOrRightOutstanding 6,985,070us-gaap_ClassOfWarrantOrRightOutstanding                   3,601,474us-gaap_ClassOfWarrantOrRightOutstanding
    Fair value of warrants at issuance for cash (in dollars)     3,599,831trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration                        
    Fair value of warrants issued for services (in dollars)     198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration 142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration                      
    Derivative financial instruments   3,006,021us-gaap_DerivativeLiabilitiesNoncurrent 4,431,871us-gaap_DerivativeLiabilitiesNoncurrent                        
    Gain (loss) from change in fair value of derivative instruments-warrants   1,425,850us-gaap_UnrealizedGainLossOnDerivatives (1,084,114)us-gaap_UnrealizedGainLossOnDerivatives (6,720,805)us-gaap_UnrealizedGainLossOnDerivatives                      
    Proceeds from investor     18,829,644us-gaap_ProceedsFromIssuanceOfCommonStock 15,323,548us-gaap_ProceedsFromIssuanceOfCommonStock                      
    Warrants exercised (in shares)   36,666trov_ClassOfWarrantOrRightNumberExercised 728,488trov_ClassOfWarrantOrRightNumberExercised 16,667trov_ClassOfWarrantOrRightNumberExercised                      
    Issuance of common stock upon net exercise of warrant (in shares)       8,602trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet                      
    Exercise price of warrants exercised (in dollars per share)   $ 3.00trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised $ 4.99trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised $ 3.00trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised                      
    Proceeds from exercise of options     38,249us-gaap_ProceedsFromStockOptionsExercised 600us-gaap_ProceedsFromStockOptionsExercised                      
    Exercise price of stock options exercised (in dollars per share)       $ 3.00us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice                      
    Number of shares sold   18,915,793us-gaap_CommonStockSharesIssued 18,902,782us-gaap_CommonStockSharesIssued                        
    Net proceeds from shares of common stock sold     18,829,644us-gaap_StockIssuedDuringPeriodValueNewIssues                        
    Warrant exercise price of $3.00                              
    Number of shares that can be purchased from exercise of each warrant     12,745us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
    / trov_WarrantExercisePriceAxis
    = trov_WarrantExercisePriceTwoMember    		                        
    Exercise price of warrants (in dollars per share)     3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_WarrantExercisePriceAxis
    = trov_WarrantExercisePriceTwoMember    		                        
    Selling agents                              
    Number of common shares that can be purchased upon exercise of warrant       174,100us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember    		 174,100us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember    		                    
    Units issued (in shares)       174,100trov_UnitsIssuedDuringPeriodForNoncashConsideration
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember    		                      
    Consulting agreements                              
    Common stock issued in lieu of cash for services       22,381us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		                      
    Common stock issued in lieu of cash (in shares)       9,916us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		                      
    Panetta Partners, Ltd.                              
    Number of common shares that can be purchased upon exercise of warrant       40,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember    		 40,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember    		                    
    Units issued (in shares)       40,000trov_UnitsIssuedDuringPeriodForNoncashConsideration
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember    		                      
    Exercise price of warrants (in dollars per share)       5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember    		 5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember    		                    
    Term of warrants       5 years                      
    Amount charged to general and administrative expense       133,000us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember    		                      
    Panetta Partners, Ltd. | Consulting agreements                              
    Number of common shares that can be purchased upon exercise of warrant       50,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		 50,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		                    
    Exercise price of warrants (in dollars per share)       4.14us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		 4.14us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = trov_PanettaPartnersLtdMember
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		                    
    Warrants | Selling agents                              
    Number of common shares that can be purchased upon exercise of warrant       143,650us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		 143,650us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		 30,450us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		     30,450us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		            
    Exercise price of warrants (in dollars per share)       5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		 5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		 3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		     3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		            
    Term of warrants         5 years                    
    Price protected warrants                              
    Reclassification of derivative liability to equity (in shares)       713,784trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_StatementEquityComponentsAxis
    = trov_PriceProtectedWarrantsMember    		 1,288,650trov_DerivativeFinancialInstrumentsNumberOfPriceProtectedUnitsIssued
    / us-gaap_StatementEquityComponentsAxis
    = trov_PriceProtectedWarrantsMember    		                    
    Term of warrants         5 years                    
    Common stock including additional paid in capital                              
    Common stock issued in lieu of cash (in shares)       40,000us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember    		                      
    Common stock including additional paid in capital | Selling agents                              
    Common stock issued in lieu of cash (in shares)       174,100us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember    		                      
    Common Stock                              
    Common stock issued in lieu of cash for services       1us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Common stock issued in lieu of cash (in shares)       9,916us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Exercise price of warrants (in dollars per share)   3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                          
    Fair value of warrants at issuance for cash (in dollars)     72trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Warrants issued for cash (in shares)     715,743trov_NumberOfWarrantsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Issuance of common stock upon net exercise of warrant (in shares)   13,011trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 7,284trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 8,602trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Shares issued upon exercise of options     10,833us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 200us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Shares issued upon net exercise of options     22,955trov_StockIssuedDuringPeriodSharesStockOptionsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Total shares of Common Stock issued     3,424,605trov_AggregateStockIssuedDuringPeriodShares
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Shares of common stock sold     2,631,332us-gaap_StockIssuedDuringPeriodSharesNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Net proceeds from shares of common stock sold     263us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Number of common shares issued upon conversion     36,458us-gaap_ConversionOfStockSharesIssued1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Number of common stock issued for exercise of stock options     33,788trov_NumberOfStockIssuedForStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Common Stock | Option exercise price of $4.50                              
    Shares issued upon exercise of options     41,667us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
    = trov_OptionExercisePriceOneMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Exercise price of stock options exercised (in dollars per share)     $ 4.50us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
    / us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
    = trov_OptionExercisePriceOneMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Common Stock | Option exercise price, weighted average of $3.53                              
    Shares issued upon exercise of options     10,833us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
    = trov_OptionExercisePriceTwoMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Exercise price of stock options exercised (in dollars per share)     $ 3.53us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
    / us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
    = trov_OptionExercisePriceTwoMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Common Stock | Warrant exercise price, weighted average of $5.02                              
    Exercise price of warrants (in dollars per share)     5.02us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    / trov_WarrantExercisePriceAxis
    = trov_WarrantExercisePriceOneMember    		                        
    Common Stock | Shareholder of the Company                              
    Aggregate proceeds for stock and warrants issued as a unit (in dollars)       21trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = us-gaap_InvestorMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Units issued (in shares)       214,100trov_UnitsIssuedDuringPeriodForNoncashConsideration
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = us-gaap_InvestorMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Private placements of units of common stock and warrants to purchase common stock during 2012                              
    Number of common shares that can be purchased upon exercise of warrant       1,738,333us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		 1,738,333us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                    
    Aggregate proceeds for stock and warrants issued as a unit (in dollars)       6,320,000trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                      
    Price per share (in dollars per share)         $ 4.00us-gaap_EquityIssuancePerShareAmount
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                    
    Price per unit (in dollars per share)           $ 3.00trov_IssuanceOfCommonStockAndWarrantsForCashPricePerUnit
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                  
    Units issued (in shares)         1,105,000trov_UnitsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		 633,333trov_UnitsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                  
    Exercise price of warrants (in dollars per share)       5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		 5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		 3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		     3.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		            
    Finder's fees paid         24,989trov_PaymentOfFindersFees
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		 96,500trov_PaymentOfFindersFees
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                  
    Fair value of warrants at issuance for cash (in dollars)         1,031,281trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                    
    Term of warrants         5 years 8 years                  
    Number of private placement financings       5trov_NumberOfPrivatePlacementFinancings
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                      
    Private placements of units of common stock and warrants to purchase common stock during 2012 | Common stock including additional paid in capital                              
    Stock issued for cash (in shares)       1,738,333us-gaap_StockIssuedDuringPeriodSharesIssuedForCash
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember
    / trov_TypeOfOfferingAxis
    = trov_PrivatePlacements2012Member    		                      
    Underwritten Public Offering 2012                              
    Aggregate proceeds for stock and warrants issued as a unit (in dollars)             9,100,000trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Exercise of overallotment option by underwriters (in units)               172,500trov_UnitsExercisedByUnderwritersDueToOverallotmentOfOption
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		              
    Price per unit (in dollars per share)             $ 8.00trov_IssuanceOfCommonStockAndWarrantsForCashPricePerUnit
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Units issued (in shares)             1,150,000trov_UnitsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Number of shares that can be purchased from exercise of each warrant             1us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Exercise price of warrants (in dollars per share)             5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Warrants issued for cash (in shares)                 1,414,500trov_NumberOfWarrantsIssuedDuringPeriodForCashConsideration
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		            
    Number of shares of common stock in each unit             2trov_SaleOfCapitalUnitNumberOfCommonSharesInEachUnit
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Number of warrants in each unit             1trov_SaleOfCapitalUnitNumberOfWarrantsInEachUnit
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Term of warrants                 5 years            
    Amount of underwriting discounts and commissions             700,000trov_EquityIssuanceAmountOfUnderwritingDiscountsAndCommissions
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Amount of offering expenses             700,000trov_EquityIssuanceAmountOfOfferingExpenses
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Underwritten Public Offering 2012 | Selling agents                              
    Number of common shares that can be purchased upon exercise of warrant             92,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Exercise price of warrants (in dollars per share)             7.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		                
    Public Offering and Controlled Equity Offering                              
    Gross proceeds from sale of shares                   15,000,000us-gaap_ProceedsFromIssuanceOrSaleOfEquity
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		          
    Number of shares sold                   2,142,857us-gaap_CommonStockSharesIssued
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		          
    Agent | Public Offering and Controlled Equity Offering                              
    Commission as percentage of gross proceeds                     3.00%trov_CommissionAsPercentageOfGrossProceeds
    / dei_LegalEntityAxis
    = trov_CantorFitzgeraldAndCoMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		        
    Gross proceeds from sale of shares     4,200,000us-gaap_ProceedsFromIssuanceOrSaleOfEquity
    / dei_LegalEntityAxis
    = trov_CantorFitzgeraldAndCoMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		                        
    Number of shares sold     488,476us-gaap_CommonStockSharesIssued
    / dei_LegalEntityAxis
    = trov_CantorFitzgeraldAndCoMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		                        
    MultiGen Diagnostics, Inc                              
    Common stock issued in connection with an asset purchase agreement (in shares)       125,000us-gaap_StockIssuedDuringPeriodSharesAcquisitions
    / dei_LegalEntityAxis
    = trov_MultiGenDiagnosticsIncMember    		                      
    Fair value of the shares issued in connection with merger       187,500us-gaap_StockIssuedDuringPeriodValueAcquisitions
    / dei_LegalEntityAxis
    = trov_MultiGenDiagnosticsIncMember    		               187,500us-gaap_StockIssuedDuringPeriodValueAcquisitions
    / dei_LegalEntityAxis
    = trov_MultiGenDiagnosticsIncMember    		      
    Maximum                              
    Stock split ratio                         0.50us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember    		    
    Maximum | Underwritten Public Offering 2012                              
    Exercise price of warrants (in dollars per share)           7.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		     7.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		            
    Maximum | Public Offering and Controlled Equity Offering                              
    Aggregate initial offering price                     150,000,000trov_AggregateInitialOfferingPrice
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		        
    Maximum | Agent | Public Offering and Controlled Equity Offering                              
    Aggregate initial offering price                     30,000,000trov_AggregateInitialOfferingPrice
    / dei_LegalEntityAxis
    = trov_CantorFitzgeraldAndCoMember
    / us-gaap_RangeAxis
    = us-gaap_MaximumMember
    / us-gaap_TypeOfArrangementAxis
    = trov_PublicOfferingAndControlledEquityOfferingMember    		        
    Minimum                              
    Stock split ratio                         0.1667us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember    		    
    Minimum | Underwritten Public Offering 2012                              
    Exercise price of warrants (in dollars per share)           5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		     5.32us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOffering2012Member    		            
    Secured Debt | Loan and Security Agreement                              
    Number of common shares that can be purchased upon exercise of warrant                           85,470us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Value of warrants recorded as debt discount and additional paid in capital                           235,857trov_OriginalValueOfWarrants
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Exercise price of warrants (in dollars per share)                           3.51us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Aggregate principal amount   $ 15,000,000us-gaap_DebtInstrumentFaceAmount
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		                          
    Interest rate (as a percent)                           7.07%us-gaap_DebtInstrumentInterestRateStatedPercentage
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember    		  
    Secured Debt | Loan and Security Agreement | Warrants                              
    Number of common shares that can be purchased upon exercise of warrant                           85,470us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		  
    Black Scholes Option Pricing Method | Secured Debt | Loan and Security Agreement                              
    Dividend yield (as a percent)                           0.00%us-gaap_FairValueAssumptionsExpectedDividendRate
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		  
    Risk-free interest rate (as a percent)                           2.53%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		  
    Expected volatility (as a percent)                           73.80%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_CreditFacilityAxis
    = us-gaap_LineOfCreditMember
    / us-gaap_LongtermDebtTypeAxis
    = us-gaap_SecuredDebtMember
    / us-gaap_ValuationTechniqueAxis
    = trov_BlackScholesOptionPricingMethodMember    		  
    Expected life                           10 years  
    XML 79 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Statements of Stockholders' Equity (Deficiency) (USD $)
    Preferred Stock
    Series A Convertible Preferred Stock
    USD ($)
    Preferred Stock
    USD ($)
    Common Stock
    Units issued via registered underwritten direct and private placement of units
    USD ($)
    Common Stock
    Shareholder of the Company
    USD ($)
    Common Stock
    MultiGen Diagnostics, Inc
    USD ($)
    Common Stock
    USD ($)
    Additional Paid-in Capital
    Units issued via registered underwritten direct and private placement of units
    USD ($)
    Additional Paid-in Capital
    Shareholder of the Company
    USD ($)
    Additional Paid-in Capital
    MultiGen Diagnostics, Inc
    USD ($)
    Additional Paid-in Capital
    USD ($)
    Deficit Accumulated
    USD ($)
    Units issued via registered underwritten direct and private placement of units
    USD ($)
    Selling agents
    Consulting agreements
    USD ($)
    Series A Convertible Preferred Stock
    USD ($)
    MultiGen Diagnostics, Inc
    USD ($)
    Total
    USD ($)
    Balance at Dec. 31, 2011   $ 96us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       $ 1,073us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       $ 39,365,994us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 $ (43,598,431)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           $ (4,231,268)us-gaap_StockholdersEquity
    Balance (in shares) at Dec. 31, 2011   95,600us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       10,737,026us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Increase (Decrease) in Stockholders' Equity                                  
    Common stock issued in lieu of cash for services           1us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       22,380us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		       22,381us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		     22,381us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
    Common stock issued in lieu of cash (in shares)           9,916us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		               9,916us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_ConsultingAgreementMember    		      
    Issuance of common stock and warrant as finder's fees (in shares)       214,100trov_UnitsIssuedDuringPeriodForNoncashConsideration
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = us-gaap_InvestorMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                 174,100trov_UnitsIssuedDuringPeriodForNoncashConsideration
    / us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis
    = trov_SellingAgentsMember    		        
    Issuance of units of common stock and warrants     438trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOfferingAndPrivatePlacementMember    		 21trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = us-gaap_InvestorMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     16,899,562trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOfferingAndPrivatePlacementMember    		 (21)trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
    = us-gaap_InvestorMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		       16,900,000trov_StockAndWarrantsIssuedDuringPeriodValueNewIssues
    / trov_TypeOfOfferingAxis
    = trov_PublicOfferingAndPrivatePlacementMember    		          
    Issuance of units of common stock and warrants (in shares)     4,383,333trov_UnitsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    / trov_TypeOfOfferingAxis
    = trov_PublicOfferingAndPrivatePlacementMember    		                            
    Issuance of warrants in connection with services                   142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             142,508trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    Warrants reclassified to additional paid in capital                   3,317,463trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             3,317,463trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    Stock based compensation                   532,140us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             532,140us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    Issuance of common stock upon net exercise of warrant           1trov_StockIssuedDuringPeriodValueWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       (1)trov_StockIssuedDuringPeriodValueWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		              
    Issuance of common stock upon net exercise of warrant (in shares)           8,602trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                     8,602trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    Issuance of common stock upon exercise of stock options                   600us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             600us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    Issuance of common stock upon exercise of stock options (in shares)           200us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Fees and expenses related to financing transactions                   (1,576,452)trov_StockIssuanceCostsAdjustmentToEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             (1,576,452)trov_StockIssuanceCostsAdjustmentToEquity
    Preferred stock dividend                     (38,240)us-gaap_DividendsPreferredStock
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		       (38,240)us-gaap_DividendsPreferredStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		   (38,240)us-gaap_DividendsPreferredStock
    Derivative liability-fair value of warrants and price protected units issued                   (1,796,610)trov_WarrantsAndPriceProtectedUnitsClassifiedAsDerivativeLiabilitiesValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             (1,796,610)trov_WarrantsAndPriceProtectedUnitsClassifiedAsDerivativeLiabilitiesValue
    Correction of error in derivative liability - fair value of warrants price protected units issued                   274,967trov_ReclassificationOfDerivativeFinancialInstrumentsCorrectionOfError
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             274,967trov_ReclassificationOfDerivativeFinancialInstrumentsCorrectionOfError
    Issuance of common stock pursuant to acquisitions         13us-gaap_StockIssuedDuringPeriodValueAcquisitions
    / us-gaap_BusinessAcquisitionAxis
    = trov_MultiGenDiagnosticsIncMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       187,487us-gaap_StockIssuedDuringPeriodValueAcquisitions
    / us-gaap_BusinessAcquisitionAxis
    = trov_MultiGenDiagnosticsIncMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             187,500us-gaap_StockIssuedDuringPeriodValueAcquisitions
    / us-gaap_BusinessAcquisitionAxis
    = trov_MultiGenDiagnosticsIncMember    		  
    Common stock issued in connection with an asset purchase agreement (in shares)         125,000us-gaap_StockIssuedDuringPeriodSharesAcquisitions
    / us-gaap_BusinessAcquisitionAxis
    = trov_MultiGenDiagnosticsIncMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                        
    Net loss                     (11,565,961)us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           (11,565,961)us-gaap_NetIncomeLoss
    Balance at Dec. 31, 2012   96us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       1,547us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       57,370,017us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (55,202,632)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           2,169,028us-gaap_StockholdersEquity
    Balance (in shares) at Dec. 31, 2012   95,600us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       15,478,177us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Increase (Decrease) in Stockholders' Equity                                  
    Sale of common stock, net of expenses           263us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       18,829,381us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             18,829,644us-gaap_StockIssuedDuringPeriodValueNewIssues
    Sale of common stock, net of expenses (in shares)           2,631,332us-gaap_StockIssuedDuringPeriodSharesNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Issuance of warrants in connection with services                   198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             198,791trov_AdjustmentToAdditionalPaidInCapitalForWarrantsIssuedAsNoncashConsideration
    Warrants reclassified to additional paid in capital                   5,417,871trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             5,417,871trov_AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount
    Stock based compensation                   1,979,364us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             1,979,364us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    Issuance of common stock upon net exercise of warrant           1trov_StockIssuedDuringPeriodValueWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       (1)trov_StockIssuedDuringPeriodValueWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		              
    Issuance of common stock upon net exercise of warrant (in shares)           7,284trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Issuance of common stock upon exercise of warrant           72trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       3,599,759trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             3,599,831trov_ValueOfWarrantsIssuedDuringPeriodForCashConsideration
    Issuance of common stock upon exercise of warrant (in shares)           715,743trov_NumberOfWarrantsIssuedDuringPeriodForCashConsideration
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Issuance of common stock upon net exercise of stock option           2trov_StockIssuedDuringPeriodValueStockOptionsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       (2)trov_StockIssuedDuringPeriodValueStockOptionsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		              
    Issuance of common stock upon net exercise of stock option (in shares)           22,955trov_StockIssuedDuringPeriodSharesStockOptionsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Issuance of common stock upon exercise of stock options           1us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       38,248us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             38,249us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    Issuance of common stock upon exercise of stock options (in shares)           10,833us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Conversion of preferred stock and issuance of common stock           4us-gaap_ConversionOfStockAmountIssued1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       32us-gaap_ConversionOfStockAmountIssued1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		              
    Conversion of Series A preferred stock and issuance of common stock (in shares) (35,000)us-gaap_ConversionOfStockSharesConverted1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		                           (35,000)us-gaap_ConversionOfStockSharesConverted1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		    
    Conversion of Series A preferred stock and issuance of common stock (36)us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		                                
    Number of shares issued upon conversion of preferred stock into common stock           36,458us-gaap_ConversionOfStockSharesIssued1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                 36,458us-gaap_ConversionOfStockSharesIssued1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		    
    Preferred stock dividend                     (29,840)us-gaap_DividendsPreferredStock
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		       (29,840)us-gaap_DividendsPreferredStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		   (29,840)us-gaap_DividendsPreferredStock
    Net loss                     (11,810,938)us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           (11,810,938)us-gaap_NetIncomeLoss
    Balance at Dec. 31, 2013   60us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       1,890us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       87,433,460us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (67,043,410)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           20,392,000us-gaap_StockholdersEquity
    Balance (in shares) at Dec. 31, 2013   60,600us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       18,902,782us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Increase (Decrease) in Stockholders' Equity                                  
    Issuance of warrants in connection with debt agreement                   235,857trov_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedDebtAgreement
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             235,857trov_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedDebtAgreement
    Stock based compensation                   2,070,195us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		             2,070,195us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    Issuance of common stock upon net exercise of warrant           1trov_StockIssuedDuringPeriodValueWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       (1)trov_StockIssuedDuringPeriodValueWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		              
    Issuance of common stock upon net exercise of warrant (in shares)           13,011trov_StockIssuedDuringPeriodSharesWarrantsExercisedNet
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    Preferred stock dividend                     (23,015)us-gaap_DividendsPreferredStock
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		       (23,015)us-gaap_DividendsPreferredStock
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_ConvertiblePreferredStockMember    		   (23,015)us-gaap_DividendsPreferredStock
    Net loss                     (14,325,484)us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           (14,325,484)us-gaap_NetIncomeLoss
    Balance at Dec. 31, 2014   $ 60us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       $ 1,891us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       $ 89,739,511us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 $ (81,391,909)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		           $ 8,349,553us-gaap_StockholdersEquity
    Balance (in shares) at Dec. 31, 2014   60,600us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       18,915,793us-gaap_SharesIssued
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		                      
    XML 80 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Asset Purchase
    		 12 Months Ended
    Dec. 31, 2014
    Asset Purchase  
    Asset Purchase

       

    3.  Asset Purchase

     

    On February 1, 2012 the Company entered into an asset purchase agreement with MultiGen Diagnostics, Inc.   The Company determined that the acquired asset did not meet the definition of a business, as defined in ASC 805, Business Combinations and was accounted for under ASC 350, Intangibles- Goodwill and Other.   In connection with the acquisition, the Company issued 125,000 shares of restricted common stock to MultiGEN.   In addition, up to an additional $3.7 million may be paid in a combination of common stock and cash to MultiGEN upon the achievement of specific sales and earnings targets.  The Company is no longer offering these tests and has no plans to offer these tests. The Company does not anticipate any additional payments will become due. In addition, in connection with the acquisition, the Company entered into a Reagent Supply Agreement dated as of February 1, 2012 pursuant to which MultiGEN will supply and deliver reagents to be used in connection with a CLIA laboratory.   The total purchase consideration was determined to be $187,500 which was paid in the Company’s common stock and allocated to an indefinite lived intangible asset related to the CLIA license.

     

    Under ASC Topic 805, Business Combinations, the Company was required to assess the fair value of the assets acquired and the contingent consideration at the date of acquisition.  Therefore, the Company assessed the fair value of the assets purchased and concluded that the purchase price would be allocated entirely to one intangible asset, a CLIA license.   The contingent consideration of the $3.7 million milestone was determined to have no fair value by applying a weighted average probability on the achievement of the milestones developed during the valuation process.   The Company assesses the fair value of the contingent consideration at each quarter and makes adjustments as necessary until the milestone dates have expired.   As of December 31, 2014 and 2013, no adjustments to the fair value of the contingent consideration have been necessary, and therefore the fair value of the contingent consideration remains unchanged.

     

       

    XML 81 R58.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Employee Benefit Plan (Details)
    		 12 Months Ended
    Dec. 31, 2014
    Defined Contribution Plan  
    Threshold age to be eligible to make catch-up contributions to the plan per IRS code 55 years
    XML 82 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Option Plan (Tables)
    		 12 Months Ended
    Dec. 31, 2014
    Stock Option Plan  
    Schedule of stock-based compensation expense

     

     

     

    Years ended December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    In research and development expenses

     

    $
    796,008 

     

    $
    549,465 

     

    $
    136,148 

     

    In general and administrative expenses

     
    1,274,186 

     
    1,429,899 

     
    395,992 

     

    Total stock based compensation

     

    $
    2,070,194 

     

    $
    1,979,364 

     

    $
    532,140 

     

     

    Schedule of assumptions to estimate fair value of stock option awards

     

     

     

    Years ended December 31,

     

     

     

    2014

     

    2013

     

    2012

     

    Risk-free interest rate

     

    1.42% - 2.1%

     

    .74% - 1.5%

     

    .62% - 1.04%

     

    Dividend yield

     

    0%

     

    0%

     

    0%

     

    Expected volatility

     

    81% - 86%

     

    82% - 100%

     

    90% - 97%

     

    Expected term (in years)

     

    5.0 yrs

     

    5.0 yrs

     

    5.0 yrs

     

    Stock price

     

    $3.00 - $6.74

     

    $5.53 - $8.15

     

    $0.50 - $4.87

     

     

    Summary of stock option activity and of changes in stock options outstanding

     

     

     

    Number of
    Options

     

    Weighted
    Average
    Exercise
    Price Per
    Share

     

    Intrinsic
    Value

     

    Weighted Average
    Remaining
    Contractual Life

     

    Balance outstanding, December 31, 2011

     
    2,426,192

     

    $
    5.22

     

    $

    —

     

    6.7 years

     

    Granted

     
    1,294,668

     

    $
    3.74

     

     

     

     

     

    Exercised

     
    (200

    )

    $
    3.00

     

    $
    640

     

     

     

    Forfeited

     
    (9,357

    )

    $
    3.00

     

     

     

     

     

    Balance outstanding, December 31, 2012

     
    3,711,303

     

    $
    4.69

     

    $
    8,301,484

     

    6.3 years

     

    Granted

     
    1,144,760

     

    $
    6.33

     

     

     

     

     

    Exercised

     
    (52,500

    )

    $
    4.30

     

    $
    275,492

     

     

     

    Forfeited

     
    (516,018

    )

    $
    4.35

     

     

     

     

     

    Balance outstanding, December 31, 2013

     
    4,287,545

     

    $
    5.18

     

    $
    5,896,329

     

    6.7 years

     

    Granted

     
    1,410,038

     

    $
    4.42

     

     

     

     

     

    Forfeited

     
    (784,111

    )

    $
    7.08

     

     

     

     

     

    Balance outstanding, December 31, 2014

     
    4,913,472

     

    $
    4.66

     

    $
    2,808,083

     

    7.6 years

     

    Vested and exercisable, December 31, 2014

     
    2,434,124

     

    $
    4.65

     

    $
    1,990,187

     

    6.2 years

     

     

    XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 305 337 1 false 89 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.trovagene.com/role/DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.trovagene.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.trovagene.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.trovagene.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss false false R5.htm 00300 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency) Sheet http://www.trovagene.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficiency Consolidated Statements of Stockholders' Equity (Deficiency) false false R6.htm 00400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.trovagene.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R7.htm 00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.trovagene.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical Consolidated Statements of Cash Flows (Parenthetical) false false R8.htm 10101 - Disclosure - Business Overview and Liquidity Sheet http://www.trovagene.com/role/DisclosureBusinessOverviewAndLiquidity Business Overview and Liquidity false false R9.htm 10201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies false false R10.htm 10301 - Disclosure - Asset Purchase Sheet http://www.trovagene.com/role/DisclosureAssetPurchase Asset Purchase false false R11.htm 10401 - Disclosure - Property and Equipment Sheet http://www.trovagene.com/role/DisclosurePropertyAndEquipment Property and Equipment false false R12.htm 10501 - Disclosure - Stockholders' Equity (Deficiency) Sheet http://www.trovagene.com/role/DisclosureStockholdersEquityDeficiency Stockholders' Equity (Deficiency) false false R13.htm 10601 - Disclosure - Stock Option Plan Sheet http://www.trovagene.com/role/DisclosureStockOptionPlan Stock Option Plan false false R14.htm 10701 - Disclosure - Derivative Financial Instruments - Warrants Sheet http://www.trovagene.com/role/DisclosureDerivativeFinancialInstrumentsWarrants Derivative Financial Instruments - Warrants false false R15.htm 10801 - Disclosure - Fair Value Measurements Sheet http://www.trovagene.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R16.htm 10901 - Disclosure - Debt Sheet http://www.trovagene.com/role/DisclosureDebt Debt false false R17.htm 11001 - Disclosure - Income Taxes Sheet http://www.trovagene.com/role/DisclosureIncomeTaxes Income Taxes false false R18.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://www.trovagene.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies false false R19.htm 11201 - Disclosure - Employee Benefit Plan Sheet http://www.trovagene.com/role/DisclosureEmployeeBenefitPlan Employee Benefit Plan false false R20.htm 11301 - Disclosure - Related Party Transactions Sheet http://www.trovagene.com/role/DisclosureRelatedPartyTransactions Related Party Transactions false false R21.htm 11401 - Disclosure - Selected Quarterly Financial Data (Unaudited) Sheet http://www.trovagene.com/role/DisclosureSelectedQuarterlyFinancialDataUnaudited Selected Quarterly Financial Data (Unaudited) false false R22.htm 11501 - Disclosure - Subsequent Events Sheet http://www.trovagene.com/role/DisclosureSubsequentEvents Subsequent Events false false R23.htm 20202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) false false R24.htm 30203 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) false false R25.htm 30403 - Disclosure - Property and Equipment (Tables) Sheet http://www.trovagene.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) false false R26.htm 30503 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.trovagene.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) false false R27.htm 30603 - Disclosure - Stock Option Plan (Tables) Sheet http://www.trovagene.com/role/DisclosureStockOptionPlanTables Stock Option Plan (Tables) false false R28.htm 30703 - Disclosure - Derivative Financial Instruments - Warrants (Tables) Sheet http://www.trovagene.com/role/DisclosureDerivativeFinancialInstrumentsWarrantsTables Derivative Financial Instruments - Warrants (Tables) false false R29.htm 30803 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.trovagene.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) false false R30.htm 30903 - Disclosure - Debt (Tables) Sheet http://www.trovagene.com/role/DisclosureDebtTables Debt (Tables) false false R31.htm 31003 - Disclosure - Income Taxes (Tables) Sheet http://www.trovagene.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) false false R32.htm 31103 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.trovagene.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R33.htm 31403 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.trovagene.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables Selected Quarterly Financial Data (Unaudited) (Tables) false false R34.htm 40101 - Disclosure - Business Overview and Liquidity (Details) Sheet http://www.trovagene.com/role/DisclosureBusinessOverviewAndLiquidityDetails Business Overview and Liquidity (Details) false false R35.htm 40201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) false false R36.htm 40202 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 2) Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails2 Basis of Presentation and Summary of Significant Accounting Policies (Details 2) false false R37.htm 40203 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 3) Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails3 Basis of Presentation and Summary of Significant Accounting Policies (Details 3) false false R38.htm 40204 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details 4) Sheet http://www.trovagene.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails4 Basis of Presentation and Summary of Significant Accounting Policies (Details 4) false false R39.htm 40301 - Disclosure - Asset Purchase (Details) Sheet http://www.trovagene.com/role/DisclosureAssetPurchaseDetails Asset Purchase (Details) false false R40.htm 40401 - Disclosure - Property and Equipment (Details) Sheet http://www.trovagene.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) false false R41.htm 40501 - Disclosure - Stockholders' Equity (Deficiency) (Details) Sheet http://www.trovagene.com/role/DisclosureStockholdersEquityDeficiencyDetails Stockholders' Equity (Deficiency) (Details) false false R42.htm 40502 - Disclosure - Stockholders' Equity (Deficiency) (Details 2) Sheet http://www.trovagene.com/role/DisclosureStockholdersEquityDeficiencyDetails2 Stockholders' Equity (Deficiency) (Details 2) false false R43.htm 40503 - Disclosure - Stockholders' Equity (Deficiency) (Details 3) Sheet http://www.trovagene.com/role/DisclosureStockholdersEquityDeficiencyDetails3 Stockholders' Equity (Deficiency) (Details 3) false false R44.htm 40601 - Disclosure - Stock Option Plan (Details) Sheet http://www.trovagene.com/role/DisclosureStockOptionPlanDetails Stock Option Plan (Details) false false R45.htm 40602 - Disclosure - Stock Option Plan (Details 2) Sheet http://www.trovagene.com/role/DisclosureStockOptionPlanDetails2 Stock Option Plan (Details 2) false false R46.htm 40603 - Disclosure - Stock Option Plan (Details 3) Sheet http://www.trovagene.com/role/DisclosureStockOptionPlanDetails3 Stock Option Plan (Details 3) false false R47.htm 40701 - Disclosure - Derivative Financial Instruments - Warrants (Details) Sheet http://www.trovagene.com/role/DisclosureDerivativeFinancialInstrumentsWarrantsDetails Derivative Financial Instruments - Warrants (Details) false false R48.htm 40801 - Disclosure - Fair Value Measurements (Details) Sheet http://www.trovagene.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) false false R49.htm 40802 - Disclosure - Fair Value Measurements (Details 2) Sheet http://www.trovagene.com/role/DisclosureFairValueMeasurementsDetails2 Fair Value Measurements (Details 2) false false R50.htm 40901 - Disclosure - Debt (Details) Sheet http://www.trovagene.com/role/DisclosureDebtDetails Debt (Details) false false R51.htm 41001 - Disclosure - Income Taxes (Details) Sheet http://www.trovagene.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) false false R52.htm 41002 - Disclosure - Income Taxes (Details 2) Sheet http://www.trovagene.com/role/DisclosureIncomeTaxesDetails2 Income Taxes (Details 2) false false R53.htm 41003 - Disclosure - Income Taxes (Details 3) Sheet http://www.trovagene.com/role/DisclosureIncomeTaxesDetails3 Income Taxes (Details 3) false false R54.htm 41101 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.trovagene.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R55.htm 41102 - Disclosure - Commitments and Contingencies (Details 2) Sheet http://www.trovagene.com/role/DisclosureCommitmentsAndContingenciesDetails2 Commitments and Contingencies (Details 2) false false R56.htm 41103 - Disclosure - Commitments and Contingencies (Details 3) Sheet http://www.trovagene.com/role/DisclosureCommitmentsAndContingenciesDetails3 Commitments and Contingencies (Details 3) false false R57.htm 41104 - Disclosure - Commitments and Contingencies (Details 4) Sheet http://www.trovagene.com/role/DisclosureCommitmentsAndContingenciesDetails4 Commitments and Contingencies (Details 4) false false R58.htm 41201 - Disclosure - Employee Benefit Plan (Details) Sheet http://www.trovagene.com/role/DisclosureEmployeeBenefitPlanDetails Employee Benefit Plan (Details) false false R59.htm 41401 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details) Sheet http://www.trovagene.com/role/DisclosureSelectedQuarterlyFinancialDataUnauditedDetails Selected Quarterly Financial Data (Unaudited) (Details) false false R60.htm 41501 - Disclosure - Subsequent Events (Details) Sheet http://www.trovagene.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 3. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 0. Element us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 had a mix of decimals attribute values: 2 4. Process Flow-Through: 00100 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: 00400 - Statement - Consolidated Statements of Cash Flows Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: 00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical) trov-20141231.xml trov-20141231.xsd trov-20141231_cal.xml trov-20141231_def.xml trov-20141231_lab.xml trov-20141231_pre.xml true true XML 84 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Basis of Presentation and Summary of Significant Accounting Policies (Details 4) (USD $)
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2014
    Sep. 30, 2014
    Jun. 30, 2014
    Mar. 31, 2014
    Dec. 31, 2013
    Sep. 30, 2013
    Jun. 30, 2013
    Mar. 31, 2013
    Dec. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2012
    Numerator                      
    Net loss $ (4,689,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (5,382,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,079,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (3,198,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,038,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (4,407,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (5,279,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,117,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (14,348,499)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (11,840,778)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (11,604,201)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
    Adjustment for change in fair value of derivative instruments                 (2,422,337)trov_AdjustmentForChangeInUnrealizedGainLossOnDerivatives    
    Net loss used for diluted loss per share                 $ (16,770,836)us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted $ (11,840,778)us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted $ (11,604,201)us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted
    Denominator                      
    Weighted average shares outstanding - basic 18,904,280us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,902,783us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,902,783us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,902,783us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,900,781us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 17,870,703us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 15,583,957us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 15,510,340us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 18,904,280us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 16,978,212us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 13,066,600us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
    Adjustments to reflect assumed exercise of warrants                 166,832us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants    
    Weighted average shares used to compute diluted net loss 19,071,112us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 18,902,783us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 19,232,760us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 18,902,783us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 18,900,781us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 17,870,703us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 15,583,957us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 15,510,340us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 19,071,112us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 16,978,212us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 13,066,600us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
    Net loss per share diluted $ (0.25)us-gaap_EarningsPerShareDiluted $ (0.28)us-gaap_EarningsPerShareDiluted $ (0.17)us-gaap_EarningsPerShareDiluted $ (0.17)us-gaap_EarningsPerShareDiluted $ (0.05)us-gaap_EarningsPerShareDiluted $ (0.25)us-gaap_EarningsPerShareDiluted $ (0.34)us-gaap_EarningsPerShareDiluted $ (0.07)us-gaap_EarningsPerShareDiluted $ (0.88)us-gaap_EarningsPerShareDiluted $ (0.70)us-gaap_EarningsPerShareDiluted $ (0.89)us-gaap_EarningsPerShareDiluted
    XML 85 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Related Party Transactions
    		 12 Months Ended
    Dec. 31, 2014
    Related Party Transactions  
    Related Party Transactions

     

    13.  Related Party Transactions

     

    Gabriele M.  Cerrone, the Company’s former Co-Chairman, and former member of the Board of Directors, served as a consultant to the Company from June 27, 2005 until June 2008 and is affiliated with Panetta Partners Ltd.  Transactions between the Company and Mr.  Cerrone and Panetta Partners, Ltd.  is disclosed in, Note 5, Stockholders’ Equity (Deficiency).

     

    (YZ#T4370\3.E).P6>"XHWM&+*JJBQAU`6GCET)!A_BQ;?C MRZ=LV#U%)*JW=I8YS>'MQXT^%*9W.%DKZI5%CG6/Y2&&2,6V4`."QBOYX+U+F6Z#H)TQQOAQY[!(LSAH!R#^X2>S\2A)ANZ(:L:A3N:CP)*(E/>\4PY"AK$]@6!]:/`NBJ[KB*KSJXW>7$# M@J->):!3TJV)DNZM`IKB(W;/YZ5L\NNZH4=Q,@3A=B-?Q^M"].MSFS!U.OI1 M;;23:13-HCX_G:BDF5?*=ZK3EJH?/K[+T]-'`$;O;[T!]/,07O5O!R"!GT$* M_8MX.()1"K(@CFZSV/O[:H3_3,^]+'@*LO$=)NL=DHO/(?KQ[)=_2=+'U]J[ M!N,ABMC.GT'B5]O["<*<='*>IOFP^*[>MN2A::$/-[#_Z>0R3\C3]RKZAZ.L M^[OX7M7N]>+3R5FI::>SK6C=@L=%L(`977XNG/\:L%=!8RNQWT;F&\&B,L6) M@5-^GQH6@G_)@V%8RO"G$^6$?$Y'P)M\+M\OXR$D_"$8I?#]Y(\/1<.2K1,] M4:6DK=54PI8Y!)U2_>N&''*VTA7VG+6\(R.?M9[1O,UT'6VS$," M"9,VBCS,-44>IMESG%;KZ5HE-0MX_D4\ARG+8.1#?_9QZ<(S$S]#I[1^TP:. M*25,A;([!F7W>MAB$4&@>US%D6LX1DEWA$9**SH=0Z,PM[N!41=@%&#D!8R: M<.9V<^80$)=[S]'T3I'^?]A,(T4.(1S#-I`1DD)D'V/5T9'N>(*6#R]H5 M;1J053&0I%-)ZZF_,S/'O!)0(+?#R.W9!@:NVC,%<`5PNP1<2RN`JQ@LD%LX MG5UW#6@YGX?F8EX&3P'JVY?&`0R9G$I`+[G(ES;KON)0V!FZ8S!G`@`"``(` M++-4W7$+CB5E!#V\(>,I#D$6A$$V9N\WPM% M++]9/9M=;36O$9^`SZ[P,7NFCN'C]%13P$?`IR%\E)Y)M(_1[[#:ZZN/WS2)(08H\3/4C^R,G^]7DX/B32N[H%V;Z+N,^T^8E5$"*U8HZ; MWQ$BQ(NV>/U)?H8^4PDX?X()>%S<4$:SCR_%H:UL.R'9-2''PC1R(;MW,!ER MO4S0V>V_--,'W"\<3/P3Z6IV90WBP#M=?8?B4;6C^3VNU1X?>](VI!&3\U!U MV5)4V;!W.NSZB'`T.0"81QR)LX??JV9/$6*^1,Q[ZDZ781Z1A/-L*;HFX>JI MLX^SE0]PF6EK?_G0O.(_L$^\)"_"4[#/E^9JUYTT5$MV=0KNY`$Q1EQ"-^>? MM0E1H^=0<(4.")T4*W8YF='Q5=@>5:)LLL3`SBGHNC-)I\"M32W]!KD1EK73 M+3WK6-D%$_QV*X@W7LCEL\:1M940LGZ0Z.B,-U%$36HBM9"UPL+72;R%KP,B.1M:!;WL/B_H@CC&]X7+1MTVQ8 MLNN8LF)3L!U'@2-QO_?F-39<`E[ON9;`>O=R0E2J3:13R1+U)B*]M`N(RGH3 M1D>W'&0,UJ:^-Q59$9&QR-OPFK=Q1-Y&Y&TXFI'(VXAJ$SZCC5:7BFS-D0T: M=8&BW*2K&#!ZKBMDN7N9`U%-(L+]7:P[J281X?[6BRQ'4TYBZ[)"PT0A*'Z2:T`\(Z5UDA2O4DIB@G$?FE73`DRDD:*Y!6E^M-V:!1+'M`7!%Y&X[R M-GK/I+"A[8#0*?(V!V'VCR=O(\I)]A-LM+I4I./#2YCN0^B""6:WB,0'Q/EV M4_@4#3K[F/G@?]LJ[H#F*K(@!YT%$54VNRX]'4V5#:USW[I@_$65S6%G:U2E MYXADHDC7<#,CD:ZA6V9CB"0.5U4V:+R2'^?XEN)-G1T^PV1+UBQ3MC01*XN\ MT)'DA1Q38+U[>2$Z=3:$0K^^X,+5#Y(AB5*;!DY<\1$@FSA'M=%.IE$TB_K\=**29EY)'U6G+54_?'R7IZ>/`(S> MWWH#Z.3,5"Q3-RN#7]DKE='I MM='IZT:GFKJB6LK>AF?4AF>L&YYFZX:KZ%L,;P`2^!FDT+^(A_AW,@JJ?-4U MU:@2;FF/.X^J*3]=V]4M@_FPFO)1L175I3*LOP3I]-LOPU$8CR$DNN=JA!OZ M#H5*V?[^`E&.;#XKF3LVOC MKW7DVXXT@NA5H@=1C>@ZWT3_"H+D)PAS>)ZF^9!,-<7ZT,N@?QD\!3Z,_!N0 M-3)HVW)B7@<851V@G9PI/66MNJ0X99XH3`GK@L*;VJ/#I?##^NX>FG1W!Y/A MZXJ:EGHXNS;GE2F3R7!!-%H2?U1$HR7$+1*-MC;X&8>HF1`%MOLRXQM[I&M5 MI6LS5I5UXAP=-VJNZGINL#9R(4I6-&Z*U6*A7VL*HHG1ZH0"XV5[1:L:"H6JM%! M:_$CQ[.[ZI-?T_,\&\1)\'_0K]'^/+V_ZM_;]ZJ]]X6\>;I7R?[MQ]>3,]W" M_Z.1AUI%BE8H[?!'::LHTCTH2KLEIHU7*%94'7V+/-1^\`3QTPVHIIG=I-H3 M"$)S,CV)RG7A?[Y$TS`(YR<)'.=!![<"S'UN3R?T;-HA-#- M9LI,NNC)S*6I^700*]+$XV-6J4"(;NTC)<%7= ML#LII-LN%5+3>/-.H=G3V!"RX5)AN^1E%F\:/8N-1],I\C(+*,T>S76`KI*7 M91T!C=U;.Y-WA\7UU9VN6ES77HW5U5JLOKU:QG4$#MTZ@BVFRC>MZ9U58?VE M?U<=0>M]''$A<+V.UO1JD>R_[.\6=Z1^S4:D38M%-C:*#4\`G+=U>K-=_%3G MT14:LO(S!.W;7)/1!>TWI?WR(9)O*[LT_AOY,*DP`J_`H['7NI_M02-K]L6# MM2>N(CBW;'^;@8P0HJCWQT.((TR7&A+0UT,T)MS]QJMR`@$\(N#N.=X/`O2> MV21WRS,"EI2@'9GU:T@!CNF_/PO8)`5_//3?4UV"W5.:)/'XIO^K91$1/]W$2US&ZS@,O'&C ML_O/RKM]IC=N5.[Y*>X9*:[LPI>-E)^+*[AJEZNLNIYDJ^MG-KM[!O_V/L@` MFO'2VV@(PT\)Y:0JZ3:YNH3N12M;3*X^E6;WKBP9?/7R/=UBRY?ZT,]O+Z2[ M>!1XDJTZE?N!+CXL7`*S.\MK;)YV91106`V"K5E"FK_\("40A5?(?T""-QR! M*$!_9;$TA"!%7H64#;`^2S,I[DNPU$92"I,G).LI>M>#2'Q]U)D$7[P!UB=2 M/T[(:P`K$/(>B=_0,VF6Y$3=2"0G*\41>1!?+S!$L9XO]4&0X.N3L3KJ58`U_>L.-U=>YA*0\<6/$3DC(T;*BC0R*K8D^7F";U%\ M'@3>0`+1;'+D-4(2'Q-BA.+5P*_,>>54EPZH#B$_\*4HSJ3R=?SJ,QA+=Z@/ MI$@CU)#GQ3DF$&XYBJ/3&2.J('9A9M0X4U"R"MH`8:E74#/&]443^R%]9C9G_Y"!!)$)M(QP'X7)"!E5"]FC9X^YX%ZQN M=6ONYJ[RD_^(8S]%[R"IG8C(;:G-[I#*3(&'&\4UR:"(!K)![%.[U:7I.%#8 MD(]&80"3RHZ\XK'SQP02Y.UV/0DU>C`A.(63P]LD^?)K#BA2A"K1J9TPVA+) MRT-&EP?FU"BRA.3L*D*W/?!S,5VQ<)C4JFQ".Y-Y[QWU5K2V%,JT-O9!:]6TW7F+M-=1[X_61)U? MPX1\MV0*VKU*9F`6_C4V05?]JSX:';XT>^IW7^?(^?7U4U=!&"-"WO M67^=4[-W\X<4_I-CHCVA_RR8P;G?YP^:(4.NK*JM&C5R\TEA<1R&T"_8,_EI M`VM9[`I<]#&7T7F.'<%C%/0##Z"A>:C;-"#))C2^AO M08A,<>Q!Z*?+D+=@O%XAP]W=5X`/V[F]^<^&Y\S.';>SZP3FZ($A,(A#'R9I MF9%]S3RO&^RIH>FJ5CL8:Z&#G0;04+;/?9_0`837(/"_11=@A//&FU%>=W7+ M=&OWGK1G\#,X#SQ5]`@O=$I)N-_]303=>E\'S)8Y-1[^E M.)JFAN+5VLGW5*>AKQ5'17>UNCFG.X!]RJ-C&[IN6-Q,IKD\.BXW@]]&'ODA M_9;R:-D*O@2`V32,]0=Y&:YI,O.1FD:BNXFC:^NNJ3+S-:@G`Y:((S>#YTL< MFXY^2W%T5-U57<7=91H_X@RB0-0+8UQU<8J7)[5G?C?I!*!+^YA/W`"V#DC=^*(MV]%NF&85',2$KT1C"9 M?!H6%7T#\`2E!P@C"2^1DS+3+$9_]T/H%?5?2(N<]N,$-?R"OG]"')Y4KJ'> M@TR"_3ZI;<`ECM_!>$8KS94E[,$7!6JIEP0/12TLU@25QXZPTFIQ-M+D_QC# M8YU\%[99(@)-8R9=YDF+8GM9U%]C^1M#D$@0#<*7+J%'[/5L8KI:R)A,'IW4 MZV(;B^O%`R3;HR1XPJ5`J$NOJ'7L!Q&(/&S]RYK.!`3X\4=R_OEHDLV.^])O MEJQKBHS"TJ5:_QNN5T5>:+WSLB)8E6W=D75=K]12!UE:JZ>N%U#C?%,M_<3>2ZUX]ZW0*>WB%U>/3YDY(@46(Q2X2`]%<6\0X6+Q."DJ MRBU=)ZPNRZ()-Z44:2AL+"J;$OX-HAPD50N#K4LV2.+\<3!G>_`OS\CP_(9K M)R1#3G!?%)EXI"O6Y^"FGX,@JPL>VCCB4"(B+. MQ0X/V0#H@)`58ROU24Y3.&"(V M7-[DYWJ%>=EZ_5V`8L]Q&J33;05)@"85`.*_DY@"#V!6U^^HYJFAR)7=&Q7R MDUT-6952I=;`%M M$KC8$F_:*?O+$.B))D+=D:KU-""UZP,X)OP`R%TJ09$@+X7X-8/X&4ZVQY0E M[&0GQ02MJ,=G1(P,^5#_W]ZU/K=M)/G/=U7W/^`0!+49L#=]!XQ+VO;@TZ)M1=8SPODM0KY)CN(3JUD%1 MO?7*=S/TJSGNR%3T*+?IX:[.Q>Z-'Y8[A-G=78@J!/ M/X@]J6*W*(KG8[0L2(S"0GXK<2+^+A):TP$B"3G9)``A-FW=,+AUHW*&2JS(LZ>-4/#\>)[E9$6H-NH<;J@'6(K&Y4N[M!7Z-,L`ZLA>AJBA& MWR0?GMBU!/L^E$_61MX#DSBO`DO"@P"9C68A)5C&/=URR`I+^ITYH?X<8TM, M]L=C/O1AYH.GJG6%>9/6>$YJL+^DKWU:235_\*9`6N$G_,J'=\BNO^K&R)0/$PD21V\.1=[2E&,P#[M/%9KN=?M$L M:7(.'O(@@IF[MC(2+/#OPE<8N?.XM1*'R#V6XBQ$R^C;$"](9"/WH(I&8!ON M(]QZS8*$+B*:BZ6D7*5ET_J4V07LG3MQ[@IX$>=G/6N&;>D]IUN'6_,C/GT1/1AY M+:1"5\E00CER.NO\^Q4($F(H[)8\NB*9'[O5H;+'8[0K=;&1S+L/UU2@N4%G M$;<4/KPSKL3,.E?'Q=M%SXV!*%>\]N8Y\#'%WR.`9770>EX0]^E"6@Z$P;$_4Y MRK^.Y(%(^4N'J;?"B=+)1H"S(2[BM24,6,.//3Q*U6,3!0K#!S]!G5;/6*I) MURP`I(48O0*?=HA#6T4VK#8&=!8*]G)%F1\.V1W#ICE`3J_G`+,E!Z36(S-?S:P_\+AC'F(Y/6+:.4(8. M;`*!PCP$1&R@#XS>&@*FV(%" MLE:Q!+/(++O8*RZ?F:9NN<;Z0-SB\(DHR8-TRS`/BV)5G'RJ)!A=O=+1V:PB M^+YG#^2'J$NO8,M3G]1%+K((R<0E(_X-Y1Y_.Y-KLW/K>DFVYX\`"11#&+,G MK%D`C^"!QZF/\6P45\);^BK.MD)^;D8&;$I2I5M"Y%"1E<"`FG MPY-+8#!0_\Y/_W.'+MIP:ACX/[35J58_7^`RBKKT^#>DYH@"W\J1EG'L^UUU,CJZ;;CYAVIV7@J1!'&+I%F^QH$6YX; M+Z/O8G^P&)FN]0U'[]O6W`:+$`>:R^\M`AQ16?HH7RFC,?%.F%4/8R MA`(,ZQK&/'>G*#Z;ELZ*ZJPH/%L&@*=3W+2_D2[;W_HO.6WM_I(#ZFRR@M(* MYP*17*21\APEED(^8*4Y!G@,+6001(_)JU.?4.6DBT=_F-Y#.]V7HAFXFE)T M[4$P-T%/)KS#S)A7OY=/G^+VS;B[&J5)O33*L2O"V- M1H^D0(I@&DU>&9,4ZT:X]L.;`?ZKY1=)\.9>%:W3=5J.TG[HTC_%#>+@E]GG M#\K>?8CDQXPP=%H<;V/MI_SSMEU$H[TV7VN46Y4J:02$!AP/\64`K7H]LWKE M[W/=JP;(E\7NM8_\3;1[[83"G5:/6]/8"-V]X?%X#\)H[,R3/80PBN]QY?L" M9QX$L=Z3OV7>U[LXRL(AAA)1_$K[X?+R[=MW[];E3'%BE+&033)RU"'^+H)U)90?!1%+7R%9Q=7\!9J6WNL:NMVW M6SE:&96[#96CYV3S+@#O;/>0AFO,K9K7J'G'<%L-/WI+<6P:;IR[Y>Q03GYO M?G(SF'9X?_G4O.+WZ!/7Y$6:%.PW"[D.ZT[:1D\?6#MP)T]H8J33>&SHO3__ M[)`B:G?<';A")R2=$C9.B*(=ILZ.Q_!_/XFR?(EA?T[!L3N3:P4ZC0Q8?Q3[ M__8YE<=@@O^VD8BOO9"[5W&?$8V&R'^KZZ=):YL0..F$P%LZQZ9-"&RNHW?[.[`=WX44]C:"UV=Y0,P7>Z@QZK:P?7TYH)]4FVKG6:^M-VO32 M-D(DZTVT-K]T%`4GXI"Q=E;:O$TS\S9NF[=I\S8-HJC-V[35)LV,-@ZZ5-0W M7=W>15U@6VYRK#)@=P:#5I>/+W/05I.TX?XVUIVJ2=IP?^-%EN^FG*1OZ=U= MF(C3=03:M,2QI"7P`-L6V]JT1%,H:M,2NRTGL?;GT!R[)]S6DVQ53V):EFZ[ M5BM';3W)]U%/XNYU$]H)R7JCLD([JB=QVG*2-K^TC0RUY21K`\A!E^L=W=Y% ML>P)S4J;MVE0WL;J.#O8T'9"TMGF;4["['\_>9NVG.1Y@HV#+A59>'C)7O&N!.BMZ#O)"[E.*^O'EQ?:39T-<>B';UBX^K-F:VVIS1I. MG/C*P.9-ZU1^==G0PR@>LV"S*=]DOJ=(S>>X(&:R;/"J3VCU-O4(-QGZS3W7 M+J/QA(5/VITL[6%:&J4LT**15KS^1GO,_<9A%J/+F,*#*-8:AV$/M3?`Y@1^%.S:>K$34E>BPZD4/1M;YAZ7T7NN/+"D,Z`V49JY9T!LJ'&Y@BD;`[+/,*NO37BL)?<,>@$W&>["E)\6A?-I M=9=WKXV8'Z-69]116AW0(TLTGJ3^F.$\9$G.Z%L_C,8^3LDD]6$$.%"\-HZ& M/*CM]$9]BF[38OY7!A0DU*(?3K(41_#`8A]U3?R2:-$#4`TCX#K\X@79,!\# MT$\L!NF*O*^25P]1P%(_\-,GO7J3N#S.@M2?0.,X7?>^=Y^3JMU'`3BQB8;< M#?RO/'@"$2AG`MH"-A5\0?Y7FA]%\8C[:09/Q\"KN2S(13M+@.Y['X8.XP*. M#%G*J$/)[.D&\QE?1+'VZ*?W?EB=H,4S$OO)U_-1S&4GT"D*F1\-$[4Q#_0T M9EZ:07N!/\H%I>"=GVBW+(%Q1>+^/SO7'>TFYBS)XB?MR>?!4/.R^`'G5..C M$1"!$X"W#K%;:([TB_JOL#7E\7BJM[FT>,#:@),XRB?``/'X,?;3E(.(0M#B M>W!IQ`DOX+8_V).B,ET!#R"68Y"Y84[YT*`6@ M!)T\P+P\H#2Q6YP?GR=+U/'"\R"4@L$%4GH7ZR;"#6#V5QQ.)#XA4\'PWMW/ MH4W*;0B$>`%+$G_DH_#&T1A`-A\H23X::B0^4M_";$?0N1N"/-,[`5I6SQ?./2$!<2)+/2!`?[4#"*%NF:`A;!U!^"R MRBD_23*@E3JJ`FP"PA_>81_$B#.G8YG(@K,^@B[V2Y@,:,MHK"2S(YQ:%):+B41$5+;^+H M@=WQD)=^X>!GA#46/"6@SE*!/.@8'F?X_>+Z4G,-1T?I3A4D@[NQQU(S4!2_ M(F`]@<0D]R`^3V..E()RAR"A]&/"TS3@^#L^@.W%_`[@D(8LL!A9$O@\4YF* MGW/4(4M8KU(7H2J_AFZZKMYS%(F0P#:*LA@8_5?&8IQ":)RTI,:VL^U-^P.? M8]M)WJJVO;R[*G5PNR)X)*X+Y:TU\*V!/PD#7VM?=A3;M)':UI&:-&*LD!B0 M]$D6>_<@-9HX05+B-4XV>&ICD"0AY`BNM;#H5D(>?=TXSUHA]JGU$&HL,0R0 MW8$2Y?8*;,`#F%>P8O&#<"!X0``*U_P0+"UH/2FTM-AT&5I+-%1]@+\@44,X M\-EX!=,K2K,"'26"SX!],2./Y)6BOL&$%II<5<\2_U\'S/MZ?NT!:N*<"2.` M[0IC)/"]O'T4!4'T2#X),'%,MR>OZH;+%$CR0[3W22JP"4;1[=CF2YAI'[D+ M_!'(@A?@UP(S%$"$2X/^RRIVEI!2<'4%%L(XT'2@$UAAX9DQ, M:QWDX0OI%;"(H0&@=/:KA6H)/8D+0V.N$^D2W0R=XE.H&0 M.IVN!CP-R%/DMVF)5V"H3P@AS(YCK8L0?:OCSL,(B*JV1@C388XP5<#&49R"P$J3(:F4T"%=8LQ"*NY1$($DE@P5;I;_H#!I MS-/[:+@5\(@%)X]CDT>-/$7=PYY1YU&PYQ:BBUHZKL'<\T0)30&4P$.`R<<0 MZ%/,(9;'F/<:X687I![SI!W87.3.&:E=D019:P9%YB7!0/=5ZP!,R^;AIM>8 MK01=W@1>>X4I3]^K;50KN?-&&J2D,UN"O>Y8M5]EJF(C`01_1)@88+*?!L+" M@%GB:"J\;)P%(BV=F]`DC]3)Q)9I*.C)2VD=FRX$FDT,&- MJGHWOV6A$J9CZOF:3])I-T@D5NO]HUL.TA.BH2/_IO9Q]**Z3JW9+N:BY(4< MNY[3*AW#:O8S`4]&XX%PK721\4[N,6U9[QS6IQ[IMOE^'Y&-X:E>R:+BRM^9 M:=MZUW'HEC/3-/2N#71"SQ-AZ8'E,"CF>3%Z@LI<9B'EZ">%*`CGM9CB/+,F M_,<+V8;D8^8ZW+*`L;'+/>0JMBH%:>A?SPF?F0'=QP/2K MY>HF?JDX15-.0 M>UUH^*:(2RG[,(+8@X86BZ'50<2OT2.'QG0`''#J*2*BU9(29=;KG]"Z+)ZM M`HL87!BE.H$IW$>7V6CD@V@3>L"(BUCPOFIZ-AT2K3%6QO0C^YL2X@WAR03Q M#&+P\(ZR[]H$V!(#J`@4XR'FU0![!2.U.QAIF*\5K348Z/M6[3L#+L0P_=BX M1RNV8JT*UT.14H&="0]]N`'^XW]A6GS#GCVUYS%&K&*9+O6]0#`6D#F*)Y%< MY<$NH9\8&4-K4L,(C,'`_AQJ`P:AH=Y M?C%%!>^&&K@$MV+);$,9:<&[J>!M[1F\?_?_RM"A`'G?!73_.0&]00T(RG8Q M0Y2`WY+E2O7H$PZ=9Y-<0R1`ZG6PMT./&Y<.QI3^J>)(2@[5/RF)I*01Q9JE MGVAGAEKO-0DR82-RYP\=(NGU%5Y>JU%-U2A[SQHEI#-!6=^=2_26@206L>"& M*N$I-\G82Z:**X8*7P>@\$%R8.CPB-DQG/*A5K>:JEO.GG7K.KM-`+IQY?43X],GY)(*!>6TD<>P'-$=,Z0.CVGG(1@K+#5 M9X-.K]OJ>O-UO;=G7;_(T@B#8D\K+>HN%/UUH8"_98%2L8JI+91I7?.%&A;K MRS,Z2=XCN(6FTW%5SQ#5W^Q2FHY[`AM`M\@B#MF3S-&A$PKDL#MJV]4MRYIG M72=4ROJD)C5N.4;>T&@U@P>]5GN:33O0XY1;1K%'51ORP,?%388I":15^L/; M..`Z-B(=#7*2)[BV6F+;IDD,\DG*AR\%FZ[SNH`Z:%F0$E;7TD41Y@AR4 MS@<9M7JZ[;AS-%K'91HF*J^+QVY9XL\IG5Y]_:),RF/&BHNA];IZK]O5B[_Q MIH&#GS))^B*W)&KJE[__E"7G=XQ- M7A$G)<@*-Q:K:=_XB1=$21;S&]"@UP'<\\O__+>F_7WQ8_3K]23PT]),?D9_ MSJ!*8FCJ,Q_]XP7H!CEY7^PO9O\+2LJ7FTCY(COY\AE3P!??_*3XY0_VS1]G MXS](!E_0W@9J\4_X8-@OP(IX/LQA@B_$_*7;<;K+")T_XF;0ZX"MYC<>Z)I2^/HX?@E?G\7Q9=8-+&. MO!%W;IXF_&IT);>VE5S[1+O7^*>`><)#QD>V%;,/^3ZCBV*7V"?F#S^$EV*+ MXZIBV+=<"*56Y&N%09LP]F,48D'*I=S;)Q(HFR@VM?L:*]??1]$PN0B'T#0? M3X+HB?-KN:?A)F9APJ@6YO73=38!`.9Q.2\X"E$.>Y%7&J_(M<'`Z*W+LCK2 M#\O"`XF]^5:.U`.Z]Y$)!J(E,;@Y:V\>RR"S$=75KL`5F5J;#V M+J=FSS(LRUR1%P4-NZ,;7!.H?+DU/6II\60+W`;RQV-8-ZH09E`DN!"$/"AF-3\THI3YQCXSZIBO,G4 MT<4KL4&F>)=%HV#67%F-:VDY""\N'ED\G!&KMSFLEOV<``^>&\Z,KKNR%]P< M;NQ:(AP,LHZ."Z6W<:EL8I618%'N]R>N""N=0C@6)J^?\JX_X=I'F=8BX!4W M5NZX"ODS)0CLFL12.Q?J'3>/T7,E:YX%':CFY[!9/G,ZZ^+V5T&$F9$_`[U; MI_B^9]K7U)BUHJ8:/MKN+<<=?;*MQWFAP^O;@L#\K4$9QDM MIFFYQFJD+![4(8@[3([U1%FX?WA%1JVH-D?/J/7Q\WD9LU&J;CDPNN:@9]NK MD;)>NF;S43^O!P$<6!D.&LJ!M677[*UH_#<@>.NDU++!]U8UY5N&2\^=:=Q* MCIO+E#4AR7)->W`>SSRL^RK2-B<5&[4@_D+M<7\_UB^>7O<7(.5YE_%6KO^&V&##2'-V`)@Q#+6;'`QV6'@N$.^"*ALI=:&=VQYE^KP=6ZD_B MR.-\F.3;8_*14HD]F\#E;W2<(VU4-3I6?O:C/.R1]M#)72=TFKOL^#'*@F%Q MS%GU^(URWVU.C*10>2V?W/6"QUC('2TQI\TV2)38<(<'&=')A65J0XL\VHH[ MU&[Y*`("\MT%6GD89GM4VD&![+,\O_@3BP&PRKR35B2>OG?P,IUG!J_?6#B% M73ET/=))$_2F!-K^PVCWGYRP\IQJ.COM)AIK%T,V3G10Y%B[O&=X[$^HX_FW MN(.8-N6)0R?>Q`IRT3/BM-+\L&NED^+<:W@X2VK/I)U,Q`9B[#7EWGT8!='= MDSCME';X1O`@L`+/EJG?B81(5E+CYSN=\R-1\1V3M.6*SI&;';MR]IL_U,X& M]$H01%JQ/Q@;0VS,26EW%FVZLVA>B%&-1&[8MTN06#^]9''\!-S'ZHL+<3** M&HM<)%^N1DKP4411'T*P2QR:D2OA_XI+%<@Z)!G><:SK#80+P+Y M@XX:7HU%YX[IN(9:`["$]MTQ:LW$VWFO;W;=KG/XD>YQ2N6+0S:?3G/0!2P] MQ'2NF6D[-[JN;1CVX4>:K^?E^:&KT>7]S"Y`\9.:YGD'UII2/>5&S>]SIAN. M<(8+L.$.#L"GZ53=LH':`,7J=ME##;3I$[H=GQ)^-7HKW[BPWOP=;:IU683Y M9T(G7Q1<.7EWNU')L!LZ6X9/6'GJ4]WI(S*2`Z]UG+]N3+SKZ_W%Q:?R=6XP M/'97O`R)WO;'"VFG\V;*5WS(U^>)$TO+C!&FV\@IIBP5W,_E2]>4MV6*DYX* MRR=24R$&H-CSO&?2Z9-6ZBG-7_!6-YQ8Q!#%.YK$*=G*T3?36:_ZDS3$^]3$ M:T,0!3#W-O0Q%R?>\@1PE"B<6RD"W5,05T6L*IH58'N!!VWAH6-OY/D<&(SA M+`C'Y4-8$\YMZ<'9UL#MJ^'5NH/9(REKFMY>=S#H[HZ4?Q$&\N&%.-?I(V5O MKT9O\(`X+JNIKY34[191TDQ99;?7JZS&KSF6_1%"TF7-$ZYI.AS'Z%IV8^F8 MKR73A/0&?=HV5[)FGGK-$M\[A'-2/Y)]$;$?Q^0`-.S>*7DF(O;J MD#P3#7MU1IY+F/;KB#RO2NS'"3D`#:N;"2#"-MW&8--&SD?#)F*OCL$C#2D;[S'4E'TI'\]9?7 M&;86D#+DDLM:ZZQ9LR"Q70>1R67-9W7`;(1JO_SGIW]\_6>];O4H!!YTK.>E M=0/`ZM]UEK_LI+@D@NKTVBU&^UF MZX/5OOC0NFA]MA[NU@GO>"7&*#,E1N3[A?CSS(NT7AFZ8/84SL#`M8,Z7=:F MGC>_:#1>7E[.7I\I/G/IA(MJ=AKK7-(4XEM]E:PN'M5;[7JG=?;*G)K%54=8 M4+9"(:ODO(9;J5\ZJ[2MQA]W@U%0^3HBS`/$WN3:*R7*U_KRY4LC^'6=E!>/ M4BJT%LVU9UE?J8OA(QQ;@8P+;SF'ES6&9G,LR@Z>32D<7]8\ZBZX!EKGK7:( M_^>1QXF<0>+U7,)8#!V(CR/K0`PBSV"H^0&FBRL%X2T?_6?P";RN;:F=`UBB%$/P=`K! MT\F!QP;8]G'0H`?\MPB#**J0`3*F)?CJ0>)`9_T4>:(0[F0TFU;=6HOCGWO# M^]%P<-OO/EWWK:ONH'O?N[9&_[V^?AII0`P`++VNIAH[0* M]7Q*N69WZI68YL^/G0\?6Y\^?O[XZ;SUB7_^T(G5/&8M7;H-`E![)9]_W#.@ M;8ZB%`TF!A`AK8XX^:O\8^K.-FJ+"G%U*NQ2!U(^=ZA9/N/U<.>B#(!KU@M$ MDZD7_%(&'<)[$&X3_R=&CP7`HG?M>CU`Z9(/F4''*Z%)*:\Y]*F3M4]P?JBF M$A]Y1>P1VI#C><;P'GH9S3(E2S5HUD88L=LVC5WN%L\!<<\RL-YP`,619S2)8/N]KU-[6YQDSO MWB5V:@--3'L*;*E7W-0F-D#@&6'D(2B6FD:>:W^?NIC7E0G+\Y8[C&4G+QF$ MQ,)B*P%!ZDFD^] MG=AH%O.YU`H`#2:4^M!1;I72]-6B50.CJ7[7P"63)TAG??CL!=/[.?(`'D#` MX/`9HTFXK931!^O(J)`%'([;6#=/"=E!YF"T'11J`"?5'_0A10M>[P6,J2-S M1I:1JPI4QOG`Y<%N;F%:-,V)A)2FL.<)AN) M"Y=*Z$QUIWON;.:23!)WDU6(025HIC;#KN.@L"H/`#FW)!KW97.AY-05(E,' MH:E#XJ,(UR#0N0:4(#)A?';GSP0#T.G#,;*1S/7)SE@AIG."C4@_SR;]:V,G M^.4H$3%:L9,Q0J3A,NW]<)E8<9L?F.6.K4V)%B".M56FI1FP64)+N8=>&.8D MJMI=`(3%JM:3&^O2(],2`8KV3K/1SEU&9[!524F[WTIC3A//R4Z\D6X0+2'PHW[;?264>=:HT)$Q1%:"I MD#>GR*5\9`_\YU(\*G<)L+>,H,B\IZU$6V`_F\"C"AL);E(V*E/;7U3G1VB[ M$Q)X]7>(J\!S";R#WM1UMA/\O7&&]OQB74&58;\8Y*;.?@?(CL+%1I`N^!>6 MWL2EZ:O"MQY`4R?`ZQ$K"@?,])Q6ZR[SAN/TMKF5 MQF`B4^E(6EW,@J7G077*&HL9Y.H28?=]C@6[061GI(OK5QO[XOQUU_[+1Q0Z MM^2!NKSS80*]=%#.+;$ZUE&T$E0&ZHTME36O@A@+5,2Y`_0[C*E--L629JB. M)6AB5!FZ2R?Z5TBX,C#'U'5FB"#FT6#7.IWMC%S5H3P/4)7EZ])YOR4+/L<0 M/5GH]<@73Q)2FL=OGK4O56"FSJQNB05'=2586Z;%"9W6^]K"X7("*P M#HF80(H;&6*'4!&-'\PC>;MB*,^6B`'$H>%.EEO[][.YL!..5:J+,(<`RA@/_%@X$KK M+67%#\0O'U()%3C7"140PBW=JXW*V3`75>7]N2#7N5I^8V+FS)%Q%]WG7OHF MYF$_'D`]9TFQ`$D57,\_NC;OS<+#`]EHBQ%J5.^@R_M.I$'1:C!U7^VPD!)3 M?("BV=()/C&=X;^CMX M+K$5E:QOU%)RJ\;47=EXQ8=C<7DU@` M%N>1880KPB0SCOV4;]4<%#6ALBQ1^H;_:`J"2V%A$,8."4L;1)(3OU$ST%!& M9`D?31LHWLXZY/'-X8"%RT\%.IK[U]6*)^'AG*)20?"P6L0M!V M"-?(^<9(/U0S$?&?3>L0^"R:BHL(^C#\S_4E;A_;*"WI6ER]S&_,4@I03F0L M7XR;CNYCVK\(5-E6]K.^6XJ>:E9K7,T3,)3M6T25C60[V[N!J*ME91SR%5!S MC&/G[C.Q%+-W;99VOY(F[-V0#E76RKR,"X^2*#*,^BIX)TY1J#G6=IR=N$/4 M8&J4'6\0P?[ZDQN%>$OO4)8%(`*(7?!(IBC4'',[SDAVB!I,W1R, MMY5;QGSQEJ?A.!:9I]`+)>8SQQB.R&IZWZ.N%U/C4>)H?@>4BEB)5TAM)#_; MFY;EW2;45&*LVYMHW/$;;+5ZBWC&=]/048S>*<*2/)0M-TQT?<.@FFQE^[); M/S+SO=N*AEY,/?021[.R=[T[PC4DO%M,+@VIGZ0I_,Q$X:\HCI$J.5=QWFPW MSZVZM2F:?PE*%\I@;2IAK6IA_2NJAW7^;^//8"B>U.DC M['O2+CR'G-(#ZK6OH[WH"[0Z2[XX#R!]_[L&5(1"AHH)X@*9$/?8QX? M,_B@(.E#M*64MC4K>`4XLH:@7EW/H^C9]R([`1A'CBD?IJ/I;NK^;#Z)YK6< MG):PMP5;H#Y.XHHJB=[V%)8V!FO)J*3I'*Z!G-WM$5W_U;9-?,\GRKU1^LC4]DWEM6H4II=@HVHB[WVE1QP=;@"BP8M_[B`0WX-X$;WAX?/^\""D M6H%8*R[W5,:','!\K9H-M)WFDY*NC$[BSB5P&5Z@>.,3AWN\/>[7+KF_DO9R MJXQL\XG`1KFH] M@=?UMD!;;91H-9OMW5$B%&8%TC;+^VW#!X>U"J*C`5=<56/I6\FDJ4M:>PHK M(]YX0&QN=X$U2.K8]6Z@(^YH%5=A^;Q*RTU^[A]E`2ZB#'/:N"+[.^M01];$ M24Q=)&H([E?C'O.`EXQCW8J>6>=E?L@LDJ?D#I#-`Q-V"7#V) MVSY*&4^2U`/AG420D@3>:MNJ'UT[R1.$/KSPD$*B,'9?1+B67JO7$'R2-G-D M^'JWZ)AE4\$)[\WFJ.9PL9N[BM:AA#'G/3H_=&;149Y9=-1F%AW#9Q:Q]IQ] M*E>6N)SY?69'U,N8ZJL*,*_%IK.V/>L_".5)>/M[&(.-%TWVXWDJ17@FL--X MH]D>KF#,464W2&PTK8ID*1`NQWJ:K9E_6#V+')3X16U\4-Z(= MHZ@W8F3'TE0Y:PA)\'K\.PIW<,8N?0'48;&7QR7U/H>(JI;9%*Z)DUB2V.^) M5]>\B+#9+=#*XY940K4,IB@%Y%QF2)IC?FV$#$63,_[D_U!+`P04````"`!W MAFQ&71Y:],]#``#IRP0`%0`<`'1R;W8M,C`Q-#$R,S%?9&5F+GAM;%54"0`# M8?P!56'\`55U>`L``00E#@``!#D!``#M?5MSX[B2YOM&['_0UCS,.0]5Y4O= MNN/T;LBW&F_8)8_MZI[9EPZ8A&2>HD@W+[9U?OT")"61$@`")"Y)E5ZZ72)N MF5\"2"0R$__X/Z_S'+X[>#/"D1?[033[[4V>OD6I%P1O_L__ M_I__XQ__Z^W;T6F"48;]T<-B=(V3)`C#T6F7EW>M#$KZ+DQEI MZN#X_:H6MP3]U]MEL;?TI[>'1V^/#]^]IOZ;$6%=E!9]2W2R+$Y&V"C]_C^OZZO[HK!OPVB-$.1MZZUU4M5[_"77WYY7WQ=%27=!X(!;35-OOK9JD*] M\,?WY<#HJNOLU6SSAW]ZDP?PII&T5OSTF>/K;FRR)GPFS M#C\<'I6L^K>[C&`^QU%V&D=I'`8^%8'5C^ED>I?%WH_'./2)))[_E0?9X@Q/ M`R\@LKAX,Z(=?[^];!!%.T$S'.%W7CQ_3TN\[]E+P0XI)-\;Y\419X&'0GVJ%<9HG^`PGP3.9K,_X(HB(:`8HO"1"FN3% M8/]`28+(_^_10XA3:19T;=X)!T[R-(APFD[(2OP_1:Y^#'ZL1(-1TD3-F M*T[H.8WG\R`KY)RHQ:=Q<9XA6D2O8[I,HT"I[8*F5*M`Z>VRTTNUZD:;R1]2 M_%=.1G;^W&^SX[:D3%B-0VC(G_CB%XWO?7C.0HBC4/<;EK'>(NFWL[Q_`$G.@?;;%?# M2!_)H!(O?\!O5XS0.%YFZWKE`4]1'F9F!&+9=C5B\N\@"NAQXXJT6[5.QV/Z MDJE&&G[-<.1C?_5KD-'^R3IP<#!Z.UHU2OZN=[;^D([BZ:C>W[^/RAY'?UOW M^7>%5:?@#<4S]AHC#>EE:IPP42B:FJ+TH6@O3]_.$'JB=[7'[W&8I0O2`P^("FEGHOW.X;&V:Q',^@ZLAQ-*DY"D96%R< MWU'H!J"-@9TU=I<-8#AE#0&RO2])HB$2M3HX'')V`90_/QU__'3X^=.73Y\_ M''XA?W\\MH'3KB.L'^.DBB(9JD0&EYAJYA\Z(D)CXA>8&Q;1N@O?]Z3 M&I/I9$K61M(50]?EEG*@W7*6(+YVRQV\>58R52%!.<>Z:8LP<)BI11,UP$Z0 M6F4?%NO7(3EV?LV"L7BHF5^]!&83<;L!8;5*,A]&ZH0 M6=,)[G`8TBUP1DU?_/V?60R"C4B/H*\4`R:=)OA.;X6(7!9]);A%^Q(4AF`F MTHR!@%H(*^OJ$C%$Z?+.4.8>:;N\`R6*8[Y0N$/:)@,`*/5!";DR; M8#4,K@PZAHT#;/6@'S90;XG(2ON,DRP@U@L_G4=;/A$@$4#OHG.3P+US.)>D#VG1:!:P-J@ZA=A@STCJ031FL6 MTFMJB_J*H[,`S:(XS0(OO8P\OK%.7!["OB,M?"N3G)@F`/-IM8!?$\:=8L`F$.Z<"F M010X5"@YY>#.]K4G4A^"_KFF/MU`X$X%(J.R*\ M51G",JHDR1+`;A$Y*&3+WXDXT]2=7=#=:`""P[NY22!X%P*^&OJW./+( MZ*D_0T"X4J04[+)^MS5H51XXUS6&%_4V%@Q$/C9DFT5,K_6!W2#T'4%NPJ@O M'6QNZ!,5CL'H.V%QNCTX.;P[M6`58(X)O<<"T(EFXS"6/AZ1OTSIIJB8=VS# M*I2?S4"I3K7#.7G:;T(RJCL/@>DJN1)SD4&N<>S&_C_SM,@Z=1]S0EK)R)K$ MCE/9M59GZU:1_V)F\NKDAT712+FCK89:B3-^R%9>Q6)QZ-:B51'XQ;0(=.,! M)-C36^Q15\#B/9KQG.9M[PD[LT6[:_Z!<]R93(!V").AIS@RT`1:/@W>QU%: M+%VWN+P9748OE/L?H3F>E>`6&RCGJ&:^6[O29NZJQ#RG[)P2.`K6_SHV9!=5_;=M?6@W#NZWG)*O`]VN+3F?M+WD>P5P5_*=;JVU-R=Z;:_\ M=NRBJ_^6K0?I;K=9#="V->1\YO81;;DMUP:ZYJ]2F51TN$'EM&-7#MSS%,4J[EH!S^UZ$":MG*P*`=PF#":&C"#YU:#OXTGVB),[[)%%)PNX M+HR=6K*+L_XK\5[$PY2%+?%57)PW*ME%6/^]J2R=]LY5*/+P:9QF:?TVEQF0 MH5#/+DR&[C;E2(4V["&EEA7!+6%^!> M81"=3,4OPY[&1$Z]LN1YDJQ[J8N!AD;MRH"AJT$-?("VA(O.][5`["[Q`4ANE+$[-H?`\(EBP,AHR M2PSA)4;FP+6M8;+,+3MGYA?:_NPX\Y-`&)8,;8X7,C?KN8J.#H`D95+D,).& M?;XED8+$DY)]6J5]6J7]<<-L*B6M!PO-ZNM9D%*IR1,LMFHL+6&%?*ZI%&FO MQP>?#XZ)QKKN@OYCUR,^#:ZYHBD?JZ587AZ+@G'H\(`/O9]M"$V3;YQ8'D114+EQ@40-E0 M-<$"4LW6!Y4U#?PD1-Z/.^^1T)F6_F+T(H;LH=XQ]OBHN61&"T;)-Y%8Z MNB1-1G`(HGA.]FHU#-HK0=#BY/G?3@^`%:Q^%2D^*3%+NCLJ"0;>N''?W/:' M>EBZ0$%2)AV*GO(LK5T<_V>.Z%F](/(RFL;)O)1/2N\](>HDY'M<]&X5PI24 M%(7>M)IW@_(>L9^'>#)=/433#Z67$.'0MB5@(T=;=.(1DG"V@ZR;9 MX5E[F?5\\DQ#QO'+./*OR+X3^-0^AS,4A')'[`\'AP>'FT?L9>.C9>LC%/FC M5?NCOU4]&#M79VW?.B:=5CF%],R%^\7O#?1^>^\0SGSMG&0\ZJ[AM.N M%#.99R1!.<=GUA9QX#!3RRF5P\[F*_#D^Q%?K>:7=1Y,*)(*SHOW]?&;X&QS MTO!48G%1^SJQS-!7#&6N"_:UXI\MW]U1#\A@I;6[0X5&56:YH4-;!N(3)6L> M1U7L0'2.O$?ZE:F+JC;A4N-4@DJ9,G=PK?(F=(.*5=UE@F\],+&H@N;`5ST1 M6PUUDMP&L\<5`>L@K%.R8V#_9$$):9;E&`,TM.LRH[>L`&@DU_CD70;\K-:/ MC0RIU190QAO@A#>).S7C,CFSTF3N1)V=S+VK2)1K;@(X2)Z\)-0J>G0DLN4S.KZ30<"]ZFT^^/VI<\N"B]?=CGTY8I01K5/ MIBN!HN?,(/7HKS1.BZX709HR?(SZ-N8RG6Z'XV`G&AV!N:3I_)5FU61/.MF: M3M/?:L!IFZ)!**O+M;[8DM=*=_65FX6A4U-.<\YJT4E;230^$9G#NL?)O!4[ M]>I.4\0J34DELEQ>(*$T(..\27!*U*?"3$26\KM\/D<)(?,NF$5%P&J4C;UB MI:?;=QP&'CG]J%TP'3$NF&CG-."HWGUQR50-@'ZK#6&T'L-H.0CSMU`_G7?G M>A`GBV\H(U@)O#MYA=W?="EX=_*(`+!'KH?V#G'H0J[9:Y@THIPP$/TZ1H-6AV!@Z`(8/-3"@U7ML'QC@?@MQ M'ABP=RW?NY;O70FGU9B!,*TFP MU8F#=E?)S,M*7PC.DV3[V5WI6@,(EY*F9=C76"L!;[W'.C)ZCS4Z`GZ3M8Z< MNTEBPCL1&X.6";9`+!>#55XNMPJ M!>$$";2*^#(OPA>Z5^I$!!1!0B'E([8B,@"`!-L&SHO MT6$/M6-O7/_)C.M[D^[>I+M+)EWNDM=FX96IZ,[@*T]6PR0HO1,,U3#,I>M[ MBJ=Y>!5,>382J9H0IF`WZ*7(&[8U<65J;;4F;F4VUFM-/!Z,-7%,2/"#,*<6 MYG6(]?FK%^:$-+D#`"Y$I M75VR@.@*S9>>A7"TUH+@2-(%H%;"`$#6<]UOL^[H:]Z=#4@WB]B6(CT*^E#M M23VI+_."F)'!9=MPMPD]HJB)30YM6^,TQ=E-GGB/Q7.Y*ADQ*\@UU7SE^CO=F.V.S?Y,6_INT^^=1 MA_,\:I7"J$SDQ[<2"\I#=#OILJI(D`H`N/J@A#8X5D$@EM96X6,D1&O0`0"' M6YQF2>!E,L=Z3ED(9B^^.#5+>3LMI7/A6 M4:6T_IK.39R1GP(4WJ#%?#L"6'OK$"YXNB*OG1G0HL,Y(EVDN.^^`#"JNWQ% MQ_#\9U`+8?HOC=M%ANUQ6+1.RBP?@RDLX.S'';2U[?+E'%M37Y(5T";^2?5& MZFD\?PBB8LB<16SU?"QG#>C4DLMW>'0M!YT(=WB#MO1>KSNNJUVD?=B^2%LV M6OAYKYH=WH7:/B7$/B7$/B6$:^,5V)00'#6L'FD]F9*]!(LS`4:<*$!8`X)IHV.F`"%=`)`:0EX-CLEAA_)J M[,-_?ZKPWS/\E&`O*$XNY.\05W&DXWF<9,&_6.^4JU4%O6`*P9>C#]I9GTOK MUR1.E>=N50GT&BL$L8TR:/"-/2^?YR'*L"\C?USR.$#K:QZ"C;>;2.CC`33A MX0[U&^8)A+@*!)NNYGE?T.70,+>=9/B,-.H%./(6:@:ZC]L&NGKC_SXJFZ?F MN64'?S=OJ^/=8:QOVK<8P+*ZR5;:.VVUV,W4N+]WT-H[:.T=M'[RC'$=,YD9 MRABW6P%%1WU7YWWPT""#ATZ)&AHG%T'VKQE.4.@3E?0TYE\;"(N##AT2CGP? MEB5::(.SV(=Q9&.0@;BUCH&HX3VP0`8/_V^^2"O857V,'N\E'7[L*C"20VPB6- M7QS('B.6-3$H)@U1)R'R?A#A(32E9N3KH6+0Q(`8&ICHM%$W\A(UK_< MD[]2Y!6A1L(-7[D5(*N<4"P;3C>J!/ZLT(+6RDW!K5]?Y^Q^-_E#&'B3Z133 MD-[B;B(B'\(0^^4*M/S$WP>5FX"P(W84Y=5&J4RT"?!*Z5L-8GL#Y)9RL/5] M[KOU<8DQSUJFYBTHYW@S:A$.#C--*MDWQ2/T^(:HE^6<(T6.!$N*J+C+Y:-5 M-M8+A(@$\RMY"W^Y95U>]RHPESM^`%K2*AMBN8[1U-)Q5.PS$NDXV74<+-=? M=)U46D@#`-C&P(1F%DY9(* M9)AF^JPZ9)_-),I#X"Y3*.I;KF#\`&2:B,4\CLI$2A%]?(`J9KX?E&.Z08%_ M&9VBIR!#8B#A:XL>I!"MKN@`XC[M[@(8+M!"=%%:N?W MDT7]BRA(1:$!!_K8+[KT,14Z@>$JU,Q8!8&H9>JRR0,,D()V&3WCE+0M7.LV M"T%0(O@25>?ZYLB-*&@HPEF&Z$@B,G&O,L%M([\LA*U=S-,6`@`(<_G2)TJQ M_S6._+DF6B6:6WJGBSN\J>G,,")Z%#?LU$7L9('VH[]/8D?H%`L M"1!N4WT;!;*EZ9DP?01FDS%&$LWB,*1GCQDW1Q:_&(2M3H\$KQ/"LN@T$AQ& ME",:VD/[2C`69Y03%(:P-6K&0$"M"20J*\KY*]DR@F6>7\Y%([^LBYVL=]A_ M"TVVN,V_>Q25AG`#V28[0B:;7-9UL;GAI7$$Q#5%%^N9Q-E"8Q*Q4UO(5'!^ M/]PN7D+VUTBQQ>[[%T'H=4L%YS?&/=E=(P74F8-:8LF,+]QVJT=6\NPQ3H)_ M8?][1+A1;&&5DVZ(J#6I05=;4AXC/;G8Z'MGD##*D6'+U#95DH=;C3V!._%J MGYF:A)#/PKT0]NL)I*(W?,&TIF*68Y'7,,7E85EVM$^GE;8DYH(EG(2JJ;@\ M+.N/59R`*;5+M[2KMF:"'V;H&]Q5F9KO7L*`_K& MTS/Y1,BZI3)]R(54M1D0TU8(?7?:H"5(KIX+K\[%D^0VF#UFR]?;BIAUPG^< MGB(:V'*R6/K4506YR:SZM@K!'TI.!'J3:ORQQ$D2S`+27/%0XVJD3`,^MRB$ MW.82JS%W_-"FG>@MS?+GBSCY%D<>2A\;;^EU>8JTK4$(.X MB/@)GO$%D<'("U!X&:5D_RZB?Y9+0M-'^3MA=UJ.G#4?>S=I%5K>0Y/M\[8W MG=#F-W-7F.19FJ&(.C.K[)N-:E8!_:Q]8VS0`@TTX0/GJ^7EE*PM:HLPLP&K M0'XQL.@RJ1HFI*P=HQ?$[`:M0OZ+>>M5)TRXX#5=NKZ..0F7J<6[(+5W7JD2A>TY;6T>5`"B-*&R>"+ M%6(\CW/N>UOB*G:!ZV7[$1-B9U(M3;[^R:*P(+^0+G&2GN7X/IX\TVSS89Q1 M2B;3TD;,G5P=6K*+52H'99T)V.;O\[V2H M$8S>.',W;EJZ[XD=&[(+3R>C2A_RC.,W]O^9IX7B>Q]S,FR0D36'/4YES^TZ M6[?K%=#=`*.39FB[X04*DD*2QV38\V(HY&3U5-S'G`7/9.21?TLXQ-D!Y:O; M!;N3`4>=*&AH%@:+8E\6.=)6!>PBTL\KIS9L:#QG2;C\J9$'#M*?@*L%OJ"^[DM++`F6(`]"$2C0A[G$R[[`\ ME-7L0MW+VM1.C/'#\]*TV=_ZT;4ENWAUMTYUI<^\,PFBL1O5N9Q>82Q'6ETW ME1XO$355\^[?E)NP"UIWFY4R8>[06LE5-Z18U>V&(/1P^%$ARCA"S#L`NARW M7I.H5[>+4'YJ166J!! M]CU*,`II6.E7PHRKF`A?M":"=SW96LLN9+TL2JVT0(/L)HD]C/WT@A#+='GA M@"91SRYLO8P\$M08W\":;GVE.]]DNO(9HT_2!*E'?TV+1[_F\R!-&8%9?1NS M"UMWMY\>)#K"JF&IET*Y;B6=88K&7T:LILZH),=I0]Y;A=IYJ"Z+-3\ MANSBUR,33S?RH,W5^AE(96I*U+.+9"^;BP0UT(!C)_JJ/S-]LEB7J=QUQR\H M\3=H2R^C4G1%^T_K#;"=0=@5J5XV(=NL,>^Z.YLE>$9(OZ2,1^'R-,>2#YD* M=K'L'A+60H9Y#7QEPQBG1!`\,EB"_F3Z-8G3=+EP,55KN8IV<>AN^9$D!]HZ MS30R)N4M6FDF4;&U;E2TBUTO5QD9\5,S>RZMM%M%=4 ME`)5`P&T]#7MC">CNETX^RWBTM_LXH44>T(_>/]FE[2Z8_RQ^9OU1`:!+^\O+RCXR&'R@B_\^+Y^X)< MZJT8QFF>X.W'/_)KAR%]#F049[?##P<>#H]'; MT;II\H]ZZ_\^*ML?_6W=P]_I/XI.1D=_)PW.PRAMC'T%V-'!P?%[VM\#2O$; M+2X'LH\G-MP+VBL-(?Z6_4Y]ST#;S49=O)+9G*\Z'LGL1CN`;5'/B^P]96*S M47"O7/:9+WT$9I,Q9NYPHS0/J7?ZF!RSB@V+_\B=HGV+'`"@5%96YF+'*0-AJQ'*4IWS&V,WDM:U\1K4 MTFS-WS[$Y2%PERD4ZP2OPO$#D.FMQZ,WY+GVW<&*?ZQKQ:^1`87IPF6D40+( M2BY\9[PQ8``LOB:,FN=S(9,WRD!831B24>?RQH@A\!F]MO.Y60:"ZM_&Y^:( M3>R$]Z3&.IB7L0)S2SE8AS_T78>YQ)AG+5-W%I1SO-JV"`>'F2;-+C?Y0QAX MRY[(]R.!OL8MZW)U;96*M;[&'3^`M99_3<,[NM<*&N(_"D/I$R#_=DEB+=G@ M/QV0G_WJQ5&&7[/SL.C@MS!NT'?B(5_6(B8C?*[>\U5/'O*5_J*<.F15 MR^7<44)#FJ)])A>%Q!$&`;&9*D`XC*<@Z0!(5V!%._E)-=&7"%Q+O!=_W6Z#K.0'U>MK1B-\9$[[1L(!4X\#^#?@.!QDU@$R_#V_PNFT5,(B]/"E>7SE%88C]DT6+ M"J.M59AG$FD!T,:'_8MZ1C4<77/=_6M[!E<#-9-YOZ:L"L,GN_,>J`5\%]Z* M^VQF6CMZ1XZ#WOH]K2H?(@K7*=S26N[$6M0"?820G;-33Y-64?YB!N7>3#". M?$5=8P%AC$?@P=9>U2J2OYA!4II8>X@]!>5>3U<-5[LJ;?"&B4.=!D;1=>.S\T9_O3\!2ZRPR+JVV_-=ZS5NG^/N M9\IQIX?C'*NU$(&6.A"22D@CTD(+`(1NZ8$CPOXY2B+Z@*`X$0``&.?&EYS:L1]:G@],K%/#>\P-?P=#L,B^3D6II-E%H.@OVA/1]6SODCU$E^Q>;VONO:YW,(K;`D#%HX(ZEM2.#0TDQK[FV8\+WD'ME5G1`S&>4;(R0)O_?0G\_366L=E M*(G*8:&5$&@BW[SUJ_L6K6/$.9-!KJK+T!&U:2)'#VP`R[P--""I^G5)1GI) MV)Y@E/#T_P[M.(TPZ8.M%'70@%Z-L4D+!TYN::?!(6J@<6F`!DUS?#6+Y&3U*/8%J8G'K^PT#J3/;..39#[12&,@ZWVXC"!CXZ)2T6G0A8)>(DF. M93S*@^%D>A:$.75_I8<%%!6ZT\80UX<.=IX8'ADY.E#'C0]NC;P\K:UT$O2RDD9^X<<%5JBGETD.UF0%*@9"'"E]5<1M54E MNY#U,AVUD0(-K^9Z40ZV_1FMUEIV;_\U&H08M+@.Q)L4O=V$**K"XMXT^,@- MO?MT<,@,O1N5#8YHBZM0.V.!=IKN8]:^-RLW*NKDBJ,4E<*5T.=>BS/-R6)= M9IGGE#Y'Q(K?,]"^BUE\3S&?3"^)Q#X'?HY"@2,LIZS[$#]C6-=G.X=Z`"OQ MULC^"++'6QP6-*>/P=-]?!YE-!97Y-*JW`H0'U:A!`L!;"/P9X7VST_''S\= M?O[TY=/G#T?`\H];'.G*R^D!'(0AHX1>&L$&P16;M!\4?O7&;<1F:<1E1CYW@ M&=,"8E:W5(`0TM#"[A8*H%F?RMV(]"+8B#?*N(_#M+(3;U`-`*ON1*YIB7RI M'<9,5T#4`J;,LX,O=5*_EZ"^78'6=)Q(%=33]ODRJG:M?`@/WH+R$%0LD_.F MD;*&SP8`H-Y2:@5Z0NV[`QV!Y\5E4D>H40P%'W'>E'H)(+OQEE1M,1C0%+@F MC)KG,X+!K' M/IMD^@1*E/*\.64K@TBT8D109#D`#?;.W*CV=B+04QQD]/&5RZA4#W4O/Z*> M0&2"@;7RB-CE2&U?+H;5T,K8C,DS3FJ&;Z[VI+%=$*EL;"GHJLQQ)!OE0.BX MT`Q?!>BA>#E07@9X]4$DO[&%-8\)N[;;?"TSFU7KV=B7YR6Z:TUOL1?/(JJ%E`B?QFF6R@4/:NW+Q8YX&1&YPNO` MV6J@`K<+80V(084&Y*&^(*X>$[$H`!8,.AQ'/EG^!F'\1,=>V6-:WES2J(F!&S\6P<+GC.QKE[<.2(9 M8AC;*TFK7C94#Z7=N_;B+#,61$O?'9CE$_O*EZ;UQ'ZL<&(_'LR)?9_B9["A MDBY2^NQ#)?>ADKL6*KF/8-M'L%E>NEWDF]E'L.TCV/81;";XO(]@L\+G82;> M=)'09)]X=.N[B/]^UV.MK'^UJ6MPL4)(4_USA-\WGI]D4.H-XS].(QGB_$#O>?RM`['G0"2(`"O,F?T&*\T,[T0\J1-,<&L)D.(8Z''2J"0W":XBM M(&6V>*E4)&-5@4$G?M`@$Q4;0&*H+>#J#QS,'HG`CLOPTN+C&5EO5_S3O:5V M'<6@LTLXVEZ[\AJ:R$NY-WZC;T6FE#!*>GH?9RBL?ZAWT%JCT.ID@7D_C9S6/'!Z.A4?6.T<^@[X2L2R.#@;LFBS5F;EPL++>$XAJ-,GIJZS0L/9!! M2[.MD[(T-W]2T78KSSMWXE9<11P(_0`EO>T1'^$-L19IUSF"'3O3FY1XG6S? M.:E?TN=4\!4'L6/V!Y>RK\CYG1-_QEG9Q010'L:.641<3@%EW@]N$LB?T!WH M^-*]#_J@"DK'EV;YKDGZV/>#IJ;A;N3X'[=)KU/S2PKA=D\TM3:SP M*1*^V&*WZUVPL4@M``:6VA;6[IHLU[8Y*P(LZ&\7["36I5;`3Y"B^M!.ZD.[ M+M0D57L$HD2'NV#8Z":LAABZ:]+*/S_<8HHQ^?TTC@I6YRBD`9A'AL2XTTAV MP6IA7;X[<7K7!)]_9.4QP<+Z+3^27;!=N%S8Y3D-3?"EHDGNT>L)CHAH9+<8 MA316Y()`MSP[3*:Z0M_4^MG=I\<-,,OADQ]GY&#YC.@#21=!A"(OH`=,,BWS MPOK]!TJ*^\WJT8XW#?RX#X%\/CC+;XC>5@CR`O,*PWF^@\/Y1K91#A$`%O7UT%I?TV`7!9*I M5RQ4;#"`/6M1+3G"=+P;92`8,D425.?[QM!-/#&^7+3'6>/VY_C=P0&3J[*5 M(%C>VM@L2XM%OG]\=WRDS/=Z)0A&I#Y\K],"8(&AIJ12'\3>8Q3\E8LV7EYA M.(^O2&R\/")`@B'8^$IK0\XM"I20[< M9;8F_OHD61'"%MPF2ZMU2I(F(S@$43PGYRPU#-HK0=B;Y?G?3H\)WE-;0!S1 MD^UD>OK(>6A+6!+..RR"55](@1V^,M?PEK*.%W`)"1$PU^32K8.]C6;L^G!8`V65%0&]PJ_^/: M\BFT+"BUX'+3E4:O$V4`L+P%_1(FYRY:XC!VJVDSWK]GN7_/TN1IBB$9^_XJY8GUY@EW;VA)A@X^V9DX$^;M>?GOH@3\@UG].>K`#W0ARF"U@`* M#>U"F'B2XJ"!6GTN+)S#R7F:!7.4X;5*-YE6"COK7"(L#F'OT2:YJ^.+D&1H M+D9M;W`HS,MF-0C33BNV\J0/`6.%!_F`OJO'L59:PWP8C]_U?OH+[`M>G&.Q M]3D/_9FMGJ\8`GV,D..G;!U]4R\&[)%.-2(/:NIMKB9%J-IAQ9$F=D62%#.`T1&1!+$/JW:546OMB2A?Y\ M`2\.=_E#BO_*2>&J?C0S(2',;JP*S2]#$1HFJQS+D6B\XWF<1]DM&7*0D.-J M?(*_X@@GA;6"L%J+@.GNWZZ5Z`"&Z.EFHG&9K+;UTR5T6QM:Y=&&W8!A49X'B#6!*SX#^QU;D5"";`EMN6 MSK1!L^R0W2!-5W<+D^26QCG7(OYY?D>MU9R[BG67WX8;4BNAQB<.8?TPDJ83VJ2K+RZK/>%;''EYDN"M.U#I6B[738U3KI5.XS-N M[/\S3[/R^!:OTT[NL4>EJ:B0#@%F')KEEZC5@O[N"D/3`"+-X@5@]]?JA)EHH*6=,FI9$ M"A+U0.T;ID1(@@_0?!6NXP@OKE'R`V<7>>2GX^P4)I1,@DG$FW=.+[G6OFZ%D$&N7Z'.;;P#WI3+`FL8O"B8)46I78Q``$1+@R\0H#69M$PB4"`]#Z M=$?U0>S3D0F7)T8Y"*N36)KJ&#`(`,!^V"\5+3?!Y M_V:Q%3[3'6-M6]ZZG-MR&N>4=OEVL9``GA*_L;(/]<*;:@CWE88PCOS*:'N% M48HG#V$P*Z^;3H61`(IM0)AF*J"K40?-VBTW_%[(PK@IT0XI/"R7;Z_2UQBC MM##_H.@' M\VF>C0(P,N&V4:(28.& MJ^!EDLFT,`T5U[:G1)W&_LEB^?1!59![B]6W50@O=RI(0&]Z!R$6C7?;5A\[ MR4)K4Q!>X>PK`*U$6GZKD)Y7>0]'\$J">)-2=@_E$6&?)3E-)<*XZR^2?`36A2J)\8I5^UH*0OB94999O/),/_(U#Q.,OH^ MS@W]/W4;I6ZE(1G']R?J,U6-B\5\Z:IVL>AN0U"C"MJ.WLD*!,KZ<]C?L#!4 ML\\-6M#=K#(UEK$QXAPM4C7MPM??]"!%%#0,KU%6J?^3:?U6GB^'+9F7^C1H M%_'N)A$=M$(3!#G;\VH+28NWCR(O>*(A'-_P:W;_@L-G?!U'V6,_L[UT'Q#N MG_O/'_4+`&D/&UBSE$/K?&"7W+W$O(9/O!,*UH`LID^?0+HL9&1?7B5][ M-Q"N*^&*6LFC'1:VBSCGNIGK[@7"G2M842M9Y#"`ZC(B/^)[](K5GFT\/-B. MHRK;&A6-#26>:O*$$X)7-*/!;45:X6D94R=\@;&UEIM#<@7E.,\>"WD2^`WS M"L.)L9)$IGDN9A,%8/'>'IHPKH%?'(C'L5C8Q*``BF[0!$LC1=AG8!G5^D/% M)`\$>F0C)[W?XF<&M9SA&W'FPB__%RP=[ M)\,MXVGJJ(@.GZ(*+J88@/)S39SLJ]=DE(`G`9L<E:]Q2DF#'H4QY9O%()P$I44QT;$^089`-@_ M5.,H1PM4VY[V=M&]771O60-G63.H+K19,=HJN3-@R)'3JA`,W&S!UHA$<;7" M&A`,%YJ`U1]DJWDCJX*U3W!$>)V=$E$+HCR(9I4%)H[25=%FYM46=U>='4"P M'ZO+@TX.@!6?YH`Y)(^S"TQXBT(:6)N3(2W6]5'&,QQI[@/49JYMUC$%3@_# M!B)S1;`V?9B$]!S6#+1J4L5O!<)FY$1N^"PQ'K_&&=$-3N8HHL'Z#%U1I2*$ M#<4,IBI<&,@$/WVD*=8NHS,\Q0G9@NE9J'B-B$:QEHP(P_@%19[B3J+4,`2_ M4"?+@!*7!B)2D^P1)V/_GWF:%8ZN:G*S71M"+B`GPK'-"K`2T&2+VJD%1DXB M2PAOD@X-T?/IE#Z&](P;^BJ+"]4GI7.KMM8A;!CJAU9MY`]#:C9&W^F31$D5(\G?9K$L)1U;$0.3RTR@RO_03;I14(QUD#N'?FQQ`7 MBOZG7.V]0-!@'"\G@S[\RO.NMRX,XPAL75C8K'#HH'P:S^=!>12GH;[%\$A9 M+U"-ESWMM3U"D3]JM&X^@)87V$-&04'+4;@>(,L?N;6TDXMSTL%D.J9I M^&;%[;[($9E=UKT3LB0.C;MR-BT`%LW:F-(R115:_W)/_DI1\1)S*G0M4FX% MB#^84![K`"H3"`#:I9\G&>\9?L9A_%10N!ZWE+-K:VT(1_F.4LSRBFVE5QNR M*?;>S>)GLC<&):CDCTTLR4]_7N$9"L_)YL/TBF66<.\*J[!(,BFPSN6R M\D4R(?1R]5S:JY0DET^"$:;?3>W5U*N"UJ+A+VTT[BT4C-\'9 MKS@B(_$J__BRZ:O[,SYO6RJX-':TSA-#V-4Y[/0Z\676[F'5'N1:_YIS(PZ<&G:G-"-;W"S6HZGB6X M-,A,R;).Z'P*(ZI]3_049(?EG54H>X:S\NE1O],M"5"]!6_:O`HZL36;*JL,ZTBO+D MK.F"\BY]&3NNV`)J@`)%-PMNNO]&$9?/)O:#HR(`]'VG;(*FP^T$37(7G@8S M-G&VE]IDR(F>6OYCN7(Q$P'+5]M?@O:Y!%5`9G\;NK\-U:MU7FW(VQ]!]GB6 MI!>(5`W(J*ZQEWM>P#=Z*38P\'O.+B2;@(VL%*Q17-[<3;Z>?[L;LW.8J%6% MX!C<%RII8BV"-+[[?CLFO0NOF.3K0O#C-003@UJ+.%VAA],X>5+&:*,>!(=8 M0_AL4&ISH8M^#Y[C.R\)'O`]]AXC>C%$%.PN)Z]V-! MZN*S`,TBW:/7`?F,%:#RO,!W,J#/,T#O/Y0X#6 MGF-Z)('?KEU),&1[T<,*5WOU?^8XS6H*FO*RSFO`+K9VC34\FLVXH87%QE^& M]D4^4\_.""GDRQ3?>0&.A+MSO_;LHFK(MM./!18GYUG^`Z^7"NKFT_BA4B@6 M*;W?5)ZX71JW"[]=TU$7?EB4!>H.2SIZ[6)/8M2UBZ1=`Q*#7),75>Q;TBN1 MI[!T54"#%-\DA#FKCYT$H[4IEY=J1J2AE6+CB_(Z ML_1]//;]H&R<:MF7T2EZ"C(47L3)=&/6Z6#9VJT+")P M>\/);\_IM9IQ:/ET@X"Y*YR.K\.,PP8\(G(EQ:T1D<<=(R*/;4=$GL^?PK@T MZ14TIWE(QR41%"E;1="(A7(!;!@WE+*!%M8 M[3N0=+W=MZT:+5`X+]R&&B6`;#%;\K+%8$#"79T#A$S>*`-ALV!(1IW+&R,V ML=[?8A0&_RH,R"=QE-,+)R\/RW\OSFD.2W*82C%];X6U>'1LP\$"PS(>J"\P M'>EUC1PSC7CG5APO4+WDMA.()M.6NX+QST_''S\=?O[TY=/G#T>?R=\?CVT@ MBZ>(3#)HT#*9842]WNP]#%'R^=W'@QN7B(.H%K9"2/"F""1-8#GB2,\=)LO6(4 M!=6<;UU:@!00:-ZS+L\(L5G@W>((OZ"P3*)\02@\C_S)]!QYCW0DM43*3`^Z M#JTXW\YZ8->%7N-0;B[[YV$P"QZ"D/2Y].>E5%:FXOL$T>3V9VB17L3)&<[J M6;.O4?(#9X6_I\PA3U=/SG?.'B)ABB+_3/!JX#%941)/?C//@%S-H\@FVCN9W&IM#""O=LR>1 M`H+J5-U(_3/(;N MY$G$$O,20XT0=)!^?93U*("3Q;K,,DG5"TK\*A4'O>*M;>4M=#&%R?80[,J9 M9NNP=6X9%\&*?A1EJWSZI._'<'&!F5N=N+Q=<#4;D<6D.0SA7>]SY\^4A"JL M]DV#K]RPW8\'AYMAN^L&1V6+JU!=8X&ZFG*%-#G!BN(5%W62X&1C)*0_0=03 MM[3[T%T9%!H92'BD`(C/88R-Z%2+F+4`HR6B`!@T#2?Z+T`B"G3" MQ200'H+"(#A.60C!<*V"*``)4"CB,--&<$*D9?>>?9Z(?9X(#4F`BUQ`D^F4 M'-G((:+,GT/H#K%__E=.3@/+3_QX`>4F(*Q\?1,1*!-M\&A;/_V5SWF/?21Z MYD6NWB[DBY"C%%S"R`QEQ5BK)+6%2Z7H1,4O[S[L6_E,Q2<&`#3U00EU=E9! M(#M4JW@Q\B0WZ("`P]K76*A%,,I!V'[X8M3@_?;@C;R%7&@LJ[V,DW*"5&28)ZA_!0"['(01J;(DB$Q4KF)/=6F89$\I4]N?Y532RBN[XF8O M_89?BD]\=5.N,H0#A!+$DG2!FXG%`,N!%Z%8G`@+B?(N0U4[0<8G!1I*RZ3S MU'&'#I@Z&;$;NJS^XAZ(``-I""@`5`!P`=')O M=BTR,#$T,3(S,5]L86(N>&UL550)``-A_`%58?P!575X"P`!!"4.```$.0$` M`.V]_W/D-I(G^ON+>/\#WMS&C1U1;;OMF=V=N;V[J-87K]ZI6UI)MF]?Q\4$ M1:(DK%EDF61)7?/7/R0`DF`5OQ,@DO+&W8[550#R2R$_F0`2B7_YGU^V(7FA M2%]_D(\31 M7\D/W[[__MOOOWO_9_+]7__\_J_O_YG1DR1? M4O;7U'^F6^\Z]@5/__T/SUFV^^NWW[Z^OG[SY3$)OXF3)S[4=S]\6_1J;`'_ M>IP9%?MGKA(KJ]_XO?_G+M^+;HBDGSUH8*H;FVB/D7Y(XI'=T0\08?\T. M._K?_Y"R[2X$VN*SYX1NZL<+D^1;Z/]M1)_@1P4-_04T]/X?04/_17U\[3W2 M\`\$6OYT=]7(VE\J8ZE.0J9>ZOUV-GD>N+G044+I/0=+)F+307-#EW?H;U;PSGN"%Z'1NY_N!PCS/W(BQ(L"(LD0C.FC(,O=VY/G[<"O_/`M#;,T_P0F^0_OOGNOD/Z_J(__=I]Q(P;.'KS'$D^4 M?AH;(9W`[4+!;*UO@7!J=C`Z=AX6PY'/8L#_@V#F<>BG5_S/M$L%>L.ES,`3 MX6IG8=%J"3/QE%D#LQ$&)6+4DREI1+),#U/F%L^*1'R%\Q@[D"GV?WV.PX#K M\X^$_K8'3_950#?,9WR5=?AZ*J"DU/_F*7[Y-J!,8@G_XQA"^$=_DT[TCCXQ M<-%1]LG;'KNOEF9(X:-+,`"/IC8(H:.3U;&S4$50Y:@$AIUWZIUQNTJ\\(HO M4K[\+WIH%/VT'?K)UR!:=?8=-4(]_9IXG3C_U+!$C$OXP'/-P'PY\<"'K1'Z MZ&O$\ZU.D'R:Z=\AG5VU+$Y>(\)H<\^D6YJPF"^`@W,>,K1(>MQN`7.K5K3C M259IA'RVU?,Z>=K)80D?E\#`<\W`-2<>``.7H?=4(_7Q]XAG7*TH^4RK?(ET MAM7S.'9F%:,1&&ZN^72V3Q*0@*6^%_X[]9)F4&MIBGB6=0F83[BF=DCG7B>[ M8Z>A&IC(D0D,/3O(R8#Q%QJ&_RN*7Z-[ZJ5Q1(.K--W3I$897>T13\]>HE:7 M$@V-D4[4?CQ/7%K`\.]^A?%)3H!("O-.V9_C)4[$8ELAQ9]YFD>A]1W=QDK'H"?8T]\WSL+$Y^NG8+NC1 MWDMM6]23LX/EJ3LQRL<7PQ,Y_KQS5=C'&0\KGN*D>4/PN!7ZF5DK5G5"5IJ@ MGH?UG$Z/M-H[$`>#]L\>5=;//(.\.$BN;8;^]$_JIV$?H(]_(Q-!N9J/JK_Y=']S?76^?K@X)Q_6 MU^M/9Q?D_E\O+A[NW-D,_B>J'T^5IM@7AF-C`Z^M12#$<^ MYP,ZRD>U(I5K(U+;=+ULZ;3M(DRJ0<13RSIJB-[`FOB=-B-7Q=8M#H,S+64N MG2=&_ZL[`SSSTN=U%,!_+G[;LQ\1PWXOMT6&;&IR4HZ\('[\(Y!Q%;[/( MG!2CN[/:VX3N/!9@CW M8R>YHD$4$>&K!!ERM%)S8^!SJH!*(JG002QTX&':/^FS@L5OR9TVNQ3K-#L) M9[&V.//"WILADT5Z`'+$KVR%N'2@,5]N9(=;+HVH^L)C\1V<;/"(H1%\6KL@ M-[0^`E=]97-[Q&;8B^WQKD$.OB)B>%G')R<@`F!7;G$&H86TM)0V.I5V/O/5 M_/XG/O=;/6)36^0&VRJB;JFU#1&;:#N_8Z=I-4HM!W9CD39E=.TZI5BM,0-^ MZZH*<1IP(K:?(P;-'@;/&5D:"BE=V\,U\QY9R#)&4^Y[]=I(%Z(R4L=!]X#N MR&UJJ")TJ^O;%[%=#A9A[+37"!4A*(_/7)^=.Y._6HY,$D,!!_TR75H[+,?D M>^2\-+=>AEF;S@O1AL:3`F-1WES$L"3A,!DF/]"Y]0YPF-/OS/.D,7(#;1>R M[IRSVA*Q878P//F<3XV+Y$S3EI0[.:Y3,TSV-#B%G6:%-+;';XSMHA[98WUC MW";9P?.$^0HCDSJ7Z/(;L M2=2M[[#7H6,@M^%1*JD$P4,&0&SKX^08'2IS:N^X36X)T%,9IH(B$22)1M,Q M,,RKF#RF%B5/X@CR*,-"5P%GP57=\7G5L-Y".$,>XR2)7SEVLL@/]X'XHSAS MUI8=F+8'>J_#%@".O2*;184T%OS[?#%,USZ\!>&J:1XX3*X7$DV"L068YB`E M#`]8,)OP,`'F"%$P1R8&%0'QQXJ$-$T+1%!Q"NZHQ'0XLM)B,A20>$X3]L)E M?:&:"^C,I.GNA1P$>XJMHU]'%\2PUY?ST:5)BO&+79F#]X_9L^44'GW#_YT?_\/M:8>]F29,%Z(M>,(BC)3;MB-=M3>`[E=]1"W4E"B MN3EBN^O#]>B][')LN7S61W?E]N84V-=')U]]BC-*WK^?_)SFE$)_`[-9EYR_ M.BQC=9$YJA:S,NNR,,DZRQ+VN,\@Q01BV%L/18[;;&J@CI-1;_E8E(?G,AVW MK;Q3?4OD%MLBWM&]_^-FB&VTC=L)E]KEF'G5;3'L2KXF9&=%W<.UVI4TE9+^ MPW???/?=>[+S$O(BA?[^N]5WWXG_(ZDL/N[ML^`_CO/^3<-M@?"L2T)0]16*U[J7DGJ]F>?\U!#%<%1D# M!#SZ&<@KRYYYJ,Y!(A`;SV0G&E"U9?(/__C=/PHV6RF[C>]5L?C6RG&GS9#C M2I-@Q^&[W@8QHC2R.B5N+2OXH\`26S+J*%*%D?=_;L61]_^\^LO[/Z_^Z2_2 M4N&?WWV_^J=__H$PH2A95Z0_O/#Q=]3/7FCH,)Y8!X$H]NR%MQX+KB)U?M;P MFS2W1F[_'6)6TG3KFR)&@RZ.1Y]Y%N,2&!@RK]30CA)T[0899O9SS MV>4=S3P6T>#"2^#`)%W[_GZ[%T<'YW3#?-:T7N_5$;FU]A=>-]SN7HAM>`#S M8Z=Y3H+D-,A7&A6BR)SL3FG>SWX$:U9N/8=2,2(U<+L##N.[G)1+,BMDBI M?,IF31^5*5!(W5,7KH!2/CZ\+K;M>ZFPIM.B@+%)Z&9`/.ZQ&"!L9-P8`*KG MJTL2&$#/HM@*[$X.O'!9=/.K]/U[+="F&]ZE[]EE859M\F7Z)K-N>97>G5W; M$;QJV+%EP0?'+>9%_[071^WQIH?,KM#LNLP-NBU2@_JG\;5V7Q2^=2NB&>B: M^RX&\7J(8`SZ-%JD)+:R^&;C0!2TJ(P^67NKIHP];:GC<(&C)4(-W`;JUQ,Y M;`P0OR&;;X&[/T.X-Y/SAW#?9T8EC-SQ<0("/;-&\F>Q@P"X]O-.!%:IE7W55'1>FD66Q6SU5IETR59ZA'')JW4:M[];IW/( MW'O;=#X3OHK\>$O%\F?;_?Q,GAGMQ2WSPPNQP1U]HU+C'?=((^42M M%ZIR%Z72`O&T;&!T]!T3.1Q1XSFZ2V)')B8LV.65,"'/'?7CITA<6/O(0LK= M540_4K[.#:H-FG>&1@V$W21'*Z=ZA6SH*)A->[PPXZ^8B1&)1G-%"JI$DEV1 MHV;.]J,<:*A4QH:Z?;7`AZ=H(+^:)B_\'VF[BVYKCQP:.D6MWA%H:(S8T+MY M'G\K0(PLT^/5V&Y]NWU9W=KEO1<6(GVBC4793EHAM\$&L2J7'ZM-$-M;$Z<3 MO>:*\,$7@9F;3?O2X;@-U=TI MM,5?R:'GOJ,IY5;WS%=JYYR9,-[!L8="PXLO\)@C1\>U_]N>)32XBFZ3F"_F M4A"@<;=FRHC(4<>`NJH;F:.'0XQH)J0:OZ21M(7GU:CG(0?YJF"`Y!Q`Q3S% M`P$FG-760J*VH*3NKO(6/EWD@9S#72<:AB!V%'STDE^I%K:#N[/3'VG$EY4AEW0=;%G$ M8$D))?[:C;6[%W*+[2FV;K8=71#;;E_.QTYI-;Z8TE4*;JUX3KF]"@5$VYM] M=Y/PVVRC:*W;F(CMLIG7L3.R&+'8MD2R5VE0,FI5LJZ3(/.2R;.@N%,^!Q@B M,TROX[0312HMEX(CI^+5(DG9;`E84L/M=)N3@Y*O8%A+6PZ]#<^@@#`(@?ISSDC[6O>T%7I#JQ6K:F25)J@-K)[3R9//RLKT+U*@B#Y!78EV MP[(DE_.=WQ\]%H%CO8D@O^AFCT(> MQ,9C>6TM@6^1%_F,&SJ+TBS9@YE;5<)#%]ZYTL2KER0<45,2[!/8O,F>1;%U M%@9MD'A=B6Z6Z M[Q#[0GZ#CH."J#[=WN6J=^=?^`*]<]?VN`URWU$KDNXI*@T0^X5Z/D<7!:)9 M=5]VSG?-.BW5O*Q@E6ZVGNW((HZ-^:B[A#YSW`4HJ1/155GI<_;"N#\(TJ,R M(U?;7?-EF8%#(`>>,0II+C'=WA\Q;(T2PU"I:5*06^5@5U`DDJ2K0->16D0Q M*;ZJE>20!!KK%X^%X'8>8JV@EGKY[(.7,K\/M/8:!3EFC%1+8SC3/01BY!@K MB<&0*"<*\9!>@D[171%!&4&,-)-ZD$11,TI;O%"=3X,>;U0;T4B/NP/N=%(; M>XY1U7P>)W_:/*_4WN97FMHB]QZM(NH^HK8A8D_0SN_8Z9R/6CXKX!3/[0A9 MV"P\&I`;I'@W\1UYK!/6G46>LW"?-1:):VZ],*L\$K/-+E73!5GF,<SB"QE;9!T/BSZA;*G9\[!FNO%>Z*R9/K-YJ2HG,44#UK#NP\$&[2FOT_>IB.&C+!.&N]32 M`XB;AE@>%'=*,A,8.XU0G>FF%9`#9E,G7;N&6'0B0%H"[XY3SN/=`J&1>2QK M^C'NLYPO'(JC.N[G-=8@(34[=!2'[-L7N8<:I()**9,^'1%[HV'\CR^AEF?6 MG>F9=07Q5'@CC?X?B>2`?'5.-\QG-/(/#E\*+1B57)UQ"(PCX'O]A37EF'7U M68I%M(E<:PEU'99@`:U\C]X$E-.X')5\AG%/*JC.N&5=%?,\WGHL:MH^:VB+ M?.ZVBEC9K*YKB'BNMO-K:HZ2SW)@1V5^'0OI*MWP(X7`M4$G#4V1VV&;@,UI M@K(=8BML9==4VM]G.:XC&YQ#1!3/M[9:75T[Y";7*%K#ZZSHC:V9U_&+D3() MSK&9V17.G8&M@T!<1/;"6X\%5]&9MV.9%[8:6U]QL;C8\'H8JRZ>[B,VMD!I4AUA@20U-')M0$/OB[K(XONGW*TQ?"=$D M8V(7@D6;.-G*HR,_]-*4;1BWK<<#`8G$C7-%^!LKYE4'(+:D?E`2Y8-.V`KM M95:U6YMM[99C6J=;FHV-EF5>AG;[/GE;,=7D7<$L\:+4\X61O3XS_YEL/?'V M>+@/*`G`@83B"`H.OSY1_F&B#OGHI86FZEP?+'GGV-!C_&<9!R MA7V*([K=A?&!TOQY]8*X6:55DE$FC8AX4\>0 M8*.3']5@SK-8ANHA9[PUW67RH&_,SNJ5-L7.JB.^(3MK$&Q2DC$1](E@0$0& M&@LDYX%H3)#2/)UF\&!0WKM'37E>#^6MNK4W8;F6OZ?W!#F`S4NS^F9(8:5+ ML&+)5=,&^_*JC>7Q)R<[SJM(`F7-JZK\=41!6$#2_#[,!+\)[=C=:6N,&4@ZA2S@I+$E=E#I9MS\+HU?T.3S M4A&=&TKLR5V.3(JA7<+*+)*6OR."&S%G<&BI+@_UN0U3TQXI*O46M?86S'%C MS&N=3IY'3UH8L+C;Y7S30)>O=2.@MB'R:=HL7"7U]Z05XHG9PNRT&7E3S$BG MZV1K\L5=\LV9:Q^]0+;+8T@'W'?I[H7=&ON)7O-;"L;;B@B=T<6)ZV6LA$-11X'4U(IW&E,_'F M?BH\3EJCR)-&R"VM7JC3M\'S%H@MK('1\?N;^:SI5."YO8];P;G>(Y#<=AG1OI5]WB3SC:_@AG M6C_2Z)QY3U&<9LR']\.:3[<[VB,UV-ZB%F?<;8VQ'W/WXMU`$@W$2SDMHA$3 M#^5]`Y>P?!E-D5>6/:N;7]")]X9:4/P_(K^<15E,O$@^#5]>5"B.66<^+;>J M/C$X.5(8Z,OEJ;E]B>MFB,O%JY]0SMPYE?^]JCQT)2N5W<5A>!DGKU[2])K, M\%&0HN-$M537QX.&0!SJC)5D_`I;TH&*J_*OK^$6:FU1UL]`F"C*SI;B:/7C M^%9$>B5N437H[:@)4F&2;8Y$_O+W90&:*":G)?CXZ886@0_Z/Q2>1E2#)$TB&2T(H(4BO"BR=LEL4]ID!*PPN*% ME:-R`5`V!1TH2B\P$A5/.R\3%AN4T`,7CWHN#QB;!+"!C'E4AQ0:C:NB#S9: MCP;'XZ1Q?2P.%N7G?'E]YJ7/8Y1W/,"2X;%6&;TALM)[J3!9+\3X\ILO-(QW MXC[7O:BP=@&;]@P@4H?1$C@5K&[BA``'"-'3K(:D%E@IM<]'18^89G4`HXFE M]3%N%OKP,O(/WWWSW7?OOU_)/WX05ZIC47K/V\9[.$@J'W%&OT0O]/>)(Q87 M$*X%LH`FXC!NS+J]<\!EPO(`9?5=X;>/MCS8'B*4?1A7.P,:BBN.2(4E5+`^ MAP;/=%@KJX.&C.X%ZH&&0%NI*FF"#K:.<+].2Y,<2<.`RX2M`Z'/>-&0`HV$]11)*(-ZXX]-6VD M-*.WOXNGUO=Z?=-`;OU!*IH\CQ2X$2G<\'462+KW^2HF+?S[S,EH,RM,EH&M MVR&=&5IW,62_OC3GK#E1C)H_MA?Y[=EZ,TO>N,;7*DR#@<@J:7_D?]#VG>,I M5?Q$990H^$45MAYXCCYV#,SN9:Q*RN*``P?`[F)&RS/ZM0'(:):)>6R[\_PL MOTOV`G3*ERDJ%=E//5%"=W$BZDM)GS1WN<&YU79?*"4G6>]W!%EGQW)N=+-^ M>DKHDZBM7AS>PQY#XSSB^.N)&$<`;Q"'H9?,OP/M1EFZ@^I^"V&6A<[9M%5. M77?,/FB$(GJL;T[Z8O<\8T29965SNJQ!LXHQKYF.)72Y1SF M%'R87["T8ED'_[%/,X"-A[CA"5LN?-57KM.^&V5&1\?L8(&:?^2K%Z@!OZ'YQF-)N;JJB87KM_+P++80_1(E M*U"M^OCY[_(=;*'\XY4:5S6B+4%$6OWY:'+FD13JFT"&`OHNJY5;AY/R4WH3.N21O5 MH'2@PCWZF!4UV=OU.G+$9<0O4]15$[.,&6XY<A?,]P;0O\V MZ<:?YK&4T%"^9)/DRU0._Q6T:O$&`0]B>8ND8,WW\D?H^HK*V8OX0JCR"X/N.G2(PB-F^.?I\9R2*-9.96O)Y?;YLF MXBS\V42?81VG/PRL<[HB!:]$,9L?V6KLNDGA1Z]_F4IKY$VG73;D\>1. MX^(+37S&F?A$:Q=X(\9`"H235%)-NQPP`/9EVVAYS*5=GB:_J+48?`*E+:BB M[W`M-KN:FFN>J,S*(NHKR!).UU66Y9RJ:^5I MSZJ>47AK*2]/>)6;37.2>M\L[K$#8<;@2)I0AO"X,5,&:?JW M&Z45.5CM]XMF3`KOS&!SHZAJ]I5:4Z74YW2AY`+4<"H2&2J%KJSF8;4O%MQH MJMV#]5@MS.+9,BC'AU4>/A-FM3U-/X=?'#8/=L4^4ROA* M:R&NW9':RNMO:)Q[N[]RI*?!#LOY#3%'BOKER-SZ%/2T=*(BOKO9@5B33E5: MQL'LI::HIM?I2M,@V#W4))DF+Z(JA<1$N0&9[YP7NSC>OI'M8\D2CIT_NYKJ M/&B1#11IU*ZLD*V M0E3R59S7S!9WV[^N6$]EN>#ODP12F-V5%9I=:=T',8L`8\M:&H_&SE<)CJ95 MY?2S5DO*/-%5@6[VZT?JG3(.4L"T0/$P7;Y)W M_1X/E?ST6^\@/E[#Z]6K'(]6!2")"[>2];FOICG49!DH6W\HN.6LW/54JH:` M/<(_I\[*ICI&>BL<[SR=Q1%?9Z2J9_0NO=I M[X'8T_1D?/P+&_GP,+\%@96ZK&SS;?@>+\#-*OB.6R1-$HZ&95%%U@`+B&Q= MHJ+\.!M@[C7]EF;Q3:*W&OUQIR79?2/O1DU?A08%&5=AX>SB\RB#R[T>A`08 M'LJTKZA/QQ<[[(@.T57]#1UH$6HY2 MSRE^#AH&/:*.DV8:R`B:I""J=@<+LG"[4Q`F)66WN.M"29.0V#42G>#OP/77 M<:=%X$N7T#U"L06NO^H9MQ&$65Q_]=F8LBQY&5;DAGRZ*^47+"`+K\PKH57Z MNB4JB[C;F(J!7=E%@+5G<9JE>L'@"W&YIO5$N[T?4G0;+/IIJE!+I\5D!O61 MP=!-`3Z;][+4)U](J3M;7I8E['&?>1`S\2E>YFP*Q^\#9UH%K_3953*033V5 M1\Q":$%F1:IE[B\L5'CK65)P%AUEY4`KU6A4#Y.KJN#*3)<9'BE7'5%:&>B4&QAX)&99Q2&JWAC20("G;` M&+PL*CF3">0K\OK,X*GSA))'"C:IU8#UTKIBN9S?%?^<@\F61?G**X\V9PXM M4>C]%UW+@@U2\$'D.WQG%:66O!"-&9D)Z20Z1:'&\].I=G@W=#ZK[0"#[N2X MA/3-IF3T,B_%?556XCZ+N=_T9U>3T"ZZAEQ<1"JS/[#7>E_$VW*#1;!XKTNGA^W&@'F%Z(GQ[[__ M\^J[[[[+SRF/,^%V^P3:RO=WTY1FY):+_@SO#A9/QLGWW#Y"`/9$(W+.O*:)V'%N/LV\G\ZQQ5GDM MIN?<*J;;_,MU2LRIZWP9$-]KEWJAX213']:W[C*^V@)V;#=2#NPSCUW3]R!<,GG][/]$,I+_E:V46T.##X:>4!E?1S4Y4/(R>UMQ47\2F^UD< M\0_V_#/U)0>)#CLP-CARBS&K1-VVS(R,V`H-"S@ZRY,[(%'`-6<$[NE_!;QP MG_4U*=@A)3^P/9IS1$J6R.>6JXJO: M>$NOXY1_WE-M':!GB11R"+2IX,8G.@W100R/5L6=?FXGGN(LV(*J=D0R1KX" MUKZ&KP?"JG/\7(+*DT+E4!@NY"S!I_"W*":]EPHF<0T&_]5A!BZDEOM,.!K^ M=TCACW4$[THG&?M[W4GUP*[(07*(`BJ)NCWZ(0:Q0>R/S^8IB:Q(049D[NB$ M'"6ZSJT"(;?7(O>,&RBP@_/A^-GBIE5Y4V/DIMTN9&6[I+8E8O/M8-ATM31' M9TR6A!2[GZ>O9N)(O_Z9T!WX+?XO M=P^5V%>A7'<(.D01DH\4ELK):;EZAV0N)4`PDK\ZV)R&4C-KW`4M5Q''[J.SP=*5&(5`%L#R5$@SWUV9]Y^6! M18L2.H"BIN>R0*)-`-,`(:IC:@>Z@IJKZBDSZ2(?'A)5-5W$0A=>K09)!;O9<_)T2/R^!B,G0<\2[]0Z`09!O(@NC:;5T!L-GQV"+`X4A M2NH7)K2-M"@`&220K5!"$9>)7*JNGT8?R^[#S+H*:%V\L9/$5_")4%11F!6T M)]UV-!-G7OC6-.,Z<*>5@*6[./5"63$QAX\F;2QE!64EB,./,&:49FZEA!B'#`GF M?F6$:OMG3O55MG]8S;H('7A=YF_"V=C^&3[X,L%LI!)[@-K`D9<';F,%M`1R M!3O+W?Z96Z.ERG!L_VAA:UXC^68C2Y^V/2_9IQ]R=.HM>M,2KK838DSIS[N9 MA8E>&M;;54U6N-KT2!*WA#HR'5RH@B>ES?G7LBR-#N M]/D4-S"GWFZ[^$(3GZ6-"60=718$;DT"-^':%..[AS'+ M$E,UKOZ0#PX3%B!ULQ.162Y]T&=CKJ'?@HRY5?3&S>:Z3@LQZW;>#6TLBXO6 MBDAAX8[>E)Y;>-W,XYWCQT]TX:_CZ.F!)EMU)'8-Z:(WCR%[:MTA'C;"@BR_ MISJ:,*"C^T+0H*\49DSCND@USH]E!4&B4<00P]M6RH)7%CVEY"NX+2(/ MP[]6\)&?-!'>0:YY$AHPAP=/]?,;&R5$G-?4J7*YM6%4`1H$[*.`)K):7O'2T5(/:JSL%>,'"3-*,W<@@QA< M#`GF_@!FB::WGJLZ=3HM!5R>V\0ZZC@A]X$L?TV<3JA[`2\Z28& M)#"BLZ(;1L42B".*]T!IY`S&=6E77'Z:9JU&56F"WJ).!:J:4_D]:ENJ87.\ M(>?&3VGOK[!![?64\YS6X`[EO^)86' M?D0FWSF#O=FBLF*=1KHZ8`;Q7L(64-[:&CN@]V/>`*S#DT\%@.URJNI-J4#1 M+I?*/_G9-G[SP0KQ6MO["CB/0^A9(,:M%'`"IFJ\1KA;;N!P[V<1X1`[( MEWU\R),EGZWI)8F>QUN/'>-NS=>()U:=(/FLTK]#.J5J61P[G_*9)(>;>?M@ M;FGFVRR\29Z\2#U@#*\/QB$+Y*%>%-S*^$$]GZSV2;SPGG\B0MRNC4138R.U M4"LJU#<@C0R,$!OLR#0@<:_NV=/$=LP'ZHVE+R0G!EW$UUP#P5" M2]XY&&CLGFJN*Q*8."1R8S&A,-V_HOO MWIV7-Z%[+I3[]5S6)+>ZXM+HX%JDSJ0(+';?6)J_PW/UZ8?I+T3 M8AOOS_N$XB""0OLS%`AF=W_?-G"(I<[YGGYN2/\E6H(-J#]ZHZ5J&[BSPC9,'18XE9I2F`\RT$1&C MCB'!)EF>JFHMHO`%6-H'71-='GKZJ&_%UMK5-LK8ZH=\"];6(=E8<]/\NWSP MIN"`*!:(X&%%!!?OA-&3XA%DZS%!CZ+2KE6(";%HPEZX\"_T*N)XO)?0'`7_ M2H.G2F7&4F==@<&D$;$CU71U55!J_'"8$C41M= M9XPP;B/&SS(6["15C\X;(2E6XDYM]%J)KC<)R;-.,6/(AV'J^&.9DQN M.@[QKP-&P(\<0]5Q!!M]N^/&C,%2C*YZN=V%\8%2\H%&=,,RQ^E9MUQN*?5- M]DR3VYB+68BO6!S@6"<,A]Q0IBJJ<@]RY%B(36BR2*/O`4K"PL4(TJ1*.[T#@#M/1#;?$_&1]_VH2'U84X7=+1$7Z!$OOHI\O8! MXVT7&SODT)[;._KN>BK*!5@+'64&<$&B$$[FXF12P$ M%N[WCRG];<^7O1G2R/GL?%P$2.C&>N=I:^ M:6F_L-G:7MJFJ?&"YJM!X#V>L`A\SHS2NC//GU)ZL[E(,\9=*3U^4K&Q$7)# MK!=*M[YJ"\0FU\#HV)G'AX,*$<6`*UG&_4`^J_\ZMSK+`CL\1??29T@BX/^! M2E0O7@B6+]7>F7S3LR]RNQRD@LJ9>9^.B*UX&/^CTT?X\#)O!/[0".&SWI'_?@I8L!:/Z?>IQ]R\^XM M>O50LJ,38E/OS_OXPS9!@6@D\!GY;&H8Y:FS)'X!8_W3^^^5J<(G?UN'8?SJ M\3E]&2?G\?XQV^Q#]9Y51Q@^HCM2PQVK"+#?H7T=FW$0^Z)8CW`6$W]0PP4: MLV=*O/(EM9VTZDVFW$&L3-KI."EI`\IY8_,9<6H.<,[;!I!$-Q MO)X;%JT=D&)C?V'KR]8AP[^V,*8'T]-+IR'<=IA%[OJ2<>_<%XPKR^?JMS=D MR=MU%%R)Q147`-*;E7Z:CD9&C83<[B>HIW*P-WP8Q$@Q19K1QV-:C6J=ZBHO MSPQ;>@5ED8V?HH,:)XJ#&M;O/IPH#D%UOYN-EKE3@&(KR/3MBQQ6!JF@MNI? M6T?$T#&,?P/E\/C*JM;UXHM#9E3-2ZZ:3:$:5E)"^%)DOP7&@.[(\6&H(GJ] M#KFFQ[%1(?1#C0"RW>R`3=!'274(X71<3E;>,D8W]W'%%<;7<< MUH#+F^2#&*,LRGMZ.)=!4\$]AH55Q`H`%_O!&-$,K`B!6^D9*[X M$AMR8M?VABLQH#P<8QD5P'JB<`3%#WM"9'-S[#C7(6AMP<,%(4X7R]-K_B$T M?/M"(RUTV#.+=,@`R.UWN#)ZEFY;CHV/$,)*83)\0#"K9I"4:$NSF\V]%_;' M@I8.Z&V_2]BJK3>U1FW;G4R/G[&I"$+%X!AMU[KD*K?,9<9H2OE\APSX<\Y+ M&(M=EXLO<&!#6\]$^O5$;K\#Q*_FC79V0VS10[@?GS0I:0@?K5$AB@P^:W>I M%7?V?^$E$0\:TEN:B&/B?BZ[NQ=RN^\IMF[S'5T0VWM?SD<7)53C$TY`ONJ- MS[IMZ^`3S>WG7X69SC+N=-5=L$$(.2_:46TD&-4X%,;19 M%'9T1J1B"9;].E.DY(KD;!&8($1C3!2..`FSR.<'#XX_G2,EIJ1X_!PVU")`<)Y$)TZQ;.WXHK$[11XAS,VMLO]UZR2&_L`D0 MZD6'/Z8%+$5\^8D%FAK3!4[8TW./8IP3 MQD..&9-551^F#!P,,<),E\F$O>FT_T@D=0+D5R1G`/)7)0MH0,FA[LJ@Y542 M(?!6PPM3(.4_\W'Y*HQ%^?=WF*@SY*J&U9P9HDM`CIMR6QD%9@_:Z:8(\WW MKDL.9?Y,SB.13!+!)4+TQ:S^5%S6EMKV-78(E=D/&*"X5-BM=X#0=LV=1B!\ MFKS)GL(M5JG%--UOY6<#=[\,$5D,Z)I4:D,0:H#"(N#5J*!&PE4-0A5+1/"T MDI&LJF"1KDC!&-$X0PBAZ%3L:>K*8D)596^RJ=QV%^A*8E4O!%A&<9!;[X%T M;:Y5M#X:1`\+K`<-NK"`'*D<*9!L1I7'F%BSLM<,/A"D\=X.!#. MK;X=D?5_61Q/J:5#W:2ODZ-0@5GV%0-$$,6XT<6J@ M)IZTZ!,SGF_^%5'*`_6?(_;;GJZ_L*8';QH;(Y^-[4+JD[*^)>*YV<'PV"E: MAN'%N.0SC(QJJI['6X\=%S'NT7QQT[4J:/N$E6T7-66/6#8Z:>78CM:+*$2= M4!O^0^CYO_)8CPN;RFCN-F$^#Y@^TNPY#C[2[2--CF0?U!&I)0X7OJ@$WZL7 M]AKPPX08GV*^X]R+I`'()!)$WRFJ>32_DW3)5A`FK\_,?R8L)7M8-4$Y\)?" M$GBL'Y21E5;-;^9B\?,H3U`AN;94!5A%B$A*Y+.DY:(^/!HEF$1#%L5;YH7# MD+!')]0HV%?H$@&[>J!'O]X"F$(^17#)H&==9X62\&&=8]DQ[%Y=LXA>973; MM'50WQ(I\/40KWXGJVB&>/G5QJV)'2T8E8AAG;]F845`9`6CBYK95]%NGZ77 MS'MDH;A2]&][N&N4":ZO(NXVMG(IVN<$;?JHR$W;D-IJ"]./&Q(Q9)B2S$`Q M>\G!BF@\K(C.!='80),WX%J!38D"(J#,8AY"1::\\!,#XX4B"SH\1B$6=L9.R+/?."CC52 M/MP^]!(2G#R*F%"8")QFL>;SB)H:Y77A1_K$(K@'*+_?R114;MSP)95GX?"G M_&+FY2$>+>M0>%:YM716)@K4OEI6<.3)F&A[$38NM&8SJ$59'*$T\/B&2R4%-E]NQE!,J>;'.= M0HNDO`+"O];CZ(B[Y*10^:-0N1_RP=F&\=;[B".B?`!Y![=G$P:YNR%49(9DY@Y@-0;@M2A"AZ+N'WIO!%` M'BSNC'B](CIWB-%L6$<94DBU>T8+.1`%DT M$.540YM]!IL]VXJBPD)1`:>.`6,N-AOJRWUJ]:#0'0]2C_!Y8(6W,4,N!GO& M*ZRA4L#@\1:!21/$,G+?/R=/RO>L"'"`-9Q"H[F4\;7NAOE03:6Z[U>-F3)X M($RLC\5F-F<11FMDX=JS%P-P(%=7#VH"!%@%C8^0Q86@%72V7!&.2HB-- M5DW(54GN5SK68>B^`0J#3-.*\9P])T7QS3!PR8`!<)XLH9JMB:.:W. MADY4,>%\T"DE2AHL[W;_&#(_)\"__[[Y^F1+6\PVV"5B88A-#;%;8R??8Z>? M[AFAB#RW29B%*H]U)\@6Y@:FMX^82C;DD6QAL+`54E1RYIUW7`//$,]66@G+ MCWT1\09P_`N"S&S#UC0I!R;ZR"YO25J3\R<`Y=>$91F-R)'0X@>U%C1<-UQZ M[&B*&;@Z!&P((*Z1W'L<&$2>(R@;=CF1?^Q+WJISW,(G&_@-,3A1[3J^C"\Y_AVSJ)AP^!&0M'*J2\ M0S6L/W;L'"N.H2(9D:`FCG($I9.03\=6RID0D2%)XW#VRTXS*PKHB0M,DB*! M04`8='(Q:VEF77SJ7O6R,GB*^6)2?,5%(L5[;^>N\(N;BWM M:V:-#9>3OP0TTMW4=E^DJVE61+>;.>V[6!?3(HIQ]U)N&^1W?$X\2P4L,'D8 M"WKJ\"[%.&00I24Q53 M1-4CQL`>74\1R5"4+6]5PL/P(A1J/;539^Z0UN=SMDBP%YNZLB`.[(;#OYQ4 MLW&AR)RFOJ-3Z*P(PD%90%I4"*7P#J6]>'P7ITQ46<2D)K';+@KH:M,,(NX@ M#D,O2<6'`KW=!-\N='([1AL3_!(PG5XH_\<]<7%`RSW\^9X^Q#=<2]Q+QR+M M]&8CB]K6:6OT2)B]TS3U%`YJW##8?=1$J:9'=C*=)(_>1`R\UWA0*6`\Y(MU M1O+*W9J/4IY)1M#"\/C$2%G:D:PRLRMSI&]!EESH6M8I$TX:#JAOJCK>J/K7 M#K:7'.GI0EM%U$ZXX^D)X"ZFL$E`EP?9N>M:;^,]B%BH@,_XZV3+!ME,(XLA8YVE216A*(&E=3 M,V(6V8HY+33@:%P)Z^;)@>PD,(^[Q=9)>3*JOFUZY&;D4$@AU(2".H_X.L99 MVJE>7W$L'.052T6YW:>G9N2-9H86IYHJU+'+U5$<+.#8#L:D'>M;PK5"0FF] M3FP=T1TIGHY51!&7#NB+/3@=(\KH2[[%9JS80E//*F M9S2TPPQR;:(5:%;7"&&XU\WKV+DE!B5J5/(Y']?%337[\ADTG$]QQ"(N#TVS M#]2#522PS5&C8(\Y MI@DU)?K8RK&TS3&9T$1%"HV\5U!]!HEE>_E"GU>4*%3O(/'8G-*,!%"@5J0? M,MA8D\\$/!Y$RTL:P$DA.9?C$R&7Z'L6)[M8EM*9.8YQHWR-*E%D97J4(DR` M,E&D\STY1=P!#+M7TJ-2DIB?:L85\VN53V0,#TY_.'R">NET_85UOSE]U!@I M@/<3LO[E:;TEPBBJ)\-CIW`Y[`I`4([,0RH^]JC"1:8GZR=O2\]%:89.O52: M+F:BG@I8/TW+=HN8I#7L3I^B!$8EG^6XSM](MR+BJEW&^4Q0;0C4UA=K:H/< MZ&I%TJVMT@"QF=7S.7;RY7M6;BI<697)X>'H'3R,U1)BZ=\CMYL3472;*;Y$ M;"^G/([.V8"1G(='@HM69*ZV6,+\:D9E[6OL<\P0>JE9YA2/+-; M+>>X#7+;J15)MYY*`\3V4\_GV!F7OW3@UH:LR.30?.0>5KOY'+7!;CYU(E7, M1V^`V7QJ^1P]U=2VNV/SL2&3P[]+V:0&"K"^!((760]-^/9^TR/8.770:O_.-S0+CEKW9$Y;(;?L!K%T*SYJ@MAB MFSB=,A_WJ<2PG*BB\L5!#`%5+X.$T\8@:_\#;0D'9 MOWMUY>40@,!/*=WLPVNV:=H2[==SJ3!P*GXO'"B[+1$(:KBWM`Z4E`B00H8$ M!G5PD69L*UY*W$MQ0_;BTN&7>]_K*&,!"_>0.5W6L;_X(A^=N>0FDL3\1!4OY,20T20(X@=I=:?NIB@@!B7+`DZ^O12L0/7(76& M]&,N3_WF:C9#X?Z`5K.B^Q21(X.,ZA;APJ+Y!#C MQAQ2CRY`UP`$T3',&50U>RH[F+ M>+'=A?&!RA0O61^^_<"KI3URL^X4M7((UM08L2%W\SQZF:I&5DF+"^'4:.[ZF>;ERD=T6WK8 MHF`&S7\=_,<^%0\OP@.]SU`)Y"KZ*4JH%[*_T^!'CT4`/3=160.M]B&#D>-@ M!I$IJBEP9LP@V*%HDDRCX]JBQ#"+?$XJI>2K@,J_OH9'MR+N)?E7\99"'DS^ MO'KH[T-//4LGO2G-8UVZ4^^!D*\N;N^_7A&NK'THVHH8&2H.^T(Z4<;88XEZ MY9WS$)1%#Z&J<2(4-O<3MVY^AX*H?).]4%!)F`!E\A70_IIPUZ*1=X##&+0T M;!JY6W/Q2/-*F!!H9)U'!`^Q]J2[NMBO8M.&D'C,.$A=P635Z,NWP8,@7M>- MEV7*@D^2S,&E(`L.0!(F.N454;3MX$Z<>6';RM"-BD)8*A8N,'=[XM/B"2R# M$>0YC>(MB[J6D/7-D!I]EV!%>%?3!GOTUL;RLI>2-B33QG2[G+0LG+N8XPK" M>3%C0X6+`%#I.LL2]KC/%&)Z82C/Y^$1Z[Q\<`/L3AL1*2095)<>D4P8#G%L M8D*JL4:ET2Y"$D&=Z.0A8#G/CVDN-AOJB[4M\*128^3SZ4V5LN?9VG:IQW() ME8*R..*$H"0O3;E_"XIW"Z<^8F?ZSLL]>XK8AOEPW\?_;<]2EFOFG*6[./7" MM-^]E@$#(8>L\@Z_X:R1WED0[S^?I% M+);::ZHWM$5N'*TB5NJLUS5$/,7;^1U=J[P85>61.B[#;EM(7T80*8SNT+UU M@]1U1ZKHP"&06^T8A529[A>,SS^>)")'\9W.WK(=M9',$A&@_<^5\I@R<[H>@>( MZNLV.8R.CA1"+*FQV)(T-S3VG4P+DHZUPI_S$[U=/C+9R:'AD5'PXH^PSZ;2 M+<4CI&"QNG>7C]YNO0-YI+PS"[13Z$(*^+,4@XAU[Y-8H9-]%,#NO@:27JD4 M(DX"I%)FWI5%]"OU]"`E.Z*HNJ;O@B.B6'*P$8Q(GU7E9'$Q<^64+Z>VF.LP MZ?<[:/@,SNF9T1]W#C-G?&.[%;Y45O>1Q. MUZ$8G;?YM(<`_V:S!E=;FPAE<.R%.[!!*ASBOGH-_`:B2%E MDP#!,Z")F M[.R!/1CL+\#X(X4=YUSM1VSB9"O7;%"]U.[BYBNX3X'),5>;7=<$V*#H+VR?WL/I$`W0%P]TFEI MCCBBZ MC%LJX"V(("O=;59PN===2OQ4)_&,!71\'JK"E4D:G&M/"?"_0PI_<$6LM1<% M&I74H%2#PR.'"-.*K%32,30V8M@Q+N+H-.22$:)SLB(%+\*$=6XXF%5A;57% M-;.`]A>IS8@^`9-MD(9&J=O%)=EY;=NQ-2-!HF M='D(U]4#^X9*?P$FIU,'-/-8"#LH^L9*0N7$SF)YX;)XOYT*'N8^'YM/'9!= MKM'(WZMWGDI^'4=//.;;GM/'[/CMY>/E6WU3I";>1\#*'D)-.\2!0"N[H_T/ M'_0=C$I@6"3O11]+VEHAO['QPF9IL1B2Y&,ZC\2J(K;&80U- M%S4MFV.PNG:+F9J&XI*3R>DT^'(JXHQK(1;1FXWDJ_WTOZXA--+ MEOW]B29>&*RCX"QNSAUL;X[4KOH*6FQOM[3%OK'=AW6K.8*2`5)R0/ZKM]W] M-W(6S[RG;5,3IT)"AN!9[#(GT*:\ZR>G27^PU7.S69>765M6@4UMD6)3+Q%U MMU_;$+'G;^=W]*4TV/R#*U#:!6?PE9_BZ)U^Z?F!_YE"H0.X8^5ZV:@Q"W>E M.*\:JSJGK1'M\%&03_V1:JDDO`P;`K&YC)5D-+)K](03JU(\,B"G,;93U72# MRX0U<4-L?KM_#)E_L]G0A`=7PI]'_(LPI($\-<^_:H[7AP^!%"RF**2(ZP?V MQQ[KCQ7':OR_$TS!C1%!6I4QR?E2Z2W%US.O">;6F*1'\E'5*J%0ALI]*;YV MN'IPK1FO53,F056\J$%O0\^7T,Z;?-\"H*W-48-EMZ`E,#:W10^"/5@?7ZJY M$>4D5;(KR,)J9!\Q^<=)<9N\`K%$2%6/X+2Z4^S[^T35S@`YYH9'B[I48Y/J MX$XA;P9IS=HNJ`V-AX`8C8 MS;L)2(3G8\J)"_@%CZ7)*BN[G/[\$&9/>%F,IQB]*+[O&,5L"US\E@@*Z6M/ M(UU%\&(U1*M!(`H00>$Z%EQ%9]Z.95[8NHLV9ARDZ#99-96,CJ&#(-Y+&R_+ M^(*'Y1-CI*!)2J($J/)OB*+K>$O-F89D3,,*#7FEAHH"D9*NR6#'BVB6>;=> MDD5<,]=9T!+H-+=%"@.]1"P#G(:&Z(.;+KX-;&Y!\:;F#2[X5G%!N<2(6!JJ& M(DNAO1=Y3T!T)ZG,'4G9TO2Q\D!W3B.HN025L\0@H*EH[T(]=21K+9X>C7>U MQ0QH72(6@-;4$#N@=?(]?J4&SI6FZ@*JA)?\42RY2"N?QIH96ZP)K08F^;!][=>FG6=YH-WM%TB19H*'%:WRUY/*`V/T,2-QF@DZ1X9,(: MQIN;B#:O7[HZ+`UU3H1M!9ZB]1*QYY1YJP?VQ0[N*\N>^;+CE;*G9]CL\UYH MXCW1&M3ZX9N__)D$<1AZ28H`NLPIK,&@.0&7"Y1Y9*[^S*O3>MEQ]L$,)*:3.H-Y*F0OS9!"?G-F4=JR! M'X&9&-CYE8X)BCI54VLA`3N4WJYQ=ZG7D'$WD7F;QMTI[>A2,T"="*:(SA61 M;)&2+R(84T?LDC510S4]CG840#BMQH!6U>\>3U2]JM'UOD'7JV'*GK!"E%3[ M[WMUM$>*=[U%+9:';8VQKPY[\6Y]<1C+^=RP-OS3-W]VM3:TJAYEQ;@VN.:0 MN&9="+^Q7:AJWR6IKO$"HFGD?2X>IGIOS?_X!#W*9TU8] MTYI#XEX;\_"K.\S*#KTTO=FH/;B;Y`XXS-]Z5?6+&$W//+C<]^&09ZFKAHT% M'2>/BA1##:NMDK\];4C$RU93DHW.7`;Z8&OY3G.<$#&T_B1SR0>1C$#:1W%- M)._AZ,4BUQHLU93?;),+3G%UR/)0YO_S&UYX['?O*7!DKNN-(^A@O17NM M:@.$J5/;J#L[#9'N.177&]D+O621%_G,"Z^B-$M$+)7F.JG>3/H)[CY>I>F> M!G6.=/J02+'>I,**D'KB>-BC;E/B&;H+$!66=W2W45WH98)J?D,7>O`0GL5S M7WUTK;62/BD8(!H'FIL\OD@IV""2C[D?OT*ANSOJ@WMA&^;+12!74E#J,\R? M*8<5H2JA\A7+'>C7#A8^KA7VJ9]-VE922]R`0DUFYY7C!>7-/DLS+X(+@T-B MM&HWI&'"4,$[UWQ:GZ4MZNI8M[!JT\A8P089!%Q$K4\N6E?`!X]WK%PVX.HH MQR=\#0$1"Q6OO&O!BW7HE&3N,R_)EJ"@1_K$(K$I.Z^:QJY,3:JHV,"`0FXL MVLMW"_FRT_/]>!]EQ4EQC6N!K1`4+D66%`._"C_W+4W$T^:1>Y37J6GH\R\L6K#`=1_L^$1-+P8>DEI[07GAG9( MC;13-*U2PVDC[!LXK3P;VI7QQ'P&;[P11/Z8D@TG(^N'N-Z+L:(`-2B(K(8E M,*Z3D@D6Q+L\^1F=+-FMR";!5\Y-'CIY)*5A**)+MR\K7'HL^=D+]W3-O<56 MG#>G%U]V8A_BG+VP@*\+[KR,-GB:`=V1XO!81>B!4]^^B(.HP2*,-G).B`A* M1",%^:22&,FI$2#GYIQT-F44LAX8#?E2TH.R/]Q?^1P3'*Z41+@HXKP&!54: M(#?L4V%.,O_%MXB-LX;):7GV8BP[FSIQRF#YWV9>)L41F>F[44L2H_(^]+H) M8%YH+R,!U!GF(>&3V-Z<4?9^MQ_,RSRCB#T6VP:%_.@EO]*LS.0TO<"V%S+> ML?37RX32JXA/"IIF`T/&AN[(/'+&:T MH@T8]-T&I&:YU`EX`%3!H[CR]F,XV``DMBAA!QT+*JW_D:L,3*(H=T'8;@`$Z>V,6-K MFXMYH,EVA&=2W9`C7E_!^T99T`-27&4?K=*-+<J+CE_^%0ME&7"];\IP]N\C6G%"V]BFX%^K3IN',_;R8FD$8` M;G^4[I+BMCA`O*'F2!&FJV,3G6,HZJ8WS"]F";97JE*V5B0;ZGL2R?RJRXVZ M3S@]UZD[EF^*R7JHCGSJR(#QZ)9MTNPU+X/734R)V.:XB/E6]\&:SH1"6 MU[F]7AV0NJC^PA:KSM;6V)>1_9@W=2H/_G(HJ(B M4EZ.$@!DQ5M2WB?ADUY]D,?I*UC6R/)2HO8B2^7P4'61?Y-ZH;R%XA'.!$NS M1!)(N7*$;9,-4Q5!9<45>.I]YJ6FW5^C&)VHX4D^OD7?UKX$G$O@^OEF#A"]WZ_KTPHZ?PX08 M.Y$?Y-Z7&EU>)^/C0UD]04#5^RGNKT?RXKK`/0YFC*-?G@C#OQ;%]T2J#%QS MS^O5YB':W+MKLRBPI$*\E-Q65"DHD9R4BWTP!RIHFTWN=FMR82\YMN0%^ZY;S:R;$Y#X-ZK(U(('2Z\OI/1W0OQ[L,`YL<71%(0*2IOYT0@5`0R,/DE M(5=Y+C.HX,>JKQ"*2)7P$OP-!D):T=07'GG=AIXOHFM58#5ZJHV">O5":K\# MQ2[BG^XNV(.?`1+8J/4--,DN)PIUIA15WC2)]T_/Y/69^<_:-EO% MY(8.D@??9E))N:"06"@)$4E)I;7)=#@7NSPS*>%!3(3R)/-,;O#=:_/!PAZW M)A/`.?SK*`^L]KK/L.Z8(6^$(DZVOWOTQ0Y^8T0Q@(`E[E7VLYO@CXB%!.^\ M#[.6A$Q'6^!SZ$Y["%J'2A$PB@\41:>W8MPHI&X&@5[TIXHK$\8@G*HX>,T] MA=B;_TB!JSK=-+;$#)+MXA5X6-\,._1U<#U^"X1/OJU,T.3HE7E,O.VFWN80 M)(F7TQ03E44OE$_01"QU=OO'D/D)V-$>,_KT$;7`H+;&"+>?^O,\ MN<0`H(JZ,OL9"!!%P87!696X#`ER,O/4QOD1/AE<&:?LA=D&^XO=IRJ.ZH(] M,A@@P1P5<9XD3>>[0C.HI;,:CB*$YG5.'.6@LD+V^Q8,J*V5]YKH0AV M)':_NEZBRX(1[%B">6IZ"9J8$4GVUO3Z2)]8),X8QVC7K4L>NG4^=O0W[J`';<6/&OIWX*XM;>V;\-JH3P#< M:-GTX@[9P8(;I>H'$-A=Q]`SB[&COW'7,>@,9-30OP/78>E,Q4PQ>L1'+VZT M;+X0O843G?G*T)L_]YG?=<"S6@:.>CJ'69PSZ*>8=M1O'P-K MS+&"92W5O4-H!Q!NRMW.T8QKR.8]V7H'J)OJZNZ3(\5U`ZQ&'?F.O7UM??#"O-A`.9LT_31MS./:@4>C MIX:-=MNN;!T$(J7#"\]9ZH=QNN?J'QS:=HVR.!?62RWM[JMUB$7%M?TD,8^Z M)5VB$488TMI54(Y(*^*5"@E*0@8AXIJOXJ.TO+(F"Z?<>JQV)[2U-6:3[Q:S M,.WFIMBCSQZ<&]I)S!^1\+WT6=;:K[P5`K=3*93N@N>DX.-05)TYO+2H M&36T=@%5U1Z"T1W`E451E6`[6X)U/?1H4;3\&1BO%!'F+H>5B/HB`?:59<_$ M4S-91'$6;N,>2W@7'[PP.^3/:U7>1+@7-[NA^57DQ]O:IZJ]!]$+0:J'.]*" M=6ZXP+MC%S.KFD^=D")?O/AX\M9+R0.13"#P5?-.3:6A/G/)?,&%RC&:^I\X MX[Z&!C_!PVUUZNK?%3-P#U3`<46&KG[8X7BH&%/VA%N2/04">PF\E)5DQ0:4 M:+;+&5%/",H:2#/#Z5QJRK<@CJ^["^$!I7H;[@3.9 M>F+?XVQ]NBO1CU'2A ME@.C86#@$9"&>%/(+MS#99RL]UD,13?]LSAZX5IKJOG9W0SS9F_^QDU7&/AF\.I&M"-N0!+*P5`5AL0-*?]N+Q.8\7XO'CVPKWZ#FS6/> M)H&XX86EHEPK!)I\!$9?*,<*&7N&8?R:'AVW^4*&3`6C=$,3("+K%(NORZ+& M0;X$ MXQ5Z\1OU,N<#UVJ2BGK>NL?H?&.M9U>DR#M&`=5GKKO[(0[F!K$_'H9S!!14 M5M78:F7[$;7..&L6)9SMM_M0OG`4Y.*C>D>MJ@5YF@^OX*I/<[6D5]&:_]M+ MFMY2&S/.HL!A@&J:D:+'((N!C2&R&,,0E?XBWH_.ORKH0K:(HHP!4N90T-KW M$_&$>(DS^TADSAP'H#G\F$Q5;_67P3#;4R_;\&WCF(0AHD*<[JL48>PQ/%F,S+[[F MT=815&KKKJX*?C.LP^91@2;R\;RQ?E):E5"^)G>S.6>A6`CF#V_R5>B1\.O@ M/_9I!M96>XAJ9MCEP.@DQ36`[*@QEP7!TT0T=&"K=M-450IY__$(K*59LA2R MN_Z#^IEX0JG@2.R0!$H$<7`+,LS]2!(&S1Z#^6VQ49GS08IGAT%I)V"O,>,< M[AVIT-)LG"%\OI%IN/PO^7"H_#J,(>7]W@MI*I25O\SW(/<8S[U##P]BALAR M_(E!I7:&\*,I+,O7F!38^$,5C9OOIS@@^2R3[7&`)+(MX"4N;SHZ::8Z!'6IX">&%XR%YZS_'(<<(6\VVJ\%/PH->)#!?Q;Y@OAD/SR%W+(]\F1%#_#-HVDM MWTM/%]V0O\YK'[X(/DX>?(8-&@Y%*X5#`E@>)4K)_;VWY&/=_2C]O&W!'_FY M^+4J'E@R*;87.5MYH(7>\[K3>\,SY_)EK7R6*QO0:WQ^_]UI/@EN!VILB?H6 MEZ%FEIIO9FH!Z\=+DOXJ+?IH-PM]!:TCK.[5FM>GY43M&UBEL'3 M;#[#T$T9R-O=AW#UO,B*YWYZ1Z-4J'T-5WF>Q+WU],.A;)/?7G_UDN`!]F<: M$C9,CH_4&UE39>4NC*G!$6<_F9=Q=-*QXD24D-#NP.C<$)T=J`RE-\P+4@B> MR&?!U4E9M_FL_(%EH-:K2.0H[;UP_84UY1DVM45N?:TBZI94VQ"Q5;3S.SKU M!T:%Z5V.2S[#R)AFZ2\L>[ZCH3"W])GM'N(+L3%ZSGTH.XY\QX^RM)G=3RVM M<[Y]B"590T])IMG)3<5.@"31:9*'F$BJY+.D.W,)3U?:J2@AZU3"?%!RSA+J M\[$_0M)BTJ"MDT;(@:!>*-W.JRT0FW$#H^-OS\KAR&<2DOD>-P&N3G5BJ1;4Z4!8F.JYW/TA0>Q9('AG`>$XY>!I4JB MX)8KXI.WI:U1HR52R$W`IH+K*WF8HX/8(*V*.^TB]8>.?8P/:A]#-:SN8VC0 MP/DCP"`!#AU'O2C5??';'D)AM0'D/"#NU%&3BJY91*\RNFUR^D8&7CI,]E;> M(%#L''7)$-A?.!/%BYH`KV/?%I@A@ANLT#:#&L7QU3>*N@UJ)0(_!6,_Y;!+HV,9U!WDHAG^)+78M:&/;9T&RND+*@ M53P>$=MJLXV*8Q4Z5XN`UN59F">!%.5L*K1:*,[<^-C3RFR).ZE\0:7`W(K` MKR_R;YY$U=X`*@'MHXR%XD-9A"[3TWLT)/Q*FO37Q!,8*!^!G_MR+#8E]]LV M>&S;-E",'9=0=O*Z$C;UUE15GN!8'(?:>8Z>^#9=[[/G.&%_I\>/[-FD@]0= M65>MD.C+Q]) M7SP60@KA99S\"'&-Y1^IAMSO!%>;%&T#7H]I_0Y0ME%D5&";!_QYH4F(I5"?MJX.6IR7*3NPKCJ.@[DA@VZS%.XD3(: MK_60FYY\%)3$+VH?3MNCJVDL"XI#!B:*T[:9E=EXQ%9"6WZ$=J6I54_,LKU# MW.,1*-=:_&1L#EIW$%+V&UGPY)IYCRQDV:&_9AO[+P_PVU71`>SUG9<)X!VR M&`)J?Y\D$(2'.0'BI7G1R49$`O<[H11K#'4G>?-W-:MZ3T\$ M@%V_-^$#+/T>C5BO<%P1)`5%-'!N22%*[EC)'3;)O9Q-(K''7JQO?DSBU/C= MB59*2)W`#.HUN4E40^8-;Q*U28MADTCR5^X/P2>5Q%;$JRA(6IKT1\7"1>:2OW(:.8B0K^+\5;1]Q+*TK//X M-?=@?"VER&B5AQ.ZBQ/]@DDU@PW%B@C)S]PG(;U?/OIQ4$$*3HE@%6>"NDO= M7Q:64R[=I[A.0PNVHF[DQ787Q@=*[VGRPLVT09Y@A`O58\MU2V:N^!W'9[B*M;8$MSQ';4A^NQUB#')L7@ M)!_=>8&L!JE;*UUU]5GF;&ZN/=7:87DSVE!YHI8Y[;26$S:IY[/E.YI2;@?/ MZR@XIR\TC'?`H(+YNW3VZ(;;Q(=R//P&6-$3)-HU*GI#N MN&;JK"KPZE7@SNA_I!%-O)`+OPZV+&)I!I?!7V@?L^_;%[GA#U*!;OJ].B(V M_F'\CSX8DE2$]5?I(`&`>=7@-:KA9(]U/A0PL_2_[JC4:)X*MBC]A4+/)TZS+^EGN/#PXPQ%'(.DWW6WEBPCW/1YH] MQT$4WJ'*5_BB%&P2S1^1=RF M<4P^YSPOK3#OC+_&+Y0]/6)<_K>J5)-\(=M^Q]-?+A-*KB/]B-,WNO*SQ MY'8&NK\GW&Y3O374KB/Z>\'L5MG1(?:*`+\$&"8YQP18?@-X;>67@$'?;4!= M+%=7`G=POO*X]X.T,)^S-.KR,D+& MVW5$?R^XW2H[0MS.^24YPV\%MJW\$(62#HR&P=M&ZY]C>.X3;N?-C=T/M!NDQXW;)\EM#;L,_1J&QEU)CJ`#\L5M_CT/T!R7K6U\_ MLD5P"7!M5=DG*&V%&G9PMBLT9DRV]N!%/R#&J?A".UF-=A80*]=>N5=[5%:8L@#D,O22$^E[>H'4;HO=)U/L6J**E0<"H* M9.O?0\K.ISC[=YJ5R3P=*2AST$7N&F93_>!M^ M@EE06R?\>T3N6OG=H_^J/,@NVU'/P>0;Y=$>[1OB%67^57>Z`U>3PDQ?EL6 M&,,FNL8B^0Q,$L6EG=V4&;;)+2G]Y-&7-P&K4BK[OT1!Y_<#IE756L)12>3W M`:%'LB)#S_S%:BNP*0.[B\CJ(XGF5?U!/5T3:T[&RT3Y9$C-5@_8^\Y+LS6CQD3ZQ2"P!>NMR.6[JX@M-?)9"55*K;JJ.SAMW4XVJ->FF3HB\ M83?5+"L&-Z5Q9]5-67^BQ;R:?Y:[6%#'@):#C_)2RT%6S4<=I1$I!=-;>$X! MED^;N?9<^C/RQK%Y_(]C:8W1DXLWC.X3E($!_BNKE),F2PB=JDZG7/8PXG.-\V17[+_M:`%FSXX-7A1;09/ M/'WEA>CWT=]5?E.X?QDG&\JR/?^%78+_<#;>N@<8^<,8=0,#>7C+OF"L*E`X M!(WYM^\5YOZE%+TE.H?^IU\.-N'Z4U^Z*S#[,U@Z4G^KP&]8`Q@VX2K'[\L$ M>22_RIC3^K?D`=9!(*YT>.$Y2_TP3L&KVGH:I2?--X[VO51N$N-;";YA9.\G M-P8\+SDE&JN+/SE?^@^P7%C/G62Q0!+7#*^B+&%1RGR;Y>EZDG[C(#_D![`0 MS[?2?<.0/TA\#,!3,*QOVQ3\6BPO-U<$;_>G4+0*-0KEI:W:6PZ(:Z?CLR!W M&[TW#M>=JK:4^/2[`>9NF3&@<26YZ4V@L#V]Y]`[1&<+J*I_NO]4U9OQJOI] M""X!?:TJVTA5_4YJV/'7KM`8`+BRL8T'@'$J7MN[ONBQ=_V&T+DY;_0N+V%T M%D=BFVGOA?"&P?>6?MYQG+QQ/)_P\Y@$^A%LO&$/,$4;&%Q#^\6#0@:B";'$ MQU@<_EJU$?V)IG7]7K/-@KU(\QESDXYG"/X'$N/WBXV9AZ M(F`@'>1.P)IJ!Y>''D($,8#;DW6&(L^<+Z(8(SEG!"9,F;,8;Q93Q7]6+8/J M'B6UE)3%^\>`9I;$+P"%?WK_O0)"^.1OOWB)N&ZUSBHIEC]\\]UW'VE-M;3> MG9!"U#"A`6_Z]7`,'D'L[R$.$%-TU$\V>:Y>19LXV33,5464Q>%6WR MRK)G'B/D2;>4[$1A$V[]_P",E+FUWU@!@#J$G4DY.06RSHXRM87@GR69F3/^ MYI9=_/Q'16WX;U_]Z>UCVY^_^>'[P=A6Z;1`;#L5N@O;RAX+Q;8:`=Q@&S"" M#=L,*J<9VX3@^+#-ANP-V%;]Z0UB&X2D<03W)F\V9\^P,[#^PHZ7H.TM,:-8 MNW@%=-4WPXY7'5R;`*G'`P$!8`KZ@L+,J&-)Q')8D$P.3#[#T"?P8M2VSF/8 M..LG:-%V6?95%;'%PF3#Y=G8$=]CI^`=W7&&Q12$+`L0(2W-##[T,N+S0,#; M;*@OLS+@A6MIE[PA_XIE=`NIW_#=AD5>Y#,O)"F71EZ%=VZLAG2EF>M-::YR M;? M$(*EU.$0+?R9PN@/+H!U7PS,?714U M!RM(Q88N1SG/]^,D$*7X1)0L8),FVS3/5&-P>4,H947VZ=X+PP/9[V"II<[S M`#5)NJ,^VS`X9=K&^RASM(ZR]K,42PE)@4@2^5.'"%91UB0_YX.]<'MXH>2: M>8\LA-EX&2>Y)GZ*6.;P6J;R%)K6VT%G_'C8`4C2>H0S^V&]`= M\8'<&"E&!Q7J19FSK<1@MU'*S4=%C76#9 MWAPIW/05M%B/MK3%OA3MP[JA52C-2=7/TID7>S8%+\;68S@NJ1K?P0)O'FFK MO^L#)^P]48Y,?KS=\K6^W"XP5VFM`:(T$<\$89&OQ:-5D>U5IYW.'IB!JI^X M!5:U-\<.5SVY-X18VGPN9FJ^H\4;\77'']/*Y)X9PRQKHPI>DH),XEPUOU0U M`YA9%OOBRTXN%*MP)C92YT$PV!2#S=2*?#RXS+?I>,!YYJ7/-XE*8TW%$I)XV&'3W-"&<(7$MES:<1([[,\.WVY\BI'V.[T%=Q4@'J`28( M_V_.AO98(7#BP`.XU=S-9L-%E\E_Q?RU[A3*;<_+/)_@JCA52^&.U\U&22BE ME1N>'`K.0F^?U@:^!L;$[!I,J:SP#E,'Q.X@C,EGR$>HTVEQDPC^'?!E9G&D MK.$7_+MP%LI+2*@O0W7R[*7$*PU6V6\A`?&%"#/[`.<:UTY3"@Z(QH*X)0LZ MSN&^>IX"BI.<.'`#SI6G3NJX=AIF4S'=$#F"^_UC2G_;\\:J?_1D0[GU9-ZR MNVA1K#$/4D/CK3N5-I&7ZV<(T_>1"!R=4^B7%M+F>:.. M)31XB#_0'VE$$W%LPI'!B-\T3G^Y#M7.3]'3TYHEOFP7;$D7HRLB<*^XY7"Q MW6^53P.4*9VAR%5^C?=A0"(JDR`>*7G*V1(7HTK'RMUEG(ADYIAD"7MZ4GG- MG?XYH:$8#OH=A0%Y"(#*UR+[%3N=<*?SE4R3G&OU.Q>,RVAM$1X:V4_SL<6X MP*+4I%?&TF4HL[GN(MGS+@[#RSB!>EC#?XN&49;K1MO4TM,9U@V!,*MQJB36 MH*Q,0_X,=(DB[.(FAP/UG*EKD>JV(UR4\R+(C`A*O957()FFM[#0VZ,7@G.U MD06DI6WVK)77FG,P:CC,Z&)`4:?)19"T#%M*I1VRE-`\_47&6W%YD\)5=I,#C3>DK:,M+.I< M8;_TFY/AR'J@HP+&3WNXAW2ST>-N&HCK/]K]H.%>M/>XF&'?I.IZAIG]!L7N M"(S*:,@C1(+JR68L-T=8N:4.01R%MCH#^$^%_FHO"^K7":VH3[KJBR@8&=?/ MI,CF`NO)I;>/U(,KP,%- M=`=%)^"$E#?X%$=)_L\/7LK2!Z@=?O0KV1@?J0>VILJFBZV3!D>X%61/1@,K M!D57X,J*%+1%8JU.G7P6I$=5#S)LRA\.&M.7B=AQ]@\U]0:']5R*^76+7VM8 MS=V68#(]N!]]PE`.3(J1)U3Q,SS;Z^2NK?\WK.=29GNW^+6SO;G;$F9[#^[- M0K\^\9W4PW.C@M5`';@U_[3PSJW5G7IV72``-"F@"P&.^RT,`AK9-QS^:=&? MV\)-LRBA%/81`FL$IO[A4/SYKXPFW%B>#]?TA=M M2S#Y?@*8\'K%\"C#W/14#8,#WK8QEF(*0U32Z0*;!EB"80R2P[13U#[7S`9= MD#R+8KH5X``YKJ+=/DL%4+[O%QC7]E@**C2+6XL!I\V78/$M7!N8QG)T(H?' M$NM:$/G?]C&)'+_F5JGH)5P'DGOM>V%32\"O!$GF/X1!' MT]$/@TW]AR6;^@_#3/V'19KZ,=>&3?T'A*9N2N1[]A2Q#;?C*",_1?$C5(F! M\YI<`/@)1^/7+*)7&=UV;I49HH$<7:RHU'3*1D$`,3[9D=/$ M-EY#Q)[S1.*H+:%#,$8^`VM$\.8Z+,*C7UGN;ZOMKKB#1JF5&N3O>&*A3S_D M$-9;=!V6.CLAAIK^O(^=WI+"JBG@![1MU+T#:>`T#$/!3?\UMLI:B\'C-ABNWFVXG#MV"@LY4=Y63.["&I9XLXP MM>7#\+"Y=V?D)CM,";K]]NN)V)@'"C!VLFMDL,;3\VO"863=+NPH#2W=S(>; M]V+->OK&3W'95NV4E65@NBW=C2.WK!'IS34B",X'VK<&Q5Z@?OPI3C_YU]R0 M>"]Q3;[7;4YS9)#CARW%UAX4&**!&*.LB6KBN*#[C$#PM:I)("!5WE!=!BWJ MA)V%7IKVRY6O[;,44VT3N2$S_K3#$HRHE>^IP>J!B#'Q9,!/AXQC??7+FK=( M=RD695OUEKQA/=$E6+9UV0VD#M:ZRYL3=]G#6WXXD!/4P7&!8`F_PV-_[2T2 MM<^\T-^'XL^:JKCV?KE&NK\?U&Y7O274KB?Z^T#M#MEQK7)61&/7:;7DY?P2 M1YY/500K2X3!WAH5YW2_L.SY1'5I5:ST[BCY3'FGM@P.6[26 M`M8V5-QUZ74RH26`LA5Y39=6>>6QG+ZVEM:0E;HU_D"C: M6,[210G+16FLH7REC>K^?=0`ZQOQ1-Y#O`X"!NKPPEN/!5?<9>]8YK57TS9& M`JE?L:G0TYE!GYVG-6)-%X@?+_7L$-V7%VX+JS+QER M]10`$G76%[9H=17ZX#RC7\867@%_M/(Z;@3Y2;^;LIS"QOMB5-QF0T9 MT9O-64*YX[GT?"%W6^I36WODZ-DI:C7]L:$Q8G3JYGE\,D0D`A/P+.8^9]B(.@BOL-B5U9X-7 M$1>*"&0S*`I%?D/!`?&V\7YV9+&F@5M-[`T]32R<`5-FDXU\Y:7$RW_= M455]&T!FO8V3##:P;^&_<72S@9O1(9?GIQWLJ"LNZJ3OWQ4S!`U40(%(/?MA M!ZBA8HPNC".P!T#)RRF2G20)'\+M^Q"F.IP_B9@6Y&3;;I3^BAT($#4%R$'N8]VEA'@6'>;63D@1=9C0Q^<=S3T0;\'V9'S2Z0=)!9)6@Z+\H%XN_$!G)WN."\2J%#K5WN M,ZC3N*TH+RR4%SC-OP!=/'3JHE@_<>W=)BSRV0`9US!=9>\`4;3<`9D:P1R9NC MPJVHU,OQZ<_88;!T(@U:^7?J)0^O\22%#R#R)H!PJ%*'(V%?"HN'PL&"SH.% M)5NMN`C,<5R,,:/A;!KF./6/;P,..5^-]T',D_D=0:*N6%N@"#1^)[!8$14A M,`)_RX=&(UKFJ/5/;P(<+_F/95_IBLKO!QIUM5I"1B#Q^P#&BJ3X*-SN:<(FC)[CT+-YCV\AR?VG;C>#N7LA1JZ?8.@IU=$&,*GTY M'SN#B_$)$"`5"NZO"U]%?KRE#]Z7]3Y[CB$#K.4=@,;&R.=SNY#5T_:ZEHAG M;P?#X\_485C"QR7%P,X+_I_*VEJGOZ7YXN9K-Q MR#ISDE?DA7>0=;RG]S1Y83Z]NKO_2.'F8%OR3&LO]!;;2^R3Q*[F+JCMMQ_G MDQ*Z(/E8$2"*`KDB=^2>?)9DG!FT7>$O:<#CQ5'5[1KNI9QY(>,!9\2\6AML M:H/4XEI%*JZ4'#?`?G>DD5\#E]I8Q$?>RK+R?"V2<0+WVS*]7D"-NB'%82@`K^B@J\^W5RGHZZPV[;[P1I;LI4/,^Y%VK154\9FO=-],C=+ M=U;YX'V156EUH=K.*UL[(+?*;F%UJVQNC=@J>S`]=J+"[K&J8*P/[OY8LE;F MEI/)MO9+G,%-YY.-C9<6T\SI/C([): M@P([][=%1J)Z">0#C>B&BQM'&8OV+'I2&Z-QE!9-JX_#=91R,DH`.0:85V9M M;N_DT1$CC`4A1U>@WVRHG[$7>`*RR*Z]@SR(X[<@55'%Y@)0#NRYRF.#6M>9 M2C"\S[QLSUDZE/VYH%V_D2$:2[%JDRJM-6P3!)9@VT;EM&W>4`];<4(*5H[[ MN(U2<"E6Q#7Q=K?/:`#*$X_/*P6FA0(YB)_<]7<.DZ`1NHZ":TXY+-K0SAMP MO4=9)M1UJ:4'F#4-L3RXZI3$?KPA6!`WS`436GNX3HX0B:SI3&HB\[ZL2$3% M2P8YTO#/R*,$/(,)T@WRW=)DZT4TRNIV*0=U1`H0PX4O4JQ[]<*>>#U,"`/I MV.`TO>)I#_A7P#@^))3_1'Q>9Z^4BE<8XB03):`%`,"<5X]ODJ_4Y/]:X`1\ MZG>V++SVXX%XNUUX$!G@0)OW23/FU_AQ;4!PZ2EDC',IX-_JJZ\@5_%K`A.) M4\C7<20N%G(\2,@2]KC/Y&-?,>2?2[42!GJ=.=-\GM]:Q_AJO%D0DOO5#K+2 MY]%`AYS.@\&S9RX7O8K.*;>[A`9P;3=-:9;^[(5[N=40AO&K%_D#%\K#!D;J M$B\3N9K4T`.>CKLN#X,: M);`/-((TT6BC!!+C"A(#(L""ZA[AL-.9!=EZO9@]CMF68,L-'!M8HESD:T4U M]HGW,F.4,507="#I+5_UL!1<]B9.M"7MZ>.W\UEF@9R5W?FZ@U#UU:!C>7.C M([=\PVK4D<+0T(B1Q;2$]J,(]58TBK/X>NT=J6C4";R9D1=IN:/4UVVU@X9= MG,6.D\Z^M?8[6EA0&BZG,#`- M8>*0;\`-#$E0F#+>PH$??>H">J1WF\A@`,0:\AKZR-Z=Y#!J%*3P,U$M1?K# M\"&PYT),D,A08H0R`.^)_F=RQ,S)$0Y^_-Z)NNX3)QQHYTAHY2)N%Q'G3L^P M,$\%J3NRK-:A`?+;2,2P)2G*K`STL?5_YFB,.OV9O'6_5-!K4\:X8YK%056K M$+,=MF""%"L:6?O97KS'5XGF4>_#6M%#\S$YFNW5,[Y*BR/Y`N&)(X&-&^8] M\@D,CQ5VG)"/&PDYDDY0CPZI(X9!C*U3I!G]?$-!$[8PZH(XL4=:4FXYT9X' M;]UK*EP8,@!J7QLHPUMAH06I%/\C"B=D6IV"%5?IP#E4/-E<"$ M"&0&U^4?-L+2@&58Y?X!W9<$)A;+W=?""+Z"_W.J!#1Q^F"'P>/;$V$>ZNJ6 MI7G14!ZMB6L'=4<8XX=""@0F%%2[`F% M!Q*PU.?&3H.93V9=_8:U>/]07\PQ)47Y9%!S[=VG&8YIG4WW:I5EH0,YS\K) MA2ERY'_DGZD+-[`@Y_^5X7,4J/LWZ?VSE]`/7,9`;W`6I[U7L&9((75!CF/70,Q(8_6I3I;DOSVJ?^7;]18;'J7(]TWMDUM"ZJ M3-<>L>6W(@(4->J\+8O4+;K("T6N811<11GEOT:F=A\;%#M\%.30,E(M#;7N M^@R!&%C&2F*D-EY!$:Y$*)IB(S^GFN_U.RYE.9MNE-12H-#?%GH;2@_/1 M2P.5E2$335BTB9.M]'4)#6&9#3D??DD?3I$4`VE>9(#_S;+#S&D=%G6B#4W* ML@J7PD3HAHE(A&"LE3[[.IPCM6Q5-"!2&3*:L_18ROAE(.J#>;!_K%2S^> M?U]5D+R+E+#'(@M/AM;9]A7[.(-E;:[^R!&9WZB=M^GETT1WB& M-81KTV>W0$%6`K=CBRT9;/.(79[*PS&5+)G_1".?N2SL=LO5^,P9O'D,V5.= MJVIMB-16NX73CYQ/6R&TS![,CJZ-JH8DY9ANCHLMR*921&5*C,J5>:1DYS&3 M7O"6)BP.X+@FR;/4;C;%V?-ZPR6'>^,AE=_<C+VO`?!-=0?U?N0_M)8>?HI"F MZ<67C$8!#3X5"^S35]L3^<426[1PFRFS;>VBV MSC^0E<(*7LE>,$NHXA;>(]L*?LFK9+CLC\JE.%)Z#Y^CE*SQ1B1SY$)3LN2/ M*`;+[N@\DW-%VYK.[A;XU\R7A:W2K.F:^5$3I%ZG32!].:]_CW@A7\OFV`FL M!A.UU1Q5)38JSQU]H=&>JC<2I&P;2O.W+0U&B(KM=13<[Q\5J3)KO/$V5K]N M2"UIJ.!%.-:C#_;H:H@(5F]LY=-:O/11L%)ZC+F?1YU#,=>:S"45[9;&E!M< M'0:>T_B%9<_G27KI\:Z,2_N1^GO?9\VGZ4,'6(+1#U+&B?GWZKT4(!@FC-73 M>*\$`OBD@`+RRGDCG+EOB&1/&)!BT!%,S*.VZV.$(+\H5>2:6)>:<'F4[UHM MKT=J\7JH90*H45N(?V2_$@N"%ADD2`.JE1$=*(U)6ZQ'QB M(]5E'L+O?SWPOO2<>4]1G&;,3S_\/!B[6P=9(&AW*Z4+K9M'6"A,]Q#((3XK M[HC&'OGP,PY^O[MN1M:Z M1IB1LU&H`AE/6F!'OF:&[2);)!\0(;O\%ML1N.5\D?MODF_"F4'-O%(>R`/) M!2)WY-HE))F73KP208H+B>NVGY)\)K/%>1^OKS_N(QYFTN2:[G_UMHQRDG%+ MC=>Q`V%&K4G*Z8KYVD?!CG[3A'(8^W$.22UX8??U7ZH4\*J;\'SY-!^-SQS`+1.<^BNG"YK8Q%HK, MO42:"Y=/@M:<.R+9(SE_.##9JNY:$+E)*PC1V(&*6B>.#22^^.*'^Y2]T&,% M7,;)K9?Q/^[8TW.6@CY^]%C@1?%E[*VCX"Y.TY:$>T/C8L9JDZHKP-O$H-C1 MW*B,MC">)8%Z:\H_,B\*][Q$EQXKJ`8,>E_T"OR,V)(E^/ M%>EU*G(F+W,6A_OM(_/*TM)FO$S+N&_%RW2I;I27:1KT+7F93AG1>AG^Y3,/ M%P_$IV%(0KYPIUOFD4<6;[WD5RX+8I]B3>LC?$K.B_[&P$(\BA,U-GB4(6HT MOW_T;WN:9MIIYN"=H\8!,'N(4*S6*CA/K!*,$."4YJ[,_PNU0GQ7B8K^E*=^N M1E$N<1R1UKQ:K35.KQE#YG.^8"QC=7CCN?*!.OHXI%`^?W`X/6IPS![`N!*[ MPO#A(V/W#>8%=1:^`XOZ0E?LYQ]]EA_A2&]*[B7+IX[:T+:_5JK]M>7NO?%3,N#E1`S]JUUT@>99M8O_94C/$E!B-* MF/#O28Z/9,,B+_*9%Q+U*P%B^N$>BI\SOE0E&51O_88\///V91LOH62?RK*W M@:J-"Z/&B6A?05TO36-.`8KD"GL*XBT'8;(5AI22@'(>)+68,Q@G9.M%/$KY M0L5Y)AQR2AXP%<\U^:LH!]1<0/?:\C-Z_>I@.E>$Q0K"=_&!Q[^'6^\`_UJG MMY2KD)OL$[W9J.]4_?)6&!XWW!*@>8*B&FL-#QAK*1`^130#L:YX=TD.S__V M,O$!_P96>"PEL7R$3Z+VSH/7+@*:B$:G8;"70KBLN(:',_*!$\6XXRK%5#$+\.8 MDVWT^K;D@.@LR-W`G(F5_IU\>@8"8O&O0;%1?:TIBC!"I9%*>.N MM/:A78-AZD<6L>U^NXZBO1OJ,$S:47X*1YE3JA/V0L/."%!=`,LD`/G`0*!DXC3<3QI M76^G0:0B223-(F0$70FR!.@B"!RMJT8I()]*B::(7FH;$V+O1&ZY$`I$3U<6]-9`W0? MSZV9P7NLFMX`&(\"W;<`KFY`E'K^\Z+02&B5]>8N[5#3O0#91B[!SN]9RM.#PJ^!$;A7[! MD?:JK7ADO3AHFON&\3P*NZCJH21D]Z7;BR_4WV?.?FA.%G?>7DXV:*$#IRL MZ;E,G&P3Q!E."J9(SA4*A+2AIT:$K,J/#R'G4D;-9+"!D'?4"]G?Q23]$$?[ M],P+_7TH_WVXB+B&=@E+Z<]>N*?K+ZPVS7'$&)CQ#[#\5`R2%^!P9DAUH+Q2"8(BT4B"0DJB1%`EGX&N M*U`Y%UG_4S57C/)6@*6JEE'0(H=X2^!R))&A#?UC@'"Z;^5$'6V`\:$.,"1E M%T$9.OW4`FJ#?J:L9(]%"T,O^:=O_OS=+4WNG[V$MJQC>W?%#)X#%5"N8?OU MPPZ30\6PA8U>1H`J"00#(HN?I$!_[I7J3/HXL>V2$MSL((*6TU6J6T60GIHP M#7WO__3-G\9B7WW?Q8%?BPK:T:^FXR+AKTT.B_@GR.($0!L::3!\J06\$#BC M*DA?79@&P>^__^:?QX)@?=_%@6"+"MI!L*;C(D&P30Z+("C(X@1!&QIIL'RI M!;P@.*,J2%]=F`;!'[[[YKNQ(%C?=W$@V**"=A"LZ;A($&R3PR(("K(X0="& M1AHL7VH!+PC.J`K25QJ-&@@'JZ%_2O#U4DJ$C9#D/ZN$H4@_ M-O?#]$M!OG9:*PR9.JR@\4U2(]@#3;;M"FGKM@S\[12\!G@;^RP'<;M%&#N% M'P"T^$!P$`VI@N6,YA_47;5P!F[V=*"9,B$/5ED<7'++OHB"F\V%YS\#^9M-(5*=%D:-@AG/QJNE@+?A M0V!'NPD2&5IV[P1%R+)X?6;^LPSHCJT#BAAZ.:M>&$(9.N$-2!7@N21-$DDB@!&R`74D%`F.3@LVX"GQE`UH&";H]F6F5V%?.I M,LL:9I?%3,J+D#VQ1Q:R[/!I#RN@FPWX()4^_I!X`?=%Y]XAO8R33,[(#?JK9HG],^3#;;1R1-(O]7\EVGV90%X+^!K4! MLAB"6?H%"@^*3NF.^FS#^+_D6%#92K[>7,3[)SGMCA-2T?R*QTF9&F/D4_&C M:KP1Q1P![H2J*_Q!:\DA$2PB2&Y%J&MYK8*6C*UZ6-`\#E$3&?0$5G@/1CA0 MTRW#+-25=2FFCY]J&F/!3JA3)%,%@WI[BQS^2[?0;5LKY9=$D/K;GB5J6UW! M`97D-&P$(K),D=A#PNQ@+/Y";=Y#]P+2AXC?2)#&Y15F45`-Y!]/Z]/H\M^@@?H+W;/C**1"/`-Q$`YQ"<]/^?X$ M=*3Q9D7V.VC$/TPWGI]O7?BR.`*@O133-4#;4_HQ*,OGJ@I2A-/"@\.VU+"> M9;+-4Q3B*CKC,O$5S#/7A5C)1+Q+>)3-F:=P]M'ZE,&7!.R3E=BGLL2PD9?F M'*8+:BO#O%@\:TN`/&TRKWPC`_=3"&"1'/,%CA'$FW_J%$,_0*\<@:\``83@ M:M$`HI/8]_>):U?B\B=JJ_W`E0SBAS@K=J&?WM>:P^PIHZW2A( MP:.>GOZL9R5IZ\2P7UD8BEVL?(`^?FU%V.9M>S*[/]UH;U:R)?+$CGS;(CR: M3ULSZDQG/PS=MLL,&:[[]"M/Y9*ZC\6Q7D9\(P_*.HP+S/TPKK;?K[[I5 M;,CU-1-ZVUZPA]PS.T16OM#$ MX[[@5N9H7D!FYT/\@GB\S\Z\?4IELOG)WG#=CV:; M(&:G.HNR"\]JE1IV]SJ/\&9O!4F@R'UEYOU*`9W!4>H/KY]Z3A@33CL*J?\=V?+0XQF?R[[/C5AJ0KR7>Y%; M[SDW7GN_:1_2;]^-]_X!##OT3KJ_#]?>7PUFG;RXGUKO*JM/)[$K4XQI,NV_^.:=]X%S[D;EU%5P38!OA?K MQ^W_(DIK5DWG!^7-:^,&="Z^+G9Z>(WG#=8DP;?OSCN4/<.JG%/[?;CN+N%_ M1ZOR=/^8\F%%5E3\GXMSPT*_, MA)-EORQ@]D96_7/^4G-L`/PC^@V`\SU]B&7:`_]6ICU(S9C]F5OIO,U8H%NU M!KQ],Y&WZ\][R/R&UO3ZFALR?W*`DHL8*$T`17A%])"GMLF+L*"6Q3ALB[^I M"9?,V8/V9X5^\XPWR>.B/*Y%5;>MQ%N7W@TK[T"J_61:FW2=<(\*M!;H:ELG M"9`4]?(_',HV2MGK5R\)+K[0Q&@>Q`I#"T=F7Q`O[.>1#4(*9 MJJ/568:T9[UA[J<%WRNB<5X][.[CH5VXYH7]1HKJ"&,QZ(?58Q)>E-W3Y(7Y M-/T(2^?P<$EK-ZT[VF/V<'U$+=Q16V/LOJ,7[\;+#VTE#;*A MDA%UL`8]$;PI8U51Y>`D'YVHX0D?WP%`6A7W8Y^??PQP*=J"[L9+'P7Q??KN MR?-VG(GW/WQ+PRS-/P&(^^'==^_?*9!3'__MFG(NTYN=V#2(GM:/:99X_G$U MMN[62`&NIY@`;QU-'8-;G:WVY7CT*X-BW!4I1B:?\[%G?K=N%DDGODEGQAX+ MV:2H=["5\@6"-OJ)-EEE5Q_DMME+9-U"6SL@MM-^?(^=PZ65YG9[)S87)845 MX33<&*U=L8605(Z'QFPO]]D^H1]9Q+;[K5I1I7RQU.%>AX^R+-/NJY868^\: M8CGFWUL27BEX0N5>P`GEH0*9DQIB=ORG]%#QA4D0X,W2*?\S>A29IJXW@Q<30&+YR##O#H<=^X<] M2@/V;V:SU)W5G],-/+I'\8I5TC'68RYT9&CAF$UZJAB:&C$J&-:PK&FJ/@@.B-$<4*\*"""%U)E MA@AN2,F.\^,>W.KD@QG,,*V3E5.`I5WZ'(?!^HF>>9G__--.;W*DN&DC(44F M`^HI\E7'#8,]DW6B5(9R7+.<'/%DW?7\8G*JWD0N[B7S?VZ]7RGQ@:EW^YU, MV%9LI?G%_QUG2SPF!?^XNKOGK0(Z<^JK(\TV`@XI*!-.F@C:A"M0;^@@9=:1 MFAXJ,V[:),LGF+L`MJPO<`$O`S[`/8L&Q]C0%"F`]Q%0CQ/KVB$.^EK9'7TS MJ:RK(48EG\6X)X&8N^G)Z:V_L*8-V.;6"YND1V*VS5/5=$%3]9AC8[,51N;+ M!SXVKAE['F\]=AQ#]6F_O%E;%;5CWLK&RYJY1SP;GKMR=$<+7RS2.K/5CW3[ M2)-^VBG:+LM&JR*VV*=LN!S;/.+77`0D!\9ADG,+.?WN,ER0RC.4H:S9>;(. MO&U::VE#^B&UNL&B']]I;NV$?4=HD`P&]G]8M(F3K;R.SU?3F2^.+;*_V M!K.H8T$>XBT1#$'#'>>;!94+S\5U:-':V^W"0_Y^(A^#98<_0L$I_SF*P_CI M`(-P/J`(7[Q/2<2Y6ZT;Q2:.%3+GF+>%JBP5,.T/;H=K$<[KA.[M84VK2 M0L7)&U%PDI/]$]!JWD1J:XS4:OH)659D;6J)?8^HF_&QT^^J<3<(MFZ`&!'$ MB:0N,EOFKE1J37A=,B&J,$:'VS'V1"W$,X@N%[_M67:XXM89P6,:T*`=8;HZ M8$:97L(62-/:&CO:]&/>%N*\_Q.1#)""`Q>H8U<)QQ(*L5VCCUV1Y2][=6L0 M@&[WCR'S;S8;FO`I!+4YFK&GI2UFV.D2L4"3^%]0/HKWDO7:LVPU:%)L=%??[EVY*Q:_X7_S#_2`W(/_G_`5!+`P04````"`!WAFQ&>0.B M';MF``"E\@<`%0`<`'1R;W8M,C`Q-#$R,S%?<')E+GAM;%54"0`#8?P!56'\ M`55U>`L``00E#@``!#D!``#MO=MSXSC2)_I^(L[_H%/[\,T\=)CFY!',,P')U'\2**O80,,/KEEZ+AF8=)*_*7_W/V M<#,Z^?5X]4LY0H3^-CI]?WSR_N3H^./HY&\?C_]V_&5T?[MJ>$LF,86M+4.( M?OR-_I]G\LG1&X9_P_X+F'LWD9_-Z1_O7I)D\;?W[W_^_/GKVW,<_AK%,S+4 MT>G[52]F"_I?OY3-?J%_^N7XY)?3XU_?QO+S&8_N-=$D>OA`/''XY/_[4O>8$)C2F9Q'"$Q==(CJP$:JO M/!C_YH4IN`4>_>]L3AV(9(QC2)+/7;1&WLW(C*\1F0]X\MXZ;58;O8W,GYP" MYC#)9)Z=";+]D.BD;ILO=S0C]%V2YM$2@#,RXRE,.NJYQE&,T/,`0FK/$M,U M63X1]8,]/SO0=2"*/929W0B$P"?S^5=*)@3B<+G2N1=>XGU'7DJ,6!!TV:5$ M1S9#=_J,P1\I63.7KQU5>'V(P5GZABQ^PY9_GZD_><_ASOE5?M2:,T9G+O`& ML^2\T9DV]E`VG#/ZD54?Q^(S1V=2Y8:WY_S1F6#N:,;.(CWD]VQ6FU1.%IV) M:!C#MC-*9]H$QK39"NZN0^7&M\XG?@$2#X:=S!Z140=G!?;@AXJO#I5?)V88 M=C)(N>EUL6!M\#3UAW#"0151U!FO32!;1U1F232-9[!WJ#D[)\>WQ M#W4GF3^<=11V69LMXQGS@O7!Z;-A&Z?BP^I.1M,@EE#3!6>-HUA"3Q?=WSB* M;9[*[N@3&=12:KN@4VA42^GM@EZA42VEMXN+0VA46V*%NJ]:WF`VWRST.#%) M?L"*:)L>Y+)&DJ8KFWI)7-,\JOV_YO-`8$:#MVZ\9Q"^:^5(TUAA'&\,15\8 M?J4O#(\_93S;_$+_J3Z!&`/]\ZU^IICTHN)-O2$?*3Y%!U/T,K!"#GA+``JR M:++\KS"AGSDBDST:_3(J!ZK^TT/!*!]UU.W!848FE4[D;\PEI,]0H[AM=="_ M_)M'X?B9G"T]/RD'"BE[__%.K,M[J=D5Q&:$8N#_.HM>WP<`TN>WI_0?=.:G MOQP=%^]@_P?YT[_SCS^`&:3?1,F=-P=;4V4U^_>GTX^?CC]_^O+I\X>3+^3? M'T\K,ZX"9QQOSMZ+_?(;Y)\U+&U*JFCQ?I&]./K%?X'A"B#3.)J+\K*80"1) M4!0'(/['N^-WHQ23:4:9F\0+=R>;D(T)1(9X3 M`^(I"7LBPS9(I?KSH(712D@A@U.#,K@',8P(20$QEWC"V&CGA%3:*2K$\\&` M>,9DA@&=Y57HS1K$LO'[H,713DDAAH\&Q'">QI36*V)_>^%_`R]F+Q16TT$+ M1XJH0DZ?C&WXOX,P_-\H^HD>@8LD)LGXV)[;`"+**9>,YK5(&5+J;FY`\*2 M(*R0V5=C,LOP=$X4]2R*V0>?C58.2*B=GO),>F1,,O?II`G-&$93PK'U'*>3`U*3)J\4HTF'PMI. MO2)_:=JC&"T'+3`9FDHIF70YY//,C]]B/I%[A^,C>N^P&H[\^WQR]SBYN;X8/UU>C,[&-^.[\\O1XS\O+Y\>=5TZ M5$$Z]?!S-EZ*?YEYWB)'*@@37/YE&[+%G_^](F(R7=TMWD<80'Q!B<9T!#HZ11"NM++O.P=%E!$(.&N\(7%7#^T28HY M2KS0J#[('X[2$-*D^GJ4J$.F(F!WL10$TDM?DD)'-H>*AKN+D,]=^XUMW1"_ M.&E.Z7JNDG=#LAQ:'-'G-]![AB%,(*`/(.IOJ5N\!:+=K8%#5V=1+T(=4?<5 M'HCYDM@=K,&#$OERX;)'_J;RD'SO+>D)6P+QG#[`SQRL"TB-'N!A,'D.X2RO`L7'B-08[N&F M/_F.'#V$E/MIWW=KF-" MEG3F([Y!JPEI/^H`/*>:`-/-E5I_3#@L,^2^G&U&/B\.JZ&E=9#H#0)1(A4Y MR#:UA:D]I7A&P0W"VVKFGN2%*%1T]C`O]G$0P'SN]QX,KE%Q`&/Y19M;NP<" M&4(=\6,]T`1="`277HR(A83'OI_.TZP&8IZ^FF4IM'=T#Q\=:59U_JA`96U9 M?K#%LA2V*-W#A2"-BLX8IL^A;89WQQ`-ZV"ASTLA3C\S^45?R!AYG'>?\?P% M)-!?&QNM+_4^BK_4&_UEXQ-_?7=XN6?F)$G$,(FSR0:9.7T/XNR9MM#ADM79 M&@W1-7BK!YF.A&1L#/URJT9VEF52&`!Y:_>$SZ%+E;O!-L&W M&Y7"^<2<@("@.5E/ZMD7![MR.ZW^B"?3R0+$>4!A%@DR)]]Z`0C3*+((BR:, M.JDGC*I\;OT#'D73T?J+61F+C6^.BH]:[)?*2X>M2&*XHIBMC%QC14LOI&4? M7@%B'@\V&UFSJEO8O7$!U4Z!(XZB@L0'X$N&*3G8&D*U6 M0Y2N"`F.Q#L75A2:%:F,VM)",ML/4:'*3VICOT_4DCHNT;W<42V M-4R9Q;3Z.H_H'*94\\(1(_$1A"&E&P6W7OP#5!C,LAZ8'9R#C"2ICAB1WP`B M;`L)U>-@#E%60)(^-N3#HJ67<]CH0J\C5XXUUHE:HLZ!0(Q"#0&OQ@.?5Y3G MQGS5A@4X>SB:T\OV)C2T'*)\1@T1"EU(8I@%?80!0@+=X=3U?L.\*9(88(AAZT\-!K; M#A$`XH2P2S\.RS#8IO@"AFG"#"5BM'9!U#Q22F$/_7;Y=P!G+X3(\2N(O1FX M2^?/()Y,:Q&QO+4N-<80@=&?P!(N0W\]P.!$L5)$X\HE1W$(,E(DEJ!1[UTT M$7%>3^Z0IXO?N^_1OD71W]9?W,X>1"$$Q8*]C&3&J>8 MVA.UGUG!!!N-K%GV4J+83('32@\S,PB1:)=5-M\8*XA#JR,N1BKN""X!:.R>E+T:E M(R%]C/R-7!AP^S@)"7F*'8GOVT[?R,5%T<8H8[S)$ M,7=Z)?R_3Y]#Z*\F@8+[+,``W(>>GY'3J')ENEHC*1FF;XFJ#ZG&C72AE=>H M4)GM7)"I,%V.F-KE!2$(OD510#-KW)%-8[X(HR4`Y0Z67H-:`Z-^'ACU/&":[TI6?OE6:$:M#;9^;VAFG\#4\WY+38ARP58U M3R\ATC#)2(A!RY;.;+R'@I?CQ9YN$B53N>>Q?H/N%_0T\LP1G]#Z+C?T<'EU M*W('M-W>/F#UNO\1(H_I#3+C]T>O($X@(5;B&JBEE[U2%1)0TWV`/+W&C1%% M`*EPC+O#U!NZ!P,Q$AVQ0QY`5J/IWHN39667PV?+ZB\M++ M=`^;>]`;Q=QM8+.1=4+L*8^Z@`7H=43K5QG$U?KUAN[#0)!F1[:!LQ1#!##. M4AT569/9.I_1VCI0=%+P,L0Q$SLH\2C=4J_(-X`NH#=#$4Z@3U^IL9U*O/;6 MR4:&S5L.(VDZ'='732S+4Y,!KOIN[><(./K1ZX@F7^F\&\*#:_+/5G?-JJ%U M,.CGI^'3Y4S.%C\&'@87(/_?:U0/3G^(PO`JBG]Z,>OYGN0H]@*%+_,F8[\_ MX8[L+JK*%MN`!Q5B;=(L0H0KPL,"Q#"B;Z?BQ)8$;P*E@JRL#Z09%H*E@_I: M%G5`&%,3.;$7*0WHN<^FE95/NP,_LU_8)H=`WWU!36=>.'.]V,B`?#5U1-)6 M9^N@U%WHP@`288%+%@N+`_G?R9H\]_!+%Q1M#&`=DG:JE$09HN@)Q"N(GR,; MD96MTQ4;[B+D$T[0\"48E%7-.NQ\_`'W&WE=&:3A%89YZUMH<3;QJ)?Z:QK0 M.E`JAD]7S2C,*ZVE2DX5W3]\1S#!=9K%0-9A!.M0I5;5J>*(\1+$K&CW+-`& M!;][<>RA)BJYA\1.8^P#9)3P1)&[NX]I)JUESONIF%IW:\"B3JS"VD6,&8JV M)0TH&0?_2?-4_$\1XY4^H7*3EV,LND^I&]T:C&E42)JYI:C"ME808B;E!=G% M(@3/R>I1"Q]X74;<+[`IXY"&_/UKX_MX]UC##\"G0[/ M.@YQHVQ45F!!RZF587N7:_WR#<0^),RH5[SJ-(;C0%/'D]ZE%G:,FMP=V!,V M[$&LP8TZ"8NA1I(E]AYC,^9,INPSOZC;H]-`UN!'H]Y1QQAE!3M4*Y\RC7A_ M%'4;R1H8*1;X%I(4,L=XP$4'XR?[;9+-M)S`7CB/-%1W&D'G[6'03A*,`> M9R#KP*<&)I*Q-O+X&[BRR]/28#+W,I=)YFW.^7/,0!>_DW5(TJ/&.C!!584N M\R&L->+SY5,D.9)`SG8_Z\#300'Q(_") M2DX@\V5&AY&L0Y1.==2?,[T+PEF&NMJBD]S:-CKM%9:DF%#"QL*XFI7!YR$? MG$X< MOZ(`(0RM4?KE\RH1/ME4HP3XY"-9%.SY.CH'7X"LB@1\!3?0>X9AMK@414<;0"Z\13N(TB[8YC\C4_;SE M91ROOU)%7^]!]P%Z>IA4XDYEM(GQ6#V>DZZ2(*O+P]5J=\=1IX0=);[Z!A1L M6N"V(BP_D72'6+V_=1CKA09)O[8F/OM>S>5JJ2U2WLP>;I]U9_Q),ICAH],MH-0+Y=W7D M]0]X%$U'=/!1.?H\1)C#%_H9^ISBGXU\R<029$_I.1OQ8]$<@PRU0YNC<4A(N@M M&T(7^8[$7@S?^M0HXQY&Z=!QL?&$CKY_0SX,P0;Y3Y$@WUMTE(Y/[3=*=\91 M1S+*?_,@HDR9H$`3-^'F?C)OT.0X0#15_=Q`O_D9;@3Z7K`G@)^.:+JUL5@J\_>>4Z$ M6N,#G#IQ2$-2:^-O!:JKAMY0/B<7$/LT-O4^!G.8SEDF7UN_`\;Z,DM1IF*[ MX.;[,2C84+"`!;!ZRP.DY-FC*,FP9=>YWU$,O!#^"8*U);J.KF!Y05IZ'>#5 MCU5]<[[N*"(JNZ?(-OS+-[K?`_I"GIS0:<$^-"NR!K$3O[;V/,"H/[LT%#XS MOO75;\Q6_"T26K5XV<0'.$!0&=<4)?HT?6ALX`)]Q;-F+\8@8>V;8IVM`UU/ MR0M!290/SCS"J_.`6*+4^J3))@&Q#YY#5FI$D:[["")!+O1U7UD,(7(*7GBP M-!.$X;/9;1^A(\"!ODXKBV%3+IQ[;TE7#?4!DU-Q2F:Y?L$AK8MX@^TCQ#KS M18/[:GC!/5J">JR#X:X#.%3S3I5C/R(+SCZH7J-7@'7%H4D.;@UT%<6AJ2#? MD7M)LD&4^;KI,Y`8;`0%D'VC+0Q#?`!K4+0#=-2AV)-/SAQ%"=D^``&^(J)H M"$,109SX"'L.N9Z,TJ#BC-]!]1.`EEUVOT&J@7=N&X;%*W0]AJ'DX-9`5Y%A MJ()\#?%&IO?I,@$086XTGT>(EP"GM9\UF-D!%OA[LCA[''G<4"6^R/%2)EIE M;:V\+@%T[Z&^IJ MGSR'<,8]'$B,<`!='T8INKJP+$U)L\%0\H=&)4L98M6.![AUX(^BT-PA.$4$ M^:[EA+G?V-3`N[YQOG8[1?KCTFH0*G)OR(*E=Q2`8;!0'HQ10/^'>KI?O9#> MP(P);^)X2;C`*PDLU'>P`.E.G:+]+\_D0Z8=)WL&$$,IH':%D&-E6TUSLJ<= M/]M-%XLP8YL7EFR[1M,HGN&(K=0ZXM&^1F0&`"=]HW@"Z@-T,1V?E] M?(W\6S!_!HU&,:^]53)LE25)M8$/\EY\`826H-* M_4'NX>7XB/Q_AIAFFZA(&06/Z7SNQ\(_OY+ZK47KG31H/?I5 MZJ&I?C?3?,67Z6^5;X_6'Q]5OFZQ:JQSBZ'O>`U-*#$&('@X:%-8?8:T1CFU M"[2J<923/$SMDB7LO4]C_\5;IQUM41>G=761#3.JC&/QPB\-NO-H_DPVDXTG M1:SUP>E"P?#QZ/CSER\?CCXEOBREQG"FL4O M++ZM%\K]*!WF8J^7I+\`4VK-(%_4)_*QONBKH_[7*!]W])?UR-;?WFXSY2Y* M`//^EM_8F$NT-B?Q92_AFJYP07^"?&`A_E(XV* MH2Q>T.NY9^F_5C4L'T!(@T[.(YS@S/E-)QB4V6-;C/Y^@U)4??CR^>OGKU^. M3KX>G7[Z?&2H+J\H&6=5,MHT2,]1JVON],B"@X0&8==5D@ZF#?6RAA]YN?T: MJ$6#?:YKL/7XH]4'1I4OD":5C]BLVU:$5&9/#-A_@F"VD;VDXM1I5FR]1C)3 M4EQZPJUZJ\>0UB@M!9#8+">NF"?#-)ZN/!AG;Z)N@4?_.V.#H`+Z4E=`=+A1 M-MYH:T"+E/3/<4/,8V70[%YO>UB+%RZ''ZU+6;*OD21[(E-L6^YR@UBC`#J)=B,- M7W^ZAZDD+N>+,%H"<$9^G\)$_&[@N"$TL!QL5(PV@/N!JK.52/X!)#`_CHNH M!/&>1H(`R.SRN665V.\C,IG5)`L)2:B&KL/9I"1D1;T1)J"2_F$JB^(VXMZ+ MD^53[!%>^AO/:UHT1D-T8#'B*!MRM#6FQ6J#Q0F&KFAO;D)!L&8EKA,D1K!& M#8B*KKKV^](YS.7^"$+@$[+_E1*Z01PN5]=E%U[B?4=>&L"DLL[YJ[\A0K#\ MP&CUA.-3,(X8Z:&ML0AG4YU1)4-JF!\0Z6Z,"Q(1550`] M"!SHVD^?,?@C)>-%/042H\P$!A MT9/`$BC#]YGB9#)]]$)Q8+`Z#!8(4@25@A^^QQ0#PDIZ8W`!7D$899;;Y1L] M#0+NB4>@YT"AT)6R$A/F'*=J,''IQ8BP"M^#./,0B&F$EEX#Q4(7JDH<#-V5 M>@=^5I@51XC\TP>5,[\8,&2'&2A2E)!90D>]-];:&)RLB(=8!,[IT/7+^1_#/GM_1<0I"&83,=DH@$,4^IQ?@1^ M&F?Y4R[?Z`$>!%=D25(O=5HFM=_6S*V1?V MR:33 MG6^0[%,#:A--NQBP7D^R*[6V/];7=G-JZ4&L[.&GE5[M5LVS*Q-F3N('.'L1 M>(#2=3QK-$"'M--*:1ZP5EBGH992"9\8*J&:C'H@^D!I5NJ^@QD^5!0Y0QYI M"44?-`=KT:A/OSB$%6&^?Q)2LM*5&7T2QPZUW[-&'ZF!%..$L@.>.7=:KJ7K M'O_TXJ"B`#&--LM9AW$ZS_\F>8A6\9&]@+`V1CGRG*B)4U495#E5I'U>=L:J MW,![AD\%S%'TSLG2S/]21N/GNM$HD?]_*.;DH1#`*\@DU?KZ)6MECT;1E:Z? M32;3SC(AO=6>^P3\%P3_2,'X#;)>KC!'-/8B$99@W MMTZ*$O(0$2:'2N,''\8[U+/0\W\0`X4,C@N/30Q]HI5N0?(2!;=@_@SB+3&+ M=QR`P#DR6XN\)\76"A^B:$[L(CG!MW5R2^B=J'7DN+C>Y(BQ#ZX3,&?MV@TM MK8-!MRU;E#)'1+YZ'WF-%FF";Z#W#,/,./U72LY*,"GLV'5:/!'W0,]1+882 M'Q1U..G@A*W;R]KO0;T=$:+''O+O%P_-`+YZ`DAU\IY/:P1T`UPX8,LS@ MH\:2;E*>I2]USQ*CL-M`O$AN5'BKZ,U"!L$$/=#8SIC89UD8M?">)#.6-PK<0@3GZ?R!PBHLP]"NHGBR`#15-IK=D%.5 MM"KI,;8UBJ5WG5!][!BF/2M8(DQ*"34\ZY0J%#80I33XBF'KM<"OCB6G9B3& MLD:MR-<34T?O,/7&68HA`AA/7NF3$O`SL]/^2"%9P)Y(CTFTW(6#7&Y MC%;6"$>*EULB$"1KEQ)HC*MEMK-+"H+LY`IA@"&T]^ES"/V2`/+["3MXDM76 M9D&*!TM*46>K.#=UR0TC\)'7U"YA=M2-,K09CWUDB/([@@F^QC@%P45*R"6ZVRQRONRVQ-Z79EM7-4V&/)F>>PN8>"$E\BZE MFBD+EIM'*'N8B:_1I>>_T%\;(P[EAG`&$BKHME5#,&DKWX9VA$2]N_MP$*39 MD?*,YZ&'\8KH(IM/R8IUELES+PQ!<+:D+-ELR_"1]1[7!:#I98:M-2'IMDN+ M'JXT*\T+,$9!N;"*39@^0@)D6V8II0[#N(`9I;0K*B"YB##,`OE5&[67;R#V M(::@_X[(5'^2A4#@>)&"IXCZ0\F"B+(;,'*,6W#M6^F1G,&*0O*-UYUDF3=; M\*\;]EDH[AWXF?W2>,B5'<,9?"@AW'@Y2:Z7HU27XSE-[0YW.(,4U0P_:#=!C,&:RHY8#Q4I-2H"D95A25D4#(=D_'X2!$KB-%)!LM M]W*SS::20OA)HQ8AL=Q=PH81F\U4A M&5CX%A%6G$=$;<:($=[`;&>-=/5$#`B3;-S;JF8/>:`!/`@$9>F,L>^G\S3+ MPG@!IM"ON3_$.UJ#%#G!UC>'CJ0JNJ;9S!VY(&:F2)O2>[=B5YA MD!WIR<'^&JW"=->9]O*@X)3\K?BQ?K)1,Z@S0-/`!@UJ:@W!$V,0S-^UW$08 MCU\]&&;!G5'%'5F4!,@*`+$Q)S.*2R#K3;>6M+BVJK;"?%"KV@0'=0EUJMF@ MX8JI`8+6UL&4"^X^:0CN5E((2>FZ M./-"ZL6ZNK@^OT99GH[.#4(5.W;)5D MB43<=1O7K'#.EGJUR MX`FQA4)'=&OAV&U\7=#8QF)QMTBL+NQVPAR1\J%:0@?BK-IF#]42A(1IL\(^ M5$N0EMG6R>A0+>%0+6&_JB4\T$S;G+UZ];MU(N^V/?/I8;KAC8F&:S=76E@G M'CZC&8*Q6<&J$6J1E8DKUHTV=@J6,[>Z:-OI<46XN:N4+]QJ&Q>$VTJ/(SOE MH:Z0=%TA18C6$B#R$-`M#;T<@DX72K4&9PTF@N%$.(3A M1&L(P^CD$,2@.[_E?1PM0)PL[T.*"!10);N@$=F\FVS1[M9H$[DK[E[D675S MRIS_V9*FN^+X;01Z6B-=)7*KPZ`K"X:!`$H"]X9&H*=U".@J,@GAMU#OB"=B M12[7%['5:CAP:!%B'0XBE#HB^JLT1C`+2D'!%7RC_\)<%+`[.`P(2:(=\6$- M][9'L6T@=`UD1V#&X1K(025]N`9R6;B':R!WMU#F]M-V*]3>T3H8[.I`+G29 MU/=MI+7`^8[!-`UOX)3EKA/H:1UT.LI:`C0MQ`^T^$Q_[_^:BVW>_UHM*[7> M_].#]U^W]W],9A7`,*6W9.O,LI=O?I@2D5^1%7D>S1=IF;>ES+=Q#^(L`;;8 M'8&*CUBCG[K>)&AC@E7>YIY4GBV;!^!X'#1^T1K,[1!-=0COFL$#P'/K*\2V M;M8A:]="%H79?CQQO)POPF@)\K"F_!4!_]J%U7X@N))^!BE'L".H&/[#5T72 M%WX$.W374![,F$"R.=^7$\\@S\5`2R]74=&%;$<\03UWZS9'HZKAK4/>$.UG M(=?FT!5?3Q[E>8;TH#D?VSHH:T65"* MYU2D@Y$3VS;`^=-G-;=/K4AY-Z7(,GXJ8Z7_2^$A>;3R$K)OSZXE>8M5@/I*2?Y3$4Q#CX3XJS:FBTCMX+C6RY1M]1 M#+P0_@F";^3(2EDP0>L'9]LGJ\[C#!LJ:LG6^C;OV';],, M&UAJR5;E%8H2+^R?.9VAA2X`33*$V@R5AF;6B%J%J2)*GXM5%GX'M+(1",:T M0N<,K"H"9Z7()VF"$W)>)(SEF2I28UB#'"G1-UP@]";:+D-%#9R(YHRSVDM> M6*UI/TZ2&#ZG2:%)O;#(:X8K14$9X.HQHBM04\V"W20DL$*/%5MT;57*:3+6 M**X`3`79=AD\>CQR?'N9T=H:D/0TE;J0N:L*0EJ=^&.,07*?QOZ+AX%CV6;+11.=Q0*JN8C`[^IV=#DC0N7/U*(8;EA$ADM M(NR%6"S\6'0@:Q:_B`";@XQ[D:HA\!(#_]=9]/H^`#"'`/G'MN3)G_Y]`V9> M>(G(6EPVA/HVM+!&5HIEL!:N*-$&I9;/K#$0=OMG:^0ERM9-0;228NOEUFT: M)O`;0!?0FZ$()]#'Y(3"3MS-:V^5#%LELN4WDB;,N$159:`L"BP7I;,SGRCG M.06SO372UZ9QN['`JE0/U1ES'RC4&]HG7RDQU,4H2*(CZ_P!$/L0^HE(P'!C M6^OD+RB_NN#%R7-%]@XDY5&LPP]5&@[I>0X97"S-X#)TX0KHJIN6)Q8R0U@' M#7V6=U^NN%0VX!KC%`07*2VO?`]B&!67.U7.,`]Q@OWM@U9?!#0=Y_HP0TOI M`"6N'0%6G4=9*#<]0Y%?8$!CK$B;^R@A?X)>>.\MZ0&KR1&D;G27,;8+5CGR MQ(NQ#&G=/=!=I=6ZNXPV);S0ZUJ M;)?AI9]1CIAG#?>S#`5?%IY9,K1:AY%<1J!JMA1X^SBL%'YEPL)JKD*Y4)8/ M]5"6EJV*&$M#!S.+:\NVSM1V'SX0O]?Y\_??YR?'QZ:N@AR+X5Y.DG M(5X,C,J2/<;?!QWJ]QSJ]QSJ][2+3$+XMM?O89R.JO5&)E-B;P%^B1ZQ3L,! M@'"!EAZ$&Y>]&I5Q`XB91M\]7L\7A!E9$`6_@@^GAX,(Z4JU(YZX0VFOK4<2 MXIIAZ(GC#K4G#-6>&+K.N`!DOC[,Y$?^'8(B/=9X'L4)_#/[.P,Z(EVM`X^R MZA.=J=?ZXMC0&STF5[_%$996/5DG=Y'3@6Y'E,W8]]-Y&GH)"$26#Y-1#$"I M&MY=Z&GE4%]3ZFL.4@1F='XV&E-W0-H?3;JX"R=IJC7<$^[Z(7(U]Q"E-UE> M@"E-J(C\I=QESL?Z94YU\/\:YJM6)X%ZDL)I;(^$.PA&1[`!O2MG?5BE[K7$B//$9F?DXG"Y,KSLVA0CBJO-[1&ZDH5N2"='&^<82-]DP!^ M-HN&IM9(55(@;9)T7WU3]^)DFE/-CUJI-;16P4*JMA?)5 MU/WAAWP5AWP5AWP50H*JBW9O\E7<0M0NW&H;%X3;2H]5P1+N)TI5LEU*)D5M M>OBGI(;'(4/JME1:23&N2QDW!N<>(DVO8/+G#,1>&(Q1>'7!JZ#=5F5_GSZ' MT)],R1P@FF5;%B(_A"$(\A52_L36_Y)#6`<-%>+=VCE4L,16Q.0K:45;?6M@ MM+)&[DHV!1DB"TE^[KD=",FC\:#$;&>73`39R17"`(]/]UG-7G`?>GZNA$B3 M$XZZ93>W69SB9K/DT6F`!:ZZ2L(LRUO9CMK1-INUCJAI<< M=<;%JBA,+J\RG:4$1GZ8TJ*_XR"`.37W'@RNT;FW@(D7X]#C60::/%E!# MO2/67X49HI!Q&Q+M(A]Z8J`'D+WVO_=B8@%7O(9GR^HOO/@\X0&L`8G:`+Y^ M]!)Z5*.;+"%I`EL"2/:S?T M&]0:)&D$07^D"?#,ULWK$80A/7_3:A\#E>&#=L&.(O'+67;R#V85E3BA&6PVIKC?#5!>=(D5HN M[;ZILR1$Q([48;>V2TQ2'!:0S@#WV28R)JCY;6=[!_O%*ZY;Y0D=DHR??G(> MN'`[N"YC/J'&]U#51SIZ,0*(!9(9('D]Y#1YB6+X)PB^(T)LMH,5R<%"CWI- M-]C5]FA?PY?L0J!Z-X)>1I5:J@[A@0&Q3K.@PT'9EZP!XJXQI!2]4MRU=8_- MZ1$WHWCM78*5E'"W=F=I'@T('%S[B]?^`(Z./'+%2<$W(48! MY8KVFDTX&:_.=!YZ&$^FQ;EX$C_`V4MREU*E2M8I328*$PCPN4=?@IXMRQ#; MHB%+%?4?D;3X8-`FCH-<:6* M:"V]]%&11KD`V2M;^`JNR'I"/O3":X23.,U>W)8Z=?-%R'<$$YPSI$GS M]!QR^'C2Q@5.+C85QI*I[-1-N_DD37#B(?IX1,8:JG0;/HYZ4#JDO*<+SI;93>!/\@VBN2Y2\!1-7FFVX3!**-LFT_QBCZE+ MI$<:/D14$\^.`+)I[RF7PF1:>85?V74+RS]W1("8\J<)-!V&<00QJBC7"#"8-@UHMV'CS`E%)?A@GT=R\T0^F3P%5EFQ?$>?V4-W(%!"TVEH/OZAVV[ M06A"_P/$/ZYB`*X1@27`B:2Z:.KN#DYZ45RB2(^OV%0PCF1B%LJ]3-2W('F) M`@FT:?B2.\#<%7-*#.L)I+9(#99&P&]12/@4DNEUM)LV!W`'<3UI+H&DQ^$] M3&4HA3DMWW('GKMC3XEDIYSEO-7]!.)Y!T5(N[F#KTZ4EE"Q)B";X>DJ+Y#Z M>TB[C31\F*@FOD1.7\>Z;A_IHT=?H1?N.7HI7O*@B)O(PX`1O8=D19E(#N$( M5E1078+$=D6A;$7H'FET@LH,X@@TU=)=`L=V9VK@2?@?T M_X)@3-\HSD!+W+V\4NDXOB,`T\Z2$GMZ,EK8F$FEDJF8"K+E:QRT;82&^7S9`UT/!QHYCV,E-A7U^ZD=%$K?V&#Z!^I)9X M45DAP+BCKSD!_YAN\+.,M_ALN6Y3/(L;__3B8(MG^!KE*Y%G.[1&=NUB$N[@ MV`*^E8NBK_=;^^8[GLUB,".,OD;D0UY8NEB:<-G>8?@8ZDAC*6^5X="*RL"6 M7M,Q)ECV*?]GY+#R+8XP+A5^XYE0I*,C\NY.:REWE4YGT];1ZM8FSL--`^]/R,-T42PU?ZGT(+:6O)S>&H1H4%^`Y6:>TO_)\?OY)5O/A M(Z,3A24D=`7L&O*Y;/*@^J8P8VNPMK6$8,(;P%7@2--<0DE7B*^-N?['/K&^ M<)88A!6K)]S?'2#U([DL+Z++#6P7CO(77)UA5.ON/(K$*"Y!Y)1O>!W5V)#] MM7Q1.HG/0P\R"XE*C>$.F/J372+*[CS+*P_8P>&=J2]Y@U%V4@/$S3F+/WW:.MS56$VWIOX`@ M#`BYQLZ6C^EB$4(0C]\@ MTQSL-:@U:.@A8UY8F3*>#!I()747T=R#S%*HO0:U!D@:,=`?:`(\8P+->'@: MPFE(G_J.9S'(C+%;0.VKYI`T1N/!PT1`@K60-1E>V"K^@A4"LF]NN8>"EV!$ MF>UIX+&)JV-:OF73F&["4YH4@&._\/I8@QJUYHDTR4Q\F"MBNYHUUZAH;&N- M5+L+I"Y4<4J-JW@U,"CN`QLW@L8VUHE=7&1U<;=39ES,K.)H6<73F)RU:>+; M\E:7O9_SVELGTG:Q;&W2TM09%ZN:U?M`7UAQMN75[]:(6.D6S">O?)!MQ7:; M396K92LMK)&6&*,9@G%_^=U"!.?IG"O6C39V"E9(SXK3XXIPO;=VX5;;N"#< M5GJ,GW$9]M`3Z;%.6-:P)3):62,T)1NC#)%EX'K/[5%('HVG2V8[NV0BR$ZN M$&P^1[(.&.ES"/V2`/+[">=PP6AKLR#%/8!2U!D7IV(?X"I4H\WQUQS385SH MRKU]?#K+8!.EP6I*UG-Y*!ZC($^7]A"%M(XO3G/1_72J?$_<; M_8MT1MRBES-`Z$.OK0>EO4B$K%OP8ID@NXK^:RYZE#W5H47M=HB`!8P[R#_K MM4?29]/+/%5WDKTM3S!W9S$<#Q,R_2A6=&K(;89+5(>-5HM!+DLS(Q9;]?#6 M**-^1Q3='!F4E2)'MR:`60.LG>!#/1Q-'9I4Y>A2P`+9PU6GT0\XU<=&A[7F M_M6M&"@^]1Y!]?FAE9`N=TKM-/H!G_K8V/>0;+'^W)W5:?*D/#PX&CIX:[4Z MF^M-2Q^P^<-8HPA9SYXQD#4R42EL<1+*L&?J) MURRTK-O[+,+6L;+SJ:%M;1P$,)_P.DN)_*[&'<4:;:5A4Y,GW%9S_(98<@BO MG][F";WO/=AX]&.WMD;:*H6V!05)ZA5M/QK\`]N$/$1++TR69=6HC7HQCUED M)FU^C?QHWIA*I\]X^PB:,L$WM]@$(PG1;X%O4 M&-6P2C<'_)08.Q#@L^(*8/*PID]"UVI@\9"YC;=52? MRD*CI>]>8:,++TJG8M\29LK1,0[^D^*$*L2G:,TBZAR]1N?>`B8>#?/?/#B, M\5V$?)$CF;K1]P%AFKE58G#H;W2SQ*;9PF.-(,&EX'M?>A8%0+H_ MNS.3'9R6TLF$?`N2ER@@&CS3UK]%(?EK"),EK6C*PY+J;^T3+'?"NQ+AYF*/ MK$#V`\0_KF(`JI5Z]>"ZZ4L'5"OE7(EI<[$'5F"ZU`(7\)68-RC0KZNK7SI@ M6BGG2DSWO3XPC>GO*`9>"/\D_/(@NHF(5-#:V\2Z)VCIM2=8Z\*%$CT!I9=A,#\_*]C4174O=EE7$3 M2&!^7TX\(YV;IKJEEW68$)1I`Q@Z$.H(,O16;7)/ZPN3['#5)AO6NKQ`ZD(5 MI]21Q5X<6#M6;;)![.(BJXN[G3)'Q,RX'^6*G=O'*1C(4VK\:8JB6D+4QX%` M<.G%"*)9<]4O?F.G@"!!HO'G^V:N&W9=@]P=)+.74*SI@[RKMJ/XGC(.$A1**C9^T&4"@ M45U`Q7;4:2!'P*&.=D6&2QFUO_>OAH:+*.[H$'B0I`F16D3 M-%@=ZXD3Z([3A!S[$^CG40J8H1C:^@Q?K-W)-)[Z0,TBWHQ-J0:4K[.M,9:W M2-?A(Z0WM<8S&.@`2I[3D29S*/Y:,@1?$TG&P(M9QUOI<5R%4%?2C><]4(.G M%;6;7&&@AM':'6S($&@^N8$.E7+OQ9,XXU^0G>F(6LTV9B$]PNKL#D!ZT*LJ M$<&F5:H^!?.VAS#;?HG9]3&]TE"H8UDG,J..$^30`DIID\AS"62:O\V@^CU#^[30P86W%,"7@H\XB39=?#'_7+\S]AX7P(=3F&7:2.=@,JWP M@Y(-`K)$">&Y%[LW"CM_;F_PJ)9#YA_==T:F,LVWS]I-5H.9R[&K\B%@QH,\ MPB@S07'Q``X$QZQ`A[9^PT=,/U)+@/3U,5L0'M-,?WYS)HF/HI/SX.#162*C MKU.YUUVU#B=03GJERIB0]Z?6RQUP="&T1$=?%W&KOT=__I9)-O7[T$-%-I5W M&])B9FSY='3W7N8QJ',G'0E#9&^?C6 MJ!TUD-F(>]#*(ZM2FCQ1)3*97A,%^PJ#U`LY#]4:VUH#@]T(KPX6<:[8+?C? M8?*2+1DR*?P"%T_1)4IH(C'>DS/)4:P#B[CP!`3?@79'G@]=P!CX9&SNB^C- M1O9#H8,XFZZZ6XEV!`.YXB1?X>P@&VVL0\"N=XYV;EB5`Z<[4]:$HH`>1NZ\ M.1!\R:SN4];!K5W\#9;IKACCB%*Z+-\$K\_7W#V*V=XZ].P,"740RC')$20] M4+YRMK;5[_8A9F_MPJVV<4&XK?0XDF"MM$8XVVRUB76BW?5.V\H,SBO? M\G[KQ*RHN<=`RP]PK>QG2\SFDQ?K3>7:VB=?^4`IX2218C6V5H@2J:&D:+-5 MG'E*I&M$7_/!5T`;\$7*[>"`6.7IK7>_PFECH M4E*&+MS)_L]O`">KQ"FLN#R5G[`/S7K0I1#&HERT=9?MKB5R`P-O5@1O-+74 M?F+_0+HS+EJ0I,T>2>#_7(8VJE"_K._L'[MVR4E'R.7<0 M_NK!D)I[5U'\C>;/T@ST[<\=\+X3CBI*IM=20'3'X3QA-C@(FCE)J_(BS`HR M%NN\O^CLP1\-1S?C6.O,]\+V(HMS"F!"ZP5?H_R8H%K1LK^TORC>%3,5Y1E4 M!'FIDUZYFQ04Y\_<)L2^J3B1F6:PLG'W#Z)Z66<\':(4!G.2*(7>#-Q`[QF& M!/GB6&ON?\!4-Q8YDB&QK^[_EF<3+M3^MSC"RF\1V%_:/^SNFIF*\C;J3L*F MEAW7*(DAPM#/LM1U\M7V^-[^@=H,2U4EI&QRK M_UW`0T<<@,K]>.U?/37HD%HSJLTA=2KAD#H].*2&XI`ZY#TT[WAR/N_A(5N5 MMFQ5=@CXD*WJD*UJ:(;W(5O5(5O5(5N5A=FJ[$C`>,A6Y>!*/62K4B=+R<\`<$?4N1>>3#.8NS'&*?S/!1_C();D+Q$011&LR7C;FN'7[8/^]8_$^K)W'W7 MYTWL>X#XQU4,P#4B9`&7# M"MKM"A+@OJ*4;_;M0,_MO'R6X25-"\G-,JOE@X<5PU\QNV.ZBTGB,O[H- M%H624)19SGR^6J'G*W<1>@68,HFR$3]%B1=6?Z<1XW=1\M\@63]N:?'":O^N M.PM(U@=KAK6.Q&9H8UXEBK37*\Z^W[9N79B!ZPZ732OW=_,BSY%UE._:5U%< M_(FV8YV.=SN)P\K:]BEK7`8>]BBRL1;;?/"9> MG+BR"1S2*3NS%"13++ME"]$S5IZ1_R*-5S7_,G[AZ@'L\@W$/L3LRF'2`QU` MO`%B-?SK:[-\S3&*P(QFM!CPY<6A0HT]T-X1@_O>]S9BW[R&=LA>/SZL`MW\ M571WG5OLE\B995!LF_0=BM9E4/O.82]0N0K$V&M7_3([%D!%;%M7]Z5%F07$ M4)%.=^71%)R(.TO(H+>S#Z_W_>V<'#?-KAMW%HM:#!M;7`?'ZB97F8^$1<+, ME"PT=3,X+#9EBTVS4)QTWO;E:S!==?+AI>*@URF34X,$TL M-,EI');:SI::"LDX^]II#P]L[OC)73FQ'3SK(BY9`XM,\.N'S MS8;[:7>61V?4:MM4Y!GOXA,QA:;#3E8-\WN'I:+WC".^/MQSBS^W<_"YW8+= MY*#R9$*M'SRL$-8*V1V[M>;;^CS,)<(^?3X`FG"<_/T\0IE04R^D*9I.-*V= M#C,Y+"H-BTJ5'+2ZL4UFB%2CL`1YNX.=2G0FA]6F=POK)0>M_@5#YI]0UH0G M[^T,(#"%R0/P0IH3X8J`I#QF3J:JLL[(?,>=E2+K6-L-*S5XEW=0L_T"Q/"5 M#/$*KB#RD`^IWX,HFS2[6/[=B[.XJ*+J^KL-6#`KN7\^.MZNY+[^S&CUG5'E M0Z1)^:U5C7?;*[RO2*K0,4;!/T$P(PIR[).?B"8'>,T(5GGW/B,9J7&TFC"O M0OM6*VOTCP+!;90U$B#3JDK:ZPF?+>\\&A;"*737W-@:6Z5N(LE6!K M+?.FIA9+KU4./"'N1U'Q8I_DUI?;:&.QN*6+?[<39ES*U-RBLOMP?%)(COZE MG#D>)QN!"J>_'ATUBE*LDPNR[4&I\>RF].[ M@/S$"?P7!/](>>97B_D,%Q[NNABHD<"O.T^&S=+=1Q``(7U^'=*;96^!!%<^B%G\GT_(5ZG1MV8DY+ZT0KMPW+4L:TOS0)HW%3Y;:U1B"R MK&T5R@#WTM+(KV<=;#\"L?K8+F#Y(Y`4I<9%K<9^+GA5H7E5U6?M5U%,?@-9T,L-])YI07#8^NJW][@6PXD/C#JD]/#" M^(;".,E?X@3.:=+R%=F3:7%^;3K$#R/ MYO,(92^2[D&PKKS.)NP\]_#+)"[>6N*<;!!3 M@IL0UVO`_<2;>I85:/MB&]KX*XN>>TR?,?@C)8V+_FBF`XD-GSF`4R-M635\F%=J%9^>VP: MQ3H,R8=*J*3MBLVF0X37IE_=Q'RTYA*1"!DN*&7XUJH#Q<4Q3%HVI;&P7]2G.3.LVB= MC_;>@\$U.O<6,/'"\K+A`?AT\<`I!$'N:FC:LOJ-Z#B0='&H;R##YE;WU)B$ M]\2,OOJ.XB))ZS;=STE;JQ`9% MX0S]3*6VN*J*>TPPZSDWZ$I^N`W>?1BNUTTD MT-,:`.Q&L!P@2?+(3H@TDPU[,=!8S!SJ"]#L, ME%-IH)SN.5!X]#L2=%PF'YM,5PR0S;8M,\1>0*DW0XS?:-KC$KQIR4NJ]!OV MHG/7]KZ'0$*DX6RNL=9<,A1K,JBCQ(O-`B+ MBGJ6WY_$.EL'&!.;5`]6.7)VU!\H;0.V>LBY#IHNQ&O8KHR_T.`SM9-RM:O,Y-B>Y^J`ZTXS(JEUE^&*F`VO"KN)/ M')#,S6^CDECW"V+3*]&77R`_3`!"&7GHQS2G4>E#5_?W#LE%L MMZB10-^4/PK2M!P,>Y:I:3CUR]!72`=V*RIT:B"YS`5X3N1RR7RMYY*A@PPE M<4Q&L&B(7W-CBH$/QQ\^?3SZ<'3\]?.7KR>GZ&4=^?/ M;&_=+BO!^*;X'QDRK;J"W9PTYSZ^WM`Z&@1FI$YS.EN]40^QM'734VM$WQ?C2U, M),?5:#K8>HL$K@IO;FR?6$7%TBY1]Q7Y(SW\@8`2S-7CM7;6BUU*D8N1YXC, M'SPTXRGOU>_VR;BGQN93QO&<&U;3V;RYZ[/2PCJI\;G.D)+[R_`6(CA/YURQ M;K2Q4["MX@YN6*%=&:^L$WG=S ME:%340T-NQZN$@/TJ3!`QR@H[NAO@(?!Y#F$L_RVY9S[`EIJ#.L0)(.`YL-7 M/]H5[1VO('Z.C'M:VEG1"T-["1Z=FY)YU%PCH@\!3B[?%@#A[*Z3`9&&EH[A M091"%Z.E-CE'MG+06%^UK;ECB)`B4ZM]HBHJM*P/=.:A']N;0;V!(^(4)$Q1 MB(K%Z[K4<`]>`AX3&E=V#V*?RG#&"H@0'\`1L"@B7%$QK4T+H8<^4'1YWU2[ MOEQ9F4,\BV4[]\(0!&?+LH9TT9`9J=%O5,>`IX,;BDKB*MJ;-&+Q\HTL2XA! M5O]N]6,G`+8,M0^HZ\*"`FI?[(`:PPPJ*"GHHPXK5H7EYI:."%^6PD*V7^VP MD!BRG<1P!LFLLF#D-6B;A,MHZI)T94@L?6%'5LOW/@8+;YD=R`#`3`.6V]8E M"4O16(I83_I'52(FI^PX@7\2(YO^+WV32=]LAH2^[POZ/J>@MTGB@EU=`D`? MDDL\J+Q>L^+0*^T"WRO7=W>7][%3;L_R6'_O+:GA4UP4Y;E$^'F'!7HZAIFN M%)?`T>,8-02<6R\ISN&3:36*D+VH6MY1=1_0,9@I9D2)/J>\NF(WEZN=GW"2 MG."1#Q$N>?H+P%=Q&*'GI=R4L^`WK,*H895TOE_NPSY&H-S%&K>7% M8-E_`R]^^AGU`K/H1PYHUL`_1^+\5'**S(OY3EGQ9PZ0UL)!1^K3*>35590R MWWVJ_B>R0+$1/AH1G,O9=7XIGF.&\S+X]'2RQK=(""8Z@KO0I95V1]6]([3 MY"4[1',>%38WMD9V?832Y%X3)M9RB7(?A+.:6R=5"7F("-/]9^&9?YC,^P&\ M`I2"1Q"_0A]C7TYUX(B:9#T&N4<&,;5^0I M3IQQOP8K$AS\_%]TS"5;>%M-G)*="&V.G-[9]LE-RS-4@9[6@4*--=:5+>$X$>.30(+DX^ MG'SZ\O7KT4=#;\_)[/*'^U7D\GPJ[`[6K7%9_M?7MB2Q5AW)&^?.\;,PVULG M5TFI"(IU&(Z6QJG?>7-^`KZ67L.0L(3GI0N]Q@_8BC)^$6$11K_PDWYM-!J& M^%O$5P>!`)&.R-Q%?WIO)2_O2J^?U^P0YL&5?G"E'USI#KG2-9J";`4.*%--=.2J:T7/?W M$I:#4NDWK,.?9NAPL*J-G1JTZAKH7ZT">I8TBE:Q)U\.*W1A&/SWD2V[4$@/O+TXU\]"N+*9:<3Q)7D`\#OZ3XB1[!",' MUNW>!T3V8936W*NF8;B[N6T8?3(#H\OI%/@)?`4; MYZDF?A<_23EL%(UN'4R5>&MT,L?>RF'-5&^1ULE!HV!DZX"F$R.BB.S/02UE M4(SOP"+PHVE=S2ZM,YM5\C+J7>AZ,#0OLP2I'WI]7ZW/%#J36KVAY*G8H]E#K=RX=2 MIY^.OAY]^FSLH=1Y-%]$*$^35%.OU%:%WC.M?`I!6Y+7#B-9IUAD)597%JJX MX$A,5HT%=R`IDBMG15G@%/HBGCSI<:R#EBI@U"&GAC>N`D[ZM;?$"-:!3`T4 M!"!FR^OPGOZ+&EV-GG5.(UDHFEA2_JVX#*1; M!OG?G-LH*.X&\>,+$>(9L8*#:H/S"`MOG@H^Y3QN=\X\1]YGU+>*!HW);[R_ MV&K5>NI3TQI&Q[>8&A#<:C3@]JB$B3[JLFB3[Y"ATN]6=!+#.J2]'H%T9.LD')M-Q'-,-C^B]/Y%^8,(5:P-QL;)*C6"-Z>>'5!:^"=N/WX6J3LA(V7(!7$$:+C)=K M=@AE:VWI;1UX5`"@#JL^W+`*3ACXO\ZBU_;I@"Y3;8=`B ME:=,:_ZC8YVNRAM&VG&!'M;(N-]II2NEBO2R^5NM^Y0H+0^#R7,(9YF\&.Z, M>L,!0(`OQ+J70I!(XP:S3O]6<>]V^>:':0#1;.S_D4)"TC6ZCR,?8,P)Q>\Q MHH-H4LT-169_'Z7#V%WN`=FP`GK^C,LKW$J33J+T0Y+_:FZCSHF`1+NH7,79#9GN'@-2-5LZ1R7`" MQ8(.N@>SKO^K3=R5))L\3J+6FO`,QU.)EKL^KI>[%@NHLK[^]=!"JBIZ)"6' ML/P_RLT%,V.K!+I9LU3[!5EUI=2J,!W'HJVZRJ2N?`]A5X>PJ^&&7;7H]')% M_`Z3EXL87WFD*R3$W@(_]7W(OFV0&L`Z6*@-J%+$$%NQ0A1H$W'7]X^3;Y=W MC^/F,KHR7?/WAS$ABALD(MIWC[$AQ@M;W8H,HL@GSJ-X M(0V,C7Y[#(IV/AAW[4GN(^@W^!H]^C%\!D_`?T$T>(,;V]N;E-$="*(;T#ZPYM#0*0><8+9.PVT#V!1 MQY@"4%^&"*@K#\:O$/S\)_!"HBZ+^S=I./&&V6,P2;.E@-)7JZ&4A1]A^`JV M2;Z*XGLO(?]X@+.7!%,.?/-@X*'H*O((IQ\BC#FN.A7C[@/8M/&I=.P=:8&? M]*V\`OB=1V$Z?X;>^A&%&OBQQCW`KP>?2OBI="SO;"/]5PIP4CEG2&^AS0/L M`Z#Z,Z1$CIZ2@.K>4829*5EFPVX\L":$A>27*7CT(4!<6ZS/>/N`*^7\*6&F MTH6],P5UD?X`:S5,X\HW_E"8J$M,P[VDE9?\X/L`0+W,*M&HIW:?9C32IW)D MOF]=G.>UOGN,)3%>E%"QVSO.#X6ZX3TX%.QJ#5`4A7[UIMW6"_MMJ.=)0N_) M858DQF?=>D@"YTNJ)8JGA61;0W:VR7B(EF3S6]Y[RXPH?`]BGTIH!B;3XK?B M;0!7#708;F^0TIW9\2R9QYMF^2^E! MBR@XX*=Q5N;EW`M#^JZU:(>+AJS5WW-4%_&EDS6*HGHL1>/E&]ES(0;W,>'] MZL=.$&P9:N]PUX4?&J*+E&QHX^`_*PN8>.%5%)_CE/$(8!D4%F*9M4-WH+H)L%RQ2%(2TB#"D98`,:KE'+UQE M`+@#K'1!6ZUH7$!.H M>B&N_#T[94QBRJXL'1)@%K+O/:[3<-/"'!VQ15K\1K<0P7DZ'R.4>F'AWR"* M^0K&./EOX`D],FT;PT7XJ&.$CCB@G4'E`?@`OM*[FRSA5F_8L,;;:PA),45' M<-#.X-05-GL-CYT%[UB1J&C-H[9$1:<=$Q6='A(5*4U4=#E?A%%^8Y)]$J,Q3!SALL^6@!'+2\->G#C&'AXS$!K^#_\Q!\)L3)XJ.A M\_[B0Y09QD.9%.7BISSDV!2KWZU!A'H[@D^CAH*!/<7%+_^Y;F&-R,08S1", MS3I:C5`+-P17K!MM[!0L9VYUT;;38URXC`WX`7@A_#/C[EF$4AI.XJ=A_M_+ M2UJ^:1%##'[SPK1)L78:PQJ!JU.^ZOC`#`/=N;@;2[MV',4ND2L15`_A-]!ZL&!0RCC_\^J$K-!KZ M[BTV1'EA_/PF`XZ3DU^_=`5'0]^]!8YXZ\4_0)(]A1'Q MCJCYDLO0VR'';+6%.2RHD$3Y,)]'Z#&)_!^2V&,-LZ?`DF*'K=80A[X+#X;+ M8JG\1G-/@CPQBB1J6,/L*6JDV*&A$(,6U'RG3]@)U_*7>!,D@11&UWU"APP+ M-%15T'TM1)]D8JHB7^BM:+81DR[AEL^A=#1(WA;)#;Y/J%++)%N?8LM3?4NY MO`@AM0FW.*`&>YP/'/#7AU$::D-8@,%KY,<9N[WM!:D>CNQO'9"IB&<:JDZH MR1T+7D'L(1\4B8N5Y.I\"GOJ`++]$(W]9/'X"L MAX76OGO7M[J??D:[UKLDFA'*EEB M%@=X:^>FOE0"QC!_D8*G*#]1D%_S$T7.$K6H9G_G@%L%_-)1$T0-,JF7CM(; M5`FNO@@\6Z[;E/FD?WIQ4"1AI!%`%6NJA46-H-WM%)S&LP6LU%'31%&9KXR[ M'DI6!3\)&2_A\@HTF@B\]BZ#2)KN4N+J+Y(,9_#Y\&Y#=)P,/A\Z9O#Y<,C@ MTRV#CZ**`(#P%4\660)7LF":"6EI;8TNZ)S5IPN!QH,QU2!@16Q.^P,U`M_H MSLE)<&G=R1Y!"/P$!/]*O9A\.EQ>0>0A M'WKAA9=XWY&7!I#\++>[?:CO;N5W1JL/C59?&M%/C?ZR^MA?A[+K-3.M1>/S M.U%H??CR]>CXZ]>OIQ]/OG[\\FFHY0%M4"4=F%W?E$2(-+ZYJ++C<#*9%K0R M9+[1QDV)MY.HR--GOMCQZO!6W`.V^E7*=FY*7HQ,1YQN1)E=(V(4@)L(X_$K MV7%IP-A35,E808T@,LLS#T.?@0S)4=S$C0HF*'*MF=;W&08KBK54XX@*HV9]-4 MU)77U)KUW,;\#9>4*"%6E?/>&J.U-?*2ED6[&'DDVB[)QHH^K>VM MER9/)$("M;D>CQ8P<(NS-;8=`@B$*B;(4^D(!-36WK81`A):79Q`JPIFFB^V M;8/)Y%,A""[_2&&R+']BE]61 M',(Z:*@0[U;\B0J6V(J8AI?K-#W,13P.O'FS$A'NMP_8Z,P'#:]0C#_9?"32 MS%AP'GH83Z;9C1KO\,AJ;QUR^AP?I8A45/Q54:!)9<;FXAKVP61MWN>BOKY-=! M\\J0Q@GG*#?3$RTB8=?6;FIGC5AD>,N5B,TZ5.AT17[_*'J,6K>U69#B]4:E MJ#,N3BT.U!M&\=&VYM8`0/W-")]&1\*E,H/@&N,4!!NB^_?+\#/[.? MV`<>DJ%>F.S6B%]=9^:@A#&>4Y1[+Z)NC'W\^_M<3C`/%B1_^?\!4$L#!!0````( M`'>&;$:Y(A(@)QD``%0J`0`1`!P`=')O=BTR,#$T,3(S,2YX!=XP\FY"CO_WUW__MY_\X M/K;Z#",?SZSIQGK$C!''L?HN6[L,^2#`.CX."6^0!U3PRV\WSP_6QXE7R/(16V#_ M":VPMT8V_G*T]/WU]>GIZ^OKB<_<%[3`%)_8[HI+NCJ_N#P_LI#O,S(-?'SG MLM4`SU'@^*`X_3U`CO@\V,/!*TS]%$&B&`Q(O6NH1NI[KY5/!$!9PA2Z/ MS\Z/N4J2A2ML9`%)[A#Z75TG4.'RE!=/`=-872B=^3%#DOC3J2S<6H:46^:8 M4,]'U$Y]@&@JE*6G>,&;52''YU/F.F!729:P*__94QI6E"@L:]!D0AUR1@UU M/__\^?.I*(U(&9X75OWJ%$IC/5UJT'I<>IQO0;Q(K:DH46CZYF@0^.TA4?\9 M)NG&X&'[9.&^G$)!4C#T6,L2?191ZOIBU!"_1;^NUX3.W?`G^)$;Z9HC,8$Z M6OR/;\_WFG8M4!Z#8-%G^R[U7(?,..8WR.$-9KS$V/>.+`)MQ8`NKDE4EQF> M$TI$O:$%GYU9QU8L!O[N#Y_&PX?[06]R.[!N>@^]I_ZM-?[[[>UD_/-I5D!6 M=@"#YI#^5?R]9M@#D<)"W-(A=TBBX[218P=.#<9MS8KYPE\C1/8!5/RC-YP/ MUUA.+5Z/SOKN"JRRQ-0C+_C!]70H5A"BA_@B#W'B,]L"SW+GUO9+%J(S*_4M MBW^L:P/5VT`?>MI_RL'%IEA!G)>5UN!GA=@_K^Q6>H+=X>+S(PJ4BT:($ MCO!%%B4IQ!)2MB/A10=.-7`NR\&Y+`7GT@R*3W[S)W22$#R3S%%"6E60ER'5XW5_P@Q*%YB'SPWQS04 MD&8JBPM\,H\+6'])B>ZZ8(TUXMAW[>]+UYEAYG$_SM\,H)+@@U-[8[ALU(K0 MPWU99269_,Y_6O)+?`2.OM7AOTN,P+1K&S"710]R7=PD>M!U]BK1A,`C%'O> M\`6S%X)?83Y](-!A9M!E91X\P6Y%_!T,%<-M)G&V M$E",`VP=.!IPREU90UH]6)_R8'6>Z\,F-@0X`#0!]=[4BOA@31%J16`:"FZ18Q>I(]0`I0A,)86&244)< MAY@&L=O5VG$W&-]`^9SX*B]-1:)'2!%&B(18H93.6RM#YAD[/&HZ0K!4G(`; MY"%;9-%EX2FDTV.DB!:$DBPARDK*ZH#2+7*P@VVPVS\"L!MFSB9V9P?(1]\H M"F9$Y%=G%C^&;'H8%?&%2+`52TXXV%RV]9=8>K=\U2(;3#W\>P`:W[ZHO.I< MN1XK57@AEF!)$1T>>XJB[R.:;A15OSB[R.)]M9H)FCK-MIE0 MHJ[%7$*+R24G-=-BY->[]E)U)T#=#C24>GRO\O@6I=UVB-79'E#C54BG1^M3 M'BWUMD"'5>4M`0U0.2(]2C\4H)3<'N@@:FZ?0(U<)5X]H#_F`:VP9]!!77OS M0(VLCE0/Y$]Y(`M/*W2@F>TH%/6^J9D#\EG5MZ:=NU%UFT$-0YY`BT;Y680. ME9WV'M0HE3/H43O/HZ;=A^A@;#":6N`W5F+6PZM8HU6*K'9P[YK.7'!NTH1% M!^U5C>3F[ACE>QUUW\-)]]*#[GM)>NZ:S'LUF=Q1W49DEC6:/<7TNS/![]5L M(&Y%9UFSV%-CO3BM7/VQ1,.,H:?2PEAZ]Z":#G?/\"]`R8=R?KO\.S M*3QSD[<13QFBNCN1KX&][H+!L1JS'I4 M=SLAUXV@.U_/EQM']<1Z-'_*CZ9E%_1U8VKYKG=A/YP:WG=9<*JNZSXU+^(K MOX>O]!H^[6F[#IA=][X+@#+@T`-7]11>AV1#2.;F*1.6,BQSLY49EMV\TJOR1==J86H!%5;4R\+51*V@H5;5*MZTV*N6@:56E M@`4[^]'GY]/LPVWA+^D'WL3S;J":RWR+YIYHU+]&)]]W?'!M(2[]T)SR*<13 M[/A>+.MX*^L$:A%575\CW2MVV@IE>?@?M6I0]H1A0252;`YC*:YC+N?X_.+X M_(>:%5$_,FA2ER3GDV1LLCKUJM)4/3*/4II40K#P?\6/7_)J7/)J5&ZHN;K=]3^2^Y;B(>ES1Y5S5AJ/"Y5E'S+T??*!&OV_H\ MJ=$-_"5FM,_?Z709)>@1KZ:821>+C['_-".7`[5\BO-ZYJX0H?<^7G$W`TP` M?I5/_(`;X"MS@_67(_&8Z34XPZLC"T$I0[;//Q@`.26.P\].1/^6M##<$G,;0=YGGBG=.+V9C,QTR%G MA,CL'E1=$S^Z-U\8I'')TG92RY5+P>-DFQK&FR/'*[3>5+[;`:;#4^+7M*E^ MPW."V6HX'V$&+<8?P1#"+TCPL;A"JN^@(+K>6AAQ=U%)JT5U;]IJ[VR?[?HC MY*>+!DVFE'YP5M1IV%OQS.AG4)(PWN-N\%=863(^R]\Q=[6+>9O^[+OV>1NJ M5;_3:UYNZH4529K1B#RI/OP&)GG/V2)2,*ZT2*"!&D?Y%/>>%^#9(.`5&PE) M8L!_PJ^BQ#L*;5.#+U/;G=J!3M6B)E#1?$H`,S9KYS10T'VE!R:,$S/MAX_=A[Z'E;XSP0-"4.X6M/T;H2G:\9 M<3N9L3'W(]?R>K/_"SRY[U'H3$4&2'I>K`U@:@*[C)6)XQ_94<0X3E;Q!'I[=OJTQ]3"O MI4N]P.$[9V-^Y->.CI-O)P0#AH-QW4<,SS$,H#.AV8"\D!FFLYYMPX=F"<5+ MZ-HQ-.35D]G_PSG4'?`1)^\32BE+:[@@,_]Z">7,#J:B`>]IZ7%V?I$+_!23M$Z;=`=_(%1T3Z]P"$A0M&PE(ARU_#(BG%7Y M%`0#=O90Q4OO9P_HU"PWUEA/M M_RH3J58KXO%Q/M_%:\DX&#=.K6,TK(6^:KE1\@P'8P&QB(T;]9`]D\72E\'/ MJ*&'/Z;#(HR,V_ M$'0WFRW)"&U$&/$5L9D\V>9]#8>.WRS@KDK!==S)GEQ.V]Y5_!@[#E^A+_CB-H>: MLK1]8"7O/`*S>R):RMTG<*76K@=](+KB1@3\>HX3YCE$`XJX!R<566M,9/O& MHVU[S8BX+MLSA/\YM^`NM^5?6!GF:GFY4>_?[#-;F"J^0Y*N@[V MPK/P`#MTC4?L+]U9KN,8TK>N*]T0ZJX`'2,=RVE;IU^<%9/:&!B%X7Y5^DP! MX0Y[!1^1CQ#WMF?7<>YK.W8!AOGY>76YLUF%NX2MW& M5'H\8<;F"?X+Z.=0`<\#+&V,9YG@OPE]:D3@1!\]S>,7S+A_'RXPP"%%SL3E MZ\GDBI-O)WN@#4<.&CK_:1#@B2OG;BAU86GIAEBG7,-]B&]A=N!D[ M"(=MOX:O]/$68O``7CWUL+A8FZ<7B']$\XJ7#0`:4;0<&"0YJQAW6>>\5`HTOX/!3=1_!VA4*>&[I)N.4-2ET MGREYQ0<'RA?$`NC;-VB)Q..N9+P1#YZF6*CPIU:0X[B^W*21P:YL2ZDAX*-; M3)@G"M:)\D0?`PDT9VCO4E>XG>R4; MRK=O:R*_PF?U*CO5526W<,)7ZQA%^4(]Y'S`^W/B3MQ>`'X/(W^D\I.;$?>^ MP4.3;@6?7(D#8]OH>)B8DNQ+.JK6Q'[@5^QGSC M0N:N1$Y0IH_L)*6%_>$AX\5R[W[`O#OD@`HP1#YB.[!MDML3JLC7NOTA<.!5 M*OPCP)Z?2%W(;Y17XSL4O0?!=[P]6<\=O]0/?\?(\9?CC<>3E$UM4D?FH=CK M*Z8N=/XW50:,.4OKM%4X1#GU-#2MTR=Q`%%F4ZIW1?5D;=O_+&A?]Z/Q\.OM MT[@W-FV1>8[6`0CK+3O@$:14Q<<^?L'_BRB9NC0_-57@:9^^%):3:P8K3.%D M#*`=(G9^=7)U%F4DY-4U9CD,;2\N3GZJJ*V2Y3"TO3P[.:NHK9+E,+3]\>13 M1655'.W353GB]*@/0TW@C>UEL#0`4*5@.15N^ M$N1/,X=^;!0T,U189\D/1\O'AX3&@`!1F#SCXCE8$P[=<9JIV&?^AV&'\?>,0BA.+_IM? M3&V@XVV=_L\P1)$_!-6-2P.OO[U4]F:3F;0SQ^FKL]:+N[_'0?LJNN2.X==A M;EU#R+9D>7R37U6C"0PFB7;:1=K?6:?L#L_N!F;I3;3CD4H.W68"R)>" MC@J,55&&\EQ\G9Q3G?Z['XNOHF58]@SKL8V)N*]49'#5M5"QF#^5M2I:Y8"T MW^[1#YDBVIS9D3.B;N'.6]8EN'7(@LCC-]L;0@!5&268,,0/F@S0AE]I-L!^ M,G_Z$;'O6%X&JO$YFOK`8=ER@(BS"97[Q76"%8ZNSC,Q5#'WN_:FG6Y,S:J7 MR_(N-4@AQ\$,*1K_.TIQE0=51)_@!U4R3KGBY&"#,EN7+%%=-W'N?^T0/JQD M]-S)9EJY;?/]=E,/G']Y?3O*MI3&+*C[1-N,V5O`',[?Q+CGC[T@)[HE*#O/ ME="U-2%UP%^QP>(5/D:FH@+\4-ADR;#'KY;H+7`?^?;RVSI)DCJX6D_`8]8TYBG MMDB='7<;1O8;FZQPR9[B#KM:W&T;8I5*;&^9W[XV:6R!$N:/-<`^^E:#?:HD MK%_-"=&XG&T8DDRFJ;H2]VG$O0]`U92.9[,FL8F%[F"Y9NZ:2-WN#^ZK2`V7 M5TRI(BZ&]!^MEOZ8L,J--^9HVP231B2ZW&-`'!%3CN[YE:]5),%*/'M2B&]- M:3LM;_?:K(<`[2)U0"P1=#=HYB7\AZ!X8@G>!^>!/UZ"'.P)%'UW0[?&6'954S4<*X[Q>^GP0#1OI%M)Y7:/UY5S2-6B1^%YQ7C!^ZHG+"IJ!UTQ MO@AS.VEF#_]K2=\7*[-UO(QA)2XOK13Q,.'6!`PKNUG[7:&/$$PW/AHAYE/` M[,&?Y8>P0I+6#5_9UQ(\]3M:.JK6Z63XON.014=H=GLGLDA.ZW8+TZ^AR0=6 M4["6O)^FX?C@-J!^#3G"K^]ZOI=TS^7S"]&894C[08^F1AE,^XDL1OM?A@Y( MCOS#5W)1'D<,8MHUEB^EJ1(_2A@^6C%M]:(!*`;B":>N9JO.^]'JQNY>\C(H M0P^QE.7C8S9]J"C/P??_6/#[WF8B\2)_2X:.JGVSK.,$/-M7=6Y34=:Z^N?? M(LF=P"HF:9TVQ=&!'#CEI*W3KF!$$\&C>H.AAO5CDO^JW$R37A9?GIR=%8*L MH6T=R@5U_G1RF5^1&-"V3K\^V^0]8P\C9B]AXAWZRY2.M27LK9\6G;DPJ)OHWK)JQ)7JA54?ZNKJ3N>PZOC^'WD M;\A['/3$0XHN[7,]6!_SE/945% MY5'!,L[6Z:Z^@EE>LCR4FVOQNW:E-S<7L7W,.J)\ZH\VE!,K(YC.$]=,*S(UD$MBJ^M]W$M&YT?7(I?\P8>KU_`ZLA?JLY\I8W M"(YU-3C?]>5-1ZJ%;J)4J5V<<1?9>ES-&]XK:$-&%N!+.IGL MXDC3XN+]]N0MDGOJR".&U]+1OL,X<05>I+BFO)67!^84!)>/^?P!I!'_/[]F MBI_>=T";;VN7/D?:1?J:DQ]6=D_>+MO33(6G#\)F'@[5>.HG'D/.GHNH*>70 M)T(9OKJGO,&3%WQQ=G[%KT>)7)WPTHT2(G5/:L0_VFO?2LS5P*)07$?0H-)[ M59*_J+-"]CU?7\I@`W(>)H.THF5$AZ+L9'('C<=EX^>'M(*J@D-1ZO;-=@(/ M.EXV2G+GLA'B3XO*I'+Q?A*,7(BZ=R[BS_2XGDF_%!45%P%)5_HZ\W0]K6UPD>_5+2'HKJ\0GN" MWIZQ[5*;.$1(!@=YA6CH_,:K!U/B`WP7Q/'V": M']+M57%>?J54B?>0UD<_G_)PL2=^@7_^/U!+`0(>`Q0````(`'>&;$;G^3;( MVUX!`.(\%P`1`!@```````$```"D@0````!T`Q0````(`'>&;$:,!DH+BPP` M``FQ```5`!@```````$```"D@29?`0!T`L``00E#@``!#D!``!02P$"'@,4````"`!WAFQ&71Y:],]# M``#IRP0`%0`8```````!````I($`;`$`=')O=BTR,#$T,3(S,5]D968N>&UL M550%``-A_`%5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`=X9L1NZK/[B' MH@``VD(*`!4`&````````0```*2!'K`!`'1R;W8M,C`Q-#$R,S%?;&%B+GAM M;%54!0`#8?P!575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'>&;$9Y`Z(= MNV8``*7R!P`5`!@```````$```"D@?12`@!T`L``00E#@``!#D!``!02P$"'@,4````"`!WAFQ&N2(2 M("<9``!4*@$`$0`8```````!````I('^N0(`=')O=BTR,#$T,3(S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``<-,"```` ` end XML 41 R56.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Commitments and Contingencies (Details 3) (USD $)
    		 12 Months Ended
    Dec. 31, 2014
    Executive Agreement with Antonius Schuh [Member]  
    Employment and Consulting Agreements  
    Period by which agreement is renewed automatically at the end of each term 1 year
    Realization bonus eligibility, number of consecutive trading days 90 days
    Amount of realization bonus payable either in cash or registered common stock or a combination thereof $ 3,466,466trov_RealizationBonusUnderConditionOneAmount
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Period of base compensation which would be received as severance payment, if termination occurs within 10 months 3 months
    Period within which if termination occurs, employee will be eligible for severance payment equal to 3 months of base compensation 10 months
    Period of base compensation which would be received as severance payment, if termination occurs after 10 months 6 months
    Period within which if termination occurs, employee will be eligible for severance payment equal to 6 months of base compensation 10 months
    Period of base compensation received as severance payment if termination occurs due to change in control 12 months
    Exercise period after termination due to change in control 6 months
    Executive Agreement with Antonius Schuh [Member] | Enterprise Value Dollar 7.50 Per Share [Member]  
    Employment and Consulting Agreements  
    Realization bonus calculation, enterprise value per share (in dollars per share) $ 7.50trov_RealizationBonusCalculationInCaseOfChangeOfControlEnterpriseValuePerShare
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar7.50PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Percentage by which enterprise value is multiplied for determining realization bonus 4.00%trov_RealizationBonusCalculationInCaseOfChangeOfControlMultiplierOfEnterpriseValue
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar7.50PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Executive Agreement with Antonius Schuh [Member] | Enterprise Value Dollar 14.40 Per Share [Member]  
    Employment and Consulting Agreements  
    Realization bonus calculation, enterprise value per share (in dollars per share) $ 14.40trov_RealizationBonusCalculationInCaseOfChangeOfControlEnterpriseValuePerShare
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar14.40PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Percentage by which incremental enterprise value is multiplied for determining realization bonus 2.50%trov_RealizationBonusCalculationInCaseOfChangeOfControlMultiplierOfIncrementalEnterpriseValue
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar14.40PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Executive Agreement with Antonius Schuh [Member] | Enterprise Value Dollar 22.80 Per Share [Member]  
    Employment and Consulting Agreements  
    Realization bonus calculation, enterprise value per share (in dollars per share) $ 22.80trov_RealizationBonusCalculationInCaseOfChangeOfControlEnterpriseValuePerShare
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar22.80PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Percentage by which incremental enterprise value is multiplied for determining realization bonus 2.00%trov_RealizationBonusCalculationInCaseOfChangeOfControlMultiplierOfIncrementalEnterpriseValue
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar22.80PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Executive Agreement with Antonius Schuh [Member] | Enterprise Value Dollar 30.00 Per Share [Member]  
    Employment and Consulting Agreements  
    Realization bonus calculation, enterprise value per share (in dollars per share) $ 30.00trov_RealizationBonusCalculationInCaseOfChangeOfControlEnterpriseValuePerShare
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar30.00PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Percentage by which incremental enterprise value is multiplied for determining realization bonus 1.50%trov_RealizationBonusCalculationInCaseOfChangeOfControlMultiplierOfIncrementalEnterpriseValue
    / trov_RealizationBonusCalculationByEnterpriseValueAxis
    = trov_EnterpriseValueDollar30.00PerShareMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Executive Agreement with Antonius Schuh [Member] | Minimum  
    Employment and Consulting Agreements  
    Realization bonus eligibility, market price of common stock (in dollars per share) $ 7.50trov_RealizationBonusEligibilityMarketPriceOfCommonStock
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Realization bonus eligibility, amount of daily trading volume of common stock $ 125,000trov_RealizationBonusEligibilityDailyTradingVolumeAmount
    / us-gaap_RangeAxis
    = us-gaap_MinimumMember
    / us-gaap_TypeOfArrangementAxis
    = trov_ExecutiveAgreementWithAntoniusSchuhMember
    Executive Agreement with Steve Zaniboni [Member]  
    Employment and Consulting Agreements  
    Period of base compensation which would be received as severance payment, if termination occurs within 10 months 3 months
    Period within which if termination occurs, employee will be eligible for severance payment equal to 3 months of base compensation 10 months
    Period of base compensation which would be received as severance payment, if termination occurs after 10 months 6 months
    Period within which if termination occurs, employee will be eligible for severance payment equal to 6 months of base compensation 10 months
    Period of base compensation received as severance payment if termination occurs due to change in control 12 months
    Exercise period after termination due to change in control 6 months